

0000950170-24-12536510-Q Oncocyte Corp 2024111122041112160834160834160834 0 000095011 70-24-125365 10-Q 74 20240930 20241112 20241112 Oncocyte Corp 0001642380 2835 271041563 Ka 1231 10-Q 34 001-37648 241448110 15 CUSHING IRVINE Ka 92618 949-409-7600 15 CUSHING IRVINE Ka 92618 OncoCyte Corp 20200205 OncoCyte Corp 20150513 10-Q 1 ocx-20240930.htm 10-Q 10-Q false0001642380Q3--12-310001642380srt:RevisionOfPriorPeriodReclassificationAdjustmentMember2023-09-300001642380ocx:PharmaServicesCompanyCMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-09-300001642380us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-09-300001642380ocx:InsightGeneticsIncMemberocx:MilestoneOneMember2024-09-300001642380ocx:PreFundedWarrantMemberocx:SecuritiesPurchaseAgreementMember2024-04-150001642380ocx:PharmaServicesCompanyBMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-07-012023-09-300001642380us-gaap:CommonStockMember2024-07-012024-09-300001642380ocx:OperatingAndFinancingLeasesMember2023-12-310001642380ocx:TwoThousandEighteenIncentivePlanMemberus-gaap:SubsequentEventMember2024-10-112024-10-1100016423802024-04-052024-04-050001642380us-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-300001642380ocx:PharmaServicesCompanyBMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-07-012024-09-300001642380ocx:RazorStockPurchaseAgreementMemberocx:RazorGenomicsIncMember2023-02-160001642380ocx:SeriesARedeemableConvertiblePreferredStockMemberus-gaap:PreferredStockMemberocx:InterestMember2022-04-130001642380us-gaap:RetainedEarningsMember2024-01-012024-09-300001642380ocx:PharmaServicesMember2023-01-012023-09-300001642380ocx:ExecutiveOfficersMember2023-01-012023-12-310001642380us-gaap:CommonStockMemberocx:SecuritiesPurchaseAgreementMemberocx:BroadwoodPartnersLPMember2023-04-032023-04-030001642380us-gaap:ValuationTechniqueDiscountedCashFlowMemberocx:ChronixMergerMember2024-01-012024-09-300001642380ocx:BioRadLaboratoriesIncMember2024-09-300001642380us-gaap:CommonStockMemberocx:SecuritiesPurchaseAgreementMember2024-04-152024-04-150001642380us-gaap:FairValueInputsLevel3Memberocx:ChronixMergerMember2022-12-310001642380ocx:OfficeSubleaseAgreementMember2023-08-082023-08-080001642380ocx:SeriesARedeemableConvertiblePreferredStockMember2022-04-130001642380ocx:SalesAgreementMember2024-08-092024-08-090001642380us-gaap:RetainedEarningsMember2023-07-012023-09-300001642380us-gaap:RetainedEarningsMember2023-01-012023-09-300001642380us-gaap:CommonStockMember2022-12-310001642380us-gaap:CustomerRelationshipsMember2023-01-012023-12-310001642380us-gaap:EquipmentMembersrt:MinimumMember2024-09-300001642380us-gaap:FairValueInputsLevel3Membersrt:MaximumMemberocx:ChronixMergerMemberus-gaap:MeasurementInputExpectedTermMember2024-01-012024-09-300001642380ocx:LeaseAgreementMember2023-12-310001642380us-gaap:CommonStockMember2023-12-310001642380ocx:SubleasePeriodFiveMemberocx:OfficeSubleaseAgreementMember2024-01-012024-09-300001642380us-gaap:CommonStockMemberocx:SecuritiesPurchaseAgreementMember2024-04-150001642380us-gaap:RestrictedStockUnitsRSUMember2024-07-012024-09-300001642380us-gaap:CustomerRelationshipsMember2023-12-310001642380ocx:SeriesARedeemableConvertiblePreferredStockMemberocx:SecuritiesPurchaseAgreementMember2022-04-130001642380ocx:InsightGeneticsIncMemberus-gaap:FairValueInputsLevel3Memberocx:MeasurementInputManagementProbabilityEstimateMembersrt:MaximumMember2023-09-300001642380ocx:InsightGeneticsIncMemberus-gaap:FairValueInputsLevel3Member2023-12-310001642380us-gaap:CommonStockMemberocx:SecuritiesPurchaseAgreementMemberocx:BioRadLaboratoriesIncMemberus-gaap:SubsequentEventMember2024-10-042024-10-040001642380ocx:RazorStockPurchaseAgreementMemberocx:RazorGenomicsIncMember2022-01-012022-12-310001642380us-gaap:WarrantMember2023-01-012023-09-300001642380us-gaap:SellingAndMarketingExpenseMember2024-01-012024-09-300001642380ocx:SeriesARedeemableConvertiblePreferredStockMember2023-07-012023-09-300001642380ocx:SalesAgreementMember2024-09-300001642380us-gaap:FairValueInputsLevel3Memberocx:InsightGeneticsIncMember2024-01-012024-09-300001642380us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberocx:OutsideOfUnitedStatesMemberocx:PharmaServicesMember2023-07-012023-09-300001642380us-gaap:WarrantMember2023-07-012023-09-300001642380us-gaap:PrivatePlacementMember2024-04-152024-04-150001642380us-gaap:StockOptionMember2023-07-012023-09-300001642380ocx:PharmaServicesMember2023-12-310001642380ocx:LaboratoryDevelopedTestServicesMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMembercountry:US2023-01-012023-09-3000016423802024-08-012024-08-010001642380ocx:SecuritiesPurchaseAgreementMemberus-gaap:SubsequentEventMemberus-gaap:PrivatePlacementMember2024-10-042024-10-040001642380us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001642380us-gaap:FairValueInputsLevel3Memberocx:ChronixMergerMember2024-09-300001642380ocx:LeaseAgreementMemberocx:MPCHoldingsLLCMember2024-01-012024-01-010001642380ocx:UnderwrittenOfferingMemberocx:PuraVidaInvestmentsLLCMember2022-04-130001642380us-gaap:CommonStockMemberocx:SecuritiesPurchaseAgreementMemberus-gaap:SubsequentEventMember2024-10-042024-10-040001642380ocx:TwoThousandTenPlanAndTwoThousandEighteenIncentivePlanActivityMember2023-12-310001642380ocx:InsightGeneticsIncMember2024-01-012024-09-300001642380ocx:CustomerOneMemberus-gaap:AccountsReceivableMemberocx:PharmaServicesMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-09-3000016423802023-09-300001642380ocx:ChronixAcquisitionMember2024-01-012024-09-300001642380us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberocx:PharmaServicesMembercountry:US2023-01-012023-09-300001642380us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberocx:OutsideOfUnitedStatesMemberocx:PharmaServicesMember2023-01-012023-09-300001642380us-gaap:MeasurementInputDiscountRateMember2023-09-3000016423802023-10-012023-12-310001642380ocx:InsightGeneticsIncMemberus-gaap:FairValueInputsLevel3Memberocx:MeasurementInputManagementProbabilityEstimateMembersrt:MinimumMember2023-09-300001642380ocx:ArnosSonMember2022-01-012023-07-270001642380ocx:CostOfRevenuesMember2024-07-012024-09-300001642380ocx:InsightGeneticsIncMemberus-gaap:FairValueInputsLevel3Membersrt:MinimumMemberus-gaap:MeasurementInputDiscountRateMember2024-09-300001642380ocx:FirstTenCalendarMemberocx:OfficeLeaseAgreementMember2019-12-232019-12-230001642380us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-300001642380ocx:SeriesARedeemableConvertiblePreferredStockMemberocx:SecuritiesPurchaseAgreementMember2024-04-150001642380us-gaap:SalesRevenueNetMemberocx:PharmaServicesCompanyAMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-09-300001642380us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300001642380ocx:SeriesARedeemableConvertiblePreferredStockMemberocx:SecuritiesPurchaseAgreementMember2024-04-152024-04-150001642380ocx:ChronixMergerMember2024-01-012024-09-3000016423802023-07-012023-09-300001642380ocx:TwoThousandTenStockOptionPlanMember2023-12-310001642380us-gaap:CommonStockMember2023-07-012023-09-3000016423802024-04-050001642380ocx:LifeTechnologiesCorporationMember2024-01-012024-09-300001642380us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300001642380us-gaap:CommonStockMemberocx:SecuritiesPurchaseAgreementMember2023-04-030001642380ocx:RazorStockPurchaseAgreementMemberocx:RazorGenomicsIncMember2023-02-162023-02-160001642380us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2023-07-012023-09-300001642380us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2024-07-012024-09-300001642380us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberocx:PharmaServicesMembercountry:US2023-07-012023-09-300001642380ocx:OfficeSubleaseAgreementMember2024-01-012024-09-300001642380ocx:PharmaServicesCompanyBMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-09-300001642380ocx:LeaseAgreementMember2021-08-272021-08-270001642380us-gaap:SellingAndMarketingExpenseMember2023-01-012023-09-300001642380ocx:RazorGenomicsIncMember2021-02-230001642380ocx:InsightGeneticsIncMemberocx:MilestoneThreeMember2024-09-300001642380us-gaap:CommonStockMemberocx:SecuritiesPurchaseAgreementMemberus-gaap:SubsequentEventMember2024-10-040001642380us-gaap:SalesRevenueNetMemberocx:PharmaServicesCompanyAMemberus-gaap:CustomerConcentrationRiskMember2023-07-012023-09-300001642380ocx:SeriesARedeemableConvertiblePreferredStockMemberus-gaap:PreferredStockMember2024-09-300001642380us-gaap:RetainedEarningsMember2024-09-3000016423802024-06-300001642380ocx:UnderwritersMemberocx:BroadwoodCapitalLPMemberocx:UnderwrittenOfferingMember2022-04-130001642380us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberocx:PharmaServicesMemberocx:CustomerThreeMember2024-01-012024-09-300001642380us-gaap:SalesRevenueNetMemberocx:PharmaServicesCompanyDMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-09-300001642380ocx:LaboratoryDevelopedTestServicesMember2023-01-012023-09-300001642380ocx:HalleSpecialSituationsFundLLCMemberocx:UnderwrittenOfferingMembersrt:MaximumMember2022-04-130001642380us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001642380us-gaap:CommonStockMemberus-gaap:SubsequentEventMemberus-gaap:PrivatePlacementMember2024-10-042024-10-040001642380ocx:BioRadLaboratoriesIncMemberocx:LaboratoryEquipmentMember2023-01-012023-09-300001642380ocx:BroadwoodCapitalLPMemberocx:UnderwrittenOfferingMember2022-04-130001642380ocx:DetermalOMember2024-01-012024-09-300001642380ocx:SeriesARedeemableConvertiblePreferredStockMember2024-07-012024-09-300001642380ocx:PharmaServicesCompanyBMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-09-300001642380us-gaap:CommonStockMember2024-09-300001642380ocx:SeriesARedeemableConvertiblePreferredStockMember2023-01-012023-09-300001642380srt:RevisionOfPriorPeriodReclassificationAdjustmentMember2023-01-012023-09-300001642380us-gaap:FairValueInputsLevel3Memberocx:ChronixMergerMember2023-09-300001642380ocx:RazorStockPurchaseAgreementMemberocx:RazorGenomicsIncMember2023-02-152023-02-160001642380us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberocx:OutsideOfUnitedStatesMemberocx:PharmaServicesMember2024-01-012024-09-300001642380ocx:SeriesARedeemableConvertiblePreferredStockMemberocx:SecuritiesPurchaseAgreementMember2022-04-130001642380ocx:RazorGenomicsIncMemberus-gaap:DiscontinuedOperationsHeldforsaleMember2023-01-012023-09-300001642380us-gaap:FairValueInputsLevel3Memberocx:InsightGeneticsIncMember2023-01-012023-09-300001642380ocx:InsightGeneticsIncMemberocx:RoyaltyOneMember2024-09-300001642380us-gaap:CommonStockMemberocx:SecuritiesPurchaseAgreementMemberocx:MrGutfreundMember2023-04-032023-04-030001642380us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-3000016423802023-01-012023-09-300001642380us-gaap:CommonStockMemberus-gaap:SubsequentEventMemberus-gaap:PrivatePlacementMember2024-10-040001642380ocx:LaboratoryDevelopedTestServicesMember2024-01-012024-09-300001642380ocx:LaboratoryDevelopedTestServicesMember2024-07-012024-09-300001642380ocx:RazorStockPurchaseAgreementMemberocx:DragonScientificLLCMemberocx:RazorGenomicsIncMember2022-12-152022-12-150001642380ocx:SecuritiesPurchaseAgreementMemberus-gaap:SubsequentEventMember2024-10-042024-10-040001642380ocx:SeriesARedeemableConvertiblePreferredStockMemberocx:SecuritiesPurchaseAgreementMemberocx:InvestorsMember2022-04-122022-04-130001642380us-gaap:GeneralAndAdministrativeExpenseMember2024-07-012024-09-300001642380ocx:CustomerOneMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberocx:PharmaServicesMember2023-01-012023-12-310001642380country:DE2024-09-300001642380ocx:LaboratoryDevelopedTestServicesMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMembercountry:US2023-07-012023-09-300001642380ocx:OfficeLeaseAgreementMember2024-01-012024-09-3000016423802024-01-012024-03-310001642380us-gaap:ValuationTechniqueDiscountedCashFlowMemberocx:InsightGeneticsIncMember2024-01-012024-09-300001642380ocx:BroadwoodCapitalLPMemberocx:UnderwrittenOfferingMembersrt:MaximumMember2022-04-122022-04-1300016423802024-11-050001642380ocx:SeriesARedeemableConvertiblePreferredStockMemberocx:SecuritiesPurchaseAgreementMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2022-04-122022-04-130001642380ocx:UnderwrittenOfferingMemberocx:PuraVidaInvestmentsLLCMembersrt:MaximumMember2022-04-130001642380us-gaap:CommonStockMember2023-06-300001642380ocx:OfficeLeaseAgreementMember2021-06-212021-06-210001642380ocx:InsightGeneticsIncMemberocx:RoyaltyTwoMember2024-09-300001642380us-gaap:FairValueInputsLevel3Memberocx:InsightGeneticsIncMembersrt:MinimumMemberus-gaap:MeasurementInputDiscountRateMember2023-09-300001642380us-gaap:FairValueInputsLevel3Memberocx:InsightGeneticsIncMember2022-12-310001642380ocx:ChronixAcquisitionMember2023-01-012023-12-310001642380us-gaap:InProcessResearchAndDevelopmentMemberocx:DetermalOMember2023-01-012023-12-310001642380us-gaap:MachineryAndEquipmentMembersrt:MaximumMember2024-09-300001642380us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberocx:PharmaServicesMember2023-01-012023-09-300001642380us-gaap:CommonStockMemberocx:HalleSpecialSituationsFundLLCMemberocx:UnderwrittenOfferingMember2022-04-122022-04-130001642380us-gaap:CommonStockMemberocx:ArnoMemberocx:SecuritiesPurchaseAgreementMember2023-04-032023-04-030001642380us-gaap:FairValueInputsLevel3Memberocx:ChronixMergerMember2023-12-310001642380ocx:LaboratoryDevelopedTestServicesMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2023-01-012023-09-300001642380us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-130001642380ocx:LeaseAgreementMember2023-07-012023-09-300001642380ocx:SeriesARedeemableConvertiblePreferredStockMember2022-04-130001642380us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300001642380ocx:OfficeLeaseAgreementMember2024-09-300001642380us-gaap:SalesRevenueNetMemberocx:PharmaServicesCompanyAMemberus-gaap:CustomerConcentrationRiskMember2024-07-012024-09-300001642380us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMembersrt:MinimumMemberocx:ChronixMergerMember2023-09-300001642380us-gaap:CommonStockMemberocx:SecuritiesPurchaseAgreementMemberocx:MrGutfreundMember2023-04-052023-04-050001642380us-gaap:SubsequentEventMember2024-10-042024-10-040001642380ocx:InsightGeneticsIncMemberus-gaap:FairValueInputsLevel3Member2024-09-300001642380us-gaap:SeriesBPreferredStockMemberocx:RegisteredDirectOfferingMember2023-

04-032023-04-030001642380us-gaap:MachineryAndEquipmentMemberbsrt:MinimumMemberMember2024-09-300001642380us-gaap:WarrantMemberMember2024-07-012024-09-300001642380srt:ScenarioPreviouslyReportedMember2023-01-012023-09-300001642380us-gaap:CommonStockMembercox:ArnoMembercox:SecuritiesPurchaseAgreementMembercox:MrGutfreundMember2023-04-032023-04-030001642380ocx:CustomerFourMemberus-gaap:AccountsReceivableMembercox:PharmaServicesMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-09-300001642380us-gaap:RetainedEarningsMember2023-06-300001642380us-gaap:WarrantMember2019-10-310001642380us-gaap:FairValueInputsLevel3Membercox:InsightGeneticsIncMembercox:MeasurementInputManagementProbabilityEstimateMembersrt:MaximumMember2024-09-300001642380us-gaap:SeriesAPreferredStockMembercox:RegisteredDirectOfferingMember2023-04-042023-04-050001642380ocx:ExecutiveOfficersMember2024-01-012024-09-300001642380us-gaap:CommonStockMember2023-09-300001642380us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMembercox:PharmaServicesMember2023-07-012023-09-300001642380ocx:SeriesARedeemableConvertiblePreferredStockMemberus-gaap:PreferredStockMember2022-12-310001642380us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2024-01-012024-09-300001642380us-gaap:CommonStockMemberus-gaap:PrivatePlacementMember2024-04-152024-04-150001642380ocx:SalesAgreementMember2024-01-012024-09-300001642380ocx:ExpenseIncludedInDiscontinuedOperationsMember2023-01-012023-09-300001642380ocx:PharmaServicesMember2024-07-012024-09-300001642380us-gaap:CommonStockMembercox:SecuritiesPurchaseAgreementMembercox:BroadwoodPartnersLPMember2024-04-152024-04-150001642380ocx:MPEEMValuationApproachMember2024-01-012024-09-300001642380ocx:InsightGeneticsIncMemberus-gaap:FairValueInputsLevel3Member2023-09-300001642380us-gaap:FairValueInputsLevel3Membercox:InsightGeneticsIncMembersrt:MinimumMemberus-gaap:MeasurementInputExpectedTermMember2024-01-012024-09-300001642380ocx:SeriesARedeemableConvertiblePreferredStockMemberus-gaap:PreferredStockMember2024-01-012024-09-300001642380us-gaap:FairValueInputsLevel3Membercox:InsightGeneticsIncMembersrt:MaximumMemberus-gaap:MeasurementInputExpectedTermMember2023-01-012023-09-300001642380ocx:MonteCarloValuationTechniqueMembersrt:MinimumMember2023-08-012023-08-310001642380ocx:PharmaServicesMember2024-09-300001642380us-gaap:CommonStockMembercox:UnderwrittenOfferingMembercox:PuraVidaInvestmentsLLCMember2022-04-122022-04-1300016423802024-01-012024-09-300001642380us-gaap:SeriesAPreferredStockMembercox:SecuritiesPurchaseAgreementMembercox:MrGutfreundMember2022-04-122022-04-130001642380ocx:TwoThousandEighteenIncentivePlanMember2024-09-300001642380ocx:OtherInvestorsMembercox:RegisteredDirectOfferingMember2023-04-030001642380us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001642380ocx:SeriesARedeemableConvertiblePreferredStockMembercox:SecuritiesPurchaseAgreementMember2024-04-152024-04-1500016423802023-08-012023-08-310001642380ocx:SeriesARedeemableConvertiblePreferredStockMemberus-gaap:PreferredStockMember2023-12-310001642380ocx:CustomerTwoMemberus-gaap:AccountsReceivableMembercox:PharmaServicesMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-12-310001642380ocx:SecuritiesPurchaseAgreementMember2024-04-152024-04-150001642380us-gaap:WarrantMember2017-02-280001642380us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-300001642380us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001642380ocx:SalesAgreementMember2024-08-090001642380ocx:PharmaServicesMember2023-07-012023-09-300001642380ocx:CostOfRevenuesMember2023-01-012023-09-300001642380us-gaap:SalesRevenueNetMembercox:PharmaServicesCompanyAMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-09-300001642380ocx:BioRadLaboratoriesIncMember2023-12-310001642380us-gaap:StockOptionMember2024-01-012024-09-300001642380us-gaap:FairValueInputsLevel3Membercox:ChronixMergerMember2024-01-012024-09-300001642380ocx:TwoThousandTenPlanAndTwoThousandEighteenIncentivePlanActivityMember2024-01-012024-09-300001642380us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001642380ocx:MonthlyRentMembercox:OfficeSubleaseAgreementMember2024-01-012024-09-300001642380us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMembersrt:MaximumMembercox:ChronixMergerMember2023-09-300001642380srt:MaximumMember2024-09-300001642380us-gaap:GeneralAndAdministrativeExpenseMember2023-07-012023-09-300001642380ocx:PreFundedWarrantMember2024-09-300001642380ocx:LaboratoryDevelopedTestServicesMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2023-07-012023-09-300001642380ocx:TwoThousandTenPlanAndTwoThousandEighteenIncentivePlanActivityMember2024-09-300001642380us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMembersrt:MaximumMembercox:ChronixMergerMember2024-09-300001642380ocx:SeriesARedeemableConvertiblePreferredStockMemberus-gaap:PreferredStockMember2023-01-012023-09-3000016423802022-12-310001642380us-gaap:FairValueInputsLevel3Membersrt:MinimumMembercox:ChronixMergerMemberus-gaap:MeasurementInputExpectedTermMember2024-01-012024-09-300001642380ocx:MPEEMValuationApproachMember2023-03-312023-03-310001642380us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300001642380us-gaap:CustomerRelationshipsMember2024-01-012024-09-300001642380us-gaap:EquipmentMembersrt:MaximumMember2024-09-300001642380ocx:LeaseAgreementMembercox:MPCHoldingsLLCMember2024-01-012024-09-300001642380ocx:SubleasePeriodOneMembercox:OfficeSubleaseAgreementMember2024-01-012024-09-300001642380us-gaap:InProcessResearchAndDevelopmentMembercox:DetermaCNIAndVitaGraftMember2024-01-012024-09-300001642380ocx:BoardMembersMembercox:RegisteredDirectOfferingMember2023-04-030001642380ocx:LaboratoryDevelopedTestServicesMember2022-12-310001642380us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMembercox:PharmaServicesMember2024-01-012024-09-300001642380ocx:InsightGeneticsIncMemberus-gaap:FairValueInputsLevel3Membersrt:MaximumMemberus-gaap:MeasurementInputExpectedTermMember2024-01-012024-09-300001642380ocx:LaboratoryDevelopedTestServicesMember2023-03-310001642380ocx:TwoThousandTenPlanAndTwoThousandEighteenIncentivePlanActivityMember2023-01-012023-09-300001642380ocx:SubleasePeriodThreeMembercox:OfficeSubleaseAgreementMember2024-01-012024-09-300001642380ocx:PerformanceBasedOptionsMember2023-08-012023-08-310001642380ocx:OfficeSubleaseAgreementMember2024-09-300001642380us-gaap:CommonStockMember2024-06-300001642380us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-09-300001642380us-gaap:StockOptionMember2024-07-012024-09-300001642380us-gaap:CommonStockMembercox:BioRadLaboratoriesIncMembercox:SecuritiesPurchaseAgreementMember2024-04-152024-04-150001642380us-gaap:CommonStockMembercox:AVMMembercox:SecuritiesPurchaseAgreementMember2023-04-032023-04-030001642380us-gaap:CommonStockMemberus-gaap:PrivatePlacementMember2024-04-150001642380us-gaap:RestrictedStockUnitsRSUMember2023-07-012023-09-300001642380ocx:InsightGeneticsIncMember2024-09-300001642380us-gaap:StockOptionMember2023-01-012023-09-300001642380us-gaap:SeriesAPreferredStockMembercox:RegisteredDirectOfferingMember2024-04-152024-04-150001642380us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2023-01-012023-09-300001642380ocx:OperatingAndFinancingLeasesMember2024-09-3000016423802023-06-300001642380us-gaap:RetainedEarningsMember2024-06-300001642380us-gaap:CommonStockMembercox:BroadwoodCapitalLPMembercox:UnderwrittenOfferingMember2022-04-122022-04-130001642380ocx:UnderwritersMembercox:HalleSpecialSituationsFundLLCMembercox:UnderwrittenOfferingMember2022-04-122022-04-130001642380srt:ScenarioPreviouslyReportedMember2023-09-300001642380us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMembercox:OutsideOfUnitedStatesMembercox:PharmaServicesMember2024-07-012024-09-300001642380ocx:UnderwritersMembercox:UnderwrittenOfferingMembercox:PuraVidaInvestmentsLLCMember2022-04-122022-04-130001642380srt:MaximumMembercox:RegisteredDirectOfferingMember2023-04-032023-04-030001642380ocx:SubleasePeriodTwoMembercox:OfficeSubleaseAgreementMember2024-01-012024-09-300001642380us-gaap:RetainedEarningsMember2024-07-012024-09-300001642380us-gaap:SeriesAPreferredStockMembercox:BroadwoodCapitalLPMembercox:SecuritiesPurchaseAgreementMember2022-04-122022-04-130001642380ocx:CustomerTwoMemberus-gaap:AccountsReceivableMembercox:PharmaServicesMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-09-300001642380country:DE2023-12-310001642380ocx:LaboratoryDevelopedTestServicesMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMembercountry:US2024-07-012024-09-300001642380us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMembercox:PharmaServicesMember2024-07-012024-09-300001642380us-gaap:FairValueInputsLevel3Membercox:InsightGeneticsIncMemberus-gaap:MeasurementInputDiscountRateMembersrt:MaximumMember2024-09-300001642380ocx:RazorStockPurchaseAgreementMembercox:DragonScientificLLCMembercox:RazorGenomicsIncMember2023-02-160001642380ocx:PreFundedWarrantMembercox:SecuritiesPurchaseAgreementMember2024-04-152024-04-150001642380ocx:LeaseAgreementMember2021-08-270001642380ocx:SeriesARedeemableConvertiblePreferredStockMemberus-gaap:PreferredStockMember2023-06-3000016423802023-07-242023-07-240001642380ocx:SeriesARedeemableConvertiblePreferredStockMember2023-12-310001642380ocx:SecuritiesPurchaseAgreementMemberus-gaap:SubsequentEventMember2024-10-042024-10-040001642380ocx:ChronixMember2024-01-012024-09-300001642380us-gaap:FairValueInputsLevel3Membercox:ChronixMergerMember2023-01-012023-09-300001642380ocx:RazorStockPurchaseAgreementMembercox:DragonScientificLLCMembercox:RazorGenomicsIncMember2022-12-150001642380us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001642380us-gaap:SellingAndMarketingExpenseMember2023-07-012023-09-300001642380us-gaap:WarrantMember2024-01-012024-09-300001642380us-gaap:SellingAndMarketingExpenseMember2024-07-012024-09-300001642380ocx:BioRadLaboratoriesIncMembercox:LaboratoryEquipmentMember2024-01-012024-09-300001642380us-gaap:RetainedEarningsMember2023-12-310001642380us-gaap:InProcessResearchAndDevelopmentMembercox:DetermaIOMember2024-01-012024-09-3000016423802024-07-012024-09-300001642380us-gaap:CommonStockMembercox:SecuritiesPurchaseAgreementMember2023-04-032023-04-030001642380ocx:LaboratoryDevelopedTestServicesMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2024-07-012024-09-300001642380ocx:RazorStockPurchaseAgreementMembercox:RazorGenomicsIncMember2023-01-012023-03-310001642380us-gaap:CommonStockMembercox:AVMMembercox:SecuritiesPurchaseAgreementMember2024-04-152024-04-150001642380us-gaap:RetainedEarningsMember2023-09-300001642380ocx:LaboratoryDevelopedTestServicesMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMembercountry:US2024-01-012024-09-300001642380ocx:LeaseAgreementMember2023-01-012023-12-310001642380ocx:InsightGeneticsIncMemberus-gaap:FairValueInputsLevel3Membersrt:MinimumMemberus-gaap:MeasurementInputExpectedTermMember2023-01-012023-09-300001642380us-gaap:ResearchMemberus-gaap:CaliforniaFranchiseTaxBoardMembersrt:MaximumMember2024-06-270001642380ocx:MPCHoldingsLLCMembercox:LeaseAgreementMember2024-01-010001642380us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMembercox:PharmaServicesMembercountry:US2024-01-012024-09-300001642380us-gaap:CommonStockMember2023-01-012023-09-300001642380us-gaap:CommonStockMember2024-04-150001642380ocx:MonteCarloValuationTechniqueMember2023-08-012023-08-310001642380ocx:MonteCarloValuationTechniqueMembersrt:MaximumMember2023-08-012023-08-3100016423802024-09-300001642380srt:MinimumMember2024-09-300001642380ocx:OfficeLeaseAgreementMember2019-12-230001642380us-gaap:FairValueInputsLevel3Membersrt:MinimumMembercox:ChronixMergerMemberus-gaap:MeasurementInputExpectedTermMember2023-01-012023-09-300001642380us-gaap:CommonStockMembercox:ArnoMembercox:SecuritiesPurchaseAgreementMember2024-04-152024-04-150001642380us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300001642380ocx:MPEEMValuationApproachMember2023-03-310001642380ocx:InsightGeneticsIncMembercox:MilestoneTwoMember2024-09-300001642380ocx:TwoThousandTenPlanAndTwoThousandEighteenIncentivePlanActivityMember2023-01-012023-12-310001642380ocx:LeaseAgreementMembercox:MPCHoldingsLLCMember2024-09-300001642380us-gaap:InProcessResearchAndDevelopmentMembercox:DetermaCNIAndVitaGraftMember2023-01-012023-12-310001642380us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMembersrt:MinimumMembercox:ChronixMergerMember2024-09-300001642380ocx:LeaseAgreementMember2024-01-012024-09-300001642380ocx:LaboratoryDevelopedTestServicesMember2023-07-012023-09-300001642380ocx:SubleasePeriodFourMembercox:OfficeSubleaseAgreementMember2024-01-012024-09-300001642380us-gaap:WarrantMember2017-03-310001642380ocx:OfficeSubleaseAgreementMember2023-08-080001642380us-gaap:CommonStockMembercox:SecuritiesPurchaseAgreementMembercox:PuraVidaMember2023-04-032023-04-0300016423802023-01-012023-12-310001642380us-gaap:FairValueInputsLevel3Membercox:InsightGeneticsIncMembercox:MeasurementInputManagementProbabilityEstimateMembersrt:MinimumMember2024-09-300001642380us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300001642380ocx:CostOfRevenuesMember2023-07-012023-09-300001642380ocx:PharmaServicesMember2024-01-012024-09-30xbrli:pureurt:sqftiso4217:USDxbrli:sharesxbrli:sharesiso4217:USD Á Á UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Á FORM 10-Q Á Á QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Á For the quarterly period ended September 30, 2024 OR Á Á TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Á For the transition period from to Á Commission File Number: 1-37648 Á Oncocyte Corporation (Exact name of registrant as specified in its charter) Á California Á 27-1041563 (State or other jurisdiction Á (I.R.S. Employer of incorporation or organization) Á Identification No.) Á 15 Cushing Irvine, California 92618 (Address of principal executive offices) (Zip Code) Á (949) 409-7600 (Registrant's telephone number, including area code) Á N/A (Former name, former address and former fiscal year, if changed since last report) Á Securities registered pursuant to Section 12(b) of the Exchange Act: Á Title of each class Á Trading Symbol Á Name of each exchange on which registered Common Stock, no par value Á OCX Á The Nasdaq Á Stock Market LLC Á Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Á Yes Á No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Á§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Á Yes Á No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of Álarge accelerated filer,Á Áaccelerated filer,Á Ásmaller reporting company,Á Áemerging growth companyÁ Á In Rule 12b-2 of the Exchange Act. Á Large accelerated filer Á Accelerated filer Á Non-accelerated filer Á Smaller reporting company Á Emerging growth company Á Á If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Á Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Á Yes Á No The number of shares of common stock outstanding as of November 5, 2024 was 16,835,247. Á Á ONCYCOTE CORPORATION TABLE OF CONTENTS Á For the quarterly period ended September 30, 2024 Á Á Page CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 3 Á PART I - FINANCIAL INFORMATION 4 Á Item 1. Financial Statements 4 CONDENSED CONSOLIDATED BALANCE SHEETS 4 UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS 5 UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS 6 UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF SERIES A REDEEMABLE CONVERTIBLE PREFERRED STOCK AND SHAREHOLDERS' EQUITY 7 UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS 9 NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 10 Á Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 44 Á Item 3. Quantitative and Qualitative Disclosures about Market Risk 56 Á Item 4. Controls and Procedures 56 Á PART II - OTHER INFORMATION 57 Á Item 1. Legal Proceedings 57 Á Item 1A. Risk Factors 57 Á Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 58 Á Item 3. Defaults Upon Senior Securities 58 Á Item 4. Mine Safety Disclosures 58 Á Item 5. Other Information 59 Á Item 6. Exhibits 60 Á SIGNATURES 61

[illegible]

test that assesses the tumor microenvironment to predict response to immunotherapies, and the pipeline test DetermaCNIâ, is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients.Razor TransactionsOncocyteâ™s first product for commercial release was a proprietary treatment stratification test called DetermaRx that identifies which patients with early-stage non-small cell lung cancer may benefit from chemotherapy, resulting in a significantly higher, five-year survival rate. Beginning in September 2019 through February 23, 2021, Oncocyte held a 25% equity interest in Razor Genomics, Inc. (â€œRazorâ€), a privately held company, that had developed and licensed to Oncocyte the lung cancer treatment stratification laboratory test that Oncocyte was commercializing as DetermaRx. On February 24, 2021, Oncocyte completed the purchase of all the remaining issued and outstanding shares of common stock of Razor. As a result of the purchase of the Razor common stock, Oncocyte became the sole shareholder of Razor.On December 15, 2022, the Company entered into a Stock Purchase Agreement (the â€œRazor Stock Purchase Agreementâ€) with Dragon Scientific, LLC, a Delaware limited liability company (â€œDragonâ€), and Razor. Pursuant to the Razor Stock Purchase Agreement, Oncocyte agreed to sell to Dragon, 3,188,181 shares of common stock of Razor, which constituted approximately 70% of the issued and outstanding equity interests of Razor on a fully-diluted basis, and transfer to Razor all of the assets and liabilities related to DetermaRx (the â€œRazor Sale Transactionâ€).On February 16, 2023, Oncocyte completed the Razor Sale Transaction (the â€œRazor Closingâ€). In connection with the Razor Closing, Oncocyte transferred to Razor all of the assets and liabilities related to DetermaRx. While no monetary consideration was received for the sale of 70% of the equity interests of Razor, the transaction allowed the Company to eliminate all development and commercialization costs with respect to DetermaRx. Following the Razor Closing, Oncocyte continues to own 1,366,364 shares of common stock of Razor, which constitutes approximately 30% of the issued and outstanding equity interests of Razor on a fully-diluted basis.As a result of the divestiture of Razor, the Company has reflected the 2023 operations of Razor as a discontinued operation. See Note 11, â€œDiscontinued Operations of Razorâ€ for additional information.Going ConcernOncocyte has incurred operating losses and negative cash flows since inception and had an accumulated deficit of \$317.0 million as of September 30, 2024. Oncocyte expects to continue to incur operating losses and negative cash flows for the foreseeable future. Since its formation, Oncocyte has financed its operations primarily through the sale of shares of its common stock, convertible preferred stock and warrants to acquire common stock. As of September 30, 2024, Oncocyte had \$3.4 million of cash and cash equivalents. On October 4, 2024, we raised additional capital as discussed below.As of September 30, 2024, Oncocyte is completing clinical development and planning commercialization of DetermaIO, although DetermaIO is currently available for biopharma diagnostic development and RUO as a companion test in immunotherapy drug development to select patients for clinical trials. Oncocyte received a positive coverage decision from MoLDx for VitaGraft Kidney in August of 2023, and it became commercially available for ordering in January 2024 through Oncocyteâ™s Clinical Laboratory Improvements Amendment (â€œCLIAâ€) Laboratory in Nashville, Tennessee. VitaGraft Kidney is now broadly available to transplant professionals upon request. In July 2024, Oncocyte began to commercialize the technology underlying VitaGraft Kidney by distributing its sister product, GraftAssure, which is intended to be sold and used for research purposes and is labeled as RUO. Oncocyte expects to distribute its RUO production through a mix of direct sales, partnering and distribution agreements, and licensing.On April 5, 2024, the Company entered into an agreement with Bio-Rad Laboratories, Inc. (â€œBio-Radâ€), our global strategic partner, to collaborate in the development and the commercialization of RUO and in vitro diagnostic (â€œIVDâ€) kitted transplant products. See Note 10, â€œCollaborative Arrangementsâ€ for additional information. On November 8, 2024, the Company and Bio-Rad entered into a memorandum of understanding with respect to such agreement to establish additional activities to be performed by each party pursuant to such agreement (see Note 10 for additional information). 10 ONCOCYTE CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTSâ Prior Period Revisionsâ On April 15, 2024, the Company consummated a private placement of its securities to certain accredited investors (the â€œApril 2024 Offeringâ€). The resulting net proceeds were approximately \$9.9 million, after deducting offering expenses of \$538,000 and deducting \$5.4 million for the redemption of all remaining shares of the Company's Series A Redeemable Convertible Preferred Stock. These net proceeds are inclusive of an investment from Bio-Rad (see Note 9), our aforementioned global strategic partner. See Note 7, â€œCommon Stock â€ April 2024 Offeringâ€ for additional information.On August 1, 2024, the Company filed a shelf registration statement on Form S-3, pursuant to which it registered for sale up to \$100.0 million of any combination of its common stock, preferred stock, warrants and/or units from time to time and at prices and on terms that it may determine (the â€œPrimary Shelf Registration Statementâ€). On August 9, 2024, the Company entered into a sales agreement with a sales agent, pursuant to which the Company may offer and sell from time to time up to an aggregate of \$7.5 million of shares of the Companyâ™s common stock, registered on the Primary Shelf Registration Statement, through the sales agent through an at-the-market facility (the â€œAugust 2024 Offeringâ€). As of September 30, 2024, net proceeds to the Company from the sale of such shares were approximately \$17,000. See Note 7, â€œCommon Stock â€ August 2024 Offeringâ€ for additional information.On October 4, 2024, the Company consummated a private placement of its securities to certain accredited investors (the â€œOctober 2024 Offeringâ€). The gross proceeds from the October 2024 Offering were approximately \$10.2 million. After deducting placement agent fees and expenses and offering expenses payable by the Company of \$795,000, the resulting net proceeds were approximately \$9.4 million. These net proceeds are inclusive of an investment from Bio-Rad (see Note 9), our aforementioned global strategic partner. See Note 12, â€œSubsequent Eventsâ€ for additional information.In addition to general economic and capital market trends and conditions, Oncocyteâ™s ability to raise sufficient additional capital to finance its operations from time to time will depend on a number of factors specific to Oncocyteâ™s operations such as operating revenues and expenses, progress in our collaborative arrangement for the development and the commercialization of RUO and IVD kitted transplant products, progress in obtaining regulatory approval to distribute our products for clinical use, and progress in the development of, or in obtaining reimbursement coverage from Medicare for DetermaIO and other future laboratory tests that Oncocyte may develop or acquire.The unavailability or inadequacy of financing or revenues to meet future capital needs could force Oncocyte to modify, curtail, delay, or suspend some or all aspects of planned operations. Sales of additional equity securities could result in the dilution of the interests of Oncocyte's current stockholders. Oncocyte cannot assure that adequate long-term financing will be available on favorable terms, if at all.In accordance with Accounting Standards Codification (â€œASCâ€) 205-40, Going Concern, we evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern within one year after the date that the consolidated financial statements included in this Report are issued. This evaluation initially does not take into consideration the potential mitigating effect of our plans that have not been fully implemented as of the date the consolidated financial statements included in this Report are issued. When substantial doubt exists under this methodology, we evaluate whether the mitigating effect of our plans sufficiently alleviates substantial doubt about our ability to continue as a going concern. The mitigating effect of our plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that such financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about our ability to continue as a going concern within one year after the date that such financial statements are issued. In performing this analysis, we excluded certain elements of our operating plan that cannot be considered probable.Our expectation to generate operating losses and negative operating cash flows in the future and the need for additional funding to support our planned operations raise substantial doubt regarding our ability to continue as a going concern for a period of one year after the date that the consolidated financial statements are issued. Management intends to complete additional equity financings while maintaining reduced spending levels. However, due to several factors, including those outside managementâ™s control, there can be no assurance that we will be able to complete additional equity financings. If we are unable to complete additional financings, managementâ™s plans include further reducing or delaying operating expenses. We have concluded the likelihood that our plan to successfully obtain sufficient funding from one or more of these sources or adequately reduce expenditures, while reasonably possible, is less than probable. Accordingly, we have concluded that substantial doubt exists about our ability to continue as a going concern for a period of at least one year from the date of issuance of these consolidated financial statements.â 11 ONCOCYTE CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTSâ The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above. 2. Summary of Significant Accounting PoliciesAccounting PrinciplesThe consolidated financial statements and accompanying notes are prepared on the accrual basis of accounting in accordance with U.S. generally accepted accounting principles (â€œGAAPâ€).Principles of Consolidation and Basis of PresentationThe unaudited condensed consolidated interim financial statements presented herein have been prepared in accordance with GAAP for financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. In accordance with those rules and regulations, certain information and footnote disclosures normally included in comprehensive consolidated financial statements may have been condensed or omitted. The consolidated balance sheet as of December 31, 2023 was derived from the audited consolidated financial statements at that date. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in Oncocyteâ™s Annual Report on Form 10-K for the year ended December 31, 2023. The accompanying unaudited condensed consolidated financial statements, in the opinion of management, include all adjustments of a normal recurring nature necessary for a fair presentation of Oncocyteâ™s financial condition and results of operations. The consolidated results of operations are not necessarily indicative of the results to be expected for any other interim period or for the entire year. On January 31, 2020, with the acquisition of Insight Genetics, Inc. (â€œInsightâ€) through a merger with a newly incorporated wholly-owned subsidiary of Oncocyte (the â€œInsight Mergerâ€) under the terms of an Agreement and Plan of Merger (the â€œInsight Merger Agreementâ€), Insight became a wholly-owned subsidiary of Oncocyte, and on that date Oncocyte began consolidating Insightâ™s operations and results with Oncocyteâ™s operations and results (see Note 3).On April 15, 2021, with the acquisition of Chronix Biomedical, Inc. (â€œChronixâ€) pursuant to an Agreement and Plan of Merger dated February 2, 2021, amended February 23, 2021, and amended and restated as of April 15, 2021 (as amended and restated, the â€œChronix Merger Agreementâ€), by and among Oncocyte, CNI Monitor Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Oncocyte (â€œMerger Subâ€), Chronix became a wholly-owned subsidiary of Oncocyte (the â€œChronix Mergerâ€), and on that date Oncocyte began consolidating Chronixâ™s operations and results with Oncocyteâ™s operations and results (see Note 3).All material intercompany accounts and transactions have been eliminated in consolidation.We have reflected the 2023 operations of Razor as discontinued operations. See Note 11 for further information. Amounts and disclosures throughout these notes to consolidated financial statements relate solely to continuing operations and exclude all discontinued operations, unless otherwise noted. Discontinued operations comprise activities that were disposed of or discontinued at the end of the period, represent a separate major line of business that can be clearly distinguished for operational and financial reporting purposes and represent a strategic business shift having a major effect on the Companyâ™s operations and financial results.On July 24, 2023, the Company implemented a 1-for-20 reverse stock split of the outstanding shares of its common stock. The par value per share and the authorized number of shares of common stock and preferred stock were not adjusted as a result of the reverse stock split. All common stock share and per-share amounts for all periods presented in these consolidated financial statements have been adjusted to reflect the reverse stock split. The number of authorized shares of common stock remains at 230,000,000 shares.ReclassificationsCertain prior period amounts in the consolidated financial statements and notes to consolidated financial statements have been reclassified to conform to the current period presentation. Included in such prior period amounts is contingent consideration liabilities, current, which was previously presented in the noncurrent balance. These changes had no impact on the previously reported consolidated financial condition, results of operations or cash flows.â 12 ONCOCYTE CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTSâ Prior Period RevisionsIn connection with the preparation of the Companyâ™s consolidated financial statements for the year ended December 31, 2023, the Company recorded certain adjustments that impacted previously reported financial statement amounts from the period ended September 30, 2023. As further discussed below in â€œRevenue Recognition â€ Laboratory Developed Test Services â€ Allowance for Credit Losses,â€ as a result of the January 1, 2023 adoption of the new current expected credit loss accounting policy, the Company adjusted its accounts receivable. In addition, the Company reclassified cash sold in discontinued operations from an operating cash outflow to an investing cash outflow. See Note 11, â€œDiscontinued Operations of Razorâ€ for additional information. The following are the relevant line items from the Companyâ™s prior period consolidated financial statements illustrating the effect of the revisions to the period presented:â ¤ ¤ For the Period Ended September 30, 2023 â ¤ As Previously Reported â ¤ Adjustment â ¤ As Adjusted â ¤ (In thousands) â ¤ Balance Sheet and Shareholders' Equity: â ¤ â ¤ â ¤ â ¤ Accounts receivable, net at January 1, 2023 (Note 2) â ¤ 2,012 â ¤ 1,419 â ¤ 593 â ¤ Accumulated deficit at January 1, 2023 â ¤ (260,676) â ¤ (1,419) â ¤ (262,095) â ¤ Total Shareholders' equity at January 1, 2023 â ¤ 34,292 â ¤ (1,419) â ¤ 32,873 â ¤ Statement of Cash Flows: â ¤ â ¤ â ¤ â ¤ Loss on disposal of discontinued operations â ¤ 1,659 â ¤ (138) â ¤ 1,521 â ¤ Net cash used in operating activities â ¤ (18,763) â ¤ (138) â ¤ (18,901) â ¤ Cash sold in discontinued operations (Note 11) â ¤ (1,510) â ¤ 138 â ¤ (1,372) â ¤ Net cash used in investing activities â ¤ (1,173) â ¤ 138 â ¤ (1,035) â ¤ Use of EstimatesThe preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and contingent assets and liabilities, at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates estimates which are subject to significant judgment, including, but not limited to, valuation methods used, assumptions requiring the use of judgment to prepare financial projections and forecasted financial information, timing of potential commercialization of acquired in-process intangible assets, applicable discount rates, probabilities of the likelihood of multiple outcomes of certain events related to contingent consideration, comparable companies or transactions, determination of fair value of the assets acquired and liabilities assumed (including those relating to contingent consideration), the carrying value of goodwill and other intangibles, impairments, assumptions related to going concern assessments, revenue recognition, allocation of direct and indirect expenses, useful lives associated with long-lived intangible and other assets, key assumptions in operating and financing leases including incremental borrowing rates, loss contingencies, valuation allowances related to deferred income taxes, allowances for credit losses, and assumptions used to value stock-based awards and other equity instruments. These assessments are made in the context of information reasonably available to Oncocyte. Actual results may differ materially from those estimates.SegmentsOncocyteâ™s executive management team, as a group, represents the entityâ™s chief operating decision makers. To date, Oncocyteâ™s executive management team has viewed Oncocyteâ™s operations as one segment that includes the research, development and commercialization of diagnostic tests, including molecular diagnostic services to pharmaceutical customers. As a result, the financial information disclosed materially represents all of the financial information related to Oncocyteâ™s sole operating segment.â 13 ONCOCYTE CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTSâ Fair Value Measurements, Business Combinations and Contingent Consideration LiabilitiesOncocyte accounts for business combinations in accordance with ASC 805, which requires the purchase consideration transferred to be measured at fair value on the acquisition date in accordance with ASC 820, Fair Value Measurement. ASC 820 establishes a single authoritative definition of fair value, sets out a framework for measuring fair value and expands on required disclosures about fair value measurement. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. ASC 820 describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value, which are the following:â ¤Level 1 â ¤ Quoted prices in active markets for identical assets and liabilities.â ¤Level 2 â ¤ Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted market prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.â ¤Level 3 â ¤ Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Such inputs reflect managementâ™s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. Management estimates include certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs, including the entityâ™s own assumptions in determining fair value.When a part of the purchase consideration consists of shares of Oncocyte common stock, Oncocyte calculates the purchase price attributable to those shares, a Level 1 security, by determining the fair value of those shares as of the acquisition date based on prices quoted on the principal national securities exchange on which the shares traded. Oncocyte recognizes estimated fair values of the tangible assets and identifiable intangible assets acquired, including in-process research and development (â€œIPR&Dâ€), and liabilities assumed, including any contingent consideration, as of the acquisition date. Goodwill is recognized as any amount of excess consideration transferred over the fair

value of the tangible and identifiable intangible assets acquired net of the liabilities assumed. ASC 805 precludes the recognition of an assembled workforce as an asset, effectively subsuming any assembled workforce value into goodwill. In determining fair value, Oncocyte utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, and also considers counterparty credit risk in its assessment of fair value. For the periods presented, Oncocyte has no financial assets recorded at fair value on a recurring basis, except for money market funds. These assets are measured at fair value using the period-end quoted market prices as a Level 1 input. Certain of Oncocyte's asset and business acquisitions involve the potential for future payment of consideration to third-parties and former selling shareholders in amounts determined as a percentage of future net revenues generated, or upon attainment of revenue milestones, from Pharma Services or laboratory tests, as applicable, or annual minimum royalties to certain licensors, as provided in the applicable agreements. The fair value of such liabilities is determined using unobservable inputs. These inputs include the estimated amount and timing of projected cash flows and the risk-adjusted discount rate used to present value the cash flows. These obligations are referred to as contingent consideration, which are carried at fair value based on Level 3 inputs on a recurring basis. ASC 805 requires that contingent consideration be estimated and recorded at fair value as of the acquisition date as part of the total consideration transferred. Contingent consideration is an obligation of the acquirer to transfer additional assets or equity interests to the selling shareholders in the future if certain future events occur or conditions are met, such as the attainment of product development milestones. Contingent consideration also includes additional future payments to selling shareholders based on achievement of components of earnings, such as earnings-out provisions or percentage of future revenues, including royalties paid to the selling shareholders based on a percentage of certain revenues generated. The fair value of contingent consideration after the acquisition date is reassessed by Oncocyte as changes in circumstances and conditions occur, with the subsequent change in fair value recorded in the consolidated statements of operations. Changes in key assumptions can materially affect the estimated fair value of contingent consideration liabilities and, accordingly, the resulting gain or loss that Oncocyte records in its consolidated financial statements. See Note 3 for a full discussion of these liabilities and additional Level 3 fair value disclosures. A 14 ONCOCYTE CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

The carrying amounts of cash and cash equivalents, restricted cash, net accounts receivable, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities approximate fair values because of the short-term nature of these items. In accordance with GAAP, from time to time, the Company measures certain assets at fair value on a nonrecurring basis. The Company reviews the carrying value of intangibles, including IPR&D (see Note 5), and other long-lived assets for indications of impairment at least annually. Refer to related discussions of impairments below. Cash, Cash Equivalents and Restricted Cash Oncocyte considers all highly liquid securities with original maturities of three months or less when purchased to be cash equivalents. For the periods presented, Oncocyte's cash equivalents are comprised of investments in AAA rated money market funds that invest in first-tier only securities, which primarily include domestic commercial paper and securities issued or guaranteed by the U.S. government or its agencies. Restricted cash relates to a bank letter of credit required under our office lease arrangement, refer to Note 6 for additional information. Marketable Equity Securities Oncocyte accounts for shares of public common stock it may hold as marketable equity securities in accordance with ASC 321-10, Investments in Equity Securities, as the shares have a readily determinable fair value quoted on national stock exchange. The securities are measured at fair value, with related gains and losses in the value of such securities recorded in the consolidated statements of operations in other income or expense, and are reported as current assets in the consolidated balance sheet based on the closing trading price of the security as of the date being presented. During the fourth quarter of 2023, Oncocyte sold its remaining marketable equity securities for an aggregate realized loss of approximately \$1.4 million. During the nine months ended September 30, 2023, Oncocyte recorded an unrealized gain on marketable equity securities of \$8,000. Investments in Privately Held Companies Oncocyte evaluates whether investments held in common stock of other companies require consolidation of the company under, first, the variable interest entity (VIE) model, and then under the voting interest model in accordance with accounting guidance for consolidations under ASC 810-10. If consolidation of the entity is not required under either the VIE model or the voting interest model, Oncocyte determines whether the equity method of accounting should be applied in accordance with ASC 323, Investments in Equity Method and Joint Ventures. The equity method applies to investments in common stock or in-substance common stock if Oncocyte exercises significant influence over, but does not control, the entity, where significant influence is typically represented by ownership of 20% or more, but less than majority ownership, of the voting interests of a company. Oncocyte initially records equity method investments at fair value on the date of the acquisition with subsequent adjustments to the investment balance based on Oncocyte's pro rata share of earnings or losses from the investment. Since February 16, 2023, Oncocyte continues to own an equity interest Razor, however, based on the Razor transactions as discussed in Note 1, the remaining common stock held is accounted for at historical cost less impairment, which is currently zero. Inventories Inventories include raw materials, work-in-process and finished goods and are valued at the lower of cost or net realizable value. In September 2024, the Company capitalized certain initial RUO inventory costs in connection with its collaboration arrangement with Bio-Rad to develop and commercialize its GraftAssure RUO kitted tests and eventual IVD kitted transplant testing products. See Note 10, Collaborative Arrangements for additional information. As of September 30, 2024, inventories, comprised primarily of raw materials, totaled \$232,000. A 15 ONCOCYTE CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Assets Held for Sale and Discontinued Operations Assets and liabilities are classified as held for sale when all of the following criteria for a plan of sale have been met: (1) management, having the authority to approve the action, commits to a plan to sell the assets; (2) the assets are available for immediate sale, in their present condition, subject only to terms that are usual and customary for sales of such assets; (3) an active program to locate a buyer and other actions required to complete the plan to sell the assets have been initiated; (4) the sale of the assets is probable and is expected to be completed within one year; (5) the assets are being actively marketed for a price that is reasonable in relation to their current fair value; and (6) actions required to complete the plan indicate that it is unlikely that significant changes to the plan will be made or the plan will be withdrawn. When all of these criteria have been met, the assets and liabilities are classified as held for sale in the consolidated balance sheet. Assets classified as held for sale are reported at the lower of their carrying value or fair value less costs to sell. Depreciation and amortization of assets ceases upon designation as held for sale. The Company has entered into various agreements to sell laboratory equipment. As a result, the Company classified the equipment as held for sale current assets in the consolidated balance sheets, as all the criteria of ASC subtopic 360-10, Property, Plant, and Equipment had been met. The equipment was written down to its fair value, less cost to sell, the remainder of which was \$32,000 and \$139,000 as of September 30, 2024 and December 31, 2023, respectively. During the nine months ended September 30, 2024 and 2023, the Company recorded an impairment loss on held for sale assets of \$169,000 and \$1.3 million, respectively, in the consolidated statements of operations. Discontinued operations comprise activities that were disposed of, discontinued or held for sale at the end of the period, represent a separate major line of business that can be clearly distinguished for operational and financial reporting purposes and represent a strategic business shift having a major effect on the Company's operations and financial results according to ASC Topic 205, Presentation of Financial Statements. Razor has been reflected as a discontinued operation in the 2023 consolidated financial statements. See Note 11, Discontinued Operations of Razor for additional information. Machinery and Equipment, Net, Financing Leases, Net, and Construction in Progress Machinery and equipment are stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally over a period of 3 to 10 years. For equipment purchased under financing leases, Oncocyte depreciates the equipment based on the shorter of the useful life of the equipment or the term of the lease, ranging from 3 to 5 years, depending on the nature and classification of the financing lease. Maintenance and repairs are expensed as incurred whereas significant renewals and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and the related accumulated depreciation are removed from the respective accounts and any resulting gain or loss is reflected in Oncocyte's results of operations. Construction in progress, comprised primarily of leasehold improvements under construction, is not depreciated until the underlying asset is placed into service. Intangible Assets In accordance with ASC 350, Intangibles, Goodwill and Other, IPR&D projects acquired in a business combination that are not complete as of the acquisition date are capitalized and accounted for as indefinite-lived intangible assets until completion or abandonment of the related research and development efforts. Upon successful completion of the project, the capitalized amount is amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts are written off immediately. Oncocyte considers various factors and risks for potential impairment of IPR&D assets, including the current legal and regulatory environment and the competitive landscape. Adverse clinical trial results, significant delays or inability to obtain local coverage determination (LCD) from the Centers for Medicare and Medicaid Services (CMS) for Medicare reimbursement for a diagnostic test, the inability to bring a diagnostic test to market and the introduction or advancement of competitors' diagnostic tests could result in partial or full impairment of the related intangible assets. Consequently, the eventual realized value of the IPR&D project may vary from its fair value at the date of acquisition, and IPR&D impairment charges may occur in future periods. During the period between completion or abandonment, the IPR&D assets will not be amortized but will be tested for impairment on an annual basis and between annual tests if Oncocyte becomes aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&D projects below their respective carrying amounts. Oncocyte does not have intangible assets with indefinite useful lives other than the acquired IPR&D discussed in Note 5, which as of September 30, 2024, has been partially impaired. A 16 ONCOCYTE CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Goodwill represents the excess of the purchase price over the fair value of net identifiable assets and liabilities. Goodwill, similar to IPR&D, is not amortized but is tested for impairment at least annually, or if circumstances indicate that it is more-likely-than-not that the carrying value of the associated reporting unit exceeds its fair value. Qualitative factors considered in this assessment include industry and market conditions, overall financial performance, and other relevant events and factors affecting Oncocyte's business. Based on the qualitative assessment, if it is determined that the fair value of goodwill is more-likely-than-not to be less than its carrying amount, the fair value of a reporting unit will be calculated and compared with its carrying amount and an impairment charge will be recognized for the amount that the carrying value exceeds the fair value. Oncocyte continues to operate in one segment and considered to be the sole reporting unit and, therefore, goodwill is tested for impairment at the enterprise level, when applicable. In accordance with ASC 350, we review and evaluate our long-lived assets, including intangible assets with finite lives, for impairment whenever events or changes in circumstances indicate that we may not recover their net book value. When applicable, we test goodwill for impairment on an annual basis in the fourth quarter of each year, and between annual tests, if indicators of potential impairment exist, using a fair-value approach. We typically use an income method to estimate the fair value of these assets, which is based on forecasts of the expected future cash flows attributable to the respective assets. Significant estimates and assumptions inherent in the valuations reflect a consideration of other marketplace participants and include the amount and timing of future cash flows (including expected growth rates). Estimates utilized in the projected cash flows include consideration of macroeconomic conditions, overall category growth rates, competitive activities, cost containment and margin expansion, Company business plans, the underlying product or technology life cycles, economic barriers to entry, and the discount rate applied to the cash flows. Unanticipated market or macroeconomic events and circumstances may occur, which could affect the accuracy or validity of the estimates and assumptions. Long-Lived Intangible Assets Long-lived intangible assets subject to amortization are stated at acquired cost, less accumulated amortization. We amortize intangible assets not considered to have an indefinite useful life using the straight-line method over their estimated period of benefit, which generally ranges from 1 to 9 years. Each reporting period, we evaluate the estimated remaining useful life of intangible assets and assess whether events or changes in circumstances warrant a revision to the remaining period of amortization or indicate that impairment exists. Long-lived intangible assets currently consist of acquired customer relationships with an estimated useful life of 5 years (see Note 5). Impairment of Long-Lived Assets Oncocyte assesses the impairment of long-lived assets whenever events or changes in circumstances indicate that such assets might be impaired and the carrying value may not be recoverable. Oncocyte's long-lived assets consist primarily of intangible assets, right-of-use assets for operating and financing leases, customer relationships, and machinery and equipment. If events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable and the expected undiscounted future cash flows attributable to the asset are less than the carrying amount of the asset, an impairment loss, equal to the excess of the carrying value of the asset over its fair value, is recorded. Leases Oncocyte accounts for leases in accordance with ASC 842, Leases. Oncocyte determines if an arrangement is a lease at inception. Leases are classified as either financing or operating, with classification affecting the pattern of expense recognition in the consolidated statements of operations. Under the available practical expedients for the adoption of ASC 842, Oncocyte accounts for the lease and non-lease components as a single lease component. Oncocyte recognizes right-of-use (ROU) assets and lease liabilities for leases with terms greater than twelve months in the consolidated balance sheet. ROU assets represent the right to use an underlying asset during the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most leases do not provide an implicit rate, Oncocyte uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. Oncocyte uses the implicit rate when it is readily determinable. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. Lease terms may include options to extend or terminate the lease when it is reasonably certain that Oncocyte will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Operating leases include office leases and related ROU lease liabilities, current and long-term, in the consolidated balance sheets. Financing leases include machinery and equipment and related financing lease liabilities, current and long-term, in the consolidated balance sheets. Oncocyte discloses the amortization of our operating lease ROU assets and payments as a net amount in the consolidated statements of cash flows. Oncocyte has entered into various operating and financing leases in accordance with ASC 842 as further discussed in Note 6. A 17 ONCOCYTE CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Accounting for Warrants Oncocyte determines the accounting classification of warrants it issues, as either liability or equity classified, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity, then in accordance with ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company's Own Stock. Under ASC 480, warrants are considered liability classified if the warrants are mandatorily redeemable, obligate Oncocyte to settle the warrants or the underlying shares by paying cash or other assets or warrants that must or may require settlement by issuing variable number of shares. If warrants do not meet liability classification under ASC 480, Oncocyte assesses the requirements under ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. This liability classification guidance also applies to financial instruments that may require cash or other form of settlement for transactions outside of the company's control and, in which the form of consideration to the warrant holder may not be the same as to all other shareholders in connection with the transaction. However, if a transaction is not within the company's control but the holder of the financial instrument can solely receive the same type or form of consideration as is being offered to all the shareholders in the transaction, then equity classification of the financial instrument is not precluded, if all other applicable equity classification criteria are met. After all relevant assessments, Oncocyte concludes whether the warrants are classified as liability or equity. Liability classified warrants require fair value accounting at issuance and subsequent to initial issuance with all changes in fair value after the issuance date recorded in the statements of operations. Equity classified warrants only require fair value accounting at issuance with no changes recognized subsequent to the issuance date. Based on the above guidance and, among other factors, the fact that our warrants cannot be cash settled under any circumstance but require share settlement, all of our outstanding warrants meet the equity classification criteria and have been classified as equity. Refer to Note 7 for details about our outstanding warrants. Revenue Recognition Pursuant to ASC 606, Revenue from Contracts with Customers, revenues are recognized when control of services performed is transferred to customers, in an amount that reflects the consideration Oncocyte expects to be entitled to in exchange for those services. ASC 606 provides for a five-step model that includes: (i) identifying the contract with a customer, (ii) identifying the performance obligations in the contract, (iii) determining the transaction price, (iv) allocating the transaction price to the performance obligations, and (v) recognizing revenue when, or as, an entity satisfies a performance obligation. Oncocyte determines transaction prices based on the amount of consideration we expect to receive for transferring the promised goods or services in the contract. Consideration may be fixed, variable, or a combination of both. The Company considers any constraints on the variable consideration and includes in the transaction price variable consideration to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The following table presents consolidated revenues by service: A Three Months Ended September 30, A Nine Months Ended September 30, A 2024 A 2023 A 2024 A 2023 A (In thousands) A Pharma Services A \$

\$ A \$ 423 Å \$ 373 Å \$ 1,160 Å Laboratory Developed Test Services Å Å æ“ Å Å Å 6 Å Å 22 Å Å 29 Å Total Å \$115 Å \$ 429 Å \$ 395 Å \$ 1,189 Å Å 18

ONCOCYTE CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTSÅ Pharma Services RevenueRevenues recognized include Pharma Services performed by Oncocyteæ™’s Insight and Chronix subsidiaries for its pharmaceutical customers, including testing for biomarker discovery, assay design and development, clinical trial support, and a broad spectrum of biomarker tests. These Pharma Services are generally performed under individual scope of work (â€œSOWâ€) arrangements or license agreements (together with SOW the â€œPharma Services Agreementsâ€) with specific deliverables defined by the customer. Pharma Services are performed on a (i) time and materials basis or (ii) per test completed basis.

Upon completion of the service to the customer in accordance with a Pharma Services Agreement, Oncocyte has the right to bill the customer for the agreed upon price (either on a per test or per deliverable basis) and recognizes Pharma Service revenue at that time. Insight identifies each service of its Pharma Service offering as a single performance obligation. Offerings include services such as recurring fees for project management, fees for storage and handling, pass through expenses for shipping or calibration, training, proficiency, reproducibility tests, etc. Chronix identifies the processing of test samples as a separate performance obligation (considered a series) within license agreements with customers.Completion of the service and satisfaction of the performance obligation is typically evidenced by acknowledgment of completed services, and access to the report or test made available to the customer or any other form or applicable manner of delivery defined in the Pharma Services Agreements. However, for certain SOWs under which work is performed pursuant to the customeræ™’s highly customized specifications, Oncocyte has the enforceable right to bill the customer for work completed, rather than upon completion of the SOW. For those SOWs, Oncocyte recognizes revenue over a period during which the work is performed using a formula that accounts for expended efforts, generally measured in labor hours, as a percentage of total estimated efforts for the completion of the SOW. As performance obligations are satisfied under the Pharma Services Agreements, any amounts earned as revenue and billed to the customer are included in accounts receivable. Any revenues earned but not yet billed to the customer as of the date of Oncocyteæ™’s consolidated financial statements are recorded as contract assets and are included in prepaids and other current assets as of the financial statement date. Amounts recorded in contract assets are reclassified to accounts receivable in Oncocyteæ™’s consolidated balance sheets when the customer is invoiced according to the billing schedule in the contract.As of September 30, 2024 and December 31, 2023, Oncocyte had gross accounts receivable from Pharma Services customers of \$211,000 and \$489,000, respectively.Allowance for Credit LossesOncocyte establishes an allowance for credit losses based on the evaluation of the collectability of its Pharma Services accounts receivables after considering a variety of factors, including the length of time receivables are past due, significant events that may impair the customeræ™’s ability to pay, such as a bankruptcy filing or deterioration in the customeræ™’s operating results or financial position, reasonable and supportable forecast that affect the collectability of the reported amount, and historical experience. If circumstances related to customers change, estimates of the recoverability of receivables would be further adjusted. Oncocyte continuously monitors collections and payments from customers and maintains a provision for estimated credit losses and uncollectible accounts, if any, based upon its historical experience and any specific customer collection issues that have been identified. Amounts determined to be uncollectible are written off against the credit loss reserve accounts. As of September 30, 2024 and December 31, 2023, Oncocyte had an allowance for credit losses of \$2,000 and \$5,000, respectively, related to Pharma Services.Laboratory Developed Test ServicesPrior to the Razor Sale Transaction, Oncocyte generated revenue from performing DetermaRx tests on clinical samples through orders received from physicians, hospitals, and other healthcare providers. In determining whether all the revenue recognition criteria in (i) through (v) above are met with respect to DetermaRx tests, each test result is considered a single performance obligation and is generally considered complete when the test result is delivered or made available to the prescribing physician electronically, and, as such, there are no shipping or handling fees incurred by Oncocyte or billed to customers. Although Oncocyte has billed a list price for all tests ordered and completed for all payer types, Oncocyte considers constraints on the variable consideration when recognizing revenue for DetermaRx. Because DetermaRx is a novel test and there are no current reimbursement arrangements with third-party payers other than Medicare, the transaction price represents variable consideration. Application of the constraint for variable consideration is an area that requires significant judgment. For all payers other than Medicare, Oncocyte must consider the novelty of the test, the uncertainty of receiving payment, or being subject to claims for a refund, from payers with whom it does not have a sufficient payment collection history or contractual reimbursement agreements. Accordingly, for those payers, Oncocyte has recognized revenue upon payment because it has had insufficient history to reliably estimate payment patterns.Å 19 ONCOCYTE CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTSÅ As of September 30, 2024 and December 31, 2023, Oncocyte had no accounts receivable from Medicare and Medicare Advantage covered DetermaRx tests. Laboratory Developed Test Services revenue recorded during the nine months ended September 30, 2024 was the result of payments received.Allowance for Credit LossesWe maintained an allowance for credit losses related to Laboratory Developed Test Services at an amount we estimated to be sufficient to provide adequate protection against losses resulting from extending credit to our customers. We based this allowance, in the aggregate, on historical collection experience, age of receivables and general economic conditions, as well as specific identification of uncollectible accounts. We initially established an allowance in 2022 in connection with remaining Medicare and Medicare Advantage account balances and continued to add to the allowance as appropriate. In the first quarter of 2023, in connection with the adoption of the new current expected credit loss model, the Company determined that the Medicare and Medicare Advantage accounts receivable net balance of approximately \$1.4 million was uncollectible and should therefore be written-off as of the adoption date, January 1, 2023. Refer to additional information above in â€œPrinciples of Consolidation and Basis of Presentation æ” Prior Period Revisions.Æ As of December 31, 2023, we had no allowance for credit losses related to Laboratory Developed Test Services. The 2023 allowance for credit losses activity included a beginning balance of \$154,000, no credit loss provisions, and the full write-off to an ending balance of zero as of December 31, 2023.Licensing RevenueRevenues that may be recognized include licensing revenue derived from agreements with customers for exclusive rights to market Oncocyteæ™’s proprietary testing technology. Under the agreements, Oncocyte grants exclusive rights to certain trademarks and technology of Oncocyte for the purpose of marketing Oncocyteæ™’s tests within a defined geographic territory. A license agreement may specify milestone deliverables or performance obligations, for which Oncocyte recognizes revenue when its licensee confirms the completion of Oncocyteæ™’s performance obligation. A licensing agreement may also include ongoing sales support from Oncocyte and typically includes non-refundable licensing fees and per-test Pharma Services revenues discussed above, for which Oncocyte treats the licensing of the technology, trademarks, and ongoing support as a single performance obligation satisfied by the passage of time over the term of the agreement.Disaggregation of Revenues and Concentrations of Credit RiskThe following table presents the percentage of consolidated revenues by service:Å Three Months EndedSeptember 30, Å Nine Months EndedSeptember 30, Å 2024 Å 2023 Å 2024 Å 2023 Å Pharma Services Å 100 % Å 99 % Å 94 % Å 98 %Laboratory Developed Test Services Å 0 % Å 1 % Å 6 % Å 2 %Total Å 100 % Å 100 % Å 100 % Å 100 % Å The following table presents the percentage of consolidated revenues generated by unaffiliated customers, based on the respective periods presented, that individually represented greater than ten percent of consolidated revenues:Å Three Months EndedSeptember 30, Å Nine Months EndedSeptember 30, Å 2024 Å 2023 Å 2024 Å 2023 Å Pharma services - Company A Å 74 % Å 57 % Å 37 % Å 42 %Pharma services - Company B Å 26 % Å 41 % Å 29 % Å 34 %Pharma services - Company C Å * Å * Å * Å 12 % Å * Å Pharma services - Company D Å * Å * Å * Å 11 % Å * Å * Less than 10% Å 20 ONCOCYTE CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTSÅ The following table presents the percentage of consolidated revenues attributable to geographical locations, based on country of domicile:Å Three Months EndedSeptember 30, Å Nine Months EndedSeptember 30, Å 2024 Å 2023 Å 2024 Å 2023 Å United States æ” Laboratoy Developed Test Services Å 0 % Å 1 % Å 6 % Å 4 %Total Å 100 % Å 100 % Å 100 % Å 100 % ÅAs of September 30, 2024 and December 31, 2023, the Company held long-lived tangible assets in Germany in the amount of \$392,000 and \$66,000, respectively.Financial instruments that potentially subject the Company to concentrations of credit risk are cash equivalents and accounts receivable. The Company places its cash equivalents primarily in highly rated money market funds. Cash and cash equivalents are also invested in deposits with certain financial institutions and may, at times, exceed federally insured limits. The Company has not experienced any significant losses on its deposits of cash and cash equivalents.Four Pharma Services customers individually represented approximately 51%, 20%, 17% and 12% of accounts receivable as of September 30, 2024. Two Pharma Services customers individually represented approximately 79% and 13% of accounts receivable as of December 31, 2023.Cost of RevenuesCost of revenues generally consists of cost of materials, direct labor including benefits, bonus and stock-based compensation, equipment and infrastructure expenses, clinical sample related costs associated with performing Pharma Services and Laboratory Developed Test Services, providing deliverables according to our licensing agreements, license fees due to third-parties, and amortization of acquired intangible assets such as the customer relationship intangible assets (see Note 5). Infrastructure expenses include depreciation of laboratory equipment, allocated rent costs, leasehold improvements, and allocated information technology costs for operations at Oncocyteæ™’s CLIA laboratory in Tennessee. Costs associated with generating the revenues are recorded as the tests or services are performed regardless of whether revenue was recognized. Royalties or revenue share payments for licensed technology calculated as a percentage of revenues generated using the associated technology are recorded as expenses at the time the related revenues are recognized.Research and Development ExpensesResearch and development expenses are comprised of costs incurred to develop technology, which include salaries and benefits (including stock-based compensation), laboratory expenses (including reagents and supplies used in research and development laboratory work), infrastructure expenses (including allocated facility occupancy costs), and contract services and other outside costs. Indirect research and development expenses are allocated primarily based on headcount, as applicable, and include rent and utilities, common area maintenance, telecommunications, property taxes and insurance. Research and development costs are expensed as incurred. Certain research and development expenses are attributed to our collaboration arrangement with Bio-Rad, our global strategic partner, for commercializing our RUO kitted tests and IVD kitted transplant testing products. See Note 10, â€œCollaborative Arrangementsâ€ for additional information.Sales and Marketing ExpensesSales and marketing expenses consist primarily of personnel costs and related benefits, including stock-based compensation, trade show expenses, branding and positioning expenses, and consulting fees. Sales and marketing expenses also include indirect expenses for applicable overhead allocated based on headcount, and include allocated costs for rent and utilities, common area maintenance, telecommunications, property taxes and insurance. During the three months ended September 30, 2024 and 2023, Oncocyteæ™’s total advertising expenses were \$40,000 and \$46,000, respectively. During the nine months ended September 30, 2024 and 2023, Oncocyteæ™’s total advertising expenses were \$123,000 and \$125,000, respectively. Certain sales and marketing expenses are attributed to our collaboration arrangement with Bio-Rad, our global strategic partner, for commercializing our RUO kitted tests and IVD kitted transplant testing products. See Note 10, â€œCollaborative Arrangementsâ€ for additional information.Å 21 ONCOCYTE CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTSÅ General and Administrative ExpensesGeneral and administrative expenses consist primarily of compensation and related benefits (including stock-based compensation) for executive and corporate personnel, professional and consulting fees, rent and utilities, common area maintenance, telecommunications, property taxes and insurance.Stock-Based CompensationOncocyte recognizes compensation expense related to employee, Board of Director and other non-employee option grants and restricted stock grants in accordance with ASC 718, Compensation æ” Stock Compensation.Oncocyte estimates the fair value of stock-based payment awards on the grant date and recognizes the resulting fair value over the requisite service period, which is generally a four-year vesting period. For stock-based awards that vest only upon the attainment of one or more performance goals set by Oncocyte at the time of the grant (sometimes referred to as milestone vesting), compensation cost is recognized if and when Oncocyte determines that it is probable that the performance condition or conditions will be, or have been, achieved. Oncocyte uses the Black-Scholes option pricing model for estimating the fair value of time-based options granted under Oncocyteæ™’s equity plan. The fair value of each restricted stock unit (â€œRSUâ€) or award is determined by the product of the number of units or shares granted and the grant date market price of the underlying common stock. Oncocyte has elected to treat stock-based payment awards with graded vesting schedules and time-based service conditions as a single award and recognizes stock-based compensation ratably on a straight-line basis over the requisite service period. Options have a maximum contractual term of ten years. Forfeitures are accounted for as they occur. Refer to Note 8 for additional information.The Black-Scholes option pricing model requires Oncocyte to make certain assumptions including the expected option term, the expected volatility, the risk-free interest rate and the dividend yield. The expected term of employee stock options represents the weighted average period that the stock options are expected to remain outstanding. Oncocyte estimates the expected term of options granted based on its own experience. Oncocyte estimates the expected volatility using its own stock price volatility for a period equal to the expected term of the options. The risk-free interest rate assumption is based upon observed interest rates on the United States government securities appropriate for the expected term of Oncocyteæ™’s stock options. The dividend yield assumption is based on Oncocyteæ™’s history and expectation of dividend payouts. Oncocyte has never declared or paid any cash dividends on its common stock, and Oncocyte does not anticipate paying any cash dividends in the foreseeable future.All excess tax benefits and tax deficiencies from stock-based compensation awards accounted for under ASC 718 are recognized as income tax benefit or expense, respectively, in the statements of operations. An excess income tax benefit arises when the tax deduction of a share-based award for income tax purposes exceeds the compensation cost recognized for financial reporting purposes and, a tax deficiency arises when the compensation cost exceeds the tax deduction. Because Oncocyte has a full valuation allowance for all periods presented (see â€œIncome Taxesâ€ below), there was no impact to Oncocyte statements of operations for any excess tax benefits or deficiencies, as any excess benefit or deficiency would be offset by the change in the valuation allowance.Retirement PlanOncocyte has an employee savings and retirement plan under Section 401(k) of the Internal Revenue Code. The plan is a defined contribution plan in which eligible employees may elect to have a percentage of their compensation contributed to the plan, subject to certain guidelines issued by the Internal Revenue Service. During the three months ended September 30, 2024 and 2023, Oncocyteæ™’s total contributions to the plan were \$81,000 and \$67,000, respectively. During the nine months ended September 30, 2024 and 2023, Oncocyteæ™’s total contributions to the plan were \$248,000 and \$245,000, respectively.Å 22 ONCOCYTE CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTSÅ Collaborative ArrangementsThe Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808, Collaborative Arrangements, which includes determining whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. To the extent that the arrangement falls within the scope of ASC 808, the Company assesses whether the payments between the Company and its collaboration partner fall within the scope of other accounting literature. If the Company concludes that payments from the collaboration partner to the Company would represent consideration from a customer, the Company accounts for those payments within the scope of ASC 606. However, if the Company concludes that its collaboration partner is not a customer for certain activities and associated payments, the Company presents such payments as a reduction of research and development expense or general and administrative expense, based on where the Company presents the underlying expense. See Note 10, â€œCollaborative Arrangementsâ€ for additional information.Income TaxesThe provision for income taxes for interim periods is determined using an estimated annual effective tax rate in accordance with ASC 740-2

California research tax credits to \$5.0 million each year for our fiscal years 2025-2027. On June 29, 2024, California enacted SB-175, which provides a refund mechanism for the incremental tax that was paid as a result of SB-167. The Company is evaluating the impact of the law changes but does not expect these law changes to have a material impact on the Company's consolidated financial statements. Net Loss Per Common Share Basic loss per share is computed by dividing the net loss applicable to common stockholders after deducting cumulative unpaid dividends and accretion of the preferred stock, by the weighted average number of shares of common stock outstanding during the year. The 2024 weighted average shares outstanding - basic in the following table includes the effects of pre-funded warrants that were issued in April 2024 (refer to Note 7, "Common Stock Purchase Warrants" for additional information). Diluted loss per share is computed by dividing the net loss applicable to common stockholders after deducting cumulative unpaid dividends and accretion of the preferred stock, by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued, using the treasury stock method or the if-converted method, or the two-class method for participating securities, whichever is more dilutive. Potential common shares are excluded from the computation if their effect is antidilutive. 23 ONCYCOTE CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the three and nine months ended September 30, 2024 and 2023, all common stock equivalents are antidilutive because Oncocyte reported a net loss. The following table presents the calculation of basic and diluted loss per share of common stock:

Three Months Ended September 30, 2024	Three Months Ended September 30, 2023
Net loss from continuing operations - basic and diluted	Net loss from continuing operations - basic and diluted
Net loss from discontinued operations - basic and diluted	Net loss from discontinued operations - basic and diluted
Net loss attributable to common stockholders - basic and diluted	Net loss attributable to common stockholders - basic and diluted
Weighted average shares outstanding - basic and diluted	Weighted average shares outstanding - basic and diluted
Loss per share - basic and diluted	Loss per share - basic and diluted

Recent Accounting Pronouncements Not Yet Adopted In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, to improve financial reporting by requiring disclosure of incremental segment information on an annual and interim basis for all public entities to enable investors to develop more decision-useful financial analyses. The amendments in this Update: (i) require enhanced disclosures about significant segment expenses, (ii) clarify that if the chief operating decision maker ("CODM") uses more than one measure of a segment's profit or loss, a public entity may report one or more of those additional measures of segment profit or loss, (iii) require disclosure of the title and position of the CODM and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources, and (iv) require that a public entity that has a single reportable segment provide all the disclosures required by the amendments in this Update and all existing segment disclosures in Topic 280. The amendments in this Update should be applied retrospectively, and are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. Management is currently evaluating the impact that the amendments in this Update will have on the Company's financial statement disclosures. The adoption of this new standard will not have an impact on the Company's consolidated balance sheets and consolidated statements of operations, comprehensive loss, shareholders' equity and cash flows. 24 ONCYCOTE CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

In December 2023, the FASB issued ASU No. 2024-03, Income Statement Reporting Comprehensive Income ("Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, to address investor requests for more detailed information about certain types of reported costs and expenses. The amendments in this Update require disclosure, in the notes to financial statements, at each interim and annual reporting period an entity: 1) disclose the amounts of (a) purchases of inventory, (b) employee compensation, (c) depreciation, and (d) intangible asset amortization included in each expense caption presented on the face of the income statement within continuing operations; 2) include certain amounts that are already required to be disclosed under current GAAP in the same disclosure as the other disaggregation requirements; 3) disclose a qualitative description of the amounts remaining that are not separately disaggregated quantitatively; and 4) disclose the total amount of selling expenses and, in annual reporting periods, an entity's definition of selling expenses. The amendments in this Update should be applied either prospectively or retrospectively, and are effective for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027, with early adoption permitted. Management is currently evaluating the impact that the amendments in this Update will have on the Company's financial statement disclosures. The adoption of this new standard will not have an impact on the Company's consolidated balance sheets and consolidated statements of operations, comprehensive loss, shareholders' equity and cash flows. 3. Business Combinations and Contingent Consideration Liabilities Acquisition of Insight Genetics, Inc. On January 31, 2020 (the "Insight Merger Date"), Oncocyte completed its acquisition of Insight pursuant to the Insight Merger Agreement. Oncocyte determined there are two types of contingent consideration in connection with the Insight Merger, the Milestone Contingent Consideration and the Royalty Contingent Consideration discussed below. There were three milestones comprising the Milestone Contingent Consideration, in connection with the Insight Merger which Oncocyte valued and recorded as part of the contingent consideration as of the Insight Merger Date (see table below), which consisted of (i) a payment for clinical trial completion and related data publication ("Milestone 1"), (ii) a payment for an affirmative final LCD from CMS for a specified lung cancer test ("Milestone 2"), and (iii) a payment for achieving specified CMS reimbursement milestones ("Milestone 3"). If achieved, any respective Milestone will be paid at the contractual value shown below, with the payment made either in cash or in shares of Oncocyte's common stock as determined by Oncocyte. There can be no assurance that any of the Milestones will be achieved. The following table shows the Insight Merger Date contractual payment amounts, as applicable, and the corresponding fair value of each respective contingent consideration liability:

Contractual Value	Fair Value on the Merger Date
Milestone 1	\$ 1,500
Milestone 2	\$ 1,340
Milestone 3	\$ 3,000

As defined, Royalty Payments are based on a percentage of future revenues of DetermaIO and Pharma Services over their respective useful life, accordingly there is no fixed contractual value for the Royalty Contingent Consideration. 25 ONCYCOTE CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

The fair value of the contingent consideration after the Insight Merger Date is reassessed by Oncocyte as changes in circumstances and conditions occur, with the subsequent change in fair value recorded in Oncocyte's consolidated statements of operations. Since December 2023, Milestone 1 and Royalty 2 (Pharma Services) are not expected to be paid and are excluded from the current fair value. During 2024, based on Oncocyte's reassessment of significant assumptions, there was an increase of approximately \$30,000 to the fair value of the contingent consideration primarily attributable to revised estimates of the possible future payouts and, accordingly, this increase was recorded as change in fair value of contingent consideration in the consolidated statement of operations for the nine months ended September 30, 2024. Oncocyte uses a discounted cash flow valuation technique to determine the fair value of its Level 3 contingent consideration liabilities. The significant unobservable inputs used in Insight's contingent consideration valuation on September 30, 2024, included: (i) a discount period, based on the expected Milestone payment dates, ranging from 1.7 years to 8.0 years, (ii) a discount rate of 13.3% to 13.5%, and (iii) a management probability estimate of 25% to 50%. The significant unobservable inputs used in Insight's contingent consideration valuation on September 30, 2023, included: (i) a discount period, based on the expected Milestone payment dates, ranging from 0.50 years to 1.5 years, (ii) a discount rate of 15.2% to 15.4%, and (iii) a management probability estimate of 15% to 50%. Changes to significant unobservable inputs to different amounts could result in a significantly higher or lower fair value measurement at the reporting date. The following tables reflect the activity for the Insight contingent consideration measured at fair value using Level 3 inputs:

Fair Value	(In thousands)
Balance at December 31, 2022	\$ 5,370
Change in estimated fair value	\$ (3,080)
Balance at September 30, 2023	\$ 2,290
Balance at December 31, 2023	\$ 2,040

Change in estimated fair value \$ 30 Balance at September 30, 2024 \$ 2,070

The accompanying balance sheets separately present the Insight and Chronix total contingent consideration liabilities as current and noncurrent. Contingent consideration is not deductible for tax purposes, even if paid; therefore, no deferred tax assets related to the contingent consideration were recorded. Acquisition of Chronix Biomedical, Inc. On April 15, 2021 (the "Chronix Merger Date"), Oncocyte completed its acquisition of Chronix pursuant to the Chronix Merger Agreement. As additional consideration for holders of certain classes and series of Chronix capital stock, the Chronix Merger Agreement required Oncocyte to pay certain contingent consideration. On February 8, 2023, the Company and the equity holder representative named in the Chronix Merger Agreement entered into Amendment No. 1 to the Chronix Merger Agreement, pursuant to which the parties agreed that (i) Chronix's equity holders will be paid earned consideration of 10% of net collections for sales of specified tests and products, until the expiration of intellectual property related to such tests and products, (ii) Chronix's equity holders will be paid 5% of the gross proceeds received from any sale of all or substantially all of the rights, titles, and interests in and to Chronix's patents for use in transplantation medicine to such third-party, and (iii) all of the previous payment obligations were eliminated. The fair value of the Chronix contingent consideration after the Chronix Merger Date is reassessed by Oncocyte as changes in circumstances and conditions occur, with the subsequent change in fair value recorded in Oncocyte's consolidated statements of operations. During 2024, based on Oncocyte's reassessment of significant assumptions, there was an increase of approximately \$9.4 million to the fair value of the contingent consideration primarily attributable to revised estimates of the possible future payouts and, accordingly, this increase was recorded as a change in fair value of contingent consideration in the consolidated statement of operations for the nine months ended September 30, 2024. Oncocyte uses a discounted cash flow valuation technique to determine the fair value of its Level 3 contingent consideration liabilities. The significant unobservable inputs used in Chronix's contingent consideration valuation on September 30, 2024, included: (i) a discount period, based on the related patent expiration dates, ranging from 9.1 years to 11.0 years, (ii) a discount rate of 13.3% to 14.3%, and (iii) a payout percentage of 10% based on the earned provision. The significant unobservable inputs used in Chronix's contingent consideration valuation on September 30, 2023, included: (i) a discount period, based on the related patent expiration dates, ranging from 10.4 years to 12.2 years, (ii) a discount rate of 15.5% to 16.4%, and (iii) a payout percentage of 10% based on the earned provision. Changes to significant unobservable inputs to different amounts could result in a significantly higher or lower fair value measurement at the reporting date. The following tables reflect the activity for the Chronix contingent consideration measured at fair value using Level 3 inputs:

Fair Value	(In thousands)
Balance at December 31, 2022	\$ 40,292
Change in estimated fair value	\$ (13,867)
Balance at September 30, 2023	\$ 26,425
Balance at December 31, 2023	\$ 37,860
Change in estimated fair value	\$ 9,391
Balance at September 30, 2024	\$ 47,251

Property and Equipment Right-of-use and financing lease assets, net, machinery and equipment, net, and construction in progress were as follows:

September 30, 2024	December 31, 2023
Right-of-use and financing lease assets	\$ 5,323
Machinery, equipment and leasehold improvements	\$ 7,923
Accumulated depreciation and amortization	\$ (7,053)
Right-of-use and financing lease assets and machinery and equipment, net	\$ 6,193
Construction in progress	\$ 302
Total	\$ 6,495

Fixed asset depreciation and amortization expense amounted to \$318,000 and \$404,000 for the three months ended September 30, 2024 and 2023, respectively, and \$935,000 and \$1.3 million for the nine months ended September 30, 2024 and 2023, respectively. During the third quarter of 2023, in connection with a new sublease arrangement (see Note 7), the Company identified circumstances that indicated a potential impairment of certain leasehold improvements and after a valuation was performed, management concluded that such leasehold improvements were impaired. Accordingly, the Company recorded an impairment of approximately \$1.8 million. The Company used a discounted cash flow valuation method to determine the Level 3 fair value of the leasehold improvements. The significant unobservable inputs used, effective as of September 30, 2023, included: (i) a discount period of 50 months based on the required sublease payments, and (ii) a discount rate of 7.25%. This valuation approach yielded a fair value of \$1.2 million as of September 30, 2023. 27 ONCYCOTE CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

5. Intangible Assets. NetAs part of the Insight and Chronix acquisitions completed on January 31, 2020 and April 15, 2021, respectively, the Company has acquired IPR&D and customer relationships (see Note 3). During the first quarter of 2023, due to changes in management and the economic condition of the Company, management shifted the Company's business strategy to direct efforts on fewer studies and to transition from tests that are laboratory developed tests to RUO. Due to the change in strategy, the Company's long range plan forecasts were updated, resulting in a change to anticipated future benefits derived from the Company's assets. The change in strategy represented a significant indicator for change in value of the Company's long-lived assets. The original IPR&D balances were reassessed based on the updated long range plan, using the multi-period excess earnings method ("MPEM") approach. The results of the valuation noted that the carrying value of the DetermaIO related IPR&D intangible assets was greater than the fair market value, whereas the carrying values of the CNI and VitaGraft related IPR&D intangible assets were lower than the fair market value. Accordingly, the Company recorded an impairment of approximately \$5.0 million related to DetermaIO as of March 31, 2023. During the fourth quarter of 2023, the IPR&D balances were reassessed using the MPEM approach and the results of the valuation noted that the carrying values of the DetermaIO, CNI and VitaGraft related IPR&D intangible assets were lower than the fair market value. Accordingly, the Company did not record any additional adjustment as of December 31, 2023, and no such adjustments have been recorded in 2024. The MPEM valuation approach is a discounted cash flow valuation technique and was used to determine the Level 3 fair value of Insight's IPR&D discussed above. The significant unobservable inputs used as of March 31, 2023, included: (i) a discount period of 20.0 years, based on the expected life of patent, (ii) a royalty rate of 0.3%, and (iii) a weighted average cost of capital rate of 30.0%. This valuation approach yielded a fair value of \$9.7 million as of March 31, 2023. As market conditions change, the Company will re-evaluate assumptions used in the determination of fair value for IPR&D and is uncertain to the extent of the volatility in the unobservable inputs in the foreseeable future. Refer to Note 2, "Intangible Assets" for additional IPR&D information. Intangible assets, net, consisted of the following:

September 30, 2024	December 31, 2023
Intangible assets	\$ 9,700
Acquired IPR&D - DetermaIO	\$ 9,700
Acquired IPR&D - VitaGraft	\$ 46,800
Acquired IPR&D - CNI	\$ 46,800
Intangible assets subject to amortization	\$ 103,300
Accumulated amortization - customer relationship	\$ (411)
Total intangible assets	\$ 102,889

Intangible assets, net \$ 56,529 \$ 56,595 (1) See Note 3 for information on the Insight Merger. (2) See Note 3 for information on the Chronix Merger. (3) Amortization of intangible assets is included in Cost of revenues "amortization of acquired intangibles" on the consolidated statements of operations because the intangible assets pertain directly to the revenues

generated from the acquired intangible assets. Intangible asset amortization expense amounted to \$22,000 for the three months ended September 30, 2024 and 2023, and \$66,000 for the nine months ended September 30, 2024 and 2023. Future amortization expense of intangible assets subject to amortization is as follows: A. Amortization A. (In thousands) A. Year ending December 31, A. A. A. 2024 A. \$ 22 A. A. 2025 A. A. 7 A. Total A. A. \$ 29 A. A. A. 28 ONCOCYTE CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS A. 6.

Commitments and Contingencies Office and Facilities Leases Irvine Office Lease On December 23, 2019, Oncocyte and Cushing Ventures, LLC (the "Landlord") entered into an Office Lease Agreement (the "Irvine Lease") of a building containing approximately 26,800 square feet of rentable space located at 15 Cushing in Irvine, California (the "Premises") that serves as Oncocyte's principal executive and administrative offices. The Irvine Lease has an initial term of 89 calendar months (the "Term"), which commenced on June 1, 2020 (the "Commencement Date") and will end in September of 2027. Oncocyte has an option to extend the Term for a period of five years (the "Extended Term"). Oncocyte agreed to pay base monthly rent in the amount of \$61,640 during the first 12 months of the Term. Base monthly rent increases annually, over the base monthly rent then in effect, by 3.5%. Oncocyte was entitled to an abatement of 50% of the base monthly rent during the first ten calendar months of the Term. If the Irvine Lease is terminated based on the occurrence of an event of default, Oncocyte will be obligated to pay the abated rent to the lessor. If Oncocyte exercises its option to extend the Term, the initial base monthly rent during the Extended Term will be the greater of the base monthly rent in effect during the last year of the Term or the prevailing market rate. The prevailing market rate will be determined based on annual rental rates per square foot for comparable space in the area where the Premises are located. If Oncocyte does not agree with the prevailing market rate proposed by the lessor, the rate may be determined through an appraisal process. The base monthly rent during the Extended Term shall be subject to the same annual rent adjustment as applicable for base monthly rent during the Term. In addition to base monthly rent, Oncocyte agreed to pay in monthly installments (a) all costs and expenses, other than certain excluded expenses, incurred by the lessor in each calendar year in connection with operating, maintaining, repairing (including replacements if repairs are not feasible or would not be effective) and managing the Premises and the building in which the Premises are located (the "Expenses"), and (b) all real estate taxes and assessments on the Premises and the building in which the Premises are located, all personal property taxes for property that is owned by lessor and used in connection with the operation, maintenance and repair of the Premises, and costs and fees incurred in connection with seeking reductions in such tax liabilities (the "Taxes"). Subject to certain exceptions, Expenses shall not be increased by more than 4% annually on a cumulative, compounded basis. Oncocyte was entitled to an abatement of its obligations to pay Expenses and Taxes while constructing improvements to the Premises constituting Tenant's Work under the Irvine Lease prior to the Commencement Date, except that Oncocyte was obligated to pay 43.7% of Expenses and Taxes during the period prior to the Commencement Date for its use of the second floor of the Premises, which was already built out as office space. The lessor provided Oncocyte with a Tenant Improvement Allowance in the amount of \$1.3 million to pay for the plan, design, permitting, and construction of the improvements constituting Tenant's Work. The lessor retained 1.5% of the Tenant Improvement Allowance as an administrative fee as provided in the Irvine Lease. As of June 2021, the lessor had provided \$1.3 million of the total Tenant Improvement Allowance, which is being amortized over the Term. Oncocyte has provided the lessor with a security deposit in the amount of \$150,000 and a letter of credit in the amount of \$1.7 million. The lessor may apply the security deposit, in whole or in part, for the payment of rent and any other amount that Oncocyte is or becomes obligated to pay under the Irvine Lease but fails to pay when due and beyond any cure period. The lessor may draw on the letter of credit from time to time to pay any amount that is unpaid and due, or if the original issuing bank notifies the lessor that the letter of credit will not be renewed or extended for the period required under the Irvine Lease and Oncocyte fails to timely provide a replacement letter of credit, or an event of default under the Irvine Lease occurs and continues beyond the applicable cure period, or if certain instances of insolvency or bankruptcy with respect to Oncocyte occur. Oncocyte is required to restore any portion of the security deposit that is applied by the lessor to payments due under the Irvine Lease, and Oncocyte is required to restore the amount available under the letter of credit to the required amount if any portion of the letter of credit is drawn by the lessor. The Irvine Lease provides that commencing on the 34th month of the Term, (a) the amount of the letter of credit that Oncocyte is required to maintain shall be reduced on a monthly basis, in equal installments, to amortize the required amount to zero at the end of the Term, and (b) Oncocyte has the right to cancel the letter of credit at any time if it meets certain market capitalization and balance sheets thresholds; provided, in each case, that Oncocyte is not then in default under the Irvine Lease beyond any applicable notice and cure period and the lessor has not determined that an event exists that would lead to an event of default. As of September 30, 2024, Oncocyte was not in default based on any provision of the Irvine Lease, however, neither of the provisions discussed in the preceding sentence were available to Oncocyte based on the lessor's related rights. A. 29 ONCOCYTE CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS A. To obtain the letter of credit, Oncocyte has provided the issuing bank with a restricted cash deposit that the bank will hold to cover its obligation to pay any draws on the letter of credit by the lessor. The restricted cash may not be used for any other purpose. Accordingly, Oncocyte has reflected \$1.7 million as restricted cash in the accompanying consolidated balance sheets as of September 30, 2024 and December 31, 2023. Irvine Office Sublease On August 8, 2023, Oncocyte and Induce Biologics USA, Inc. (the "Subtenant") entered into a Sublease Agreement (the "Sublease Agreement"), which subsequently became effective as of September 14, 2023, upon the execution and delivery by the Company, Subtenant, and Landlord, of that certain Landlord's Consent to Sublease dated September 12, 2023 (the "Consent Agreement"), under which Landlord consented to the Sublease Agreement, on the terms and subject to the conditions set forth therein. The Sublease Agreement is subject and subordinate to the Irvine Lease. Under the Sublease Agreement, the Company agreed to initially sublet to Subtenant a portion of the Premises consisting of approximately 13,400 square feet of rentable space for a term (the "Initial Period") commencing on the date that is 120 days after the effective date of the Consent Agreement (the "Sublease Commencement Date") and ending on the date that is 18 months following the Sublease Commencement Date or such earlier date as Subtenant may elect upon the exercise of its one-time option to accelerate such date upon 90 days prior written notice to the Company (the date on which the Initial Period ends, the "Expansion Date"). On the Expansion Date, the portion of the Premises that is subleased to Subtenant under the Sublease Agreement will automatically increase to include the remaining portion of the Premises, which consists of approximately 13,400 square feet of additional rentable space for a term (the "Expansion Period") beginning on the Expansion Date through the expiration of the Irvine Lease on October 31, 2027, unless earlier terminated. The Sublease Agreement provides that, from and after the Sublease Commencement Date, Subtenant will pay to the Company monthly base rent in the following amounts: (i) \$36,850 for rental periods beginning on the Sublease Commencement Date and ending on or before December 31, 2024 (subject to adjustment in the event that Subtenant exercises its option to accelerate the Expansion Date, such that the Expansion Period begins prior to December 31, 2024); (ii) \$37,955 for rental periods beginning on or after January 1, 2025 and ending on or before June 30, 2025 (subject to adjustment in the event that Subtenant exercises its option to accelerate the Expansion Date, such that the Expansion Period begins prior to June 30, 2025); (iii) \$75,844 for rental periods beginning on or after July 1, 2025 and ending on or before December 31, 2025; (iv) \$78,188 for rental periods beginning on or after January 1, 2026 and ending on or before December 31, 2026; and (v) \$80,534 for rental periods beginning on or after January 1, 2027 and ending on or before October 31, 2027. Following the Sublease Commencement Date, Subtenant is responsible for the payment of Additional Rent, including Expenses and Taxes (as each such term is defined in the Irvine Lease), provided that, with respect to the Initial Period, Subtenant will be responsible for only 50% of the Expenses and Taxes due. In addition, Subtenant will pay the Company a security deposit in the amount of \$101,987 in connection with the transactions contemplated by the Sublease Agreement. The Sublease Agreement contains customary provisions with respect to, among other things, Subtenant's obligation to comply with the Irvine Lease and applicable laws, the payment of utilities and similar services utilized by Subtenant with respect to use of the Premises, the indemnification of the Company by Subtenant, and the right of the Company to terminate the Sublease Agreement in its entirety and retake the Premises if Subtenant fails to remedy certain defaults of its obligations under the Sublease Agreement within specified time periods. Nashville Leases Insight operates a CLIA-certified laboratory and has additional office space located at 2 International Plaza, Nashville, Tennessee, under lease arrangements with MPC Holdings, LLC. As of December 31, 2023, the Company had Nashville office leases that comprised 8,362 square feet of rentable office space with a term ending April 2024. On January 1, 2024, the Company renewed its existing leases with MPC Holdings, LLC and added a new lease agreement to further expand its Nashville office space. The new lease contains 2,319 square feet for an aggregate of 10,681 square feet of rentable space as of September 30, 2024. Lab space is approximately 4,826 square feet of the total. The new lease agreements each have an initial term of 36 months, which commenced on January 1, 2024 and will end in January 2027. The Company has the option to renew the term of each lease for four additional one year periods. A. 30 ONCOCYTE CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS A. The office and facilities leases discussed above are operating leases under ASC 842 and are included in the tables below. The tables below provide the amounts recorded in connection with the application of ASC 842 for Oncocyte's operating and financing leases (see Note 2 for additional policy information). Financing Leases As of September 30, 2024, Oncocyte had various financing leases for certain laboratory equipment, as shown in the tables below. As of December 31, 2023, Oncocyte had no financing lease obligations. Oncocyte's lease obligations are collateralized by the equipment financed under the lease schedules. Operating and Financing Leases The following table presents supplemental balance sheet information related to operating and financing leases: A. September 30, 2024 A. A. December 31, 2023 A. A. (In thousands) A. Operating leases A. A. A. A. A. Right-of-use assets, net A. \$ 1,931 A. A. A. \$ 1,637 A. A. A. A. A. Right-of-use lease liabilities, current A. \$ 882 A. A. A. \$ 628 A. A. A. Right-of-use lease liabilities, noncurrent A. A. A. A. 1,953 A. A. A. 2,102 A. Total operating lease liabilities A. \$ 2,835 A. A. A. \$ 2,730 A. A. A. A. Financing leases A. A. A. A. A. Machinery and equipment A. \$ 1,673 A. A. A. \$ 537 A. A. A. Accumulated depreciation A. (603) A. A. A. (537) A. Machinery and equipment, net A. \$ 1,070 A. A. A. \$ 66 A. A. A. A. A. Current liabilities A. \$ 364 A. A. A. \$ 66 A. A. A. Noncurrent liabilities A. A. 653 A. A. A. A. Total financing lease liabilities A. \$ 1,017 A. A. A. \$ 66 A. A. A. A. A. A. Weighted average remaining lease term: A. A. A. A. Operating lease 2.9A years A. A. 3.7A years A. A. Financing lease 2.6A years A. A. n/a A. A. A. A. A. A. Weighted average discount rate: A. A. A. A. Operating lease A. 10.42 % A. A. 11.31 % Financing lease A. 10.27 % A. n/a A. A. A. Future minimum lease commitments are as follows: A. A. Operating A. A. Financing A. A. Leases A. A. Leases A. A. (In thousands) A. Year Ending December 31, A. A. A. A. A. A. 2024 A. \$ 279 A. A. A. \$ 107 A. 2025 A. A. 1,144 A. A. A. 455 A. 2026 A. A. 1,182 A. A. A. 400 A. 2027 A. A. 695 A. A. A. 191 A. Total minimum lease payments A. \$ 3,300 A. A. A. \$ 1,153 A. Less amounts representing interest A. (465) A. A. A. (136) Present value of net minimum lease payments A. \$ 2,835 A. A. A. \$ 1,017 A. A. A. 31 ONCOCYTE CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS A. The following table presents supplemental cash flow information related to operating and financing leases: A. A. Nine Months Ended September 30, A. A. 2024 A. A. 2023 A. A. (In thousands) A. Cash paid for amounts included in the measurement of lease liabilities: A. A. A. A. Operating cash flows from operating leases A. \$ 827 A. A. \$ 793 A. Operating cash flows from financing leases A. \$ 17 A. A. \$ 7 A. Financing cash flows from financing leases A. \$ 119 A. A. \$ 86 A. The Company incurred total lease cost, including short-term lease expense, of \$234,000 and \$183,000, which was net of sublease income of \$111,000 and \$28,000, for the three months ended September 30, 2024 and 2023, respectively. The Company incurred total lease cost, including short-term lease expense, of \$532,000 and \$636,000, which was net of sublease income of \$332,000 and \$64,000, for the nine months ended September 30, 2024 and 2023, respectively. Litigation At General Oncocyte may be subject to various claims and contingencies in the ordinary course of its business, including those related to litigation, business transactions, employee-related matters, and other matters. When Oncocyte is aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, Oncocyte will record a liability for the loss. If the loss is not probable or the amount of the loss cannot be reasonably estimated, Oncocyte discloses the claim if the likelihood of a potential loss is reasonably possible and the amount involved could be material. Tax Filings Oncocyte tax filings are subject to audit by taxing authorities in jurisdictions where it conducts business. These audits may result in assessments of additional taxes that are subsequently resolved with the authorities or potentially through the courts. Management believes Oncocyte has adequately provided for any ultimate amounts

On July 15, 2022, the Company received such shareholder approval to remove the beneficial ownership limitation with respect to the Series A Preferred Stock held by Broadwood Partners, L.P. (the "Broadwood Deal"). In the event of the Company's liquidation, dissolution, or winding up, holders of Series A Preferred Stock would have received a payment equal to the stated value of the Series A Preferred Stock plus accrued but unpaid dividends and any other amounts that may have become payable on the Series A Preferred Stock due to any failure or delay that may have occurred in issuing shares of common stock upon conversion of a portion of the Series A Preferred Stock, before any distribution or payment to the holders of common stock or any of our other junior equity. 33 ONCOCYTE CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Shares of Series A Preferred Stock generally had no voting rights, except as required by law and except that the consent of holders of a majority of the outstanding Series A Preferred Stock would be required to amend any provision of our certificate of incorporation that would have had a materially adverse effect on the rights of the holders of the Series A Preferred Stock. Additionally, as long as any shares of Series A Preferred Stock remained outstanding, unless the holders of at least 51% of the then outstanding shares of Series A Preferred Stock shall have otherwise given prior written consent, we, on a consolidated basis with our subsidiaries, were not permitted to (1) have less than \$8 million of unrestricted, unencumbered cash on hand (the "Cash Minimum Requirement"); (2) other than certain permitted indebtedness, incur indebtedness to the extent that our aggregate indebtedness exceeds \$15 million; (3) enter into any agreement (including any indenture, credit agreement or other debt instrument) that by its terms prohibited, prevented, or otherwise limited our ability to pay dividends on, or redeem, the Series A Preferred Stock in accordance with the terms of the Certificate of Determination; or (4) authorize or issue any class or series of preferred stock or other capital stock of the Company that ranks senior or pari passu with the Series A Preferred Stock. Shares of Series A Preferred Stock were entitled to receive cumulative dividends at a rate per share (as a percentage of stated value) of 6% per annum, payable quarterly in cash or, at our option, by accreting such dividends to the stated value. The Company was required to redeem, for cash, the shares of Series A Preferred Stock on the earlier to occur of (1) April 8, 2024, (2) the commencement of certain a voluntary or involuntary bankruptcy, receivership, or similar proceedings against the Company or its assets, (3) a Change of Control Transaction (as defined) and (4) at the election and upon notice of 51% in interest of the holders, if the Company failed to meet the Cash Minimum Requirement. Additionally, the Company had the right to redeem the Series A Preferred Stock for cash upon 30 days prior notice to the holders; provided if the Company undertakes a capital raise in connection with such redemption, the Investors will have the right to participate in such financing. On April 5, 2023, the Company redeemed 1,064 shares of the Series A Preferred Stock for approximately \$1.1 million (see "Common Stock" April 2023 Offering below). In connection with the April 2023 redemption, the Company recorded a deemed dividend of \$118,000 based on the difference between the Series A Preferred Stock redemption value and carrying value. On April 15, 2024, Company redeemed the remaining 4,818 shares of the Series A Preferred Stock for approximately \$5.4 million (see "Common Stock" April 2024 Offering below). As of April 15, 2024, the Company accreted dividends of \$570,000, net of the April 2023 redemption. The issuance and sale of the Series A Preferred Stock was completed pursuant to the Company's effective shelf registration statement on Form S-3 (Registration No. 333-256650), filed with the SEC on May 28, 2021 and declared effective by the SEC on June 8, 2021, and an accompanying prospectus dated June 8, 2021 as supplemented by a prospectus supplement dated April 13, 2022. As of September 30, 2024 and December 31, 2023, Oncocyte had zero and 4,818 shares of the Series A Preferred Stock issued and outstanding, respectively. Preferred Stock As of September 30, 2024 and December 31, 2023, Oncocyte had 5,000,000 shares of preferred stock, no-par value, authorized. As of September 30, 2024 and December 31, 2023, Oncocyte had no shares of preferred stock issued and outstanding. Common Stock As of September 30, 2024 and December 31, 2023, Oncocyte had 230,000,000 shares of common stock, no-par value, authorized. As of September 30, 2024 and December 31, 2023, Oncocyte had 13,374,109 and 8,261,073 shares of common stock issued and outstanding, respectively. April 2023 Offering On April 3, 2023, the Company entered into an agreement (the "April 2023 Offering") with several institutional and accredited investors, including Broadwood, the Company's largest shareholder, and certain members of the Company's board of directors (and certain of their affiliated parties), relating to their purchase of an aggregate of up to 2,278,121 shares of the Company's common stock at an offering price of \$7.08 per share to board members and \$6.03 per share to the other investors participating in the April 2023 Offering. The April 2023 Offering was intended to be priced at the market for purposes of complying with applicable Nasdaq Listing Rules. The Company issued an aggregate of 2,274,709 shares of common stock from this offering, as further discussed in Note 9, "Related Party Transactions." The aggregate gross proceeds from the offering were approximately \$13.9 million. The Company used approximately \$1.1 million of the net proceeds to immediately redeem an aggregate of 1,064 shares of its Series A Preferred Stock. A 34 ONCOCYTE CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS April 2024 Offering On April 15, 2024, the Company consummated a private placement of its securities to certain accredited investors for the issuance and sale of 5,076,900 shares of the Company's common stock and Pre-Funded Warrants to purchase 342,888 shares of the Company's common stock, with an exercise price of \$0.0001 per share. The purchase price for one common share was \$2.9164, and the purchase price for one Pre-Funded Warrant was \$2.9163. Certain insiders of the Company subscribed for 42,373 of the shares of common stock sold in the private placement, at a purchase price of \$2.95 per share (see Note 9). The related securities purchase agreement contains customary representations, warranties and agreements by the Company, indemnification obligations of the Company and the accredited investors, including for liabilities under the Securities Act, other obligations of the parties and termination provisions. A holder of the Pre-Funded Warrants may not exercise any portion of such holder's Pre-Funded Warrants to the extent that the holder, together with its affiliates, would beneficially own more than 4.99% (or, at the election of the holder, 9.99%) of the Company's outstanding shares of common stock immediately after exercise, except that upon at least 61 days' prior notice from the holder to the Company, the holder may increase the beneficial ownership limitation to up to 9.99% of the number of shares of common stock outstanding immediately after giving effect to the exercise. The Pre-Funded Warrants are exercisable immediately and will expire when exercised in full. As of September 30, 2024, no Pre-Funded Warrants have been exercised. See Note 9 "Related Party Transactions" for additional information. The gross proceeds to the Company from the April 2024 Offering were approximately \$15.8 million, before deducting approximately \$538,000 in placement agent fees and expenses and offering expenses payable by the Company. The Company is using the net proceeds received for general corporate purposes and working capital. In addition, approximately \$5.4 million of the net proceeds was used to redeem the outstanding shares of the Company's Series A Redeemable Convertible Preferred Stock. August 2024 Offering On August 9, 2024, the Company entered into a sales agreement with a sales agent, pursuant to which the Company may offer and sell from time to time up to an aggregate of \$7.5 million of shares of the Company's common stock (the "Placement Shares"), through the sales agent. Sales of the Placement Shares may be made in sales deemed to be "at-the-market offerings" as defined in Rule 415 promulgated under the Securities Act. The sales agent will use commercially reasonable efforts to sell, on the Company's behalf, all of the Placement Shares requested to be sold by the Company, consistent with its normal trading and sales practices, the terms of the sales agreement, and applicable law and regulations. The Company may also sell Placement Shares to the sales agent as principal in negotiated transactions. The Company has no obligation to sell any Placement Shares, and may at any time suspend offers under the sales agreement or terminate the sales agreement. The Company intends to use the net proceeds from this offering for working capital and other general corporate purposes. The sales agreement will terminate, and offer and sale of the Placement Shares pursuant to the sales agreement will cease, upon the earlier of (a) the issuance and sale of all of the Placement Shares subject to the sales agreement or (b) the termination of the sales agreement by the sales agent or the Company pursuant to the terms thereof. The sales agreement contains customary representations, warranties and agreements by the Company, as well as indemnification obligations of the Company for certain liabilities under the Securities Act. Under the terms of the sales agreement, the Company will pay the sales agent a commission equal to 3.0% of the aggregate gross proceeds from each sale of Placement Shares. As of September 30, 2024, the Company has sold 5,722 Placement Shares for net proceeds of approximately \$17,000, at an average purchase price of \$3.25 per share. In addition, the Company agreed to pay certain expenses incurred by the sales agent in connection with the offering. Total offering expenses incurred in the amount of \$286,000 are being deferred and expensed over a one year period. As of September 30, 2024, the remaining deferred financing costs of \$285,000 are included in deferred financing costs in the consolidated balance sheet. The Placement Shares were registered under the Securities Act pursuant to the Registration Statement on Form S-3 (File No. 333-281159) filed with the SEC on August 1, 2024 and declared effective by the SEC on August 7, 2024, the base prospectus contained within the Registration Statement, and a prospectus supplement dated August 9, 2024. October 2024 Offering On October 4, 2024, the Company consummated the October 2024 Offering. The gross proceeds from the October 2024 Offering were approximately \$10.2 million. After deducting placement agent fees and expenses and offering expenses payable by the Company of \$795,000, the resulting net proceeds were approximately \$9.4 million. See Note 12, "Subsequent Events" for additional information. A 35 ONCOCYTE CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Unregistered Restricted Stock Issuance During the nine months ended September 30, 2024, the Company issued 26,664 shares of restricted common stock in connection with an ongoing consulting service arrangement for a total fair value of \$72,000. During the nine months ended September 30, 2023, the Company issued 9,091 shares of restricted common stock to this consulting firm for a total fair value of \$36,000. Common Stock Purchase Warrants As of September 30, 2024 and December 31, 2023, Oncocyte had common stock purchase warrants issued and outstanding of 760,866 and 819,767, respectively. During the nine months ended September 30, 2024, 58,901 warrants expired. As of September 30, 2024, the outstanding warrants had exercise prices ranging from \$30.60 to \$109.20 per share, are set to expire on various dates ranging from February 2027 to October 2029 and have a weighted average remaining life of 2.57 years. Certain warrants have "cashless exercise" provisions meaning that the value of a portion of warrant shares may be used to pay the exercise price rather than payment in cash, which may be exercised under any circumstances in the case of the Bank Warrants discussed below or, in the case of certain other warrants, only if a registration statement for the warrants and underlying shares of common stock is not effective under the Securities Act or a prospectus in the registration statement is not available for the issuance of shares upon the exercise of the warrants. All of the outstanding warrants meet the equity classification criteria and have been classified as equity, refer to Note 2, "Accounting for Warrants" for additional information. In connection with the April 2024 Offering, discussed above, the Company issued Pre-Funded Warrants to purchase 342,888 shares of common stock. For accounting purposes, the Pre-Funded Warrants are equity-classified, contain no contingencies to exercise and are therefore considered outstanding for purposes of calculating basic earnings per share. As of September 30, 2024, no Pre-Funded Warrants have been exercised. Bank Warrants In connection with a loan that matured in September 2022 from Silicon Valley Bank (the "Bank"), in February 2017, Oncocyte issued common stock purchase warrants to the Bank (the "2017 Bank Warrants"). The Bank was issued warrants to purchase 412 shares of Oncocyte common stock at an exercise price of \$97.00 per share, through February 21, 2027. In March 2017, the Bank was issued warrants to purchase an additional 366 shares at an exercise price of \$109.20 per share, through March 23, 2027. In October 2019, Oncocyte issued a common stock purchase warrant to the Bank (the "2019 Bank Warrant") entitling the Bank to purchase 4,928 shares of Oncocyte common stock at an exercise price of \$33.80 per share, through October 17, 2029. The Bank may elect to exercise the 2017 Bank Warrants and the 2019 Bank Warrant on a "cashless exercise" basis and receive a number of shares determined by multiplying the number of shares for which the Bank Warrant is being exercised by (A) the excess of the fair market value of the common stock over the applicable Warrant Price, divided by (B) the fair market value of the common stock. The fair market value of the common stock will be last closing or sale price on a national securities exchange, interdealer quotation system, or over-the-counter market. These warrants meet the equity classification criteria and have been classified as equity. As of September 30, 2024, no Bank Warrants have been exercised. 8. Stock-Based Compensation Equity Incentive Plan On August 27, 2018, Oncocyte shareholders approved a new Equity Incentive Plan (the "2018 Incentive Plan") to replace the 2010 Stock Option Plan (the "2010 Plan"). In adopting the 2018 Incentive Plan, Oncocyte terminated the 2010 Plan and ceased to grant any additional stock options or sell any stock under restricted stock purchase agreements under the 2010 Plan; however, stock options issued under the 2010 Plan continue in effect in accordance with their terms and the terms of the 2010 Plan until the exercise or expiration of the individual options. Total remaining stock options outstanding under the 2010 Plan as of September 30, 2024 and December 31, 2023 were 16,217. A 36 ONCOCYTE CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS As of September 30, 2024, 1,310,000 aggregate shares of common stock have been reserved for issuance under the equity incentive plans for the grant of stock options or the sale of restricted stock or for the settlement of RSUs. Oncocyte may also grant stock appreciation rights under the 2018 Incentive Plan. Upon the exercise of stock options, the sale of restricted stock, or the delivery of shares pursuant to vested RSUs, it is Oncocyte's policy to issue new shares of common stock. The Board may amend or modify the 2018 Incentive Plan at any time, subject to any required stockholder approval. As of September 30, 2024, 124,768 shares were available for grant under the 2018 Incentive Plan. On October 11, 2024, Oncocyte shareholders approved an amendment and restatement of the 2018 Incentive Plan to provide for, among other things, an additional 1,250,000 shares of common stock to be available for the issuance of equity awards thereunder. Plan Activity A summary of Oncocyte's 2010 Plan and 2018 Incentive Plan activity and related information follows: A Options A Nonvested RSUs A Number Outstanding

As of September 30, 2024, we had \$2.1 million, which will be amortized over a weighted average remaining recognition period of 2.06 years. Other Information: The determination of stock-based compensation is inherently uncertain and subjective and involves the application of valuation models and assumptions requiring the use of judgment. If Oncocyte had made different assumptions, its stock-based compensation expense and net loss for the periods presented may have been significantly different. Refer to Note 2 of our Consolidated Financial Statements for additional information. Oncocyte does not recognize deferred income taxes for incentive stock option compensation expense and records a tax deduction only when a disqualified disposition has occurred.

38 ONCOCYTE CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

9. Related Party Transactions

On April 13, 2022, Oncocyte entered into the Securities Purchase Agreement with the Investors, including Broadwood and John Peter Gutfreund, a former director of Oncocyte, for the Series A Preferred Stock offering. Each of Broadwood and Mr. Gutfreund has a direct material interest in the Series A Preferred Stock offering and agreed to purchase 5,882 and 1,176 shares, respectively, in the Series A Preferred Stock offering and on the same terms as other investors. Additionally, Halle Capital Management, L.P. received \$85,000 from the Company as reimbursement for its legal fees and expenses. Mr. Gutfreund is the Managing Partner of Halle Capital Management, L.P. On April 5, 2023, Oncocyte redeemed all of the 588 shares of Series A Preferred Stock held by Mr. Gutfreund for \$618,672. Mr. Gutfreund is no longer a related party as of June 23, 2023. See Note 7 for additional information about the Series A Preferred Stock offering. Further, on April 13, 2022, Oncocyte entered into an underwriting agreement pursuant to which the Company agreed to issue and sell certain shares of common stock and warrants to purchase common stock (the "April 2022 Warrants"). The April 2022 Warrants have an exercise price of \$30.60 per share and will expire on April 19, 2027. Pursuant to the underwritten offering, Broadwood acquired from us (i) 261,032 shares of common stock, and (ii) 300,187 April 2022 Warrants to purchase up to 150,093 shares of common stock. However, the total number of shares of common stock that Broadwood purchased in the underwritten offering was 300,187, of which 39,154 existing shares were acquired by the underwriters in the open market and re-sold to Broadwood. Pura Vida acquired from us (i) 249,204 shares of common stock, and (ii) 286,585 April 2022 Warrants to purchase up to 143,292 shares of common stock. However, the total number of shares of common stock that Pura Vida purchased in the underwritten offering was 286,585, of which 37,380 existing shares were acquired by the underwriters in the open market and re-sold to Pura Vida. Halle Special Situations Fund LLC purchased from us (i) 309,976 shares of common stock, and (ii) 356,472 April 2022 Warrants to purchase up to 178,236 shares of common stock. Mr. Gutfreund is the investment manager and a control person of Halle Capital Partners GP LLC, the managing member of Halle Special Situations Fund LLC. However, the total number of shares of common stock that Halle Special Situations Fund LLC purchased in the underwritten offering was 356,472, of which 46,496 existing shares were acquired by the underwriters in the open market and re-sold to Halle Special Situations Fund LLC. Mr. Gutfreund is no longer a related party as of June 23, 2023. On April 3, 2023, Oncocyte entered into a securities purchase agreement with certain investors, including Broadwood, Pura Vida and entities affiliated with AWM, and certain individuals, including Oncocyte's Chairman, Andrew Arno, and former director, John Peter Gutfreund, and certain of their affiliated parties, which provided for the sale and issuance by the Company of an aggregate of 2,274,709 shares of common stock at an offering price of: (i) \$6.03 to investors who are not considered to be "insiders" of the Company pursuant to Nasdaq Listing Rules (the "Insiders"), which amount reflected the average closing price of our common stock on Nasdaq during the five trading day period immediately prior to pricing, and (ii) \$7.08 to Insiders, which amount reflected the final closing price of our common stock on Nasdaq on the last trading day immediately prior to pricing. Broadwood purchased 1,341,381 shares of common stock for \$8,093,362, Pura Vida purchased 33,150 shares of common stock for \$200,014 and entities affiliated with AWM purchased 472,354 shares of common stock for \$2,850,000. Mr. Arno and his affiliated parties purchased 21,162 shares of common stock for \$150,001, and Mr. Gutfreund and his affiliated parties purchased 85,250 for \$604,252. See Note 7, "Common Stock," April 2023 Offering for additional information. On April 15, 2024, Oncocyte consummated a private placement of its securities to certain investors, including Broadwood, entities affiliated with AWM, Bio-Rad, and certain individuals, including Oncocyte's Chairman, Andrew Arno, for the issuance and sale of 5,076,900 shares of its common stock and Pre-Funded Warrants to purchase 342,888 shares of its common stock. The purchase price for one share of common stock was \$2.9164, and the purchase price for one Pre-Funded Warrant was \$2.9163. Insiders subscribed for 42,373 of the shares of common stock sold in the private placement, at a purchase price of \$2.95 per share of common stock, which amount reflected the final closing price of the common stock on Nasdaq on the last trading day immediately prior to pricing. Broadwood purchased 2,420,000 shares of common stock for \$7,057,688, entities affiliated with AWM purchased 342,889 shares of common stock and 342,889 Pre-Funded Warrants for \$2,000,000, and Bio-Rad purchased 1,200,109 shares of common stock for \$3,499,998. Mr. Arno purchased 33,898 shares of common stock for \$100,000. One of Oncocyte's directors, Andrew Last, served as the Executive Vice President and Chief Operating Officer of Bio-Rad before retiring on September 6, 2024. See Note 7, "Common Stock," April 2024 Offering for additional information. A 39 ONCOCYTE CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

On October 4, 2024, Oncocyte consummated the October 2024 Offering involving certain investors, including Broadwood, Bio-Rad, and certain individuals, including Oncocyte's Chief Financial Officer, Andrea James. The gross proceeds from the October 2024 Offering were approximately \$10.2 million. After deducting placement agent fees and expenses and offering expenses payable by the Company of \$795,000, the resulting net proceeds were approximately \$9.4 million. Insiders subscribed for 37,037 of the shares of common stock sold in the October 2024 Offering, at a purchase price of \$2.97 per share of common stock. Broadwood purchased 1,315,339 shares of common stock for approximately \$3,878,000, and Bio-Rad purchased 310,835 shares of common stock for approximately \$916,000. Ms. James purchased 33,670 shares of common stock for \$100,000. See Note 12, "Subsequent Events," for additional information. Other Transactions: The Company previously employed the son of Andrew Arno, Chairman of the Board as its Senior Manager, Investor Relations, Corporate Planning & Development. The total compensation paid by the Company to Mr. Arno's son since January 1, 2022 is approximately \$200,000. Mr. Arno's son is no longer an employee of the Company as of July 28, 2023. During 2024, the Company purchased \$294,000 in laboratory equipment and incurred \$230,000 in laboratory related costs from Bio-Rad. During 2024, the Company also made finance lease payments of \$126,000 under four laboratory equipment leases from Bio-Rad with an initial capitalized total value of \$976,000. During 2023, the Company purchased \$581,000 in laboratory equipment and incurred \$375,000 in laboratory related costs from Bio-Rad. As of September 30, 2024 and December 31, 2023, the Company had accounts payable due to Bio-Rad of \$7,000 and \$206,000, respectively. One of Oncocyte's directors, Andrew Last, served as the Executive Vice President and Chief Operating Officer of Bio-Rad before retiring on September 6, 2024. On April 5, 2024, the Company entered into an agreement with Bio-Rad to collaborate in the development and the commercialization of RUO and IVD kitted transplant products (the "Collaboration Agreement"). Under the Collaboration Agreement, Bio-Rad agreed to purchase shares of our common stock equal to 9.99% of the total number of shares of common stock issued and outstanding immediately after the closing of such investment, provided that the total purchase price would not exceed \$3,500,000 unless Bio-Rad chooses to exceed such limit (the "Bio-Rad Investment"). (see "Financing Transactions" above). The Bio-Rad Investment was completed in connection with a private placement (See Note 7, "Common Stock," April 2024 Offering). In addition, we will pay Bio-Rad a single digit royalty payment based on certain net sales under the Collaboration Agreement, and Bio-Rad has an option for the exclusive right to promote, market and sell certain kits worldwide subject to certain conditions. If and when such option is exercised, Bio-Rad will purchase additional shares of our common stock, at the then-current market price per share, up to a specified maximum aggregate purchase price. One of Oncocyte's directors, Dr. Last, recused himself from all Board discussions related to transactions with Bio-Rad. See Note 10, "Collaborative Arrangements" for additional information. On November 8, 2024, the Company and Bio-Rad entered into a memorandum of understanding with respect to the Collaboration Agreement to establish additional activities to be performed by each party pursuant to the Collaboration Agreement (see Note 10 for additional information).

10. Collaborative Arrangements: Bio-Rad On April 5, 2024, the Company entered into the Collaboration Agreement with Bio-Rad to collaborate in the development and the commercialization of RUO and IVD kitted transplant products using Bio-Rad's ddPCR instruments and reagents. The Collaboration Agreement has a term of 10 years unless earlier terminated pursuant to customary termination provisions. The Collaboration Agreement provides that through the oversight of a joint steering committee comprised of representatives from both parties, the parties will collaborate on the development of (i) the Company's "VitaGrift," a series of GraftAssure, a Transplant Monitoring Assays to measure and test the concentration of donor-derived cell free DNA for RUO (the "RUO Assays"); and (ii) the Company's "VitaGrift," a Transplant Monitoring Assays that have received regulatory approval as an in vitro diagnostic device (the "IVD Kits") for exclusive use on one or more Bio-Rad ddPCR instruments. Pursuant to the Collaboration Agreement, and toward the development of the RUO Assays and the IVD Kits, the Company will collect and screen samples, conduct feasibility testing and stability studies, and perform analytical validation, among other things; and Bio-Rad will supply its ddPCR instruments and platforms as well as manufacture and supply all consumables. A 40 ONCOCYTE CORPORATION NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Prior to the commercial launch of the RUO Assays, under the Collaboration Agreement, the parties will develop a plan to market and sell the RUO Assays. The Company will be responsible for the manufacture and supply of all RUO Assays, and Bio-Rad will supply to the Company Bio-Rad's ddPCR instruments and reagents for use in commercializing the RUO Assays, which products will be purchased by the Company exclusively from Bio-Rad. The Company and Bio-Rad will be jointly responsible for co-promoting and co-marketing the RUO Assays within the United States and Germany (the "Territory"). The Company has the exclusive right to sell the RUO Assays in the Territory exclusively with the use of Bio-Rad ddPCR instruments and reagents. Bio-Rad will be responsible for promoting and marketing, and has the exclusive right to sell, the RUO Assays outside the Territory. For the sales of the RUO Assays in the Territory, the Company will pay to Bio-Rad a single digit royalty payment based on net sales. The Company will manufacture and supply the RUO Assays to Bio-Rad for resale outside the Territory. Additionally, the Collaboration Agreement provides Bio-Rad an option for the exclusive right to promote, market and sell IVD Kits worldwide subject to certain conditions. If and when such option is exercised, Bio-Rad will purchase additional shares of the Company's common stock, no par value per share, at the then-current market price per share, up to a specified maximum aggregate purchase price, and the Company will manufacture and supply IVD Kits exclusively for Bio-Rad. See Note 9 "Related Party Transactions" for additional information. For the three and nine months ended September 30, 2024, the income statement amounts attributable to transactions arising from the Collaboration Agreement have not been significant. Beginning in September 2024, the Company has capitalized certain inventory costs (see Note 2 of our Consolidated Financial Statements for additional information). On November 8, 2024, Oncocyte and Bio-Rad entered into a binding Memorandum of Understanding (the "Memorandum") in connection with the Collaboration Agreement. The Memorandum establishes additional activities (described below) to be performed by Oncocyte and Bio-Rad prior to the commercial launch of the RUO Assays specifically related to pilot study sites outside the Territory (the "Pilot Sites"). Pursuant to the Memorandum, Oncocyte (i) will setup commercialization of Pilot Sites to use the RUO Assays, (ii) may sell RUO Assays to Pilot Sites, (iii) will train and support the Pilot Sites on the use of the RUO Assays, and (iv) if Oncocyte receives any net sales from the sale of the RUO Assays to the Pilot Sites, then Oncocyte shall pay to Bio-Rad a royalty payment based on a percentage of such net sales under the terms and conditions of the Collaboration Agreement. In addition, pursuant to the Memorandum, Bio-Rad will evaluate commercialization efforts for the RUO Assays, which will include (i) supporting installation and training for Pilot Sites, and (ii) evaluating distribution of the RUO Assays to Pilot Sites. The foregoing description of the material terms and conditions of the Memorandum does not purport to be complete and is qualified in its entirety by the full text of the Memorandum, which is attached hereto as Exhibit 10.6. Life Technologies Corporation In January 2022, Oncocyte entered into a collaboration agreement (the "LTC Agreement") with Life Technologies Corporation, a Delaware corporation and subsidiary of Thermo Fisher Scientific (the "LTC"), in order to partner in the development and collaborate in the commercialization of Thermo Fisher Scientific's existing Oncomine Comprehensive Assay Plus and Oncocyte's DetermaIO assay for use with LTC's Ion TorrentTM GenexusTM Integrated Sequencer and LTC's Ion TorrentTM GenexusTM Purification System in order to obtain IVD regulatory approval. In February 2023, Oncocyte entered into a Termination Agreement with LTC, pursuant to which the parties terminated the LTC Agreement. As of the termination date, Oncocyte was responsible for reimbursing LTC for \$749,000 of certain development costs under the terms of the LTC Agreement, which were fully paid in 2023.

11. Discontinued Operations of Razor: On December 15, 2022, the Company entered into the Razor Stock Purchase Agreement with Dragon and Razor. Pursuant to the Razor Stock Purchase Agreement, Oncocyte agreed to sell, and Dragon agreed to purchase, 3,188,181 shares of common stock of Razor, which constitutes approximately 70% of the issued and outstanding equity interests of Razor on a fully-diluted basis. On February 16, 2023, Oncocyte completed the Razor Sale Transaction. In connection with the Razor Closing, Oncocyte transferred to Razor all of the assets and liabilities related to DetermaRx. Refer to additional Razor information in Note 1. In addition to the transfer of 70% of the equity interests of Razor, the Razor Stock Purchase Agreement provided that Dragon would purchase furniture, fixtures, and equipment from the Company for a cash consideration of approximately \$116,000. Upon the Razor Closing, the Company deconsolid

physicians and their patients. VitaGraft®, is a clinical blood-based solid organ transplantation monitoring test, GraftAssure®, is a RUO blood-based donor-derived cell-free DNA test, DetermaIO®, is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies, and the pipeline test DetermaCNI®, is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. Our mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. We do this primarily by developing molecular diagnostic test kits that empower our customers to run their own tests to participate in the patient care value chain, which is counter-positioned with the central laboratory model. Our decentralized approach also puts testing in the hands of researchers to enable more studies, which inspires innovation, which can improve standards of care while also creating demand for more testing. We develop tests that measure both established biomarkers as well as pioneer the adoption of new and more effective biomarkers. We believe that combining innovative science with a simple, but disruptive, business model can create enormous value. This model is designed to empower doctors to reduce uncertainty to make better decisions to save lives as well as enable researchers to measure biomarkers to inspire innovation. Our customer institutions are hospitals, transplant centers, and labs. The decision to deploy our tests on behalf of patients or research studies comes from front line doctors, including surgeons, nephrologists and oncologists, as well as researchers, pathologists, lab directors, medical directors, department heads, lab managers, and chief medical officers. Our operating premise is that democratizing access to testing to foster scientific innovation and better treatments ultimately reduces the cost of care, while expanding access and improving outcomes. At the heart, we are a science-driven organization that champions scientific integrity and inquiry. We employ world-renowned scientists who generate intellectual property in our strategic target markets. We have built and acquired an intellectual property portfolio that we believe will enable us to gain share in well-established clinical and research markets. Our primary near-term strategic market is organ transplant. Oncocyte® is molecular diagnostic tests are designed to help the industry to better address one of the leading challenges in the transplantation market – which is the body’s potential to reject the donor organ. We do this by detecting early evidence of graft organ damage in the blood through assessing a known biomarker known as donor-derived cell-free DNA. VitaGraft Kidney, for example, can find donor kidney damage up to 10 months sooner than other protocols. VitaGraft is analytically and clinically validated in three major solid organ transplant types (kidney, liver and heart) by peer reviewed international publications. We received a positive coverage decision from MoDx for VitaGraft Kidney in August of 2023, and it became commercially available for ordering in January 2024 through our CLIA Laboratory in Nashville, Tennessee. VitaGraft Kidney is now broadly available to transplant professionals upon request. In July 2024, we began to commercialize the technology underlying VitaGraft Kidney by distributing its sister product, GraftAssure, which is intended to be sold and used for research purposes and is labeled as RUO. We expect to distribute our RUO production through a mix of direct sales, partnering and distribution agreements, and licensing. We have entered into an agreement with Bio-Rad, our global strategic partner, to collaborate in the development and the commercialization of RUO and IVD kitted transplant products (see Note 10, “Collaborative Arrangements,” to our consolidated financial statements included elsewhere in this Report for additional information). 44 Under strict regulatory rules, our tests may not be used in a clinical treatment setting until they have attained IVD approval from the Food and Drug Administration (FDA) in the U.S. and In Vitro Diagnostic Medical Devices Regulation approval in the European Union. As such, we are working with these regulatory bodies to attain such approval, supporting future distribution and higher sales of our products for clinical use. We also have a laboratory and pharma services lab, certified under the CLIA and accredited by the College of American Pathologists, in Nashville, Tennessee, and a research and development lab in Göttingen, Germany. Our innovation centers in Nashville and Germany employ world-renowned research scientists who are leaders in their field. Our secondary strategic market is in the field of oncology – namely through diagnostic tests that can measure and predict which patients will best respond to certain types of therapies, as well as provide efficacy monitoring for therapies. For example, we are continuing to develop DetermaIO, a test with promising data supporting its potential to help identify patients likely to respond to checkpoint inhibitor drugs. This new class of drugs modulate the immune response and show activity in multiple solid tumor types including non-small cell lung cancer, and triple negative breast cancer. DetermaIO is currently available as part of an early access program with leaders in the immuno-oncology field. A kitted research product format of the underlying technology began proof-of-concept development in 2023. The application of immunotherapy is a global problem, so we expect partnering opportunities for each of our products as they reach clinical maturity. We also expect to begin commercializing our oncology product line, which includes DetermaIO, over the next 18 months. We also perform other assay development and clinical testing services for pharmaceutical and biotechnology companies through our Pharma Services operations. The inherent uncertainties of developing and commercializing new diagnostic tests for medical use make it impossible to predict the amount of time and expense that will be required to complete the development and commercialization of those tests. There is no assurance that we will be successful in developing new technology or diagnostic tests, nor that any technology or diagnostic tests that we may develop will be proven safe and effective in diagnosis of cancer in humans or will be successfully commercialized. We expect that our operating expenses will continue to increase if we successfully complete the development of DetermaIO and commercialize this test. Recent Developments Collaboration Agreement On April 5, 2024, we entered into an agreement with Bio-Rad, our global strategic partner, to collaborate in the development and the commercialization of RUO and IVD kitted transplant products. On November 8, 2024, Oncocyte and Bio-Rad entered into a memorandum of understanding with respect to such agreement to establish additional activities to be performed by each party pursuant to such agreement. See Note 10, “Collaborative Arrangements,” to our consolidated financial statements included elsewhere in this Report for additional information. April 2024 Offering On April 15, 2024, we consummated the April 2024 Offering. The gross proceeds from the April 2024 Offering were approximately \$15.8 million. See Note 7, “Common Stock,” April 2024 Offering, to our consolidated financial statements included elsewhere in this Report for additional information. August 2024 Offering On August 9, 2024, we entered into a sales agreement with a sales agent, pursuant to which the Company may offer and sell from time to time up to an aggregate of \$7.5 million of shares of our common stock, through the sales agent through an at-the-market facility. As of September 30, 2024, we received net proceeds from the sale of such shares of approximately \$17,000. See Note 7, “Common Stock,” August 2024 Offering, to our consolidated financial statements included elsewhere in this Report for additional information. October 2024 Offering On October 4, 2024, we consummated the October 2024 Offering. The gross proceeds from the October 2024 Offering were approximately \$10.2 million. See Note 12, “Subsequent Events,” to our consolidated financial statements included elsewhere in this Report for additional information. 45 Results of Operations Summary Results of Operations 30, 2024 30, 2023 30, 2022 30, 2021 30, 2020 30, 2019 30, 2018 30, 2017 30, 2016 30, 2015 30, 2014 30, 2013 30, 2012 30, 2011 30, 2010 30, 2009 30, 2008 30, 2007 30, 2006 30, 2005 30, 2004 30, 2003 30, 2002 30, 2001 30, 2000 30, 1999 30, 1998 30, 1997 30, 1996 30, 1995 30, 1994 30, 1993 30, 1992 30, 1991 30, 1990 30, 1989 30, 1988 30, 1987 30, 1986 30, 1985 30, 1984 30, 1983 30, 1982 30, 1981 30, 1980 30, 1979 30, 1978 30, 1977 30, 1976 30, 1975 30, 1974 30, 1973 30, 1972 30, 1971 30, 1970 30, 1969 30, 1968 30, 1967 30, 1966 30, 1965 30, 1964 30, 1963 30, 1962 30, 1961 30, 1960 30, 1959 30, 1958 30, 1957 30, 1956 30, 1955 30, 1954 30, 1953 30, 1952 30, 1951 30, 1950 30, 1949 30, 1948 30, 1947 30, 1946 30, 1945 30, 1944 30, 1943 30, 1942 30, 1941 30, 1940 30, 1939 30, 1938 30, 1937 30, 1936 30, 1935 30, 1934 30, 1933 30, 1932 30, 1931 30, 1930 30, 1929 30, 1928 30, 1927 30, 1926 30, 1925 30, 1924 30, 1923 30, 1922 30, 1921 30, 1920 30, 1919 30, 1918 30, 1917 30, 1916 30, 1915 30, 1914 30, 1913 30, 1912 30, 1911 30, 1910 30, 1909 30, 1908 30, 1907 30, 1906 30, 1905 30, 1904 30, 1903 30, 1902 30, 1901 30, 1900 30, 1899 30, 1898 30, 1897 30, 1896 30, 1895 30, 1894 30, 1893 30, 1892 30, 1891 30, 1890 30, 1889 30, 1888 30, 1887 30, 1886 30, 1885 30, 1884 30, 1883 30, 1882 30, 1881 30, 1880 30, 1879 30, 1878 30, 1877 30, 1876 30, 1875 30, 1874 30, 1873 30, 1872 30, 1871 30, 1870 30, 1869 30, 1868 30, 1867 30, 1866 30, 1865 30, 1864 30, 1863 30, 1862 30, 1861 30, 1860 30, 1859 30, 1858 30, 1857 30, 1856 30, 1855 30, 1854 30, 1853 30, 1852 30, 1851 30, 1850 30, 1849 30, 1848 30, 1847 30, 1846 30, 1845 30, 1844 30, 1843 30, 1842 30, 1841 30, 1840 30, 1839 30, 1838 30, 1837 30, 1836 30, 1835 30, 1834 30, 1833 30, 1832 30, 1831 30, 1830 30, 1829 30, 1828 30, 1827 30, 1826 30, 1825 30, 1824 30, 1823 30, 1822 30, 1821 30, 1820 30, 1819 30, 1818 30, 1817 30, 1816 30, 1815 30, 1814 30, 1813 30, 1812 30, 1811 30, 1810 30, 1809 30, 1808 30, 1807 30, 1806 30, 1805 30, 1804 30, 1803 30, 1802 30, 1801 30, 1800 30, 1799 30, 1798 30, 1797 30, 1796 30, 1795 30, 1794 30, 1793 30, 1792 30, 1791 30, 1790 30, 1789 30, 1788 30, 1787 30, 1786 30, 1785 30, 1784 30, 1783 30, 1782 30, 1781 30, 1780 30, 1779 30, 1778 30, 1777 30, 1776 30, 1775 30, 1774 30, 1773 30, 1772 30, 1771 30, 1770 30, 1769 30, 1768 30, 1767 30, 1766 30, 1765 30, 1764 30, 1763 30, 1762 30, 1761 30, 1760 30, 1759 30, 1758 30, 1757 30, 1756 30, 1755 30, 1754 30, 1753 30, 1752 30, 1751 30, 1750 30, 1749 30, 1748 30, 1747 30, 1746 30, 1745 30, 1744 30, 1743 30, 1742 30, 1741 30, 1740 30, 1739 30, 1738 30, 1737 30, 1736 30, 1735 30, 1734 30, 1733 30, 1732 30, 1731 30, 1730 30, 1729 30, 1728 30, 1727 30, 1726 30, 1725 30, 1724 30, 1723 30, 1722 30, 1721 30, 1720 30, 1719 30, 1718 30, 1717 30, 1716 30, 1715 30, 1714 30, 1713 30, 1712 30, 1711 30, 1710 30, 1709 30, 1708 30, 1707 30, 1706 30, 1705 30, 1704 30, 1703 30, 1702 30, 1701 30, 1700 30, 1699 30, 1698 30, 1697 30, 1696 30, 1695 30, 1694 30, 1693 30, 1692 30, 1691 30, 1690 30, 1689 30, 1688 30, 1687 30, 1686 30, 1685 30, 1684 30, 1683 30, 1682 30, 1681 30, 1680 30, 1679 30, 1678 30, 1677 30, 1676 30, 1675 30, 1674 30, 1673 30, 1672 30, 1671 30, 1670 30, 1669 30, 1668 30, 1667 30, 1666 30, 1665 30, 1664 30, 1663 30, 1662 30, 1661 30, 1660 30, 1659 30, 1658 30, 1657 30, 1656 30, 1655 30, 1654 30, 1653 30, 1652 30, 1651 30, 1650 30, 1649 30, 1648 30, 1647 30, 1646 30, 1645 30, 1644 30, 1643 30, 1642 30, 1641 30, 1640 30, 1639 30, 1638 30, 1637 30, 1636 30, 1635 30, 1634 30, 1633 30, 1632 30, 1631 30, 1630 30, 1629 30, 1628 30, 1627 30, 1626 30, 1625 30, 1624 30, 1623 30, 1622 30, 1621 30, 1620 30, 1619 30, 1618 30, 1617 30, 1616 30, 1615 30, 1614 30, 1613 30, 1612 30, 1611 30, 1610 30, 1609 30, 1608 30, 1607 30, 1606 30, 1605 30, 1604 30, 1603 30, 1602 30, 1601 30, 1600 30, 1599 30, 1598 30, 1597 30, 1596 30, 1595 30, 1594 30, 1593 30, 1592 30, 1591 30, 1590 30, 1589 30, 1588 30, 1587 30, 1586 30, 1585 30, 1584 30, 1583 30, 1582 30, 1581 30, 1580 30, 1579 30, 1578 30, 1577 30, 1576 30, 1575 30, 1574 30, 1573 30, 1572 30, 1571 30, 1570 30, 1569 30, 1568 30, 1567 30, 1566 30, 1565 30, 1564 30, 1563 30, 1562 30, 1561 30, 1560 30, 1559 30, 1558 30, 1557 30, 1556 30, 1555 30, 1554 30, 1553 30, 1552 30, 1551 30, 1550 30, 1549 30, 1548 30, 1547 30, 1546 30, 1545 30, 1544 30, 1543 30, 1542 30, 1541 30, 1540 30, 1539 30, 1538 30, 1537 30, 1536 30, 1535 30, 1534 30, 1533 30, 1532 30, 1531 30, 1530 30, 1529 30, 1528 30, 1527 30, 1526 30, 1525 30, 1524 30, 1523 30, 1522 30, 1521 30, 1520 30, 1519 30, 1518 30, 1517 30, 1516 30, 1515 30, 1514 30, 1513 30, 1512 30, 1511 30, 1510 30, 1509 30, 1508 30, 1507 30, 1506 30, 1505 30, 1504 30, 1503 30, 1502 30, 1501 30, 1500 30, 1499 30, 1498 30, 1497 30, 1496 30, 1495 30, 1494 30, 1493 30, 1492 30, 1491 30, 1490 30, 1489 30, 1488 30, 1487 30, 1486 30, 1485 30, 1484 30, 1483 30, 1482 30, 1481 30, 1480 30, 1479 30, 1478 30, 1477 30, 1476 30, 1475 30, 1474 30, 1473 30, 1472 30, 1471 30, 1470 30, 1469 30, 1468 30, 1467 30, 1466 30, 1465 30, 1464 30, 1463 30, 1462 30, 1461 30, 1460 30, 1459 30, 1458 30, 1457 30, 1456 30, 1455 30, 1454 30, 1453 30, 1452 30, 1451 30, 1450 30, 1449 30, 1448 30, 1447 30, 1446 30, 1445 30, 1444 30, 1443 30, 1442 30, 1441 30, 1440 30, 1439 30, 1438 30, 1437 30, 1436 30, 1435 30, 1434 30, 1433 30, 1432 30, 1431 30, 1430 30, 1429 30, 1428 30, 1427 30, 1426 30, 1425 30, 1424 30, 1423 30, 1422 30, 1421 30, 1420 30, 1419 30, 1418 30, 1417 30, 1416 30, 1415 30, 1414 30, 1413 30, 1412 30, 1411 30, 1410 30, 1409 30, 1408 30, 1407 30, 1406 30, 1405 30, 1404 30, 1403 30, 1402 30, 1401 30, 1400 30, 1399 30, 1398 30, 1397 30, 1396 30, 1395 30, 1394 30, 1393 30, 1392 30, 1391 30, 1390 30, 1389 30, 1388 30, 1387 30, 1386 30, 1385 30, 1384 30, 1383 30, 1382 30, 1381 30, 1380 30, 1379 30, 1378 30, 1377 30, 1376 30, 1375 30, 1374 30, 1373 30, 1372 30, 1371 30, 1370 30, 1369 30, 1368 30, 1367 30, 1366 30, 1365 30, 1364 30, 1363 30, 1362 30, 1361 30, 1360 30, 1359 30, 1358 30, 1357 30, 1356 30, 1355 30, 1354 30, 1353 30, 1352 30, 1351 30, 1350 30, 1349 30, 1348 30, 1347 30, 1346 30, 1345 30, 1344 30, 1343 30, 1342 30, 1341 30, 1340 30, 1339 30, 1338 30, 1337 30, 1336 30, 1335 30, 1334 30, 1333 30, 1332 30, 1331 30, 1330 30, 1329 30, 1328 30, 1327 30, 1326 30, 1325 30, 1324 30, 1323 30, 1322 30, 1321 30, 1320 30, 1319 30, 1318 30, 1317 30, 1316 30, 1315 30, 1314 30, 1313 30, 1312 30, 1311 30, 1310 30, 1309 30, 1308 30, 1307 30, 1306 30, 1305 30, 1304 30, 1303 30, 1302 30, 1301 30, 1300 30, 1299 30, 1298 30, 1297 30, 1296 30, 1295 30, 1294 30, 1293 30, 1292 30, 1291 30, 1290 30, 1289 30, 1288 30, 1287 30, 1286 30, 1285 30, 1284 30, 1283 30, 1282 30, 1281 30, 1280 30, 1279 30, 1278 30, 1277 30, 1276 30, 1275 30, 1274 30, 1273 30, 1272 30, 1271 30, 1270 30, 1269 30, 1268 30, 1267 30, 1266 30, 1265 30, 1264 30, 1263 30, 1262 30, 1261 30, 1260 30, 1259 30, 1258 30, 1257 30, 1256 30, 1255 30, 1254 30, 1253 30, 1252 30, 1251 30, 1250 30, 1249 30, 1248 30, 1247 30, 1246 30, 1245 30, 1244 30, 1243 30, 1242 30, 1241 30, 1240 30, 1239 30, 1238 30, 1237 30, 1236 30, 1235 30, 1234 30, 1233 30, 1232 30, 1231 30, 1230 30, 1229 30, 1228 30, 1227 30, 1226 30, 1225 30, 1224 30, 1223 30, 1222 30, 1221 30, 1220 30, 1219 30, 1218 30, 1217 30, 1216 30, 1215 30, 1214 30, 1213 30, 1212 30, 1211 30, 1210 30, 1209 30, 1208 30, 1207 30, 1206 30, 1205 30, 1204 30, 1203 30, 1202 30, 1201 30, 1200 30, 1199 30, 1198 30, 1197 30, 1196 30, 1195 30, 1194 30, 1193 30, 1192 30, 1191 30, 1190 30, 1189 30, 1188 30, 1187 30, 1186 30, 1185 30, 1184 30, 1183 30, 1182 30, 1181 30, 1180 30, 1179 30, 1178 30, 1177 30, 1176 30, 1175 30, 1174 30, 1173 30, 1172 30, 1171 30, 1170 30, 1169 30, 1168 30, 1167 30, 1166 30, 1165 30, 1164 30, 1163 30, 1162 30, 1161 30, 1160 30, 1159 30, 1158 30, 1157 30, 1156 30, 1155 30, 1154 30, 1153 30, 1152 30, 1151 30, 1150 30, 1149 30, 1148 30, 1147 30, 1146 30, 1145 30, 1144 30, 1143 30, 1142 30, 1141 30, 1140 30, 1139 30, 1138 30, 1137 30, 1136 30, 1135 30, 1134 30, 1133 30, 1132 30, 1131 30, 1130 30, 1129 30, 1128 30, 1127 30, 1126 30, 1125 30, 1124 30, 1123 30, 1122 30, 1121 30, 1120 30, 1119 30, 1118 30, 1117 30, 1116 30, 1115 30, 1114 30, 1113 30, 1112 30, 1111 30, 1110 30, 1109 30, 1108 30, 1107 30, 1106 30, 1105 30, 1104 30, 1103 30, 1102 30, 1101 30, 1100 30, 1099 30, 1098 30, 1097 30, 1096 30, 1095 30, 1094 30, 1093 30, 1092 30, 1091 30, 1090 30, 1089 30, 1088 30, 1087 30, 1086 30, 1085 30, 1084 30, 1083 30, 1082 30, 1081 30, 1080 30, 1079 30, 1078 30, 1077 30, 1076 30, 1075 30, 1074 30, 1073 30, 1072 30, 1071 30, 1070 30, 1069 30, 1068 30, 1067 30, 1066 30, 1065 30, 1064 30, 1063 30, 1062 30, 1061 30, 1060 30, 1059 30, 1058 30, 1057 30, 1056 30, 1055 30, 1054 30, 1053 30, 1052 30, 1051 30, 1050 30, 1049 30, 1048 30, 1047 30, 1046 30, 1045 30, 1044 30, 1043 30, 1042 30, 1041 30, 1040 30, 1039 30, 1038 30, 1037 30, 1036 30, 1035 30, 1034 30, 1033 30, 1032 30, 1031 30, 1030 30, 1029 30, 1028 30, 1027 30, 1026 30, 1025 30, 1024 30, 1023 30, 1022 30, 1021 30, 1020 30, 1019 30, 1018 30, 1017 30, 1016 30, 1015 30, 1014 30, 1013 30, 1012 30, 1011 30, 1010 30, 1009 30, 1008 30, 1007 30, 1006 30, 1005 30, 1004 30, 1003 30, 1002 30, 1001 30, 1000 30, 999 30, 998 30, 997 30, 996 30, 995 30, 994 30, 993 30, 992 30, 991 30, 990 30, 989 30, 988 30, 987 30, 986 30, 985 30, 984 30, 983 30, 982 30, 981 30, 980 30, 979 30, 978 30, 977 30, 976 30, 975 30, 974 30, 973 30, 972 30, 971 30, 970 30, 969 30, 968 30, 967 30, 966 30, 965 30, 964 30, 963 30, 962 30, 961 30, 960 30, 959 30, 958 30, 957 30, 956 30, 955 30, 954 30, 953 30, 952 30, 951 30, 950 30, 949 30, 948 30, 947 30, 946 30, 945 30, 944 30, 943 30, 942 30, 941 30, 940 30, 939 30, 938 30, 937 30, 936 30, 935 30, 934 30, 933 30, 932 30, 931 30, 930 30, 929 30, 928 30, 927 30, 926 30, 925 30, 924 30, 923 30, 922 30, 921 30, 920 30, 919 30, 918 30, 917 30, 916 30, 915 30, 914 30, 913 30, 912 30, 911 30, 910 30, 909 30, 908 30, 907 30, 906 30, 905 30, 904 30, 903 30, 902 30, 901 30, 900 30, 899 30, 898 30, 897 30, 896 30, 895 30, 894 30, 893 30, 892 30, 891 30, 890 30, 889 30, 888 30, 887 30, 886 30, 885 30, 884 30, 883 30, 882 30, 881 30, 880 30, 879 30, 878 30, 877 30, 876 30, 875 30, 874 30, 873 30, 872 30, 871 30, 870 30, 869 30, 868 30, 867 30, 866 30, 865 30, 864 30, 863 30, 862 30, 861 30, 860 30, 859 30, 858 30, 857 30, 856 30, 855 30, 854 30, 853 30, 852 30, 851 30, 850 30, 849 30, 848 30, 847 30, 846 30, 845 30, 844 30, 843 30, 842 30, 841 30, 840 30, 839 30, 838 30, 837 30, 836 30, 835 30, 834 30, 833 30, 832 30, 831 30, 830 30, 829 30, 828 30, 827 30, 826 30, 825 30, 824 30, 823 30, 822 30, 821 30, 820 30, 819 30, 818 30, 817 30, 816 3

% A \$ 509 % A A A 1940 % A A 1919 % A A 567 % A A A 1352 % A A 48 A We expect to continue to incur a significant amount of research and development expenses during the foreseeable future. We will continue development of VitaGraft, DetermaIO and DetermaCNI. Our future research and development efforts and expenses will also depend on the amount of capital that we are able to raise to finance those activities and whether we acquire rights to any new diagnostic tests. A portion of our costs for leasing and operating our CLIA laboratory in Tennessee, and in Germany with Chronix, will also be included in research and development expenses to the extent allocated to the development of our diagnostic tests. We may commence clinical trials of DetermaIO if we develop that diagnostic test to the point where we determine that its use as a clinical diagnostic appears to be feasible. Sales and Marketing Expenses A summary of the main drivers of the change in sales and marketing expenses is as follows: A Three Months EndedSeptember 30, A Nine Months EndedSeptember 30, A 2024 A A 2023 A A \$ Change A A % Change A A 2024 A A 2023 A A \$ Change A A % Change A A (In thousands, except percentage change values) A Personnel-related expenses A \$ 703 A A \$ 486 A A \$ 217 A A \$ 45 % A \$ 1,918 A A \$ 1,494 A A \$ 424 A A 28 % Stock-based compensation A A 44 A A 64 A A (20) A A (31)% A A 127 A A 203 A A (76) A A (37)% Facilities and insurance A A 79 A A 58 A A 21 A A 36 % A A 128 A A 174 A A (46) A A (26)% Professional fees, legal, and outside services A A 45 A A 28 A A 17 A A 61 % A A 166 A A 140 A A 26 A A 19 % Marketing & Advertising A A 41 A A 44 A A (3) A A (7)% A A 123 A A 107 A A 16 A A 15 % Other A A 131 A A 33 A A 98 A A 297 % A A 280 A A 95 A A 185 A A 195 % Total A \$ 1,043 A A \$ 713 A A \$ 330 A A 46 % A \$ 2,742 A A \$ 2,213 A A \$ 529 A A 24 % % of Net Revenue A A 907 % A A 166 % A A A 741 % A A 694 % A A 186 % A A A 508 % A We expect to continue to incur sales and marketing expenses during the foreseeable future as we complete product development and begin commercialization efforts for DetermaIO as a clinical test. Sales and marketing expenses will also increase if we successfully develop and begin commercializing VitaGraft and DetermaCNI, or if we acquire and commercialize other diagnostic tests. Our commercialization efforts and expenses will also depend on the amount of capital that we are able to raise to finance commercialization of our tests. Our future expenditures on sales and marketing will also depend on the amount of revenue that those efforts are likely to generate. Because physicians are more likely to prescribe a test for their patients if the cost is covered by Medicare or health insurance, demand for our diagnostic and other tests and our expenditures on sales and marketing are likely to increase if our diagnostic or other tests qualify for reimbursement by Medicare or private health insurance companies. General and Administrative Expenses A summary of the main drivers of the change in general and administrative expenses is as follows: A Three Months EndedSeptember 30, A Nine Months EndedSeptember 30, A 2024 A A \$ Change A A % Change A A 2024 A A 2023 A A \$ Change A A % Change A A (In thousands, except percentage change values) A Personnel-related expenses and board fees A \$ 1,078 A A \$ 756 A A \$ 322 A A 43 % A \$ 2,995 A A \$ 2,846 A A \$ 149 A A 5 % Professional fees, legal, and outside services A A 735 A A 774 A A (39) A A (5)% A A 2,473 A A 2,720 A A (247) A A (9)% Facilities and insurance A A 410 A A 572 A A (162) A A (28)% A A 1,235 A A 1,791 A A (556) A A (31)% Stock-based compensation A A 206 A A 252 A A (46) A A (18)% A A 520 A A 1,119 A A (599) A A (54)% Severance A A æ” A A 17 A A (17) A A (100)% A A æ” A A 498 A A (498) A A (100)% Other A A 136 A A 116 A A 20 A A 17 % A A 422 A A 456 A A (34) A A (7)% Total A \$ 2,565 A A \$ 2,487 A A 78 A A 3 % A \$ 7,645 A A \$ 9,430 A A (1,785) A A (19)% % of Net Revenue A 2230 % A A 580 % A A A 1651 % A A 1935 % A A 793 % A A A 1142 % A A 49 A Change in Fair Value of Contingent Consideration We will pay contingent consideration if various payment milestones are triggered under the merger agreements through which we acquired Insight and Chronix. See Note 3 to our consolidated financial statements included elsewhere in this Report. Changes in the fair value of the contingent consideration will be based on our reassessment of the key assumptions underlying the determination of this liability as changes in circumstances and conditions occur from the Insight and Chronix acquisition dates to the reporting periods being presented, with the subsequent changes in fair value recorded as part of our consolidated results from operations for such periods. See above change explanation for additional information. Other Income and Expenses Other income and expenses are primarily comprised of interest income and expense, and unrealized gains/losses from marketable equity securities, which were sold in 2023 (see Note 2, æœœMarketable Equity Securities,æœœ to our consolidated financial statements included elsewhere in this Report). Interest income is earned from money market funds we hold for capital preservation. Interest expense was incurred mainly from our financing lease obligations (see Note 6) and insurance financing activity. Income Taxes We did not record any provision or benefit for income taxes for the three and nine months ended September 30, 2024 and 2023, as we had a full valuation allowance for the periods presented (see Note 2 to our consolidated financial statements included elsewhere in this Report). A valuation allowance is provided when it is more-likely-than-not that some portion of the deferred tax assets will not be realized. We established a full valuation allowance for all periods presented due to the uncertainty of realizing future tax benefits from our net operating loss carry-forwards and other deferred tax assets. Inflation Although historically not significant to our results of operations, financial condition and cash flows, we may experience inflationary pressures, primarily in personnel costs and with certain laboratory supplies. The extent of any future impacts from inflation on our business and our results of operations will be dependent upon how long elevated inflation levels persist and the extent to which the rate of inflation were to increase, if at all, neither of which we are able to predict. If elevated levels of inflation were to persist or if the rate of inflation were to accelerate, the purchasing power of our cash and cash equivalents may be diminished, our expenses could increase faster than anticipated and we may utilize our capital resources sooner than expected. Further, given the complexities of the reimbursement landscape in which we operate, our payors may be unwilling or unable to increase reimbursement rates to compensate for inflationary impacts. As such, the effects of inflation may adversely impact our results of operations, financial condition and cash flows. Liquidity and Capital Resources Our foreseeable material cash requirements as of September 30, 2024, are recognized as liabilities or generally are otherwise described in Note 6, æœœCommitments and Contingencies,æœœ to our consolidated financial statements included elsewhere in this Report. Cash requirements are generally derived from our operating and investing activities including expenditures for working capital, human capital, business development, investments in intellectual property, and business combinations. Our office lease obligations, net of sublease payments, and contingent consideration obligations are further described in Note 6 and Note 3, respectively. Historically, we have not entered into any off-balance sheet arrangements. As of September 30, 2024 and December 31, 2023, we had unrecognized tax benefits totaling \$2.3 million (see Note 2, æœœIncome Taxesæœœ). Since formation, we have financed our operations primarily through the sale of our common stock, preferred stock and warrants. We have incurred operating losses and negative cash flows since inception and had an accumulated deficit of \$317.0 million as of September 30, 2024. At September 30, 2024, we had \$3.4 million of cash and cash equivalents. On October 4, 2024, we raised additional capital as discussed below. We expect to continue to incur operating losses and negative cash flows for the near future. Our expectation to generate operating losses and negative operating cash flows in the future and the need for additional funding to support our planned operations raise substantial doubt regarding our ability to continue as a going concern for a period of one year after the date that the financial statements are issued (see Note 1). A 50 A On April 3, 2023, we entered into an agreement with certain members of our Board of Directors, and several institutional and accredited investors, including Broadwood, our largest shareholder, relating to their purchase of an aggregate of up to 2,278,121 shares of our common stock at an offering price of \$7.08 per share to board members and \$6.03 per share to the other investors participating in the offering (see Note 7). The offering was intended to be priced at-the-market for purposes of complying with applicable Nasdaq Listing Rules. The aggregate gross proceeds from the offering were approximately \$13.9 million before deducting offering expenses payable by us. We used approximately \$1.1 million of the net proceeds to immediately redeem an aggregate of 1,064 shares of our Series A Redeemable Convertible Preferred Stock. On April 15, 2024, we consummated the April 2024 Offering. The resulting net proceeds were approximately \$9.9 million, after deducting offering expenses of \$538,000 and deducting \$5.4 million for the redemption of all remaining shares of our Series A Redeemable Convertible Preferred Stock. These net proceeds are inclusive of an investment from Bio-Rad (see Note 9), our global strategic partner. See Note 7, æœœCommon Stock æœœ April 2024 Offering,æœœ to our consolidated financial statements included elsewhere in this Report for additional information. On August 1, 2024, we filed a shelf registration statement on Form S-3, pursuant to which we registered for sale up to \$100.0 million of any combination of our common stock, preferred stock, warrants and/or units from time to time and at prices and on terms that we may determine (the æœœPrimary Shelf Registration Statementæœœ). On August 9, 2024, we entered into a sales agreement with a sales agent, pursuant to which we may offer and sell from time to time up to an aggregate of \$7.5 million of shares of our common stock, registered on the Primary Shelf Registration Statement, pursuant to the August 2024 Offering. As of September 30, 2024, we received net proceeds from the sale of such shares of approximately \$17,000. See Note 7, æœœCommon Stock æœœ August 2024 Offering,æœœ to our consolidated financial statements included elsewhere in this Report for additional information. On October 4, 2024, we consummated the October 2024 Offering. The gross proceeds from the October 2024 Offering were approximately \$10.2 million. After deducting placement agent fees and expenses and offering expenses payable by the Company of \$795,000, the resulting net proceeds were approximately \$9.4 million. See Note 12, æœœSubsequent Events,æœœ to our consolidated financial statements included elsewhere in this Report for additional information. We expect that our general operating expenses will be commensurate with the market opportunity as we continue to manage our available cash. Although we intend to market our diagnostic tests in the United States through our own sales force, we are also beginning to make marketing arrangements with distributors in other countries. We may also explore a range of other commercialization options in order to enter overseas markets and to reduce our capital needs and expenditures, and the risks associated with the timelines and uncertainty for attaining the Medicare reimbursement approvals that will be essential for the successful commercialization of additional cancer diagnostic tests. Those alternative arrangements could include marketing arrangements with other diagnostic companies through which we might receive a licensing fee and royalty on sales, or through which we might form a joint venture to market one or more tests and share in net revenues, in the United States or abroad. On April 5, 2024, we entered into an agreement with Bio-Rad, our global strategic partner, to collaborate in the development and the commercialization of RUO and IVD kitted transplant products. On November 8, 2024, Oncocyte and Bio-Rad entered into a memorandum of understanding with respect to such agreement to establish additional activities to be performed by each party pursuant to such agreement. See Note 10, æœœCollaborative Arrangements,æœœ to our consolidated financial statements included elsewhere in this Report for additional information. In addition to sales and marketing expenses, we will incur expenses from leasing and improving our offices and laboratory facilities in Nashville, Tennessee. During the third quarter of 2023, we entered into a sublease arrangement for our main office in Irvine, California. In January 2024, we expanded our Nashville facility by adding one new office lease and renewing and extending our existing leases. During the second and third quarters of 2024, we added five financing leases for certain laboratory equipment to be used in our Nashville facility. See Note 6, æœœCommitments and Contingencies,æœœ to our consolidated financial statements included elsewhere in this Report for additional leasing information. We may need to meet significant cash payment or stock obligations to former Insight and Chronix shareholders in connection with our acquisition of those companies, as disclosed in Note 3 to the consolidated financial statements included elsewhere in this Report. To meet the future cash payment obligations, we may have to utilize cash on hand that would otherwise be available to us for other business and operational purposes, which could cause us to delay or reduce activities in the development and commercialization of our cancer tests. A 51 A We will need to continue to raise additional capital to finance our operations, including the development and commercialization of our diagnostic tests, and making payments that may become due under our obligations to former Chronix shareholders and former Insight shareholders, until such time as we are able to generate sufficient revenues to cover our operating expenses. Delays in our collaborative arrangement for the development and the commercialization of RUO and IVD kitted transplant products, or delays in obtaining regulatory approval to distribute our products for clinical use, or delays in the development of, or in obtaining reimbursement coverage from Medicare for DetermaIO and other future laboratory tests that we may develop or acquire, could prevent us from raising sufficient additional capital to finance the completion of development and commercial launch of those tests. Investors may be reluctant to provide us with capital until our tests are approved for reimbursement by Medicare or reimbursement by private healthcare insurers or healthcare providers, or until we begin generating significant amounts of revenue from performing those tests. The unavailability or inadequacy of financing or revenues to meet future capital needs could force us to modify, curtail, delay, or suspend some or all aspects of our planned operations. Sales of additional equity securities could result in the dilution of the interests of our shareholders. We cannot assure that adequate long-term financing will be available on favorable terms, if at all. See Note 1 and Note 7 to our consolidated financial statements included elsewhere in this Report for additional information about our going concern discussion and equity offerings, respectively. Cash Used in Operations During the nine months ended September 30, 2024, our total research and development expenses were \$7.6 million, our sales and marketing expenses were \$2.7 million, and our general and administrative expenses were \$7.6 million. We also incurred \$250,000 in total cost of revenues, including \$66,000 amortization of intangible expenses. Consolidated net loss for the period was \$27.2 million, and our consolidated net cash used in operating activities amounted to \$15.4 million. Our cash used in operating activities during 2024 did not include the following noncash items: \$1.0 million in depreciation and amortization expenses, \$1.3 million in stock-based compensation, \$110,000 in other equity compensation expenses, \$9.4 million loss from change in fair value of contingent consideration, and \$169,000 impairment loss on held for sale assets. Net changes in operating assets and liabilities for the period were \$162,000 as an additional use of cash. During the nine months ended September 30, 2023, our total research and development expenses were \$6.7 million, our sales and marketing expenses were \$2.2 million, and our general and administrative expenses were \$9.4 million. We also incurred \$659,000 in total cost of revenues, including \$66,000 amortization of intangible expenses. Consolidated net loss for the period was \$11.8 million, and our consolidated net cash used in operating activities amounted to \$18.9 million. Our cash used in operating activities during 2023 did not include the following noncash items: \$1.4 million in depreciation and amortization expenses, \$2.3 million in stock-based compensation, \$16.9 million gain from change in fair value of contingent consideration, \$6.8 million loss from asset impairments, \$1.5 million loss related to discontinued operations, \$1.3 million loss on disposal and held for sale assets, \$108,000 in other equity compensation expenses, and \$8,000 in unrealized gain on marketable equity securities. Net changes in operating assets and liabilities for the period were \$3.5 million as an additional use of cash. Cash Used in Investing Activities During the nine months ended September 30, 2024, net cash used in investing activities was \$302,000 from cash paid for construction in progress and purchase of furniture and equipment. During the nine months ended September 30, 2023, net cash used in investing activities was \$1.0 million primarily from cash sold in discontinued operations, partially offset by proceeds from the sale of equipment. Cash Provided by Financing Activities During the nine months ended September 30, 2024, net cash provided by financing activities was \$9.6 million from \$15.1 million of net cash proceeds from the April 2024 Offering and the August 2024 Offering, partially offset by the redemption of our remaining Series A Preferred Stock of \$5.4 million and repayments of financing lease obligations of \$119,000. During the nine months ended September 30, 2023, net cash provided by financing activities was \$12.2 million from \$13.4 million of net cash proceeds from the sale of shares of common stock, partially offset by the partial redemption of Series A Preferred Stock of \$1.1 million and repayments of financing lease obligations of \$87,000. A 52 A Critical Accounting Estimates Our consolidated financial statements are prepared in conformity with GAAP. In preparing these financial statements, we make assumptions, judgments and estimates that involve a significant level of estimation uncertainty and have had or are reasonably likely to have a material impact on our financial condition or results of operations. We base our assumptions, judgments and estimates on historical experience and various other factors that we believe to be reasonable under the circumstances. Actual results could differ materially from these estimates under different assumptions or conditions. On a regular basis, we evaluate our assumptions, judgments and estimates and make changes accordingly. We believe that of the significant accounting policies discussed in Note 2 to our consolidated financial statements included elsewhere in this Report, the following accounting policies involve a significant level of estimation uncertainty and require our most difficult, subjective or complex assumptions, judgments and estimates: æœœGoing Concern Assessment; æœœContingent Consideration Liabilities; æœœIntangible Assets; æœœImpairment of Long-Lived Assets; æœœRevenue Recognition and Allowance for Credit Losses; æœœStock-Based Compensation; and æœœIncome Taxes. Going Concern Assessment We assess going concern uncertainty in our consolidated financial statements to determine if we have sufficient cash and cash equivalents on hand and working capital, including available loans or lines of credit, if any, to operate for a period of at least one year from the date our consolidated financial statements are issued (the æœœlook-forward periodæœœ). As part of this assessment, based on conditions that are known and reasonably knowable to us, we consider various scenarios, forecasts, projections and estimates, and we make certain key assumptions, including the timing and nature of projected cash expenditures or programs, and our ability to delay or curtail those expenditures or programs, if necessary, among other factors. Based on this assessment, as necessary or applicable, we make certain assumptions around implementing curtailments or delays in the nature and timing of programs and expenditures to the extent we deem probable those implementations can be achieved and we have the proper authority to execute them within the look-forward period. For additional information, refer to Note 1 to our consolidated financial statements included elsewhere in this Report. Contingent Consideration Liabilities Contingent consideration is estimated and recorded at fair value as of the acquisition date as part of the total consideration transferred. Contingent consideration is an obligation of the acquirer to transfer

additional assets or equity interests to the selling shareholders in the future if certain future events occur or conditions are met, such as the attainment of product development milestones. Contingent consideration also includes additional future payments to selling shareholders based on achievement of components of earnings, such as “earn-out” provisions or percentage of future revenues, including royalties paid to the selling shareholders based on a percentage of certain revenues generated. The fair value of milestone-based contingent consideration was determined using a scenario analysis valuation method which incorporates our assumptions with respect to the likelihood of achievement of the milestones, as defined in the merger agreements, credit risk, timing of the contingent consideration payments and a risk-adjusted discount rate to estimate the present value of the expected payments, all of which require significant management judgment and assumptions. Since the contingent consideration payments are based on nonfinancial, binary events, management believes the use of the scenario analysis method is appropriate. The fair value of royalty or revenue share-based contingent consideration was determined using a single scenario analysis method to value those payments. The single scenario method incorporates our assumptions with respect to specified future revenues generated over their respective useful lives, credit risk, and a risk-adjusted discount rate to estimate the present value of the expected royalty payments, all of which require significant management judgment and assumptions. Since the royalty-based contingent consideration payments are based on future revenues and linear payouts, management believes the use of the single scenario method is appropriate. A 53 A The fair value of contingent consideration after the acquisition date is reassessed by us as changes in circumstances and conditions occur, with the subsequent change in fair value recorded in our consolidated statements of operations. Changes in key assumptions can materially affect the estimated fair value of contingent consideration liabilities and, accordingly, the resulting gain or loss that we record in our consolidated financial statements. During the nine months ended September 30, 2024 and 2023, we recorded a loss of \$9.4 million and a gain of \$16.9 million, respectively, related to the fair value of contingent consideration. As of September 30, 2024 and December 31, 2023, contingent consideration liabilities were \$49.3 million and \$39.9 million, respectively. For additional information, refer to Note 3 to our consolidated financial statements included elsewhere in this Report. Intangible Assets We consider various factors and risks for potential impairment of IPR&D intangible assets, including the current legal and regulatory environment and the competitive landscape. Adverse clinical trial results, significant delays or inability to obtain LCD from the Centers for Medicare and Medicaid Services for Medicare reimbursement for a diagnostic test, the inability to bring a diagnostic test to market and the introduction or advancement of competitors’ diagnostic tests could result in partial or full impairment of the related intangible assets. Consequently, the eventual realized value of the IPR&D project may vary from its fair value at the date of acquisition, and IPR&D impairment charges may occur in future periods. During the period between completion or abandonment, the IPR&D assets will not be amortized but will be tested for impairment on an annual basis and between annual tests if we become aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&D projects below their respective carrying amounts. During the first quarter of 2023, due to changes in management and our economic condition, management shifted our business strategy to direct efforts on fewer studies and to transition from tests that are laboratory developed tests (“LDTs”) to RUO sales. Due to the change in strategy, our long range plan forecasts were updated and anticipated future benefits derived from our assets. The change in strategy represent a significant indicator for change in value of our long-lived assets. The original IPR&D balances were reassessed based on the updated long range plan, using the multi-period excess earnings method approach, the results of the valuation noted that the carrying value of certain IPR&D intangible assets was greater than the fair market value. Accordingly, we recorded an impairment of approximately \$5.0 million as of March 31, 2023. We have not recorded any additional impairment adjustments as of September 30, 2024. For additional information, refer to Note 5 to our consolidated financial statements included elsewhere in this Report. Impairment of Long-Lived Assets We assess the impairment of long-lived assets, which consists primarily of long-lived intangible assets, right-of-use assets, and machinery and equipment, whenever events or changes in circumstances indicate that such assets might be impaired and the carrying value may not be recoverable. When such events or changes in circumstances are present, we estimate the future cash flows expected to result from the use of the asset (or asset group) and its eventual disposition. If the sum of the expected undiscounted future cash flows is less than the carrying amount, we recognize an impairment based on the fair value of such assets. During the nine months ended September 30, 2024 and 2023, we recognized impairment losses on held for sales assets of \$169,000 and \$1.3 million, respectively. For additional information, refer to Note 2, “Assets Held for Sale and Discontinued Operations,” to our consolidated financial statements included elsewhere in this Report. Revenue Recognition and Allowance for Credit Losses Pharma Services revenue Pharma Services are generally performed under individual scope of work (“SOW”) arrangements or license agreements (together with SOW the “Pharma Services Agreements”) with specific deliverables defined by the customer. Pharma Services are performed on a (i) time and materials basis or (ii) per test completed basis. Upon completion of the service to the customer in accordance with a Pharma Services Agreement, we have the right to bill the customer for the agreed upon price (either on a per test or per deliverable basis) and recognizes Pharma Service revenue at that time. Insight identifies each sale of its Pharma Service offering as a single performance obligation. Chronix identifies the processing of test samples as a separate performance obligation (considered a series) within license agreements with customers. Completion of the service and satisfaction of the performance obligation is typically evidenced by access to the report or test made available to the customer or any other form or applicable manner of delivery defined in the Pharma Services Agreements. However, for certain SOWs under which work is performed pursuant to the customer’s highly customized specifications, we have the enforceable right to bill the customer for work completed, rather than upon completion of the SOW. For those SOWs, we recognize revenue over a period during which the work is performed using a formula that accounts for expended efforts, generally measured in labor hours, as a percentage of total estimated efforts for the completion of the SOW. As performance obligations are satisfied under the Pharma Services Agreements, any amounts earned as revenue and billed to the customer are included in accounts receivable. A 54 A We establish an allowance for credit losses based on the evaluation of the collectability of its Pharma Services accounts receivables after considering a variety of factors, including the length of time receivables are past due, significant events that may impair the customer’s ability to pay, such as a bankruptcy filing or deterioration in the customer’s operating results or financial position, reasonable and supportable forecast that affect the collectability of the reported amount, and historical experience. We continuously monitor collections and payments from customers and maintains a provision for estimated credit losses and uncollectible accounts, if any, based upon its historical experience and any specific customer collection issues that have been identified. Amounts determined to be uncollectible are written off against the credit loss reserve accounts. As of September 30, 2024 and December 31, 2023, we had an allowance for credit losses of \$2,000 and \$5,000, respectively, related to Pharma Services. Laboratory Developed Test Services Although we have billed a list price for all tests ordered and completed for all payer types, we consider constraints on the variable consideration when recognizing revenue for DetermaRx. Because DetermaRx is a novel test and there are no current reimbursement arrangements with third-party payers other than Medicare, the transaction price represents variable consideration. Application of the constraint for variable consideration is an area that requires significant judgment. For all payers other than Medicare, we must consider the novelty of the test, the uncertainty of receiving payment, or being subject to claims for a refund, from payers with whom it does not have a sufficient payment collection history or contractual reimbursement agreements. Accordingly, for those payers, we have recognized revenue upon payment because it has had insufficient history to reliably estimate payment patterns. We maintained an allowance for credit losses related to Laboratory Developed Test Services at an amount we estimated to be sufficient to provide adequate protection against losses resulting from extending credit to our customers. We based this allowance, in the aggregate, on historical collection experience, age of receivables and general economic conditions, as well as specific identification of uncollectible accounts. We initially established an allowance in 2022 in connection with remaining Medicare and Medicare Advantage account balances and continued to add to the allowance as appropriate. In the first quarter of 2023, in connection with the adoption of the new current expected credit loss model, the Company determined that the Medicare and Medicare Advantage accounts receivable net balance of approximately \$1.4 million was uncollectible and should therefore be written-off as of the adoption date, January 1, 2023. As of September 30, 2024 and December 31, 2023, we had no receivables nor allowance for credit losses related to Laboratory Developed Test Services. Stock-Based Compensation We recognize compensation expense related to share-based payment awards made to employees, board directors and other non-employees based on estimated fair values. We estimate the fair value of stock-based payment awards on the grant date and recognize the resulting fair value over the requisite service period on a straight-line basis. For stock-based awards that vest only upon the attainment of one or more performance goals, compensation cost is recognized if and when we determine that it is probable that the performance condition or conditions will be, or have been, achieved. For grants with market-based and time-based vesting conditions, the fair value is estimated using the Monte Carlo simulation model, which includes the estimated period to achievement of the performance and market conditions, which are subject to the achievement of the market-based goals established by us and continued employment. We utilize the Black-Scholes option pricing model for determining the fair value of standard time-based stock options. Our determination of fair value of share-based payment awards on the date of grant using an option pricing model is affected by our stock price as well as assumptions regarding a number of complex and subjective variables. These variables include, but are not limited to, expected stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors. We estimate the expected volatility using our own stock price volatility for a period equal to the expected term of the options. The expected term of options granted is based on our own experience. The risk-free rate is based on the U.S. Treasury rates in effect during the corresponding period of grant. Key inputs and assumptions may change as we continue to develop our own company estimates, experience and key inputs including our expected term, and stock price volatility based on the trading history of our stock in the public market. Changes in these subjective assumptions can materially affect the estimated value of equity grants and the stock-based compensation that we record in our consolidated financial statements. During the nine months ended September 30, 2024 and 2023, we recognized total stock-based compensation of \$1.3 million and \$2.3 million, respectively. For additional information, refer to Note 8 to our consolidated financial statements included elsewhere in this Report. A 55 A Income Taxes We account for income taxes in accordance with ASC 740, Income Taxes, which prescribes the use of the asset and liability method, whereby deferred tax asset or liability account balances are calculated at the balance sheet date using current tax laws and rates in effect. The provision for income taxes for interim periods is determined using an estimated annual effective tax rate in accordance with ASC 740-270, Income Taxes, Interim Reporting. Valuation allowances are established when necessary to reduce deferred tax assets when it is more-likely-than-not that a portion or all of the deferred tax assets will not be realized. Our judgments regarding future taxable income may change over time due to changes in market conditions, changes in tax laws, tax planning strategies or other factors. If our assumptions and consequently our estimates change in the future, the valuation allowance may be increased or decreased, which may have a material impact on our statements of operations. The guidance also prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not sustainable upon examination by taxing authorities. We will recognize accrued interest and penalties, if any, related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties as of the financial statement periods presented herein. We account for uncertain tax positions by assessing all material positions taken in any assessment or challenge by relevant taxing authorities. We are currently unaware of any tax issues under review. Refer to Note 2, “Income Taxes,” to our consolidated financial statements included elsewhere in this Report. Item 3. Quantitative and Qualitative Disclosures about Market Risk Under SEC rules and regulations, as a smaller reporting company, we are not required to provide the information required by this item. Item 4. Controls and Procedures. Evaluation of Disclosure Controls and Procedures It is management’s responsibility to establish and maintain adequate internal control over all financial reporting pursuant to Rule 13a-15 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Our management, including our principal executive officer and principal financial officer, have reviewed and evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Report. Following this review and evaluation, the principal executive officer and principal financial officer determined that our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act (i) is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and (ii) is accumulated and communicated to management, including our principal executive officer, and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. Changes in Internal Controls There were no changes in our internal control over financial reporting that occurred during the quarterly period covered by this Report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. A 56 A PART II - OTHER INFORMATION Item 1. Legal Proceedings. From time to time, we may be involved in routine litigation incidental to the conduct of our business. We are not presently involved in any material pending litigation or proceedings. See Note 6 to our consolidated financial statements included elsewhere in this Report for additional information regarding commitments and contingencies. Item 1A. Risk Factors. Our business, financial condition, results of operations and future growth prospects are subject to various risks, including those described in Item 1A “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on April 16, 2024, which we encourage you to review. Other than as noted below, there have been no material changes from the risk factors disclosed in our most recent Annual Report on Form 10-K. If the FDA takes the position that any of our tests are not within the scope of its policy on enforcement discretion for laboratory-developed tests, or otherwise determines that it will seek to actively regulate one or more of our diagnostic tests, responding to such a regulatory position could lead to delays in commercialization, or (if encountered after commercialization) requirements to halt the commercial provision of our tests until FDA marketing authorization is obtained. In May 2024, the FDA published a final rule that phases out its enforcement discretion for LDTs, unless exempt, and amends the FDA’s regulations to make explicit that IVDs are medical devices under the Federal Food, Drug, and Cosmetic Act (“FDCA”), including when the manufacturer of the diagnostic product is a laboratory. The American Clinical Laboratory Association and a private laboratory have filed lawsuits against the FDA to challenge its authority to regulate LDTs under this final rule. The full impact of this final rule and the existing (and any future) challenges against currently remains to be seen. If the FDA were to ultimately regulate our tests as traditional IVDs, some or all of our tests may become subject to certain FDA medical device regulations, including, in some cases, pre-market review. If required, the regulatory marketing authorization process may involve, among other things, successfully completing additional clinical trials and submitting a pre-market clearance (510(k)) submission or filing a de novo or pre-market approval application with the FDA. If pre-market review and approval is required by the FDA for any of our tests, we may need to incur additional expenses or require additional time to seek it, or we may be unable to satisfy FDA standards, and our applicable tests may not be cleared or approved on a timely basis, if at all, and the labeling claims permitted by the FDA may not be consistent with our currently planned claims or adequate to support adoption of and reimbursement for our tests. Ongoing compliance with any applicable FDA medical device regulations to which we could become subject in connection with any of our tests that FDA may regulate as traditional IVDs would increase the cost of conducting our business, and subject us to inspection by, and potential enforcement of certain regulatory requirements, of the FDA, for example registration and listing, adherence to good manufacturing practices under the Quality System Regulation (“QSR”), and medical device reporting. Enforcement action for noncompliance with these requirements could range from warning or untitled letters to civil and criminal penalties, injunctions, product seizure or recall, import bans, restrictions on the conduct of our operations and total or partial suspension of production. Our laboratories are operating under CLIA and are not currently operating as registered device manufacturing facilities or in compliance with FDA’s QSR. Because these standards differ, we may face challenges establishing FDA-compliant quality systems or be unable to do so. If after commercialization under the LDT framework, our tests are allowed to remain on the market but there is uncertainty about the regulatory status of our tests, which is likely, given the current state of industry challenges to FDA’s final rule, including questions that may be raised if competitors object to our regulatory positioning as an LDT, we may encounter ongoing regulatory and legal challenges and related costs. Such challenges or related developments (for example if the labeling claims the FDA allows us to make are more limited than the claims we currently plan to make) may impact our commercialization efforts as orders or reimbursement may be less than anticipated. Any of these regulatory developments may cause our business to suffer. If the FDA is successful in overcoming challenges to the final rule and ultimately regulates certain LDTs as intended under the final rule, our tests may be subject to certain additional regulatory requirements, the scope of which may vary from one test to another based on various considerations. Complying with the FDA’s requirements can be expensive, time-consuming, and subject us to significant or unanticipated delays. To the extent we are required to obtain premarket clearance or approval to perform or continue performing any of our tests, we cannot guarantee that we will be able to obtain such authorization. Even if we obtain regulatory clearance or approval where required, such authorization may not be for the intended uses that we believe are commercially attractive or are critical to the commercial success of our tests. Based on these and other considerations, the implementation of the FDA’s final rule on LDTs could materially and adversely affect our business, financial condition, and results of operations. A 57 A We currently market certain IVDs that have not been cleared by the FDA in reliance on the regulatory exemption for IVDs intended for RUO, but if the FDA determines that our RUO

tests do not meet the applicable requirements for exemption or have intended uses that are inconsistent with RUO tests, we may be required to suspend commercialization of such products until we can obtain the requisite FDA clearance and/or subject to FDA warning or untitled letters, seizure, injunction, fines, or other enforcement action. Some of our tests are marketed for RUO, which allows us to sell such products without the premarket clearance that FDA requires for the marketing of traditional devices. An RUO product may not be marketed for clinical diagnostic use and must be labeled “For Research Use Only. Not for use in diagnostic procedures.” Products that are intended for research use only and are properly labeled as RUO are exempt from compliance with the FDA’s pre- and post-market requirements to which traditional devices are subject, including the requirement that the product be cleared or approved before commercialization and QSR requirements. However, merely including the required RUO labeling will not necessarily exempt the device from the FDA’s 510(k) clearance, premarket approval, or other requirements if the circumstances surrounding the distribution of the product indicate an objective intent to market the product for clinical diagnostic use. According to the FDA guidance, circumstances indicating manufacturer intent to market an in vitro device for diagnostic use may include written or verbal marketing claims regarding a product’s clinical efficacy or performance in clinical applications, instructions for clinical interpretation, clinical information, product names, or descriptors that claim or suggest that the IVD product may be used for any clinical diagnostic use, including a clinical investigation that is not exempt from the FDA’s investigational device exemption regulations. Other indications include a manufacturer’s provision of technical support for clinical validation or clinical applications or solicitation of business from clinical laboratories that do not conduct research activities, all of which could be considered evidence of intended uses that conflict with RUO labeling. In general, if (i) evidence shows that one or more of our IVDs are inappropriately labeled RUO (but marketed for clinical diagnostic use), such test(s) will not qualify for an IDE exemption and will be deemed misbranded under the FDCA. Device manufacturers found in violation of the FDCA may be subject to a wide range of enforcement action, including warning letters, seizure, injunction, criminal prosecution, monetary penalties, and others. We believe that our promotional activities for our RUO products fall within the scope of the applicable premarket exemptions for RUO tests and the FDA’s enforcement discretion, as described in its relevant guidance. However, the FDA could disagree and require us to (i) stop promoting our RUO devices unless/until we obtain FDA clearance or approval (among other possible outcomes). Any adverse determination in relation to our marketing of current or future products for RUO will likely have a material adverse impact on our business. Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. Recent Sales of Unregistered Securities None. Repurchases None. Item 3. Defaults Upon Senior Securities. None. Item 4. Mine Safety Disclosures. Not applicable. A 58 A Item 5. Other Information. (a) On November 8, 2024, Oncocyte and Bio-Rad entered into a binding Memorandum of Understanding (the “Memorandum”) in connection with the Collaboration Agreement. The Memorandum establishes additional activities (described below) to be performed by Oncocyte and Bio-Rad prior to the commercial launch of the RUO Assays specifically related to pilot study sites outside the Territory (the “Pilot Sites”). Pursuant to the Memorandum, Oncocyte (i) will setup commercialization of Pilot Sites to use the RUO Assays, (ii) may sell RUO Assays to Pilot Sites, (iii) will train and support the Pilot Sites on the use of the RUO Assays, and (iv) if Oncocyte receives any net sales from the sale of the RUO Assays to the Pilot Sites, then Oncocyte shall pay to Bio-Rad a royalty payment based on a percentage of such net sales under the terms and conditions of the Collaboration Agreement. In addition, pursuant to the Memorandum, Bio-Rad will evaluate commercialization efforts for the RUO Assays, which will include (i) supporting installation and training for Pilot Sites, and (ii) evaluating distribution of the RUO Assays to Pilot Sites. The foregoing description of the material terms and conditions of the Memorandum does not purport to be complete and is qualified in its entirety by the full text of the Memorandum, which is attached hereto as Exhibit 10.6. For additional information, refer to Note 10, “Collaborative Arrangements,” to our consolidated financial statements included elsewhere in this Report. (b) None. (c) None. A 59 A Item 6. Exhibits. A Exhibit Numbers A Exhibit Description A A 10.1 A Sales Agreement, dated August 9, 2024, by and between the Oncocyte Corporation and Needham & Company, LLC (Incorporated by reference to Oncocyte Corporation’s Current Report on Form 8-K filed with the Securities and Exchange Commission on August 9, 2024) A A 10.2+ A Securities Purchase Agreement, dated October 2, 2024, by and among the Company and the investors signatory thereto (Incorporated by reference to Oncocyte Corporation’s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 3, 2024) A A 10.3+ A Registration Rights Agreement, dated October 2, 2024, by and among the Company and the investors signatory thereto (Incorporated by reference to Oncocyte Corporation’s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 3, 2024) A A 10.4+ A Amended and Restated 2018 Equity Incentive Plan (Incorporated by reference to Oncocyte Corporation’s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 16, 2024) A A 10.5+ A Collaboration Agreement, dated April 5, 2024, between the Company and Bio-Rad Laboratories, Inc. (Incorporated by reference to Oncocyte Corporation’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 15, 2024) A A 10.6+ A Memorandum of Understanding, dated November 8, 2024, between the Company and Bio-Rad Laboratories, Inc. A 31.1* A Certification of the Principal Executive Officer of Oncocyte Corporation pursuant to Rule 13a-14 of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Rule 302 of the Sarbanes-Oxley Act of 2002 A 31.2* A Certification of the Principal Financial Officer of Oncocyte Corporation pursuant to Rule 13a-14 of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Rule 302 of the Sarbanes-Oxley Act of 2002 A 32.1** A Certifications pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 A 101.INS A Inline XBRL Instance Document “the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document. A A 101.SCH A Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents A A 104 A Cover Page Interactive Data File (embedded within the Inline XBRL document) A * Filed herewith ** The certifications attached as Exhibit 32.1 that accompany this Report are not deemed filed with the SEC and are not to be incorporated by reference into any filing of Oncocyte under the Securities Act, or the Exchange Act, whether made before or after the date of this Report, regardless of any general incorporation language contained in any filing. # The referenced exhibit is a management contract, compensatory plan or arrangement. + Schedules have been omitted from this filing pursuant to Item 601(b)(10) of Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted schedule to the SEC upon its request; provided, however, that the Company may request confidential treatment pursuant to Rule 24b-2 of the Exchange Act for any schedule so furnished. Certain portions of this exhibit (indicated by “”) have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed. A 60 A SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized. A A ONCYCOTE CORPORATION A Date: November 12, 2024 /s/ Joshua Riggs A Joshua Riggs A President and Chief Executive Officer (Principal Executive Officer) A Date: November 12, 2024 /s/ Andrea James A Andrea James A Chief Financial Officer (Principal Financial Officer) A 61 EX-10.6 2 ocx-ex10.6.htm EX-10.6 EX-10.6 Exhibit 10.6 A Certain information contained in this document, marked by brackets [“”], has been omitted pursuant to Regulation S-K, Item 601(b)(10) because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. A Memorandum of Understanding A Oncocyte Corporation (“Oncocyte”) and Bio-Rad Laboratories, Inc. (“Bio-Rad”) (each, a “Party”, and collectively the “Parties”) have executed a Collaboration Agreement for the development and commercialization of RUO and IVD kitted transplant products, effective April 5, 2024 (the “Agreement”). This binding Memorandum of Understanding (“Memorandum”) identifies certain activities that the Parties will perform prior to completion of the Product Commercialization Plan and in addition to the activities to be performed under the Agreement. Any capitalized term used in this Memorandum but not defined herein shall have the meaning ascribed to such term in the Agreement. A Bio-Rad Activities: A Evaluate commercialization efforts for the RUO Assays. A Support installation and training for pilot study sites outside the Territory (“Pilot Sites”). An initial list of Pilot Sites is set forth below in Appendix A, which may be amended by mutual agreement. A Evaluate distribution of the RUO Assays to Pilot Sites outside the Territory. Oncocyte Activities: A Set up commercialization of Pilot Sites outside the Territory to use the RUO Assays. A Oncocyte may sell RUO Assays to Pilot Sites. A Train and support the Pilot Sites on the use of the RUO Assays. A Notwithstanding anything to the contrary in the Agreement, if Oncocyte receives any Net Sales from the sale of the RUO Assays to the Pilot Sites, then Oncocyte shall pay to Bio-Rad a Royalty Payment of [“”] percent ([“”]%) of the Net Sales under the terms and conditions of ARTICLE VII. The Parties shall continue to co-develop the Product Commercialization Plan, including for outside the Territory, under the terms of the Agreement. Once decisions are made concerning the Product Commercialization Plan and are reduced to writing from minutes of the Joint Steering Committee, these Pilot Sites shall be governed by the terms of the Agreement as determined by the Joint Steering Committee, including the Product Commercialization Plan, and not this Memorandum. A Except as expressly set forth herein, the Agreement remains unchanged and in full force and effect. A A Oncocyte Corporation Bio-Rad Laboratories, Inc. A A A A 4863-8022-9100v2/106866-0000 A A A /s/ Scott Crowder /s/ Josh Riggs A By: Scott Crowder By: Josh Riggs Title: Vice President, Business Development Title: CEO Date: 11/7/2024 Date: 11/8/2024 A Bio-Rad Oncocyte A Appendix A- RUO Assay Pilot Study Sites Outside the Territory: A [“”] A 4863-8022-9100v2/106866-0000 EX-31.1 3 ocx-ex31.1.htm EX-31.1 Exhibit 31.1 CERTIFICATION I, Josh Riggs, certify that: 1.I have reviewed this quarterly report on Form 10-Q of Oncocyte Corporation; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this periodic report is being prepared; (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and 5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. A Date: November 12, 2024 A /s/ Josh Riggs Josh Riggs President and Chief Executive Officer (Principal Executive Officer) A EX-31.2 4 ocx-ex31.2.htm EX-31.2 EX-31.2 Exhibit 31.2 CERTIFICATION I, Andrea James, certify that: 1.I have reviewed this quarterly report on Form 10-Q of Oncocyte Corporation; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this periodic report is being prepared; (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and 5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. A Date: November 12, 2024 A /s/ Andrea James Andrea James Chief Financial Officer (Principal Financial Officer) A EX-32.1 5 ocx-ex32.1.htm EX-32.1 EX-32.1 Exhibit 32.1 CERTIFICATIONS PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Quarterly Report on Form 10-Q of Oncocyte Corporation (the “Company”) for the quarter ended September 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Josh Riggs, President and Chief Executive Officer of the Company, and Andrea James, Chief Financial Officer of the Company, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that: 1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and 2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Date: November 12, 2024 A /s/ Josh Riggs Josh Riggs President and Chief Executive Officer (Principal Executive Officer) /s/ Andrea James Andrea James Chief Financial Officer (Principal Financial Officer) A EX-101.SCH 6 ocx-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 100010 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 100020 - Disclosure - Schedule of Future Minimum Lease Commitments for Operating and Financing Leases (Details) 2 link:presentationLink link:calculationLink link:definitionLink 100030 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100040 - Statement - Condensed Consolidated Statements of Operations (Unaudited) 2 link:presentationLink link:calculationLink link:definitionLink 100050 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100060 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100070 - Statement - Condensed Consolidated Statements of Series A Redeemable Convertible Preferred Stock and Shareholders’ Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100080 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 995455 - Disclosure - Organization and Description of the Business link:presentationLink link:calculationLink link:definitionLink 995465 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995475 - Disclosure - Business Combinations and Contingent Consideration Liabilities link:presentationLink link:calculationLink link:definitionLink 995485 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 995495 - Disclosure - Intangible Assets, Net link:presentationLink link:calculationLink link:definitionLink 995505 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - Series A Redeemable Convertible Preferred Stock and Shareholders’ Equity link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 995545 - Disclosure - Collaborative Arrangements link:presentationLink link:calculationLink link:definitionLink 995555 - Disclosure - Discontinued Operations of Razor link:presentationLink link:calculationLink link:definitionLink 995565 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 995575 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink

link:calculationLink link:definitionLink 995585 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 995595 - Disclosure - Business Combinations and Contingent Consideration Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 995605 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 995615 - Disclosure - Intangible Assets, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 995625 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 995635 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 995645 - Disclosure - Discontinued Operations of Razor (Tables) link:presentationLink link:calculationLink link:definitionLink 995655 - Disclosure - Organization and Description of the Business (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995665 - Disclosure - Summary of Significant Accounting Policies - Schedule of Prior Period Revisions (Details) link:presentationLink link:calculationLink link:definitionLink 995675 - Disclosure - Summary of Significant Accounting Policies - Schedule of Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 995685 - Disclosure - Summary of Significant Accounting Policies - Schedule of Concentration of Risk (Details) link:presentationLink link:calculationLink link:definitionLink 995695 - Disclosure - Summary of Significant Accounting Policies - Schedule of Consolidated Revenues Generated by Unaffiliated Customers (Details) link:presentationLink link:calculationLink link:definitionLink 995705 - Disclosure - Summary of Significant Accounting Policies - Schedule of Percentage of Consolidated Revenues Attributable to Geographical Locations (Details) link:presentationLink link:calculationLink link:definitionLink 995715 - Disclosure - Summary of Significant Accounting Policies - Schedule of Common Stock Computation of Diluted Net Loss Per Share of Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 995725 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995735 - Disclosure - Business Combinations and Contingent Consideration Liabilities - Schedule of Fair Value of Contingent Consideration Liability (Details) link:presentationLink link:calculationLink link:definitionLink 995745 - Disclosure - Business Combinations and Contingent Consideration Liabilities - Schedule of Contingent Consideration, Measured at Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 995755 - Disclosure - Business Combinations and Contingent Consideration Liabilities - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995765 - Disclosure - Property and Equipment - Schedule of Right-of-use and Financing Lease Assets, Machinery and Equipment, Net, and Construction in Progress (Details) link:presentationLink link:calculationLink link:definitionLink 995775 - Disclosure - Property and Equipment (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995785 - Disclosure - Schedule of Intangible Assets, Net (Details) link:presentationLink link:calculationLink link:definitionLink 995795 - Disclosure - Schedule of Intangible Assets Future Amortization Expense (Details) link:presentationLink link:calculationLink link:definitionLink 995805 - Disclosure - Intangible Assets, Net (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995815 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995825 - Disclosure - Schedule of Supplemental Balance Sheet Information Related to Operating and Financing Leases (Details) link:presentationLink link:calculationLink link:definitionLink 995835 - Disclosure - Schedule of Future Minimum Lease Commitments for Operating and Financing Leases (Details) link:presentationLink link:calculationLink link:definitionLink 995845 - Disclosure - Schedule of Supplemental Cash Flow Information Related to Operating and Financing Lease (Details) link:presentationLink link:calculationLink link:definitionLink 995855 - Disclosure - Series A Redeemable Convertible Preferred Stock and Shareholdersâ€™ Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995865 - Disclosure - Summary of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 995875 - Disclosure - Schedule of Assumptions Used to Calculate Fair Value of Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 995885 - Disclosure - Summary of Stock-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 995895 - Disclosure - Stock-Based Compensation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995905 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995915 - Disclosure - Collaborative Arrangements (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995925 - Disclosure - Schedule of Discontinued Operations (Details) link:presentationLink link:calculationLink link:definitionLink 995935 - Disclosure - Schedule of Assets and Liabilities Discontinued Operations (Details) link:presentationLink link:calculationLink link:definitionLink 995945 - Disclosure - Discontinued Operations of Razor (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995955 - Disclosure - Subsequent Events - (Details Narrative) link:presentationLink link:calculationLink link:definitionLink Collaborative Arrangements Collaborative Arrangement, Accounting Policy [Policy Text Block] Statement [Line Items] Chronix [Member] Chronix [Member] Accounts receivable Increase (Decrease) in Accounts Receivable Plan Name [Domain] Temporary equity, liquidation preference Weighted average exercise price, options outstanding, exercisable Share based compensation arrangement by share based payment award option outstanding weighted average exercise price. ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice Conversion price Entity Address, Postal Zip Code Pharma Services Company A [Member] Pharma Services Company A [Member] Disposal Group Name [Axis] Unrealized (loss) gain on marketable equity securities Unrealized loss of marketable equity securities Entity Incorporation, State or Country Code Total minimum lease payments Finance Lease, Liability, to be Paid Purchase price of common stock value Purchase price of common stock value. Cash paid for interest Derivative liability measurement input Derivative Liability, Measurement Input Unrecognized stock based compensation expense for RSUs Share-Based Payment Arrangement, Tranche One [Member] Business Combinations and Contingent Consideration Liabilities Right-of-use and financing lease liabilities, current Right of use and financing lease liabilities current. Accumulated depreciation Finance Lease, Right-of-Use Asset, Accumulated Amortization Pharma Services Company B [Member] Pharma Services Company B [Member] Income Tax Authority, Name [Domain] Schedule of Supplemental Balance Sheet Information Related to Operating and Financing Leases Schedule of operating and finance lease balance sheet [TableTextBlock] Reverse stock split Value issued restricted Balance, shares Balance, shares Shares, Outstanding Fair Value Hierarchy and NAV [Axis] Temporary equity, shares issued Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Net loss from continuing operations - diluted Net (loss) income from continuing operations - diluted Business combination consideration transferred Consideration transferred Contractual Value Business Combination, Contingent Consideration, Liability Contractual value. 2024 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Tax Credit Carryforward, Name [Domain] Commitments and Contingencies Shares issued upon vesting of RSUs Stock, Class of Stock [Table] Merger Agreement [Member] Merger Agreement [Member] Product and Service [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Investment, Name [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] SUPPLEMENTAL SCHEDULE OF NONCASH INVESTING AND FINANCING ACTIVITIES Related Party Transaction [Line Items] Concentration Risk Benchmark [Axis] Series A Redeemable Convertible Preferred Stock and Shareholdersâ€™ Equity Title and Position [Axis] Realized loss of marketable equity securities Stock-based compensation Sale of Stock [Domain] Broadwood Capital LP [Member] Broadwood Capital LP [Member] First Ten Calendar [Member] First Ten Calendar [Member] Long-lived intangible assets, useful life Inventories Inventory, Policy [Policy Text Block] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Entity Central Index Key Accrued interest and penalties Conversion of stock, conditions Warrant [Member] Cash sold in discontinued operations (Note 11) Payment for cash sold in discontinued operations. PaymentForCashSoldInDiscontinuedOperations Number of options, forfeited/expired Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Maximum amount of stock and warrants offered under shelf registration Maximum Amount of Stock and Warrants Offered under Shelf Registration Maximum amount of stock and warrants offered under shelf registration. Changes in operating assets and liabilities: Advertising expense Valuation Technique, Discounted Cash Flow [Member] Registered Direct Offering [Member] Registered Direct Offering [Member] Common stock, shares issued Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] DetermaCNI and VitaGraft [Member] DetermaCNI and VitaGraft+ [Member] DetermaCNI and VitaGraft [Member] Fair Value Measurement Inputs and Valuation Techniques [Table] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Percentage of shares issued and outstanding Percentage Of Shares Issued And Outstanding Percentage of shares issued and outstanding. Loss from continuing operations Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Preferred Stock [Member] Income Statement [Abstract] Entity Address, State or Province 2025 Finance Lease, Liability, to be Paid, Year One Other expenses Loss from continuing operations Revision of Prior Period [Axis] Net loss from discontinued operations per share - diluted Life Technologies Corporation [Member] Life Technologies Corporation [Member] Concentration Risk Type [Domain] Compensation paid Customer [Axis] Customer Concentration Risk [Member] Beneficial ownership considered Beneficial ownership considered to sale shares under agreement. Sales and marketing Disposal group including discontinued operation sales and marketing. DisposalGroupIncludingDiscontinuedOperationSalesAndMarketing Loss from discontinued operations (Note 11) Net loss from discontinued operations Stock options, time-based awards granted Share Based Compensation Arrangement By Share Based Payment Time Based Award Options Grants In Period Share based compensation arrangement by share based payment time based award options grants in period. Pre-Funded Warrant [Member] Pre-Funded Warrant [Member] Proceeds from sale of equipment Number of common shares issuable upon conversion Cover [Abstract] Subsequent Event [Line Items] Net loss attributable to common stockholders per share - basic Net (loss) income attributable to common stockholders per share - basic Lease, option to extend, description Lessee, Operating Lease, Option to Extend Operating expenses: Temporary equity, no par value Temporary equity no par value. Finance lease payments Financing cash flows from financing leases Offering expenses Earnout percentage on collections for sales Earnout percentage on collections for sales. Selling and Marketing Expense [Member] Unobservable Measurement Input, Uncertainty, Description Unobservable measurement input, uncertainty, description Stock-based compensation expense Office Lease Agreement [Member] Office Lease Agreement [Member] Weighted average discount rate, Financing lease Laboratory Developed Test Services [Member] Laboratory Developed Test Services [Member] Accumulated deficit Accumulated deficit Plan Name [Axis] Number of options outstanding, beginning of period Number of options outstanding, end of period Stock options outstanding CURRENT ASSETS Common stock reserved for future issuance UNITED STATES Equity compensation for bonus awards and consulting services Equity compensation for bonus awards and consulting services. Net cash used in operating activities Net cash used in operating activities Weighted average exercise price, options outstanding, RSUs forfeited Product and Service [Domain] Accumulated other comprehensive income Pura Vida Investments LLC [Member] Pura Vida Investments LLC [Member] Lease term General and administrative Disposal Group, Including Discontinued Operation, General and Administrative Expense Right-of-use and financing lease assets and machinery and equipment, net Property, Plant and Equipment, Net CASH FLOWS FROM OPERATING ACTIVITIES: Vesting [Axis] Operating and Financing Leases [Member] Operating and Financing Leases [Member] Accrued royalties Accrued expenses and other current liabilities Preferred stock outstanding percentage Preferred stock remains outstanding percentage. Series A Redeemable Convertible Preferred Stock, no par value; stated value \$1,000 per share; 5 shares issued and outstanding at December 31, 2023; aggregate liquidation preference of \$5,296 as of December 31, 2023 Intangible Assets, Net Measurement Input Type [Domain] Disposal Groups, Including Discontinued Operations [Table] Research and development Disposal group including discontinued operation research and development. DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment Statement of Cash Flows [Abstract] Rent receivable Sublease Rent Expenses Sublease rent expenses. Antidilutive Securities, Name [Domain] Preferred stock, no par value Preferred stock, no par value Loss on disposal of discontinued operations Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal Purchase of warrant Warrant to purchase common stock Entity [Domain] Beginning on or After January 1, 2025 and Ending on or Before June 20, 2025 [Member] Sublease Period Two [Member] Sublease period two. Equity Components [Axis] Entity Address, Address Line One Related Party Transaction [Table] Number of shares granted Schedule of Concentration of Risk Valuation Approach and Technique [Axis] Subsequent Event Type [Axis] Equity Option [Member] Business combination, contingent consideration, liability, measurement input Business Combination, Contingent Consideration, Liability, Measurement Input Total other income, net Nonoperating Income (Expense) Risk-free interest rates Risk-free interest rate Number of RSUs Outstanding, beginning of period Number of RSUs Outstanding, end of period Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Amendment Flag Chronix Acquisition [Member] Chronix Acquisition [Member] Right-of-use and financing lease liabilities, noncurrent Right of use liabilities non current. Loss from impairment of held for sale assets Lease assets and liabilities Right-of-use lease liabilities, noncurrent Milestone 3 [Member] Milestone 3 [Member] Pharma Services [Member] Pharma Services [Member] Pharma Services And Laboratory Developed Test Services [Member] Pharma Services And Laboratory Developed Test Services [Member] Pharma services and laboratory developed test services. Sale of stock price per share Sale of stock price per share Net loss Net loss Lessee, Lease, Description [Table] Laboratory Equipment [Member] Laboratory Equipment [Member] Number of Options, Options Outstanding and exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Net loss from discontinued operations - diluted Research and Development Expense [Member] Customer [Domain] Construction in progress, machinery and equipment purchases included in accounts payable and accrued liabilities Construction in progress, machinery and equipment purchases included in accounts payable and accrued liabilities. Equity Component [Domain] Statistical Measurement [Domain] Percentage of administrative fee paid on original cost of equipment Percentage of administrative fee paid on original cost of equipment. General and Administrative Expense, Total General and administrative Contingent consideration liabilities, noncurrent Balance Balance Other income, net Option maximum contractual term Arno [Member] Arno [Member] Revision of Prior Period, Reclassification, Adjustment [Member] Underwritten Offering [Member] Underwritten Offering [Member] Preferred stock, shares issued Additional shares of common stock to be available for issuance Share Based Compensation Arrangement By Share Based Payment Award Additional Number of Shares Available for Grant Share based compensation arrangement by share based payment award additional number of shares available for grant. Offering price to Insiders Sale Of Stock Offering Price Per Share To Insiders Sale of stock offering price per share to insiders. Operating cash flows from operating leases Retirement Plan Fair value of options granted Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Fair Value, Gross proceeds percentage Earnout percentage on collections for sale. Net cash used in investing activities Beginning on or After July 1, 2025 and Ending on or Before December 31, 2025 [Member] Sublease Period Three [Member] Sublease period three. Acquired intangible assets Prepaid expenses and other current assets Weighted average exercise price, forfeited/expired Weighted average remaining recognition of period Share based compensation arrangement by share based payment award options outstanding weighted average remaining contractual term. Obligated to pay expenses and taxes percentage Obligated to pay expenses and taxes percentage. Restricted cash Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Class of Stock [Domain] Severance costs Schedule of Prior Period Revisions Schedule of Prior Period Revisions [Table Text Block] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Common stock, shares outstanding Finite-Lived Intangible Assets, Major Class Name [Domain] Long-lived tangible assets amount Long Lived Tangible Assets Long-lived tangible assets. Interest expense Interest Income (Expense), Operating, Total Interest expense Contingent Consideration by Type [Axis] Stated value per share Revenue Benchmark [Member] Antidilutive Securities [Axis] Tax credit carryforward limitations on use Tax Credit Carryforward, Limitations on Use Cash in hand Expense Included In Discontinued Operations [Member] Expense Included In Discontinued Operations [Member] Discontinued Operations and Disposal Groups [Abstract] Warrants expired Warrant expired. Entity Interactive Data Current Investments in Privately Held Companies Lease expiration date Lease Expiration Date Impairment of leasehold Impairment of Leasehold Product Concentration Risk [Member] Document Quarterly Report Weighted average exercise price, RSUs vested Related Party Transaction [Domain] Related Party Transactions Less amounts representing interest Finance Lease, Liability, Undiscounted Excess Amount Statistical Measurement [Axis] Research Tax Credit [Member] Research Tax Credit Carryforward [Member] Total lease cost Related and Nonrelated Parties [Domain] Stock-based compensation expense for RSUs Percentage of sales agent commission Payment of Sales Agent Commission Percentage Payment of sales agent commission percentage Area of lab Area of lab. Schedule of Disaggregation of Revenue Sales and marketing expenses Selling and Marketing Expense, Total Sales and marketing Operating cash flows from financing leases Number of shares available for grant Net proceeds from issuance of private placement Net proceeds from issuance of private placement used for general corporate purposes and working capital Net Proceeds from Issuance of Private Placement used for General Corporate Purposes and Working Capital Net proceeds from issuance of private placement used for general corporate purposes and working capital. Share price Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted average Grant Date Fair Value Weighted average remaining recognition period Proceeds from private placement Beginning on or After January 1, 2027 and Ending on or Before October 31, 2027 [Member] Sublease Period Five [Member] Sublease period five. Machinery and Equipment [Member] Total contributions to the plan Research and Development Expenses Statement of Income Location, Balance [Axis] Indefinite-Lived Intangible Assets [Line Items] TOTAL ASSETS Assets Expected life (in years) Number of RSUs Outstanding, options outstanding vested Number of shares vested 2010 Plan and 2018 Incentive Plan Activity [Member] 2010 Plan and 2018 Incentive Plan Activity [Member] Business

Acquisition [Line Items] Recent Accounting Pronouncements Entity Address, City or Town AOCI Attributable to Parent [Member] Equity [Abstract] Financing costs to issue common shares Payments of Stock Issuance Costs Weighted average exercise price, options outstanding RSUs forfeited Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period 2026 Finance Lease, Liability, to be Paid, Year Two Oncocyte Corp [Member] Oncocyte Corp [Member] Unobservable measurement input, royalty rate Unobservable Inputs Of Royalty Rate Unobservable Inputs Of Royalty Rate Germany [Member] GERMANY Royalty 1 [Member] Royalty 1 [Member] Weighted average remaining contractual life vested and expected to vest Chronix Biomedical Inc [Member] Chronix Biomedical Inc [Member] Performance-Based Options [Member] Performance-Based Options [Member] Revision of Prior Period [Domain] Private Placement [Member] Private Placement [Member] Stock-Based Compensation Pharma Services Company E [Member] Pharma Services Company E [Member] Pharma services company E. Total Right of use assets machinery and equipment continuing operations. RightofuseAssetsMachineryAndEquipmentContinuingOperations Series A Preferred Stock [Member] Security [Member] Security [Member] Weighted average discount rate, Operating lease Monte Carlo Valuation Technique [Member] Monte Carlo Valuation Technique [Member] Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Assets held for sale Schedule of Future Minimum Lease Commitments for Operating and Financing Leases Schedule of future minimum lease commitments for operating and financing leases [Table Text Block] Sale of common shares under at-the-market transactions, net of financing costs Preferred stock offering value in tranche Common stock shares issued Operating sublease, description Accrued severance from acquisition Accrued severance from acquisition current. Lessee, Lease, Description [Line Items] CURRENT LIABILITIES Proceeds from sale of common shares under at-the-market transactions Proceeds from sale of common shares under at-the-market transactions Proceeds from sale of common shares under the market transactions. Long-Lived Intangible Assets Lease Contractual Term [Axis] Redemption of SeriesA redeemable convertible preferred stock, shares Number of stock redeem, shares Accounts Receivable [Member] Lease assets obtained in exchange for lease liabilities Cash paid for income taxes Document Type Schedule of Intangible Assets, Net Fair Value Measurements, Business Combinations and Contingent Consideration Liabilities Business Combinations and Fair Value Measurements [Policy Text Block] Maximum percentage of annual lease expenses Maximum Percentage Of Annual Lease Expenses Maximum percentage of annual lease expenses. Title of 12(b) Security Cash and cash equivalents Customer One [Member] Customer One [Member] Statement of Stockholders' Equity [Abstract] Document Fiscal Period Focus Research and development expenses Research and Development Expense, Total Research and development Unrealized gain on marketable equity securities Marketable Security, Gain (Loss) Number of options outstanding, Options granted Stock option grant Machinery and equipment, net, and construction in progress Machinery and equipment net and construction in progress. Indefinite-Lived Intangible Assets [Axis] Dividends rate Product Information [Line Items] Subsequent Event Type [Domain] Right-of-use and financing lease assets, net Machinery and equipment, net Leases Expected term [Member] Measurement Input, Expected Term [Member] Schedule of Assumptions Used to Calculate Fair Value of Stock Options AVM [Member] AVM [Member] Tenant improvement allowance Payment to related party Discontinued Operations of Razor Beginning on Commencement Date and Ending on or Before December 31, 2024 [Member] Sublease Period One [Member] Sublease period one. Payments for rent Warrant exercise price, per share Warrant exercise price Razor Genomics, Inc. [Member] Razor Genomics, Inc. [Member] 2018 Incentive Plan [Member] 2018 Incentive Plan [Member] Threshold consecutive trading days Convertible Preferred Stock Threshold Consecutive Trading Days Convertible preferred stock threshold consecutive trading days. NONCURRENT ASSETS Schedule of Percentage of Consolidated Revenues Attributable to Geographical Locations Sale of Stock [Axis] CASH FLOWS FROM INVESTING ACTIVITIES: At The Market Offering [Member] At The Market Offering [Member] At The Market Offering. Net revenue Revenues by service Schedule of Discontinued Operations Series B Preferred Stock [Member] Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract] Sale of common shares, net of financing costs A Total Finite-Lived Intangible Assets, Net Depreciation and amortization expense Depreciation expense LIABILITIES AND SHAREHOLDERSâ€™ EQUITY Schedule of Consolidated Revenues Generated by Unaffiliated Customers Document Period End Date Net provided by financing activities Net Cash Provided by (Used in) Financing Activities Rentable area Stock-based compensation expense for the period NONCURRENT LIABILITIES Business combination, contingent consideration, liability, milestone payment Business Combination, Contingent Consideration, Liability, Milestone Payment Business combination, contingent consideration, liability, milestone payment. Shares issued restricted Collaborative Arrangements Co development agreement with life technologies corporation [TextBlock] Co development agreementwith life technologies corporation [TextBlock] Total Mr Gutfreund [Member] Mr Gutfreund [Member] Accretion of Series A redeemable convertible preferred stock Accretion of redeemable convertible preferred stock. AccretionOfRedeemableConvertiblePreferredStock equity interest Ownership percentage Equity method investment ownership percentage Accrued compensation Securities Purchase Agreement [Member] Securities Purchase Agreement [Member] Income Tax Authority, Name [Axis] Machinery, equipment and leasehold improvements Trading Symbol Total shareholdersâ€™ equity Balance Balance Equity, Attributable to Parent Pura Vida [Member] Pura Vida [Member] Impairment losses Impairment losses Impairment of intangible assets Long-Lived Tangible Asset [Axis] Warrants issued and outstanding Restricted Stock Units (RSUs) [Member] Number of sale of shares Number of sale of shares Sale of stock, shares Related Party Transactions [Abstract] Net loss from discontinued operations per share - basic MPC Holdings LLC [Member] MPC Holdings LLC [Member] Cumulative change in accounting principle (Note 2) Cumulative change in accounting principle. Unrecognized stock based compensation expense Redemption of Series A redeemable convertible preferred stock Value of redeemed shares General and Administrative Expenses Milestone 2 [Member] Milestone 2 [Member] Summary of Stock-based Compensation Expense Measurement Input, Discount Rate [Member] Discount rate [Member] Measurement Input, Discount Rate [Member] Security deposit Disposal Group Classification [Axis] Measurement Input Type [Axis] Unobservable measurement input, weighted average cost of capital Weighted Average Cost of Capital Weighted Average Cost of Capital Geographical [Axis] 2027 Finance Lease, Liability, to be Paid, Year Three Area of land Equipment [Member] Use of Estimates Collaboration Agreement [Member] Collaborative Arrangement [Member] Percentage of revenues Percentage of consolidated revenues Concentration risk percentage Arno's Son [Member] Arno's Son [Member] Class of Stock [Line Items] Beginning on or After January 1, 2026 and Ending on or Before December 31, 2026 [Member] Sublease Period Four [Member] Sublease period four. Schedule of Business Acquisitions, by Acquisition [Table] Outside Of United States [Member] Outside Of United States [Member] Scenario [Axis] Dividend yield Marketable Equity Securities MPEEM Valuation Approach [Member] MPEEM Valuation Approach [Member] Schedule of Contingent Consideration, Measured at Fair Value Schedule of contingent consideration measured at fair value [Table Text Block] Security Exchange Name Intangible assets acquired Net loss from continuing operations per share - basic Net (loss) income from continuing operations per share - basic Business Acquisition, Acquiree [Domain] Total operating expenses Operating Expenses Customer Two [Member] Customer Two [Member] Long-Lived Tangible Asset [Domain] Share issued, value Shares issued for consultant services Class of Stock [Axis] Accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Legal Entity [Axis] Collaborative Arrangements Segments Segments [Policy Text Block] 2027 Fair value grants DetermaIO [Member] Determal O [Member] Subsequent Event [Member] Subsequent Event [Member] Maximum [Member] Maximum [Member] Financing costs for at-the-market sales Financing costs for at-the-market sales Payment Of Financing Costs For At The Market Sales Payment of financing costs for at the market sales. TOTAL LIABILITIES AND SHAREHOLDERSâ€™ EQUITY Liabilities and Equity Total intangible assets Development costs Investors [Member] Investors [Member] Right-of-use assets, net SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Milestone 1 [Member] Milestone 1 [Member] Net loss attributable to common stockholders per share - diluted Net (loss) income attributable to common stockholders per share - diluted Number of stock redeem value TOTAL LIABILITIES Liabilities Monthly Rent [Member] Monthly Rent [Member] Accounts receivable Fair Value Hierarchy and NAV [Domain] Bio Rad Laboratories Inc [Member] Bio Rad Laboratories Inc [Member] Total current assets Assets, Current Net cash used in investing activities Net cash provided by (used in) investing activities Payout percentage Business Combination, Contingent Consideration, Liability, Payout Percentage Business combination, contingent consideration, liability, payout percentage Redemption of Series A redeemable convertible preferred shares Payments for Repurchase of Redeemable Convertible Preferred Stock Sale of common shares under at-the-market transactions, net of financing costs, shares Number of shares issued Unrecognized tax benefits James [Member] James. Option vesting period Lessee, Operating Lease, Existence of Option to Extend [true false] Cost of revenues Disposal Group, Including Discontinued Operation, Costs of Goods Sold Accretion of Series A convertible preferred stock to redemption value Accretion of Series A redeemable convertible preferred stock Accretion of Series A convertible preferred stock to redemption value. Entity Filer Category Property, Plant and Equipment [Abstract] Warrants to purchase shares Warrants to purchase shares Net loss attributable to common stockholders - diluted Net (loss) income attributable to common stockholders - diluted Organization and Description of the Business Customer Four [Member] Customer four. Other (expenses) income: Current Fiscal Year End Date Machinery and Equipment, Net, Financing Leases, Net, and Construction in Progress Machinery and Equipment, Net, and Construction in Progress Less amounts representing interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Loss on disposal Equity Method Investment, Realized Gain (Loss) on Disposal Temporary equity, stated par value Stock-based compensation Unrecognized stock-based compensation expense Interest [Member] Interest [Member] Legal fees Related Party Transaction [Axis] Aggregate intrinsic value balance Aggregate intrinsic value balance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Schedule of Common Stock Computation of Diluted Net Loss Per Share of Common Stock Related and Unrelated Parties [Axis] Insight Genetics Inc [Member] Insight Genetics Inc [Member] Collaborative agreement, term period Collaborative Agreement, Term Period Collaborative agreement, term period. Offering expenses Offering Expenses Offering expenses. Contingent consideration liabilities, current Business Combination, Contingent Consideration, Liability, Current Net revenue Disposal Group, Including Discontinued Operation, Revenue Entity Registrant Name Fair Value on the Merger Date Weighted average remaining lease term, Financing lease Indefinite-Lived Intangible Assets, Major Class Name [Domain] Pharma Services Other [Member] Pharma Services Other [Member] Pharma services other. Gross profit Gross Profit Vesting of bonus awards Stock issued during period value vesting of bonus awards. Cost of revenues Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Entity Emerging Growth Company Deemed dividend on Series A redeemable convertible preferred stock Deemed dividend on Series A redeemable convertible preferred stock. Weighted average shares outstanding - basic Vesting [Domain] Noncurrent liabilities Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Change in fair value of contingent consideration Change in estimated fair value Warrant exercised Warrant Exercised Warrant exercised. Common stock, shares authorized Estimated useful life of plant and equipment Cost of revenues â€” amortization of acquired intangibles Cost of revenues & amortization of acquired intangibles. Sublease income Proceeds from sale of common shares Proceeds from issuance of common stock Concentration Risk Type [Axis] Net proceeds from sale of placement shares Net Proceeds From Sale of Placement Shares Net proceeds from sale of placement shares. Customer Three [Member] Customer three. Aggregate fair value of RSUs vested Accounts payable and accrued liabilities Accounts payable and accrued liabilities Weighted average exercise price, options vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Weighted average exercise price, Options granted Accounts payable current Amortization of intangible assets Intangible asset amortization expense Laboratory related costs Laboratory related expenses Weighted average remaining contractual life CASH FLOWS FROM OPERATING ACTIVITIES: Net Loss Per Common Share General and Administrative Expense [Member] Impairment loss on held for sale assets Impairment, Long-Lived Asset, Held-for-Use Impairment, Long-Lived Asset, Held-for-Use, Total Broadwood Partners LP [Member] Broadwood Partners LP [Member] Share-Based Payment Arrangement [Abstract] Underwriters [Member] Underwriters [Member] Impairment of Long-Lived Assets Collaborative Arrangement and Arrangement Other than Collaborative [Table] Repayment of financing lease obligations Repayment of financing lease obligations. RepaymentOfFinancingLeaseObligations Unobservable measurement input, discount period on expected life of patent Discount Period On Expected Life Of Patent Discount Period On Expected Life Of Patent Accounting Policies [Abstract] Summary of Stock Option Activity 2024 Finance Lease, Liability, to be Paid, Remainder of Fiscal Year SHAREHOLDERSâ€™ EQUITY Lease Agreement [Member] Lease Agreement [Member] Inventories Inventory, Raw Materials and Supplies, Gross Inventory, Raw Materials and Supplies, Gross, Total Office Sublease Agreement [Member] Office Sublease Agreement [Member] Office sublease agreement. Cash, Cash Equivalents and Restricted Cash Disposal Group Name [Domain] Statement [Table] Schedule of Right-of-use and Financing Lease Assets, Machinery and Equipment, Net, and Construction in Progress Inventory write down Inventory Write-down Subsequent Event [Table] Preferred stock, shares authorized Common stock, shares authorized Disposal Group Classification [Domain] Entity File Number NET CHANGE IN CASH, CASH EQUIVALENTS (INCLUDES DISCONTINUED OPERATIONS) AND RESTRICTED CASH Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Threshold percentage of conversion price trigger Convertible Preferred Stock Threshold Percentage of Conversion Price Trigger Convertible preferred stock threshold percentage of conversion price trigger. Net loss per share (Note 2): Weighted average remaining life Lease Contractual Term [Domain] Statement of Financial Position [Abstract] Tax Credit Carryforward [Axis] Loss from operations Operating Income (Loss) Share price Share price Volatility Expected volatility Common stock, no par value Common stock no par value Halle Special Situations Fund LLC [Member] Halle Special Situations Fund LLC [Member] Entity Shell Company Assets Held for Sale and Discontinued Operations Entity Tax Identification Number ASSETS Construction in progress Entity Current Reporting Status Net loss attributable to common stockholders - basic Net (loss) income attributable to common stockholders - basic Weighted average remaining contractual life exercisable Chronix Milestone [Member] Chronix Milestone [Member] Property and Equipment Subsequent Events [Abstract] Revenue Recognition Previously Reported [Member] Geographical [Domain] Document Fiscal Year Focus Other Investors [Member] Other Investors [Member] Preferred stock, no par value, 5,000 shares authorized; no shares issued and outstanding Net cash used in operating activities Cash Provided by (Used in) Operating Activities, Discontinued Operations Executive Officers [Member] Executive Officers [Member] Related party transaction, description Gross proceeds from the private placement Proceeds from Issuance of Private Placement Gross Proceeds from issuance of private placement, gross, Finite-lived intangible assets, accumulated amortization Finite-lived intangible assets, accumulated amortization Right-of-use and financing lease assets Right-of-use and financing lease assets. California Franchise Tax Board [Member] Trading days Convertible Preferred Stock Threshold Trading Days Convertible preferred stock threshold trading days. CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING CASH, CASH EQUIVALENTS (INCLUDES DISCONTINUED OPERATIONS) AND RESTRICTED CASH, BEGINNING Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Cost of Revenues Business Acquisition [Axis] Tax credits Tax Credit Carryforward, Amount City Area Code Reclassifications Total current liabilities Liabilities, Current Balance at January 1, 2023, as adjusted Total Shareholders equity Adjusted stockholders' equity. Inventories Inventory, Net Inventory, Net, Total Discontinued Operations, Held-for-Sale [Member] Lease expiration month and year Lease Expiration Month And Year Lease expiration month and year. Impairment loss on held for sale assets Gain (Loss) on Disposition of Other Assets Intangible Assets Schedule of Supplemental Cash Flow Information Related to Operating and Financing Lease Schedule of operating and finance lease cashflow [Table Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] Local Phone Number Schedule of Fair Value of Contingent Consideration Liability Preferred stock, shares outstanding Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Sale of common shares, net of financing costs, shares Issuance of shares Offering price to investors Sale Of Stock Offering Price Per Share To Investors Sale of stock offering price per share to investors. Income Taxes Commitments and Contingencies Disclosure [Abstract] Deferred financing costs Debt Issuance Costs, Net Debt Issuance Costs, Net, Total Management probability estimate [Member] Measurement Input, Management Probability Estimate [Member] Measurement input, management probability estimate. Derivative assets liabilities at fair value net Derivative Assets (Liabilities), at Fair Value, Net Derivative Assets (Liabilities), at Fair Value, Net, Total Right-of-use lease liabilities, current Unobservable measurement input, valuation approach yielded fair value Valuation Approach Yielded Fair Value Valuation Approach Yielded Fair Value In Process Research and Development [Member] Foreign currency translation adjustments Foreign currency translation adjustment Accumulated Deficit [Member] Retained Earnings [Member] Construction in progress and purchases of furniture and equipment Purchased laboratory equipment Document Transition Report Business combination, contingent consideration, liability, related patent expiration range term Business Combination, Contingent Consideration, Liability, Related Patent Expiration Range Term Business combination, contingent consideration, liability, related patent expiration range term. Board Members [Member] Board Members [Member] 2026 Valuation Approach and Technique [Domain] Accretion of Series A convertible preferred stock Accretion of series convertible preferred stock. Antidilutive Security, Excluded EPS Calculation [Table] Conversion of stock, description 2024 Razor Stock Purchase Agreement [Member] Razor Stock Purchase Agreement [Member] Minimum [Member] Minimum [Member] Common Stock [Member] Restricted cash Restricted Cash Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Investment, Name [Axis] Weighted average exercise price, options outstanding, beginning of period Weighted average exercise price, exercisable, end of period Share-Based Compensation Arrangement by Share-Based Payment Award, Equity

Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value 2010 Stock Option Plan [Member] 2010 Stock Option Plan [Member] Adjustments to reconcile net loss to net cash used in operating activities: Statement of Income Location, Balance [Domain] 2025 Lessee, Operating Lease, Liability, to be Paid, Year One Pharma Services Company D [Member] Pharma Services Company D [Member] Other noncurrent assets Chronix Merger [Member] Chronix Merger [Member] Fair value Fair value of contingent consideration. Dragon Scientific LLC [Member] Dragon Scientific LLC [Member] Goodwill and Intangible Assets Disclosure [Abstract] Entity Common Stock, Shares Outstanding Net loss from continuing operations per share - diluted Net (loss) income from continuing operations per share - diluted Sales Agreement [Member] Sales Agreement [Member] Sales agreement Net loss from continuing operations - basic Net (loss) income from continuing operations - basic Principles of Consolidation and Basis of Presentation 2025 Scenario [Domain] Daily trading volume threshold common stock trigger Convertible Preferred Stock Daily Trading Volume Threshold Stock Trigger Convertible preferred stock daily trading volume threshold stock trigger. Title and Position [Domain] Customer Relationships [Member] Current liabilities Machinery and equipment Accounting Principles Accounting Principles [Policy Text Block] Common stock, no par value, 230,000 shares authorized; 13,374 and 8,261 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Line of credit Schedule of Intangible Assets Future Amortization Expense Impairment loss on held for sale assets Gain (Loss) on Disposition of Assets Cost Of Revenues [Member] Cost Of Revenues [Member] Sales and Marketing Expenses Sale sAnd Marketing Expenses [Policy Text Block] Prior Period Revisions Prior Period Revisions Policy [Text Block] Indebtedness expenses Indebtedness expenses. Contingent Consideration Type [Domain] Total operating lease liabilities Present value of net minimum lease payments Financing costs for at-the-market sales included in accrued liabilities Financing costs for at the market sales included in accrued liabilities. Commitments and contingencies (Note 6) Loss from discontinued operations Weighted average shares outstanding - diluted Summary of Significant Accounting Policies Accounts receivable, net of allowance for credit losses of \$2 and \$5, respectively Accounts receivable, net Accounts receivable Lease extension term Lessee, Operating Lease, Renewal Term Chronix Equity [Member] Chronix Equity [Member] Number of options, vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Total minimum lease payments Lessee, Operating Lease, Liability, to be Paid Inventories Increase (Decrease) in Inventories Increase (Decrease) in Inventories, Total Royalty 2 [Member] Royalty 2 [Member] Accounting for Warrants Accounting for Warrants [Policy Text Block] Concentration Risk Benchmark [Domain] Finance lease Total financing lease liabilities Present value of net minimum lease payments Finance Lease, Liability Pharma Services Company C [Member] Pharma Services Company C [Member] Entity Small Business Intangible Asset, Indefinite-Lived [Table] Shares issued for consultant services, shares Current liabilities of discontinued operations (Note 11) Adjusted balance, shares Adjusted shares outstanding. Shares issued upon vesting of RSU, shares Stock-Based Compensation Compensation Related Costs, Policy [Policy Text Block] CASH FLOWS FROM FINANCING ACTIVITIES: Weghted average exercise price, beginning of period Number of options outstanding, ending of period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Initial capitalized total value Initial Capitalized Amount Initial capitalized amount. Intangible assets, net Intangible assets, net Net loss from discontinued operations - basic Maximum beneficial ownership considered Maximum beneficial ownership considered to sale shares under agreement. Nature of Operation, Product Information, Concentration of Risk [Table] Net proceeds Temporary equity, shares outstanding Level 3 [Member] Fair Value, Inputs, Level 3 [Member] Weighted average remaining lease term, Operating lease Subsequent Events Subsequent Events [Text Block] Interest rate on lease agreement Refers to annual interest rate on capital lease agreement. Accounts payable Accounts payable due Allowance for credit losses Accounts Receivable, Allowance for Credit Loss, Current Percentage of sales agent commission Percentage Of Sales Agent Commission Percentage of sales agent commission. Series A Redeemable Convertible Preferred Stock [Member] Series A Redeemable Convertible Preferred Stock [Member] Accounts receivable, allowance for credit loss XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Cover - shares 9 Months Ended Sep. 30, 2024 Nov. 05, 2024 Cover [Abstract] A A Document Type 10-Q A Amendment Flag false A Document Quarterly Report true A Document Transition Report false A Document Period End Date Sep. 30, 2024 A Document Fiscal Period Focus Q3 A Document Fiscal Year Focus 2024 A Current Fiscal Year End Date --12-31 A Entity File Number 1-37648 A Entity Registrant Name Oncocyte Corporation A Entity Central Index Key 0001642380 A Entity Tax Identification Number 27-1041563 A Entity Incorporation, State or Country Code CA A Entity Address, Address Line One 15 Cushing A Entity Address, City or Town Irvine A Entity Address, State or Province CA A Entity Address, Postal Zip Code 92618 A City Area Code (949) A Local Phone Number 409-7600 A Title of 12(b) Security Common Stock, no par value A Trading Symbol OCX A Security Exchange Name NASDAQ A Entity Current Reporting Status Yes A Entity Interactive Data Current Yes A Entity Filer Category Non-accelerated Filer A Entity Small Business true A Entity Emerging Growth Company false A Entity Shell Company false A Entity Common Stock, Shares Outstanding A 16,835,247 X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei AmendmentFlag Namespace Prefix: dei_Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_Data Type: xbrli:MonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_Data Type: xbrli:dateTimeItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a> + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1> + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_Data Type: dei:submissionTypeItem Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_Data Type: dei:stateOrProvinceItem Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2> + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_Data Type: dei:centralIndexKeyItem Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_Data Type: xbrli:sharesItem Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_Data Type: dei:yesNoItem Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2> + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_Data Type: dei:fileNumberItem Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2> + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_Data Type: dei:filerCategoryItem Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_Data Type: dei:edgarStateCountryItem Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Regulation S-T -Number 232 -Section 405> + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_Data Type: dei:yesNoItem Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2> + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_Data Type: xbrli:normalizedStringItem Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2> + Details Name: dei_EntityShellCompany Namespace Prefix: dei_Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2> + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2> + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_Data Type: dei:employerIdItem Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_Data Type: xbrli:normalizedStringItem Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b> + Details Name: dei_Security12bTitle Namespace Prefix: dei_Data Type: dei:securityTitleItem Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1> + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_Data Type: dei:edgarExchangeCodeItem Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_Data Type: dei:tradingSymbolItem Balance Type: na Period Type: duration XML 9 R2.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets - USD (\$) in Thousands Sep. 30, 2024 Dec. 31, 2023 CURRENT ASSETS A Cash and cash equivalents \$ 3,363 \$ 9,432 Accounts receivable, net of allowance for credit losses of \$2 and \$5, respectively 209 484 Inventories 232 Deferred financing costs 330 Prepaid expenses and other current assets 627 643 Assets held for sale 32 139 Total current assets 4,793 10,698 NONCURRENT ASSETS A Right-of-use and financing lease assets, net 3,001 1,637 Machinery and equipment, net, and construction in progress 3,494 3,799 Intangible assets, net 56,529 56,595 Restricted cash 1,700 1,700 Other noncurrent assets 699 463 TOTAL ASSETS 70,216 74,892 CURRENT LIABILITIES A Accounts payable 872 953 Accrued compensation 1,906 1,649 Accrued royalties 1,116 1,116 Accrued expenses and other current liabilities 985 452 Accrued severance from acquisition 2,314 2,314 Right-of-use and financing lease liabilities, current 1,283 665 Current liabilities of discontinued operations (Note 11) 45 Contingent consideration liabilities, current 614 393 Total current liabilities 9,090 7,587 NONCURRENT LIABILITIES A Right-of-use and financing lease liabilities, noncurrent 2,708 2,204 Contingent consideration liabilities, noncurrent 48,707 39,507 TOTAL LIABILITIES 60,505 49,298 Commitments and contingencies (Note 6) Series A Redeemable Convertible Preferred Stock, no par value; stated value, \$1,000 per share; 5 shares issued and outstanding at December 31, 2023; aggregate liquidation preference of \$5,296 as of December 31, 2023 5,126 SHAREHOLDERSâ€™ EQUITY A Preferred stock, no par value, 5,000 shares authorized; no shares issued and outstanding Common stock, no par value, 230,000 shares authorized; 13,374 and 8,261 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively 326,682 310,295 Accumulated other comprehensive income 57 49 Accumulated deficit (317,028) (289,876) Total shareholdersâ€™ equity 9,711 20,468 TOTAL LIABILITIES AND SHAREHOLDERSâ€™ EQUITY \$ 70,216 \$ 74,892 X - DefinitionAccrued severance from acquisition current. + ReferencesNo definition available. + Details Name: ocx AccruedSeveranceFromAcquisitionCurrent Namespace Prefix: ocx_Data Type: xbrli:monetaryItem Balance Type: credit Period Type: instant X - DefinitionMachinery and equipment net and construction in progress. + ReferencesNo definition available. + Details Name: ocx_MachineryAndEquipmentNetAndConstructionInProgress Namespace Prefix: ocx_Data Type: xbrli:monetaryItem Balance Type: debit Period Type: instant X - DefinitionRight of use liabilities non current. + ReferencesNo definition available. + Details Name: ocx_RightOfUseLiabilitiesNoncurrent Namespace Prefix: ocx_Data Type: xbrli:monetaryItem Balance Type: credit Period Type: instant X - DefinitionRight of use and financing lease liabilities current. + ReferencesNo definition available. + Details Name: ocx_RightofUseAndFinancingLeaseLiabilitiesCurrent Namespace Prefix: ocx_Data Type: xbrli:monetaryItem Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: us-gaap AccountsPayableAndOtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(19\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/1147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/1147480566/210-10-S99-1) Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10> + Details Name: us-gaap AccountsPayableCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of

right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2> + Details Name: us-gaap AccountsReceivableNetCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap AccruedLiabilitiesCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 8 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 8 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8) + Details Name: us-gaap AccruedRoyaltiesCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 15 -Paragraph 4 -Subparagraph \(b\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482309/360-10-15-4](http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap AssetsCurrentAbstract Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap AssetsNoncurrentAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemBalance Type: na Period Type: duration X - DefinitionAmount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer. + ReferencesReference 1: <a href=) + Details Name: us-gaap AssetsHeldForSaleNotPartOfDisposalGroupCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap AssetsNoncurrentAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemBalance Type: na Period Type: duration X - DefinitionAmount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6) + Details Name: us-gaap BusinessCombinationContingentConsiderationLiabilityCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6) + Details Name: us-gaap BusinessCombinationContingentConsiderationLiabilityNoncurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4](http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4)

+ Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.9-03\(17\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-03(17))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2>: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(25\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(25))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3>: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-03\(a\)\(19\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-03(a)(19))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4>: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-04\(15\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-04(15))) -Publisher FASB -URI [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)](https://asc.fasb.org/1943274/2147479170/946-210-S99-1+Details Name: us-gaap CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: <a href=) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2>: <http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3>: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-03\(a\)\(22\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-03(a)(22))) -Publisher FASB -URI [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 835-SubTopic 30-Name Accounting Standards Codification-Section 45-Paragraph 1A-Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1Reference 2](https://asc.fasb.org/1943274/2147478777/944-210-S99-1+Details Name: us-gaap CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs. + ReferencesReference 1: <a href=): <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 835-SubTopic 30-Name Accounting Standards Codification-Section 45-Paragraph 2-Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3>: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 835-SubTopic 30-Name Accounting Standards Codification-Section 50-Paragraph 1-Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4>: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 350-SubTopic 30-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)\(1\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 350-SubTopic 30-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)(1)-Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2): [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 350-SubTopic 30-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(b\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 350-SubTopic 30-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (b)-Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3): [http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2](http://www.xbrl.org/2003/role/disclosureRef-Topic 350-SubTopic 30-Name Accounting Standards Codification-Section 45-Paragraph 1-Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1+Details Name: us-gaap IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: <a href=): [http://www.xbrl.org/2003/role/exampleRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1-Subparagraph \(b\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3](http://www.xbrl.org/2003/role/exampleRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1-Subparagraph (b)-Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3): [http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(6\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(6))) -Publisher FASB -URI [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(22\)\)-SubTopic 10-Topic 210-Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2](https://asc.fasb.org/1943274/2147480566/210-10-S99-1+Details Name: us-gaap InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: <a href=): [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(20\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(20))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3>: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(24\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(24))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4>: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(19\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(19))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5>: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(19\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(19))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6>: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(25\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(25))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7>: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(23\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(23))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8>: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(21\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(21))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9>: [http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10](http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10): [http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 11](http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 11): [http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 12](http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 12): [http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 13](http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 13): [http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 14](http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(g)(1)(ii))-Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 14): [http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph \(f\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15](http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)-Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15): <http://www.xbrl.org/2003/role/exampleRef-Topic 946-SubTopic 830-Name Accounting Standards Codification-Section 55-Paragraph 12-Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16>: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-04\(14\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-04(14))-Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17): [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 18](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(i))-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 18): [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 19](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(ii))-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 19): [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 20](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iii)(A))-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 20): [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 21](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iv))-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 21): [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(5\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 22](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(5))-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 22): [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 23](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(i))-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 23): [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 24](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(A))-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 24): [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 25](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(B))-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 25): [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 26](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iv))-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 26): [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(5\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 27](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(5))-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 27): [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph \(a\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph (a)-Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28): [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph \(b\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph (b)-Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29): [http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2](http://www.xbrl.org/2003/role/exampleRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 30-Subparagraph (d)-Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30+Details Name: us-gaap Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: <a href=): [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-03\(a\)\(25\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-03(a)(25))-Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3): [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(g)(1)(ii))-Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4): [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5): [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph \(f\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)-Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6): [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.9-03\(23\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-03(23))-Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7): [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(21\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(32))-Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1+Details Name: us-gaap LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: <a href=): [http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3](http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3):

<http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 20: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481404/852-10-50-7>Reference 21: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481404/852-10-50-7> + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesNoncurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483475/205-20-45-10>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-5C>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 205 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-5B>Reference 6: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482130/360-10-45-9>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-5B>Reference 6: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482099/360-10-50-3>Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483475/205-20-45-11> + Details Name: us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1> + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash restricted as to withdrawal or use, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Name Accounting Standards Codification -Section 45 -Paragraph 5 -SubTopic 210 -Topic 954 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477220/954-210-45-5>Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482913/230-10-50-8> + Details Name: us-gaap_RestrictedCashNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480016/944-40-65-2>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480016/944-40-65-2>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480990/946-20-50-11>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 8: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1> + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 4: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 5: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-12>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-2>Reference 8: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 11: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 12: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 13: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 14: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480418/310-10-S99-2> + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.E.Q2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479830/718-10-S99-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B> + Details Name: us-gaap_TemporaryEquityCarryingAmountAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 10 R3.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets (Parenthetical) - USD (\$) in Thousands Sep. 30, 2024 Dec. 31, 2023 Allowance for credit losses \$ 2 \$ 5 Preferred stock, no par value \$ 0 \$ 0 Preferred stock, shares authorized 5,000,000 5,000,000 Preferred stock, shares issued 0 0 Preferred stock, shares outstanding 0 0 Common stock, no par value \$ 0 \$ 0 Common stock, shares authorized 230,000,000 230,000,000 Common stock, shares issued 13,374,109 8,261,073 Common stock, shares outstanding 13,374,109 8,261,073 Series A Redeemable Convertible Preferred Stock [Member] Å Temporary equity, no par value Å \$ 0 Temporary equity, stated par value Å \$ 1,000 Temporary equity, shares issued Å 5,000 Temporary equity, shares outstanding Å 5,000 Temporary equity, liquidation preference Å \$ 5,296 X - DefinitionTemporary equity no par value. + ReferencesNo definition available. + Details Name: ocx_TemporaryEquityNoParValue Namespace Prefix: ocx_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionAmount of allowance for credit loss on accounts receivable, classified as current. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479344/326-20-45-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481962/310-10-50-4> + Details Name: us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFace amount per share of no-par value common stock. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_CommonStockNoParValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-2>Reference 4: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 6:

[http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(7\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3) + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionFace amount per share of no-par value preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13) + Details Name: us-gaap_PreferredStockNoParValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(16\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1) + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13) + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.6-05\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2)Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(4\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(16\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1)Reference 5: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(7\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3) + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionThe aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. + ReferencesNo definition available. + Details Name: us-gaap_TemporaryEquityLiquidationPreference Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionPer share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(27\)\) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 480 -SubTopic 10 -Section S99 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1> + Details Name: us-gaap_TemporaryEquityParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionThe number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(27\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap_TemporaryEquitySharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionThe number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(27\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap_TemporaryEquitySharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - Details Name: us-gaap_StatementOfClassOfStockAxis=ocx_SeriesARedeemableConvertiblePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 11 R4.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Operations (Unaudited) - USD (\$) shares in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Income Statement [Abstract] A A A Net revenue \$ 115,000 \$ 429,000 \$ 395,000 \$ 1,189,000 Cost of revenues 43,000 159,000 184,000 593,000 Cost of revenues â€” amortization of acquired intangibles 22,000 22,000 66,000 66,000 Gross profit 50,000 248,000 145,000 530,000 Operating expenses: A A A Research and development 2,817,000 2,185,000 7,582,000 6,747,000 Sales and marketing 1,043,000 713,000 2,742,000 2,213,000 General and administrative 2,565,000 2,487,000 7,645,000 9,430,000 Change in fair value of contingent consideration 7,140,000 (435,000) 9,421,000 (16,947,000) Impairment losses A 1,811,000 6,761,000 Impairment loss on held for sale assets A 169,000 1,283,000 Total operating expenses 13,565,000 6,761,000 27,559,000 9,487,000 Loss from operations (13,515,000) (6,513,000) (27,414,000) (8,957,000) Other (expenses) income: A A A Interest expense (31,000) (14,000) (54,000) (39,000) Unrealized (loss) gain on marketable equity securities A (89,000) A 8,000 Other income, net 53,000 127,000 316,000 125,000 Total other income, net 22,000 24,000 262,000 94,000 Loss from continuing operations (13,493,000) (6,489,000) (27,152,000) (8,863,000) Loss from discontinued operations (Note 11) A A (2,926,000) Net loss (13,493,000) (6,489,000) (27,152,000) (11,789,000) Net loss per share (Note 2): A A A Net loss from continuing operations - basic (13,493,000) (6,687,000) (27,415,000) (9,602,000) Net loss from continuing operations - diluted (13,493,000) (6,687,000) (27,415,000) (9,602,000) Net loss from discontinued operations - basic (2,926,000) Net loss from discontinued operations - diluted (2,926,000) Net loss attributable to common stockholders - basic (13,493,000) (6,687,000) (27,415,000) (12,528,000) Net loss attributable to common stockholders - diluted \$ (13,493,000) \$ (6,687,000) \$ (27,415,000) \$ (12,528,000) Net loss from continuing operations per share - basic \$ (0.98) \$ (0.81) \$ (2.36) \$ (1.29) Net loss from continuing operations per share - diluted (0.98) (0.81) (2.36) (1.29) Net loss from discontinued operations per share - basic (0.98) (0.81) (2.36) (1.68) Net loss attributable to common stockholders per share - diluted \$ (0.98) \$ (0.81) \$ (2.36) \$ (1.68) Weighted average shares outstanding - basic 13,714 8,256 11,624 7,446 Weighted average shares outstanding - diluted 13,714 8,256 11,624 7,446 X - DefinitionCost of revenues & amortization of acquired intangibles. + ReferencesNo definition available. + Details Name: ocx_CostOfRevenuesAmortizationOfAcquiredIntangibles Namespace Prefix: ocx_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4](http://www.xbrl.org/2003/role/disclosureRef-Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4) + Details Name: us-gaap_BusinessCombinationContingentConsiderationArrangementsChangelnAmountOfContingentConsiderationLiability1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionThe aggregate cost of goods produced and sold and services rendered during the reporting period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(2\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 7: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(ii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(ii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(v\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(v)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1) + Details Name: us-gaap_CostOfRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/exampleRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15>Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(e\)\(4\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fas](http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)

<https://asc.fasb.org/1943274/2147483443/250-10-50-7>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2>Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B)Reference 14: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 16: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10>Reference 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(25\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(27\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(23\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 20: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7> + Details Name: us-gaap EarningsPerShareBasic Namespace Prefix: us-gaap Data Type: dt:types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)Reference 5: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15>Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(e\)\(4\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 9: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11>Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7)Reference 12: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2>Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B)Reference 14: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(25\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(27\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(23\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 19: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7> + Details Name: us-gaap EarningsPerShareDiluted Namespace Prefix: us-gaap Data Type: dt:types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of other assets. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap GainLossOnSaleOfOtherAssets Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(2\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1) + Details Name: us-gaap GeneralAndAdministrativeExpense Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionAggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30)Reference 5: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1)Reference 6: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(ee\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 7: [http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 8: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(2\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 9: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 14: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(v\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(v)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(v\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(v)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 23: <http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31> + Details Name: us-gaap GrossProfit Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionThe amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2>Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3)Reference 3:

ASB - <https://www.fasb.org/1943274/2147480097/470-10-S99-1Reference> 23: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification -Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification -Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference) 24: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification -Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification -Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference) 25: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification -Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification -Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference) 26: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification -Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification -Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference) 27: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification -Section 50-Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference](http://www.xbrl.org/2003/role/exampleRef-Topic 280-SubTopic 10-Name Accounting Standards Codification -Section 50-Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31+Details Name: us-gaap IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: <a href=) 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification -Section 65-Paragraph 1-Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification -Section 65-Paragraph 1-Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference) 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification -Section 65-Paragraph 2-Subparagraph \(g\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification -Section 65-Paragraph 2-Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference) 4: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification -Section S99-Paragraph 2-Subparagraph \(SX 210.5-03\(13\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification -Section S99-Paragraph 2-Subparagraph (SX 210.5-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference) 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification -Section 50-Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference> 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification -Section 50-Paragraph 1-Subparagraph \(b\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification -Section 50-Paragraph 1-Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference) 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification -Section 65-Paragraph 1-Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification -Section 65-Paragraph 1-Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference) 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification -Section 50-Paragraph 11-Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification -Section 50-Paragraph 11-Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference) 9: <http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification -Section 45-Paragraph 2-Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference> 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification -Section 45-Paragraph 60B-Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference](http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification -Section 45-Paragraph 60B-Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference) 11: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification -Section 50-Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference> 12: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 944-SubTopic 220-Name Accounting Standards Codification -Section S99-Paragraph 1-Subparagraph \(SX 210.7-04\(23\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 944-SubTopic 220-Name Accounting Standards Codification -Section S99-Paragraph 1-Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference) 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification -Section S99-Paragraph 2-Subparagraph \(SX 210.5-03\(25\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification -Section S99-Paragraph 2-Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference) 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 220-Name Accounting Standards Codification -Section S99-Paragraph 1-Subparagraph \(SX 210.9-04\(27\)\) -Publisher FASB -](http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 220-Name Accounting Standards Codification -Section S99-Paragraph 1-Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/214748524/942-220-S99-1Reference)

<https://www.name-accountingstandardscodification-section50-paragraph11-publisherfasb-urihttps://asc.fasb.org/1943274/2147483443/250-10-50-11Reference16:>
<http://www.xbrl.org/2003/role/disclosureRef-Topic250-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph4-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483443/250-10-50-4Reference17:>
<http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic220-NameAccountingStandardsCodification-Section45-Paragraph7-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147479105/946-220-45-7Reference19:>
[http://www.xbrl.org/2003/role/disclosureRef-Topic944-SubTopic220-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.7-04\(18\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147477250/944-220-599-1Reference20:](http://www.xbrl.org/2003/role/disclosureRef-Topic944-SubTopic220-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.7-04(18))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147477250/944-220-599-1Reference20:)
[http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic220-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.6-07\(9\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147479134/946-220-599-1Reference21:](http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic220-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.6-07(9))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147479134/946-220-599-1Reference21:)
[http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph3-Subparagraph\(SX210.6-09\(1\)\(d\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147479134/946-220-599-3Reference22:](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph3-Subparagraph(SX210.6-09(1)(d))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147479134/946-220-599-3Reference22:)
[http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph\(SX210.13-01\(a\)\(4\)\(i\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-599-1AReference23:](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph(SX210.13-01(a)(4)(i))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-599-1AReference23:)
[http://www.xbrl.org/2009/role/commonPracticeRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph\(SX210.13-01\(a\)\(4\)\(iii\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-599-1AReference24:](http://www.xbrl.org/2009/role/commonPracticeRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph(SX210.13-01(a)(4)(iii))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-599-1AReference24:)
[http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph\(SX210.13-01\(a\)\(4\)\(iii\)\(A\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-599-1AReference25:](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph(SX210.13-01(a)(4)(iii)(A))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-599-1AReference25:)
[http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph\(SX210.13-01\(a\)\(4\)\(iv\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-599-1AReference26:](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph(SX210.13-01(a)(4)(iv))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-599-1AReference26:)
[http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph\(SX210.13-02\(a\)\(4\)\(i\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-599-1BReference27:](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph(SX210.13-02(a)(4)(i))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-599-1BReference27:)
[http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph\(SX210.13-02\(a\)\(4\)\(ii\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-599-1BReference28:](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph(SX210.13-02(a)(4)(ii))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-599-1BReference28:)
[http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph\(SX210.13-02\(a\)\(4\)\(iii\)\(A\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-599-1BReference29:](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph(SX210.13-02(a)(4)(iii)(A))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-599-1BReference29:)
[http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph\(SX210.13-02\(a\)\(4\)\(iii\)\(B\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-599-1BReference30:](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph(SX210.13-02(a)(4)(iii)(B))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-599-1BReference30:)
[http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph\(SX210.13-02\(a\)\(4\)\(iv\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-599-1BReference31:](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph(SX210.13-02(a)(4)(iv))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-599-1BReference31:)
[http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph\(SX210.13-02\(a\)\(5\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-599-1BReference32:](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph(SX210.13-02(a)(5))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-599-1BReference32:)
[http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-Section45-Paragraph60B-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482689/260-10-45-60BReference33:](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-Section45-Paragraph60B-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482689/260-10-45-60BReference33:)
<http://www.xbrl.org/2003/role/disclosureRef-Topic205-SubTopic20-NameAccountingStandardsCodification-Section50-Paragraph7-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483499/205-20-50-7Reference34:>
[http://www.x](http://www.xbrl.org/2003/role/disclosureRef-Topic230-SubTopic10-NameAccountingStandardsCodification-Section45-Paragraph28-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482740/230-10-45-28Reference35:)

Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SAB Topic 11.L\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-599-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-599-1)Reference 7: <http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5>Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30)Reference 9: <http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42>Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22)Reference 11: <http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40>Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 -Details Name: us-gaap RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X -DefinitionThe aggregate total amount of expenses directly related to the marketing or selling of products or services. +ReferencesNo definition available. +Details Name: us-gaap SellingAndMarketingExpense Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X -DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. +ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10> +Details Name: us-gaap WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X -DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. +ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10> +Details Name: us-gaap WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration XML 12 R5.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD (\$) \$ in Thousands 3 Months Ended 9 Months Ended Sep 30, 2024 Sep 30, 2023 Sep 30, 2023 Sep 30, 2024 Sep 30, 2023 Income Statement [Abstract] Å Å Å Net loss \$ (13,493) \$ (6,489) \$ (27,152) \$ (11,789) Foreign currency translation adjustments 20 (9) 8 (7) Comprehensive loss \$ (13,473) \$ (6,498) \$ (27,144) X -DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. +ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 2 -Subparagraph \(SX 210.5-03\(24\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-599-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-599-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SX 210.9-04\(26\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-599-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-599-1)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SX 210.7-04\(22\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-599-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-599-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SX 210.7-04\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-599-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-599-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5 -Details Name: us-gaap ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X -ReferencesNo definition available. +Details Name: us-gaap IncomeStatementAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X -DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. +ReferencesReference 1: <a href=)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 2 -Subparagraph \(SX 210.5-03\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-599-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-599-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-599-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-599-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 9: <http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 13: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 16: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 17: <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7>Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SX 210.7-04\(18\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-599-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-599-1)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SX 210.6-07\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-599-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-599-1)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 599 -Paragraph 3 -Subparagraph \(SX 210.6-09\(1\)\(d\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-599-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 599 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-599-3)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A)Reference 23: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A)Reference 24: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A)Reference 26: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A)Reference 27: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B)Reference 28: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B)Reference 29: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B)Reference 30: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B)Reference 31: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B)Reference 32: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B)Reference 33: <http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 34: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 35: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A)Reference 36: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B)Reference 37:

14 Å 14 Å Å Sale of common shares under at-the-market transactions, net of financing costs 17 Å 17 Å Å Sale of common shares under at-the-market transactions, net of financing costs, shares Å 6 Å Å Deemed dividend on Series A redeemable convertible preferred stock Å Å Å Accretion of Series A convertible preferred stock to redemption value Å Å Å Balance at Sep. 30, 2024 \$ 9,711 Å \$ 326,682 \$ 57 \$ (317,028) Balance, shares at Sep. 30, 2024 Å 13,374 Å X - DefinitionAdjusted shares outstanding. + ReferencesNo definition available. + Details Name: ocx AdjustedSharesOutstanding Namespace Prefix: ocx Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionAdjusted stockholders' equity. + ReferencesNo definition available. + Details Name: ocx AdjustedStockholdersEquity Namespace Prefix: ocx Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionCumulative change in accounting principle. + ReferencesNo definition available. + Details Name: ocx CumulativeChangeInAccountingPrinciple Namespace Prefix: ocx Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionDeemed dividend on Series A redeemable convertible preferred stock. + ReferencesNo definition available. + Details Name: ocx DeemedDividendOnSeriesRedeemableConvertiblePreferredStock Namespace Prefix: ocx Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionAccretion of Series A convertible preferred stock to redemption value. + ReferencesNo definition available. + Details Name: ocx StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue Namespace Prefix: ocx Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionStock issued during period value vesting of bonus awards. + ReferencesNo definition available. + Details Name: ocx StockIssuedDuringPeriodValueVestingOfBonusAwards Namespace Prefix: ocx Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-50-3](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-50-3)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-50-3)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 9: <http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 13: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 16: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 17: <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7>Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(18\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-50-1)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-50-1)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(1\)\(d\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-50-3)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-50-1)Reference 23: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-50-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-50-1)Reference 24: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-50-1)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-50-1)Reference 26: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-50-1)Reference 27: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-50-1)Reference 28: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-50-1)Reference 29: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-50-1)Reference 30: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-50-1)Reference 31: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-50-1)Reference 32: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B)Reference 33: <http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 34: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 35: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1)Reference 36: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1)Reference 37: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(22\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-50-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-50-1) + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph \(a\) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (a) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(19\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-50-1) + Details Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionNumber of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-50-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-50-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-50-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-50-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(4\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-50-3)Reference 7: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.3-04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-50-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-50-1) + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionNumber of shares of stock issued attributable to transactions classified as other. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodSharesOther Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionNumber of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-50-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-50-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-50-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-50-1)Reference 4: <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11>Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4)Reference 6: <http://asc.fasb.org/1943274/2147478448/946-505-50-2>Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(4\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-50-3)Reference 8: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.3-04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-50-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-50-1) + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionValue of shares of stock issued attributable to transactions classified as other. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodValueIssuedForServices Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionValue, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP). + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionNumber of stock bought back by the entity at

Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3>: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(31\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4): <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-1Reference 5>: <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(19\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7): [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.6-05\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8): [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(4\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9): [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(6\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10): [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(7\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11): [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12): [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13): [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14): [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(b\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquityNamespacePrefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 14 R7.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 CASH FLOWS FROM OPERATING ACTIVITIES: Â Net loss $ (27,152,000) $ (11,789,000) Adjustments to reconcile net loss to net cash used in operating activities: Â Depreciation and amortization expense 935,000 1,289,000 Amortization of intangible assets 66,000 66,000 Stock-based compensation 1,254,000 2,276,000 Equity compensation for bonus awards and consulting services 110,000 108,000 Unrealized gain on marketable equity securities (8,000) Change in fair value of contingent consideration 9,421,000 (16,947,000) Impairment losses 6,761,000 Loss on disposal of discontinued operations 1,521,000 Impairment loss on held for sale assets 169,000 1,283,000 Changes in operating assets and liabilities: Â Accounts receivable 275,000 130,000 Inventories (232,000) Prepaid expenses and other assets (345,000) 645,000 Accounts payable and accrued liabilities 263,000 (4,193,000) Lease assets and liabilities (123,000) (43,000) Net cash used in operating activities (15,359,000) (18,901,000) CASH FLOWS FROM INVESTING ACTIVITIES: Â Proceeds from sale of equipment 354,000 Construction in progress and purchases of furniture and equipment (302,000) (17,000) Cash sold in discontinued operations (Note 11) (1,372,000) Net cash used in investing activities (302,000) (1,035,000) CASH FLOWS FROM FINANCING ACTIVITIES: Â Proceeds from sale of common shares 15,807,000 13,848,000 Financing costs to issue common shares (538,000) (427,000) Proceeds from sale of common shares under at-the-market transactions 18,000 Â Financing costs for at-the-market sales (187,000) Â Redemption of Series A redeemable convertible preferred shares (5,389,000) (1,118,000) Repayment of financing lease obligations (119,000) (87,000) Net provided by financing activities 9,592,000 12,216,000 NET CHANGE IN CASH, CASH EQUIVALENTS (INCLUDES DISCONTINUED OPERATIONS) AND RESTRICTED CASH (6,069,000) (7,720,000) CASH, CASH EQUIVALENTS (INCLUDES DISCONTINUED OPERATIONS) AND RESTRICTED CASH, BEGINNING 11,132,000 23,203,000 CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING 5,063,000 15,483,000 SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Â Cash paid for interest 17,000 Cash paid for income taxes SUPPLEMENTAL SCHEDULE OF NONCASH INVESTING AND FINANCING ACTIVITIES Â Construction in progress, machinery and equipment purchases included in accounts payable and accrued liabilities 301,000 215,000 Accretion of Series A convertible preferred stock 263,000 621,000 Financing costs for at-the-market sales included in accrued liabilities 100,000 Â Lease assets obtained in exchange for lease liabilities $ 1,202,000 X - DefinitionAccretion of series convertible preferred stock. + ReferencesNo definition available. + Details Name: ocx_AccretionOfSeriesConvertiblePreferredStock Namespace Prefix: ocx_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionConstruction in progress, machinery and equipment purchases included in accounts payable and accrued liabilities. + ReferencesNo definition available. + Details Name: ocx_ConstructionInProgressMachineryAndEquipmentPurchasesIncludedInAccountsPayableAndAccruedLiabilities Namespace Prefix: ocx_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionEquity compensation for bonus awards and consulting services. + ReferencesNo definition available. + Details Name: ocx_EquityCompensationForBonusAwardsAndConsultingServices Namespace Prefix: ocx_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFinancing costs for at the market sales included in accrued liabilities. + ReferencesNo definition available. + Details Name: ocx_FinancingCostsForAtTheMarketSalesIncludedInAccruedLiabilities Namespace Prefix: ocx_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPayment for cash sold in discontinued operations. + ReferencesNo definition available. + Details Name: ocx_PaymentForCashSoldInDiscontinuedOperations Namespace Prefix: ocx_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPayment of financing costs for at the market sales. + ReferencesNo definition available. + Details Name: ocx_PaymentOffinancingCostsForAtTheMarketSales Namespace Prefix: ocx_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionProceeds from sale of common shares under at the market transactions. + ReferencesNo definition available. + Details Name: ocx_ProceedsFromSaleOfCommonSharesUnderAtTheMarketTransactions Namespace Prefix: ocx_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRepayment of financing lease obligations. + ReferencesNo definition available. + Details Name: ocx_RepaymentOfFinancingLeaseObligations Namespace Prefix: ocx_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: <a href=): <http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 3>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4](http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4): [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2](http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2 + Details Name: us-gaap_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. + ReferencesReference 1: <a href=): [http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2](http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4 + Details Name: us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <a href=): <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3>: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2](http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <a href=): [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(b\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. + ReferencesReference 1: <a href=): [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_DepreciationAndAmortization Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations. + ReferencesReference 1: <a href=): [http://www.xbrl.org/2003/role/disclosureRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 3](http://www.xbrl.org/2003/role/disclosureRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 3): <http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2Reference 2>: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3Reference 3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3Reference 3): [http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2AReference 2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ImpairmentOfIntangibleAssetsFinitelived Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax. + ReferencesReference 1: <a href=): <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23Reference 3>: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22Reference 4>: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2): [http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(g\)\(1\) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_IncreaseDecreaseInOperatingLeaseLiability](http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_IncreaseDecreaseInOperatingLeaseLiability)

Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1:

S99-1Reference 7:

Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 18 R11.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] A Summary of Significant Accounting Policies 2. Summary of Significant Accounting PoliciesAccounting PrinciplesThe consolidated financial statements and accompanying notes are prepared on the accrual basis of accounting in accordance with U.S. generally accepted accounting principles (theGAAP).Principles of Consolidation and Basis of PresentationThe unaudited condensed consolidated interim financial statements presented herein have been prepared in accordance with GAAP for financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. In accordance with those rules and regulations, certain information and footnote disclosures normally included in comprehensive consolidated financial statements may have been condensed or omitted. The consolidated balance sheet as of December 31, 2023 was derived from the audited consolidated financial statements at that date. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in Oncocyte's Annual Report on Form 10-K for the year ended December 31, 2023. The accompanying unaudited condensed consolidated financial statements, in the opinion of management, include all adjustments of a normal recurring nature necessary for a fair presentation of Oncocyte's financial condition and results of operations. The consolidated results of operations are not necessarily indicative of the results to be expected for any other interim period or for the entire year.On January 31, 2020, with the acquisition of Insight Genetics, Inc. (theInsight) through a merger with a newly incorporated wholly-owned subsidiary of Oncocyte (theInsight Merger) under the terms of an Agreement and Plan of Merger (theInsight Merger Agreement), Insight became a wholly-owned subsidiary of Oncocyte, and on that date Oncocyte began consolidating Insight's operations and results with Oncocyte's operations and results (see Note 3).On April 15, 2021, with the acquisition of Chronix Biomedical, Inc. (theChronix) pursuant to an Agreement and Plan of Merger dated February 2, 2021, amended February 23, 2021, and amended and restated as of April 15, 2021 (as amended and restated, theChronix Merger Agreement), by and among Oncocyte, CNI Monitor Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Oncocyte (theMerger Sub), Chronix became a wholly-owned subsidiary of Oncocyte (theChronix Merger), and on that date Oncocyte began consolidating Chronix's operations and results with Oncocyte's operations and results (see Note 3).All material intercompany accounts and transactions have been eliminated in consolidation.We have reflected the 2023 operations of Razor as discontinued operations. See Note 11 for further information. Amounts and disclosures throughout these notes to consolidated financial statements relate solely to continuing operations and exclude all discontinued operations, unless otherwise noted. Discontinued operations comprise activities that were disposed of or discontinued at the end of the period, represent a separate major line of business that can be clearly distinguished for operational and financial reporting purposes and represent a strategic business shift having a major effect on the Company's operations and financial results.On July 24, 2023, the Company implemented a 1-for-20 reverse stock split of the outstanding shares of its common stock. The par value per share and the authorized number of shares of common stock and preferred stock were not adjusted as a result of the reverse stock split. All common stock share and per-share amounts for all periods presented in these consolidated financial statements have been adjusted to reflect the reverse stock split. The number of authorized shares of common stock remains at 230,000,000 shares.ReclassificationsCertain prior period amounts in the consolidated financial statements and notes to consolidated financial statements have been reclassified to conform to the current period presentation. Included in such prior period amounts is contingent consideration liabilities, current, which was previously presented in the noncurrent balance. These changes had no impact on the previously reported consolidated financial condition, results of operations or cash flows.Prior Period RevisionsIn connection with the preparation of the Company's consolidated financial statements for the year ended December 31, 2023, the Company recorded certain adjustments that impacted previously reported financial statement amounts from the period ended September 30, 2023. As further discussed below in theRevenue Recognition Laboratory Developed Test Services Allowance for Credit Losses, as a result of the January 1, 2023 adoption of the new current expected credit loss accounting policy, the Company adjusted its accounts receivable. In addition, the Company reclassified cash sold in discontinued operations from an operating cash outflow to an investing cash outflow. See Note 11, Discontinued Operations of Razor for additional information. The following are the relevant line items from the Company's prior period consolidated financial statements illustrating the effect of the revisions to the period presented: A For the Period Ended September 30, 2023 A As Previously Reported A Adjustment A As Adjusted A (In thousands) A Balance Sheet and Shareholders' Equity: A A A A A A A Accounts receivable, net at January 1, 2023 (Note 2) A \$ 2,012 A \$ (1,419) A \$ 593 A Accumulated deficit at January 1, 2023 A \$ (260,676) A \$ (1,419) A \$ (262,095) A Total Shareholders' equity at January 1, 2023 A \$ 34,292 A \$ (1,419) A \$ 32,873 A Statement of Cash Flows: A A A A A A Loss on disposal of discontinued operations A \$ 1,659 A \$ (138) A \$ 1,521 A Net cash used in operating activities A \$ (18,763) A \$ (138) A \$ (18,901) A Cash sold in discontinued operations (Note 11) A \$ (1,510) A \$ 138 A \$ (1,372) A Net cash used in investing activities A \$ (1,173) A \$ 138 A \$ (1,035) A Use of EstimatesThe preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and contingent assets and liabilities, at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates estimates which are subject to significant judgment, including, but not limited to, valuation methods used, assumptions requiring the use of judgment to prepare financial projections and forecasted financial information, timing of potential commercialization of acquired in-process intangible assets, applicable discount rates, probabilities of the likelihood of multiple outcomes of certain events related to contingent consideration, comparable companies or transactions, determination of fair value of the assets acquired and liabilities assumed (including those relating to contingent consideration), the carrying value of goodwill and other intangibles, impairments, assumptions related to going concern assessments, revenue recognition, allocation of direct and indirect expenses, useful lives associated with long-lived intangible and other assets, key assumptions in operating and financing leases including incremental borrowing rates, loss contingencies, valuation allowances related to deferred income taxes, allowances for credit losses, and assumptions used to value stock-based awards and other equity instruments. These assessments are made in the context of information reasonably available to Oncocyte. Actual results may differ materially from those estimates.SegmentsOncocyte's executive management team, as a group, represents the entity's chief operating decision makers. To date, Oncocyte's executive management team has viewed Oncocyte's operations as one segment that includes the research, development and commercialization of diagnostic tests, including molecular diagnostic services pharmaceutical customers. As a result, the financial information disclosed materially represents all of the financial information related to Oncocyte's sole operating segment.Fair Value Measurements, Business Combinations and Contingent Consideration LiabilitiesOncocyte accounts for business combinations in accordance with ASC 805, which requires the purchase consideration transferred to be measured at fair value on the acquisition date in accordance with ASC 820, Fair Value Measurement. ASC 820 establishes a single authoritative definition of fair value, sets out a framework for measuring fair value and expands on required disclosures about fair value measurement. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. ASC 820 describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value, which are the following: Level 1 Quoted prices in active markets for identical assets and liabilities. Level 2 Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted market prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Such inputs reflect management's best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. Management estimates include certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs, including the entity's own assumptions in determining fair value.When a part of the purchase consideration consists of shares of Oncocyte common stock, Oncocyte calculates the purchase price attributable to those shares, a Level 1 security, by determining the fair value of those shares as of the acquisition date based on prices quoted on the principal national securities exchange on which the shares traded. Oncocyte recognizes estimated fair values of the tangible assets and identifiable intangible assets acquired, including in-process research and development (thePR&D), and liabilities assumed, including any contingent consideration, as of the acquisition date. Goodwill is recognized as any amount of excess consideration transferred over the fair value of the tangible and identifiable intangible assets acquired net of the liabilities assumed. ASC 805 precludes the recognition of an assembled workforce as an asset, effectively subsuming any assembled workforce value into goodwill.In determining fair value, Oncocyte utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, and also considers counterparty credit risk in its assessment of fair value. For the periods presented, Oncocyte has no financial assets recorded at fair value on a recurring basis, except for money market funds. These assets are measured at fair value using the period-end quoted market prices as a Level 1 input.Certain of Oncocyte's asset and business acquisitions involve the potential for future payment of consideration to third-parties and former selling shareholders in amounts determined as a percentage of future net revenues generated, or upon attainment of revenue milestones, from Pharma Services or laboratory tests, as applicable, or annual minimum royalties to certain licensors, as provided in the applicable agreements. The fair value of such liabilities is determined using unobservable inputs. These inputs include the estimated amount and timing of projected cash flows and the risk-adjusted discount rate used to present value the cash flows. These obligations are referred to as contingent consideration, which are carried at fair value based on Level 3 inputs on a recurring basis.ASC 805 requires that contingent consideration be estimated and recorded at fair value as of the acquisition date as part of the total consideration transferred. Contingent consideration is an obligation of the acquirer to transfer additional assets or equity interests to the selling shareholders in the future if certain future events occur or conditions are met, such as the attainment of product development milestones. Contingent consideration also includes additional future payments to selling shareholders based on achievement of components of earnings, such as earn-out provisions or percentage of future revenues, including royalties paid to the selling shareholders based on a percentage of certain revenues generated.The fair value of contingent consideration after the acquisition date is reassessed by Oncocyte as changes in circumstances and conditions occur, with the subsequent change in fair value recorded in the consolidated statements of operations. Changes in key assumptions can materially affect the estimated fair value of contingent consideration liabilities and, accordingly, the resulting gain or loss that Oncocyte records in its consolidated financial statements. See Note 3 for a full discussion of these liabilities and additional Level 3 fair value disclosures.The carrying amounts of cash and cash equivalents, restricted cash, net accounts receivable, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities approximate fair values because of the short-term nature of these items.In accordance with GAAP, from time to time, the Company measures certain assets at fair value on a nonrecurring basis. The Company reviews the carrying value of intangibles, including IP&D (see Note 5), and other long-lived assets for indications of impairment at least annually. Refer to related discussions of impairments below.Cash, Cash Equivalents and Restricted CashOncocyte considers all highly liquid securities with original maturities of three months or less when purchased to be cash equivalents. For the periods presented, Oncocyte's cash equivalents are comprised of investments in AAA rated money market funds that invest in first-tier only securities, which primarily include domestic commercial paper and securities issued or guaranteed by the U.S. government or its agencies. Restricted cash relates to a bank letter of credit required under our office lease arrangement, refer to Note 6 for additional information.Marketable Equity SecuritiesOncocyte accounts for shares of public common stock it may hold as marketable equity securities in accordance with ASC 321-10, Investments in Equity Securities, as the shares have a readily determinable fair value quoted on national stock exchange. The securities are measured at fair value, with related gains and losses in the value of such securities recorded in the consolidated statements of operations in other income or expense, and are reported as current assets in the consolidated balance sheet based on the closing trading price of the security as of the date being presented. During the fourth quarter of 2023, Oncocyte sold its remaining marketable equity securities for an aggregate realized loss of approximately \$1.4 million. During the nine months ended September 30, 2023, Oncocyte recorded an unrealized gain on marketable equity securities of \$8,000.Investments in Privately Held CompaniesOncocyte evaluates whether investments held in common stock of other companies require consolidation of the company under, first, the variable interest entity (theVIE) model, and then under the voting interest model in accordance with accounting guidance for consolidations under ASC 810-10. If consolidation of the entity is not required under either the VIE model or the voting interest model, Oncocyte determines whether the equity method of accounting should be applied in accordance with ASC 323, Investments in Equity Method and Joint Ventures. The equity method applies to investments in common stock or in-substance common stock if Oncocyte exercises significant influence over, but does not control, the entity, where significant influence is typically represented by ownership of 20% or more, but less than majority ownership, of the voting interests of a company.Oncocyte initially records equity method investments at fair value on the date of the acquisition with subsequent adjustments to the investment balance based on Oncocyte's pro rata share of earnings or losses from the investment.Since February 16, 2023, Oncocyte continues to own an equity interest in Razor, however, based on the Razor transactions as discussed in Note 1, the remaining common stock held is accounted for at historical cost less impairment, which is currently zero.InventoriesInventories include raw materials, work-in-process and finished goods and are valued at the lower of cost or net realizable value. In September 2024, the Company capitalized certain initial RUO inventory costs in connection with its collaboration arrangement with Bio-Rad to develop and commercialize its GraftAssure RUO kitted tests and eventual IVD kitted transplant testing products. See Note 10, Collaborative Arrangements for additional information. As of September 30, 2024, inventories, comprised primarily of raw materials, totaled \$232,000.Assets Held for Sale and Discontinued OperationsAssets and liabilities are classified as held for sale when all of the following criteria for a plan of sale have been met: (1) management, having the authority to approve the action, commits to a plan to sell the assets; (2) the assets are available for immediate sale, in their present condition, subject only to terms that are usual and customary for sales of such assets; (3) an active program to locate a buyer and other actions required to complete the plan to sell the assets have been initiated; (4) the sale of the assets is probable and is expected to be completed within one year; (5) the assets are being actively marketed for a price that is reasonable in relation to their current fair value; and (6) actions required to complete the plan indicate that it is unlikely that significant changes to the plan will be made or the plan will be withdrawn. When all of these criteria have been met, the assets and liabilities are classified as held for sale in the consolidated balance sheet. Assets classified as held for sale are reported at the lower of their carrying value or fair value less costs to sell. Depreciation and amortization of assets ceases upon designation as held for sale.The Company has entered into various agreements to sell laboratory equipment. As a result, the Company classified the equipment as held for sale current assets in the consolidated balance sheets, as all the criteria of ASC subtopic 360-10, Property, Plant, and Equipment had been met. The equipment was written down to its fair value, less cost to sell, the remainder of which was \$32,000 and \$139,000 as of September 30, 2024 and December 31, 2023, respectively. During the nine months ended September 30, 2024 and 2023, the Company recorded an impairment loss on held for sale assets of \$169,000 and \$1.3 million, respectively, in the consolidated statements of operations.Discontinued operations comprise activities that were disposed of, discontinued or held for sale at the end of the period, represent a separate major line of business that can be clearly distinguished for operational and financial reporting purposes and represent a strategic business shift having a major effect on the Company's operations and financial results according to ASC Topic 205, Presentation of Financial Statements. Razor has been reflected as a discontinued operation in the 2023 consolidated financial statements. See Note 11, Discontinued Operations of Razor for additional information.Machinery and Equipment, Net, Financing Leases, Net, and Construction in ProgressMachinery and equipment are stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally over a period of 3 to 10 years. For equipment purchased under financing leases, Oncocyte depreciates the equipment based on the shorter of the useful life of the equipment or the term of the lease, ranging from 3 to 5 years, depending on the nature and classification of the financing lease. Maintenance and repairs are expensed as incurred whereas significant renewals and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and the related accumulated depreciation are removed from the respective accounts and any resulting gain or loss is reflected in Oncocyte's results of operations.Construction in progress, comprised primarily of leasehold improvements under construction, is not depreciated until

the underlying asset is placed into service.Intangible AssetsIn accordance with ASC 350, Intangibles â€” Goodwill and Other, IPR&D projects acquired in a business combination that are not complete as of the acquisition date are capitalized and accounted for as indefinite-lived intangible assets until completion or abandonment of the related research and development efforts. Upon successful completion of the project, the capitalized amount is amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts are written off immediately. Oncocyte considers various factors and risks for potential impairment of IPR&D assets, including the current legal and regulatory environment and the competitive landscape. Adverse clinical trial results, significant delays or inability to obtain local coverage determination (â€œLCDâ€) from the Centers for Medicare and Medicaid Services (â€œCMSâ€) for Medicare reimbursement for a diagnostic test, the inability to bring a diagnostic test to market and the introduction or advancement of competitorsâ€” diagnostic tests could result in partial or full impairment of the related intangible assets. Consequently, the eventual realized value of the IPR&D project may vary from its fair value at the date of acquisition, and IPR&D impairment charges may occur in future periods. During the period between completion or abandonment, the IPR&D assets will not be amortized but will be tested for impairment on an annual basis and between annual tests if Oncocyte becomes aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&D projects below their respective carrying amounts.Oncocyte does not have intangible assets with indefinite useful lives other than the acquired IPR&D discussed in Note 5, which as of September 30, 2024, has been partially impaired.Goodwill represents the excess of the purchase price over the fair value of net identifiable assets and liabilities. Goodwill, similar to IPR&D, is not amortized but is tested for impairment at least annually, or if circumstances indicate that it is more-likely-than-not that the carrying value of the associated reporting unit exceeds its fair value. Qualitative factors considered in this assessment include industry and market conditions, overall financial performance, and other relevant events and factors affecting Oncocyteâ€”s business. Based on the qualitative assessment, if it is determined that the fair value of goodwill is more-likely-than-not to be less than its carrying amount, the fair value of a reporting unit will be calculated and compared with its carrying amount and an impairment charge will be recognized for the amount that the carrying value exceeds the fair value. Oncocyte continues to operate in one segment and considered to be the sole reporting unit and, therefore, goodwill is tested for impairment at the enterprise level, when applicable.In accordance with ASC 350, we review and evaluate our long-lived assets, including intangible assets with finite lives, for impairment whenever events or changes in circumstances indicate that we may not recover their net book value. When applicable, we test goodwill for impairment on an annual basis in the fourth quarter of each year, and between annual tests, if indicators of potential impairment exist, using a fair-value approach. We typically use an income method to estimate the fair value of these assets, which is based on forecasts of the expected future cash flows attributable to the respective assets. Significant estimates and assumptions inherent in the valuations reflect a consideration of other marketplace participants and include the amount and timing of future cash flows (including expected growth rates). Estimates utilized in the projected cash flows include consideration of macroeconomic conditions, overall category growth rates, competitive activities, cost containment and margin expansion, Company business plans, the underlying product or technology life cycles, economic barriers to entry, and the discount rate applied to the cash flows. Unanticipated market or macroeconomic events and circumstances may occur, which could affect the accuracy or validity of the estimates and assumptions.Long-Lived Intangible AssetsLong-lived intangible assets subject to amortization are stated at acquired cost, less accumulated amortization. We amortize intangible assets not considered to have an indefinite useful life using the straight-line method over their estimated period of benefit, which generally ranges from 1 to 9 years. Each reporting period, we evaluate the estimated remaining useful life of intangible assets and assess whether events or changes in circumstances warrant a revision to the remaining period of amortization or indicate that impairment exists. Long-lived intangible assets currently consist of acquired customer relationships with an estimated useful life of 5 years (see Note 5).Impairment of Long-Lived AssetsOncocyte assesses the impairment of long-lived assets whenever events or changes in circumstances indicate that such assets might be impaired and the carrying value may not be recoverable. Oncocyteâ€”s long-lived assets consist primarily of intangible assets, right-of-use assets for operating and financing leases, customer relationships, and machinery and equipment. If events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable and the expected undiscounted future cash flows attributable to the asset are less than the carrying amount of the asset, an impairment loss, equal to the excess of the carrying value of the asset over its fair value, is recorded.LeasesOncocyte accounts for leases in accordance with ASC 842, Leases. Oncocyte determines if an arrangement is a lease at inception. Leases are classified as either financing or operating, with classification affecting the pattern of expense recognition in the consolidated statements of operations. Under the available practical expedients for the adoption of ASC 842, Oncocyte accounts for the lease and non-lease components as a single lease component. Oncocyte recognizes right-of-use (â€œROUâ€) assets and lease liabilities for leases with terms greater than twelve months in the consolidated balance sheet. ROU assets represent the right to use an underlying asset during the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most leases do not provide an implicit rate, Oncocyte uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. Oncocyte uses the implicit rate when it is readily determinable. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. Lease terms may include options to extend or terminate the lease when it is reasonably certain that Oncocyte will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Operating leases include office leases and related ROU lease liabilities, current and long-term, in the consolidated balance sheets. Financing leases include machinery and equipment and related financing lease liabilities, current and long-term, in the consolidated balance sheets. Oncocyte discloses the amortization of our operating lease ROU assets and payments as a net amount in the consolidated statements of cash flows. Oncocyte has entered into various operating and financing leases in accordance with ASC 842 as further discussed in Note 6.Accounting for WarrantsOncocyte determines the accounting classification of warrants it issues, as either liability or equity classified, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity, then in accordance with ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Companyâ€”s Own Stock. Under ASC 480, warrants are considered liability classified if the warrants are mandatorily redeemable, obligate Oncocyte to settle the warrants or the underlying shares by paying cash or other assets or warrants that must or may require settlement by issuing variable number of shares. If warrants do not meet liability classification under ASC 480, Oncocyte assesses the requirements under ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. This liability classification guidance also applies to financial instruments that may require cash or other form of settlement for transactions outside of the companyâ€”s control and, in which the form of consideration to the warrant holder may not be the same as to all other shareholders in connection with the transaction. However, if a transaction is not within the companyâ€”s control but the holder of the financial instrument can solely receive the same type or form of consideration as is being offered to all the shareholders in the transaction, then equity classification of the financial instrument is not precluded, if all other applicable equity classification criteria are met.After all relevant assessments, Oncocyte concludes whether the warrants are classified as liability or equity. Liability classified warrants require fair value accounting at issuance and subsequent to initial issuance with all changes in fair value after the issuance date recorded in the statements of operations. Equity classified warrants only require fair value accounting at issuance with no changes recognized subsequent to the issuance date. Based on the above guidance and, among other factors, the fact that our warrants cannot be cash settled under any circumstance but require share settlement, all of our outstanding warrants meet the equity classification criteria and have been classified as equity. Refer to Note 7 for details about our outstanding warrants.Revenue RecognitionPursuant to ASC 606, Revenue from Contracts with Customers, revenues are recognized when control of services performed is transferred to customers, in an amount that reflects the consideration Oncocyte expects to be entitled to in exchange for those services. ASC 606 provides for a five-step model that includes:(i)identifying the contract with a customer,(ii)identifying the performance obligations in the contract, (iii)determining the transaction price,(iv)allocating the transaction price to the performance obligations, and(v)recognizing revenue when, or as, an entity satisfies a performance obligation.Oncocyte determines transaction prices based on the amount of consideration we expect to receive for transferring the promised goods or services in the contract. Consideration may be fixed, variable, or a combination of both. The Company considers any constraints on the variable consideration and includes in the transaction price variable consideration to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved.The following table presents consolidated revenues by service:Â Three Months EndedSeptember 30, Â Nine Months EndedSeptember 30, Â 2024 Â 2023 Â 2024 Â 2023 Â (In thousands) Â Pharma Services Â \$ 115 Â \$ 423 Â \$ 373 Â \$ 1,160 Â Laboratory Developed Test Services Â \$ 46 Â \$ 6 Â \$ 22 Â \$ 29 Â Total Â \$ 115 Â \$ 429 Â \$ 395 Â \$ 1,189 Â Â Pharma Services RevenueRevenues recognized include Pharma Services performed by Oncocyteâ€”s Insight and Chronix subsidiaries for its pharmaceutical customers, including testing for biomarker discovery, assay design and development, clinical trial support, and a broad spectrum of biomarker tests. These Pharma Services are generally performed under individual scope of work (â€œSOWâ€) arrangements or license agreements (together with SOW the â€œPharma Services Agreementsâ€) with specific deliverables defined by the customer. Pharma Services are performed on a (i) time and materials basis or (ii) per test completed basis. Upon completion of the service to the customer in accordance with a Pharma Services Agreement, Oncocyte has the right to bill the customer for the agreed upon price (either on a per test or per deliverable basis) and recognizes Pharma Service revenue at that time. Insight identifies each service of its Pharma Service offering as a single performance obligation. Offerings include services such as recurring fees for project management, fees for storage and handling, pass through expenses for shipping or calibration, training, proficiency, reproducibility tests, etc. Chronix identifies the processing of test samples as a separate performance obligation (considered a series) within license agreements with customers.Completion of the service and satisfaction of the performance obligation is typically evidenced by acknowledgment of completed services, and access to the report or test made available to the customer or any other form or applicable manner of delivery defined in the Pharma Services Agreements. However, for certain SOWs under which work is performed pursuant to the customerâ€”s highly customized specifications, Oncocyte has the enforceable right to bill the customer for work completed, rather than upon completion of the SOW. For those SOWs, Oncocyte recognizes revenue over a period during which the work is performed using a formula that accounts for expended efforts, generally measured in labor hours, as a percentage of total estimated efforts for the completion of the SOW. As performance obligations are satisfied under the Pharma Services Agreements, any amounts earned as revenue and billed to the customer are included in accounts receivable. Any revenues earned but not yet billed to the customer as of the date of Oncocyteâ€”s consolidated financial statements are recorded as contract assets and are included in prepaids and other current assets as of the financial statement date. Amounts recorded in contract assets are reclassified to accounts receivable in Oncocyteâ€”s consolidated balance sheets when the customer is invoiced according to the billing schedule in the contract.As of September 30, 2024 and December 31, 2023, Oncocyte had gross accounts receivable from Pharma Services customers of \$211,000 and \$489,000, respectively.Allowance for Credit LossesOncocyte establishes an allowance for credit losses based on the evaluation of the collectability of its Pharma Services accounts receivables after considering a variety of factors, including the length of time receivables are past due, significant events that may impair the customerâ€”s ability to pay, such as a bankruptcy filing or deterioration in the customerâ€”s operating results or financial position, reasonable and supportable forecast that affect the collectability of the reported amount, and historical experience. If circumstances related to customers change, estimates of the recoverability of receivables would be further adjusted. Oncocyte continuously monitors collections and payments from customers and maintains a provision for estimated credit losses and uncollectible accounts, if any, based upon its historical experience and any specific customer collection issues that have been identified. Amounts determined to be uncollectible are written off against the credit loss reserve accounts. As of September 30, 2024 and December 31, 2023, Oncocyte had an allowance for credit losses of \$2,000 and \$5,000, respectively, related to Pharma Services.Laboratory Developed Test ServicesPrior to the Razor Sale Transaction, Oncocyte generated revenue from performing DetermaRx tests on clinical samples through orders received from physicians, hospitals, and other healthcare providers. In determining whether all the revenue recognition criteria in (i) through (v) above are met with respect to DetermaRx tests, each test result is considered a single performance obligation and is generally considered complete when the test result is delivered or made available to the prescribing physician electronically, and, as such, there are no shipping or handling fees incurred by Oncocyte or billed to customers. Although Oncocyte has billed a list price for all tests ordered and completed for all payer types, Oncocyte considers constraints on the variable consideration when recognizing revenue for DetermaRx. Because DetermaRx is a novel test and there are no current reimbursement arrangements with third-party payers other than Medicare, the transaction price represents variable consideration. Application of the constraint for variable consideration is an area that requires significant judgment. For all payers other than Medicare, Oncocyte must consider the novelty of the test, the uncertainty of receiving payment, or being subject to claims for a refund, from payers with whom it does not have a sufficient payment collection history or contractual reimbursement agreements. Accordingly, for those payers, Oncocyte has recognized revenue upon payment because it has had insufficient history to reliably estimate payment patterns.As of September 30, 2024 and December 31, 2023, Oncocyte had no accounts receivable from Medicare and Medicare Advantage covered DetermaRx tests. Laboratory Developed Test Services revenue recorded during the nine months ended September 30, 2024 was the result of payments received.Allowance for Credit LossesWe maintained an allowance for credit losses related to Laboratory Developed Test Services at an amount we estimated to be sufficient to provide adequate protection against losses resulting from extending credit to our customers. We based this allowance, in the aggregate, on historical collection experience, age of receivables and general economic conditions, as well as specific identification of uncollectible accounts. We initially established an allowance in 2022 in connection with remaining Medicare and Medicare Advantage account balances and continued to add to the allowance as appropriate. In the first quarter of 2023, in connection with the adoption of the new current expected credit loss model, the Company determined that the Medicare and Medicare Advantage accounts receivable net balance of approximately \$1.4 million was uncollectible and should therefore be written-off as of the adoption date, January 1, 2023. Refer to additional information above in â€œPrinciples of Consolidation and Basis of Presentation â€” Prior Period Revisions.â€ As of December 31, 2023, we had no allowance for credit losses related to Laboratory Developed Test Services. The 2023 allowance for credit losses activity included a beginning balance of \$154,000, no credit loss provisions, and the full write-off to an ending balance of zero as of December 31, 2023.Licensing RevenueRevenues that may be recognized include licensing revenue derived from agreements with customers for exclusive rights to market Oncocyteâ€”s proprietary testing technology. Under the agreements, Oncocyte grants exclusive rights to certain trademarks and technology of Oncocyte for the purpose of marketing Oncocyteâ€”s tests within a defined geographic territory. A license agreement may specify milestone deliverables or performance obligations, for which Oncocyte recognizes revenue when its licensee confirms the completion of Oncocyteâ€”s performance obligation. A licensing agreement may also include ongoing sales support from Oncocyte and typically includes non-refundable licensing fees and per-test Pharma Services revenues discussed above, for which Oncocyte treats the licensing of the technology, trademarks, and ongoing support as a single performance obligation satisfied by the passage of time over the term of the agreement.Disaggregation of Revenues and Concentrations of Credit RiskThe following table presents the percentage of consolidated revenues by service:Â Three Months EndedSeptember 30, Â Nine Months EndedSeptember 30, Â 2024 Â 2023 Â 2024 Â 2023 Â Pharma Services Â 100 % Â 99 % Â 94 % Â 98 % Laboratory Developed Test Services Â 0 % Â 1 % Â 6 % Â 2 % Total Â 100 % Â 100 % Â 100 % Â 100 % Â The following table presents the percentage of consolidated revenues generated by unaffiliated customers, based on the respective periods presented, that individually represented greater than ten percent of consolidated revenues:Â Three Months EndedSeptember 30, Â Nine Months EndedSeptember 30, Â 2024 Â 2023 Â 2024 Â 2023 Â Pharma services - Company A Â 74 % Â 57 % Â 37 % Â 42 % Pharma services - Company B Â 26 % Â 41 % Â 29 % Â 34 % Pharma services - Company C Â * Â * Â * Â * Â 12 % Â * Â Pharma services - Company D Â * Â * Â * Â * Â 11 % Â * Â * Less than 10%The following table presents the percentage of consolidated revenues attributable to geographical locations, based on country of domicile:Â Three Months EndedSeptember 30, Â Nine Months EndedSeptember 30, Â 2024 Â 2023 Â 2024 Â 2023 Â United States â€” Pharma Services Â 100 % Â 42 % Â 46 % Â 54 % Outside of the United States â€” Pharma Services Â 0 % Â 57 % Â 48 % Â 42 % United States â€” Laboratory Developed Test Services Â 0 % Â 1 % Â 6 % Â 4 % Total Â 100 % Â 100 % Â 100 % Â 100 % Â As of September 30, 2024 and December 31, 2023, the Company held long-lived tangible assets in Germany in the amount of \$392,000 and \$66,000, respectively.Financial instruments that potentially subject the Company to concentrations of credit risk are cash equivalents and accounts receivable. The Company places its cash equivalents primarily in highly rated money market funds. Cash and cash equivalents are also invested in deposits with certain financial institutions and may, at times, exceed federally insured limits. The Company has not experienced any significant losses on its deposits of cash and cash equivalents.Four Pharma Services customers individually

represented approximately 51%, 20%, 17% and 12% of accounts receivable as of September 30, 2024. Two Pharma Services customers individually represented approximately 79% and 13% of accounts receivable as of December 31, 2023.

Cost of Revenues Cost of revenues generally consists of cost of materials, direct labor including benefits, bonus and stock-based compensation, equipment and infrastructure expenses, clinical sample related costs associated with performing Pharma Services and Laboratory Developed Test Services, providing deliverables according to our licensing agreements, license fees due to third-parties, and amortization of acquired intangible assets such as the customer relationship intangible assets (see Note 5). Infrastructure expenses include depreciation of laboratory equipment, allocated rent costs, leasehold improvements, and allocated information technology costs for operations at Oncocyteâ€™s CLIA laboratory in Tennessee. Costs associated with generating the revenues are recorded as the tests or services are performed regardless of whether revenue was recognized. Royalties or revenue share payments for licensed technology calculated as a percentage of revenues generated using the associated technology are recorded as expenses at the time the related revenues are recognized.

Research and Development Expenses Research and development expenses are comprised of costs incurred to develop technology, which include salaries and benefits (including stock-based compensation), laboratory expenses (including reagents and supplies used in research and development laboratory work), infrastructure expenses (including allocated facility occupancy costs), and contract services and other outside costs. Indirect research and development expenses are allocated primarily based on headcount, as applicable, and include rent and utilities, common area maintenance, telecommunications, property taxes and insurance. Research and development costs are expensed as incurred. Certain research and development expenses are attributed to our collaboration arrangement with Bio-Rad, our global strategic partner, for commercializing our RUO kitted tests and IVD kitted transplant testing products. See Note 10, â€œCollaborative Arrangementsâ€ for additional information.

Sales and Marketing Expenses Sales and marketing expenses consist primarily of personnel costs and related benefits, including stock-based compensation, trade show expenses, branding and positioning expenses, and consulting fees. Sales and marketing expenses also include indirect expenses for applicable overhead allocated based on headcount, and include allocated costs for rent and utilities, common area maintenance, telecommunications, property taxes and insurance. During the three months ended September 30, 2024 and 2023, Oncocyteâ€™s total advertising expenses were \$40,000 and \$46,000, respectively. During the nine months ended September 30, 2024 and 2023, Oncocyteâ€™s total advertising expenses were \$123,000 and \$125,000, respectively. Certain sales and marketing expenses are attributed to our collaboration arrangement with Bio-Rad, our global strategic partner, for commercializing our RUO kitted tests and IVD kitted transplant testing products. See Note 10, â€œCollaborative Arrangementsâ€ for additional information.

General and Administrative Expenses General and administrative expenses consist primarily of compensation and related benefits (including stock-based compensation) for executive and corporate personnel, professional and consulting fees, rent and utilities, common area maintenance, telecommunications, property taxes and insurance.

Stock-Based Compensation Oncocyte recognizes compensation expense related to employee, Board of Director and other non-employee option grants and restricted stock grants in accordance with ASC 718, Compensation â€ Stock Compensation. Oncocyte estimates the fair value of stock-based payment awards on the grant date and recognizes the resulting fair value over the requisite service period, which is generally a four-year vesting period. For stock-based awards that vest only upon the attainment of one or more performance goals set by Oncocyte at the time of the grant (sometimes referred to as milestone vesting), compensation cost is recognized if and when Oncocyte determines that it is probable that the performance condition or conditions will be, or have been, achieved. Oncocyte uses the Black-Scholes option pricing model for estimating the fair value of time-based options granted under Oncocyteâ€™s equity plan. The fair value of each restricted stock unit (â€œRSUâ€) or award is determined by the product of the number of units or shares granted and the grant date market price of the underlying common stock. Oncocyte has elected to treat stock-based payment awards with graded vesting schedules and time-based service conditions as a single award and recognizes stock-based compensation ratably on a straight-line basis over the requisite service period. Options have a maximum contractual term of ten years. Forfeitures are accounted for as they occur. Refer to Note 8 for additional information.

The Black-Scholes option pricing model requires Oncocyte to make certain assumptions including the expected option term, the expected volatility, the risk-free interest rate and the dividend yield. The expected term of employee stock options represents the weighted average period that the stock options are expected to remain outstanding. Oncocyte estimates the expected term of options granted based on its own experience. Oncocyte estimates the expected volatility using its own stock price volatility for a period equal to the expected term of the options. The risk-free interest rate assumption is based upon observed interest rates on the United States government securities appropriate for the expected term of Oncocyteâ€™s stock options. The dividend yield assumption is based on Oncocyteâ€™s history and expectation of dividend payouts. Oncocyte has never declared or paid any cash dividends on its common stock, and Oncocyte does not anticipate paying any cash dividends in the foreseeable future.

All excess tax benefits and tax deficiencies from stock-based compensation awards accounted for under ASC 718 are recognized as income tax benefit or expense, respectively, in the statements of operations. An excess income tax benefit arises when the tax deduction of a share-based award for income tax purposes exceeds the compensation cost recognized for financial reporting purposes and, a tax deficiency arises when the compensation cost exceeds the tax deduction. Because Oncocyte has a full valuation allowance for all periods presented (see â€œIncome Taxesâ€ below), there was no impact to Oncocyte's statements of operations for any excess tax benefits or deficiencies, as any excess benefit or deficiency would be offset by the change in the valuation allowance.

Retirement Plan Oncocyte has an employee savings and retirement plan under Section 401(k) of the Internal Revenue Code. The plan is a defined contribution plan in which eligible employees may elect to have a percentage of their compensation contributed to the plan, subject to certain guidelines issued by the Internal Revenue Service. During the three months ended September 30, 2024 and 2023, Oncocyteâ€™s total contributions to the plan were \$81,000 and \$67,000, respectively. During the nine months ended September 30, 2024 and 2023, Oncocyteâ€™s total contributions to the plan were \$248,000 and \$245,000, respectively.

Collaborative Arrangements The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808, Collaborative Arrangements, which includes determining whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. To the extent that the arrangement falls within the scope of ASC 808, the Company assesses whether the payments between the Company and its collaboration partner fall within the scope of other accounting literature. If the Company concludes that payments from the collaboration partner to the Company would represent consideration from a customer, the Company accounts for those payments within the scope of ASC 606. However, if the Company concludes that its collaboration partner is not a customer for certain activities and associated payments, the Company presents such payments as a reduction of research and development expense or general and administrative expense, based on where the Company presents the underlying expense. See Note 10, â€œCollaborative Arrangementsâ€ for additional information.

Income Taxes The provision for income taxes for interim periods is determined using an estimated annual effective tax rate in accordance with ASC 740-270, Income Taxes, Interim Reporting. The effective tax rate may be subject to fluctuations during the year as new information is obtained, which may affect the assumptions used to estimate the annual effective tax rate, including factors such as valuation allowances against deferred tax assets, the recognition or de-recognition of tax benefits related to uncertain tax positions, if any, and changes in or the interpretation of tax laws in jurisdictions where Oncocyte conducts business. Oncocyte did not record any provision or benefit for income taxes for the three and nine months ended September 30, 2024 and 2023, as Oncocyte had a full valuation allowance for the periods presented. A valuation allowance is provided when it is more likely than not that some portion of the deferred tax assets will not be realized. Oncocyte established a full valuation allowance for all periods presented due to the uncertainty of realizing future tax benefits from its net operating loss carry-forwards and other deferred tax assets.

The guidance also prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not sustainable upon examination by taxing authorities. Oncocyte will recognize accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties as of September 30, 2024 and December 31, 2023. Oncocyte is not aware of any uncertain tax positions that could result in significant additional payments, accruals, or other material deviation as of September 30, 2024. Oncocyte is currently unaware of any tax issues under review. As of September 30, 2024 and December 31, 2023, the Company had unrecognized tax benefits totaling \$2.3 million.

On June 27, 2024, California enacted SB-167, which suspends the use of California net operating loss and limits the use of California research tax credits to \$5.0 million each year for our fiscal years 2025-2027. On June 29, 2024, California enacted SB-175, which provides a refund mechanism for the incremental tax that was paid as a result of SB-167. The Company is evaluating the impact of the law changes but does not expect these law changes to have a material impact on the Companyâ€™s consolidated financial statements.

Net Loss Per Common Share Basic loss per share is computed by dividing the net loss applicable to common stockholders after deducting cumulative unpaid dividends and accretion of the preferred stock, by the weighted average number of shares of common stock outstanding during the year. The 2024 weighted average shares outstanding - basic in the following table includes the effects of pre-funded warrants that were issued in April 2024 (refer to Note 7, â€œCommon Stock Purchase Warrantsâ€ for additional information). Diluted loss per share is computed by dividing the net loss applicable to common stockholders after deducting cumulative unpaid dividends and accretion of the preferred stock, by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued, using the treasury stock method or the if-converted method, or the two-class method for participating securities, whichever is more dilutive. Potential common shares are excluded from the computation if their effect is antidilutive. For the three and nine months ended September 30, 2024 and 2023, all common stock equivalents are antidilutive because Oncocyte reported a net loss. The following table presents the calculation of basic and diluted loss per share of common stock:

	Three Months Ended September 30, 2024	Nine Months Ended September 30, 2024	Three Months Ended September 30, 2023	Nine Months Ended September 30, 2023
(In thousands, except per share data)				
Numerator:				
Loss from continuing operations	\$ (13,493)	\$ (6,489)	\$ (27,152)	\$ (8,863)
Accretion of Series A redeemable convertible preferred stock	\$ (198)	\$ (263)	\$ (621)	\$ (621)
Deemed dividend on Series A redeemable convertible preferred stock	\$ (118)	\$ (118)	\$ (118)	\$ (118)
Net loss from continuing operations - basic and diluted	\$ (13,493)	\$ (6,687)	\$ (27,415)	\$ (9,602)
Net loss from discontinued operations - basic and diluted	\$ (2,926)	\$ (2,926)	\$ (2,926)	\$ (2,926)
Net loss	\$ (13,493)	\$ (6,489)	\$ (27,152)	\$ (8,863)
Denominator:				
Weighted average shares outstanding - basic and diluted	13,714	8,256	11,624	7,461
Net loss per share	\$ (0.98)	\$ (0.81)	\$ (2.36)	\$ (1.29)
Net loss from continuing operations per share - basic and diluted	\$ (0.98)	\$ (0.81)	\$ (2.36)	\$ (1.29)
Net loss attributable to common stockholders per share - basic and diluted	\$ (0.98)	\$ (0.81)	\$ (2.36)	\$ (1.29)
Anti-dilutive potential common shares excluded from the computation of diluted net loss per common share	-	-	-	-
Stock options	855	501	855	501
Series A redeemable convertible preferred stock	501	501	501	501
Total	1,616	1,331	1,616	1,331
Recent Accounting Pronouncements Not Yet Adopted				
In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, to improve financial reporting by requiring disclosure of incremental segment information on an annual and interim basis for all public entities to enable investors to develop more decision-useful financial analyses. The amendments in this Update: (i) require enhanced disclosures about significant segment expenses, (ii) clarify that if the chief operating decision maker (CODM) uses more than one measure of a segmentâ€™s profit or loss, a public entity may report one or more of those additional measures of segment profit or loss, (iii) require disclosure of the title and position of the CODM and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources, and (iv) require that a public entity that has a single reportable segment provide all the disclosures required by the amendments in this Update and all existing segment disclosures in Topic 280. The amendments in this Update should be applied retrospectively, and are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. Management is currently evaluating the impact that the amendments in this Update will have on the Companyâ€™s financial statement disclosures. The adoption of this new standard will not have an impact on the Companyâ€™s consolidated balance sheets and consolidated statements of operations, comprehensive loss, shareholders' equity and cash flows. In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, to address investor requests for more transparency about income tax information by requiring improvements to income tax disclosures, including, (i) consistent categories and greater disaggregation of information in the rate reconciliation, and (ii) income taxes paid disaggregated by jurisdiction. Additional amendments in this Update improve the effectiveness and comparability of disclosures by, (				

payment amounts, as applicable, and the corresponding fair value of each respective contingent consideration liability: (a) Contractual Value (b) Fair Value on the Merger Date (c) (In thousands) (d) Milestone 1 (e) \$ 1,500 (f) \$ 1,340 (g) Milestone 2 (h) \$ 3,000 (i) \$ 1,830 (j) Milestone 3 (a) \$ 1,500 (b) \$ 770 (c) Royalty 1 (b) (c) See (b) (d) \$ 5,980 (e) Royalty 2 (b) (c) See (b) (d) \$ 1,210 (e) Total (f) \$ 6,000 (g) \$ 11,130 (h) (i) Indicates the maximum amount payable if the Milestone is achieved. (b) As defined, Royalty Payments are based on a percentage of future revenues of DetermaIO and Pharma Services over their respective useful life, accordingly there is no fixed contractual value for the Royalty Contingent Consideration. The fair value of the contingent consideration after the Insight Merger Date is reassessed by Oncocyte as changes in circumstances and conditions occur, with the subsequent change in fair value recorded in Oncocyte's consolidated statements of operations. Since December 2023, Milestone 1 and Royalty 2 (Pharma Services) are not expected to be paid and are excluded from the current fair value. During 2024, based on Oncocyte's reassessment of significant assumptions, there was an increase of approximately \$30,000 to the fair value of the contingent consideration primarily attributable to revised estimates of the possible future payouts and, accordingly, this increase was recorded as change in fair value of contingent consideration in the consolidated statement of operations for the nine months ended September 30, 2024. Oncocyte uses a discounted cash flow valuation technique to determine the fair value of its Level 3 contingent consideration liabilities. The significant unobservable inputs used in Insight's contingent consideration valuation on September 30, 2024, included: (i) a discount period, based on the expected Milestone payment dates, ranging from 1.7 years to 8.0 years, (ii) a discount rate of 13.3% to 13.5%, and (iii) a management probability estimate of 25% to 50%. The significant unobservable inputs used in Insight's contingent consideration valuation on September 30, 2023, included: (i) a discount period, based on the expected Milestone payment dates, ranging from 0.50 years to 1.5 years, (ii) a discount rate of 15.2% to 15.4%, and (iii) a management probability estimate of 15% to 50%. Changes to significant unobservable inputs to different amounts could result in a significantly higher or lower fair value measurement at the reporting date. The following tables reflect the activity for the Insight contingent consideration measured at fair value using Level 3 inputs: (a) Fair Value (b) (In thousands) (c) Balance at December 31, 2022 (d) \$ 5,370 (e) Change in estimated fair value (f) \$ (3,080) (g) Balance at September 30, 2023 (h) \$ 2,290 (i) (a) Balance at December 31, 2023 (j) \$ 2,040 (k) Change in estimated fair value (l) \$ 30 (m) Balance at September 30, 2024 (n) \$ 2,070 (o) The accompanying balance sheets separately present the Insight and Chronix total contingent consideration liabilities as current and noncurrent. Contingent consideration is not deductible for tax purposes, even if paid; therefore, no deferred tax assets related to the contingent consideration were recorded. Acquisition of Chronix Biomedical, Inc. On April 15, 2021 (the "Chronix Merger Date"), Oncocyte completed its acquisition of Chronix pursuant to the Chronix Merger Agreement. As additional consideration for holders of certain classes and series of Chronix capital stock, the Chronix Merger Agreement required Oncocyte to pay certain contingent consideration. On February 8, 2023, the Company and the equity holder representative named in the Chronix Merger Agreement entered into Amendment No. 1 to the Chronix Merger Agreement, pursuant to which the parties agreed that (i) Chronix's equity holders will be paid earnout consideration of 10% of net collections for sales of specified tests and products, until the expiration of intellectual property related to such tests and products, (ii) Chronix's equity holders will be paid 5% of the gross proceeds received from any sale of all or substantially all of the rights, titles, and interests in and to Chronix's patents for use in transplantation medicine to such third-party, and (iii) all of the previous payment obligations were eliminated. The fair value of the Chronix contingent consideration after the Chronix Merger Date is reassessed by Oncocyte as changes in circumstances and conditions occur, with the subsequent change in fair value recorded in Oncocyte's consolidated statements of operations. During 2024, based on Oncocyte's reassessment of significant assumptions, there was an increase of approximately \$9.4 million to the fair value of the contingent consideration primarily attributable to revised estimates of the possible future payouts and, accordingly, this increase was recorded as a change in fair value of contingent consideration in the consolidated statement of operations for the nine months ended September 30, 2024. Oncocyte uses a discounted cash flow valuation technique to determine the fair value of its Level 3 contingent consideration liabilities. The significant unobservable inputs used in Chronix's contingent consideration valuation on September 30, 2024, included: (i) a discount period, based on the related patent expiration dates, ranging from 9.1 years to 11.0 years, (ii) a discount rate of 13.3% to 14.3%, and (iii) a payout percentage of 10% based on the earnout provision. The significant unobservable inputs used in Chronix's contingent consideration valuation on September 30, 2023, included: (i) a discount period, based on the related patent expiration dates, ranging from 10.4 years to 12.2 years, (ii) a discount rate of 15.5% to 16.4%, and (iii) a payout percentage of 10% based on the earnout provision. Changes to significant unobservable inputs to different amounts could result in a significantly higher or lower fair value measurement at the reporting date. The following tables reflect the activity for the Chronix contingent consideration measured at fair value using Level 3 inputs: (a) Fair Value (b) (In thousands) (c) Balance at December 31, 2022 (d) \$ 40,292 (e) Change in estimated fair value (f) \$ (13,867) (g) Balance at September 30, 2023 (h) \$ 26,425 (i) (a) Balance at December 31, 2023 (j) \$ 37,860 (k) Change in estimated fair value (l) \$ 9,391 (m) Balance at September 30, 2024 (n) \$ 47,251 (o) X - References: No definition available. + Details Name: us-gaap_BusinessCombinationAndAssetAcquisitionAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na:Period Type: duration X - Definition: The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable). + References: Reference 1:

in accordance with the lessor's "s related rights. To obtain a letter of credit, Oncocyte has provided the bank with a restricted cash deposit that the bank will hold to cover its obligation to pay any draws on the letter of credit by the lessor. The restricted cash may not be used for any other purpose. Accordingly, Oncocyte has reflected \$1.7 million as restricted cash in the accompanying consolidated balance sheets as of September 30, 2024 and December 31, 2023.

Irvine Office Sublease

On August 8, 2023, Oncocyte and Induce Biologics USA, Inc. (the "Subtenant") entered into a Sublease Agreement (the "Sublease Agreement"), which subsequently became effective as of September 14, 2023, upon the execution and delivery by the Company, Subtenant, and Landlord, of that certain Landlord's Consent to Sublease dated September 12, 2023 (the "Consent Agreement"), under which Landlord consented to the Sublease Agreement, on the terms and subject to the conditions set forth therein. The Sublease Agreement is subject and subordinate to the Irvine Lease. Under the Sublease Agreement, the Company agreed to initially sublet to Subtenant a portion of the Premises consisting of approximately 13,400 square feet of rentable space for a term (the "Initial Period") commencing on the date that is 120 days after the effective date of the Consent Agreement (the "Sublease Commencement Date") and ending on the date that is 18 months following the Sublease Commencement Date or such earlier date as Subtenant may elect upon the exercise of its one-time option to accelerate such date upon 90 days prior written notice to the Company (the date on which the Initial Period ends, the "Expansion Date"). On the Expansion Date, the portion of the Premises that is subleased to Subtenant under the Sublease Agreement will automatically increase to include the remaining portion of the Premises, which consists of approximately 13,400 square feet of additional rentable space for a term (the "Expansion Period") beginning on the Expansion Date through the expiration of the Irvine Lease on October 31, 2027, unless earlier terminated. The Sublease Agreement provides that, from and after the Sublease Commencement Date, Subtenant will pay to the Company monthly base rent in the following amounts: (i) \$36,850 for rental periods beginning on the Sublease Commencement Date and ending on or before December 31, 2024 (subject to adjustment in the event that Subtenant exercises its option to accelerate the Expansion Date, such that the Expansion Period begins prior to December 31, 2024); (ii) \$37,955 for rental periods beginning on or after January 1, 2025 and ending on or before June 20, 2025 (subject to adjustment in the event that Subtenant exercises its option to accelerate the Expansion Date, such that the Expansion Period begins prior to June 20, 2025); (iii) \$75,844 for rental periods beginning on or after July 1, 2025 and ending on or before December 31, 2025; (iv) \$78,188 for rental periods beginning on or after January 1, 2026 and ending on or before December 31, 2026; and (v) \$80,534 for rental periods beginning on or after January 1, 2027 and ending on or before October 31, 2027. Following the Sublease Commencement Date, Subtenant is responsible for the payment of Additional Rent, including Expenses and Taxes (as each such term is defined in the Irvine Lease), provided that, with respect to the Initial Period, Subtenant will be responsible for only 50% of the Expenses and Taxes due. In addition, Subtenant will pay the Company a security deposit in the amount of \$101,987 in connection with the transactions contemplated by the Sublease Agreement. The Sublease Agreement contains customary provisions with respect to, among other things, Subtenant's obligation to comply with the Irvine Lease and applicable laws, the payment of utilities and similar services utilized by Subtenant with respect to its use of the Premises, the indemnification of the Company by Subtenant, and the right of the Company to terminate the Sublease Agreement in its entirety and retake the Premises if Subtenant fails to remedy certain defaults of its obligations under the Sublease Agreement within specified time periods.

Nashville Leases

Insight operates a CLIA-certified laboratory and has additional office space located at 2 International Plaza, Nashville, Tennessee, under lease arrangements with MPC Holdings, LLC. As of December 31, 2023, the Company had Nashville office leases that comprised 8,362 square feet of rentable office space with a term ending April 2024. On January 1, 2024, the Company renewed its existing leases with MPC Holdings, LLC and added a new lease agreement to further expand its Nashville office space. The new lease contains 2,319 square feet for an aggregate of 10,681 square feet of rentable space as of September 30, 2024. Lab space is approximately 4,826 square feet of the total. The new lease agreements each have an initial term of 36 months, which commenced on January 1, 2024 and will end in January 2027. The Company has the option to renew the term of each lease for four additional one year periods. The office and facilities leases discussed above are operating leases under ASC 842 and are included in the tables below. The tables below provide the amounts recorded in connection with the application of ASC 842 for Oncocyte's operating and financing leases (see Note 2 for additional policy information).

Financing Leases

As of September 30, 2024, Oncocyte had various financing leases for certain laboratory equipment, as shown in the tables below. As of December 31, 2023, Oncocyte had no financing lease obligations. Oncocyte's lease obligations are collateralized by the equipment financed under the lease schedules.

Operating and Financing Leases

The following table presents supplemental balance sheet information related to operating and financing leases:

	September 30, 2024	December 31, 2023
Operating leases	\$1,931	\$1,637
Right-of-use assets, net	\$1,931	\$1,637
Right-of-use lease liabilities, current	\$882	\$628
Right-of-use lease liabilities, noncurrent	\$1,953	\$2,102
Total operating lease liabilities	\$2,835	\$2,730
Financing leases	\$1,070	\$1,070
Machinery and equipment	\$1,673	\$537
Accumulated depreciation	(603)	(537)
Machinery and equipment, net	\$1,070	\$1,070
Current liabilities	\$364	\$29
Noncurrent liabilities	\$653	\$653
Total financing lease liabilities	\$1,017	\$1,017
Weighted average discount rate	10.42%	11.31%
Operating lease	10.27%	n/a
Future minimum lease commitments	\$107	\$107
Operating lease	\$107	\$107
Financing lease	\$695	\$695
Leases	\$191	\$191
(In thousands)		
Year Ending December 31, 2024	\$279	\$144
2025	\$455	\$455
2026	\$1,182	\$400
2027	\$695	\$191
Total minimum lease payments	\$3,000	\$1,153
Less amounts representing interest	(465)	(136)
Present value of net minimum lease payments	\$2,835	\$1,017

The following table presents supplemental cash flow information related to operating and financing leases:

	Nine Months Ended September 30, 2024	2023
Cash paid for amounts included in the measurement of lease liabilities	\$17	\$7
Operating cash flows from operating leases	\$827	\$793
Operating cash flows from financing leases	\$119	\$86
The Company incurred total lease cost, including short-term lease expense, of \$234,000 and \$183,000, which was net of sublease income of \$111,000 and \$28,000, for the three months ended September 30, 2024 and 2023, respectively. The Company incurred total lease cost, including short-term lease expense, of \$532,000 and \$636,000, which was net of sublease income of \$332,000 and \$64,000, for the nine months ended September 30, 2024 and 2023, respectively.		

Litigation

General

Oncocyte may be subject to various claims and contingencies in the ordinary course of its business, including those related to litigation, business transactions, employee-related matters, and other matters. When Oncocyte is aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, Oncocyte will record a liability for the loss. If the loss is not probable or the amount of the loss cannot be reasonably estimated, Oncocyte discloses the claim if the likelihood of a potential loss is reasonably possible and the amount involved could be material.

Tax Filings

Oncocyte tax filings are subject to audit by taxing authorities in jurisdictions where it conducts business. These audits may result in assessments of additional taxes that are subsequently resolved with the authorities or potentially through the courts. Management believes Oncocyte has adequately provided for any ultimate amounts that are likely to result from these audits; however, final assessments, if any, could be significantly different than the amounts recorded in the consolidated financial statements.

Employment

Contracts

Oncocyte has entered into employment and severance benefit contracts with certain executive officers. Under the provisions of the contracts, Oncocyte may be required to incur severance obligations for matters relating to changes in control, as defined in the respective contracts, and certain terminations of executives. As of September 30, 2024 and December 31, 2023, Oncocyte has accrued approximately \$2.3 million and \$2.7 million, respectively, in severance obligations for certain executive officers, in accordance with the severance benefit provisions of their respective employment and severance benefit agreements, primarily related to Oncocyte's acquisition of Chronix in 2021. For the periods presented, management has classified \$2.3 million of the accrued severance obligations related to the Chronix acquisition as current based on our expectations of the timing of product commercialization and subsequent revenues that trigger the payouts.

Indemnification

In the normal course of business, Oncocyte may provide indemnification of varying scope under Oncocyte's agreements with other companies or consultants, typically Oncocyte's clinical research organizations, investigators, clinical sites, suppliers and others. Pursuant to these agreements, Oncocyte will generally agree to indemnify, hold harmless, and reimburse the indemnified parties for losses and expenses suffered or incurred by the indemnified parties arising from claims of third parties in connection with the use or testing of Oncocyte's diagnostic tests. Indemnification provisions could also cover third party infringement claims with respect to patent rights, copyrights, or other intellectual property pertaining to Oncocyte's diagnostic tests. Oncocyte's office and laboratory facility leases also will generally contain indemnification obligations, including obligations for indemnification of the lessor for environmental law matters and injuries to persons or property of others, arising from Oncocyte's use or occupancy of the leased property. The term of these indemnification agreements will generally continue in effect after the termination or expiration of the particular research, development, services, lease, or license agreement to which they relate. The Razor Stock Purchase Agreement also contains provisions under which Oncocyte has agreed to indemnify Razor and Encore Clinical, Inc., a former stockholder of Razor, from losses and expenses resulting from breaches or inaccuracy of Oncocyte's representations and warranties and breaches or nonfulfillment of Oncocyte's covenants, agreements, and obligations under the Razor Stock Purchase Agreement. Oncocyte periodically enters into underwriting and securities sales agreements with broker-dealers in connection with the offer and sale of Oncocyte securities. The terms of those underwriting and securities sales agreements include indemnification provisions pursuant to which Oncocyte agrees to indemnify the broker-dealers from certain liabilities, including liabilities arising under the Securities Act of 1933, as amended (the "Securities Act"), in connection with the offer and sale of Oncocyte securities. The potential future payments Oncocyte could be required to make under these indemnification agreements will generally not be subject to any specified maximum amounts. Historically, Oncocyte has not been subject to any claims or demands for indemnification. Oncocyte also maintains various liability insurance policies that limit Oncocyte's financial exposure. As a result, Oncocyte management believes that the fair value of these indemnification agreements is minimal. Accordingly, Oncocyte has not recorded any liabilities for these agreements as of September 30, 2024 and December 31, 2023.

X - References

No definition available. + Details Name: us-gaap-CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Definition The entire disclosure for commitments and contingencies. + Reference Reference 1:

Oncocyte had 5,000,000 shares of preferred stock, par value, authorized. As of September 30, 2024 and December 31, 2023, Oncocyte had no shares of preferred stock issued and outstanding. Common Stock As of September 30, 2024 and December 31, 2023, Oncocyte had 230,000,000 shares of common stock, no-par value, authorized. As of September 30, 2024 and December 31, 2023, Oncocyte had 13,374,109 and 8,261,073 shares of common stock issued and outstanding, respectively. April 2023 Offering On April 3, 2023, the Company entered into an agreement (the "April 2023 Offering") with several institutional and accredited investors, including Broadwood, the Company's largest shareholder, and certain members of the Company's board of directors (and certain of their affiliated parties), relating to their purchase of an aggregate of up to 2,278,121 shares of the Company's common stock at an offering price of \$7.08 per share to board members and \$6.03 per share to the other investors participating in the April 2023 Offering. The April 2023 Offering was intended to be priced at-the-market for purposes of complying with applicable Nasdaq Listing Rules. The Company issued an aggregate of 2,274,709 shares of common stock from this offering, as further discussed in Note 9, "Related Party Transactions." The aggregate gross proceeds from the offering were approximately \$13.9 million. The Company used approximately \$1.1 million of the net proceeds to immediately redeem an aggregate of 1,064 shares of its Series A Preferred Stock. April 2024 Offering On April 15, 2024, the Company consummated a private placement of its securities to certain accredited investors for the issuance and sale of 5,076,900 shares of the Company's common stock and Pre-Funded Warrants to purchase 342,888 shares of the Company's common stock, with an exercise price of \$0.0001 per share. The purchase price for one common share was \$2.9164, and the purchase price for one Pre-Funded Warrant was \$2.9163. Certain insiders of the Company subscribed for 42,373 of the shares of common stock sold in the private placement, at a purchase price of \$2.95 per share (see Note 9). The related securities purchase agreement contains customary representations, warranties and agreements by the Company, indemnification obligations of the Company and the accredited investors, including for liabilities under the Securities Act, other obligations of the parties and termination provisions. A holder of the Pre-Funded Warrants may not exercise any portion of such holder's Pre-Funded Warrants to the extent that the holder, together with its affiliates, would beneficially own more than 4.99% (or, at the election of the holder, 9.99%) of the Company's outstanding shares of common stock immediately after exercise, except that upon at least 61 days' prior notice from the holder to the Company, the holder may increase the beneficial ownership limitation to up to 9.99% of the number of shares of common stock outstanding immediately after giving effect to the exercise. The Pre-Funded Warrants are exercisable immediately and will expire when exercised in full. As of September 30, 2024, no Pre-Funded Warrants have been exercised. See Note 9 "Related Party Transactions" for additional information. The gross proceeds to the Company from the April 2024 Offering were approximately \$15.8 million, before deducting approximately \$538,000 in placement agent fees and expenses and offering expenses payable by the Company. The Company is using the net proceeds received for general corporate purposes and working capital. In addition, approximately \$5.4 million of the net proceeds was used to redeem the outstanding shares of the Company's Series A Redeemable Convertible Preferred Stock. August 2024 Offering On August 9, 2024, the Company entered into a sales agreement with a sales agent, pursuant to which the Company may offer and sell from time to time up to an aggregate of \$7.5 million of shares of the Company's common stock (the "Placement Shares"), through the sales agent. Sales of the Placement Shares may be made in sales deemed to be "at-the-market offerings" as defined in Rule 415 promulgated under the Securities Act. The sales agent will use commercially reasonable efforts to sell, on the Company's behalf, all of the Placement Shares requested to be sold by the Company, consistent with its normal trading and sales practices, the terms of the sales agreement, and applicable law and regulations. The Company may also sell Placement Shares to the sales agent as principal in negotiated transactions. The Company has no obligation to sell any Placement Shares, and may at any time suspend offers under the sales agreement or terminate the sales agreement. The Company intends to use the net proceeds from this offering for working capital and other general corporate purposes. The sales agreement will terminate, and offer and sale of the Placement Shares pursuant to the sales agreement will cease, upon the earlier of (a) the issuance and sale of all of the Placement Shares subject to the sales agreement or (b) the termination of the sales agreement by the sales agent or the Company pursuant to the terms thereof. The sales agreement contains customary representations, warranties and agreements by the Company, as well as indemnification obligations of the Company for certain liabilities under the Securities Act. Under the terms of the sales agreement, the Company will pay the sales agent a commission equal to 3.0% of the aggregate gross proceeds from each sale of Placement Shares. As of September 30, 2024, the Company has sold 5,722 Placement Shares for net proceeds of approximately \$17,000, at an average purchase price of \$3.25 per share. In addition, the Company agreed to pay certain expenses incurred by the sales agent in connection with the offering. Total offering expenses incurred in the amount of \$286,000 are being deferred and expensed over a one year period. As of September 30, 2024, the remaining deferred financing costs of \$285,000 are included in deferred financing costs in the consolidated balance sheet. The Placement Shares were registered under the Securities Act pursuant to the Registration Statement on Form S-3 (File No. 333-281159) filed with the SEC on August 1, 2024 and declared effective by the SEC on August 7, 2024, the base prospectus contained within the Registration Statement, and a prospectus supplement dated August 9, 2024. October 2024 Offering On October 4, 2024, the Company consummated the October 2024 Offering. The gross proceeds from the October 2024 Offering were approximately \$10.2 million. After deducting placement agent fees and expenses and offering expenses payable by the Company of \$795,000, the resulting net proceeds were approximately \$9.4 million. See Note 12, "Subsequent Events" for additional information. Unregistered Restricted Stock Issuance During the nine months ended September 30, 2024, the Company issued 26,664 shares of restricted common stock in connection with an ongoing consulting service arrangement for a total fair value of \$72,000. During the nine months ended September 30, 2023, the Company issued 9,091 shares of restricted common stock to this consulting firm for a total fair value of \$36,000. Common Stock Purchase Warrants As of September 30, 2024 and December 31, 2023, Oncocyte had common stock purchase warrants issued and outstanding of 760,866 and 819,767, respectively. During the nine months ended September 30, 2024, 58,901 warrants expired. As of September 30, 2024, the outstanding warrants had exercise prices ranging from \$30.60 to \$109.20 per share, are set to expire on various dates ranging from February 2027 to October 2029 and have a weighted average remaining life of 2.57 years. Certain warrants have "cashless exercise" provisions meaning that the value of a portion of warrant shares may be used to pay the exercise price rather than payment in cash, which may be exercised under any circumstances in the case of the Bank Warrants discussed below or, in the case of certain other warrants, only if a registration statement for the warrants and underlying shares of common stock is not effective under the Securities Act or a prospectus in the registration statement is not available for the issuance of shares upon the exercise of the warrants. All of the outstanding warrants meet the equity classification criteria and have been classified as equity, refer to Note 2, "Accounting for Warrants" for additional information. In connection with the April 2024 Offering, discussed above, the Company issued Pre-Funded Warrants to purchase 342,888 shares of common stock. For accounting purposes, the Pre-Funded Warrants are equity-classified, contain no contingencies to exercise and are therefore considered outstanding for purposes of calculating basic earnings per share. As of September 30, 2024, no Pre-Funded Warrants have been exercised. Bank Warrants In connection with a loan that matured in September 2022 from Silicon Valley Bank (the "Bank"), in February 2017, Oncocyte issued common stock purchase warrants to the Bank (the "2017 Bank Warrants"). The Bank was issued warrants to purchase 412 shares of Oncocyte common stock at an exercise price of \$97.00 per share, through February 21, 2027. In March 2017, the Bank was issued warrants to purchase an additional 366 shares at an exercise price of \$109.20 per share, through March 23, 2027. In October 2019, Oncocyte issued a common stock purchase warrant to the Bank (the "2019 Bank Warrant") entitling the Bank to purchase 4,928 shares of Oncocyte common stock at an exercise price of \$33.80 per share, through October 17, 2029. The Bank may elect to exercise the 2017 Bank Warrants and the 2019 Bank Warrant on a "cashless exercise" basis and receive a number of shares determined by multiplying the number of shares for which the Bank Warrant is being exercised by (A) the excess of the fair market value of the common stock over the applicable Warrant Price, divided by (B) the fair market value of the common stock. The fair market value of the common stock will be last closing or sale price on a national securities exchange, interdealer quotation system, or over-the-counter market. These warrants meet the equity classification criteria and have been classified as equity. As of September 30, 2024, no Bank Warrants have been exercised. X - References No definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The entire disclosure for equity. + References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13-Reference 2](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13-Reference 2): [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(h\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13-Reference 3](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (h)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13-Reference 3): [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14-Reference 4](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14-Reference 4): [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14-Reference 5](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14-Reference 5): [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14-Reference 6](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14-Reference 6): [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14-Reference 7](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14-Reference 7): [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14-Reference 8](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14-Reference 8):

À 127 Å Å 203 Å General and administrative Å 206 Å Å 252 Å Å 520 Å Å 1,119 Å Expense included in discontinued operations Å å€" Å Å å€" Å Å Å å€" Å Å 18 Å Total Å 450 Å Å 608 Å Å 1,254 Å Å 2,276 Å Å Total unrecognized stock-based compensation expense as of September 30, 2024 was \$2.1 million, which will be amortized over a weighted average remaining recognition period of 2.06 years.Other InformationThe determination of stock-based compensation is inherently uncertain and subjective and involves the application of valuation models and assumptions requiring the use of judgment. If Oncocyte had made different assumptions, its stock-based compensation expense and net loss for the periods presented may have been significantly different. Refer to Note 2 å€"Stock-Based Compensationå€" for additional information.Oncocyte does not recognize deferred income taxes for incentive stock option compensation expense and records a tax deduction only when a disqualified disposition has occurred. X - DefinitionThe entire disclosure for share-based payment arrangement. + ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)\(1\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/exampleRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)(1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/718/tableOfContentReference>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(h\)\(2\)\(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (h)(2)(i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(h\)\(2\)\(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (h)(2)(i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(l\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (l)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 25 R18.htm IDEA: XBRL DOCUMENT v3.24.3 Related Party Transactions 9 Months Ended Sep. 30, 2024 Related Party Transactions [Abstract] Å Related Party Transactions 9. Related Party TransactionsFinancing TransactionsOn April 13, 2022, Oncocyte entered into the Securities Purchase Agreement with the Investors, including Broadwood and John Peter Gutfreund, a former director of Oncocyte, for the Series A Preferred Stock offering. Each of Broadwood and Mr. Gutfreund has a direct material interest in the Series A Preferred Stock offering and agreed to purchase 5,882 and 1,176 shares, respectively, in the Series A Preferred Stock offering and on the same terms as other investors. Additionally, Halle Capital Management, L.P. received \$85,000 from the Company as reimbursement for its legal fees and expenses. Mr. Gutfreund is the Managing Partner of Halle Capital Management, L.P. On April 5, 2023, Oncocyte redeemed all of the 588 shares of Series A Preferred Stock held by Mr. Gutfreund for \$618,672. Mr. Gutfreund is no longer a related party as of June 23, 2023. See Note 7 for additional information about the Series A Preferred Stock offering.Further, on April 13, 2022, Oncocyte entered into an underwriting agreement pursuant to which the Company agreed to issue and sell certain shares of common stock and warrants to purchase common stock (å€"April 2022 Warrantså€"). The April 2022 Warrants have an exercise price of \$30.60 per share and will expire on April 19, 2027. Pursuant to the underwritten offering, Broadwood acquired from us (i) 261,032 shares of common stock, and (ii) 300,187 April 2022 Warrants to purchase up to 150,093 shares of common stock. However, the total number of shares of common stock that Broadwood purchased in the underwritten offering was 300,187, of which 39,154 existing shares were acquired by the underwriters in the open market and re-sold to Broadwood. Pura Vida acquired from us (i) 249,204 shares of common stock, and (ii) 286,585 April 2022 Warrants to purchase up to 143,292 shares of common stock. However, the total number of shares of common stock that Pura Vida purchased in the underwritten offering was 286,585, of which 37,380 existing shares were acquired by the underwriters in the open market and re-sold to Pura Vida. Halle Special Situations Fund LLC purchased from us (i) 309,976 shares of common stock, and (ii) 356,472 April 2022 Warrants to purchase up to 178,236 shares of common stock. Mr. Gutfreund is the investment manager and a control person of Halle Capital Partners GP LLC, the managing member of Halle Special Situations Fund LLC. However, the total number of shares of common stock that Halle Special Situations Fund LLC purchased in the underwritten offering was 356,472, of which 46,496 existing shares were acquired by the underwriters in the open market and re-sold to Halle Special Situations Fund LLC. Mr. Gutfreund is no longer a related party as of June 23, 2023.On April 3, 2023, Oncocyte entered into a securities purchase agreement with certain investors, including Broadwood, Pura Vida and entities affiliated with AWM, and certain individuals, including Oncocyte's Chairman, Andrew Arno, and former director, John Peter Gutfreund, and certain of their affiliated parties, which provided for the sale and issuance by the Company of an aggregate of 2,274,709 shares of common stock at an offering price of: (i) \$6.03 to investors who are not considered to be å€"insiderså€" of the Company pursuant to Nasdaq Listing Rules (å€"Insiderså€"), which amount reflected the average closing price of our common stock on Nasdaq during the five trading day period immediately prior to pricing, and (ii) \$7.08 to Insiders, which amount reflected the final closing price of our common stock on Nasdaq on the last trading day immediately prior to pricing. Broadwood purchased 1,341,381 shares of common stock for \$8,093,362, Pura Vida purchased 33,150 shares of common stock for \$200,014 and entities affiliated with AWM purchased 472,354 shares of common stock for \$2,850,000. Mr. Arno and his affiliated parties purchased 21,162 shares of common stock for \$150,001, and Mr. Gutfreund and his affiliated parties purchased 85,250 for \$604,252. See Note 7, å€"Common Stock å€" April 2023 Offeringå€" for additional information.On April 15, 2024, Oncocyte consummated a private placement of its securities to certain investors, including Broadwood, entities affiliated with AWM, Bio-Rad, and certain individuals, including Oncocyte's Chairman, Andrew Arno, for the issuance and sale of 5,076,900 shares of its common stock and Pre-Funded Warrants to purchase 342,888 shares of its common stock. The purchase price for one share of common stock was \$2.9164, and the purchase price for one Pre-Funded Warrant was \$2.9163. Insiders subscribed for 42,373 of the shares of common stock sold in the private placement, at a purchase price of \$2.95 per share of common stock, which amount reflected the final closing price of the common stock on Nasdaq on the last trading day immediately prior to pricing. Broadwood purchased 2,420,000 shares of common stock for \$7,057,688, entities affiliated with AWM purchased 342,889 shares of common stock and 342,889 Pre-Funded Warrants for \$2,000,000, and Bio-Rad purchased 1,200,109 shares of common stock for \$3,499,998. Mr. Arno purchased 33,898 shares of common stock for \$100,000. One of Oncocyte's directors, Andrew Last, served as the Executive Vice President and Chief Operating Officer of Bio-Rad before retiring on September 6, 2024. See Note 7, å€"Common Stock å€" April 2024 Offeringå€" for additional information.On October 4, 2024, Oncocyte consummated the October 2024 Offering involving certain investors, including Broadwood, Bio-Rad, and certain individuals, including Oncocyte's Chief Financial Officer, Andrea James. The gross proceeds from the October 2024 Offering were approximately \$10.2 million. After deducting placement agent fees and expenses and offering expenses payable by the Company of \$795,000, the resulting net proceeds were approximately \$9.4 million. Insiders subscribed for 37,037 of the shares of common stock sold in the October 2024 Offering, at a purchase price of \$2.97 per share of common stock. Broadwood purchased 1,315,339 shares of common stock for approximately \$3,878,000, and Bio-Rad purchased 310,835 shares of common stock for approximately \$916,000. Ms. James purchased 33,670 shares of common stock for \$100,000. See Note 12, å€"Subsequent Eventså€" for additional information.Other TransactionsThe Company previously employed the son of Andrew Arno, Chairman of the Board as its Senior Manager, Investor Relations, Corporate Planning & Development. The total compensation paid by the Company to Mr. Arnoå€"™s son since January 1, 2022 is approximately \$200,000. Mr. Arnoå€"™s son is no longer an employee of the Company as of July 28, 2023.During 2024, the Company purchased \$294,000 in laboratory equipment and incurred \$230,000 in laboratory related costs from Bio-Rad. During 2024, the Company also made finance lease payments of \$126,000 under four laboratory equipment leases from Bio-Rad with an initial capitalized total value of \$976,000. During 2023, the Company purchased \$581,000 in laboratory equipment and incurred \$375,000 in laboratory related costs from Bio-Rad. As of September 30, 2024 and December 31, 2023, the Company had accounts payable due to Bio-Rad of \$7,000 and \$206,000, respectively. One of Oncocyte's directors, Andrew Last, served as the Executive Vice President and Chief Operating Officer of Bio-Rad before retiring on September 6, 2024.On April 5, 2024, the Company entered into an agreement with Bio-Rad to collaborate in the development and the commercialization of RUO and IVD kitted transplant products (the å€"Collaboration Agreementå€"). Under the Collaboration Agreement, Bio-Rad agreed to purchase shares of our common stock equal to 9.99% of the total number of shares of common stock issued and outstanding immediately after the closing of such investment, provided that the total purchase price would not exceed \$3,500,000 unless Bio-Rad chooses to exceed such limit (the å€"Bio-Rad Investmentå€") (see "Financing Transactions" above). The Bio-Rad Investment was completed in connection with a private placement (See Note 7, å€"Common Stock å€" April 2024 Offeringå€"). In addition, we will pay Bio-Rad a single digit royalty payment based on certain net sales under the Collaboration Agreement, and Bio-Rad has an option for the exclusive right to promote, market and sell certain kits worldwide subject to certain conditions. If and when such option is exercised, Bio-Rad will purchase additional shares of our common stock, at the then-current market price per share, up to a specified maximum aggregate purchase price. One of Oncocyte's directors, Dr. Last, recused himself from all Board discussions related to transactions with Bio-Rad. See Note 10, "Collaborative Arrangements" for additional information. On November 8, 2024, the Company and Bio-Rad entered into a memorandum of understanding with respect to the Collaboration Agreement to establish additional activities to be performed by each party pursuant to the Collaboration Agreement (see Note 10 for additional information). X - ReferencesNo definition available. + Details Name: us-gaap_RelatedPartyTransactionsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147480990/946-20-50-2>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 5-Publisher FASB-URI https://asc.fasb.org/1943274/2147480990/946-20-50-5>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147480990/946-20-50-6>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 235-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 235-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 235-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(e\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 235-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 850-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 850-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 850-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 850-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 850-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 850-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 850-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 850-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic 850-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 850-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1) + Details Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 26 R19.htm IDEA: XBRL DOCUMENT v3.24.3 Collaborative Arrangements 9 Months Ended Sep. 30, 2024 Collaborative Arrangements Å Collaborative Arrangements 10. Collaborative ArrangementsBio-RadOn April 5, 2024, the Company entered into the Collaboration Agreement with Bio-Rad to collaborate in the development and the commercialization of RUO and IVD kitted transplant products using Bio-Radå€"™s ddPCR instruments and reagents. The Collaboration Agreement has a term of 10 years unless earlier terminated pursuant to customary termination provisions.The Collaboration Agreement provides that through the oversight of a joint steering committee comprised of representatives from both parties, the parties will collaborate on the development of (i) the Companyå€"™s series of GraftAssureå€" Transplant Monitoring Assays to measure and test the concentration of donor-derived cell free DNA for RUO (the å€"cRUO Assayså€"); and (ii) the Companyå€"™s VitaGraftå€" Transplant Monitoring Assays that have received regulatory approval as an in vitro diagnostic device (the å€"cIVD Kitså€") for exclusive use on one or more Bio-Rad ddPCR instruments. Pursuant to the Collaboration Agreement, and toward the development of the RUO Assays and the IVD Kits, the Company will collect and screen samples, conduct feasibility testing and stability studies, and perform analytical validation, among other things; and Bio-Rad will supply its ddPCR instruments and platforms as well as manufacture and supply all consumables.Prior to the commercial launch of the RUO Assays, under the Collaboration Agreement, the parties will develop a plan to market and sell the RUO Assays. The Company will be responsible for the manufacture and supply of all RUO Assays, and Bio-Rad will supply to the Company Bio-Radå€"™s ddPCR instruments and reagents for use in commercializing the RUO Assays, which products will be purchased by the Company exclusively from Bio-Rad. The Company and Bio-Rad will be jointly responsible for co-promoting and co-marketing the RUO Assays within the United States and Germany (the å€"Territoryå€"). The Company has the exclusive right to sell the RUO Assays in the Territory exclusively with the use of Bio-Rad ddPCR instruments and reagents. Bio-Rad will be responsible for promoting and marketing, and has the exclusive right to sell, the RUO Assays outside the Territory. For the sales of the RUO Assays in the Territory, the Company will pay to Bio-Rad a single digit royalty payment based on net sales. The Company will manufacture and supply the RUO Assays to Bio-Rad for resale outside the Territory. Additionally, the Collaboration Agreement provides Bio-Rad an option for the exclusive right to promote, market and sell IVD Kits worldwide subject to certain conditions. If and when such option is exercised, Bio-Rad will purchase additional shares of the Companyå€"™s common stock, no par value per share, at the then-current market price per share, up to a specified maximum aggregate purchase price, and the Company will manufacture and supply IVD Kits exclusively for Bio-Rad. See Note 9 "Related Party Transactions" for additional information.For the three and nine months ended September 30, 2024, the income statement amounts attributable to transactions arising from the Collaboration Agreement have not been significant. Beginning in September 2024, the Company has capitalized certain inventory costs (see Note 2 å€"Inventorieså€" for additional information).On November 8, 2024, Oncocyte and Bio-Rad entered into a binding Memorandum of Understanding (the å€"Memorandumå€") in connection with the Collaboration Agreement. The Memorandum establishes additional activities (described below) to be performed by Oncocyte and Bio-Rad prior to the commercial launch of the RUO Assays specifically related to pilot study sites outside the Territory (the å€"Pilot Siteså€").Pursuant to the Memorandum, Oncocyte (i) will setup commercialization of Pilot Sites to use the RUO Assays, (ii) may sell RUO Assays to Pilot Sites, (iii) will train and support the Pilot Sites on the use of the RUO Assays, and (iv) if Oncocyte receives any net sales from the sale of the RUO Assays to the Pilot Sites, then Oncocyte shall pay to Bio-Rad a royalty payment based on a percentage of such net sales under the terms and conditions of the Collaboration Agreement. In addition, pursuant to the Memorandum, Bio-Rad will evaluate commercialization efforts for the RUO Assays, which will include (i) supporting installation and training for Pilot Sites, and (ii) evaluating distribution of the RUO Assays to Pilot Sites.The foregoing description of the material terms and conditions of the Memorandum does not purport to be complete and is qualified in its entirety by the full text of the Memorandum, which is attached hereto as Exhibit 10.6.Life Technologies CorporationIn January 2022, Oncocyte entered into a collaboration agreement (the å€"LTC Agreementå€") with Life Technologies Corporation, a Delaware corporation and subsidiary of Thermo Fisher Scientific (å€"LTCå€"), in order to partner in the development and collaborate in the commercialization of Thermo Fisher Scientificå€"™s existing Oncomine Comprehensive Assay Plus and Oncocyteå€"™s DetermaIO assay for use with LTCå€"™s Ion TorrentTM GenexusTM Integrated Sequencer and LTCå€"™s Ion TorrentTM GenexusTM Purification System in order to obtain IVD regulatory approval. In February 2023, Oncocyte entered into a Termination Agreement with LTC, pursuant to which the parties terminated the LTC Agreement. As of the termination date, Oncocyte was responsible for reimbursing LTC for \$749,000 of certain development costs under the terms of the LTC Agreement, which were fully paid in 2023. X - DefinitionCo development agreementwith life technologies corporation [TextBlock] + ReferencesNo definition available. + Details Name: ocx_CoDevelopmentAgreementwithLifeTechnologiesCorporationTextBlock Namespace Prefix: ocx_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name:

ocx DisclosureCollaborativeArrangementsAbstract Namespace Prefix: ocx Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 27 R20.htm IDEA: XBRL DOCUMENT v3.24.3 Discontinued Operations of Razor 9 Months Ended Sep. 30, 2024 Discontinued Operations and Disposal Groups [Abstract] Á Discontinued Operations of Razor 11. Discontinued Operations of RazorOn December 15, 2022, the Company entered into the Razor Stock Purchase Agreement with Dragon and Razor. Pursuant to the Razor Stock Purchase Agreement, Oncocyte agreed to sell, and Dragon agreed to purchase, 3,188,181 shares of common stock of Razor, which constitutes approximately 70% of the issued and outstanding equity interests of Razor on a fully-diluted basis. On February 16, 2023, Oncocyte completed the Razor Sale Transaction. In connection with the Razor Closing, Oncocyte transferred to Razor all of the assets and liabilities related to DetermaRx. Refer to additional Razor information in Note 1. In addition to the transfer of 70% of the equity interests of Razor, the Razor Stock Purchase Agreement provided that Dragon would purchase furniture, fixtures, and equipment from the Company for a cash consideration of approximately \$116,000. Upon the Razor Closing, the Company deconsolidated the assets and liabilities of Razor as control of Razor had transferred to Dragon. The Company recorded the final adjustment related to the disposal, including final working capital adjustments, and recognized an impairment loss of \$1.3 million during the first quarter of 2023. Including the impairment losses we recognized as of December 31, 2022 related to this transaction, we recorded an overall impairment loss of \$27.2 million. The operating results for Razor have been recorded in discontinued operations of the accompanying 2023 consolidated statement of operations and we have reclassified the remaining liabilities as discontinued operations in the accompanying balance sheet. The 2023 discontinued operations reflect operating results of Razor up to the closing of the sale. The Companyâ€™s 2023 consolidated balance sheet and consolidated statement of operations report discontinued operations separate from continuing operations. Our 2023 consolidated statement of comprehensive loss, statement of shareholdersâ€™ equity and statement of cash flows combined continuing and discontinued operations. A summary of financial information related to the Companyâ€™s discontinued operations is as follows. As of December 31, 2023, the Companyâ€™s consolidated balance sheet included \$45,000 in accounts payable related to discontinued operations, which was paid during the first quarter of 2024. The following table represents the results of the discontinued operations of Razor: Á Nine Months Ended September 30, 2023 Á (In thousands) Á Net revenue Á \$ 421 Á Á Á Cost of revenues Á \$ 507 Á Research and development Á \$ 702 Á Sales and marketing Á \$ 498 Á General and administrative Á \$ 329 Á Loss from impairment of held for sale assets Á \$ 1,311 Á Net loss from discontinued operations Á \$ (2,926) Á The following table summarizes cash used related to the discontinued operations of Razor: Á Nine Months Ended September 30, 2023 Á (In thousands) Á CASH FLOWS FROM OPERATING ACTIVITIES: Á Á Á Net cash used in operating activities Á \$ (2,985) Á Á Á CASH FLOWS FROM INVESTING ACTIVITIES: Á Á Á Net cash used in investing activities Á \$ (1,372) Á X - References No definition available. + Details Name: us-gaap Discontinued Operations And Disposal Groups Abstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Definition The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205-20/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/360/tableOfContent + Details Name: us-gaap Discontinued Operations Including Discontinued Operations Disclosure Text Block Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 28 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Subsequent Events 9 Months Ended Sep. 30, 2024 Subsequent Events [Abstract] Á Subsequent Events 12. Subsequent Events Securities Purchase Agreement On October 4, 2024, the Company consummated a private placement of its securities to certain accredited investors (collectively, the â€œPurchasersâ€) for the issuance and sale of 3,461,138 shares of the Company's common stock. The purchase price for one common share was \$2.948. Certain insiders of the Company subscribed for 37,037 of the shares of common stock sold in the private placement, at a purchase price of \$2.97 per share. The related securities purchase agreement contains customary representations, warranties and agreements by the Company, indemnification obligations of the Company and the Purchasers, including for liabilities under the Securities Act, other obligations of the parties and termination provisions. The gross proceeds to the Company from the October 2024 Offering were approximately \$10.2 million, before deducting approximately \$795,000 in placement agent fees and expenses and offering expenses payable by the Company. The Company intends to use the net proceeds received of approximately \$9.4 million for general corporate purposes and working capital. Collaboration Agreement Amendment On November 8, 2024, Oncocyte and Bio-Rad entered into the Memorandum in connection with the Collaboration Agreement. The Memorandum establishes additional activities to be performed by Oncocyte and Bio-Rad prior to the commercial launch of the RUO Assays specifically related to Pilot Sites. See Note 10, "Collaborative Arrangements" for additional information. X - References No definition available. + Details Name: us-gaap Subsequent Events Abstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Definition The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/855/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 - Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap Subsequent Events Text Block Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 29 R22.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies (Policies) 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Á Accounting Principles Accounting Principles The consolidated financial statements and accompanying notes are prepared on the accrual basis of accounting in accordance with U.S. generally accepted accounting principles (â€œGAAPâ€). Principles of Consolidation and Basis of Presentation Principles of Consolidation and Basis of Presentation The unaudited condensed consolidated interim financial statements presented herein have been prepared in accordance with GAAP for financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. In accordance with those rules and regulations, certain information and footnote disclosures normally included in comprehensive consolidated financial statements may have been condensed or omitted. The consolidated balance sheet as of December 31, 2023 was derived from the audited consolidated financial statements at that date. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in Oncocyteâ€™s Annual Report on Form 10-K for the year ended December 31, 2023. The accompanying unaudited condensed consolidated financial statements, in the opinion of management, include all adjustments of a normal recurring nature necessary for a fair presentation of Oncocyteâ€™s financial condition and results of operations. The consolidated results of operations are not necessarily indicative of the results to be expected for any other interim period or for the entire year. On January 31, 2020, with the acquisition of Insight Genetics, Inc. (â€œInsightâ€) through a merger with a newly incorporated wholly-owned subsidiary of Oncocyte (the â€œInsight Mergerâ€) under the terms of an Agreement and Plan of Merger (the â€œInsight Merger Agreementâ€), Insight became a wholly-owned subsidiary of Oncocyte, and on that date Oncocyte began consolidating Insightâ€™s operations and results with Oncocyteâ€™s operations and results (see Note 3). On April 15, 2021, with the acquisition of Chronix Biomedical, Inc. (â€œChronixâ€) pursuant to an Agreement and Plan of Merger dated February 2, 2021, amended February 23, 2021, and amended and restated as of April 15, 2021 (as amended and restated, the â€œChronix Merger Agreementâ€), by and among Oncocyte, CNI Monitor Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Oncocyte (â€œMerger Subâ€), Chronix became a wholly-owned subsidiary of Oncocyte (the â€œChronix Mergerâ€), and on that date Oncocyte began consolidating Chronixâ€™s operations and results with Oncocyteâ€™s operations and results (see Note 3). All material intercompany accounts and transactions have been eliminated in consolidation. We have reflected the 2023 operations of Razor as discontinued operations. See Note 11 for further information. Amounts and disclosures throughout these notes to consolidated financial statements relate solely to continuing operations and exclude all discontinued operations, unless otherwise noted. Discontinued operations comprise activities that were disposed of or discontinued at the end of the period, represent a separate major line of business that can be clearly distinguished for operational and financial reporting purposes and represent a strategic business shift having a major effect on the Companyâ€™s operations and financial results. On July 24, 2023, the Company implemented a 1-for-20 reverse stock split of the outstanding shares of its common stock. The par value per share and the authorized number of shares of common stock and preferred stock were not adjusted as a result of the reverse stock split. All common stock share and per-share amounts for all periods presented in these consolidated financial statements have been adjusted to reflect the reverse stock split. The number of authorized shares of common stock remains at 230,000,000 shares. Reclassifications Reclassifications Certain prior period amounts in the consolidated financial statements and notes to consolidated financial statements have been reclassified to conform to the current period presentation. Included in such prior period amounts is contingent consideration liabilities, current, which was previously presented in the noncurrent balance. These changes had no impact on the previously reported consolidated financial condition, results of operations or cash flows. Prior Period Revisions Prior Period Revisions In connection with the preparation of the Companyâ€™s consolidated financial statements for the year ended December 31, 2023, the Company recorded certain adjustments that impacted previously reported financial statement amounts from the period ended September 30, 2023. As further discussed below in â€œRevenue Recognition â€ Laboratory Developed Test Services â€ Allowance for Credit Losses, â€ as a result of the January 1, 2023 adoption of the new current expected credit loss accounting policy, the Company adjusted its accounts receivable. In addition, the Company reclassified cash sold in discontinued operations from an operating cash outflow to an investing cash outflow. See Note 11, â€œDiscontinued Operations of Razorâ€ for additional information. The following are the relevant line items from the Companyâ€™s prior period consolidated financial statements illustrating the effect of the revisions to the period presented: Á For the Period Ended September 30, 2023 Á Á As Previously Reported Á Á Adjustment Á Á As Adjusted Á Á (In thousands) Á Balance Sheet and Shareholders' Equity: Á Á Á Á Á Á Á Accounts receivable, net at January 1, 2023 (Note 2) Á \$ 2,012 Á Á \$ (1,419) Á \$ 593 Á Accumulated deficit at January 1, 2023 Á \$ (260,676) Á \$ (1,419) Á \$ (262,095) Á Total Shareholders' equity at January 1, 2023 Á \$ 34,292 Á Á \$ (1,419) Á \$ 32,873 Á Statement of Cash Flows: Á Á Á Á Á Á Á Loss on disposal of discontinued operations Á \$ 1,659 Á Á \$ (138) Á \$ 1,521 Á Net cash used in operating activities Á \$ (18,763) Á Á \$ (138) Á \$ (18,901) Á Cash sold in discontinued operations (Note 11) Á \$ (1,510) Á Á \$ 138 Á Á \$ (1,372) Á Net cash used in investing activities Á \$ (1,173) Á Á \$ 138 Á Á \$ (1,035) Á Use of Estimates Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and contingent assets and liabilities, at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates estimates which are subject to significant judgment, including, but not limited to, valuation methods used, assumptions requiring the use of judgment to prepare financial projections and forecasted financial information, timing of potential commercialization of acquired in-process intangible assets, applicable discount rates, probabilities of the likelihood of multiple outcomes of certain events related to contingent consideration, comparable companies or transactions, determination of fair value of the assets acquired and liabilities assumed (including those relating to contingent consideration), the carrying value of goodwill and other intangibles, impairments, assumptions related to going concern assessments, revenue recognition, allocation of direct and indirect expenses, useful lives associated with long-lived intangible and other assets, key assumptions in operating and financing leases including incremental borrowing rates, loss contingencies, valuation allowances related to deferred income taxes, allowances for credit losses, and assumptions used to value stock-based awards and other equity instruments. These assessments are made in the context of information reasonably available to Oncocyte. Actual results may differ materially from those estimates. Segments Segments Oncocyteâ€™s executive management team, as a group, represents the entityâ€™s chief operating decision makers. To date, Oncocyteâ€™s executive management team has viewed Oncocyteâ€™s operations as one segment that includes the research, development and commercialization of diagnostic tests, including molecular diagnostic services to pharmaceutical customers. As a result, the financial information disclosed materially represents all of the financial information related to Oncocyteâ€™s sole operating segment. Fair Value Measurements, Business Combinations and Contingent Consideration Liabilities Fair Value Measurements, Business Combinations and Contingent Consideration Liabilities Oncocyte accounts for business combinations in accordance with ASC 805, which requires the purchase consideration transferred to be measured at fair value on the acquisition date in accordance with ASC 820, Fair Value Measurement. ASC 820 establishes a single authoritative definition of fair value, sets out a framework for measuring fair value and expands on required disclosures about fair value measurement. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. ASC 820 describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value, which are the following: â€ Level 1 â€ Quoted prices in active markets for identical assets and liabilities. â€ Level 2 â€ Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted market prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. â€ Level 3 â€ Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Such inputs reflect managementâ€™s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. Management estimates include certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs, including the entityâ€™s own assumptions in determining fair value. When a part of the purchase consideration consists of shares of Oncocyte common stock, Oncocyte calculates the purchase price attributable to those shares, a Level 1 security, by determining the fair value of those shares as of the acquisition date based on prices quoted on the principal national securities exchange on which the shares traded. Oncocyte recognizes estimated fair values of the tangible assets and identifiable intangible assets acquired, including in-process research and development (â€œIPR&Dâ€), and liabilities assumed, including any contingent consideration, as of the acquisition date. Goodwill is recognized as any amount of excess consideration transferred over the fair value of the tangible and identifiable intangible assets acquired net of the liabilities assumed. ASC 805 precludes the recognition of an assembled workforce as an asset, effectively subsuming any assembled workforce value into goodwill. In determining fair value, Oncocyte utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, and also considers counterparty credit risk in its assessment of fair value. For the periods presented, Oncocyte has no financial assets recorded at fair value on a recurring basis, except for money market funds. These assets are measured at fair value using the period-end quoted market prices as a Level 1 input. Certain of Oncocyteâ€™s asset and business acquisitions involve the potential for future payment of consideration to third-parties and former selling shareholders in amounts determined as a percentage of future net revenues generated, or upon attainment of revenue milestones, from Pharma Services or laboratory tests, as applicable, or annual minimum royalties to certain licensors, as provided in the applicable agreements. The fair value of such liabilities is determined using unobservable inputs. These inputs include the estimated amount and timing of projected cash flows and the risk-adjusted discount rate used to present value the cash flows. These obligations are referred to as contingent consideration, which are carried at fair value based on Level 3 inputs on a recurring basis. ASC 805 requires that contingent consideration be estimated and recorded at fair value as of the acquisition date as part of the total consideration transferred. Contingent consideration is an obligation of the acquirer to transfer additional assets or equity interests to the selling shareholders in the future if certain future events occur or conditions are met, such as the attainment of product development milestones. Contingent consideration also includes additional future payments to selling shareholders based on achievement of components of earnings, such as â€œearn-outâ€ provisions or percentage of future revenues, including royalties paid to the selling shareholders based on a percentage of certain revenues generated. The fair value of contingent consideration after the acquisition date is reassessed by Oncocyte as changes in circumstances and conditions occur, with the subsequent change in fair value recorded in the consolidated statements of operations. Changes in key assumptions can materially affect the estimated fair value of contingent consideration liabilities and, accordingly, the resulting gain or loss that Oncocyte records in its consolidated financial statements. See Note 3 for a full discussion of these liabilities and additional Level 3 fair value disclosures. The carrying amounts of cash and cash equivalents, restricted cash, net accounts receivable, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities approximate fair values because of the short-term nature of these items. In accordance with GAAP, from time to time, the Company measures certain assets at fair value on a nonrecurring basis. The Company reviews the carrying value of intangibles, including IPR&D (see Note 5), and other long-lived assets for indications of impairment at least annually. Refer to related discussions of impairments

below. Cash, Cash Equivalents and Restricted Cash Cash, Cash Equivalents and Restricted CashOncocyte considers all highly liquid securities with original maturities of three months or less when purchased to be cash equivalents. For the periods presented, Oncocyteâ€™s cash equivalents are comprised of investments in AAA rated money market funds that invest in first-tier only securities, which primarily include domestic commercial paper and securities issued or guaranteed by the U.S. government or its agencies. Restricted cash relates to a bank letter of credit required under our office lease arrangement, refer to Note 6 for additional information. Marketable Equity SecuritiesMarketable Equity SecuritiesOncocyte accounts for shares of public common stock it may hold as marketable equity securities in accordance with ASC 321-10, Investments â€” Equity Securities, as the shares have a readily determinable fair value quoted on national stock exchange. The securities are measured at fair value, with related gains and losses in the value of such securities recorded in the consolidated statements of operations in other income or expense, and are reported as current assets in the consolidated balance sheet based on the closing trading price of the security as of the date being presented. During the fourth quarter of 2023, Oncocyte sold its remaining marketable equity securities for an aggregate realized loss of approximately \$1.4 million. During the nine months ended September 30, 2023, Oncocyte recorded an unrealized gain on marketable equity securities of \$8,000. Investments in Privately Held Companies Investments in Privately Held CompaniesOncocyte evaluates whether investments held in common stock of other companies require consolidation of the company under, first, the variable interest entity (â€œVIEâ€) model, and then under the voting interest model in accordance with accounting guidance for consolidations under ASC 810-10. If consolidation of the entity is not required under either the VIE model or the voting interest model, Oncocyte determines whether the equity method of accounting should be applied in accordance with ASC 323, Investments â€” Equity Method and Joint Ventures. The equity method applies to investments in common stock or in-substance common stock if Oncocyte exercises significant influence over, but does not control, the entity, where significant influence is typically represented by ownership of 20% or more, but less than majority ownership, of the voting interests of a company.Oncocyte initially records equity method investments at fair value on the date of the acquisition with subsequent adjustments to the investment balance based on Oncocyteâ€™s pro rata share of earnings or losses from the investment.Since February 16, 2023, Oncocyte continues to own an equity interest Razor, however, based on the Razor transactions as discussed in Note 1, the remaining common stock held is accounted for at historical cost less impairment, which is currently zero. InventoriesInventoriesInventories include raw materials, work-in-process and finished goods and are valued at the lower of cost or net realizable value. In September 2024, the Company capitalized certain initial RUO inventory costs in connection with its collaboration arrangement with Bio-Rad to develop and commercialize its GraftAssure RUO kitted tests and eventual IVD kitted transplant testing products. See Note 10, â€œCollaborative Arrangementsâ€ for additional information. As of September 30, 2024, inventories, comprised primarily of raw materials, totaled \$232,000. Assets Held for Sale and Discontinued Operations Assets Held for Sale and Discontinued OperationsAssets and liabilities are classified as held for sale when all of the following criteria for a plan of sale have been met: (1) management, having the authority to approve the action, commits to a plan to sell the assets; (2) the assets are available for immediate sale, in their present condition, subject only to terms that are usual and customary for sales of such assets; (3) an active program to locate a buyer and other actions required to complete the plan to sell the assets have been initiated; (4) the sale of the assets is probable and is expected to be completed within one year; (5) the assets are being actively marketed for a price that is reasonable in relation to their current fair value; and (6) actions required to complete the plan indicate that it is unlikely that significant changes to the plan will be made or the plan will be withdrawn. When all of these criteria have been met, the assets and liabilities are classified as held for sale in the consolidated balance sheet. Assets classified as held for sale are reported at the lower of their carrying value or fair value less costs to sell. Depreciation and amortization of assets ceases upon designation as held for sale.The Company has entered into various agreements to sell laboratory equipment. As a result, the Company classified the equipment as held for sale current assets in the consolidated balance sheets, as all the criteria of ASC subtopic 360-10, Property, Plant, and Equipment had been met. The equipment was written down to its fair value, less cost to sell, the remainder of which was \$32,000 and \$139,000 as of September 30, 2024 and December 31, 2023, respectively. During the nine months ended September 30, 2024 and 2023, the Company recorded an impairment loss on held for sale assets of \$169,000 and \$1.3 million, respectively, in the consolidated statements of operations.Discontinued operations comprise activities that were disposed of, discontinued or held for sale at the end of the period, represent a separate major line of business that can be clearly distinguished for operational and financial reporting purposes and represent a strategic business shift having a major effect on the Companyâ€™s operations and financial results according to ASC Topic 205, Presentation of Financial Statements. Razor has been reflected as a discontinued operation in the 2023 consolidated financial statements. See Note 11, â€œDiscontinued Operations of Razorâ€ for additional information. Machinery and Equipment, Net, Financing Leases, Net, and Construction in Progress Machinery and Equipment, Net, Financing Leases, Net, and Construction in ProgressMachinery and equipment are stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally over a period of 3 to 10 years. For equipment purchased under financing leases, Oncocyte depreciates the equipment based on the shorter of the useful life of the equipment or the term of the lease, ranging from 3 to 5 years, depending on the nature and classification of the financing lease. Maintenance and repairs are expensed as incurred whereas significant renewals and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and the related accumulated depreciation are removed from the respective accounts and any resulting gain or loss is reflected in Oncocyteâ€™s results of operations.Construction in progress, comprised primarily of leasehold improvements under construction, is not depreciated until the underlying asset is placed into service. Intangible AssetsIntangible AssetsIn accordance with ASC 350, Intangibles â€” Goodwill and Other, IPR&D projects acquired in a business combination that are not complete as of the acquisition date are capitalized and accounted for as indefinite-lived intangible assets until completion or abandonment of the related research and development efforts. Upon successful completion of the project, the capitalized amount is amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts are written off immediately. Oncocyte considers various factors and risks for potential impairment of IPR&D assets, including the current legal and regulatory environment and the competitive landscape. Adverse clinical trial results, significant delays or inability to obtain local coverage determination (â€œLCDâ€) from the Centers for Medicare and Medicaid Services (â€œCMSâ€) for Medicare reimbursement for a diagnostic test, the inability to bring a diagnostic test to market and the introduction or advancement of competitorsâ€™ diagnostic tests could result in partial or full impairment of the related intangible assets. Consequently, the eventual realized value of the IPR&D project may vary from its fair value at the date of acquisition, and IPR&D impairment charges may occur in future periods. During the period between completion or abandonment, the IPR&D assets will not be amortized but will be tested for impairment on an annual basis and between annual tests if Oncocyte becomes aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&D projects below their respective carrying amounts.Oncocyte does not have intangible assets with indefinite useful lives other than the acquired IPR&D discussed in Note 5, which as of September 30, 2024, has been partially impaired.Goodwill represents the excess of the purchase price over the fair value of net identifiable assets and liabilities. Goodwill, similar to IPR&D, is not amortized but is tested for impairment at least annually, or if circumstances indicate that it is more-likely-than-not that the carrying value of the associated reporting unit exceeds its fair value. Qualitative factors considered in this assessment include industry and market conditions, overall financial performance, and other relevant events and factors affecting Oncocyteâ€™s business. Based on the qualitative assessment, if it is determined that the fair value of goodwill is more-likely-than-not to be less than its carrying amount, the fair value of a reporting unit will be calculated and compared with its carrying amount and an impairment charge will be recognized for the amount that the carrying value exceeds the fair value. Oncocyte continues to operate in one segment and considered to be the sole reporting unit and, therefore, goodwill is tested for impairment at the enterprise level, when applicable.In accordance with ASC 350, we review and evaluate our long-lived assets, including intangible assets with finite lives, for impairment whenever events or changes in circumstances indicate that we may not recover their net book value. When applicable, we test goodwill for impairment on an annual basis in the fourth quarter of each year, and between annual tests, if indicators of potential impairment exist, using a fair-value approach. We typically use an income method to estimate the fair value of these assets, which is based on forecasts of the expected future cash flows attributable to the respective assets. Significant estimates and assumptions inherent in the valuations reflect a consideration of other marketplace participants and include the amount and timing of future cash flows (including expected growth rates). Estimates utilized in the projected cash flows include consideration of macroeconomic conditions, overall category growth rates, competitive activities, cost containment and margin expansion, Company business plans, the underlying product or technology life cycles, economic barriers to entry, and the discount rate applied to the cash flows. Unanticipated market or macroeconomic events and circumstances may occur, which could affect the accuracy or validity of the estimates and assumptions. Long-Lived Intangible Assets Long-Lived Intangible AssetsLong-lived intangible assets subject to amortization are stated at acquired cost, less accumulated amortization. We amortize intangible assets not considered to have an indefinite useful life using the straight-line method over their estimated period of benefit, which generally ranges from 1 to 9 years. Each reporting period, we evaluate the estimated remaining useful life of intangible assets and assess whether events or changes in circumstances warrant a revision to the remaining period of amortization or indicate that impairment exists. Long-lived intangible assets currently consist of acquired customer relationships with an estimated useful life of 5 years (see Note 5). Impairment of Long-Lived Assets Impairment of Long-Lived AssetsOncocyte assesses the impairment of long-lived assets whenever events or changes in circumstances indicate that such assets might be impaired and the carrying value may not be recoverable. Oncocyteâ€™s long-lived assets consist primarily of intangible assets, right-of-use assets for operating and financing leases, customer relationships, and machinery and equipment. If events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable and the expected undiscounted future cash flows attributable to the asset are less than the carrying amount of the asset, an impairment loss, equal to the excess of the carrying value of the asset over its fair value, is recorded. LeasesLeasesOncocyte accounts for leases in accordance with ASC 842, Leases. Oncocyte determines if an arrangement is a lease at inception. Leases are classified as either financing or operating, with classification affecting the pattern of expense recognition in the consolidated statements of operations. Under the available practical expedients for the adoption of ASC 842, Oncocyte accounts for the lease and non-lease components as a single lease component. Oncocyte recognizes right-of-use (â€œROUâ€) assets and lease liabilities for leases with terms greater than twelve months in the consolidated balance sheet. ROU assets represent the right to use an underlying asset during the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most leases do not provide an implicit rate, Oncocyte uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. Oncocyte uses the implicit rate when it is readily determinable. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. Lease terms may include options to extend or terminate the lease when it is reasonably certain that Oncocyte will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Operating leases include office leases and related ROU lease liabilities, current and long-term, in the consolidated balance sheets. Financing leases include machinery and equipment and related financing lease liabilities, current and long-term, in the consolidated balance sheets. Oncocyte discloses the amortization of our operating lease ROU assets and payments as a net amount in the consolidated statements of cash flows. Oncocyte has entered into various operating and financing leases in accordance with ASC 842 as further discussed in Note 6. Accounting for Warrants Accounting for WarrantsOncocyte determines the accounting classification of warrants it issues, as either liability or equity classified, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity, then in accordance with ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Companyâ€™s Own Stock. Under ASC 480, warrants are considered liability classified if the warrants are mandatorily redeemable, obligate Oncocyte to settle the warrants or the underlying shares by paying cash or other assets or warrants that must or may require settlement by issuing variable number of shares. If warrants do not meet liability classification under ASC 480, Oncocyte assesses the requirements under ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. This liability classification guidance also applies to financial instruments that may require cash or other form of settlement for transactions outside of the companyâ€™s control and, in which the form of consideration to the warrant holder may not be the same as to all other shareholders in connection with the transaction. However, if a transaction is not within the companyâ€™s control but the holder of the financial instrument can solely receive the same type or form of consideration as is being offered to all the shareholders in the transaction, then equity classification of the financial instrument is not precluded, if all other applicable equity classification criteria are met.After all relevant assessments, Oncocyte concludes whether the warrants are classified as liability or equity. Liability classified warrants require fair value accounting at issuance and subsequent to initial issuance with all changes in fair value after the issuance date recorded in the statements of operations. Equity classified warrants only require fair value accounting at issuance with no changes recognized subsequent to the issuance date. Based on the above guidance and, among other factors, the fact that our warrants cannot be cash settled under any circumstance but require share settlement, all of our outstanding warrants meet the equity classification criteria and have been classified as equity. Refer to Note 7 for details about our outstanding warrants. Revenue Recognition Revenue RecognitionPursuant to ASC 606, Revenue from Contracts with Customers, revenues are recognized when control of services performed is transferred to customers, in an amount that reflects the consideration Oncocyte expects to be entitled to in exchange for those services. ASC 606 provides for a five-step model that includes:(i)identifying the contract with a customer,(ii)identifying the performance obligations in the contract,(iii)determining the transaction price,(iv)allocating the transaction price to the performance obligations, and(v)recognizing revenue when, or as, an entity satisfies a performance obligation.Oncocyte determines transaction prices based on the amount of consideration we expect to receive for transferring the promised goods or services in the contract. Consideration may be fixed, variable, or a combination of both. The Company considers any constraints on the variable consideration and includes in the transaction price variable consideration to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved.The following table presents consolidated revenues by service:Â Â Three Months EndedSeptember 30, Â Â Nine Months EndedSeptember 30, Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â (In thousands) Â Â Pharma Services Â Â \$ 115 Â Â \$ 423 Â Â \$ 373 Â Â \$ 1,160 Â Â Laboratory Developed Test Services Â Â \$ 6 Â Â \$ 6 Â Â \$ 22 Â Â \$ 29 Â Â Total Â Â \$ 115 Â Â \$ 429 Â Â \$ 395 Â Â \$ 1,189 Â Â Pharma Services RevenueRevenues recognized include Pharma Services performed by Oncocyteâ€™s Insight and Chronix subsidiaries for its pharmaceutical customers, including testing for biomarker discovery, assay design and development, clinical trial support, and a broad spectrum of biomarker tests. These Pharma Services are generally performed under individual scope of work (â€œSOWâ€) arrangements or license agreements (together with SOW the â€œPharma Services Agreementsâ€) with specific deliverables defined by the customer. Pharma Services are performed on a (i) time and materials basis or (ii) per test completed basis. Upon completion of the service to the customer in accordance with a Pharma Services Agreement, Oncocyte has the right to bill the customer for the agreed upon price (either on a per test or per deliverable basis) and recognizes Pharma Service revenue at that time. Insight identifies each service of its Pharma Service offering as a single performance obligation. Offerings include services such as recurring fees for project management, fees for storage and handling, pass through expenses for shipping or calibration, training, proficiency, reproducibility tests, etc. Chronix identifies the processing of test samples as a separate performance obligation (considered a series) within license agreements with customers.Completion of the service and satisfaction of the performance obligation is typically evidenced by acknowledgment of completed services, and access to the report or test made available to the customer or any other form or applicable manner of delivery defined in the Pharma Services Agreements. However, for certain SOWs under which work is performed pursuant to the customerâ€™s highly customized specifications, Oncocyte has the enforceable right to bill the customer for work completed, rather than upon completion of the SOW. For those SOWs, Oncocyte recognizes revenue over a period during which the work is performed using a formula that accounts for expended efforts, generally measured in labor hours, as a percentage of total estimated efforts for the completion of the SOW. As performance obligations are satisfied under the Pharma Services Agreements, any amounts earned as revenue and billed to the customer are included in accounts receivable. Any revenues earned but not yet billed to the customer as of the date of Oncocyteâ€™s consolidated financial statements are recorded as contract assets and are included in prepaids and other current assets as of the financial statement date. Amounts recorded in contract assets are reclassified to accounts receivable in Oncocyteâ€™s consolidated balance sheets when the customer is invoiced according to the billing schedule in the contract.As of September 30, 2024 and December 31, 2023, Oncocyte had gross accounts receivable from Pharma Services customers of \$211,000 and \$489,000, respectively.Allowance for Credit LossesOncocyte establishes an allowance for credit losses based on the evaluation of the collectability of its Pharma Services accounts receivables after considering a variety of factors, including the length of time receivables are past due, significant events that may impair the customerâ€™s ability to pay, such as a bankruptcy filing or

operations in the customer's s operating results or financial position, reasonable and supportable forecast that affect the collectability of the reported amount, and historical experience. If circumstances related to customers change, estimates of the recoverability of receivables would be further adjusted. Oncocyte continuously monitors collections and payments from customers and maintains a provision for estimated credit losses and uncollectible accounts, if any, based upon its historical experience and any specific customer collection issues that have been identified. Amounts determined to be uncollectible are written off against the credit loss reserve accounts. As of September 30, 2024 and December 31, 2023, Oncocyte had an allowance for credit losses of \$2,000 and \$5,000, respectively, related to Pharma Services.Laboratory Developed Test ServicesPrior to the Razor Sale Transaction, Oncocyte generated revenue from performing DetermaRx tests on clinical samples through orders received from physicians, hospitals, and other healthcare providers. In determining whether all the revenue recognition criteria in (i) through (v) above are met with respect to DetermaRx tests, each test result is considered a single performance obligation and is generally considered complete when the test result is delivered or made available to the prescribing physician electronically, and, as such, there are no shipping or handling fees incurred by Oncocyte or billed to customers. Although Oncocyte has billed a list price for all tests ordered and completed for all payer types, Oncocyte considers constraints on the variable consideration when recognizing revenue for DetermaRx. Because DetermaRx is a novel test and there are no current reimbursement arrangements with third-party payers other than Medicare, the transaction price represents variable consideration. Application of the constraint for variable consideration is an area that requires significant judgment. For all payers other than Medicare, Oncocyte must consider the novelty of the test, the uncertainty of receiving payment, or being subject to claims for a refund, from payers with whom it does not have a sufficient payment collection history or contractual reimbursement agreements. Accordingly, for those payers, Oncocyte has recognized revenue upon payment because it has had insufficient history to reliably estimate payment patterns.As of September 30, 2024 and December 31, 2023, Oncocyte had no accounts receivable from Medicare and Medicare Advantage covered DetermaRx tests. Laboratory Developed Test Services revenue recorded during the nine months ended September 30, 2024 was the result of payments received.Allowance for Credit LossesWe maintained an allowance for credit losses related to Laboratory Developed Test Services at an amount we estimated to be sufficient to provide adequate protection against losses resulting from extending credit to our customers. We based this allowance, in the aggregate, on historical collection experience, age of receivables and general economic conditions, as well as specific identification of uncollectible accounts. We initially established an allowance in 2022 in connection with remaining Medicare and Medicare Advantage account balances and continued to add to the allowance as appropriate. In the first quarter of 2023, in connection with the adoption of the new current expected credit loss model, the Company determined that the Medicare and Medicare Advantage accounts receivable net balance of approximately \$1.4 million was uncollectible and should therefore be written-off as of the adoption date, January 1, 2023. Refer to additional information above in the Principles of Consolidation and Basis of Presentation for Prior Period Revisions.As of December 31, 2023, we had no allowance for credit losses related to Laboratory Developed Test Services. The 2023 allowance for credit losses activity included beginning balance of \$154,000, no credit loss provisions, and the full write-off to an ending balance of zero as of December 31, 2023.Licensing RevenueRevenues that may be recognized include licensing revenue derived from agreements with customers for exclusive rights to market Oncocyte's proprietary testing technology. Under the agreements, Oncocyte grants exclusive rights to certain trademarks and technology of Oncocyte for the purpose of marketing Oncocyte's tests within a defined geographic territory. A license agreement may specify milestone deliverables or performance obligations, for which Oncocyte recognizes revenue when its licensee confirms the completion of Oncocyte's performance obligation. A licensing agreement may also include ongoing sales support from Oncocyte and typically includes non-refundable licensing fees and per-test Pharma Services revenues discussed above, for which Oncocyte treats the licensing of the technology, trademarks, and ongoing support as a single performance obligation satisfied by the passage of time over the term of the agreement.Disaggregation of Revenues and Concentrations of Credit RiskThe following table presents the percentage of consolidated revenues by service: Three Months EndedSeptember 30, Nine Months EndedSeptember 30, 2024 2023 2024 2023 Pharma Services 100% 99% 94% 98% Laboratory Developed Test Services 0% 1% 6% 2% Total 100% 100% 100% 100% The following table presents the percentage of consolidated revenues generated by unaffiliated customers, based on the respective periods presented, that individually represented greater than ten percent of consolidated revenues: Three Months EndedSeptember 30, Nine Months EndedSeptember 30, 2024 2023 2024 2023 Pharma Services - Company C 12% 12% 12% 12% Pharma Services - Company D 11% 11% 11% 11% Less than 10%The following table presents the percentage of consolidated revenues attributable to geographical locations, based on country of domicile: Three Months EndedSeptember 30, Nine Months EndedSeptember 30, 2024 2023 2024 2023 United States 100% 100% 100% 100% Outside of the United States 0% 0% 0% 0% United States 100% 100% 100% 100% Laboratory Developed Test Services 0% 1% 6% 4% Total 100% 100% 100% 100% As of September 30, 2024 and December 31, 2023, the Company held long-lived tangible assets in Germany in the amount of \$392,000 and \$66,000, respectively.Financial instruments that potentially subject the Company to concentrations of credit risk are cash equivalents and accounts receivable. The Company places its cash equivalents primarily in highly rated money market funds. Cash and cash equivalents are also invested in deposits with certain financial institutions and may, at times, exceed federally insured limits. The Company has not experienced any significant losses on its deposits of cash and cash equivalents.Four Pharma Services customers individually represented approximately 51%, 20%, 17% and 12% of accounts receivable as of September 30, 2024. Two Pharma Services customers individually represented approximately 79% and 13% of accounts receivable as of December 31, 2023. Cost of Revenues Cost of revenues generally consists of cost of materials, direct labor including benefits, bonus and stock-based compensation, equipment and infrastructure expenses, clinical sample related costs associated with performing Pharma Services and Laboratory Developed Test Services, providing deliverables according to our licensing agreements, license fees due to third-parties, and amortization of acquired intangible assets such as the customer relationship intangible assets (see Note 5). Infrastructure expenses include depreciation of laboratory equipment, allocated rent costs, leasehold improvements, and allocated information technology costs for operations at Oncocyte's CLIA laboratory in Tennessee. Costs associated with generating the revenues are recorded as the tests or services are performed regardless of whether revenue was recognized. Royalties or revenue share payments for licensed technology calculated as a percentage of revenues generated using the associated technology are recorded as expenses at the time the related revenues are recognized. Research and Development Expenses Research and Development ExpensesResearch and development expenses are comprised of costs incurred to develop technology, which include salaries and benefits (including stock-based compensation), laboratory expenses (including reagents and supplies used in research and development laboratory work), infrastructure expenses (including allocated facility occupancy costs), and contract services and other outside costs. Indirect research and development expenses are allocated primarily based on headcount, as applicable, and include rent and utilities, common area maintenance, telecommunications, property taxes and insurance. Research and development costs are expensed as incurred. Certain research and development expenses are attributed to our collaboration arrangement with Bio-Rad, our global strategic partner, for commercializing our RUO kitted tests and IVD kitted transplant testing products. See Note 10, Collaborative Arrangements for additional information. Sales and Marketing Expenses Sales and Marketing ExpensesSales and marketing expenses consist primarily of personnel costs and related benefits, including stock-based compensation, trade show expenses, branding and positioning expenses, and consulting fees. Sales and marketing expenses also include indirect expenses for applicable overhead allocated based on headcount, and include allocated costs for rent and utilities, common area maintenance, telecommunications, property taxes and insurance. During the three months ended September 30, 2024 and 2023, Oncocyte's total advertising expenses were \$40,000 and \$46,000, respectively. During the nine months ended September 30, 2024 and 2023, Oncocyte's total advertising expenses were \$123,000 and \$125,000, respectively. Certain sales and marketing expenses are attributed to our collaboration arrangement with Bio-Rad, our global strategic partner, for commercializing our RUO kitted tests and IVD kitted transplant testing products. See Note 10, Collaborative Arrangements for additional information. General and Administrative Expenses General and Administrative ExpensesGeneral and administrative expenses consist primarily of compensation and related benefits (including stock-based compensation) for executive and corporate personnel, professional and consulting fees, rent and utilities, common area maintenance, telecommunications, property taxes and insurance. Stock-Based Compensation Stock-Based CompensationOncocyte recognizes compensation expense related to employee, Board of Director and other non-employee option grants and restricted stock grants in accordance with ASC 718, Compensation Stock Compensation.Oncocyte estimates the fair value of stock-based payment awards on the grant date and recognizes the resulting fair value over the requisite service period, which is generally a four-year vesting period. For stock-based awards that vest only upon the attainment of one or more performance goals set by Oncocyte at the time of the grant (sometimes referred to as milestone vesting), compensation cost is recognized if and when Oncocyte determines that it is probable that the performance condition or conditions will be, or have been, achieved. Oncocyte uses the Black-Scholes option pricing model for estimating the fair value of time-based options granted under Oncocyte's equity plan. The fair value of each restricted stock unit (RSU) or award is determined by the product of the number of units or shares granted and the grant date market price of the underlying common stock. Oncocyte has elected to treat stock-based payment awards with graded vesting schedules and time-based service conditions as a single award and recognizes stock-based compensation ratably on a straight-line basis over the requisite service period. Options have a maximum contractual term of ten years. Forfeitures are accounted for as they occur. Refer to Note 8 for additional information. The Black-Scholes option pricing model requires Oncocyte to make certain assumptions including the expected option term, the expected volatility, the risk-free interest rate and the dividend yield. The expected term of employee stock options represents the weighted average period that the stock options are expected to remain outstanding. Oncocyte estimates the expected term of options granted based on its own experience. Oncocyte estimates the expected volatility using its own stock price volatility for a period equal to the expected term of the options. The risk-free interest rate assumption is based upon observed interest rates on the United States government securities appropriate for the expected term of Oncocyte's stock options. The dividend yield assumption is based on Oncocyte's history and expectation of dividend payouts. Oncocyte has never declared or paid any cash dividends on its common stock, and Oncocyte does not anticipate paying any cash dividends in the foreseeable future.All excess tax benefits and tax deficiencies from stock-based compensation awards accounted for under ASC 718 are recognized as income tax benefit or expense, respectively, in the statements of operations. An excess income tax benefit arises when the tax deduction of a share-based award for income tax purposes exceeds the compensation cost recognized for financial reporting purposes and, a tax deficiency arises when the compensation cost exceeds the tax deduction. Because Oncocyte has a full valuation allowance for all periods presented (see Income Taxes below), there was no impact to Oncocyte statements of operations for any excess tax benefits or deficiencies, as any excess benefit or deficiency would be offset by the change in the valuation allowance. Retirement Plan Retirement PlanOncocyte has an employee savings and retirement plan under Section 401(k) of the Internal Revenue Code. The plan is a defined contribution plan in which eligible employees may elect to have a percentage of their compensation contributed to the plan, subject to certain guidelines issued by the Internal Revenue Service. During the three months ended September 30, 2024 and 2023, Oncocyte's total contributions to the plan were \$81,000 and \$67,000, respectively. During the nine months ended September 30, 2024 and 2023, Oncocyte's total contributions to the plan were \$248,000 and \$245,000, respectively. Collaborative Arrangements Collaborative ArrangementsThe Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808, Collaborative Arrangements, which includes determining whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. To the extent that the arrangement falls within the scope of ASC 808, the Company assesses whether the payments between the Company and its collaboration partner fall within the scope of other accounting literature. If the Company concludes that payments from the collaboration partner to the Company would represent consideration from a customer, the Company accounts for those payments within the scope of ASC 606. However, if the Company concludes that its collaboration partner is not a customer for certain activities and associated payments, the Company presents such payments as a reduction of research and development expense or general and administrative expense, based on where the Company presents the underlying expense. See Note 10, Collaborative Arrangements for additional information. Income Taxes Income TaxesThe provision for income taxes for interim periods is determined using an estimated annual effective tax rate in accordance with ASC 740-270, Income Taxes, Interim Reporting. The effective tax rate may be subject to fluctuations during the year as new information is obtained, which may affect the assumptions used to estimate the annual effective tax rate, including factors such as valuation allowances against deferred tax assets, the recognition or de-recognition of tax benefits related to uncertain tax positions, if any, and changes in or the interpretation of tax laws in jurisdictions where Oncocyte conducts business.Oncocyte did not record any provision or benefit for income taxes for the three and nine months ended September 30, 2024 and 2023, as Oncocyte had a full valuation allowance for the periods presented.A valuation allowance is provided when it is more likely than not that some portion of the deferred tax assets will not be realized. Oncocyte established a full valuation allowance for all periods presented due to the uncertainty of realizing future tax benefits from its net operating loss carry-forwards and other deferred tax assets.The guidance also prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not sustainable upon examination by taxing authorities. Oncocyte will recognize accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties as of September 30, 2024 and December 31, 2023. Oncocyte is not aware of any uncertain tax positions that could result in significant additional payments, accruals, or other material deviation as of September 30, 2024. Oncocyte is currently unaware of any tax issues under review. As of September 30, 2024 and December 31, 2023, the Company had unrecognized tax benefits totaling \$2.3 million.On June 27, 2024, California enacted SB-167, which suspends the use of California net operating loss and limits the use of California research tax credits to \$5.0 million each year for our fiscal years 2025-2027. On June 29, 2024, California enacted SB-175, which provides a refund mechanism for the incremental tax that was paid as a result of SB-167. The Company is evaluating the impact of the law changes but does not expect these law changes to have a material impact on the Company's consolidated financial statements. Net Loss Per Common Share Net Loss Per Common ShareBasic loss per share is computed by dividing the net loss applicable to common stockholders after deducting cumulative unpaid dividends and accretion of the preferred stock, by the weighted average number of shares of common stock outstanding during the year. The 2024 weighted average shares outstanding - basic in the following table includes the effects of pre-funded warrants that were issued in April 2024 (refer to Note 7, Common Stock Purchase Warrants for additional information). Diluted loss per share is computed by dividing the net loss applicable to common stockholders after deducting cumulative unpaid dividends and accretion of the preferred stock, by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued, using the treasury stock method or the if-converted method, or the two-class method for participating securities, whichever is more dilutive. Potential common shares are excluded from the computation if their effect is antidilutive.For the three and nine months ended September 30, 2024 and 2023, all common stock equivalents are antidilutive because Oncocyte reported a net loss. The following table presents the calculation of basic and diluted loss per share of common stock: Three Months EndedSeptember 30, Nine Months EndedSeptember 30, 2024 2023 2024 2023 (In thousands, except per share data) Numerators: Loss from continuing operations \$ (13,493) \$ (6,489) \$ (27,152) \$ (8,863) Accretion of Series A redeemable convertible preferred stock \$ (198) \$ (263) \$ (621) Deemed dividend on Series A redeemable convertible preferred stock \$ (118) Net loss from continuing operations - basic and diluted \$ (13,493)

common share:

Series A redeemable convertible preferred stock

Recent Accounting Pronouncements Not Yet Adopted In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, to improve financial reporting by requiring disclosure of incremental segment information on an annual and interim basis for all public entities to enable investors to enable investors to develop more decision-useful financial analyses. The amendments in this Update: (i) require enhanced disclosures about significant segment expenses, (ii) clarify that if the chief operating decision maker (CODM) uses more than one measure of a segment's profit or loss, a public entity may report one or more of those additional measures of segment profit or loss, (iii) require disclosure of the title and position of the CODM and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources, and (iv) require that a public entity that has a single reportable segment provide all the disclosures required by the amendments in this Update and all existing segment disclosures in Topic 280. The amendments in this Update should be applied retrospectively, and are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. Management is currently evaluating the impact that the amendments in this Update will have on the Company's financial statement disclosures. The adoption of this new standard will not have an impact on the Company's consolidated balance sheets and consolidated statements of operations, comprehensive loss, shareholders' equity and cash flows. In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, to address investor requests for more transparency about income tax information by requiring improvements to income tax disclosures, including, (i) consistent categories and greater disaggregation of information in the rate reconciliation, and (ii) income taxes paid disaggregated by jurisdiction. Additional amendments in this Update improve the effectiveness and comparability of disclosures by, (i) adding disclosures of pretax income (or loss) and income tax expense (or benefit), and (ii) removing disclosures that no longer are considered cost beneficial or relevant. The amendments in this Update should be applied prospectively (retrospective application is permitted) and are effective for annual periods beginning after December 15, 2024, with early adoption permitted. Management is currently evaluating the impact that the amendments in this Update will have on the Company's financial statement disclosures. The adoption of this new standard will not have an impact on the Company's consolidated balance sheets and consolidated statements of operations, comprehensive loss, shareholders' equity and cash flows. In November 2024, the FASB issued ASU No. 2024-03, Income Statement Reporting Comprehensive Income Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, to address investor requests for more detailed information about certain types of reported costs and expenses. The amendments in this Update require disclosure, in the notes to financial statements, at each interim and annual reporting period an entity: 1) disclose the amounts of (a) purchases of inventory, (b) employee compensation, (c) depreciation, and (d) intangible asset amortization included in each expense caption presented on the face of the income statement within continuing operations; 2) include certain amounts that are already required to be disclosed under current GAAP in the same disclosure as the other disaggregation requirements; 3) disclose a qualitative description of the amounts remaining that are not separately disaggregated quantitatively; and 4) disclose the total amount of selling expenses and, in annual reporting periods, an entity's definition of selling expenses. The amendments in this Update should be applied either prospectively or retrospectively, and are effective for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027, with early adoption permitted. Management is currently evaluating the impact that the amendments in this Update will have on the Company's financial statement disclosures. The adoption of this new standard will not have an impact on the Company's consolidated balance sheets and consolidated statements of operations, comprehensive loss, shareholders' equity and cash flows. X - DefinitionAccounting For Warrants [Policy Text Block] + ReferencesNo definition available. + Details Name: ocx_AccountingForWarrantsPolicyTextBlock Namespace Prefix: ocx_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionAccounting Principles [Policy Text Block] + ReferencesNo definition available. + Details Name: ocx_AccountingPrinciplesPolicyTextBlock Namespace Prefix: ocx_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionBusiness Combinations And Fair Value Measurements [Policy Text Block] + ReferencesNo definition available. + Details Name: ocx_BusinessCombinationsAndFairValueMeasurementsPolicyTextBlock Namespace Prefix: ocx_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionPrior Period Revisions Policy [Policy Text Block] + ReferencesNo definition available. + Details Name: ocx_PriorPeriodRevisionsPolicyTextBlock Namespace Prefix: ocx_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionSale And Marketing Expenses [Policy Text Block] + ReferencesNo definition available. + Details Name: ocx_SalesAndMarketingExpensesPolicyTextBlock Namespace Prefix: ocx_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionSegments [Policy Text Block] + ReferencesNo definition available. + Details Name: ocx_SegmentsPolicyTextBlock Namespace Prefix: ocx_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionEntity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03)(1)(a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1 + Details Name: us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for collaborative arrangements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementAccountingPolicy Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_CompensationRelatedCostsPolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for cost of product sold and service rendered. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Topic 705 -Publisher FASB -URI https://asc.fasb.org/705/tableOfContent + Details Name: us-gaap_CostOfSalesPolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for discontinued operations. Includes, but is not limited to, method of interest allocation to a discontinued operation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section S99 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480781/205-20-S99-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1 + Details Name: us-gaap_DiscontinuedOperationsPolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 + Details Name: us-gaap_EarningsPerSharePolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 21D -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-21D + Details Name: us-gaap_EquityMethodInvestmentsPolicy Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContentReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent + Details Name: us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.CC) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 05 -Paragraph 4 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4 + Details Name: us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 19 -Publisher FAS

Subparagraph (a) - SubTopic 10 - Topic 270 - Publisher FASB -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6 + Details Name: us-gaap_InventoryPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for leasing arrangement entered into by lessee. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1) + Details Name: us-gaap_LesseeLeasesPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for investment classified as marketable security. + ReferencesReference 1:

need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 + Details Name: us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark. + ReferencesReference 1: <a href=)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20)Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-16>Reference 6: [http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-50-55-40](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/TabOfContentReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/TabOfContent + Details Name: us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets. + ReferencesReference 1: <a href=)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph \(f\)\(2\) -Name Accounting Standards](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + ReferencesReference 1: <a href=)

Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 36 R29.htm IDEA: XBRL DOCUMENT v3.24.3 Discontinued Operations of Razor (Tables) 9 Months Ended Sep. 30, 2024 Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] A Schedule of Discontinued Operations The following table represents the results of the discontinued operations of Razor: A A Nine Months Ended September 30, 2023 A A (In thousands) A Net revenue A \$ 421 A A A Cost of revenues A A 507 A Research and development A A 702 A Sales and marketing A A 498 A General and administrative A A 329 A Loss from impairment of held for sale assets A A 1,311 A Net loss from discontinued operations A \$ (2,926) A The following table summarizes cash used related to the discontinued operations of Razor: A A Nine Months Ended September 30, 2023 A A (In thousands) A CASH FLOWS FROM OPERATING ACTIVITIES: A A A Net cash used in operating activities A \$ (2,985) A A A CASH FLOWS FROM INVESTING ACTIVITIES: A A A Net cash used in investing activities A \$ (1,372) X - Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Definition Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 3 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-3AReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4AReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5AReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5D -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5DReference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3AReference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-3 + Details Name: us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 37 R30.htm IDEA: XBRL DOCUMENT v3.24.3 Organization and Description of the Business (Details Narrative) - USD (\$) 3 Months Ended 9 Months Ended Oct. 04, 2024 Aug. 09, 2024 Aug. 09, 2024 Aug. 01, 2024 Apr. 15, 2024 Feb. 16, 2023 Dec. 30, 2024 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Feb. 23, 2021 Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] A A A A A Accumulated deficit A A A A A \$ 317,028,000 \$ 317,028,000 \$ 262,095,000 \$ 289,876,000 A Cash and cash equivalents A A A A A \$ 3,363,000 \$ 3,363,000 A \$ 9,432,000 A Common stock shares issued A A A A A \$ 17,000,17,000 A A A Maximum amount of stock and warrants offered under shelf registration A A \$ 100,000,000 A A A A A A Proceeds from issuance of common stock A A A A A A 15,807,000 \$ 13,848,000 A A Subsequent Event [Member] A A A A A A A Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] A A A A A A A Proceeds from private placement \$ 10,200,000 A A A A A A A Net proceeds from issuance of private placement 9,400,000 A A A A A A A Other expenses 795,000 A A A A A A A Private Placement [Member] A A A A A A A Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] A A A A A A A Proceeds from private placement A A \$ 9,900,000 A A A A A A Securities Purchase Agreement [Member] | Subsequent Event [Member] A A A A A A A Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] A A A A A A A Proceeds from private placement 10,200,000 A A A A A A A Net proceeds from issuance of private placement 9,400,000 A A A A A A A Other expenses \$ 795,000 A A A A A A A Securities Purchase Agreement [Member] | Series A Redeemable Convertible Preferred Stock [Member] A A A A A A A Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] A A A A A A A A Offering expenses A A A 538,000 A A A A A Value of redeemed shares A A \$ 5,400,000 A A A A A A Sales Agreement [Member] A A A A A A A Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] A A A A A A A Common stock shares issued A \$ 7,500,000 A A A A A A A Proceeds from issuance of common stock A A A A A A \$ 17,000 A A A A Razor Genomics, Inc. [Member] A A A A A A A Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] A A A A A A A A Equity interest A A A A A A A 25.00% Razor Genomics, Inc. [Member] | Razor Stock Purchase Agreement [Member] A A A A A A A A Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] A A A A A A A A Equity interest A A A A A A A 30.00% A A A A Number of shares issued A A A 1,366,364 A A A A Razor Genomics, Inc. [Member] | Razor Stock Purchase Agreement [Member] | Dragon Scientific LLC [Member] A A A A A A A A Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] A A A A A A A A Equity interest A A A 70.00% 70.00% A A A A Number of shares issued A A A A 3,188,181 A A A X - DefinitionMaximum amount of stock and warrants offered under shelf registration. + ReferencesNo definition available. + Details Name: ocx_MaximumAmountOfStockAndWarrantsOfferedUnderShelfRegistration Namespace Prefix: ocx_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionNet proceeds from issuance of private placement used for general corporate purposes and working capital. + ReferencesNo definition available. + Details Name: ocx_NetProceedsFromIssuanceOfPrivatePlacementUsedForGeneralCorporatePurposesAndWorkingCapital Namespace Prefix: ocx_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 + Details Name: us-gaap_EquityMethodInvestmentOwnershipPercentage Namespace Prefix: us-gaap_Data Type: dtr-types:percentItem Type Balance Type: na Period Type: instant X - DefinitionAmount of expense classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherExpenses Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionThe cumulative amount of offering costs allocated to the preferred partners. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 4.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-5 + Details Name: us-gaap_PreferredUnitsOfferingCosts Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from entity's raising of capital via private rather than public placement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfPrivatePlacement Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionEquity impact of the value of stock bought back by the entity at the exercise price or redemption price. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 + Details Name: us-gaap_StockRedeemedOrCalledDuringPeriodValue Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - Details Name: us-gaap_SubsequentEventItemTypeAxis-us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period

Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=ocx_SecuritiesPurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=ocx_SeriesARedeemableConvertiblePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=ocx_SalesAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ocx_RazorGenomicIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=ocx_RazorStockPurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ocx_DragonScientificLLCMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 38 R31.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies - Schedule of Prior Period Revisions (Details) - USD (\$) in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2023 Sep. 30, 2023 Dec. 31, 2023 Accounts receivable, net \$ 593 \$ 209 \$ 593 \$ 484 Accumulated deficit (262,095) (\$17,028) (262,095) \$ (289,876) Total Shareholders equity 42,181 Å 32,873 Å Loss on disposal of discontinued operations Å 1,521 Å Net cash used in operating activities Å (15,359) (18,901) Å Cash sold in discontinued operations (Note 11) Å (1,372) Å Net cash used in investing activities Å \$ (302) (1,035) Å Previously Reported [Member] Å Å Å Accounts receivable, net 2,012 Å 2,012 Å Accumulated deficit (260,676) Å (260,676) Å Total Shareholders equity Å Å 34,292 Å Loss on disposal of discontinued operations Å 1,659 Å Net cash used in operating activities Å (18,763) Å Cash sold in discontinued operations (Note 11) Å Å (1,510) Å Net cash used in investing activities Å Å (1,173) Å Revision of Prior Period, Reclassification, Adjustment [Member] Å Å Å Accounts receivable, net (1,419) Å (1,419) Å Accumulated deficit \$ (1,419) Å (1,419) Å Total Shareholders equity Å (1,419) Å Loss on disposal of discontinued operations Å (138) Å Net cash used in operating activities Å Å (138) Å Cash sold in discontinued operations (Note 11) Å 138 Å Net cash used in investing activities Å Å 138 Å X - DefinitionAdjusted stockholders' equity. + ReferencesNo definition available. + Details Name: ocx_AdjustedStockholdersEquity Namespace Prefix: ocx_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPayment for cash sold in discontinued operations. + ReferencesNo definition available. + Details Name: ocx_PaymentForCashSoldInDiscontinuedOperations Namespace Prefix: ocx_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: <http://www.xbrli.org/2009/role/commonPracticeRef-Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2> + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations. + ReferencesReference 1: [http://www.xbrli.org/2009/role/commonPracticeRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://www.xbrli.org/2009/role/commonPracticeRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)Reference 2: [http://www.xbrli.org/2003/role/disclosureRef-Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3](http://www.xbrli.org/2003/role/disclosureRef-Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3)Reference 3: <http://www.xbrli.org/2009/role/commonPracticeRef-Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-5> + Details Name: us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: <http://www.xbrli.org/2003/role/disclosureRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24> + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25> + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SX 210.5-02/30\)\(a\)\(3\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.5-02/30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1)Reference 2: <http://www.xbrli.org/2003/role/exampleRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 3: [http://www.xbrli.org/2003/role/disclosureRef-Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2)Reference 4: [http://www.xbrli.org/2003/role/disclosureRef-Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(h\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2)Reference 5: <http://www.xbrli.org/2003/role/disclosureRef-Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11>Reference 6: [http://www.xbrli.org/2003/role/disclosureRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(23\)\(a\)\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-599-1](http://www.xbrli.org/2003/role/disclosureRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-599-1)Reference 7: [http://www.xbrli.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SX 210.6-04\(17\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-599-1](http://www.xbrli.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-599-1)Reference 8: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SX 210.3-04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-599-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-599-1) + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 39 R32.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies - Schedule of Disaggregation of Revenue (Details) - USD (\$) in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Revenues by service \$ 115 \$ 429 \$ 395 \$ 1,189 Pharma Services [Member] Å Å Å Revenues by service 115 423 373 1,160 Laboratory Developed Test Services [Member] Å Å Å Revenues by service \$ 6 \$ 22 \$ 29 X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: [http://www.xbrli.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41](http://www.xbrli.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41)Reference 2: [http://www.xbrli.org/2003/role/disclosureRef-Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrli.org/2003/role/disclosureRef-Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1)Reference 3: [http://www.xbrli.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(ee\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrli.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 4: [http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 5: [http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 6: [http://www.xbrli.org/2003/role/disclosureRef-Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SAB Topic 11.L\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-599-1](http://www.xbrli.org/2003/role/disclosureRef-Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-599-1)Reference 7: <http://www.xbrli.org/2003/role/disclosureRef-Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5>Reference 8: [http://www.xbrli.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrli.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30)Reference 9: <http://www.xbrli.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42>Reference 10: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21)Reference 11: <http://www.xbrli.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40>Reference 12: [http://www.xbrli.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrli.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22)Reference 13: [http://www.xbrli.org/2003/role/disclosureRef-Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4](http://www.xbrli.org/2003/role/disclosureRef-Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4) + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=ocx_LaboratoryDevelopedTestServicesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=ocx_LaboratoryDevelopedTestServicesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 40 R33.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies - Schedule of Concentration of Risk (Details) - Revenue Benchmark [Member] - Product Concentration Risk [Member] 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Product Information [Line Items] Å Å Å Percentage of revenues 100.00% 100.00% 100.00% 100.00% Pharma Services [Member] Å Å Å Product Information [Line Items] Å Å Å Percentage of revenues 100.00% 99.00% 94.00% 98.00% Laboratory Developed Test Services [Member] Å Å Å Product Information [Line Items] Å Å Å Percentage of revenues 0.00% 1.00% 6.00% 2.00% X - DefinitionFor an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + ReferencesReference 1: <http://www.xbrli.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21)Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20> + Details Name: us-gaap_ConcentrationRiskPercentage1 Namespace Prefix: us-gaap_Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ProductInformationLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=ocx_PharmaServicesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=ocx_LaboratoryDevelopedTestServicesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 41 R34.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies - Schedule of Consolidated Revenues Generated by Unaffiliated Customers (Details) - Revenue Benchmark [Member] - Customer Concentration Risk [Member] 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Pharma Services Company A [Member] Å Å Å Product Information [Line Items] Å Å Å Percentage of consolidated revenues 74.00% 57.00% 37.00% 42.00% Pharma Services Company B [Member] Å Å Å Product Information [Line Items] Å Å Å Percentage of consolidated revenues 26.00% 41.00% 29.00% 34.00% Pharma Services Company C [Member] Å Å Å Product Information [Line Items] Å Å Å Percentage of consolidated revenues Å Å 12.00% Å Pharma Services Company D [Member] Å Å Å Product Information [Line Items] Å Å Å Percentage of consolidated revenues Å Å 11.00% Å X - DefinitionFor an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + ReferencesReference 1: <http://www.xbrli.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 50 -Paragraph 42 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 50 -Paragraph 42 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21)Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20> + Details Name: us-gaap_ConcentrationRiskPercentage1 Namespace Prefix: us-gaap_Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ProductInformationLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=ocx_PharmaServicesCompanyBMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=ocx_PharmaServicesCompanyCMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=ocx_PharmaServicesCompanyDMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 42 R35.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies - Schedule of Percentage of Consolidated Revenues Attributable to Geographical Locations (Details) - Revenue Benchmark [Member] - Product Concentration Risk [Member] 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Product Information [Line Items] Å Å Å Percentage of revenues 100.00% 100.00% 99.00% 94.00% 98.00% Laboratory Developed Test Services [Member] Å Å Å Product Information [Line Items] Å Å Å Percentage of revenues 0.00% 1.00% 6.00% 2.00% UNITED STATES | Pharma Services [Member] Å Å Å Product Information [Line Items] Å Å Å Percentage of revenues 100.00% 42.00% 46.00% 54.00% UNITED STATES | Laboratory Developed Test Services [Member] Å Å Å Product Information [Line Items] Å Å Å Percentage of revenues 0.00% 1.00% 6.00% 4.00% Outside Of United States [Member] | Pharma Services [Member] Å Å Å Product Information [Line Items] Å Å Å

À Percentage of revenues 0.00% 57.00% 48.00% 42.00% X - DefinitionFor an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21)Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20> + Details Name: us-gaap_ConcentrationRiskPercentage1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ProductInformationLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=ocx_PharmaServicesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=ocx_LaboratoryDevelopedTestServicesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_US Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=ocx_OutsideOfUnitedStatesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 43 R36.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies - Schedule of Common Stock Computation of Diluted Net Loss Per Share of Common Stock (Details) - USD (\$) / \$ / shares in Units, shares in Thousands, \$ in Thousands 3 Months Ended 9 Months Ended Sep 30, 2023 Sep 30, 2024 Sep 30, 2023 Sep 30, 2024 Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] À À À À Loss from continuing operations \$ (13,493) \$ (6,489) \$ (27,152) \$ (8,863) Accretion of Series A redeemable convertible preferred stock (198) (263) (621) Deemed dividend on Series A redeemable convertible preferred stock (118) Net (loss) income from continuing operations - basic (13,493) (6,687) (27,415) (9,602) Net (loss) income from continuing operations - diluted (13,493) (6,687) (27,415) (9,602) Loss from discontinued operations (2,926) Net loss from discontinued operations - basic (2,926) Net loss from discontinued operations - diluted (2,926) Net loss (13,493) (6,489) (27,152) (11,789) Accretion of Series A redeemable convertible preferred stock (198) (263) (621) Net loss attributable to common stockholders - basic (13,493) (6,687) (27,415) (12,528) Net loss attributable to common stockholders - diluted \$ (13,493) \$ (6,687) \$ (27,415) \$ (12,528) Weighted average shares outstanding - basic 13,714 8,256 11,624 7,446 Weighted average shares outstanding - diluted 13,714 8,256 11,624 7,446 Net (loss) income from continuing operations per share - basic (0.98) (0.81) (2.36) (1.29) Net (loss) income from continuing operations per share - diluted (0.98) (0.81) (2.36) (1.29) Net loss from discontinued operations per share - basic (0.39) Net loss from discontinued operations per share - diluted (0.39) Net loss attributable to common stockholders per share - basic (0.98) (0.81) (2.36) (1.68) Net loss attributable to common stockholders per share - diluted \$ (0.98) \$ (0.81) \$ (2.36) \$ (1.68) Total 1,616 1,331 1,616 1,331 Equity Option [Member] À À À À Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] À À À À Total 855 501 855 501 Restricted Stock Units (RSUs) [Member] À À À À Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] À À À À Total 5 Warrant [Member] À À À À Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] À À À À Total 761 820 761 820 Series A Redeemable Convertible Preferred Stock [Member] À À À À Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] À À À À Total 5 X - DefinitionAccretion of redeemable convertible preferred stock. + ReferencesNo definition available. + Details Name: ocx_AccretionOfRedeemableConvertiblePreferredStock Namespace Prefix: ocx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDeemed dividend on Series A redeemable convertible preferred stock. + ReferencesNo definition available. + Details Name: ocx_DeemedDividendOnSeriesRedeemableConvertiblePreferredStock Namespace Prefix: ocx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAccretion of Series A convertible preferred stock to redemption value. + ReferencesNo definition available. + Details Name: ocx_StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue Namespace Prefix: ocx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1) + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemtype Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemtype Balance Type: na Period Type: duration X - DefinitionAmount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(12\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3A>Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B)Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3B>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4>Reference 6: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1)Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3>Reference 8: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(14\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2) + Details Name: us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemtype Balance Type: credit Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)Reference 5: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15>Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(e\)\(4\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 12: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2>Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B)Reference 14: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 16: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10>Reference 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(25\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(27\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(23\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 20: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7> + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemtype Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)Reference 5: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15>Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(e\)\(4\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 12: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2>Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B)Reference 14: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(25\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(27\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1)Reference 18:

[Section 50 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 32 - Subparagraph \(ee\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6:](#)

[http://www.xbrl.org/2009/role/commonPracticeRef - Topic 280 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 32 - Subparagraph \(c\) - Publisher](#)

[FASB - URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8:](#)

[http://www.xbrl.org/2003/role/disclosureRef - Topic 944 - SubTopic 220 - Name Accounting Standards Codification](#)

[- Section S99 - Paragraph 1 - Subparagraph \(SX 210.7-04\(1\)\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9:](#)

[http://www.xbrl.org/2003/role/exampleRef - Topic 280 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 31 - Publisher FASB - URI](#)

[https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 10:](#)

[http://www.xbrl.org/2003/role/disclosureRef - Topic 942 - SubTopic 235 - Name Accounting Standards Codification - Section](#)

[S99 - Paragraph 1 - Subparagraph \(SX 210.9-05\(b\)\(2\)\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 11:](#)

[http://fasb.org/us-gaap/role/ref/legacyRef - Topic 220 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 2 - Subparagraph \(SX 210.5-03\(10\)\) - Publisher FASB - URI](#)

[https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12:](#)

[http://fasb.org/us-gaap/role/ref/legacyRef - Topic 942 - SubTopic 220 - Name Accounting Standards Codification - Section S99](#)

[- Paragraph 1 - Subparagraph \(SX 210.9-04\(15\)\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-](#)

[gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterests Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit](#)

[Period Type: duration X - DefinitionThe amount of net income \(loss\) from continuing operations per each share of common stock or unit outstanding during the reporting period. +](#)

[ReferencesReference 1:](#)

[http://www.xbrl.org/2003/role/disclosureRef - Topic 250 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 6 - Publisher FASB - URI](#)

[https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2:](#)

[http://www.xbrl.org/2003/role/disclosureRef - Topic 805 - SubTopic 60 - Name Accounting Standards Codification - Section 65 -](#)

[Paragraph 1 - Subparagraph \(g\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3:](#)

[http://www.xbrl.org/2003/role/disclosureRef - Topic 740 - SubTopic 323 -](#)

[Name Accounting Standards Codification - Section 65 - Paragraph 2 - Subparagraph \(g\)\(3\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 4:](#)

[http://fasb.org/us-gaap/role/ref/legacyRef - Topic 220 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 2 - Subparagraph \(SX 210.5-03\(13\)\) - Publisher FASB - URI](#)

[https://asc.fasb.org/1943274/21474783621/220-10-S99-2Reference 5:](#)

[http://www.xbrl.org/2003/role/disclosureRef - Topic 250 - SubTopic 10 - Name Accounting Standards Codification - Section 50 -](#)

[Paragraph 3 - Publisher FASB - URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6:](#)

[http://www.xbrl.org/2003/role/disclosureRef - Topic 250 - SubTopic 10 - Name Accounting](#)

[Standards Codification - Section 50 - Paragraph 1 - Subparagraph \(b\)\(2\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 7:](#)

[http://www.xbrl.org/2003/role/disclosureRef - Topic 815 - SubTopic 40 - Name Accounting Standards Codification - Section 65 - Paragraph 1 - Subparagraph \(f\) - Publisher FASB - URI](#)

[https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8:](#)

[http://www.xbrl.org/2003/role/disclosureRef - Topic 250 - SubTopic 10 - Name Accounting Standards Codification - Section 50 -](#)

[Paragraph 11 - Subparagraph \(a\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 9:](#)

[http://www.xbrl.org/2003/role/disclosureRef - Topic 250 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 11 - Subparagraph \(b\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10:](#)

[http://www.xbrl.org/2003/role/disclosureRef - Topic 260 - SubTopic 10 - Name Accounting Standards Codification - Section 45 - Paragraph 2 - Publisher FASB - URI](#)

[https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 11:](#)

[http://www.xbrl.org/2003/role/disclosureRef - Topic 260 - SubTopic 10 - Name Accounting Standards Codification - Section 45 -](#)

[Paragraph 60B - Subparagraph \(d\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 12:](#)

[http://www.xbrl.org/2003/role/disclosureRef - Topic 250 -](#)

[SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 4 - Publisher FASB - URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 13:](#)

[http://www.xbrl.org/2009/role/commonPracticeRef - Topic 944 - SubTopic 220 - Name Accounting Standards Codification - Section S99 - Paragraph 1 - Subparagraph \(SX 210.7-04\(23\)\) - Publisher](#)

[FASB - URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 14:](#)

[http://www.xbrl.org/2003/role/disclosureRef - Topic 220 - SubTopic 10 - Name Accounting Standards](#)

[Codification - Section S99 - Paragraph 2 - Subparagraph \(SX 210.5-03\(25\)\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 15:](#)

[http://www.xbrl.org/2003/role/disclosureRef - Topic 942 - SubTopic 220 - Name Accounting Standards Codification - Section S99 - Paragraph 1 - Subparagraph \(SX 210.9-04\(27\)\) - Publisher FASB -](#)

[URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 16:](#)

[http://www.xbrl.org/2003/role/disclosureRef - Topic 260 - SubTopic 10 - Name Accounting Standards Codification -](#)

[Section 45 - Paragraph 7 - Publisher FASB - URI https://asc.fasb.org/1943274/2147482689/260-10-45-7Reference 17:](#)

[http://fasb.org/us-gaap/role/ref/legacyRef - Topic 942 - SubTopic 220 - Name](#)

[Accounting Standards Codification - Section S99 - Paragraph 1 - Subparagraph \(SX 210.9-04\(20\)\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name:](#)

[us-gaap IncomeLossFromContinuingOperationsPerBasicShare Namespace Prefix: us-gaap Data Type: dt-types:perShareItemBalanceType na Period Type: duration X - DefinitionThe](#)

[amount of net income \(loss\) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each](#)

[share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. +](#)

[ReferencesReference 1:](#)

[http://www.xbrl.org/2003/role/disclosureRef - Topic 250 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 6 - Publisher FASB - URI](#)

[https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2:](#)

[http://www.xbrl.org/2003/role/disclosureRef - Topic 805 - SubTopic 60 - Name Accounting Standards Codification - Section 65 -](#)

[Paragraph 1 - Subparagraph \(g\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3:](#)

[http://fasb.org/us-gaap/role/ref/legacyRef - Topic 220 - SubTopic 10 -](#)

[Name Accounting Standards Codification - Section S99 - Paragraph 2 - Subparagraph \(SX 210.5-03\(13\)\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 4:](#)

[http://www.xbrl.org/2003/role/disclosureRef - Topic 250 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 3 - Publisher FASB - URI](#)

[https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 5:](#)

[http://www.xbrl.org/2003/role/disclosureRef - Topic 250 - SubTopic 10 - Name Accounting Standards Codification - Section 50 -](#)

[Paragraph 1 - Subparagraph \(b\)\(2\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 6:](#)

[http://www.xbrl.org/2003/role/disclosureRef - Topic 815 - SubTopic 40 -](#)

[Name Accounting Standards Codification - Section 65 - Paragraph 1 - Subparagraph \(f\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 7:](#)

[http://www.xbrl.org/2003/role/disclosureRef - Topic 250 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 11 - Subparagraph \(a\) - Publisher FASB - URI](#)

[https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 8:](#)

[http://www.xbrl.org/2003/role/disclosureRef - Topic 250 - SubTopic 10 - Name Accounting Standards Codification - Section 50 -](#)

[Paragraph 11 - Subparagraph \(b\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147483443/250-10-50-](#)

[http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Supparaph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Supparaph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Supparaph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34:](#) [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37:](#) [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(22\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap NetIncomeLoss Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income \(loss\) available to common shareholders. + ReferencesReference 1:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 2:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 3:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 4:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 5:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 6:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph \(SAB Topic 6.B\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 7:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 8:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 9:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11Reference 10:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B + Details Name: us-gaap NetIncomeLossAvailableToCommonStockholdersBasic Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income \(loss\) available to common shareholders. + ReferencesReference 1:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph \(SAB Topic 6.B\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 2:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16Reference 4:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph \(b\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 5:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 6:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 7:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph \(b\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 8:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph \(b\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40 + Details Name: us-gaap NetIncomeLossAvailableToCommonStockholdersDiluted Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income \(loss\) from continuing operations available to common shareholders. + ReferencesReference 1:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16Reference 3:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph \(b\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 4:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph \(b\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 5:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph \(b\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40 + Details Name: us-gaap NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income \(loss\) from continuing operations available to common shareholders. + ReferencesReference 1:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16Reference 3:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph \(b\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/21474826](#)

Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1 + Details Name: us-gaap_AdvertisingExpense Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of allowance for credit loss on accounts receivable. + ReferencesReference 1:

Paragraph 1 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6 + Details Name: us-gaap_BusinessCombinationContingentConsiderationLiability Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_BusinessAcquisitionAxis=ocx_InsigntGeneticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ContingentConsiderationByTypeAxis=ocx_MilestoneOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ContingentConsiderationByTypeAxis=ocx_MilestoneTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ContingentConsiderationByTypeAxis=ocx_MilestoneThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ContingentConsiderationByTypeAxis=ocx_RoyaltyOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ContingentConsiderationByTypeAxis=ocx_RoyaltyTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: IDEA: XBRL DOCUMENT v3.24.3 Business Combinations and Contingent Consideration Liabilities - Schedule of Contingent Consideration, Measured at Fair Value (Details) - USD (\$) \$ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Business Acquisition [Line Items] Á Á Á Balance Á Á \$ 39,507 Á Change in estimated fair value \$ 7,140 \$ (435) 9,421 \$ (16,947) Balance 48,707 Á 48,707 Á Fair Value, Inputs, Level 3 [Member] | Insight Genetics Inc [Member] Á Á Á Business Acquisition [Line Items] Á Á Á Balance Á Á 2,040 5,370 Change in estimated fair value Á Á 30 (3,080) Balance 2,070 2,290 2,070 2,290 Fair Value, Inputs, Level 3 [Member] | Chronix Merger [Member] Á Á Á Business Acquisition [Line Items] Á Á Á Balance Á Á 37,860 40,292 Change in estimated fair value Á Á 9,391 (13,867) Balance \$ 47,251 \$ 26,425 \$ 47,251 \$ 26,425 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5 + Details Name: us-gaap_BusinessAcquisitionLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4 + Details Name: us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6 + Details Name: us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=ocx_InsigntGeneticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=ocx_ChronixMergerMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 47 R40.htm IDEA: XBRL DOCUMENT v3.24.3 Business Combinations and Contingent Consideration Liabilities - Additional Information (Details) 9 Months Ended Feb. 08, 2023 Sep. 30, 2024 USD (\$) Sep. 30, 2023 Business Acquisition [Line Items] Á Á Á Fair value Á \$ 30,000 Á Chronix [Member] Á Á Á Business Acquisition [Line Items] Á Á Á Fair value Á \$ 9,400,000 Á Merger Agreement [Member] | Chronix Equity [Member] Á Á Á Business Acquisition [Line Items] Á Á Á Earnout percentage on collections for sales 10.00% Á Á Gross proceeds percentage 5.00% Á Á Insight Genetics Inc [Member] | Maximum [Member] | Discount rate [Member] | Level 3 [Member] Á Á Á Business Acquisition [Line Items] Á Á Á Business combination, contingent consideration, liability, measurement input Á 0.135 0.154 Insight Genetics Inc [Member] | Maximum [Member] | Management probability estimate [Member] | Level 3 [Member] Á Á Á Business Acquisition [Line Items] Á Á Á Business combination, contingent consideration, liability, measurement input Á 0.50 0.50 Insight Genetics Inc [Member] | Maximum [Member] | Expected term [Member] | Level 3 [Member] Á Á Á Business Acquisition [Line Items] Á Á Á Business combination, contingent consideration, liability, milestone payment Á 8 years 1 year 6 months Insight Genetics Inc [Member] | Minimum [Member] | Discount rate [Member] | Level 3 [Member] Á Á Á Business Acquisition [Line Items] Á Á Á Business combination, contingent consideration, liability, measurement input Á 0.133 0.152 Insight Genetics Inc [Member] | Minimum [Member] | Management probability estimate [Member] | Level 3 [Member] Á Á Á Business Acquisition [Line Items] Á Á Á Business combination, contingent consideration, liability, measurement input Á 0.25 0.15 Insight Genetics Inc [Member] | Minimum [Member] | Expected term [Member] | Level 3 [Member] Á Á Á Business Acquisition [Line Items] Á Á Á Business combination, contingent consideration, liability, milestone payment Á 1 year 8 months 12 days 6 months Insight Genetics Inc [Member] | Valuation Technique, Discounted Cash Flow [Member] Á Á Á Business Acquisition [Line Items] Á Á Á Unobservable Measurement Input, Uncertainty, Description Á The significant unobservable inputs used in Insightâ€™s contingent consideration valuation on September 30, 2024, included: (i) a discount period, based on the expected Milestone payment dates, ranging from 1.7 years to 8.0 years, (ii) a discount rate of 13.3% to 13.5%, and (iii) a management probability estimate of 25% to 50%. The significant unobservable inputs used in Insightâ€™s contingent consideration valuation on September 30, 2023, included: (i) a discount period, based on the expected Milestone payment dates, ranging from 0.50 years to 1.5 years, (ii) a discount rate of 15.2% to 15.4%, and (iii) a management probability estimate of 15% to 50%. Á Chronix Merger [Member] | Level 3 [Member] Á Á Á Business Acquisition [Line Items] Á Á Á Payout percentage Á 10.00% 10.00% Chronix Merger [Member] | Maximum [Member] | Discount rate [Member] | Level 3 [Member] Á Á Á Business Acquisition [Line Items] Á Á Á Business combination, contingent consideration, liability, measurement input Á 0.143 0.164 Chronix Merger [Member] | Maximum [Member] | Expected term [Member] | Level 3 [Member] Á Á Á Business Acquisition [Line Items] Á Á Á Business combination, contingent consideration, liability, related patent expiration range term Á 11 years 12 years 2 months 12 days Chronix Merger [Member] | Minimum [Member] | Discount rate [Member] | Level 3 [Member] Á Á Á Business Acquisition [Line Items] Á Á Á Business combination, contingent consideration, liability, measurement input Á 0.133 0.155 Chronix Merger [Member] | Minimum [Member] | Expected term [Member] | Level 3 [Member] Á Á Á Business Acquisition [Line Items] Á Á Á Business combination, contingent consideration, liability, related patent expiration range term Á 9 years 1 month 6 days 10 years 4 months 24 days Chronix Merger [Member] | Valuation Technique, Discounted Cash Flow [Member] Á Á Á Business Acquisition [Line Items] Á Á Á Unobservable Measurement Input, Uncertainty, Description Á The significant unobservable inputs used in Chronixâ€™s contingent consideration valuation on September 30, 2024, included: (i) a discount period, based on the related patent expiration dates, ranging from 9.1 years to 11.0 years, (ii) a discount rate of 13.3% to 14.3%, and (iii) a payout percentage of 10% based on the earnout provision. The significant unobservable inputs used in Chronixâ€™s contingent consideration valuation on September 30, 2023, included: (i) a discount period, based on the related patent expiration dates, ranging from 10.4 years to 12.2 years, (ii) a discount rate of 15.5% to 16.4%, and (iii) a payout percentage of 10% based on the earnout provision. Á X - DefinitionBusiness combination, contingent consideration, liability, milestone payment. + ReferencesNo definition available. + Details Name: ocx_BusinessCombinationContingentConsiderationLiabilityMilestonePayment Namespace Prefix: ocx_Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionBusiness combination, contingent consideration, liability, payout percentage + ReferencesNo definition available. + Details Name: ocx_BusinessCombinationContingentConsiderationLiabilityPayoutPercentage Namespace Prefix: ocx_Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionBusiness combination, contingent consideration, liability, related patent expiration range term. + ReferencesNo definition available. + Details Name: ocx_BusinessCombinationContingentConsiderationLiabilityRelatedPatentExpirationRangeTerm Namespace Prefix: ocx_Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionEarnout percentage on collections for sale. + ReferencesNo definition available. + Details Name: ocx_EarnoutPercentageOnCollectionsForSale Namespace Prefix: ocx_Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionEarnout percentage on collections for sales. + ReferencesNo definition available. + Details Name: ocx_EarnoutPercentageOnCollectionsForSales Namespace Prefix: ocx_Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionFair value of contingent consideration. + ReferencesNo definition available. + Details Name: ocx_FairValueOfContingentConsideration Namespace Prefix: ocx_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5 + Details Name: us-gaap_BusinessAcquisitionLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionValue of input used to measure contingent consideration liability from business combination. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput Namespace Prefix: us-gaap_Data Type: xbrli:decimalItemType Balance Type: na Period Type: instant X - DefinitionDescription of uncertainty of fair value measurement from use of unobservable input, including, but not limited to, inter-relationships among inputs used in fair value measurement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementsSensitivityAnalysisDescription Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: dei_LegalEntityAxis=ocx_ChronixMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=ocx_MergerAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=ocx_ChronixEquityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=ocx_InsigntGeneticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=ocx_MeasurementInputManagementProbabilityEstimateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=ocx_ChronixMergerMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 48 R41.htm IDEA: XBRL DOCUMENT v3.24.3 Property and Equipment - Schedule of Right-of-use and Financing Lease Assets, Machinery and Equipment, Net, and Construction in Progress (Details) - USD (\$) \$ in Thousands Sep. 30, 2024 Dec. 31, 2023 Property, Plant and Equipment [Abstract] Á Á Right-of-use and financing lease assets \$ 5,323 \$ 4,036 Machinery, equipment and leasehold improvements 7,923 6,909 Accumulated depreciation and amortization (7,053) (6,235) Right-of-use and financing lease assets and machinery and equipment, net 6,193 4,710 Construction in progress 302 726 Total \$ 6,495 \$ 5,436 X - DefinitionRight-of-use and financing lease assets. + ReferencesNo definition available. + Details Name: ocx_RightOfUseAndFinancingLeaseAssets Namespace Prefix: ocx_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRight of use assets machinery and equipment continuing operations. + ReferencesNo definition available. + Details Name: ocx_RightOfUseAssetsMachineryAndEquipmentContinuingOperations Namespace Prefix: ocx_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_ConstructionInProgressGross Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_MachineryAndEquipmentGross Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 49 R42.htm IDEA: XBRL DOCUMENT v3.24.3 Property and Equipment (Details Narrative) 3 Months Ended 9 Months Ended Sep. 30, 2024 USD (\$) Sep.

30, 2023 USD (\$) Sep. 30, 2024 USD (\$) Sep. 30, 2023 USD (\$) Fair Value Measurement Inputs and Valuation Techniques [Line Items] $\text{\$ 318,000}$ $\text{\$ 404,000}$ $\text{\$ 935,000}$ $\text{\$ 1,289,000}$ Impairment of leasehold $\text{\$ 1,800,000}$ $\text{\$ 4}$ Derivative assets liabilities at fair value net $\text{\$ 1,200,000}$ $\text{\$ 1,200,000}$ Measurement Input, Discount Rate [Member] $\text{\$ 4}$ $\text{\$ 4}$ Fair Value Measurement Inputs and Valuation Techniques [Line Items] $\text{\$ 4}$ $\text{\$ 4}$ $\text{\$ 4}$ Derivative liability measurement input $\text{\$ 0.0725}$ $\text{\$ 0.0725}$ X - Definition The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(b\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 5 -SubTopic 10 -Topic 815 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480463/815-10-45-5](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap DepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments. + ReferencesReference 1: <a href=)Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(bbb\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(bbb\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(bbb\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2) + Details Name: us-gaap DerivativeAssetsLiabilitiesAtFairValueNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition Value of input used to measure derivative liability. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(bbb\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(bbb\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(bbb\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2) + Details Name: us-gaap DerivativeLiabilityMeasurementInput Namespace Prefix: us-gaap_ Data Type: xbrli:decimalItemType Balance Type: na Period Type: instant X - Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(bbb\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(bbb\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(bbb\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2) + Details Name: us-gaap FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The adjustment to reduce the value of existing agreements that specify the lessee's rights to use the leased property. This expense is charged when the estimates of future profits generated by the leased property are reduced. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(b\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4> + Details Name: us-gaap ImpairmentOfLeasehold Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap MeasurementInputTypeAxis=us-gaap MeasurementInputDiscountRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R43.htm IDEA: XBRL DOCUMENT v3.24.3 Schedule of Intangible Assets, Net (Details) - USD (\$) in Thousands 9 Months Ended Sep. 30, 2024 Dec. 31, 2023 Indefinite-Lived Intangible Assets [Line Items] $\text{\$ 4}$ $\text{\$ 4}$ Total intangible assets $\text{\$ 56,940}$ $\text{\$ 56,940}$ Intangible assets, net $\text{\$ 56,529}$ $\text{\$ 56,595}$ Customer Relationships [Member] $\text{\$ 4}$ $\text{\$ 4}$ Indefinite-Lived Intangible Assets [Line Items] $\text{\$ 4}$ $\text{\$ 4}$ Acquired intangible assets $\text{\$ 440}$ $\text{\$ 440}$ Finite-lived intangible assets, accumulated amortization [1] (411) (345) In Process Research and Development [Member] $\text{\$ 4}$ $\text{\$ 4}$ Indefinite-Lived Intangible Assets [Line Items] $\text{\$ 4}$ $\text{\$ 4}$ Intangible assets acquired [2] $\text{\$ 9,700}$ $\text{\$ 9,700}$ In Process Research and Development [Member] $\text{\$ 4}$ $\text{\$ 4}$ DeterminaCNI and VitaGraft [Member] $\text{\$ 4}$ $\text{\$ 4}$ Indefinite-Lived Intangible Assets [Line Items] $\text{\$ 4}$ $\text{\$ 4}$ Intangible assets acquired [3] $\text{\$ 46,800}$ $\text{\$ 46,800}$ [1] Amortization of intangible assets is included in $\text{\$ 4}$ $\text{\$ 4}$ Cost of revenues $\text{\$ 4}$ $\text{\$ 4}$ amortization of acquired intangibles $\text{\$ 4}$ $\text{\$ 4}$ on the consolidated statements of operations because the intangible assets pertain directly to the revenues generated from the acquired intangibles. [2] See Note 3 for information on the Insight Merger. [3] See Note 3 for information on the Chronix Merger. X - Definition Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-55-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-55-1>Reference 4: <http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 + Details Name: us-gaap IndefiniteLivedIntangibleAssetsByMajorClassLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition. + ReferencesReference 1: <a href=)Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2) + Details Name: us-gaap IndefinitelivedIntangibleAssetsAcquired Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Amount before accumulated amortization of intangible assets, excluding goodwill. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1 + Details Name: us-gaap IntangibleAssetsGrossExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definition Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: <a href=)Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2)Reference 3: [http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40](http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1 + Details Name: us-gaap IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap CustomerRelationshipsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap InProcessResearchAndDevelopmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei LegalEntityAxis=ocx DeterminaCNIAndVitaGraftMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R44.htm IDEA: XBRL DOCUMENT v3.24.3 Schedule of Intangible Assets Future Amortization Expense (Details) $\text{\$ 3}$ in Thousands Sep. 30, 2024 USD ($) Goodwill and Intangible Assets Disclosure [Abstract] $\text{\$ 2024}$ $\text{\$ 2025}$ $\text{\$ 2025}$ $\text{\$ 29}$ X - Definition Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: <a href=)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2)Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(b\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 52 R45.htm IDEA: XBRL DOCUMENT v3.24.3 Intangible Assets, Net (Details Narrative) - USD ($) 3 Months Ended Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2023 Impairment of intangible assets $\text{\$ 4}$ $\text{\$ 1,811,000}$ $\text{\$ 6,761,000}$ Intangible asset amortization expense $\text{\$ 22,000}$ $\text{\$ 22,000}$ $\text{\$ 66,000}$ $\text{\$ 66,000}$ MPEEM Valuation Approach [Member] $\text{\$ 4}$ $\text{\$ 4}$ $\text{\$ 4}$ Unobservable measurement input, uncertainty, description $\text{\$ 4}$ $\text{\$ 4}$ The significant unobservable inputs used as of March 31, 2023, included: (i) a discount period of 20.0 years, based on the expected life of patent, (ii) a royalty rate of 0.3%, and (iii) a weighted average cost of capital rate of 30.0%. This valuation approach yielded a fair value of $\text{\$ 9.7 million}$ as of March 31, 2023. As market conditions change, the Company will re-evaluate assumptions used in the determination of fair value for IP&R&D and is uncertain to the extent of the volatility in the unobservable inputs in the foreseeable future. $\text{\$ 4}$ Unobservable measurement input, discount period on expected life of patent 20 years $\text{\$ 4}$ $\text{\$ 4}$ $\text{\$ 4}$ Unobservable measurement input, royalty rate 0.30% $\text{\$ 4}$ $\text{\$ 4}$ $\text{\$ 4}$ Unobservable measurement input, weighted average cost of capital 30.00% $\text{\$ 4}$ $\text{\$ 4}$ $\text{\$ 4}$ Unobservable measurement input, valuation approach yielded fair value $\text{\$ 9,700,000}$ $\text{\$ 4}$ $\text{\$ 4}$ DeterminaIO [Member] $\text{\$ 4}$ $\text{\$ 4}$ $\text{\$ 4}$ Impairment of intangible assets $\text{\$ 4}$ $\text{\$ 5,000,000}$ $\text{\$ 4}$ $\text{\$ 4}$ X - Definition Discount Period On Expected Life Of Patent + ReferencesNo definition available. + Details Name: ocx DiscountPeriodOnExpectedLifeOfPatent Namespace Prefix: ocx_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Definition Unobservable Inputs Of Royalty Rate + ReferencesNo definition available. + Details Name: ocx UnobservableInputsOfRoyaltyRate Namespace Prefix: ocx_ Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - Definition Valuation Approach Yielded Fair Value + ReferencesNo definition available. + Details Name: ocx ValuationApproachYieldedFairValue Namespace Prefix: ocx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Definition Weighted Average Cost of Capital + ReferencesNo definition available. + Details Name: ocx WeightedAverageCostOfCapital Namespace Prefix: ocx_ Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - Definition The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: <a href=)Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2)Reference 4: <http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2>Reference 2:

[http://www.xbrl.org/2009/role/commonPracticeRef-Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-3-Reference 3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-3-Reference 3):

Description [Line Items] Â Â Total operating lease liabilities \$ 2,835 Â Machinery and equipment, net 3,001 \$ 1,637 Total financing lease liabilities 1,017 Â Operating and Financing Leases [Member] Â Â Lessee, Lease, Description [Line Items] Â Â Right-of-use assets, net 1,931 1,637 Right-of-use lease liabilities, current 882 628 Right-of-use lease liabilities, noncurrent 1,953 2,102 Total operating lease liabilities 2,835 2,730 Machinery and equipment 1,673 537 Accumulated depreciation (603) (537) Machinery and equipment, net 1,070 Current liabilities 364 Noncurrent liabilities 653 Total financing lease liabilities \$ 1,017 Weighted average remaining lease term, Operating lease 2 years 10 months 24 days 3 years 8 months 12 days Weighted average remaining lease term, Financing lease 2 years 7 months 6 days Â Weighted average discount rate, Operating lease 10.42% 11.31% Weighted average discount rate, Financing lease 10.27% Â X - DefinitionPresent value of lessee's discounted obligation for lease payments from finance lease. + ReferencesReference 1: <http://www.xbrli.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6>Reference 2: [Reference 2: \[Reference 2:\]\(http://www.xbrli.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(g\)\(4\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_Data Type: dtr-types:percentItem Type Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term for finance lease, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrli.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_Data Type: dtr-types:percentItem Type Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrli.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 2: <a href=\)](http://www.xbrli.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseLiability Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from finance lease, classified as current. + ReferencesReference 1: http://www.xbrli.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrli.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount, after accumulated amortization, of right-of-use asset from finance lease. + ReferencesReference 1: http://www.xbrli.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated amortization of right-of-use asset from finance lease. + ReferencesReference 1: http://www.xbrli.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4Reference 2: <a href=)

[illegible]

-Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-13>Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(h\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(27\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 13: <http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-03\(i\)\(2\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-03\(i\)\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-03\(i\)\(2\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-03\(i\)\(2\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3) + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3> + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionNumber of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3> + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionFace amount per share of no-par value common stock. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap_CommonStockNoParValue Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(16\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1) + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.6-05\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2)Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(4\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(16\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1)Reference 6: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(7\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3) + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionA unique description of a noncash or part noncash stock conversion. The description would be expected to include sufficient information to provide an understanding of the nature and purpose of the conversion. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5> + Details Name: us-gaap_ConversionOfStockDescription Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionDescription of conversion terms for preferred stock. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(27\)\) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3)Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6>Reference 6: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7> + Details Name: us-gaap_ConvertiblePreferredStockTermsOfConversion Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionAmount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2>Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1>Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D) + Details Name: us-gaap_DeferredFinanceCostsNet Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionAmount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.3-04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1)Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -SubTopic 405 -Topic 942 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477787/942-405-45-2> + Details Name: us-gaap_Dividends Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionThe percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3) + Details Name: us-gaap_EquityMethodInvestmentOwnershipPercentage Namespace Prefix: us-gaap_Data Type: dtr-types:percentItem Type Balance Type: na Period Type: instant X - DefinitionAmount of expense classified as other. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(6\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2) + Details Name: us-gaap_OtherExpenses Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionPer share conversion price of preferred stock. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13) + Details Name: us-gaap_PREFERREDStockConvertibleConversionPrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionNumber of common shares issuable upon conversion of preferred stock. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13) + Details Name: us-gaap_PREFERREDStockConvertibleSharesIssuable Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionThe percentage rate used to calculate dividend payments on preferred stock. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.12-12A\(Column A\)\(Footnote 3\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.12-12A(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.12-12\(Column A\)\(Footnote 4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.12-12B\(Column A\)\(Footnote 3\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph \(SX 210.12-14\(Column A\)\(Footnote 3\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6) + Details Name: us-gaap_PREFERREDStockDividendRatePercentage Namespace Prefix: us-gaap_Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - DefinitionFace amount per share of no-par value preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13) + Details Name: us-gaap_PREFERREDStockNoParValue Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2:

URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionProceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap ProceedsFromIssuanceOfPreferredStockAndPreferenceStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from entity's raising of capital via private rather than public placement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap ProceedsFromIssuanceOfPrivatePlacement Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionThe number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + ReferencesNo definition available. + Details Name: us-gaap SaleOfStockNumberOfSharesIssuedInTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionPer share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + ReferencesNo definition available. + Details Name: us-gaap SaleOfStockPricePerShare Namespace Prefix: us-gaap_ Data Type: dr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap SharesIssuedPricePerShare Namespace Prefix: us-gaap_ Data Type: dr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionTotal number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap StockIssuedDuringPeriodSharesRestrictedStockAwardGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionValue of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders. + ReferencesNo definition available. + Details Name: us-gaap StockIssuedDuringPeriodValueIssuedForServices Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionAggregate value of stock related to Restricted Stock Awards issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap StockIssuedDuringPeriodValueRestrictedStockAwardGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionNumber of stock bought back by the entity at the exercise price or redemption price. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 + Details Name: us-gaap StockRedeemedOrCalledDuringPeriodShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of stock bought back by the entity at the exercise price or redemption price. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 + Details Name: us-gaap StockRedeemedOrCalledDuringPeriodValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionThe number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap TemporaryEquitySharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionThe number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap TemporaryEquitySharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYmMnDThHnMns' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap WarrantsAndRightsOutstandingTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItem Type Balance Type: na Period Type: instant X - Details Name: us-gaap SubsequentEventTypeAxis=us-gaap SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap SubsidiarySaleOfStockAxis=us-gaap PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt RangeAxis=srt MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt RangeAxis=srt MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap StatementEquityComponentsAxis=us-gaap CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap StatementEquityComponentsAxis=ocx PreFundedWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap StatementEquityComponentsAxis=us-gaap WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap TypeOfArrangementAxis=ocx RegisteredDirectOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt TitleOfIndividualAxis=ocx BoardMembersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt TitleOfIndividualAxis=ocx OtherInvestorsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap TypeOfArrangementAxis=ocx SecuritiesPurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap StatementClassOfStockAxis=ocx SeriesARedeemableConvertiblePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap StatementEquityComponentsAxis=us-gaap PreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ocx InterestMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap VestingAxis=us-gaap ShareBasedCompensationAwardTrancheOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt TitleOfIndividualAxis=ocx InvestorsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap StatementClassOfStockAxis=us-gaap SeriesAPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap StatementClassOfStockAxis=us-gaap SeriesBPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 58 R51.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Stock Option Activity (Details) - USD (\$) / shares in Units, \$ in Thousands 9 Months Ended 12 Months Ended Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Á Á Á Unrecognized stock-based compensation expense \$ 1,254 \$ 2,276 Á 2010 Plan and 2018 Incentive Plan Activity [Member] Á Á Á Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Á Á Á Number of options outstanding, beginning of period 532,000 Á Á Weighted average exercise price, beginning of period \$ 24.56 Á Á Weighted average remaining contractual life 8 years 5 months 4 days Á 8 years 3 months 18 days Aggregate intrinsic value balance \$ 0 Á Á Number of RSUs Outstanding, beginning of period 5,000 Á Á Weighted average exercise price, options outstanding, beginning of period \$ 4 Á Á Number of options outstanding, Options granted 362,000 297,808 Á Weighted average exercise price, Options granted \$ 2.81 Á Á Number of RSUs Outstanding, options outstanding vested (4,000) Á Á Weighted average exercise price,RSUs vested \$ 4 Á Á Number of options, forfeited/expired (39,000) Á Á Weighted average exercise price, forfeited/expired \$ 26.69 Á Á Weighted average exercise price, options outstanding RSUs forfeited (1,000) Á Á Weighted average exercise price, options outstanding, RSUs forfeited \$ 4 Á Á Number of options outstanding, end of period 855,000 Á 532,000 Number of options outstanding, ending of period \$ 15.23 Á \$ 24.56 Aggregate intrinsic value balance \$ 24 Á \$ 0 Number of RSUs Outstanding, end of period 0 Á 5,000 Weighted average exercise price, exercisable, end of period \$ 0 Á \$ 4 Number of options, vested and expected to vest 855,000 Á Á Weighted average exercise price, options vested and expected to vest \$ 15.23 Á Á Weighted average remaining contractual life vested and expected to vest 8 years 5 months 4 days Á Á Number of Options, Options Outstanding and exercisable 229,000 Á Á Weighted average exercise price, options outstanding, exercisable \$ 42.59 Á Á Weighted average remaining contractual life exercisable 6 years 2 months 26 days Á Á Stock-based compensation expense for the period \$ 1,249 Á Á Stock-based compensation expense for RSUs 5 Á Á Unrecognized stock-based compensation expense 2,105 Á Á Unrecognized stock based compensation expense for RSUs \$ 0 Á Á Weighted average remaining recognition of period 2 years 21 days Á Á X - DefinitionShare based compensation arrangement by share based payment award option outstanding weighted average exercise price. + ReferencesNo definition available. + Details Name: ocx ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice

Namespace Prefix: ocx_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionShare based compensation arrangement by share based payment award options outstanding weighted average remaining contractual term. + ReferencesNo definition available. + Details Name:

ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm Namespace Prefix: ocx_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense for employee benefit and equity-based compensation. + ReferencesNo definition available. + Details Name: us-gaap_EmployeeBenefitsAndShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncash expense for award of restricted stock or unit under share-based payment arrangement. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph \(b\)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph (b)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap_RestrictedStockExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph \(a\)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph (a)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(2\)\(iii\)\(03\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(2)(iii)(03)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(2\)\(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: \[http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\(c\\)\\(2\\)\\(ii\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2\]\(http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(2\)\(ii\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2\) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPer share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: \[http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\(c\\)\\(2\\)\\(i\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: \\[http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\\(c\\\)\\\(2\\\)\\\(ii\\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2\\]\\(http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\(c\\)\\(2\\)\\(ii\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2\\) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe number of equity-based payment instruments, excluding stock \\(or unit\\) options, that vested during the reporting period. + ReferencesReference 1: \\[http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\\(c\\\)\\\(2\\\)\\\(iii\\\)\\\(02\\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2\\]\\(http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\(c\\)\\(2\\)\\(iii\\)\\(02\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2\\) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock \\(or unit\\) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. + ReferencesReference 1: \\[http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\\(c\\\)\\\(2\\\)\\\(iii\\\)\\\(02\\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2\\]\\(http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\(c\\)\\(2\\)\\(iii\\)\\(02\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2\\) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: \\[http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\\(c\\\)\\\(1\\\)\\\(i\\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: \\\[http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\\\(c\\\\)\\\\(1\\\\)\\\\(i\\\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: \\\\[http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\\\\(c\\\\\)\\\\\(1\\\\\)\\\\\(i\\\\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: \\\\\[http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\\\\\(c\\\\\\)\\\\\\(1\\\\\\)\\\\\\(i\\\\\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4:\\\\\]\\\\\(http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\\\\(c\\\\\)\\\\\(2\\\\\)\\\\\(i\\\\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\\\\(c\\\\\)\\\\\(2\\\\\)\\\\\(ii\\\\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\\\\(c\\\\\)\\\\\(2\\\\\)\\\\\(iii\\\\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\\\\(c\\\\\)\\\\\(2\\\\\)\\\\\(iii\\\\\)\\\\\(01\\\\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\\\\(c\\\\\)\\\\\(2\\\\\)\\\\\(iii\\\\\)\\\\\(02\\\\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\\\\(c\\\\\)\\\\\(2\\\\\)\\\\\(iii\\\\\)\\\\\(03\\\\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\\\\(d\\\\\)\\\\\(1\\\\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\\\\(d\\\\\)\\\\\(2\\\\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\\\\(e\\\\\)\\\\\(1\\\\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\\\\(e\\\\\)\\\\\(2\\\\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\\\\(f\\\\\)\\\\\(2\\\\\)\\\\\(i\\\\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\\\\(f\\\\\)\\\\\(2\\\\\)\\\\\(ii\\\\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\\\\(f\\\\\)\\\\\(2\\\\\)\\\\\(iii\\\\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\\\\(f\\\\\)\\\\\(2\\\\\)\\\\\(iv\\\\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\\\\(f\\\\\)\\\\\(2\\\\\)\\\\\(v\\\\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2\\\\\)\\\\]\\\\(http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\\\(c\\\\)\\\\(2\\\\)\\\\(i\\\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\\\(c\\\\)\\\\(2\\\\)\\\\(ii\\\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\\\(c\\\\)\\\\(2\\\\)\\\\(iii\\\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\\\(c\\\\)\\\\(2\\\\)\\\\(iii\\\\)\\\\(01\\\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\\\(c\\\\)\\\\(2\\\\)\\\\(iii\\\\)\\\\(02\\\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\\\(c\\\\)\\\\(2\\\\)\\\\(iii\\\\)\\\\(03\\\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\\\(d\\\\)\\\\(1\\\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\\\(d\\\\)\\\\(2\\\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\\\(e\\\\)\\\\(1\\\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\\\(e\\\\)\\\\(2\\\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\\\(f\\\\)\\\\(2\\\\)\\\\(i\\\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\\\(f\\\\)\\\\(2\\\\)\\\\(ii\\\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\\\(f\\\\)\\\\(2\\\\)\\\\(iii\\\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\\\(f\\\\)\\\\(2\\\\)\\\\(iv\\\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\\\(f\\\\)\\\\(2\\\\)\\\\(v\\\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2\\\\)\\\]\\\(http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\\(c\\\)\\\(2\\\)\\\(i\\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\\(c\\\)\\\(2\\\)\\\(ii\\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\\(c\\\)\\\(2\\\)\\\(iii\\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\\(c\\\)\\\(2\\\)\\\(iii\\\)\\\(01\\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\\(c\\\)\\\(2\\\)\\\(iii\\\)\\\(02\\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\\(c\\\)\\\(2\\\)\\\(iii\\\)\\\(03\\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\\(d\\\)\\\(1\\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\\(d\\\)\\\(2\\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\\(e\\\)\\\(1\\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\\(e\\\)\\\(2\\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\\(f\\\)\\\(2\\\)\\\(i\\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\\(f\\\)\\\(2\\\)\\\(ii\\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\\(f\\\)\\\(2\\\)\\\(iii\\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\\(f\\\)\\\(2\\\)\\\(iv\\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\\(f\\\)\\\(2\\\)\\\(v\\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2\\\)\\]\\(http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 35-Paragraph 1D-Publisher FASB-URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 35-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\(a\\)\\(1\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\(a\\)\\(2\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\(a\\)\\(3\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\(c\\)\\(1\\)\\(i\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\(c\\)\\(1\\)\\(ii\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\(c\\)\\(1\\)\\(iii\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\(c\\)\\(1\\)\\(iv\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\(c\\)\\(1\\)\\(iv\\)\\(01\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\(c\\)\\(1\\)\\(iv\\)\\(02\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\(c\\)\\(1\\)\\(iv\\)\\(03\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\(c\\)\\(1\\)\\(iv\\)\\(04\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\(c\\)\\(2\\)\\(i\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\(c\\)\\(2\\)\\(ii\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\(c\\)\\(2\\)\\(iii\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\(c\\)\\(2\\)\\(iii\\)\\(01\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\(c\\)\\(2\\)\\(iii\\)\\(02\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\(c\\)\\(2\\)\\(iii\\)\\(03\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\(d\\)\\(1\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\(d\\)\\(2\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\(e\\)\\(1\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\(e\\)\\(2\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\(f\\)\\(2\\)\\(i\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\(f\\)\\(2\\)\\(ii\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\(f\\)\\(2\\)\\(iii\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\(f\\)\\(2\\)\\(iv\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \\(f\\)\\(2\\)\\(v\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2\\)\]\(http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(2\)\(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(2\)\(ii\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(2)(i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(2)(ii)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)

types:perShareItem

Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem

Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_Data Type: xbrli:durationItem

Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_Data Type: xbrli:durationItem

Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_Data Type: xbrli:durationItem

Balance Type: na Period Type: duration X - Details Name: us-gaap_PlanNameAxis=ocx_TwoThousandAndTenPlanAndTwoThousandEighteenIncentivePlanActivityMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 59 R52.htm IDEA: XBRL DOCUMENT v3.24.3 Schedule of Assumptions Used to Calculate Fair Value of Stock Options (Details) 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Share-Based Payment Arrangement [Abstract] A A Expected life (in years) 6 years 2 months 19 days 6 years 3 months Risk-free interest rates 4.45% 3.76% Volatility 107.31% 105.99% Dividend yield 0.00% 0.00% X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItem

Balance Type: na Period Type: duration X - DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_Data Type: dtr-types:percentItem

Balance Type: na Period Type: duration X - DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap_Data Type: dtr-types:percentItem

Balance Type: na Period Type: duration X - DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap_Data Type: dtr-types:percentItem

Balance Type: na Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_Data Type: xbrli:durationItem

Balance Type: na Period Type: duration X - Details Name: us-gaap_CompensationExpense (Details) - USD (\$) in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2023 Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] A A A Stock-based compensation expense \$ 450 \$ 608 \$ 1,254 \$ 2,276 Cost Of Revenues [Member] A A A Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] A A A Stock-based compensation expense 2 (2) A 10 Research and Development Expense [Member] A A A Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] A A A Stock-based compensation expense 198 294 607 926 Selling and Marketing Expense [Member] A A A Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] A A A Stock-based compensation expense 44 64 127 203 General and Administrative Expense [Member] A A A Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] A A A Stock-based compensation expense \$ 206 \$ 252 \$ 520 1,119 Expense Included In Discontinued Operations [Member] A A A Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] A A A Stock-based compensation expense A A \$ 18 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479830/718-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem

Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItem

Balance Type: na Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=ocx_CostOfRevenuesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=ocx_ExpenseIncludedInDiscontinuedOperationsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 61 R54.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation (Details Narrative) - USD (\$) \$ / shares in Units, \$ in Thousands 1 Months Ended 9 Months Ended Oct. 11, 2024 Aug. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] A A A Risk-free interest rate A A 4.45% 3.76% A Expected life (in years) A A 6 years 2 months 19 days 6 years 3 months A Expected volatility A A 107.31% 105.99% A Dividend yield A A 0.00% 0.00% A Fair value of options granted A \$ 156,000 A A A Unrecognized stock based compensation expense A \$ 2,100 A A Weighted average remaining recognition period A A 2 years 21 days A A Restricted Stock Units (RSUs) [Member] A A A Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] A A A Number of shares vested A A 0 A A Number of shares granted A A 0 A A Share price A A \$ 4 A Aggregate fair value of RSUs vested A A \$ 11,000 \$ 87,000 A Monte Carlo Valuation Technique [Member] A A A Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] A A A Risk-free interest rate A 4.81% A A Expected life (in years) A 6 years 2 months 8 days A A Expected volatility A 91.00% A A Dividend yield A 0.00% A A Monte Carlo Valuation Technique [Member] | Minimum [Member] A A A Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] A A A Fair value grants A \$ 1.09 A A Monte Carlo Valuation Technique [Member] | Maximum [Member] A A A Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] A A A Fair value grants A \$ 1.74 A A 2010 Stock Option Plan [Member] A A A Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] A A A Stock options outstanding A A 16,217 A 16,217 2018 Incentive Plan [Member] A A A Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] A A A Common stock reserved for future issuance A A 1,310,000 A A Number of shares available for grant A A 124,768 A A 2018 Incentive Plan [Member] | Subsequent Event [Member] A A A Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] A A A Additional shares of common stock to be available for issuance 1,250,000 A A A 2010 Plan and 2018 Incentive Plan Activity [Member] A A A Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] A A A Stock options outstanding A 855,000 A 532,000 Stock option grant A A 362,000 297,808 A Stock options, time-based awards granted A A 362,000 177,808 A Fair value grants A \$ 2.37 \$ 4.41 A Number of shares vested A A 4,000 A A Performance-Based Options [Member] A A A Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] A A A Stock option grant A 120,000 A A X - DefinitionShare based compensation arrangement by share based payment award additional number of shares available for grant. + ReferencesNo definition available. + Details Name: ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant Namespace Prefix: ocx_Data Type: xbrli:sharesItem

Balance Type: na Period Type: duration X - DefinitionShare Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Fair Value. + ReferencesNo definition available. + Details Name: ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue Namespace Prefix: ocx_Data Type: xbrli:monetaryItem

Balance Type: debit Period Type: duration X - DefinitionShare based compensation arrangement by share based payment time based award options grants in period. + ReferencesNo definition available. + Details Name: ocx_ShareBasedCompensationArrangementByShareBasedPaymentTimeBasedAwardOptionsGrantsInPeriod Namespace Prefix: ocx_Data Type: xbrli:sharesItem

Balance Type: na Period Type: duration X - DefinitionAggregate number of common shares reserved for future issuance. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem

Balance Type: na Period Type: instant X - DefinitionAmount of cost not yet recognized for nonvested award under share-based payment arrangement. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem

Balance Type: debit Period Type: instant X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_Data Type: xbrli:durationItem

Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem

Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem

Balance Type: na Period Type: duration X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsVestedInPeriod Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem

Balance Type: na Period Type: duration X - DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap_Data Type: dtr-types:percentItem

Balance Type: na Period Type: duration X - DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap. Data Type: dtr-types:percentType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1:

Purchase Agreement [Member] | Common Stock [Member] | Arno [Member] | Number of shares issued 33,898 | Common stock shares issued \$ 100,000 | Securities Purchase Agreement [Member] | Subsequent Event [Member] | Related Party Transaction [Line Items] | Number of shares issued 33,670 | Common stock shares issued \$ 100,000 | Securities Purchase Agreement [Member] | Private Placement [Member] | Subsequent Event [Member] | Related Party Transaction [Line Items] | Other expenses \$ 795,000 | Securities Purchase Agreement [Member] | Mr Gutfreund [Member] | Common Stock [Member] | Related Party Transaction [Line Items] | Number of shares issued 588,85,250 | Common stock shares issued \$ 618,672 | Securities Purchase Agreement [Member] | Mr Gutfreund [Member] | Common Stock [Member] | Arno [Member] | Related Party Transaction [Line Items] | Number of shares issued 21,162 | Securities Purchase Agreement [Member] | Bio Rad Laboratories Inc [Member] | Common Stock [Member] | Related Party Transaction [Line Items] | Number of shares issued 1,200,109 | Common stock shares issued \$ 3,499,998 | Securities Purchase Agreement [Member] | Bio Rad Laboratories Inc [Member] | Common Stock [Member] | Subsequent Event [Member] | Related Party Transaction [Line Items] | Number of shares issued 310,835 | Common stock shares issued \$ 916,000 | Securities Purchase Agreement [Member] | Broadwood Partners LP [Member] | Common Stock [Member] | Related Party Transaction [Line Items] | Number of shares issued 2,420,000 | 1,341,381 | Common stock shares issued \$ 7,057,688 | \$ 8,093,362 | Securities Purchase Agreement [Member] | Broadwood Partners LP [Member] | Common Stock [Member] | Subsequent Event [Member] | Related Party Transaction [Line Items] | Number of shares issued 1,315,339 | Common stock shares issued \$ 3,878,000 | Securities Purchase Agreement [Member] | Pura Vida [Member] | Common Stock [Member] | Related Party Transaction [Line Items] | Number of shares issued 33,150 | Common stock shares issued \$ 200,014 | Securities Purchase Agreement [Member] | AVM [Member] | Common Stock [Member] | Related Party Transaction [Line Items] | Number of shares issued 342,889 | 472,354 | Common stock shares issued \$ 2,850,000 | Securities Purchase Agreement [Member] | Series A Preferred Stock [Member] | Mr Gutfreund [Member] | Related Party Transaction [Line Items] | Number of shares issued 1,176 | Securities Purchase Agreement [Member] | Series A Preferred Stock [Member] | Broadwood Capital LP [Member] | Related Party Transaction [Line Items] | Number of shares issued 5,882 | Legal fees \$ 85,000 | Laboratory Equipment [Member] | Bio Rad Laboratories Inc [Member] | Related Party Transaction [Line Items] | Purchased laboratory equipment \$ 294,000 | \$ 581,000 | Laboratory related costs \$ 230,000 | \$ 375,000 | Finance lease payments \$ 126,000 | Initial capitalized total value \$ 976,000 | X - DefinitionInitial capitalized amount. + ReferencesNo definition available. + Details Name: ocx InitialCapitalizedAmount Namespace Prefix: ocx_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNet proceeds from issuance of private placement used for general corporate purposes and working capital. + ReferencesNo definition available. + Details Name: ocx NetProceedsFromIssuanceOfPrivatePlacementUsedForGeneralCorporatePurposesAndWorkingCapital Namespace Prefix: ocx_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPercentage of shares issued and outstanding. + ReferencesNo definition available. + Details Name: ocx PercentageOfSharesIssuedAndOutstanding Namespace Prefix: ocx_Data Type: dtr-types:percentItem Type Balance Type: na Period Type: instant X - DefinitionPurchase price of common stock value. + ReferencesNo definition available. + Details Name: ocx PurchasePriceOfCommonStockValue Namespace Prefix: ocx_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionSale of stock offering price per share to insiders. + ReferencesNo definition available. + Details Name: ocx SaleOfStockOfferingPricePerShareToInsiders Namespace Prefix: ocx_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionSale of stock offering price per share to investors. + ReferencesNo definition available. + Details Name: ocx SaleOfStockOfferingPricePerShareToInvestors Namespace Prefix: ocx_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: [http://www.xbrli.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap AccountsPayableCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: <http://www.xbrli.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3> + Details Name: us-gaap ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionNumber of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares. + ReferencesNo definition available. + Details Name: us-gaap ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: <http://www.xbrli.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3> + Details Name: us-gaap ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionCosts of sales and operating expenses for the period incurred from transactions with related parties. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(2\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2) + Details Name: us-gaap CostsAndExpensesRelatedParty Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow for principal payment on finance lease. + ReferencesReference 1: [http://www.xbrli.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(g\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4](http://www.xbrli.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4)Reference 2: [http://www.xbrli.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5](http://www.xbrli.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5) + Details Name: us-gaap FinanceLeasePrincipalPayments Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionThe amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings. + ReferencesReference 1: [http://www.xbrli.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(6\)\) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrli.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(6)) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2) + Details Name: us-gaap LegalFees Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionAmount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold. + ReferencesReference 1: [http://www.xbrli.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrli.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2) + Details Name: us-gaap OfficersCompensation Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionAmount of expense classified as other. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(6\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2) + Details Name: us-gaap OtherExpenses Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13) + Details Name: us-gaap PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from entity's raising of capital via private rather than public placement. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14) + Details Name: us-gaap ProceedsFromIssuanceOfPrivatePlacement Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionA description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 840 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481440/840-10-50-1>Reference 2: [http://www.xbrli.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1](http://www.xbrli.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1)Reference 3: [http://www.xbrli.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(23\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrli.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 4: <http://www.xbrli.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7>Reference 5: <http://www.xbrli.org/2003/role/disclosureRef -Topic 842 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479773/842-30-50-4>Reference 6: <http://www.xbrli.org/2003/role/disclosureRef -Topic 842 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479741/842-40-50-1> + Details Name: us-gaap RelatedPartyTransactionDescriptionOfTransaction Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <http://www.xbrli.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13>Reference 2: [http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(2\)\(c\)\(2\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1](http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1)Reference 3: [http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(2\)\(c\)\(2\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1](http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1)Reference 4: [http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-09\(4\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 5: [http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2)Reference 6: [http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2)Reference 7: [http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2)Reference 8: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 9: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 10: [http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2)Reference 11: <http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4>Reference 12: [http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2)Reference 13: [http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2)Reference 14: [http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2)Reference 15: [http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2)Reference 16: [http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2)Reference 17: [http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2)Reference 18: [http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2)Reference 19: [http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2)Reference 20: [http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2)Reference 21: [http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2)Reference 22: [http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2)Reference 23: [http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2)Reference 24: [http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2)Reference 25: [http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2)Reference 26: [http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2)Reference 27: [http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2)Reference 28: [http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2)Reference 29: [http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2)Reference 30: [http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2)Reference 31: [http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2)Reference 32: [http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2](http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2)Reference 33:

10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_SubsequentEventItemTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=ocx_ArnosSonMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ocx_BioRadLaboratoriesIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=ocx_BroadwoodCapitalLPMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=ocx_UnderwrittenOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=ocx_UnderwritersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=ocx_PuraVidaInvestmentsLLCMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=ocx_HalleSpecialSituationsFundLLCMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=ocx_SecuritiesPurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=ocx_PreFundedWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=ocx_ArnoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=ocx_JamesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=ocx_MrGutfreundMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=ocx_BroadwoodPartnersLPMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=ocx_PuraVidaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=ocx_AVMMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=ocx_LaboratoryEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 63 R56.htm IDEA: XBRL DOCUMENT v3.24.3 Collaborative Arrangements (Details Narrative) - USD (\$) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Research and development expenses \$ 2,817,000 \$ 2,185,000 \$ 7,582,000 \$ 6,747,000 Sales and marketing expenses 1,043,000 713,000 2,742,000 2,213,000 Interest expense \$ 31,000 \$ 14,000 54,000 \$ 39,000 Life Technologies Corporation [Member] Á Á Á Á Development costs Á Á Á \$ 749,000 Á Collaborative agreement, term period Á Á 10 years Á X - DefinitionCollaborative agreement, term period. + ReferencesNo definition available. + Details Name: ocx_CollaborativeAgreementTermPeriod Namespace Prefix: ocx_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of capitalized development cost incurred during period and excluded from amortization for oil- and gas-producing activities accounted for under full cost method. Excludes acquisition and exploration costs and capitalized interest. + ReferencesReference 1: http://www.xbrli.org/2009/role/commonPracticeRef -Topic 932 -SubTopic 360 -Name Accounting Standards Codification -Section S50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477385/932-360-S50-1Reference 2: http://www.xbrli.org/2009/role/commonPracticeRef -Topic 932 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-10(c)(7)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479664/932-10-S99-1 + Details Name: us-gaap_DevelopmentCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest income (expense) classified as operating. + ReferencesReference 1: http://www.xbrli.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section S50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-S50-22Reference 2: http://www.xbrli.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_InterestIncomeExpenseNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writteoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrli.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section S55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-S55-48Reference 2: http://www.xbrli.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section S50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-S50-2Reference 3: http://www.xbrli.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section S50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-S50-1Reference 4: http://www.xbrli.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate total amount of expenses directly related to the marketing or selling of products or services. + ReferencesNo definition available. + Details Name: us-gaap_SellingAndMarketingExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: dei_LegalEntityAxis=ocx_LifeTechnologiesCorporationMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 64 R57.htm IDEA: XBRL DOCUMENT v3.24.3 Schedule of Discontinued Operations (Details) \$ in Thousands 9 Months Ended Sep. 30, 2023 USD (\$) Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Á Net loss from discontinued operations \$ (2,926) Discontinued Operations, Held-for-Sale [Member] | Razor Genomics, Inc. [Member] Á Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Á Net revenue 421 Cost of revenues 507 Research and development 702 Sales and marketing 498 General and administrative 329 Loss from impairment of held for sale assets 1,311 Net loss from discontinued operations \$ (2,926) X - DefinitionDisposal group including discontinued operation research and development. + ReferencesNo definition available. + Details Name: ocx_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment Namespace Prefix: ocx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDisposal group including discontinued operation sales and marketing. + ReferencesNo definition available. + Details Name: ocx_DisposalGroupIncludingDiscontinuedOperationSalesAndMarketing Namespace Prefix: ocx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: http://www.xbrli.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section S50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-S50-7Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-S50-5B + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-S50-5B + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of revenue attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: http://www.xbrli.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section S50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-S50-7Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-S50-5B + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal. + ReferencesReference 1: http://www.xbrli.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrli.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477349/740-270-45-3Reference 3: http://www.xbrli.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-S50-7Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3AReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-S50-5CReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3BReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-S50-1Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3 + Details Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount before tax of income (loss) from an individually significant component disposed of or held-for-sale attributable to noncontrolling interest. Excludes discontinued operations. + ReferencesNo definition available. + Details Name: us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToNoncontrollingInterestBeforeIncomeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ocx_RazorGenomicsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 65 R58.htm IDEA: XBRL DOCUMENT v3.24.3 Schedule of Assets and Liabilities Discontinued Operations (Details) - Discontinued Operations, Held-for-Sale [Member] - Razor Genomics, Inc. [Member] \$ in Thousands 9 Months Ended Sep. 30, 2023 USD (\$) CASH FLOWS FROM OPERATING ACTIVITIES: Á Net cash used in operating activities \$ (2,985) CASH FLOWS FROM INVESTING ACTIVITIES: Á Net cash used in investing activities \$ (1,372) X - DefinitionAmount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-S50-5B + Details Name: us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-S50-5B + Details Name: us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ocx_RazorGenomicsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 66 R59.htm IDEA: XBRL DOCUMENT v3.24.3 Discontinued Operations of Razor (Details Narrative) - USD (\$) 3 Months Ended 12 Months Ended Feb. 16, 2023 Feb. 16, 2023 Dec. 15, 2022 Mar. 31, 2024 Mar. 31, 2023 Dec. 31, 2022 Feb. 23, 2021 Payment to related party Á Á Á \$ 45,000 Á Á Razor Genomics, Inc. [Member] Á Á Á Á Á Equity method investment ownership percentage Á Á Á Á Á 25.00% Razor Stock Purchase Agreement [Member] | Razor Genomics, Inc. [Member] Á Á Á Á Á Á Number of shares issued Á 1,366,364 Á Á Á Á Equity method investment ownership percentage 30.00% 30.00% Á Á Á Á Consideration transferred \$ 116,000 Á Á Á Á Á Loss on disposal Á Á Á Á \$ 1,300,000 \$ 27,200,000 Á Razor Stock Purchase Agreement [Member] | Razor Genomics, Inc. [Member] | Dragon Scientific LLC [Member] Á Á Á Á Á Number of shares issued Á 3,188,181 Á Á Á Á Equity method investment ownership percentage 70.00% 70.00% 70.00% Á Á Á X - DefinitionAmount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 8 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 7 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479637/805-30-7 + Details Name: us-gaap_BusinessCombinationConsiderationTransferred1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + ReferencesReference 1: http://www.xbrli.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 + Details Name: us-gaap_EquityMethodInvestmentOwnershipPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAmount of gain (loss) on sale or disposal of an equity method investment. + ReferencesReference 1: http://www.xbrli.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX


```
X80>*:DQNU1U"YU>AMKO9JDJG$+LF0]#@3R"E[Q_-YX'GP:4I[WR M=(B>[&H&:!P<90?CK?%S0KGG_6'$F3NNJ]"J:BY;EM%
MOJ|HWVE7;7_Z&MUWZ$S_(!D!X;M;"|W;W)K&ULS5MM8KNL;+AZCZ_R")|PS!C)S*?|[I,Q,R|R7)E]~Z]$E_<&0"-M|J>
[GVX,7]SX\^FNC$GJ<[NX\^]&+E=ZN^/C6;U^_17QN.PL?6IWP-2B/ MXSH87J?;@MCD^F4X?|[?;NH-7+&C_A_#JA|U28YWY$%3LVE:'S6O3^>)N7![.#
M_L)'NUPENG$ZLS<+|V52|]8?PCX=CS,AM06N&B]A$17AY3 E@4QCJD0S:QJ]JL|=DS[ZF[~90])|SFJ_R3>1_UA^=GJ@
M]B\XFW^;|D;*U3C|UYZR\APPRX0-.6&Y9B$%HY-^]2+X&Q7H:32$ MLXZ,AAZ5V|GF-B>R:O_N%2BNC7G<1HV)<9RP(HT[ MKO+LKV7VDSMF?
Z9^>BZMHQJKTJV|?X8D@|BGO3BOCZY=(\S5Y2I|_).IF> MG-TSW^FP_5>_1_0!VY^H2^+B;VP|;N-#;~<X!^MU?&^-=I75C;K"10-TIJC^
MVZ|>4P^_ _GN7AD2 L_T'D^|]P>Z,BVUK16N$8'K_][IGCZ2-[MG5;|;|_][A4|,N1CG_T^1D^<KR_>|OL^<+~| MJ,U;NUPU^<^?T%' IK7;-
JR7RKL$KKG*T&K/U29:P,A%OHFMVJ#64 CAZ4C|8I/^ M(>A% A#.3Y^+D!74;RL@;|YX7Q|2**H5PQ7;AQ44(CBNM$|7%OO;+!|NB4+
M_U$Y46,73#EQ 0^|J5Z|]1WC6?P28?_&^U^;|6|K5W/AS6'B^@8FL|J8>+ M8(QC^XB+ 7&).(8^?N^#2.*/;9|QW1Z%?'072>D8#?
W'1D)=|WNVM@K> MN&L;O_>W8|4^4|JLD^1IKN^|JKTGRMYSS&|;VV)DYZA:JU71M^K'R3|;|N|:4 MJ-Q4J2Z|;+P@<BIKO(+I!)E%@M8HMH0F^K$ U,;
[Z/'^2-)F-HSCPC\?P M+&R 3,1)W6$[M!*PUIK D24@94$B=-)1#RT#M8D9$Q8V.C$R|XDRQ)D09- M AN-J?N=?OPLJB70T9-
0|LW^P7|J|S@T;:5@<69S&|,2L^>^<86L|1)5=-A MVVWE|K=ZH.P9|A|]MURI|[T]=*2#DU_, M_K)&$|@=#56|3E7_Z;|QVYQ'50 BD%,XI?^C#. U,
R%M^P78T0IYMCR"! M0|D)2<Z>_L> B2ASIOQ^/_EV M<(<9A&+ B O|_VD(EP8#(<_RZOC%GMQ1#PC>&HA|1
4_@_@&")^ER7""$11!D'DD!D;+>|SWUGS1VIBQQ"8^<X)<+!T7EM|(SR3F MAUZ2BRB$U0@49%71+|"!AU""$O^FZ"7$/^JLN)/U43]^_<E(>:~:~?0-)8+&
MMI:4W5@|]MPW|,*G0)M,4L_VLXIQ|QJTO+G17)=5NA0$W7&'<10!;?LLI$ MG4YF3Y_B_|F7K#C)H0%)>DDP=>0)O4;D^6Q;|84G4 A6-N<=-2-
GQO#C,KH@>: MJ$77(-4M4N$97)M^ZLI4B|(2WQ^GL^'9UZ+QD&+V-?_13*$2$|JM-DAW.VQ MK_@<BDC<~$W|;<6;~&Q4C=E=SK_LGVK'?9>#)=Y;C,6T|
#2L.MF J509^D|76.R,D,N093A-8L9D<0-D;A1J-(4Y|JWSL|Q,E^JAO9V_?>UHH MI^4|U8G|B(=U1^N\|C;S2:GCO_C_1O=XBBXQ_C_1PZ'V|M-
QB(A0AF1_] MAE=LR045NEGWI<*>%"6F+E;60G=CKYIZ?.H(J=>H=QZ*FR&|)!&K?;|1|E| M|DX TG5MZ2X2NW72+^!Y?"D#A17R(6N2-
L0!A2|8|AG,? B@Z""UKJO"KKNW$U^"8@V"$S&K|1I|,G1U,PRJ;A M$2S|B|^ZT 2@_R+MG4%? :S-0?~9X_<R$K| O6UMHV8#"86|^>9D=JRUKR-
LHM<5"A M#0.Q1XX +GHEEUY,420N V56KRGED9H|H1 M.;?M1,*Y+J+Y5+VWVN EQ9,U06RJVD MGL0DX;=L|D?Y-QPT>ZWD?9$N.A!=
YJ:C:DJ#NRS3?D";#MO|):*U%XC(G* M42DMMVK^/JG9R#F).G*^T_)R)M2Z0+F8N,/0$P.4!D|SD,!*~U1E J> Z_Z0 M.0@E 8Y@G>5A2&?
|<2(SP2<<G&S^R*4(|DJXUB$Y008M.6Z0(G=?S-UE.<+ MCW(8N4|D;_1Y|EW^P?%1$(R7EM_!^!Q:T (-Q*VZL3|R$C=|3+!|LO$SX)&+
M.M2P52_1,S;Y*^T|6D\A'IVM|XPQ' L=-JVN;@B^C1B 1VU_>#~#~9!G M BU
DL(C=6GD[&AULM&CG|]87|IBGU/(H>NWy'34:1|ND_')JOTYVZK4M MEG5UU|(^&=T#8=HE?+$$ $=3$9$'L_/&4C(99>/>OC!A@3-
R)4E+20&FUJ|SS M^&|BZZ+&VIG|41RU=, _>ORV_-MN+&*>+Z1)+9*^X&R2B4+Y<0<#3+%(#-X M4=*G"OQUN*1=2:S|A|A59LC*"?
+Q;L,6.Q|3/7|WTC|IR?0%"A-<25A@EV M^".PWZMM1LSY^PYT6%#80$LA|=SGZ=FO711^*8TZ/WTZF4ZGXIK#P|A>Y/N>M|F KIATZP<3|QV|2%,*Y?
TE JSD>~!?"<1@|V1|K^@+1+|VG(E<2;1EV| MM5DJQ<@&NFBX2E|A|=7)%N^DUJ-SM/NSI-!;|H|"+FQS%TN7OC5D^M^F)Q) MT^R,PE
M^G,B2^D@.R@|PRRR6|,CW\ 3I@5K9CUR1V-.I5R^=)MD|A#>R<@|J@9ECK-$Y
NK9UDA61;:23T29#29$8$=4DW$|_&W,C,7$7LF:Z17W=TC$^>|G>J"6Mq>2 M^<-
!S5;UGW7|1,O90A+3;LH8+W,WYK9RRPE);G8HWA:W:6|O7|3.R0E+2+2EL ML,1,3HOC;#7,M!#|2Y55CD;8ZI&T^F0|P|Q&2^X'L+74G#
M:RM8B8KOB#9W4_8M9|=[L^VK+>RWJ$XGG6R<K-GG# ^@I_O5OL+SGLK4+F M?R$|S$O?DQN6>7JJ-
E!E7N^Y;Z,)=6)#T:8<~GC'L1N"Q,=N0AA|7WHL M^|WA0#_?;"E,T_LG.TWR2GE:|+;V2CJ_X,T,3L9<?5S2-5|UCFKJ$/V5LG-RNK/IV-;ENAM>12=<
MEDUYNP+8|DYL=N+G$W5;BQW &#16M1>KF-WA[X1<C^Q>HH5X>H0RB#_9+ M98M_E R6 3W- KP09I2_!#-&HL|DJVJ+
|>J1|0Y4Y:N).E=TO)G06OK.H;=>=(3|+CH^P.=5DI=9#%H^|XJXDZG0NU^P",99.UT_ MC9>2"N2_?J*<830HM+2^TEY_1YXCWV^EW#? 4
"OGU.BN|6(SH28,-M|, M(C.C-ZR1V$6&8/3 9&Z|ZR@5^X3@KD 9#*6ZB1,?Q871 W)+MXC1(DONV/86 MH9YN|0+$5@>X%_@00|
(LK4>>94|F@HR>3X;|Q(3DKD0<0<:[Y:9*Y^?>QJ M*^&@61<7T-RW^#@JC41-D%L2SL7R?)5?E0LRLSK;G
|JQNV1+/OR^+J<=>|2/*Q1|D|3Z9CHS+SVV1R|FOLN27>@<(K0P,76VM)+W@&XSM G$G7F0,P:W6|B3),GP^ M0.Z ZUDAI$KX9Y+66.T-
J9PFP/YDA='N'|;PL2JRB.RVQ;BEA$#%;#HQ>>#0 MT= K)?FH^MKPE'-CG|PV*$O|3Y)7&CC| 8/.1|; FEW^NL)ZMVUC/EOR *[X
M96P+4^B:VUQ;4^F17|6MCH^FG--8ZMIL:~|XX-B|W+S|1^W^V 9^CXA? MG2G|NU|S1^U;/8M%2^6N=31 MR12DH4A+C:4$Q$Q;~
D+>9M;TX|QLCLH67_Q_XZ4_P6#SOMX?D|)> TJD MW_LJ_Q^('PFY^_?^143; &F/ZFWV1@G_WLD M6YQK|2^8DZ/5VAU+C>Q>=-
:~XW|5F3^VQNYWM|K04A=W 3AO_6N7Y3|_ 0.Q*RC3-&8 M4_? S9|YHWB;R3O$!+|$C?A5*/O~);?E2V|[[#&8^| 5R^SD)R&M9?71(YC9 M^N&
7|H+>_M%A%G,1@TC1KZP(PD5A7):CX|YZA&Q|&1T|ZVM#152ZV(H?O MAC@UY^?YUXP/8(C:2H6YOCN^'JOO|*+?K-YB^<"H|<-YV-&%NE
M5/$R2|3%M,NOD.16^7+CG9L|GF)A6H9>FJ>WRN6#>T5N_9,7H\|E$ 3^= ME/CYQ9D<($S^*8^R^N;AN;B#GR|][@A^*3,H;$#IE@>SXX^1:OZZ?
VRY,09/ M2S;Z,N^P;K 3<6%BA^TSN5DQ_.J^L-Z3@+;(>W10M^$CXL!|*"(??+/'K8 M<4E^N^S<'7Y9<2$_*|@?
EY|E_*3^TCIRCP6&3H^>G!^H#|UD^)_K_GG|> Z MR;?Y^YK_6|;@/L+#!Z:O| "P"|_7OT34$|#!0 (V!;%EX:P?E<"D M^*F& 9>&PO=V|R:W-H965T?
FW7#|I=Z^*7MI6@TUNQ^V9E??"E"K_A;EBV;HJ|V M^|JD&|;K+U^Y|F_-D|OZAX_E>M/C/QZ|?+>+UN|2|
```


(<;MAC@Y44#<Q3.3L20GCZ<#A]/UC>M4.@Y_\\$?)??O -+T MP'1<N>Q6XHC^<^/'J:G3?4G9VF3[X_NW/I%0WZJBB:/Z?<?78#S&J=<B M,"M? N@?>?C/G[TE&T+CGZ2D_N_7U/+&#Q4E!1#?>F])<GWC[IT MJ3(';<?G!0DL>+V1 &^<'7EX:38R8&QN_ G_U "H-r K'O+>JV6B, MXS/8B^131Y#Z#;R&CA:[4=V9_Z@U H\$<,"^+G%/438\$R)>#>:VV6MW@7RF3D5L.<3AQ? *8Z MJ/S L_~.-ODG"=UZT"K \$Y&R4FC MG>#>[JTQ4,+IXZ_XL"0C#KUW; .9RX[XTH'R:R+>F]J>T>M[J M Q7^</(.QIU+Y, ML3[X]_I^C^8<7/0I#<;C,"*!<"C& 0"VE:#39!A 3N XCFJ.3Y4L\$),^FWP M\$;RUJ]#Q@<U+5GUU5;IJ&W\$J0;3TF>="> 14"V07[XIY15L(3084JJ;DUN.Y M03(X3D3ME%)(@4-BE%)#\$S\$H<<0,SM@=I(3L*Y^),R8? #W>W[#-0.#9-*O MA^FISU ASJ]J68O!^YC7P8UJ6]7[\+<P&J/NL*2RU8,1R8QG#@LVS ?JVD= M72=OR^A">E"0+<46GK!>I(L>K!2)% <354P(@<K9D\$#PD)18U0^ M%1R]HXK2,E9_\$I45#Z[ZXC6V]L^YQO^JUR&ISKP&YJZ906%K)I6X8E(FB\$ MZ\$S/<I(YX^~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~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|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~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|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|M X=ROH]1J3^SPTIEQL^&F])>[RG6%&)>FGXLOF0I(D^R^< MU;U^1-1Y^NB^=5\$>J0^\$I.1).0_)/A,.51J]X)4R^KT,)_L\K!4:KIS)3 ME "WHK2O9?0!>NR299])J_A.A-GR1@>JTY^*#R6JQ495^DUJ1V, MN^F-9H2U^3Z9AB) Q3J=Y.W& =8B6P=V1^N=PA5ZUR6M!>M^BVO^>(1M<+<F6G=EQ)I&,-0+8#TK1ZH9DIB&R12OM=VUE9V(<#A\$8^R^R^W)GC\$>Y09YAB M&T4F#9FQ4RQ(S^Y-Q^&M@ZVY;6&XFQ4D>VK2UBWDE\|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~F;0I MXPYH@>C.YE+EF/E:EA4>0)54HZ00B4X2H4-WP1!&@>GU,5SF9Q MO B]E.+>=>-N5_*NM8Z>VNL;03^RQ_*L)CXVA=JF(SQJ7SAIXQ C20.>_V MTTQ+2AAB(YLG1RZ-95C4 @5X B>8+J)R]R[61CAB1,0!]>1,)(6_S2B@D63 M^S([I]8RC^CGJRKMR9300UTJ]>WIO4^Y?A5XV=ON@>BEMFJNZ>@>WO(D^>ETR]K MT.[XX7]AE 4P+^<Q%>#>-FGWQ^O7Y:3^7M^<J]1VWP]>^>BLG =0\ \$=<5 M^WQW(R!NGL.TV^O M=K.%P49D^%#PR<=<#=>KUX8\$J6WH8;>GMBTV&0!< M^TS4T-8M&_C[NU&KN33L4 #A(I^E3AX=9R2)=I1;QA&N8I>0M&XOCN)Q ML@>I^>N>P>O)ONL=Q3O QM5=<^<_KY)*Z^A3E^*O2P^118U3WN+HJW@7^~^KB MNL" 7DE=,X4#1Y\$OC6&I;>ZDC HEZ\$%>^>!!!!1P822-LGR (7%161Cs#5WCLPH\$); M+OWU708^>=J]F,M>BAIOFNB2=I84 \KP147_29A^U.;JG0RH/=..LA7WPJ (MYMXTM=E[BL/A]#>^<L^I^2&H^Y%PFPT=XR8E_%*NLCI?/S#Y+AJL:N-T1&EO ML=/19VZ\$G*>^&TFUB.E4!-J0R#W66 9V\$[OH9F]L^>6.Y;AX5.6;0Y MDH64/H^;EK7DK[A3.N.RMHC95- JVWHG=>M>?37.R?>8SK#DXSP^WN9J?FQ?1BX7^X#)I#MC MN!!(LI+1;? HQ&R88=-..37NB&0NY^8FTL9^>^!\$Y6Y<1;1\$O&M^>7D/(IHV1&H1 MY8XR PB^U#B^D(P^F! 68Y_HCZZ:4UAJWL-V.K;TQ!75U_PVJ(U+KQE!J< M""JRONXH^YPML^!>IRZUX:~1U2TIV>9-5>;2W84T:&G^0Z%G&NC\+3DE7H> M3IR+3INW4=3#&313JATMA#[~P7&Z^?>?>?>U<8;O- %VW^L1<1K8_1U1+?>DUH\$ MO _H=[X?8@,?>?Z\$5?S%>+>HHU[?>PX]0^2^W]A;1MC^[W4/O%>?0C%QN,G9 M4DUO:EP^OJ14P\$>U>BV<G;|/GKK(XRVY)-ZSQ&#ITK^=#[O^~^~^F?L8ZYX M;HBR>5^-ZA&U2J]H4N7^WW3J]L E5YU/5N)]WGT9<+>\$ONE? >UJN3%:_*I M)9>O9=9%I?>TS..F="Z<D9KJZ#@71^2XA0H&RY<,>TH;P]_!N]V^D/6!<><>#>DQ/BNCCX\$>^R;O M=/[G^D3G_IFQT.B:2 T-&/ M&Y?>!>O !^>S5@>Z07W^!)>[F@E]^>#U!+ P04 _~@6Q9WXT^MX<^! 8 M(P @>A!>W=O&C3 M^KOVP\$DE)O4V8M^M-ZT7^>#>M^E^H^T842.K\$% (#C,SM^Q W_~^>9;MNP~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~>7&973R]V4\$%>A!X1ME\ MR^YQ3LBACP^NW?E^N->MR+S,I1) MEB (9, (S9K7\$WJ]J^&J&R^>AM39&NX3:S#0M=RIW?>SNDHLX;=<4C^ASTY/G M-J^BSR^P3F94F^!4!>^&^>#)7%2EQ MF7.I:~@>@>HH P??2? C)JL3L2KXYW+G@SOB=IG3Z2T@>CNJ5_2K^@>V9F^GYI\CL M#8N^:1BZW_\$DI+<+<V3@>(28^#L?>JYV.VR_?J70<^X4Z3K2^V.]MC-T+OSSOX M.NQ>Q? U741!^X(TH_Y/(M^Z9DT02,2^S.R57FY^!=FU\$>_>O,8E^<^IB4P)(H25T F>H LE^PKUT9HT^HJ M[X_OG-QJY^=!3_3W^,A? 2=3&C!^07R0@>#WGMTJ(^95IBO-R^? J428,505 M508^PTOGAY^! XA^O^7U/+<8<=<V^>H^#P4J^>_K2Q1, M^\$XYCRB49>*>[>]>I.@H2?>2>W&? 9I4)ZC^*[E"">,>K49LG>5I]^F/CCH MG.R18@W.+E] &QBC0!>J^FAW)673K6@=I M4!=P51W/J_P"?>O^F OEB""+6CFK^H#(<2) 4 H^/3UNE2&2- I41TLB\$N, MFLX5UIR@>Q>F\$Y04Z+<^&QUB2^M5Z!+!+>+>[H@VB EF Y7!>^333OP.ZE]9[2 MC^R]AA!"T5\$%>#J^P!>_1NJEIFF M- 34HO%PS/Y\$W\$UQ=5Z(Y3S MG44,0S.1^V^H48BG^0/TQ_0 NKK-P8U M^I\$#M4<U@>U=3J;U2ZGF0035:1_6RK@EXL@>U^>A,YGPO=;Y 9Y51+VZJ MS!>RO\$&^6D!>P!0!>#B^Q>J]T,J14)I?>+_E6U\$M2J7)4@>ZNCXPBE1L4D53%)^>T>,W5=;\J82HW8#5A[C4^>WNE:L8<J^V 7/7&\^*FW1JF?C M&E^&H\$S16EVR;Q0-QGN4L>V^F(U@>J=>D^0BX^R^I.U4J3K^R^?>J,IMX M^>@A^YJ]0%ZB^R9L04V=I9FF!&B#WE<@<2A5W#WYU +>0JY#T@>W>-[P]"L7!>KX+E>^>Z(M;3DUBD9XK^RED^RD[RX:>@DO)=G=7^!L]R!^0G\$[3:05YDSH\$55P94+X7 M,^T.IPZ;K.V8>==M1S9B@43A)!>X[W6#_T%SWWE>%9_!>K8-XYWB4NL^_ M4\$>TJ%L0#M9LX<_ %2MO>? 3PM3/NEI]:CIM^5L3WZP@B@>!:JW!U:C9\$J) M^K^<H)=9? 830&O#M^>V^P]O2!SC^>5\$J)H0.YR0:~A=3I^T^C0J]5RW4E34I^_VM) V^VJ6R=NZ^W8Y1F0RI^>= M]HCCT730QM^WVR7%#@OGC3HZ_V]AVA 8LAY^Z8>*/-/>Q_T]MWSJ/U4P+VWMJ M:~K3TJ^U+QIOC=1KWQ(GK=U#9Q5X^>KZG.K!>^WN2^S/@>5]JOCC E=N3[F^>M,

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i8^#EKV=F[+L(N9>5@#8="F]1^E4_EVD_M 7]9=U4E% C=K^,72AHT^HT)7Z 7V9(8.ZY7;\$*@KSCK\Y-HD2MU:X%M H M#P??R)&^IUF4)BE^I4D:8[!IBZ2A;P^H>+>+> MX\$S+V\$KJMA, <=&[09E]TG03VHM;&R;^ \B0/8Q; 4#0\$UCY]T1M _V""^IYE, M3A8IY\Q- XL'E2ZY-XX2.DOG@DW:B@OIY-%W,@C>FZ9S>R7MH" =^10G?H]M] M@X&T#WJ07(6(M?.\$3'X)D5TLO^1H]=T^~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~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~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{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

MRH:S*2OP0S0U,H';,*6X[+QSAQ]G1(CC78M@Ji4I+5P]GUS(P0Y!Q"G(4(L#;B; N!#3598091 LL9>^'M7
MVFX)C"U]I+>A;^GFSUF1[9]=>B\1%"KE3>H+=3Z]<]Q%K#Y_DPNNH4+%,M(L#; M3)2I4,P=W_*:C[5K*XD881PFZ5TWA;/2TGM9.XQ
Q2S"ZE/N+P<|J%#GG8N M*2_QCQI0=D4-ZY4H*4A\$KY;>|~)7+^H&GIP(7!|9RDXI+PS#E\Y]26?0C_] M%LQW=G(L@\$!HB8BR9@,\VQ29:N=;]*J[2)
(J.D.U2.A4:F**&\$*W@A[M]1)[M@DXZO[Q0N]FW,"9 L0V7)](L(HUBQ;5B# ^GT (5A,H9&+ [OWMM3H(19%" M241.8=B0*N5]A&;YABL2N^H!M7,
FT1!<(DI/@,~&*) VYER^E-QW,ZN M9"]1 T615/F20(8B!A: =|;JKT)*[4X(HX3S+>2\>9>NS76XZ @HLH\T1Y(LKYI] MO8+=LS>@
(J%W\$=(=0>4DA?KEI,EH\$ES@ M.7(?7VY^*V&@+>3P?_+"043@J]=D<[Y.H102%(EB>C3AV**508I%25.L-R< M CCDO"EP=;)-1?9J#V6>I5-
L[6KJ@*^M^Z81Z+T]G"72Y#0KW15/9 !7 P\$;+H^RX9;|Z&,1DUO,KHFS(BF) M+J26F7 ETN\$RR#XQQJ\$@0)2T.G\|9:.X&Z?
_||\J(-0BK2SS@E5B9Y74B" MI#U?>WRE >B; 848HT+1>U4]>93V<C]_Y1I RV6SV;#J_NI|!V*#.OCW
M;VGUSXA!IF+Q)XQ9;N#1"8<6GN5#0(O)KNVY#XA),CD881(2<|R3>^2C\$L3& M2"C.V.QI!V!2NP9XR7M0[>ZVXWR+/\ 7,EPJ%)91D/H.%#8U.VG@N
M_5(Z%>7Q8X^08Z0Z6OQEYTGXP\N^7EKX9[|VS(VFQQF4S&-_SZ=3*]@OJ MS(X6FI\D'0-.I;7 LR'OU^VU%G\$R\$S5,CSNK">^WD954U-[K-F))

:L8EJ M\$Z50/\$L&318,Q8:"I:CX)Q;|1X@)O/1#LBRU!4|/>GHA| (L]5\4-#8D2>AD+7 M(I6@=.E:Q!P_0R|=(M)9P\,HBT+VV0XGW^("U(" ,IA?'TG.!1Z_)
[JY-VD M) A]E\Y\$X*L;3UV<6X(KE.1I6^BQ+U-.KA\$]1(7XO?I MU@|P*?,Y41,[C(R&HKG8F%|9B6%;%BD^5]D=I\Y;A,[.M.VS>ZH'SHXM4'2
M5!+^+C.]"%E?3<=ZG](T+ 66SWYH6(;_A4A530\B&0G[M+X)@D8HV;@!71D>U2JDT.52Z%&YF9\$PF+K M@TV?
)\UNETA2S6L6>;3K.7-1Y9GQF%,1N]D]J MEGK@2.>.%Y,BVKM;6T+;NMULS).[4*Z\$;^A2+L.W?0 _EGN#?4*41%]=S. M=MN>@Y\$;.'?
N[16IYC2*90DBIK)?[XYO""B^C=6.]@G>QIDW0Z)%S\'.7Z MJPE70?SH6Z<8\$JR^8T@+>+3*HRU-4(M/E-OZ-^U<98
M#6%=18'.4ZC24!))M]H[1Q2>9P<|), 3-1XAH#Y1\$IHQDM\$C_Z7[2_ M\Q1C??:H9DV!Q:O1YA79;|1@>.<-9-V/P4AS4M"VPTP:4%ZC+R9R\$9=?
D&|;Q8 [4C>@UT(I)FA) MBZ?RSH?;+VP 209;(OAE7F5\$|].?0@DS1;G_.X5XY?Q9TZ@ @&J8<O?7 M#8J2;ZT,B:C9XX"VI&>: 9J-Q&T*+>F+(
MW+|3A[X,G(KBZI|JLQ<^<)XOI]"4B\$B/36E%|JZ]J4R397&S~"7"M O>D) M3KD|,4DGC-RJIGY"PK,IA%\$V.)F]J\$>A:QO4>*3[4J;?FX5-7=XLHW(N
M+Z[8*BOIOEX:GAWW\4H4<@<|XN)%EX,3_P5!>V>4)VK12<^Y%G8-[5\$@8VOK
MH9@'8;+76&XVZ"]26^<^&=KPI^1W4NRBSW:.E]]/8;I]Q('N= _J\X915D 2 M5\$STO:GKR61^6"O4E4N'^T.>76+&("T4.0X)V1]WHJ/2,.S.:Y]N
M3W5BTI'Z=567Q.6#X-4_N'RL.D?W!W<93(1"YC-\| #N,QY-VPKG+2>=>;KS M=?;,%P_?S)VA\$)FG@7Q:W\$TTAF"]];.3*+&<3\$-5^<\$.SM!3: +=O:?
S21GE M]4TDX> #>)-QK7?WHO>YW3162,8B,VLGGE5)H?R^N@KY]"JYZI1VV^&|7NGC
MTA!Z]8'E.Y3"M^T^NB1S"\"H[R8VPBI%U'Z3M=5;%WVLMINZKG<|#9S:(SDT MOID) 1LV"IF-X5YG, .G)U=.4
[C<3PT54H.GQ1=Z#97!4]W|O(U)IX+S% MU3BYOKJ2GN#D)EE<+52_R?79 C_3F|&D_9X|<\\ZC5BT.];6DS:*W=;&K|;
M.,W)3/CO"L\$;,@(WHVGT&52OK_#8U#?'7RN[M]X-95@W%;X!K0:LB M\$R2M4ZX.:2@V30,155U|T#]J]M+VW@T7[7#;M&U1_+Y39+|J3]-/N
MW=O:|JH970@;7+DRR%AGJMSJ[X79]<>^U.S#MUX# 3XBS+GZZ7"~<_W/0; MM->4%>L%Y| -JU>R=>203NFC7LZ3?;W3QL17TMAO&
R\\6=A;#)JE4N!U'RE3 MIHG\$=2AT]!VQ+=O I5Y+HX@E9;@T6:W5\$R*!SX:"[B1Z[3 7X\$'+>OOM-9 MSF[DH+W4UE':C,GSQE/XP+U:7.D05T)-
,W>2C'7./U; M),K6+243L.]Z,KNFUC@=KOA#6I^8>|X^Q3|]-E[6>O@D\$A*]1 PZ:+4 O|<6 M,WU\$51P/'3AT?>Z<'.UL<#&C;Z?.L)5KB@R|].-=|/[&40LTH]
(VJ"i+R>TTB(MRW)9)F5G'7/SH)^M\U7C1@)H.\$(1^9?!=A!|_284AR,[W^+1,9|K0=0)GA)MVXB(0D?'L;TFL [E+>0 MMSW 4+Z>C^E7
M!&C=.W8)O[UPW#FE%#K/P,M&JZ1W/NGK-/OG/_,RL/^M?'\$A(3-KL);RZ> MOK?|4|J]8"U:DF5Z?BK_KD\$3\$X>B!|Z,J00/EIW#(1Y+C^1"?
K48\$VE_FQ* M_GQ U*M6G7P6 VRYP#_.Q'C &-+82'T]! V(Q>*XY"M"JL_L^COQ*T,J6& M_Q8293M 20Y@4+@; MS2K?R5H79U^5M-,"\$;JH?
F9HVEX?B?B;C\JD+O?I M-X>695V7_.ZY-1KND?| W6N)-,=T'ACU"]_C=02P,\$% @ #8%L67V, M(LQ"\"P \$! \D !X;|JW;W)K&ULK5E;<|LV
M6G[7K]"XETEF%|B]@+I;BQ#M-VTN[FH4TF;M]G7V 2\$A"OQ\$*0-I6? U^YNP",M%2;<>F8?+/,")SK=SZ ;^Z->K62E7B85.4\YNP[N]W9NJJVK|/7;96&^DBLU4E
MWBR-W<@*MW9U[K96R9PG;8KS-(ZGYQNIR|.K- SLD[UZ8^J]T*7Z9(6K-QMI
M=S>J];=OSY*SYL%G05I7;@ZLU6KM2M]KYL/UG!_RNU;WK70NR&5;5[KYD@|]BTDA5:BL@D2_^[4.U44) AJ? LR
ME;HE:6+ NI^_,JL.6Q;2]7>F^\$G|U?KMV>Q;Y&HIZZ>Z;|.K L8(5Y*7F<+>Q MK[CW8]>C,Y5KC*;;|D\$;3I_N'X(?>A%E\8D(:)J2LMU^ (M7PO*WGUQII
M86DTI-\$%F\JSH9PN*2BWE<5;C7G5U6UELJ^O;F!7+M29#6+M)+GKS7D%Z33F M/ N2;KRD](2DN?C%E-
7.B9 *7.7|\\A5:M:VJAVDSX1%9M(\$S*AR*'_T_\$3 M2M]J.2-S6HE;RVM;"9^DCMD5B6NK97E2O?UZX7K(B)(D_)@;|I+^A^73:7S MVFUEIMZ>H3:
(1%>D&A2&9#/,M,MJN4<-.32M2ER99V0ZTU=Y J M18EJ]"IN1;56X1J'09FD:7Y*P@_?)KEA?2#]DM(6*B@&1@>:>W%GRUK>TO: MO^A'T/W-+@4
M:W.O|I0='BRDG:LA|, @4D:\$8=5DKH4NAEDN (%W)+#,VEW !<*9:TQQM V7+^ M9I(C?V>6!P)KR"OXF710-M/O&G:JAZVV/G_."%WF^D[G-
,P2U(S\$;Z;"K574 M)2@8!'ZJ^U=A=7ISS!3)V@. *K59X&V#";SQ>Y6%IPD '8E[995(IL,TN1"1 MN#XQ>2B2X2B)AW\$^/@3O&PE.557A 0LC/|]^@7O;
M%-Y(9&7AFB3UDZDN5:9)D]QJ8,D.RZ)2'S98NA^'J J4'CZI+^"Q"*<I%-H= MS_>^17&#&G>UH-&<[8OQ,"//L.2- MD3;WGH"7ED(61V
MX>=B.FM4Y:24=U(7<@&7431Q|C/XF\$H#?CUEE2:'2++ +_G|+;SHG^>4(A0?9 MW23-3_ 9)*%>@I90""\$&%6DPG|1\$>2)
Q)+N#O6283GP)G2@ (FZ.W5K%3_Q_5-?5V&G#=-,\$>:|"A-IN'Z3|@;0=XE!2.]>CVQI=I8 MF@(? QE^:LI>QDZ^+7F&/_!3 \VXOK%C\A@Q>?*
Z,K7#FO">=>LB0 M*DB&|,I&P8D]R|= 5_R<^+,@M2\CP34:1^QZDXV@R%;-H)9%(NS?P;K!69"NIP8\\9C>U9[P
MX+E&|]>LQ>BV%83OETICV#G#W0Q_49S!H=H^E7V|(INBD5PF MY)YD\$5&L1LVC<+>0.O3ML=C*,@8;\$2@|UO/7.20F51(1Q*6DZ)|/2:/(7TP@/
M#F(I\^QNP:ODZ|,X4K-T7:5ME=4FY6&Z9B\$3@9?2O0#LRKU7PVN/24(F@^3 M>-);^X_#|.T:>Q#,
L+>:11@|_H4LO>U>;>@89J!E^4V#HDW#42"ED<13"H8 M<^<O-F;75/<?>M>?>HER)_1L,HKZ M9\$B8@-G0M(D+9Q<>|<!,J?
%0T0""B]TP|]\$#7X>R09\$1 USCPR0 %S|U5V% H MI:(<2\$ 2X7+B+>P?M?OZ:@GF#!>?%#:1/P@1M%5/PP^-W 3ET0 M]"?Q131^
H9'/F>R"KQA)U612YBO*_.#|VVYU&HV6IHEJ]2A|_6["T7 MOHUF|555C:^(7G>N(PBAD(*G^W;J."K*5I(8^X/^O*;*Z1F/RU7P!.*S
M19W[7+^"O3X4^9XKAQUB>@?-=6% HMAJ=X@<LB'5E:XV3|<X"5W:4;W,@^ M|;D.N;76Y|,D6_<>X_#K<7E!4!829@;@;K?
%DL=N/=M"UV5#169MM879| MB35VX<M-O-05H_ MB3#B1M]7SZ\$3;G(ATNB,*\$=>R.8"JW:6"VM%^\V2L.Q7V4^M)
M[!A2AJ/"9FN\5T3D+>|;\$I);UJ;_QWIK+(G_>R^03Y4\$*C8F!|(9F)EE[R/IN> M3J-
D|@'MLBN97K%(R#R)XF[B'A0M+SH:W(T[43^EPP%G KORAI'V4]Q55L^UB6 MZ_\$%T/W/2W4*@5+=+5H.L_ *6M>9>3:FC2+ORT*.'=3%KM(UV 3?
F8%6/5PAS93 2 M(>R&L^|B|L)DM^KJ0+=U4^<B6V%;UTU2Z5MYHL^&O9WZ0;\$/T=5,1? MYFIS88X5A3/J9|FZ(LAH'8,R8#V0(IU =SWK8)^
N_>G>(\$RCY\$!V)TI="Y]H86M/6>+>0>W[0G@]^&U-5= G5^O MQB4Z[K6W:WTY>|!>Z@ 6VEE0\$8,SX>X?EWO[P"0>?9M2\$NM&#[*,\$;P6;C M9#X#-
QZ+>7PAYNET<"N):7=>G.P:X 48M.H:'HP& U(E;"E/@|!]Y|Y.YWD _MGV+D4Y2,4EC|&N29,YTT;O2(S+Y-->N:|J=8UJ|#_GLX\$J\$1>36+|3D%B
M>>,T&?,*6=|"/J9V5A3AY@^JQ*HT1LT/DPI2\$RW >?7#!@>@U\$W^!T^/J M>G+O455[VR.D]I_E?B=>?S&AW3-T7!= M%|GLX26@W|,B1147 -
X>5TK97;I&@|2]F5_ZM:4:NW]"_L|6&V|J]"OP" M:#89!&|Z^62->M+HE%|P|A^A5T|T(3;.">P6TG.64 MAW%@3?!)>2NZ4^B|+P65|1?/H03-UOC
M?;JM*"U-59L.7:X4LL30 [Y<&H0DWM\$#|\$?S] M?U!+ P04 _"-@6Q94+X>2/<_ ,#Y* &0 _AL+W=OJ:BZML.S.35#)QQ7-YV-H' MB(0D;\$B" 4@KVJ_?
TP!4|;(D.VY)=JGU+>+% H|&7TZJJK%V=G(E)F)G)N^*D6!7Q9Y\$S"5[T,Z46/+63\NPL"/L/Q6S5DHJ)U[V+PXG)(X^V
WZ58F\YG1CN9%+%OKO>?>=\$4ADAD M(JE L>?6W\$ELHP\$08VOC'NR1-|]'VTG^T^>=>YMR(*Y7)(=,J];HW|;44 M+>B=59_5^F21|&=\$\A*5&?
L_6[NQ,08GM:E4WDR&|KDLI%_<K;#%9(T/#(A M:B9\$5F^WD-7R#; X^2NMUDS3;\$BC#W:K=C:4DP4Y;2^%5B7G7^662|SBF|
MYKK:L@U+PRW|CQ*OSBK(IU%G22/KTLF^CLB:L8^J]%;&O2UD>|/X->J?K*1 M5^X^R.BGP1I1|)H\$>W^XVMO+BIV^>?>B;B|;_ZM&G=GA8+7-
M"U/R1+SN(3&,T+>B= [#WP;C4)I8>MTL-3TA_IH= R9GUV&D_RH(7B2R6 MNX|_>RBU#)C|@JAZ(KP#*)IA),?70D^>+2K%J)=B-
2&HM*RD,NZYULD+^ ML(NE@%)7^&VJY4=|JZX%8AM;0),3;(Z154OM>+I6JF42)E|J6J8-<\"ME/ M=;70HB[2@-%&0(1GJ=1(^696K3J!|1CHX8F%2[8-
9)<:>+QIE+>)%XS&5RS6 M9V|Y|+>|NZM^U/W/M<@S]8T6W+>.(NDB>T6;Q:5/AVP,6LY(Y62%ELP/I#3,* MIM/(C@,(I,Q,RLN0'
S13"PE6V"1ZWBG#&#<^<Q)Y8Y|]=,X9&G&G;F?7:1 MII^R^E[+^|CIR FA,|@K8A_Y|UHJ JD| F;CH(P#-E#)JPN M59?;_V_7>UX5@DVZO
UG:4PMK'M1;#.6"%V!#3,G*@\\AS[&ZDKCUEP#8!>W638&?7TA|]- MHRAZ?9 ^K_FDGVE\\+9WVW*]OY, !9>TOZ(-J\$3B1\$8TPB2),G|"];<U84_E
M,Q;-|T\$81T?,\$EA%GDH.C,P&\$PGIW76M5=TM?]* S"67Q\$;|_K_-BE@* M_*4Y511YW.76T=<5^XU=F.7S'U2'30 "J:74/2*:+F7@6#9\$F%<:&U_-
MFFM|QO>@&0JKM"!;^,6(@>Z]1<O5+*1%L^-RFS@M2I:'W'VNTSY\$>./9T5 M#N\W?C0=I/ZI?&^!9!
^OFT^U_P G8[CS"^U|UK_#D03_.Q|MBMOT&HFJ0 MLJ@ZWLBJY|VA(\$S\\&JLXN5^?)P%L\$;LG5MS*M>;8CV6O@\\N5ER"&Q0! MNRA2C";W0A?
*'=FCQL\$Q#MU9S_#B|N;D2TE5#G_5(K:~32EEP;GK@'294? M'8/POO?< \$!)?OD2IEM"(GV/@F@R#";A|"@OH-
#81J|(OV2\L4H!U|Y6F*KU|I[H5DVK>VN?"H' M7)NA%5^3_F&D\$>B#,L<7)8FXP=L<# (I^X=XPQ>;C E H>:R.84Y:)="9"7->93JB(_0HV/48=&
MNB5WX8%|UKU3R9?BV";9K&)1SB&S4NV18C)ERY59W_00I&R!=VGH;LT|- MB0I.MZP=>Q5/I(_TY10>MP009<83I|(P|/6-
'21&#%T4=\$ # M!^54SS_S|>^\$MQX,6PRT#1 A(|-GDR#F9A-RII6W M(L)V>M9].X:~B>X#";E%(J@ZW^V@XN|/\$^W/QN,ATUL5<=EW%6Q*RI!&.'F@
M8!;>FT3+>5,KH\\LB3WH'HET2P0;G G');%08ULX<5A]U^K@|Y/Y'QF\$<_ M_>68%P7#R |R&A:~%3S!5%DS,I MH\$U8.CA>B)V@&
(P1'XV|O+<C#F9/9|-'T" TR|J|_UC/B2EISBFS">?T2,O9 M|S^.@GA5&=VK0-3;N5@|K_.L.M|J@=\$^U\$Z&?> 9@C'H74:~"?0?;H2T,=
MC^<3;^_7.0WNOI3.!(/PF :CQX%6.7&4RT\$D8VE74@93^ZIU2VDM\$D|B-JL M08\$WQ->.@N7MK=@>-.9Y.3WNVOG_AFNWQ=#B5JK:8
,B+S.U:1^U.408H12> M>?>@ N%1<6RRCFGC"JHO|@<&>504-R#%JT+> 4J72E,%06FLYBB<*"GWO*BYWB!)" MW)D,L=|ETJ7A/CO>D;|;S!?
>1&TY|MPOV+X>J,I|I^O?N)I|(>)>6R\$?|I28 M#>T;"T2)B,S|DX"AK#R!+>727 9FI[FH(A<7A@N#|D2]2I&|AJ OJ\$6DQ?Q7*> M.KY|I|J\$34>^H96-
R\\A|Y&+^|L@T-!W'=33SMU=VY\$ 3KB,R"1WNB,I^1_ ; M!|. #;WE6-ZD_F_CDV6H<|?];#IXC-WBR>B1=KMH;F!\\.770%;R&Y\$T3P?! M 457G
[9\$Z]6V|Q:V\$A10C.+RV2I%\$'L5Q TC=Z|7 =W*Q^|<^U^6V|_SE| MAU5^*6J A5-8X1OCBD6Y!H>T!#"ITH2BR,\$-/[VR<X-WO;|>7.C% B007
M!A6VL6/2]YA3T2 X&X#MWMW9N|=[>7T)]:#'+HXW&[G8_#A"Q] M^X-G =F,=TCR0/4^U=EFNN55V9^AL@>KP?>IACX56TT&0N|K-Q08,=@>
MFMD#VJT&>U5YK6I4;V+_.9RW^-9 M8FS4K9L&>4J&8I?IV%<"D!:'E'>1/>"0K#8\$!I!> W)MH,H5O9/0.?C>N2#| M0F5|K726KA\$IQ
7_3:9=,X[8%<W9]"-=PMW5|D2A?-[HP*?>_ GW|+VQC[M M&2;6NQ\$^\$L;];|BB><6V>UEB?7>160+@/(F|@56IY|A81Q>=8] = M6+!]=^
'SB8Q!..O+62.,>RU<6#<O =^TJEP>_&BU?8.AFMLO NNC7Y7JH M;V,E^E^N^V!W1L2(I^!K!D!X60*^P+@>?)7L7"|G(L6"1PCPP@(VX%ENL
MKDU)E?;1R+1XICXFSC-ISEU%|;MM|J'9W^K*7@981B?H31=W05+NW64?6CB M!&.S\$U9YUC_T@M-9YW4T5).E?>F.H |UVKV9UCYMW^N[<^*S;8>
[EP(&_P0=V]R;W-H965TWLWN]=M)DF|GVF) MMG@KD2I)Q?^<^CT I?2K|@=+&T|IO/E KBJ5&1'TTGDQ='A=1F='7!SV|=U86M M0JZ-
NR7"5T4AW>JMRNWRA2_EKN!7DRL_8;W=RDEZ,]&:1RE032(I^G4;U3 M>4Z*8;W6N>HW9(6J|;[1_8=_@RDUZ|L_E=|JRR|&KD4C57%9YN+/?>ZK;
MGS/2E|C<|_B&66G+T";U@RG;C=C^M J|S+>[PMGE&^1+>31!|O*VJ&<=A24^<^#P|;Z< 50301|GWBK[?;F8K|1ER73N?B+.(I%B%36%B4T]P\$
M1)53X= FVJ/5B_*ZWKA%.M#^H.LU0G9I)536,Q+4_4.(BA97)J4GR6^*)1+ MM,SU?Z*Q=W7S2SP,W7|^*#;#@!'IUCNRUQB>=EL6B7PH/+>+)H]?
MU?3X MY;D7;7K|I@Y;^N"JZ'FI G\$MZ.90/QQ(I.0%O^X(#..VJ^EL_&E?>^"USG M6CG^71M)9165|Q4911YSU&A+>A6@>2#2#FL?>5-9#
[9FN51YH^*A+G.V6F0,D7U4 MSA)D\$U2 &T1^<H|<O^P|H82.)B;Y!K0 MP;9\$)S\$K| 52I]TS CE0YT6L|D>KDVU|KKGJ?8YQ\$;F!SN 2GWW^Z%FA1
MG#(M)LFDD[.Z3|NP0^_.SY^=|PX>H<+7W60;/Q/F4TQRB1*RJE\$4LE.+I< M0FFE9\$G|E+@>#*4_8Z."M2+1?&^J 3PE4G:F Q)?N_=6CM9;?
44Y(CS;61 MY3DWC\\@X\$48SDVU;63H;CMY>6>JAU^U.U2NG1;O.E1AV1;M(VIOZIH/D6|08;-&59;Y2L^F^R 2_2_5/05E1I!> M^M(M4(T)Q3166N1[?!"-
GQ< QH.XV8U10W"9R69DDVP1R\$9)V=P|D=DH MSSHVH^12RXZ&Z^A+PS>JZ,PH87T)V54LPPRC-3O)>K|HK|>NX|M MTRQN|FNNJ?>
8YMB|LF|9X\$.Q:2]WQ;K|?0&)<P+Y|,++_O^)-D&[M|UG@03E^9+J-&|H*#4HDNYXP7%G/Y;J|IO^W2 1SEGII;Y;CI9:Z#K M0^T#-\$2GA28FSP|<^*]

[@/.\\$1UL\X/H/- "5*7DM&V\D8F*M]%;BOZH4.PMF5S.%\$D&(RG^*RH4(-"HYWVW)>.<IHS;]>I@07X(.Z78Y>IZDF M9D
AMD\8(I/H/*W**FHJ)?,MH.=>?%&ES0<3Z-K/V2;:2. 4W<3K.. M@OE7<0B1?[(IU(U4 T];>#;/'75<0&!Q5W-[.@. (Y@0)FB@YFV*,<JIC!>9L M%3-
*&Z'JJ/V&F&IHJ177?0A.SZI ;8XIOF>.D)@UJ!K0 M"P.8\$PPGH!*UT;:0%N129][F,81H(Y\$E9C3T!1X 8_YI\X@MB-D2%#9>/'@&
MRVD\514BZ*;UI^X!SG2+!] GC-QLR'L&L^ ~%gD%>@4@!1.#%-6H K'WQ!F M;A5?[(CX0IT>T;]?^E3?R;4C7ZPH4!Y; EZ!1*1@7K;*9J@>^5.2-Z@G
MK[I>U5!A"4;P:@A&A![-!@IAMN:XH^J! "DG*\$S&L8"V1 90S.H#K1.SK M0:El%AV!][TCL&],F'APR%K/J!*~&H\$YQ<[.FZ?2M#J#@*OTT@V
M==0B.Z&R&8&I\H6C2&%MF/^@;H-H>FMC2"C5/A)IG7";P>FIB%4-061A>3%7 M;E?Z["01C%MP ;'B^D%A\$A!@:2,1&YZ.F%0:[J.D>7_EXI+^Z
Q*S4L4S0 M3B'Z]5 [KRBMU5/8W*!47/7D\$D+&3B1*6)&+ YXRG#@~")XC_A4Y*[U' O=>+: Q;3)(M'GVFSYQ_/7PKDNKEF:9 M6/=:@3B*]^
L'(P)I\ZZ6,XS)4FRX4**SX0[3IQGVA";PG#CH;FIV' MA*QU7!H\N@N21RQVOQ!;0=M*7[L;.&+?
KWRO*%WGS&:"\$D\$>X%F&K;WK^@%0QZL">OB(X\U13U**RQN\$ M;N&X1=RK[Y4R.. "V<M!M]5S*V&7[U<><(\ 23OC:8!&K2W089A./JB9:Y+J M9'=2/?
1>W:VJW(210RZ&=& _I ?>#-+C0?9AEF[KL ~^).4T?K?V+-%\$NZR'+LU\$[GSOWP9;.(6-F0! %7V9*PB\2.*Y& -??4;M%<VKOX'4\$L#!0 M (
V!%;EOT_G+8@ (40 9 >=&P=VJR.W-H965TU*=G#:-!IW'P#;VGWV5=)[_<UN;9HH.'7!7VH,Y5^U^S^!);!>V MITLL^&6J32XJ5^<KIR2!5X;L!6>
M_ -XC\$K?#S11I_EP(V>9XP JP_U2S";[G-Y;>?BMOT!982%6E;H @].%SE&T M=M=SQB>2_P1>+JK3%UVT-G10(1342EWH^U.C(91^!BH>CQ
MAO_295&D0&NEMD+!>Z.KTL?1Q/K#)7.7ZL"\$>R,5MOA=MJSI4CPH\$[J8M'< M8?>P]U?1UN#=:UZ,%EZ,GD/_3XE['C*>O
2*EP5<(H)YA,T\$&WZG,1=EJU0UIK^,5262-T8-B=G;H)P*;"4H3 MNYKH"/=QZXTKG=AGLDDH\7'.NDJ1]*B+(U^D'0<4#W")@!^8W&F*ZWE\$+>)Q
M&H76T8,L9H#?2ND>.384(1<M@65Z,'4>OPCE8H04XYVTO8XY.G!1;/&BGH4^YD.B)T!8M<="=:P[16"-
MN(*84*1Q3UB++K2,DF(BE722XF%0"1=43HD23B\$;ZIDKBN5+BJ\$ MA6IG*!WZPH:C8=.EAID;G2STPY6A!(FPH%\$S(1&HG9+?=:X@HIX! M
'KPN61_?Y*&SE&M1*IJJ) ^91<+!+I+";AC'69/WS*1_ICCX?T;EO6#%DS M:6UG*CEQ(OV;=B?O=BO;0)[6L!+>V4A4Y-L]Z/#&S^&)*\$S;PJA#R79FA?SN
M.P8D&9?&FZ 0>%(H3+TAI7?>133RC!<(&6L@V 4'"X4!W<^'5U#P#2,C,B M 9MX+<KV-Q5P;1F&N+3LH;8A82^AN ^#0Z3U/>68&FOE^7B]S?<
LOX1UF*U\$ MD.J)3A#6UTR3G'N\$ "6+Q9(":(VV9KTTFGT5)\$E(&F-R\$&"I4&@N5\$S)^*7 M-SWRQ)LD:XJ*24YEG7&#?
QCP'9A4;36<9%SUFP0HDB0?GE."I|<.@.TYE M?&1;.%&6!59EAW-J2)\$F\$M%1JN%3!O! :B:M=W9%1)9X^3C\4L_EMJXM>PM MEH%>,%ZBX+^<-
TJTXI&BZV];(8A^(\ MQH-H2N=OG@3YA;[M\$V-Y=2XTX.CYKS.O-S.12!A=N3^X8FS0%ASZ,AM&G7ZRR!59T;B4ICR*BA<(VYS7F@U^+EA+ MIB]-
G5\$HO."!%P>^<,>VPXMM:CE>F.N:VI?ZGL;EY2M11/UQIL+[C]=6]_FIA<[!<4,D!&UI(=NTHG380+8^0:?(%(\L MH\$S?H>^ZT>
[.QGLL>*KY%9'2]4/R:9C043",=S<^H#SA=Z:>F0X0]I >9YQ M/S;[4]0=11%GJQ9JZ]Q_#6@ [N]&6_!V95!#2+=LMJ[V*XOIBNWH_X;VY&C\ M
XNCZ!_J]N/P!R>W%U0N;B_ QGO>I2<65&Q/D/O?&P=VJR.W-H965T/95*MT6R\I\ZZ&HV!<="K5*O3 M\U)I4Z6!^#V8)=S4WLE-3Q8YNJRY/9X
H<L%LD:1<>Y7;G:6&TG%="VOP MGZL'BU^C#J60]6G C686-HMD;-ZZF9)]_P'PU\UADIR8WYO0A]%(LD)4@
M0'A"X\BSAUMOBH"0QM<,&^FV),?>XO^6]'.6G+NX-H?V3A=XMDEK _KQ6 M_M\$+)&M,TN\$R9JYTW9_#. #4NKXRY^_./0<9NDW'+&(ON\
MXT!Y: <^!7TM_B01SR_7>=[@:PNW:LT][?+KY MR",L_3D2#<1-A,B^ 7')[HSV_<^<Z0*%_XCI-QREI_-JF[@&NHAFR2#EB6 M9M-W\"]=QDG
FWRO10;O.G?>8D7?>TIN1)N>1J,NW7(5%!(L T/T'R^V9'1P;E&4501)3CV4%NQPTIFJZT*%;GH7K-[MX4T.EDUCW ?<
[X#+=FK+B^LB\$T:%M/12,LK*%;ZR2F\$8@K_9,(F;N.=O&\$" MK,>Q@]TG+!22?*>?]:T=>PGK-S0FGM0Q[C9QP^S+\$N06WK6A87Q]<^,AT^P MD,[57
M@7!/?<06T'60P/1/51,BGHH'F7 M9[PK]C7#-;.%QC(ZAC^&=QJ0;H&YKN0X(%..:V;V\)<0.H%EINI B^S.1 *M;B/_Z_0\$GT_Y?<
V:X\$QL3@HCVU4=5M1F# MQ5\$9.5761"4=(2[6&N<@[OJ (OIGV;XVO^L-IV [4"N]JLP!+/_ V!>=\ J] MGR0U@SIB-L;L;1/K1N;F YH!C
@Z&HL;C1Y[7YQ>79(\$U3ROMS_ ^YA_- M- +@^0]=UWR8=O=NM>)'GF/QO/Q^U_-(@W M%"^TU902 V2 \L55H^MC U56N-;2Y#>7>(G>")4J5]@KV-H
H)TM>?>]XR*WP6 M];SYT^RAI!#V\H\$SKX411Q^[@^T:;QXYA@UV# YFE3=08G(NJA+&B\$6M&X. M^@(TNR8>)<
[>|^FYXR3%;\$H\%&@.0*\$S%EN"ATORP\CCZ2_2)#(A)MDB; M-*B06IGL\$BE.*U%KNV1\ W_5<L R@([?"2I&]6/7NNC_07Q;(VS\$LMU
M#8!1PJW&>18F/55[\-W4H]O8ETE(4D^!U/&VAE_ #4V?2J'=0?K;<"NB,5EK M'Z'.W6IW\5K%^:S>;RUW7&[I7FB8(.NZ?<
#B+&\$VWH3BAS=5M^WDQN"/_! [MO#R"6,B,SHHX*FP .H+N.+O^4\$L#!0 (V!;%GFJN]^P4D &D-0 9 M>=&P=VJR.W-H965T_5[=5_&Y=JY-
/FV*LOGZ77;E]\^66SN";K)E46U"? M+ZJN7WFOM?S77S;VF5+>FE3?#D!C/_#OKYN\8LOO_EJFZW=E6M_V;ZOX=.7?1EOG'E
MDU=E4K05UT\OIR]>G^V^D<".\XF@S[U<^*+&]F]= 3M;"/QFGC7N=57FB_?Z?>?7CQ-EFZ5 M\8KV0W7JGTX6=&C+&JBH?FM_+L]=_DL6O::B,O
P2;O.1 LT^R\$0JY8280 MT\$9[R!_1E&^R-OOF][JZ36]&D;#&VBI#8 EY=X^E=M#;_ F%[IS162I*E*M MDJM\7>:K?)&5;?Y6%2[LLW+=?^*^O)%
[IGD0/\Z_&K+&J;^Y)K9 MR#3DW=5V5XWR;?ETBWC][\S\$D#W<X7J\U6SO@&=N.T.CM-D=CP[W3>B=>^# M\$QKO9&2[H07_[MYT]; -
_J]K;_Y\WNGP^B97C3%;&^>@?@JW?UC70ZS;_ J MR_3!^4>:s!J]M?^1H^<@K^RD6!+UPP!^1G#)#J^NV11E0ULPS)KW3)9Y64&
M/V9%TK3P!=S)MDFR<@E7:E%MMEEYAR_450LO9[5+8,%;>9P*UK83\XK-! MVW!/[@8Q+00SYB5]JIV@9H#_M
M7RYFL<7WU>?OJ<_IR\]WNV^,QO!>G>O3\$;A_ JOM!# 36_ DH7/QZ/MVSI MEZ\$C^#M,OT>T^!/=,L>-<@<:
IWD0!QY67KZGSP;Q^@X>NW:U@U.XSFY< M;G-N#;SAI?>@/(P= \ %<@1VJN]JUT4;V_ J_ G72I_VY7.3 TYZ]C9(!0XN(M!FA@= VG1V3ILY:>(G
X6;7-2UPL^-OF*%T,P9J374,";)1DR]^ 3?-JD;8)?L&> M+79U390Q:P'QDA*@(1IDMKB4+%EE>;WWD%\$67N_M2 /X<|J_-L-[('C0E""B MU7P3!G!N)#DBTW
L'J^6+Z<?S\$O@T_0)N]S!>I?>PC4\$;2KY M'K@< D DXC[?E8N)IO?R!YI^Y?&O=^AKV-;^?^KD\0WL9J!P^O\$B8?>@/ORN557CC"\$
M3N@]7;]=5,VIX3!<_0L,W2P;P/X!;"41B6F* < &G^NUEEI_/QTFPC MH9K%#X-JM)DJO!QY^<Q+&OD12>J(1WZ)?J(IJF>T9%QX_]-9QAF7]?7N75
MQB\$B%IU#EP?]&6QW=;-#616P[Z]YZOPG907A(S!0:VE@A)^.7\$ _X3RC?PL M"VQI";\^*2 _AVZ.DT;,>N2QP_?F=S%O!|81C??WC6Y2?
|Q8NUM5NSAL^ M((!+&)&_M^X9XQ)P3_-!P2!P8.@^BHCT&"/_JCM8:'X>AYLS_3AAZ^10<M! :@723P*!_ ,U3@&(23_84 M2I&D0^)=P=2A&JE|IR-
I2U!6FBOEW=^@9L KY5WA#"? M2HX_&JYXM^1NQ@PJA34) MTP6T;E#AQ15NLM]@)3!;?YKH&_&ID+&+D?R^M9C7L DR#R G\$ZUJ8H0<8 M-
H_3K^5-0DRI+>+L:H15<=& T"(ZWP19FVN\U6+R,(O9@*%6ZT BU2G>LU8 M.H;L%>)>V;_.P!_LJ^R4FK2?(-Z")/U@BR9'H\$RSJ;TJ\$!>-
W6""34YNLF')A!/[4B]1%\$ M^SK_28N=R3-P3!A0#L800,[MW(UZB?^!6\$ "RC(LB#&\$SF3=09+IK8/O?C1(M S ^))/[BYYP%_-@N:5"
M)QJFZGV+ZPPFPUBIN ESP0,4 RF1K7C+SJD8[H\$[81=9<)ZNBNMV+8<|| MACV[SRX^8][G#?P @#9C;8YXZ!"=94NHXJZR8/KXP-
=KJ4>HABFI"/_? MJA?P45N&U2F!)?>N>7@H0U \$*[2H,4#&JCE?EZL0\$Z:Y"Q MSM^LCW@F8AWLH_V^CNYJ-8E^<^T=-.7R0_9'570"J3"-_18
>BQ3^X&01BF MJVJR4#3JHT!YJULRA>|FO09B#GSEAPJF;?*1%8>HN"?0:BG)EM76GA7H> Z> M>FUUP.#-
-1\$)D2T[M]^Y<^),G(P+>I;ZC)VIL7C@U32!G2,U(N.F) MW= 168A/IK44_@I HM>K>(E\$JTF+V],8M5U;H<Q_W?+%D^_DOLDE_W8\$PY| @K/M^?<
27S\$ _\$LY<2<^Y\$XPB/ M1YK\$Z_ \$8G?%CO@&=5?2!\$S9 LK= 'OR+>BPI=V+>Y=J9\$D!5MDP5VL;:" MFQTF7X
B>CR=P;|'_J/F"WYT]/^A=ALT;)^E@Y89\$XX\$KXX.SJ.SY^= MTZMW&P/P%AG]^EAP^>EJ8=,MY?)-B2/XA!<^_4UGS[00GR^E4Z?G73&.#Z!L]C#&B||:
[S8R];^:4A^!18F1LUUD"D">@26T6/> M-WQ92Q6+\$&N^IZ!&(\$))-A);YNLHJP; TL9-IHFMUF*SX!Y&P97W>^Z!>0 ME^FAL L!0:2Z2\$3">XPP-?
H8CTR6J]H\$#&#^JFHR!#&#^%|UWBV:E\$S#W!\$S MOXS^1P2)-^D^!&A)P;Y;:G7H&M&A;UBROV<+>;_ T8]5^6!-=#MENN
MK3\$ADY!@VQ)%4*S!"L7:<#XZEN% V4%T0>J/H)/C|= 4[1@^= 6<6GY#9 MKVU=>861N.L@/1E3;RIAK< NT1;R1I^WL)U@Z/+6/UR-3Z;_ ^Y1CRR#
[(Z M@FG00HV&^!E6W1[X8]0;+04KD+SQC;_ U8!KM^7W/R40!P;18-135E!],4J#@<: MBM%6I/<+K?>L\$PMBL_Z^@XR[X]^?>P^P-
4IAF#2QW\$X#UE<661U36X1;_ M]N;V+JAPX2WZLMH](SEY;5>C AG_8PBL-L^LEK;-IY VY+>B3BBL^8HAY=M^P+Q;+&U^N;NZ?#&#WJQ4D3U:Z
C;CA+:@ 6+XCFA N7J9@; M[=92[1?HF-B A)5](E(5'D8)S8BM2N_L"H@#P6!^CJ3V^V^T"CQUFJ7+QFR' M\AVQJ^QJ^IH3HI(S29;J-IM^X3!7?
K5;UA>T!LG^C_B+>^!)@.KMKZ!_M+-I=L#N1HW29 Y&O09T5WA7!\$;7TJQ!N-SSQN?^L5LXY(UB!/?-B?;3NR M^~06.WM^+6>
[FLDW* LJZKG9;8U9LO/&K-6KZ">Y6!NF6;D%>+?(&D^B(Z5 M/F)^4.N.Y"9WMRCO[!^HT0&2.*\$G)-"R1+10U^H^LNK!M;D>+F_2B#]F9
M9^NR@F; !@>->TOUMFRJ] J MLMH^U:~C^AYP\$!-!-MG^PH@4R IQHAW#H? H? M\$ZOA&_Q;.<.:#3Z9S4SM&AJZS2G)ENW#S.EQB+0ZWHEMAWR%
M_RO=UW=PBW:UBANOU.X+JM1<6 1X>+>IFK^_\$.S\$4_!+XP&(SUWP)]_5XW1DI MF3=K+^R@ |\$EEU>ODXOC,S5!>:&2U+X=X&)N2B3Z!I
OH^ H!\$5AE>O^V!->J]J2C;F?>?)L3L MT2F3 37,-@ZC%VF> 6(?>@9^D391^TT(AT5L(Z>);(I#F9H)KX: SQN& MBVWE1^T^L:D0M?>%Q=+B/Y
G=8|_IFKH@#>D@%MNYX^&\$4&EKOD) YTGX^% MT9^RED< !>4D? M E#;6J3DRA@E0&-@E%ZS/^&LKUR5WD]VE,@6!B M"
<+L[Z^R]4QW""<@ (MD*65!(4^!<G^@9Y^!^7N5&BVFM8:E%VRR.G^9_ (!@)E-O&/RO7>563F(7 MN4;MRI\$R/0%(2V8>PUK?
I#ZSC(^EO>?2)80^GG9U44X+2K+=E80U\$D!5S# MN4OJE+^A^!^/WQAFQ3H&0%M\$X.21\$PJ8!HL!RI?Z7EBK+M(0#UXMVH"7%#@F
MTCDC3!BML^SKQ^U;G9O,SOI\$,"V!_QE#NINC^YF1TCGM@6BNN+13.(% M+=+?YQ&_S+T/XK> VNZTHUO 6C-
ORW&6E@DEY4[P3U\SJJ_ =X_1U.U2J^70C+&^12\$*2/>9G97+51S'B'78H^H\$YZ8C0))7L,Y
ME[JX.F]^PN@B, U>V2CMO^K0V]J^7HB)RZ9:NF^2O#6;6!VJOT(BV17^"+5B) M@W=0?Q4-6ZW;9*.
F@T)55.M<#**H!6:TA'B7MDC""H5HH<*\$K^VP^KPEJ.M;'22+K3I8Z2,V5&2TVI(^R0HG[L4H9P.PPA|4>#PHSG 4)3A,47Q(11AI5\HM^K7,Z^JXC8
M/RP^&\$0ZBH3Y+OU8"2 M-V%;_ @!74ID.<2W88-9"IZ37ZL;"2GL\$[(M/_2/W@S=J]18_47\$;7N1 M+A@|>QS5B-.N8((E)=@ RT D;[P@F(K'I^J@7|
D]KN-[NCOJR^*EFOXJTC MOJPK;?;7#C3&@C!N@ PV^!+8^0RL<<43>7/T!626-9=.S3=&E=FAZ^TM ML2HP2=2#U8LM;M'71^89%ITY;B|
[JBG[V0F!F;SHB#6WYX@N;"Y.RJN]T^? M%L%BA-0@*U.HT^T-Q\$<8934H!&I!"D">?G\$QWD,13LS\7-!5JCN75)(J6^J
MXH9/+5B1.22.@JRWV9WN<.>FX4^F]?*(.+GS1NL-!B2YHO!A3.(A(^%3S/Z^ MFAI;!M>.)9Z"1W\$M[!=N< IZ_0"0)LNRT>1XNK5N#4+>KL\$@@HG
6<#AG(MWI-)&C,49@C62QMR 4WOI-4V0<.&JHO=LD=767%1PM5WF>#L^L^LJEJ^ (MZDV@^%\$DQIR>62J!J)3!^(GD7DM1\FB&#&D&
[I+BE]PLE3CH>GD>011@K@ M+V!@Y4JFDCP.?*>^!@3X^43C;C; AW\$>K^"%@E!5)K\$Q[OPIS0\$S]>N6.5 M^+2NYI^X;KXFRRLF 4-7-
%!E8_W(VO&XH7FT>02).\$@J@>-B M&5&K)63S^ MIB;6%+3HRK^HF?MJC&LD;E94T&0 ABNS=5 S8AIBOY;N@K^W0J7S(T&M^X0,IV0\$-1FD-
DBXE6U8@ M"A3\$6WG&#&B(W!E>#Z1!&H?HRBB.9ZM6)*. ^?XACPOR5M8H@PFR!>#OZ+7. MZ!5N@WKN0DB PO;\$.9)@#(8"!PC(Q(E6
U5^QH!\$XRWOL_!N^N!T_5H MM1MKMO&#&TG7>S1-MDQ+MQ^9V,4UL>=&O5A\$9R(!^JU(KO< MZS0W(4DGF^M^TDTCP7=>\$.M^X+HCVCBB)-
LU^DY);U?^IO^\$SFG8!4 D(S MR^J];?& AJQ^PG&XG7(R9T;KW[PH6E4F?<JZ MPF_EE2G)U>U^_UKV>F_ M30U6!&S^QV%6?^JZO.
(#&21>9WD<#P!E,E,21#I E'E9^X=IX8\$USNR;\$ M'(K8UQ>NP+82^YQ& M#;/HWCV-D^\$SMA59J+B;)!^0AW.(MO13>73LO-UPJ.->3X_)J9_NJ;^!)CRC
MT^O RK2TCX\$;3?IYTW?@;@UI^A@IZQZ[S]76!QC=X?PEM (0)59V0>[R+ M&T0X^T&I^9N4_9_.\$CS4#9_!8M+6K_4
J,]PH^2+U^CM+VW^@YC20)2,4EWM M^*3+R!N\$[9C=E49JG?@?>\$7\$T>Q_!DD @&%;16M7,0ZfV6@Z),NG2PP,02J FM(7^K<^<|C)XA=W+@: [2H!<
<[S(0.+&#H/=MA">#*;_DV,1DOX*.:P/M IBIF^ER4>)_19C5BFX/ M0A_ ,0XFO&^"THP6H08Y)L8%V7&[7\$4=IX9IS1_V1D\$FULH<%#TS[F?)/11K
M(XX+^G=1,9JY^A1:AMHUW18[!<^<1ZJ]7QADE;#QHDZ6TJEB\$7@IFR>=H0 MVTT^/R!4:9*!>?|PJ^XN\$<\$?BZ!>Q^QJL+&B41 G,NB&C^3YL4B?<
J&J3L M=4;BGD97.#X&LKDVO M^PXXMD.CE^U:._@&T#6HG1V\$*1Q^<+ZD|OKTY&]>#3# M3M28+D?;>#KBK^2^1^THCV^QHAO;V6ZMT#*.
VJC^OZ^!H)/Z_U/5RQ%M!BC%?_ *MR&%?0OPE\#-!U3#M\$M2NT0D0@^XCB+OYX80B4124BU2GSH51N6^TM MN:3TBN/^VI/_^O9G_-WA@?GUJ:-
/2;2LJR^#TY!&E,BD0_V8;@/DC KN1 MD^Y^FX:0)NWT[LL_4Q(6\$S)Z?I]J#@&7;U_9P+S<>XR;ZG
M3C694+&#&ENL(8)^Z3083[8^& V7B!_@/D;C,]8&@BLY\$V\$J(34W\$?_ NI M8D7G<4^TAEP#XTBBX!B!@37.>&OM?@Y&J-
C0;FL>H^,VFGR44E6)=U3^IAS% M!Y*>7 HD&<7,3)C05&6-AGDF+^T"8 YSBR+S\$P/4^+>+23\$@@@RU "BGBE"0*9W/?-? GQ84!GB@ MYG@JC-@A#
BZD[K.N6?><)R N[K^RRE^K:OI BI5^>U+G^&^\$SSX[<3^>K>)] MG=UZTPM] 57J!&G^R^ GFH/R^Q;[Y(A!&)-_@ (GD;R+ MJP?4J
<"DL799K)4OLF>=E.18WHBB0?>OF)^HD3P!.HPD94IXCFV!<1jO M_2PH OS(J[PZ^!);^*9-WO!GH!&@_!J5NE0W\$J/_UJFS\$7@.24-PT/P
MJJJO_*(AMN)"(C4D.T;J5\$E@V.2N8Z0 LR66 MGE(RMHEF9>Y:~^LWB MG\$J00@85%_TP!&31N>^2^9G1@65I-

```
%<?>GZ1R$R0*B[~/*1N=Y"90136F2<22;F* 7B8'L,H MJP)3~7W .AF2-EAGA|J|;9&C 8T4CE&2R2<^:@T-& ^0>5/3'!R?MFU4?N!P M9JWQA ,W71/RD)T M7J?<:~%M,@P-8PU""^8F--Q8Y?E2(^2TZ+ ^FWQX600#"+ 2X+QX/SP@1LDDID.= MDF;=E906=,?765%)00>:=XHC4)S'7!(EU*AE?|!-60)- *34*R=|3C*W2~(Q)= MAC3*~>QGNUMXE|WVCV|IXAY|S?>LTK45Q0H.&F"4POT5!0I,5=2Q)E M&TR+UE> A?GVY""+?2.PP .25#1?QR1FC(1R)1DLJ4$U"N.@~@O:WP?CDDT MVV+M4ULLV)"S85(025,R;K;JE&A+3CNY8IZ;,|J4J"2 (U!Q*Q*(DY/S8(K MO: 1BH)R/%:S:EGM~^|;#@$4=(>^4L*_8<6(VQK9,6P)"I2HF:!=S-B" *I M1EG9<,EG~^I/4.80ID,$ K:-G_.$G>;+C*=?J0 V?~NQ0H^U9?">ZHGX14/ MJH!,"|S|J"Z^9C1G3,^?VR5-3M3*L#.9#|JL.N)@JAGL|JT?S6>=QAK_*K|74QD7N1?>?>S(XA:R)|>2^>2K M0+^U#<09..A! ?8?#5,2CV@H.51%D)I? 2510R&5$U5T(#$S#SG*~S+O6ASN1 M/ 78C044C^BJJTU^@SJ#S".(WDKJ24;87,UJ9N5EQ0|B#4IA HA3G48(K$K!^> 3 M#2.T C-> *8;;AU7#Y,9Q<%-8G14&JJ3SJ>+PDAV-(^4Q&%%]@#U9ZE)? QT M@W.NC[1D@U@6FJ6 A;M;4/XXZ1"<;"$CUNCC*M$%Z;9V+0F;FII!>TB.LY< MHVE-10$K%$DW$W5531-W"C"N"HA<[. |:(Z,|4J1J+-N2/W8J|EW:RET:5;#I M.-B-|KP7=37>/?;#A1DM51-Q0$#8UC9G<8A>#*BN@X) 41))#NI?< MA>|2T U5H=Z&J&D6CP?U2/& K%K%OS&3D)12LSM5_!U/O?R)+S5Q$1+U M:"*ZT9@|F$Z91"E#70M9;07(W>BY=>R- W0_OC:00NH$D>UXS'Z#,2<5WIS# M:~6/I+-X/QJ|*R( T!M P%|0$0!]&:UO2"LT"+L|+YH00.S!HX=10LFZQH: M5(^B|P#|73RGF:F0Z(KW)L#.1C**PEM+>1$P5,89J5M|4BBLB73ZB2L@O) ML^I%7LJ;C^P4#/,|HJ%>0->4X1)|KX|""W%B%-J.3QE>Y+6->S1TSPGMW/W.=|X8E,Q MC<@1@ "M" _5K_?#;9VB88$DUO"O*RP,1(1$ _#^(1OB|PNZLPCGVW=OEF MOH,5T>+9Y-|74_66&<6-9J,NTR>5L.$%- MC%~C|M22"7)9S=X|6VX)NYR M:%HM=1/G,66@T,JT1&TQ-IU38REZ+D8$>Y%Z-Y%)-SL[--+>6V>|KJS?~NF1 M&@JN""K%1Y(K#%V: ^D8DL)B6!C.@ U22;UV7~(W%#<@?Z$ T5ZH,@|FLHJ M2EC2S@J$!$Y11HX=X8(H=+*32X4+AL.Z2ST6"Z+E/A8@#!(,|P=(F/75S MQ|5CN HSYK0GSMHC0)T|Y|XQRT$M#"Y#<6-G/3* M8)YQ=LMM<^95-JU/PC^&Z, QO00Q,E4XWE$^ND:G M2 D M<+>|>(<:OM1$=L$=LL$S"? 3 _>GWX=A+42V7DY0V7=PFK1G6FJ~HJWL^M)Y2GX+H+Z1Y3,I,PU@QF)^K&|)NOR|UBD=|+54T;*U:3^PDM M|^>O."AWB11_Y9J<;F8J|(<47I&- )M@W>|@R?S,+"E"GN.>|KR9|Q>|JFC"MK MD^4W? ID@^<^<7+>Q1|:(3 M?7D9?G4,@Q1!8K G8XYK4B/(OFW+S4BP06(|Q-IF%AKI,-ZBEA'# KBC>P MVSYZFR3DP=5L7J/2ZGXJ7Q2TV"DM!?:YU$5,8M7DP.***R%X8<@Z8.4DRA MEDOFTF$!"|CZ|V?V =,8B)PZXBO|O+@/RC4|L.LHC^6HQ|AEHYIO9EKW^47(HE%L+|(I2/FU_D)M?IUY 1<=>D7>.,Y$U54L0 JQO< ML=UK<;>@) 8/_)SR_6JB?C|Q? 1=*19YBIJ-IK7$3?+A+R76WL#C,|FS&45 M;9-A@S&|*UHC:K%":#*$U-;,@B6 80F2 K96D5&RAYQ|52RA4.ET?YWI M^Y!T_D"DIV$6E|? +OEA@0@_VAJ:$9NR->@0| 78$8NP?97HD@| S-3*)|A M>ASP70Y^TROW4#LR4+9@R0C&X3FPE?7N(|&^&EFQD+ZW|3!>~X&Y&|SJK$5 M%ANLE3N_97VRW#K:0CC%XH 818Y.DB!#>@ "SNZ5 I99D(DY9#16IPY+COW) M=5=>[C 96!/># F!U:(3QNXA!|2IBG;-VAH-LB9I*J_+RBF"P M9<42JXI"(NXB0R'9KZR!'&IC#W|Q)&') M5YX=KDAX.DO%|9E,!H/D=<4,=)%LS0@59RP1ORP$4591X72?&+3V|(H7M;;,A+YFDS.%P**2(-L_!- |,OWCYM#4PTH(WU,C MC MJ>@49+BN7=9Z,JNMP^HGVB?S@. OF#P4BM_#.*H1$A?HE&U7_ F8KF#~"IY M#<XAE&M;_Y;18 M2;$E0-1Q&6#R- L|P6@H2VW#. .QW+LB+~*95A4X5U)VACFKWJXHVJB.#(.. MH8L.UWI<~UQ51_98 JV8Z< E7#L SK:27,P>PF)~X6Y8 M0^0%F=5:S5X MR2PTB6OD 21))2ITC= D07ID4:I 5MHMH.(J3$M6S=BAY,R1Q800*M4:11^7 M-R ;B*;9|&^5I8V>>+E+&183U_FB#E89)<^UT,(U<^PH";,S%T-I&*M |>Y M=<^72$Q(^9L@S. $P2%|<1#BQ|32=( 8$4,B<#|~S9|&5.1HAM^Y4M?P%#5* M6<|[R40@.PWU@&VJ8 A>YF,5ZCRUF/LZ;TEY, <8.4+6|J6D+I+S04)**$P MVUJGP1W1R3"EP96K8:GELT8$>$X|J~|P-Y;O5MNDJ-59T)D>HDFQF| 04) MA4HE,,HD16M7|,00 46 LEQ MTP<^|+U:7 M,1,="JXAC6(*R&V^YTVV97%$F,I^#WN+HJ_@4 MN*= N40C<^XI?DL^FCS7+&,IP32 I2 ?J@<;#2*RFA%0)(,<>&N>NY|8J51 MTP?|,? @XH"1|BQK=SY9ER2DZ+@|PD=6+^OGM|NODA0R|JZ_ MQ;10YQ| 6 M+>#8T/F+^6S4(5)EZH$AQLE^74YG=<+3H|8J5G|@!F?M%3/- =E,KJEF C=+">P|9@-^V,2QXFBJ_-Z?>8T#P,475FZ+ MJ,K@ P4)J9XG7$S+N=D"Z3NRYSKA^DDI&RW"MI0T)"#23Y3TT:114Q.ASQ M7$LNS|YES;E|J,(9AV1&FTU|Y=(Q6$K^A|6T=ULG/>(^|B0CZ8JSABKL<^F M4TV9&"K_9E8C9+7#.@9C2&. 91>T$.J2- |KOMZF,.#RV3^60NG%(@.#%),HX@ M$TJVU|;>E!%(A|DBWT-78!3CRZB:BQ^T11WL;R|-Z2,1 V0;0F9YKRV3GY MU# "- D TT@|H2|W8UVK$;RRSME|J$;5S|_!+|J0TK*(N1ZR&0"TK$F31VN-)%M|L#MQ JD<|Q!#2|RJ11CW:A^AR9H|J|A7C445;UL_.ED^MM")Z&:U>D3'I MT6WS|(KE5)D2-E26CK&1ATX4YEGJ_Z. O1%8X|Y*U+&$6A^BDP/B^R"O @X.BC"/GJ4Y^NQB-X-6OD_@|321|,DVJER6 M13SM59/XOE8|J0P0I4H8B%:(N*$(NCA*~NRT+?%<(AQ&44ER&^X;K+H%< MFH(16WZ$@BNH_$!0Y,/5*H8LMF+2HD+5!-=N- HT&JW=|T3|JG+5DIV1#V# M7B0!^%&3MWY,%25^9A""^6EV3 X RP|R|J|MI/X6CT-KS>-7E8)D9!70C@ MS:~O+3;VF&DC.C0J2X|)">=EKI"GP<+G+CVH14|>+>9D8R,"NZPP#8 M7|;A8*Q#|V65UPKFS+~+X^A6P3!4;2ADGRL78_9XF-GG|O|""2YQRK MA.Q0|6>?|Y+Y|J|.G)YIZLW|)S20F#XL7L+NV|003$X.4(1UZ.2W5K8)?; M4;)"#5SG^PG_P#GDD@X.ZZ>WYQ=SMM|_BF:Z@|A|72Q6=%14Q.5&W M9^EY8Y@2L;D&^UUKI529-^*%5QB^R-CAB=^|SLJZ|=/?J>_89,S<-7J$ M^Y7Y|U^FE5U(BF_~KVPJW6YCBV0Z8|_GG^SV&G|Y&~ H&#&C(2>+J|ZIB|WHN^S8'HJ_|LQCN| ILZL5|.14V3.3^ M4^94V=57?B0XD7^99K>9Y|~R-3^+P0?E|@6U0|HKBN|4P|!>^HD2+VQ-! MYVXN1-J- P)>6^5(N+9G75082#!( D%_1 OH!T*~UIW-P|958@,"-O!,@@Z M$8$%H-L-P-QR|Q3L2:6.C*N?>@V.#%.D@_N+=,A<:M^O#|JJS1(MH3Z|3>@O M|W5AN_00^CFX@@|L$V|J9ASD|JH.W:NDNJ>?P61PR6&A9*MWD5E4=GQ^J4 MU&A;|?;REZ:>@=2^3R4 I7^+?=>@2/GN^G#UH/D2+ |J3|CQPU|UPQW5L M| 7"UY>><OL|4JD#;.5J3F=?Y9 M3O#B#A,M^Y^K|@<3_PRC126W9XQZ,1 MU/>10;J3
```


(ZJZE6Y1YT M,?^+H:OGINHV,I(H<@J1U,"A(WZQ/G3_K<ZFGG[B-R;B!..B!^Y/J]!%JF1.MT,I2C0"BN&6G;1.Q!;'CP9B7VSHO&)]#.NY-850N/D!;V7L=D
L\$Z=J[R^Y7 MNPXQ;]>@T.W.Y^5 COZQ;8M=T.'CFWV)W^<C(488RLWP9:ISSA+WCVQ.FF77 M&0=9#->?JHZ->37X!L.O5!L+H3U0-Z.Z(U5T= ##
\$#/BZ*=4?VMOJR,JJJGO M4#EH-7JQ[I_!'(54D[M-16V%>A*;IW7 9H^N5(8PQAS"\$5,U7[-R,TEH]H) M#/W='J9%BB*^O+VT/S.?+XYDHK.T@J^-V7N:#+
2)5J\$D)0;.E.AF!A!#1 M67T(.5QVY9J@/EDATJ^W&T<92 T+XYO)>=BCEQKAL(W@SOIB^0@F9ZDI)/ MDD/Z<|Z>7CR7OT?VF9J[-Y-
%>G\$;#SVYM?PBDIL@S(7^MDE@L)Y)N]G+I9 M 4SZ_ (&ACEPA)QW-H7IWW"3"N\81M+UF5-T_X4IIS#EDQ^5-NW9E!.0QW8
MJ?+.9V+G3J=G\N%]>GX,NV;VGMH=:#D?;||XK+/T^>R!|^!W8.\$/P/F+LAR/!
M=)H^PU_!&";G;G(Z8^@PG:5GLPM:%M:O*O*FOGCRZR/DI:SLOS/EL>@JW M<79VCL=Q*K0!9CLJ#TORJ.##%@Y JD(^Q=1Y/Z)CX\$XNI+G)/R/QA9
M\YF/CVKX+P3AY/EC3_/!6>Y'N(EK.CH7I: ^GRJ2Z M/7=I#L.V|>^(5Q4J= MG)TE9!>3 ??)AZM? OTX"W\J|3UIGYW0#T!C_??)YUXA.|@40\$C/IX!|Z?
C&J|O|^O^NJK;^>2^708;|_ AD2A. ?E275*QJ]*C+X&N ;_?D5^-^|>^&G M/U83FO|H& 3Z*!<=(X)). ^#G;@N8/LX/GR10W#16P<+^#S29^WS#;>3IEC(
ME#J|B|3N#X39S;2|(!_! DZU/05MO9&SK#ZBX<1N;|!#F G|T!_.SIC:B|.>@& MW#E,&I:Z4A0CC\$]4|_) 66IU"W(PGT\$8MQJ5QC(R9_=&VS#(!:JMLXH?
J\$ MO_@U\$ZJSMW^F&D4 M8(KRY/TIO_!IS3M_S!0M3!5TS">)|RH"W4;N6=|;E
M=B\$F4)U7J32K&HU&YF. M^RRN.SQWG=,MTY|DOI@4J)M>+4MWT@UPCJVP4D^ED MH4T:JLSY1WRPN)?&|:J#YG_-U9,+<27-
@BG^J*QLI2/6UD^|(<7C&#I*A*_|.INVFTS.M M:&,ON_I(Q)/^J*#&_4. 9PPL.8QJ%U^+?H.6W)??3.=S2*+<+##5L 06S&Z1V3G
M)SU^Q+XWV^XC'(B<051L,V=?:2.T/CBAV+&8/L-BV&F|H2Q;|^%&ZG=M-1;_|%GY3MOV^?^N^1*^PLP*=%^NH>X/QG!&8R>H5WJ8IC4|J@+K?
SIV>D0 M?PI/IOD2\$*B;8U#9#!=<9J5RI2LZ@MA\$13I213|>60L-XH86=Z|PKQCSM(X MG5/6%Y)Z1W\$GFJ|9^9(6LMLV:MA%WG(I6B:MO|M%U1?
C7*(F?Q@6U#KI17+ MEQ^4Z8;U%DJ 60%T?|ROE<<^&R-@ ?J2!84VV%\$KM)6P)&9^QZM?A\$) 6JE MY*TFJ ^\$+!|J4C^O44/B-/DT"P:!
(GJICLZ7=>RHG187ODGJH(OIKZ20EAA M|807W%GZ|81P:/D|E\$F-753K108Y>|.S)(N1>11RO=^?O?) ?6SLO|I7BIW
ME-G1|XJG^"UFJ?;VV?^T0J^R4RNS"\$ M7.^DE!N7>WB2D,2KFWG\Y|HJBM_!Q;#MB%DT;|@I/M8#JLI Q46F;#BB0U;.5YF(D 2DQ>LKP=(PODQ-
S'AG6+ =>PPZ>)<6G1*7),J_*3 NK M>^ ^ IE\$;0!9W">;X-^PK*,6=R_I@\$X|B" E&7S=Q,9Q+I)01@\$S2_JR#,EL MIVM/OBCPW^LJW2\$?
SY^D7G,E^C^D^/DAB?R0+&A^6V>|[[5GZ3J;UWVXAHQ M7I+T;|V(^<:KC.O7[K?^&R.GWJ]%;, <+8C^/UT|OIB|O9TR AS?#X-UJM MX>S>9?
4:~WT5;@60^>G3WE N3Z 3@4#HE1J6VUH3^QM(RK)Q'X54!>9BP< &8 9>+&PO=VJR M:W-H965TR=JS9@F M^XN15\$?
CM=;Z62BTC4KJ#H1&U;"FZ60!=5P*U<3M9&,9F92D4J7E M^/S4/+N6YZ>BTCDOV;4DJBH*A|N6^|NS|.N^UPPU=KC0|FYZ<;NF)SIM|N
MKB7<33J4I>L5%R41+&+EV7CF3"12^&_&_!90=JY(F)Q)OHCW>/-S=C:V42&6 MLU0C H73;MD>8Y H.;!G/DXPM M:97K&W". \$VOL"1 0%;DRIW+?
C+7)*V45D4S&30H>%F?Z?I7@>#B"69|U7)ESRE M2:S-155J7FY(MG\$PV"?*9) (@1 ME70L0?I8D'L)51953T CS\$*+:BX03W="VPB@T4W=A) W
P%Y;H;45 MFN:|/ FJJAUHE>#&2W|L3W?>FW\$>|/?2JC7J 6JDFHY> M"Z4(E*#R,JXU0(I7>PW4J)D*(5F_U65^L,DEF"?%QM|QPI<9. 0&.);5A5YK?
0-B'B>V Z8;W108C2B"%DCXCBM#P/ MKI4|O|J%|d J@^U>^G'5*J:EA-Y>QBV|J\$8R*&@RZ^@Z|RZXHJN5!MC"7X M!|*)@7UJ:30(VY_XMY!72Y%#;-&
(C;PFYBU'R7P)69H(FLY2JR>)" XF:=L M.KI=2>80>55\$R^!>C+&"0EASKK0:3|-KH&Y!:(D-KF&|#1KXD>88Y4*- MK^E"0%#@,/D*^
,HARAFYA2|M)QONNZJ(2R7N\$F3'5M)(?27!#5DG)"D!\$= MR,"C0E8I#H*46FXCM7|OG_-OPY&|LLAT|OE0^N^00|/6.2^Q|Q|M^HPD"1Y|
M/,3DV3%QP5D. \$+XN3"ECDN-JH_C0%"B+BC14X*R=-<J-ZYX?68DU AZ|HJ26 M=+GD.3?WEZ:]@4+:%
[AAL5D^M=S:I=S=)6,|NT?|D68T0%|1MF^@/4 NE M;J6RS(C|L 3P,H;EE4TA 51LN XU@0(^#V+C#@Q|C9:0B0?T^GTVJ9<5+B\$VQ
MH26LV"1",@41^#P|^B2P^,O8 7\$4<@|6JGH^8/C+|EWI ?K3/RW<="PJWH8 MHN+&#Z941(C'F)EW+&R/KY#>L2\$2H|J)M9|4=4|T@(^X^U:2;M;0#.?
DM4CK M):Z/L-Z?|&:TCWE5KO*Y:UR.TPU753=TV>B@+XG_YS*+&D/J(Y15IJZ|[PB M_?4*R41|)\$R-/FMTHIGQC0T|C@DNZ6G^|?T|_XQ&KH?
T8U3K#<4>HAD4! MP9AKD;XWO<@ (MJ05%<|KM A|(^=|L 4GKUQ). 9A G|G7H|T;JEX;+&7F+P MB\$SKXK+;|J|U)
(%#H)PIKXQ>REB\$3>|=50V346.8-?<S<+BN& IA?;_#F%L(GW06#@W0J+U#3T.=A|OCZ9'4P%|OXQFM^|X;G;+&?XB#.414Z[M=;|J4
MZV01|C\$%Y^Q(@A2ET,I613,;|OVI10%;ICM.E1GXZMM>4G;9|=6G<[3(B MRPG)%=JXI=CZ_M#FY+"NKI7 "K>O|2&+\$ M38XFZZ?
DM:JOT(5O.2I\$?PB-H88Q|E8I+);438"6F;Z-2785JJ,(E3FOL*X; M3YA%&X %2VXHN=X.VBS\$=U4NTV-1>BX. !+;3GDV^ MIL |C|C;X?
6G^>I7%P1U=VJR.W-H965TJ|F3:EU<^|_LJ2B&CZDH4D.- (F1&3;EJ|J^?32VBS+>#SQO MU|HRYW\$S/8J|R,5E)JS|XD46664;E? A>|N>|=|<
<)&W&I|G8 J|I/UC?T9ZKI8B;#CD@S&J,AW75KD9R+&#)=>(21QFNTXMEJ;|^*7(KLC7+ MJ0F5(C2/L2/7+^J KLVG8C%
(.TKN&#TSSC0#12Z>Z9J#NISU-9(QD/WH8'A9 M&OY.&J)Z2>S20*O)K'D|^=GT?G6@|'6I/ED\$GXI,45R3T7I)XP: #+VPB\$UJ| MP0F%?J, &24?(0?-
(D56>40^WT.V!OG7,7|X8RXKE5!|Y@|J|X%<@O.XN>? M")W2P904-V8-?#-H2'G=<=%JPMTE M+CD0D9_E\$GRB?>2ML|6W?Z8+JW6GE,@B>"X
R\$RT:9FB4K#3A&-W6|T9I N MO!+4\$9 (64C<^&W^%M;^DKF\$24^F^W%#;^E6+08G&A#58H-L^E82 MXJ6V|I|HE!
(S^G8;LO@+^Z,W7O+&R^>0;8M#;T:YL=|6|FW*|6:5Y>|>X8Z MU (3|I-WQ^>^GF?>XH|A3KO>(<=&^ M)\$ YC5TIY|7H: JY+N!
|_6>A4;J|C(VD#KONN^GH5>85 B#W?<=S 6%9F MAXB:-N4L,2.0M)B&.@H9;""<J:N^U#FR|7LQBZ13Q4Z^&I\$NP.9L045^ MC+ ?
CQ:3@34Y)Q,I+I(=%|T\$#;NRKWVT&_U**#71(GEED)FRQ^I. QKV5 MMU|4G+&4F(2^V*3;+YWLRL8EG N2.)>D\$2|A^H#ZP4;4E@S/U7J5QT"&S4'
M&WVSP\$|9<;Dj<*PQ(3J5HD=\$UBGM>;Q1'5*7.0FQ/9QL\$>R5CJ36|J)9Y4 M1|;BVQ*8V?TVY YSR|&465Z46EWW7AWZIUB6E-;| H/R'B*
|I9/0MT=|^@'4I M=5\$4P/U*DO*B\$Q;&AC+&9E|)|(<:^1-VAX".D#7'42A0@7N,'4ZJ)93?(& M9VV+7J>Q0845JDA^8V;
AIW#M|M^M'D7.7NI=L>LODZP3ZEP?)I*\$Y^?XGW^0' M\$)XVA?^ J3 |K7T08=>#%#|+<^AE+(SR01#=(S:2XLT1^XH&|/39CA&N+&B
MG+KAU#^KS|^8#8;^48^V6|_QF5&=N:PH#?#2>D=4??=;/W(=N|JFO_Z_3J,G5/ MY8;ACSR^!)=Z5V/VY+5!5J:;%82|::+QBV,|4|W0@S00<3X30=<,&8&Z)
MB|!4\$&L!|0 (V!;M6D\$;?>:;|/_L/8 9>+&PO=VJR.W-H965T M#R?>-BAE+XD |CD^Y|^J^GFV5.FY?1 L_*R^!>BMK<^B MR&0E5YLR|)5C,M@;?-C*
|V8|>#8+G&E MP15Q20I?>5R>0-5Q(T^O=@. M.3P|^IEX_ "9X;|>8-SLE;JN^N\$S=|J 2AP,PZ;D; &|Q (1P1R?C1<0+J) MD\$YXMIJUC?^VDJY>VW(>O
@@@QX(UPGY0VS?8^1D|ODP)X|^P|6+C M ++&6%5U8%0<=G^V<|N#X!|)!T@|K;A;S*5|RRQ4RK+6@736RNX:UZ-(GC MTFW*M=4TRPEG%RM-
^ZOM+V RAL?#;|XQ:./K^U0,|BRPMXD^CK";|PF3 M?Q|X4I)6QJXE#GF|_ \$1B>L5)CN%Y|E|PFNL3R"-OTCB9'2 +^T=IYXO_8_C
M\$%:"D="7|QKINU|9J.BO?|EE0F4|F=W|.3.URW>T 4QJ&I6#QJ,IS\$>P_H M^06Z1X?8%]=T' -&(*@) -UYKHKGCA^OX#673>9<N
=TAF13%GH30A7^N) M1S 8WQ#>((WW8=9UA.#AAZ^&6J^C M:(X^C|J0(3V\$U211 Z|(H\$WZ&8,G(930D_".3P=M+-+&J|1K|+941"A?
&6=MF2(|Y2V_<|<\$2X>)S";4F89* X?&W=2AGI+A M<|J2G=-A^AX\$OK4IG\$|^IED|(%9|LCJ)|Q-QSX;HW0^<^XYV=*<@5:@WONP: MVKQ&VK8VJ;-
J95^V!>TVO^T6KIC><G(5T^0^_1T^|(N2VW;L:KVY6VM+!5+ MWRSI=4+M FB^4+4,KN.FZ|_ KU_ %02P,%% @&L66ZNNNA3I P G D M |D
|X;|JW;W)K&IG59M;JLV\$|N7W^0A| &M7\$N6|21^19RD|PPA:1!G^89A^VC|;^E2>DXG2_ODU=<4>WY9<". #S187/ MW?
&.&V5 FK6B19>,R^..%A;NQF\$H4G6F#^34AN4|&6I=,8L+?4J|-N+&5^ MF0CC*+H,|9E,!GYO4<J>G:<G<"B|Q48|)LXSI\$^6ENW\$4Y& M&|;".=K?-
H^:5F&%DO(I>%*@L;E.)BV|S<J)|%|OG#(*)\$L_ AVTAVR(A)#=69:4R,8WP>'

'E3@2;1,2115H+*.F%TC+)6@4N9R-A1;BQF M"J0^07>8E(MVLU?229)6N:\$PFT;M_UOFR;??G>ZBW&_+J)M74?0VGE6Z?
9A1A^N=H4_M%V|9|)V6MMRKPQWH7C:O*:P8 M#CE1:UK|3>T^K_*6*6WY|SUCAVN_\$Q6?5FFY+&X>7-
FF^@VXWE\$H4\$8U\$2P20+..I\$ TCH|)|0WN4|JOMWE1; UOK=JVS^*_M8CH M=-#T)Q.1IS|N&NA=A^T_L,K7>4C|6&LZ.. M-
|/2PEXFL+!P,4GBLNEGIFR|JBVL/MWUWD#V0:4*;4?/|C|L;Z^C'L90U
MX*JL.MKIP|8ASLW8M8J.GJL7&HCN;3%Y5GM5D^>7^C_A00WBWVW3^XG1R! M2U^6E<42UV|!8J\$51M_RZ4I3KVTS4JGU | ?
J^5%1|Y<@J)YIDDQJ02P,\$ N% @_#8%L6<8BSV2V! WPP ID !X;|JW)W&K&ULI5=M;(^X\$|L|K|RMZM68LD)-@J9N=96N>U7IW>ITN@|F<#<: M),
[3MG^>^QO;(01*N570^XZ3F?^SC)|9F_&BVJR#;#(CSPKY,19^U5>N^Y, MUT!3V>,E/AER45.54|RI6E)H:ISQS|^+W)RRPIF.S;M|,1WS2F6L@'M!
M9)7G5?Q0<8W\$)=WMB|>V&M|J| MW.B|I^N:@_BCO!<|<|)DK*?5I6H|<88.26%J|TPI|,VO4|,9Z@|SZ3Y)90: MUG-(4DG%)JH9\$>2LL^|J4?>
A9QR^V\$#PN.U^N4U570ZGQ#A+&;&K|4#7> M"(X5>E/F2N|7AGYJ.N-YSA1F64E^BY3,>*&8L8(B82#)V2=9^#QZ|'M;2' MF|JQKVS+D|Q(\$U90-
1M6H(N>_08H8:EKT,KK29B MONJTRS;F18W9MB+6PBQVF/D>YF6#.3.8+SHH\$@7Y H11RC4D|<30=LYN^Z+6 MO)+H*<|_|.6MV/T4>^_%A)
(%1^4+&^H3R">|&H| W8Q3C^X;&F62,+EC& M%"JGBT4K!)"^<^PP-H&ZG3|&+K1LN-@A|T6|H|/(=6;X/M2V)X8/NL-P M,8X|H#W|RGIW-
#DC1LEGDW&X^O%RMRB059QB.,.5TF2957-LTIX 8S;@_& MC\$1>2,YQ1=R_EJX7:~|V,/Q|P|MAX>?>.K..U#|D,JW;+|LN+&?-(LS^UL3F MX6"
|D+&BTG|<^"0O5J|&D0Y1P?2M &>DS-N>NO.07ASH@06|SGH\$*2<|>|. MDXHV46U3N/3E0BGV#EKA(X^+P+&T^P05X.(^)|_ =05\$?J1,Q008S?38YT20&
M39.8_23N\$4F|FAWF(|RFVEDW8CQ?)|OUIX">|X7ZB1#42RSQIMV2A|J#N M;*=Q091QR^j@1T6^>^X0?KPT2Y|C4"?|I>X1%6C1?
K@P.4C|_OD_Y@H*>1 MGf+QJCV/3V,2C=|BY=-"W\$=TF<+>+>R&G<|J|R%"D|@AUS0^+RZY6DLK\$#A
M@51840UH8\$K+&R,LK7MK0YH5IG+TB7URE*|LK>RZ&3J^|J|+&#9\$;EFMS^ M+KSI|&FFEY-_NYDFBX2PWWC6?(%|2S=WFQBL&?
|%|C)CAE9:DI6.UVLR+& M*O3#IS1&D6-@%&MINYC<|VK+>X&4I?|VRP|^N=P:ZS<6C|3(2LM%/5 MZC8_X^/K&AE&1_7EMBZ=.8B5N5I+8EJ?
O7V|YO;^Z6J|M|_|=7_CHH5^R0N MO\$17KQ=C1Q^V.FTGBI?F^KO@>"B_&YG&- T!:_!ON1<2>Z>8_S?1P4\$M! M!!0 (V!;%FNA<6;C04 %<-9
>&PO=VJR.W-H965T=9(8:6|8&TH09R+8A+&W#V9I.N73>Z2S|=2|>@EHH&G B_U16=IS,JLU|I M\$@NN?;G^DE:F4A77296W@E|C6.V.PELRD?+
OG|^+3F)88ZIL0B<^HJXA7EN@8C&SP:S MTVYI7?7^6_2/S;G:R9<8U7LG|A|C,|J(S|\$^&P@Z\$!::2.+1D8%*!L_G_R|<..PO U!>8H,,>
|WLBOQ.&C|^57(T,RIH1F M|Y4ITWD1&F#,C6*5>7IF?4R/3A_279E<+5+&"C6FCMWG7SCLQSUZ7G/T#96 MN)Q;0V=Z15/ M|.)#1:1/6)G_.Y-F 0?
C#&OM|S|Q|^J|TITH|!|OZ^<KERP|C:WA=D+ GXIU^L\$L9:5I3IT?&SIQ66^J5>2^J*(C_!J51I|JZEUR#EKA(X^+P+&T^P05X.(^)|_ =05\$?J1,Q008S?38YT20&
<3Y@'R'F<=|@I_|_@K+&^A,E3M\$? MAE#VN/UYUJ|VO9EL@5K|(%@F?4*7^IN: 9'9&+|;SVVQ3Z/_I L\$R?>S%"36 MPZ>54^1^
M'(R;S3H0\$50I^=#P&73^>Z>IG%>4Z PC^U|PM@G1P|J_K^M.UUNQL&,800^<K9|&^DF_|U?2?;J:509^RB,C:Q9S(|D@|TL1=KK^Z0,J^<0&;RS|X_J
M|55H#U1+J |!=#&-SLP/DH: ?#>F1?A.W 28^W H#H15Y^OJ_Q-3;#QZ|VN MHW^|J2RYOT?N5#PG><5|C6DU;^MPRI9#;
M1>;+&VWH8>|'+@/H5JP<. 7VVJ|&(93>R<^36|!SU^V?6J70#8A&Y/V.)=F2.QF>T1U3V-N/|T9-106,XA90%TM#\$\$>3>O^M-*|R=ZQ#)C1YBI
K>G|V3\$MX OD.06_2T(4=^_A_J|GUE>;>3|8|O4|_5F| MKXS-5\$>|J02L9-2X^4L\$!|0 (V! M;%EQD^*37P_8'9>&PO=VJR.W-
H965T|ZB|1|N>P^VH.)^F^U8V^M!V;FUV_9 M0(5 +.04#*=KUZJ5Q5J1V5?C1Q^4^L0&VM<Q").""B|?<6,ZA#.L2|J|QWZO<^>2M3,B65 +6#*OBL-
9S,V%6V<.>Z&E<X|3+70HPUT? 3Z%IX(M.3)=PS|, NT?>SLV:|SC.H| B987D |D.C.TZ|J;^Q_!FIA4#0B) M91:ISFP31DPPE=*2|P%.*%J,I='
_JLS2V5H_4&KJCI-#A1 M95PNX9BH?Sx2 YA0-/7(3TW=&N^Z;KVJ)|2I=@/J|,ZA4&@J|_ :UU?>YPO M^HU.+T3F%/DBHW;-
*H+OY^P/43X..LL1^DIOYSM9K^LDZF3/7EH#-G^FH0;R M!>?;#^T^KD>NXUGI^% 937).I)567HPLQYXYFN3N,"0(^0">N<=>#6<P
M735P&5TWD2>Z33WUYS1CE^EJP^XCN)&PJCF_OJ>JG>TCG|G|Q|@'(H"; #M,NF;JRCN\$HJQ>-1V4,+&OJ@>|<149^T# D7&#& &7<K9;+<J6 MU&
'|TO_9Q W;^<K.(=HFFY^O|J.I%>F|_ @_O'E M2P+WTY^F|FPYGD^< & (YGDJ?);*7="U^UAPN0M&;TOIH;".J6;2_@9 M_+=I?|&I?
&99I#N^3M=0SGA(JHBM)N5!>J?>Q(%-55)NQF;J6KJZ PWL_ J' M\X M /53/0@_4\$L#-!!0 (V!;%F6J/>)| H".4 9>+&PO=VJR.W-H
M965T|Q^Z2FZMXFRVCW;A+E^72|6H7|Q\$;GZZJ|WZ=YP<^_1_ M5C500;G^L#>I!0?>G=|J|J|4^;12J3S3%XXKB9A=|ZJK|X^<KRC8+?%K)|2
MHJ|M^5(>XOA+<=>=7G=ZQ1J)I9AD!1^F_SV^6|<%E^*^E|+M';8LR@|OOVL M6|L7G|^8AS 5M_ 'RWJ\$T6UQWIAUE^F;A=IE|C|<4;Z@0>%-
XF6Z^Z|H^E^H0|TFTV=V9TJV;J;9I7I:GR@R&R,^JFRL|ADH1 M^P^Y4_JG|2GXQ7+CG+&U MQ^7+SE?>_W@KRIGNQN5\$TWHLK M| YOY=
|Y4VOWH^CM>QJB^7!&=IY3=>5YJ(M+|S|J|>|?T#| B?4^5 MJWEJWZ1;SBS7;ZU W7^TYWDW^0.72KWHMR W\$3<3J_O_#2 HPWXW^LTK4.PX
MO\$LWX41<=_(J@U0DCZ)S|X^_JOYI^16(&B9DD9I&836(B;DDYI&83V(! MA-4"W|C|O^_3;J^Y)MO5=AEF8EKL<\$3*&L^J11I&U(2,Tc.)#&+Q&P2<_8

M<C(=454ZO&UVJ][FC7J]JUW7T|3N#92WJG2VI#K3<G"SI-RPY&H|NAR=+!M">+ MK<O5C<C&0|J,VS!=[#9RD^*^&+J-/L-EQJ%+F^+(AI=K&@|0,\$C-)S" (QF2< M/3M8?M/KO TT^%Z2G(HKL3HZVE4VA ME+IMOTEBY|HF9)&:1F\$UB#HFHY|-.Z:J|B.CDY ^>JC. NDDSB=7+X"P6M|& MAJR- I7F[WSZD^9RM.#!|A9?? LH5@|B:3P*":7:1HS\$#!(S2:CFHUI M:76T'S4)J"UVA3=)J|AF0MDL|Q&C#>F5VV8_VD-T|[]^=BMDTE|)J|9J&:C MFH- J+|JY|.C6D|J|61J53(U:3) %EF>QXJOFH%E|:A54XXJ;0FXV|&|BVV|L4Y%XP>2)7"N,*N^=N2NWB?>6T3J M428YUGH*BC;1H)J):A~J~V|CJ^>:AZJ~|@64%#HJN|N%5KCSIX|P-..\$L0JAFH MJ9\$A6HVJCFHY\$*:AVH^J@645D|J|U8RDRKN1_LH!) [0G"=4,5#/#5TWZ=|;AA MPFZAP|JHYJ":BVH>JOFH%E|:9A5'Y,J;V2Z'Y-U-M\$F612)6|;3)9A&F^*,9XG MHKXOK?RIM/HT5SYHZ^RB? 4RH9J\$A6HVJCFHY\$*:AVH^J@645@|XJU?2DCMY M/QOOMCT(U|J,5+5+-0S48U|J5<5/-0S4>U@-+J:;:KE1YSJ5?V<|>G|:PO?#! M+M17A6HFEJFHJ:~@VHNJGCHYJ~0&GU,Q04#5:~M*6^~&~"W'.U#W;EJJ|(V MJ^AFHIJ%:C~J:~CFHIJ":CZJ|916#VK5&Z7)>Z- > V17.VV0%:OQ@55Y0ZQBH MC5"H9J&:C6H|KFHYJ&:CVH!|=5C6#5":?)&J|/3(FD6.B|EE|V?#AZ7(MYZ_KIY%0D47|+A\$SD11_AW> ^Q,IV7\$K^~3JUGXJ|J|J9J&:AFHUJ|JJYJ|.AFHIJ :75TUZU M<6GR-JY/Q9_*1^NY?+|;|=Y"-0/5S% (|GND|/-_%:7046U4/H.G.O MFXA.Z.:~@VHNJGCHYJ~0&GU1%|J4Y|]=^H^7|;SVY.Y;V,BT:8I5#-0S40U M"J5L5'-0S44U#J5|5_LHK1|J|JK- *NWSS"2S:9H5J|J9J&:AFHUJ|JJY|.A MFHIJ :75TUZU66GRDNTU.JVB&L=W--S'U.T+G9_*718\$J4L5+-1S4\$U%|4| M5/-1+:"T>B=K9BBM33- 4FQ.^R>'6^43|IE#-1#4+U6Q4U@-+JV:UZI'3UK>>V.MG,B=29ROK\$U62ZT3BO:.(5J)J|9J&:CFH-J M+JIYJ.C6H|JXZ.I0>J|&QQFIO44'ET%3G|!>G^L'O*GLG|W^~|,HZ94L3"|I M_3?V G#L%>#82|'QUX|C+P+?'@6.00P<>QTX|D)P_XJ&*+UJA-+|; |YGC;91 MH9J:;B|6:AFHYJ#~BZJ~:CFHUI :?6T5|U6NK59Z|PJ;|3"~M4,5#-1S2J|U M^EZ87C|;|Z- #.JCFHIJ":CZJ|916#V'57Z7+^ZM^WA8|QKMK>+WVN:U<:AU& MM+T^U4Q4L_2&:|WIPZ\$^[|?2+1S"M5<5/-0S4>U@-+J@:PZIW3Y:~F@F6Z^ MD|&S|WBMW\$^B_(EH%DV4<+B53X71EB14,U#-1#4+U6Q4U@+V.2@Z'6BFH=J|JH^%Q|;+5KJ|JM>J_X=HL_B'^B2B%EQ&L=W|J5.1^1Q5WWGJ<7C MW8JYN|=S<_Q03:1.E6681;3^6_F+V11|/X4X6;ZK|:D=YG+|L7NUN+D0X M\$4FQ0|I+|ZSYSO^>Q|F+ZSYSO^>?|5!+ P04 _"-@6Q9R|Q&P+H%!) M)0 &0 'AL+W=OR/L<7CVP|!O?>B+B CR1.^?5@~|3N M?*:K5 /AK.K'=Z0%1%?=@M,W@TKE(@F).64I2 CZ^O!#;Q|S)G_5 TTALKP>3 8C(&N>Q^,P>? B=E0D6(8MY|Y1<|E&= OAS+EAD M&L&L\$|H>|O&|DH@C XFC-T'E 3K5P^T+?!|XJR!5QIXIQ|,2H,B|>A|X|^X M_L|N|K8|C4: (FF+@KV^VO)|TU5H:Q\$K^ETD|,5H<~ 6P-5G23T0C<2K M31BR|4TW8 EBVE("O<78"7+~.1CHD80|HRL'3R(P?R9ZJTN^?+4 \$|C\$ _MD|_K@+P_MT9>=H^KYL6B9&|JRQ5&PY6*01 MB33V<|J|U&_E'Q5I*\$GTFZ1\$7!%=A^ ZYP#Y"17%|_IYI|&/'B=|X79|/"A M-(Q*O&- %>+UJE2|JGZ6:~WF,|8G48B1?^VV6|Y#1D><+ MY.LD1JU,-><~;~0I)7MB7@+KY/Q|9L|V->G_6HRGIDS/H+\$\$S@&JRW.R.);% M\$|AT.R?5 |GZ<9'LRFWZHD" _2=WW1O M2J>EBR;C=CE8 1WK?H=U.S'M?>5Y8BKQ!^K@B?6PD_9/L|LD+MR#GDF&Y M Y4DRRVMZ\$ZD|N:CFXC%;^ZQJUYW%G|<47M|TPV;3|TVGY9?". YJ?BQ<F/C^ M^RZY7 4E|J+4WC_B0F" (#S3\$60\$|TOL"|"T=3S1..^_48MX2Z\$WB)|6Q\$ _J M%3)-|X2?4A,A&V+Y|3|N;B^NT: JF&C=(M|U/68J|K029TZH;7;=*YS&2S*GO1 M^%&VK3N6J;PA/=+FRY;~J8 M2QIHUC42*6EXS5N|0#PB9:4*(UFF,33M%;|EID^Y:5D&SKGIE?VQ&|ST|-M\$" MV|5OT&^W? PM;|O|UP(FA?>BUME,VYOYJ?0MC5A;~G^OMM86C+Y|/6A| ML59|25MM^M^%|FBRB|; K\$Z7^@4Y|~#MY?);*~>40^4#MN,VYMFZV@|U&E* MV/E=Q);3)O6UJ(1F5?GTRW'D">5SV9R';>|^\$5:007GX";Z+^G+;~39N;-3C-Z<~6T^~; \$F|BLR" M|,26043Q?|*@V5E?|DN7GS\$HRVF3P5HY(K- R|>6NF|Z+@|J6T0+4E9A:NMJ" MBZ):8R*\$SQGQENVY&|ST|5@4JT|A4Z\$J;+^%>.D6U.D5F=7KB=MV,VYMYJTH5 M=96|JCOFW\$*JH\$JK|(+%1?WZR;?'>2 J M:6FTG^&C+WD*~JHEJ|JHIY2|=16W8\$; MFWBK4K5\$|W66|PZ,C(PG)-L59'02*ANYP\$*526ITNBE.P;2>S^%E<#9C M4|<#AG=X6Q#Y? LOD|6\$=#Z,90+9X=S.X4:P77\$PY9X)P9+B-/(@60 MZ#G/J|A9J93+@6V+*(4+|C/L51;GMABR0"!!I6MNLX/3O^A%K! MT)Q->3|D^YD1'E..Q/K|790|BK(ZMC;O_N29)*26 PR5.8_R<3GE/F 7 M^-#J|@OK""P&#DWG<&DK^V-P7<~&|S1EAK)G+&GO?2D:CRQ'|P091\$(S8/58 MPRUDF2928?PN..W!0|NKKV|LGXUV166.|=RR|>~93J|RFKP4PP0.GG/E^@ M-/U5?|+A/E\$F|+6L5'T\$|+E)5A)D|:/J%SF8<=+~!J|@EP#S^&| O!+@ MG>K|+P^~J1ZZ)-.#UTQZA,|9K0&.(?-B,OV| VRIE5=[<|=|&B/A#);7R';^(-=Q_9IX M;D^>W5R_L_Y|)^|R7#JYK|(WS^&WQEY06:OR !? |TBJ"MQ0=(S)/K^6@>= M3G=HKW?3=FSCN|?|-N&QC7=J#P..|W7U2K0GTZ|>HTRIRE65Q.%0H% 'GD' M^1SXKS|MC4SZ|A^()8Y@9*G;7: <K.#J|NTC|/5372V2V6235HBVRM'MRI' MMXVN^TBZC5UW;/K#V.OZXMYO/Z!S:3.5^|I|I>);/7*;|GC..5.7=*@4 M9V1B\$-#""E: (S:2_VTMDD6MDDV:8ELKT+|J|D+|AJQD:0^1%17A|/1U=8J M;-5C^|JZ-O:DV;T=Z9*G+P|B1GG|!#*0?24)U6\$^..&90.SL>=P6VGYCQ4 M\$V8Q\$+ |2%~I^>8)H0)EL%~NG,N^~^J1X,?5&|F69J:9,ZDF+~.U90,7NH M|PO&Y';C'51S= _4\$!#~!0 (V!;)%F1H%3:>0, &00 9>>PO M=V|JR:W- H965TR<|22|W_YLOVC@~.WN.@|)F/G_S.R8P9/9B?&G MD0%('JW|J9@|F93|&|<5208%%@.V|ZJN;|DOL%2G?;.*>0<~&E&1N|I|G3=P" M^~J\$S.S.VXN&.'61..*P\$X\$B~BP/S|G)VJFCM^YSSP2:9U-N-OC';Q| K5? M<77FU124\$ %811QV,Z=V^~|/2TP/C|3> D+H21=F7#V),^N4OGCJ?O") (MI\$9@|7..\$>2Y)J|G|^+>".O6<6GAY?~;.9Q75FRP@."7+_R&IS;..MB-2V.)# M+A_9Z1-4#HTU+V&Y;_ H5-EZ#DH.0K*B\$J|L^ @M?_&W*A 7 L71%OB5P&+ M1B|(@DH0O'6&4248076&<24PKKNE|R9P\$98XG^V0EQ.*YH^~.~\$W:A40005" M64NNKA^ED^&Z7?&?&=: |?C9D@13B6&3A|VH)'25BPG'0&|_D|KMA430P|; M^LEH E1R;~M^IAZ>*\$ 12 QR<7OROH1CD /@9 DTQ|H2^J\$/*Q Y5750Q MEAX2V<(8QMEJYDKEH+Y-~ZF<693.^~|X\$Z_1F4F4\$Q32#OT4;J^VJ-W56#K MZ/KGZ'|7N :J@,4>|^0|_ FCCOM9OET>=+GS: |/'SU|Q@|0~|PPM>X)U3 M2D?>+^J83_N5>~&|?'|87HS^>~43=1&?7NU@~^~!S.LEAM:|J|B11-6Q0OK22_K1|683\$MF\$Q99@C71, MZG1,K)>|BZ1:: M=&G/Q^++> ?L|12A_6S55J(02KV0>=G2EB-2|4W/MF%2=8#F. < M<Z@JQ6 M,7D^14Z?RR\$ P%02P,% @ #8%L64+6?A0O P @|< !D !X;|JW M;W)K&ULM9AM;^X\$>_B1635K027?;(E!X@%9+; MK7254-'NO5C="Y,.8#6Q.=O |MNO|81 4!JUG/<-Q,|,SYD9YP^>T8'Q9|\$! MD.A'D5,Q=C92;N| <520;+^X85N@ZLZ*0)+>1K5VPYX,PX;D;~>|?+3" A MSF1DYN9J,F(F1,~\$~.STJDO9\$ZPIV,MG@-Y!?'MW.N M1FY-R4@|5!|&8\$? 5V+GW|Q T@&|XAN|@SB|J|C46|/O^0C1U?Q|DD\$J- PM.IK\$S|(H^*T'G; Z@2<~;..@.T.0>407#I\$ MKSB\$E4/XUA6BRB\$ZZPJRL&\$|I:QF|3%6.+>)B+,#XMI:T?2R;|Q5ODB5&^4 MA>3J+E%~+4B.3'CF8D%N\$?8Y"8Y.*3(E.. M: HTW:@|>4?;Z%8 OJ7W3RZZ+52H%*|]=YZ(N)D-G*ERH*.Q4VKB*=EQ,\$K M\$8?HD5&Y\$2BA&60M_G&W_|#~WU79KTL0\$LP#3J|'JC>H-#|'05>\$+4|S^SM M|F%~./|O|>3JU10).O|&|I^ I|OOL|J4<+X^N2J|TU8|46TQ=TWUGQ3|6 MVCNQQ2F,'26F0J|F7SXS>|J? |EVR8LM@E++&A8G|PD2&KY6&ZR7K21 M RU G2?;^/UO980>?|2BM2R15;+8A,4V88DE6^LO;HLO>|W|;B61O6;KD4Y M/1=E7HER6V5Z-! |7^> <2|&C:7?W^>|3:CWJ|1%+<9A1=&29M1%-1&C3|JY1BV|J4G0|>0^~NTJ|N^X^|3;"7UWVFW28|NTQ|:M69|3="4|6N6 MU1.J55ILE9;8HC6+- AW,\$|L33|BOB94H|Q6:BEU M+6^1UZV>|N|9%O3SUPR^5EA+C>|,^#0:~U,2:/|U W72?_102P,\$ M @_#8%L6;^70^?| 5AT !D !X;|JW|W)K&ULK9C;N,V\$9(2A^'IH@5:Z^~|J-0VDS'J^D#2>~?DO5CT@19HFXA\$NB0=M;X\$^?&E)D2R'D@|NY^+68>8;#8? ZS3&G|RZ>Y980A:YF*9,S9Z04|M)U9;PE M&98|OB~WUESD6&E3|7&E3M|<|(|9:D;~>|(|S3IESGR:7UN(^93054H960@D M|UF&Q3_7).6'F>|, |KQ<>ZS:KS 5W/MWA#5D2|;1;"WF512\$9H1)RAD29#US MKOS&R|)8A|SB#TH_|N@8F516G#<|D|MDYGCFB4A*8F406'^|D|N2IH:DG^/O M\$N14,8WC|?K<~<|>9W;"DMRP|;..*V,Y?LH(2L|3Y5# SP&RD3&A|>S#.9 M T>|M9S4+R7BF=ELWZ^C++B\$WAM|^+ (07/L#D'I\$+0=|N|X|S\$N'_DJ^RMIJ|2HV)R M<^~R|^Z+&0C>~&8\$^NN=;~26*6\$ (2BW_8|3_I|=U~J2|^|ENOXZ@4NRZZ&^ MJQ.*O&|>92;C|OW>~E|6_3PUX=T^O\$S;_FI_JG=-A;=|EM6B*(I^<|&81M^M&O&A|2:3EA)8C?>J3QE|+&|PN8|LZC^N|QYUYW^\$5UZL/KA=. MH4XZU>OVI?2J3XF&D)WPUUX^V^U&+9VP6V5VH?)"^BN_J^GWI?HQ M M'Z|>HR7Z%YVSL.A&GSLC06DA^"V^HC6+%-1%"L#5HD1"%0>2% H+2(BA:LSAU M|^AW=C+G*\$;_Y^K#8N+U!D%;~.Q6;Q3#9C4_19JNUKM M6N+RB?>?OV892@7XD<91=#39";""&PRS8T,3/SMF6IO%>~;)+^0E7P^X^+=+ MF^LE19,1LXP|-T+~|JWR^27;B3A^22U^V2Y2|/|SAL;LZ6J| ||W|J+U M1J@:P_GEUE_3)17WUW|KX852A@E,(TBEB).5U>#~WSA6B8J^27^C>A3MO<9 MJ;\$|,9-77P(KP8C|40TH%06+||T@?>X5DGR. |R7HH+*I%|<_Z/|_F0|> M#N;|S^B^Q5^B4&RN!M,|N^NG*W|7BCCW|1P.(L_Q|E;~C 01VF61) MJ2R?((G2XJ_HR1B3T^BP_JD5"!M?N @E4J6^TMV^6"W=?^N%3(ASXLQIX3_MY_K^GU|RJH2XD19HZD;?JXM^8I2%2A+P>6WD=03|V41((BMT#):|J\$|^OQ4_MHL@8+M41.D.W;X("B*:H?>H^ <_TW,5422|8DDA^+P4+OJF+4|XN>OE=VX4 M|P0-T=|RT#^R+&S.WE^EQN=^S3.7^C^*L|<2_G|IHK,W|J\$;~29DLYO&+| M- !+9N|T;GS=LE EP^&^5:Q?>H5D1(UK&2CORE&3PZ.WD?^6'HV&?+2D; MOJ?G7VGT|A|3E3O(LSMNB|9P2?>GRJ|J0V1\$;~.IY%OW5+6@XOV;=> |'U|AE6_9M9M6CF<~P+N6_1B|4)*!|"UUL..14('H_0CBG>0;K3A+VK^G^3R58;L?|(|@15%;^R+9^0*|&A5GE#_2P?SWW| S^@-RD\$DPUR28 M9PBLX4|J|O.)|DTQ0\$Q;3IW:9&LVLXK8^W892|E|D|EY2K\$+Z6 MBVQ|Y9K_(+..IL217R2Y2L_1|H|4&^Q|D5K@C|L\$S28MX@A MXXK1X %%"#L\$P:|T|F&J-E597L2|;"Z\$#~1HBM6+1.G=-FR=P9PC'-83C.8 O M|13VP^3RPS3K;5ZG|5RXKZ5|VS \$JJ9P+UEN5%\$%"<3X|G R8R(8XTTDK M^@\$I,K^QN|61@-C,&1&8D&E%R-0D(6%1!4&43/M1 H@!E !2\$^6 V&%9A4E MLYYY/8RRD@@Y_2970MYPBOTA;..PO^F@-" FQ(\$9QJ.Z0A)=#;OX&^Z^C^ M/X^P4T^N^N*2^O!..K+>5Y7A(UPKIGC>@NGL&X(R#46Y)5>5DG->ND^~L@G:1? MSH3D@((0\$H,J0M LGNSA <~;|S986VJ;KPKUYDX-ZM/70A)=0M&2.I@98CK M9@+KNXJ\$=OI^|..A|=G^>).D9_E^SE&Q^E.L3H|TSI@_Y8^M^Q^5+M_QN1 O8;K1@/K.XT3>=\$EKW&_[@N2@Y@|Q\$|F(+~.9NIF NN|B2_Y#X9R_OAR M3OEK^OQS\$MN)3|A|J(HW7!:TZVML3;#=#9J,K-B5CITT& (8=8K>YZ(I-/M0 MCJv+>|JROZOLQHON;~FT-P65WM|Q2|L|<~4D%<~"M3QK^6^ KM^J?>B| MJY3J;9W"OZE^WA205P+UY;~^NY\$F_2KY7)=0J\$!>J0(6.YJ(^4@54|B^~PY M4)RONA4@^E;@Q6318M;JM1#~8L?H IO@N @Q#5UU4 TU?JG)OP8".WKL8. M=MI#!J0LJS&/EC>..SF".LZGNCK>_+|A(C_T3;O#_|^HDF#Y2#6U=ZH%/W MKHRBN4;1%-H39?4#01Q7L5>)'G|CH#&H2;17*- HGBFTID/K/HCH^Z'X#601H M7;C=A+1^HV|>|;~CDG<3\$FZNK,A^1|FCCF9R^0E4GU>:1'-HGFFTJ|'5>J|.S)J M?1?ZQM|WBROXUB>8:1?- H34=NG=<3M|&^LX_W5WB8;J M5A: T)2,VMEF|Y)W!^DYNNKKL_1=7|5% E=O2DUVMLANJRVHRN#1YABM|J9-# MTB2:~Q3- ,X76=%K=R^KCUY%CC+;!1M%;2F0^LVV+OHQW;..9.UEG= M;J.C6J|U\$65L^0<_JH?4+Y.G^G(4YZ?CB)-UMWIOXCI_6Z|U_P9?+~#|P MW|477O%61 U?0*3QR>?K^U03%?2U.A|(^3%~|!|>~;~2.#_0J,")D'S4 M#RE7 O+|%6/B^4(9J-X^F7V4\$!#~!0 (V!;%G0)DCY9P|,1_9 M >~&PO=VJR:W-H965T|@Y\$B_OL_Q+>R%|725J|.IF7Y?+EZ6DQGR+2(LU3D|N; M MR6OC93@9U@V;+? X=R MBXV=|J|K6M2_M ^~/7IT_ZA>|J+|FHBJ|>|DM4R2 M6J&|4>+G|S|K|MN_OQ=|Y|=KW|F_ZL1H_B_NVVT|V^Z^LILT3:N1K" (TX= HZ_M\$|^I^P|CM&^"V#QBU#4:-ABW#<~&NS&B;7|Q: -CVV5&QS<9|UB/TRZAUG23#5K^J.KRSR|?WF?>75/S3SM&E? MS:PXK4|J8YE7? XVX=N75QX<0\$MF-^|C?IO^~/(W24KR>3K-56L;IK7B?)?&T MEH5X+E|/9G\$="B_0AG.NP^F2910GQ2_5)K|J M,3//_UR>516@ZN|.JVV M[E^& (BY8R!|2Y+RWD4|0F95WM-/W|BWWM|7U|P|O |J6SNGXJ>S|/|1M3 M^P:KY|4P1|^G.3""?4^&OEN7PAAH.F+~BGN:50;LEIU@S8V;M|>|.JJS9T? M& |S|8|U|I|O_KX7+JU>N+.=@P_TS=|%N;~WV#!FYI.L%Q'^+~#QACN|JWDV M6TU+>6)_?UMM)/Q2+HK_IHSPS8,XZA?KH_S+8AE- Y:N3ZC|>R|Q.GES|J^& M9|^"OOFE.8A:~>23FD1A+8AZ^>206D|G(84J0C=9!-M+I5Q_DG_ZIWTWOS(X;L^Y|O+|LRAX.'RY/ M|S8#Z. MK8.WM+6|<^S4|A|E^S6.A|G^PVI+V03P1).UE/VLF>= XHJ6>G M2+~B|J\$^CJM.I+|JYT.=^"OC^BZ_B4.5WEUXB2+OBFly8_-M4C,>L F&U#H M&/6%=FI0V(NB7DDYI-80&(AA^G|=+8.IC-M,V6YC|:3MH.C@TG\$K-(S#|; MBLWGYQ=;H>F0?K;?9YO)>B1/? HD%I|8&~%*E)ROH^1<~R5U0L_3V>1+~2552 MIV64WL9U=5%|B? DD%I|8&~%*%VLH^A^<~^Y^UE|@+DA|M)UW;6|VOAAN^P_.Z|J03|V.M;ZQ^>33%I|8&~*G#& MW7++0#_K9GDYIT4|MODXGV|.SW4PY MRS"WYYW;PQGF>'M^HCOAHUJ :B&EJ3-Y8^0T,|D7Y?~4L*=+)|IEPJ7,XZSW M&HW>.7HNDYJ%:C.J.7N>_J'N5 0=AX=|J|H|G|J92FAI19A=1YB\$1M8B^QHO5 MODRSM,RC;F*\$E^*~;~6UKQZ@<B-005;~%1S|KPK2QD 37_1/%3542U M9#2 MU.#J5L\$-|?K? U>|>L.K^HB.GX|ZH.M\$*4F2CG4BR3^T+>G09O-4V\$YASHR<) MOU>X6VTSNYZ|<21AVYN9H^V+V|/IBC0B,77)&M0#50D139W6W|&SHEXRK MD|JY= 2=9#>J;J5J5B:93LNCZJ|X^>U^M";~\$UH?>=N8J-COL| MJ-\$_U0+4V=PMVBKZ?>?V0^4^SV|2YZE|J|5GF2ZX;6Q<_S M1P^<\$;~9_3-I-

JWJ;IHMJZA>^NCW0:H%*E%..JN[56%ORS/J9K(TUS.XE), MHSS =I/EJUS^\$^TFIB,OH(?VHLHB:07*XTC4U)IV7U003QS7-C4FUP/X^GMURHU& MJ2Q0%MI1YU6P8:18RZJ-R/[O+;E%)\HKNUQ/G(8_6G|8B 6<9+49X8RJC|H M3TQ0%U4ID|?K?N)A6:6USLE?/2OR|_M 9"1% [XH*NAJ].:CVH|JH64IKZ3=\$OB MAGY-W\$ _O9%IF^:Y|H EWP;C7UK= _L.2"BB|FHYAC;Z|J|^~^"BO7|JHY|:-@&HA MI:GQT"U^&_HEV_ Q|SWZ42G#DVT4 #5+>2S4B\$+|IU|.7.XZ+EXT+|=+9+LRSS\$8YQPX.1?MU3ML5WVUTP#50DI3 MYW6W;F JU^>W?SZ|/?"\$^5G |E84^8T,7|%-0C4;U1Q40K:CFHUJ B&EJ6< ME0Z8Y PI^Ei&E&HJMFHY?|:BVH>JOHFHJ|:2&EJP4U?|:~^D\$JZ.7U06I M|JAZ+; 9>M1\$ U|J5L5~: [6(CPQN|&N|LTJRYZ>[WS|,+QUDE6H2:|B&E MJ= +VA4A#|5%""|?5OGI/M-FE?J|'AMVJ&:AFHUJ#|JY|.AFHJ|:J%E*:& M<5? J,.1+^89HJ0.J6:AFHYJ#>BZJ>:CFHUJ |B&EJ0?7E3H,J|:4.1V>5~N_H M:\$ _J0?5;1S6DW~|,Q'227:I=2?;I3%|E%2B?0:H%E*:&AP;W ; M?J)OR'I MG.=2? [2/2|J2CXXZ|D0|!P'V5+&+L0038FPFP=Q~@;R? WD_@KZC^?|U&\$; ^ M'F.(UF.@FH5J|JHY|.BFH=J|JH?|92FAIP73W&<-_M|XY~*|?%#2S4,U& M~:~? 5^N5X9Z S2K3& |J5 M0+>0T-8J2Z|'AOA+D|JL G?H+&+3J|U|2@FH6 MJMFHYJ?|:BVH>JOHFHJ|:2&EJ' B^/33|OR|:=4L5+~1S6F0U^GGUF5-M. (\$U7Q4"U MI#0U MBKJ*D2Z<^XN1M|F#K0J^>AA+WLDD6J9^>1_ ,^961MH;4VC|":|9|&:CFH-J M+JYJ.:C6H|J|:6IMT#MZEE& SQE*%5)ZAFH9J- @:ZJN:CFH9J|:@&|A92F M!EQ7>3+2WP+BQS|UH^ @Z|?ZU|:~?3*X|_FH-VZ*":BVK> B?#1SL,4"WL M&;XQ5FX;I89 5PLRTM>""@A2KURJ#Q*"T0548U|J5<5-04>UH-7VWCLW MI+15PZ>K%AGIJT7>Q6ESKQG=-&>.#IVT"IL.5+~1S4\$U%|4|5/-1+4"UD~+4 M _NJ.\$9|%<<(K>)-_005;%1S4,U^0-0 5?%0+4^VD-#7@NBJ.D;Z*XX=NC|JRW MCXX|_4B-YFO|>X,,+=Y ->>I_ 6BP_10S4>U -5^2E/CJ:OG&.GK.=ZU=R/4 M9HAHH06J6:AFHYJ#>BZJ>:CFHUJ |B&EJ0?6%5J|, ^&+5\$|IH@6H6|MFHYJ?|:BMVH>JOHFHJ|:2&EJP6%#B-JH<6/98AHT<6>-D5[LO NMA8|1C7GR70EHN/P M4,U'M0#50DI3(ZHKNACIBRX>YXC3 _M|MOU -5^2E,B=+R5:(SY\$HTQ M6?|:A;J:CFHJ|+AZJ?|:~^6H|J|:6K =24:8WV)1G-G>VVT@A#UFZUO=R='BA91^H9J.:@VHNJGFHYJ|:-@&HAI:DQV-6&C(=| MKHC6BJ?|:A6HVJCFHYJ*AVH^J@6H%E*:&G|=KA*SO M\$|J|,HNK85Q|YD?P8|W'UM\$AV^C6K.D_?1L,2M|>^7HVS* _ZP5;1S4,U^0-0 5?%0+4^VD~&+&NQJ2 M|83|)-&:E2S4,U^0-0?57%3S4,U'M0#50DI3 Z2K*1GK|U?SPYDDGE^R9|J#& M0)~HLADJ.8|?>=<="">|JOHFHJ|:2&EJ6'65(V-JY<+3KT.B52.H9J&:C6H. MJKFHYJ&:CVH|JH64ID9=5UTRON"S1|!(~4L5+~1S4\$U%|4|5/-1+4"UD~*4 M@)MT12(3_7UIWL|JHD**4^:(OM/2- CPVM|4/17&5\$QV&CFO/D07+1<7BHYJ-: M@&HAI:DATY5Y3|1E'D^~^KJAWCXXFM _U6Q4H|JIS=95G|_ M1=|@/LN_+MSJ7|02P,\$% @_#8%L6>3*^@. ! ^!(_|D |X;|JW M;W)K&ULM5AM;|JLV\$XKA&8;+9!|HN2W9+!:Q\$6W M T6Q&OW(<@_6CK91^71)2D|_O<|4HKDQ0%;3NLF713(Y|C|KS<;@6|IM: M &CRD>%&GD+K9?GOJ_ B|>1,G8HE|@F%3)G&H=RNJNE|);837GFAT'0|W& M'V|'M',W2|#+F/Q<0B;6(X|ZCQ.W?+|09L|?#Y=L#E/07Y8W M\$D=^@Y+P' K%14\$DI"/O@IY/PH|98%=[Y;166]_ \$N#=(3XIL97^4C+S",((~8 M&PB&_ U8P@2PS2,CC>PWJ-3;-QNWG1_1/UGET9L843\$3V'T_ T8N0-)) RLI, MWXKUWU [U#5XL&S M#30ZL|&J-T36T8J9=>|LCTVP|E&-I%F-:|;GHW=C=[PPH1QJB6^Y;A|CR|+ MA3- *D8G(9|Q|YFP5846"\$X7FQ1P?|X53T#& M!OS9S.>>WCG>5G> ,#/?2Q122^6P?O/XJ,R6+8>3A MEZE KL | _X;|05_@A#>' (A3XV49^X|90LJT*UCV %T;_0)A&LQKT@("G^ M:H A3F.XXS2|+8Z^Z 60:Y|SD 1UNY=\$I=?=(D\$IC0ZQPZ#8LNDX6USP# *_@P M/+01US|C310C0|1K_/9>7U|J.-R#<;PCW? UU3 =UP=|@|I:M 8'KRNI@|:)*+ _M 1)G#8FS^Y14Z)24\$^7^<@&S?|ZXNJQOQESENUB?ZZKFJ|,|9A&IY,5;2,Z M=6;AGY=6C?=\$6X- #8Z|V9Z|JW6KLB1+C?,L.%JDSMO@&G|7C6,YM#:#N M6O|C|NJZJY=-7G|TAV|=\$S=N"P-U|O\$C1-G;8;= OJY|W&WV|?LDJ|+M*W(H- MR_!'G|OPND&.U41;4.C@#73LK%+^A2Y9 MA&UA^IU%)&%NWBZ08X|XK"M1"%|@Y_YSNIV+.>MSN25*UB-M_VSGX;TN2Q> ML|J|+\$S=>SK3EIC0W4|L^*,>_.\$QTE?&|R#>5|FA.6BQ^YSR39LAITH3RMO MF|K)L~.%QQ6D|R2^V7?;1.3LBC|F|8)L<^%9=)L+ <"B3DR1I8>8YQC<|00 M|JAN|;U\$G%|?#CB% 2O(G|WJ8UOFP7# 9EB*EL|JSPM)\$Q@#0 1|94?* M!6F9D8RG<(*8B\$3;).SC5DI+>E"D)0 ((EX|T*M;"1381\$;YH>[:~J0?W M|@ERHP5S?>+0^IY>U4\$VL|45S24|G|B;C&? S%V^T|@FCO6|ZC|&PO=VJR;W-H965T M!SZ1Q5H7|,17.\$%|(X|LGB|TL62^2 M,0)31&#<^? RF|GF,*QWR02RY1^U \$0/(T YP^X-O|PA& 6P#< M4SUX|< [U4.G_2AF|08<^%|+//XR.@& 64MV=1#KGZ.EGJ15&V49|D+>X M,9YD|YPCJ8TF9\$4J^QQA~(#J2^1 M(A7KD) *6SZ(|@FA1+F|)49!&\$#7@;7|H 5O2G5+B9U7 MB2=~.*\$SK&Z0:UTAQW^IAO5,3X>[3>|~!_IQ=SK8KCE?G\$O>M_787_LP(M) F_@08@Q|"]@(|_1|TKXEM|KIE2E|):O< @C0J9*#FP-QOCWV^RNJ4>3VCK) M?|UD@2:R2EZ|,B|>& MX@F.T.\$G\$0 MRZK|94763BEKIU76Z1+>+J@G|J|&Y+DF2^|NB=>|_9'<^WD|?#2MC=,NSNI,N|>| J|K|^KYVS:2G_N M-CG|9;#)94607JE7KU6OW9%XA>[352;X%7J -<3(1|>|(9D|'X|^E5<=<# M_H04| FY C^+2?Q6|V>^Z>KD|S219H|JNDKE^FKJ_0.OKS(M_,E|G6:") MK)'709F7P:4E|J5XKOHZR? S|0:5RK^KQ#PZ-.F|:B|8MK7K RS-JU4|X;DZ M:F7S"[9J]D=RZC@TVUZ|5|Z;D7D=E7|KS^FOUP;WZZ=YDY0Q|5OY)7,%7:48 MG5V,CHX#;|ID- "4OLOUC"V^M1U6|P|WDTXV7RM;H(NMFKI= V;_#QV8K;4% MT|KF:V4+>+5|L-KP^R+>|!VY-DYT-J)6R5>MOK=P^JT:&99SD#YT@YVG59 MNMXVJYWP;#%ULOEOV0?#FNJ=6X|5M>WVNT=-:WO7N|D7-V|N% .PGN= HC9|J057L#;J|SWR MQR7@'|@RD|S2L7KBW0)_DXP @502P,\$% @_#8%L6:|65_C6' \$ \$H M |D |X;|JW;W)K&ULQ5QK;^,V%OTKA-LIH#7 MEBC9<=<+0\$":Z0:8 (FT_U0| =8F^B>@TIYP^LCR|JR:+HD>@HN=H&02+) MO(?DH7A|)#R^E|>_ _R6GVL;H#E3<3'9QD5^~I+>+<L3(F993E/YR5W&U+@ (M4WX^SFG)|J-DGB.'6|R8 MN|)/A=8 ;90%<@;K|YS&KS:P#LPP,L> [V|S\$M MJJZ4|2D|(M_SCTBKDI+.'50DEE-R^ZS5|>W|:~^EITS=>L/L.R/O^&|&NLF3# M4J|&0R^210)'6K#TGJ|:A0LHKS|'UF9_-B5C JT+_0910Q=9G\$Z\$#JM|D-5 MZ^U")B|?YO)#-5)7-P|D)5U63<\$^33M&-K'HKT,UWML9O?TGR&*/D|C%G(BAKS|1QM\$#B7>TBS.K|5#.*K|E":9|L|: M<^3^/'RA309OE089BX;.A96,JRW40\$&_K KRAR8;RSMO(BC^4\$DBP C,8H;9 3 M,++>G\$Y+2^HAP0@ (/*DX;DS2,2?OM4_Y.OIN|I|J|3,2>|C7H6#5\$TK^QT MW%|>1\$SFZ0>.4)NHJ>3|Y?>?KY^E^>+<6R=MM9^AO(&"18 @1GDGC|DGL| MVU-(*B' B P@TK7T>&D8|U3/Q*>2GF|:-*Z8 DFS)*K0-J@62,B 2) MJ>BBM48 ;RI/&MT=MG7W%,6U|Z>HH02L>~5+,#2?%=T4@^J7&HT MY2|;OMD|!#Y|J3|F%WY0S2Z^>ZQ+4+DU=X@AN22D|LB0|J?#F#UJL.UO@&4 M|X^B!S|HYN|HZ>..H^U<4/\$BA9 H9E|_OWCV@70Z+X|5\$;|"MCRG G&.R M3**T G+MTN@57N^CARZ#41J|A@ODL |%5&@: \$4FCD46D>Y(P@1%U1)|:(% M4&CFJ|K764MBNI=|B Y@46\$4FF<_L) (\$7=3;|QJ* 9'K- S):Q+| 5'+~W2 M\$BU14|8%;-1JU87MJNHNHUV IJ^JP-VJ|;57@P4-/N07NCA^P%F'8+L)>XOF 586|@8,) MA40+H- #,P=&2#R|&| V@^@T4+81",_G4^@U;5X1?>I^'OLS1E,'21: (5F#H66>'@U@A< U6F@: \$4FLFGUFG8 MJEO&UQ6@DNY(9VIUL*K5 7(QBLASM|ZP|U 8'A|NWEVT7+>?Q|XEVU4^IW M&FY3|FU|XW\$D|DBH@M^A3+U.FUJZ(P?MY0-/J4&CF &B%Y|DC|(^E6F@ M: \$4FLFGUEFF>/0_W-\$)8J- Q60\$76*|X| M:095;T<: ON6(CD74W;0B+>NVMM|QD|I-H);>58BN19^|,/*R>_ "Z2?6Y M-4ZDK^W- " *=KL\$IQ^L##>130Z0^_9SXB@+|ZD%|LFA;|E-E^4AVT^W MD|E2| =SQ+DSDZJU1149&@UJK#Q80)N6VSMEV;|PRA0A3%&38@Z(%4&@FGUK8>_> <[=C+ M4?;J|U_ ZER|@^~JGO>+7LVP|A:MWMV>3K(|Q|,D;^@29EH=;)|T6T ML|<=>|_@^@IT4+>@_LWD4^MTWYJ)? 8/X#0FZ@|Y|J94(|J|K|84^KZGY9W? M.1J@O|C| URW|_J|S|37L@1;1%|;XK6@|I^VZV.J-@)|JH8,YALT60N%9@Z" M5EO^""MJ75^118H60*&9? +8>Y|MGM|J3;JQ|,?<^6VL(HJ)? CR^P?S2^T+>MNXN?M|_D_NR5S^8 M<| \$+Q2:2;T6BOX(&W%)4,T'BA9 H9D/Q&O-M| GHZ,|I%+) [A|V\$3|J|D26N_PN^ 9:8KOF/M2\$|>_@O/GJ\$3| M,ZE7#JE|D5VKBWC37U>~W19OLSGX|J5>Q94+R2D_-6|DFJ(E|P%*-|_>G, M3F1XR_07#U4G19:7+^399\$61)>7AEA|Y^Z@|I|_+@V|OJZ|Y5B0Z|I4\$|L# M!|0 (V|;|@E-J1_U@,) 9>2@P=VJR;W-H965T4 FOPH>*D63JYU=>6Z^LVAH.I2 M5%#BS\$;(@FKLR|JVK^@DTLZ^""N|JGQ6Y|6>DD*#XV|2.#>_D;WUJ?3+6F A^U| M|I|=6.VJYHPJ6@G|FF92|(DTUNC-- &QL M+|K5L)-D<:TESC+&Z60EL2^D_DEHF9&7WVM688HTN2|KE|>LYD#M^AMC<7HC_ M1-W&MZRD18I^?D#6,R;52H- 6(0*5IC@O(\$W32_U@=>#LO^3LZ,@1%TO M@G>DUXM;|:LXK:6J^VEH|@TCF|KVQ|N.R0~36\$|VAJ|K21J\$7Q)W1\$>PXQR> MY=R5|8A ER_#W3+>|<| (*RHI=F|F|KDW^T0^M":S'O>^43SS9L/T|J|@/HF?><<<| M_A|U8J>*HV,'_AP|>@A67\$ _SN/9J|^43@9>|B)IVHR5E1IZ=?U9Y^OR0G MO? 4#SS AV+>9^ 4^K2C.#U+|8/OE_QF78V5AS.HA~";H|,T^~^Z,D,M MUU10M:DPKQNS>9<3%"2;Z|?I:'9&^Q.:+P;3/'GPM(8X#&SR^T? <=&PO=VJR;W-H965T MQFL2I[4|I|V|<| (OLE3:D6:5|@=NYYSG?<>;&H>|> 0@T%,2IWQB1\$D M9Z;PP@2S\$|H|JELZ0LP4(NV%?&-!&^* (XG^6;/4XC19F+8QG;CFJ|PBH39,YISA=? R,N,VNF%R9%|>@="NB7 M |VZ6<2N\$^=C@;TQHQ0&E+5D4P|Z^QHM|T5252=U7+>|BPM =CG- EXIYSD|7QBS-0Q|X|NOTL>~1.0|J-)>5,X|34|55WQC&Y7^H4F^@F6@6=1|JL09<>VA9UMA< MUY.|J|S>GMF |K9R.WOF07|9K8S^7M=F+N5\$W6V.;>9FL5UVA=(EB6;0 MT;BIZ4Q;B=Y;@059OQZ.2N%>=KIT&G1\$MI|H097HP10%QX;*8@F 5H=O> 04_|J-0G01=|@:;<[N3V|M|XA1DMEUK-)=>KT M7S2K+IT&SLM4FK6IH@V\$J|;QSIJE|:QVJPGQ7 J&+ _G|JMFV#;#ORXFR M&_#_TA? CZ^5F^Y+&J|P26T|5U,5^T\$S|,|JY\$2D^R,Y%0-3|O+| MDE^Q72@_U9SM_0%02P,\$% @_#8%L63V'H.6|JA(|D |X;|JW M;W)K&ULM5AM;|JLX#|XK<C<,&|J#6+W>VB1 FJ\$N M JQ=T6R|J^|5|4&PF-F+F20WV>%^ _@Y>+>8<==#"A2~+9\$R4>D1&NPNY*[MC 4>4P3|H=61-3|JW+>9E\$5\$Y1E?<_9!1FBYUM/ 7|R,EI|ZP1X,57<|_U-25 MK< WNT |XQ28C#DC A9#ZJ|(J|GA=K6 DOL6PECO|1(8 Q)H|0CQ|;4*N|PJ15WGY_0/YK@,9@YE3#FR=JQJ*AU;-(' N: M)>J.K_~^34|MC1?P1|K_9+V1=2P29%+Q=*,_J0QRW_IXX:(^06W=4#|VRAX M^PKM P|JMC4|K7Z\$S0,?^B&F34P1;^&^+Xf0DLFCGXP9IIM##|J^MUG M2N|LC|J^~^#K,K,%^0*5.4+>_YOEU**4|>D|O,0/<34#1.Y=R2K|.)N3| MYP+8+8D9^1+Q3Q(6RH&M|T^4: <L^/((.5&6DY)|1S+>_H6;U02|H|AKU5HJ|K6|6=O=O|O MBF\$M8A8K/V\$A1%6%X?PZC=Z?O. MP|8#>8YJ97|<+>+>=J.7TWW_3@>#5>=DCM,NF6|J_3TG:Z7Z|7HG.X63G48G MQV9' 4^N(%ZXY510,)4NH9T#J|(VC|H|7YI|P|KQ=XM8N^<=DEUC|Gd7 9_AB|1S|5E7U^JGH5VJ|6;D9+J|PLM HY=|L1\$S6|5|3!|G M"+ (TPSS&9|9RH>_ 34|7A^#5.G>K5NV>B6G47|J|U^P*O\$6KY|K4=;;_LO; M,D|N|D0 2BQ5^50\$&<CEDS> 7NU%79>JJA|A|_M_ N:/JYL92;;;XT?X^% M5F9HIW%Q7|N<Q>:Q<>1T,I|>%L^O>=>|U@?>9^7U<S8|>=>6%>)=G|76= _M^WA.JAS@MB-R&YN,_UD2XYNID?H6* JGH O577%9J.A58F;-LVN? ZK5TAC M_9B/HZ\$5N9CVZ^Y+>SOFBND&>R^54|8N|);^IU>U^2\$>SRN^J-N|LBVZ7\$; M^PAJ M|+G<-1?^A5SE(2XQ|+DBPT|RUY|Z;G> <|F\$NEY056& M FG^7O2B= MMEJ 5ML):3|0B54|'3 7L,G<6A.:ZGP1Q>LU-I|2)01LD< II),I|5+U\$. MOT09=%6H)*?1^\$C6?BW|*AT;|)"~3,U;EV1F8 Y(8K^|VRX +G|AL4\$T|N M|Y1|?65 KD\$LO?R.QC@26,G/3QIU^600?*BG6DQ>?>C|D|F_|_S8L1HM+E2MS ME5 9|YR,2WJ9KH8^YA|*V)_J;GFHIEC^PGL\$|SSED7LU#2^G^R/YB^<(KW.2TL>_8P3YI^K^>8R>+^F1#XB7QL?W= MG|PGC3;M@! MB^ELHN@0^SF86BS DIN3W4#BE8VVIO_Y|I0SC M^J%)1C+E+LM;ZT14W^2^G^&O^MD^M^CX3:P25C2K(QO>~_@E?P|_1^Y;-3EC6W<^GE^Y%CL0C>|BR^#|E MWNGF(W1YO,%2^N^K.GV1@+>:H|NZ|_DH|2|?J=PX^@#A |A|W@-C|JH6| MRR5^GB9&-LRXW<P3|CZJ|Y,YH=<6&A54\$X3%TE?~: M.;=J.0JZU84W5N M+>|E5S76A|J2&Q0_N3_#WOZ(2RPXR4@%*>L^,F%+LO=&VYRFT2(OER|&'6 M>;AH|<3>8#JE(VC-RR.X@E|6"W9|=') SQAQ>JSQ7VVV~.G^&JUCIOA)2, M; V\$6P|;26U=P* G.XN&_I100^Y6E1I,XJRC;+>XS@)=P^DUY|N^E29|2BYH>?^T^TU| MH>G_ MB|J|BZ^3\$S.COON^Q?A01.X^+03-UNA+).P5|T>D8&PO=VJR;W-H965T M7^E=I79|,KJ.\$U#?LUN|I7%K\$K4LEX2@0L+<CJ7|OG<|33 M/C|8"/WGHD> MRCWG#|IP^5UT'-TCB^"%4FH+BWQIF\$,>."?OQ;TG:J6QJX|SCGUN|H^#N:<2 M9CS^BT5J|==\$Y|9 (%C2/U3>^~1W* 8TT^IAC:7|D|FA|NJ0,)>)*R48>Y^P MM|BGCZ4C|@J1 6 5P^|YX^7+ Q*P."U^H8E8|@<_J|_I5B>0~%K+8Q+P-CX MOG^6|;1/9U!- |O|H5LCFWXPE;=*8%O&>+>4J|5%VR^QC(I92@ M9|>|Q?G|T0=6G2S)5RHU>|). (L_|J\$N??"SW=:)?%GC^V9|9598|5ZP,B W M/%4K28(T@J@|'|3CSUKP?1QQ-6QO-^PKKY7PAHH>&A=XCG>H&D|I? |R|!#N M&BP>Z_Z^MYD/7B;J?DO6Z_Y-5^J|(IN?PB N3A^9E6FF/ M569X,#C.W'E ZI6P6&K|?B@U?QGK6K.%7.^+4Z|8V^&|(#QKG4?LNLTP M&J|(WS>0W(X|F1K93.M(FE6^3++1)-K=\$5A-Y7(D;A7Y>|KO-2? 5WTP^ M5.8^3\$QC:9>T&L\$3_2NB;G=C^C=UD@<@F9X3=JW6CI6>YMDODVRX|?R|K M|O(M4|9@<(47OYOMN-ZZ6)|<08<C2|PFNT_B= [I;J+K8(XQQ3@/RD7TBES1, MACQ@G@P\$XY&>=&|/(<5N^E_9G7-B94H4FM51+U8CMD=>=,N,*A2XBU2&2_M MC=668+YC7CN|P? LNH6FD&Y@6&Y.GZLZM06#>34NS:(7THPI&E?0_Z?A?0)_ MRR195W&#IN+&ED\$<_1JRP)73M#^P=V>J\$TSRXMBT;G!_#Y,TS|/\$ T;TD^<1 MT|R2A^LJM UHYQW7(I3+>+1;P/D-AWZP>9(5_-A5K@E @4|,|NBCVAR MKT^X|23|N|6V7R&| (5)5MKDMMKJ|XW1.XGNV#I';&HY6VR>9;90M^MOU8 M-^CM^T7(^8FDN 7#^H3>XHB|P7JN&B|~|JFS^IE|I|KL-J8&^ MF#1^V4_TQ:T&G;GV6##&PO

M=VJR-W-H965T#PJ7 MA/+J+#+%[3;|0DVT>A3&[34FV7: JJ/D#BY+JY\$R M>GGA2WB ROD+Y]>7& ^>?67Y;YO/M/CM?*C,5|B%K\$@YX1? .>|W; HXE*Q" 6Z&C7 M)V^X _+3LN5+U;FSL 831+J^RUSDJZO1?0D6;EOH Q+|FBS>H5T|@5)E)7 M3Q|K|XY|-AF>;*N&Q=+L |CZK_ ^4|TA|AHH|Q,- U+J|VK>|5C?0#AM,3C28 MU TF|PU4|40#06Z@'S:8GF@PK1M,^S:8U0UF?1=I7C>8'S0X^3E20I?W_A1_*=<5JV+T96&/2^JIG MQ: ^&1;0| ^B99K|J|S| (|WZ1(=#)G(2/Q/8N#D&7DE<C/R|XPR|@_ 37T^E^|?2 MGN=^M|SQ>5|W855=|I">ZT.BG EU|EQ(P7:- '2W|&WO^A|J|G.^|Z\$\$. "UUVZC MJ2|:f8,j%5T _2D/&RAE1Q^J\$+/-2^E)FW&D&2-V7|O:JL|X9H MXWHK|_#L_IXF64T^O@N9K&|EM?4T3FQ& 0|U|_ :70R@XF|SKXP|K^|V8.< M+&4@9ZN6)2P@|?C.P=MLXP|T:E3_AE+|ICHNEB|Z;BU=|)"8<0<1.);1F\$5A MTQ+C.U/U|LS|IW>? ZP7RC(3IV>G;K(3KWN3H5|/MD-IHETD^|+ MOO/7=X-6E@_?K|JX:N6<)&O6-G:EP-"QB|0,)&8B,8K\$ M+|UHM^F*EPN^F@UA9\$|W8W67I=|_L? 4C2 =-HREVM|AC,0,)&8B,8K\$+^1F(SS\$B:E(S -A MOH^-=@4VDT-|I(=E?AQ4>S596TU)@:\$.UA<0,)&8B,8K\$+^1F(S%GUK+^#U:.' MC^S4Z^4J(3YKA+FTDHPGUBPY4>RR.2E,@Q8FDEG&BDVM^|0F(\$3^1D9BP\$ MQ&PDYB Q%XEY(SRHKX M=25W\$ZPC;8:6%| (SD|B)Q^@2LY^8C<2+EX M<4% ^S|,M(TL_REC|B/T|N#M4,Z":=5HQZ?%MWIK2\$2?PH9J#E1SH9^|TL3B M:T|K^+^S^G6D:OJ8F5UG9\$RX(T+>M|NK2|HR72HW9D U\$Z1J&9-1NJ,1T# M|W,<,%SSLC^YP+HO%(A4CWUBZ)LLD)3XD|HYJH|?5=,"6Y2- RM>4=Z_?2M8POI+K@N^FC4 J|Z4|W6 MVL5>48W2C">_-06-44 U|Z|J^U,M:~6)-,D.1|I+<_9B|Y|N-ZDR4-UFLR| MHN21GTEN+2)H_ J&5#- K#4AQIQV3I3V2:,%73X,JCE0S85J^DH32Z0)5BCR M,9.6M.-TLUF\$<9GEU61Y9,D8V?EAL:@94,Z\$;K35%>0SC8_ \$|GW:"E"U.% XT? 0?5#^AF0C5:YW76EK0;FVHYD U%ZIY^SVLG^9_ MH2;7JYPZMBUO|A|H\$W^J&9^=|QJ?><75@V=\$ELJ,9 -1>|2A-+^*OF M:**3|W|&^7|4M00)G|J4KD200:7#500,64,V\$A2J65#-AFH.5'.AFH?2 MQ#|JL|_2W\$Q>3&J^2A+^4F_:'31% OHO">Y ??B=|R,9_WIUC^N.YN?|4 M_-2: MXO":_ \$7QO:BU,J^ABHZE^ASDU>W&^?W&9ZW%,_U10#4*U2RH9D,U|Z|JY4,U# M:6|A-6\$+37|>O|D0|ZN_')5>#BP7|Y<8- (\$U|ARH|J&:|=5L|J9TC+EOQJ|:O MY|RBAI_8>R1?>2D96:~|NCRKXR|SEI_7L_!|0>V|)M%&V,8BBHX_ ^65Y=/(M(915)X:RLR5?^FC1_5_F6Z+E|E^|Y|L1)X_(RX1?9.%KP%G|VSC|W|7 MX6ORLS8|F^OCW,6:|E21?F|R1.W8?QC%OD<0=2U:N HL7|9L+ZXX5(B,&^|I# M\$^_ /JYB05T4)_H<%,5|P?_?2:58^DN9E*=D#_ X5OF|UU94|L#4)^_BO_L|WK MJOT=&8\$KQ|RMN93#2?X:KC95B@U\$3B?|Z6UUX7Y>5GP=&8;XA7:TJ^? 2 M%5NHW\$2SLPM=|IQ\$ *KNE-T_7CK| ^D|S_ GX3->& MK^*OY^QDG4|5+7Y:SUFH^R|L|8D3+JX#97J^2_?M2*(?DM,2=9Z:L8^?2 MP3Y_!OL &NP3:* Y+;CF0#47JGDH32S|J|>ER7_ :/QXND7CQ72RX,KB|HY NJ MF5"-0C4+JME0S=&:~PFD3>?ZT4,2H5DNE^863I|ETN19KN\$37S&_ O3JYM^*IM M&A2|EDBG0&A(##H94,V\$A2J65#- AFH.5'.AFH?2Q\$INTF2:|W69PJ\$1L>@_ MF@'53*A&H9H\$U6RHYM2|+S^V85^J|40F@E#;6+A-)DP39X^Y\$|I/#0>)^Q M@1US(##1V|M4,J&9^-0K5+^AF0S4JKE0S4-IXI|FW3:I^=UCT^RH6A|075 M#^AF0C4*U2RH9D,U|I:VY|?9|J.#|V#DVP|H32Q)H\$VZ0C*X;Z&CCM|0U_M|=,@?D^ERGTJ-D-0S81J^*I94,V\$:@Y4U?4|L? YNLD\$U&8L|@|EJ_Q^>?ZCUWR@U5| ^S|^M> RV::,\$7RQ" MWL^?2|D?S_ =|N7ZPI8(Z IZ\$^VLW^8,Y&8?H^Q%?_**Y4:\$RE8Q654SO7 M#G0Q^25H)H-U|IRHYD(U#Z4)|:0WB1I=GDCAU|3Z=Q\$C|K_SF/R8W|J:\$U! M_0-JF5^-0C4+JME0S8%J+&E3L_85%R:JKL#I6|I_ S>@B@<9^H)D|U2A4LZ":#<4:;D MP&TSY=+@_H,&2J":="4H5+|TX_ ^|JBD7|I?^@_ ,|LK3A2;|H32Q+|J2B|_ /| MBW\$? P.D4="2ATKK;4 C6| -1,J4:AF034;JCE0S85J^DH3:ZN); ^CR^:2 M= " H|<3|EOY,T&%Q|TYP^5*%2SH)H-U|IRHYD(U#Z6)Q==\$0/0>\$90.(O M9P?O_4^C(%#- A&H4JEE0S89J3L? ^UNH(22Q,IM,B5ZOTQ)UP^#N;D MO2;>|N5#-0VEB|34Y5E?FAAT |I;#H%J|E0S MH1J%:E:M^8|&4 GRN^|V#V| ^G+K13#26)I=+D/3YR?;F|!:=5V\$GXL;YD7|,|H|Q|O4(U^ZK94,V|:BY4U":6#Y-U\$+O\$|4XN7F;ZO- M|V_-6>O, 8U30#43JE&H9D\$U&ZHY4,V%:AY^JPKI/%LOEAM^|E|?KEEZSVY8 M%&4DX_ |N^KO8_ .|5XLOA,NBT)2W|J|71^='KEO+65EI>=Y2W;OGZ><-?7V| M>_)3|M;Z\$=L670U2C,K9|PTO^_ M2LFE15%&(9&D)_ ^3>?GCBOD+EQ(W/^ ^M3+|Y12>P6,2_E&NSQ5_5!+ P04_ "@6Q9-TIY^*P\$ L|& &Q M^ |AL+W=Q\$RENN1+6Z0<)"Q9%":_M>S8QHFUG2^Y7ZDORF|ORE= MPASDE_2)JRN|0@G^S|L|L|1Q6\$RLC_AZ10^ 2,72(6\$S^P\$ D|;PPIEU2W <3 M|RI&().)?@_BJ_JUA|E&DD12^R6H5>VI W<_ :|O:12\$R:Z_??4#O4)B@SRN6^14B MQK94(C05VR|)WQ2\$21=A2^ ^1Z_00<4B_)7QF#K|7X7C/-S=# |>5=95_1^/ MY^AN|X#^_ "0^Q3WT^T(GX=|IM.W|46W4N|Q3|M_@O@?CNP+MJKD5|2|JZ M3P#|#=;T|I^PY_S1IOL8^N>|4^K@E^I^GIA&5+D3:"Q2"|6.0AE^ZU_N M(=+T<4|U|ZRD9N8.QO=Y59=SW1%712E7? J,J1^BMBU|_FNOT_LC\$1=|^#<@V M007:8\$>0ZSCX0%" H|I|K|:M\$=T4|S=^_ HBJ^H^P?=-AB|P/V|KW|=^% MKU+E&56|<;|>X3X|7AK81F!? |6PS@2VY|&P|F#X?QTNPW-Z<":P|O|&E0C^8EPWS,^:W|S<Z.G.%S2:-X?M| MAPQG^*Y:~#W|E1:6_F<+MNU|4.4);=NHHF|9V- RS_ZR.C#>=,TCK7EZ MG-|I|C+|JOHN^+>VTD;K\$W|ONFC.5>><31-6|)L|Z=?|ZVJ^+I6|^<2U^|P_M_3N_UB>|Q|V=WW3YW5:EYHT(>@7^! <.(BEDB5P^1|/K|H:YMKLS>PW|)KM(7^_ M15JWY&Z;V-SV\$J2D:O|&AUQ+S|U|A5H7718<1Z<1AB|I3_3%|OU+&E#X M+%5,K9C^CLJ. <@=,=@K|N<1_W^"LZ5B(=T:V?21ZU@#\$.|):^HYXHN4_#17D ML^#5^|U@=D|KW+T>|1^R|I=A(A3|A8)W+H?J|R.3%|ZGB0K(T?|OSPI|DH|Q>_R>V%? F%4O2<@_M02P.\$% #8%L6=H9;N9@ P_E@L M_D_!X:"IW:W\$K&ULK59=:JHP|TK5E9-F|2; M:"\$|HBTMJHV|?=70VF:ICT8N^|UQ,YL|JL|/JM Q|U.V-<+LL?>|ZU2O|W M0_7BNUP#>229TO,Q+52Q9GOR_D:0%;?UERD|E|V+ER|_65QOGEA M\$^1^3BCSTK%|Q7IE:R>C@>JAY?2 **|KM3(O_ '1^4V4|&_ PV3D>@&(!=|8G^5NZ-D4EEQOEW,WFWF^B| M4009S|4)0?1C Q>092:2UO&C#NHUG :XWZ,?F63U|G,B(0+GGVF^|6>>\$./ M+6|JRDQ|X-NW4">4F|WASGDG|B|:U|V|L^|U|JGM=>K2^Q^GK^J2^WHC|@|AV (L M:T|H=5=\$5N4E420="|Y^P|S|6T^",WB2W2^"\$. W:U^Y^05":2,75&DY_7BL|KY2@>K|V|F4@E|H_ZY\$JL\$T^?3)V=RB+;8>+H0|@E^E^M\$Y_A)^C=D5|4H=U4-4_ :KDT5:C\$HDRL:M|P:K|&P=5OZ^J^Z.^7505^M^ZC MPKC?>W/%#5=|C^MQ<<4.KF^HYDH:KN08U|H#E1OP);/8335HJ_-=5'=\$P8&\$^H^MX9AHV^8J<\$4!^ (Y+T)?|WDMG^H\$R|GBF^7MDN&|DE2H&4WHV24>2-46_80KK2_Q_?2^YLS:14#J,623C8&630Z1>5 MQ<=^XF|I_ :JX? QO7V|E^#G14 &C909W|XDJ3_ 6^&K;|UH_ :SFSC@?BH M^3K=HH8186LK^|RS07S4|YU^<1U&,(M;#LCO_U^<6>5T6&4B^M_M|N|< Q|ZZ^L<^2UB=BZ^NVWT^XVCC|X|N?+XUSOO|W59|F.H(6)%F=3QE0H6 MG_YT5|J|JN|XH5MO&9Z<09A%NCO2|H5X|T&P0=VJR-W- H965TJNZ4-J\$MCMX^N|_ MABN|T0_ R5\$^*)|NYC4>_9P4AQ|A8|D_4Z0U&|C|8#_ @P_Z|P#=#|M^M\$|V556E-F6^A4,D5^|M_+91>5-A M^9M,V%V<&46S>%,*C\$9<<028P^XN^|VY181PF3^*=P0Y|TFZ(^+;_U|13_ M8_Q&PI<^%0V^?3_1PTFFF|AL|S_2JW_Z1<_RKL_@/3S_IG|Z<@8GD GXFL2 M\$T(74|ZK0HW;K\$2:8W^_V7<^%2351%#&K \$NY=MTZ^3^_ M^6=8G\$7 M>P>^Y_?VZ|G|V:QL|S_ZW8MNQ= <|P#>1>9X9Z|_N^U|0MN0HDJ^H89KIB\$M=M^H0?UW-M%_V_G_M,K|2H5_5\$H4KZ_ (|PY=>XU|B4|X|D|TQ#|JL<^_D:WR MH|? ZT30&KZ0H_6H9\$SR|DQ_!M;=M|EFKNH_4VM6P97OB#H;OB>ZWHOO_#H|K|AAT35W?T-09UOS;LA@O^*51P<5?Q9>?|P<^|C M8;=SN25Y- <8BY+L^I2P_6JXN^:ED^4U_H^K|H^ZKFKDU|9|9^X#7FGF M%&E_J44F_62\$55W/B_55WEZXZ1154HYD0V;V^3VJ&P_52=2FG7+M^MM>\$? 4\$|H#|H0 (V|:%E>#(P|X^D)_02_P9>&P0=VJR-W-H965T M^*A|_!9H_3ZA.G#<NG+>+OM|P^C^MN2;U8;/_ =_SF|A?2WSW;K^|3Q|6^YO=8JHMOG^ |RQX>?>A=O=N_YBEF|5A MH8?-V.PF+Q|6^RW;|H_ =/B_0SF^W_ M|H|:Y|I?2ZY3K_LZ^U|KU|VNU+^S_P5C^&92:E& |295X>B+/_J_HOGD9M|RQ_OJ|DVX=-W7|R:3XM|F&W^=-ZE= _&V|ENEMXNG32|; M|HN:"M_1N/26N|W^V|_ MRW^9P1MM^<3/_P_?E8LM>%AOG_|_1?2XG;BMH|Q>_M6<\$XKF|DG-VBMAOK/^N6^?25/6S_!N/6K?|HZZ0>N7_T3UT_ M\$W<^|H|N|XW|T8#|V|B|<NB_7R|Q_3|WNM5^LQW|D|56@3_ WFK5=1N_!0U^U^G/^N^#|J3+M|LX2;M^_92@6.8WV^T|T5C&_MQ|AC>SZH5_ EZ_Y8?2 |JZN:Z^U1^S&T?|OHZ=<?J>25AQVKV|>LGQU=>;_ MC7|>B^A8W^W5024JW|_V^TX>#5;YU_>I=|SWXSTB|_|I^_7|9K|H5M^? M73U6K^X_6XT8_3JZN**7YGGT?5YQ^I2O7JTR^Y6GW;LGJA7M|_Q</_NE9O M|_#P|2^|V_XBO=AL|COM=WM_0|_RR^KGEY^K#_?Q|I^|LS- NK&RCW_>|MBV7ZYMB^W^29L_3<_A=L0A_5|F|OC&E^HCG|_0F\$MB^HGY|:06\$AB^M\$8G%)^?Q(3)H_F&_M|RI|5(L_ L^MX^(XT|X>LW)> |C7MMO=|_>|+_J^T M^H8E9DD9I&836_|B;DDYC&EDP-6GECY_?Z?#>_#G|Y|K|<@.61PU9_A.61\$ M8C&|^1^3)9-6">QB_Q_KXZW^MZ>VFWQE- 0LO7^F>=>N^R<2^1FD|A^8C;_M_23FDIGWC(UK<3>_>?72CERT_#04^RT_C^06-R4\$>BDL02^&M\$V_0EPB;7 M|Z%M=M^|KCM(^+S9;5=X^F^X45B)HE9)&3F\$B+HEYDI_H79LD<_%X<+MR-&BBV^Y^""Q^2)1#6B^KI2U|_ E5%578HX|G|=BBLEUS>N2,PD,8O\$;H\$S_M2,PE,6|Z;|(X8+PX7D<^%X6|R_.\$%BDL02^&N\$ECYX2-WRMD+V^+O;DM9I&BFH5J_ M2,PD,8O\$;|)S2,PE,6|V^134SBMRN;#B<^\$Y7|Q|N)>@<31^8^>\$PAIY^7) M|_EWY=7N^*=GB^U|O;WK^BTEVC>T2,PD,8O\$;|)S2,PE,6|<_3(X8+PX7D M<^%X6|R_.\$%BDL02^&N\$ECYX2-WRMD+V^+O;DM9I&BFH5J_ |JYJ_?BFG?4 MZK_383>3BZ?N_0^3BZ?N^X^D4^NHT2U1^>^96|Y;O7|N07Y|_9Z_M9Q;F|:AFH9|_@ZJN:CF;7ZKZ4^\$Y^F#>CBQRW_#J<4- TW^ACW|DQ70T M83NOR&#JDE42RBM&6E&6E& TB|V3?2RYR93_57K0=^@_M2.3%=(F6|8|E+2\$ZTPV|Q_53%2\$Y^U&_0257%3S4_U^M>"H_6Z|<|&7?1 M=BTYG(UF9TM&Z;|J^903:);0FG-"SNX|>5JH<^T_7|F|7VR+|B|VY(OOV M^X\$|)14|H_C-1/5+2\$S4OGYWF5K|7/HO?RH9J&C6H_ M|JFHYJ&7|0H_83DY2Z^@8|F|T|6R5YD|I^A9B5|_H|E\$M|H_1FA^4W|>OJN_H_ MUB|G;_7+|L|LOU>N+^|W|L_?B6H6|MEHYJ^_BVH>JO|FH^|ARUQ|7|R60R;L2= M^6+SP5QOIQVY;3&J^523J)906C/MJFZ_KBX&_+/<|LRF|_ :J9J&AFHUI_M#JYJ_?AFHJ|@7Y^8W_GOMWY8|W|=N2VQ:@F4\$VB6D|H\$;2K;@6ZNE?PK^+)_M:MO|9>^N2^+;|8NL^+; U4Q4LU#_1C4^U5Q4_356_ ^GD|L;FE2D4_K|E>_M\$^?C|AYCS03Y=^M^7U|P2>H|E\$MH;1FEH7%_UW=^A|M3KXSH9<<|H^F_ |MEHEJ^|K9J|_@FHM|GGY<Q_YX_A_H01#_P2?J_HB|H_0#6|);@FE_9|<_M6S45^53XZ^|V^7>VR?TVOOQE^JN\$CPLMKJ9OU>Q_ =L(#L|L#>L C58E03 M|^91+>T9G|6?0E#W9?X^/H|G_ |QF&YSS?I<O= HO3A4YIU/G97;?7.3;0M M@6H6|MEHYJ^_BVH>JO|FH^|B&H|JL6H|E!_ HEI^_WRU|Q^8K3|O|E|H|W|L1%#&LQ^9FZODQO_11VGZ@W|3>L|F^RV9C|K|X^V2=<^1F<^M^L? NG8^D9J&C6H|JKEHYJ&C|VH|JH6H^JQ#&C^H^U22J)936\$>J8F^H^R8B MOT^S|G|WNMVG624ZH^_V_OFX(PS1W@BJ6:AFHYJ#;BZ|>CFHUI_>B&J|@6_MHY1_8EJ^4U|P|JQ6|LHH|A|T^ZA^M6GE=+1/5+2\$S4F|<^@FHE|J^K9J|_@FHM|J^KY_MJ|_@6H|A|S:K%J^903:);0FG_-\$SZ_ :E>3KZGZM\$>S2H9AZUQF6F>=<|5_L=MUD8U|H5<5^-0S4>U -5^5(M0+48U@6H2U1)^*!9C5I^6A^7+1^WVF&APIT|A^D\$U|4L5+1\$4\$U%|6|HZ8/-M&S>9S6^_5D<<36X^D|J^A;JV:CFH|J+MY1:Q\$X#@J1M41- SK7?2J9H&AFHUI#JYJ_?AFHJ_?%J|A_M6H|Q M4DJB64UD5;JK_SG^S^W&A|H5.5+0S48U|H5<5^-0S4>U_5^5(M0 M+48U@6H2U1)^*!9C5=H9J|>LB9_?24_L_N5|NADH|%^@^L&#=#(U2+44Y@ED2U_M_A^*@5=59H92SF>3H3^VQYQ|BGQ^<#K3#RT/8-JYO!^?|AR|C- 9JTR(3J|_MC6H|JKEHYJ&C|VH|JH6H^JQ#&C^H^U22J)9362_91U8|9J6?L_Q?>=SY>ZM|_M+N=M|4H\$M= (W\$5_1#4+U6Q42B|K^8V9D9AZU_2T:C9OYNV_Y)|V|CFHYJ^_AVH^J|@6H^M^A&H|Q|E4DZB64%HS&_OJR^@|JB_*TYC%#WO_P_W>@_Y1BG9F4_U_1O5_M^1\$4U_5^5(M0+48U@6H2U1)^*!9GU9D97=V9N7R^|R>_J_PAM/6_M|(G|S7NG(MJ&034_U|Q4B-1Q4_U_0C4;U|Q4_SE4S M|KLZ|&BFH5J_?JYJ_?BFH=|JH^|J|B6H|J|H5|_HEE|_S_K2D_Q|K|C MZAYS|C_WBE^B;J6:AFHYJ#;BZ|>CFHUI_>B&J|_@6HYHX;LVI@<8WK6<7 M|RIH^N;G3H|+U9_K5+MML|AE6\$O|G|AR|S(8|LP_/T-898&B9|M5,5+0 MS48U|H5<5^-0S4>U_5^5(M0+48U@6H2U1)^*!9C5=H9J|>LB9_?24_L_N5|NADH|%^@^L&#=#(U2+44Y@ED2U_M_A^*@5=59H92SF>3H3^VQYQ|BGQ^<#K3#RT/8-JYO!^?|AR|C- |4<#)HAU<^H|NOI^%=5_M:1DK_?E^_UMZM|JG;9_N^_>=IW>;>WJE^J+5%E0S4|JO|FH^|B&H|JL6H|E!_HEI^_CJF7MU_5^ M5(M0+48U@6H2U1)^*!9DU8@9JQLQ5QRN_>6HL77U_5^5(M0+48U@6H2U1)^*!B M4<6BNF|SW1^|K|IM^M^M^_!XKCI05P_7.3K2_@VH6|MEHYJ^_BVH>JO|FH^|B&H|JL6H|E!_HEI^_HX\$|2_?T_K^AEHYJ#;C;J_?CFHJ^CZJ|_@6 MHEJ\$;C&J^523J)906C_ JSL^5^U@_H|H_>A@L9E|U>^|2H3|_?4\$U|4L5+1\$4\$U%|4|5_1+4^U\$_4B5(M|3:~M1+6\$T|H16Y6_>N|C|_L_T9(4)H9J&C;CFH^J_?JYJ_?C6H|J|G|L|J;CFD_U MB6H|D|37SLRH63=3SYUPZ\$S^+1_AFHJ^%O9|H|Q^J3VX&P_A_EH60C4U7Q4 M^U M1+4(U6)4Z@F42VAM&8.5F6AR849<|+E4|_U^E>>WGZQB|W6=J<|K8S_M(M&R\$^J9J&AFHUI#JYJ_?AFHJ_?J|H^A6H|Q M4DJB64UHS2JE_TF_! MY&AK^_5,5+0S48U|H5<5^-0S4>U_5^5(M0+48U@6H2U1)^*!3GM&H-395W_MU_>

```

=>VFM<OE>K<1=E^E^V;...7SJIRIUVOUZ5EY*Z,E0MJIU05#,#FFI4CH4<M-X/1?>X1&K;086U4+32=>3Q: MR$+M5'-0347U3Q4\U$M0+40U2)4BU%-
HJIS$M832FQE8?>7RFRGO<KIS@H_U_M^CT:9_>|51^UOHZ6^0>M#>#S8I6@5#>0C4:U1Q4E=URB M=2\4LU_0347U3Q4\U$M0+40U2)4BU%-
HJIS$M832FQE8?>9U8&FZKFON>LYI-8 MP2#>C ZIO&M^Z^":A6HVJCFHYJ^:AVH^J@6H%)>A&HQJ@E4DZB64%HS^ZNZ
MSU1=|HWNFI=2\|M/MUWQNT+L ZGW^<K^>=E254_U8-02573S4_U MOE2+4^U8-8%J$M422FN8&=7YF1^='^W?FCSN1K3?
N3W7QJ\RT^H9J^:A6HV MJCFHYJ^:AVH^J@6H%)>A&HQJ@E4DZB64%HS@ZNRTO^OM^TW1LA^JE:AFH9J^_M:@ZJN:CFH9J^:@&JA:@6H5J^:@+5)*HEE-
(>SUE5%JHRT7#^B/O^WR3^M^P?>#=>S_-F.BP=>=>PAC$= M30>MDKR#^NNBFH=J|JH%|>B6HJ^:H)5).HEE!_&JE#Q4GE0KG|L^KM
MWBEE^N01T2UO^U+E9ZY-L^7(86U4V48R3I7SMJBUD4Y@9RZB_V@FGG4KMBGFI0ULH^@FHMJ|JKYJ^@M6HAJ$K%|903|>0FG-7^Q_>S_U_>=?
BRQ^:|IEN^TOJ^%&T4TH|XH)HY M.V43#42&:#9K)R^:UT$U|I5<5-054>U_-5^5(M0+48U@6H2U1)*.R9CU=>9 MJ2LZOY34TJHIMESOC\2\I^78C?
R6^>=>8A_VH^JYE^K^<|>@:#>X=2+3# M@VH|JKFYHJ&C^MVTUJH6H%|>C&H^U22D)936#>BJPS.#>CR=M_STK>^H-Z9W MLJ+U^52S4_U&0?
57%3S4_U MO^50E2+4^U&-8%J$M422FQO>U72E^UGIE^CWH6U$U4L5+1S4$U%U4I5/1+4^U$U-4B5(M13^:1+6$TAKY^:J.W.U?>2"
MQ?>CVGKCAI>^:AU-O&#>I2^28AJ^JK9J^:~@FHMJ|JKYJ^:~@6HAJ$K%|90 M3|>0FG->^RZ.W-U=Z?/M?
CQ:SL^M^UX5DNNH4_5+0S48U|H5+0?>0S4+U M-5^5(M0+48U@6H2U1)*^>B4-6B>AZ?>@V2G^PGI^K=&KAJH3F6JA^U^M^F^HJH9J&:CFH-
J+JYJ^:C6HJ|G1J^:CFD_UB6H|J36^MEKFS(D2IV4EJYES|NX&S@TOJ_H^>@ZJN:CFH9J^:@&JA:@6H5J^:@+5)*HE ME-9.QKR.U=??
BY=X$%>JAF^K75JN.P^85HRP?5%1S4B P>4U0W3^-5B5L.HDE$MH:1FP^4M MG?F%ELYB4^SLG5^VHPPYM&.#>B:J6:AFHYJ^:BZJ>:CFHUJ
^B&JL^:6HYH1-8E4?>4UPLIV.S1CLT<I=B@FHEJ^JK9J^:~@FHMJ|JKYJ^:~@6HAJ$K%|90 M3|>0FF_-0^5^UC|H|/K^~QQW44
MDOW88CE.Y1R6|AD^+I2+05%$64K0L-I&R^QG.UR^LNY+>QG.JRP8FK_#W6 MIV=K4
VY(CE8183+|=9+L&X5FH.ZEYI80W^WO=>%ZS^8FV^EC.8CF.Y1R6 MOM?7^7N<I2B4FEU3F2_>6$Y4G9W/_>ZS MXP.7CANRXT8L^|<8#G)
<@G&M2)P7(M=55&IMDRW>+|N_2TMC|7B@^V^>X MNCG>7N^>VW7&EFA.W+Q^4I0-8^AV2H>|NY MIENZ2M_Q_=-
JGW8;3^G6;XN7A|E=-.#>G|FB.TC1|@+F2QGL9S<@+|N2SG ML9S<@+>A2P7L5S.^VUDM^I_OA8?N53I06^B;1^6LUC.9CF^ MY5R6\UC.9JF
Y4^6BU@N9CGJ^HJCN^I^25NHS$=IHR2^H MLKJL Z^:Z^:X8HV@5C.9#F+Y6R63XLI0?>J0=%P^8&G7HJ^I^J9+&>QG.UR
MSHFCKGR>=3TDR:U2Z8=1)_E I8+62YBN9CE|MOEDLPK45|M9Z.KNH>_M5-M^BE/5|NT+O67NQ10_T3$)U|A^4LEK-
9SCQE=NEOZJ$X+6+>NQ^&BP7L$S^M2SGLUS^N MT04ZVZN/V5$%RTF62S^NE9:UMDTY<^WI&?MZDIW9^K=-I%)2SGLUS_2/E|RTUJHC
M^CZ_>@F+3HG#5^06^XN^DL^H|6$77H(T^6+M>#>S&^>2P7L$S(BKE7?^*UW_2HJ^=F4K^R=2^F4+>|7 M^U3IY2XK+W9O+QWD^#>J?
XZ2G.ER%L09+>PG.MR^LOY+>P7.AR$Y#/_GU0SF0YB<5LEG-8SF4YC^5IE@M8+^F2YB.5BEA.L
M0UDNP^A6HM^H9Z>+|J0Q33#^/5C4B^U=ZGQ^>3R^I^ZNSHZG^Z^S^I^T^ MY2R6LUC_7^U^?#Y6@TG9Z=KAN08=0)_E
I8+62YBN9CE|MOEDLPK46- MMTQ6BR|2.2)EG10SF0YB^5LEG-G^ZLJH@9G^62%U-HZA.N^S!>Y MNM^@|HJ^C7I^L^$8N^OZY|
(|RIDL9I&=7+>Q&^>S7^IR M(SG^YR7)QC7#^UBK| POS$=S^UWN^IRN86HUGH^<J9+&>QG.UR MSHFK)JLK4S^@_WLLYI^?
71#^<5G|0SF>YJ@>5^EHHM8^F8Y MP2^2Y1^>64C8M^I^>PYM0LF<^>I52K M^~^>L2^D+<^>M^I^>=UFNX2CW15Y.=WR
MZZ6)MIK+|XW7YVQ76Y9V4WY^H5|B@>666%ITU^>~#516M^JFMIX^7W MZ^7%CBM>|N|3XN-BL=7ZOK?>BU=O;16;JR_/H6^W+|FFSTG9?
MMK#>DN+|1= M_70SG_?TBV9.BMV3UES2XHO:X ^D=IBNVK.*?VWXAM0SK-52.7T;7E8?/2
M3_K-B^W#^_M.MOZUG^SVQ>KE^M.M.O%EEI^W4Q>|T=TFI^ZNE^0%IMS^8U^E MLWY8YXLR^I3|I NOI^?C7+52)N;K6GQ_(&?
5Y_#|QI0P8ROOXV2?>M5 M-1TJ=N6+=N_GI0GH6IR|TIV^6?2OS_42+M|H=B$S4.AV^<M^29H8Q^?2SPU?
Z/_XNY8|8IW>|AI%^<_UL^|AQM^<MLOT MI_485N?_RFD7M=W^B%|H;Z_<H7U9;S;=J=M^MN|YS=;?%>W3^JQO MZQIM=^GZ=GWWQ?OLK%
^N2N3IK^_>U77|_?OW7LW.M^I^Y6^6S^RPG62|N^>3^T_-U37X3KW^HK2^M6Z_*?RO$@>VXQ#_9IE+>S M6OH>_9+AWV^<%KJEO&3P^>YS>LU?
ELX_8^N_-VG MF^?S5^SW6+U9=>#?4Y:7Z5@MOY.W+WJ7I4Y_>F^TIK^>#0Y6^6$RPG M62|H-N-9?A5I3LBM^J00ZX^>VJ_6P_2,TJ
<8T2D4<@>XL=V&8YA^5Y6>5^EHHM8^F8YP?2Y1^>R5EK.LW5_-N|6O7W_1B WE2^EGKUUM90M^M^>RG.5R_LLY+>RG.=R/L^L^ZZRG.5R-
LLY+>RG.=R/L^L^ZX5 MG|H(SC9XA^I^Q2PG6&ZR7OQK>^L%?>^Z^N^>.%QCG2^|MOI^T2B&TYS7^IR(SG^YR7OQK7BL5;O&UZH
M^I^W9^SJR^GSM^MU$|AER$>5_EK-8SF8YA^5Y@>5^EHHM8^F8YP?2Y1^>R^J^>)^ M^DID1=|N^KU>^T^DL^H^DO|YS#^MT05B^5LEG-8
MSF4YC^5IE@M8+^F2YB.5BEA.LUDNP^A66|NUL&G1|N0=4R4.UG^CE.Y1R6 MY&C=XO:A5^%TY+45AT92M^2 M^&>QG.UR^SHEK^I$GTH^9V<|V&
(7RODL^|N<|<^+|^X+98M^_JPW|ET/UCF>1_EK-8SF8Y MA^5Y@>5^EHHM8^F8YP?2Y1^>Z5OK6PU8B=*$
I%#>Y056A83|L.LLW^>^>C|95G@>5^EHHM8^F8YP?2Y1^>X5@<K3|U4O>GNO<^CGZS^_IR(SG^YR7OQK5BL^8M^KEV8>WY L^O?
H%K;BA^<FRUDEL9D2+>3I<7.2+|SH|H=E=^B^>M^TSO^O|O^>Z_H=6^2T^ VNSP?ZG^<A|>^J8= MH+BX2Z_%&E?>IK5-
>EMLPN^I^F6NQ19>N|^YUOM$<|/|^|>|>IXM5 MF4+|>W>WRTP?E^|VV>^>M_G^<P_02P,$%>@_#8%L65TG5^|@>M>^"X^|D
IX^|TW^WK&ULQ9I=;|LV^C_<N$5 M0PLDM^D1IQ.D2_TF8076^>B7|+>8I2W3ME|H^>|M_-OU(R59$BY.DC<ENYDM
M13RD2^>OJ_>YVU^OM$>UQ@Q|CZ^>W^W6C&UNLB_K&Z^#>X<3_99F2&#%>^M32^6CNB$8+>)&<32^EN6B^8A0
```

MZM@M(<*,V%TCB*IKI).M45E:UO"-PI8%<*->,"VYQ_H8;I44W1*|MNV)?3:4:MOZ":0:%<O^YXL7N;Y>#E52:@#J4Y4)4U3TK0GXVE32*+'MAJ+10E9>F\$518-15F7W*IG8B7R0R*|SN|<DLILJ\$&I3E0F@NE<L1-P*5M+6:|M0F00TP*VITEPHC:~H9LH#*+<L'NELOA23A0TLY|>710=>YK&S*MY8CJY(-VA)B1VJZ+9./9M(U6U77P(N&=8:|M:JZ5MK56&S19#C#|S2L>|>C>+1F&EUT97C:J+|SRI43ZPUODQ^+U7)?%M1*~M1K=62:HE6420^W7+M/Q><D3>?LLM2:9LEVQXZ:RZ79G36-VHSE:3ZMS+9MYIS2UGV7W:~&KQJPCN*~(H+>T>DWQ6A29T6E=>P^L129+2<U^Q^MT73E*K/I(LVB6QGQ^WBF4+9&2^Q:JA^HL0S12PBPU:~TEPHC:~HNMBS+62-MM2UD0VTA*~VITEPHC:~H>L.H:~&MH7:~L%T9:<~L16-D0-UH32HA6RM6K6IWO8R7N<|&R=L>W~M~C=17#L/QO5:IG:<X8WQORBSV*~TROIP?7\$~1M%=>QJN5+<87^BJC|N=BDNOJ31~M51R%*~TRC(AVZD6.HX.T^IOHJBL5+EL%AMK^CY-P%02P.\$%<#8%L695V&V^M(0=>%8~1D<X:~W.V)K&ULM=UK:IO(H<~OKT^D1<62I>V)U6:9#<~Y1#8~M1J~B~8BTZSRD7DU-031(6WY)%~R6S\$~M^V<~025N~"02S:~SILEK~M9_1#~+1H+>Y>:G9Y~VYVLT71S87XJKO(0^QJF6):~7^2KKV^~MQ>K+31_ZS_92^7^1=V^L+5RIOH%~V+ICYMWZ)O+OZ4V/RZ6&FJFV6T~M1JY^>O:Z,Z(KCWK5%G<~1^1J~FJJOIM44%80B2E_CXNWQ6)14>61+93GSWLM-JP^>+1N^~^~*~9IOBK~KQ:~FL~VGGYV~MGD6SXB7_76Q_77W)BMUW~*RIR15B<~>T9?~BWO/HLO:S79UO=NX(I<K^?+^M-/2=S^<Q@:IP2:Q+L~XM8&C^XAV6V0G+J^P6Z~P:D:~#<~#~|H~N@&I&M~P~QCO~ABW~Q@~LL%DM^DU^FVNPVFOJ2O?~S7:FXP>V^3AEWWR:IN_W7W~M|W?+>Z6?~RC3?YJ|>KE>~HG7V~&K~G#WU+~L:OGPRSI=5#~10U^<6~SLOM~MMJH+~1^YMLA6f~1UJOTFW6^W1W^=A\$Z3DQ~O~M\$Q~^7J=5VY<~27ZL~O~MT^B~|~JY8MMN22?>~YVUVOZ?~XD3TET<~KY2:3A+~+635ILKT:~S|H:GL~MWKX?EZA/I:GUVA~JFIBB/BWRZW%U%O~|R#>~@R&1#6_~^F91526^CVZ>~MGKXV~^Q>F)JH_?~#IV7~LO_KZXN8B2WJ?N_Z\$~D:=1V\$~)05U=7Y^~9H=P>~&IUAU8G6YU?I<~>7>GBNXL4ZAL^TO:M=7WXS^YFT2+~L^J^OZOULVZCXI79^4YZ#~HRE~M+~AU31B1D1025R2F~*QC37L39L~H1Q8~>1J202FT8_P8_P+V^CAXB~A&A3~M4V6^O~RB15^F+~+K)OU)~VAR+5M#&BT22TE.D)@D.45B&8GIF4T^OWI8:1&~MH&:C_ZC11Z9@S_06N:~(V#T7H>~FZ+<412K~L^BBY6UQ+U^A16N2P~PE~M4%4B~DL04B62CPR2Y^/M|H_V\$>~FB4Q=>~@3(=)QOP:C_YR:SDH1#2+>~ME^~J^JZOHGLF&I3E?~104.V:(1~)~P<~IY38ZQWAI@6Y4TEBB10R&M.D9DC.MDIB#~*~0TX<~3L1+~7Y3@P~W@71N1~1Y009J|=K09EG+8+S|>RV40IYI+~M\$DOOL7I<~&OHC>=3ENY)~(X^"Q>~MKRZ+8K:)KM:KZ^ID17.9Z>AF4>|Q15L3.1&|LGQW_H^O@VO_~R20U@6H2~MU12J9:BF4#HT%~&S^HJE~H~H~M055~H95+~HYBC~*YVK=C&F:JIS_VWXJUE^Q^TVQ~MW1I^|SCV#H1LX^<GP2_S1^@RJ^523J^90+4.UC6H8U2RJ4KS8UA7:~KACLWK~M17+U^YOH?~77~&1A#QK4^U%~8~J\$M44JF6HIE~H)1%~4+I2F+KODY=~*X+M2&B~H5251~HDE%~H5J&AK5#~I95:4YH>X|@UP^6~M2OK_N~W^7V)~?~M18N^C:~LY_MGU_27H=OVB_~5251.H)E%~H5J&AK5#~I95:4YL>U|B|U|<~.~)E%1+~M44V@FD0UA6H9JFE4ZAF4I2^~JC-8:J|BIV)1=728~%M~@QU#2VJH|@F4S|YBFD^U~2U\$~I6^~0B:G7D3WR<08_HJJC~|HJ=DIH^O8~M|HJ^7G_7G@<~YRAW214\$Z@F44VA6H9J&M4JEE4(MJ^H)5:HIE~M0S6~<5+~HY2O~#7>0XB>I2+256^W19V~I~&=MP>254E0J3^913:~%~A16R_X_ZJO>H|CARBFJ^TV5UAR@=XBZ343QC#~M~6T~H9I~8EJ^M6RG24+~#RG(T^Z^?3IK1B^S^U~M(51+44V@FD0UA6H9JNGX86H+~(N^XSC6H^TZ+YRC~CUE=IHG#~1~MKHQNHNTJNME/AA#~(S|KHB0)GWKO~\$DW~>244+ZB6HUI~8EJ^M4R5~H9E#~HJJC~#~\$>G2F^(&HNXZ~MM0Z+G=H:AV)J^>3^FZ&X%JDE44ZB6H9I&~8~J%~M41#>2>~LHEJ^@+5^H15.M03~<036+~HJ2_~#79:~D73:3)6A|M~5251.H)E%~H5J&AK5#~I95:4YH>X|@EXF)WN>+~WLTU300H~EXI#3~M1:QP7C09R.D180&=V106@:K5.E33I&90S:~H50_C(U50<M(^~NSFM~M~XKU?~2I)A)=SNM>~&S=OH5U^A~U|@MUL2MUL4MUL6MUL8MUL~MULM~MG:SE~D=H23<~&~>1^VEI^Q=DN^&\$~Z|OBM&~\$>~@+5^H15.M03~<036+~HJ2~#7K:5D>~Y36K3)A&HJ@E4DBF4^U~8U|M4LJCE^T<~Z=2^<?~H1%~M(V<~219M^8+~#~NTY>~J<~51&L^B1Q^ME=QYL8GTC)EH6G%~M1361A+5%~HEJ^91S:~135:7Y^ZXI3K4Y7I#3~2HEJ^@+5~M)~H15.MVEK=2P>~&4\$IZE\$&S^*~(=Q+W1HZO^~NKKJ^213I&I2J25EM~M9M~&~&S1>1>1>~Y:Q8?UG/MJMB&?WMZJH8SYJ~M44(U@6H2U=1.PZA^X.DGLM(33.9D(U@M@VH6U1RE^6FLVTR^JH|WSN\$CGGNB^I=XS6H~8%~\$M44JF6HIE~H)1%~M~4~I2NCK^M3@716H~5JH0K44U02J2513P):AFD8U@VH6U1RE>2S>U~A#H8U1RE^M~2~<I~Q~S~NOTS~R2HJ@:F45VBFMIH@S:HWXO:8^CT:UJ5~H9E~49J?QK13-80Z~M5<5ZAWU=J_~I=(XSVK5~8%~J\$M44JF6HIE~H)1%~4~I2NCKKM7P7%VK(=JU~M0K44U02J2513P):AFD8U@VH6U1RE^2&NNU~#TH67=H=8)S2~6%~H)5~H~M|H~<IHET^YPTI^1HZTK5%~H9E~49J?RHU~ORWKM1=KOHG~9~N~GEYV^S~MK6:VD3.02W~X3~S\$~U%~4\$JDE44ZB6H9I&~8~J\$M4Z~J^U0S|K&91S&~<RZ9S518B&H|Q~GIB0~A|Y|SBC~M12U4\$Z@F44VA6H9J&M4JEE4:~&~O12H4L5M13:~146H^THRRI+~#7FR:M(35:~MN4(U@VH6U1RE><~J4NV1~JY0C6#A:5~*Y2:PI5Z~PYRK+~%~XLB>G137.IS121^OKW~MJS23321OEI/Q^Q>~^=(XP6K5I~H)1S~85J&H5~H9E~49J2I+H~3I7~MT6J\$~JU0+44U@6H2U1RE>2J2513P):AFD8U@VH6U1RE^2&NNU~#TH67=H=8)S2~6%~H)5~H~M|H~<IHET^YPTI^1HZTK5%~H9E~49J?RHU~ORWKM1=KOHG~9~N~GEYV^S~MK6:VD3.02W~X3~S\$~U%~4\$JDE44ZB6H9I&~8~J\$M4Z~J^U0S|K&91S&~<RZ9S518B&H|Q~GIB0~A|Y|SBC~M12U4\$Z@F44VA6H9J&M4JEE4:~&~O12H4L5M13:~146H^THRRI+~#7FR:M(35:~MN4(U@VH6U1RE><~J4NV1~JY0C6#A:5~*Y2:PI5Z~PYRK+~%~XLB>G137.IS121^OKW~MJS23321OEI/Q^Q>~^=(XP6K5I~H)1S~85J&H5~H9E~49J2I+H~3I7~MT6J\$~JU0+44U@6H2U1RE>2J2513P):AFD8U@VH6U1RE^2&NNU~#TH67=H=

```

A-M 60L:2%D"X@9V?M"+6V?Z.N.O$>Q:S.HMY1-1N1Y(EC^AVRY,+0#0Y9H3-M4AOMN9I#-Z"3^T%MX%/-
IPGS(6$!)R$A$60L!@ (UC/H# /11&Q23I0"9-5B-M1&18X1$58CNX;+C2@DXU?0:~IQPMNMYKC?I3YQIR*1)"R$A$60L!@ (UO/3MM//31+!+=5Z<#4/-
17RB#J^LUC3O")R"R$A$20LH+UC/+>>=<YPE*P5-MVZC2")P-1(60L(B2@.1L9RK9;M/KQ96DM=,R&O,E*Q88)G\Y28X=50#I?F@M
44K;TWB0HG6M9WV14+&9-M.U8Z=>$VXY<$QK-Q,3=77-YWBW;>246D?YJ@Z^NE-CZO3^UDPT+22%L-M
$H106D1*YV&HO7MI+58V8&Y.M)H/LDN:WM.-%FM/14IO<=>6G8$06M@=JB*MK26"1+^9+<#^~9_@MOSHGR:NAU3R3^F4H0SLG&
A2#TJ+H6B-M,2>H-UP2M@=VJR-W-HM965TL-V%2YPS31GFZ23IN^G$XJ(4I)*TO&I+^GWG?QX<@CO*OF&$>^MTB3C4VJ0+G"5$9I
<8V4"/(E#ZJ-Q64I=31FT02-M&B@D5=>7+H0652Z%7.0HG1U@X5JYV(1@&8"U^FMJ@+HM07JHU2@NZ/K,2ZPP+1H$N%-
IRS2U49Z:LK2DB3-U&I>"R6IC64L-M%L4#)H+D@GPZU;^Y^IGL;."PG'-QCQKZS6-EIU7=^#-CVIGKI#5JL)N-M5%7Q?EY%.E+YTA<
2HXIY"/HJBM^B-SFfG#05=R5L$4QJHEIF1<(<2%2$1R15X+^D22L1+^ZT(Q9JH)=USF3+W9B3AA6+^,2OH:AMXO?/"6-MPEK8?
HWMG<^<RIT^/9I1@>^1R3G+2)KEELI9Y4).JRXCKO4A9XN1?TJ;R-M.J@/ISQ?OCKZDEH^YV.L#X=H-WV=HDMQ364-6Y$-C0I@OU-4%=
4X3DCY-MNL&RFBYH8U)?Z^W8H-&P^0/>YF/H1D:~Q3-#V:YE:XUD7Y5X)5,7DG&N-M+I(^A-OE2C03?1N"8-FXE(5+!8Q(2#><^BC90.<+
FY3G<+V14UCHM-MT-X=GMGE6>17A:6WZAF1YVU0$;SWSR&L1@9)B%8H-8L:1US5O0.3%U
M3EB=2%:ERU9;-1HH8<600M%2L:6UZK5I0Y1Y9B5&S-PPX&IV&GG<^RTMP600YF:Q6BB"-VK-Q6:)QMILYK2@6:4^BXT<^<
M4Z2="IF=ZNCX=4PU>M;FP^@/1^/13VZ6JL>B&I@QZRN-1U"0M#VL*0T7-Z-M>4@5U1PB-*G#UV-TN8%=)FARTO50!)^W%7-&Y(K#D#G#_DI
L22I(9R"<^SM>#Y9LHP=-YTO?U"O-M7W0N87^CMG26Q9YRZK,Y4IKTVN9)UKJ;=BBH@/#52FLZ%Z3QHZ39RZQT-M@U=
MXI)EYNSIT^LRD?7J02L,DA#3XXH+Jf;ICV1+U8:IGS-9QDD"5C+>NQK*MPV19V7V3P-Ri=-J@0-QW-P00?T9RZQT-M@U=
M(V1;%DY-1S8P,+86->^&PQ5V5GGI2FM-W")=^X12/D#TJH/K;@R3CK>E-M3?=>S+62)YQBMVZ#1)V6^16.W$?
(VYR4GKCIYML$BO<14HE)3#>1(WV-MKQ(ZZ$1W0/FIZD8J1-Y,~*L<IGR+<-.CKJ)?=$^<?2$XFD@<K(SGC*IO<
MA89IP00I^V1M)T06JH-@YM#298K9,S44@3VT:POY-Z^PI0U,@XIPUV/5M-MPVA0$J6H^+>Z8C1QF>05Y7^FY/LM166VL:XF&T5;
MU(GJH6Q%=>#25+1/F1+QJW2IDCGT5ZLM^#?>8.F0+O9,T8T37V:M4PIQ-5)M62+59YF(I=V1<^"U/P/FA61=#1(E:ENH-
+WGJ44-1K9)ENX2H$N59--MRPSWW#U$S-IVGF=44$GXIFF=<1<IRZIV/7>RK*YJ^P=;GJL3Q7:Q+Z^Z^U&MR2%IK,1DQVIR)/9-
-O1.GD).IM1LOSXDZ^$IF.P>IO-MIT/1R1^50/D/>7%1U^8L3:EX=CK5HL1$OYEKINGI^,++AZ;^AORY
MIRE:Y$G:ZPXFHNDU+G^#X>FCRL#C-TWCZZ@LACKG.Y$<RNFC,MR(6/SQ>^X.8G<MNS>1)M$4QIB,CL=-1V-
LWN(8-MQJF#=#&8$@TLOF&EJM/$AYP&VIOLR!1L1MCHG82/&Y/L0J11($O=J8W&@.T^ECL0WQT-
/E-G@2=&A(E@6FD7)TZ(=17=)Q-0T^FO8R^T^EOH^7%#H5J.W&E.MCQ%BMXU@LD/1^X4$1#10(V1%GX16-X00%&PO
M=VJR-VJO:VLN>^&UQ2K;MLX$1A231JBNK9MS0T@EY8W080XFC"?UJB-M,2(2J9^423K=TC&ZJU1LR9.M&W5$@7-
F2^UZTN9QOKO4C^14RDX&^*2-MT^0EBO1$JCDPK@6(3#IG73B?F-W2C-M7BQD*2YUV35^N4T-&E%10&57LK4#IG@C)H+O1&P-1G'D<
MN#2^S1^C(009XLE$CBB)I0#E&G>^A.PCR",5H@6#*1@K,S8IA^A^C$1X@>^T1+>F257-MB4<8Q051+8TL@V;M%<="6"?
T6+1N1AYAF1E9XNE83+1N+L^KQUIDR,M5?2$OGO+2^6MAV15J38GA&Z%<=3^Q(R3$1R=^2T%MAZDF(7-
-21:NEORLZLA6SE=W8K>G288Q)RR32=__$&OJU8&-JE"(>TPGF-MF(18-C-A@(<L7M1^6C-IR6-KGW:&4C>,#1),2:F3E=/GX1YQO1-"2#22%
MUA@.$F+^#W/N#P#E2K1?>^4^KIT7C3FEX18,1=0/OY-MP7-OTDF128@%MXY4QOOIS>>Q&1Y+MQRR4$UMH,V1>
<+Q1R9,0CQNA=#X/I1*%&AXAU(51+0W49JK4$Z-F#<C<M^LQ^174M1+UTB$A=TVZL-HOW%THUE@>BK>L18$.POSWLQ^C(E9)*"VT-Y9
MCQ#@8TS,0@6QA78O1030&1/IN(#<00O6-WI^O"Q4O*%=-LPGQ9B8A8IWM-1K-M6N35?B-
Y^/@KOL01$QTLBXY0K,0@6UA7>8H^ZURIO$=LX(CQ"XY#A8;M#1DJL8^JH^6UC87^ZG^KF?S;1^FA6I675U2P+X(=YM?TN,OM-W^=-M
51+P01-@6Q9F#M:GOL1#+(P&@^AL+U9R96QS+W=O#B55;IN?27F61MR1>NW1#1V1/KQY$WGY-A0E1=^Z18YZ7+9IO^C:QX?O.Q.G&:9Y63?
HX?>7=-G(57ERLWAZ737CMTZLTJ?00I#6$5(L0H1D#>R@<#H^M1#4U@Z^A#1^D%W$17/>1@>@N1K
M1VD295P2)VPM1M:DLA1#H0:"$06Y1L(3L;$&TA4%N0:2%P60;N(9L;D&XA
MLL0L-R06UO)=146E1TMG#1L$>BOJK01Z^*JM!HKZJT$>BOJK01Z^*JM
M1HKZFT$>BOJK01Z$>1M1H:ZFT$>AOJ:01ZV^QE"8>AGH;=>Z$>AN1WH9Z
M&X>AGH;=>Z$>AN1WH9Z&X>CGH1@=>Z>CN1WHYZX^>CGH1@=>X>IE-H+>C-MWDZ@MZ>3J^WHIY,H+>CWDZ@MZ>3J^WH-
Y1H@=>WD&=>Z>#>O1WH-Y1H@=>MWD&=>1P^5A+H:AW$=>J^<OZ1VH=O#H:AW$C=HMM3^1=H1#1M>>K5$
M-R>IGLIGYNOE+INOG7B;1X)AWY-$04$L1H0(V1%FEFTL9WB@M#HC3-6T-O:G1E;G125EP97=+GAM,W:74,10&X+1=FM8Z1=^
M1+1A114+T#=#K^PK4U;$Z1W0-3C1(C)KXW6L:VYSUKD^=JD>=>HS#8-G4-MIMDR1G?#6^B6U)B06T=M&IE,WYB8^OV".51S^8&
(W&K+1MI#8.8U4X2$A3ROF,69MN7^1)F3LRX1NVNPIK^7E?E31X,CC^F"-8MN:A,BK">2G2WS1HYW/JX)"M6ZR,M^O/SLIPY(H-
G6+1W1Q,GEF;1E2>=WY>2J29W?T=9-4-C1>+<K1-O1+K1>O1<#8%L62AA-MZN10MJQX1@(^1#0@AL+W=O&PO=VJR-W-
H965T&UL4$1!A0#%@-#8%L6006G1MB"-C$1@-M(^1IAD^AL+W=O1DPZ#^,1)8"@3XB1X;1W:W)K&PO=VJR-W-H965T&UL4$1!A0#%M@
#8%L63S01#1"DR@1@(^1#^AL+W=O&PO=M=VJR-W-H965T&UL4$1!A0#%@-#8%L6:SY224$0M>S^ID(^19$^AL+W=O&L^Y71^IA@&0@($O
M4@=>S&PO=VJR-W-H965T&UL4$1!A0#%@-#8%L61Y1QVNI^OPH-ID-M(^1E@8^AL+W=O&PO=VJR-W-H965T&UL4$1!A0#%@
#8%L6:19^9^%@D$H-ID(^1AJP^AL-M+W=O&PO=VJR-W-H965T&UL4$1!A0#%@-#8%L-M65?IVG#(^0Y1H-ID(^1Y1L^AL+W=O&PO=VJR-W-
H965T&UL4$1!A0#%@-#8%L6>JWU120-0T1-M-ID(^1$^AL+W=O&PO=VJR-W-H965T&UL4$1!A0#%@-#8%L609L^YH$P^P
```


(Unaudited)Sheethttp://oncocyte.com/20240930/taxonomy/role/StatementsOfCashFlowsCondensedConsolidatedStatementsOfCashFlows (Unaudited)Statements7 falsefalseR8.htm995410 - Disclosure - Pay vs Performance DisclosureSheethttp://xbrl.sec.gov/ecd/role/PvpDisclosurePay vs Performance DisclosureNotes8 falsefalseR9.htm995445 - Disclosure - Insider Trading ArrangementsSheethttp://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsInsider Trading ArrangementsNotes9 falsefalseR10.htm995455 - Disclosure - Organization and Description of the BusinessSheethttp://oncocyte.com/20240930/taxonomy/role/OrganizationAndDescriptionOfBusinessOrganization and Description of the BusinessNotes10 falsefalseR11.htm995465 - Disclosure - Summary of Significant Accounting PoliciesSheethttp://oncocyte.com/20240930/taxonomy/role/SummaryOfSignificantAccountingPoliciesSummary of Significant Accounting PoliciesNotes11 falsefalseR12.htm995475 - Disclosure - Business Combinations and Contingent Consideration LiabilitiesSheethttp://oncocyte.com/20240930/taxonomy/role/BusinessCombinationsAndContingentConsiderationLiabilitiesBusiness Combinations and Contingent Consideration LiabilitiesNotes12 falsefalseR13.htm995485 - Disclosure - Property and EquipmentSheethttp://oncocyte.com/20240930/taxonomy/role/DisclosurePropertyAndEquipment2Property and EquipmentNotes13 falsefalseR14.htm995495 - Disclosure - Intangible Assets, NetSheethttp://oncocyte.com/20240930/taxonomy/role/IntangibleAssetsNetIntangible Assets, NetNotes14 falsefalseR15.htm995505 - Disclosure - Commitments and ContingenciesSheethttp://oncocyte.com/20240930/taxonomy/role/CommitmentsAndContingenciesCommitments and ContingenciesNotes15 falsefalseR16.htm995515 - Disclosure - Series A Redeemable Convertible Preferred Stock and Shareholders??? EquitySheethttp://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquitySeries A Redeemable Convertible Preferred Stock and Shareholders??? EquityNotes16 falsefalseR17.htm995525 - Disclosure - Stock-Based CompensationSheethttp://oncocyte.com/20240930/taxonomy/role/Stock-basedCompensationStock-Based CompensationNotes17 falsefalseR18.htm995535 - Disclosure - Related Party TransactionsSheethttp://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsRelated Party TransactionsNotes18 falsefalseR19.htm995545 - Disclosure - Collaborative ArrangementsSheethttp://oncocyte.com/20240930/taxonomy/role/CollaborativeArrangementsCollaborative ArrangementsNotes19 falsefalseR20.htm995555 - Disclosure - Discontinued Operations of RazorSheethttp://oncocyte.com/20240930/taxonomy/role/DiscontinuedOperationsOfRazorDiscontinued Operations of RazorNotes20 falsefalseR21.htm995565 - Disclosure - Subsequent EventsSheethttp://oncocyte.com/20240930/taxonomy/role/DisclosureSubsequentEvents1Subsequent EventsNotes21 falsefalseR22.htm995575 - Disclosure - Summary of Significant Accounting Policies (Policies)Sheethttp://oncocyte.com/20240930/taxonomy/role/SummaryOfSignificantAccountingPoliciesPoliciesSummary of Significant Accounting Policies (Policies)Policieshttp://oncocyte.com/20240930/taxonomy/role/SummaryOfSignificantAccountingPolicies22 falsefalseR23.htm995585 - Disclosure - Summary of Significant Accounting Policies (Tables)Sheethttp://oncocyte.com/20240930/taxonomy/role/SummaryOfSignificantAccountingPoliciesTablesSummary of Significant Accounting Policies (Tables)Tableshttp://oncocyte.com/20240930/taxonomy/role/SummaryOfSignificantAccountingPolicies23 falsefalseR24.htm995595 - Disclosure - Business Combinations and Contingent Consideration Liabilities (Tables)Sheethttp://oncocyte.com/20240930/taxonomy/role/BusinessCombinationsAndContingentConsiderationLiabilitiesTablesBusiness Combinations and Contingent Consideration Liabilities (Tables)Tableshttp://oncocyte.com/20240930/taxonomy/role/BusinessCombinationsAndContingentConsiderationLiabilities24 falsefalseR25.htm995605 - Disclosure - Property and Equipment (Tables)Sheethttp://oncocyte.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentTablesProperty and Equipment (Tables)Tableshttp://oncocyte.com/20240930/taxonomy/role/DisclosurePropertyAndEquipment25 falsefalseR26.htm995615 - Disclosure - Intangible Assets, Net (Tables)Sheethttp://oncocyte.com/20240930/taxonomy/role/IntangibleAssetsNetIntangible Assets, Net (Tables)Tableshttp://oncocyte.com/20240930/taxonomy/role/IntangibleAssetsNet26 falsefalseR27.htm995625 - Disclosure - Commitments and Contingencies (Tables)Sheethttp://oncocyte.com/20240930/taxonomy/role/CommitmentsAndContingenciesTablesCommitments and Contingencies (Tables)Tableshttp://oncocyte.com/20240930/taxonomy/role/CommitmentsAndContingencies27 falsefalseR28.htm995635 - Disclosure - Stock-Based Compensation (Tables)Sheethttp://oncocyte.com/20240930/taxonomy/role/Stock-basedCompensationTablesStock-Based Compensation (Tables)Tableshttp://oncocyte.com/20240930/taxonomy/role/Stock-basedCompensation28 falsefalseR29.htm995645 - Disclosure - Discontinued Operations of Razor (Tables)Sheethttp://oncocyte.com/20240930/taxonomy/role/DiscontinuedOperationsOfRazorTablesDiscontinued Operations of Razor (Tables)Tableshttp://oncocyte.com/20240930/taxonomy/role/DiscontinuedOperationsOfRazor29 falsefalseR30.htm995655 - Disclosure - Organization and Description of the Business (Details Narrative)Sheethttp://oncocyte.com/20240930/taxonomy/role/OrganizationAndDescriptionOfBusinessDetailsNarrativeOrganization and Description of the Business (Details Narrative)Detailshttp://oncocyte.com/20240930/taxonomy/role/OrganizationAndDescriptionOfBusiness30 falsefalseR31.htm995665 - Disclosure - Summary of Significant Accounting Policies - Schedule of Prior Period Revisions (Details)Sheethttp://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPriorPeriodRevisionsDet of Significant Accounting Policies - Schedule of Prior Period Revisions (Details)Details31 falsefalseR32.htm995675 - Disclosure - Summary of Significant Accounting Policies - Schedule of Disaggregation of Revenue (Details)Sheethttp://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDisaggregationOfRevenu of Significant Accounting Policies - Schedule of Disaggregation of Revenue (Details)Details32 falsefalseR33.htm995685 - Disclosure - Summary of Significant Accounting Policies - Schedule of Concentration of Risk (Details)Sheethttp://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDet of Significant Accounting Policies - Schedule of Concentration of Risk (Details)Details33 falsefalseR34.htm995695 - Disclosure - Summary of Significant Accounting Policies - Schedule of Consolidated Revenues Generated by Unaffiliated Customers (Details)Sheethttp://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConsolidatedRevenuesG of Significant Accounting Policies - Schedule of Consolidated Revenues Generated by Unaffiliated Customers (Details)Details34 falsefalseR35.htm995705 - Disclosure - Summary of Significant Accounting Policies - Schedule of Percentage of Consolidated Revenues Attributable to Geographical Locations (Details)Sheethttp://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPercentageOfConsolidat of Significant Accounting Policies - Schedule of Percentage of Consolidated Revenues Attributable to Geographical Locations (Details)Details35 falsefalseR36.htm995715 - Disclosure - Summary of Significant Accounting Policies - Schedule of Common Stock Computation of Diluted Net Loss Per Share of Common Stock (Details)Sheethttp://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCommonStockComputat of Significant Accounting Policies - Schedule of Common Stock Computation of Diluted Net Loss Per Share of Common Stock (Details)Details36 falsefalseR37.htm995725 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)Sheethttp://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetailsSumm of Significant Accounting Policies - Additional Information (Details)Details37 falsefalseR38.htm995735 - Disclosure - Business Combinations and Contingent Consideration Liabilities - Schedule of Fair Value of Contingent Consideration Liability (Details)Sheethttp://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesScheduleOfFair Combinations and Contingent Consideration Liabilities - Schedule of Fair Value of Contingent Consideration Liability (Details)Details38 falsefalseR39.htm995745 - Disclosure - Business Combinations and Contingent Consideration Liabilities - Schedule of Contingent Consideration, Measured at Fair Value (Details)Sheethttp://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesScheduleOfCont Combinations and Contingent Consideration Liabilities - Schedule of Contingent Consideration, Measured at Fair Value (Details)Details39 falsefalseR40.htm995755 - Disclosure - Business Combinations and Contingent Consideration Liabilities - Additional Information (Details)Sheethttp://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesAdditionalInfor of Business Combinations and Contingent Consideration Liabilities - Additional Information (Details)Details40 falsefalseR41.htm995765 - Disclosure - Property and Equipment - Schedule of Right-of-use and Financing Lease Assets, Machinery and Equipment, Net, and Construction in Progress (Details)Sheethttp://oncocyte.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfRightofuseAndFinancingLeaseAssetsMachi and Equipment - Schedule of Right-of-use and Financing Lease Assets, Machinery and Equipment, Net, and Construction in Progress (Details)Details41 falsefalseR42.htm995775 - Disclosure - Property and Equipment (Details Narrative)Sheethttp://oncocyte.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentDetailsNarrativeProperty and Equipment (Details Narrative)Detailshttp://oncocyte.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentTables42 falsefalseR43.htm995785 - Disclosure - Schedule of Intangible Assets, Net (Details)Sheethttp://oncocyte.com/20240930/taxonomy/role/ScheduleOfIntangibleAssetsNetDetailsSchedule of Intangible Assets, Net (Details)Details43 falsefalseR44.htm995795 - Disclosure - Schedule of Intangible Assets Future Amortization Expense (Details)Sheethttp://oncocyte.com/20240930/taxonomy/role/ScheduleOfIntangibleAssetsFutureAmortizationExpenseDetailsSchedule of Intangible Assets Future Amortization Expense (Details)Details44 falsefalseR45.htm995805 - Disclosure - Intangible Assets, Net (Details Narrative)Sheethttp://oncocyte.com/20240930/taxonomy/role/IntangibleAssetsNetDetailsNarrativeIntangible Assets, Net (Details Narrative)Detailshttp://oncocyte.com/20240930/taxonomy/role/IntangibleAssetsNetTables45 falsefalseR46.htm995815 - Disclosure - Commitments and Contingencies (Details Narrative)Sheethttp://oncocyte.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrativeCommitments and Contingencies (Details Narrative)Detailshttp://oncocyte.com/20240930/taxonomy/role/CommitmentsAndContingenciesTables46

falsefalseR47.htm995825 -- Disclosure -- Schedule of Supplemental Balance Sheet Information Related to Operating and Financing Leases (Details)Sheethttp://oncocyte.com/20240930/taxonomy/role/DisclosureScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFin of Supplemental Balance Sheet Information Related to Operating and Financing Leases (Details)Details47 falsefalseR48.htm995835 -- Disclosure -- Schedule of Future Minimum Lease Commitments for Operating and Financing Leases (Details)Sheethttp://oncocyte.com/20240930/taxonomy/role/DisclosureScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLea of Future Minimum Lease Commitments for Operating and Financing Leases (Details)Details48 falsefalseR49.htm995845 -- Disclosure -- Schedule of Supplemental Cash Flow Information Related to Operating and Financing Lease (Details)Sheethttp://oncocyte.com/20240930/taxonomy/role/DisclosureScheduleOfSupplementalCashFlowInformationRelatedToOperatingAndFinanc of Supplemental Cash Flow Information Related to Operating and Financing Lease (Details)Details49 falsefalseR50.htm995855 -- Disclosure -- Series A Redeemable Convertible Preferred Stock and Shareholders??? Equity (Details Narrative)Sheethttp://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrativeS of A Redeemable Convertible Preferred Stock and Shareholders??? Equity (Details Narrative)Detailshttp://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquity50 falsefalseR51.htm995865 -- Disclosure -- Summary of Stock Option Activity (Details)Sheethttp://oncocyte.com/20240930/taxonomy/role/SummaryOfStockOptionActivityDetailsSummary of Stock Option Activity (Details)Details51 falsefalseR52.htm995875 -- Disclosure -- Schedule of Assumptions Used to Calculate Fair Value of Stock Options (Details)Sheethttp://oncocyte.com/20240930/taxonomy/role/ScheduleOfAssumptionsUsedToCalculateFairValueOfStockOptionsDetailsSchedule of Assumptions Used to Calculate Fair Value of Stock Options (Details)Details52 falsefalseR53.htm995885 -- Disclosure -- Summary of Stock-based Compensation Expense (Details)Sheethttp://oncocyte.com/20240930/taxonomy/role/SummaryOfStock-basedCompensationExpenseDetailsSummary of Stock-based Compensation Expense (Details)Details53 falsefalseR54.htm995895 -- Disclosure -- Stock-Based Compensation (Details Narrative)Sheethttp://oncocyte.com/20240930/taxonomy/role/Stock-basedCompensationDetailsNarrativeStock-Based Compensation (Details Narrative)Detailshttp://oncocyte.com/20240930/taxonomy/role/Stock-basedCompensationTables54 falsefalseR55.htm995905 -- Disclosure -- Related Party Transactions (Details Narrative)Sheethttp://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrativeRelated Party Transactions (Details Narrative)Detailshttp://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactions55 falsefalseR56.htm995915 -- Disclosure -- Collaborative Arrangements (Details Narrative)Sheethttp://oncocyte.com/20240930/taxonomy/role/CollaborativeArrangementsDetailsNarrativeCollaborative Arrangements (Details Narrative)Detailshttp://oncocyte.com/20240930/taxonomy/role/CollaborativeArrangements56 falsefalseR57.htm995925 -- Disclosure -- Schedule of Discontinued Operations (Details)Sheethttp://oncocyte.com/20240930/taxonomy/role/ScheduleOfDiscontinuedOperationsDetailsSchedule of Discontinued Operations (Details)Details57 falsefalseR58.htm995935 -- Disclosure -- Schedule of Assets and Liabilities Discontinued Operations (Details)Sheethttp://oncocyte.com/20240930/taxonomy/role/ScheduleOfAssetsAndLiabilitiesDiscontinuedOperationsDetailsSchedule of Assets and Liabilities Discontinued Operations (Details)Details58 falsefalseR59.htm995945 -- Disclosure -- Discontinued Operations of Razor (Details Narrative)Sheethttp://oncocyte.com/20240930/taxonomy/role/DiscontinuedOperationsOfRazorDetailsNarrativeDiscontinued Operations of Razor (Details Narrative)Detailshttp://oncocyte.com/20240930/taxonomy/role/DiscontinuedOperationsOfRazorTables59 falsefalseR60.htm995955 -- Disclosure -- Subsequent Events -- (Details Narrative)Sheethttp://oncocyte.com/20240930/taxonomy/role/DisclosureSubsequentEventsDetailsNarrativeSubsequent Events -- (Details Narrative)Detailshttp://oncocyte.com/20240930/taxonomy/role/DisclosureSubsequentEvents160 falsefalseAll ReportsBookAll Reports ccx-20240930.htmccx-20240930.xsd http://fasb.org/us-gaap/2024http://xbrl.sec.gov/dei/2024http://xbrl.sec.gov/ecd/2024falsefalse JSON 74 MetaLinks.json IDEA: XBRL DOCUMENT f {"version": "2.2", "instance": f "ocx-20240930.htm", f "nsprefix": "ocx", "nsuri": "http://oncocyte.com/20240930", "dts": f "inline": f "local": f "ocx-20240930.htm" }, "schema": f "local": f "ocx-20240930.xsd" }, "remote": f "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-x006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" } }, "keyStandard": 345, "keyCustom": 76, "axisStandard": 36, "axisCustom": 0, "memberStandard": 36, "memberCustom": 73, "hidden": f "total": 54, "http://fasb.org/us-gaap/2024": 41, "http://oncocyte.com/20240930": 9, "http://xbrl.sec.gov/dei/2024": 4, "contextCount": 350, "entityCount": 1, "segmentCount": 116, "elementCount": 788, "unitCount": 5, "baseTaxonomies": f "http://fasb.org/us-gaap/2024": 1022, "http://xbrl.sec.gov/dei/2024": 29, "http://xbrl.sec.gov/ecd/2024": 4, "report": f "R1": f "role": "http://oncocyte.com/20240930/taxonomy/role/Cover", "longName": "100000 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": f "contextRef": "C_221e72d2-4c3a-4864-b987-eece62973144", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": f "span": "p", "body": "html" }, "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true, "uniqueAnchor": f "contextRef": "C_221e72d2-4c3a-4864-b987-eece62973144", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": f "span": "p", "body": "html" }, "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true } }, "R2": f "role": "http://oncocyte.com/20240930/taxonomy/role/BalanceSheets", "longName": "100010 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": f "contextRef": "C_71c3ba12-dc37-452b-8384-1e6532648dc0", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": f "span": "p", "td": "tr", "table": "body", "html": "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "uniqueAnchor": f "contextRef": "C_71c3ba12-dc37-452b-8384-1e6532648dc0", "name": "us-gaap:InventoryNet", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": f "span": "p", "td": "tr", "table": "body", "html": "reportCount": 1, "baseRef": "ocx-20240930.htm", "unique": true } }, "R3": f "role": "http://oncocyte.com/20240930/taxonomy/role/BalanceSheetsParenthetical", "longName": "100030 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": f "contextRef": "C_71c3ba12-dc37-452b-8384-1e6532648dc0", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": f "span": "p", "td": "tr", "table": "body", "html": "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true, "uniqueAnchor": f "contextRef": "C_71c3ba12-dc37-452b-8384-1e6532648dc0", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": f "span": "p", "td": "tr", "table": "body", "html": "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true } }, "R4": f "role": "http://oncocyte.com/20240930/taxonomy/role/StatementsOfOperations", "longName": "100050 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": f "contextRef": "C_61742ba8-6cfc-4273-b59d-ce51eb29082b", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": f "span": "p", "td": "tr", "table": "body", "html": "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "uniqueAnchor": f "contextRef": "C_61742ba8-6cfc-4273-b59d-ce51eb29082b", "name": "us-gaap:CostOfRevenue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": f "span": "p", "td": "tr", "table": "body", "html": "reportCount": 1, "baseRef": "ocx-20240930.htm", "unique": true } }, "R5": f "role": "http://oncocyte.com/20240930/taxonomy/role/StatementsOfComprehensiveLoss", "longName": "100060 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)", "shortName": "Condensed Consolidated Statements of Comprehensive Loss (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": f "contextRef": "C_61742ba8-6cfc-4273-b59d-ce51eb29082b", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": f "span": "p", "td": "tr", "table": "body", "html": "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "uniqueAnchor": f "contextRef": "C_61742ba8-6cfc-4273-b59d-ce51eb29082b", "name": "us-gaap:ComprehensiveIncomeNetOfTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": f "span": "p", "td": "tr", "table": "body", "html": "reportCount": 1, "baseRef": "ocx-20240930.htm", "unique": true } }, "R6": f "role": "http://oncocyte.com/20240930/taxonomy/role/StatementsOfSeriesRedeemableConvertiblePreferredStockAndShareholdersEquity", "longName": "100070 - Statement - Condensed Consolidated Statements of Series A Redeemable Convertible Preferred Stock and Shareholders' Equity (Unaudited)", "shortName": "Condensed Consolidated Statements of Series A Redeemable Convertible Preferred Stock and Shareholders' Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": f "contextRef": "C_35715086-7648-4a66-ba36-4dac3e2c9f7f", "name": "us-gaap:StockholdersEquity", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": f "span": "p", "td": "tr", "table": "body", "html": "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true, "uniqueAnchor": f "contextRef": "C_35715086-7648-4a66-ba36-4dac3e2c9f7f", "name": "us-gaap:StockholdersEquity", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": f "span": "p", "td": "tr", "table": "body", "html": "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true } }, "R7": f "role": "http://oncocyte.com/20240930/taxonomy/role/StatementsOfCashFlows", "longName": "100080 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7",

"firstAnchor": { "contextRef": "C_221e72d2-4c3a-4864-b987-ec6a62973144", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": 3, "ancestors": [{ "span": "p", "td": "tr", "table": "body", "html": "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true }, "R8": { "role": "http://xbrl.sec.gov/ecd/role/PyvDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "C_61742ba8-6cfc-4273-b59d-ce51eb29082b", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": 3, "ancestors": [{ "span": "p", "td": "tr", "table": "body", "html": "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true }, "R9": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "C_61742ba8-6cfc-4273-b59d-ce51eb29082b", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{ "span": "div", "div": "body", "html": "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true }, "R10": { "role": "http://oncocyte.com/20240930/taxonomy/role/OrganizationAndDescriptionOfBusiness", "longName": "995455 - Disclosure - Organization and Description of the Business", "shortName": "Organization and Description of the Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "C_221e72d2-4c3a-4864-b987-ec6a62973144", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{ "div": "body", "html": "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_221e72d2-4c3a-4864-b987-ec6a62973144", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{ "div": "body", "html": "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true }, "R11": { "role": "http://oncocyte.com/20240930/taxonomy/role/SummaryOfSignificantAccountingPolicies", "longName": "995465 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "C_221e72d2-4c3a-4864-b987-ec6a62973144", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{ "div": "body", "html": "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_221e72d2-4c3a-4864-b987-ec6a62973144", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{ "div": "body", "html": "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true }, "R12": { "role": "http://oncocyte.com/20240930/taxonomy/role/BusinessCombinationsAndContingentConsiderationLiabilities", "longName": "995475 - Disclosure - Business Combinations and Contingent Consideration Liabilities", "shortName": "Business Combinations and Contingent Consideration Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "C_221e72d2-4c3a-4864-b987-ec6a62973144", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{ "div": "body", "html": "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_221e72d2-4c3a-4864-b987-ec6a62973144", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{ "div": "body", "html": "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true }, "R13": { "role": "http://oncocyte.com/20240930/taxonomy/role/DisclosurePropertyAndEquipment2", "longName": "995485 - Disclosure - Property and Equipment", "shortName": "Property and Equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "C_221e72d2-4c3a-4864-b987-ec6a62973144", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{ "div": "body", "html": "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true }, "R14": { "role": "http://oncocyte.com/20240930/taxonomy/role/IntangibleAssetsNet", "longName": "995495 - Disclosure - Intangible Assets, Net", "shortName": "Intangible Assets, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "C_221e72d2-4c3a-4864-b987-ec6a62973144", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{ "div": "body", "html": "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_221e72d2-4c3a-4864-b987-ec6a62973144", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{ "div": "body", "html": "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true }, "R15": { "role": "http://oncocyte.com/20240930/taxonomy/role/CommitmentsAndContingencies", "longName": "995505 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "C_221e72d2-4c3a-4864-b987-ec6a62973144", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{ "div": "body", "html": "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_221e72d2-4c3a-4864-b987-ec6a62973144", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{ "div": "body", "html": "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true }, "R16": { "role": "http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquity", "longName": "995515 - Disclosure - Series A Redeemable Convertible Preferred Stock and Shareholders' 2019 Equity", "shortName": "Series A Redeemable Convertible Preferred Stock and Shareholders' 2019 Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "C_221e72d2-4c3a-4864-b987-ec6a62973144", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{ "div": "body", "html": "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_221e72d2-4c3a-4864-b987-ec6a62973144", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{ "div": "body", "html": "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true }, "R17": { "role": "http://oncocyte.com/20240930/taxonomy/role/Stock-based Compensation", "longName": "995525 - Disclosure - Stock-Based Compensation", "shortName": "Stock-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "C_221e72d2-4c3a-4864-b987-ec6a62973144", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{ "div": "body", "html": "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_221e72d2-4c3a-4864-b987-ec6a62973144", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{ "div": "body", "html": "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true }, "R18": { "role": "http://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactions", "longName": "995535 - Disclosure - Related Party Transactions", "shortName": "Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "C_221e72d2-4c3a-4864-b987-ec6a62973144", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{ "div": "body", "html": "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_221e72d2-4c3a-4864-b987-ec6a62973144", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{ "div": "body", "html": "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true }, "R19": { "role": "http://oncocyte.com/20240930/taxonomy/role/CollaborativeArrangements", "longName": "995545 - Disclosure - Collaborative Arrangements", "shortName": "Collaborative Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "C_221e72d2-4c3a-4864-b987-ec6a62973144", "name": "ocx:CoDevelopmentAgreementWithLifeTechnologiesCorporationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{ "div": "body", "html": "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_221e72d2-4c3a-4864-b987-ec6a62973144", "name": "ocx:CoDevelopmentAgreementWithLifeTechnologiesCorporationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{ "div": "body", "html": "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true }, "R20": { "role": "http://oncocyte.com/20240930/taxonomy/role/DiscontinuedOperationsOfRazor", "longName": "995555 - Disclosure - Discontinued Operations of Razor", "shortName": "Discontinued Operations of Razor", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "C_221e72d2-4c3a-4864-b987-ec6a62973144", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{ "div": "body", "html": "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_221e72d2-4c3a-4864-b987-ec6a62973144", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [{ "div": "body", "html": "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true }, "R21": { "role": "http://oncocyte.com/20240930/taxonomy/role/DisclosureSubsequentEvents1", "longName": "995565 - Disclosure - Subsequent Events",

"shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21",

"firstAnchor": { "contextRef": "C_221e72d2-4c3a-4864-b987-ecea62973144", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null,

"xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html": "I", "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true,

"unique": true }, "uniqueAnchor": { "contextRef": "C_221e72d2-4c3a-4864-b987-ecea62973144", "name": "us-

gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html": "I",

"reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true } }, "R22": { "role":

"http://oncoocyte.com/20240930/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables", "longName": "995575 - Disclosure - Summary of

Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false",

"groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "22", "firstAnchor": { "contextRef": "C_221e72d2-4c3a-4864-

b987-ecea62973144", "name": "ocx:AccountingPrinciplesPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null,

"ancestors": { "div": "us-gaap:SignificantAccountingPoliciesTextBlock", "div": "body", "html": "I", "reportCount": 1, "baseRef": "ocx-20240930.htm",

"first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_221e72d2-4c3a-4864-b987-ecea62973144", "name":

"ocx:AccountingPrinciplesPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "us-

gaap:SignificantAccountingPoliciesTextBlock", "div": "body", "html": "I", "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique":

true } }, "R23": { "role": "http://oncoocyte.com/20240930/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables", "longName": "995585 -

Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)",

"isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef":

"C_221e72d2-4c3a-4864-b987-ecea62973144", "name": "ocx:ScheduleOfPriorPeriodRevisionsTableTextBlock", "unitRef": null, "xsiNil": "false",

"lang": "en-US", "decimals": null, "ancestors": { "div": "ocx:PriorPeriodRevisionsPolicyTextBlock", "div": "ix:continuation", "div": "body", "html": "I,

"reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_221e72d2-4c3a-4864-b987-

ecea62973144", "name": "ocx:ScheduleOfPriorPeriodRevisionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null,

"ancestors": { "div": "ocx:PriorPeriodRevisionsPolicyTextBlock", "div": "ix:continuation", "div": "body", "html": "I", "reportCount": 1, "baseRef": "ocx-

20240930.htm", "first": true, "unique": true } }, "R24": { "role":

"http://oncoocyte.com/20240930/taxonomy/role/BusinessCombinationsAndContingentConsiderationLiabilitiesTables", "longName": "995595 -

Disclosure - Business Combinations and Contingent Consideration Liabilities (Tables)", "shortName": "Business Combinations and Contingent

Consideration Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24",

"firstAnchor": { "contextRef": "C_b6a9b2d0-5a62-4796-93e7-c4a7d0157396", "name": "us-

gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US",

"decimals": null, "ancestors": { "div": "us-gaap:BusinessCombinationDisclosureTextBlock", "div": "body", "html": "I", "reportCount": 1, "baseRef":

"ocx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b6a9b2d0-5a62-4796-93e7-c4a7d0157396", "name": "us-

gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US",

"decimals": null, "ancestors": { "div": "us-gaap:BusinessCombinationDisclosureTextBlock", "div": "body", "html": "I", "reportCount": 1, "baseRef":

"ocx-20240930.htm", "first": true, "unique": true } }, "R25": { "role":

"http://oncoocyte.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentTables", "longName": "995605 - Disclosure - Property and

Equipment (Tables)", "shortName": "Property and Equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables",

"menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "C_221e72d2-4c3a-4864-b987-ecea62973144", "name": "us-

gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "us-

gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div": "body", "html": "I", "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true,

"unique": true }, "uniqueAnchor": { "contextRef": "C_221e72d2-4c3a-4864-b987-ecea62973144", "name": "us-

gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "us-

gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div": "body", "html": "I", "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true,

"unique": true } }, "R26": { "role": "http://oncoocyte.com/20240930/taxonomy/role/IntangibleAssetsNetTables", "longName": "995615 - Disclosure -

Intangible Assets, Net (Tables)", "shortName": "Intangible Assets, Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType":

"tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "C_221e72d2-4c3a-4864-b987-ecea62973144", "name": "us-

gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": {

"div": "us-gaap:IntangibleAssetsDisclosureTextBlock", "div": "body", "html": "I", "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true,

"unique": true }, "uniqueAnchor": { "contextRef": "C_221e72d2-4c3a-4864-b987-ecea62973144", "name": "us-

gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": {

"div": "us-gaap:IntangibleAssetsDisclosureTextBlock", "div": "body", "html": "I", "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true,

"unique": true } }, "R27": { "role": "http://oncoocyte.com/20240930/taxonomy/role/CommitmentsAndContingenciesTables", "longName": "995625 -

Disclosure - Commitments and Contingencies (Tables)", "shortName": "Commitments and Contingencies (Tables)", "isDefault": "false",

"groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "C_221e72d2-4c3a-4864-

b987-ecea62973144", "name": "ocx:ScheduleOfOperatingAndFinanceLeaseBalanceSheetTableTextBlock", "unitRef": null, "xsiNil": "false", "lang":

"en-US", "decimals": null, "ancestors": { "div": "ix:continuation", "div": "body", "html": "I", "reportCount": 1, "baseRef": "ocx-20240930.htm", "first":

true, "unique": true }, "uniqueAnchor": { "contextRef": "C_221e72d2-4c3a-4864-b987-ecea62973144", "name":

"ocx:ScheduleOfOperatingAndFinanceLeaseBalanceSheetTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null,

"ancestors": { "div": "ix:continuation", "div": "body", "html": "I", "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true } },

"R28": { "role": "http://oncoocyte.com/20240930/taxonomy/role/Stock-basedCompensationTables", "longName": "995635 - Disclosure - Stock-Based

Compensation (Tables)", "shortName": "Stock-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType":

"tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "C_221e72d2-4c3a-4864-b987-ecea62973144", "name": "us-

gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null,

"ancestors": { "div": "ix:continuation", "div": "body", "html": "I", "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true },

"uniqueAnchor": { "contextRef": "C_221e72d2-4c3a-4864-b987-ecea62973144", "name": "us-

gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null,

"ancestors": { "div": "ix:continuation", "div": "body", "html": "I", "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true } },

"R29": { "role": "http://oncoocyte.com/20240930/taxonomy/role/DiscontinuedOperationsOfRazorTables", "longName": "995645 - Disclosure -

Discontinued Operations of Razor (Tables)", "shortName": "Discontinued Operations of Razor (Tables)", "isDefault": "false", "groupType":

"disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "C_221e72d2-4c3a-4864-b987-

ecea62973144", "name": "us-

gaap:ScheduleOfDisposalGroupsIncludingDiscontinued

"contextRef": "C_1a823b0b-d23d-4f88-84ca-04f4bf9718a8", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "div", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ocx-20240930.htm", "unique": true }, "R33": { "role": "http://oncoocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails", "longName": "995685 - Disclosure - Summary of Significant Accounting Policies - Schedule of Concentration of Risk (Details)", "shortName": "Summary of Significant Accounting Policies - Schedule of Concentration of Risk (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "C_c8e6bd4f-da9d-483e-99ee-43a5b9ddadab", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true }, "uniqueAnchor": null }, "R34": { "role": "http://oncoocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConsolidatedRevenuesGeneratedByUnaffiliatedCustomers (Details)", "longName": "995695 - Disclosure - Summary of Significant Accounting Policies - Schedule of Consolidated Revenues Generated by Unaffiliated Customers (Details)", "shortName": "Summary of Significant Accounting Policies - Schedule of Consolidated Revenues Generated by Unaffiliated Customers (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "C_08869d9c-fea5-4cc7-9155-20287cd09906", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true }, "R35": { "role": "http://oncoocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPercentageOfConsolidatedRevenuesAttributableToGeographicalLocations (Details)", "longName": "995705 - Disclosure - Summary of Significant Accounting Policies - Schedule of Percentage of Consolidated Revenues Attributable to Geographical Locations (Details)", "shortName": "Summary of Significant Accounting Policies - Schedule of Percentage of Consolidated Revenues Attributable to Geographical Locations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "C_c8e6bd4f-da9d-483e-99ee-43a5b9ddadab", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_f5dd6044-2506-424d-988f-48ca6538d5e0", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ocx-20240930.htm", "unique": true }, "R36": { "role": "http://oncoocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCommonStockComputationOfDilutedNetLossPerShareOfCommonStock (Details)", "longName": "995715 - Disclosure - Summary of Significant Accounting Policies - Schedule of Common Stock Computation of Diluted Net Loss Per Share of Common Stock (Details)", "shortName": "Summary of Significant Accounting Policies - Schedule of Common Stock Computation of Diluted Net Loss Per Share of Common Stock (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "C_61742ba8-6cfc-4273-b59d-ce51eb29082b", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_61742ba8-6cfc-4273-b59d-ce51eb29082b", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true }, "R37": { "role": "http://oncoocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "longName": "995725 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)", "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "C_5b151bc5-3c84-4553-842e-cb61ee8a6ac6", "name": "us-gaap:StockholdersEquityReverseStockSplit", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:BasisOfAccountingPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_5b151bc5-3c84-4553-842e-cb61ee8a6ac6", "name": "us-gaap:StockholdersEquityReverseStockSplit", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:BasisOfAccountingPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true }, "R38": { "role": "http://oncoocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesScheduleOfFairValueOfContingentConsiderationLiability (Details)", "longName": "995735 - Disclosure - Business Combinations and Contingent Consideration Liabilities - Schedule of Fair Value of Contingent Consideration Liability (Details)", "shortName": "Business Combinations and Contingent Consideration Liabilities - Schedule of Fair Value of Contingent Consideration Liability (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "C_48fd7444-cf95-4a28-a566-a497f8e85133", "name": "ocx:ContingentConsiderationLiabilityContractualValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_48fd7444-cf95-4a28-a566-a497f8e85133", "name": "ocx:ContingentConsiderationLiabilityContractualValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true }, "R39": { "role": "http://oncoocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesScheduleOfContingentConsiderationMeasuredAtFairValue (Details)", "longName": "995745 - Disclosure - Business Combinations and Contingent Consideration Liabilities - Schedule of Contingent Consideration Measured at Fair Value (Details)", "shortName": "Business Combinations and Contingent Consideration Liabilities - Schedule of Contingent Consideration Measured at Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "C_fdf60bb1-c5c7-4b92-9403-43f219a2ae7e", "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfContingentConsiderationMeasuredAtFairValueTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ocx-20240930.htm", "unique": true }, "R40": { "role": "http://oncoocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesAdditionalInformationDetails", "longName": "995755 - Disclosure - Business Combinations and Contingent Consideration Liabilities - Additional Information (Details)", "shortName": "Business Combinations and Contingent Consideration Liabilities - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "C_221e72d2-4c3a-4864-b987-ec6a62973144", "name": "ocx:FairValueOfContingentConsideration", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_221e72d2-4c3a-4864-b987-ec6a62973144", "name": "ocx:FairValueOfContingentConsideration", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true }, "R41": { "role": "http://oncoocyte.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfRightofuseAndFinancingLeaseAssetsMachineryAndEquipment (Details)", "longName": "995765 - Disclosure - Property and Equipment - Schedule of Right-of-use and Financing Lease Assets, Machinery and Equipment, Net, and Construction in Progress (Details)", "shortName": "Property and Equipment - Schedule of Right-of-use and Financing Lease Assets, Machinery and Equipment, Net, and Construction in Progress (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "C_71e3ba12-de37-452b-8384-1e6532648dc0", "name": "ocx:RightOfUseAndFinancingLeaseAssets", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "

16532648dc0", "name": "ocx:RightOfUseAndFinancingLeaseAssets", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": ".3", "ancestors": f "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" l, "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true } }, "R42": f "role": "http://oncocyte.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentDetailsNarrative", "longName": "995775 - Disclosure - Property and Equipment (Details Narrative)", "shortName": "Property and Equipment (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": f "contextRef": "C_61742ba8-6cfc-4273-b59d-ce51eb29082b", "name": "us-gaap:DepreciationAndAmortization", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": ".0", "ancestors": f "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" l, "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true } }, "R43": f "role": "http://oncocyte.com/20240930/taxonomy/role/ScheduleOfIntangibleAssetsNetDetails", "longName": "995785 - Disclosure - Schedule of Intangible Assets, Net (Details)", "shortName": "Schedule of Intangible Assets, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": f "contextRef": "C_71c3ba12-dc37-452b-8384-1e6532648dc0", "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": ".3", "ancestors": f "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "div", "body", "html" l, "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true } }, "R44": f "role": "http://oncocyte.com/20240930/taxonomy/role/ScheduleOfIntangibleAssetsFutureAmortizationExpenseDetails", "longName": "995795 - Disclosure - Schedule of Intangible Assets Future Amortization Expense (Details)", "shortName": "Schedule of Intangible Assets Future Amortization Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": f "contextRef": "C_71c3ba12-dc37-452b-8384-1e6532648dc0", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOffFiscalYear", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": ".3", "ancestors": f "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "div", "body", "html" l, "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true } }, "R45": f "role": "http://oncocyte.com/20240930/taxonomy/role/IntangibleAssetsNetDetailsNarrative", "longName": "995805 - Disclosure - Intangible Assets, Net (Details Narrative)", "shortName": "Intangible Assets, Net (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": f "contextRef": "C_c1b76a4a-4e3f-40b2-9b91-6c16b6bcb6b", "name": "us-gaap:ImpairmentOfIntangibleAssetsFiniteLived", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": ".3", "ancestors": f "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "div", "body", "html" l, "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true } }, "R46": f "role": "http://oncocyte.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative", "longName": "995815 - Disclosure - Commitments and Contingencies (Details Narrative)", "shortName": "Commitments and Contingencies (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": f "contextRef": "C_71c3ba12-dc37-452b-8384-1e6532648dc0", "name": "us-gaap:RestrictedCash", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": ".5", "ancestors": f "span", "p", "td", "tr", "table", "us-gaap:FairValueMeasurementsSensitivityAnalysisDescription", "div", "body", "html" l, "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true } }, "R47": f "role": "http://oncocyte.com/20240930/taxonomy/role/DisclosureScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeases", "longName": "995825 - Disclosure - Schedule of Supplemental Balance Sheet Information Related to Operating and Financing Leases (Details)", "shortName": "Schedule of Supplemental Balance Sheet Information Related to Operating and Financing Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": f "contextRef": "C_71c3ba12-dc37-452b-8384-1e6532648dc0", "name": "us-gaap:OperatingLeaseLiability", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": ".3", "ancestors": f "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesTableTextBlock", "div", "body", "html" l, "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true } }, "R48": f "role": "http://oncocyte.com/20240930/taxonomy/role/DisclosureScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails", "longName": "995835 - Disclosure - Schedule of Future Minimum Lease Commitments for Operating and Financing Leases (Details)", "shortName": "Schedule of Future Minimum Lease Commitments for Operating and Financing Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": f "contextRef": "C_71c3ba12-dc37-452b-8384-1e6532648dc0", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOffFiscalYear", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": ".3", "ancestors": f "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesTableTextBlock", "div", "body", "html" l, "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true } }, "R49": f "role": "http://oncocyte.com/20240930/taxonomy/role/DisclosureScheduleOfSupplementalCashFlowInformationRelatedToOperatingAndFinancingLeaseDetails", "longName": "995845 - Disclosure - Schedule of Supplemental Cash Flow Information Related to Operating and Financing Lease (Details)", "shortName": "Schedule of Supplemental Cash Flow Information Related to Operating and Financing Lease (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": f "contextRef": "C_221e72d2-4c3a-4864-b987-ecce62973144", "name": "us-gaap:OperatingLeasePayments", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": ".3", "ancestors": f "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfOperatingAndFinanceLeaseCashFlowTableTextBlock", "div", "body", "html" l, "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true } }, "R50": f "role": "http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative", "longName": "995855 - Disclosure - Series A Redeemable Convertible Preferred Stock and Shareholders'2019 Equity (Details Narrative)", "shortName": "Series A Redeemable Convertible Preferred Stock and Shareholders'2019 Equity (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": f "contextRef": "C_61742ba8-6cfc-4273-b59d-ce51eb29082b", "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": ".3", "ancestors": f "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfOperatingAndFinanceLeaseCashFlowTableTextBlock", "div", "body", "html" l, "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true } }, "R51": f "role": "http://oncocyte.com/20240930/taxonomy/role/SummaryOfStockOptionActivityDetails", "longName": "995865 - Disclosure - Summary of Stock Option Activity (Details)", "shortName": "Summary of Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": f "contextRef": "C_221e72d2-4c3a-4864-b987-ecce62973144", "name": "us-gaap:ShareBasedCompensation", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": ".3", "ancestors": f "span", "p", "td", "tr", "table", "us-gaap:ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": f "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "body", "html" l, "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true } }, "R52": f "role": "http://oncocyte.com/20240930/taxonomy/role/SummaryOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "body", "html" l, "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true } }, "R53": f "role": "http://oncocyte.com/20240930/taxonomy/role/SummaryOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "body", "html" l, "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true } }, "R54": f "role": "http://oncocyte.com/20240930/taxonomy/role/SummaryOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "body", "html" l, "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true } }, "R55": f "role": "http://oncocyte.com/20240930/taxonomy/role/SummaryOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "body", "html" l, "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true } }, "R56": f "role": "http://oncocyte.com/20240930/taxonomy/role/SummaryOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "body", "html" l, "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true } }, "R57": f "role": "http://oncocyte.com/20240930/taxonomy/role/SummaryOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "body", "html" l, "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true } }, "R58": f "role": "http://oncocyte.com/20240930/taxonomy/role/SummaryOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "body", "html" l, "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true } }, "R59": f "role": "http://oncocyte.com/20240930/taxonomy/role/SummaryOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "body", "html" l, "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true } }, "R60": f "role": "http://oncocyte.com/20240930/taxonomy/role/SummaryOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "body", "html" l, "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique":

[http://oncocyte.com/20240930/taxonomy/role/ScheduleOfAssumptionsUsedToCalculateFairValueOfStockOptionsDetails", "longName": "995875 - Disclosure - Schedule of Assumptions Used to Calculate Fair Value of Stock Options \(Details\)", "shortName": "Schedule of Assumptions Used to Calculate Fair Value of Stock Options \(Details\)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "C-221e72d2-4c3a-4864-b987-ecea62973144", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": \[{ "span": "p", "td": "tr", "table": "ix:continuation", "div": "ix:continuation", "body": "html" } \], "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C-61742ba8-6cfe-4273-b59d-ce51eb29082b", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": \[{ "span": "p", "td": "tr", "table": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div": "ix:continuation", "div": "body", "html" } \], "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C-61742ba8-6cfe-4273-b59d-ce51eb29082b", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": \[{ "span": "p", "td": "tr", "table": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div": "ix:continuation", "div": "body", "html" } \], "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true } \] }, "R54": { "role": "http://oncocyte.com/20240930/taxonomy/role/Stock-basedCompensationDetailsNarrative", "longName": "995895 - Disclosure - Summary of Stock-based Compensation Expense \(Details\)", "shortName": "Summary of Stock-based Compensation Expense \(Details\)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "C-61742ba8-6cfe-4273-b59d-ce51eb29082b", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": \[{ "span": "p", "td": "tr", "table": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div": "ix:continuation", "div": "body", "html" } \], "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C-277b8810-de06-41d7-ae9f-6d7f3df59e46", "name": "ocx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": \[{ "span": "p", "td": "tr", "table": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": \[{ "span": "p", "td": "tr", "table": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "div": "ix:continuation", "div": "body", "html" } \], "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true } \] }, "R55": { "role": "http://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative", "longName": "995905 - Disclosure - Related Party Transactions \(Details Narrative\)", "shortName": "Related Party Transactions \(Details Narrative\)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "C-61742ba8-6cfe-4273-b59d-ce51eb29082b", "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": \[{ "span": "p", "td": "tr", "table": "body", "html" } \], "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C-8a61b68b-feb4-46cf-84d2-1cc3d244ba01", "name": "ocx:PurchasePriceOfCommonStockValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": \[{ "span": "p", "td": "tr", "table": "ix:continuation", "div": "body", "html" } \], "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true } \] }, "R56": { "role": "http://oncocyte.com/20240930/taxonomy/role/CollaborativeArrangementsDetailsNarrative", "longName": "995915 - Disclosure - Collaborative Arrangements \(Details Narrative\)", "shortName": "Collaborative Arrangements \(Details Narrative\)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "C-61742ba8-6cfe-4273-b59d-ce51eb29082b", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": \[{ "span": "p", "td": "tr", "table": "body", "html" } \], "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C-c5d67644-e809-4c36-aa10-39b81bfab028", "name": "us-gaap:DevelopmentCosts", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": \[{ "span": "p", "td": "tr", "table": "ix:continuation", "div": "body", "html" } \], "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true } \] }, "R57": { "role": "http://oncocyte.com/20240930/taxonomy/role/ScheduleOfDiscontinuedOperationsDetails", "longName": "995925 - Disclosure - Schedule of Discontinued Operations \(Details\)", "shortName": "Schedule of Discontinued Operations \(Details\)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "C-d040529-4a5e-490f-9c35-d8a5b516c4f5", "name": "us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": \[{ "span": "p", "td": "tr", "table": "body", "html" } \], "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C-dbbf7260-a45c-449b-b468-b877fb7917a1", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": \[{ "span": "p", "td": "tr", "table": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "div": "ix:continuation", "div": "body", "html" } \], "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true } \] }, "R58": { "role": "http://oncocyte.com/20240930/taxonomy/role/ScheduleOfAssetsAndLiabilitiesDiscontinuedOperationsDetails", "longName": "995935 - Disclosure - Schedule of Assets and Liabilities Discontinued Operations \(Details\)", "shortName": "Schedule of Assets and Liabilities Discontinued Operations \(Details\)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "C-dbbf7260-a45c-449b-b468-b877fb7917a1", "name": "us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": \[{ "span": "p", "td": "tr", "table": "ix:continuation", "div": "ix:continuation", "div": "body", "html" } \], "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C-dbbf7260-a45c-449b-b468-b877fb7917a1", "name": "us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": \[{ "span": "p", "td": "tr", "table": "ix:continuation", "div": "ix:continuation", "div": "body", "html" } \], "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true } \] }, "R59": { "role": "http://oncocyte.com/20240930/taxonomy/role/DiscontinuedOperationsOfRazorDetailsNarrative", "longName": "995945 - Disclosure - Discontinued Operations of Razor \(Details Narrative\)", "shortName": "Discontinued Operations of Razor \(Details Narrative\)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "C-e71aac24-d84d-425e-aa52-3671a7dbf060", "name": "us-gaap:RepaymentsOfRelatedPartyDebt", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": \[{ "span": "p", "td": "tr", "table": "ix:continuation", "div": "body", "html" } \], "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C-e71aac24-d84d-425e-aa52-3671a7dbf060", "name": "us-gaap:RepaymentsOfRelatedPartyDebt", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": \[{ "span": "p", "td": "tr", "table": "ix:continuation", "div": "body", "html" } \], "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true } \] }, "R60": { "role": "http://oncocyte.com/20240930/taxonomy/role/DisclosureSubsequentEventsDetailsNarrative", "longName": "995955 - Disclosure - Subsequent Events - \(Details Narrative\)", "shortName": "Subsequent Events - \(Details Narrative\)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "C-acf1c09c-b9ea-4520-92e3-fb42b10fee33", "name": "us-gaap:ProceedsFromIssuanceOfPrivatePlacement", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "5", "ancestors": \[{ "span": "p", "td": "tr", "table": "ix:continuation", "div": "body", "html" } \], "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C-acf1c09c-b9ea-4520-92e3-fb42b10fee33", "name": "us-gaap:ProceedsFromIssuanceOfPrivatePlacement", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "5", "ancestors": \[{ "span": "p", "td": "tr", "table": "ix:continuation", "div": "body", "html" } \], "reportCount": 1, "baseRef": "ocx-20240930.htm", "first": true, "unique": true } \] }, "R61": { "role": "http://oncocyte.com/20240930/taxonomy/role/AccountingForWarrantsPolicyTextBlock", "longName": "Accounting For Warrants Policy Text Block", "shortName": "Accounting For Warrants Policy Text Block", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "C-acf1c09c-b9ea-4520-92e3-fb42b10fee33", "name":](#)

us": { "role": { "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } }, "auth_ref": { "r729" } }, "us-gaap:AccountsReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNet", "crdr": "debit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label": "Accounts receivable", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business." } } }, "auth_ref": { "r664", "r728", "r804", "r1044", "r1045" } }, "us-gaap:AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/BalanceSheets": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPriorPeriodRevisionsDetails": { "lang": { "en-us": { "role": { "label": "Accounts receivable, net of allowance for credit losses of \$2 and \$5, respectively", "verboseLabel": "Accounts receivable, net", "terseLabel": "Accounts receivable", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": { "r950" } }, "ocx:AccretionOfRedeemableConvertiblePreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "AccretionOfRedeemableConvertiblePreferredStock", "crdr": "debit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCommonStockComputationOfDiluted": { "lang": { "en-us": { "role": { "negatedLabel": "Accretion of Series A redeemable convertible preferred stock", "documentation": "Accretion of redeemable convertible preferred stock", "label": "AccretionOfRedeemableConvertiblePreferredStock" } } }, "auth_ref": { "r930" } }, "ocx:AccretionOfSeriesConvertiblePreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "AccretionOfSeriesConvertiblePreferredStock", "crdr": "debit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/StatementsOfCashFlows": { "lang": { "en-us": { "role": { "label": "Accretion of Series A convertible preferred stock", "documentation": "Accretion of series convertible preferred stock" } } }, "auth_ref": { "r930" } }, "us-gaap:AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/BalanceSheets": { "lang": { "en-us": { "role": { "label": "Accrued compensation", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": { "r96" } }, "us-gaap:AccruedRoyaltiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedRoyaltiesCurrent", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/BalanceSheets": { "lang": { "en-us": { "role": { "label": "Accrued royalties", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": { "r96", "r749" } }, "ocx:AccruedSeveranceFromAcquisitionCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "AccruedSeveranceFromAcquisitionCurrent", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/BalanceSheets": { "lang": { "en-us": { "role": { "label": "Accrued severance from acquisition", "documentation": "Accrued severance from acquisition current." } } }, "auth_ref": { "r96" } }, "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfRightOfUseAndFinancingLeaseAssetsMachineryAndEquipment": { "lang": { "en-us": { "role": { "negatedLabel": "Accumulated depreciation and amortization", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": { "r53", "r195", "r584" } }, "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/BalanceSheets": { "lang": { "en-us": { "role": { "label": "Accumulated other comprehensive income", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": { "r28", "r29", "r109", "r204", "r579", "r609", "r613" } }, "us-gaap:AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/StatementsOfSeriesRedeemableConvertiblePreferredStockAndShareholdersEquity": { "lang": { "en-us": { "role": { "label": "AOI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": { "r5", "r19", "r29", "r459", "r462", "r514", "r604", "r605", "r924", "r925", "r926", "r935", "r936", "r937", "r940" } }, "ecd:Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": { "r48" } }, "ecd:AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": { "r861" } }, "ecd:AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation" } } }, "auth_ref": { "r861" } }, "ecd:AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO-NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO-NEO Compensation Footnote" } } }, "auth_ref": { "r861" } }, "ecd:AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": { "r861" } }, "ocx:AdjustedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "AdjustedSharesOutstanding", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/StatementsOfSeriesRedeemableConvertiblePreferredStockAndShareholdersEquity": { "lang": { "en-us": { "role": { "label": "Adjusted balance, shares", "documentation": "Adjusted shares outstanding." } } }, "auth_ref": { "r930" } }, "ocx:AdjustedStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "AdjustedStockholdersEquity", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPriorPeriodRevisionsDetails": { "http://oncocyte.com/20240930/taxonomy/role/StatementsOfSeriesRedeemableConvertiblePreferredStockAndShareholdersEquity": { "lang": { "en-us": { "role": { "label": "Balance at January 1, 2023, as adjusted", "verboseLabel": "Total Shareholders equity", "documentation": "Adjusted stockholders' equity." } } }, "auth_ref": { "r930" } }, "us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/StatementsOfCashFlows": { "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities." } } }, "auth_ref": { "r930" } }, "us-gaap:AdvertisingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdvertisingExpense", "crdr": "debit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label": "Advertising expense", "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line." } } }, "auth_ref": { "r423", "r774" } }, "ecd:AggtChngPnsnValInSummryCompstnTblForAplblyrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblyrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": { "r894" } }, "ecd:AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": { "r820", "r830", "r840", "r872" } }, "ecd:AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": { "r823", "r833", "r843", "r875" } }, "ecd:AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": { "r895" } },

"ecdfAllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation", "auth_ref": { "r861": { "ecdAllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories", "auth_ref": { "r868": { "ecdAllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals", "auth_ref": { "r824": { "r834": { "r844": { "r868": { "r876": { "r880": { "r888": { "ecdAllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements", "auth_ref": { "r886": { "us-gaapAllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/SummaryOfStock-basedCompensationExpenseDetails": { "lang": { "en-us": { "role": { "label": "Stock-based compensation expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": { "r415": { "r421": { "us-gaapAllowanceForDoubtfulAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label": "Accounts receivable, allowance for credit loss", "documentation": "Amount of allowance for credit loss on accounts receivable." } } }, "auth_ref": { "r205": { "r278": { "r287": { "r288": { "r289": { "r1045": { "us-gaapAllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/BalanceSheetsParenthetical": { "lang": { "en-us": { "role": { "terseLabel": "Allowance for credit losses", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": { "r205": { "r278": { "r287": { "deiAmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/Cover": { "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously filed or accepted submission." } } }, "auth_ref": { "us-gaapAmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/IntangibleAssetsNetDetailsNarrative": { "http://oncocyte.com/20240930/taxonomy/role/StatementsOfCashFlows": { "lang": { "en-us": { "role": { "label": "Amortization of intangible assets", "verboseLabel": "Intangible asset amortization expense", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": { "r14": { "r297": { "r304": { "r758": { "us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCommonStockComputationOfDiluted": { "lang": { "en-us": { "role": { "label": "Total", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": { "r260": { "us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCommonStockComputationOfDiluted": { "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": { "r40": { "us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCommonStockComputationOfDiluted": { "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "us-gaapAntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCommonStockComputationOfDiluted": { "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": { "r40": { "ocxAreaOfLab": { "xbrltype": "areaItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "AreaOfLab", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Area of lab", "documentation": "Area of lab." } } }, "auth_ref": { "us-gaapAreaOfLand": { "xbrltype": "areaItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AreaOfLand", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Area of land", "documentation": "Area of land held." } } }, "auth_ref": { "ocxArnoMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "ArnoMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Arno [Member]", "documentation": "Arno [Member]" } } }, "auth_ref": { "ocxArnosSonMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "ArnosSonMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Arno's Son [Member]", "documentation": "Arno's Son [Member]" } } }, "auth_ref": { "us-gaapArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/CollaborativeArrangementsDetailsNarrative": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesAdditionalInformationDetails": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSubsequentEventsDetailsNarrative": { "http://oncocyte.com/20240930/taxonomy/role/DiscontinuedOperationsOfRazorDetailsNarrative": { "http://oncocyte.com/20240930/taxonomy/role/OrganizationAndDescriptionOfBusinessDetailsNarrative": { "http://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative": { "http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative": { "http://oncocyte.com/20240930/taxonomy/role/Stock-basedCompensationDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": { "r453": { "us-gaapAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/BalanceSheets": { "lang": { "en-us": { "role": { "totalLabel": "TOTAL ASSETS", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": { "r161": { "r171": { "r199": { "r228": { "r263": { "r267": { "r271": { "r272": { "r282": { "r323": { "r324": { "r325": { "r326": { "r327": { "r328": { "r329": { "r330": { "r331": { "r454": { "r456": { "r481": { "r572": { "r669": { "r755": { "r756": { "r784": { "r811": { "r974": { "r975": { "r1030": { "us-gaapAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/BalanceSheets": { "lang": { "en-us": { "role": { "label": "ASSETS", "auth_ref": { "us-gaapAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/BalanceSheets": { "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": { "r191": { "r208": { "r228": { "r282": { "r323": { "r324": { "r325": { "r326": { "r327": { "r328": { "r329": { "r330": { "r331": { "r454": { "r456": { "r481": { "r784": { "r974": { "r975": { "r1030": { "us-gaapAssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": { "http://onc

"Amount of assets held for sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer." } }
}, "auth_ref": { "r134", "r784" } }, "us-gaap_AssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AssetsNoncurrentAbstract", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/BalanceSheets" }, "lang": { "en-us": {
"role": { "label": "NONCURRENT ASSETS" } } }, "auth_ref": { } }, "ocx_AtTheMarketOfferingMember": { "xbrltype": "domainItemType", "nsuri":
"http://oncocyte.com/20240930", "localname": "AtTheMarketOfferingMember", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/StatementsOfSeriesRedeemableConvertiblePreferredStockAndShareholdersEquity" }, "lang": { "en-
us": { "role": { "terseLabel": "At The Market Offering [Member]", "label": "At The Market Offering [Member]", "documentation": "At The Market
Offering." } } }, "auth_ref": { } }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AwardExrcPrice", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "label": "Award Exercise
Price", "terseLabel": "Exercise Price" } } }, "auth_ref": { "r893" } }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" },
"lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": { "r894" } },
"ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems",
"lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": { "r879" } }
}, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AwardTmgHowMnpiCnsdrdTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": {
"label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": { "r879" } }
}, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AwardTmgMethodTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "label":
"Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": { "r879" } }, "ecd_AwardTmgMnpiCnsdrdFlag": {
"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": {
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel":
"Award Timing MNPI Considered" } } }, "auth_ref": { "r879" } }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
}, "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } },
"auth_ref": { "r879" } }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AwardTmgPredtrmndFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "label": "Award
Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": { "r879" } }, "us-gaap_AwardTypeAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/Stock-basedCompensationDetailsNarrative", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" },
"lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-
based payment arrangement." } } }, "auth_ref": { "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400",
"r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414" } }, "ecd_AwardUndrlygSecuritiesAmt":
{ "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": {
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel":
"Underlying Securities" } } }, "auth_ref": { "r882" } }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": {
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual
Name", "terseLabel": "Name" } } }, "auth_ref": { "r881" } }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
}, "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI
Disclosures" } } }, "auth_ref": { "r880" } }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": {
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text
Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": { "r880" } }, "us-
gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"BasisOfAccountingPolicyPolicyTextBlock", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" }, "lang": { "en-us": { "role": { "label": "Principles
of Consolidation and Basis of Presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation,
used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting,
IFRS)." } } }, "auth_ref": { } }, "ocx_BeneficialOwnershipConsideredToSaleSharesUnderAgreement": { "xbrltype": "percentItemType", "nsuri":
"http://oncocyte.com/20240930", "localname": "BeneficialOwnershipConsideredToSaleSharesUnderAgreement", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative" }, "lang": {
"en-us": { "role": { "label": "Beneficial ownership considered", "documentation": "Beneficial ownership considered to sale shares under
agreement." } } }, "auth_ref": { } }, "ocx_BioRadLaboratoriesIncMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20240930",
"localname": "BioRadLaboratoriesIncMember", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative" }, "lang": { "en-us": { "role": { "label": "Bio Rad
Laboratories Inc [Member]", "documentation": "Bio Rad Laboratories Inc [Member]" } } }, "auth_ref": { } }, "ocx_BoardMembersMember": {
"xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "BoardMembersMember", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative" }, "lang": {
"en-us": { "role": { "label": "Board Members [Member]", "documentation": "Board Members [Member]" } } }, "auth_ref": { } },
"ocx_BroadwoodCapitalLPMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20240930", "localname":
"BroadwoodCapitalLPMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative" },
"lang": { "en-us": { "role": { "label": "Broadwood Capital LP [Member]", "documentation": "Broadwood Capital LP [Member]" } } }, "auth_ref": { } },
"ocx_BroadwoodPartnersLPMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20240930", "localname":
"BroadwoodPartnersLPMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative" },
"lang": { "en-us": { "role": { "label": "Broadwood Partners LP [Member]", "documentation": "Broadwood Partners LP [Member]" } } }, "auth_ref": { } }
}, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"BusinessAcquisitionAcquireeDomain", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/BusinessCombinationsAndContingentConsiderationLiabilitiesTables",
"http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesAdditionalInformationDetails",
"http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesScheduleOfContingentConsid",
"http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesScheduleOffFairValueOfConti",
"lang": { "en-us": { "role": { "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material
business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of
the acquiree." } } }, "auth_ref": { "r298", "r299", "r300", "r301", "r302", "r447", "r769", "r770" } }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/BusinessCombinationsAndContingentConsiderationLiabilitiesTables",
"http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesAdditionalInformationDetails",
"http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesScheduleOfContingentConsid",
"http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesScheduleOffFairValueOfConti",
"lang": { "en-us": { "role": { "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of
individually immaterial business combinations." } } }, "auth_ref": { "r63", "r64", "r298", "r299", "r300", "r301", "r302", "r447", "r769", "r770" } }
}, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"BusinessAcquisitionLineItems", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/BusinessCombinationsAndContingentConsiderationLiabilitiesTables",
"http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesAdditionalInformationDetails",
"http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesScheduleOfContingentConsid",
"http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesScheduleOffFairValueOfConti",
"lang": { "en-us": { "role": { "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a
table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } },
"auth_ref": { "r447" } }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Business Combination, Asset
Acquisition, and Joint Venture Formation [Abstract]" } } }, "auth_ref": { } }, "us-gaap_BusinessCombinationConsiderationTransferred1": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationConsiderationTransferred1", "crdr":
"credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DiscontinuedOperationsOfRazorDetailsNarrative" }, "lang": { "en-us": {
"role": { "label": "Business combination consideration transferred", "verboseLabel": "Consideration transferred", "documentation": "Amount of
consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and
equity interest issued by the acquirer." } } }, "auth_ref": { "r1", "r2", "r18" } }, "us-

gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationLiability1", "crdr": "debit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesScheduleOfContingentConsid": "http://oncocyte.com/20240930/taxonomy/role/StatementsOfCashFlows", "http://oncocyte.com/20240930/taxonomy/role/StatementsOfOperations" }, "lang": { "en-us": { "role": { "label": "Change in fair value of contingent consideration", "verboseLabel": "Change in estimated fair value", "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement." } } }, "auth_ref": { "r450", "r930" } }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesScheduleOfFairValueOfConti": { "lang": { "en-us": { "role": { "label": "Fair Value on the Merger Date", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": { "r66", "r155", "r449", "r471", "r472", "r473" } }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/BalanceSheets": { "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration liabilities, current", "label": "Business Combination, Contingent Consideration, Liability, Current", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer." } } }, "auth_ref": { "r66", "r155" } }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Business combination, contingent consideration, liability, measurement input", "label": "Business Combination, Contingent Consideration, Liability, Measurement Input", "documentation": "Value of input used to measure contingent consideration liability from business combination." } } }, "auth_ref": { "r471", "r472", "r473" } }, "ocx_BusinessCombinationContingentConsiderationLiabilityMilestonePayment": { "xbrltype": "durationItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "BusinessCombinationContingentConsiderationLiabilityMilestonePayment", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Business combination, contingent consideration, liability, milestone payment", "label": "Business Combination, Contingent Consideration, Liability, Milestone Payment", "documentation": "Business combination, contingent consideration, liability, milestone payment." } } }, "auth_ref": { } }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/BalanceSheets": { "lang": { "en-us": { "role": { "label": "Contingent consideration liabilities, noncurrent", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer." } } }, "auth_ref": { "r66", "r155" } }, "ocx_BusinessCombinationContingentConsiderationLiabilityPayoutPercentage": { "xbrltype": "percentItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "BusinessCombinationContingentConsiderationLiabilityPayoutPercentage", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Payout percentage", "label": "Business Combination, Contingent Consideration, Liability, Payout Percentage", "documentation": "Business combination, contingent consideration, liability, payout percentage." } } }, "auth_ref": { } }, "ocx_BusinessCombinationContingentConsiderationLiabilityRelatedPatentExpirationRangeTerm": { "xbrltype": "durationItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "BusinessCombinationContingentConsiderationLiabilityRelatedPatentExpirationRangeTerm", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Business combination, contingent consideration, liability, related patent expiration range term", "label": "Business Combination, Contingent Consideration, Liability, Related Patent Expiration Range Term", "documentation": "Business combination, contingent consideration, liability, related patent expiration range term." } } }, "auth_ref": { } }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/BusinessCombinationsAndContingentConsiderationLiabilities": { "lang": { "en-us": { "role": { "label": "Business Combinations and Contingent Consideration Liabilities", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": { "r154", "r448" } }, "ocx_BusinessCombinationsAndFairValueMeasurementsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "BusinessCombinationsAndFairValueMeasurementsPolicyTextBlock", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies": { "lang": { "en-us": { "role": { "label": "Fair Value Measurements, Business Combinations and Contingent Consideration Liabilities", "documentation": "Business Combinations and Fair Value Measurements [Policy Text Block]" } } }, "auth_ref": { } }, "us-gaap_CaliforniaFranchiseTaxBoardMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CaliforniaFranchiseTaxBoardMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label": "California Franchise Tax Board [Member]", "documentation": "Designated tax department of the government of the state of California." } } }, "auth_ref": { } }, "ocx_CapitalLeaseAgreementImputedAnnualInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "CapitalLeaseAgreementImputedAnnualInterestRate", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Interest rate on lease agreement", "documentation": "Refers to annual interest rate on capital lease agreement." } } }, "auth_ref": { } }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Cash", "crdr": "debit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Cash in hand", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": { "r173", "r575", "r640", "r663", "r784", "r811", "r918" } }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/BalanceSheets": { "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": { "r33", "r194", "r747" } }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies": { "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents and Restricted Cash", "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits." } } }, "auth_ref": { "r34", "r160" } }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/StatementsOfCashFlows": { "lang": { "en-us": { "role": { "periodEndLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING", "periodStartLabel": "CASH, CASH EQUIVALENTS (INCLUDES DISCONTINUED OPERATIONS) AND RESTRICTED CASH, BEGINNING", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Including Disposal Group and Discontinued Operations", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": { "r33", "r126", "r225" } }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {

"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/StatementsOfCashFlows": { "lang": { "en-us": { "role": { "totalLabel": "NET CHANGE IN CASH, CASH EQUIVALENTS (INCLUDES DISCONTINUED OPERATIONS) AND RESTRICTED CASH", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": { "r3": "r126" } }, "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations", "crdr": "debit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/ScheduleOfAssetsAndLiabilitiesDiscontinuedOperationsDetails": { "lang": { "en-us": { "role": { "label": "Net cash used in investing activities", "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": { "r88": "r126" } }, "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations", "crdr": "debit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/ScheduleOfAssetsAndLiabilitiesDiscontinuedOperationsDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Net cash used in operating activities", "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations", "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": { "r88": "r126" } }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": { "r859" } }, "ecd_ChngInFrValAsOfVstngDtOfPrYrEqtyAwrdVsYstDnCyrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrYrEqtyAwrdVsYstDnCyrdYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": { "r856" } }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdVsGrntdInPrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdVsGrntdInPrYrsMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": { "r854" } }, "ocx_ChronixAcquisitionMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "ChronixAcquisitionMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Chronix Acquisition [Member]", "documentation": "Chronix Acquisition [Member]" } } }, "auth_ref": { "ocx_ChronixBiomedicalIncMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "ChronixBiomedicalIncMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label": "Chronix Biomedical Inc [Member]", "documentation": "Chronix Biomedical Inc [Member]" } } }, "auth_ref": { "ocx_ChronixEquityMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "ChronixEquityMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label": "Chronix Equity [Member]", "documentation": "Chronix Equity [Member]" } } }, "auth_ref": { "ocx_ChronixMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "ChronixMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label": "Chronix [Member]", "documentation": "Chronix [Member]" } } }, "auth_ref": { "ocx_ChronixMergerMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "ChronixMergerMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/BusinessCombinationsAndContingentConsiderationLiabilitiesTables": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesAdditionalInformationDetails": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesScheduleOfContingentConsid": { "lang": { "en-us": { "role": { "label": "Chronix Merger [Member]", "documentation": "Chronix Merger [Member]" } } }, "auth_ref": { "ocx_ChronixMilestoneMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "ChronixMilestoneMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label": "Chronix Milestone [Member]", "documentation": "Chronix Milestone [Member]" } } }, "auth_ref": { "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/Cover": { "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": { "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/BalanceSheetsParenthetical": { "http://oncocyte.com/20240930/taxonomy/role/OrganizationAndDescriptionOfBusinessDetailsNarrative": { "http://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative": { "http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative": { "http://oncocyte.com/20240930/taxonomy/role/StatementsOfSeriesRedeemableConvertiblePreferredStockAndShareholdersEquity": { "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": { "r185": "r201", "r201": "r202", "r202": "r203", "r203": "r228", "r228": "r249", "r249": "r250", "r250": "r257", "r257": "r259", "r259": "r265", "r265": "r266", "r266": "r282", "r282": "r323", "r323": "r325", "r325": "r326", "r326": "r327", "r327": "r330", "r330": "r331", "r331": "r334", "r334": "r335", "r335": "r339", "r339": "r342", "r342": "r349", "r349": "r481", "r481": "r621", "r621": "r622", "r622": "r623", "r623": "r624", "r624": "r629", "r629": "r630", "r630": "r631", "r631": "r632", "r632": "r633", "r633": "r634", "r634": "r635", "r635": "r636", "r636": "r637", "r637": "r638", "r638": "r639", "r639": "r641", "r641": "r655", "r655": "r678", "r678": "r700", "r700": "r721", "r721": "r722", "r722": "r723", "r723": "r724", "r724": "r725", "r725": "r898", "r898": "r933", "r933": "r942" } }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r201": "r202", "r202": "r203", "r203": "r265", "r265": "r334", "r334": "r335", "r335": "r337", "r337": "r339", "r339": "r342", "r342": "r347", "r347": "r349", "r349": "r621", "r621": "r622", "r622": "r623", "r623": "r624", "r624": "r761", "r761": "r898", "r898": "r933" } }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative": { "http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Warrant exercise price, per share", "verboseLabel": "Warrant exercise price", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": { "r350" } }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative": { "http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Warrants to purchase shares", "label": "Warrants to purchase shares", "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares." } } }, "auth_ref": { "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative": { "http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Purchase of warrant", "verboseLabel": "Warrant to purchase common stock", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": { "r350" } }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Warrants issued and outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": { "ocx_CoDevelopmentAgreementWithLifeTechnologiesCorporationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "CoDevelopmentAgreementWithLifeTechnologiesCorporationTextBlock", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/CollaborativeArrangements": { "lang": { "en-us": { "role": { "verboseLabel": "Collaborative

Arrangements", "documentation": "Co development agreement with life technologies corporation [TextBlock]" } } }, "label": "Co development agreement with life technologies corporation [TextBlock]" } } }, "auth_ref": "1", "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": { "r860" } }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": { "r860" } }, "ocx_CollaborativeAgreementTermPeriod": { "xbrltype": "durationItemType", "nsuri": "http://oncoocyte.com/20240930", "localname": "CollaborativeAgreementTermPeriod", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/CollaborativeArrangementsDetailsNarrative" }, "lang": { "en-us": { "role": { "terseLabel": "Collaborative agreement, term period" } } }, "label": "Collaborative Agreement, Term Period", "documentation": "Collaborative agreement, term period." } } }, "auth_ref": { "us-gaap_CollaborativeArrangementAccountingPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementAccountingPolicy", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" }, "lang": { "en-us": { "role": { "verboseLabel": "Collaborative Arrangements", "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for collaborative arrangements." } } }, "auth_ref": { "r178" } }, "us-gaap_CollaborativeArrangementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementMember", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/CollaborativeArrangementsDetailsNarrative" }, "lang": { "en-us": { "role": { "terseLabel": "Collaboration Agreement [Member]", "label": "Collaborative Arrangement [Member]", "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity." } } }, "auth_ref": { "r453" } }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/OrganizationAndDescriptionOfBusinessDetailsNarrative" }, "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r453" } }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/BalanceSheets" }, "lang": { "en-us": { "role": { "label": "Commitments and contingencies (Note 6)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": { "r100", "r163", "r574", "r654" } }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": { "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/CommitmentsAndContingencies" }, "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": { "r141", "r317", "r318", "r730", "r969", "r971" } }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/Stock-basedCompensationDetailsNarrative" }, "lang": { "en-us": { "role": { "label": "Common stock reserved for future issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": { "r104" } }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/DisclosureSubsequentEventsDetailsNarrative", "http://oncoocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative", "http://oncoocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative", "http://oncoocyte.com/20240930/taxonomy/role/StatementsOfSeriesRedeemableConvertiblePreferredStockAndShareholdersEquity" }, "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": { "r801", "r802", "r803", "r805", "r806", "r807", "r808", "r935", "r936", "r940", "r1015", "r1078", "r1079" } }, "us-gaap_CommonStockNoParValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockNoParValue", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/BalanceSheetsParenthetical", "http://oncoocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative" }, "lang": { "en-us": { "role": { "label": "Common stock, no par value", "verboseLabel": "Common stock no par value", "documentation": "Face amount per share of no-par value common stock." } } }, "auth_ref": { "r104" } }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/BalanceSheetsParenthetical", "http://oncoocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://oncoocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative" }, "lang": { "en-us": { "role": { "label": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": { "r104", "r655" } }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/BalanceSheetsParenthetical", "http://oncoocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative" }, "lang": { "en-us": { "role": { "label": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": { "r104" } }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/BalanceSheetsParenthetical", "http://oncoocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative" }, "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": { "r20", "r104", "r655", "r675", "r1079", "r1080" } }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/BalanceSheets" }, "lang": { "en-us": { "role": { "label": "Common stock, no par value, 230,000 shares authorized; 13,374 and 8,261 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": { "r104", "r577", "r784" } }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": { "r865" } }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": { "r864" } }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": { "r866" } }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": { "r863" } }, "us-gaap_CompensationRelatedCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CompensationRelatedCostsPolicyTextBlock", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" }, "lang": { "en-us": { "role": { "verboseLabel": "Stock-Based Compensation", "label": "Compensation Related Costs, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense." } } }, "auth_ref": { "r149", "r151" } }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri":


```

"uri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "presentation": "http://oncoocyte.com/20240930/taxonomy/role/StatementsOfComprehensiveLoss", "lang": "en-us", "role": "totalLabel", "label": "Comprehensive loss", "documentation": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." }, { "auth_ref": "r30", "r210", "r212", "r217", "r568", "r590", "r591" }, { "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": "http://oncoocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://oncoocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails", "http://oncoocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConsolidatedRevenuesGeneratedByUn", "http://oncoocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPercentageOfConsolidatedRevenuesAt", "lang": "en-us", "role": "label", "Concentration Risk Benchmark [Axis]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." }, { "auth_ref": "r44", "r45", "r67", "r68", "r276", "r729" }, { "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": "http://oncoocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://oncoocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails", "http://oncoocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConsolidatedRevenuesGeneratedByUn", "http://oncoocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPercentageOfConsolidatedRevenuesAt", "lang": "en-us", "role": "label", "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." }, { "auth_ref": "r44", "r45", "r67", "r68", "r276", "r615", "r729" }, { "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": "http://oncoocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://oncoocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails", "http://oncoocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConsolidatedRevenuesGeneratedByUn", "http://oncoocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPercentageOfConsolidatedRevenuesAt", "lang": "en-us", "role": "label", "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." }, { "auth_ref": "r44", "r45", "r67", "r68", "r276", "r729", "r907" }, { "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": "http://oncoocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://oncoocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails", "http://oncoocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConsolidatedRevenuesGeneratedByUn", "http://oncoocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPercentageOfConsolidatedRevenuesAt", "lang": "en-us", "role": "label", "Percentage of revenues", "verboseLabel": "Percentage of consolidated revenues", "terseLabel": "Concentration risk percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the benchmark (or denominator) in the equation, this concept represents the concentration percentage derived from the division." }, { "auth_ref": "r44", "r45", "r67", "r68", "r276" }, { "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": "http://oncoocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://oncoocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails", "http://oncoocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConsolidatedRevenuesGeneratedByUn", "http://oncoocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPercentageOfConsolidatedRevenuesAt", "lang": "en-us", "role": "label", "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." }, { "auth_ref": "r44", "r45", "r67", "r68", "r276", "r729" }, { "us-gaap_ConstructionInProgressGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConstructionInProgressGross", "crdr": "debit", "presentation": "http://oncoocyte.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfRightofuseAndFinancingLeaseAssetsMachineryAndEqui", "lang": "en-us", "role": "label", "Construction in progress", "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." }, { "auth_ref": "r136" }, { "ocx_ConstructionInProgressMachineryAndEquipmentPurchasesIncludedInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://oncoocyte.com/20240930", "localname": "ConstructionInProgressMachineryAndEquipmentPurchasesIncludedInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "presentation": "http://oncoocyte.com/20240930/taxonomy/role/StatementsOfCashFlows", "lang": "en-us", "role": "label", "Construction in progress, machinery and equipment purchases included in accounts payable and accrued liabilities", "documentation": "Construction in progress, machinery and equipment purchases included in accounts payable and accrued liabilities." }, { "auth_ref": "us-gaap_ContingentConsiderationByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContingentConsiderationByTypeAxis", "presentation": "http://oncoocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesScheduleOffairValueOfConti", "lang": "en-us", "role": "label", "Contingent Consideration by Type [Axis]", "documentation": "Information by type of contingent consideration." }, { "auth_ref": "ocx_ContingentConsiderationLiabilityContractualValue": { "xbrltype": "monetaryItemType", "nsuri": "http://oncoocyte.com/20240930", "localname": "ContingentConsiderationLiabilityContractualValue", "crdr": "debit", "presentation": "http://oncoocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesScheduleOffairValueOfConti", "lang": "en-us", "role": "label", "Contractual Value", "documentation": "Business Combination, Contingent Consideration, Liability Contractual value." }, { "auth_ref": "us-gaap_ContingentConsiderationTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContingentConsiderationTypeDomain", "presentation": "http://oncoocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesScheduleOffairValueOfConti", "lang": "en-us", "role": "label", "Contingent Consideration Type [Domain]", "documentation": "Description of contingent payment arrangement." }, { "auth_ref": "us-gaap_ConversionOfStockDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConversionOfStockDescription", "presentation": "http://oncoocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative", "lang": "en-us", "role": "label", "Conversion of stock, description", "documentation": "A unique description of a noncash or part noncash stock conversion. The description would be expected to include sufficient information to provide an understanding of the nature and purpose of the conversion. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period." }, { "auth_ref": "r36", "r37", "r38" }, { "ocx_ConvertiblePreferredStockDailyTradingVolumeThresholdStockTrigger": { "xbrltype": "sharesItemType", "nsuri": "http://oncoocyte.com/20240930", "localname": "ConvertiblePreferredStockDailyTradingVolumeThresholdStockTrigger", "presentation": "http://oncoocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative", "lang": "en-us", "role": "label", "Daily trading volume threshold common stock trigger", "label": "Convertible Preferred Stock Daily Trading Volume Threshold Stock Trigger", "documentation": "Convertible preferred stock daily trading volume threshold stock trigger." }, { "auth_ref": "us-gaap_ConvertiblePreferredStockTermsOfConversion": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertiblePreferredStockTermsOfConversion", "presentation": "http://oncoocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative", "lang": "en-us", "role": "label", "Conversion of stock, conditions", "documentation": "Description of conversion terms for preferred stock." }, { "auth_ref": "r25", "r57", "r60", "r103", "r144", "r145" }, { "ocx_ConvertiblePreferredStockThresholdConsecutiveTradingDays": { "xbrltype": "integerItemType", "nsuri": "http://oncoocyte.com/20240930", "localname": "ConvertiblePreferredStockThresholdConsecutiveTradingDays", "presentation": "http://oncoocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative", "lang": "en-us", "role": "label", "Threshold consecutive trading days", "label": "Convertible Preferred Stock Threshold Consecutive Trading Days", "documentation": "Convertible preferred stock threshold consecutive trading days." }, { "auth_ref": "ocx_ConvertiblePreferredStockThresholdPercentageOfConversionPriceTrigger": { "xbrltype": "percentItemType", "nsuri": "http://oncoocyte.com/20240930", "localname": "ConvertiblePreferredStockThresholdPercentageOfConversionPriceTrigger", "presentation": "http://oncoocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative", "lang": "en-us", "role": "label", "Threshold percentage of conversion price trigger", "label": "Convertible Preferred Stock Threshold Percentage of Conversion Price Trigger", "documentation": "Convertible preferred stock threshold percentage of conversion price trigger." }, { "auth_ref": "ocx_ConvertiblePreferredStockThresholdTradingDays": { "xbrltype": "integerItemType", "nsuri": "http://oncoocyte.com/20240930", "localname": "ConvertiblePreferredStockThresholdTradingDays", "presentation": "http://oncoocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative", "lang": "en-us", "role": "label", "Threshold consecutive trading days", "label": "Convertible Preferred Stock Threshold Consecutive Trading Days", "documentation": "Convertible preferred stock threshold consecutive trading days." }, { "auth_ref": "ocx_ConvertiblePreferredStockThresholdPercentageOfConversionPriceTrigger": { "xbrltype": "percentItemType", "nsuri": "http://oncoocyte.com/20240930", "localname": "ConvertiblePreferredStockThresholdPercentageOfConversionPriceTrigger", "presentation": "http://oncoocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative", "lang": "en-us", "role": "label", "Threshold percentage of conversion price trigger", "label": "Convertible Preferred Stock Threshold Percentage of Conversion Price Trigger", "documentation": "Convertible preferred stock threshold percentage of conversion price trigger." }, { "auth_ref": "ocx_ConvertiblePreferredStockThresholdTradingDays": { "xbrltype": "integerItemType", "nsuri": "http://oncoocyte.com/20240930", "localname": "ConvertiblePreferredStockThresholdTradingDays", "presentation": "http://oncoocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative", "lang": "en-us", "role": "label", "Threshold consecutive trading days", "label": "Convertible Preferred Stock Threshold Consecutive Trading Days", "documentation": "Convertible preferred stock threshold consecutive trading days." }, { "auth_ref": "ocx_ConvertiblePreferredStockThresholdPercentageOfConversionPriceTrigger": { "xbrltype": "percentItemType", "nsuri": "http://oncoocyte.com/20240930", "localname": "ConvertiblePreferredStockThresholdPercentageOfConversionPriceTrigger", "presentation": "http://oncoocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative", "lang": "en-us", "role": "label", "Threshold percentage of conversion price trigger", "label": "Convertible Preferred Stock Threshold Percentage of Conversion Price Trigger", "documentation": "Convertible preferred stock threshold percentage of conversion price trigger." }, { "auth_ref": "ocx_ConvertiblePreferredStockThresholdTradingDays": { "xbrltype": "integerItemType", "nsuri": "http://oncoocyte.com/20240930", "localname": "Convertible
```


"en-us": { "role": { "terseLabel": "Trading days", "label": "Convertible Preferred Stock Threshold Trading Days", "documentation": "Convertible preferred stock threshold trading days." } }, "auth_ref": { } }, "us-gaap-CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfRevenue", "crdr": "debit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/StatementsOfOperations": { "lang": { "en-us": { "role": { "label": "Cost of revenues", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": { "r114", "r228", "r282", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r481", "r555", "r974" } }, "ocx-CostOfRevenuesAmortizationOfAcquiredIntangibles": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "CostOfRevenuesAmortizationOfAcquiredIntangibles", "crdr": "debit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/StatementsOfOperations": { "lang": { "en-us": { "role": { "label": "Cost of revenues \u2013 2013 amortization of acquired intangibles", "documentation": "Cost of revenues & amortization of acquired intangibles." } } }, "auth_ref": { } }, "ocx-CostOfRevenuesMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "CostOfRevenuesMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/SummaryOfStock-basedCompensationExpenseDetails": { "lang": { "en-us": { "role": { "label": "Cost Of Revenues [Member]", "documentation": "Cost Of Revenues [Member]" } } }, "auth_ref": { } }, "us-gaap-CostOfSalesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfSalesPolicyTextBlock", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies": { "lang": { "en-us": { "role": { "label": "Cost of Revenues", "documentation": "Disclosure of accounting policy for cost of product sold and service rendered." } } }, "auth_ref": { "r916" } }, "us-gaap-CostsAndExpensesRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpensesRelatedParty", "crdr": "debit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative": { "lang": { "en-us": { "role": { "terseLabel": "Laboratory related costs", "label": "Laboratory related expenses", "documentation": "Costs of sales and operating expenses for the period incurred from transactions with related parties." } } }, "auth_ref": { "r114" } }, "dei-CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": { } }, "ocx-CumulativeChangeInAccountingPrinciple": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "CumulativeChangeInAccountingPrinciple", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/StatementsOfSeriesRedeemableConvertiblePreferredStockAndShareholdersEquity": { "lang": { "en-us": { "role": { "label": "Cumulative change in accounting principle (Note 2)", "documentation": "Cumulative change in accounting principle." } } }, "auth_ref": { } }, "dei-CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/Cover": { "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format \u2013MM-DD." } } }, "auth_ref": { } }, "us-gaap-CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConsolidatedRevenuesGeneratedByUn": { "lang": { "en-us": { "role": { "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": { "r130", "r276" } }, "ocx-CustomerFourMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "CustomerFourMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label": "Customer Four [Member]", "documentation": "Customer four." } } }, "auth_ref": { } }, "ocx-CustomerOneMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "CustomerOneMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label": "Customer One [Member]", "documentation": "Customer One [Member]" } } }, "auth_ref": { } }, "us-gaap-CustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerRelationshipsMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/ScheduleOfIntangibleAssetsNetDetails": { "lang": { "en-us": { "role": { "label": "Customer Relationships [Member]", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships." } } }, "auth_ref": { "r65", "r956", "r957", "r958", "r959", "r961", "r962", "r965", "r966" } }, "ocx-CustomerThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "CustomerThreeMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label": "Customer Three [Member]", "documentation": "Customer three." } } }, "auth_ref": { } }, "ocx-CustomerTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "CustomerTwoMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label": "Customer Two [Member]", "documentation": "Customer Two [Member]" } } }, "auth_ref": { } }, "country_DE": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "DE", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Germany [Member]", "label": "GERMANY" } } }, "auth_ref": { } }, "ocx-DeemedDividendOnSeriesRedeemableConvertiblePreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "DeemedDividendOnSeriesRedeemableConvertiblePreferredStock", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCommonStockComputationOfDiluted": { "http://oncocyte.com/20240930/taxonomy/role/StatementsOfSeriesRedeemableConvertiblePreferredStockAndShareholdersEquity": { "lang": { "en-us": { "role": { "label": "Deemed dividend on Series A redeemable convertible preferred stock", "documentation": "Deemed dividend on Series A redeemable convertible preferred stock." } } }, "auth_ref": { } }, "us-gaap-DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/BalanceSheets": { "http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative": { "lang": { "en-us": { "role": { "terseLabel": "Deferred financing costs", "label": "Debt Issuance Costs, Net", "totalLabel": "Debt Issuance Costs, Net, Total", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": { "r977", "r1021", "r1022", "r1023" } }, "us-gaap-DefinedBenefitPlanContributionsByEmployer": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanContributionsByEmployer", "crdr": "debit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label": "Total contributions to the plan", "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets." } } }, "auth_ref": { "r363", "r366", "r379", "r765", "r766", "r767", "r768" } }, "us-gaap-DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationAndAmortization", "crdr": "debit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentDetailsNarrative": { "http://oncocyte.com/20240930/taxonomy/role/StatementsOfCashFlows": { "lang": { "en-us": { "role": { "label": "Depreciation and amortization expense", "verboseLabel": "Depreciation expense", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": { "r14", "r52" } }, "us-gaap-DerivativeAssetsLiabilitiesAtFairValueNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssetsLiabilitiesAtFairValueNet", "crdr": "debit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentDetailsNarrative": { "lang": { "en-us": { "role": { "terseLabel": "Derivative assets liabilities at fair value net", "label": "Derivative Assets (Liabilities), at Fair Value, Net", "totalLabel": "Derivative Assets (Liabilities), at Fair Value, Net, Total", "documentation": "Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments." } } }, "auth_ref": { "r15", "r1017", "r1018", "r1019" } }, "us-gaap-DerivativeLiabilityMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilityMeasurementInput", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentDetailsNarrative": { "lang": { "en-us": { "role": { "terseLabel": "Derivative liability measurement input", "label": "Derivative Liability, Measurement Input", "documentation": "Value of input used to measure derivative liability." } } }, "auth_ref": { "r471", "r472", "r473" } }, "ocx-DetermaCNIAndVitaGraftMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "DetermaCNIAndVitaGraftMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/ScheduleOfIntangibleAssetsNetDetails": { "lang": { "en-us": { "role": { "terseLabel": "DetermaCNI and VitaGraft [Member]", "label": "DetermaCNI and VitaGraft+ [Member]", "documentation": "DetermaCNI and VitaGraft [Member]" } } }, "auth_ref": { } }, "ocx-DetermaIOMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "DetermaIOMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/ScheduleOfIntangibleAssetsNetDetailsNarrative": { "http://oncocyte.com/20240930/taxonomy/role/ScheduleOfIntangibleAssetsNetDetails": { "lang": { "en-us": { "role": { "label": "DetermaIO [Member]", "documentation": "DetermaIO [Member]" } } }, "auth_ref": { } }, "us-gaap-DevelopmentCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DevelopmentCosts", "crdr": "debit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/CollaborativeArrangementsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Development

costs", "documentation": "Amount of capitalized development cost incurred during period and excluded from amortization for oil- and gas-producing activities accounted for under full cost method. Excludes acquisition and exploration costs and capitalized interest." } } }, "auth_ref": { "r1039", "r1040" } }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables", "lang": { "en-us": { "role": { "label": "Schedule of Disaggregation of Revenue", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": { "r980" } }, "ocx_DisclosureCollaborativeArrangementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "DisclosureCollaborativeArrangementsAbstract", "lang": { "en-us": { "role": { "label": "Collaborative Arrangements" } } }, "auth_ref": { } }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/Stock-basedCompensation", "lang": { "en-us": { "role": { "label": "Stock-Based Compensation", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": { "r385", "r388", "r416", "r417", "r419", "r772" } }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": { } }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCommonStockComputationOfDiluted", "lang": { "en-us": { "role": { "label": "Loss from discontinued operations", "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": { "r76", "r77", "r78", "r79", "r80", "r86", "r113", "r1046" } }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "lang": { "en-us": { "role": { "label": "Discontinued Operations and Disposal Groups [Abstract]" } } }, "auth_ref": { } }, "us-gaap_DiscontinuedOperationsHeldforsaleMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationsHeldforsaleMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DiscontinuedOperationsOfRazorTables", "http://oncocyte.com/20240930/taxonomy/role/ScheduleOfAssetsAndLiabilitiesDiscontinuedOperationsDetails", "http://oncocyte.com/20240930/taxonomy/role/ScheduleOfDiscontinuedOperationsDetails", "lang": { "en-us": { "role": { "label": "Discontinued Operations, Held-for-Sale [Member]", "documentation": "Component or group of components representing strategic shift that has or will have major effect on operation and financial result and business and nonprofit activity on acquisition and upon joint venture formation, classified as held-for-sale." } } }, "auth_ref": { "r8", "r9", "r189" } }, "us-gaap_DiscontinuedOperationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationsPolicyTextBlock", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies", "lang": { "en-us": { "role": { "label": "Assets Held for Sale and Discontinued Operations", "documentation": "Disclosure of accounting policy for discontinued operations. Includes, but is not limited to, method of interest allocation to a discontinued operation." } } }, "auth_ref": { "r17", "r27" } }, "ocx_DiscountPeriodOnExpectedLifeOfPatent": { "xbrltype": "durationItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "DiscountPeriodOnExpectedLifeOfPatent", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/IntangibleAssetsNetDetailsNarrative", "lang": { "en-us": { "role": { "label": "Unobservable measurement input, discount period on expected life of patent", "documentation": "Discount Period On Expected Life Of Patent" } } }, "auth_ref": { } }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationAxis", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DiscontinuedOperationsOfRazorTables", "http://oncocyte.com/20240930/taxonomy/role/ScheduleOfAssetsAndLiabilitiesDiscontinuedOperationsDetails", "http://oncocyte.com/20240930/taxonomy/role/ScheduleOfDiscontinuedOperationsDetails", "lang": { "en-us": { "role": { "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": { "r189" } }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationDomain", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DiscontinuedOperationsOfRazorTables", "http://oncocyte.com/20240930/taxonomy/role/ScheduleOfAssetsAndLiabilitiesDiscontinuedOperationsDetails", "http://oncocyte.com/20240930/taxonomy/role/ScheduleOfDiscontinuedOperationsDetails", "lang": { "en-us": { "role": { "label": "Disposal Group Classification [Domain]", "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": { } }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DiscontinuedOperationsOfRazorDetailsNarrative", "lang": { "en-us": { "role": { "label": "Accounts payable current", "documentation": "Amount classified as accounts payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": { "r4", "r75", "r89", "r135", "r138" } }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold", "crdr": "debit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/ScheduleOfDiscontinuedOperationsDetails", "lang": { "en-us": { "role": { "label": "Cost of revenues", "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": { "r87", "r190" } }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense", "crdr": "debit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/ScheduleOfDiscontinuedOperationsDetails", "lang": { "en-us": { "role": { "label": "General and administrative", "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": { "r87" } }, "ocx_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment", "crdr": "debit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/ScheduleOfDiscontinuedOperationsDetails", "lang": { "en-us": { "role": { "label": "Research and development", "documentation": "Disposal group including discontinued operation research and development." } } }, "auth_ref": { } }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/ScheduleOfDiscontinuedOperationsDetails", "lang": { "en-us": { "role": { "label": "Net revenue", "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": { "r87", "r190" } }, "ocx_DisposalGroupIncludingDiscontinuedOperationSalesAndMarketing": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "DisposalGroupIncludingDiscontinuedOperationSalesAndMarketing", "crdr": "debit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/ScheduleOfDiscontinuedOperationsDetails", "lang": { "en-us": { "role": { "label": "Sales and marketing", "documentation": "Disposal group including discontinued operation sales and marketing." } } }, "auth_ref": { } }, "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPriorPeriodRevisionsDetails", "http://oncocyte.com/20240930/taxonomy/role/StatementsOfCashFlows", "lang": { "en-us": { "role": { "label": "Loss on disposal of discontinued operations", "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations." } } }, "auth_ref": { "r313", "r931", "r968" } }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DiscontinuedOperationsOfRazor", "lang": { "en-us": { "role": { "label": "Discontinued Operations of Razor", "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": { "r74", "r133" } }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/ScheduleOfAssetsAndLiabilitiesDiscontinuedOperationsDetails", "http://oncocyte.com/20240930/taxonomy/role/ScheduleOfDiscontinuedOperationsDetails", "lang": { "en-us": { "role": { "label": "Disposal Group

"Name": "Name of disposal group." } } }, {"auth_ref": "r769", "r770", "us-gAAP Dividends": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Dividends", "crdr": "debit", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Number of stock redeem value.", "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock." } } }, "auth_ref": { "r10", "r146" } }, "dei DocumentFiscalPeriodFocus": { "xbrlType": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/Cover": { "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": { "r11", "dei DocumentFiscalYearFocus": { "xbrlType": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/Cover": { "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": { "dei DocumentPeriodEndDate": { "xbrlType": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/Cover": { "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K, the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A, the filing date; for all other submission types, the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": { "dei DocumentQuarterlyReport": { "xbrlType": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/Cover": { "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": { "r815" } }, "dei DocumentTransitionReport": { "xbrlType": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/Cover": { "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": { "r847" } } }, "dei DocumentType": { "xbrlType": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/Cover": { "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": { "ocx DragonScientificLLCMember": { "xbrlType": "domainItemType", "nsuri": "http://oncoocyte.com/20240930", "localname": "DragonScientificLLCMember", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/DiscontinuedOperationsOfRazorDetailsNarrative": { "http://oncoocyte.com/20240930/taxonomy/role/OrganizationAndDescriptionOfBusinessDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Dragon Scientific LLC [Member]", "documentation": "Dragon Scientific LLC [Member]" } } }, "auth_ref": { "ecd DvddsOrOthrErngsPdOnEqtyAwrdNtOthrRsRflctdInTtlCompForCvrdYrMember": { "xbrlType": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdNtOthrRsRflctdInTtlCompForCvrdYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PypDisclosure": { "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": { "r858" } }, "us-gAAP EarningsPerShareAbstract": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/StatementsOfOperations": { "lang": { "en-us": { "role": { "label": "Net loss per share (Note 2)." } } }, "auth_ref": { "r11", "us-gAAP EarningsPerShareBasic": { "xbrlType": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCommonStockComputationOfDiluted": { "http://oncoocyte.com/20240930/taxonomy/role/StatementsOfOperations": { "lang": { "en-us": { "role": { "totalLabel": "Net loss attributable to common stockholders per share - basic", "label": "Net (loss) income attributable to common stockholders per share - basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": { "r218", "r234", "r235", "r237", "r238", "r239", "r241", "r246", "r249", "r257", "r258", "r259", "r262", "r445", "r452", "r467", "r468", "r569", "r592", "r752" } }, "us-gAAP EarningsPerShareDiluted": { "xbrlType": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCommonStockComputationOfDiluted": { "http://oncoocyte.com/20240930/taxonomy/role/StatementsOfOperations": { "lang": { "en-us": { "role": { "totalLabel": "Net loss attributable to common stockholders per share - diluted", "label": "Net (loss) income attributable to common stockholders per share - diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": { "r218", "r234", "r235", "r237", "r238", "r239", "r241", "r249", "r257", "r258", "r259", "r262", "r445", "r452", "r467", "r468", "r569", "r592", "r752" } }, "us-gAAP EarningsPerSharePolicyTextBlock": { "xbrlType": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/SummaryOfSignificantAccountingPolicies": { "lang": { "en-us": { "role": { "label": "Net Loss Per Common Share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": { "r40", "r41", "r261" } }, "ocx EarnoutPercentageOnCollectionsForSale": { "xbrlType": "percentItemType", "nsuri": "http://oncoocyte.com/20240930", "localname": "EarnoutPercentageOnCollectionsForSale", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label": "Gross proceeds percentage", "documentation": "Earnout percentage on collections for sale." } } }, "auth_ref": { "ocx EarnoutPercentageOnCollectionsForSales": { "xbrlType": "percentItemType", "nsuri": "http://oncoocyte.com/20240930", "localname": "EarnoutPercentageOnCollectionsForSales", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label": "Earnout percentage on collections for sales", "documentation": "Earnout percentage on collections for sales." } } }, "auth_ref": { "us-gAAP EmployeeBenefitsAndShareBasedCompensation": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeBenefitsAndShareBasedCompensation", "crdr": "debit", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/SummaryOfStockOptionActivityDetails": { "lang": { "en-us": { "role": { "label": "Stock-based compensation expense for the period", "documentation": "Amount of expense for employee benefit and equity-based compensation." } } }, "auth_ref": { "us-gAAP EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/SummaryOfStock-basedCompensationExpenseDetails": { "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "us-gAAP EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/Stock-basedCompensationDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Unrecognized stock based compensation expense", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": { "r418" } }, "us-gAAP EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrlType": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/Stock-basedCompensationDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Weighted average remaining recognition period", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in PnYnMnDtHnMnS format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r418" } }, "us-gAAP EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/SummaryOfStockOptionActivityDetails": { "lang": { "en-us": { "role": { "label": "Unrecognized stock based compensation expense for RSUs", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": { "r1007" } }, "us-gAAP EmployeeStockOptionMember": { "xbrlType": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "label":

"Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": { } }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": { } }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": { } }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": { } }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": { } }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": { "r813" } }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": { } }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": { } }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/CollaborativeArrangementsDetailsNarrative", "http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesAdditionalInformationDetails", "http://oncocyte.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative", "http://oncocyte.com/20240930/taxonomy/role/IntangibleAssetsNetDetailsNarrative", "http://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative", "http://oncocyte.com/20240930/taxonomy/role/ScheduleOfIntangibleAssetsNetDetails" }, "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": { } }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": { "r813" } }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/Cover" }, "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": { } }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": { "r813" } }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": { } }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": { "r897" } }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": { "r813" } }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": { "r813" } }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": { "r813" } }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": { "r813" } }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": { "r852" } }, "ecd_EqtyAwrdsAdjExclgValRprtdInSummaryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjExclgValRprtdInSummaryCompstnTblMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": { "r893" } }, "ecd_EqtyAwrdsAdjMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": { "r893" } }, "ecd_EqtyAwrdsInSummaryCompstnTblForAplblyrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummaryCompstnTblForAplblyrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": { "r893" } }, "us-gaap_EquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquipmentMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "label": "Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services." } } }, "auth_ref": { } }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": { } }, "ocx_EquityCompensationForBonusAwardsAndConsultingServices": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "EquityCompensationForBonusAwardsAndConsultingServices", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/StatementsOfCashFlows" }, "lang": { "en-us": { "role": { "label": "Equity compensation for bonus awards and consulting services", "documentation": "Equity compensation for bonus awards and consulting services." } } }, "auth_ref": { } }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSubsequentEventsDetailsNarrative", "http://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative", "http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative", "http://oncocyte.com/20240930/taxonomy/role/StatementsOfSeriesRedeemableConvertiblePreferredStockAndShareholdersEquity" }, "lang": { "en-

us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } }, "auth_ref": { "r20", "r186", "r214", "r215", "r216", "r229", "r230", "r231", "r233", "r239", "r242", "r244", "r264", "r283", "r286", "r312", "r351", "r438", "r439", "r442", "r443", "r444", "r446", "r451", "r452", "r458", "r459", "r460", "r461", "r462", "r463", "r466", "r482", "r483", "r484", "r485", "r486", "r487", "r490", "r492", "r514", "r589", "r604", "r605", "r606", "r629", "r700" } }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "EquityMethodInvesteeNameDomain", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DiscontinuedOperationsOfRazorDetailsNarrative", "http://oncocyte.com/20240930/taxonomy/role/OrganizationAndDescriptionOfBusinessDetailsNarrative", "http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative" } }, "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } }, "auth_ref": { "r279", "r280", "r281", "r441", "r900", "r901", "r902", "r1011", "r1012", "r1013", "r1014" } }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DiscontinuedOperationsOfRazorDetailsNarrative", "http://oncocyte.com/20240930/taxonomy/role/OrganizationAndDescriptionOfBusinessDetailsNarrative", "http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative" } }, "lang": { "en-us": { "role": { "label": "Equity interest", "verboseLabel": "Ownership percentage", "terseLabel": "Equity method investment ownership percentage", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } }, "auth_ref": { "r279" } }, "us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentRealizedGainLossOnDisposal", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DiscontinuedOperationsOfRazorDetailsNarrative" } }, "lang": { "en-us": { "role": { "negatedLabel": "Loss on disposal", "label": "Equity Method Investment, Realized Gain (Loss) on Disposal", "documentation": "Amount of gain (loss) on sale or disposal of an equity method investment." } }, "auth_ref": { "r928", "r929", "r931" } }, "us-gaap_EquityMethodInvestmentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentsPolicy", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" } }, "lang": { "en-us": { "role": { "label": "Investments in Privately Held Companies", "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received." } }, "auth_ref": { "r11", "r69", "r280" } }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } }, "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } }, "auth_ref": { "r862" } }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" } }, "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } }, "auth_ref": { "r820", "r830", "r840", "r872" } }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" } }, "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } }, "auth_ref": { "r817", "r827", "r837", "r869" } }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } }, "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category" } }, "auth_ref": { "r868" } }, "ocx_ExecutiveOfficersMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "ExecutiveOfficersMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative" } }, "lang": { "en-us": { "role": { "label": "Executive Officers [Member]", "documentation": "Executive Officers [Member]" } }, "auth_ref": { "ocx_ExpenseIncludedInDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "ExpenseIncludedInDiscontinuedOperationsMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/SummaryOfStock-basedCompensationExpenseDetails" } }, "lang": { "en-us": { "role": { "label": "Expense Included In Discontinued Operations [Member]", "documentation": "Expense Included In Discontinued Operations [Member]" } }, "auth_ref": { "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentDetailsNarrative" } }, "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } }, "auth_ref": { "r471", "r472", "r473", "r779" } }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentDetailsNarrative" } }, "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } }, "auth_ref": { "r471", "r472", "r473", "r779" } }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesAdditionalInformationDetails" } }, "http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesScheduleOfContingentConsid", "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } }, "auth_ref": { "r332", "r366", "r367", "r368", "r369", "r370", "r371", "r469", "r470", "r471", "r472", "r473", "r477", "r478", "r480", "r524", "r525", "r526", "r759", "r760", "r765", "r766", "r767", "r776", "r779" } }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesAdditionalInformationDetails" } }, "http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesScheduleOfContingentConsid", "lang": { "en-us": { "role": { "terseLabel": "Level 3 [Member]", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } }, "auth_ref": { "r332", "r366", "r367", "r368", "r369", "r370", "r371", "r470", "r471", "r472", "r473", "r477", "r478", "r524", "r525", "r526", "r759", "r760", "r765", "r766", "r767", "r776", "r779" } }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesAdditionalInformationDetails" } }, "http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesScheduleOfContingentConsid", "http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesScheduleOfContingentConsid", "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } }, "auth_ref": { "r332", "r366", "r367", "r368", "r369", "r370", "r371", "r469", "r470", "r471", "r472", "r473", "r477", "r478", "r480", "r524", "r525", "r526", "r759", "r760", "r765", "r766", "r767", "r776", "r779" } }, "us-gaap_FairValueMeasurementsSensitivityAnalysisDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsSensitivityAnalysisDescription", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesAdditionalInformationDetails" } }, "http://oncocyte.com/20240930/taxonomy/role/IntangibleAssetsNetDetailsNarrative", "lang": { "en-us": { "role": { "label": "Unobservable Measurement Input, Uncertainty, Description", "verboseLabel": "Unobservable measurement input, uncertainty, description", "documentation": "Description of uncertainty of fair value measurement from use of unobservable input, including, but not limited to, inter-relationships among inputs used in fair value measurement." } }, "auth_ref": { "r476" } }, "ocx_FairValueOfContingentConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "FairValueOfContingentConsideration", "crdr": "debit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesAdditionalInformationDetails" } }, "lang": { "en-us": { "role": { "label": "Fair value", "documentation": "Fair value of contingent consideration." } }, "auth_ref": { "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseInterestPaymentOnLiability", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureScheduleOfSupplementalCashFlowInformationRelatedToOperatingAndFinancingLeaseDeta", "lang": { "en-us": { "role": { "label": "Operating cash flows from financing leases", "documentation": "Amount of interest paid on finance lease liability." } }, "auth_ref": { "r496", "r504" } }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "presentation": {

"http://oncocyte.com/20240930/taxonomy/role/DisclosureScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails"
l, "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": { }, "us-gaap_FinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiability", "crdr": "credit", "presentation": { }
"http://oncocyte.com/20240930/taxonomy/role/DisclosureScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails"
"http://oncocyte.com/20240930/taxonomy/role/DisclosureScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeases"
l, "lang": { "en-us": { "role": { "label": "Finance Lease", "totalLabel": "Total financing lease liabilities", "verboseLabel": "Present value of net minimum lease payments", "label": "Finance Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease." } } }, "auth_ref": { "r494", "r507" } }, "us-gaap_FinanceLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityCurrent", "crdr": "credit", "presentation": { }
"http://oncocyte.com/20240930/taxonomy/role/DisclosureScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeases"
l, "lang": { "en-us": { "role": { "label": "Current liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current." } } }, "auth_ref": { "r494" } }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": { }
"http://oncocyte.com/20240930/taxonomy/role/DisclosureScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeases"
l, "lang": { "en-us": { "role": { "label": "Noncurrent liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent." } } }, "auth_ref": { "r494" } }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": { }
"http://oncocyte.com/20240930/taxonomy/role/DisclosureScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails"
l, "lang": { "en-us": { "role": { "totalLabel": "Total minimum lease payments", "label": "Finance Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease." } } }, "auth_ref": { "r507" } }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": { }
"http://oncocyte.com/20240930/taxonomy/role/DisclosureScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails"
l, "lang": { "en-us": { "role": { "verboseLabel": "2025", "label": "Finance Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r507" } }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": { }
"http://oncocyte.com/20240930/taxonomy/role/DisclosureScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails"
l, "lang": { "en-us": { "role": { "verboseLabel": "2027", "label": "Finance Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r507" } }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": { }
"http://oncocyte.com/20240930/taxonomy/role/DisclosureScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails"
l, "lang": { "en-us": { "role": { "verboseLabel": "2026", "label": "Finance Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r507" } }, "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "presentation": { }
"http://oncocyte.com/20240930/taxonomy/role/DisclosureScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails"
l, "lang": { "en-us": { "role": { "verboseLabel": "2024", "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year." } } }, "auth_ref": { "r1025" } }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": { }
"http://oncocyte.com/20240930/taxonomy/role/DisclosureScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails"
l, "lang": { "en-us": { "role": { "negatedLabel": "Less amounts representing interest", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease." } } }, "auth_ref": { "r507" } }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "presentation": { }
"http://oncocyte.com/20240930/taxonomy/role/DisclosureScheduleOfSupplementalCashFlowInformationRelatedToOperatingAndFinancingLeasesDetails"
"http://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative" l, "lang": { "en-us": { "role": { "label": "Finance lease payments", "label": "Financing cash flows from financing leases", "documentation": "Amount of cash outflow for principal payment on finance lease." } } }, "auth_ref": { "r495", "r504" } }, "us-gaap_FinanceLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAsset", "crdr": "debit", "presentation": { }
"http://oncocyte.com/20240930/taxonomy/role/BalanceSheets"
"http://oncocyte.com/20240930/taxonomy/role/DisclosureScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeases"
l, "lang": { "en-us": { "role": { "label": "Right-of-use and financing lease assets, net", "totalLabel": "Machinery and equipment, net", "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease." } } }, "auth_ref": { "r493" } }, "us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAssetAccumulatedAmortization", "crdr": "credit", "presentation": { }
"http://oncocyte.com/20240930/taxonomy/role/DisclosureScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeases"
l, "lang": { "en-us": { "role": { "negatedLabel": "Accumulated depreciation", "label": "Finance Lease, Right-of-Use Asset, Accumulated Amortization", "documentation": "Amount of accumulated amortization of right-of-use asset from finance lease." } } }, "auth_ref": { "r905", "r910" } }, "us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization", "crdr": "debit", "presentation": { }
"http://oncocyte.com/20240930/taxonomy/role/DisclosureScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeases"
l, "lang": { "en-us": { "role": { "label": "Machinery and equipment", "documentation": "Amount, before accumulated amortization, of right-of-use asset from finance lease." } } }, "auth_ref": { "r904" } }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "presentation": { }
"http://oncocyte.com/20240930/taxonomy/role/DisclosureScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeases"
l, "lang": { "en-us": { "role": { "label": "Weighted average discount rate, Financing lease", "documentation": "Weighted average discount rate for finance lease calculated at point in time." } } }, "auth_ref": { "r506", "r783" } }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "presentation": { }
"http://oncocyte.com/20240930/taxonomy/role/DisclosureScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeases"
l, "lang": { "en-us": { "role": { "label": "Weighted average remaining lease term, Financing lease", "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r505", "r783" } }, "ocx_FinancingCostsForAtTheMarketSalesIncludedInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "FinancingCostsForAtTheMarketSalesIncludedInAccruedLiabilities", "crdr": "debit", "presentation": { }
"http://oncocyte.com/20240930/taxonomy/role/StatementsOfCashFlows" l, "lang": { "en-us": { "role": { "label": "Financing costs for at-the-market sales included in accrued liabilities", "documentation": "Financing costs for at the market sales included in accrued liabilities." } } }, "auth_ref": { } }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": { }
"http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" l, "lang": { "en-us": { "role": { "label": "Long-lived intangible assets, useful life", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { }
l, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": { }
"http://oncocyte.com/20240930/taxonomy/role/ScheduleOfIntangibleAssetsNetDetails" l, "lang": { "en-us": { "role": { "negatedLabel": "Finite-lived intangible assets, accumulated amortization", "label": "Finite-lived intangible assets, accumulated amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": { "r197", "r294", "r303", "r758" } }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "presentation": { }
"http://oncocyte.com/20240930/taxonomy/role/ScheduleOfIntangibleAssetsFutureAmortizationExpenseDetails" l, "lang": { "en-us": { "role": { "label": "2025", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r305", "r743", "r758" } },

"us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "crdr": "debit", "presentation": "http://oncocyte.com/20240930/taxonomy/role/ScheduleOfIntangibleAssetsFutureAmortizationExpenseDetails" }, "lang": { "en-us": { "role": { "label": "2024", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year." } } }, "auth_ref": { "r1081" } }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": "http://oncocyte.com/20240930/taxonomy/role/ScheduleOfIntangibleAssetsNetDetails" }, "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": { "r296", "r298", "r299", "r300", "r302", "r303", "r307", "r308", "r535", "r536", "r743" } }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrlType": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": "http://oncocyte.com/20240930/taxonomy/role/ScheduleOfIntangibleAssetsNetDetails" }, "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": { "r296", "r298", "r299", "r300", "r302", "r303", "r307", "r308", "r743" } }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "presentation": "http://oncocyte.com/20240930/taxonomy/role/ScheduleOfIntangibleAssetsFutureAmortizationExpenseDetails" }, "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": { "r535", "r962" } }, "us-gaap_FiniteLivedIntangibleAssetsAcquired1": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "FiniteLivedIntangibleAssetsAcquired1", "crdr": "debit", "presentation": "http://oncocyte.com/20240930/taxonomy/role/ScheduleOfIntangibleAssetsNetDetails" }, "lang": { "en-us": { "role": { "label": "Acquired intangible assets", "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition." } } }, "auth_ref": { "r298" } }, "ocx_FirstTenCalendarMember": { "xbrlType": "domainItemType", "nsuri": "http://oncocyte.com/20240930", "localName": "FirstTenCalendarMember", "presentation": "http://oncocyte.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative" }, "lang": { "en-us": { "role": { "label": "First Ten Calendar [Member]", "documentation": "First Ten Calendar [Member]" } } }, "auth_ref": { } }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrlType": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localName": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": { "r824", "r834", "r844", "r876" } }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrlType": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localName": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": { "r824", "r834", "r844", "r876" } }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrlType": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localName": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": { "r824", "r834", "r844", "r876" } }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrlType": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localName": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": { "r824", "r834", "r844", "r876" } }, "ecd_ForgoneRecoveryIndName": { "xbrlType": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localName": "ForgoneRecoveryIndName", "presentation": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": { "r824", "r834", "r844", "r876" } }, "ecd_FrValAsOfPrYrEndOfEqtyAwrdsGrntdInPrYrsFldVstngCondsDrngCvrdYrMember": { "xbrlType": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localName": "FrValAsOfPrYrEndOfEqtyAwrdsGrntdInPrYrsFldVstngCondsDrngCvrdYrMember", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": { "r857" } }, "us-gaap_GainLossOnDispositionOfAssets1": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "GainLossOnDispositionOfAssets1", "crdr": "credit", "presentation": "http://oncocyte.com/20240930/taxonomy/role/StatementsOfCashFlows" }, "lang": { "en-us": { "role": { "negatedLabel": "Impairment loss on held for sale assets", "label": "Gain (Loss) on Disposition of Assets", "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee." } } }, "auth_ref": { "r931" } }, "us-gaap_GainLossOnSaleOfOtherAssets": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "GainLossOnSaleOfOtherAssets", "crdr": "credit", "presentation": "http://oncocyte.com/20240930/taxonomy/role/StatementsOfOperations" }, "lang": { "en-us": { "role": { "negatedLabel": "Impairment loss on held for sale assets", "label": "Gain (Loss) on Disposition of Other Assets", "documentation": "Amount of gain (loss) on sale or disposal of other assets." } } }, "auth_ref": { "r931" } }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "GeneralAndAdministrativeExpense", "crdr": "debit", "presentation": "http://oncocyte.com/20240930/taxonomy/role/StatementsOfOperations" }, "lang": { "en-us": { "role": { "totalLabel": "General and Administrative Expense, Total", "label": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": { "r116", "r680" } }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrlType": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "GeneralAndAdministrativeExpenseMember", "presentation": "http://oncocyte.com/20240930/taxonomy/role/SummaryOfStock-basedCompensationExpenseDetails" }, "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": { "r116" } }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": { } }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "xbrlType": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "GoodwillAndIntangibleAssetsPolicyTextBlock", "presentation": "http://oncocyte.com/20240930/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" }, "lang": { "en-us": { "role": { "label": "Intangible Assets", "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets." } } }, "auth_ref": { "r954", "r955" } }, "us-gaap_GrossProfit": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "GrossProfit", "crdr": "credit", "presentation": "http://oncocyte.com/20240930/taxonomy/role/StatementsOfOperations" }, "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": { "r110", "r114", "r170", "r228", "r282", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r481", "r754", "r755", "r943", "r944", "r945", "r946", "r947", "r974" } }, "ocx_HalleSpecialSituationsFundLLCMember": { "xbrlType": "domainItemType", "nsuri": "http://oncocyte.com/20240930", "localName": "HalleSpecialSituationsFundLLCMember", "presentation": "http://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative" }, "lang": { "en-us": { "role": { "label": "Halle Special Situations Fund LLC [Member]", "documentation": "Halle Special Situations Fund LLC [Member]" } } }, "auth_ref": { } }, "us-gaap_ImpairmentOfIntangibleAssetsFiniteLived": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "ImpairmentOfIntangibleAssetsFiniteLived", "crdr": "debit", "presentation": "http://oncocyte.com/20240930/taxonomy/role/IntangibleAssetsNetDetailsNarrative" }, "http://oncocyte.com/20240930/taxonomy/role/StatementsOfCashFlows", "http://oncocyte.com/20240930/taxonomy/role/StatementsOfOperations" }, "lang": { "en-us": { "role": { "label": "Impairment losses", "terseLabel": "Impairment losses", "verboseLabel": "Impairment of intangible assets", "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value." } } }, "auth_ref": { "r297", "r931", "r967" } }, "us-gaap_ImpairmentOfLeasehold": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "ImpairmentOfLeasehold", "crdr": "debit", "presentation": "http://oncocyte.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentDetailsNarrative" }, "lang": { "en-us": { "role": { "terseLabel": "Impairment of leasehold", "label": "Impairment of Leasehold", "documentation": "The adjustment to reduce the value of existing agreements that specify the lessee's rights to use the leased property. This expense is charged when the estimates of future profits generated by the leased property are reduced." } } }, "auth_ref": { "r14", "r51" } }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "ImpairmentOfLongLivedAssetsHeldForUse", "crdr": "debit", "presentation": "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Impairment loss on held for sale assets", "label": "Impairment, Long-Lived Asset, Held-for-Use", "totalLabel": "Impairment loss on held for sale assets, label: Impairment, Long-Lived Asset, Held-for-Use, totalLabel: "}}}

Impairment, Long-Lived Asset, Held-for-Use, Total", "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for use (including those held for disposal by means other than sale)." } } }, "auth_ref": { "r14", "r51", "r137", "r777" } }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies", "lang": { "en-us": { "role": { "label": "Impairment of Long-Lived Assets", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": { "r0", "r140" } }, "us-gaap_InProcessResearchAndDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InProcessResearchAndDevelopmentMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/ScheduleOfIntangibleAssetsNetDetails", "lang": { "en-us": { "role": { "label": "In Process Research and Development [Member]", "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process." } } }, "auth_ref": { "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r964", "r965", "r966" } }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCommonStockComputationOfDiluted", "lang": { "en-us": { "role": { "label": "Loss from continuing operations", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": { "r111", "r165", "r170", "r570", "r586", "r754", "r755", "r943", "r944", "r945", "r946", "r947" } }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/StatementsOfOperations", "lang": { "en-us": { "role": { "label": "Loss from continuing operations", "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest." } } }, "auth_ref": { "r157", "r170", "r228", "r232", "r239", "r282", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r445", "r452", "r468", "r481", "r586", "r754", "r943", "r944", "r945", "r946", "r947", "r974" } }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCommonStockComputationOfDiluted", "http://oncocyte.com/20240930/taxonomy/role/StatementsOfOperations", "lang": { "en-us": { "role": { "label": "Net loss from continuing operations per share - basic", "label": "Net (loss) income from continuing operations per share - basic", "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": { "r112", "r166", "r218", "r232", "r234", "r235", "r237", "r238", "r239", "r249", "r257", "r258", "r445", "r452", "r468", "r569", "r1047" } }, "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsPerDilutedShare", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/StatementsOfOperations", "lang": { "en-us": { "role": { "label": "Net loss from continuing operations per share - diluted", "label": "Net (loss) income from continuing operations per share - diluted", "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": { "r112", "r218", "r232", "r234", "r235", "r237", "r238", "r239", "r249", "r257", "r258", "r259", "r452", "r468", "r569", "r1047" } }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/ScheduleOfDiscontinuedOperationsDetails", "http://oncocyte.com/20240930/taxonomy/role/StatementsOfOperations", "lang": { "en-us": { "role": { "label": "Loss from discontinued operations (Note 1)", "label": "Net loss from discontinued operations", "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": { "r76", "r77", "r78", "r79", "r80", "r91", "r190", "r440", "r587" } }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCommonStockComputationOfDiluted", "http://oncocyte.com/20240930/taxonomy/role/StatementsOfOperations", "lang": { "en-us": { "role": { "label": "Net loss from discontinued operations per share - basic", "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation." } } }, "auth_ref": { "r113", "r218", "r250", "r257", "r258", "r1042", "r1047" } }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCommonStockComputationOfDiluted", "http://oncocyte.com/20240930/taxonomy/role/StatementsOfOperations", "lang": { "en-us": { "role": { "label": "Net loss from discontinued operations per share - diluted", "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation." } } }, "auth_ref": { "r158", "r250", "r257", "r258" } }, "us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToNoncontrollingInterest", "crdr": "debit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/ScheduleOfDiscontinuedOperationsDetails", "lang": { "en-us": { "role": { "label": "Loss from impairment of held for sale assets", "documentation": "Amount before tax of income (loss) from an individually significant component disposed of or held for sale attributable to noncontrolling interest. Excludes discontinued operations." } } }, "auth_ref": { "r11", "r112", "r113", "r218", "r250", "r257", "r258" } }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r17", "r23", "r26", "r75", "r81", "r82", "r83", "r84", "r85", "r90", "r92", "r93", "r139" } }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/ScheduleOfAssetsAndLiabilitiesDiscontinuedOperationsDetails", "http://oncocyte.com/20240930/taxonomy/role/DiscontinuedOperationsOfRazorTables", "lang": { "en-us": { "role": { "label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": { "r769", "r770" } }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/ScheduleOfAssetsAndLiabilitiesDiscontinuedOperationsDetails", "http://oncocyte.com/20240930/taxonomy/role/DiscontinuedOperationsOfRazorTables", "lang": { "en-us": { "role": { "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r17", "r23", "r26", "r75", "r81", "r82", "r83", "r84", "r85", "r90", "r92", "r93", "r139" } }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDisaggregationOfRevenueDetails", "http://oncocyte.com/20240930/taxonomy/role/SummaryOfStock-basedCompensationExpenseDetails", "lang": { "en-us": { "role": { "label": "Disposal Groups, Including Discontinued Operations [Table]", "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": { "r17", "r23", "r26", "r75", "r81", "r82", "r83", "r84", "r85", "r90", "r92", "r93", "r139" } }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDisaggregationOfRevenueDetails", "http://oncocyte.com/20240930/taxonomy/role/SummaryOfStock-basedCompensationExpenseDetails", "lang": { "en-us": { "role": { "label": "Disposal Groups, Including Discontinued Operations [Table]", "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": { "r17", "r23", "r26", "r75", "r81", "r82", "r83", "r84

```

Statement of Income Location, Balance [Axis], "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": { "r314", "r315", "r316", "r474", "r475", "r479", "r601", "r603", "r685", "r743", "r778", "r1049" } }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDisaggregationOfRevenueDetails": { "http://oncoocyte.com/20240930/taxonomy/role/SummaryOfStock-basedCompensationExpenseDetails" } }, "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": { "r315", "r316", "r474", "r475", "r479", "r601", "r603", "r685", "r743", "r778", "r1049" } }, "us-gaap_IncomeTaxAuthorityNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityNameAxis", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" } }, "lang": { "en-us": { "role": { "label": "Income Tax Authority, Name [Axis]", "documentation": "Information by name of taxing authority." } } }, "auth_ref": { "r429", "r1010" } }, "us-gaap_IncomeTaxAuthorityNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityNameDomain", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" } }, "lang": { "en-us": { "role": { "label": "Income Tax Authority, Name [Domain]", "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "auth_ref": { "r429", "r1010" } }, "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued", "crdr": "credit", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" } }, "lang": { "en-us": { "role": { "label": "Accrued interest and penalties", "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations." } } }, "auth_ref": { "r1009" } }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxPolicyTextBlock", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" } }, "lang": { "en-us": { "role": { "label": "Income Taxes", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": { "r213", "r427", "r428", "r431", "r432", "r433", "r437", "r620" } }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaidNet", "crdr": "debit", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/StatementsOfCashFlows" } }, "lang": { "en-us": { "role": { "label": "Cash paid for income taxes", "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": { "r35", "r224", "r434", "r435" } }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/StatementsOfCashFlows" } }, "lang": { "en-us": { "role": { "label": "Accounts payable and accrued liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": { "r13" } }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/StatementsOfCashFlows" } }, "lang": { "en-us": { "role": { "label": "Accounts receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": { "r13" } }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/StatementsOfCashFlows" } }, "lang": { "en-us": { "role": { "label": "Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": { "r13" } }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/StatementsOfCashFlows" } }, "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities." } } }, "auth_ref": { "r13" } }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/StatementsOfCashFlows" } }, "lang": { "en-us": { "role": { "label": "Lease assets and liabilities", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": { "r911", "r930" } }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/StatementsOfCashFlows" } }, "lang": { "en-us": { "role": { "label": "Prepaid expenses and other assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": { "r13" } }, "ocx_IndebtednessExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://oncoocyte.com/20240930", "localname": "IndebtednessExpenses", "crdr": "debit", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative" } }, "lang": { "en-us": { "role": { "label": "Indebtedness expenses", "documentation": "Indebtedness expenses." } } }, "auth_ref": { "r13" } }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/ScheduleOfIntangibleAssetsNetDetails" } }, "lang": { "en-us": { "role": { "label": "Indefinite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r296", "r306", "r310", "r758" } }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/ScheduleOfIntangibleAssetsNetDetails" } }, "lang": { "en-us": { "role": { "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "auth_ref": { "r296", "r301", "r306", "r758" } }, "us-gaap_IndefiniteLivedIntangibleAssetsAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsAcquired", "crdr": "debit", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/ScheduleOfIntangibleAssetsNetDetails" } }, "lang": { "en-us": { "role": { "label": "Intangible assets acquired", "documentation": "Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition." } } }, "auth_ref": { "r301", "r964" } }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } }, "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual." } } }, "auth_ref": { "r824", "r834", "r844", "r868", "r876", "r880", "r889" } }, "ocx_InitialCapitalizedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://oncoocyte.com/20240930", "localname": "InitialCapitalizedAmount", "crdr": "credit", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative" } }, "lang": { "en-us": { "role": { "label": "Initial capitalized total value", "documentation": "Initial capitalized amount." } } }, "auth_ref": { "r13" } }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures Adopted [Flag]", "documentation": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": { "r816", "r892" } }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProcLineItems" } }, "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": { "r816", "r892" } }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": {

```

"http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" }, "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": { "r816", "r892" } }, "ocx_InsightGeneticsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "InsightGeneticsIncMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/BusinessCombinationsAndContingentConsiderationLiabilitiesTables", "http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesAdditionalInformationDetails", "http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesScheduleOfContingentConsiderationLiabilities", "http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesScheduleOfFairValueOfContingentConsiderationLiabilities", "lang": { "en-us": { "role": { "label": "Insight Genetics Inc [Member]", "documentation": "Insight Genetics Inc [Member]" } } }, "auth_ref": { "us-gaap_IntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsDisclosureTextBlock", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/IntangibleAssetsNet", "lang": { "en-us": { "role": { "label": "Intangible Assets, Net", "documentation": "The entire disclosure for all or part of the information related to intangible assets." } } }, "auth_ref": { "r295", "r309", "r311", "r742", "r743" } }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsFiniteLivedPolicy", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/ScheduleOfIntangibleAssetsNetDetails", "lang": { "en-us": { "role": { "label": "Total intangible assets", "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill." } } }, "auth_ref": { "r196" } }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/BalanceSheets", "http://oncocyte.com/20240930/taxonomy/role/ScheduleOfIntangibleAssetsNetDetails", "lang": { "en-us": { "role": { "totalLabel": "Intangible assets, net", "label": "Intangible assets, net", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": { "r296", "r962", "r964" } }, "us-gaap_InterestIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeExpenseNet", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/CollaborativeArrangementsDetailsNarrative", "http://oncocyte.com/20240930/taxonomy/role/StatementsOfOperations", "lang": { "en-us": { "role": { "negatedLabel": "Interest expense", "totalLabel": "Interest Income (Expense), Operating, Total", "label": "Interest expense", "documentation": "Amount of interest income (expense) classified as operating." } } }, "auth_ref": { "r567", "r944" } }, "ocx_InterestMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "InterestMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative", "lang": { "en-us": { "role": { "label": "Interest [Member]", "documentation": "Interest [Member]" } } }, "auth_ref": { "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/StatementsOfCashFlows", "lang": { "en-us": { "role": { "label": "Cash paid for interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": { "r220", "r222", "r223" } }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/BalanceSheets", "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Inventory, Net", "totalLabel": "Inventory, Net, Total", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": { "r207", "r748", "r784" } }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryPolicyTextBlock", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/SummaryOfSignificantAccountingPolicies", "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Inventory, Policy [Policy Text Block]", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": { "r175", "r193", "r206", "r290", "r291", "r293", "r530", "r751" } }, "us-gaap_InventoryRawMaterialsAndSupplies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterialsAndSupplies", "crdr": "debit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Inventory, Raw Materials and Supplies, Gross", "totalLabel": "Inventory, Raw Materials and Supplies, Gross, Total", "documentation": "Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed." } } }, "auth_ref": { "r922" } }, "us-gaap_InventoryWriteDown": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWriteDown", "crdr": "debit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "Inventory write down", "label": "Inventory Write down", "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels." } } }, "auth_ref": { "r292" } }, "ocx_InvestorsMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "InvestorsMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative", "lang": { "en-us": { "role": { "label": "Investors [Member]", "documentation": "Investors [Member]" } } }, "auth_ref": { "ocx_JamesMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "JamesMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative", "lang": { "en-us": { "role": { "label": "James [Member]", "documentation": "James" } } }, "auth_ref": { "ocx_LaboratoryDevelopedTestServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "LaboratoryDevelopedTestServicesMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails", "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConsolidatedRevenuesGeneratedByUnconsolidatedRevenues", "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDisaggregationOfRevenueDetails", "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPercentageOfConsolidatedRevenuesAttributableTo", "lang": { "en-us": { "role": { "label": "Laboratory Developed Test Services [Member]", "documentation": "Laboratory Developed Test Services [Member]" } } }, "auth_ref": { "ocx_LaboratoryEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "LaboratoryEquipmentMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative", "lang": { "en-us": { "role": { "label": "Laboratory Equipment [Member]", "documentation": "Laboratory Equipment [Member]" } } }, "auth_ref": { "ocx_LeaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "LeaseAgreementMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative", "lang": { "en-us": { "role": { "label": "Lease Agreement [Member]", "documentation": "Lease Agreement [Member]" } } }, "auth_ref": { "us-gaap_LeaseContractualTermAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseContractualTermAxis", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeases", "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Axis]", "documentation": "Information by contractual term of lease arrangement." } } }, "auth_ref": { "r510", "r909" } }, "us-gaap_LeaseContractualTermDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseContractualTermDomain", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeases", "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Domain]", "documentation": "Contractual term of lease arrangement." } } }, "auth_ref": { "r510", "r909" } }, "us-gaap_LeaseExpirationDate1": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseExpirationDate1", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative", "lang": { "en-us": { "role": { "terseLabel": "Lease expiration date", "label": "Lease Expiration Date", "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format." } } }, "auth_ref": { "ocx_LeaseExpirationMonthAndYear": { "xbrltype": "gYearMonthItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "LeaseExpirationMonthAndYear", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative", "lang": { "en-us": { "role": { "terseLabel": "Lease expiration month and year", "label": "Lease Expiration Month And Year", "documentation": "Lease expiration month and year." } } }, "auth_ref": { "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/CollaborativeArrangementsDetailsNarrative", "http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesAdditionalInformationDetails

"http://oncocyte.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative",
"http://oncocyte.com/20240930/taxonomy/role/IntangibleAssetsNetDetailsNarrative",
"http://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative",
"http://oncocyte.com/20240930/taxonomy/role/ScheduleOfIntangibleAssetsNetDetails", "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]",
"documentation": "The set of legal entities associated with a report." } } }, "auth_ref": { "us-gaap_LegalFees": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "LegalFees", "crdr": "debit", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative" } }, "lang": { "en-us": { "role": { "label": "Legal fees",
"documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to
resolved, pending or threatened litigation, including arbitration and mediation proceedings." } } }, "auth_ref": { "r915" } }, "us-
gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LesseeLeaseDescriptionLineItems", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/DisclosureScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeases
": { "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts
included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to
the table." } } }, "auth_ref": { "r499", "r510" } }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionTable", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/DisclosureScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeases
": { "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }
}, "auth_ref": { "r499", "r510" } }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "LesseeLeasesPolicyTextBlock", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies": { "lang": { "en-us": { "role": { "label": "Leases",
"documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": { "r498" } }, "us-
gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LesseeOperatingLeaseExistenceOfOptionToExtend", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative" } }, "lang": { "en-us": { "role": { "label":
"Lessee, Operating Lease, Existence of Option to Extend [true false]", "documentation": "Indicates (true false) whether lessee has option to extend
operating lease." } } }, "auth_ref": { "r500" } }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/DisclosureScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails"
": { "lang": { "en-us": { "role": { "totalLabel": "Total minimum lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid",
"documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": { "r507" } }, "us-
gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/DisclosureScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails"
": { "lang": { "en-us": { "role": { "verboseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation":
"Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year.
Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }
}, "auth_ref": { "r507" } }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/DisclosureScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails"
": { "lang": { "en-us": { "role": { "label": "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease
to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current
statement of financial position date (rolling approach)." } } }, "auth_ref": { "r507" } }, "us-
gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/DisclosureScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails"
": { "lang": { "en-us": { "role": { "label": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease
to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current
statement of financial position date (rolling approach)." } } }, "auth_ref": { "r507" } }, "us-
gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/DisclosureScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails"
": { "lang": { "en-us": { "role": { "verboseLabel": "2024", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
"documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in
excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": { "r1025" } }, "us-
gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/DisclosureScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails"
": { "lang": { "en-us": { "role": { "negatedLabel": "Less amounts representing interest", "label": "Lessee, Operating Lease, Liability, Undiscounted
Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease
payments for operating lease." } } }, "auth_ref": { "r507" } }, "us-gaap_LesseeOperatingLeaseOptionToExtend": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseOptionToExtend", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative" } }, "lang": { "en-us": { "role": {
"terseLabel": "Lease, option to extend, description", "label": "Lessee, Operating Lease, Option to Extend", "documentation": "Description of terms
and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-
use asset and lease liability." } } }, "auth_ref": { "r500" } }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative" } }, "lang": { "en-us": { "role": {
"terseLabel": "Lease extension term", "label": "Lessee, Operating Lease, Renewal Term", "documentation": "Term of lessee's operating lease
renewal in 'PnYnMnDnHnMnS' format, for example, 'PY5M13D' represents reported fact of one year, five months, and thirteen days." } } }
}, "auth_ref": { "r1024" } }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative",
"http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails": { "lang": { "en-
us": { "role": { "label": "Lease term", "documentation": "Term of lessee's operating lease, in 'PnYnMnDnHnMnS' format, for example, 'PY5M13D'
represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r1024" } }, "us-
gaap_LesseeOperatingSubleaseResidualValueGuaranteeDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LesseeOperatingSubleaseResidualValueGuaranteeDescription", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative" } }, "lang": { "en-us": { "role": { "label":
"Operating sublease, description", "documentation": "Description of terms and conditions of residual value guarantee provided by sublessee for
operating sublease." } } }, "auth_ref": { "r501" } }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "Liabilities", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/BalanceSheets": { "lang": { "en-us": {
"role": { "totalLabel": "TOTAL LIABILITIES", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation
requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": { "r24", "r95", "r96", "r97", "r98", "r99", "r100", "r101",
"r228", "r282", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r455", "r456", "r457", "r481", "r653", "r753", "r811", "r974",
"r1030", "r1031" } } }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/BalanceSheets": {
"lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS'2019 EQUITY", "label": "Liabilities and Equity",
"documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }
}, "auth_ref": { "r108", "r164", "r581", "r784", "r934", "r951", "r1020" } }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/BalanceSheets": { "lang": { "en-us": { "role": { "label": "LIABILITIES AND SHAREHOLDERS'2019
EQUITY" } } }, "auth_ref": { "us-gaap_LiabilitiesAssumed1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LiabilitiesAssumed1", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/StatementsOfCashFlows": {
"lang": { "en-us": { "role": { "label": "Lease assets obtained in exchange for lease liabilities", "documentation": "The fair value of liabilities
assumed in noncash investing or financing activities." } } }, "auth_ref": { "r36", "r37", "r38" } }, "us-gaap_LiabilitiesCurrent": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/BalanceSheets": { "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label":
"Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following

```

"two months or within one business cycle, if longer." } } ], "auth_ref": [ "r97", "r192", "r228", "r282", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r455", "r456", "r457", "r481", "r784", "r974", "r1030", "r1031" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/BalanceSheets": { "lang": { "en-us": { "role": { "label": "CURRENT LIABILITIES" } } }, "auth_ref": [ ] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrentAbstract", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/BalanceSheets": { "lang": { "en-us": { "role": { "label": "NONCURRENT LIABILITIES" } } }, "auth_ref": [ ] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/BalanceSheets": { "lang": { "en-us": { "role": { "label": "Current liabilities of discontinued operations (Note 11)", "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r4", "r75", "r89", "r135", "r138", "r189", "r190" ] }, "ocx_LifeTechnologiesCorporationMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "LifeTechnologiesCorporationMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/CollaborativeArrangementsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Life Technologies Corporation [Member]", "documentation": "Life Technologies Corporation [Member]" } } }, "auth_ref": [ ] }, "us-gaap_LinesOfCreditCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LinesOfCreditCurrent", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Line of credit", "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long-term obligation to refinance the short-term obligation on a long-term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long-term basis and the following conditions are met: (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r95", "r162" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/Cover": { "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [ ] }, "ocx_LongLivedTangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "LongLivedTangibleAssets", "crdr": "debit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Long-lived tangible assets amount", "label": "Long Lived Tangible Assets", "documentation": "Long-lived tangible assets." } } }, "auth_ref": [ ] }, "ocx_MPCHoldingsLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "MPCHoldingsLLCMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative": { "lang": { "en-us": { "role": { "label": "MPC Holdings LLC [Member]", "documentation": "MPC Holdings LLC [Member]" } } }, "auth_ref": [ ] }, "ocx_MPEEMValuationApproachMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "MPEEMValuationApproachMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/IntangibleAssetsNetDetailsNarrative": { "lang": { "en-us": { "role": { "label": "MPEEM Valuation Approach [Member]", "documentation": "MPEEM Valuation Approach [Member]" } } }, "auth_ref": [ ] }, "us-gaap_MachineryAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MachineryAndEquipmentGross", "crdr": "debit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfRightofuseAndFinancingLeaseAssetsMachineryAndEquip": { "lang": { "en-us": { "role": { "label": "Machinery, equipment and leasehold improvements", "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } }, "auth_ref": [ "r136" ] }, "us-gaap_MachineryAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MachineryAndEquipmentMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label": "Machinery and Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } }, "auth_ref": [ ] }, "ocx_MachineryAndEquipmentNetAndConstructionInProgress": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "MachineryAndEquipmentNetAndConstructionInProgress", "crdr": "debit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/BalanceSheets": { "lang": { "en-us": { "role": { "label": "Machinery and equipment, net, and construction in progress", "documentation": "Machinery and equipment net and construction in progress." } } }, "auth_ref": [ ] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConsolidatedRevenuesGeneratedByUn": { "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "auth_ref": [ "r276", "r764", "r794", "r798", "r980", "r1048", "r1050", "r1051", "r1053", "r1054", "r1055", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077" ] }, "us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/StatementsOfCashFlows": { "lang": { "en-us": { "role": { "negatedLabel": "Unrealized gain on marketable equity securities", "label": "Marketable Security, Gain (Loss)", "documentation": "Amount of realized and unrealized gain (loss) on investment in marketable security." } } }, "auth_ref": [ ] }, "us-gaap_MarketableSecuritiesPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesPolicy", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies": { "lang": { "en-us": { "role": { "label": "Marketable Equity Securities", "documentation": "Disclosure of accounting policy for investment classified as marketable security." } } }, "auth_ref": [ "r72" ] }, "us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails": { "lang": { "en-us": { "role": { "label": "Realized loss of marketable equity securities", "documentation": "Amount of realized gain (loss) on investment in marketable security." } } }, "auth_ref": [ ] }, "us-gaap_MarketableSecuritiesUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesUnrealizedGainLoss", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails": { "http://oncocyte.com/20240930/taxonomy/role/StatementsOfOperations": { "lang": { "en-us": { "role": { "label": "Unrealized (loss) gain on marketable equity securities", "verboseLabel": "Unrealized loss of marketable equity securities", "documentation": "Amount of unrealized gain (loss) on investment in marketable security." } } }, "auth_ref": [ "r119" ] }, "ocx_MaximumAmountOfStockAndWarrantsOfferedUnderShelfRegistration": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "MaximumAmountOfStockAndWarrantsOfferedUnderShelfRegistration", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/OrganizationAndDescriptionOfBusinessDetailsNarrative": { "lang": { "en-us": { "role": { "terseLabel": "Maximum amount of stock and warrants offered under shelf registration", "label": "Maximum Amount of Stock and Warrants Offered under Shelf Registration", "documentation": "Maximum amount of stock and warrants offered under shelf registration." } } }, "auth_ref": [ ] }, "ocx_MaximumBeneficialOwnershipConsideredToSaleSharesUnderAgreement": { "xbrltype": "percentItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "MaximumBeneficialOwnershipConsideredToSaleSharesUnderAgreement", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Maximum beneficial ownership considered", "documentation": "Maximum beneficial ownership considered to sale shares under agreement." } } }, "auth_ref": [ ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesAdditionalInformationDetails": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails": { "http://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative": { "http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative": { "http://oncocyte.com/20240930/taxonomy/role/Stock-basedCompensationDetailsNarrative": { "lang": { "en-us": { "role": { "terseLabel": "Maximum [Member]", "label": "Maximum [Member]" } } }, "auth_ref": [ "r319", "r320", "r321", "r322", "r383", "r422", "r473", "r529", "r600", "r602", "r614", "r645", "r646", "r708", "r711", "r715", "r716", "r718", "r740", "r741", "r757", "r761", "r771", "r779", "r780", "r781", "r782", "r795", "r976", "r1032",
```

"http://oncocyte.com/20240930/", "localname": "MaximumPercentageOfAnnualLeaseExpenses", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative": {
"lang": { "en-us": { "role": {
"terseLabel": "Maximum percentage of annual lease expenses", "label": "Maximum Percentage Of Annual Lease Expenses", "documentation":
"Maximum percentage of annual lease expenses." } } }, "auth_ref": { "r860" }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": {
"lang": { "en-us": {
"role": { "label": "Measure [Axis]", "terseLabel": "Measure." } } }, "auth_ref": { "r860" }, "ecd_MeasureName": { "xbrltype":
"normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": {
"http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": { "r860"
"us-gaap-MeasurementInputDiscountRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"MeasurementInputDiscountRateMember", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesAdditionalInformationDetails
"http://oncocyte.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentDetailsNarrative": { "lang": { "en-us": { "role": { "verboseLabel":
"Measurement Input, Discount Rate [Member]", "terseLabel": "Discount rate [Member]", "label": "Measurement Input, Discount Rate [Member]",
"documentation": "Measurement input using interest rate to determine present value of future cash flows." } } }, "auth_ref": { "r1017", "r1018",
"r1019" }, "us-gaap-MeasurementInputExpectedTermMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "MeasurementInputExpectedTermMember", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesAdditionalInformationDetails
"http://oncocyte.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentDetailsNarrative": { "lang": { "en-us": { "role": { "label":
"Measurement Input, Expected Term [Member]", "terseLabel": "Expected term [Member]", "label": "Measurement Input, Expected Term [Member]", "documentation":
"Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date." } } }, "auth_ref": { "r1017", "r1018",
"r1019" }, "ocx-MeasurementInputManagementProbabilityEstimateMember": { "xbrltype": "domainItemType", "nsuri":
"http://oncocyte.com/20240930", "localname": "MeasurementInputManagementProbabilityEstimateMember", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesAdditionalInformationDetails
"http://oncocyte.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentDetailsNarrative": { "lang": { "en-us": { "role": { "label":
"Management probability estimate [Member]", "terseLabel": "Management probability estimate [Member]", "label": "Management Input, Management Probability
Estimate [Member]", "documentation": "Measurement input, management probability estimate." } } }, "auth_ref": { "us-
gaap-MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"MeasurementInputTypeAxis", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesAdditionalInformationDetails
"http://oncocyte.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentDetailsNarrative": { "lang": { "en-us": { "role": { "label":
"Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }
"auth_ref": { "r471", "r472", "r473", "r779" }, "us-gaap-MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeDomain", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesAdditionalInformationDetails
"http://oncocyte.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentDetailsNarrative": { "lang": { "en-us": { "role": { "label":
"Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": {
"r471", "r472", "r473", "r779" }, "ocx-MergerAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20240930",
"localname": "MergerAgreementMember", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesAdditionalInformationDetails
"http://oncocyte.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentDetailsNarrative": { "lang": { "en-us": { "role": { "label":
"Merger Agreement [Member]", "documentation": "Merger Agreement [Member]" } } }, "auth_ref": { "us-
gaap-MilestoneOneMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "MilestoneOneMember",
"presentation": {
"http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesScheduleOffFairValueOfConti
"http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesScheduleOffFairValueOfConti
"lang": { "en-us": { "role": { "label": "Milestone 1 [Member]", "documentation": "Milestone 1 [Member]" } } }, "auth_ref": { "us-
gaap-MilestoneThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "MilestoneThreeMember",
"presentation": {
"http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesScheduleOffFairValueOfConti
"http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesScheduleOffFairValueOfConti
"lang": { "en-us": { "role": { "label": "Milestone 3 [Member]", "documentation": "Milestone 3 [Member]" } } }, "auth_ref": { "us-
gaap-MilestoneTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "MilestoneTwoMember",
"presentation": {
"http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesScheduleOffFairValueOfConti
"http://oncocyte.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentDetailsNarrative": { "lang": { "en-us": { "role": { "label":
"Milestone 2 [Member]", "documentation": "Milestone 2 [Member]" } } }, "auth_ref": { "us-
gaap-MilestoneTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "MilestoneTwoMember",
"presentation": {
"http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesScheduleOffFairValueOfConti
"http://oncocyte.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentDetailsNarrative": { "lang": { "en-us": { "role": { "label":
"Minimum Member", "documentation": "Minimum Member", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesAdditionalInformationDetails
"http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails
"http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails
"http://oncocyte.com/20240930/taxonomy/role/Stock-basedCompensationDetailsNarrative": { "lang": { "en-us": { "role": { "terseLabel": "Minimum
[Member]", "label": "Minimum [Member]" } } }, "auth_ref": { "r319", "r320", "r321", "r322", "r383", "r422", "r473", "r529", "r600", "r602", "r614",
"r645", "r646", "r708", "r711", "r715", "r716", "r718", "r740", "r741", "r757", "r761", "r771", "r779", "r780", "r781", "r795", "r976", "r1032",
"r1033", "r1034", "r1035", "r1036", "r1037" }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": {
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value
[Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": { "r879" },
"ocx-MonteCarloValuationTechniqueMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20240930", "localname":
"MonteCarloValuationTechniqueMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/Stock-
basedCompensationDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Monte Carlo Valuation Technique [Member]", "documentation":
"Monte Carlo Valuation Technique [Member]" } } }, "auth_ref": { "us-
gaap-MonthlyRentMember": { "xbrltype": "domainItemType", "nsuri":
"http://oncocyte.com/20240930", "localname": "MonthlyRentMember", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative": { "lang": { "en-us": { "role": { "label":
"Monthly Rent [Member]", "documentation": "Monthly Rent [Member]" } } }, "auth_ref": { "us-
gaap-MrGutfreundMember": { "xbrltype":
"domainItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "MrGutfreundMember", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Mr Gutfreund
[Member]", "documentation": "Mr Gutfreund [Member]" } } }, "auth_ref": { "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": {
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text
Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": { "r887" }, "srt_NameOfMajorCustomerDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails
"http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConsolidatedRevenuesGeneratedByUn
"lang": { "en-us": { "role": { "label": "Customer [Domain]" } } }, "auth_ref": { "r276", "r764", "r794", "r798", "r980", "r1048", "r1050", "r1051",
"r1053", "r1054", "r1055", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068",
"r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077" }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": {
"http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel":
"Named Executive Officers, Footnote" } } }, "auth_ref": { "r861" }, "us-gaap-NetCashProvidedByUsedInDiscontinuedOperationsAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInDiscontinuedOperationsAbstract",
"presentation": { "http://oncocyte.com/20240930/taxonomy/role/ScheduleOfAssetsAndLiabilitiesDiscontinuedOperationsDetails": { "lang": { "en-us":
"role": { "verboseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES." } } }, "auth_ref": { "us-
gaap-NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/StatementsOfCashFlows": { "lang": { "en-us": { "role": { "totalLabel": "Net provided by financing
activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing
activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a
return on, and a return of, their investment; borrowing money and repaying amounts borrowed; or settling the obligation; and obtaining and
paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": { "r221" }, "us-
gaap-NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/StatementsOfCashFlows":
"lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES." } } }, "auth_ref": { "us-
gaap-NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPriorPeriodRevisionsDetails":

"http://oncocyte.com/20240930/taxonomy/role/StatementsOfCashFlows" }, "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net cash provided by (used in) investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": { "r221" } }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/ScheduleOfAssetsAndLiabilitiesDiscontinuedOperationsDetails", "http://oncocyte.com/20240930/taxonomy/role/StatementsOfCashFlows" }, "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "auth_ref": { "r1" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPriorPeriodRevisionsDetails", "http://oncocyte.com/20240930/taxonomy/role/StatementsOfCashFlows" }, "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": { "r126", "r127", "r128" } }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/StatementsOfCashFlows" }, "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "auth_ref": { "r1" }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCommonStockComputationOfDiluted", "http://oncocyte.com/20240930/taxonomy/role/StatementsOfCashFlows", "http://oncocyte.com/20240930/taxonomy/role/StatementsOfComprehensiveLoss", "http://oncocyte.com/20240930/taxonomy/role/StatementsOfOperations", "http://oncocyte.com/20240930/taxonomy/role/StatementsOfSeriesRedeemableConvertiblePreferredStockAndShareholdersEquity", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "verboseLabel": "Net loss", "totalLabel": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": { "r115", "r128", "r167", "r190", "r209", "r211", "r216", "r228", "r232", "r234", "r235", "r237", "r238", "r239", "r243", "r244", "r255", "r282", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r445", "r452", "r468", "r481", "r588", "r677", "r698", "r699", "r809", "r974" } }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCommonStockComputationOfDiluted", "http://oncocyte.com/20240930/taxonomy/role/StatementsOfOperations" }, "lang": { "en-us": { "role": { "totalLabel": "Net loss attributable to common stockholders - basic", "label": "Net (loss) income attributable to common stockholders - basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, of income (loss) available to common shareholders." } } }, "auth_ref": { "r219", "r234", "r235", "r237", "r238", "r246", "r247", "r256", "r259", "r452" } }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCommonStockComputationOfDiluted", "http://oncocyte.com/20240930/taxonomy/role/StatementsOfOperations" }, "lang": { "en-us": { "role": { "totalLabel": "Net loss attributable to common stockholders - diluted", "label": "Net (loss) income attributable to common stockholders - diluted", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares, of income (loss) available to common shareholders." } } }, "auth_ref": { "r219", "r248", "r251", "r252", "r253", "r254", "r256", "r259" } }, "us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCommonStockComputationOfDiluted", "http://oncocyte.com/20240930/taxonomy/role/StatementsOfOperations" }, "lang": { "en-us": { "role": { "terseLabel": "Net loss from continuing operations - basic", "label": "Net (loss) income from continuing operations - basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, of income (loss) from continuing operations available to common shareholders." } } }, "auth_ref": { "r247", "r259" } }, "us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCommonStockComputationOfDiluted", "http://oncocyte.com/20240930/taxonomy/role/StatementsOfOperations" }, "lang": { "en-us": { "role": { "terseLabel": "Net loss from continuing operations - diluted", "label": "Net (loss) income from continuing operations - diluted", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares, of income (loss) from continuing operations available to common shareholders." } } }, "auth_ref": { "r248", "r252", "r253", "r254", "r259" } }, "us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCommonStockComputationOfDiluted", "http://oncocyte.com/20240930/taxonomy/role/StatementsOfOperations" }, "lang": { "en-us": { "role": { "label": "Net loss from discontinued operations - basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, of income (loss) from discontinued operations available to common shareholders." } } }, "auth_ref": { "r1" }, "us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCommonStockComputationOfDiluted", "http://oncocyte.com/20240930/taxonomy/role/StatementsOfOperations" }, "lang": { "en-us": { "role": { "label": "Net loss from discontinued operations - diluted", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares, of income (loss) from discontinued operations available to common shareholders." } } }, "auth_ref": { "r1" }, "ocx_NetProceedsFromIssuanceOfPrivatePlacementUsedForGeneralCorporatePurposesAndWorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "NetProceedsFromIssuanceOfPrivatePlacementUsedForGeneralCorporatePurposesAndWorkingCapital", "crdr": "debit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSubsequentEventsDetailsNarrative", "http://oncocyte.com/20240930/taxonomy/role/OrganizationAndDescriptionOfBusinessDetailsNarrative", "http://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative", "http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative" }, "lang": { "en-us": { "role": { "verboseLabel": "Net proceeds from issuance of private placement", "terseLabel": "Net proceeds from issuance of private placement used for general corporate purposes and working capital", "label": "Net Proceeds from Issuance of Private Placement used for General Corporate Purposes and Working Capital", "documentation": "Net proceeds from issuance of private placement used for general corporate purposes and working capital." } } }, "auth_ref": { "r1" }, "ocx_NetProceedsFromSaleOfPlacementShares": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "NetProceedsFromSaleOfPlacementShares", "crdr": "debit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative" }, "lang": { "en-us": { "role": { "terseLabel": "Net proceeds from sale of placement shares", "label": "Net Proceeds From Sale of Placement Shares", "documentation": "Net proceeds from sale of placement shares." } } }, "auth_ref": { "r1" }, "us-gaap_NetRentableArea": { "xbrltype": "areaItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetRentableArea", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative" }, "lang": { "en-us": { "role": { "label": "Rentable area", "documentation": "Net rentable area for properties owned." } } }, "auth_ref": { "r1" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" }, "lang": { "en-us": { "role": { "label": "Recent Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": { "r1" }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": { "r860" } }

Non-NEOsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNEOsMember", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": { "r824", "r834", "r844", "r868", "r876" } }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Non-PEO-NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO-NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": { "r851" } }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Non-PEO-NEO Average Total Compensation Amount", "terseLabel": "Non-PEO-NEO Average Total Compensation Amount" } } }, "auth_ref": { "r850" } }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Non-PEO-NEO [Member]", "terseLabel": "Non-PEO-NEO" } } }, "auth_ref": { "r868" } }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted {Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": { "r887" } }, "ecd_NonRule10b51ArrTrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmndFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated {Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": { "r887" } }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/StatementsOfCashFlows", "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL SCHEDULE OF NONCASH INVESTING AND FINANCING ACTIVITIES" } } }, "auth_ref": { "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/StatementsOfOperations", "lang": { "en-us": { "role": { "totalLabel": "Total other income, net", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "auth_ref": { "r119" } }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/StatementsOfOperations", "lang": { "en-us": { "role": { "label": "Other (expenses) income:" } } }, "auth_ref": { "ocx_ObligatedToPayExpensesAndTaxesPercentage": { "xbrltype": "percentItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "ObligatedToPayExpensesAndTaxesPercentage", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative", "lang": { "en-us": { "role": { "label": "Obligated to pay expenses and taxes percentage.", "documentation": "Obligated to pay expenses and taxes percentage." } } }, "auth_ref": { "ocx_OfferingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "OfferingExpenses", "crdr": "debit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative", "lang": { "en-us": { "role": { "terseLabel": "Offering expenses", "label": "Offering Expenses", "documentation": "Offering expenses." } } }, "auth_ref": { "ocx_OfficeLeaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "OfficeLeaseAgreementMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative", "lang": { "en-us": { "role": { "label": "Office Lease Agreement [Member]", "documentation": "Office Lease Agreement [Member]" } } }, "auth_ref": { "ocx_OfficeSubleaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "OfficeSubleaseAgreementMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative", "lang": { "en-us": { "role": { "terseLabel": "Office Sublease Agreement [Member]", "label": "Office Sublease Agreement [Member]", "documentation": "Office sublease agreement.", "auth_ref": { "us-gaap_OfficersCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OfficersCompensation", "crdr": "debit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative", "lang": { "en-us": { "role": { "label": "Compensation paid", "documentation": "Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold." } } }, "auth_ref": { "r927" } }, "ocx_OncocyteCorpMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "OncocyteCorpMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative", "lang": { "en-us": { "role": { "label": "Oncocyte Corp [Member]", "documentation": "Oncocyte Corp [Member]" } } }, "auth_ref": { "ocx_OperatingAndFinancingLeasesMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "OperatingAndFinancingLeasesMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeases", "lang": { "en-us": { "role": { "label": "Operating and Financing Leases [Member]", "documentation": "Operating and Financing Leases [Member]" } } }, "auth_ref": { "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/StatementsOfOperations", "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "auth_ref": { "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/StatementsOfOperations", "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "auth_ref": { "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/StatementsOfOperations", "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "auth_ref": { "r170", "r754", "r943", "r944", "r945", "r946", "r947" } }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative", "lang": { "en-us": { "role": { "label": "Total lease cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "auth_ref": { "r502", "r783" } }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails", "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": { "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails", "lang": { "en-us": { "role": { "totalLabel": "Total operating lease liabilities", "label": "Present value of net minimum lease payments", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "auth_ref": { "r494" } }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeases", "lang": { "en-us": { "role": { "label": "Right-of-use lease liabilities, current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": { "r494" } }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeases", "lang": { "en-us": { "role": { "label": "Right-of-use lease liabilities, noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": { "r494" } }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureScheduleOfSupplementalCashFlowInformationRelatedToOperatingAndFinancingLeases", "lang": { "en-us": { "role": { "label": "Operating cash flows from operating leases", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "auth_ref": { "r497", "r504" } }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeases", "lang": { "en-us": { "role": { "label": "Right-of-use lease asset", "documentation": "Right-of-use lease asset, at cost, less accumulated depreciation and impairment." } } }, "auth_ref": { "r505" } }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRight

1, "lang": { "en-us": { "role": { "label": "Right-of-use assets, net", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": { "r493" } }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeases 1, "lang": { "en-us": { "role": { "label": "Weighted average discount rate, Operating lease", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": { "r506", "r783" } }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeases 1, "lang": { "en-us": { "role": { "label": "Weighted average remaining lease term, Operating lease", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMns' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r505", "r783" } }, "us-gaap_OrganizationConsolidationAndPresentationOffFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOffFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": { } }, "us-gaap_OrganizationConsolidationAndPresentationOffFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOffFinancialStatementsDisclosureTextBlock", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/OrganizationAndDescriptionOfBusiness" }, "lang": { "en-us": { "role": { "label": "Organization and Description of the Business", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": { "r73", "r156", "r616", "r617" } }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/BalanceSheets" }, "lang": { "en-us": { "role": { "label": "Other noncurrent assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": { "r198" } }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/StatementsOfComprehensiveLoss", "http://oncocyte.com/20240930/taxonomy/role/StatementsOfSeriesRedeemableConvertiblePreferredStockAndShareholdersEquity" }, "lang": { "en-us": { "role": { "label": "Foreign currency translation adjustments", "verboseLabel": "Foreign currency translation adjustment", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term investment nature." } } }, "auth_ref": { "r6", "r589" } }, "us-gaap_OtherExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherExpenses", "crdr": "debit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSubsequentEventsDetailsNarrative", "http://oncocyte.com/20240930/taxonomy/role/OrganizationAndDescriptionOfBusinessDetailsNarrative", "http://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative", "http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative" }, "lang": { "en-us": { "role": { "label": "Other expenses", "documentation": "Amount of expense classified as other." } } }, "auth_ref": { "r116", "r117" } }, "ocx_OtherInvestorsMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "OtherInvestorsMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative" }, "lang": { "en-us": { "role": { "label": "Other Investors [Member]", "documentation": "Other Investors [Member]" } } }, "auth_ref": { } }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/StatementsOfOperations" }, "lang": { "en-us": { "role": { "label": "Other income, net", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": { "r120" } }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": { "r860" } }, "ocx_OutsideOfUnitedStatesMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "OutsideOfUnitedStatesMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPercentageOfConsolidatedRevenuesAt 1, "lang": { "en-us": { "role": { "label": "Outside Of United States [Member]", "documentation": "Outside Of United States [Member]" } } }, "auth_ref": { } }, "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": { "r822", "r832", "r842", "r874" } }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": { "r825", "r835", "r845", "r877" } }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": { "r825", "r835", "r845", "r877" } }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": { "r849" } }, "ocx_PaymentOfSalesAgentCommissionPercentage": { "xbrltype": "percentItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "PaymentOfSalesAgentCommissionPercentage", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative" }, "lang": { "en-us": { "role": { "terseLabel": "Percentage of sales agent commission", "label": "Payment of Sales Agent Commission Percentage", "documentation": "Payment of sales agent commission percentage" } } }, "auth_ref": { } }, "ocx_PaymentForCashSoldInDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "PaymentForCashSoldInDiscontinuedOperations", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPriorPeriodRevisionsDetails", "http://oncocyte.com/20240930/taxonomy/role/StatementsOfCashFlows" }, "lang": { "en-us": { "role": { "negatedLabel": "Cash sold in discontinued operations (Note 11)", "documentation": "Payment for cash sold in discontinued operations." }, "label": "PaymentForCashSoldInDiscontinuedOperations" } } }, "auth_ref": { } }, "ocx_PaymentOfFinancingCostsForAtTheMarketSales": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "PaymentOfFinancingCostsForAtTheMarketSales", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/StatementsOfCashFlows" }, "lang": { "en-us": { "role": { "negatedLabel": "Financing costs for at the market sales", "terseLabel": "Financing costs for at the market sales", "label": "Payment Of Financing Costs For At The Market Sales", "documentation": "Payment of financing costs for at the market sales." } } }, "auth_ref": { } }, "us-gaap_PaymentsForProceedsFromTenantAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForProceedsFromTenantAllowance", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative" }, "lang": { "en-us": { "role": { "label": "Tenant improvement allowance", "documentation": "Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy." } } }, "auth_ref": { "r31", "r122" } }, "us-gaap_PaymentsForRent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRent", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative" }, "lang": { "en-us": { "role": { "label": "Payments for rent", "documentation": "Cash payments to lessor's for use of assets under operating leases." } } }, "auth_ref": { "r12" } }, "us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/StatementsOfCashFlows" }, "lang": { "en-us": { "role": { "negatedLabel": "Redemption of Series A redeemable convertible preferred shares", "label": "Payments for Repurchase of Redeemable Convertible Preferred Stock", "documentation": "The cash outflow to reacquire callable preferred stock which is identified as being convertible to another type of financial security." } } }, "auth_ref": { "r124" } }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/StatementsOfCashFlows" }, "lang": { "en-us": { "role": { "negatedLabel": "Financing costs to issue common shares", "label": "Payments of Stock Issuance Costs", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": { "r32" } }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative"

"http://oncoocyte.com/20240930/taxonomy/role/StatementsOfCashFlows" }, {"lang": "en-us", "role": "negatedLabel", "documentation": "Construction in progress and purchases of furniture and equipment", "label": "Purchased Laboratory equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, {"auth_ref": "r123" } }, {"ecdc_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, {"lang": "en-us", "role": "label", "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, {"auth_ref": "r859" } }, {"ecdc_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, {"lang": "en-us", "role": "label", "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, {"auth_ref": "r859" } }, {"us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" }, {"lang": "en-us", "role": "label", "label": "Retirement Plan", "documentation": "The entire disclosure for retirement benefits." } } }, {"auth_ref": "r362", "r364", "r365", "r374", "r372", "r374", "r375", "r376", "r377", "r378", "r380", "r381", "r382", "r767" } }, {"ecdc_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, {"lang": "en-us", "role": "label", "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, {"auth_ref": "r851" } }, {"ecdc_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, {"lang": "en-us", "role": "label", "label": "PEO [Member]", "terseLabel": "PEO" } } }, {"auth_ref": "r868" } }, {"ecdc_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, {"lang": "en-us", "role": "label", "label": "PEO Name", "terseLabel": "PEO Name" } } }, {"auth_ref": "r861" } }, {"ecdc_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, {"lang": "en-us", "role": "label", "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, {"auth_ref": "r850" } }, {"ocx_PercentageOfAdministrativeFeePaidOnOriginalCostOfEquipment": { "xbrltype": "percentItemType", "nsuri": "http://oncoocyte.com/20240930", "localname": "PercentageOfAdministrativeFeePaidOnOriginalCostOfEquipment", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative" }, {"lang": "en-us", "role": "label", "label": "Percentage of administrative fee paid on original cost of equipment", "documentation": "Percentage of administrative fee paid on original cost of equipment." } } }, {"auth_ref": "r1" } }, {"ocx_PercentageOfSalesAgentCommission": { "xbrltype": "monetaryItemType", "nsuri": "http://oncoocyte.com/20240930", "localname": "PercentageOfSalesAgentCommission", "crdr": "debit", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative" }, {"lang": "en-us", "role": "label", "label": "Percentage of sales agent commission", "documentation": "Percentage of sales agent commission." } } }, {"auth_ref": "r1" } }, {"ocx_PercentageOfSharesIssuedAndOutstanding": { "xbrltype": "percentItemType", "nsuri": "http://oncoocyte.com/20240930", "localname": "PercentageOfSharesIssuedAndOutstanding", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative" }, {"lang": "en-us", "role": "label", "label": "Percentage of shares issued and outstanding", "documentation": "Percentage of shares issued and outstanding." } } }, {"auth_ref": "r1" } }, {"ocx_PerformanceBasedOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://oncoocyte.com/20240930", "localname": "PerformanceBasedOptionsMember", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/Stock-basedCompensationDetailsNarrative" }, {"lang": "en-us", "role": "label", "label": "Performance-Based Options [Member]", "documentation": "Performance-Based Options [Member]" } } }, {"auth_ref": "r1" } }, {"ocx_PharmaServicesAndLaboratoryDevelopedTestServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://oncoocyte.com/20240930", "localname": "PharmaServicesAndLaboratoryDevelopedTestServicesMember", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConsolidatedRevenuesGeneratedByUnl", {"lang": "en-us", "role": "label", "label": "Pharma Services And Laboratory Developed Test Services [Member]", "documentation": "Pharma-services and laboratory-developed test-services." } } }, {"auth_ref": "r1" } }, {"ocx_PharmaServicesCompanyAMember": { "xbrltype": "domainItemType", "nsuri": "http://oncoocyte.com/20240930", "localname": "PharmaServicesCompanyAMember", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConsolidatedRevenuesGeneratedByUnl", {"lang": "en-us", "role": "label", "label": "Pharma Services Company A [Member]", "documentation": "Pharma Services Company A [Member]" } } }, {"auth_ref": "r1" } }, {"ocx_PharmaServicesCompanyBMember": { "xbrltype": "domainItemType", "nsuri": "http://oncoocyte.com/20240930", "localname": "PharmaServicesCompanyBMember", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConsolidatedRevenuesGeneratedByUnl", {"lang": "en-us", "role": "label", "label": "Pharma Services Company B [Member]", "documentation": "Pharma Services Company B [Member]" } } }, {"auth_ref": "r1" } }, {"ocx_PharmaServicesCompanyCMember": { "xbrltype": "domainItemType", "nsuri": "http://oncoocyte.com/20240930", "localname": "PharmaServicesCompanyCMember", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConsolidatedRevenuesGeneratedByUnl", {"lang": "en-us", "role": "label", "label": "Pharma Services Company C [Member]", "documentation": "Pharma Services Company C [Member]" } } }, {"auth_ref": "r1" } }, {"ocx_PharmaServicesCompanyDMember": { "xbrltype": "domainItemType", "nsuri": "http://oncoocyte.com/20240930", "localname": "PharmaServicesCompanyDMember", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConsolidatedRevenuesGeneratedByUnl", {"lang": "en-us", "role": "label", "label": "Pharma Services Company D [Member]", "documentation": "Pharma Services Company D [Member]" } } }, {"auth_ref": "r1" } }, {"ocx_PharmaServicesCompanyEMember": { "xbrltype": "domainItemType", "nsuri": "http://oncoocyte.com/20240930", "localname": "PharmaServicesCompanyEMember", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConsolidatedRevenuesGeneratedByUnl", {"lang": "en-us", "role": "label", "label": "Pharma Services Company E [Member]", "documentation": "Pharma Services Company E [Member]" } } }, {"auth_ref": "r1" } }, {"ocx_PharmaServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://oncoocyte.com/20240930", "localname": "PharmaServicesMember", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", {"http://oncoocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails", {"http://oncoocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDisaggregationOfRevenueDetails", {"http://oncoocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPercentageOfConsolidatedRevenuesAtl", {"lang": "en-us", "role": "label", "label": "Pharma Services [Member]", "documentation": "Pharma Services [Member]" } } }, {"auth_ref": "r1" } }, {"ocx_PharmaServicesOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://oncoocyte.com/20240930", "localname": "PharmaServicesOtherMember", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConsolidatedRevenuesGeneratedByUnl", {"lang": "en-us", "role": "label", "label": "Pharma Services Other [Member]", "documentation": "Pharma-services other." } } }, {"auth_ref": "r1" } }, {"us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/Stock-basedCompensationDetailsNarrative", {"http://oncoocyte.com/20240930/taxonomy/role/SummaryOfStockOptionActivityDetails" }, {"lang": "en-us", "role": "label", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, {"auth_ref": "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006" } }, {"us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/Stock-basedCompensationDetailsNarrative", {"http://oncoocyte.com/20240930/taxonomy/role/SummaryOfStockOptionActivityDetails" }, {"lang": "en-us", "role": "label", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, {"auth_ref": "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006" } }, {"ecdc_PnsnAdjsPrsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrsSvcCstMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, {"lang": "en-us", "role": "label", "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, {"auth_ref": "r852" } }, {"ecdc_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, {"lang": "en-us", "role": "label", "label": "Pension Adjustments Service Cost" } } }, {"auth_ref": "r896" } }, {"ecdc_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, {"lang": "en-us", "role": "label", "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, {"auth_ref": "r851" } }, {"ocx_PrefundedWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://oncoocyte.com/20240930", "localname": "PrefundedWarrantMember", "presentation": { "http://oncoocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative", {"http://oncoocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative" }, {"lang": "en-us", "role": "label", "label": "Pre-Funded Warrant [Member]", "documentation": "Pre-Funded Warrant [Member]" } } }, {"auth_ref": "r1" } }, {"us-

gaap-PreferredStockConvertibleConversionPrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockConvertibleConversionPrice", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Conversion price", "documentation": "Per share conversion price of preferred stock." } } }, "auth_ref": { "r336" } }, "us-gaap-PreferredStockConvertibleSharesIssuable": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockConvertibleSharesIssuable", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Number of common shares issuable upon conversion", "documentation": "Number of common shares issuable upon conversion of preferred stock." } } }, "auth_ref": { "r336" } }, "us-gaap-PreferredStockDividendRatePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockDividendRatePercentage", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Dividends rate", "documentation": "The percentage rate used to calculate dividend payments on preferred stock." } } }, "auth_ref": { "r335", "r709", "r712", "r714", "r719" } }, "us-gaap-PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative": { "http://oncocyte.com/20240930/taxonomy/role/StatementsOfSeriesRedeemableConvertiblePreferredStockAndShareholdersEquity": { "lang": { "en-us": { "role": { "label": "Preferred Stock [Member]", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": { "r801", "r802", "r805", "r806", "r807", "r808", "r1078", "r1079" } }, "us-gaap-PreferredStockNoParValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockNoParValue", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/BalanceSheetsParenthetical": { "http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Preferred stock, no par value", "documentation": "Face amount per share of no-par value preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": { "r103", "r978" } }, "us-gaap-PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Stated value per share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": { "r103", "r334" } }, "ocx-PreferredStockRemainsOutstandingPercentage": { "xbrltype": "percentItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "PreferredStockRemainsOutstandingPercentage", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Preferred stock outstanding percentage", "documentation": "Preferred stock remains outstanding percentage." } } }, "auth_ref": { "r103", "r334" } }, "us-gaap-PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/BalanceSheetsParenthetical": { "http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": { "r103", "r655" } }, "us-gaap-PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/BalanceSheetsParenthetical": { "http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Preferred stock, shares issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": { "r103", "r334" } }, "us-gaap-PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/BalanceSheetsParenthetical": { "http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": { "r103", "r655", "r675", "r1079", "r1080" } }, "us-gaap-PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/BalanceSheets": { "lang": { "en-us": { "role": { "label": "Preferred stock, no par value, 5,000 shares authorized, no shares issued and outstanding", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": { "r103", "r576", "r784" } }, "us-gaap-PreferredUnitsOfferingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredUnitsOfferingCosts", "crdr": "debit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/OrganizationAndDescriptionOfBusinessDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Offering expenses", "documentation": "The cumulative amount of offering costs allocated to the preferred partners." } } }, "auth_ref": { "r148" } }, "us-gaap-PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/BalanceSheets": { "lang": { "en-us": { "role": { "label": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": { "r923" } }, "us-gaap-PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PriorPeriodReclassificationAdjustmentDescription", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/SummaryOfSignificantAccountingPolicies": { "lang": { "en-us": { "role": { "label": "Reclassifications", "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": { "r917" } }, "ocx-PriorPeriodRevisionsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "PriorPeriodRevisionsPolicyTextBlock", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/SummaryOfSignificantAccountingPolicies": { "lang": { "en-us": { "role": { "label": "Prior Period Revisions", "documentation": "Prior Period Revisions Policy [Text Block]" } } }, "auth_ref": { "r103", "r107", "r108", "r109", "r110", "r111", "r112", "r113", "r114", "r115", "r116", "r117", "r118", "r119", "r120", "r121", "r122", "r123", "r124", "r125", "r126", "r127", "r128", "r129", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037", "r1038", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046", "r1047", "r1048", "r1049", "r1050", "r1051", "r1052", "r1053", "r1054", "r1055", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1079", "r1080", "r1081", "r1082", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1120", "r1121", "r1122", "r1123", "r1124", "r1125", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135", "r1136", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1143", "r1144", "r1145", "r1146", "r1147", "r1148", "r1149", "r1150", "r1151", "r1152", "r1153", "r1154", "r1155", "r1156", "r1157", "r1158", "r1159", "r1160", "r1161", "r1162", "r1163", "r1164", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179", "r1180", "r1181", "r1182", "r1183", "r1184", "r1185", "r1186", "r1187", "r1188", "r1189", "r1190", "r1191", "r1192", "r1193", "r1194", "r1195", "r1196", "r1197", "r1198", "r1199", "r1200", "r1201", "r1202", "r1203", "r1204", "r1205", "r1206", "r1207", "r1208", "r1209", "r1210", "r1211", "r1212", "r1213", "r1214", "r1215", "r1216", "r1217", "r1218", "r1219", "r1220", "r1221", "r1222", "r1223", "r1224", "r1225", "r1226", "r1227", "r1228", "r1229", "r1230", "r1231", "r1232", "r1233", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253", "r1254", "r1255", "r1256", "r1257", "r1258", "r1259", "r1260", "r1261", "r1262", "r1263", "r1264", "r1265", "r1266", "r1267", "r1268", "r1269", "r1270", "r1271", "r1272", "r1273", "r1274", "r1275", "r1276", "r1277", "r1278", "r1279", "r1280", "r1281", "r1282", "r1283", "r1284", "r1285", "r1286", "r1287", "r1288", "r1289", "r1290", "r1291", "r1292", "r1293", "r1294", "r1295", "r1296", "r1297", "r1298", "r1299", "r1300", "r1301", "r1302", "r1303", "r1304", "r1305", "r1306", "r1307", "r1308", "r1309", "r1310", "r1311", "r1312", "r1313", "r1314", "r1315", "r1316", "r1317", "r1318", "r1319", "r1320", "r1321", "r1322", "r1323", "r1324", "r1325", "r1326", "r1327", "r1328", "r1329", "r1330", "r1331", "r1332", "r1333", "r1334", "r1335", "r1336", "r1337", "r1338", "r1339", "r1340", "r1341", "r1342", "r1343", "r1344", "r1345", "r1346", "r1347", "r1348", "r1349", "r1350", "r1351", "r1352", "r1353", "r1354", "r1355", "r1356", "r1357", "r1358", "r1359", "r1360", "r1361", "r1362", "r1363", "r1364", "r1365", "r1366", "r1367", "r1368", "r1369", "r1370", "r1371", "r1372", "r1373", "r1374", "r1375", "r1376", "r1377", "r1378", "r1379", "r1380", "r1381", "r1382", "r1383", "r1384", "r1385", "r1386", "r1387", "r1388", "r1389", "r1390", "r1391", "r1392", "r1393", "r1394", "r1395", "r1396", "r1397", "r1398", "r1399", "r1400", "r1401", "r1402", "r1403", "r1404", "r1405", "r1406", "r1407", "r1408", "r1409", "r1410", "r1411", "r1412", "r1413", "r1414", "r1415", "r1416", "r1417", "r1418", "r1419", "r1420", "r1421", "r1422", "r1423", "r1424", "r1425", "r1426", "r1427", "r1428", "r1429", "r1430", "r1431", "r1432", "r1433", "r1434", "r1435", "r1436", "r1437", "r1438", "r1439", "r1440", "r1441", "r1442", "r1443", "r1444", "r1445", "r1446", "r1447", "r1448", "r1449", "r1450", "r1451", "r1452", "r1453", "r1454", "r1455", "r1456", "r1457", "r1458", "r1459", "r1460", "r1461", "r1462", "r1463", "r1464", "r1465", "r1466", "r1467", "r1468", "r1469", "r1470", "r1471", "r1472", "r1473", "r1474", "r1475", "r1476", "r1477", "r1478", "r1479", "r1480", "r1481", "r1482", "r1483", "r1484", "r1485", "r1486", "r1487", "r1488", "r1489", "r1490", "r1491", "r1492", "r1493", "r1494", "r1495", "r1496", "r1497", "r1498", "r1499", "r1500", "r1501", "r1502", "r1503", "r1504", "r1505", "r1506", "r1507", "r1508", "r1509", "r1510", "r1511", "r1512", "r1513", "r1514", "r1515", "r1516", "r1517", "r1518", "r1519", "r1520", "r1521", "r1522", "r1523", "r1524", "r1525", "r1526", "r1527", "r1528", "r1529", "r1530", "r1531", "r1532", "r1533", "r1534", "r1535", "r1536", "r1537", "r1538", "r1539", "r1540", "r1541", "r1542", "r1543", "r1544", "r1545", "r1546", "r1547", "r1548", "r1549", "r1550", "r1551", "r1552", "r1553", "r1554", "r1555", "r1556", "r1557", "r1558", "r1559", "r1560", "r1561", "r1562", "r1563", "r1564", "r1565", "r1566", "r1567", "r1568", "r1569", "r1570", "r1571", "r1572", "r1573", "r1574", "r1575", "r1576", "r1577", "r1578", "r1579", "r1580", "r1581", "r1582", "r1583", "r1584", "r1585", "r1586", "r1587", "r1588", "r1589", "r1590", "r1591", "r1592", "r1593", "r1594", "r1595", "r1596", "r1597", "r1

entity's raising of capital via private rather than public placement." } } }, "auth_ref": { "r7" } } },
"ocx_ProceedsFromIssuanceOfPrivatePlacementGross": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20240930", "localname":
"ProceedsFromIssuanceOfPrivatePlacementGross", "crdr": "debit", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
"http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative" } }, "lang": {
"en-us": { "role": { "terseLabel": "Gross proceeds from the private placement", "label": "Proceeds from Issuance of Private Placement Gross",
"documentation": "Proceeds from issuance of private placement, gross." } } }, "auth_ref": { } },
"ocx_ProceedsFromSaleOfCommonSharesUnderAtTheMarketTransactions": { "xbrltype": "monetaryItemType", "nsuri":
"http://oncocyte.com/20240930", "localname": "ProceedsFromSaleOfCommonSharesUnderAtTheMarketTransactions", "crdr": "debit",
"presentation": { "http://oncocyte.com/20240930/taxonomy/role/StatementsOfCashFlows" }, "lang": { "en-us": { "role": { "label": "Proceeds from
sale of common shares under at the market transactions", "terseLabel": "Proceeds from sale of common shares under at the market transactions",
"documentation": "Proceeds from sale of common shares under at the market transactions." } } }, "auth_ref": { } }, "us-
gaap_ProceedsFromSaleOfMachineryAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ProceedsFromSaleOfMachineryAndEquipment", "crdr": "debit", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/StatementsOfCashFlows" }, "lang": { "en-us": { "role": { "label": "Proceeds from sale of equipment",
"documentation": "The cash inflow from sale of machinery and equipment." } } }, "auth_ref": { "r121" } }, "us-
gaap_ProductConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ProductConcentrationRiskMember", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails",
"http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPercentageOfConsolidatedRevenuesAt
1", "lang": { "en-us": { "role": { "label": "Product Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues during
the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also
reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant
product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or
technological obsolescence." } } }, "auth_ref": { "r131" } }, "us-gaap_ProductInformationLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ProductInformationLineItems", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
"http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails",
"http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConsolidatedRevenuesGeneratedByUn
"http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPercentageOfConsolidatedRevenuesAt
1", "lang": { "en-us": { "role": { "label": "Product Information [Line Items]", "documentation": "Line items represent financial concepts included in a
table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } },
"auth_ref": { } }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"ProductOrServiceAxis", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
"http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails",
"http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPercentageOfConsolidatedRevenuesAt
1", "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce
goods and services and not intended for resale." } } }, "auth_ref": { "r273", "r534", "r593", "r594", "r595", "r596", "r597", "r598",
"r599", "r745", "r762", "r793", "r795", "r796", "r799", "r800", "r972", "r973", "r980", "r1048", "r1050", "r1051", "r1052", "r1053", "r1054", "r1055",
"r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071",
"r1072", "r1073", "r1074", "r1075", "r1076", "r1077" } }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
"http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails",
"http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPercentageOfConsolidatedRevenuesAt
1", "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "documentation": "Information by type of long-lived, physical assets used to produce
goods and services and not intended for resale." } } }, "auth_ref": { "r273", "r534", "r593", "r594", "r595", "r596", "r597", "r598",
"r599", "r745", "r762", "r793", "r795", "r796", "r799", "r800", "r972", "r973", "r980", "r1048", "r1050", "r1051", "r1052", "r1053", "r1054",
"r1055", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070",
"r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077" } }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant
and Equipment [Abstract]", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal
conduct of business to produce goods and services and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": { } }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "lang": { "en-
us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce
goods and services and not intended for resale." } } }, "auth_ref": { "r16", "r509" } }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
"presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosurePropertyAndEquipment2", "lang": { "en-us": { "role": { "label":
"Property and Equipment", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not
intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": {
"r133", "r179", "r182", "r183" } }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfRightofuseAndFinancingLeaseAssetsMachineryAndEquip
1", "lang": { "en-us": { "role": { "totalLabel": "Right of use and financing lease assets and machinery and equipment, net", "label": "Property, Plant
and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal
conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery
and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": { "r16", "r509", "r571", "r585", "r784" } }, "us-
gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PropertyPlantAndEquipmentPolicyTextBlock", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies", "lang": { "en-us": { "role": { "terseLabel":
"Machinery and Equipment, Net, Financing Leases, Net, and Construction in Progress", "label": "Machinery and Equipment, Net, and Construction
in Progress", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended
for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": { "r16",
"r179", "r182", "r583" } }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentFables", "lang": { "en-us": { "role": { "label": "Schedule of Right-
of use and Financing Lease Assets, Machinery and Equipment, Net, and Construction in Progress", "documentation": "Tabular disclosure of
physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets,
depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation." } } }, "auth_ref": { "r16" }
"us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PropertyPlantAndEquipmentTypeDomain", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "lang": { "en-
us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal
conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and
other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and
software." } } }, "auth_ref": { "r136", "r509" } }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "lang": { "en-
us": { "role": { "label": "Estimated useful life of plant and equipment", "documentation": "Useful life of long lived, physical assets used in the
normal conduct of business and not intended for resale, in PnYnMnDnTnHnMnS format, for example, P1Y5M13D represents the reported fact of
one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment,
furniture and fixtures, and computer equipment." } } }, "auth_ref": { } }, "ocx_PuraVidaInvestmentsLLCMember": { "xbrltype": "domainItemType",
"nsuri": "http://oncocyte.com/20240930", "localname": "PuraVidaInvestmentsLLCMember", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative", "lang": { "en-us": { "role": { "label": "Pura Vida
Investments LLC [Member]", "documentation": "Pura Vida Investments LLC [Member]", "auth_ref": { } }, "ocx_PuraVidaMember": { "xbrltype":
"domainItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "PuraVidaMember", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative", "lang": { "en-us": { "role": { "label": "Pura Vida
[Member]", "documentation": "Pura Vida [Member]", "auth_ref": { } }, "ocx_PurchasePriceOfCommonStockValue": { "xbrltype":
"monetaryItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "PurchasePriceOfCommonStockValue", "crdr": "credit",
"presentation": { "http://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative", "lang": { "en-us": { "role": { "label":

"Purchase price of common stock value", "documentation": "Purchase price of common stock value." } } }, "auth_ref": { } }, "ecd_PvpTable": {
"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": {
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs
Performance Disclosure" } } }, "auth_ref": { "r849" } }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us":
{ "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": { "r849" } },
"srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesAdditionalInformationDetails
"http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
"http://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative",
"http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative",
"http://oncocyte.com/20240930/taxonomy/role/Stock-basedCompensationDetailsNarrative" }, "lang": { "en-us": { "role": { "label": "Statistical
Measurement [Axis]" } } }, "auth_ref": { "r319", "r320", "r321", "r322", "r364", "r383", "r411", "r412", "r413", "r422", "r473", "r527", "r528",
"r529", "r600", "r602", "r614", "r645", "r646", "r708", "r711", "r715", "r716", "r718", "r740", "r741", "r757", "r761", "r771", "r779", "r780", "r781",
"r782", "r795", "r803", "r970", "r976", "r1018", "r1033", "r1034", "r1035", "r1036", "r1037" } }, "srt_RangeMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesAdditionalInformationDetails
"http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
"http://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative",
"http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative",
"http://oncocyte.com/20240930/taxonomy/role/Stock-basedCompensationDetailsNarrative" }, "lang": { "en-us": { "role": { "label": "Statistical
Measurement [Domain]" } } }, "auth_ref": { "r319", "r320", "r321", "r322", "r364", "r383", "r411", "r412", "r413", "r422", "r473", "r527", "r528",
"r529", "r600", "r602", "r614", "r645", "r646", "r708", "r711", "r715", "r716", "r718", "r740", "r741", "r757", "r761", "r771", "r779", "r780", "r781",
"r782", "r795", "r803", "r970", "r976", "r1018", "r1033", "r1034", "r1035", "r1036", "r1037" } }, "ocx_RazorGenomicsIncMember": { "xbrltype":
"domainItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "RazorGenomicsIncMember", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/DiscontinuedOperationsOfRazorDetailsNarrative",
"http://oncocyte.com/20240930/taxonomy/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
"http://oncocyte.com/20240930/taxonomy/role/ScheduleOfAssetsAndLiabilitiesDiscontinuedOperationsDetails",
"http://oncocyte.com/20240930/taxonomy/role/ScheduleOfDiscontinuedOperationsDetails" }, "lang": { "en-us": { "role": { "label": "Razor Genomics,
Inc. [Member]", "documentation": "Razor Genomics, Inc. [Member]" } } }, "auth_ref": { } }, "ocx_RazorStockPurchaseAgreementMember": {
"xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "RazorStockPurchaseAgreementMember", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/DiscontinuedOperationsOfRazorDetailsNarrative",
"http://oncocyte.com/20240930/taxonomy/role/OrganizationAndDescriptionOfBusinessDetailsNarrative" }, "lang": { "en-us": { "role": { "label":
"Razor Stock Purchase Agreement [Member]", "documentation": "Razor Stock Purchase Agreement [Member]" } } }, "auth_ref": { } },
"ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line
Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": { "r817", "r827", "r837", "r869" } },
"ocx_RegisteredDirectOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20240930", "localname":
"RegisteredDirectOfferingMember", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative" }, "lang": {
"en-us": { "role": { "label": "Registered Direct Offering [Member]", "documentation": "Registered Direct Offering [Member]" } } }, "auth_ref": { } },
"us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain",
"presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative",
"http://oncocyte.com/20240930/taxonomy/role/DiscontinuedOperationsOfRazorDetailsNarrative",
"http://oncocyte.com/20240930/taxonomy/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
"http://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative" }, "lang": { "en-us": { "role": { "label": "Related and
Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other
entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of
immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership
interest." } } }, "auth_ref": { "r277", "r373", "r518", "r519", "r573", "r582", "r648", "r649", "r650", "r651", "r652", "r674", "r676", "r707" } }, "us-
gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RelatedPartyTransactionAxis", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative" },
"lang": { "en-us": { "role": { "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } },
"auth_ref": { "r518", "r519", "r1029" } }, "us-gaap_RelatedPartyTransactionDescriptionOfTransaction": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionDescriptionOfTransaction", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative" }, "lang": { "en-us": { "role": { "label": "Related party
transaction, description", "documentation": "A description of the related party transaction, including transactions to which no amounts or nominal
amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial
statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received
or furnished, loans and leases to and from top management and affiliates." } } }, "auth_ref": { "r172", "r200", "r508", "r511", "r512", "r517" } },
"us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RelatedPartyTransactionDomain", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative" },
"lang": { "en-us": { "role": { "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } },
"auth_ref": { } }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RelatedPartyTransactionLineItems", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative" },
"lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included
in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } },
"auth_ref": { "r277", "r681", "r682", "r685" } }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions
[Abstract]" } } }, "auth_ref": { } }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative",
"http://oncocyte.com/20240930/taxonomy/role/DiscontinuedOperationsOfRazorDetailsNarrative",
"http://oncocyte.com/20240930/taxonomy/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
"http://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative" }, "lang": { "en-us": { "role": { "label": "Related and
Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate,
other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of
immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or
ownership interest." } } }, "auth_ref": { "r277", "r373", "r518", "r519", "r573", "r582", "r648", "r649", "r650", "r651", "r652", "r674", "r676", "r707",
"r1029" } }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactions" }, "lang": { "en-us": { "role": { "label": "Related Party Transactions",
"documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a
parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } },
"auth_ref": { "r515", "r516", "r517", "r519", "r520", "r626", "r627", "r628", "r683", "r684", "r685", "r704", "r706" } },
"ocx_RepaymentOfFinancingLeaseObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20240930", "localname":
"RepaymentOfFinancingLeaseObligations", "crdr": "credit", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/StatementsOfCashFlows" }, "lang": { "en-us": { "role": { "negatedLabel": "Repayment of financing
lease obligations", "documentation": "Repayment of financing lease obligations." } } }, "label": "RepaymentOfFinancingLeaseObligations" } } },
"auth_ref": { } }, "us-gaap_RepaymentsOfRelatedPartyDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RepaymentsOfRelatedPartyDebt", "crdr": "credit", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/DiscontinuedOperationsOfRazorDetailsNarrative" }, "lang": { "en-us": { "role": { "label": "Payment to
related party", "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can
exercise control or significant influence over another party, including affiliates, owners or officers and their immediate families, pension trusts,
and so forth. Alternate caption: Payments for Advances from Affiliates." } } }, "auth_ref": { "r125" } }, "us-gaap_ResearchAndDevelopmentExpense":
{ "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit",
"presentation": { "http://oncocyte.com/20240930/taxonomy/role/CollaborativeArrangementsDetailsNarrative",
"http://oncocyte.com/20240930/taxonomy/role/StatementsOfOperations" }, "lang": { "en-us": { "role": { "terseLabel": "Research and development
expenses", "totalLabel": "Research and Development Expense, Total", "label": "Research and development", "documentation": "Amount of expense

for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": { "r425", "r743", "r755", "r1038" } }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/SummaryOfStock-basedCompensationExpenseDetails": { "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": { "r425", "r743", "r755", "r1038" } }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies": { "lang": { "en-us": { "role": { "label": "Research and Development Expenses", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": { "r424" } }, "us-gaap_ResearchMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Research Tax Credit [Member]", "label": "Research Tax Credit Carryforward [Member]", "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes." } } }, "auth_ref": { "r1010" } }, "srt_RestatementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RestatementAxis", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPriorPeriodRevisionsDetails": { "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Axis]", "documentation": "Revision of prior period financial statements." } } }, "auth_ref": { "r187", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r240", "r241", "r242", "r243", "r244", "r245", "r262", "r284", "r285", "r443", "r444", "r445", "r446", "r451", "r452", "r465", "r466", "r467", "r468", "r489", "r491", "r513", "r514", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r618", "r948" } }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "documentation": "Restatement Determination Date." } } }, "auth_ref": { "r818", "r828", "r838", "r870" } }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date", "documentation": "Restatement Determination Date." } } }, "auth_ref": { "r819", "r829", "r839", "r871" } }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "documentation": "Restatement does not require recovery." } } }, "auth_ref": { "r826", "r836", "r846", "r878" } }, "srt_RestatementDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RestatementDomain", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPriorPeriodRevisionsDetails": { "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Domain]", "documentation": "Revision of prior period financial statements." } } }, "auth_ref": { "r187", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r240", "r241", "r242", "r243", "r244", "r245", "r262", "r284", "r285", "r443", "r444", "r445", "r446", "r451", "r452", "r465", "r466", "r467", "r468", "r489", "r491", "r513", "r514", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r618", "r948" } }, "us-gaap_RestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCash", "crdr": "debit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative": { "lang": { "en-us": { "role": { "verboseLabel": "Restricted cash", "label": "Restricted Cash", "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": { "r918", "r932", "r1041", "r1043" } }, "us-gaap_RestrictedCashNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashNoncurrent", "crdr": "debit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/BalanceSheets": { "lang": { "en-us": { "role": { "label": "Restricted cash", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": { "r174", "r919", "r932" } }, "us-gaap_RestrictedStockExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockExpense", "crdr": "debit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/SummaryOfStockOptionActivityDetails": { "lang": { "en-us": { "role": { "label": "Stock-based compensation expense for RSUs", "documentation": "Amount of noncash expense for award of restricted stock or unit under share-based payment arrangement." } } }, "auth_ref": { "r14" } }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCommonStockComputationOfDiluted": { "http://oncocyte.com/20240930/taxonomy/role/Stock-basedCompensationDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": { "r14" } }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/BalanceSheets": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPriorPeriodRevisionsDetails": { "http://oncocyte.com/20240930/taxonomy/role/OrganizationAndDescriptionOfBusinessDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": { "r105", "r146", "r580", "r608", "r613", "r625", "r656", "r784" } }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/StatementsOfSeriesRedeemableConvertiblePreferredStockAndShareholdersEquity": { "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit [Member]", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": { "r186", "r229", "r230", "r231", "r233", "r239", "r242", "r244", "r283", "r286", "r312", "r438", "r439", "r442", "r443", "r444", "r446", "r451", "r452", "r458", "r460", "r461", "r463", "r466", "r490", "r492", "r604", "r606", "r629", "r1079" } }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDisaggregationOfRevenueDetails": { "http://oncocyte.com/20240930/taxonomy/role/StatementsOfOperations": { "lang": { "en-us": { "role": { "label": "Net revenue", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": { "r168", "r169", "r263", "r268", "r269", "r270", "r272", "r273", "r274", "r276", "r360", "r361", "r534" } }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies": { "lang": { "en-us": { "role": { "label": "Revenue Recognition", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": { "r184", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r744" } }, "srt_RevisionOfPriorPeriodReclassificationAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RevisionOfPriorPeriodReclassificationAdjustmentMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPriorPeriodRevisionsDetails": { "lang": { "en-us": { "role": { "label": "Revision of Prior Period, Reclassification, Adjustment [Member]", "documentation": "Revision of prior period financial statements." } } }, "auth_ref": { "r188", "r948" } }, "ocx_RightOfUseAndFinancingLeaseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "RightOfUseAndFinancingLeaseAssets", "crdr": "debit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosurePropertyAnd

"domainItemType": "nsuri", "http://oncocyte.com/20240930", "localname": "RoyaltyOneMember", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesScheduleOfFairValueOfConti
l", "lang": { "en-us": { "role": { "label": "Royalty 1 [Member]", "documentation": "Royalty 1 [Member]" } } }, "auth_ref": { } },
"ocx_RoyaltyTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "RoyaltyTwoMember",
"presentation": {
"http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesScheduleOfFairValueOfConti
l", "lang": { "en-us": { "role": { "label": "Royalty 2 [Member]", "documentation": "Royalty 2 [Member]" } } }, "auth_ref": { } },
"ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"Rule10b51ArrAdoptedFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "label":
"Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": { "r887" } },
"ecd_Rule10b51ArrTrmtdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmtdFlag",
"presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement
Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": { "r887" } }, "us-
gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SaleOfStockNameOfTransactionDomain", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/DisclosureSubsequentEventsDetailsNarrative",
"http://oncocyte.com/20240930/taxonomy/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
"http://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative",
"http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative",
"http://oncocyte.com/20240930/taxonomy/role/StatementsOfSeriesRedeemableConvertiblePreferredStockAndShareholdersEquity" }, "lang": { "en-
us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering
(IPO) and private placement." } } }, "auth_ref": { } }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/DisclosureSubsequentEventsDetailsNarrative",
"http://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative",
"http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative" }, "lang": {
"en-us": { "role": { "terseLabel": "Number of sale of shares", "label": "Number of sale of shares", "verboseLabel": "Sale of stock, shares",
"documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": { } },
"ocx_SaleOfStockOfferingPricePerShareToInsiders": { "xbrltype": "perShareItemType", "nsuri": "http://oncocyte.com/20240930", "localname":
"SaleOfStockOfferingPricePerShareToInsiders", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative" }, "lang": { "en-us": { "role": { "terseLabel": "Offering
price to insiders", "label": "Sale Of Stock Offering Price Per Share To Insiders", "documentation": "Sale of stock offering price per share to
insiders." } } }, "auth_ref": { } }, "ocx_SaleOfStockOfferingPricePerShareToInvestors": { "xbrltype": "perShareItemType", "nsuri":
"http://oncocyte.com/20240930", "localname": "SaleOfStockOfferingPricePerShareToInvestors", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative" }, "lang": { "en-us": { "role": { "terseLabel": "Offering
price to investors", "label": "Sale Of Stock Offering Price Per Share To Investors", "documentation": "Sale of stock offering price per share to
investors." } } }, "auth_ref": { } }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "SaleOfStockPricePerShare", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/DisclosureSubsequentEventsDetailsNarrative",
"http://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative",
"http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative" }, "lang": {
"en-us": { "role": { "terseLabel": "Sale of stock price per share", "label": "Sale of stock price per share", "documentation": "Per share amount
received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": { } },
"ocx_SalesAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "SalesAgreementMember",
"presentation": { "http://oncocyte.com/20240930/taxonomy/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
"http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative" }, "lang": {
"en-us": { "role": { "terseLabel": "Sales Agreement [Member]", "label": "Sales Agreement [Member]", "documentation": "Sales agreement" } } },
"auth_ref": { } }, "ocx_SalesAndMarketingExpensesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://oncocyte.com/20240930",
"localname": "SalesAndMarketingExpensesPolicyTextBlock", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" }, "lang": { "en-us": { "role": { "label": "Sales and
Marketing Expenses", "documentation": "Sale sAnd Marketing Expenses [Policy Text Block]" } } }, "auth_ref": { } }, "us-
gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesRevenueNetMember",
"presentation": {
"http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails",
"http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConsolidatedRevenuesGeneratedByUn
"http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPercentageOfConsolidatedRevenuesAt
l", "lang": { "en-us": { "role": { "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service
and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": { "r276", "r906" } },
"srt_ScenarioPreviouslyReportedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"ScenarioPreviouslyReportedMember", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPriorPeriodRevisionsDetails" },
"lang": { "en-us": { "role": { "label": "Previously Reported [Member]" } } }, "auth_ref": { "r187", "r229", "r231", "r232", "r233", "r234", "r235",
"r244", "r262", "r443", "r445", "r446", "r451", "r452", "r465", "r466", "r467", "r489", "r491", "r604", "r605", "r606", "r607", "r608", "r609", "r610",
"r611", "r612", "r613", "r618", "r908", "r912", "r913", "r914", "r938", "r948", "r952", "r953", "r1016", "r1026", "r1027" } },
"srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain",
"presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative" }, "lang": { "en-us": {
"role": { "label": "Scenario [Domain]" } } }, "auth_ref": { "r245", "r384", "r899", "r939" } }, "us-
gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
"presentation": {
"http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCommonStockComputationOfDiluted
l", "lang": { "en-us": { "role": { "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information
about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } },
"auth_ref": { "r40" } }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/BusinessCombinationsAndContingentConsiderationLiabilitiesTables" }, "lang": { "en-us": { "role": {
"label": "Schedule of Fair Value of Contingent Consideration Liability", "documentation": "Tabular disclosure of contingent payment arrangements
including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the
potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the
period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent
options and commitments." } } }, "auth_ref": { } }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/BusinessCombinationsAndContingentConsiderationLiabilitiesTables",
"http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesAdditionalInformationDetails",
"http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesScheduleOfContingentConsid
"http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesScheduleOfFairValueOfConti
l", "lang": { "en-us": { "role": { "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Disclosure of information
about business combination. Includes, but is not limited to, recognized asset and liability." } } }, "auth_ref": { "r63", "r64", "r447" } }, "us-
gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
"presentation": { "http://oncocyte.com/20240930/taxonomy/role/OrganizationAndDescriptionOfBusinessDetailsNarrative" }, "lang": { "en-us": {
"role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information
about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } },
"auth_ref": { "r453" } }, "ocx_ScheduleOfContingentConsiderationMeasuredAtFairValueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://oncocyte.com/20240930", "localname": "ScheduleOfContingentConsiderationMeasuredAtFairValueTableTextBlock", "presentation": {
"http://oncocyte.com/20240930/taxonomy/role/BusinessCombinationsAndContingentConsiderationLiabilitiesTables" }, "lang": { "en-us": { "role": {
"label": "Schedule of Contingent Consideration, Measured at Fair Value", "documentation": "Schedule of contingent consideration measured at fair
value [Table Text Block]" } } }, "auth_ref": { } }, "us-

gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "presentation":
f"http://oncocyte.com/20240930/taxonomy/role/DiscontinuedOperationsOffRazorTables" }, "lang": { "en-us": { "role": { "label": "Schedule of
Discontinued Operations", "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a
discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant
component." } } }, "auth_ref": { "r17", "r23", "r26", "r75", "r81", "r82", "r83", "r84", "r85", "r90", "r92", "r93", "r139" } }, "us-
gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ScheduleOfEarningsPerShareBasicByCommonClassTextBlock", "presentation": f
"http://oncocyte.com/20240930/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables" }, "lang": { "en-us": { "role": { "label": "Schedule of
Common Stock Computation of Diluted Net Loss Per Share of Common Stock", "documentation": "Tabular disclosure of the effect of income (loss)
on basic earnings per share." } } }, "auth_ref": { "r39", "r42", "r941" } }, "us-
gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
"presentation": f "http://oncocyte.com/20240930/taxonomy/role/SummaryOfStock-basedCompensationExpenseDetails" }, "lang": { "en-us": { "role":
{ "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about
amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or
comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } },
"auth_ref": { "r62" } }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": f
"http://oncocyte.com/20240930/taxonomy/role/Stock-basedCompensationTables" }, "lang": { "en-us": { "role": { "label": "Summary of Stock-based
Compensation Expense", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based
payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to,
corresponding line item in financial statement." } } }, "auth_ref": { "r62" } },
"srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024",
"localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": f
"http://oncocyte.com/20240930/taxonomy/role/DiscontinuedOperationsOffRazorDetailsNarrative",
"http://oncocyte.com/20240930/taxonomy/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
"http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative" }, "lang": {
"en-us": { "role": { "label": "Investment, Name [Axis]" } } }, "auth_ref": { "r279", "r280", "r281", "r441", "r900", "r901", "r902", "r1011", "r1012",
"r1013", "r1014" } }, "ocx_ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesTableTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://oncocyte.com/20240930", "localname":
"ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesTableTextBlock", "presentation": f
"http://oncocyte.com/20240930/taxonomy/role/CommitmentsAndContingenciesTables" }, "lang": { "en-us": { "role": { "label": "Schedule of Future
Minimum Lease Commitments for Operating and Financing Leases", "documentation": "Schedule of future minimum lease commitments for
operating and financing leases [Table Text Block]" } } }, "auth_ref": { } }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable", "presentation": f
"http://oncocyte.com/20240930/taxonomy/role/ScheduleOfIntangibleAssetsNetDetails" }, "lang": { "en-us": { "role": { "label": "Intangible Asset,
Indefinite-Lived [Table]", "documentation": "Disclosure of information about indefinite-lived intangible asset. Excludes finite-lived intangible
asset." } } }, "auth_ref": { "r296", "r306", "r310", "r758" } }, "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
"presentation": f "http://oncocyte.com/20240930/taxonomy/role/IntangibleAssetsNetTables" }, "lang": { "en-us": { "role": { "label": "Schedule of
Intangible Assets, Net", "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major
class." } } }, "auth_ref": { "r954", "r955" } }, "ocx_ScheduleOfOperatingAndFinanceLeaseBalanceSheetTableTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "ScheduleOfOperatingAndFinanceLeaseBalanceSheetTableTextBlock",
"presentation": f "http://oncocyte.com/20240930/taxonomy/role/CommitmentsAndContingenciesTables" }, "lang": { "en-us": { "role": { "label":
"Schedule of Supplemental Balance Sheet Information Related to Operating and Financing Leases", "documentation": "Schedule of operating and
finance lease balance sheet [TableTextBlock]" } } }, "auth_ref": { } }, "ocx_ScheduleOfOperatingAndFinanceLeaseCashFlowTableTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://oncocyte.com/20240930", "localname":
"ScheduleOfOperatingAndFinanceLeaseCashFlowTableTextBlock", "presentation": f
"http://oncocyte.com/20240930/taxonomy/role/CommitmentsAndContingenciesTables" }, "lang": { "en-us": { "role": { "label": "Schedule of
Supplemental Cash Flow Information Related to Operating and Financing Lease", "documentation": "Schedule of operating and finance lease
cashflow [Table Text Block]" } } }, "auth_ref": { } }, "ocx_ScheduleOfPriorPeriodRevisionsTableTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://oncocyte.com/20240930", "localname": "ScheduleOfPriorPeriodRevisionsTableTextBlock", "presentation": f
"http://oncocyte.com/20240930/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables" }, "lang": { "en-us": { "role": { "label": "Schedule of
Prior Period Revisions", "documentation": "Schedule of Prior Period Revisions [Table Text Block]" } } }, "auth_ref": { } }, "us-
gaap_ScheduleOfProductInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfProductInformationTable", "presentation": f
"http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
"http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConcentrationOfRiskDetails",
"http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfConsolidatedRevenuesGeneratedByUn",
"http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPercentageOfConsolidatedRevenuesAt",
"lang": { "en-us": { "role": { "label": "Nature of Operation, Product Information, Concentration of Risk [Table]", "documentation": "Disclosure of
information about concentration risk of product within nature of operation." } } }, "auth_ref": { } }, "us-
gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": f
"http://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative" }, "lang": { "en-us": { "role": { "label": "Related Party
Transaction [Table]", "documentation": "Disclosure of information about related party transaction." } } }, "auth_ref": { "r70", "r681", "r682",
"r685" } }, "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "presentation": f
"http://oncocyte.com/20240930/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables" }, "lang": { "en-us": { "role": { "label": "Schedule of
Consolidated Revenues Generated by Unaffiliated Customers", "documentation": "Tabular disclosure of the extent of the entity's reliance on its
major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the
disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting
the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that
customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the
federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single
customer." } } }, "auth_ref": { } }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock":
{ "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "presentation": f
"http://oncocyte.com/20240930/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables" }, "lang": { "en-us": { "role": { "label": "Schedule of
Percentage of Consolidated Revenues Attributable to Geographical Locations", "documentation": "Tabular disclosure of information concerning
material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights,
deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external
customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups
of countries." } } }, "auth_ref": { "r50", "r110" } }, "us-
gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
"presentation": f "http://oncocyte.com/20240930/taxonomy/role/Stock-basedCompensationDetailsNarrative",
"http://oncocyte.com/20240930/taxonomy/role/SummaryOfStockOptionActivityDetails" }, "lang": { "en-us": { "role": { "label": "Schedule of Share-
Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based
payment arrangement." } } }, "auth_ref": { "r386", "r387", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399",
"r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414" } }, "us-
gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": f
"http://oncocyte.com/20240930/taxonomy/role/Stock-basedCompensationTables" }, "lang": { "en-us": { "role": { "label": "Summary of Stock Option
Activity", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of
year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": { "r21", "r22", "r150" } }, "us-

gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/Stock-basedCompensationTables": { "lang": { "en-us": { "role": { "label": "Schedule of Assumptions Used to Calculate Fair Value of Stock Options", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rates(s), and (e) discount for post-vesting restrictions." } } } }, "auth_ref": { "r153": { } }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } } }, "auth_ref": { "r55", "r56", "r57", "r58", "r59", "r60", "r142", "r144", "r145", "r146", "r201", "r202", "r203", "r265", "r334", "r335", "r337", "r339", "r342", "r347", "r349", "r621", "r622", "r623", "r624", "r761", "r898", "r933": { } }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/IntangibleAssetsNetTables": { "lang": { "en-us": { "role": { "label": "Schedule of Intangible Assets Future Amortization Expense", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } } }, "auth_ref": { "r758", "r963": { } }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables": { "lang": { "en-us": { "role": { "label": "Schedule of Concentration of Risk", "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark." } } } }, "auth_ref": { "r43", "r44", "r45", "r46", "r67", "r159": { } }, "ocx_SecuritiesPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "SecuritiesPurchaseAgreementMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSubsequentEventsDetailsNarrative": { "http://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative": { "http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Securities Purchase Agreement [Member]", "documentation": "Securities Purchase Agreement [Member]" } } } }, "auth_ref": { "r1": { } }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/Cover": { "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } } }, "auth_ref": { "r812": { } }, "us-gaap_SecurityDeposit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecurityDeposit", "crdr": "debit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Security deposit", "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease." } } } }, "auth_ref": { "r919": { } }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/Cover": { "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } } }, "auth_ref": { "r814": { } }, "ocx_SecurityMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "SecurityMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Security [Member]", "documentation": "Security [Member]" } } } }, "auth_ref": { "r1": { } }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPercentageOfConsolidatedRevenuesAt": { "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "documentation": "Geographical [Domain]" } } } }, "auth_ref": { "r274", "r275", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r642", "r643", "r644", "r710", "r713", "r717", "r720", "r727", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r746", "r763", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r797", "r803", "r980", "r1048", "r1050", "r1051", "r1053", "r1054", "r1055", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077": { } }, "ocx_SegmentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "SegmentsPolicyTextBlock", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/SummaryOfSignificantAccountingPolicies": { "lang": { "en-us": { "role": { "label": "Segments", "documentation": "Segments [Policy Text Block]" } } } }, "auth_ref": { "r1": { } }, "us-gaap_SellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingAndMarketingExpense", "crdr": "debit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/CollaborativeArrangementsDetailsNarrative": { "http://oncocyte.com/20240930/taxonomy/role/StatementsOfOperations": { "lang": { "en-us": { "role": { "terseLabel": "Sales and marketing expenses", "totalLabel": "Selling and Marketing Expense, Total", "label": "Sales and marketing", "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services." } } } }, "auth_ref": { "r1": { } }, "us-gaap_SellingAndMarketingExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingAndMarketingExpenseMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/SummaryOfStock-basedCompensationExpenseDetails": { "lang": { "en-us": { "role": { "label": "Selling and Marketing Expense [Member]", "documentation": "Primary financial statement caption encompassing selling and marketing expense." } } } }, "auth_ref": { "r116": { } }, "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies": { "lang": { "en-us": { "role": { "label": "General and Administrative Expenses", "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption." } } } }, "auth_ref": { "r1008": { } }, "us-gaap_SeriesAPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesAPreferredStockMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative": { "http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Series A Preferred Stock [Member]", "documentation": "Series A preferred stock." } } } }, "auth_ref": { "r920", "r921", "r979": { } }, "ocx_SeriesARedeemableConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "SeriesARedeemableConvertiblePreferredStockMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/BalanceSheetsParenthetical": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCommonStockComputationOfDiluted": { "http://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative": { "http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative": { "http://oncocyte.com/20240930/taxonomy/role/StatementsOfSeriesRedeemableConvertiblePreferredStockAndShareholdersEquity": { "lang": { "en-us": { "role": { "label": "Series A Redeemable Convertible Preferred Stock [Member]", "documentation": "Series A Redeemable Convertible Preferred Stock [Member]" } } } }, "auth_ref": { "r1": { } }, "us-gaap_SeriesBPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesBPreferredStockMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Series B Preferred Stock [Member]", "documentation": "Series B preferred stock." } } } }, "auth_ref": { "r920", "r921", "r979": { } }, "us-gaap_SeveranceCosts1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeveranceCosts1", "crdr": "debit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Severance costs", "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation." } } } }, "auth_ref": { "r14": { } }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/StatementsOfCashFlows": { "http://oncocyte.com/20240930/taxonomy/role/SummaryOfStockOptionActivityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "Unrecognized stock-based compensation expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } } }, "auth_ref": { "r13": { } }, "ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalNumberOfSharesAvailableForGrant", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/Stock-basedCompensationDetailsNarrative": { "lang": { "en-us": { "role": { "terseLabel": "Additional shares of common stock to be available for issuance", "label": "Share Based Compensation Arrangement By Share Based Payment Award Additional

Number of Shares Available for Grant", "documentation": "Share-based compensation arrangement by share-based payment award additional number of shares available for grant." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": ["http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": ["en-us"], "role": ["label", "Option vesting period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDfTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days, and thirteen days, but is not limited to, combination of market, performance or service condition."] } }, "auth_ref": ["r772"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": ["http://oncocyte.com/20240930/taxonomy/role/SummaryOfStockOptionActivityDetails"], "lang": ["en-us"], "role": ["negatedLabel", "Weighted average exercise price, options outstanding RSUs forfeited", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."] } }, "auth_ref": ["r405"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDate": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": ["http://oncocyte.com/20240930/taxonomy/role/SummaryOfStockOptionActivityDetails"], "lang": ["en-us"], "role": ["label", "Weighted average exercise price, options outstanding, RSUs forfeited", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."] } }, "auth_ref": ["r405"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": ["http://oncocyte.com/20240930/taxonomy/role/Stock-basedCompensationDetailsNarrative"], "lang": ["en-us"], "role": ["label", "Number of shares granted", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."] } }, "auth_ref": ["r403"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDate": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://oncocyte.com/20240930/taxonomy/role/Stock-basedCompensationDetailsNarrative"], "lang": ["en-us"], "role": ["label", "Weighted average exercise price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."] } }, "auth_ref": ["r403"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": ["http://oncocyte.com/20240930/taxonomy/role/SummaryOfStockOptionActivityDetails"], "lang": ["en-us"], "role": ["periodStartLabel", "Number of RSUs Outstanding, beginning of period", "periodEndLabel", "Number of RSUs Outstanding, end of period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."] } }, "auth_ref": ["r400", "r401"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDate": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": ["http://oncocyte.com/20240930/taxonomy/role/SummaryOfStockOptionActivityDetails"], "lang": ["en-us"], "role": ["periodStartLabel", "Weighted average exercise price, options outstanding, beginning of period", "periodEndLabel", "Weighted average exercise price, exercisable, end of period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."] } }, "auth_ref": ["r400", "r401"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": ["http://oncocyte.com/20240930/taxonomy/role/Stock-basedCompensationDetailsNarrative"], "lang": ["en-us"], "role": ["negatedLabel", "Number of RSUs Outstanding, options outstanding vested", "label": "Number of shares vested", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."] } }, "auth_ref": ["r404"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": ["http://oncocyte.com/20240930/taxonomy/role/ScheduleOfAssumptionsUsedToCalculateFairValueOfStockOptionsDetails", "http://oncocyte.com/20240930/taxonomy/role/Stock-basedCompensationDetailsNarrative"], "lang": ["en-us"], "role": ["label", "Dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."] } }, "auth_ref": ["r412"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": ["http://oncocyte.com/20240930/taxonomy/role/ScheduleOfAssumptionsUsedToCalculateFairValueOfStockOptionsDetails", "http://oncocyte.com/20240930/taxonomy/role/Stock-basedCompensationDetailsNarrative"], "lang": ["en-us"], "role": ["label", "Volatility", "verboseLabel": "Expected volatility", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."] } }, "auth_ref": ["r411"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": ["http://oncocyte.com/20240930/taxonomy/role/ScheduleOfAssumptionsUsedToCalculateFairValueOfStockOptionsDetails", "http://oncocyte.com/20240930/taxonomy/role/Stock-basedCompensationDetailsNarrative"], "lang": ["en-us"], "role": ["label", "Risk-free interest rates", "verboseLabel": "Risk-free interest rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."] } }, "auth_ref": ["r413"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": ["http://oncocyte.com/20240930/taxonomy/role/Stock-basedCompensationDetailsNarrative", "http://oncocyte.com/20240930/taxonomy/role/SummaryOfStockOptionActivityDetails"], "lang": ["en-us"], "role": ["label", "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."] } }, "auth_ref": ["r386", "r387", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414"] }, "us-

gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": ["http://oncocyte.com/20240930/taxonomy/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Number of shares available for grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": ["r61"] }, "ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice", "presentation": ["http://oncocyte.com/20240930/taxonomy/role/SummaryOfStockOptionActivityDetails"], "lang": { "en-us": { "role": { "periodEndLabel": "Weighted average exercise price, options outstanding, exercisable", "documentation": "Share-based compensation arrangement by share-based payment award option outstanding weighted average exercise price." }, "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": ["http://oncocyte.com/20240930/taxonomy/role/SummaryOfStockOptionActivityDetails"], "lang": { "en-us": { "role": { "periodEndLabel": "Number of Options, Options Outstanding and exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": ["r394"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": ["http://oncocyte.com/20240930/taxonomy/role/SummaryOfStockOptionActivityDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Number of options, forfeited/expired", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": ["r398"] }, "ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue", "crdr": "debit", "presentation": ["http://oncocyte.com/20240930/taxonomy/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Fair value of options granted", "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award Options Grants In Period Grant Date Fair Value." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": ["http://oncocyte.com/20240930/taxonomy/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Number of options outstanding, Options granted", "verboseLabel": "Stock option grant", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": ["r396"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://oncocyte.com/20240930/taxonomy/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Fair value grants", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option-pricing methodology." } } }, "auth_ref": ["r406"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": ["http://oncocyte.com/20240930/taxonomy/role/SummaryOfStockOptionActivityDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Aggregate intrinsic value balance", "periodEndLabel": "Aggregate intrinsic value balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": ["r61"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": ["http://oncocyte.com/20240930/taxonomy/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "periodStartLabel": "Number of options outstanding, beginning of period", "periodEndLabel": "Number of options outstanding, end of period", "label": "Stock options outstanding", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r392", "r393"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": ["http://oncocyte.com/20240930/taxonomy/role/SummaryOfStockOptionActivityDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted average exercise price, beginning of period", "periodEndLabel": "Number of options outstanding, ending of period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": ["r392", "r393"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": ["http://oncocyte.com/20240930/taxonomy/role/SummaryOfStockOptionActivityDetails"], "lang": { "en-us": { "role": { "periodEndLabel": "Number of options, vested and expected to vest", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r408"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": ["http://oncocyte.com/20240930/taxonomy/role/SummaryOfStockOptionActivityDetails"], "lang": { "en-us": { "role": { "periodEndLabel": "Weighted average exercise price, options vested and expected to vest", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r408"] }, "ocx_ShareBasedCompensationArrangementByShareBasedPaymentTimeBasedAwardOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentTimeBasedAwardOptionsGrantsInPeriod", "presentation": ["http://oncocyte.com/20240930/taxonomy/role/Stock-basedCompensationDetailsNarrative"], "lang": { "en-us": { "role": { "terseLabel": "Stock options, time-based awards granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Time Based Award Options Grants In Period", "documentation": "Share-based compensation arrangement by share-based payment time-based award options grants in period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://oncocyte.com/20240930/taxonomy/role/Stock-basedCompensationDetailsNarrative", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [

<http://oncocyte.com/20240930/taxonomy/role/SummaryOfStockOptionActivityDetails> }, {"lang": {"en-us": {"role": {"label": "Weighted average exercise price, forfeited/expired", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, {"auth_ref": {"r398" } }, {"us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": {"http://oncocyte.com/20240930/taxonomy/role/SummaryOfStockOptionActivityDetails"}, {"lang": {"en-us": {"role": {"label": "Weighted average exercise price, Options granted", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, {"auth_ref": {"r396" } }, {"us-gaap_ShareBasedCompensationAwardTrancheOneMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": {"http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative"}, {"lang": {"en-us": {"role": {"label": "Share-Based Payment Arrangement, Tranche One [Member]", "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, {"auth_ref": {"r77" } }, {"us-gaap_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested", "crdr": "debit", "presentation": {"http://oncocyte.com/20240930/taxonomy/role/Stock-basedCompensationDetailsNarrative"}, {"lang": {"en-us": {"role": {"label": "Aggregate fair value of RSUs vested", "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options." } } }, {"auth_ref": {"r77" } }, {"us-gaap_ShareBasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {"xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": {"http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"}, {"lang": {"en-us": {"role": {"label": "Option maximum contractual term", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, {"auth_ref": {"r773" } }, {"us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {"xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": {"http://oncocyte.com/20240930/taxonomy/role/ScheduleOfAssumptionsUsedToCalculateFairValueOfStockOptionsDetails"}, {"lang": {"en-us": {"role": {"label": "Expected life (in years)", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, {"auth_ref": {"r410" } }, {"us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {"xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": {"http://oncocyte.com/20240930/taxonomy/role/SummaryOfStockOptionActivityDetails"}, {"lang": {"en-us": {"role": {"label": "Weighted average remaining contractual life exercisable", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, {"auth_ref": {"r61" } }, {"ocx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm": {"xbrltype": "durationItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm", "presentation": {"http://oncocyte.com/20240930/taxonomy/role/SummaryOfStockOptionActivityDetails"}, {"lang": {"en-us": {"role": {"label": "Weighted average remaining recognition of period", "documentation": "Share-based compensation arrangement by share-based payment award options outstanding weighted average remaining contractual term." } } }, {"auth_ref": {"r77" } }, {"us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {"xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": {"http://oncocyte.com/20240930/taxonomy/role/SummaryOfStockOptionActivityDetails"}, {"lang": {"en-us": {"role": {"label": "Weighted average remaining contractual life", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, {"auth_ref": {"r152" } }, {"us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm": {"xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm", "presentation": {"http://oncocyte.com/20240930/taxonomy/role/SummaryOfStockOptionActivityDetails"}, {"lang": {"en-us": {"role": {"label": "Weighted average remaining contractual life vested and expected to vest", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, {"auth_ref": {"r409" } }, {"us-gaap_SharesIssuedPricePerShare": {"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": {"http://oncocyte.com/20240930/taxonomy/role/DisclosureSubsequentEventsDetailsNarrative"}, {"http://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative"}, {"http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative"}, {"lang": {"en-us": {"role": {"label": "Share price", "documentation": "Per share or per unit amount of equity securities issued." } } }, {"auth_ref": {"r77" } }, {"us-gaap_SharesOutstanding": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": {"http://oncocyte.com/20240930/taxonomy/role/StatementsOfSeriesRedeemableConvertiblePreferredStockAndShareholdersEquity"}, {"lang": {"en-us": {"role": {"label": "PeriodStartLabel": "Balance, shares", "periodEndLabel": "Balance, shares", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, {"auth_ref": {"r77" } }, {"us-gaap_SignificantAccountingPoliciesTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": {"http://oncocyte.com/20240930/taxonomy/role/SummaryOfSignificantAccountingPolicies"}, {"lang": {"en-us": {"role": {"label": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, {"auth_ref": {"r129", "r226" } }, {"us-gaap_StatementClassOfStockAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": {"http://oncocyte.com/20240930/taxonomy/role/BalanceSheetsParentetical"}, {"http://oncocyte.com/20240930/taxonomy/role/OrganizationAndDescriptionOfBusinessDetailsNarrative"}, {"http://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative"}, {"http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative"}, {"http://oncocyte.com/20240930/taxonomy/role/StatementsOfSeriesRedeemableConvertiblePreferredStockAndShareholdersEquity"}, {"lang": {"en-us": {"role": {"label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, {"auth_ref": {"r185", "r201", "r202", "r203", "r228", "r249", "r250", "r257", "r259", "r265", "r266", "r282", "r323", "r325", "r326", "r327", "r330", "r331", "r334", "r335", "r339", "r342", "r349", "r481", "r621", "r622", "r623", "r624", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r641", "r655", "r678", "r700", "r721", "r722", "r723", "r724", "r725", "r898", "r933", "r942" } }, {"us-gaap_StatementEquityComponentsAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": {"http://oncocyte.com/20240930/taxonomy/role/DisclosureSubsequentEventsDetailsNarrative"}, {"http://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative"}, {"http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative"}, {"http://oncocyte.com/20240930/taxonomy/role/StatementsOfSeriesRedeemableConvertiblePreferredStockAndShareholdersEquity"}, {"lang": {"en-us": {"role": {"label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, {"auth_ref": {"r20", "r104", "r106", "r107", "r186", "r214", "r215", "r216", "r229", "r230", "r231", "r233", "r239", "r242", "r244", "r264", "r283", "r286", "r312", "r351", "r438", "r439", "r442", "r443", "r444", "r446", "r451", "r452", "r458", "r459", "r460", "r461", "r462", "r463", "r466", "r482", "r483", "r484", "r485", "r486", "r487", "r490", "r492", "r514", "r589", "r604", "r605", "r606", "r629", "r700" } }, {"srt_StatementGeographicalAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": {"http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"}, {"http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPercentageOfConsolidatedRevenuesAt"}, {"lang": {"en-us": {"role": {"label": "Geographical [Axis]", "documentation": "Information by geographical area." } } }, {"auth_ref": {"r274", "r275", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561",

"r562", "r563", "r564", "r565", "r566", "r642", "r643", "r644", "r710", "r713", "r717", "r720", "r727", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r746", "r763", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r797", "r803", "r980", "r1048", "r1050", "r1051", "r1053", "r1054", "r1055", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077" }, {"us-gaap_StatementLineItems": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/BalanceSheetsParenthetical", "http://oncocyte.com/20240930/taxonomy/role/CollaborativeArrangementsDetailsNarrative", "http://oncocyte.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative", "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDisaggregationOfRevenueDetails", "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPriorPeriodRevisionsDetails", "http://oncocyte.com/20240930/taxonomy/role/DiscontinuedOperationsOfRazorDetailsNarrative", "http://oncocyte.com/20240930/taxonomy/role/IntangibleAssetsNetDetailsNarrative", "http://oncocyte.com/20240930/taxonomy/role/StatementsOfSeriesRedeemableConvertiblePreferredStockAndShareholdersEquity" }, "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r229", "r230", "r231", "r264", "r492", "r534", "r619", "r641", "r647", "r648", "r649", "r650", "r651", "r652", "r655", "r658", "r659", "r660", "r661", "r662", "r663", "r666", "r667", "r668", "r670", "r671", "r672", "r673", "r674", "r676", "r679", "r680", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r700", "r804" } }, {"us-gaap_StatementOfCashFlowsAbstract": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": { "r245", "r384", "r899", "r903", "r939" } }, {"us-gaap_StatementOfFinancialPositionAbstract": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": { "r245", "r384", "r899", "r903", "r939" } }, {"us-gaap_StatementOfStockholdersEquityAbstract": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": { "r245", "r384", "r899", "r903", "r939" } }, {"srt_StatementScenarioAxis": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative", "Scenario [Axis]" } }, "auth_ref": { "r245", "r384", "r899", "r903", "r939" } }, {"us-gaap_StatementTable": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/BalanceSheetsParenthetical", "http://oncocyte.com/20240930/taxonomy/role/CollaborativeArrangementsDetailsNarrative", "http://oncocyte.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative", "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDisaggregationOfRevenueDetails", "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPriorPeriodRevisionsDetails", "http://oncocyte.com/20240930/taxonomy/role/DiscontinuedOperationsOfRazorDetailsNarrative", "http://oncocyte.com/20240930/taxonomy/role/IntangibleAssetsNetDetailsNarrative", "http://oncocyte.com/20240930/taxonomy/role/StatementsOfSeriesRedeemableConvertiblePreferredStockAndShareholdersEquity" }, "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": { "r229", "r230", "r231", "r264", "r277", "r492", "r534", "r619", "r641", "r647", "r648", "r649", "r650", "r651", "r652", "r655", "r658", "r659", "r660", "r661", "r662", "r665", "r666", "r667", "r668", "r670", "r671", "r672", "r673", "r674", "r676", "r679", "r680", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r700", "r804" } }, {"ecd_StkPreOrTsrEstimationMethodTextBlock": { "xbrlType": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPreOrTsrEstimationMethodTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": { "r821", "r831", "r841", "r873" } }, {"us-gaap_StockAppreciationRightsSARSMember": { "xbrlType": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": { "r245", "r384", "r899", "r903", "r939" } }, {"us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "xbrlType": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/StatementsOfSeriesRedeemableConvertiblePreferredStockAndShareholdersEquity", "lang": { "en-us": { "role": { "label": "Shares issued for consultant services, shares", "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders." } } }, "auth_ref": { "r245", "r384", "r899", "r903", "r939" } }, {"us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrlType": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DiscontinuedOperationsOfRazorDetailsNarrative", "http://oncocyte.com/20240930/taxonomy/role/OrganizationAndDescriptionOfBusinessDetailsNarrative", "http://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative", "http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative", "http://oncocyte.com/20240930/taxonomy/role/StatementsOfSeriesRedeemableConvertiblePreferredStockAndShareholdersEquity", "lang": { "en-us": { "role": { "label": "Sale of common shares under at-the-market transactions, net of financing costs, shares", "label": "Number of shares issued", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": { "r20", "r103", "r104", "r146", "r621", "r700", "r722" } }, {"us-gaap_StockIssuedDuringPeriodSharesOther": { "xbrlType": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesOther", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative", "http://oncocyte.com/20240930/taxonomy/role/StatementsOfSeriesRedeemableConvertiblePreferredStockAndShareholdersEquity", "lang": { "en-us": { "role": { "label": "Sale of common shares, net of financing costs, shares", "verboseLabel": "Issuance of shares", "documentation": "Number of shares of stock issued attributable to transactions classified as other." } } }, "auth_ref": { "r245", "r384", "r899", "r903", "r939" } }, {"us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "xbrlType": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative", "http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquity", "lang": { "en-us": { "role": { "label": "Shares issued restricted", "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards." } } }, "auth_ref": { "r20", "r146" } }, {"us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOffForfeitures": { "xbrlType": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOffForfeitures", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/StatementsOfSeriesRedeemableConvertiblePreferredStockAndShareholdersEquity", "lang": { "en-us": { "role": { "label": "Shares issued upon vesting of RSU, shares", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": { "r20", "r103", "r104", "r146" } }, {"ocx_StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue": { "xbrlType": "monetaryItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCommonStockComputationOfDiluted", "http://oncocyte.com/20240930/taxonomy/role/StatementsOfSeriesRedeemableConvertiblePreferredStockAndShareholdersEquity", "lang": { "en-us": { "role": { "label": "Accretion of Series A convertible preferred stock to redemption value", "verboseLabel": "Accretion of Series A redeemable convertible preferred stock", "documentation": "Accretion of Series A convertible preferred stock to redemption value." } } }, "auth_ref": { "r245", "r384", "r899", "r903", "r939" } }, {"us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "xbrlType": "monetaryItemType", "ns

period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": { "r20", "r103", "r104", "r146", "r629", "r700", "r722", "r810" } }, "us-gaap_StockIssuedDuringPeriodValueOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueOther", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/StatementsOfSeriesRedeemableConvertiblePreferredStockAndShareholdersEquity" }, "lang": { "en-us": { "role": { "label": "Sale of common shares, net of financing costs", "documentation": "Value of shares of stock issued attributable to transactions classified as other." } } }, "auth_ref": { } }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative" }, "lang": { "en-us": { "role": { "label": "Value issued restricted", "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period." } } }, "auth_ref": { "r20", "r103", "r104", "r146" } }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOffForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOffForfeitures", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/StatementsOfSeriesRedeemableConvertiblePreferredStockAndShareholdersEquity" }, "lang": { "en-us": { "role": { "label": "Shares issued upon vesting of RSUs", "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited." } } }, "auth_ref": { "r20", "r146" } }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueShareBasedCompensationGross", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/StatementsOfSeriesRedeemableConvertiblePreferredStockAndShareholdersEquity" }, "lang": { "en-us": { "role": { "label": "Stock-based compensation", "documentation": "Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": { } }, "ocx_StockIssuedDuringPeriodValueVestingOfBonusAwards": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "StockIssuedDuringPeriodValueVestingOfBonusAwards", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/StatementsOfSeriesRedeemableConvertiblePreferredStockAndShareholdersEquity" }, "lang": { "en-us": { "role": { "label": "Vesting of bonus awards", "documentation": "Stock issued during period value vesting of bonus awards." } } }, "auth_ref": { } }, "us-gaap_StockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockOptionMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCommonStockComputationOfDiluted", "lang": { "en-us": { "role": { "label": "Equity Option [Member]", "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)." } } }, "auth_ref": { "r803" } }, "us-gaap_StockRedeemedOrCalledDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRedeemedOrCalledDuringPeriodShares", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative", "http://oncocyte.com/20240930/taxonomy/role/StatementsOfSeriesRedeemableConvertiblePreferredStockAndShareholdersEquity" }, "lang": { "en-us": { "role": { "label": "Redemption of Series A redeemable convertible preferred stock, shares", "verboseLabel": "Number of stock redeem. shares", "documentation": "Number of stock bought back by the entity at the exercise price or redemption price." } } }, "auth_ref": { "r20" } }, "us-gaap_StockRedeemedOrCalledDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRedeemedOrCalledDuringPeriodValue", "crdr": "debit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/OrganizationAndDescriptionOfBusinessDetailsNarrative", "http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative", "http://oncocyte.com/20240930/taxonomy/role/StatementsOfSeriesRedeemableConvertiblePreferredStockAndShareholdersEquity" }, "lang": { "en-us": { "role": { "label": "Redemption of Series A redeemable convertible preferred stock", "verboseLabel": "Value of redeemed shares", "documentation": "Equity impact of the value of stock bought back by the entity at the exercise price or redemption price." } } }, "auth_ref": { "r20" } }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/BalanceSheets", "http://oncocyte.com/20240930/taxonomy/role/StatementsOfSeriesRedeemableConvertiblePreferredStockAndShareholdersEquity" }, "lang": { "en-us": { "role": { "label": "Total shareholdingsu2019 equity", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": { "r104", "r106", "r107", "r132", "r657", "r675", "r701", "r702", "r784", "r811", "r934", "r951", "r1020", "r1079" } }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/BalanceSheets" }, "lang": { "en-us": { "role": { "label": "SHAREHOLDERSu2019 EQUITY" } } }, "auth_ref": { } }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquity" }, "lang": { "en-us": { "role": { "label": "Series A Redeemable Convertible Preferred Stock and Shareholdersu2019 Equity", "documentation": "The entire disclosure for equity." } } }, "auth_ref": { "r143", "r227", "r333", "r335", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r348", "r351", "r464", "r703", "r705", "r726" } }, "us-gaap_StockholdersEquityReverseStockSplit": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityReverseStockSplit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "lang": { "en-us": { "role": { "label": "Reverse stock split", "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements." } } }, "auth_ref": { "r147" } }, "us-gaap_SubleaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubleaseIncome", "crdr": "credit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative" }, "lang": { "en-us": { "role": { "label": "Sublease income", "documentation": "Amount of sublease income excluding finance and operating lease expense." } } }, "auth_ref": { "r503", "r783" } }, "ocx_SubleasePeriodFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "SubleasePeriodFiveMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative" }, "lang": { "en-us": { "role": { "terseLabel": "Beginning on or After January 1, 2027 and Ending on or Before October 31, 2027 [Member]", "label": "Sublease Period Five [Member]", "documentation": "Sublease period five." } } }, "auth_ref": { "ocx_SubleasePeriodFourMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "SubleasePeriodFourMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative" }, "lang": { "en-us": { "role": { "terseLabel": "Beginning on or After January 1, 2026 and Ending on or Before December 31, 2026 [Member]", "label": "Sublease Period Four [Member]", "documentation": "Sublease period four." } } }, "auth_ref": { "ocx_SubleasePeriodOneMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "SubleasePeriodOneMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative" }, "lang": { "en-us": { "role": { "terseLabel": "Beginning on Commencement Date and Ending on or Before December 31, 2024 [Member]", "label": "Sublease Period One [Member]", "documentation": "Sublease period one." } } }, "auth_ref": { "ocx_SubleasePeriodThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "SubleasePeriodThreeMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative" }, "lang": { "en-us": { "role": { "terseLabel": "Beginning on or After July 1, 2025 and Ending on or Before December 31, 2025 [Member]", "label": "Sublease Period Three [Member]", "documentation": "Sublease period three." } } }, "auth_ref": { "ocx_SubleasePeriodTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "SubleasePeriodTwoMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative" }, "lang": { "en-us": { "role": { "terseLabel": "Beginning on or After January 1, 2025 and Ending on or Before June 30, 2025 [Member]", "label": "Sublease Period Two [Member]", "documentation": "Sublease period two." } } }, "auth_ref": { "ocx_SubleaseRentExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "SubleaseRentExpenses", "crdr": "debit", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative" }, "lang": { "en-us": { "role": { "terseLabel": "Rent receivable", "label": "Sublease Rent Expenses", "documentation": "Sublease rent expenses." } } }, "auth_ref": { "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSubsequentEventsDetailsNarrative" }, "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": { "r488", "r522" } }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": { "http://oncocyte.com/20240930/taxonomy/role/DisclosureSubsequentEventsDetailsNarrative", "http://oncocyte.com/20240930/taxonomy/role/OrganizationAndDescriptionOfBusinessDetailsNarrative", "http://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative", "http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative", "http://oncocyte.com/20240930/taxonomy/role/Stock-basedCompensationDetailsNarrative" }, "lang": { "en-us": { "role": { "terseLabel": "Subsequent

Event [Member], **"label"**: **"Subsequent Event [Member]"**, **"documentation"**: **"Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."** } } }, **"auth_ref"**: { **"r488"**, **"r522"** } }, **"us-gaap-SubsequentEventTable"**: { **"xbrltype"**: **"stringItemType"**, **"nsuri"**: **"http://fasb.org/us-gaap/2024"**, **"localname"**: **"SubsequentEventTable"**, **"presentation"**: { **"http://oncocyte.com/20240930/taxonomy/role/DisclosureSubsequentEventsDetailsNarrative"** } }, **"lang"**: { **"en-us"**: { **"role"**: { **"label"**: **"Subsequent Event [Table]"**, **"documentation"**: **"Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."** } } }, **"auth_ref"**: { **"r488"**, **"r522"** } }, **"us-gaap-SubsequentEventTypeAxis"**: { **"xbrltype"**: **"stringItemType"**, **"nsuri"**: **"http://fasb.org/us-gaap/2024"**, **"localname"**: **"SubsequentEventTypeAxis"**, **"presentation"**: { **"http://oncocyte.com/20240930/taxonomy/role/DisclosureSubsequentEventsDetailsNarrative"**, **"http://oncocyte.com/20240930/taxonomy/role/OrganizationAndDescriptionOfBusinessDetailsNarrative"**, **"http://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative"**, **"http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative"**, **"http://oncocyte.com/20240930/taxonomy/role/Stock-basedCompensationDetailsNarrative"** } }, **"lang"**: { **"en-us"**: { **"role"**: { **"label"**: **"Subsequent Event Type [Axis]"**, **"documentation"**: **"Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."** } } }, **"auth_ref"**: { **"r488"**, **"r522"** } }, **"us-gaap-SubsequentEventTypeDomain"**: { **"xbrltype"**: **"domainItemType"**, **"nsuri"**: **"http://fasb.org/us-gaap/2024"**, **"localname"**: **"SubsequentEventTypeDomain"**, **"presentation"**: { **"http://oncocyte.com/20240930/taxonomy/role/DisclosureSubsequentEventsDetailsNarrative"**, **"http://oncocyte.com/20240930/taxonomy/role/OrganizationAndDescriptionOfBusinessDetailsNarrative"**, **"http://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative"**, **"http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative"**, **"http://oncocyte.com/20240930/taxonomy/role/Stock-basedCompensationDetailsNarrative"** } }, **"lang"**: { **"en-us"**: { **"role"**: { **"label"**: **"Subsequent Event Type [Domain]"**, **"documentation"**: **"Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."** } } }, **"auth_ref"**: { **"r488"**, **"r522"** } }, **"us-gaap-SubsequentEventsAbstract"**: { **"xbrltype"**: **"stringItemType"**, **"nsuri"**: **"http://fasb.org/us-gaap/2024"**, **"localname"**: **"SubsequentEventsAbstract"**, **"lang"**: { **"en-us"**: { **"role"**: { **"label"**: **"Subsequent Events [Abstract]"** } } }, **"auth_ref"**: { } }, **"us-gaap-SubsequentEventsTextBlock"**: { **"xbrltype"**: **"textBlockItemType"**, **"nsuri"**: **"http://fasb.org/us-gaap/2024"**, **"localname"**: **"SubsequentEventsTextBlock"**, **"presentation"**: { **"http://oncocyte.com/20240930/taxonomy/role/DisclosureSubsequentEvents1"** } }, **"lang"**: { **"en-us"**: { **"role"**: { **"terseLabel"**: **"Subsequent Events"**, **"label"**: **"Subsequent Events [Text Block]"**, **"documentation"**: **"The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."** } } }, **"auth_ref"**: { **"r521"**, **"r523"** } }, **"us-gaap-SubsidiarySaleOfStockAxis"**: { **"xbrltype"**: **"stringItemType"**, **"nsuri"**: **"http://fasb.org/us-gaap/2024"**, **"localname"**: **"SubsidiarySaleOfStockAxis"**, **"presentation"**: { **"http://oncocyte.com/20240930/taxonomy/role/DisclosureSubsequentEventsDetailsNarrative"**, **"http://oncocyte.com/20240930/taxonomy/role/OrganizationAndDescriptionOfBusinessDetailsNarrative"**, **"http://oncocyte.com/20240930/taxonomy/role/RelatedPartyTransactionsDetailsNarrative"**, **"http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative"**, **"http://oncocyte.com/20240930/taxonomy/role/StatementsOfSeriesRedeemableConvertiblePreferredStockAndShareholdersEquity"** } }, **"lang"**: { **"en-us"**: { **"role"**: { **"label"**: **"Sale of Stock [Axis]"**, **"documentation"**: **"Information by type of sale of the entity's stock."** } } }, **"auth_ref"**: { } }, **"us-gaap-SupplementalCashFlowInformationAbstract"**: { **"xbrltype"**: **"stringItemType"**, **"nsuri"**: **"http://fasb.org/us-gaap/2024"**, **"localname"**: **"SupplementalCashFlowInformationAbstract"**, **"presentation"**: { **"http://oncocyte.com/20240930/taxonomy/role/StatementsOfCashFlows"** } }, **"lang"**: { **"en-us"**: { **"role"**: { **"label"**: **"SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION"** } } }, **"auth_ref"**: { } }, **"ecd-TabularListTableTextBlock"**: { **"xbrltype"**: **"textBlockItemType"**, **"nsuri"**: **"http://xbrl.sec.gov/ecd/2024"**, **"localname"**: **"TabularListTableTextBlock"**, **"presentation"**: { **"http://xbrl.sec.gov/ecd/role/PvpDisclosure"** } }, **"lang"**: { **"en-us"**: { **"role"**: { **"label"**: **"Tabular List [Table Text Block]"**, **"terseLabel"**: **"Tabular List, Table"** } } }, **"auth_ref"**: { **"r867"** } }, **"us-gaap-TaxCreditCarryforwardAmount"**: { **"xbrltype"**: **"monetaryItemType"**, **"nsuri"**: **"http://fasb.org/us-gaap/2024"**, **"localname"**: **"TaxCreditCarryforwardAmount"**, **"crdr"**: **"debit"**, **"presentation"**: { **"http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"** } }, **"lang"**: { **"en-us"**: { **"role"**: { **"terseLabel"**: **"Tax credits"**, **"label"**: **"Tax Credit Carryforward, Amount"**, **"documentation"**: **"The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."** } } }, **"auth_ref"**: { **"r436"** } }, **"us-gaap-TaxCreditCarryforwardAxis"**: { **"xbrltype"**: **"stringItemType"**, **"nsuri"**: **"http://fasb.org/us-gaap/2024"**, **"localname"**: **"TaxCreditCarryforwardAxis"**, **"presentation"**: { **"http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"** } }, **"lang"**: { **"en-us"**: { **"role"**: { **"label"**: **"Tax Credit Carryforward [Axis]"**, **"documentation"**: **"Information by specific tax credit related to an unused tax credit."** } } }, **"auth_ref"**: { **"r436"** } }, **"us-gaap-TaxCreditCarryforwardLimitationsOnUse"**: { **"xbrltype"**: **"stringItemType"**, **"nsuri"**: **"http://fasb.org/us-gaap/2024"**, **"localname"**: **"TaxCreditCarryforwardLimitationsOnUse"**, **"presentation"**: { **"http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"** } }, **"lang"**: { **"en-us"**: { **"role"**: { **"terseLabel"**: **"Tax credit carryforward limitations on use"**, **"label"**: **"Tax Credit Carryforward, Limitations On Use"**, **"documentation"**: **"Description of the limitation related to use of the tax credit carryforward."** } } }, **"auth_ref"**: { } }, **"us-gaap-TaxCreditCarryforwardNameDomain"**: { **"xbrltype"**: **"domainItemType"**, **"nsuri"**: **"http://fasb.org/us-gaap/2024"**, **"localname"**: **"TaxCreditCarryforwardNameDomain"**, **"presentation"**: { **"http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"** } }, **"lang"**: { **"en-us"**: { **"role"**: { **"label"**: **"Tax Credit Carryforward, Name [Domain]"**, **"documentation"**: **"The name of the tax credit carryforward."** } } }, **"auth_ref"**: { **"r436"** } }, **"us-gaap-TemporaryEquityCarryingAmountAttributableToParent"**: { **"xbrltype"**: **"monetaryItemType"**, **"nsuri"**: **"http://fasb.org/us-gaap/2024"**, **"localname"**: **"TemporaryEquityCarryingAmountAttributableToParent"**, **"crdr"**: **"credit"**, **"presentation"**: { **"http://oncocyte.com/20240930/taxonomy/role/BalanceSheets"** } }, **"lang"**: { **"en-us"**: { **"role"**: { **"label"**: **"Series A Redeemable Convertible Preferred Stock, no par value; stated value \$1,000 per share; 5 shares issued and outstanding at December 31, 2023; aggregate liquidation preference of \$5,296 as of December 31, 2023"**, **"documentation"**: **"Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."** } } }, **"auth_ref"**: { **"r323"**, **"r325"**, **"r326"**, **"r327"**, **"r330"**, **"r331"**, **"r420"**, **"r578"** } }, **"us-gaap-TemporaryEquityLiquidationPreference"**: { **"xbrltype"**: **"monetaryItemType"**, **"nsuri"**: **"http://fasb.org/us-gaap/2024"**, **"localname"**: **"TemporaryEquityLiquidationPreference"**, **"crdr"**: **"credit"**, **"presentation"**: { **"http://oncocyte.com/20240930/taxonomy/role/BalanceSheetsParenthetical"** } }, **"lang"**: { **"en-us"**: { **"role"**: { **"label"**: **"Temporary equity, liquidation preference"**, **"documentation"**: **"The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."** } } }, **"auth_ref"**: { } }, **"ocx-TemporaryEquityNoParValue"**: { **"xbrltype"**: **"perShareItemType"**, **"nsuri"**: **"http://oncocyte.com/20240930"**, **"localname"**: **"TemporaryEquityNoParValue"**, **"presentation"**: { **"http://oncocyte.com/20240930/taxonomy/role/BalanceSheetsParenthetical"** } }, **"lang"**: { **"en-us"**: { **"role"**: { **"label"**: **"Temporary equity, no par value"**, **"documentation"**: **"Temporary equity no par value."** } } }, **"auth_ref"**: { } }, **"us-gaap-TemporaryEquityParOrStatedValuePerShare"**: { **"xbrltype"**: **"perShareItemType"**, **"nsuri"**: **"http://fasb.org/us-gaap/2024"**, **"localname"**: **"TemporaryEquityParOrStatedValuePerShare"**, **"presentation"**: { **"http://oncocyte.com/20240930/taxonomy/role/BalanceSheetsParenthetical"** } }, **"lang"**: { **"en-us"**: { **"role"**: { **"label"**: **"Temporary equity, stated par value"**, **"documentation"**: **"Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable."** } } }, **"auth_ref"**: { **"r25"**, **"r54"** } }, **"us-gaap-TemporaryEquitySharesIssued"**: { **"xbrltype"**: **"sharesItemType"**, **"nsuri"**: **"http://fasb.org/us-gaap/2024"**, **"localname"**: **"TemporaryEquitySharesIssued"**, **"presentation"**: { **"http://oncocyte.com/20240930/taxonomy/role/BalanceSheetsParenthetical"**, **"http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative"** } }, **"lang"**: { **"en-us"**: { **"role"**: { **"label"**: **"Temporary equity, shares issued"**, **"documentation"**: **"The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be**

[illegible]

"auth_ref": [1], "us-gaap-UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefits", "cred": "credit", "presentation": ["http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"] }, "lang": { "en-us": { "role": { "label": "Unrecognized tax benefits", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": ["r426", "r430", "r775"] }, "us-gaap-UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": ["http://oncocyte.com/20240930/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"] }, "lang": { "en-us": { "role": { "label": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": ["r47", "r48", "r49", "r176", "r177", "r180", "r181"] }, "ocx-ValuationApproachYieldedFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "ValuationApproachYieldedFairValue", "cred": "credit", "presentation": ["http://oncocyte.com/20240930/taxonomy/role/IntangibleAssetsNetDetailsNarrative"] }, "lang": { "en-us": { "role": { "terseLabel": "Unobservable measurement input, valuation approach yielded fair value", "label": "Valuation Approach Yielded Fair Value", "documentation": "Valuation Approach Yielded Fair Value" } } }, "auth_ref": [1] }, "us-gaap-ValuationTechniqueAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationTechniqueAxis", "presentation": ["http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesAdditionalInformationDetails"] }, "http://oncocyte.com/20240930/taxonomy/role/IntangibleAssetsNetDetailsNarrative"] }, "lang": { "en-us": { "role": { "label": "Valuation Approach and Technique [Axis]", "documentation": "Information by valuation approach and technique." } } }, "auth_ref": ["r471", "r472", "r779", "r1019"] }, "us-gaap-ValuationTechniqueDiscountedCashFlowMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationTechniqueDiscountedCashFlowMember", "presentation": ["http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesAdditionalInformationDetails"] }, "lang": { "en-us": { "role": { "label": "Valuation Technique, Discounted Cash Flow [Member]", "documentation": "Valuation technique calculating present value of future cash flows." } } }, "auth_ref": ["r779", "r1017", "r1018", "r1019"] }, "us-gaap-ValuationTechniqueDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationTechniqueDomain", "presentation": ["http://oncocyte.com/20240930/taxonomy/role/DisclosureBusinessCombinationsAndContingentConsiderationLiabilitiesAdditionalInformationDetails"] }, "http://oncocyte.com/20240930/taxonomy/role/IntangibleAssetsNetDetailsNarrative"] }, "lang": { "en-us": { "role": { "label": "Valuation Approach and Technique [Domain]", "documentation": "Valuation approach and technique." } } }, "auth_ref": ["r471", "r472", "r779", "r1019"] }, "us-gaap-VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingAxis", "presentation": ["http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative"] }, "lang": { "en-us": { "role": { "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": ["r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006"] }, "us-gaap-VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingDomain", "presentation": ["http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative"] }, "lang": { "en-us": { "role": { "label": "Vesting [Domain]", "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": ["r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006"] }, "ecd-VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] }, "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": ["r855"] }, "ocx-WarrantExercised": { "xbrltype": "sharesItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "WarrantExercised", "presentation": ["http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative"] }, "lang": { "en-us": { "role": { "terseLabel": "Warrant exercised", "label": "Warrant Exercised", "documentation": "Warrant exercised." } } }, "auth_ref": [1] }, "ocx-WarrantExpired": { "xbrltype": "sharesItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "WarrantExpired", "presentation": ["http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative"] }, "lang": { "en-us": { "role": { "label": "Warrants expired", "documentation": "Warrant expired." } } }, "auth_ref": [1] }, "us-gaap-WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": ["http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCommonStockComputationOfDiluted"] }, "http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative"] }, "lang": { "en-us": { "role": { "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": ["r801", "r802", "r805", "r806", "r807", "r808"] }, "us-gaap-WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": ["http://oncocyte.com/20240930/taxonomy/role/SeriesRedeemableConvertiblePreferredStockAndShareholdersEquityDetailsNarrative"] }, "lang": { "en-us": { "role": { "label": "Weighted average remaining life", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur in 'PnYnMnDInHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r1017", "r1018", "r1019"] }, "ocx-WeightedAverageCostOfCapital": { "xbrltype": "percentItemType", "nsuri": "http://oncocyte.com/20240930", "localname": "WeightedAverageCostOfCapital", "presentation": ["http://oncocyte.com/20240930/taxonomy/role/IntangibleAssetsNetDetailsNarrative"] }, "lang": { "en-us": { "role": { "terseLabel": "Unobservable measurement input, weighted average cost of capital", "label": "Weighted Average Cost of Capital", "documentation": "Weighted Average Cost of Capital" } } }, "auth_ref": [1] }, "us-gaap-WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": ["http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCommonStockComputationOfDiluted"] }, "http://oncocyte.com/20240930/taxonomy/role/StatementsOfOperations"] }, "lang": { "en-us": { "role": { "label": "Weighted average shares outstanding - diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": ["r248", "r259"] }, "us-gaap-WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": ["http://oncocyte.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfCommonStockComputationOfDiluted"] }, "http://oncocyte.com/20240930/taxonomy/role/StatementsOfOperations"] }, "lang": { "en-us": { "role": { "label": "Weighted average shares outstanding - basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r246", "r259"] }, "ecd-YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] }, "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": ["r853"] }, "std_ref": ["r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "7", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-7" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "8", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubParagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "SubParagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "SubParagraph": "(a)", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1B" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1D", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1D" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI":

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

FW88,00WQ/T?K9=>+I5J9.\$-@GQIULUANL9J9J1)<1/*4A^C&5=MBNLVMAIRT'FX2/-M<^IG'SS+PY0J1)>5;B;G(6368JH&P,J)
MX7ZH;JH:HQ%\$S&W:8MC297I:RA-^+WY80#VBY:70ZZ+CE3+&M%:8DEXM60J1^=+%YJ\$2O)&\$%N%Y%JEE\$=>EE+R2:(K'F'KUJ
M=E.QFU*YN<.:P.V<94-F4AVS)02W1N>.:TB6&X%7^7-8J>[K#-|^"WPVIO-MPR9K3;O.AZ-:(A.3103H#0Q:4B%G;.(K*MT#J+7/UUSI
HRS5.IM3.1/^<^7%7BP<.:O3.J:6" C4J7ZL4.MJO+IUN(9G*6>19BCQ.38+8YB%>.:L7?&7W8U.3UE3L2%UHH.C6R>46-%TB
M..CN<+>.:QH..IRY\$8W>1K2?Y(I*^T14=%>2D2AT7P4).VMG17(UBJ)#78V7.MUJOJ^<KM.4E+=+K7_0+%O&V.D4?IMMQ1?22GDEBMTF4
R#M"UFR=^"HUJ9R.M5LJN<1W<K^>MBBK81"BM.W5Q5:M*HFD#>FTJ_08"G<+<33;O=2\$-5FC
M5"\$GFFTHM/AMB9L.W54VZL@W>PIQ6&:W#>GO+&K%DH""21=W;.*%+(V&P.V.MKG5XEH9162?JJOE^9.OGX_E?
3I9I3HQ=A=(6FO544>7DU+MZ02T:RE).FJ.MDF?PV0BTL5550OZ8;7T;=Q""BJS'POH&DU"5X72.4JH\$4W2ZD5TX8-IHW@
M.IQQ'(E#R;=>W6GUJ#=-U10%JVS40+L.L.LOU*1.2054.O9V05/FQ4@C.M27VT@NZDI"BE-9&16ZX.C.U126P>#&..89IK(>AQ=C5B#TD5A1RZUFW!(4H
MOVBNRT#A.NPY-+;+T^NIAZH:UKZL=38+G?X<=&7C>O=^>JHJ'UX1S(+A3J@R2R@E>.%M;IDA@/%7PMNG-WJFIC)QMHWUX-B'115M"QC"1
7DM5";8ZVDT<=DAD-EWTB:K8J#Q2I.F>UH5DS>?AV*BP#HO?1D?LLA=ZIF.M&P;CB;F2^:T1P2^GV4X+L2^<^ABG>(K7V\$X5+>).CIN?
#Q7+RZOL\$=E@M%Q\$1C2K8I.M%Z5>21A\$%\$(LIHM2V8U;OKIVU@|QXHZKI78U&J2C0RL62"MXT5HF6"\$.F153RBK6WZ/QT"5^U<..W1L)
(.F5VYB^104K>X^/J3H/Y.MRW)H*10H:JUMK=DEUZHIMADAIN)-Z:2?2<5-.68<=WSHT:1&3*AH<U*90"9HJPZUZ=.:YVH."&M=P.IY5NL&%-
FTZA:AFPI6A072?0DE/0&J:676X\$6S#VHU61^IV#-MDI3;G6>G#M69V10/6050MW^U(5AD.SZ5-IRV.P7#1YS;2WJ_CK+AJ;W6IR
MIJHJ=1+>?<GNR1A<J"3D1K^<JL6J7QON9:HB2ALRKW?TMQ=IG5RWI>YH.M-#K50D?68:(+EJ&MP%"T6IP@C:.#3M+HK21HWT_SJK>#&\$JO#-.:?
^~/RM-M2B>35?EXGO=MB:M^>^FTXE3-S(AKC\$96U2I9EB7NXX2)%>19;ZITG/4"8<.:MIK\$V87?
J>RG&\$5+1%#;T2M19=AA4P^ONY9L3G.SKMA1%<M.KZH:9BAJ^>M5T<8&OLYK01P\$@+^UE5@2Q4).ZZF#%M;+HF=E7I9025P.0G7R2EH
M:N.O(BN.O/##^L.W8=QQYJKO&B@ML8G"U"N;V;.&2=L8M;+^#>2.W.GB;M.T^<UL%J"HT"JHE=G%<C+&8V+HF+D12A2Y;+?2Q?FY,1#WD?
YT>33QV7.M06&#%7!6H#TKD4VE4XQ"C7=..TI>D^V57UT@_69_IQ5KMI00JN>F_&?+M.ME-.9C61"<5!).EY8*18HIBUL%9?
FT=YOQD+FGHS9>NFEQOCC>GHRQJ/M&CYB*A18RNM87+Z=JH'XW1JK%F'E:6QPIHHQFDLB/6(K'1&UKXJ83_Y.M6NU&E.T_
%HUMM<.:8&B<#UT" C6H@*T?B6ND0#!@4'KHSI?7KEJB3:SMKN.MS1&ENBCI#-VTJF29O%:KM'1.\$)K\$84
M90_LG85LO(%)V")3*\$F.Q15+ADU45:4ULYN10R>A.Z8W25H>#5>[6* M.R\$755T^AL2?9:=G\$B\$46FW+&(+9\$#M*IKYJ2D
M%312JPDNB5DJ=P@M=M08O)<N&A<N&N^VUG*0.4G0FN.0E21MEL:4TW+DITAS@R1MUA1.M2CM#8EIS)+XIX7?12JZD3Y-U?
0L=1&2&H2^E4\$+63FZU:IBV;#KL%\$!(-MF&VQ35NP774F8V<#Z3TIRH.Y.*Y\$U'6HFT\$2.3L^I(#\$JBEME>
MJ@6Y"V;UWJ\$8LJ03JAW'HLH8&1MG=GEH5B6)B@AK32.T13C.MHR#X:@>4Z*#K8R.YK1T2-IU"1^1*81#9
MD..VOGEW_W38OFDOVO809F-58)JUFQOX\$H29:@9I.N&#90RTC=9#=#18J7M
MOJ#Q-4J@<^J5BV<HW+RL%\$Z3\$W37HG.Y8<.:1^5^86+NX1^>^<QOOD+..R>LYQXFZ-"KE2TO."J?"IWEY2I|^+=>..W/=54FYB\$M#;)RA7V*(@
4=NA84D2EU(K?27SQ.L1&S/K5NE\$13.MMXI&ATDKUB.N13.M^<QO%G1J)Y29ILE+G8F;J^B9UL03V\$=2?GHS1.M1>QIMJW50:T2LSD6
M6VC(O3'O&&JH=)Y&C;V.A0\$&&^Y&Z9;P&I>..M&0.-J&ETLEC%>U133;ZVM;9:0.>A.V(K8OE+IL:.%>O/KA<PX9I+@&(JO#B.MG'XYF39J.IAL:U36+>
JPH\$QBW6P:O?7;\$JQ74?>4>3A9^WJUT2M(VJMW.MF6S1%XL=U^<#M1>JQJFN6.E.SP)4^Q8_G6VR44J4KN1#DHACEFFBA.MK6?2NNJLJ?
QM&A1071..CUB94>?TQ20HKLLA.T\$KS1:LG4W/6.W;2M.E.;=E08R4T^&#>.:YQ=(F095B<1406375A/#0IE#G9_JRVCG2GR+9K&4XF.MVE-
(%TV.S690+K'MR=G*.A194D.UHC0TC5O&:IAJ1(=/#>+M'S=D.'K;8.MDGMNP.Y26B^0*BH5AV@W(CIOVP'>=5&.(3O+Y1.1X9>Q.FTZ6BV7?IN9
MYER.M#B\$SL9="1%@15%>JISY28@&Y<XKMRY>^94JVLUV-"%)1XL%K1<MW.M16K6G(//SY7?KDBNIQO<^..16^VUE9.
<#1ELIBR5\$R!4+1%#E:H.M5LZ?SF2V.NW\$IE8DR:>@.58IGQOE70IR.SJ..1B)M#M.P<N.MHN15"52=<..F.A*TO5?F5KWW:ZW"?ST_EJG?
&HV*..N7\$+8GG&=C/T5.MSR-(Y8#>E.C2H25+>.:L:1A.Y9Q2WG%6:0%TJ1?>3*RYCH8?727VM.C1Y^T.A3L4A@C(XJO#)#2^*G.M3^5T-
.%G.&NGJD.8MP/RJ#VYK009CW@.IJR.L76/G1VR0.ZIE@Q04^1.MNG.)M&E&FXJK@#1^X5_%#NEG.NU05:Q@;-9AX^Q=K4TO.DI#%M8/7ZIT
M0^K>J4:HJP%5)R39-1A1YRT.HIK9-UZW+YF(8Y17AG&X#;9O5UDH7&2
M8(I751155E%&@Q:HAYIY<@%3&RG_09HU&67M.NG;+YF11QIF&JM\$A.MQKFTB5N.ENEL.L%Y#H+U59VRKI.C"MYUL)-L
(QWUE5=R#95QMZ.MK8%\$W4%P#("SHV<.<.:H1&Q<#A38H^ZT..S.8>Y20APIR-17C9IC9UDQ.M+55#E2P.TUXHSIQ63GP=1?
WVCF."A5=HFM?7.HE9@SJI)C58L)L.W5F1A.M2R#SIJHJGH9KC1_ZKV^QL+^1LJ.JYMB5K30Q<IYKJRLAZMA3<12P3_.\$7
MEEXN2OH"3D7"WGU.XRZ.O+UO/PIA6IM^<B@HE8QF.L:1^LPI(EK^VP.M03_YL2^&B4_DVRKY"9+>#J9Z1Z7&1G8HE:QKL<7ALC
WU#G.DW>QO1^L.M:P5=..8JW1)3075"457VQ^V5Y:Q2RU1&&G#*8IY:E8_#1L&705WIR;7;2.PHQ&"S0E.O@2M2 IEA(
MP15.QK/5Y#J@-I^W^<#?1>Y5RQ="H817&FUW0.J5I^IN_ZZQUZ>T1I9Z2+8SM^IM4C?=%<#E10.XJA1P.RJD-AOK36=)Q>X<="HO=F^P_3Z;M?
MX.M%G.BTJ1=Q#DD.O_FTT.YT1^>F.P1+UEFFKH5V^JUL#ESQ;M1X(52^M.DDZZ?
3CK=DGKP70::#UX(N<^5<1.J+GQU0G>/HLC5MI5(=+O+^<5NE?0I.MF+3T5^H=@U=#JLV_@S.*^Q*IW2<IT5<5+BS=^J&6JZQ>C)W
UY9R4+&M.1.ADMJVRDHWCHZK54@5HV5..N1B3ININN%26%">)V3X2M.M193OC2O.M2
Z9RSD>TJH>WYX&J.H>5C<1^>A+1UJ9C8I5B1&1^7-6)L7D@+U+1.M%BZ;#M.=NMZ=D.H5W:&W9_^^WA(C_9GCWR<-TU?LOJ7=
I:#50CIV%>O.M2^6^6(+>=B%9/1^4_631O;+>JP0HF=SFTL#M=#Y#TD^6EO0>TW_%2H6H^Y^2CE
@/4)_OK7(1DP%IY2+4.1SAUC.#KN.IVWAV#6D"52.M>X(R+E+8NOD61X;#*T7EHUOMO"OXIZS*5_7JHZ>O.K#=#JH15W@|H:2LU>M<*7?)YE1J
CN%F/^1=+>N#K1I<1^FXM1@+;QH2^<ZJR"Z6"IDLSHU%1J=14R)1+7R<6IM.M#M1H>G4G^10&@J5_2R?%1.555ANQW^UTR<48"VFX&DMQI
&P85U4W.V.M1H1.H%U1R.WA&FKG&CWE;#HX.-OQGS.P.KNG&F.LAGOW69_EL.H.;918.M2SLK@SVT1P57.T.*SVIO^5K15_1OJ/Y*EKPK5IUV?<
_UH;1W1.9L^KY/3.MIZ1.*\$XS5824CN17.OL.PO+OIG4_Y^?SEV<K%Z5RR:LU<IZ\$6PH.SH.MLIG611)=5=1>2M%SD)HHT:I&+H:=ESIYG6)_J>"-
%E.M;114#_6Z%\$5W6R0+SA+09N.L4XU<=8R>#>C8@SFE*JUB1P^:PUSL4@C.MC9WJ.J2F>U1BW&X26T?Q;ZIVUQ?
M=D>?T.G>XGIPACZ#DDH8LX1W.D=MF>#(QJY9&3Y_Z1A47<=5(C0F6Y4D40R^Y<@YIAB#KYB&P.PY.YJ:IR@8Z&MUF70R4EO90^03>:O2L?
*HQS76T1M.M9GE9.RH^<=B+HIS1^10\$_.F#K.M8\$;+>OUP.R#0ZEFZY+P.Z006.K"362/Q5U1I(7AAE%1.17I2H7>3*MG99E2AU^Z^YVW0H9WM-
A.7M^UO:Q0&3+JM.M"5.F2BID@.S0L4.HQ5@5C%1A6&JM->.:R1T=G799A.YTDZKA.N:L+E.N;J.MI*5_U.J21S1S^<ZH/5%#B<IU.UV\$19K*=S1\$)?
U(HI7&WT&UJ>R2Y&6:KN.M=M0&^U.BZUSZX<K(C*KHNLASIM8>+M/9%T.TD31#83.6%M8N5PE8V5.NJL.M#<ZH/5%#B?267>JZ376#=#A8;52
*6ADV#18V;.8.15;2IOV+18:H"MA.<M9^D6)"MN@E3I_9V;.:6E7>.:82&F&#1M=UL^6C)S=4RJ.S1.I.VJN.<+..M
#*?BLNBIDJE10I+DFMM6\$TDPQX#K14I>M2=ME@>1<9=A-IU^GAR5%DIUHKAIL.MR#X^&S.)1^1CCO>#<1Q:#=12%>^R@1#T-
FR2IOFV5S1E@1.0%#>3JUU.M6+Q1DMWEAJ(D20E1>240\$%.F&CTJ2D0N&C+P+>A9@I.WM;+>@OMP.M.6.F00EY9
C.\$4A3I"3L8A)>O:.#>^/#%#P_/T.Z4+|TJ42S:SPIJMYZAD.MI)^1CF39E*.3R5\$&-"XNVN^JWB\$VFARN^/U41H4&^J.HI87T5?M.V1MO?
8&>ZW#E4^5WXYOZ2MSC4<3OIGHJAI5P)POY@WLSOKEMB.ANFB&CAEI70K_#M^RF0U@.JC2B9TIRA^CM13M&\$N06G&
P3Y>Q^O.SXU.PD="O1G231Z1#L.M2BQIY9%IS_+1W#_9#-1B.D61PTANIYEN28=34#RZ270RA&MU^NOA#MLHPWONBN8S1*16M#;1?E1Z;
J+G@519(Z@1O=R4.ZS^&)JBHS.ICL+U^0SP6?Z2_?13RT.ME1_025P.0G7R0Y*=-ZT14VY.Y\$6YIDYU17H13&0ZLEA1J=ZW^X^QNVV1Q
M8N.07D10W1(M06U@58M9HLAZAX^T.K6Z=9.CFI7LF^MIR+7(=IZVO^=Z=FEZSA(6-W0A)D#1@22@>@NY<(EHLT_9H>_J.IYI
MS_-9C76IKGW%VXCP1W)BE2*7=3"%MBY9A@H#0<1H-4LV%W=0YV5EYQ=B.MA@^J3>:376QF@-\$3B(6.1.91JEA><3
M"012GY.P.Q17R&E^:TKH.%R18O1^PLCWT@&5D.0\$1Z5\$*I2=Z1JBT8.MYX>ERIR22Y1^H1WR=+1^1C1E25ZVO^*+R1%+UNXRS*87_R+PIG)
J<..*2R<^&TG0EOY\$0.MHNEF5>.%U2J3(8&KU>E\$JHX(U5WT2^)&=A1A.D175I#EG@JH(62*5XIG;
MHC>56KTJ.MO1GDFRQJWL1@(>6>ZCG6+QJ)HXCZ.MZ7-M.H.V@PWBH#K30A^VVNFK0V6NWI0_2NTAO^1>79?2>GFPI+HBY.VD(-M2B5KM?
+6C12Y.DTK97^9G6PLWG14_.49U)\$9#0.S7@OTQ(ZI^_C%UAEZ1.P4B12.1.T981-8+1SV<^XP2.5JHSDYPL7(49RD@216)TJ:9^0WJSH3J
M8N@PI7^H0J9"%.3.H1D9V^1UHTOC&L.ZCC=HJLCW>Z1I>?SH_V.MK2>OL\$&F+02(RI>2N-06IK-8WV-
(2Y+ZUMEL\$KXFWWF)Q714V^3ITZ6.3?2R3(Z:GP15R1F)M8\$8_Q^5C^YLL7S2W14QW51_OA/TTJ00429I&H^L.#M&EVHD^1G=JD/I/HJH=H\$S
M3Y^CE-IYER+2.7EJY<16^U.O8P.T.GK.B)CZ8^1WA2+J^MYWE.H39YS.YP.A1.WE%JH#^Q6-/U.FDS<SR7A.M#KG7PIGQG@JH_9D<7Y52^X
^S^>+SIZI=161)^G#1^?HDIO.MSC1=YY#NO%_LV3F^P7B.LVIP-YIYOW")Z^>.:#B=+^?HGLB1AL.#&HB1\$M*3W3-
NA25\$18M+1D98%5A49J50>?43\$5%2GHWBB@2_T.YJ-\$C\$*YJ.M\$2FIZT.L@>.%\$H^VPIK0**("1^L*0%<1&F^*U5.DBA\$M.9MRH1@BITE%)Z-
MYT=RB3RED.OIN%)E9-8&MI#;Y\$F2ISUM/MZ)&#>.)@40H@F5\$;#P1HH.M3(V142G1L:Y.YK\$Q7N(HK167FJH=Z0-9^1.YHHS\$C^0G)9%GC-
2)>2DRM.M1G^VVO.F\$#@+O9\$A<^J)1^YX5"228I0*.H0Q:6("HE#9%>@:H1F.T2+4IT
M"0FXEPLUM%ORAJ\$%1@Q*M(M2YH&HPW^D/7H.P25M.Z1%\$S70%4%3.M.M%L""\$H2+ICH#E"\$D9A#0)&@>^?P=RZ?-
P>N1\$:.00W%\$.BH/C2HVB\$".MDX.P5.8.GH>04\$SU/(^<7JH.PI_5^:R5;YT(=>EH"1^1*\$.+WJW^A.MWB#S\$R1>P5&
H^"1C.WKNLX^K;J.D-OE>N.HQ&O7_1)5ZZ>@BW0?#*X#T.MR.D\$=ECI^XDN#+1.L+SR#RS;W>16IE^Q^KW.UA3HE%U&#15Q_6%J7_L&K/KZ\$T
H&MK+&T1H1YJ.MW1/@WSJA?YR10.H1G&H0OK\$6^U5-8RDMO:C%5RX4>HX1^>E.WZ^+?V.MGU?
WT_HJHC6NH>0J>7LHX<1^NOJY3W=HDO@>A1%\$5MC+D9_Q_?1.MZ<^2.5I^<K^:HHO^T>_FV.VCOZ?>#DY.#HVGOC++PM#_6#"I@-O=BI
M7K_8>U1+1+AYM7X#BS)DM-4/FZCWBZX&H^K12X.8-Z1\$2H=SA1#<M\$^DTB1@1E_Q^NWPFI(=*A^EP3."E&/FF44P)7*21^P=6F.9PHSR
_T9C.MW)1^11.HS*#P2=J@8V)WCRMW2KYDJRBB2GQ#<C02\$<^NU.U:EKUN8RM.M4X&=>SU_8S9R0?>N91^CY7=2W5_5B#%?
I..KZ94A<JL_S3WGS.TER.MXLM10+1#.XYP-I@X7^TXO_3^WJ@WW>X.X.T?PIJ7>7_QID+S/IWT=V7^_YEISOB/S>U^IZWCX1^>
Z&J7\$SKEAM^1Y&84IGKX9.M&=>YM219H.#X%155GEBF6.2.MX4^Y.8(2A>HX7M;.#81K1P#MCO.S1QZ0(H>+U+WN.100UJ-
@XHCQ_VJ8:127K1X^"OX2%1OL&389.F53/^M?R>C<2I+=+6&=IEN2OI_?3I=WHIC^IX_HW16GU1OWQR2O=PIJH^>)"P4.M/^*V.L.KHN"+BY_1+>?
2F.OUM90KAGUW19KM.H.EM8AB_-RWG2@C_9G59-I3=M3%ZXZF&6DJO834^C14.YX1<377>JL^JH(T1+IS^P.M16\$4
M(V.XP15RG*2^+Y+82.5GCN3I=;N3RP"OH.NXRWG^&@KV^EU.T1QT^Z1_MLRQO3N+E+H100#BEBAA16GYIYH2.F67Y(RL4"\$S_52/HG56O.F-
'3_M.40VEX9>8BYZVYIYF1#7.OUX_11=3FCOHL2_71^<91&Z.HTB:2%=S.M9*+0^41WB(HDJ3IK+1.IV.;_8^G<*1Y<1.O+GI>
>IAR4^C>G.DYFGM8HK.MW(K16Y;DOG2L/61(F82F1L(HH(F1UM2)C^AWU#_6.DU.161BK01R:(2H%1RO.FN.M%>4YVJ^KW(6>.%ZH-
<1PDM"7>..22X<0\$SRAA.IJC>H>N1Y<1^<1Q031XXVQZ(3AI&W1=N.M2?0)JG18BYUSNE^?Q4H15&DG.WT^80&58(T^S\$U.K.M=1Z^99
_RC(K1298M".TL.SP>R"\$+O.1^VJ_YT.>Z0I=QNXBI+JPIK%WHN85<DXP63I>IYXS\$?M#=#11.L.P%H^IC.V41X.VV_LZY(4EQ2W%DJD#*-
YDYPR(A&D.S1LL1E=D.V.M#BGO.A""O_?NVP2.ONQM(9^1K&I^FO^E<^XDO/EET-0X=ZE152Q<3_11X.M.7>^&U2_0RAZEM>4X<
4A+C+9G95@X2.SE2?T.D.M0.B51=T%<2APOBGL;UDK#G=23:D/U+RWT\$%\$8<3NTTX2018F=>C1V\$&4NI.M.1A0Y<7H@H_L(SF^H1CENJ2V-
*Z&35ELT8A.U.HZ=>HJP"0^>VY60X.MFN12D%>P2>.:U^A1M2L@<R^ROWT^JHKKXY=)0E.61^OG0&H16%&(K?7
M4WKRW=1H144148Z^\$7NHS.J^I^VPL=L7#1Y1^V^>TTH613^O^YU.O2NSA?2.M3\$T>D-1A.W1.21T?
S+JMJ5EL1G:QF&^NDI\$E.DYGL2^1)1Q.O.S195PSY_*M.4A_8A2^VS>=>#*IF\$5_-@K<@JCFI)22DCW#32IBDC5\$%K01<M/<>3PW.ME01:11=|
18K1QCY61F5:9&13WA.IK1OT7^16FOYP6A<#T9M|XGLU^XQ0.G.M5B"E\$@BR=..54PHZ19H&F^&@>77@G(C)S3F8A4W2/66W>^1WZR.@OUG

MPNG<^PM6@^5[W;X10Q7J NE2*G3B>,#@8A%IO%REU5-CP"Z%-)P"O+3%MP#DY=,HT<DE^K;6*Z4 MG|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f=I.P.=<^JG&C5I6XMSJF;N76Y/HJZIG<#I.CYD5AWC1;M2?<8LW+MQ(75YB.L-8X?9"VH\$PPIJF(EDS:A9/G42LC3?8THF..8;9IG.MK+I.GC2.2WE)TH54Y9TT2WCT9<5>JB;#WO3RISI.% @G&K2@^ARD) M1R^N:VCP.T4ZC?>?2G0Q*VHYGH8H5S=61.YO.JR.TI%JTEOK2"W&G8QOQ M'Z2GN)ZG\$4TJ\$>*H>ZQ.(7FX<+7B+U*?@9A=YPZJ/ES8O)Q>15 M2(TN<^J97YW+<2.Z8V2L.N3U<8.C.MXWU1P/SP.W^X>6BT7.XI&22P46S/L.#J.SIO.GKDWDZ.CA4"~A-7<C^N.M7IU^U9S^G+^WFD"Q28@Z:7M?<D7HIE6T5U.SWG7R.W^IQN7+IANZQZ2%O M2DO:ZS:1A;J+QR&D%<C@HWGO.<9KJMA<^SK>Z>W.U/E:8=OH=SS.=MIHX.3?""6BNO.P^?<O3\$1/9SSUA3)C2QE%<K&6P=7L+K&=0+M5@=NT3);5<I&Z&A1600T.OO2/IC9ZKD-GJ?)@C.MOW.SX"V".V>5OQI3A<^&8S.IX^X> (3HC.JR(QJS25<L.GU.O)MXKOF&FHR-G8P2FE>M.C.7GU.&2KD=+W.HV;L&M7H2W*=f8;Q<CQC7(ZUHX)O1PIHf.G.M~)T=NB.UQ.HO* f^NOL63.I<=2+;O16Q@Q+B>UJ4/69RO.7Y/U0IP.U99S*MY5HD^WAIOO7IZ=3R.Y+OK.\$Q\$GIP?IN?IH1L*W2+@I(+R/4N5QK&..C8-3I M&#>TZI\$FQ?>TQ.OO@=W=I=1%J2H9%N%719?Z3TXJYJHH\$CKZD-LN.MC^V4./YHHJDI>JW>IX.7^N~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f>J29.M(O6(OMWK6-9P3V? OQR.R:OD)J9D..&S(OXS2&@M.J>F"U72MD;PWWJ..P#MU;VfE.N(I&GL2)^C^>PWR<49V.XCLIVU4JH14PXN8/3WZN?E..EX.M+6OIAH?B&O? JGL.#8S647JINOYC.B9T=JN=9KYH^EE.A1MW&=I4EV.V..IY57J@MA>L"U.3H^?HP.AO)@..f^HfO1.MJ. <U3CZP\$P>P1>J@HIP)N#CXBUB6(V..OLQW6E*O"FKO.D)O5E7J@G2V3.MEJ?N^@Uf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i6<GSY/7L.Q51+*+X>*3I8MCOG&&.MDKY1L.%CH7I32AZOU2+1.9A;fLO7OIGATP6I3HI<OLM&A?>#FP.\$Q3FO M=>1(SYUIG6O*OBQ2V.S*19I<4^VEX.IHT722Z2W**LYC10HIOY<.<\$%M.WB.DR.MIO.#G=DQ6(<#67YQX74^OD5D6W9*Q4PF%Y2- /DIUO1.BI>FNUOW.MJO4*O*VPC7@CR7B+01.22J#GYNV.WO7GF2SOE)5/8"Z57R<0)*.6I;MS;88J@<DR8W/I.D=(BI2U472^HFD LfVZ8.=<KA0D"6X?2ROLRI@=.J^MLM.^I^..<f.#GL^2I..>S=fA37S.KISE8Q0I+E^2JR=>VY2N2ZXB470@Q&M^4LN+>WK> IDTW^M@AG\$Q6I>RRHY5F<=QKJNGF4E.F'L.KJOJ9IX^SAPW.M..1XN2Q=>#2W4V44YYI^ICSZV=5(N;0O..I^R#M.PN^E.=.18LS- 4.19+3@MFE.2C7I=BI=7#RIEYLYOBN&EWL^ZGZ\$XAS.MY6I4I=^V(NE^=H^<2'OS;.MTW@)=A:2< ^JN^O2O&BB^5YOIJDW+1V<2M&LME=79&HS.UI&35I8BJ\$MTVT@(<\$@(>TW"WCI>);@ZYA+@NWIT7.I&O^LU4XU>V^OI&#^RM^&HUW1fFQ MSORES)G.ABLW.T2>K+875\$S.R5P6ATR/EJH.M@G0>9I4>=>ZTH.I=75T.M>=>J76D&QV>E1W&C)MMAA5V5IQ..#K^E>AJS>.M."3X&EIRK- TKRE.M>P3Y@?=>GN2\$6Z1<C^%F046JX.M.UJ<=>3&.#0>.JOYONE.M.M1V..SI>4J3.25G<D8R(I^W1X5OD1I3RW.Z^Y0*71ZN2W.^UE M#M4^T3^EP.CYX/LH.3\$7B\$.&Z9&>RWR&SPIO.0VE.6N#A>F0^<17H.AR.M\$&.%<=KT\$S2&YZI9<^H/SL32J3?>7VZ? T.PM)<D9O7UGZ2Z74.&FUI=J4.Q.8.DAO*#^V.MU.YKM@RK)QOIE7CfD.TF.HSO.^1JZ=MD7D=SI<+>3&3%SFJHU>3@! M.S<f^XMW.NR&O.Z%8GKGP/KO"DW5F^JHDAOJU50I%19I.VX>*AK#2M*.MP#>*JfE/8C.FN^VIOHIO7?Q.O.YYY6Q=05A-AZ>HL@=Y2OW;WZ? &N#5&X2D.7.M.Z<9+H.LIOYE9.WT>HPHIGXMO@S2Y+50MI&K.MY.YB)IRAP.&P2N>1.4.6SIHMI\$SSBOAL2YD=ICQ.4HT/BGCF+^P#80 M%10AS31)k&I.fOZ>/Q3..70.IDA.ZLO7R29.7%W\$/(^U^T<=>19X?#JH@.MI+IM2Q).JG(O>8NIS^WD.%A#X.E=A/U4A^MZ%I8.^IR<SOTTKG/_SH IG.ME3.OTU.8#I/LSI>IO.3.MBIA1QIT@FK&A(L^BCN.K7Hf50U^U5OTWS.CDHT4Z""FL&C.(61X\$X9K(8F67+3A MS.S.B7I31U.7\$S=D.YL8ZOUVIOVIZM)IRX.P.6QAT.N.8Z6F8R8AWYB.L.M@P&<1TfTMRXZL(ARBG<^M@E3.%LFYDfL/308^Q2U7IQ8L@E? @M9.M%-2Z221YTCI+HU^Q@2+B/82#4@/C6ME(D%#&E.XY.M.C;fAL6X^K

[illegible]

!IGN^<(GA%)>A(I)-V:NX7L^EZ0KGTJ30 ME"-=4200%"K:K%4A+\$.U+!,I,##41B+>I&D>-@M#9S)W7(:"MXF#L(Q M
X:Q!#PH2C72,T67<9!W@4_58DU@JNU.GJM,OE026"3R%<OL@W6*+6%M-Z+BOGJ2%Y/E3BYE6P8./2"C=ICMEV4IE(CUM-
CVLE.&J\$4\$)32(G4F0NJ MP.CB36:KG\$N1R)SHFLX2"8)3IQF%5SZ@|TH6^HF@,T M/1B&T7FJ8^ZK3EZK6'6V.HTGD-3%TC)R(G,I 373/4!0-
Q>E/XC61\$&_1 @3Y^I&X.&P^K/Q W#FVHZ=L-1/TAWWV:SC+R&F6.8N8 M1\$&- (0LQAW:F&IT7A1S TG@T I.QCZ.NJW=QGT.ZEC?
\$>W&WDZ1P-WK !AFAIE\$=Y MU0L%#%XCL:98HTJC5C2&MEIAB F. ^H6<0R+:+B08Q.C%008IT+D+V MLA\$FENUBB0I&D/9 QAJ_L2
&N&+X!WDOQ+8.XORC%OCBUJKJV13.LT%UJ: M6RJHQ&Q!(F8W6Y18^H>>.TAWWV:SC+R&F6.:MED:JUQZ92S#J*#(FY^O:G M+
G%DI99IOE!E"7GS.Q RHVU3CNIY)+,5WLVW%I86H.#T:Q-W RHWA9:B6YOX.\$F^Y%G9#+D.O0 D1MVI1B%G\$+&6.8N)"(G/8/Q@
MGIAB@C..OG./4E!5W)EI30F+>%X\$>\$2^6ST&5X4 MAJO1B?DN3:3FIU2A7 M?C2<32KWAQM".W>9:"@?8>B1LSV0I"(V>T6-
>:GD=-Z<1BW12PCKR%F\$:.8 M: HVAU1.M1\$XPE4<>-1#CN% CFC0H4Q168TU/O%>^OCC3H3I F^!J0?C= MQHE?
48")BGI'EY" ^BU(M#FZ(VK\$:<\$<B9CMC: @1LQ19" !A.P33=HE4+Y M\$<0%!"0+R-HI:FFED>OGW@".?LJYV*&Q42K57YOZB\$DU:\$YK;LH0/GT-37I
M?A73\$EW&3-HWJ&B\$:.!\$1B=KM%C2EIY+7>"9T6H1W6RFWRM.D(2M2_%#* M.%@J++4DO"6\$!M&MLOYUI"(O^8C
=AFF+59XWVSVD >CvS528SLK2.2?+ M3HJ7+>G.LGJYILTAK 19D^U0TFEN(6<0L8A9% ?)+0!PB9A&SB(D4)&V"T6- M7<+!SLIFT@.14QF9U.WG%:3
/XT" D3M%Y(DBAHQVPM:(F.W6J28H\$5> MZ!UAQP3MJPGR:R^UE1&=@3LAZU14%&I4H|T/62KB!5M|@G;^!>C1?&E:|Z M: &RG:F"#D.0PY:X#
E\$;\$6!>1 V.G.\$!:"4R4BLBZ2<=<XOI"EF^ MX H#<FLOX)LA4:ISB5B!JC^&F510 Q_52\$&H^"SK!^!KHM"\$A"- @1(UA M%)2CH/== "NF#"N@=
H!Z0DCPI=E&-&NMM"/4 &24JW@|@14Y=FL -OS9ZDJ M.Y3>?SJ2B!NHJ!BQ?ZRB>=6G^D2C ES92J!>E2M0275L@W6U+4#R!> M\$#
(W+>Y2H6S@3\$(3\$807F@HC%*^Q.B=TH(ZF^ MJSDDGCBKEKW6-G EQ:|T=Y.AOL?34./ES9:WCAO7:HX|@AQN2 MN6'7IC:Q
U!NIQIG8B20+E^Q7+57F!H2FE)&LC2/(N)HA:4!(KWZ?9 M>- 1O>OD !GY& D:3NTH="V0VY:D!N0&Y.M@&D" |^XLA!9)"&-4VR!!
MT"2*#Z<#>4E=1%&I1900%QASO:HCY1WX>3.1I^Q SW? CLWGCGOIDSMP M.LJ^T T.AWGHTK3G8H1AA'M;D2L+7K\$9:;WJDJK>*<f;E|U?Y
EDY?9H M8 TO\$%DI8:6.8'Q0\$(Q48'^60\$AD^2M%LW.+7WE(BVZ 3Q)NFA(3? MJ3/!6J=X6BA!;9IFCV:3R=0
8!%JXVINEU902432.3#H7R)*UZZ/QOM (JN M@#^#%:DX|@QXS^5542@57\$98H!16^Z8IFHE %D: *?E^>)XLO OV6#Z944E M36+'UG85.BB6-
6%94X^U# K&+ZY+3+2(LY MU#>+LEF4G.@91/V=9IY")\$9H6?<QA+02/EV7%RR! M2 8%6"R(Y"8SIP(ISE:F.\$H@{3}&0?&\$
^1P!<0Q"EU<6>B4V MWCZ."T)/LOJF.=82EC7U!&A(IDIT^?I94G^6\$VE=YL2+FS3K=8Z\$<PQ4 M1@&^"Z
!>@Q)9IZBT"/S'O#FC6.U0@9F^1U#52%?^>=5IV^<^?>?Y N=L.AWD M+XBRIL?^G/G:AZU!P5Y98NDCXP<7. |1^YS>#.:?G8<.?R3FY3Y4(8G9=G
M^3(8 EX-1R5FV^I/(9N>IDDJ")2S6)XPU@B/:3B9 M?J!U@+OW+ZMY#RYV=4-B^<-(QO+T:30?>XW3FIH-/4J#>IWMY3W? M7*/ZIR-
9GK^CN7+12ICH7^C@&F^>Z UH(I0:IG07SX2P2L"Q!2Y^YV: M34=0Q_1\$>Y%YCQILYSZMZ72YK>^G.G!2P2 7A!H(BI?4J#<=t:@7US"!&-
MN5J9/4_95YQRI#S !OCHYX-WN_6/CT *|L YX<5T?QJ^Q MCP?IOI5N17" W?I^+H_5QOXN%Q^QI/#NKO/W5#DOZL?HJ!##(6\$%I/<7 P+0IFDW<
M.\$I^O\$Q/K5>?YNWZK(&Y/E!EWS5S3GHTMJI!^E9HKRY/6?0U\$EHUE1"8// M%:Z=?
Q00EY?7YTI4+RG\$Z3!&:2BFI(L NXY"1^8F4.UIOHK9_//LJGXP5DQ M8=1.PKZ\$9>HEY:MOZ<\$N!+XFO\$OK
M09&618A.B=06/C!M?:@E7F)>DXZMAIEUK.>>+CIS|HSLYW3L8UOKJ\$S.O=+J MMU@.IG5YVW%WV0050K.%5+7O=H>&R@?
5O_0.5TZ N7^<2>NJI|<2>BZ! M_5+1^W12I1=7.RZV7(KE\$LOCFGO.LR.K.FE(6DA:R\$M9A9QU8^>N:X6H9Q^D HJH_8L?_C7:Z8D5=C\$IK?<
!D5!&\$GYE(C?>6J+V L83>091%GNC|_1 ML\$+F0\$<^I">P\$H;9+!\$>R.#N?G:4YSD:9DU/T A2X9Z7MSM.PIG@TX W M+K5WLO" (#"@
/41RULATE8?9#1U9W-GJ|>^O2P_NTROJOI88W0'HSLO M0C/I<|SFHPG0Y4)EC"BYQR8|+HFBBC!D'9R!G(&E9\$":(\$-2NB!%&R&90<
M#.#H2.F8Z(\$4=(E+Q+>1 &J\$P0)@B3>V R.W)E^PC\$;1&Y9.0?T:&HZQ_MLGMFWJ5P6>1-W3\$S!JWZ26GJK\$>CSE2_D92"" MSF"HI"" MT%&XG1-
:N""&Z2P5>D)KB5-NZ)CK)'

1H^Z.LU^1YX5YNAOF\$1LVZK1&\$5.9!5C7^1I_!A:0B:"(!"^T<&%)H.RL<:I\$%8W/I^
MZU4M\$A126TN%B<3VC.3B@I#NV^T+@G9%):2Q^V+!A5+SIABIZGZ@B:5P:0@ M=1\$>J(7K@FA@KM"99"2JBAD10D!6I6VP&L?<
5!WCGLT^KGT>3!HBA4 M%ZU;^N20VM.=SICA#23^ABM^F:DOAB=A&I6+I^I20C<APR" (W7:M%I&+ MY\$7LHC
1NRANO&X^A=F./^3+N =3"1+!6DC)H6AB7D@.640@ @9P.C#0E##+ M\$*>BQI^I^I21R4+;#UPOR.O)#D8IP+58*W@H1(%NXY/TS3^5B5.DJ_H2Y
MWJ&2=2MU+VD.4&|KCTN'EZS.JD+^I4^"T/A^X^DP\$+W57+C@K%KH^V".M)LUBW4W_0BC!AK^*20G&+E=50D;?7HT<L!(40-
Z/Q/F63AE68C<=I&+V4 MTL\$31Y<@Q87.5Z.3Pl.%42&U:KVM4TCH.W="W(C#<@D3L:OIXL8./#)< MSXIHUHU9C\$+F<7L80B:M?
B\$+N=#E.O/8Q.&57E_PIIHH@H\$^O\$2Q^XUEX!M^Q3"WW^/@99\$S^IY%P\$04JKV\$<[N0!%"0:ST2MR(W0X) MLR?&BBVFAC3.@>2@K""@&?
%F=I^I8CBVH!#B5(N)->QD|,8^Z\$MJA!F^M_Y4GTKSOE%=-C-046=TC&H#H^V(XD)LMF&IJBW\$+I;%.2V.#<APR^V^W7
M#_EN^W2I5CEI0>5<0K2QN?Y\$&A!&@&:"FLU38MS@?V1TGD9?1" B2#+C(M+6226294.DGUK7/#R:368KGM9/H^I^X_! M/ZF7XJYP^UA400I)
(6LAL)\$BZ17XD:L=DB8B-U>B1NQVR^A!L2".H;HBK M+P\$G01^X\$C)2H=4G#>9.F*W#=-Z\$R!&P#7PHWOZ7)M)S7:10K/QK)I7I
MPXTC#E!O.ES0YD_QW:L%I&F^F7HNRWT:&0X9#AD/LMFNJKD"1^ML7A3J_0P#8HW44>2>4:FY8 NQY^>U1^QO_K2WS^I7>FIC!^H#_5H
MWV2(C!1^ND55)&I^9F(C=7HD:L=LA82?2Y Y9DIL0!X4Q^C%BJ&C!MBFOAL K6R>CC2I:FN6LA^F=(NAZU.8?21^7D!RJONN)CL5.TK7^:T.W
M#6.XPF4IOL=OUS^NAN!&I:5@08A>QBYEMS&PCPZ^W^SCO MD^&?2@PU6*4)IHNSRE:8=F4.D^06:2^1SCV)MU:N\$^WHMDBAZ\$P M>)A7!
=E*2""4@ @V%PZP?3:2S*4:GY=HJV6F4(XIE(CY5YK!RV2GRU_!F0:L0Q=VF MQ2%Y\$N(74SZQ!APZ"?>ZO2I!
(01MOGBA10/PB=E^I5H<8A<=AV<C^U(660H7?D)M(EL-1E^+&59=I3QX@VL^L^C/L^ VOD:)^L^S_(:FF%SBX^23U_GTW|_M_A43^5U^#EIZ*&!
I\$;A06BIA|&(&B^QYR^HRSYR-IVD(25@>B603IPI6FM MP#M%CL1E)=LJ8C(I35A&_":7FSYH)=8=I>I32C8Y#&S!2IS_+V_=@WI M#879\$H6-
!AQB%I&+V\$5QMVMQB\$W\$+F(7L8O"1.QNO:BOG7L^F=I&M=AH.GL M;J\$TVJ2QI|&(6%RM^Q@0:Y\$<2_VYI>Q"YB%Y.IF-Q^AL/DI^L^T=AHX^Q
MK8P@8B1@LDD0@_I_GLN6+!S1#(D.BZILP6^!GH^>5\$7L M(G91W.U!&(78CG:1">QA 3C<"(NFS!=M0ED.Y2:H2@U+EUMVVC I&)<^~V M;I?
O!S%="1H&24JW@I^S1=IMQ^7\$Z= XLU8!HEE5 7IXN1WY92GDP_XRTN5521=K<+MIDE9)BLP<0+&<0Y.N_1@07HQ_M19@W^F^<
AN+_&\$&B:CEW0M^+>Q)(7#0LW=EOG7+!&TGQ@W8I9_P M\$;N!\$C=BMT"1.SV2MR(W0X)\$!^*W\$C=CLD3.3N=HH:F_67.BRI(8S30AK
MGMOI^ITU62!+Y^G.E:7+HTN^4\$SU>?>DOT>30@MZ2^UX^!0\$3IFQ>FTIX MMPI<@>1RQ(6%J-(E&PES\$!)^("BCX"3WD+7.FAQ%#=/25"/PN=
IBU^O M:86C/^4HKZ!"1^NKG(3F4Y87^>L^GYC7PHQEZ4M^U=7L7L FH2U^YMT^YH MH6XWDR)(\$=LMXGZ126.TC#C%#0.2\$10%\$*
(9J\$F."2YRM/PYLOQ:80\$ _MKIZSEZ8P%LHCDV!)DZ.UH)D@=>8>@1R!)\$PX<@1R!^J\$J_<(A4N9&T4@_M,<=>+I@QD>X#\$^LRBY\$ZP^SAG.@1IAN
G&41XB3/OI&1_5^2^CLWCGYOID MSMPLI^T_4.WGHTK3G8H1A M%;HBR+7K.9<WJHJP^*M;-V!F3_U_MXVFIMO>
^43K&ZGCI=3.HQ^TQF12^I8+H.E DBH!>=UJR38UA5L/HOIA?2 M^YT^YQIRHAR\$3IDGM:GB^>) Q.G^VF7U94S1" MOI\$%""Z)N%&E!5-
B9N%RPUP#9CY)7?XN!+3D>P1@90P9\$4"MF:5@E;S^N M>H%3O4.8Z2.+>PEI^!"?NUOV^>F.R25!@516J%.0VDQV&E*.0C&DY+M15M-
>_HB!Q^2>3#<(*)R4^UPL1_F8EYQU_1Y=OF14N72^CZCYMMU M^Q4^2^SHWXQZIZGIGS3^OIYQ/H5#07&Z>A^M/6S#
(_UXI>_SF^4WA_XB+RFOSIZ@4EY&Z8I+>3_%&I|MINM#>8JU>+I7!OP/@T M.SIX^Z\$S=7K;RNP:SZ.Z=4R KS/M@+I4C_/N:P8:>R)I=3MI9\UI
_23*(H9FT M^CX:5L@&A_T09N>S.S>I5*9^T!TOE2XY^7M3M_P.OCT MX^T!H=TL!"X+!\$P\$_.AIPU.EWE(3I93=W9W%FJNXHN<I9-MZE>I82T88LP
MNMV@I2OZY#^_QVO>IH@N%RIGL.DI_NEY73931_F&)>SD#_0LRM^"6H M61\$EB)+H.1@&\$G2!\$26(DGZ^Y%W^@S!_98(P09C<Y-
Y9QR89V)B)M^>Q==7WIK^Z1\$5S6.LFWIEA_:2?;T1&Z!\$#I|BQMD\$^DPI>L@2_U)? MUAB:D)BIH(C7UEFXKEQ\$>RGC8#FS(2A8
@KKTDBTOP\$BVM)QIM^>CAEVLH!5* M=K(W.U8E1\$7YDMD\$^_0F4=QJ\$IO^4A(GK8?O>^*FTBMAMK5_2HOA9^USM)I^VW#L.VF.GAUYYD>3ZIG
E^4QRA-MC&MY4_%UI\$W5^WG>JBI4 M4_R3KIHAB#I)<<SQ?>H(O=2T3&4@19+1IUX7HH_U<\$IBOIV"5_IK_//)U/(TK#_IAN M^D-
B.VMPD1B^T9<4%(<^Q62V.NA\$M^:C9ZI\$&_3.Y5 MC0X\$W(>>& M^4K8>+>X&H MJ4KQI^+V@&QU^H2E.U2:7I&_D1^F.)75P>C@R;H8=__\$
M:WRUA2+T9!<N000CP!2VX8LTU5Y63IE.124TE JV\$^02H%<C%&BCH DIL M^H^SSYDQI@<LIZ_2S=CIZ&ZLZ)UO.A^H-
/0JG:OAH@:#RH50MSLAKI7 M%^// PNSE+UP^>HFBJ&FF55_1O2TIN!J96TY_@1R!(\$<@1R!(\$>L MG^/4<^OP?&_IR4K=?!)).%!!&H:|_!;DA:.*
(U=I(2TMSKXO&1PI|B/HU MVH.3@D\$B.NM(K<#ANG=M%#Z_^9H2VFLR0@?#W>M!T>K="JBS?HCFJK+(EK M^R%?<
T^PF@9.9&EY.YDY>ZL34P22!P&\$R&I^TPO.E:0!AE"UW#_1I9 TP MI@&84D&I\$B\$)STDJH@LD1FWCIFQG\$!2^JF^D_!^6&S?^4LUGI^="RDTI
M%_YFSSBMA74A:U+|8QKU;/F)0%\$Y\$#RG7I(1\$40^6U0R_8X91ZOL1"N:0 M.5N?P!2=
IYH#EYI^E8H2.LT.WQIK9I9080:SMYTW2E_RNJO_M^65EX3:6E M0M^@OE\$5%<^<P8OM=<^(P)G^ZL^I*J13E8GX/4CM2^6H/M17D)Q72%T
M^C#8(4H+Z.TI16#?="HJ9+5CALA?=>@R19<%(XR)(I00B)Q?7.L!6^CR8-74:B-5Z6Z<(<M-EU&E
M(W8D)\$S\$IO:+&^LID.%Z=N2WIT0CPR%V\$N(711WNQ_V\$7L(G81NRC.UJ5V MMCX^J02.40^7C\$#(F8+QML\$RD>5">.\$Z<^/C5!0:7HP#\$/S!-
H.EEY MESG=T:9CF4M^&49Z!I7:7KDTFY>APH^T_OHGIC/IXYV:POU!6V7JMHU@T M.CSHA:L1NAX2)YM^JLOB<^09_5Z/141:#>9I).
<=>9=8MC#U2)HN^YM^V MF428+!4R)H1\$=#).4^FO+>S<7TO:H/I0\$W=S9+504/I4^_IXW+?QD_J M5IE_@.T.TWBS^D:IX6)F.DFOQ@W8I9
P\$;N!\$C=BMT"1(|DWX8674+17W^& M00A-P67M00<=>@PPQ4H1^D0U^>^+@8^MJD0AYKIVSOZ^PE"J3T&_MA3R&PD0:1?>B1NOV2)B(W5Z)&F-
(6YQ^<(SA57P^A@U%0^EHP^A@<@3! MIU!)>?>?>X!^P!DL+>NVG2+H>M3F""T2EY
(1^4B?T+Z^DZNS^4NUU|JL.YIVJE\$HSL|MV510Y#8?>SPY014CFM MP+AL02A.P!CI@#K/6+44YK6W<&^2&'+A^4HWO&(H\$A@?<
5=F^UQ1^1.PB M=A&\$!^YV+02QBX|Q+KJ_G74KQ^59QI&D0T\$!6127Y9B6HMQB6FWSL EFFT^NMOR OF=^X M_+)?GAJ\$TZCBRT!%C2<I>I>
MUZHUZME 7^E6!0!<576(35I_PVQ_%YOI="OM_-H.BW\$5IE%:_%M_L:2 MP00>-6BK^AK^1CC#I JOB_8Y#V^W M+>M%I")Y\$;LH3/1=UN^I!"-
H(Y#)\$R 2\$2^L81!\$#I8S8^QIEEC^%Ww:GO M@&_EAMHT/O.58.F1J>:710@?PHZ!C^!XQ6^I(0Z4879B?Z\$C=CMD#1
MNIHO.DSCA^IUAOG3N!E2=SYXRB\$5YQ8\$8HLX4A0AA&A^>1LK5!2A8 M^G(QP=OQ&MIAFAI7Z-Q3H/K)EHL^HAIP(G"" J5Z8+=8\$. \$A=A&
I MB^T4=I6AIA%I")Y\$;LH3.3NUHL^H7D-K-HW\$=YK.SJ9N.*TF?2QI\$)F M=I.L.N1\$%#>BMPWK1>PB=C&I|B|E=9#C.ICIR|F>1A1/UC(V0+@&8"-
@8\$T0A M4M);>>>U8CXY.SN.^O1^C2Y=A=E:Z_.MUOY.8WQ?&2%+9 YR1!FDMG)R(M(FT^="TR.F5FFH^7I-
(M4@&CC\$QFIEADN!>O+Q\$ _9L7H!M\$>+I2B RL8VYM("TFPI9RI-824RI2 M\$B9^<^ERO M^>0(Y CDB%8<N0(Y CT""%2O\$=HLC
K\$&E">@4A4@/9@LPF MY^@9:P9M+^#< SW"=A/X.SQ^G/SO_!F F.^YVW.S2W)W?FAB%5;EH=IXMI
M.O=I7^R4S!"^K04&E_068UYN)H5A=EJ5"1WKKH5"62ZBY1/KC@G=GB>3 MB !^H@183T%VR\$Z5%+/-82+ZH
DRD5)KPI.D0=2MIH9S\$SY39X^U3O&T M^T\$>S.LXEDT64S>1?>M@CW&H30Q2DH_!>E2FO:1JAY&^B25GDE M1>\$4^@T6@%69P7^H|R-
L^&FU?H!0^#Z9<5E42)5M:6-LL2! MBHPC(\$!C^O.G"M\$&I|B|E/BW8I3)(FUQ=VN_!&C!Y^X+?R_2DT2VRDF^2 MAC2^<
(HFBG3ZO\$SVIHM.GLG:D9%I_!0A=<@5#%E32C^J>AB!<1@N=O+TH MRU_2H^FOY372D&R&LCFP+&F);NX2M^<^7\$*TWS%_%E!2U C_@/S>:W!2
M^-U^GK)FGD\$(A-8Q4 2&508V^9PHL!K!A9^#USD2IC-0&44QK74+WF&)<^M46B68I2<_9M_L+G+HYCROL??^XF/72@C MUI<^>^KRI5_B5^Y8N-
ZYPN2_K=E Y\$6L:C@&(34_3)44NEDL3QAKE^30IB-ISO^8:C^X^K&Q_>O+02P2 M&J1^2P&^MECY#(Q3 IDW9==FY.W<3Y^2WM2?<
ZOA8IWK^:88=>#7 M_Y7UZOP^E^PLZ@_ET:QK<?HIF@>>I0.G/3P=4X/RYWQ:RGF^ND2UYW5Q_M^REYZ%P!>"P?C?_KYVU^+AKI>8IDBN^I0K?<
2)KPN=+QI^<#P#_M33.OI M^<FT^I^IWI1SLO!Q!TGI<INUS6I!>=>&^3 Z^<^OZJ^<^H7L#P.P8G?
MG.Z%4HJ2P_AHPW4=C/Q05/NTID|<Z^T00P^AWM^?Y L5WM^S!09>^>5P+QRC_(C)Z3_RV>B23VMVZM?#W5_?9SLORM;=2AN_IY

M,MUM<8D7>L+C%CW+T<VW;KS3H^?>LXIXC^M(60%OOOP,"RFS6@V<V<X?&=<%F;5>7&5WU||H4/-I=IEBJF?I=8XY="K
M/X=B:XUFQ68:26|Q|2RC*!<OR9^N7E#>\$.8N)NG-|7+L1#(U|H|^P|JWYU ML|OHTV R|<SXX>|N7K|7U#S<EON2Z|<I7D>?RR5>M,1+
MV&LCEGF^BYIZ4ZSVW#RV>S|VM5KY|YFX>.@|_"+50S<^P5"MR0.6C:P M_LU_OF^O|E_FDI|O.W\$>#HO74OU2_O_T4NT7KR/^Q8|_..MW?
8G+G9C^..V M83-7=,Z0L1RUD|9#<GKQLXQP@1RTA-3@<(B|O|E|DP5\$>B"|H:|HQ|<%>KM
MNX=V^T9:O4UE8E2| WCT2W7T8;^4A|K=K=K=SGX|>#D8_ X52D:KU|RT M_L=CR@=4M?5-ID;A>|,/@= %FRWUOMDE?C\$<4_-NH.YW
Z#UTO_C|V|A|TR;2 MOBMYVR(5>F2D|4VKL|D|O9RQ>TA?>65;V|T:2|R_L V5-4^J|C#/#=(W^H M-BCM|_1/4@;4:5 L\$W|9:B^9VQRI\$4+&FT6^C-
&D660@_G<@C|+@K=&00Q*W M6+>% NN#X9A=)Y^N|>?3GX#H5K|L|L+Z+67|-(D|B3SYCRB<|+0 MG25@>LCUM->Z%YPIX:613.2DGC,A=B,2>F-
A9YB6C7 MV?N=^MU8Q*W MI7\$S_Y+K|+@+7#2UN_FG|25FT5WJ|NG|L|H=|+&:U|76|2G|)@.T@1#
M927WRN|L68<^"W#O|=EN|FPR5|56\$RMA6ZM5W|2Q|&C2G7#6+GS4NGR|U_MD#Y2U_U^Z|INE36|L|D=|7+U^ZV6>|<%>% ED&!"\$F
99Y#R\$|OT^9F%4 MS3+AK6^QN#N,N|@<47-N>O:&F|2.6W6%="SEMLX^*+>@<G|9J^<8|N6|+|=V2ZTNT^C>9 M|^EFFE|L_-0|HR9|F9,R|&
((U|T|B>4K\$|,.(B:\$.2^YE56./2XO_H|URC M<+>#>?>W5>|X2;DXW^L/XOF5RGS0406EHP/9%\$FOMC^ M1M^M^ZDKGWP@+6+^K.
(->W5<|J|&W|PW|X5A=7D6|<@_O|S|V|A|^%*Y|P|X3|H|RB7|HBZ>K|36|E|H|D>|>|9|X2;3R_U3^O1^?>FSN M#<18%= 7, MXTM^94UY^S1;8|F6
M|XNS&3%|J9S_1Y \$U|XU6#;IK#Q|BK^Y^W=8_-L"H2_#T^XZ;Y@;W|<79N&C7 M0.W3<=AU2N_<^#64|J|D|)%BV_HL2%\$G#|I
MD|6K|K|L M_&4:9UVW_A|H7R|>|>#EBZ_0770C|AT|7P=>BU4H|P45+M:C+3D:C@>|EY+L^<N7^<CB^M@>|<5FR%N|U|W_XF|6WNAO-3|/XY-0-
3|+Y MQ6|CQ|E|&S^<8-ST^*(<N283?P2>?YH^#|<%>=WOE|>?>ZM;U7Y|R-|R+UO|D|M^<G|30^P^P|WS MOHS3HWS2WX>N/E-
+1577X|@M%N:2XT^Y\$%MY4%M|H|L-PZ:4WA2<|S|=Z/M@HTJ (N^*8<%WHE9G_K6/1|F4CA6Z6WR|24|P^C+0/6K|L|N,O|)^98A
MKK=^*F|218>?>V4ZR6+E% MZVEB@N|L_BA(C|PDL|7N|L\$F4?>7-5\$ZNR6|/LM8M0^51&C2X|M|L4+3V>|3B|J|M^M="S|H0=^P|J-
V|>U|F8NGOC@B87HXD|H|4Y?MYG|J6XW7HU>^"H_||L_0Z MI6L>K_#<C|C|N_B8_@AEB^J|C|D2-AMA^754H^>AO_9>A8>3^%9NF|+^M|72^<2@Y
A@+6%|,T91ERX2^Q\$|T/W:7_ ELOA2X-1|W|WZCNHRO_255R M<32|>O.5ATYW)&J;#&Z\$@>3VG@|36>Q>.><\$7#A_L|@K|&Y(4)E_19#&^VF 9|N3&
M%5K_N6ZF79D>%M/(@=5|X|U|U|X|N|_|<|<=9Z|)\$Q6B7F_2 M_-^#X146|UY#5%Y^<1-WOMA E@XN|D|T|/|3^<68TQM%_W8245NN3K6_3#;3YML;|BI
M+<H^X^UTD|)>@.N|L4M+K|L R_P2B|J9CYSUBW|H|P&2Z3|UD|J9Q3YU_H|HA4 M.3|PWI#^2">."I2^*^\$U(K;G0/5&M-187;H5^V&
<+MP@5NES@LWS;DHW|< M&985|@_H6TWD6V_K2F:2|<=\$9.F.S=_.GA(C|H|5,B56LX6K5=CUXB UW^M3Q0>7|+O^Y,PG7.F5CUQT+
R_1C|RY|9S|JY|+>2|0%EL_#54GM^A^%4 M&V_L_R22-58N#>+E;3=QYM=SYN\$BTZAK|822Z|3;|=W&A?O2W#U0V^PNA^="MOOY-A2,JG|X|C#=#7?
>|D\$|90,D71^|4="=\$%#9|S|D:FI2TG^?|1P?YQ>L M^>F=WCLZ?O|X|S552EU?O2>|0T^&8|^*T^T8@4N0X\$|H|P10#G8Z;8+00T^>H0
M%>RASM94BJZ_>QUGL8H2>CK\$GGC|MN_<|V|A|0NYV_A_7|H2|7AH3|J K_MU>AL\$|LK^75_-SV|2-20^I&0D2_<D|NF>|AW1
M53|CPR#74|>77E#|U|U|@2|SFF|C|X&2DY|P<|B|L<|L&F|)9Q8K_2SE TR|XR6DUFZ1X8Y|_M.722T^U|=8G|H|WJ_>GLHW_Z;.(@ZU+Z#
(99|C|D|SK2AP>N5N^N+>_8^77P MDCX8_HH_??FU_8W_G^WFC16H_?|2|7_2M@SH|L|HY&CFZ_1R=HV_2&-2 M_-B>9|U@>|&C_5?O
M|QH|AT<_K9_?|P^+>|=^>DX+>#D|X|J8QKVB=D|8U|)^#W5K#=#6N|F|<|WH M^J|K|MMQ>^>^<?Q^>Q^>4U>C|HGM<6_B>U_ M0D488 MRH3.X+^/(<#38
AW8*0)7A,JK,&KQUMQO|L_B3,|=+>RM,46BN=EL>@B24@_M0|@>L|J#_>|QV12R7|A@>YDTQ97?>E|T|G%1V\$?Y%Q=^|T_K(|C|M7JGM5
M|HRFD2^8>2+N|M|CMLBNZ^A|>8|J6U_1|H|DZ3>1|Q6P<3E|T2F8|HWDV M+D=|LXW<@>K7^>V?H|<M1|Z|2\$11^>E|P|G|C|A=AXHC.
(4+>|U4D6^W^Z^Y#<G^ M|S^R^G|<@>P9P^PS@#<|G|71Q|0|6K|<4WS)=5(EQEBW|JAK4^=>3;5G63:=#\$S|
MWPR&|32GRI+>XC|4|OR_1|FB%4_EO1VO^3WJ8%OGUEPP3+P2BL047@PWG+0 MI_CETB81O_N:P^=,BUDQ.
(ZDU&=2VGJ#153_U_05L7BL>%;>C+>9M|S8 13M3HEL_<YRMC_2UH7_L|TQ|6D:COF+V>Z(N|9E5&>L|7^Q|0%6L_L:Z|?O
M|B|X/Z4)=D2C%DOMN>U%>LALY>9 JA|A4_<|<_>|/K^<(<DD3^YA_R02G_MER_HND|AK^N^Z|^1%8S|A^G9#>M(Y@>O\$@=URPW5HOU|F|8#>T&)>Y?
C|K;G|HQ9K^VK+>S9T73_P|<^|<|43E M|<(\$J#K6?<Y9EM^R:2|U^FD^>?<(<F\$QF:AC24=YKD@>|85_K;H|0NX8 MTK%Z9BQ\$0P)#
KN^PQ\$A|AB|P82ZRME_H91^43GH^7YO^<YU5W^R4POF.\$ MZ3N|88OV|N|S|C|A_<=U25<83>3_C|H|N5|L\$21>X6VK=8P6Y_3Y2R2+>@>
MDDRQJ54R8>38(KY&|D,B F_Y_3AWV4&WU|U<3V_N2O2^E)WC^A56R)#(<MD^-D>).^*+>@HEITHY^A(KNUU|X^|L;DRF>P<C/GPPED_1 W|H|Q?)&
<_H_L|S_V_>?>#K MW/J_B^>#>4Y\$M\$|8<^\$S|>=Y_0.H7T^>B8_>WUKAM^& MZNL3PR->@>V7J|MX|T|T|L-E;@QK;L02_9AB_K|HE_(H5)=I^"@>LEN-
RX_3 MN2-G=1^>L F^>QOR=O^>O3=MCANY\$D6_OU^>Z|A^>TQ|U126_2)>C|C;\$K|X5PU
M|J1\$E^U/C|D0B0<|=90%|<"GZU|H3F9B|86B1(HLDG^8|JL^2^>|)LZ^YK_<M^*?A95#A|^>^IH+J^>|>%"@YSQA28^Y7..K2I\$S((@>UF6R^R^W?
O_0^>M|T^M_R5_1X|=\$S|C|>@>P^>N_1U|O^F|QJ_FEM\$P2^>|U=...C3X|>?>3C<^>RD32H(A M)^>F\$S|(X3YG#7|E)?
AGZZ_9WC+>C|D|C|9|G9GSW|^>|>|RLM/&P5^A^XZP|0^>6|J2M0^<^>TO>|>^>M|D^>8|9)3C&^>HP_>P0#(<@S\$S/2 M_SN|>OOV_7^>X>><<5|SRKN2QPZ|/|<>
G=TB9N^<CB100#3?>TS3T0|E MCDP\$|S|^<M^>PR2|>|^>^>M>BNS|65>?>X2G|C|652|3Z;6X\$SGGL>B_+>OPX2E/G7H(2_OHM M^>
|>|>QHMWRBDEFEOR_6^>%"H0P|X;Y|QDF|H|0|>S|BX^>YPP#1DB1_<N\$|22 M<2_GB=5|7B>?>|CC#=>R9ZX03Q_R^98^>=C|O%>C|O|S6L|C|>3D|I%?
K|_2-|2^>MV>?>Q|T>?>MX^>=|Q&2U/>E,ERFKI&F%9P|XTCXG(\$U9C_-SO^6R.QC61)E_B3C+>SNI=TO_MFG/XOI?_6A678^#5;2-1-FU=B^9F^>_
AF8V_&S\$Y0=9%|2^>P|>#>H|T|J^>2^>M26|>2CVB|C=O>Y|GR|O^OY-L^E_H7EDXL|H7=BOWM_JA|P5KL_U=X&HHH M9KE0?>31+>
(D|B6309F4>|D0>#3XV?>M^>|L_IK0Y_1OY\$0=Z;SVUF_27M_L8^T^R0>2A;B|W|X|1:7 MRTC>|XW767_OBF99-
7S^>W#>=)P|GW%|1;F2V>E2UO=9S1@>GOZ/69)&4NC^X^<7CN;?|<+XB MABSE7LC|C M|N|B+>H_P9|V\$S7F|FV_-'9X|V_GVZ|'R8,MT|BA8A^AP?"
7#>4X|0L_3E#4M|L_ZP+STVE M\$>F7)>=>S_>|>+>NN^P3^HC0P\$U9|A^>Z(R\$S8T_3AQQXL_3|_1_0+>K4V\$SD&51ZC+?
=CCC<4X1&A|OZ\$3|W&XSH^8_EL M+|V9\$Y0^>W|_JE>9>SF20>S+S(S?>G|H^X@>0S^Y|8|U6W>8R|13|G?FSS<^M^>)"IA,BO|B#?
5H_6|_VCW^M>?>7SO|_>#^>|>_OSWY=>B>XOSO3|>?>WQK MG;Y33K=W|T_>AV?O^O|>#L%_2>F|H^>(*4QE0F17^S|/J|3E-C^J35&K|
MK^40_H<6^#>R^>=W_>|L|KB|EV_+>1ME>_>|B|>(T9?>+>|>L62|RX&_B_P+M^>|D3FS?1WGH|L_>|H^T^Q_>G^>HAN|BP<L_F|A|AFXEG/CF>M_VWRDGY0?
D|P=^>?>_Y_24T^>R>D|>M>4%K_1^>F^>3_>D2 M?U_<3|8E7|>|>C_5V&#>+>?>T-LQ^18R^4=|^>QXM^_ZS^Q(6T^F^EQ|T9|NZ|P M\$>
J|JOY>B|8T|>Q>@>|>H_B+>CZ4>S^>Y_Z>|>R^>FQK_>=^>FXH%>|>1@3#_O1 M#>R^>N^>NGO_?>3+>K^>_ZK^>?>2|F^>|>|>374=X|QD>Z^>K|2^>|>4WK0>ZC|
MB_2R+>#>K3_9_PY_ATAFM/4W>#>1N:QKB9^KO|>3O^>I2A#>2|JQ|U|TXCG2R^F2>#>ONJGL_M_>+>W1?O1YCL09^>EC\$|^>U&L#>?>1?Y^>U_TN0X M2;?>
U<7_#OR>V-L#L|JL6_1H^>64M+TJE2DH|>I7TSCF=6F53Y7|H?M/G&M4B22NZ|G_B?Q M
N:GH^9RUP>9PWW2|HG|PWG<Q_>3|348&>N|ATZP6_G|N2U^>PY_4 M^>N#>ZBAC|O|YBHCV M_2HJ (N|S_3GC|236|_#M7??>+K_>
|O|>ZXGM6_>T&_8K+>H4G_R|>E|U8N^>V M|U|U(RC=>P%|JNT0=5B|TBM>8=4RM|YK|K>60&XQQ&|D^?>K|T^>RF^>6\$>^
M|D^>C_10&AR_S|S_>^>Y|L60@>X^>@>S489|6E)>@>D_73TM^>+>EE9>=(L#>^>M^>VO^>L_>L_C2^>O|F|G8M|PM+>N7K|M^>|8^>=GONK^>RY
M|>M^>W^>^>AY>_>BRBZ2\$9L_Y^>S|>W\$5GINK%>40V+>S^>N^>H|JGM^>F2|J|U|O^>YH|L_YZ^>A|S|D|^>IY M0|7|2E|B|FOT\$>7V_>|>FF=^>6|
E8L74AM^>8^>E(V_98^>?>3^>|>35;29S M^>8F@EA&T7T8T|?U_2^>+>?>4H^>_L_>PS+>|4(4+UNN|>G>=>PXZV0USA^>M5V|VE|H@>7^>4UJ|!+>
|B0|>=>B75^>FG67&|>V^>W|P_>G0Q|E+>|3WA4_Z|_3P^>M^>N|Z M^>LBZ5&@>6-ROKKJ@>SYV8R_4 AH8+HCWRY)>Y_>1U5|>12@Z|L
M7|>0&X^>T^>T^>3>U^>T|P22^>5900H5W^>|M<2>=>U3+U/>7>?>V M\$>SW^>15W59<+>@>=&^>K^>AX60D1&_4UER4 (|S:TMKOP<6^>LMZ^>6061J_Q
M_LQ90^>TYDPV_%E|15M^>G^>^>Q_N^>RR^>1JN771JM^>H_>@>C_WY5^>XF7+>B^>NF_>(K M&_H1MEK4H&NW|2G_UM|>?>
>^>M|E|A|>U^>O5+>+>3H2H^>H2|JREC^>42M6PW|K MQ#6KK>?>YH_1K_K<655FT58W^>2Y|9M&C|T M6R^>#>D2GP6EQ8^>U^>QJW^>W9W^>
M|Q|>G|H|C|W956<4 M^>M0N6^K2VE|>D4+>J|C02M0^>L_7GR=M^>2>Q_2H>?>K|9SGH4|U^>0<M^>L9_>I2|F6XH07^>Y1^>G^>EK|>^>LOTHX M5+??
2>?>H&|J|D|>I^>?>A+>80U^>MSB^>L M^>S^>M5P@>#>YUO|>ZXSE|S|A_2PU@>I^>=NTPB_X^>N^>3^>2|>|>W<|>FJ9=^>S^>2M^>NO M8OCHY6&|>C^>A2?^>F\$^>21S&+>Q_B-
SOV_>|D_6^>Q^>A_>G+>6|3DLK6|O M^>Y^>2M194^>EY>_>H>@>BU>E|K|N+>8OD^>T|5NG_Y|I6_ZHP^>^>@>|E|S|7^>)*Q\$>E|JNA0HF4C=5JE4+7^>S^>W^>XK57(^>6TN
MN^>J5_5^>^>D=V=^>JF_B_YHJL_7X6>U_>H M^>V M|_>+>|3+>0321ZX06(^>8|>Y9OE9_>9QO<53K_Z0K^>M^>YR SM_>=6&RT1FF1 M^>4^>B T^>L^>T^>S^>T06
K_7=LC+>M9FD|K|&F^>FY1R_>|1^>N|T^>Y400G|H CHBY M|QO2A^>PDP>U3|EJ>Y8^>B_4M^>CS^>|>EJ^>2AK_W|9|E^>D^>=|>1UEF^>^>#2\$>OC MA_1|PH8B|
(1B&K&C|O|C_>C|H|A3_6|>FORD+>3_6OH^>C|P5 M|=#OW^>QOM^>4>K^>Y^>T(R|L^>U^>4&F^>W9_H2|8@>V9_>A0T\$>DE^>PDW^>V_>E26> MG26ND_R|
2^>Y8&L3AS|PBP|LQC^>W0MG@>YPO^>=YCF^>A M+>U_R2FQ_>?>R^K|>O|>2NE|H_>T^>1^>DXK1^>0\$5|2IU|4<|>S|8FSB2D^>I_>M9^>^>^>Q415A\$>^>A^>
Y|90^>AW%>Y^>(|>Y|T|>?>51X=^>W55|ATJRS^>+>4B_QF1^>#>M|J9P^>P|O|B^>FNI\$460<^>=&^>C|P>32_5ME^>32|H0^>M^>TN6&^>V|>C|H^>XVW6Y9LIUN4B&
H|98<|>7>|>@>Z|>^>^>+>W<@>@>C_>#>#>MVO+>G^>|>39AG^>U^>CO^>P^>6AL|>G7|G^>C^>G^>W2R|>|>WEIROWO3Y5Z_2K7%>Y_5 MB\$>8+59&9WLS?>^>T|TGFEN
=U^>2UF&67R^>#>F4V4|>_>6@>UK26^>^>^>GWR647J M|=5B|9373^>.%>I=20;#>4_IDV^>81X^>D_6|F^>E^>69F^>^>O|F^>XV|SH8|H^>DGC_57SPD_>8|4IS
3&9O_8^>@>U7Z7E M^>Y3#29_YG|1^>WD@>MR<8^>UO^>O|>1DGH+YRL4^>L^>W^>4^>=H|>N^>Z0Y^>M^>|S1\$>^>WH MGD9|H^>W^>Q90W^>PK6^>G7|H0+>_V^>B#>+>HX3W-
EC^>9PO6NP;M2VN0^>7|O1\$>RA ML15THZ5G\$WWW|V\$4>|>?>LZ|_>|W981XTX4L1W>9Z^>D>|XWGW0_X|>^>PS M_>=5V4M
|>SC|P_8(\$A33S^>^>YRMY^>Q^>F_>G|H|K^>E_72-1@>2^>UG9^>C^>2L_4^>A M05|15HBUOD^>^>YG50^>^>X^>T^>^>S^>GR^>?>S0^>E^>#16C7X>PHV_5+TFB_1N9^>8WR^>MUS?
&I\$BM>SLP^>Z|4G6_6W|H|PABY9;6_Q5A_R_RZ|>^>5|H0M^>_Y_5<^>5#>MFE|1+81+8899|OQ_OCY5.G^>#36|704Y2AWZ^>K^>ZM^>7YZ&X5&^>3^>750
R|N0(1R|G6NQ_P4D6QX<@>ZC|>+>D=O_>^>M^>YP^>+>S^>3|J6D6H^>P3Z8^>H^>8=|>WQ81^>B^>P&|SP|>@>KL\$0I0SZY_L_>=2RH_M
M6VRL|LK|RT|KKBV6@>+>L|TN@>P_R=7N6H_9VNU!_>50_U|>N1_>L_5_>H^>=5|>M7C5^>^>4+>R06_>@>J_4QS|K096^>MZC00_9YNN5_Y-
B|J|MTV^>2F4H|&F7R&5|^>M^>T9|57&^>^>9U2|>T9T^>M^>+>YB|3+>_E|>8\$T3H^>W^>F^>EYA=|^>@>Z+I=^>D6|>0% M1&N^>D|I?>X<^>71|O5K^>_>
>VHC|A4F|&O|>#>(>B|>)>#>NXBJ>@>M^>2^>#>^>MH7_>^>C3<^>@>R^>VYT2^>^>75Z_>GL^>K^>JU
M_>SWK^>|B7|_9PMZY3F1|DTHY\$|X&GZWE9T2PRLX_>R_>M|JR|S-BH|_J|C MX#^>^>EIP/|I|>O&J^>?>5|UF<^>#>F4A2SM\$92%>|>Y=N
M8+>J6FK&0^>WAME^>T6N\$|B|XLSM>XX;U9_9_U1H_4^>P2K^>E6#>2FVHMURJ|^>B M6M^>P<^>4H|_H:7TU>TUDER79^>V|>^>^>DHW|T<?>
S3J\$AA4\$|T_NKSOD|J M^>UF^>Y|A3@>+>Y40^>290U6LOYU|^>B^>NWT-V^>|>N^>N|Y|T^>?>7FIHJ_>V^>VXD^>|>MXNT^>PKZKCL\$>^>SJR>|>G^>V^>(9+5X|N\$>N&
&|K&T:872|2WK9@>KW8|JA9_U MNERIDJ_>)>)>H|L=B4_922=^>0A9=985Q|I
M|HRBMWOG_A(BX;MARS+PI3YN2M8ZGH^>2VT1>=>0V&F2K|N_N_0DS02NQ_P|
M^>W|MEK28W|JNZECY|Q|Z\$S^>^>QHH|I^>#>QO@>^>DY|P_>J|>Z8@>|H_G_U=RD_R M_PML_0@8^>-
D&@>^>V5|J|>R|>L&^>46WCL4|3T9>WG\$F0AER."39#OP?>D09ZZ M_|JYV|^>OIM+>S\$U|S_N2&)>B6|>P+5^>6BH|^>B0SSV_>(>UNR=>G|&^>@>I5\$
MU4V|Z+^>|>HR|^>X|LV_HC|H^>C^>^>H<^>?>H<^>?>W>?>@>T=5\$>C+4|/K822K|O(0U&^>?>MLW>|>2^>WV2C^>QD|X1+>|LMQ_O|61_G|G06N5#4\$>3V=U|9N47N?
R|1/60M2^>F=GFQ:4%>2^>U|R1 M|QSPY|Q0%5@>4^>M2=^>#>Z|T_S|C|C|WFS|M^>T^>E?>2_X=A^>D^>W^>E+>O&Q30_4%>|>MH@>1T8|M^>B&(>F|
3C^>6C)=A|XKN^>4|^>Y-O4B4_W24#9L1_>M=8M41MO>SU_L0RJB4HOHU9_M1G97HMFS_I0-LC^>P/6(9P_Q6|8|^>8|^>?>O M#>2I^>?
E4(|92G^>%&|>29;TLUNAD^>|>F2_BZ?Z|>|>+5%YV<#>|J_GOTFGO/M7\$>+D\$Q3|_6)>+>I^>G^>M^>G^>M^>K|>^>TC9K2^>G^>H|^>ALSQS^>?
HTA.MBG:MAR6A^>+>JXX9CR|MR|4N^>VU^>#>M^>_>W12_U|X|JUT_2@>|F^>|>B1^K|B|^>V|L|C|QY.MP701|J|K|MOL|^>R1Y\$>9 M|_>^>C2V6/M3FDU?>N.
(V_XY9V|>9_S|H^>Q^>+>@>SVT^>?>?>7X6R9^>4G^>9F^>M^>_>.\$>+3\$7\$^>8O^>0+>_@>6D42^>^>ECY9^>^>J5K|A@&=7M3THGVS)|>+|L5Z-R^>FC5I
^>MUAO|1P_8&K20P|>#>Y73=,SIHX3^>WU27@>|>T^>A^>V\$S_>|^>?>FZ|P^>V+>_O8^>M21X^>^>S^>G8&T7_TO42|PM=^>Y|T|O^>T^>Y5+>JL80_>)
>|>E|>GE2+>P8A^>KDP+>9WXN M4O_V|J|L^>_>AWNK_7071^>I^>EPN9|EYGV33W9|<3>|D?>M^>|AC6>B^>C8^>EB9QO-CWN^>^>^>N^>Z=|>C|>=1^>WC^>EZJ5H
M1|=E|P^>4|>X5 EL2KL_V4S|A6V5E_VNPK669>^>|>H|JWF6|TFN9|N_O|8R00^>MDP|^>|8DF39S0N^>SR77:Q7G6QZ3JY^>|JBZ&_AR|FH@>@3|2U6@>|>52PC

G<?X? M#!M:=4L;%REE36#RD):!*LUF0F~KFJU5 M/L-FHVLO+1;IJF(4CKM:Y5FC0TKD=IQ57U..6D=**U(JQA_RI&'X')QJWJC!@S>
=<20.2)9YAHG O :T.D+T>T 3<+S Mx=E1E #LV@/S!U=SAKY'LC6@N/4.60I'6!;: ("7%U(8E+XOI)TIMZ:MD
MTJ6J&S'M=52C9^K58R)NL^CD;LI9FRWV(DUJU8I8'!:K5JE6/5'NJNVI *= MTJ5%A#LZ."1 Y2HG:G*MVZ(2)6WFKZ4>/O*8)318&MX9F-JE*
KMTH)._ MJH_P008(*?R@K?O'FZR26.4"+^- 2!60G+3<8HKZ(0)6(WN ^VZ55)=@IPKR MYI
TG&=:MT+U+2(U,I2I5_P2JPN@K?I7#3&MG=5MT)04 MOJV'UA^H.THE^<;<'R'BO'DN5P!3.U1 T-J6UL@#8G+>DC8Y"BBHH?@4YO P J
MI)=5&:KY&:8.IRE^39WB\$ F : PWKE YUT 1!IKU @K!6HME5.Y/X#W!:EB0-TI0'73VZ*!=EH? MI0^?HZ4I-W: A)E.R *B^=
YH@H%K^M^%@F6I(T. G!HR.&:>:YRMJJ;:K M^T%@(G>F 4-XKAE6U2SF9:00!9(\$V6E!%52M0@85I)73'6EYJWV!>2.XIT(M)K A:KBUOV>V:;&*
I6II/OA3DIP&F&K@IP\$^KO#36.S@XB32KPB)BAN02VE MBS.D0+BJHJDSMN^@KO(28(8J:..S.S:?'P& PJVF(1S20H8MFA&GX6F83T*8
MK01^>I)H\$5:6RC'H#\$5?&PZIE:RJS!T376\$5?>87D=2.HI6.'R0!ID4F;ZS_G E MB3C:O^=>Q+!>=&ORKG4V9+VE>K9=JGL779647.(J.24_.\$&=&O?
E9I7IE8:H4J-J(U@/J:H1+5 M.TNKG"ZJ. (UP08L3OGHI.#24TJ W'IQ<=&D.PRZ03QBG!<I@>@NHIR^VO7'6FK M4IOM=%I&4 I27\$ *J T&C7#IV\$??
CEWA1A&+4L=F?N0%+Y2C DBYU\$:16\$2(3FOV?LXUD_F*EW2G! M-CH;GM.?:+>6POR?32I.II ZPZRFXFN) T / MW?I&U\$-I&:A.WI".GI8CDA:..O
!*7*1IW V\$!#>BUV61FD0!LCG7LSO@DB8 MXS' GJHN@ 3N:&=>7> "H#U02'K/F.#I|PY +Z0|ZZ?::..PD&716/EA:&N5
MC*Q7..X2Q1J)K!ZZQ6:HJ2/IV8'IR4" O< ^KS:WK7LSJ0+N_UV>/AAZW". MK>UOII=B!O IQ4.BQ(LVQ)I!MJ0 &TH\$+9P.Z#9X\$X4:UC_7Q&
I_D-VI^~M!U)ICRUU?2\$M^A7&35I.D@X7!\$!@NB|&YB.\$5FU/B!\$53ID@QV\$!U2P4T MN_QIN\$!%6Q3+>22-Q3?>O?
ZA@IPSU006G&PIR@:P5L151862JCM!27E2NNRP M.#LOEU9.'54J'8@J?>C 1^&J352VR^<'K MJ:9D8P?V7AI&H8YD? 5I@*
IVW>AFMB>D/LOX\$!^B@I*@E!8^>E+*YJ2A MY@ (37%1HMLTYZG268^FS)A!O9T&/#CKK_%S/< PHU&>*I?QJ|BR|4G-!66X
MI&2L^B5_P3E!R:SQSQZIW11 H6"!H5<@?2UC=2VPD)\$. /CS:8DM&?JF W1Y M!>OZ5DT3-V"G8#Z29M^UJ5G92V+4ILJ?
70AUMM(F\$LT)I0&K10K-H55.. M!>LDIME5*C V9J3IVJ:J&JD&<#4L!0.5C11!>? I=IBYH ^IUU>S&I"! U;G+XCGO"JGG: AMKZ@PJ1A1?K7
M4\$POMGIDKED,7RBOL&4T-1DY^F=ICBW0|Z&V!)^P7#FEJMSUWIR/VNIM1:9ZM4 68TV|40*3L|0EQ<.&3(=I)J8%6AS%+NG?(>9_ -M-ZZ:?
ALFU MXKJ|V4.:2 Mj8:5BX&@2>VX_2^E!6.41OV.'649Z323400CPX\$72&B+J&I14JX4KRM4M MU'UPY+F=
<^VIB#>=J8NY_9+<K_NV.@A#TEC9I6=U7HM8 9V|!#E@Y*8 OCP% (KO-BQ|U03J44_X0G8 A! M& 7HZM MS4614JHM-4:7:S-)H^760A=KAS%<
3&Q%T-UIZ8!QV &QPY+>4=IRW<=>I)C# MP>=>5^3D^<* YI@:M^2>MGV^FC5 MEI6"COXJU"#\$'.83A/6HJ|NDDKY|KVH:EAF-JBXVS'W
M4E65C2<=\$5^CNAPR^97VN#I:JL^@/WY/^JPN#93+J2Z\$(PAXV_X#M/J|I4A.IWYK!L)99EF9V)EB9Q"<.:.#I+HJM|U6">^IH|@^V69G4Z0F+B
M%N(K^R|G:&@U85J|A|E|~CO2J?|?N=ZWRVPQ^5.5>3^'. MEWX.5D.IJ-.I2EV0!UN8MHV6A0YFS+D=2)U.AB)!I?
Q5ZL6S28=N5=I=9_ (7)NM9VHI(2C MZ6!<I3:#0:G4I<+3H8I.O=U@J)O&+> 6*M\$IC(V+U+%>Y3Y?4+DU.QOIRT M#-%^5<68C.4IMKAE|NJA|
(*>7QF9?>15#G:DNE\$2VBR2.*OK\$!@O'69.RL!U M7.[G7GZG4AD4E&?BOE:KN6I.N2\$R/R&6VJ28H)2H_RYI38"8SMH+G-M_YB: M|DVFB 1;R<@?
4!<N^<O.7BNF3.O?C8W4!>I92?75BE.8Z:1"\$>I^* M6\$9GB^Z55G5'4T:5P:=I:HBLL>2SRD|U^BGCO+.)&?>=:K.O.L/W:R!
M|U=:=MXIX9\$=MA;I'YBYBN>.&^T<^#MKK<^I MU&|H-^0%6D:MI^=9I(L)MTV|4%YFSNMO4|V@+!|5WXLJ!> 2>0 MBHE:?
0^J3:3T@FFI28W>1Q2=U.A:NPB>V!^ MF2.^45N>L+K M9W_\$.+W+3\$UX ^R-^AIO^7N70F\$?:I 22SC#COM3/W;J5KYB+P|P8>LCPJ?9Z
M%N.C*!F?Z?8YS("T2!7WFZDXOU"V6CN+OV:VX#\$7K+<0|NJ W:|A|A=NVW M^@|I?>#5=UIO|K2S>P1<^D|!>:EXED<9@+^W|O!+
^J.P7L E|W/232.8 MFRC(C|E|F+&8IPGS IL->@0!<2S6RVL-C7L2|1\$MDDK6%2>@?7R0LC&7"?G+YIGV\$!>.:61O&6& 4:~91GM!FES
DR8(=V)%@>#F30>D|S(<+&\$N|9|K' M"DQ-OH?O|3VL%MB27F: MSCRXS6+?>S|I%Y!E%CN++&WO.:RIV ZM|HHK|O5=T-|5D8A<I0
MN\$W^~L0R.Y":P\$DUQID|2IG82!^O|2SE(P 9@>=YWDLXIC^>+^JZ_QL.S MS.FL3:YWN^S!<I|Q|QXFEPT3T13!"AFFI&4O<+>-T7\$XXG:
&32:OGV/MM^OQ:=QOWB2|Q#G+(X|1)VJEH^V7I2E8IEJ3TGF<G|CUD647+6|(B^*816\$ JZ12L#C_N:(\$15 M\$E!>EHY&3NM2M4-
NS)/1|WABPJ7\$ #RU69)Q#U@DM_V<1PD/H OF MB9-O8)M3\$QR8I^W8FJYQ_>D\$PD_-G*9G|3 U#S0IH+.%D&21:G:~*UW:/M
MP(5|>^#A'CMGB?^EL4I "89"C|V/E!1/WLC @9:GH*3UXDZDWA|N|036I MG.1I9|POF|R1#Q1XVSRI-QOR"F-?4?&*>-A&C'?#23C<1*P.,
IM(=>=W\$DV M!/?\$G(R61O.O-SG^<'KON>5*UP^>QOW>R8WNA|@V2ENR;R^>AL\$S|I.L.F) MV4W.
IJ^C4XF7QHDG?2.IV&9^XG.9I)F3NS%29Y)OXR#N12F^HOYWLPSO?>9 MR54.X5S@8M1@.IDIT0?'S:ODYNC*=?B)-XVFO-WHYR&4C0 MI/.0OPST|9
E.>2.CJ-8^L*QI=CQI+^'+8^--(#&|J3599)|* 7GX'8CM3 M0^J':?2NX2+9R#|GZ&(EQ3|B7-.G|Q6CG8(O*#Q&&I&G.IVR^<=&_&+8H
MX(Z32#_G|<^>3>43..?E&K:Y3.JW8N/O#8I7(OIB3S?043M1-6>HD+HM2 M4:ST)=NNE* @|_RJJG(GI^TJ4YRTW.N4"9O4W|L):(C143WF">
<2>@I M|J?<9%)N|1E+D.K|<I3@4.(I D)"*!&:I=WK7>^0. QO^!>=U6- M-^J!<:I?|?>^U_KHP+&G.3?QRF=YO.AO.Q^T^L|JDRJ^..O\$V1Y<^TRDFT:
<9W:N@T:G MYC8#|AFSV(OI*6\$S)ESUV+H1I "O>@Y-L%Y->?E\$ER?YDD17DIFRE39)N MDW3IX=>Y@|/92Y9F&^I31KI+
Z#G\$GIXEXH(FPQ^@>S28X-J2|Q_L>99M M0"?Q|O(X)9Y^FPDN9W?>:I2SDN|W.9ZEG2R8UHO^JXP_>X2#%QQA(G:P6LBX\$Z.Z*RUW?_L|8|I/
(K^<^I=> V- M;IPUOX4=IMC>3< O^SV#R@QI2.PK<^092E.NDEP3A(C^?9I.PF6>HD&I-Q M7->1D8N1:~%OYL9PH@ +IK73 &)IM+>
0/AH<IK;M3Q?2@NNIX&DQ)WX_HR^4X_L<7|S.O7D#-Z/3I_X:ZFFA<93%"/. :3D)9^O
M^S(\$I."QD87\$YDUJ 22I*~*A*Y>1@R2|F ZYRLIQ|ADRKGI9 M#=#N" I!"MZ.@5J42L\$53+MH90@&"&WO|P|UN"!L0B|O M@I
<V2#FMK:P1+T\$Z+R7ZM5"ZMOEPDUIR0_>X1I:"H6:H^& N@/O(I+E+<2>X M#|J\$T%265EQSLE& ZPHDZ|POY|N^N%3623G|:8;I-616|P:~J
(=-.O6 M-5(MDS|N7N>O.X7I0*ZOI=+NS>< CZMB/J?757!-/8 U++R +16U(8P1SG3 M48@-IP/XE:2/IMW:~*!T4%R*M QN?S2G20R&"W@-
X/J4+PQAS1 9|V4+M &I0|O|IKB?G:@&8 I2-\$*3:B4\$5+3U.WC0M2R0UGX<^<^J.?Q5 M\$YT^Nj575=7^*U&M#PDVZ^I@+HCGI
2^|R^YH1M#99RUJA-R>U?QO(KZ MBX#H+^A15K3T|O|OACN@* @3|UCU@^V17 61)LK7FZ- AZ8DU1B#0Z5@. M+AR>#&:~!<I|DPD:S291.>\$
~*H9|)*8J=L|H)>|F|>PSI.82 BNI4' M%FCEP*52 .@.)O(UW#"P.1K^SE;#>0.]^9UM=#8V &|@Y':N55WO%?U*A0B M=I-(LCR.8N:
|TF5D)B(61B+P.R TPF^CR.=U^L.V9Y)8J!-IY XHOH3/BO M@/I ?(^Y3P:IG|3|O*S@B M^H@:LB| X1F(H/M^*>FW53\$AY0'8+>QYP* &P(?/1D1O?)"
MVI #51-.3@E#):L^K|5F=V<U1 MP_!JB8N*: O/ KIR4<'RNK3|I^VG\$)/I-\$?XOKYCW.I++TQ)5W@:/J^ M6I2OL|VL&I+OKY0^
M/27^~W@W^~UW^~<^<I-?>P>W8-N.)|PD#4H
M>=>SEP.C5%<6^&\$9+.:5WS55J_/P#^J*)@U46#_JA0-.IQL9\$KRG)I>G1_WTUOKZ/3CAJ^AY^3T^~TV^M(Y9G/0TRNN==GYQ^>GMF?
3JU|ADS=O3|47V>G|X_?>I M|X|Y#D^C.@>6V>?X(O?WYI).GM\$YCI(H^L@_X=N\$|L)DX?MK6_SE#>=DGPC'O^#S(6X9A=7V^I M
|FFS'5I_~YJA:I-J.TIR6V3LPSO^<N-#8O)BM ME^*Z?6MC?2^W6?T Q.C=FI!"@+8+L-03MS#('80U@G3:HI|WR_ M^I-Y+~\$Z55NTX54.13.&
|4L67H|Y7ZYI_@|Q|L2D50|N=RW#MF747(7D10*!+ MY:XS\$!\$WIR>#HOF@OTU\$EPU.?HC%NU%U4>R*#_Y-@ MOA6/M^9I:
I/=>56H7V|76NJ0H/OA1UC&@&0YU1.J A^J5K0\$D.I<^<I&G MI_BXP4V^EP'UKO^~^Z)IZT)4T:~V?T OH&IK^4Q>*@/WJEK-10K.\$DN1QO
M=5SY.UOT^~YYO:AG4!&V8ORWU|8O<~74K3JD|I-QM| H-RB6M18=8M+W5H MN^~I^UIOM4+O6?T/IS?
U+F(I&H.HRS45|^@BEP&7C#EV(I2#2.'E0I&NGD M'BS^Y4H'9P")-JY7S1^UB/(VK@>ETPH^>6R3F\$=\$=^L4M8 K1E: ME-7O^P1N //8HE^3)M%
=S+I7I.8/C&YA7^#HVT#>G2LP|XF1?I (CBQC^<(M M>+j0XU^7" R(S2X>5A6I8>42UC8O_<^CL)^C> 57N^?730<(Y):S-)M|JX>NXISVOK?
584..6)U6L|K2R.(4.%%AZ M0BZ|I<:WD?6NQHFZIBHXV14X>I=1PK&>B7#>=>(SCJ'R|)Z|I^YK'K")S|OT8D-NS6JL-(41856@'=9#_F
2D+6-.3N3:-%C&GA8PYB|+."MIT+GE1F6:/#I|Z @15L.CW&(Z#6.G6|&+U56YG@EC4I/&
M|O96QGH:#^I72:Y|ZK+Z^P6@#2<.-82PPI5\$GQJ5\$M|I<0%KECC4N+PQO5Z7? MR9D-ON9SC& WZVXYLY6+@:00VI^HU^30J-T8J?0+>AI"
(I6JA@.=<I3V3X M?>H!)IOMWQUG*6@70'D&U|U|Q_CLE51K0&3M^5P=6I.ZW>V<|DY3IJ M\$.@DLV.AVSP:~D|ZE^JG4.#
(7|D^C^L8E.FMNB/Z#J\$&3D\$)&N8D.\$6B MRGYI_.C |L7RI=OZ+&S^M^29KOR|XIMX>7U#9N|NF|I8OYFTN2+IP4+>|WRF MRC?>NP'
RF&ZRI=97NI^R#17H#K|I ME_YD.=Q+AXIX^ZK%DX^*6N+<&N.@^IAO^0Z67>5!W:~@CU^N1NUZ:W\$8M M:ZVB:O:IB&I/
(U30L^539U8^R^I^3S>O>8MP2J3Y>H|S:T+>MH4.#< (MN@|JRA&4ELJ7ROP:WG=517939^F339DMOC^QCC.^!L&%=MAMGE.QE&#N!
M|6@D|I^6CP9RLU-IE/I^-.3%BP&A\$U66RV|I9^SSR3'8M7+IEDU5|PSR D=I^CAV(\$44F6&B&(2/-O(RZ3\$RDTPBTT')5 MO^94/4&016Y&6GMC>>
(TCH(U^4#> YYS3?T^E0RO^F065:5 FF8B&Z-8JV/M^+FIE?> 8OPI|88 J=CF7.2PV_9SHQ3 !H7H.PKN|WOED|"<^< 1.?@=W MOT^5190Z?>MU5(-
R@|=ZF 8T1K=&B9&W3IT&:VOIHUL^..LD^KSKU|W67E J|>@01MANHL^8I8<9FB+U31W^AZE4H (I^IK2|SHD?C|>I:ODI(ROSQ(2^M M: 7&_%
OIGG2^1&=&I E @VZ.6:\$M+>M^<K|@E.ZIZ7LV28^W74D5>@N:B M^T|I7HJ^I5:MU=I7.&MHVAF.W<6C#G8=:2|HNPCNKH|H%
ISV>'.@FIS_MQ9#SII382|P@=@>X<T MD&5XS+|T9@C2G50^GF4KJNFZ9E>(>I>7.&0%1N --CM(TI@2X9IORN:~
M9Q#>I^>I>@>AGWC.190(OX>^B7^I@BO=|B2#^3W^@>L:LOQ^<-W4S2%CA\$?>:AI|?TLPP|ZHZ.IPMI^*P4O6<6(IKIEE-YI MC-
ETO|EWCUC5M^I.O: 45#X1.E.) 1\$TFKHWIN>E.3^..WG|U M@^U|IE BGYY%IBMA:QI=G2(&+>#Z\$SE+FEF=
(80R^083.%8/N#^IMNWT>7)FR%=EAF^..G@M|C M|MJ5*=?+IC=PLR1I|J4-(\$.(VH./PG|IU3EJ? Z+W^I ZG/)@(>9<H/S&E MJBY@.QA?
0'8I2R^>24>:I^?E1@O.8^*EDH|W(SFF98%>_Y@C# G1&6^F^8& (NIFY<^> M> N8M99-@T")L1I^T-0&8NT1=I:CIJ7- W-
Y^NM|Q6O.>0>:9PPYI@>ZL M_CJ|XO7I|<=6VYW|E|?I4 MQ=BG?>U7Z5PS)|>1+E4 8.\$T#^/I:*HH[X#G#I|D]SCJW68LV=5A|<#YFH2
M5>BQ<.?U.O\$MO3A7!/+29%5GB^|KJOX3D.M.^U:U:/J-3^EM2D|>-GN MQ |I=C^*GKB=4T+M?>I| V(23!D|K|D&=S^0^C43P|BBLM-
T&DXI|/8 MK)E|6|^5CCGABW.A05X.^NG@.M@>+9:24G^P E:MH+>J=F@>(P^K|O|DNU:~I MP^K3
T03HIT^X%>@E+=V04^FCOIO2^L@JO|QM|RM1DGI_7I03V^=M^4EU#2;2UMNG@I'G LOUGOP\$A|IYLA.G<:>X(XJ\$S\$ C
6RIAF=IX\$T@GC MT^L.WFKZ21X^=3X3!5B.V|C@7 BWB/V/E: :32 |C> M2M^WBFBV^>@B\$|R:CSZ^OCWQ#>V7PV^#52#K|6<_G
WIEQ^>\$9"@: YZCU M#^+U|98B+M-IVJ:\$+G\$FEI 14B_#>T0?44LUC9+> RWGF29&OD0^KHN_?4AM3+7 ^H^ M84.-MP=6|B|J|R@/2M1S69O|
EQOODI0GMZ267P\$SY.V:ZV|F@#*1..50UUE MQ-^>.WYJ:"%7&U/7+K6^>IY3M^KD0C^<KMQFX&A3BI)55H7Z(5>:>Z3L>4^Z-#_Y!H&7|>:I^R-
C|HSYM^2 M^N+D&5O\$!(X|UZF+Z6IC=>JTS9E R^3CVTVW(85=TE69 V&-Z+33G5BU^E@UKEPHTQ@>@V6WM& M#<<(&I.7B:P.88J\$U+2
54EL:9G7W=6=8.OFXP4^US94W8Y@>W+|T-5 M+>2^CWXQ1W16(#?R:1>2UJ-%LW6I|4AOH *CHM5OQN:8^G|70.(7U954
MM^QT="HR:~Z~20X4?V.EE|I@43..>=&\$4):P:(R- TZC6NBC@>EIU+>N M3T3/2333A|V\$SF.#6/MO659Z|IFYX(E.M|V4&#SR?
O.:S.G5.G&2E2H_NYKNFBA@>I)J8_CXJ|6>I&30^>@RFPMPWZUC.FIN^GPB(W8 >H^BM_U@>+>J|U M+>+|MF^9W/CXJ6@>KGD|7|OG%1>%
(5|X@D&W|JX:FI|++9CGIGP?)YX3I.F M_CJ3CASA=QO62:|B|F|FI+8@WL<&O:>&_IO)NR=3/HCO_K=C.G.AAF9VME.YI
M0>4ZIE(ST\$U28V|T2S: 4VJO^M0C\$5)CSQ^/B|F\$5^>25DJDXR-H_ MJ M\$X(IUB9L6+^I^40Q|ST6>AB=W^?Q7G.F9^!..DO^CZ25B_!|C@=
I@.92< M.9G^PV81^&Q&(D5H^YQOW=AH^#NK|JX+L9:52RD.XIHS M^"7H#>=>F5|4EJ|+>4NQRU2|B92MA=15E5^>5E^<KZQ2EUT|PAC|W^?OT
MU_>K2E3%CI0=L55I|63K+8I6YI^22W2/@\$\$^PM^26+^ZOH|&8L^M^ZB 5\$X Y MG.% 2%K@3.#~#HJKAHTDLG(IA^BZ%>T|&JZ
MA^UN9>ZOE&>D^AK# LYKOL^GTF1+&U+5|JM|F6S M^OH#J^LW QCPY^08R:9=RWL6CT^3^>NAE#~I|IG8^K5|JB9E9DCK60G:
MGAMLO\$SE:W3|JTE.N_ W6/K^>E^FNU/24PQC^7?>: MOEW^>24&0U(X<I5I5^6UYJG X#>A>O2XU+5Z^42#T#2|K:~%O@&9787.R M4LS4E-
J^ONXXW^*OL=21_#.\$_U+|4LV|V|ADV/DB>WPPH6D|G\$=|XU|U.W MF-^I- ZE^YU M#^./8^M570&TKVKT\$@(%8#^*PIB8<~
I(+^XHU^5+>24^4)782-|VN02|9X MPC3..|TV21W) " +66|I+K.|\$6*1<1^YIY+ZU?E^XIT@>:I2X>T:USB|A
M36C5H54|J52((;&S3^P29V.)39W6+>SV L2)ZC3>|I^*0X9)EW 7K>X>^R5@HS>@=7=5_?F1=Z^0X*>>I MDNH%JWY.5_VYH|IWU+|X^89RN?
QDSVJE6 MPV^G@|R78NVV^?#"XCR3T&"<5Z^LT2Q)10X.M6JGN=>#X:H^E@ORQO=K# MNM\$5\$#(ZY<^<B7?)>4LIH1I:&V#RKHN:J^J.)

!>3/18J>P9 M2&W2NT-ZWL*%N\!>8NL:EQZHNP#I:0X@+ .P3+LWMI<%EK?<-Y
M=EH&|T|>A"NKPMX*:Q@<(B6\$|JDG|@:=7%DZ279H@28SEWRKM0)64ZF:7&:=T|P=2%A0JF+I-.TZ40I2/8<(EK2+9**CH/TO-<M/LSN?<
B2.ID%7"=E06CS*MT+D/Y<8X+IAU<5AFG=JB">:A<^N NMJ278MS.#6^>_<A>=WA/2DGM1J1<?>QD0PB2T/7?>9**Q&M&L-MX/!\$<"H66
M:|QNB1TMDP8B16|QITJ7V1|L|@:=PH63=:P|NZOUZ-L H0!<CLC260*9LRDKX/MJJ1^6IN8:>H9AS+F.DYRIBS35?>R?AVF5YW).2<QU&0.SFS
XZ4">9IDHJ4 M9:~7Y-SWXT3DZX1N9WX2A|QFN>| H7M@WB=9Y#<(A #1(9.8\$CK@UH7F:~PO M!<N8CY1MQ2RC
+.#7>3A/4+!<=MLR8&.<V0JYDZ&X=FY1DH MJ8C@. \35B.A@D+I2BULH.BA9T|=1P(I@|B'W-D N!>4 #>A2_T5U1*2%<
MAWG%J/YC:7A1SHL:2LIB*~:~7LQ2:HAI|E|Z-D-OZX@IO=3^0\$>ZXZYBK
M2.AWY~|KJ:ZW6?>MYY\$&Y. AZE.AGHA|ON6|M#40"+8LZR: GSZ|A+=D%/D MSM1|!#%|5/4-
J_4LN<44VS3T:NL@>FEA4YAZ. #58.<8XYTXR0L904DFE< M HTB.)-8LP1:50VR-R>R*B:IWTAB^Y.X6E5-[AK*%)W3KB5..P3?>2.3NO
M6DLED7392AH^510<~>K@<-9\$>|E5 J 9/(I2EL@:~FD?BW=|GB|& +>T+S81=3EHG%6MXQ%)X=J^<A/B1Q\$ MJF//488=I-X=G:7WEZ>ZV|(+<
<|13:|O*~R|/59\$<T&00H0)=4\$3/I.V/R! M=9@<K#<W= X|OI+> MAY\$.V8C.2N#|QON5|L2_P<60BD:GOC3H&P/P-|P%<C7
MUY.T73L>7_433"NE:8C2D4|A#<8ZM5B|5AR+KQTV:YQS|?M8_9WA+<8M% MNH<=T>95^C"Z=84<RVDMDH K5V|YF9|IJ.:91R:0ZOB&
M2^1^<P^EP&4X~V K3^3YLW.PUATFAPXB>GWC|TO6J."\$-VJ|S-6~M28P M\$|>ZHNJNP|UHO|Q|JZ<L>44XH.LLL_<J\$|TUYDP*~4UI|_W
X@<(DEF5H MR6KP7S|4#24^N7&: V6^=F:Q\$4-M 9U\$<S|_U@1TOQF#HG6>F|Q&EPV|* M.=70H)-V:|Y^W52+EVAF4-
|W^RWG3\$5GCB9FKHLDI|<3>:~:~IQOM9 M51_N:S|?7WNX533_<3+AZ>:|CTE|E.IIOLA:J#|Z|OI#N| WMRI.MB>|J@<7 M^6:Z|T= ?
Q<3:6.1T~"44VG2Y.1.5::18L6V.\$<3\$SUDMU> "Q.803Y(75 MES.V. <~*~W*9AW%<B#<+O|GL<|S0E|P5|?<F\$^53B&C" MD6B+C:"
<85=F#1=1@#_J=@0_VJ9PAS!>=>N9V|60W.*^<@<|W>: I4H|_U- MJ5G:V.Z:~7DN7S|48Y8*~AWN5@<|Y^F DG|HHFZQ|OIXTZRM
MC:F0Z_B#<9&|=1D< <6#P:ACPU^< #3Z|:~|JDN0=4GVQA6>A6|F%5 M^P8/ SX^8MH?
<8ZM/FZ5|>458FND@<UCI&N6<|/3^*~<ZBU|Y?~V4K:~?>R.M2X&N195BR(F4F:A88)!>^L10YZ*~N/ 46H:0.-Q= HB4(IQ66_W #5|_F^7
MAK7+!>4)Z\$EQW4U824S=7T.XWFM.6SZLK|"+ O66UH%E:FT(0\$?X<7?>+~%<|5\$|+~+~+
(AQZL|..RB0M@CHIEFMAUWUQT*~9+~BH@36="ZMT|+~\$M:~9J=W MB4Y_~*13KA\$0+<~.J=^WV5:X^0!)YONI=KE.G|<=&|!<H&OCH|&RK5_%N#<C|
T MD/9C|M0M|YBPJU?T>Y4@6T|PY^X|C:PHH5F346SP?Y>ON<?>CUV5F2L3|W+~4L586?<X=N0=3TSV.Y:|C5DV%8--<(CY_<@E5QC*~IAO=0<M_?<
M>X^<^=I-T"/L<#7NGC#<N|_ WCM3|YX:TDX8R%M.6>~A#<10\$U4P_#<K6|X M7-XV81ID9|_JL/P4U|_JZ&G?
3Y^K5247Y@HJL3VEX:NCD+3#F_3Q.61R M^#8MS.PSM7.1QSSA-.)2Y#<7+<(O|I/23.<")<|FA-@G-PC3+4F.Y)2XP9| MFZ:I?
VF.R|5U8MD%4.\$<S<ORJ2B*6|X(HRV_.\$|<G8WYVQX@C"|.AQU ML-#<#<+<9C9+<|="+ ~*G7BC%OC184R?UB@<_?>HDDP*~?5Q:Q7_2RDM1*A
M|EMD+>I^D_J|S42/H2:MIQ:<Q|T5U8&_J<7|9~W3|LH<Q<Z8W:H-5K|N8|U@P6 MV"/_J^?|<1NVEF) 2=2-
3KERE+I_42RUW8A#<+9EW_RX|BC7%78J@<9\$ M9_-|B(3Q_8RXT2.#YJ8S.7&+<50:37^*AM7U+<K5|4X\$:/K09-9X#Q2 MT(69|I-
?|D\$C*=>QJ@<RR/7|_7|A|H#AHU#<|HY9S-UHV3^6T0^<6^*~J MH..~*V|G_1-\$D-7<V3PS8<+<G?PR_UBZ#H+/\$<TX9KDE#Z<~<P|<CX|/7I& MKP?
Z83>|I|LK|0EE+R (8%F5DUJ?V655>?I&C:#0&I.WXAA4\$2W73C-M\$ME M:|S<Q989^<|<8&-%<DH^TW4#VY^40:1S4J#XVFFYM<-..00-
MCXHL6.YW>6S M+6VD9@<@#|A66P)M.T.Z-TQF:~#9H|<S|P2>I.JXM)6C/D>~2^<Z?>29L MVU1@Z^6I(P+<
|7|EPQ|KA.U?|O|OH<2^00#@<6:6|JID#\$|K|K|K0&L_N M5^3\$ ML<=<H|<MK&FA&A@|A1|<HQ5LT2V%4_~6RN>D-K^EE<~<L-J+AJ^4F^D6:~M?
ML.L% W@6& (KGY=I&@<K.LW=LUG+<=<P-|S^A2|FEA7G\$<R|D:~2+~L M6|I|OXH2N501 "A.YUN+N^~|C/2?>X<3.6NR:O M_N|YRC|O?IA)00|
<-I8>\$>+!674T/Z|ESE:2@N|SB^|GHBWZ#0+<S& ZNK/-8W#%:_ K0OWC|>24X6^VJG|BCY?E3P:U:82>2U-77)/UNJ57S
M0LUSI@<*)M^L\$2RR*16^H1+<K0.T^UEG|GA317TXHPL%K5M>K^7V-L:M +<M:8K6W=5E|W1=|T|W|X.XM:EE>~<X2HIH#<
|WS/4+<MB#%|L|UQM>~MT+~YO M^A:R:RBU?PVXU@R=I.80^BU)_<D\$D<Z>C9>|<NEI_SAQ\$H^3#~|J6E|FFU M9O|EY_<
(QIM0C>NONZ%<^T=V<~HN)D)K^ZAKRO8UX=4?:T:J:QCPL\$57 MNXJ@<T6H-0SO Z55GF-~EOY6%2>I: <~>8D9GT+<^0.M|3P|=|I^HU:@1L
M.BJM+6^CCI:SIK5<~+ZB4::|3SRN|I>HMZS.G8B8@<~<V0:QZ-R|FX.VK MPF<8FNT6M+<~<WU M:~#X|Q|0*P)#-FHAP^FMXO@FX^YN/?<
<<85325-3SQ M#|J|K\$<~+5^D^FMXR+~*|O^<~<|O^<~<|E^7G9M(X|I:9A%<1-8X8G&~W6YOZDO MN|T|F|L6IUPEOKPZ5.8P<+QW5?
UW3&=<^L.C<6P=A@..#|Z::Z@8B|D|Q|O:~M^<RVLNM^1IT898L|U^JM^#VJ|D 5^1T3|HAU./9I9236HT773Z@.OL\$<_2^<
MW<_78#..K:VC|V^MQ_OWW2C-0P|TL9|WUGZF|HO^0_#=<G|TP=|\$~|KP^<R.O MU0*8R3)6:P:G41|:<8ZA>|/I#7Q|E4>~*Y6)6|EBKH.
MX^Q|=>~<NG:K^?S5QG-8:G|E|BT7LZPO|J0^36)?DD3(I_ 2C5>I=^M9V M1QX|Y+<U&G#-I831|V#?>Y|MV923CN.2-
~:~T@<3|I2+NXJ+|JNH&#%~#R|T8/ M|C|>~<8:UVY|I|YOC8^T^R|6|XH4L M+@<|=I:~7B:E5IAP/9W>~158GBR?
3^58BA|V_|IE|U<~*9Y=|W1FE>|V3S2\$D8:~NSOM+5.8EUAW M|J20#|>~MWD-W|T5A.K:|L7-W\$|/MN|H|D^CE^/H:~D-+~:~MN|8.HQ^B3&|M=|
M^ SE^OYP|ADK^C^<^D 6%9-4><6F:~?H4EQT07=

/PY&:GSR6(.# F2XLOV@;1I#IN j|>@P/B=S=*+ONU3XDB MF=MJ W#YM*JT<=JZEA?j75>:8:J/%HVAJ\$[93WYH%MYFWWPUZ]>3. J0GQ(MV>-
YV[K.NLRR3?N^*7#K SEZQ: LB7RY>OFVHW>5-F2^J\$S@MFO(D: M0I@=W:Z36 K@{VKQI/F/HB)WY< S5<7^TW319\$;WP| 5-
C/V6R%>JJ>X:EZA|E*J5#ME.>JLE"5A7N%-59A M|O+L,>RXE95!NJI^<93P^NJI>:FGIHJ: ^JJ>:FRIHJ.S776I8E"K=M6@8@
M1PI?.\$7>9+PD\$.RN2VBO?ZY322^D(I1UZW8NCDC(QK^I)W: ^E2'HIHF626XE M88TQ1#0-(Y9R3;S0.G%#?
7J8IZ(U*SAS@>20.6J56N%)3(3*JBWG&DHKZ8 M|*!^O()M\$Q_H1HKVKY6:ECENA*^TGN:YJ|\\MUB=)j29)^O)Q^LYG!P?WFB
M+%_!K8+;JX*:9XEQ%8F60I(A,B/>"DT:&71PS.:DFHO@1F66P=E.O ^**|< M3GI6Q"
6:-3H^U6\$MSJ@N|N|O'/%=1JME5L>QS89I7,EH,2EKGD1&00 ^=H M(LI*JA(WC:|ANZRX\$8DI2KBVG@>@5,S&6<6),5-0*\$YAZ*&R|NK(X|3)ZQ::*
M:12;O@/M-BAL,Q?>=N?)D-DJB?S&|MK5^?FIOZ9V.S3U 27%-|ZBG) MHJ18D%)HDT
/=LD7OQ(C|6L>L.UIGK@O:J8D9G^AC2122(B9I0F^O6|UGD MK0V./HPLNG/WZ\$VB<@ ^_LE45KQ!:(?3>(#0K+;EA@1BA0#6GK"".!4J8-"XX MP-
>HQ9:K@D?F>>.)JG@-@YX8G1W)C.M&TVRLVYT*.3(19G&RP+9.'SU4F74Z%)Rj57+#+6 YJ2)&A"5J\$E3C>*&-*?@R<-W++ M-O).4CZ*3**SH-
@.'HBU":JF3GH;H _I/@:32>3?j57K5D|J|I=A(*I;?H MIOZ*#CA 2S*+2|C|K9QE)ADLV*:F4Sj-I2""6"P=D%F"@|J)3A2I+ 'YXV
M3CGS0?Z2|452BN45BAJ\$B5-NK@-^=8M3I?H8CUEX@BE+>9-IEN%\$SR8G MAILG(3N+>E=BG&#YJHA7>VY0KE68HK5!H?
0906GCG(IZ052A)2%"ZZ7J&?V&L MK UL.SZ| ^M&ZV^%|J|O^ _ZN-NC"@|G7.0:14|4NHX6U2)C*:/@C"DUL M.HW:TE1N.^?@?>Z&_ Q| G?
WSIGT53|6YN2SWQ_.VAB.CS^D\$X(SYB|N|ZW&M^CS6DSOYZ*:3L;1+&6<1(I#>L*E.59 M _I04#|IY0L_Q|LP+LHXEY?:CTXQDDK9<)\$
N6T; BE>|W:|L8KMC).HZA MCF/8L|>MRZS+K,-8-G6L1VYK798KHWC6B+V46SGJ|KJ.E5U_/N>:XJ^U59 MJ,U^X^YOW:HOLJ@S44U-9-=34T|-
E37UU-13LX>GILJ;.H|AH<8Q= /N9P.R M>#4YA5N?#XYJB=DC:0Y8NV#N|>#". "X(D6/!|!\$B,^-9D\$KQ*S)B7?|%/ M|V.4C3:0G)PD<- --
+4XW8\$9'6C?>10RZ=OBMO/8|K<^"V4Zj"9AHE _ , MBTQK(K^Q&K)"1@:P^V6;WPID.^G&I-E01G"l@>^>-C%E-
MG(P6@.P9IT4@16W'6F.5CPR0BW %YADBA@):AFU|GQ:"^V;|P|R<>?L|X MD-4!"W?HF.RY"l^>JZ| -F%
#%".A91EY7!\$.S9)5:9AB@NE30B"Y210%B M?- (2#Z29<#^+)H1\$T0FRIG&6LE.)5Rj\$FR)FZ-B#6BX9\$#?#4F OA#P#W#O"-14QT:PY,0
M#S3>1=SY<@(*9|7^*!M@9+1+7L.A.7N27"IX8XM.NUYU\$;ID-26QI9Q| @ M3R@BE\$U**Z)2:3T@(@)VECTALH"TLCKJ.L9(I|U?
RN0|23(O)08@XD^*PI M\$:PG/C#%\$834FXD*&-D.R5R<3P>N|@C8I=#@EJAA\$J|I M+S5OIGYDZ^J^+EA|O=S.MO 43ESIUM&O5V|
YFJ>CGHJ|@%0#Y%8&2!9 M"5JF=V.6E|>E.L.:80*(3@G |W^NS>42J|C)TF |J2\$2!|W4P|^X|J9999@. M#S5"H"9'5""K@KX^*GLL*!S)0SE):
<18J|D%5!7P7|+0STY2RAISR.Y"#\$6=S_C0:">#@ ^7EQ-6P7VCF* MY@|Z|O8/+)>2-(XOSR:S8:GW-(T<3NY9' ^PI"G VY;X|I#?T"EMI^K7CF2:"
MM6 7.^YVG.V.#69NF:1GR9.E4|F|^%X%L.S#;|S=M|O|L_D%.\$S|<@ ^UK/H M.BSNA1M|N=N>S:D:(C.W|Y%DH6%AOQ:VWV2ON?@|NOWM8 O?
OWOU M5 27PS M>|7^|J> W|T|>W|E VFIL^K'1L'=KQJ|M^I CFP^<K^<S^|X|^>|WYXO?7 ML#W07KJYJ|VX?WOIY1280? ^+VW=&|5V^/2
AU|^_@? ^W-NX|?I9DIX>J.MZ|^OV+&KLK\$S)D5C6."^1#COGOC-|3^1C>_OD _QKX#0 M6@V2_/9S^? GB:'P\$DG|X?>6C8P?C%ZUEQ3Q7^G|X MC<
@&GARGO41C&84C.^GYWC. JD=D=AN\$HW=N0Q <=;?K4)B12 MWCVPZ:YB\$& MSHE&W _|O+K6NM9= #DT4=|
|W6@A|HW|'814Y|O5|8E|T|.G|J2?|KJ|U.O M2 &MRD)5%N|,GKODC3|J|BH#|=3425;UU-134V5-/37UU.SA|F:FRIDY-O/?B MPC _&XS5?
|B|L:S| _H?AE^ZOA:~+V|@G M(7# K|8&8F6 JX5V|I|O DW=U7\$%L@ID%B ME=\$Z.2.5V (RE:Q(S&@2N&F(B,P2%\$EC#I^&O84E _!@*R.C:E
|MCVMP+9 M+H#.9YX\$FC-\$9S PA:1@)R87 _E2YD^9&+&."1^&3>+8)R3EP.'BQ|8\$.Dj2 MK#)-XHEI _D#3%F1M4EY|H-
V%F+|8BCQ;QE(C@E4GU6M9)4N5+5% ^7+|JL.UE M|BF\$1\$F 4=9) IKZ2C53M^T-9I7Y."#UY1PA9%49I&#<=;<@:|AP\$57^CZ,
M9^D^RXICCVU_*X|M|SF7H%R&R(E."LUVFHG1\$LOVIEUB468?MG#.)=UXR@# M:\$:LLXP8:A5)+G(|.:T>J#!BE)7(*M
|LCVMP+9+H|, ^A=BF#>2871%YZ(M^@A64EY<+B^?2|E 5H^L MD>UO|:=1)\$P^&#&#?&."(4 RM144ZXS|*%\$+W6Z.ON94T-ZB":15 +9.> M
|PRXj5KA-B(I7^+&^E-K.RCUJZG9|_1T^FYX/7Z5.3<|@>C.3%|J MECL|>=GD#|I^?>_?1240+&B4I+E\$#H:IXCG(A+&:6^V;B5L:FU-0V
|MBF7" _S)L4#%XZ|51NO>%GO|FIPLDG9 MIR U<4(93|URO_Q8=/_9|6XLT|Y>Q.LDE@)OZL^4.N%|)QSAO" U?*=.P M_D ^UCN?
@U#Q|N|EQY\$SBZ.TjT3+M _I2:=G\$ M\$|J2|=\$@|9*C|.1^&J.HUIF\$+*P%GQ|N+&E.|+Q+0.(3:\$A&P M3V\$.XOM-C."*QIU(^.6Q|A14FON2:
(1|S|N|J|.P.#.SB9<^UY^K3+J<^D|4^FG.M<R?J| M)Z|W=R:*^AWGM/...&GSP7BM MC.PX|X?"-582\$|D#?SA:>4.ZKB9L7-B|L5-
Y|@:~1M4XZ2D|TW#&R;B+ M3H(6.83^IB:=L(NX24U."M \$<L^_SYMROB=R*SBYN/%S2NFU5|^W^POH|^/ L^N|Z|LCR@U6|E@GCA|-L.G#Q|2=
:84 M^IAQ^+O.H?N4ED_Y06D|6|6IR^N|Y|CA)HS@83<:9(0#70=S-SX>(M.L|MIU M_|P| CW|T82?PE_Q2G>*HT;QB>9|V|V? /RQ|I#?2|IH3=7-^5%?
49:ZL M(I+O)U>.-<3E&(ED)AG+&F?6:F>#<6D5 _Q|S1+A5^/6#@+."*8T9Q\$^61:J M3<^7%|NINO^|/6JG|V| |!|?7J|!>W.-L^++&|JO@.O|I|VSAS^!|
(H=WAJ|KPM&E04.2|X2?>=<3CXN^:K|Q&L\$V0+ &3K|F=3X^IK!+E MS0DHR "W:|E.23H9| _I?EGF@ R8AQAGAX-7>D<^ M%\$X.V 52|PFTV|I?
M_6(ZF\$SPL9^|Y-| \$WOP:=Y@TC#^)=+M|VU|T?#(18SZ|UE.+S:H&H1^#&#V0^C3685R429BF.L0ZTOCL:#KY M EPTAY^_j2QY2\$"/8^PI&3^S6V4
9ZN):Y@B4I^PLIHMA5|J2KQ(W&G:G9. MA Z1F|@.=^+V3^1-(OPC)CUW7FN#M _|/9Y2|^5SVCEP-P6L+0&H25|YPI \$NUG":&G9VD^*P?I
MH|@)S16WXW?>|IOI=O?/6D?D>@9^S# :CC&S^IBYTS/ BVD:61^Y M9^N/C|A (KXG3N>IE3(DN&C|EPT7(E@KH^CT9KEGURS8^E.;O)O.TD#|=
M#MY>3MMNYO+Z.T1(\$6A|0WK= ?UIM@:T _@ (Z&ITBY MG@YED+C.O^S% X&0.#YIW>PA?#6 C>M>|FP >C|.DG.|3Z:JE7X& MKWY|>
|3^6X.Q|_IXG<^U07#PZ6|6:=EY7G:L)^VX^+WML%Q.HH@|7>=>L|MT M^,MR" RJ8Z:RXE.WC< &Y41V/DEPT:2_Y>?"S^*Q)M
P.X|X|&.K@QY6447B G2P =S|Z2U+&T (WWD<|8X.QOAB\$R<^8"?=7)CR M>Y1CG>|OY:MN.7|5%|V|9L|(5.DHO%&#DH.(NT""CH#SIMI-
V..: ^+>.:X MAB^@>.:G<-X@@.=:(CL 8N""^=IE/#!>HK198590(0!8 =U^Zi94X+&X! M@N^J=73^S8Jv|:|J1@*)UX6#;TB(^7PZ|
|MYRX^HN|(^279U6)8^|W-^<3|3CQ+AZ4WQZ)A|5+23|T\$@.RHR(T'B\$S#8|H. (KUP^" <=|S|B\$>+ M^ XU O%Y^~^<^G8TP|S2XV5
IPC^M^2H.CU>O.R@ _HR (J+L8AKJ<SOY2ZOGW+K>L1J|@P7H^D26TE0U^A-C M^7H(4MY^YSU+7+&LV^M^0<^Z^EP0#HUT-Q->O6 +M0J?
#>DDI|36:M2^"Z M).S2&CHC:PT=060|6LTFH%F/>@P:QZ5FN++OKI=&|WC^49R=3#ZO67.>CFXK M'^^~^~)8.\$?
KO^SDNA.%N.RNNB(06H+6%+=DS+60/>R&Q _+I@PO+@|V^C3|^I MU^3#I5)A30RL?KFR6.Y8+>Q>3^N|?G^YB6F%.U/O^T^HOY_10)MFS.|93W-
ML:L\$P&N)|YJMD.YS OE0@|L^|.L: M9J:PI?O\$S14D+ _15HP.GWA!^?IL\$Y98F58\$-JSD+&@^Y4YT^T4K=R|C(+&|A=L
M&|MD8C%Y.|HGO:Q|B+95HK5KOD|IQE<74>|W%LR^|J-D-7A&U2H|K@Y|L W|V|M7 AAY&.&?N.)^Q^9^2W|8#^|BX""DKZ|
(/QE^J4QI+56X&YPZ|B=|PR M#G^_YR_PVY=G^++CX|5F@<-VX|N6>N^T^G8W9|I<2D *ONPMK|=MO.A3>NDG
M7Y^|X|XOEG6D7^Z26^15KKO^&J|C_VN+ 7994+GCM=W/26|T@VE|NU9|F39 M?K%
|^~^~\$H2F8P#M#MQX6^VQZ.+L|B7KC19W<^> G#7>|>| MWMVY9|I P<^*^: ^RIQ:9|S8T/Y^1Z _|^5^U^I?^X-7|W|W| _O1Q|2OWIU&
M=.SX|O:/XQCM>-7OWG|\\V^P|P@CW=?|QO^~^~^|J|B>=Z _?O?O0_NW^~^U?
MOC|CW|Y^~^|HW:|NW1|_|GR\$# _|Y^MW^PI+LOM@U77A5U2Z=>G8^U^:PP+&# MICB>HC<<5#3/0L|S|^3I 2". W.-:O-NCL:Q^ +=AT5W
ERL|OQ+&+ C M5E\$2-IGUW+SZZY1PFY3XNG- _W6| J62 |F^FHD2G+RDLR|B:~? WT#-7NM(H? M%=W3K-9JVE?XM4 N&?
^CT^ J2242L=B.9\$.%P8HX,E^2G+3->>+<|9>?| MLCA7> _%|NW|E _J^Q7K@|S#OSX5YUPGV3!"B=V^N|K=FFX> PXDE ("JGT|/ M1|S|!"?
MYXE:EOR5|4V19-YF9|L: \$ZPXFX9^5FQW#>E|F%"@AP^L6 _B _M&XZ|S|H|F:WSX.C#|X&FY0)2P=V2?|TIWOG< L:|Z2\$|M&|R2|H9V&F#39Z
M-HZM2T2" |M|K&76*W0:LAM|)S=:E\$S\$=4G1)3@.W&?@H=(M ^?N^ 044^T M7+&+DRC:S<^D6UN|I^|BM;2? ^?P.T.%? (80R9CB|RZ|H
<1E=|M:EJO_/6A) M8W:\$:H82V.#^=A.DZ8^7LZ6>40%|@| MGKC1#&AX/O#GRPC41AXN7+PZ+C _j|>I=/_ Y|3GT+H9@-8&|P#|J9|Y|Y. M-
N&|Y.P|U.L2|/-3FL^|""**E:VK|ZD^6BL :?B=|+3|4U6^C^S|OWW:X(\$ZC:IO<&L)1^F|H|C8.A6|_O M9%X2NXS:~BB:-TSPQMMR#.\$@Q|
|/O^|H^H_X6H+&|VXOR^J>=<8|N&@:71@:ILN20LK31.9^D4YC+ZX15&Z MH.^<2?|IFX23^11U6^C^TC1KVU^RU3&F@E4(E4 2
M|D|Xj>P|Y^@^"WG:.L<^3|@|H@09@A+PH|ML^&1RG^0|DQW@/P.4#K.IDPY%.0TQ+3G+E+6%C|B=C> X)F:8+S%+Z M^ _+K|
U/F9O&G|ZR&OGQ9F?|SC22>|(E80.53|V=|K|IRL|JGBM^OK^U<^68@< M- 7LNCOC<3 8 _3!/_F|O>?H&MP4C^Y#IT.R#DE_9=2PPN1?H) _G\$^3^/8
MRHKES7HX61#K9SH9="RJK^5=*UYB_B.167/7^M)M_SFUK7WF=X>TXND2|@/ M|V13^>0?E,UWWK|BU|QF>O8!-
#G|5K3K^MONB|A5W4CWZ1|_U9&K?VH^Z _M6-A@=Q.^Y>^>|W:OVI+ZRNUN|@<M^W8Y1L.>|0+&:1^=ZO+=+^O\$+&F8\$S00 M^OZC5&E5-
@ _O.2XG|H&#&+ *?Z^<25ON|51:&Q>^ ^*O^|T ^&VWHX@N)\$1+LCZ<4(I&5.8.504X=W/W+&MXE:LO67+SNXK>L-
M:;KK2BV|M|N|F:K0^Y@^04O|O|K^P^V|8\$FB_V MVYO^T|&Y|J86((/OP\$X E#%LO3R>G5RE"GC6T^F%:1|1PF^<^KRNL^0^5;O MK9X|*"[XN/93
@K44L^77QX.C|18BZYK|BIEEK|A2S|2P/ M=>R^DK75-2MIK^&M7N+=.9G\$S|OY+VZ.P^VW=LE_6UH+W6+4^|S\$%ZEDTU_H| M.:6|AS>|2:
|ULMO/6^#C:4<#GY.P8&ELGG^+ V:#8."IU^C4:3S|4N^E' MW|5@AU94W|6E5.-VIL:/E@P2T5 _=)Z7X|/2XJ.7-<|JGBQ&&16
Y^3.7BT.T\$ML^>@2XAP MWSI|WQH07>#&4B=?^&E>Z@9H.C^|JRDW^|U|F". M3UN-NR/UZ^\$LC".89+ZX:N^R9\$@|_V^YNOO>"%<U|=%|
LSJ>1+&Tj>?MHD^X^VTEV\$ T|<.>?J5HK>HS:~E|T^6G&+P^9:G5.|JU0X0X|+SUF(C|O)538A?^?MT:|+U^/49J_-j5)0|/;&^P9VSH|&8&B|J^|SC|3S|>?
<=>|Z06 MO).EOGZ|&&(7|70P#4\$%6CE&MA;5-6^XB|J7=9K,UE^YIG9?G&\$ (C4.IQ!1 M)HCP-|^C@B-
1^|JAA|MLH%\$&HF#=#J8B1?|DF@2|S|Q(V:BMAO^24Q5S+|RF|)QOYV7 MRU1803&S|F14HQV1G^_U1^|I|Q83^6FP.UUN-VEE|+H3)|X_2^IYOL1C/(
M8|MLT1Q|L(1\$)=0XX\$|OGF\$9X%|32^D^I^|84T|N|N=UY^4^M^G&R&^_XFO_~R M:H35N1^&K^M^?U^J>S|>U^J>T:Z:H=19-|V|V73?
B&NZL88FH%"QV1^K0-67 MTB230%-&EFRWY?|O5:@N|T<=2&BS^WKW8L_-059<#Q|6|/MK+&C=WH^|O MVICO%?7OV_B^L!8V
M^CNND@31&=3.NNNWQ|X/P+&GR0@6|<)S)-*S_I6MFXC?|S&5;M?:WYH.LN
MW""4X^8|4YZTOT|MEQC|U+O2|KJZD9=LL%DUCKTU>+&80Y&|H|Q|OG:~+
M""|J&53M^OMQ&^:KD=NN:E.P|^N|NT#Z:~+>UGO^9#=#.3|K>M3_UKY35M M_.R|P:Y|\\^|B_NNSD^Y|AT?0K^XRI|>EOYX)88.Q@|J|#\$F.
(P>|LW^@S: MW^U.S.|EPV>|7H_XMN2Y|N<|JZ^_2QE^7.41M-52LXKWM=RR&20%|O0|I|MOT M%=C4U4M<15K5J|/_!_YE|QA22 |P4_LJ^KJ:~
L19676I+HT?~LRM37Y:U< MO|I|F.|I4X63EDLH.^CI>L+|=3TP:~|I?&W^M.\$j^>=S<^<?^BX74F^|:Q|
M|T|KQ?^8V^R(8E\$=\$8GQ3L.FH31^E.48122ZYQ|L^|J|<5J:R|B2D&6DH M|=^K#1:IGY0FG42X+R|TV4^S69^>9M|B_.U+E\$14|W&F%~8-JL
(E&4P@7HX=SM:%C|NY@<NU.Y5Z^*&VIRTO@0F)K+Q2=|_OUJK ML^R>V%8LN_ZK|LH^W-.>|:GY8LSL\$W2P_-Y
6WIV_1(DKG)9A|H>X^T.A\$&KSGO@0KW""7^7 M8M^J^06WYAO^IFZVGCL8K|L=|JL-G^G|U^5U^E|88|1-N|NJUMD^M5-:~
MAG_BD^Q02L=E@MVBBS5^P\$5W4G|5.SM@IP6|^J^5\$S|L-B7;J%#%:_%J^R=M|N^W?^4S^7|DE|OZ|?S|EWM6Z^U2=.%:#%4>_S+.*U?
3A|>Q#_5CHG|.PN M17A9DWW) _I-WZ|,PB2SLA^E\$31N0I@.~6HMA14RXT>E5\$UQ0P8G":R9IM M\$5S>^FY%?|Q|N|TVXV|E3YZ:W?
H8^F@>O|X|S|^N^SEIZCYE:2540FX M8-Q6G+&FVI(9V^M^OTJ|F#.^?&8-3H\$S^L^|F#<|!#P?_D|+G|5P7-4W.|H4T\$#>=|PRD@
M7|AF<^<QU+O|06B)LMH9<+&DVA-ZMM^:VGZ^\$XONU|?#22 N8A|I%+&+UZ< MKKFY+ETGLTT3B22>=JAG5\$3T^1 \$ _242%#8|>Z:>85?
EYD_6Z2TC5C0< M1R.S:AUS"=.M^VJ=|R:7) GL3=8 COP|IF2-4?j*7@|XIQ 46N.&/MG.2^ M>_K5|VMP8UK-(|A#ZC/W)2=-RK=..16>H?|87M(|
AUSV1:XZ2E<_HD+&_ ML_98D48F|IT|74C32|>DSO^|JN6V2K.C:UCS=>=&5^T^ _/NC3M^=PY23X<M^%Q|UW|L|Y_NZ^56%|JB5Z-
T2>U#N:|W64W9^J-M|C(|#?R1LR76("2".89)UD MB0F&6&L|5F&K|_SW@~R M:H35N1^&K^M^?U^J>S|>U^J>T:Z:H=19-|V|V73?
@M^W|_UB0YZK.^ED|B2WQ_C|<6N.05F|^#<2NT|CKCX|?AZ:~#U|LS>C_~8|IO>R M|^? =P\$&=.MZAX.7@-XOW^OP?
FN2LJ|X>?^56Z=R|J2G062E+738K^+|V MT24V^W+Y^%=[U37+Z_B."B4^HK|WL\$G58%"QA@2MNM58V_F6W^:E7GME04^UMNQ(J7M0X8
M>|V.AK&=9:CM)C=+&9W1:J9:ZP-13R.7/L-VN(10C.M.F^V-KA)E.V- MFV^P>R^W="W=8:X>?KN85^63M_P?6Y1NW<@+7Y%&0%\$1:
|I9@|?N.IDA|>S MFP\$%REYEKH^5L6.@@&4:D|J|>=L8DEEU^1 KA>@J&|N6B|J|UH4O7_*I+&G# M23\$^|KA:G"</p></div>

I:U%0(04)5NTGBC./L"/TIO,16WZ,Z,I:=&6G6WU85AVYND9<M;90^V=C4II:S"JE]&^I+ 0HIAJLTBSJ,5MX&
MIPSQ%5W)0)5MFWEWG+Q9?05=7?H,IL-1^S8,3C:=,FUG(2630D_0Y>#T=E=Y_..QO?OL;UC9Z/%[\$+?MC6Z;[/7;DEQ8?R]WVW<M#(-
|HQ&| ZCMFWVPVP8.TW+H1VN?EXG9K#J8F?&.3MIEB>MZQYFF:GTSB,DR8
M17#B|L4NZL_0|_N_FGR>DE|GTU^32^Z?+FM|OQ2V_X|Q20023Z8.M_5L2?#GZ|MXK7;ED6%A>-ZMA/R1?E|O)6^8N=>MPI^6M;R'-
DTWYWM|<#L6TO1;2/((M:S9J|G|1J6DASKX4T1#L+;?@/2_O:PVIL;TF951Y|QOGBJ_Q5YH|=M2B?<#C2GOJ&f.05;|<|WV^>#X7T^CG|U;?>
H5:R>TR71JK:CTD_3^O(EQ92M_VG3^#9_Z2H|OUGL_1BEL|I(5^2WGB^/N7=56L6WJKB_WU_WJU?30RZ^<^IKOO5?&FON_:EUJ76ICVBI_:7^?>
1RC.AL,O2S^>Q^?^Y.Y%N-(M.C&8R_1N^G,8ZM3:A2I:ZO_N|>R1ICs"D:=+=O@|C")17V^IFIZR*<OE(M2YW^:R+&W2Z^I^<^U.O(5/|M|O(Q|2L21?>
WJ8I<&?N_)L-LZ=>P#OJ=<=&J|M;^HSG7|OE:XWJ3|3FY_<=3.5|3:L|O6^ML>XX7M|TJTS73U5S=404+JAJZ MG?)<51;JLG^OL,8JKY.V,Y31,5-RJRD
I=|X;G|_1^74U%>394T1^2745FS MGZ>F6L;5LKQ7W*+B^N|Z:EO_XUM,Z|O_XL9FX<9P=EL|H_RRI^<W<70;M|_M(MTO)154@6U0#@#1=P!*>!
|CKI|_13N%.O+_.9_6QOJ6+W4^2G5'A>I2 MMK +I9<#S@?26DI_EHBM?/ DM?I+<KGSJY+?X62ZZ|O63W^(GN.CO-6QZ;|LW
MV3?7OOFc,6RN(GS|J2_UHUU|">_*KV:=WXSAD;IP0TE|OX/-FO16^RO+6S
M#>VO_N|,K|A_P7_<^?OES7?<./S_ISR9IF7;R21|V4^<=0^P|S;GK^<=|I|9N|D8 MWV0Z<6&KKNKZ^Y)7MA?A&#S/X%_85A+I=TV:(|@-
A+^MHICR.X@U=EA5J^<G^M5JA|<^CE+.;<QP9K87^LN93SQ^!(<^Y1+KT7SNJB|/DC@E|U((RM2%N1|DGN_M;T7;I+T+^*TTIDAIBA>-
\$1(I|CK7(BRD<=&_N|+9Z7G|_6^M^@|_1^U#)M16_M|J^V^<^UNA|JH&@U@E-I6|D")TB;<@|)D1^0^8K&Q-<^<K.WO.C6@DLTOXF4_1_M;C^Q@4L2C9-
>4455EH18;LV14=<5|<?/I|5+<?<C|<Z7^I(4)X02PZS&SWA.SBL|>O|VO;ZIEGR;2|<=AV3XA9P,8TSC%|<_S6^RL@S
MR4ED(KS/Q^#0.3RW)MLL&JIV>-Y^W^VHO^F?RI^5:#8IT4_*Z|X-"IRHWEJ_M_F^<Y09T7N_=0):CO)LFN9|C9D?QON|I^5|>+6^|_GWI3+P;J4+<_<K
J4^M^<T|UWJ|RJRI|E^QX^R4>VOQ4DIQSDP>QGC0%4/<G|_@X+E|S^TD;12^HE|&(V)BT_M-2|R6YRM#P:2BMS^PC6M^
XA1>ZMNP?08==FK7CZ4NZ;G?L MG^M5;&^#%XDIXCT;1.)TSS3^A2|1K%\$<@WADKM>:=9Y^GQ9:D^TF,\$),X| MB6CBA\$7%_.BQ9JR
Q^RD:5(J-6.B^#|_M_K\$V:9=LSS)"2K@/0(<^<4@6D002D1^Z;+R**DI|M_@4=#5|B65^\$S\$3
M5LDZ2)=6S/Q;79>MK^<UY^Y|VX=3/OU8MZP@I3>?>6|3W&Y|YH^<^O.OS73|V_M>IN^LN9|&M^J|J00W^VY9(<_#V;<+<-
"O_(|B|Z&Y^CBI;R1|M51^") M|SDT(D5|C\$R:1.N^M^W|C:G^<=&@_<KB^V/KDAB,4J|G|3;O_V9#**W9Z|
M;.@%EUU+UK5/(|Q^W|J0IE=95V5=57655GW_M9@0=STFS%"EQ40D_):5|UF5^=-9_."5CTVQE=7Y/MY)'NMS\$Y.HUPA_M^78F MJ(J8(T)+<-
ILHXF6;746>|BRW(FL8_I_4%F%715V5=A58?>DA)WQ.E|IM%_2_M@36B_*S=YHR\$H+UO_*&YUWTBWEDPJX)7@3;4.(9K\$Y0P6&)U!\$N6##:"|O|
M5L>RAR^<G0@|>Z^:RYJ355FWRZC|_4_|>TH^|_1|_FOL_ZLJ(NN2^WYZ_K3W3Z+W^B|A:GK5TMJJE9<3CK\$CY3K_C_S:D^LRN(N^9^I_#2
M6B8|>=QG(HSSQ#=<\$#9#TBEPW^B?<?<5160^?|_J|J2^D?<?<55513 M8CBWA^MK2^|_QXJ(#{S^U^QJR_5^L_0^2^R+<@<+<R
(PS1REH(MZ\$&JFOAF>ADFU_M\$UT|G|S?<EQ60^B^#M)2_JEMP5E5D2IA\$<-TT@<F0P^JW+Q^<L^V)LS^Y\$S:N^OC%R8@I3PCI<
R5>0=;RO/O:AKO1+362O:GUE.Z(^*TWU_M;W:X6|58|0T|AJB\$C8HRI^3CA^66D^%)2|/636PT5L#_"54:|I|WGACK_M\$&YH@4L\$161\$VL;#3AC11)
MR|I|>X2_>A_#1.9;"|<#X^U59#^22B#^;3^G7N9P7Y^B^G\$5XBK\$58A;H|I+^M7G(O)@+SY^T_GK8EG7AS;HO_N^I|M01;B^/R2B)SCP089-
'53^#Q9^H@^<J2_MTVRI@A7B^A.25XBK\$>+W\$=<H_+Y;LYBCL|OISHF@<O1)9@2AJ2\$Q_A8^N|78_MI2N+|RI|UCY>=<|E9+&|6|^5^):GB\$X
2UR3\$W;78G:6T5|IGD|ZP07N&|+M|YSL0>/22^65M1H3ST1U_-BE3\$<V|_5\$S|9JN^M MYJUG(|S;A/G<7AJ1NGO;5^|JL(IW35(E\$S\$A.1^"\$<-
|51RPE323EG&Y5V_MWDM_IOWQA:\$5&RLV/LG|K=CX0-B8>:=;I-S(O\$ZB01PGH^JEB4=<8J^<AJVA_M6K?>
NO7X^="2IO*RK|/X|46W;XOA!^*26|VLP;M+POW9N=Y+|L?47R@|<X2|JN|4>W|Y1.Y^--43LPD#|HIW(CP70YB|L|S^<^)
M>W#6C^<#&|T_"GU5|<#=#|_YK7N=GN^M^F:7AI@H#;"|B|O+<XCE^N^<O>5Z_M^SU_SYNH^V.JD#Q|>+<U:K4WBQ4\$H;"/"0^5_PTU&
<63ZIRQ(BINHP_9.FFU MW^<|G800+SZ@<|VFRU2+V8^I?<OX^N(G_X4+<M-09W=68WBUTA^<ZUG6_M\$|M5;G<06D
M^DC71ZBX;0WG\$|J(|AS|&%"@LR\$2%&=J=<=<BH@/4^*K(I4>DQ_E*3;)^A_M0U)HGO4!48.RY18JD/#-51R@I(CY_O^R|50-I+0^HTSD|GA^*
4E#_KF2_B_M^<TRLDI2HS^1VAB81MLHXOJ79V?IZ7G>NGO?CUM\$^I+>|)J7<?>?>J3
M7^Z9P_OIES.<^S^73H%_BX9O^X^1A2|6JIGU%RC1N^>NY-|>JLNH
MK5Q0WDIEMBH^I+XR3T\$VVM+^*9)DLC@<_3V^E^A.W&LH=2^*88.9M_M=\$WPT|^18|US@*7PAF2=>=<_<ISG?JGF^V^72?;_*UM&U+ZL-
4>E^|JVO|ZG_M|J^*F4|N^E2#|8|>|XRR0R+|U3.LEF90?>NEF%_@@OW>C&ZD:0+<F\$<2(<MDSGTTL|J_&I=PA^A'ECC<CV:=EU_MMN_!\$G|<|
(&@L@O|J^M^K^Z|D^<^VLE)O1DB.VP^<@<N|ACC9^<J=H3K>_M|MI@SX67^Y1^7FC^"59<@<L^""-|DDA1HC^";LMMK>+>+OONO(3N0|++&@Q5>
M=S_-J2^<|N.RPUFE.SV:=81^7732E>VQ<|RT96QG_P6|M^M6\$|Y^|EO|I=|_M|VS|G=LM^<Y|L|69|VN:6^!WO!^7CXPEY^9POXHH^5^JHBMT^JLM?>
I+<KGS|MY+?X62Z|O63W^<GN.C;"_064>_+<1^<?>|!>^>XX^68G;>KQ.EG.9W.WCL/Q_M<2T>>V9|0|3/U\$|SEFN-<1H178Q|2^S=D1XCVES34-
BLD\$QOK1(8A=2%2_T|M^H^O^<O%J4_3|IE+M^?A0COS|U8G?2^IH>|>J(3OR+JP&580L0V^<#Y6&A^<^<M:T.NHNC:(Q+D87|W+96^O=SKFXU:
(|I|4|U^R+|*3^DJJ^E^<VND0QO3V-GLC4_M6^)|2S1SRDAD;E@5+^FJQO|Y0019DHT5:9A.O-\$K2PL;PEOA5A^H\$SdJ^M8>+<T_JPV7+|IH|S4@*3-
+A)^*M>23^1PMB(8,H848+EIB7:&R|UJ4Z_<AJE^R:SCYE|AJB.|O%>X+BZ0FO_ML\$<XZZ(K7S^<W+7Z6BZY|>2W^%DNNO+UD|_B)
|CHVY::U|JBSK1D|TO3-NVN_MEA|58^F+KGSJY+<X62ZZ|O63W^<JGN>G^<C^UT|<BY_@HNN_J5N^<|)2V3|_3DMT_M8/W0!
P^Y9F&+<U%J|6FR^9(JR:=5-YOR_MWR@2|RI^<E=4G|I^FU|>W2QSY+4W7^W_1^<|)O|F9|LX^<AN|I>DY^SHE\$|<D\$6=\$!<=(<V|VD_3NCR3T+<7:
(:T)_%7)5R^4A|W2\$7^F29L884PV(0 MG)T7DC_MM4A..|VA-SW5&\$)B&7&4FIUG|X...P>|_0_#*%MOJ|7_>>)"J3;EJ^A7L>|<L^X%&STF\$D0!
MFKG0F_|<OV_|<@S2|46S^U=1=N^9*>R(U146?4V^%H|OW@_<9LV=K5A7
ML:YB7<6Z|I2Z+0726:B+06ISG>66)TD2IP96ACALJUE64JX|T^WY|TL|A)T|^9@#)S^I|APKGE_MS>E3#);G3%OIS1^O>8.6|F-
WZ7Y^<S1?<E_J_\$5K=X:PROUF?^R3F.S|58W_MA#?^1P54WDWK_<=:<OXB:FD?>G^L|UVLYTK9SW_MD_!JM\$G.EMX&%=X|
8F|E.D41:K92/E82>U_2|LGL((CDBAB?>X^NH%_5&5_M2<@Z-|S\$W5JDI6?G|":Q:<^U_5A5856_|8^E-E<="AJ\$D:5F\$2^_V@B.OABVO!+DME^N5GY
HL>JNH2_MO|OXSVCV^<UT|<BY_@HF^<M^EG^4W3_&@|Y^23C1E_9G\$<QXZ\$<+<DR^7J00H31(J:8MBJ8GR3^_FPO_M+Y@<|TGN^<FY;"P77?
GZ86_OLUQT?>LGO15^M<=<2N5=NMP|P2^|L_<DKA98U^<V.7|<6GWX=<Z|DYD5WCAAO^<X(CQJ3^U1#_M;_<TC|&::V|I257^<XU4HD2Y+<@G
CC.G%9|)\$<|O|E\$<1+Z88H&>B=TQ|_M2&\$Q^|O|B.E%|_M4E(=E.P\$...|YTL+SO^_HC\$@/3^LKY0|I-|4|LX_YO_6HEK%<C3^1)|<VG
M\$O.EW&A|F4FPE^05D12K|_8.7)\$S@ACO3_28M(RF^4>ZP:8;D^Y8UE>%=^%H_MPP4XKR<5D
J^_99T|(T5>FAPP^?FOXXK8^Z4B+^*4^#HIB|J\$%Z5199@_M^P95|CC23\$=4%|KJQ|1S_-01^7Y02^#*>|Q_J5=1^1DK\$?>
X1QDCC+1^EBC8E:32UNVYS^A:G@/M^LN^<_MSEW7428&5GDB98:XWJ5)H:OB@I|+<C^SMNV+L-@S.T01PU_12^7I84:1(%)_M07E4X^<-
A\$<ZF2\$RR@D3<K45^K=N^L_+54UQ|S4AIC_"<+8F8.G|21N&3.58%_MME^6%3^<=E8@AJ3>+|O6_|6S6F1W^AS^<Y:=09FL|>A|E-3CJ0@-?C^RL3
MDR&^<QJ=L_:TS45E4D0;_<45D1954&#)BY@O^T^UP+<=<45#7=F:AJV_9^J MD&Y8UE>=<=<-
YH%1W:O_("#\$R&B)E8S19S@PE)O3/#51CYBQ^T_+5E\$EC<31NB_M+0TDILI1+975IM|OI-L^)!N0+IA65V/TT565D(S2FB9^_#<+A(72DV|X^5
M.DK^Q49GFY^RP+@C@<L|Z_<B|L4|P&P^3W.O\$#J|I1W_<D&FVY_NF^<97Q2?<^8_MM^PB8^A)(N^|8|O)QU1PQ|OQPGF^<8-
YKTM|>=<G72K|GEH^8^<K^2|I9\$*^* ME=EQ|MLNB\$<?<LGM_<+<DX^&8QQ^B:NWW^KWE>^<|D>D^<|BORV|I_ZVR_<-
M+^YCU6QF|FH#D|J90_<^1|=+U-<CIW7XNM+4A29^83D14J@1+VP524:UXY9_,MGCVS^W?X^K_A3EFH?S_!D_9
>1CPI>51502EDPH!8T|K|XPKIPS^2JT_M84H|BMJ_<@E&2^XXD3;R#_U4P#?<?<^7(I_O=^A^0^LS_2S%^1VU_MJ-1^_H3&CX_Z-I
M|9#&=<+U^77^P^P^L@|<@<M/ZG^H%749+7%6^")1JG8|M2E^<D:6_P:5|G;JL_MP+^%X^Z(TC^BG^\$<M+1RL7+>5:N/K)^P>|>
|8@*P#|<@|<^FJ1U>A2^@_<V^!<M^_60C7RIB8J|E38PJ|L7^F2K&^<60L@<(GK<^<K^HO7&^U|<^6S^A_O:X?T^UL
MU@<9|V=O=D/513S:0R\$HKB^<#8S8EJOVRP^#E_R2_6V:71FXPO72^4H3-<6EG_MN,|S<C>2|<VED|3R(LF=1|:9KUO)|O^<PK36?
^O|>+<XC@P|_A_M|<HB^N_MOPO:43=^Y^3_7^<9EZGLQOA|<77_<297GN\$^7HYH|_<^POFXSAHX^G-|FCF|H|E^ZMO|2PEK^<|
M|OX?<O41|<@<3YC^<K\$<=:O8#?<SFF|O^<C-6%A21^5:K^M=<@<|O8=G_C^*@<M^BG_Z%^N\$7F6&|<I^<F^<FYT:2_%5|VMYS_0?R6E^#B?
SXC|CD^I_O,8G@UA|L|K^5Q5K^2|WFS^GM9KS^_Y|D=|S|<3?^W?<Q^O|O:S55CY_M|<M>#SW_|<^F|7XJZ:4_@+|_MKVFP|B|<^#S7|O:~#B?|<^?
6D5^J^|H|<-MN>=S_<OR4OP9IY^9GL^<X|D4&+|H|<U?<23Z0S^424S^?>2P2D17_GAIKQ_MHTS
/@X2=VU33V<^!U_|@B+5=WMIR5.X_<KFH9_A^6_X9^Y78S_+X0:MFFY2|@U67+|W^%A|?I=X|@?P+|""9G?5HXV|O-VC:~8V^*=@20>X.YM3
M^<XSI2QUIC_Y_|<IG>L9_W0G&3^7%79|UE.H>|<T.N_MY|BN_K325^W+<SQ^<YQC_@F|O)P0KU^Y|O|U^2D|>?15CAM7H|1O6F^<ZJ
M<=<ZV@<9N;9#_RV0B+|A+<Q1^<9_X^7YC1|DNX^E^S|S|G38SCVN|U|VOIY^M^L_:G1+<F+T|L@^L|<QSUPT^NS^<KWG6^|UQJML3TIH&3-?
|2B+@_<+5M^HJ|^WGP^"IO>_35|B^SU-|2|9#^#|M^?<K^2U: MT4.B_|<|>|ONWH^<JTB&B|I8F|ADW|(FN^1V?+<4NG.H:<#1BQ<71%N#?JA9
M|N^I8T1^BIE_X|30&DWG|A^<A:GA7O|_0^<F<690|9T>3|YJN3&^<T2.FUWY>#_MRK+<1^7_0^F4YPU_ZM_S@06S|<TS4F1|1-O5?Z:
M^W4+<PF<+<OES|!<@<GL^|D|_FQ5S|_95<CUW?>9>3|O|B_?<SOXNC|S^<W|Sd|<M|LD<+<COXM3|<O@|_<F^O|=W4P20|9>5^|Z57|=E+<-
|I6=|I2_MO|8^7<|_M|KV=Q9%=<@<_<JSN|J4GCFVZ7+^<V_A=KS(QM^<VV-4_O|>?V.%8-<VM,V\$|_MSY(GRI2U:O3U>%2/81AS.YN_M8OYY-WZ#|
P|>=>9@|O|M8Q?<_<WHFSUKOWT^MMR6O=T_NV3-3+<B^GMOL.E<^<3^<=:A^<^<WO_G|4>P#?|X^<C@<^<1X^W_M,9.W+<SB>8C|EF=>|>3|<7-Q?>
%3|=7CPUX=<OQ|_P|<|A|>=>G>=GCH>J|JL(MO^7=V)>H^*7S3^DB
M^2V)4^P2^1PGPB>KG^%5D>F_#%J7D:=8P9^N>O\$V@V^7TVQW@QM+4W.EN^P_M^>+..7GOU9B^V:W8@^?QF^#<Q>+<8?H<=<=<\$>2X+YQ?>
N4|A|M^<:(AFZ=YG_MEP@^M2&|U@<=>V3&^8OY?J8YXG4|E3E.937(L|:2|^L^2^6>#1-|H|<?>5!_M|^<4P_|K0X&^A)8|X9=+<GN|9Q
74|H^#:=|@O||67|N|Z.H6|M|EGK4_+3_M?<VJ|T^<|5PDO_1|+<^M|JZ^<ZT-8=^<+6=V\$EN|<^7|N^7M^M:O2AVIP_4N?>
M:8S4;3T^1^1FUL^PP^2^4:J2CNZLG7UKJ|S|!%?>JK>DSF^<^TGW:OW2NW9^L_M72@d7^<^#Q:~A9^P|_<|3LA8TG|_#Q%Z_MNIMY!
<#_B3CF9MX|^GM9_MF3|&X_<Y^|2W;Z>KWFWQ9LW=:2_RW1(YVU|E+U=XP5TDJW=H|^<?UF3FO+URC_MK8:KQ0|UEB_EWTF-IKE?_<^|SZWEP_?>
W:~K>?<Q=|I^<^HPSI&K^<X|BLXGA9NW_M43(<UA9JR|<B^Y^Q^<7WX&=<@+@<=3V^84TKM6K3QOG|<K)Y-FV|^I^E=1!<M
M9:7|9U^<Q=BOT#<O5W^2^TH2M+<9C|W_07^R^#_J^VX_<I^<=:#2VPYC|O_MCK6^<@<=OYW^F^OEPIRA^XWV|I9@N9O|S-NV|D#QC|_I|?>
=<+<4^GH|E9C|DY_M8^<=:G|CX9\$1ULBO^<B^<AD0|DNN:X7OY^F^<#;UW|V^Y|<+<Y^Y|KWB|<#_M=5@C|<M^#X0^F^<@<7<^!OOSNV|H9Y_CY_!<-
|EW!>NG?MUR<?<N9M3^H|G64P_M3<+<9>3@<9_<P_A6(P|<WNE4OSIP<?<5HUL^<K6SFV^<M/X|<22=|2^%|<M=P^5260|_1.6KY|G@<-
|EOM^<S<KH:|^<^<#?<#<#<#<JEU@<T>U4<3T329HUY>^<X3@_MLC|C|W|E|G|_<^BON_<=:S=^T^YKVT|OC^T^RWI|Y|PHER^<^<CLV6J|B_R3%>_M;EU^ZY\$?>
CXO|8P(W96<#<I|OVR>(<X_MV&4A|3Y<|O|<^<^<8G>P51V|^<+<Y:TB-(B)@C|<X_7W|<^<M0?Z_Y@F^X_M|_@#T|<9_<?GPO^<VJ^<=HPH^|C5H7S^Y-
SDI6|E2X_/6A|JW^X2MM|WY_MTM8^<AWL8|^>Q_#|J4&I^<PDO_G|S9\$<TE1>B.EHT^<2Y^<^<|S_XI^P|W+<_MC8^<+<SYHC:M|JN^WARXGMQ|<-
UN|B8^Y|O:26|JB^<O&8^<9EB36PRHS>:J_MX7DEN|BFO^<O2CB_<I^<C6N@<Y&4^WF^?W8<?<0_8L^<KSO+<9@<::|I_L^R^<-
M+N85M^DZ>D9^F_I86;1G?>D|U@<^A2@<I_VEO|:(43-M_<^<^|2L^Y|2|_8|V^HORSC<>S^BLY|^?STG2_MSZ>?^<OZ^=<L|_<LFP
|^<DR2NC|^<SOJPHD|^<#)AOSB;N^N.NFGRNLL^O_M4|<O^<AX1RE3\$8^<CX7^2BH5WVVOQJ|E^?Q+<8Q:4FR^<CYDI86N^7|GK<|UW^H^<6+8L_#|I8:~^!
1Y6HR_MSI^9.M9|S+<FCEZL2)U5Z+EJ#_BS|X^<UL;MC8^<7>2QA_1GY^IUV0MOP0^MUG:=<D8_Y|_SH^AX^<5D9|FBFS^XGL|IK7T;+<-
<+W.N:P^N^M&E|S|_V88^>M^#OF\$5|OLW|<^*65OH^<4>V^<D_ME_55^<30Z_KC:~UH2974N^AYWZQ_4Q>D|<?^2^V_23C|<ZJMN^<X(OW

MYSKJ#I09W [M/U#YWIU7;E)+:;IGTKP??>FOFNN ;'EM7VAM'VF98%Y)HI-U6%02\$1>Q:AJG MPCA0A#8:-4V /J?047;:=8? MNG+>PIYHEV/07R1'A?@M1J 7.D9#Q8#-JH0H40@EK-(7.1&2;13K=A&9R3/ M6)+1\$Q.P.BUQ#YUFC J1?Q?6E2R);##ATCT@&/#DKX2'#-.UD%3ZRM.1'4 MP">M\$TG<6A4KPZ.F\|&QI?#E1K ; @ :T& ^L.@=*=<I<?#8X#?>I7U-2AY MONVSQ6Y0Y1&LG):J(90)!>W! F.) [M&#F#] \$HAT+EDOX\$2K<=>WDGM&#<3>\$6+=HW+!N-M;QJ?M1'4 X^Y6IZ>>IS9XS\|OE@>E!A/Q>009:=7D16+U:/3J1/7D10#+Y68FC2K? M0 J'Y9W\|/1WAK""#IHE#):N1&3YUQP.A/J88=8R"".9*XD1Z2JBI'WRC W^Y31N0\$&L\FYDW@|=E?C?#&?/HL9./N?Q76S3U:HN^26&3RT05? 90=/U M&#O?#BILNR^X.XWCG^:XQ20N R^4DIPQ12+>TK/>6N(TJTC)5W!^1^ M1H.M MT'DH(03QR4@B+>S/RJHB5AB5=-22Q_XW %W@.J1A\|L? 6\$PNNH1P>L&DK@C M""GAW31BW8VGOM+G%EY2D9U.R=QE(OOCYM=XVP90%\$SK9+LVITL:UN:&L R M+ D^O'GK;!.Q->D&/7<#A+C PIT" MYG<#RBY?3'8 4G7V78H\PHITK1B' XAO'F\<+7L:=QU:R% 0+NUO.65>KO+ M2IT 7WABAW5LIEC9YL6Z Z/ L1)1TO&\$S8J(C0WA):407F8@0(+>6-98N\4 MJ\|1VYS=>? G7G^*8 /7YC=5HJML0*F"EZ:ZE^JG17J1N30N.65-[EJNFO%/: >QC>:870M05=&#&GG#GPD**1)(O(B\$M< M.DJ\-\$+O|M)?=>UL+YXO/W1ULVND M&3# >-'6! ^0BX#;3T>YLO(Q?Q):^*#[V'=?:XP5? L;#Z2:QG1 64TU.BU\$Q MJA.678HAXLE'9UIP .J5@EZSON/7Q9+F6'>1)BT(B'<5!>JW AV:-2^ MZRV%=>?#1#T:M)\$%57P(WB)Z.IN:'F? G+LEF=J+TV6KS18Y3M\JQ67G9S1W IDICI MGLIFQ BPR&W2VP:J2T-X8V\JG.0\$6R%?9Q4)W\|L5(TRO.IUW#PI:D_89= M2**+5+PQK\$X? K.)N)QM?1^G:Z#1+Y>J^A/W7JL5"DJEE96Q%AX+;<KV5+<#O\I=>X M;S5W"Z29SF NLOH\|GLJ\HJM\J80'P.FH4'Q%#S+W+CF@>?C6Y.7?G)DYS MQY>NT>R^F1?27=B-=">*QVJCLDMAYIH>=IU<+@&:=>Q9NHJ1+5+4WCB25. M400W?>(J3>8L L'X9 /?>5>24\J8E.J\|SN7\$@>#N#B2007HNNCBW7NHSJ9 MUZ\J.7#<@N86YLP.A; J\|:^^?U:- +7/0B8_7=YMK"P=XJ8(8KS58.48 M2K2EGE1>1)D86#GEOL9Y5)8)6CHB7 #JBSL\2T7X' MF5ITJ:@_8YI=<+J^=GIV(I.FKKY<- Z%>L4D.GE\$EN1A/P+Z8?6V#K>J.L1B.M:SAJW42006571+==612>O\ONTTRLV\O+PTGXW-WJZ MAF8(V\|S/+>W8L0R/F85A6RB2,3Y)P+H\|E*XJE- \$DO^054T&JL\47699&M+P^T^M&@>+<28E(P.M.(?K1&5RD4EE507P'38JER3I85K2\|TT\|B\|E9M+& G MX6NZKU8#CFL\Q"=3(DB-I'R81C% <2>TX8F47E=\$<%X1K6-)E)+ - &+V\I4 M:>4IAC)X093%4GTE\|0*#ISBN <#BE85ALE?>*/H_7)>7IWK LYKI\$1^S MAEY\|P3BVGV9H(X(4RS5X&TZ :JY2\00ZAB<))J9\$;B1P.X""^Q\$&K)J#1: QH M:4N2HO8BL\$IRJ;>0R+&B^#^A'EWS8*PRS*S@!5;^:S Z^SW? (E_Y"WBV M_5.E*K\2\DA4PH(CA21D(ET)P\|G%IOXB2I@=1%?*>G?+P&=-HB0F2\$ZX M3J5,24=V&ZSA=PEMGA*%IM# U7VB^MYSF=35RW'DMO>1=!:S3%1<5..CCI*7&V4G@W(B@8J21Z2(8\$H29Z(7*PJ&B03I8Y/R+WL M&NYE.16JNPAI8)DEP#1#K.\$'F4IUM^W\|U3.4>DHJ3:1^*XI:6TE)04#1=S M4'<#<#<(DA#<#< Q\|@AUF"KE+;LGI+3TY"TXJ35 D6J0.6^ MW%42Z &=Y4 3 Z<8C3Q-1@:(O\Z^H5*1#+4C\|IZF4@?>7A.B^&@|MYQH\Z1-X1<8"RVM#4+@G&A93. M:IEA0D00^4L^&B8MPJ+*#*! LWYE\|SQ.2.5#".SHH3\2\?<9_ BM'D&WQBR:PX M?>>VPLZSGS2+TD.632Y>2DFJX=F=A@|6WPAMGB=F=A@|P1"MC% SYDD+* M\|S\3A@RZRAK7@GD%UJ8R%3\$N"%5;\$S\$QXR:M7\N^Q/REB.KDX:ZZOM.R7 M"1G'2\|C>?2?1Q/ CY\N7D\|S0>L%Q\$U9+=.1L EN/PY@PQ30= (H^IWS\$#@P M.V69EM6GM5X91.H8+!WK?>=XN^79<)/R\|OQ^RM^TG/U^8'B-O\O\$O^1^3C M'MW)"OP/L2 X>/E9)13\|FLU:OED?>JLN?>QN 3T9V\W239Q\|#-L.N1S M1^VS?J\|LK:'7NJEL\22V\8518K;U^IRG JY173(MVDV+>B? O\O73?B#O> M>4VQ*W#6E7<=YM"DA=6P^XY_+=9\$KOW%&1&V587E6:X#% M3+8UJ2#-4=O\QON&9"\$J<C)X*7)3\$E MX1&*Q+I57G)R#N\$;:-<9IH"O< M-\$&Z9(Q60PEM(*%_=->+!#-.J\W.N+9\|&A D#;PK-V>6 M2I3>7?B\$A=|N\N\|S_UY\T#VW=K09PLW\|SBO\|U&-VY8;MYE0/2C0H7\$W4+YI M* X@B^#Z\4U\58(*IDECGM.5# NV41C#C-\$ %6V\4Q.J\|X3< *\$IB6(* M @>J\T*+;""U=7^0\3\$SU\|SBO^?IQRWL?ST^;7U:XUF\|I-OL: |R/V^O9.J# MM?M0FO:>#L?LI MH<80\$ZPBPGM\|M\|5^4D+L%IM4^MII%:BF'38AOFY\|L6O:)O:&C8M7L&F MO165? Z.K\|L280:KT?>2\$>S(Y+ED)@H>=>.CQV4BP7+HEQUF#39\$8N:8^CTR71->?7N:\$P%>@|MI@|MTV\|<^"PG:4'14)Y\$*2J M\|08+3(E8'2L\$>S^HC*6L1R&Z\$K\$G^RZU(S1B6?Q:AJO'3?>T<^C#HZ%:5L M>A7L:SRUP?2L^R^&CEO"GC M^ZLM\ :OSYWXO)1B6(#8YM8.>S\|7?B^FB\|ETTF"1->P%B%TRL=?N\|;="5P4 M\|J"7X@ISO"P+MZ"#5F>/QW9+L+3J\|O/\$MSLZ:R^S?DC6H?C>+V*J@/ MST7=ME3#;BCIPO^JIGIO&:%JZV@&1K+>E3_5.1>=H7J0.9_6HH#+>1+1X@TR\$ MM0=9^XGSD\|/P+2?+WGDO\|2\44060\|X1\|G+Z G\|W"RR:T+I^A42PY>Q@O%1=OZJ*1K^XH?HUNMK"SLT+W%1CS MRUI@RJ/+>1:A%?S:AY8\$:%I-S<+JLH6_7E=5 M:* <^R.'JCR.RPG+^67P:G'3N\|6%>@<:62TV:5FN9QZY^6"J_+>#W1 MQ@+>EZ6_-BGO7@4GMT>R^Y6^RNI:=7V:1\|D\$X#&N\|4\|F:LV=PCDR.*Y MXQPP^W+TPF^KOWD?Y^U7\|8/RKXOMJRKYR.T\|) ZXS""M.AW+M78X?QU5\|D2EZ#1F:G:G06-T:WRZ M91GZ\|N2&)GPV?2.O(_5UORI(SJX C *R\|KD19H6@G"G0.:FCD0\|R&D\|J MTME(O.82\|B3:12S\|)*<^2J*PC:Z1\$SMYVW2L T5GWMWD1:OVRN\$>_>TF M>S^TM>177=2'Z'Z^AM&S&2*J\|<16F(.YF502GB)-W4\|N8V\$-5\$Y:FC)A MB#:=O\|Q(9P>24U3VOGT\| FQ\|T>FS.RA8A1.%N\|8QT40_.V#J* M>J*"UF7P)DA+>W2J8)1R\$TE2H(R%RV6S2PU>>J\|8Y\|D\|VW=RU:B-UBBUW\|ML-\$Z\|FC^=1'R780Q16U%1056G\$W@N\$B\$).L- H4^*G5>1>Y\$V5+GC\$GK\|&Z MM \|E27\|S\|ADE(8GPYBGD\|Z\|J.N\|A-WUTJBIG:AGU/K^RZS=CI:(+& MPW&/^N&IM_NW&RQ#W4+^NGI? PKN^SN^W+>C\|J3^*(C=0R-D\$ K3\|B4 MC^O<5?WTTQ M16^924\|O&Z7LCK0\|ED ES1\$^L:JIS_ M S?3 ITYN\$V\|SOM6:^WHFSUKNKKX\|J\$F8&:%%>?>8-=YL8G2BL\|GQ_M\|X CSI6\|X^_H\$X/C3T>J\|U\$6Q\|>PPI?#S^WGSX?_2;IPP#^>NGPX#JY\|? BL^L'7OW\|V\|M'1\|M1=4WYWC2:MZM\|>?J<=<5\$1^L<=<9\$JY\$2B0^AUFPTJGX?S).O9L8XH\|M^A_P@SU9P:5P924NP=65\|K&.&6 N_&V\$#7PC2.*" &X8*F48)2\$%T0I6 : MX:6DJV"93H1W(3\$#>+U^OQ2'F\|JN^4R1\$2?6R?I2CG#""F&Z0>P%>A:M^M^0 6N(O07B:60^H5M+S2?."U>IS@)(\$F4@8#W>+&C_0FV_Z65W.58HMS? MK4S\|0PQ2UF9DF?>7=MJ:WQ^C^B2V3-)YI\|&0<-/+2^1+>RP@+>OJ^3\$) M6.DRR65.*4CM=IDM\|J\|M^M^2>?15\|F4WD9?>R&W6P^>KHJ3R:44 G1N MHZ5%#&I(#F:2LBO 3\|J\|B3 3 BG6\$ELS.(^:Y6A4F FB^+H>4G6Q(VOCB@N<2D\|NHYNV\|F6J&#%\$H0:#W:#B@N^89148&I; ML-DE* W000<1V =>>O\|A\|OWD7^CH8O\|T\|W\|<^&FEN+; (^L\|3\|WHH8\|O M71ADZ. (C: 6\$!>Z?Y%K/K0P?#4:APZ^&X?&Y;4N\|>6\$HAG^O<^*1 MQF^S7A^3Q(Y-L2L<4DJSB\$C7K:8:63 8\|T19\|DCU=#! (<:M;4& HG:EU(H MXW>R8Y.HIYAA0\$7>VB5H1K^4 U)_704 W%53?>YP6OD^5E:GPE^O+B0A6 M>N(DI215\|2+&\$N^*8U+>9X9QZD@KD\|J)TJHB6\|L0\|4FN409=>W^D6O\|3O MZ4JIRE+I\|O_P'2'DAAZ^0\|WJH>;^PZ@_)IUV^C+("5)28QXC\|U \4G2BDK>+&8H\|F60AJA+H1Q6.:GPD(SRQ-EH2\|OZL9#_5A4:1=3\$TRQ@Q2.: M(S:1\|9HK0P>5"U3Y9GD?N\|NUF19ND^U\|W:SL\$5Q#ZTR:%\$;60Q\|J8>+&817 ML\$5QN0\|JKN!<5H94"NO.42>)BU?W\|TIX?U\|< M"7\|IH...VSTN?7\$=->(I8ZCJ&6DLP\$KPEG@)WZN^972AN#):%OL_(&V\|) M@_WIC#8D^FA\|C\|6G8B-Z\|D?7L^V&9V.X?_JFHIVA>? J@:Y\|K=9\|OY^M_8UJQ?1\|TR7AU@2ZL%?)@>R+N#=#>+&4X\|1&1F2?6D8D^ O=: M^?>@O=Y\|HR201;.>%)J\|28SR37(OR2ZBVS_>=M<^*TZM/P%U-FMY(O:4 MZWIM>L@U0#7?IX^:SB9?9J#_VAY_MNE.H "P9_9\|C3X^YACB<Q^T.#Z\$X\$D7K^ _UK8YW^IV= ^L:HG^P^R\|@P3\|J^&K MZ2F-TH1640H\$1^#^K_ <#K&J\|^>4CDW#>^YQW#""VP2\|L.M""%+4%&J\|C\|HKHC^Q\|>JCF?>+FQ\$Z"HYY21@)>+B1S\|M\|^V5Y^P2 M.OARM2O\|L:C\|<3#1;AUUXO? T.Y\|ABN^5M;G^V=5-\$\|KNS\|JIM> 8." M/3.\$2P^*I:2:&Q@>(YAWO(C("5">@|M+>F-\|F\|ITCA(OO<)>FL SN^3D1 M\|^5EMFHXE.@F- @K>34@V^TLX#NDD\|J^ CW2F=RP\|WQ:EO^V2X\|9>L\|J^<Q M4R;3^KHD5V9T@RH-<1\|R\|I\|XO3A=MM_H0X7)?MTU9T\|UICEY\|S M4X\$G6;Y\$#ED@>H:P.H\|P;MP1C\|30DF4.Y:(*E&(&S4"H9L^NYGH=08XC):8 M4W2HB#@\$K<@>^>^O.\$(J(DA1#2\$B.X:TF&*I\$5:333H"PJ4#4R6F) E1CJ M&-8.V8:0"J\|GS\|BDT5WFO(O'S@YH [J.9:@'=P?)CT&E\|I:#5 8JP< M\$5Y18DM32245Y.EB\|4F)WL<?AP5>@>I\|A<#<CD<^E\|^#R9V\|&@>(G2 MKY\$)U\|V8Z.9K\|N2%&BB2XB:5A+>#>5FE&Q< < IG7.RG.TEM."I\|U\|P^PU#>+098DN^*V+1D.\$X%\$D^I M G6R\$5XQ.PP^D7I M+S*8ITY5>Y 1)ZC\|VH&P:7FBR.KG24@JB#\$5\$641 MK9DA9JEMJ(K) DV2O(\$L\|&G>30<6U>T\|3-1\|D1^C< &\$S=LS\$8YY\|4:PZ\|O:7Z\|5 M68M/P&=P\|6CEZ;3 O\|8W\|(XO^>+>UV^EP-JP^&2: |M JKGH7BGPL\|F\| M\|JDC2S\|8^1C^5GB^U?>3PA9C>""FC.D3\|Q\|E5B\|4 "D\|F\|5" L7^O\|^< MP\|S.0.S@ISK5L R^GOG%3\|G:7&3G\|8 ?C#Z \|83G\|PM1UAW10:S_# M83P>G&4+P\|F\|KG\|K:B01R>4J\|T\|L47526Q);24U^6H4R6:ETV^ARK\|.2*\$?IMY\|66\|^O8.X MN%|OKG)Y\|L8G<(^R'. (9\|LE\|S:"KX M2M-A9^WJY^>=, B W^D+G+>K\|83P9U3\|S1YAZ^G^T<^8\|HJ84@M^V^D MGKH\|E1D^6H^Y6\|R1?UF9\|^I8#0&V\|V39(ZZS.-?) (Q\|AL=E0\|.06-JS (8 M6\|OW3;W^O.PG@X_-3FQ\|IACC\$B.QQA)<12^(\#5R\|S:%M\|J2A8\|>6&6>J.Y94# M\|IRK#>+L\|GB^6EA5)=2>Q4Z\|Y\|M6PZ\$G\$Y\$EKWY?>R+69Y83 APJ\|U\$11^ M68H8:MR(Z\|6\|AG5V\|&|< (O.6S@>(N32)2)OR 42R%= M\|25M^>SGE3HV\|-2@4. @2324:Y\|VZOR \|^8^P^K\$S8B\|-I<Q\|T\|L M:9&@I#Q\|).3^+3^M-9K\|J\|RL OM:PM^E42Q. B\|:)@>V\|5J9E:8\|ZVG6?DB?>+>#AN\|5X\|8 8MY MUG566 \|^&#&J.G-PFQ.53>+W=O3-GC5=>ZU59N\|9.U.P\|^<V^PZ4YSXQ/U M\|3PZ?^T C^H?Q\|X^C@>@>-L\|X2W0<M#Z\|X^F^TY5D?>AU^P^C^Q5 M\|I\|^3\|^<?FX 23\|Z\|^' SZUT^X\|X?Q\|W5GP^AB\|^ WAX M\|^I2? 9\|J+JF_>Y\|O\|/U\|^0M5 7:~ED@AGL^P=#N#C:T3A4\|N^>3L^&@<^1\| MO&P C>=V_4&1Z\|U\|^I:40\|^>^FZ:~>S\|N\| M< Q\|W^Y\|YZ\|Y_FOV&=??"O\|(6UU6@>L>8IE3UIW\|^? 8\|<+SK^%U\|J9\|^M M8#J\|K1P65^2MZ<>JF-0\|T M9H?CAZNY_^^/- VM\|N\|P\|M@U\|^R00\$IFB5^+SY MD\|XV^R\$S_LMKC#NF=M\|^>.. 9R\|^3\|^PQ\|A>#_N1^I\|0W+B01>+>#D#\|^+ M#7DU^T7OUE.MX@? T3CGEX\|SW_G:4:5NZ9PB8\|J:8\|^FX#>""<3M^P\|OL^>Y\|^M\|^K\|FQ1S\|^L\|W^Q^&=&A@G>);X M29\|^6\|QOZZ^T^>#>+>5F:~&X#N\|J\|^I\|^0.YGE\|WYK6OAK.OF2D9Y1^LO MGLOJ8&X\|6\|S\$9T=M5#D3 OQAN+S\|0-1:"HCS\|D4\|^7\|^U7GB+12\|^8BM\|^M\|^D:TL\$^W00\|^NCA\|^S MLMO9\|^ Q2OD:(#<G^9S)=M9B0\|^BGU<1W56HP\|^UOT^YHOR\|^JNYIYC\|O^ XCS M\|^M\|^E\|^Q>3B\|^2Y\|^W+>C\|^X_2Y^X\|^JN\|^WW&@>2-Q\|^L\$GTT^2:#\|^ \|^<^FI=I#< M^N\|^I6N\|^Y^EX\|^Q>20TR+9^W7 H78R6.17&+ M^0#^VH^F0J\|^I\|^Y\|^A7^YUVE.OOCR^M1MKY\|^JVN8\|^1M<3QN7P^X\|^NZZ\|^Q=XZ7 M^?>7+M\|^NK\|^M2FD=JL_N6BKE""OYZVD^VX1=L:P4\|^>I^Q^&=>I\$9'(R4KW_MGL\|^ZA62(C:8I64Y\|^0VX>LP0ZV4B\|^I8AH-JL\|^U\$96(4 FQ5XACPX@0%>QLN M+1Q6\|^3XYG:2+98QKQ7-DN:SS:9U_K^=D\|^L\|^94SU&W\$M\|^44E:1K3Q\|^OS#8:#NZXYL%I U47%Y\|);..-Z04&EQ\|^M Y?#Q9:|S\|^RW\|^6\|^J X=N.G.DN1R\|^WY5RN^W^H4C\|^I?>F5O47:~ M&Q:S\|^J#8G:86Z^B\|^LXC\|^DZE+>X 6N>^QH68R F.@FTTS.07X#>C8Y MLZ\|^Y<[N\|^U\|^37\|^I-R\|^M^V?E OPFO @>[13BS\|^Y^7GCH\|^J\|^R\|^2^&A&^4\|^14^4&8B\|^J^>9AT>P^K 1.HGB@ M+57HH\$FBO?>@J\|^6^4FF5?>ZC\|^I\|^Y\|^*FS:SRVYF9?>5#W^%A\|^ZB\$W.0 M\|^I\|^C\|^DK7=)>?>2^D&SP&? Q26S:>KLWB=-K>D.VANE5CO MYD@E\|^4FEC9""L>38AH-PEZVCS_XD\|^AL4H:D9\|^L:AWR>3@>Q\|^XCSM\|^OZVDY^JG M^?K\|^H85LC5K?>0\|^N Y\|^V2U G\|^I\|^Q4W\|^K^W3ISZ^V\|^I\|^S>=7+^1GX^G9>@>C& MRX7^1Q\|^8X 9X\|^9L\|^EB\|^J\|^X\|^J\|^G6\|^I?7 Z2:<^I\|^P\|^U\|^V\|^W MO\|^M\|^I\|^K7EY_1\|^I\|^F>8\|^9MUY1@TC^LP^29U^U>EFGS2/EEX\|^Y^0V\|^I<@^_&^\$J:R4 ^WF WMWS^>??2V MN\|^LON.? %0H..O\|^X96>U\|^ZD26\$#R\|^R\|^R\|^P@PH25\|^VYX^FZ\|^I>^S\|^_831G\|^P0M^>G\|^XN\|^I0X?>0Y9H&"C>E\|^M\|^R\|^69:TO6V\|^T\$5->I@>6>B Y\|^9NKL\|^G6\|^ M\|^1\$SEARF_D\|^D\|^3^Q\|^H00\$5OBG>?>#YPS^R^S\|^I7+>9D_JH\|^I@P74\|^D\|^>)*\$%J6B8K2T(W:Z#&2^FNA8B\|^MSQ^0\|^I\|^E0\$R@7L_#HW2VP-1+8#='X'=9^G?K\|^ZFZ M\|^W\|^36^#F#B\|^>@KM\|^V7\|^2-3>%KU^:H\|^>C/E\|^P Z\|^RIA7>JQO98R(MQA^7\$!48OH\|^N@.#V>^O(6\$4O-=>S\|^3TM+O8M:OQ^Q\|^L\|^EAD>P+7AZ\|^G&W\|^N+ M^ZS-CNV76:4ZEB(F0B\|^LB=**\$Z?)L9:15\|^4KM\|^ZPPIZU- G*2\|^D\|^H\|^K\|^X\|^RS\|^I+286\$?>#DI166\$N2ZK<2.9^56ETXV\|^I\|^OW@W2\|^YVOWFM7-Z>O^Z>#_Q\$ 90A&8.80 MFQ\|^B4UM6O&_N6\|^I=H\|^M\|^IE20\|^A+14 M\$2%L(LY5G^60Q) 5NEV^877Q\|^I\|^D+>#S\|^?YV^*XE\|^I=WKUCV^8H\|^JQ?>8:B M^%B8+I\|^3^KZG\|^JQX1>1\|^1-&4\|^O2<^&Q\|^Y25Q@2\|^B6DD\|^>[IMM^9 M:AM^H^O^M^I^AOZN^YCG^6\|^H=0\|^JLW^?E^TU=B\|^S\|^I\|^G\|^65WD.LM\$ T(3^@HGD) M^:ZF9.XRFW^I^VNG<8\|^S\|^J\|^C\|^R\|^J9V_3^Y?GWXWC_Y5^O^K2S.U\|^BY.E.# MFI^8^E^4C^&2X.1F 5\|^M^7&7+R83P^8Z>R%Y\|^L&-6:SX? ^<(>O\|^O+>WKB5B\|^D\|^I\|^T\|^Y\|^L\|^K\|^J9\|^2X^Y9 ML>G^T\|^L\|^Y\|^J\|^O.Q.M.K.^9X_#E+3W8?88 -E\|^L92\|^I\|^8\|^1K\|^B\|^E<-T20M3 M\|^I


```

UT18%"/60A4Q^>OS^8^-WHI^/A?8]/CEN07H2K2?OF?XTIW'X"/<6F2MH+M!INO MAK^Q5>_F<8:~UBC#=#QVT^!0F:/>
IQ^%K_&()0>A=J3^FXI:P.NL)M^YOJ,&4"?^('U:>5BY6SKQJ$>2% MVV6Y:~=&Y^WSROVZF:H@5,U/9F"/G,(/IT11QXC%;PUB"VP.FTL78PO,0?OI
MD.&5-V89D3M)4D; X,J^NG.T3 M2:1@O^LA7AJ&8Q6^FXLPX'N^J12MK@C55$3&ON1A8XOA.($&SP^CP$65"/>+BXOS^JD4142OPDK 62?OI
BC)1+&S$25D^M^YR02^UY5 M=5-1V3VP&8-E>V.LV:18KJLJN^>YH%JE15.O%J5: B%[AJ:61!06"/+0/W MTJ:B%$%I2#!C^ZEW.%J.LXRB12
6L/G&_.0QS""OXIF A_!%S1 MI&EVFLQ9I59VL6MC2YWVBU)6XHO(8NABV ?8.C2:2UOM=ON3H:A JS^H'L MRS^I16(^Z6/X.)YZ_5G@)
<3!$GQ"W/>Z^!Q0%OZI O@H78W N.[+2]:YLX MM>CXI^3%$S:MLW^Z+^7F:JW4KA15[L W.3.NRHG)KI7E/N.500<14@^V4T: MJ/IIW4J_ ^!&I=-
^C.IIYYQIOQ! 51Y->A:CO>19^/IMOJ^>VU_3.Y1.) MJ^XKJIDQQIS(9L X RH+1OCJ/3T.W2VP:0L/H^WVCK:~&HRC$AJWT^4WZT8_8I?&
IA'E%OC.@-IS:> M6T6^H5ON^K=X7&2LJGQ^N(NXL<_2T15G)*1^5^"Z5RK"~$XW.6WQHO."Fl'A M/^IQ:(LZ/T:XVY.ZCGM11S-
A0H4+MNB@/SHF!^4QG^2 EU9Y12?=>KSB9 M3H50!MNR67@/UL2IW$%G.G^0.%ZPH%:ICRWCF$EQU_BZ.O!>^CILEE:->
MY1GUP:5JNYJY/UH:CDLQRQK;IE=9)30EUX1$%$:#X+AZDU(F#P)J>RBU MJBWKLXWY::YP O>AR-P M2>W(E?R3)9M^?
VA>O.5>TLK:KTUJNS$W/_L^B=ICNDUF3T 88(L>.*T%IO1 M=T>8D&E-GMK 0=@F/KS;MT6@33.ZM^7VS9TV7I+3^S#U19@IF5EQAI/PTV
MW6ENO.M6W!6L.CP=^I SS^6+P.O.O./HSV/CCI>=^XG@7?+PRN>AQAM>=: MI/1J3P>_M%9^X/80?>QX?>WY:DCT>JBZ1)N/9?
G7RL8L)1=9"81S0(EJQ053I8&1+6 M2M-JQ$O@J2OJ26D1ST?^#L:A3P/$%6.21V:#W7C1Y-F:LRP$ QOX08CB8
MWW30 T5OF)BMGRPO>|LB4>T7^U3.N2MK=+XETUX! 8:NA//OOQ9J=LC MOQ.X^XVHQ<&76 ZG>T9_GS)CXLKIPBWJ4.X9PQ!<: AH1/9
MY^NXXRO.X.KOT#."3'L3SKN3! RA7(O 15W8M)K$1JIBE1A+2F&I(-4E0D ML%2(P:4GNHR&.&TJM9RX$=ZRAV_7N4D/TK48?
EGVE^&FSX=CK=;&D;J2 M>HIKID!>6VZYU+X.M%6BK$[O~ N#1#@PIPD6WSA.EIY9(ZYW^11I$ M^F8KNT:D TOBZ=ULSR: TLO/X%'-^V-
>:#.3W/YV/^ZEU33& 0+= BR-/O (Z^>^2S!^#!"Y.IF Y: 16S/1!UC 9L5@2U.+K: B-C-1 + MI/4E^V>@GG%D:E@K$5EQ%.@6$5(14ZLLF"
(T5^GQ^I)J>+D:12HM-DU.1VUQ MAQ^7/>-CF-E10K."A61-K$@3 =NPF.4SA4^R+JLUG58"W(F2(CJL)^!P M.KDJDCG.7A3W^AB^X/E.P7=X&$X
4I SPQC^X.SF.7:6>^JJI(:#6GYRH# MI1+V&K^+2^"PI"@=L$8;(G$ &5)5C5A5$=LLU>>C1U>XF$JDI MKK>")M8G2RKJ">"P-Y150/OM./>WF=^?
I:6.6V00.4)KD.:6!^YUA2A&3R MXLWD#^X@&9XIC$S.R51^>X GP_B6RQI5$ "POD<+<U">10^<5J2RB/+> 7&0L)V1|8+Z2OE:=AH7KZFE@.D.S1A
M=4^I%55$6LWLL1JKI6D0^#V=14XQ MNDQH.4.8+EH%0K9SA6M$08.>4J$@UF EK^0@=OQO 8P!)T@^&I4SUKP^MFO:T-IXCFIGIQ
MITL8UJ,IR(!J)GA12.S06+R;8E4C:Y";Y%+Z^(*44 WRO<@J5?0$ZE4I4A M-@/J$11LMB1)"VI4LBO=9*BR9(SI $8!S:5U^FI"
4SH8U1V^"D2^NF M^7LIQ6ABIOEE..O3Z72L?7.R3 E^%@S_Q-L155>FRYF-9D30MCMXC1) ^I: MVH /B=C_OGP<^OUEFLHC.QYZ.6CF
LUG4U^K>@W+?.)9Q:ZH YB+8.C@08.VM M=X12ZYQW$ADHUZ=IR^"JZB:F^IQC@CB6T?WV1SG-
VO@B^@JL<^H/L/U>Q69NZ T^T+B&T!SA$82Y/9JXJ 2P3HL216 OYQ/H&118S73" I^MNU M6K2-5X RY:EJZS^>9G.L^C/Z=8L.@|L-
U:~C#X#XMI18+^LP18$ =I+U+N MP+180^ CN&IV12L18W=D^XI|^DRI13MR:61SDIED!>4D MQ.IT.KX
S.#YWBXM:73+5.S.;SM5:j9.%5#.#F^O$*&Y#.#L_K_B.JT.JI MA)=2|XZ<^*|I.N.M^OK ; UUI:@I9AVUN^9OI!%"1+I&? M--T>=>E?LK
^#$.B.4+@.3!TEXOB^Y!Y!A68E(BZU@/LBZ.%&|V%DBX58M MS+A+VRY=I+|T^L^BOLMOSVB^I36^=5?
M6:L^A.7^JZ4=2UP^8<@L2AMN&JL2SN6> M^=1$1F:/^#WKB6NB^EHR+F^M^M^#WU107H4Y)JF^PLJON10I0%;@)C-9-Q*
M+);/NO>AVIT A5N@X$BGB7P:M^O6K1F^=-&T);&O+E-6LWAFZIXMB.NTR# M=B%ZO.W^U+AG+=2C.TYPUSREB;&?
|3K!>+&9$-5S4+G+?7HQJZ $JAIIR MQSB 9:2@^A^P.M.&L>@O^TZIOA4!<=O5N4B7$ZSR6A| ZCF @ZA@EP5^1 MN-&L6$D.UX%0I35-
YJUN|XIJG5_07KVZJRL<^7I<^6@Z^T^VVF+>0@>A M12.M17RYS.A@X76T0&OG UT85 M4I3;W@/QH|6=5X+^U MVU6P.1W@/J.?
19^*)#FWU/G^B^8&."F29^*(^96V1C MN6)@)C:BIXLZ^#*6^7D;+X=(XPO0$6Y47;I8>_W0^<2YV4 M^*LC2H(R^TZ61)=6DC)400(R25|=2_=?$CC
YV^&I)29V3EH&A-NEUY^U: M_8FKQ%QNLW12@.(N^N^K4>58D|WWI<^ YP.(L0&NWT.A/ZWGK|&FMI MP^2XQZHV6I->EZB7MUYGNF^D6T62-
E$SK^HXH&93PE-IE!+ 6T4$; DQ5 M>8T!^#;2^&K>ZX9G:G$;G1<^8;J.V.QD>X99(8<^>H_3QGXM>GIO@^>=H?ZNM5M#|/(AU-
8H5:1+&A2Q<+;PAR4=ABW:A/M^P(VBHEP4@M6(V31^N.@8&#"IK P5^5:51@.:@8N9L:1.5A 1@)-M M=(HP)TIN0I^T9_@.@)BOX-
S+% POT1LC94:6UOES.VVC =&2 MMQE<5L%M M ME^H^TXJO=>8*6(!1/|/@GRR<1G8)$%Z^HT IO46 ""/4_+J.LR6D MWMA3NTNJS>>-.
J:RMQG^Y^HH.HIDF8CD0).PPIS8"R&9J|3EKA$NIO MH.YB^A4E6AE^9).IY^7X^EN=.%M$5E-YGNKS&WP075UVX+=KNDH/9H^U: M/8CJL
I/@&A2=MP!L^3^T.OEP:KJWJZDI4M+PV/NL^"QUOK<<I M^"HPI:$%QSTI3CBM"" TIV7JT#|PI21L&ACPRZ>3;HW>^RMTKK)&L.
M_NMCX-ORS^WQ HF^WJIG Q3?C4U9G !I:C^9B^*=4PA+U.FE;33KC:YJ M%JB>G|W_X/=<^0@/HLYV==.I^!|=C%C6>8I8>Z;=;M?
V(GOIH;3!@KM^CM<0^D>YI/Z2ACA6/-80! K&O; PISO^XI>(^IU60S/OD3>^|Y.F3|I
M673.=I|6UJNG8QI5ISM(H/^MBU..QGIZ_U99A@<ZFPQG<-26;W-8C/M80+> MJ>9!I^QW044U=U:UOFM:D^FBP3X_4M7)S(^9V:1I
M^=$J4^VJ|2)"UB$O^VWNB6^ES? UKZ.Y.XB!"KI.GWL.ZW>O>3;<IOMQT
MS#^S^#M=P+PK@RB:DWDKQI@IP>#W_XZS2=)"8^K$SVDWMV:L|:R@W+;MP+
MOE8=73X_1+D5&EQCAV^I|QULU/Z=>V&NE S>_K^3AG9J^CI7UO@U$&C: MQJ^YMI3UIE9V0I^(-HB)4+GV5TCN^M
NB^C""=+MR^N^YW$)?7.NJM9W^M/./-RfO%JLRJ| MZUI/P.OD&$YIM^>-89U797:6I#02S:ORB:<I=J@;.#T^78^89$KOF%:QSE.MK^+?
6MY2NT+>+F^N18O1|BIZ_M.5O8S&HKJ1)9BMVM4G+8C|FC3F^8C /MKZ|4.OG!Q2E<="CV^MJT.;|YU^!$%PIL^C1LP!^67?>VNS>?
^X$&A!9YLJAX$7TTI6W7YTCIHK M/P:7^TQX!IAZ3SVEU^8CB.CXR7JL<^$1+3.VIOG$4R=+RA M+ GY$2^1^BI
(O6M^*1<^>)"Y0@-992!FN"-WT9AUC^7J_D>#G+>(<^$K-C^M ML%!:+>BDF@C/ M&I49(J5D4^%1/5&X>_4DA5Z1PE7F(GI
```

09)S(U(LV:17 MK6D-# MUFSCXUJU|V|IGRX K@USMUIP16B/H2#,"7:3*E*(+ 5G")## MR=Q=+K<N,2?7Y?7XY1>D: TOX
WNW<7:3=>MTX3 WBY%Q:GZW|<E;IS^ ^>L-OV5GFG F+S S M9 S, S'W WWN><;G|? L\$V&?2?/OJC MY?V? GO>&1+^WU J0 X;
1Z9PT V <|:L=1.PX\$3YWG,73D83:Y Y19U6 MK/YO+3?^6UNNA4#ML;=A/W?G671:2EIFN+;24F M_SS#ZE(T6TVTCH17|JNK.AW|I(W@-
H+;|>|FN(F648\$4PG S67B#6,DL2HY M:GR(YB3@=G2,Z)< -4: OE+Z@< " FJ-837|JBV>S6T8U<6@#4R%|""1|P#E, M41C)##"TVPC:
(JS>7 M.Y:YQN0-W?T?LND4B,2C5?>DOB^>E02 MSV:WCS#JBR1HU""S7P",WZ00C+BE9"\$,TXU-UL:W,U>4C M.R.C:SN3V?0
MF7 /|6NT=TD;|^>^>L(D MI2. C2'=DYBYU:@[KM;K?988#|Z3-?^J=7X^O+5YP9H10,1\$>K.)ZBB-2, M\$#"7C6?>5WZ12.I&FT?>1 RJ?
WP:S|>R>=3?>R'P'D|FD,164E/|D M/9\$V"V(H8T0EY7W7.K.OIA)D?H9:|F7* *J@0^Y#&^(D4BYB*
M_=XS8MXX2|I#ABG?>5)T(92B0WF5B>^>\$L: ^E2M:=!, ^91V?+MFFO(A= M8ZSZ_OLM>|G62/ _JR2G#&|KJ
SO49:0^TWHQ?8PS+&C&931M^Y2|:@B M2RE|JXTAC+E 9*P21L85""6K@K+*R#0|N#^CT4|N#C%G X<.C+ B^GRL/I
MYOD=OUTWV|UH:D8|O%QX..O@.6+1Z044- %|P1|KMB#NB).IY M09V1PC|@G4/3^5R5>&D^-8Q&9-X)Q^|EBZQJAP8>E2D3\$/(IS|)G*U2\$4<-
/U5 T*Q>|>R4Y(6?N+Y716SKU<|CE#ZD|VPG MI7|A^M^C>@<.Y< 5/3E.|80|L V9>8V^G8@GF4|D3R <|W;N^MIC/%G ; M&|=|I@L>?@S^4W|
<+>AVP%V4A O.S3^ZRW4S2^XKS^XUEA4LHM@1|Y28H^E: M/X< "P20|,WK5V|> = W/TU>O?GUM5> OY5|RYO7QF|>XC:FSR:73BIW|
MYNU/OT>OIGX 7+?_SXRIN??H37| K'GUL 7O_MIS= ^7?E_CQS|<|20GZ MU2IQ S;Y_2UW|>?7K J 7&7|LNA:E?<
Y7?7NQJQL>@|R*M^L14G<9N018L12 M3XDV7|&8C0E* E23S0/ 3^EYM8 DJ<^>%(Q#2G:"D:J110VWD%A^C#4&2 |\$
M|Y(FSV|D|A7R?>7|NXKMW| W|SXY?>E.(W|J|C6KACS2HQZ^VY1FK^?K|<7% M/&\$S,U.TG =9JDN R601& TH>D6|I#C9+?"
+=1\$G:A\$GN1U05X=2QT^>+ _C M<..08+#+O+S0&ZBYCGXZXWD|Z/-!@QT|JT>D6GOH^=":=@|J|"+EZ#KSBI M&=9PS\$*^ ^97?
WWW|G|AGUO^|QZN^&^77D|&1RU.YW<5. ^MK=^|MFU0UB71Y 3-ZR06ZU M,18_N7^@HO)RM6LAG^W"? N.+_P%A#1-SI-::U+<|
|J>D&3M6:3! MU|HIOAN0|JZMUQ\$1D4)YREV4R|C|U|?4G|J^EA.55QL^
MSHD<@60PKW0\$KA,"EL|L|R44J:2E1#H:B(D9_FFY)"KNJ3|"/O^8J:2*6S< M|^9:FHD-<(|HG/*Z2"S^J+ 5=F15.H44:31Y+W6Y+U:2SAJCB>XIT:-
<+D^8:C M3S3BV|P228AB|)0QSZIL^ #5J:P.8)Q?|P?6ILULYD|.A|C=&28P% 41P; M86P.
91|Q R|LW?>WC4(Z>N5&4^ 2.K)Q)WE9\$5DPI(RH* |S.).6|JSYN M# ^ZFL\$FO?S\$P=4&+ C AGO: ^BO= 204S(TLRKIBGLBI=\$ ^N2(C580 *|@
M\$ 45A|D?>L Q OR|I|W. M^P"| 2X.-YQDZ0.1RF3B5>6(-P+|KQ3HF?0:59)|ITA.F3X#;\$ _:"8PD& M8+<4L|/S:FQ5 "V^BBXQS|Z2Y|(?
TA@%17 _|G%OZ&4:ZZ<|E| (24 B M(G+Q#0MK)R@2G+>=ASE@:F^*TD^1\$AM|X3JRW# 2.:9^T#UX_L%PQ(P8F
M5|).G#FGWQTZ|U#.BU|IX^A#1 N^5Y&@/M<-2|N|)Q(BHP^5PFEB?2\$ M).-R *15K+Q3 -KOS5OXI:R\$>PD=8P.3NA^#F4*9\$94/ 4B+\$/:/*PO
9+|D MRL|MO^Z|TKW^M|U|I|O#<#ZEIF5#<|I0-S|A>G^|+04-"H|). 3G#1+N> MBP1B.^=TLDDK^V2@ |#FEV>3T1|A|(EGD>G^5AB6
^23.4E0V.#J.HL.Z6Q4 M7O=F#|V_N/^"EL|C|!|S2NV=|E@TYA#6484.1D5Y1L1(AM&57^|N3J M_K5WY4K+?3 Y&HT|J|>^*2BGHPY9P"29(./-
O*6\$+|M|/24|X/P6@G4YI MBO|_IBY34>G@G/;S.C3J^NZ(!: B3(E4>2|5C?848^8ZF=)^Y3L#<\$%G5| MIAUXO|G.X|G6|SQ|> ?
9IO9NY|&| ^#1.9^WIR^VD|J|?^QRT713S02 :V M1+C@.2XRXE/7 3 &|O^R50_N-5LN5TCT?WL?%U\$| M9>689;6|>|>@>6
M@5M=PK?;U:KHS=EF?>4CD>MWU^C:OEW| A|U|UOEQ_Z>X'DW^+=;USH)? M|_+^?>(R)=+^#8G^L P#=#1\$NY@U7YT-OG|IVDQV3W3#.
|ZHUW56W+U|<# M3BZ6/^S|)3C^< Q.-W7N,4T^5YHOG|CS2?05|N DE^<A^>S=P7 |2|G24V M_Y|P2&G^M,9R#3PLP.OV MN^|NO5S
22XG^63A|^|SNG^YF0|%AK|WY9|78^GJK#T/2A^L|T+U6|J|L>7|K|J|YUSP JM9WA5Y9EMOBBP^|L&G; M><0:PCM8P5F>+S|J=7|.?<
H9W07BW?FYPM(%S_6C3W^=W#) 9: O%|B.87| M>ONPLBK4&PA) |U=S=9Q5L'6/D)?@W^PS7B-G1PJ00_(W^Z=8% YH-"R>I
MX:"DEXM,QUA&8&|(PT7+L^17M.Z.9\$US^P2.R^J&K^2XXV|ROA:MS:UWD@B.W MU|U+1:OZ.S3#=#S1W|W^O:N913Q|L?2K9:DO?@|JK@C%X-
L@1M1M?PP05?> MN\$H H^H^67RZ|=9\$ULZ.K|L\$MIO/XWT_>+S:"Y5;34|4W|RI^|):3 ^OB70U-Y2K+5@N: Y_M0/SW&V-OCG2OI=AI3N8NSZQM=
M^R\$S D?/<6G^4.AA9YR0QF>.C>F@B>32\$EJE3D2NG>>"H^ALD.9LY299^G M23^0.:D3L592PKD|@P4DS#|SI63L^N:1QY.QPR ^J\$W0?UFJ|A\$S
2#)GR MRYUQU|&=<4R6W61_9:S+U:|I=0871X2K^B^1_&|53| MV<+|+O@CPQ^XACU|^NE6&YMYZ=75>N.P(DY)UAQ^0QGL2|TYT=16
M05GNJ?Y^V^I-U6Y@B@7)20X.|B|:1TRV^OZ(D25E^>OGD^*(RD21^<+^!D M4AD|T*-DE:FRH)|#^SZ|?79X."GM2O;Z^HXIG2V-
A|<M_NKL:MB7EYI G= M&H|I|@ M0U|L6Y=VLY|J|=;R640T^*^L|S \$S_ZK&GMPUWF^|I9V+R<2:F\$Q^ _J\$ M^1+>3W.Q+SC3.S/L%: N=
<<37D|D/AZ|J2 ^R>UW%G7^MG\$AS|I0X0+M F MGG=RK/O|ZD^LDD+3&: BX6^ _16E26&RPO\$ACC& |M.Y0|I%|IV=L\$>R@U.MYHDT6
X^XV G&3\$=UW^G^RU3LX2VV%K Z Z8: MP1A>HIN|.OYT9O. E|F^XRG(C^|Z|/K| 6|F2#8SIC Z7O-ATO1=GETN|Y(W)?@>^J|Y49|2^K-
^O983QS7=K^%:W|9@/^|P8*|T M9J|KO|BE Q4&E)0D2<8%VE;28I+K|F;#K %EE%1.DV(O5OQLM3^HCAD0:NMX M^WC8KNN4+BY>:>
|WUCLW+1%N%VS4 |#_/5@>C\$^N|J#KA22_CKAV+<^MW>| M9<%YA3G_\$BAH;K3<21/8PS6|<|OB2^|VQO>YO+AL PIW68Q0#
1Z/HQMR|'87'=#G+M1|U|JHGZXS^S!>PQ# M^KVM|LGZ0N14+5R-&I9W8R8:#.&W>5>1?)B|O|=KYVIC|L\$=|M;(&I2O2| MEK@Z^+^K29+
<^9OY7Z^R|96C\$81G^%C9|N:S22?7VQ|6U=ZE=+L^8-U MBB8=WULL^E,IE U_%%N|XCOWN8FF2V.EB4(M|A.W>K^1A.P>G_D;+ M"
|P<:/T^@#O\$1ZVW^81G#E|L.AN<%R|NFX33MH&QNKGLW|W|W|Q^V89_D"(M)^QDO/E|H>-<|>7ONJ^?@V#14D/TR+XVW@
&N&P&O|&L^VRN< MP8|L8N\$?>?>^" _L_W6H/QP6K^8^A|YV5WK0@|C _^1EM85WBQ^U>_U|I+ M7Z4FI=0|I|VHUNM
"%G\$56Z9ULL^W|D|S |_NV_D5?=@&^C4X-Y^UH+|G2V M9W:73;EJ_Z 99M@|I_-NBFFV|I.Y5S?<0|>3.Z-9W@D>NT^<K=4U|UM^=7R# "5
M8H)05|<^Y1(ON3ZAFZ?NTW:NL-|7#0)CC=*=|JB9\$+;31TON^AHK2O^5DZT M/A0T0/DKCU@KBB9^W1DWT6HSL<|S-B_I|_WC_RE^?/K|
E&^G.ZY+|; \$X ME 1.OS|O|S(O|G|O<|:IPN\$G:579504|V2NY L2@VZZ>=S|T?^<^X^L MB5A6|K+>Z>K=7B^T^V M)TU^+7U=OL^+_AT6|<+Y:
A;V2C>?G<|V 8V|KZ78 MEZFA?;H.N|H=BO_ZGC?SB+WF\$KE^7+<Q?PO4 M(W^RP^C;|/5;,>|DXXTU6+=O#9
M)N^"5%706%I/3U)9OU=)ZY|@4VTN7|_ ^ +&NZP-A>ONG V.#OWPS2>O@+N^G
MF16V87)&U1|2:FY|O _%GIMS6|V|K|9SIN7DMQ1|BDOEY:OEHM^|X-| 726 M2,2R6E>B(|_D=|7D|SD2?<
URWDR|NV%) *_J ADENF^)^53EQ>KV7S^1 \$1 M|JT31DWOYD^1E.M|J-B V<%9H^LVL|VJV6K\$+%6^LTY|3KEX) ?& _M)^V
M1D|B@.DOP.162Y=9W^L|Z#Q2H>6S*7.<<4R|TPQ.PB^U.C-B^N)XE/(2AE@>?/ITAD|APQ4AL2-(7_BY6QAI^|VE 6:X#_|I>X&+|6P|?|J34|
M7_GJD+>H7:|K|D) >?WS|SO=IX560|IUD_1.GV<_J|D|W.OK^%VUZ|_ ^O.M.D4LX8.R7G^EVT|@3^0 MZ.(?
(^7E#C0Z2SG^KA0B5#O^IQNW41R2|RUKE4. 02_|M|Q M5.;^WW7?>^7M2_|@ZV9M22LZY=,PP:P8|5&5W\$^KQ?L>O^O^* 2|8J4@>9
MP|B28.AZ+X5X4|)YM5NE7W&1#LLV^J@C?L=RM6; +*8|>|^Y7SN5NLB:G<4|M)WJFA|1-AQ&^6| 1|55GCMQPA^?<2-.(5MQ8.3+*6)<16@3V:
<5Q^C3|R U ME%0I^":V.IESUYK9|CF3M.22%(D^*_AKA>#A1.FI(|@M2JW-WL6>|T=F|TELO MPY4I#56E|ZFI_2DI\$^O>
L^"|J8J39S)HMZ^*KP.73|I^*92YS|9^Z7BG< M_8^15=ZLR12\$QV+|V7D^?^0A=:@4VMW|15BHM0A|H|93Z.)NG=WMU>^A MM4X;7(?
M|B1PUV^ZAI1B@OGR^1Z9.G^>Z3|300). %|T^X\$7LDH| O%|PT M9RG2M|X|:X5W|BYNHGNIQV:4|6|5&+IHG(T^W?GE92P(&9^5M-N^YI
M0^BN=6Y\$^D|8OEK:V ^V6R7%9IL/BXGV(PU+ VJ=7Q|@+N6YQB^S|I1DSP^T M<>Z^94@E6.&TF%|W|^NA+&6A+D2P>4S6Q\$=NB^
(JQ4G.^*3|PE|S/H68 _JLR|^P+4K^?2ZDPA_4B K|H^MMO+|O?C@Z^6|T|:1^6NM-WL^TW5 +R4 |U=1 EK(SY|:MH^@KTYPR:3)&V
M9B=EV^1ZT+U.L_FCBKEH:2^40Q^T T \$F^P^#8Y|Q:5EML?ZEDS.^BQ3DCQV MN^C@B4U. K^E:A9|QZ^L0TG89Q6GR|K2? 2L1|J|?
>17D\$6FS3N^ZQ^L|L MM;2N\$VK G:C&62Q9G2^VD|@MU377Z|P|_ 8^96|E& W^70S|YJ9A-XY1PAA@ M:W@7B:-
"50G#_E;!=UEO^M^|2=WS<7#039| BP4|!%8:E:XR0|MOZQ|? MQ&6L\$9|0^N+^OQ_2T?<8;Y&68^|JP?D_IG58S13?F(
M2A^4|709|X\$_.O^>D8H^|7C|.P513V0\$1GN:HO+D&K;B.Q>?&=<N86 M+|^E(BAU6@|(SOQF9|URI:PE=OEQ,3G^>IM^|.#
TS6:BSB|&^|JR|^E-#BY ME0Z@|:RU00A@6&|V^TD:AG^_Z^TB&(R?TW^Q>PC.IG^R|@:IAM|G;+>+G|W
M;BW=+G07^8#M7:Q14>XT6N\$W|TG|LTV)-7VEQ8N|U)X\$?2PZ16KV H>;3?K M^?P?A?S;G2_IVFV|U;|"Q2G+>0>V&?
3A@|@53@("BTC|W4M|^":W2EV<45=) MK)=S-.5<7=RS6=^YGFPO|I#5V\$GE^NBH1OG\$7C>CGDLB0M^2:092|N^X|>S|V;59;>_709C00
^%T|V9A8 MZ^+OGC5FN9|H6T|I>3F+5 \$6#%V AW&QV=U(LS^?>^AE^W)5G^\$C^<3Y :A=|I=42&6^HL|/EXEW|5CSEY5M717S;_<
|JU+Q|H1 ML%U@|E6UL 7|AC|K=PAHS3^J_ |V|^VY^G\$5V>N|ZW^@9=4E@0|E|?|&M. MUUEY9^1&0:B12<@I.H^\$B<4
5|Q7K46U|OG6%|/!#S MEH^&R0C|5S. MM:Z|I(S:P6G)8NZ7W|MJD|I?^S00^ R^U+=+CTCQ|JM;|:1E^OUO M9|^>7|W|H|V@^ M|UO(|3?
ESY2|9+QLT Q|V CMQ4 ME@>L^2A0+Z8-RMQLJ|X^=Y|Z2.7Y%MOVT:PCZ>@:I2.B EYVQTS|AWHYPLW MBU=|0|3@V@|I8^5#6Z02N|J
M=|6T66T#^GHV|VIE>|%<=WEAL|PU6U@N+YVQ>:G@G>4M?5+;TVS ^!+>3TVX^Q ?^Z9O|JBM5IL^OV6:PU.U5G _="QXWV/UWF^&:/A
M6<+>9\$>^N72+1|S#? 9MBZ|D|NR_H6^|6C67<9<|XNT8|X|S0^87RZ;3M1-^8F|W:D51C|^1 B_9G: MX\$MCRM;+T-
YXYENLBQ|BIWC_|82@>6+AW&S^E?M\$5/OQ7P|UWA^TLU|L M|D46#^|S^PH2VZ|I5Q4.@N5.8^|&T;T.D;|B.FY6>:AB M6 :BOG
CTK|N@ZMY M2\$ (8KY.FP6?0(8\$CR9Y60.1 4XYT:S|ZGD^=Z^L|S|Z_2TK&2GZF@^)|I= M+KWM F010.M0N^NWB|O05R.\$P/@Z5&FWJ-
^:1N^230V-CZ09|EN- ^B.M MM^&|JR?>A>=ZUV\$IRU=V L9>A>S K^8K%="7S6^O?PIAKR|TV1WGTMV_1 M=6 BB66#
M.H^|L|:2|IRHV_*|J?>98?XMM|SWX|>C^|LZ|2IL.#Z|SZ|Y|>=PM.VM MMOC^B|UKP|T^G^E^7|Z|T|B|X^TVM|BH+^)|<#
.0U^*10%"X79"=TVL M<55:.*>?^|TZSH|:(51C-U82?X|7^E^: (PBZ U/\$5U4G|<9|TDC.KM AC#^EC^P.FWFMCYO@|@1@>5N^5KJA8R_6KF:
Z3IG_FV5<E|<RKDF L1?1 M#+&ASZ1<96D9J7^X^7B^B1@|J|&FQ|+GE-E^|I&SHIEY+4D^*H(9^R_8 #SC
M5%#DVC458SWNW\$S|_F=F(^#U7D@U0^"\$ 4D3\$+> F|I|N^P^ ^V;@60;L M|^"%WZ|^F4):F^@T ZONZ\$FNHH|LV5|
3R2X7@VN.EM|P;=OWP|FMKA^4 MZ+^NTRM^==W5#1Y+>="BC8|53T("K|I|RIQN5CTV%|U>W|>CC6W+2E0 M:W2YR8E?<
+NHFT56|3^HYL> _NUO=BSRVF+26E6134&J09DDHU=^=UN^W MZ_|M#J ?SUDX1=8)8Q^HF|WD59G.4=10EF4PQ^3M?
O|8@=F2>+>S|JH^JH^M;2D3:L42_H|P^M3-#^|6Z^Y0#W^3BN\$S^N2>6)Y4A@DDF. (8UKVN/ R^M^OL5P|J/F3|UO#K^A>^*|@K|L>U%<
<|JV:M^L^1|YKM@|R:L:GV?>1QW(KE^S1|U>9Y2(ZK7."Q78T=TV _A= DVF GF^UV=|O7 M@BOH|K+>=N.V)|H^?E|U=4Q^A?
3QOVL_6<|VVOE9H4QJ<252_9|^_M 6PU8Y8H|J|_*|J|P2|5U^&S|J|2D_2|TMWCT#:_ Q?ZAVAILACOB^|FE|E M^CQJ
F0^33VKP%\$^|LX&E.2O^E|OQK^V..=\$YS\$M(JD\$MB+YZ(FAT1% M>=>X|I52^O@TP.MZ%=ZL7L%6.<|<7 M^S2G5Y%5%KF(U.6^D|42LOBB?|I|V-
F05-ONGO.M.NY825|5 M12BUG+1#<N|LO:90&E:9Y0 &|+&+3^~0|9HS2 G5|>A2L150# S=I8^NU MTP?9&EGII^A6AE^"Y?
V".C^@4B^5TRDQ#?#& "D\$LW7R|M4ERY@96^OC?FH) MRD |^|/(=|11!%&X^K+T-65H9B>=6-9-U|<=|N18JG4X>|JQ+FP^|IB&
MAR9CQ@O|J^K\$^DV>?>^000:VDB4>04G>2|I|NTI^":<4;S^ MW^*|J>LU1WXI2FGA@TJD _#UZ\$G&8^V&6\$|9B@H#?^X\$S:|!+RU^P3(|>M^Z
M|Q&54^I)=38HJ^KN>E|>J?>KV9Q7|F.K^<N@5>|6S@Y1^R|E;+^>^#P?00O M@QYDS| DZE\$E^EQ5X12^=Q(|^";DP/3@M#3L-P|TU\$IZ-
L|LVVZ33Y4|FIZLID_V M7S: /J01?38R=|<1R8|)SQW>|L.%="AW&AP>36QV.LY2N)Q+^*3^6@DN:%6E
M^CMA2+>R^IQZ^B4XO|RCM\$M^&|>246)8RBO^H&W@V(G+E5M=U^E^I^>7^8U3 MLDX|I<_1^G7:7\$#4R?8X)82|OQV|I M=|J^6@YV->_CY44V:%
3U(CM^"XD^C\$^S|(|N_>A=|2HKK|^*W% B M.=+1B|I5EPE#-RUS^6MI^Q|J|MK%<5K0|^J^X19804:1:8F|2OBO>32|?M^
M|:%=G.S)^E^L^|J1#D>P;^EB^BM_-70Z#|I=O?1.#E-%TRC^GO M2.4E>^5P|I|W21\$&S.8%"RKQ^MA5+ CO&".0LQ0^J>^&|B0|_+O16ID09%G2(:
(DT^BOR M=:@5AVD157-:IWR1Q?2Z% O?S5K8Y\$ _J#Q^M+2SUD;@1NA# 3|/9@+^&I^P M^"M^78K%XS-
O5U^XWP11YX.6C3G5RX9C#4=#K&|L|^/=>C|UO^WITO^ZIV-7CJ2 M0^O^CI^*V0MR4+7|YKTK,F|I9="|:W@W9P#(I
G\$9&.)\$YF^2E=&B|YSG>|7%JGU M3|I|P|C|SF&C|O|H^Q.W@5>:O1A^NXT+^UV4Y1+K&@WV^/FLW.S@Z

MK*BO8B!/?<2P@/DH7IRPG#17B16 A62J8/(F9V9&)1W13M4 "TY#- ,M8G4,53DJSJ@!@UJE MH.1)3)@O :2CC J0/NK %5;2*2KF+XID0R/12=D9I\$99P'AR,QU:/ZH'G" M>M DF,V,DH)CS'6Y4G0ZP'3S@- ,6*5D@ 'Y'&TWE.=,D'&O%14S/0:9 :1X% M&%X"<IG:4&%S%T1D/Y4*(53F81J/M1/O63+EF4U)000U=.,0QE00W%I]*%IJ MNS+?(USO5?:[3IZ]/IWK8!# 'VOL.IWLONCPBG1=U ?LO&CZ+L'.9&JL.OH;M2PZ/C/<3Q08<3MRY^G16DLP.)JATVN'G+HN96\$S:N1^+D7/MBJN'=^O2^U.3 MT9:9XIV?US^,K2:306+=%IK6+W W=(Ts-.9G7^@F\$LM4V'>B><72/IB%>L)@7 (3U)IKG*TS-M>+RV/HV02GM/D03B2 M\$.3B,IA2.,"*Z.X8.0%GU&CUF*PO".PDU;J*AVBK3*8% "&MBRN=H"TVKH>MVG;DBJ+Z@-02BUB310AFICEHI@VILY'S>MP*MJ^IKM8KGP6Z,7LJYI'P9 M?UC+VW;K1\$)SI2-10V'2I&PUCZ@Y/=%>2DF95A'G'3V:Y133ZJ@3/P#->; KFFV&1 ML 5,7Q:FVG:R\$ XXWZJ7I0B&UTL0'SMM;=7?T&9+J3"1RR[MSKHQ66M90'FJ M.;MEKNRV?'&0#;IVTTE=.B(K @2='3,E#DEM&;PR4Z-.14I%F:IKJ9:F M8P1%1E^12GBNJ,Z54;W1-L='H^9<1.Q&XA|CCLJO+&M2N# 'I2,S+1RC1VJO M1Q2ML3JE BM@C+*F4I4;S8N#G.)ZO,TNM85\$;NNJK-L.T)*8\$#E6?GKBN&5\$TBIE M*'[86M'TJ1 MOGYR'22/NQ4KZ% ^OS"8Y _D4D2PQTL@ -Y MON1' OYYWGS+>?S(/>DFGRV2;7CM^LX@&1?EJBS\$B9.?M0^,GG:DI/C&;? M.@4P=3'7A&I'CK#X2.;LA-1VUW&;# ,UJR(OF*0GW\$F<6B1';KB<^TED>2< J=J|JJKOK,5K*(OFJBLD,D1^*^C0^+&6U51056\$USO'N#YW^2Z/JU,|C| _=, +& MORPZT9J3=1=6FH'12QSR03B HX%N3G;0GR J=J|J|JBLSMTEI\$R&N\$*J M|J) (S Q%*MB+6&\$6' CQ5E5+/"R)Q?>QYI;|D2DD^-&51.ZC92-6WB M_HM)^C.M.O(R#S>C&A*F+8OGX;IMA0 MFIB@GA.1*(B 0KXY 9%;6CBXE6TD57XUJDDTG@-MBK\$|B3@J2%/J2- 2U.'M.32(8DWH&@DU1\$8D)E226JK'W5.O1K+^+^H0T|CSA: M=?MH2JD1BFN2T6MPH-O:BIXO-ZT'4%V!I2\$:.09+&E8"NL7W .3&K<5H+LR2& MY|BWYM@H@QZ0,5J5 :>.-+&X-OT9 0*AA&H5RGPGWRICBQI2>09U'M'BSB@R MY/FM2Q1>U"/JBE0Z'C _G9EJ BR7#8T"1L0OK/<5S1*LS|XJC3\$N+ "Z:6U MIL,SE%+;JL2 KE@BT0.EIF0)XOJC(Y)5Y /WM6G6N8J(K+J+J5.\$NPN515H Y MPSLH UL:K+=@|TJ\$JHJ4CEVP*;>M+J|V?I:09:6SN' \$Z0^ZY@-I7JUK"V.%-IN MS1%K=2H/W"0OYWZUG%5LP,J5SF+Y-OER%ZIR/>B9732<6;OHO+ZKZW#^ M+OJP":936%2A;NM,3V8 EZF4>U&D6M6QE(U%SJ<3K4K FIVXR\$#|+3J%>Y& M0-.50MS&\$S _[G=\$+07U2-1FROMRH|T"E=(F6^W+&?< O:B:P/<#7 MFZ\$V.XYI C10F1-*Z>|J|B1>QGIN6 KR8810&9|BWRSV<-|YT-L|QX>|8'. MDA:B"BJTP<#\$.0<6I9?>P2WOFU.92GJF*UUXY&TJY.HD999"">?D*#&@.U'#Z@&BNJ*=&AFAZ?4UW MT7.WUTC.6D<.&? FT#|ZN>|18W=I^YX|@/(Q=7 M^X8FVW5IQ|U:9=U;ZZ#N'#=THP-2,6J6JS P).U0V3)NL 7 MZ="EE\$J&8Y4KDC1 D?2(IXDEP@R-7L54&7&\$=-N4CJ.Z#1>SH)I|=+V<3@1 M^;BS>LRMW95ZUXM;9IYKYZ>ZS>D#% MH=2%K3NQY+I28 _=QRSJTAUS|782W|R?X\$X;|Z+K.+ (5;6)M<+&L3 K.;9 M5UM9I|=>9PK*1LZ(3 8@4RM#K"EC6*3.UIKJ2&N<30HA.IS0|H<.-Z<0TN@RC.S.XDD= VGI15#. M5IOMNUH|Q+L;|RSWLMSVF!M4+J|A#&Q'F?>#?F|G|T9N|J|,^IA;RVOG M^SHV|L|6=4P'N|AGDBG4.2.^>OB.#>7VJFMLJ+JO-&H| _BT:70"0C.\$8* MCC6|MY1|KNLV^-M2> _=(.Y|N>|JMEF7Z9^PHS;|DRUYVJN9+RS% MG:TW.QC\$?;8"MI9LEFYHK#;4EIT27\$O|SIW' M|A\$X79>YID.KW5=|5;"|JZP0/Q/TWC;7=7T^\$=S1;8WXI|^|;#WBTV-4?-IA'M^+>X3>U=U2Q8E=PD|M^Q M ZI8|X5GH\$SJM@F:QA7 :|LO8L2|=AK|ZIDJ?Z5I'Y|EQHVJW|%;*FYL+QJ1U>?LJX#N-IF8^0ZFE3U^?>XNTKN2M48Y M:00H.Y.5? C;JXQ^|L|:@9S;J+6609/|^ (I5#%#Z/MO|K+LG|O3 K6@Q|BJP#3-SM+FB28M-.30|KU|FK@+9 MCD9C(%M|XBN5"1.6|2BDH+PWYU9ZY ZEC##9'1>&?D39@+I-R3#&RUTU M%><#DO&^&?D8="EP"%QLT122^4 ^R|S%CLD2 M7<-^7FEWJ? VYTOMW4|KA3JA:SYSK'# 9%!=NE## (STC)'8T2|2>.YOU= (M%"WFE") BM0G-WI@P%Q'J7Q'T8MMJ>3J8F3Y0>.,|I>1603>G'2G\$.6FFN\$S,6&R%098M|(IHY%RG| M:7.O+2|&0ZN*D8I3B@S) ??)4*9RSS*H6J1T Z8 _Z2BYO(IW"5 \$Z'2GJ MN(MOJR\$*=5WQ7P/HM4+8@"L&6Y?S62PA2N F)="U? L2XFWO&26PRRO54> H M8RIZ=4- O1=|^ZWI9E6'0XKM4 2I%L2090EQO.Q^2>G&9*N+L1F0@#Z&L:4 M20\$O.;|B7D _M,K.K&30V2=.3\$@? F"|"P+&U|>CLPZ\$X\$ W51>6&2UR+LNL M@>VZCQ Y5VR\$X2BI'W\$|J 7YXN+>?U@M>QJUUX99LZR)HE'4J^+UD _U4L10AS" M.(. [* _+|/K|KDIZ|JOGE(OYGG:|^56>L3X1)=I^EDIV."|9W+R.T. MRS. D7|Z@>G>.|I;+*=- +L?F;|)MB,D,E"+TGSZX:>7.2.*7KR+|P)?R M>N39Q2|/F=8@M.FF-U&<2B^D+Z^O M45|FDWXYOZ4D^O^E0|3S.V.FBNC+&4J\$Y55CP(C.O+<7;IRU6V6Q=? M6\$E4I5Q-\$<0V);J)?65"2%Y#2WE6I2WFG.U%ZPRF\$O/I|5 _1.5=U D2> MZDQ'Q'79%-%;|J71(+&-+N/HOL6I99WR6+1^|J#M|F&A1:EN?5?88J;|F4 M?1VLV9F")BGNU#;D94+EI\$CL1=:(SF=|8)H'T;L\$|O|C| 0J\$O33FWD FI MQG|XP\$ (9Y.|@:9XJ 9M|3.4XPR&T&DC8HXO;#-88\$K2+;W\$|J%(-\$YYQ720N4I)FISB@::24#HJV|I.863*6LW47?^L=3|^X.T|M8B*W00+^68\$&@) /PK*8(3DXO;9 # 4FVU8L^|I8)S\$(-<5 M|I3 60A+6U.F.9=NAOR)QE S7YMIJTG^TVG1NLX4MY 8-IWBUS(6&9%#=# MWR@HL<9|>U@-BN5@E4J _K\$FJ|>)=1.91)75BNN^ M97T7;#C@JD-FP:L2U1U|3|3.ZPI\$SN=4).G2K+&MZLO/N|I|>5X2KK'889 MBFF=4.C.U.'&|^2@P@3:4LEP1PZ|@%|=...F9J?UX0H53.DP.8#&C.I W M"@QH:0@#|VC.^^ '< M=2A-2UW|I4|ZX=%E|8|P>N'9=I^O .W/R: ^VR&L B%WAKSK5FK98?(6* MU\$UJEPV=@9!;J _9.E4PSKVPQ:ZVU1V6? XYWYYP25J&U5D6|>I@UEON;5J=JREXX%#2^>XNWQ,U7M^-N97M. M0<3E6J |TWP|H+MZJ>^6|>^ I_529P'T15|V0B3|06M;W9\$WQ(FENN.O:@ M.7;PFL8@UH2N;EX?QC-UV'Q%I-EQIGRIU Y4=MLV#.^|I(N M&#=(S2JG.WSB5;? =8+UKE6@'9^Y6&7=KN=YY4W4NMZU.*N*^+>EHT2WNOT M.S0W?LWM-=U|IQL7NIO>X.|IQQ:>QJ9|MTTJ|<^"UB5>^*8HR:D>4H-! _L M@L:95V|MB=4"? H1>=K9"XOZ2CR9BG-LPS|0" M9%\$+&@.14F=BE74D M20B4@ASD^K/R=# ODV9-..A9|HPXIOB1' :HW\$5;+3^I3 _I |PQ<|N#&-L M.(9/^W6;8ESIM>.GRG#@ H6D#N U-3-O+>+O*#;NS# 7A6NS8>O&>W3P4.C7XSKLUV#N@/%KK;L=YT-DDBQ;K3|<>ZR M)UD+|T")8ECE2<|>>&BCU;GU/-X\$|OMI")9)O"0?QA5=\$O9|=DMDG;<<9 M|+T9!%|JBNGVU6L'AMXSR3\$=4?>N,E^Z16VI@|!O&T**6X 90#;U Q|N|L MQ.LJ^AN:TNYRY2?^S94>\$D>>459V.56.L2")UJ30:IRJ#?SLTTIN+UGV. MY2MDPVXN| \$I&"+4"IR96A&K ? ED9CA)-2M"8ZJT2&#PU|)9H47D0DB LU\$ MFDRA4RJ|O"QD\$5":N|+NG7(I U/."9M4L.V+>Q-D)YR' ^HW3V2.>*H ^X6A M1|FJZ\$*TL38B 69 MRKE8"7#I'E"(RQ4Q.KAS1X-O&K0.O.L<=Q|M@H)H:5V&|0|F E32(4(PHGBR1 M/@KB<9*1|I"4,<=8*? U@8C^F'CZ15@TNB0Y4I9.*S/M.'>S)7>3(6M0B 7%FA@Z(+2JOFFG=MQ,S\$25(<C'.44\$K;Z7 MNIM?WL JS/&Z3^7;BX;@8YE)EBI)O><-; 8;J|IFJOR.O+=+ITTM9K6F(MP6|&SL\$|S=8-^ ^C09G ;EBR:Q\$ _>FPOJ9YOOQGL4GTU5IW4.R)D_5 MF4W17JW(N88|LQBM|6@T>^SVV4TW+Q(A53"/>U22VV4527EJN>Z2D|RF>#&I^VC#\$4WEBYTVZ8XW2)JL&%&FS0^FBI^7 #? BHB>C. QO'R|L%#&J?9\$?|D|)\$J M)^M2T116WFM. S7*TK|G:Q'V=KE-7MJN:01B|@PD.*O M=6)| 18N^L|<\$VG=7 7<+&- :MNH\$GC.%|N:OL4 _6^ULG2J3G-4":2L MZ:2|J|F\$R(SB)?FUIE?%MC|CSKHU|E|L.HMOJF%WO@@"S'I|H:|0W|JXUBB M0EGUH;A&"SCMT46|ZG1| OG\$SRS|&QJ:76 VU9=Y<#&5QI&STX|P-| 7R M8M.; D%:@.X|G7|FRNXU) ^?7Q.HUNF5"S6^Z)&?|+ .4Q+&- "KX&V:8 M5|4M4K1U#|5.XJFM=0.M|L3XB)Z?F5^I=57;|W.-HMBCV# ZC:6ZS90/? M%|I=6.Y.POG8H|@|0G5 _&E#1W6"RN#66\$Z|PQ:?"FH<>|A(I(WJD+2|IZO MDU.4|(TE@09*)+Y&^T2B29P&D#G;Q'R>+|^+6^F."Z RYI"+V%|E;J MU@ 6/Q;J _>=KAGIJSXG?<2R;& IP &T8;G6M;#<#74J|3H| 16V" I O@Z:4I^3H|O;I|^&N|I-3SHZUS S&^>R9AP=UFB/YVE.@|IHN:|0| MR=?T2|I|VQ'F^10^U ;Z4UR|YVAV)UZXC4KME5.&S@A^EL&(IUI9?7U7YCWM M^3M8| (=F>FW2OZI2YH:2R'B6;WJ/7^&.1A=#6P2O0C8%*(K"P>+M'F=99X MAM0BLN^O..Z2:L4Q?XYRT6L+7.< >W32>"T8&QA'0& M6U3|(+*M=F=81|VF9I|J |V^S _=X%&793I^OK-IF|UBL"MI9?7R3X>.-16H MQ=GD|^..40YN>7KC4.;X|I#F=77.R(I)DQ _JB=X|%-K)1(VF29#0>_ M6.YGX1*+O&(\$OYVKLR|I)&6X% 5*W%>QE|O)N2+*"|SW>_VAV%/NO.8|4.< M.XXJW?45ZF!4\$XMRIV%F|X8&9BHI:I#&G9O.B.22\$<>#)(OY:W5E-|C#| M;&?<-SIR|9:"TG?<10=| _/K51ZB%G^>AC 07M:C1R2P(2.B|3&6KG|5-QV M46 (>GQ?2;GN.^7V|<#>|LQ|66R#C.^7^ICC3^Y.+3<1Y2Q3D?&=.%X) ^E8@Q D=3:FJYM=S; Y*- MSQ: ^E|MU> _|M.;5*^K &H4@ON>O|HRKC9N-JG>XBNXN:ELFZ^C ^2ZU2S|M|26VT,+"=%2A/FS20? 0P|I9|Z2|TJ|88\$AA7:8CF0NC>#&|B7Y=|N>PBB;W M^6|+4.RCFZN8S4T|@MWWHMR@MUV6(O^I,WLM)&8I5FWHI|^XPW774"&M6L%\$-M0D2I1^&+3C _|E|T|^&D21-^O^"ECN|EFZ5F4(5IY9.V;|/HT:Y64EE+U MV'P:BS%+HI4\$V1FJG |ZP&0%"FO.BDIE%|FG2U1|I" (<^|=NVOY=OG|L; ML&8WGVK+XNZ U54 _U7 ^OLN>Q^I/4XSCUN7U9*7793Q;1DO;)|YG,IN^RD|H| UFM@98Q-SWF?L1N%X? M3NMK|IX+%|58;Y3U6.YWB?R^NN.R>D|UYD|7VIX*GG6K|E|PW=AGO _FMK? MB67|Z.T+RWSAQ/+7P|X|3A| _ZRWB'T|CJGL9NL|CGK _PZ&H^*B*.57 MK1;N4*ZCA^|K;-(^8.U|LMCL8|; M3*59+MD6YEF7FHB0;EWLX6XS0;A M'EQQM*^|V|U;589|A 6NOOYL9|KO|TA;W-|SJ| D1W+7 _#@<+?OB.<^Y6IVD|R3ILZ|6 M)^&|J5YJ _J1K|^T(698>G=SO..AN'/1?T :UN0|=U"ULJYIGQ:O5+U45 M8<=G65MY.Q2&RM|F16E5+^IAR DE.2\$|J022^NEIY;MW:=T2|7^AJQF:6L5 M.1T":24&9<170U5^OCK8|F|8Z;GN@XJ..@+2I|52I8|=.'G&|R? 9&G8SJ M.(WML+&WUBA&|X%WG;DV=?MO4^N:YA."E|S)=[5>LE0(&0|I|GAL-E3| _MG":L\$ _|B |4|S|Q;I?Y9?Q|3M|U|98|A|G\$|ZOM5|G#=#MSL*W\$7^KO+IKP8 M**QV|&P56^1V9>|Y4|^7.OE3K|6>:#77WEY8S< _UU#@&WAP2|IB9OQ:QW-VS B|H178K5^C6 M#+P%*WD,|B#E#44<X|L" D918E.-G5|I(6NN+&Q)(ND|N272L-WB.#(TEAB M)% (I:E=B@KL=\$|R|,6\$>|EV@.8|LG2#\$V37=ORI,JXV|/6VXI _B::; MIO MZ|I;Z?A)F&PR7#6@L+ IP|, @7AD191(D8\$|43I'&RC5^66-9QY;+V*6"SK M- "M1R|Q\$CY3|^438:TSXK^5-J|M0|Y7@TJ3I|^&?&|J=G<#&Q7FUR.817QI? M=GC8Z@/MM.*G 182J- >6HT@LY+A&^&OCT|I^X%&F5U@FV7:WP|LXS2;MLEIR MXDO>UFA0Q2Z4XS?;J51JEO"SDSKSUD;TMNBM<#W.>B5.TXF|I;|^J^ MU019\$Q2(9J0I=R@("1V-|(<4.1D2EJ)%5L&5'-1AW5P#|9Q(V?M.. MC\$KPE(>#SR!2AN^OHV^Y>ESEP|IU)KLX=8=|J3|03E| _A T7>^FL\$2>Y\$W M). ^YEHA2E^P6GL;|J#|9P#|EXHN|58|;XF6QVL|DD+&*I75B|Q)OAMT M^A76QOT9=-.00<=&.NDL\$CU^K!+ |9CC(XQ.L;H&*KPGI&CW;N<=&BYLSOD29"G M\$|D=8W2.T3%&9|IWI _J;7I9-|MPP0AABY.TSZZ?H3^R 1Z|ZX^VO&I M.OHZ9FX2.W?IKOM(? YV-0>|IAJ^>3JDI|ZX^VO^&G|G3.W#\$2Y99V|^M^WGT+&?&#L<|^8^5:\$5J|5'5FWL>B IP>#GZ XB=POQ|L<86-TOKCNZ%)9IEZ? #+IM>".J|E:TVX;|U7^3*RM|UIAF@YVY^\$MK M..WJ-&=AC1V|N-J-VYW/"G&W39H^H^N"A(F<%4^208@QZ@DEF|W2Z% MIP3(K|JMN|JS2? +JUX V%G%&LI9D+?)ZXZ(TZG NK89^=&EPI;3@XD93'22F M,0\$9|)%PX|S^ 6-"BA"5(KH-W7L_U=@P 4/@6P\$9EZ&.N.A)>*L)V1|&1@ M2+|SEC6I|VID<43" +IACKP1WD3&.\$W8R3QPDH33^M/0\$81\$T\$51\$D|Q.X&C.JNG2ZUNE+W|I8H|@UUJM MWPY+RX. (D7XWCNX|A@>*^@F|AFU4@Z|^LP83AQ_?@ZS9356 _J1|^+ M7|I@ 6X2V|<XE|_9)*E71|I(|I(=%(.XX2 M2@9KQVC(P9090|YAO M3&IVZ63ZX|FX^M|JZ V^DTR^S08-1|/*?)<(W:MF@T=Z@SE;H;4|ER M%2;A^C|J>.-0M=P@|DH+76DDN6P:4V|ZOIV*? LLX:Z#|SYI|G#&@>|>V3F MF%AB.NZ2YPY|Y3#B(4EOHP1#6&DHB7;|Z|WY8=WME.#NCOE?XKGM#>#S|I#(MS\$3VS^H- EUD9E|& #9'09|6AS1I|>YVO..TO;^^^K2.H|IC75)O?I>S8 M=>?PMU-QGDS%T2PH9EU\$S\$H|PJE1R G)D.\$QZ1'-2|JW3.4YI-3J#7^'A M|@FPVB|!+>ZP?27ZE36Q^6N=O>Q80I3H24 L|L@XSQ+7GR\$P^D\$U<"P# M-CYL%41OC2D=#0=U _C.M|I2|<Z%|Q-%R8@-YV3KX|9303|E=JXO*\$YGD M^BF<C(N08\$|2K1#3*TE(M4W;|PA^&CPB?XGU>M(NRL8VA7G;:#)74W-|5A< M1? QQ\$7W^93RL/NXB|U|T1D43RH0K7%8X|11PL2#0"0:F2 QTIB'(*2OPMLV M>&7J9|@ _|OBA&GP_Q1|C?>4Y1??" L:2G=&10;Q\$A|U|68|J236@|JECNFSW:C5|U8Y.E^E:7>Q|CX=N&SINZ.C@16Y#516Z@2A9 MO+>+NGA9R R.KXF5;MY@+&+ A|JHJ53<0>8&T|P1&E|D3Q@|0CFN5I.O.FP50S<8# M8Y0^15R3+C#V%GY^*W|WP-MLON-CISP|^_DB#&4/6|X8B|Y|Q|)RECRK| M_H?CP7)%@6.- 17W:"H#BYW^TC6|+|X..1%J5"BSB\$>.+!VU|ZQO'6(&OC> MM"+XUOG>X|??=&I.WR@VEFIS|RKNN(3*8=8I=I|AUW=??7T'1|VW-IQOV=====5 MUE7SC+)|.(&|(1UIFZ|E@&BSW|TC&O6"|AXR^6U9=8CD<17V5&@N^?VL' MRH9;|IC0X>7G?0:0I=|(IC3X3H=KM/A.AVNXX:N MZ+NC|X"PPX.^&S|J3C.EGL^4BBY0|W+UHM\$43"EBD0XX^C.QYM8;+5&IGG. M\$H.UXNA;S12EM5|8\$|5YE2>#L|VO_CW|L-R? #0<_W>\$E|6A@.@+&1.G|HW?HWD0\$FSH:T-6; V\$XE|7BD@_Q7' /+ MOCW\$3=C6V\$S=AJZW|W6'-&2CGO|NDXO>NWO-


```

XSSGMRAY>CMSWLVJWJW+Q# M@U VPV2408>YY<6@-XC%.2SEK"SB(2PHH?Y7G5EJ008P670-<ZANM6>4CN ML:8GF"Z.%0X[
(:MYO)Q(ORR)D4"=62.G-TZ50WJTY=#4KO#P@I/XD5XQSJ(K+J)B^T6 [JWOBLL,7WZP[MBJ2*
M8,>Q2+8W*KIE44#%,VDL>=9 [J&WDS1:257"J@.8Y31%IYRPB1=K9+=, M-68%;Y^K_EZJSI^@/^\>|8N#3T_3WT?M,M8@UIHO[X2,:#?
SU4ASGBS26 M>XXD1YB8&'40DQNT" E*CM MIC36+2*R#G/W/608,2R4#HAPPP%+49:4XPB95%#8UB0+23Q5N OW^>D1:RQ
MOT36JT,J.GDX:I^0CDHA+IA"CG&+&B3/&@K-L-:4M)5#10Q#W+=B2(V>T M0M%*"PSA&.&|<=K^+
(9)/OZGU8=:55G/I/!=74:3) JSTVR>G<(:?NW# MA6^*=,SD7,D1I-I05!O,(C'I UIPZ?-LBV1YW,46*NP@+ AE>W44Q227 M3(Z'17"
(G_0SE,8K2NU: R>"QC?915SR>@ALB2BS5UE31'P)=19FI|,1B+6 M!OFACT&D") (<OPYIB.*(2JL+8N%|:|% N0ZJ MWR@#%IQ&QS_17KZD)O,F^I)"
|JL#Z*HFCZDOLHL0WE<#)-ZGY7XY@OQ_ ON"SUK:11G?EO"CD#> MS+;B0B8UI8WK+P?UDOU+M8X^++R?HWEL-
|+JZ+Q+X(NCK*%G)MMH7S, M%LI?W>B7?U>R4C8505 :SE6Q^ZUMZ+;K&#HHZZ(L:5.+7@.4W74X=H=5*:J|
M_%+O^"OX97.R03+DGZY1R(6H MUHVSVG""JUL>="35OZUHS2U:I-IR/|2/68<:(RAB01/7BB/M:~X"59'MJ(R-
C7AX2)AC00WB5D3$#4I/(<"90T%:D1""DWAL"(Z&E'YOK=-:YGP+= M5HWO2Z_1$Z51C$404T.L0T4.#WV/=&=O(5MWW !HG?
>56MK=Y6B39>|H# M5AKNI#~2W/=<0%PCESQO/C")JDU+*1KHQW?DA*7^KA%|FXD Q(=3'OX^++R4 MU' Q6M8^8Z&OE+AX,
|>+8=#CX3>|Y4+Q"A^4"(E/ / M%G3(1($XDG(IUDE,I,J)|P8.LGTE.QS3I.MLP&#YVW%&|:(E5S'FT|+,*H_ )H2_UM&U3|+;M<,<^13%?NUE10|#:9^OK
M9W:57SJEN|/"#<078V&@/&)/ L+>:-"B@T*.1X@"UM1XRYVD|5.ZGOX+Q:XQ M'19V?N|-|M^WK=>B<-07/9B_TX-
E#N|TS(Z@3_1J1O&J53@0#):@D2Q<"D M^<+&@UIX(CX@IJ5NK2J,X^"JBYK:RI25EGKO#JW.W4%@IX'K(= 00P(HT4@E
MYI/2#KK4<&4:~"ABIOA36UNC<00"1ZJJIUQOL3.JL:P_+B+Y+O4CS10Z(UB16>YIGAR/G@7>N5%
MWUZ^S7I|=V%#GA^QD,7>JU<-73J#Z8L.WM@I54$?/N8EA6DU+>CF*V3K % MQ5K7>8+|CZ>FRGLDOB||=96DW<^N.= M^=I)8QMJI-I?
SRX|@ZH|K"JXM8YO@Y=I, G=I64X+HA>|>4:>UOY6I+A MW@TR:34U1P190->'ST_OCI?YI^+X2? E_|.7@I/|X#Z%N1.S:O&(WV&C#
M:WUT?/KQI#@I+OXX.OCCP^IOPIP/$M M2I9B|RZ">NT&R'0_ |OJ&NZ->B+|=CRY:N2_ "8.|3L19I|0!> M<7EY9Z_N1_>+I1.06MCL#F4QR:&5?
|&M8|7Y/M47X|?2GX2ZZ=QH=2KW7A&6 M2-U|J+3*3KJZ@|I-XS:U7L'MKA9>#QC.6V?|62|~|J@KOVN^#Y8T<3 Q^J'K ML:XN-U>
8>:JVO487/L0""O|,RM7GD&GJC+91"8 MKG7>|I"(U7#>Q3M>1?A.LAOIX5Z?MLT@57_ 41UD&6?GEL^ &JZEL.% M JOE.XI/I+BYR@4JJ=X1-
K.O4O599": 6J7Z9UB2MFAH6|P?|P?FU-JW MJH/P_YO.OY2K=VWZ$J,(I!OUWLO&CI-W=: LK5.@H7|JF1P(4.MO:V5Y
M|_7L|E|3_1K4UBM7+&4O1+3+|S|9L9|N| NM|~(NK)2R3_ B*QPR6#VCZLEF2J_|&#SQW_|>2|~LYM9-LT)|USW=
M=*S#=#0F|4E>#13#T<9D10$@W:0$K(B8.25LQPAI%J5/|~F|+;7H*W/7.3 M^|0U$#@AQ-35=(WIDWN+TCDJ*34-90P0A2|_?_&
"3X8A5U5DT?>*&L=M.CUCUDHHA^ZW2?>X5F1_U|@U:3:2%R@>|ZDCR@8RQ_ D$/:IR_9K0U!-#=> M-@:ZM(C:X'A)
9NVTVA7M>*Z3J?MD^ (63+VJEEQO338:TS25Y0VQ(WV^M7 M35$AIS V3^+&HVA+& W%O^H^|"(^<7&2B@V>V5K7S)8+ .VX")77GE|:7*"I
MCH>YHWU_X=)K|I/O&?D^R77%IE+:T5W'S:<562$6*H4BCX7G1NLD(GO->N8DH@3H**JL-R'DN@>=>#PIC)/_KD.I^2 M%|T.H-&2D#L_1Z0-9+
/U&|&+&$Q_|.89|1>4C1V?HLOBVP.MBWK2,KR:V/ M+B3D*RCW#B/+HD#6%"BFE"XGZIFY|2$@A4J|<|BENJ_/Y#T$"/0@3|&OE>OFBR
MA4KO9+57V/A9%Y_K+7:#J39MEI9BN|N|,2E6>OVP?27+7FKOY:(PU8|@J% M|2|OB$=@3B5ID_#Q|VX4DYK_
)"Q|)Q@#CXCDE(I|582,)$+A_ :ROXF^/- M)?R8:Y^L$7RONPVZA*R96|=I"G:|BB5<,2VT:"FFBG97(92 EHSS'KT4XC M%GR2-
L4@*:.I.PEY&#YAI0:9|DZYNHK+L|E:|Y_1YUAML#H|<:"6156>H5=RP&9#&#12^1 M?@US$&6JA4D)(8;18/MHO1#2-14|I|JRC|I|D?
93U9#":.S*U^?2,2KSJ MW+&S55>|Y5VF/59&S5:|4[R>#&+&K/'P#8P!>P>2>5")28DXTT-S&0
M:0P4_Q@XB#SX#QD)7R1)"$&3XFF#2:GW9,J6C.1KF2*7^<(E:|+50V7E0U))M|+5 MP8Q<#&=C(JRYROVJ97%3=DII&4FSJ|Y:Z^4C#%G!%2^!-
J>9+D.S2.ML4#_ MBOYN$KZ/>_OOLK_V9Y=>64C|X/R$ MY:J1KMNRZ|Z*HX?N@002|G_*(J(K:_|Q-WX4LHOR_&91QED|5SS*LIJ
MD|X_1|T<11E,X|G|T3:B3YA18.GH$ _U@D%$1C^>:903.50&|MD|E$ NIS =#Q?0|Z^W@~LT|TQ?_ /73?7>Z>W>N^JM?M9K5MK"JHF|5VTWR&
M:NSD|T=|TJA_'DC|T8D|NWSMTWTXWH_@M#B:=~H7W(7W_VSX:~|IHUV?T=L MU"H@+& W-*G: 1::XL=4IS2QHT MD-DM1A6Y|I|K#-R-
I2Q2$IP5@'8ZV%L9|>F=|S|84BD3|F46FEN0|EJ$B$7NM-GH'O_!-@>EDS'N>5.1"Y8A8P7-E%|/!>- @&:
MAL24MAQ^>G7X>#=#FN|=T0'E3IYU2D-PI>4T)T_4IS2IBZ8^>~*IRU,F"" M>41R:24WE"~CHD),&B.X(,LD:1DI=>2AF0|X8(KB)&AAF)'-
&'1BYX#~BK MAQY>~#GM?/UTWGG&|NEUA&J-P-PP0=UTF^Y+6|P MD3_."!$4<<(U<@FDI:8X.N)3LE?EQ:~JB5#
(@C^=2|A|S6:|H@L93$9K|AW MC7+:SRLMC.|S18=?W9&^?P2ACQ:O:4+2_-|<(W=(|Z%0($Y@*B_-MME1$;1% MGB-/CM@|_&K)*W?
XM8&_Y9R38Q# MO.5F)O9(+58C:"MH5XX2|GX9+&H:O-H@L?04Z&_&.(A7RG&$F$K?&J9D MKV?&+XE5A|U?>G5^'O+OBWFO.&$>16G^?K3.
(QAIY9ZAW4=Z2N KRALD_X0|0$&$4^7:~%@+1 M+EGJG& UK-B*FVPE4@+FB<@O|(FLMOE)YRC#DE(AM^ME|H|U?>#5>DK@|15
M|+&42&1H|E|I^82JH5(I&LDXUDE8?IV^X'S|4V^1$1+G_ L4|V1@MLB&P:$.$ M.SYN-Y+&SICAU_=D:X"_*"8AN_UJ_S:
<2YXZ14>88XE|8&F4S6%+FA- M34+|B0CX4U15R%COXZX@OFF%"/I:U^O/&8>3^K_L1P|8NK7&ZN7^+@SBR_7%>Z20 +&$)-J%KE%T M!
QVJ@T"798C%YCS6E76/+J-68TL%$L3D64>:(|T|_90DG&+8Y7.04W M&B^OTKC#KPZ_ QOJX|=ASBIO86LY8$9E@>8Y8W"SB*BDD8A M8?+
$(M.O|U#R'(R=))*NVBE^="G6(7YU1_H*|M9CO"/$6GE 8NP|0@4 M*(>L23($RN'G>|V_.$W6*|U1Q$R S0F:F&#%*(<|T-H
B|E_O&T$|Z|L?T>2Q3W=YY>F28|H&_ M2J>V|L|IAYZB|I|=6G"=-+|I%~#BPXO.KSH|*~#BPXO.KSH|*~#BPXO.N57
MOYH(830BV3W/EOK(N9|O,L9|&F$N%?'02PE4F&G|(LO?D80A|Y$&_DB'LZ_ MRVW%WSB?E%O'B|7
```

#SIID0=TCY/U9+/(+^+(5@6#2U6UQ\^|JKE MT4PJJZM>V#U510'X=W%L*Q>Z6W51 7. MX9T; LC\$ /=|ZX:C\$S=PZO. OIC/J?&=GV# NST/75*S1)R9&*1(FPT6IQ\T MJ;UT4P> 98SM:/S63L;#=[M (*I/ZXHVB(VB 1/9I" WUO: V1ORW9M?YK0 ^ MO2; /*L=K\$AQ@;P;9-IJ:MS22/GCH 2/I _IJ&/Q OC+Y^,OIZ>?QT>/ ?H- M+Z 8#3;:%L2?9I^"/E.CXL C@|^~^IX^O\$#', 1AXI') 5/I> >7XXR/I_ M.CPZ.'I >!/;<7(* S^|>CT9+M;JGRHNB3)'IH.EA Q&I0MP6;>|VVJ|E(L M^&'P")WGR D0\$?NX#>? 3.ZWALZPPA+JC6@D3\$B(YJ>8E\$A@#)FHH65\$@IQ\$;Y M^1I6L8-(IK+W.X)OD. -S#V+K 2BSIGJOPVASI,1^P1=CA-Z#U.G.P.N.BL^C'NAX(FI)31M3R(7;2(D:C6^JMN415I VU>LBQ<^61^!-PD37ID.5UG9H+D/\$>?7 MAYI7OIQO.= T_ O;"7U057I7MK'8\$1.H@)CB\$0X1>L4?6"H%2I\$S(R:TWBC;8> M#R&PIJ?EQ^D&2I&:T3++>JZKR8GY-^136#.+I"H%T &I0Q5Y-%&QNY6&I M1YKQ@I^VGD>M-1->YN/WH8<|>DHCN^&7^4.7P:COX6IV^YIIV/IQ?#42?I/ M1'X T@'0_Z_AZ\$ 8YVFCY UADME04S+E%22MRXYC:@S=8 LNJ4R<^|H>#>0@2@C^")0)8#<(V 4D@S!Y+1:~%R>|^F0<|HA@A72J3" MK99DR+5I^N+Z#>G=2\$1+5^1= DZM:\$2%NG.P#HC&BEA*EI+.-F6I|SKD\$A\$* MC\$F.68;& R4U+>?2 6NG6JT&ZD'R@>K27" B:DW^D@861C3F^4@?7^NO8/S M:I2&<5^IIP F9W-;("XN1C@C(YR/FDDN, _8@&A|UUFKJ|JOW^R^L45(3|M:V MLSQK#ODY#>R/A:\$&%%TFFO/A-D@:FP,(OV3+X&& ^+W8NW+B1O:Q>8GC1F0A7H75" MYI^U^|SXSIGV=VV10I6SY!7PF|-?;IIN-IV:M6+28E ?>KWC 8S3Q2IJ MH_BM-YR4H\$S\$XO^|J:MYB.U5IJC^K93\$SG/PZM^JGR0709 _02I^|KV> MTI57\$K=U6A2IY=N, '(55|I MO!@I/OJ IJLOW?7(C28G|XD5U8=33^B^K0% M")=JGG4\$ZL+VPG6G|^@XSIZK.DG4ND|>=G+37^TPXF=619D+UZOEUNT=1N M18E2YS0S^&=TJN50@/TJ@>S\$SXYSL2WTCO=D1\$Z\$8QIIC&XH89#6M0SPG M^I64N^\$^3<- Y?N0%?7YTV|^6X>~*PE@>8>28T?R|^"%&6+91D D5+^R64;U M")T&JL-7I+AIZWR>G>0.911T%M4@81PRA7ABNI&M^P 1X MEFB44JZ23U(B;7U S\$?>9A.E9XU^K< V.L-C>3HJ|(^=^?1X+^~)H?FA=PX M_1\$^O5@=+P'(OO>,D;.+OB^=5EL# '+X^PMZ^%0 S|9C3J^7"3(9^T+7.46 M3)|IY5%QAN,B(O26Q8):7IP^T^0IX? E.\$>49G|Q88^CRP1=ETC999R^Y\$S("NE=H(XW33Q _@I@JXS8^|O^2@P^I^YWH7MSZ#4V18C:9O JIX. M^N">C#8#;D60RPI>ETK:G&SIF/6R.NX,2PD3?T;IG(IJWC6FNC\$FNS600 M.F.SWR!|KL^H-@>1 AD^IHHR:F,VDD>'6Q,IX \$QM1/HEX9:R@0@H>|L;+1N^D4Q M Z6!PIV:*6 /HHT*35I&CYTV>M4N9I|>7F*) ?;*"/Y.D5%J5@0I^6">#*1 M31#D4VFC3+4M8^X>VNAI59>E66!9EYV.G,5I 1#1I%.RMP>ST^Z6^+S2+G^ MROR3I)J;P>=U% N|S2Y(7I|/53; A)^&|MAY:9YZ> >=1R\$%96G@/(ICFD+)=^ICYSN-P5K6-Q=U87FE,5,2LI MC&3D>51PRJUUOT(^<H-DI51I M5IL-HQA0\$2(7D|/53; A)^&|MAY:9YZ> MLBANFT:YEY.-+W)=YI?8OIQO= WL:W\$YSWN^SUN^+XJB|I@J9OUJ^*R^OH|B M75E0F>S^S:ES+/'Y7L;L1(LZHDKAECV|SWV|BSZ95:36A @|=ZX4J/&S^"RNXEQ_@ M23CIAVJN= R1^Q9:&1ERF >0=WR.+>^\$009\$+.-V; 7TFTQBV^TD3N:6 MUUCDWEDN2D;.(N(I^Y1ST-:(SHE:Z5^@S|=^<#*DVE2DIY7.JJ:~%V13%5ZG M^MR^F;^|)CK33) 3:F@/Q=|^IPW7D+OV1<YXOV^| BIS+&XLVT=I%H2GQW>K^>D7GGI:O%">+<1 @%E<#|MI^O.1(W @4F9#9>1V?>I&^&@.S^&U^PK0^J. M.M9P1R(QIOMH0_!6I5IYX= M0:~\$AV>Y^R^XM^|JB|B^R\$*2TGKQ5U7>5 @SCT^~^5E-GBZIA:%Z&L5=,+O) M8=|Z^NE^ESNN2W1.Y^<@I^R^C?M:\$<\$2B-VB^7X8I4I500AHDD_KK^<^Y5J M|O|^~^12L:%7PM +O^M^S.V06.EZ@Y^459C&I^TSU-PNG#:=UD^L3?HW3T,0- M&5VP+^C)MUJ5^U^LTJD4J6=NB0-X M|@|V|^~^XN9^HUKK5^VN70I)5L M^U^I 5YYMKC0_!PYK-Y7^52>FQ2N2)I5L M^E^T^K +NYS.W6I4U=VS+W^E MYT:WE.7ZIN62^=634<".QOH# _2%:9Z _1:5MIY%PJ5R'(S_9J0?."\$J^H^" M>V9S/C0^U48K%'T\$/ JGLSYN@: OFZ^32UZ?/G*>ZA?#Y_1=X9 DX4* <7Y%N-8E6) M^W^W^L^X^E^J^V^A@<^~^W^1LLC5#IDP>:RZ#1C3WJ^<@+&^P51D7&L1F2=6-QQ: M7@2D) 2:VPRGDID+&Y; |HF+EF|5Z&T|>6>GK >?;Q7G1V^I&C.QJW83(" M2>4<303ID|748|NH^@EE=S3A>~\$@ZP-4YX79V M096VEFW&2@Z5=ZLF|AK:D67,RMZ-)O|V:M0_12V45E1Y,VMOC^\$.&UAWK MJA@9(S^5&@.14%79" E8&A9>9F=(IOI)_!,"K#%I82ZV1_VUDT_B@+>^C^ _-Q^L76V>U>#T^O",VV&U;+C\$ M7E:~WGFT^>H&I(YGB+2^MRIG4^|V|^<2V+MAE.~5:9 _\$6U=|."#JH=+N, MBHOV8_ZI2L; 'M7E:&GWII^?^MO:"0%WVG9^8S;.%50&KE@3VPJ12I^J M7N06:4MZQ29:O3!T^TOMU, 3ZWE?LS&RN.*Y_I2:UZ9I7U6EEX9R& MLA%068H>'@.L9K.Y#1=G4Q^D4Y^@Q^NNU^~+>ZL3SQM:70I60^UI.9Z\$BD:S MQU,| ^ZV_4080^JWJ|=L4E:LZ^%L_J9F-|OR2&7E. IV^KI|SMG^|(PLRZ3>Y^7I3VMLEI MG.3AN.LVN>.-#;MNDRT<5V^06NTUNU^~UJ;^YIF4NV5/0=^WDT^VK5_7 MW0:N\$B5HV 13A3^"14 7K03U:Z&Y:2,7 @+^Y&KVKA=@,+4RZEBLW#&N4J MVSCTP<5UKI/FYKIM_#|^3J:V=62ENH1I7E9LC)Z?>I^89SUKLK:X2C:I5 MGIZU=ECDAKGFF+J^4=8J_X-?7;N;6 M-(-NO _@^@^@RB^~Q^R;|19M^@E:PUOH^NK;JA82^F18+M@JNM>=\$M.II>BR2H M8I2^ZL_JYI: TQF^A6XG9GN6PS:K0^~+ =QIT@=,YI6\$^TS;)VN^LU; LN M_#7?R^6PAQ-IAFO-16::=5Y4>?7.A8VVQ^C5IEAAJ\$SCL^S3R|L|^NS)(8 MG1\$5_ /WFMGJ->T^I2,13N/OM.NPN=U:KH=CT<I^O^E7>?K7H^MVU^L")/-N MUNNCL!7.6O)5;XLV^I@)FIS(XI?VSFH&I:O:"9IPHRY_% KG%WMZ#2D36 M2?I7\$6LZ|PL+P&%|I6+3^> &H)9E^@P|I5^OQ;^ZI49^|O93L193-L^@: M75TWI^NN2I^JZ@8I^B:WPN^GR0U:(5I8_1P^VU^*ZT#Y_OI\$H2(E2I|^<4^; M8G:/LNAO4R4BUY_*I M^PKRZK&C)7Z:FM4=ZKD=-E,3ZV6-0 @_JU4JVOY+M M9I:G<:VE7YP&OZ6+R1:7UFOI2QG#-PUFXQ:OAWXSIN>SBZ|H;HPI_+Q:W^#>& M&F4HO8F\$%F ^&8-9JOT^N<7Z;~R#%|GJ:5T66ABY6| 63K.ZD+7)P:@WBD^M4 M4Y="FE3NA5UI/FE-+&+U^U;^+<.@JS+EZ^WE5M.CBL6 ML^*A? 2X5Y+#!/@U:WB6NYTM^"1KNI?0L^K8II(? _Z?MF4NM!-VXUP!& MO0?0+IIG|NC^ZO.I3^*6_3R^H^"=@1=^YV^B4U:11L6|IV6>^IVE^EJ#;.G MY^>DV1I47IJK06L^X&|..E^H565M^TZ>9TLE; JC^\$*L M,L,K^&"T^@UE8?>VW_/O2X@91>SA,3IJOG+FBJR|W7ZIZL)^6-#IL#)^T^B4 M^O^F1E:OIHO(0%\$SNI 6="UI^HAW6>FN=9I%-5^UF^>K^"S^H=S)3_V5."S<|^1^7IR M5=#UB.(HILX=^CC?>Y^Q^LI:ZE=ULOC7E551 ^A>.C(M7@=6R9_VASEYZZ%)G=YC5=8:\$+VB14=+JZV MN\$KXM_!CEZ)K7(AN&H_0^J:"WI+S46U/=ZS%EU|74IF^DOTYMC>KR9H+L MS7>9I^"WR_KT^5_6=Z^T^E_EIKR|IO(Y9K)^B^N@) L H9;K2GE^L5 M&VV7(HDV9Q2XX)\$G^B#7. 6Y1XT(A&^<5+&L.P1|2&_Y\$V29.UI?K M1|3I^ET@IEO/I72>?WIMN?G|I^PU7IO^WL.G+L|^I%57M^ MN|9PNV 6C7^8I|^84UOAECM3X8^@,|R?^4=-B=XI7>@T.M/LB|L|DKJY+? MN19.Y-YU3?RJ^GX!!/?B%&7:GRJTD|>70ZIX0^S>M^QTI5BWO WKRI)+ M?_IZMBSC- _GWZMS_K_BOO! FGI(OOS8+^~4:WMCC5A6WWS^AID5K;K4I|J6X MKI?"^C.A-MOW#>3G;| B|4TBJ00&^J (9\$2I)EDB\$037.C3P5)C_H|P-&&9 M6U1^R8.XP(9_HHCQ+I+)&B:K2JZ|DRF1KP6+O+FK3:PMJSE7YI^O>|MGP&R,N;K^T^M_!IA6 M6%13N;5&H%8S8I7T93>#? M7G^4^EM<=\$54WF73W7IE<>M+<OY9^U7*2KYIKQ MTJ&NGJN%AW+4U7-ML9YKHV|A7:7G@C|LI0\$X=K-WDN3^JLO:RZ2IJE>|B6 MTQRF/ONI>=98EOI6>?^N.=44<^/3JH&I4C_P8 MEI7ZU#HE/FA.\$I>~%HEO:%E|CG+^L(1T)9L)OW_)>2.TNT|BA1F=5U_RJ M<^I1161H%>2>JF1GZ)=0:WVWQO!|MLT?%@C^I^N)38U(NJN1(O^E2R.G& MVY3S?>8BQ:R_J M5W+0>NE&3Y;@.ZH=6.172QKF8N|WNT7% (+D:YAL81CE2<@?ET66)_JYS(SAB&LBD?72 M USZ\$131^NB&S^PON2.DA31@C^+M<^T-DX9ZQAQ/&+<I^OFWRIV^D)65I72TMGV9S=XHE M0_RJ B=WYKSZ=E4I%N2MYGN.XODT>WG1<+?EVK5.\$>6UO|LOY|< M5II%."VX);WIAZCF^HF-IV#7IK^66KT M|70QB5B1+I^*N.K5(U^Q_BI+JL:7I|^DI^ME.B74C.S9-A;QJ^UYV| M(I%Y^20M9|3;5>BA9MEQV7I#|^I7)8L.C.BPN+1I_9KWV2I.BG)R^CY- N:W7^6MWMXU033(K-Q)-TK>RP M^L8I4F^FKS6CG60^_QBS^QJWJ2Q|JZ3W^YU?A)AOQJ^*?U.6SV64XUJ MKLI_OO/K=+I^TWG|7,ZK-? OV5#O5I%|IKZ+ZIZ_UIBTIROLO31WD4Z=T7D_V M4<;Y.M1WUX JV-XQ(8WM6|OCOXI_ OE#5EER4|>U;.9EM1=62H;IWFID: M8I\$55WMN@51W7P|N|N?^A7IEF.14I5B|JREF3?UETI\$12NO:D_W+^#>=F^XK_!MY@_JO8U94 XR+^_AZMVM5I^"GB&KK_P^#4&JCJ?IO-8_FKIU.1M.M^O^_ZPYD^M^L^E14IY)JLULOW=,B_ZG0^OX\$#^;B:5I1MKNWHLDI^S7 M7PVLQ_UWIIOW>Z_ZCR8-8O:7HR+2N\$4L9J?PTNCB*->I_3ZL.G1|S|TZ_NI&M_O|HTL>SCYW+^G-0MCUHI=W2#1=7C6X5DK|&Q^3GW=5OQTF-V\$PTEI^Z^I M^>\$GWH9M>#YXJ93M)KX0-KDIP4E=REF3A^UZZ2I52RU41D8@|@I MA43^\$X8XM9Q0OCB2DAD5>0@-R>Z.Y<4E1A9+GP|I|5QJ9^32B6G\$&6W^BC M>+^_ZDO-FVNCFPVPLEN(@: MND6H?^+)^\$I>N5.Z^X44N=|^/=&IDF5EIVB^&C;Z9>+^J6+23O+9(Z8L1= MB^B^T^O:"VZ"! B:1.SZ9=4+Y3C|3@_YND8BAM2- 56G:*Y 47S^U^I9PY^G|GYO5^?R^BZ MCPS)|V7OY9^H^?>@I\$8Z;@U(BBBV@7I=?% 9X\$|BI5.JBI:2W-U.@^R:IBG M\$R1+J3R^124(08G|^<8V0L&^\$|I^@2P8+21A.OQ0@%66N^|/AIQIB:YB^LJB0OQM6DX?JIE^=F^DL5|V>VKPS?2_OI|^7^\$E5^*LL M14D\$#;+^YI9W2B^ECM51\$6I4HZR=F:BJR|8R6W|KXCX0A4O9I3^V-2^<KJ+&Z6 MY>@^@S3P7AI<7;A^P;B=E-|;..R;B^EBX?LIT!ORMY PCXEG5H1_!\$&M;M0(O2.0DP#1M)HUV6(N:MEJ)D#>J7+Q^C>?I0^5S2L1K^+E-F7W|E|U:L(H M^_GK.VLZ5^|HJNY-IV" <|/=>15Y2_!>?^/;Y#T=^*PI>GQ|^?^#T|OYTW#RTXY M8:O^T%TREV(AF^=TII|4K+3K+|OHF= MLIV5.IIV#8&A.#\$&|A \$O/K3W?X\$^*E)@^FR5^T=BR0PUWZ>Z>|IZ9&^M^K^+O9YW@%&_YO< SW@_ @B@_AIXPI+G.BV+P!| (/Z,^; P|^>=>|# M=#K6:A5D1? NS^NGQOZ9H.ESJENT?OIGIRIL.MC..|JOPX87G^Y^IF=CPLYW- M=C;#I|JL^Y<=SKJ=9QM|93-GN@|G0UUV903=>J.L.WY7W+W+>S5F^X>_5J; M^<^W>+>)Q.YL;-I)5ZS^2816QN^1Y>/_XN?^F_F^Z4I,IT/1^VZS+JL MGK84S2%T @:#Z:3D=|>3;MW />D&Z,2B99_IJ#SGZIA^Y7OE.K2OLK4HWY M^CJZXP05W4|^+4.4.-XVON|T^?F^TYLA|L_H5G6%W1K.WMN^FEL^ET M2|X7.R^J..*L1P^EO94D).GN2_R^KQI.G MX2QB=8W7DBX^;=\$VE@E^&N^I|Y^BPR@ESW6_L2960KH +=QI^KYPSC="4N MXC)8FLKPILL.^R^!;5<|>^X_---=VEJG=&TEW4J^YRAXD.ILK+=|0Q&_MHCMMHRMX8V%"TO>9D.G;:@S\$FR|FV|JUQ:YVM)X->?^!U@^V^TR^0-K^UVVLV MIY-QMSV>C/U=N^W^K07>32^E 7Z^YQ^0^F^C@I^/IZ XP2ZDI2BQO#510ANNU5 MEI6@#QJ^?BAQO:WHE#F^V(Y+7EP=U_UO/E=;G|YK=Z;7I+G>J#GR08>M+O^7ML? M1GK3.OE?7_0EAW?XYZTF_VIKO<#I2T6#|3SOMT7#;GMXIIID+D_YCI+AN.MZ:5M5I3I\$- (=EOK3I)T%\$> ^IC:9I^C%!U6N/>(0E4RWEQ*4N%6N^ER&NR MY6A8S|U83:1)LG|HTN)VVIW^-.|I4H+^WF (2XVGG>XWY.C^IR>)SY-IVV|PSF@4ZW7^H9.MK=|^F|I |V3WH.^V4 M^0>#I_WLCOR^I^V7#50FNH^M|^\$4<^/L.NT.YZ?=IC^6^AHOW^;PVIUFMP<" MX2:EQ) >6<|Z<#>WOYUNLR?>C=WR_8C^9-M^_VAL^<^%\$S1.S8(YH^H^%33 M^8W^4^I;S9^S?&^@HS1^WFC4^MI6X|J3F|ZOL_K^#1 I^MC9ONJ#< C7DZ M:(X|8_AK.A6#;:OONQ.Y3C6_VP^D#^O6E@T=UPLI9I6_U Y6|^I^AQRR^MI=9V?>^>_>#J)#6="&5Z@*WJIE3V7PY8.O^NY>_U1IPEJIV^12Q.OXS5! M:#IRZOM>NWWGOO>?>4C.II:=ELU)1W;."KAU1UIC5.R3AM^EJZ0^@I)Z1^M3^H;U7>!G_JOKV.6/8_OTL<8;I_73KQ_>7^+7/W_X>/GOV +7YTO M7^&+WWI2^/7+2H2L|5AU92%IO-JU-8G0:6I%5IIT?(>^JTED@E6^I4:G\$QIK MGI&X|? HVN2R&&4ICYI^+ *6B=GE^|^>^F1^F^F^F4H|O|J|8|UN8H2&542BEP|U M9F0\$&\$;.&|F^6Y5F@:B5UC&GH^B I&WBS\$WW^XY-SJ34LRXY>@-*3K<@ M6):32OVN@BAQOL^@ZY:S14H8)C#;3>><Z5>74OG\$AU15:1I1N10.2Z|I_OHVKSSO _"(SW MOYAW+I6X?)_O_P/R:8I4/OQ/I ^UUBWGM|RI&^#B#B^T^O\$&K|VOIF^&D ME>S2^B^N53^K4(2T^KV+O.K.HT#_2I4Z^M^N3I^FI^Y;I&1Z^T5%?G50&_IGP_M78RR ^I8:ZO1\$Q8F/K|TCN@|TG0+N(E^6-Q^PV8\$GVI:4R|7)CDH&6-S/D^F V|L=@?GS9HUL+SU:J|VJ)=.P0-T/^" M)HU.W%AH\$.)Z' ^|D7W^<+&51R\$HMI>^N-QYNA^H6CN^EW:G-BZ43@H(WP^<Q<: U6N;-2Y.TSK5|^I26>/WDG^5|R8+M)Z20#OP=ZK|1L=L.HHCB- /QWY(ZA5^+HW3^PJR\$81ZS=6^|MV?E^W^L(I^NG5+&3C(TY3_MAI<7;_QVL9^&@>8=VFPW? X97G9I|@<=0PU7QIJO7\$4S9^E_0T^AX9#Q.U> M9O.QQ^OG<0L#I;05.8@^PHZ^S-.\$>CES?^ V.C|Q39H^1U^S MX:~<2/GRTIL6EK)%VI S5.9VQ3:YCA@ (#0(M4|J79T.EWH|5@)0JLA<@ MRRN8|TRY^X_U_FIGIDL^DRT:9EX^JZ22:15^KV6I:62->|WA&WKI9^2.L< M7XFK\$ 1<6#E2E160Q57&L/KM_D_0# "6^<+1IC^=ES-(SDI\$B7W_9(Q5_MLK00#ZP2?OKE\$X^2@&M_&5 V0I2YALSJ@9?TEINT%Q^IP+7-P&E M=4CDITZ>?RF81:3E\$**KV^L\$HPO_?21KK@ZJ20?3%LS2VX5^18&.#D98+ MILN|7^8^A5^X^X^7M|W\$B-OQ(=Y6)P%PJI^18\$HEYI M^J&H5U:2_P_LX2F<|H^U7^EQ.-K^4@^2_.EYO.TI\$50 M+^("WF3^B^"B^G^I-4A@^L^14_OI>@SOR MH.!^4YJ;)Q!^7:-L4.CGRLE(Z^/+>1AVOCQ+CUV^I.=L02#> LOPD+3V.#^G&K8HZI.3D?<^;110 MG8D?7QLSJ|^ODOFPL;Z:BPPIMX5(JGGRF| @Z:XH%63,T L496.8P0RZQY M+0?GRTO-I@X^_ID\$#=\$^I9R4L^*IO@^@-OV^K0&Z- _?I8Z>2M387K1I MK+H>@KCOW=E8I22|P|7=HI

[illegible]

```
[M+661PY+L.D@F"">+I]'+>W8*)@HF"CNMSH:POI|,9DHF"B8".X5G5&7O9A,$T=$$R>V$[N.=O:#$M/27B4RHY2KTHOGG;AM*?IPBAT.
[+HII%RJ]?#(HIO/69449NQ9GNM^N<+I6!^SCYAO"/7 [UIO.F MKK+^PCS&0W#<^#A|3CLM67Z.;3 NL=+)R#V^%=, DE :F@I
M.:Z^"BC7ZKZWN|JBCIUWSU;7C|4+K2|U9B|09#".29N|N. |GVYZ. )/YIKS9 MO9@&K:JUUAZB8I QI.@G8<70M*+0"S|>=+A2I|%5Z5TE$HTS*
I:6Z<^"O5 MB9HNLPIUW;8. 8M*U|65'AQ?<A&NGAU|@=[3%|G M5Q.TAIY58(T=B&Q)O-5|;2)G|+XKD+ ^PL*U78!":.$8BXN17US*
(%G.HD0H+53MIS'(BLI|/#.-|&RXL539.TEBT' MZKU|105|462X3*OB/2L0Q.O2Q0|OY|'TT|=[3H'E4 MGVCZ/F|
<52T">^&C|&I701^&UM.B)Q:0@@"^%8ES |I '=0!&I)8^U 3%4H M0@. ^G$7PA8"UX|U0(TUE-S.)1<;TLO=WJK"1B#":.XIPZ80P.X25V$($|^Y
MB=2):CF7S@+:"|J#5D3000|^UCB&3B"%QC%TJ.C&8! F?>??KATLG$ !
MD43Q5B;^2K4&4H8|8|8|J| @N.&I:=ZH9:|F5|J|X&I:&82)ST|(4E/2P M$$. <-! DO%K$021)Q)XV7Z.-/J8SCO=75N:*P#MX:7F<!)$V%TN8SCE."
B- MMWKQ%OY1(>EJBG)C|I| (X=K89;.|B|2.+P@:R|>|@D7 &F%>4B Z* 9J+HUC5.4)=>5NG|HL (M+*A $ $W2:#|R:|@2.UJ^D
7SHZG4/CEBBJ^IS 33AQZ =>O*K|SIN.) J M0-YH.WS0!/LC">|T="20 .5.6VVZVW=|D+< (2|6&AYKN5"P#H|LV&@5<+4 68J MH=:
=Y3H|+E>2: ^AE|4=4UVGTQKT"|^5-4:4; * K#E|2=57AE X|:MXG<@O M&ROW?E|< OC0V@<UX9MESWV|ISW+>|W5<+4
EQUAB_1GWN.N8SN3;F226.H M>O:E02=ZYOC8H J-#L(5M:YMRD SD.>|<>XSW?5|5?%G5|: ^|OYZ.2|1^%
M0'R=Q5(ZO|'GF79<^"GW|_OCL0|DTZ?"F+LV2<6%|?VMI M2G7Z=VS4/2W"/LV@|7 _|UI3|BX|PK).@QBN#->|IY:A6G&FSSK' M?XGK@Q')#-
R#Z2T|MRIPNVZ|JDB<^ECO'Y3RLBM|JG6X0 TONQ>=>|MXK>+J9 MYR.C:2|IY:O6E4M#;Y9 _:M<4P5NMZ*17.6CXQ_@1Q^5EX>?|:=ANH
M"G4:XV6A3(VUP0038169^HYEAFN^<XMP|7B3/?K'.S'<^6XGA9<.W7>2F.X.M.EQ/"Z|X.X?OI<9W?
6:4=5MYXXO58L.KWGO+>*V'UR|J|Y:OF05 _/> M|2Q0/O=GOEE%8%N<$@.NGOW=6*CV.IE|K#84B<*92ZH83R'L1-&@/?$H3 MK7SI!E?
_X|3|<(24R8%6>ZUCDAV3|AN)X67-GOOQW#=#V9I9K7|2CS+#+=-1 M|Y:A6G&F5W.7N'M<.;MB>+6=39Z|2K+./UQ@;|W.J.8KX_6T|V|KK336&
M*/UM.#JUOF(XVLF0.>SWV|^ $W$WV2BPBOGO|1|<>^<M0C#=#P-|8&-|Z^SB8U6&X7IB<.6X>8;KWGO+
<^TXTV=USN .82..VU|%;9WC5#@#X.@/W M5'K=|N|JXK*^S'@|L.RVZ|52.EX9KR<+5|IY9KCN0:<.UZ|PK?2|1|K|Z^W5W
MOCIE.ODS"SX|_Q.0%|GG36WU M$XFCHT#Y3C89|B3#W>=|JDRZPTL1.0DMPT|M MIC$+" _"|1+1$)W= Y&|6F|!:%XZ%">|R4C
M."TP+1P+73&N|ON.SQ> MX%/W3!;$. (9|6|D|'"21"L.# O. "||V|J8W48.TP+3 M|'"<="V.)>8%Y@ M7F|>6.IX<.R|P&D17C|W"/A5L|OVQ=CWLWC
M4'ON:|1|+|4|O#9BK|8@|HGGDD4'79|.%$P431 MW"Z| <|N|NLS331|D|TFV|VQ2S5B= _F|Y4<#CA".:5TTY+EYX0OUOKJ.%ZZ
M&+@G'MS|N.Z7R#%P$;@G"EQWQ'.BZ0"7C<5C#&L:BIQT'8LLR=+|VIA+BU
M6KJR+5|X5TP"27|N:~#UMK.ZB^7^E.E'39258KE5_.XU5!;UB _SH/U?2'H'E80 MSAWTIT_IR-N%|!(GB1S|6H6IQ+|5Z*6OHT4 Q8C0=Z
#WR3|>D7A'GQ|_I.M.8|M6U#U#%+"JG|F.FDY?YK MXXT^D<S&FCH42Z&EHZ;8|UJZGM1ZF@:|.F04E@9A@?1|B?@E%E/3-N@=Q|_M-
|OHGRE1>^"G|CL>^BNO2R?"BT<^7XFK.#Y|JICAN5|@A>WG.L9T. ? E? M^O'X|B.OYE$%(OE-4|LH|TP#14.P*3@2).FO4)K^F*|0A)
|<4"N4$%S M2BVS|TA-|7?K:632+Q<O.MB$XM@6|2|(FA.WD^H|H%#?).P#M|!^AC|6B6PY M.Y>2+2.YQ66R|P30U<-(.HY7Q 5S:B|4$?|J&D|!
W2IV%M S$$.~|X.M|6#P M.'7A7^|A'3.I=^23/D@2% @OS.O|DAG(B4YC*0&=&.. <02<6Q*XA?FUFE M.3?
X$>J@|7.748KE6"U9;J^N%N9HNJ3F05|&FM).%KKR")6US""=SI$ M812ADKKU>Q51WMCN|L3032) O|OE&
<9>Q:K.$1C*VTJ"OY$.|31|ESX|V9 M|.JBN|2.3|>#C|VQ0T76$|AQ@HU:|FP1.6|J2.B93J.IY.Q%>@B32|LB! ; MP |8>'V|&8AFE
M"11 * T+4Y7?:K2?WV4Q@@"P$8J^EN98+@7R9#0.INJ.L-^N^>=^|XD^5+|1 MS|I?&1G|JNMT6H-^~^N|Q5'?QMF.PDC?
7KSY8^VK@GO#)LN>XQ|>X9>^8^W9L.N.H.7Z|CP2HC^X4-4.D.52-6G O M Y Y:~#H0J.=4*4D^VY&O@VY<=YR! V&.7?KKK|:GL::N - ?
U5|(I6HQ" (MKI-82N 8HM MMS#T486.HIT&B|O|_ # #4Y8|(MM^~) L4>|3|P3Q@GC9#M.OE.<.$X8R|V7.$88R(VR7.$88R(VR7.UX8R|VR7U
HB^EFNYM|L|5AFX#-Q#G|BZX|7.&O(I7V=ZG)OG<3256JLH% %MDC>0%Z)
MH&39"9:~+&LKY6N^@UPA|S|95|^I2>=9+UF8X8KR<^UV&=|X|BO#>|>3PN0 M9|JT>P^Jv2|1|BX<^ ^EMPS|75Z*67@5MYJZPWK'.G'.C|C
M|JM00..RT2:~(9L2ON+2.VJG+W|S|@O:~# S$S|S|LLV|-_UI|UEO%6:6|9K5^G|I=4ZMO'OAC-Q3|I:Z"|L-R.V |UEQ%9&|_#L|D0580?>
M6T9L5>VX7^L$AFS7.G)%;G=J^TK|H9SH?%W_SX|8F|V|T|+O.)ACDG61 M|_AD;JP-9I@.*YTIUUGG8-$.KB>@U7^>|<-8KX_6T|V|6ZVR0|F#-
@X|XJ M#<P|W>^?V2D'E|O&:D59|K|9TPK QO+>U.DDZXZ|YL|HCEA%16H@|ZX K#%BV M.AFY)XO<F=5Y6|AK|T3+|S?
Z|5B4+|PJTZ.V^&I9L5N0>:V|J^@CIG MHV^X.EQ|_ZYGM<H^K^PDBN|<W+=|P^X^YNA>ZK09.6.L7@O67.5|SIWKC. MP6:5|K:>'UK-Z
9<.6D7NJR#U=PY:/@C|7CXE.ODS$3X1(1.0%|GG36WU M$XFCHT#Y3C89|T5#W>=|F3J=G=WN.V>T3|U.X>|J P+S O' |ON.P+S O.
M|P+Z|EFF|:8%|6F9>*>|CO.&EAFM>+HQ&8^Y@2-NV.=G:7|HP^8+U|N8M MYH5|(|.|W$S+S O. "18#|.|@E^"">3A#L<-AAF @G2GCS MX|I$6/#
MC8F"B:~^1-5:O92>QD31$.%$<21$=S=41QF^6)O:~#GAP|QT.W:G|@XN M.4628%7B152)Q|F#$S@DF^B8*)H|I16?O M4G|
RBE2|GL|=LH4N|M3|^8TL9?T)=1T%?K0AG.W#24^|5%#C@?VW1|2+M4.
MY2^L7SG1%.H.$^RVL9IGSSQO|1>.1D7>B|71V+H=H>R0|<^|K(K3C3 M_1$|JW2
^".O.Q SK3>=7671A^FL^X$7XG:9:LORE<^>#OEOC>:UBUY|I. MJL@=W?GOV2.D.G(9N:15S3/>720_20R&4:~S-Z|N'/MEG_T%|R|7ES>S$-
Y&W35|T$A6|F$=1.@Q?^47 M@5B>XZ|7^~|^'K|P|9=0|F5VW|Q|84<@|JY|>:=YB.'M%OG:VOP5 'L'|5V-4%|Z|L%XMB|'96EXTU_RNQ_421G>8R%
M:~T* Q5'.Q(1)'B#167L1?@BR*~:G0O=.%M3Z:~#O*Y8V9MTD4^|9|O.H5G6N M$FB(MW5>WLU$>"4=%3H_ "Q4|_Q%|*C%RY1T|>(<#^&?
6H%)"29;Z.M# MO0W>|T3F3^G.5H>.71<-34N1:OBE*~S|WO.A$ZB0
```

I=-9(GO+""NPAR.UF*(PWP-QPL;G^9X MB>*7[E #L;WCL#>W30.NUEY#G5&W=&HNR8%W&4FD1&9GDEH34-MA&Z&R=^ M]>A01(P9,S-
0U(LI?>R#"CYCL4;/#\$SLY C,Q.PZ#4I>08U;L1[R;G;JT MXL#33;3F:079DBA=C.IIR5GHIW<Y">.VDVWUOIEEN88K&+279;S;U&0 MM&?
I=G@U&0?0/=8I=CH+66DT5NIDPUOB+;7YECUQCXMN62@\\(O|A|O|RLB): M#\$29LF5^J<-<^Z41,*%'+>>^MHCR+7\$K<-&E-E)*ZGT3^Q|E,?
G%Z>+4%@ MTNL\\WTI&5.IVQ&09\$A|A|ALZX %>G3=57F/D1.0Y6#M E.Y=">1MD\\MEY&52I7KVXBII59+2(O:Q:NYU#A#1F>K_NN3<I_) <&7?
I|W01AKHU^86X3+UT&07\$?<I9;7-YE-FF8J>O9 M#K13C&+L|O9I/U M&(#B'R">J&#NG:|JY02VXZR5210.G:G-
(I +T.R5U#+|OTEX.:K>A&6=P.M|06I.X?RZ&Y+O D|K8I +=Y+ H_XK)K#JO<05MWEL.JC#JL^G@5I^Y<7M^S> ML5Z5)HB6+
;CC+/\$&R#AO%:0^ZN%EEEXT^XW>S>Y#8N MN706 GO?%KEI"8I2O^<8I M?183;I7V26^DJ.IRKD^&OTI97GAJK"G^>K:5";F(:.EW-5I'&+J|I13B.O
M5I:KOU|&7VGDS4^WKBA6M (R"W3^V|K_&)=CEUV.+^5RO!..=3K^Q3W^*OD M|P:(JTC7X|I5K1&^DAUT^*)/OS^&^ \$'?^QOIR|E)>UBJ-
P=(O|OB:3)D OM2>6\$A KT.W Q192)-8%><3&BLVAMVE.|D6 MBWT8DXO4^?7=^V*!|TE.Z:W>9.;(KYH)#8XFNZS&^ED=7.ZF9+;BVW;<F
M|2RU8&*&Z| 6:KN)A|&%&%2CD|I62(I C4M:V3V(@P131E?<#2 N7@>UG|Q
M.V|34K58U^*S8)AB/7.D|I&:IS%870Q+>NNDM&S|Y+; UOFHM25S1;BT|09F7X+A|&9WUE=M>R>Z40F M-U^*&OE=<<.,ZC&RV%CK@?
59F S(4&4B8C#VHA:7?#PZ|S|519?%:E)EN ^|NA4|J|U UK<.;|I@M=N-Z-I|ON Q#"|C:W#|>+^TE.I13 M9 M8KBA^E?
I@W6J1(@L(I,.\$<00ABCH.LSLV3PIMNB+3JZ<1<Z'F2CLIZTW*4O.4M_'SC_)YD<.)M>+.R@|I|O|A|7| D|2TM|J|01.30:70DNUFS3T+.7E&KZ_QAH3)
<P:Q65U|J|S ML:G=L+I+AVMK3-K-E U2|A|I59D?I<+5'Z|DD| 4BZ|6K^*^I54870:5I'
MX|9M_S|J=Y_5|O=30^>|3C|I9>Q&K9;MSL=TBHN^0"\\T|DMS^CM/KX|K4| MOAEM1M.F>K:S+|V|66|&:TN|7.W1A74|I>|(60Z9ZW*
PY%&H&D8|&I28;.<| M3K^*2; 0I%=&IB6YV.MH58AWO!X#V PE,TR)%=IA#Z|KTP&YNI10BMT|DJ- M+G8RZ")I|T|ISTZ" T
V^R^Y%=&LW|ZXG3Q?2FXC=H4^*F5R#RQ@/MC=V| MXY<^M^05|T|L:K1C6N.+659-A>A>=
M:4C|P^*01Q&&=&VRU?|OV9FRK=OY3J#7>6BQ+|2O.61)=28J5I2T">+LI MA4^OM^TR?
S&O@UZS. <>NJ&47<6^X|F;_N#4083/VXYF|I<=>0^K<|4|_9V M(E|NS?;!M|X\$Z,J9@&@<6|B^*S^UA+! %3/ '(E|U=MB#R=286V^V14H9BN!
M|S&=&G=&:F7>^L1^2TH>+>K0(I2);8I&E;9G|A;|I7.K:TM2K:NL3:VY-S+&G|U>U|OQ9|E|@(| ^HO M^4"6KZ|L; />4Z.F5_O|RL
H)67^XP|3K#5|0^Y|B.E|OY|B|&+|2>4E MSL.H-D6R(A-HXR&:#VPI#&*O-80&9)P5D7\$X+|(OEMJ^*O|7|&=|I&7FZ M<B5H\$8&D:/"@=S9|X?
XNP05S^M>3 %48)MX-^3\$Z1G|WANZ:<^\$26A #SW0 M^|X^K<6>WPY^AYTE|B+AX|7<0ST0A|:RC2-"5LY|@#=:W@?% M0N&Y2R4C|1%3MW
ZG/I7Z YQ^|KC^>N^Y^7&#&|I|T2C\$%4 "Q&\$E8QXXR#-F5 M0#6C|3|CQ6|OYRO\$E.4HBW=LS<75|M+AQ(*.L+&\$^X5=3|I|@RA8G|\$=+8LQC
MM.0S%|5)=X&78).S^F>+>+&|I|>("PA0>U|* U|M_ ITP^J8>BD|1NK% MAX)AE?1")<A7+; LU|1X|+V:OR?;
+FU|T+L(C=:G8^&+W|/I|I92-KW#| M3|6|&+Q|J-K-Z06&#0^TVU|V|+H^&E+HS>Z&5T|>X^P|I%|82N23UFY M*;
(:CR3HB^AF>4^W22Y|NZB16VBN 3&K1Z_AD@>0SE@OTI.AG>+2(9^# M3.OOP/F&)K|9+&)=&(TY&G G+&)RQR|?"NBS33.|M63PO|9=)
|I7PE4L(T M:R0OZ&+>RW6\$^C^EKXJ3+|I7I^CEQ@&L?N2-H6^M9F5|I=+&@M97<_ M|J:8B ^OMCK<.<";
(^P<|48|@#HS.-86)6VD>06\$P^L\$Z\$4>7R^MP^T|A M|P|U+&=CHB28(O+&)Q3S?_7Y=O&?UX|X|J=S2N50K0I%-I;5XU|9:NO'S"6 MTOUY-
F@_1D\$>79U(93XG^1^? 2/9@&(J-.N6)-3H^4&%PB1*!|:8%QP.7" MU/K+>.)ZHM<+0LJPM)RM7X|K\$9H<_7J4R=NM^%OY|I|P2^&:&8"1%_0|!
MDB^?<|&4&Z|&|"/PFJ85%5;%E:R50%?C+&.HBG.2>GTA97RE.5(2EXB|B|I M/N^7+80G^QX|M^X)%6K|AM\$#|I|B<|@I%+Y<@D5I
_DKID ;|B3^K4|EQ4@ MRW7P.P@F&ROP^YUA<6&KG^N|Q|A+29&B|@W|AX< \$%#HHC5D8SW-!<65F M4B^" M50@:L44+(M_A^GNW#I?
2DPA8J|V|E^7M9 MBTHY?6(=>UZ)RROX^1B50\$ZIR1)&(G|OKC,GK8V3GNU2=5U4^\$)\$^*9UM%BF M-
UF\$8%.RY%&A>WXWUG\$P7|TGA7|L^F*^2>#|>#|<5^M2O=ZO|@=(R ^4_0 M|J5+&Y>A2&^26D|8/(I45|JOU+9+8 %W;D|@_0A^QH_YB>8B>0:2
VJG13GNB M|P?=<4XD5-Q2D&Z:3;9:03)X(N# VA=&G22>C|_&S3|8_0\$5.4."IP4| ME<C@_7X\$8:U@AW2Y^*|X3D"
U5#8>K+OY.W3R.Q8&V+V%|U0W9UW43-|7 M/K?(-&0%-F#|CB/|A0L4.U^X>@QPY00B63T_9 F|>_M4M^J^_MT^>.2_3 M%B8E(DT.5^4:|6?N3?
5EJ6V37.8>=M14H9K^?2+XFXI4P MT:AU3^07.37|6DBEGZ%|. \$11%|O.L4^DE.ER ^256M<9VDXPS9I_ W0%&O| M-7.HEPE3#Z^W3|1%R@W&4R?
H4Y|O|QDSM5F C4|X|L>F MC18 E-7N@=&.QJ2BHX_"23->|I\$5AF/OT5Y38X^+9&".|IYFF&|K8ADF MF.BDVK F+P|X-#^A+|I%;E)Q98%|
M|Y|6YTG5Z-1.H|WA(9%TY(X|O) M+|I|S3V^C^*G|@|0D\$R|J|COT@I)=IR^AH^C.C|Z7B<=&?@W@H-.L^BDQ&9E
MUW&B|H|QIECA&|B5PRZQ|O+LA) 8<15&G^T^*S|=RZK|ZR@67C_:=S|<B1Z10B6GK|8^>|KLNH%L9./\$.)|&4|61@P|!"S(GY MN93#|D|>|Z%
|4H4N4)|5TWL#NZN25<_I?D5Z2|O6FEX-P^GW/V!..RVZMY6 MW>^&ZK|>5MT?=>71 8?O|O7VHPK=>=>=O:R|'05N0A.|=O D|C^@Q|!(N|J.O
MA<2F^W|ZG1^=>0"56| 2R|S|I|S|J2K_ G851U 1#X% MNH-S|3Y?WR97^ZIL+A2S= |3|8N 1VY5?>67?P|B|HUEK1.#SE&L2\$22B_Z>\$8K4U(2^
ME^WQ_JKBWZ%_87|R|3RDHOHO|? P-2+RP|D2E:&D7RQ?!(=O=E^GZ|AV^7F= M6@.S|RK@XWH.3&^1\$CG.O^U2YXT=6C65>R-
3VBRB;JG|L9H5\$S.6>5@XU M^)|P\$^Z^F+^"RR1@:LY^*05D|I)!\$S16@K^*G>CO|JW|SP+&#B:O)"#|9 M.BE^/R:R=#O41.R7C0^*XD|=I?D
#K85N|7C|K0\$OX-|I|/32&1S^&8RT3< M|26-0|N|JXZ=&|&#L:F&9CR5W3@P7ZL.Y9%ZT81!"\$FMA|UXA0O|I7H:E#A#TV+L.KLC6I-C5@&A|Z.)
MCA-Z7M|GLDB+VJL<74H_VT8|(A|D|77C:|UT:MYT=38.T-I<=&\$P4:9|Y#M M:NT8H1>SB=H4\$<|2^DK=-
M8E+=7%|0=P|2@:_8R<_K6S3&-89/&6^WIR5DOS^5E|F|B:CA5=I-L|B69K3 M2(MPE)84EB@A3V.|T_2|<|@:TD4|8R>N#("L5^R\$|7Q:K\$0;Y'
|W|D|@ MKE-|I|B2CUHH\$-|8Y&=&+Y@S=-=1."6<|.I?S3|CPE^I?>2RGTT7^P?M^QMAH=KB%|IC6Z^K|O:O?I=?I=S@WOQN^1X-3;S:E?
J/FW5=>678BY+ MD&5|&:ARE<>N3|O)G&- Y*|Y|P|<=&E.1+<%6?UM#UG|S+L+XX|7B|U<+0S|W&-V.H6P M108_OPMJ|.!!S3;H&#^
I4\$-6 NV>10W<4.X|>D^?T|O<(\$&Y)B^*\$M99\$3PK\$OA\$|>5ZE22^O|H|E|L.R|72U^\$|@QF.4Q|4|Q|E@|JOPU476(VZB M^6^&7P&|2^T^9|).R(%
07<|XCR930^&(W-|B|B6@BRH^Z6.F|XEGAS7|R|S| M+CP|H|@-OT+|@5|XSB%3Y|TUWKOKR|H^&^F^M +=.5. MXY-
(59UX|&|C|BKGF|C|C|V|3(C?|V^NRN^0S2_&|XB|D^)* BLMLQ6ZOTGO ML|X@PDT3^6@)>|R|>U=BWA|/HIMPZ|LU Y.0\$G|I^|SK?MOBV|V6
MOM>@|+W3EKPX?=&G|&KEPE4L^*GXF<.CZEXL^IYUZMAU5|OW |(3@|#+K|T8>_ MOCX.#M^M4?C|YNCXU_T|AT?O|J4B8=,?
_5B>>>|A|CMTZ)CWXO>\$L<|_7 M^O>A.W60A4|7%#ABV.3P|+&R|'93|R^OO-TQA2F099")@H.+|E^|FX.M M8@YHB|7.DD-
MGRC:%@&P|2C5C-EEY298?5">F8|Z+9\$+&P1|ON&P.2\$H|WWJ.Q=<9|S\$XQW_.02BP|Q1^G|B0-ZOX@_J|A
M)56^*BP41U+H|H.OH|J%).*S5Z^Q01N|H|D|WV&Y|A|A2Y|D|G|I^O=O|N^ZR6. M\$^3.7D/C>9Z(M2-
B:7D.N.O^&(HMG07^.=B^8L^X&0.7XO|EY=IR3@4+EH> MN=|X|I^>=&=O.K.T|S_4<@DKC@T8^EM08M|<.>W&Y^@F-Y|CXA|V227%HS^*
M.L|W@|)XV?GU3X5MH7X4?S^C 9%..|TU2H82+R=9:1%Q^?|J^TOJW&V M0^JX O^*F 8/I<|L^NCG6|C=I+&#G|LZ|K7:C?>3|YAR\$/\$FVE|A.
M|WP."+|065:FVK7/!=G|VQ|PYG2#^FU^EZO|O|P;SB_&H8\$>6A" YEJ2QX M7M|WS:^^^KYKZ_E^I3^M9)*
7<=&L^?|>998I9E|3D|A RH^9T=&+^*XO MZ<#&S|Y^6SF^V& HKI(KM F^75L^9CS89^H90K.I2R|M<-_OZM|MK(I_!!1&U "GDJ(K|M)?IY
M(OX^E% 8R+B^WB3(I5T55;>|7<+I/G^5;#0|I<=&|B4 M^| +C+AQ).3GCH).CB=R^W<@&2RZ#U^G("?)@0ZM|MK(I_!!1&U "GDJ(K|M)?IY
UE(JI-.06|>2<@&C|V)E\$|JH6;H H^")|I|CC3NOIT96^Y|D|O8.O-J M+V6E6MLOY+Y^+Z5/EN&(# \$O/-!6E\$?DU M^Y0YP6E=9O|J:ER3H
EO|D^\$|R<=&Q|W-8=A|&R66T\$GT3;KG|J^M^_3 \$ M04?2.L9#314GT07\$|HAAQ-B|X:3E?|78N^|J_2|NU^M^|I|27_8+&Y&8>GV.W|Y|>|>-
+|URB M^..V%&D%(HY8C?IY4>289NKQ(5E7^K:5ME-ID_@TZV>|A>#55@)|D|I M|+R^P8GANM|&^2G H^|"S(I=9EHA5.(Q|2001 MIF4
1^6UQ\$P_ D2?#&M^*-P^1&5HUQJ=-2JSU#^ @6U8Q4^:#5^VRUL2PMT M28JBNBW^-_&|J0DM.=8^/ZA.#)V|3(-Z.86FKIY(L026&%(7KI|6I?7:S
MP<5.SE+&|).UBC_P<08N2ZX^30CMU|MGQZ=V.AMXZL<0S)O|NA|6|30H|3OC MC0^1XOWD.B.0\$B-FG4|F-?
(C15)\$C3NU22T|Q1|I>@A|WZ9|HZ|@^|I8ATU MDK#|C|I\$Y^&Y2F^E.O|E|&|S0B^H^&8A+GHS|4>U:7V|?|FE6S|+1=/\$R M.+G_.9H|M|J|
S|EO|)=HS1EV7^M36AX+7GN|01IN-HD3>H^P\$W_66|39BMT ML9YB|P|>U|40.K:("I+8|J^9D|B+X_8V|4A"IV35?
6|P|:=^|084J|S|K.RDVC&4|W^3%HXXLG7UY>O_7UPK|T|ZU MT^R=0|MA^?KR|6D|5M5&#AFR-EO|2C|<6|I|BPZ=?7TV M"(OM8M7L?
904".7S2;^3=&#P5U -8M(6PU+O&C|I?&4S3+|PU=5;319^F5 MHG>8B^ZDP2C\$B R6+&E^WUFZ7^A>24ZY^E|BAT^O^O BF M\$+?;
38WR|BGV@OUS|I+SB014-H.ZB.A45>9-DC74 5C_74X|LXMI3S9.R= M=2YB43DSVE+A4P-3GYN^2@>9-3F47^ZT&D0 |C5W?PF%|_S
5>:Y4J.R:5- MN8F|F|I<|A|P|Z|Y|=+0|&J^|U_&C-H.M|Q|H|XWVC":OP9<6)C#^*(0=O
M6<I9\$5C3^SB4^*M_H|0SBI|^*J4^&PM&D^5.R0>3^Y>H;MA0:6D>6^DM 5 M^5TG|9C(|I|AWL|E|A|6A|3LK0R)N.1:HIV.IU8C(CA3YH=
(X(V@AN:AOW^5 MIR^3(I5T55;>+>=6ZVD+3>D.DHAZ5Q+1XU5O@|I^HBR^E|L^H8&|IYU MI-22+&^#DIEA|H>WOLN?&XRJ|J|.R4^BN^389YO-
\$=Z3#A%|8SYB^IT2 M^ACNB^G2+U:L^NI64IUZ=T.AH:L+7|I)%-5|E ML9(WX@3+&RJDG5^NOE|I9:GWA5&X+_V
D=EQNHK|11G|Z+&_B:7Y0DNXK^>Z MR|FC^&5E\$Z6AL&A29^FG3R7L|E:F|WCWBE^EN^|E:6T_Q.EPON|LT|S|EX^& MNG^&X:|X|2I|O
|ETH>4Y8|H8Q31L^#8?&P2^SS>@<|I|T|A2W|NKZT|L|H|XO M4B^+&@D+&GYZ>NB|R&H8Y61?Q=U\$H9#%\$ZX1^U|H|Q3|D|:WUT>IU.<&=>3<)
M^&.LO(85|?81V8O:P|J3XYKJS.FX (5OM^OS4L(*)|L.D.RT:B?"@X75QV MC|E.*(5G\$26P67_ RZP.)L>^*J\$8NG&RH^*JX.L@|I|V.1EHE=;(2Y8Z2=
M|C("6WS5X>D.D|2D|J02EX#P+K^ME|JQ27-Z|J#RX\$C\$W33B|Y^44SCS^>1D|TGYQ6WB+&G7V M^I|Q|P&OE\$VUG..83M9KO#H>9=U|HDD)H%?
D@9|LH|+&_5X2^|H^U64DG N^M^H|I9@O>=&J|J5S|J_9FN0T|7&3^?>=R.M.G|&H55>7:55/N5|Z>|>L:BD|3&<
|TY<75L3ACWD5=%8|917|56YREZ# M7D#|K|B-|T|JVL^4@!_6Y^Y25:B^K^%S8+V01PXK8Q8@T%)C9CK+U)09RVN
M13N:GD#PK@R|55|5F|D^5TY@>9XO|IKT>F2PT3^25#|M^ M7|E|4_10V+&^ MAI99(\$<>N?GNW&+7V^?
007N^3|)6&M=3F|8L|HUJ|/A.8:H|J5K3|). MW5WR=1\$.XP&W8.R.JJ|5F\$^05P|D2UCH59^0G:*|9JZ:R6OSK8;TC?AO"-
MD9\$R(G|S+WG.%4B2>.17>^&NO|B&:7@XF.LL|9G|J|J|-Q#|J|S|Z7;+3 MAGNP5-2E^*#3^Q82X+G1\$M4^DVPS5ITZ-P?
^V.YNOT:\$@RPM?)S0 Z:HVN M|O|ACXHO3>B|OUV|I#|I: QS>&-ZB8(6@|7Z>IT6?2: ML^&EQ|35^+&#3_ UP3W@^X^7E@8:2 MB>@=|H|I-
R:2Z=8&FGK|^ZI55R-.LS-(-3) 33:ODI^J?3|I)^9_ MKU^QO: 7?|16&I|RL48>+2<|>K9ESWJ^E0^C|R|A|NRY7UT8-I|01QST M|I/|
J|Y|INVW>8>NMR^OP\$H^BN&U|&K^*SY|O1G^I90F9P0.LPG|6GR#|Y MF|LD3K|U\$ KEY^O^M^R^CXLU09@P|DIHLSR=>^4^@.0WN\$|UD_
79F8XO+4 M_2&L4R?HL|?|BKW\$:"6LX|X^)*2G +U|Q|14MOF(|L6|+ZBQ5=|K=7;
M7E>V&K|WVY|Q|TPF:V3R=^>N4|BXMUWL^>D>A+2:A8F>Z|KZCZTFBULU-UT M1G^F%|G^V^I>=&H:"KW A^R3@=7|J\$
MV5.M^L<|H&1WO XH33Z^9":JFGF&+O|QS@/|M@<0O|V|NVJNT|)5U>_ MWSY(9U)3PE_O8O^5|XE^H^G|JNO<^<^<1V-IV>2G+G|+Q
W|I|=6B|4.M.&%O\$.AQT49709(|I^<^K9S MY=?^8+(L)AB5OU7OZ3.G>+4EJ+5GMVHA\$S4#B8:|A^CK|I|T|(I^PGN|&BH
M2(G|M|A>=&ZZ%HEPT|I>|+..8.GCDGSX^E|I>K^&+&#1.H6 M599:8(N|O7&O.010XO@^O5P MP^J")4W2HG@4E^5OM2+XAVT|S5
M&7YK|+L|O|@#&XZ_&I&Z=PIN5|E5R^K^I^P41-V9J4.K8Q|I>|DBJ\$&#|< M<^&C^"W|P^R+S.4&H9B@|CQ^4P974#M|:SIXUR^T|K&F^W;Y
4&_ M\$C|I|M+R=W@M^SCT?#R5L2UH&Y&0?|J|XB+H: 9VOF40:W_3CD:QSLFY^78S MJEAS7|&|Y1R(ZXAR6/K&S:|A|K^8?<
L|X9|SY99|E|T|B|1%8ZLWISGAO=M.W.T\$W5WAF-I=ABL=-&4Y.S2C2P4Y \$H5|@&^3ZL>_ 3XVD |X|>+&#N#&|)%_4L=|
|H|0%&W|AJ&L^V|O=X^9X M^U:Y%W9^_VM<=&QO^TPV7UOWJ>_2Y|96.QZ.|H|MR0OXJCU8|6ZXW=V->G>J M>W^>BYU|2R_7@R|6R-0
M\$=M|J_7|G|J|HB4-O7KUOLW:3TK0|L-5W_|S|@?U|I^R^&NB!%:9?ZCE^GX@3Z MU:K52@E|4 IMZO^V4O|I>K_G^?^O_L|E^/_Z>&(ZIU^F|9|?
Z|OKE^7F#& MOJ>23|E\$1^<N<-RO?>+<0?Q|)^P4OQK^ZQ16H|+&|.URCTPR_!4;|B|R|
MS.TBO+^+|&U|>|B|U4^86L&3SE|JU7(17|75+Z MSWR5<|A^L|396?>R|
M|K6|T|L?_EC?|X|HLOH36|JCU|XRCB|6|4I^J+AH<|I-1MP4A(A|3S|:9A6 M?U%O|T.GCDRTZ&W_<CE>4-0OU6S@Z45

X.R.3Y15E6437VJ|@#Q/Z:W-K:K8S* M-UB*+S|K^1OBLLE^5LVK6F(WO3QJ1Y,X?W6J0]>|G-JY6FXJ0==<1ANZ%EO
MVR:=@0+1^K6Q:M ZF1W^C4G^/;<2WRWZ^I(0A,STPI\$GM^@6^24AMWH)=5:;<?VB@V#K*VOMH(M^CJ7YXA M<12>0CUC-3-
P.L6%\$%~6Q|~2+Z%YBJ@|X|RN\$|~^=POOB9.AHCOC.MP2I MTTX\$% JJJR%~:~?Q=@:27U:9>I.*C|HDCV:DIW=>H^3^H1A.JDI
MHO55/PC5 M7M:W'HER|TUL|S|&|&M'!\$?|I6N< MT^ U3&MFF&|Z9:86ZJHMY^KW^JV|6D<#M=4 O:44YP^NPT1&W2BUR_LL3G#(I
M10PB0KA<6Z^"(OQPA+0|V|6|E^&D.@OY6V.T|I99>9&6CJOTQD&M@6N^L 26\$S|QUAZVIG -G^M5\$%K#12^4ES"@X@/FP-XEH: MO.\$=18AYO?
IT=X.O/9>00^M&1FJ M:YDISI?I?M>ZT?JNU6&M05EN+M6ZJ M_%HUMW|O-I-U:|+N2PL|JZX+|I.7X:~"8|SUXE8Y+XEXG2 =2/5.S@OPU
MTKI:GFODI RS0:~C'B^G^XUI|@#N10|10 W Q|Y#D|VG:RK^,QI C&6X^! (MBM16Y)^5^JKC^|MT8MWN-
1/E=K9JYD9TX GH_U^%K9ZZV.Q "SYF25B^# MUY AKP3Q.QE/53P.2D=4X&NU^6 CYL2.5MIU\$AQOUU|I|Z@M'^ISM5:@:BLP MO!^*LK4 38AU>
(3@/0YO:HXOGGYM,/#LJL # T?>72K9J|UWBK _|J3D5|O M:9^31/!(0K2&OS.D?^ESFC.XKJ: |8PG:|@3%0@B(00?H_ EGU9B11>(W| M>82=
(252V17K 8RGD^MX16|6LN>#QRI^5|I|<SR67X-UDI>|<SNO^N^I.OQ.M.M.I?BY^I#8TKG881I
1R1A|<26SY=CBI=3E2?I%56=A^LU.3A.W<"5G|@S^M M.O.6C9ID#>ZH1^6#>QI^I^Q06F|ECVC@|AI(E.PIC|AL>I8:~J2<@C06BK
M4|JW:\$89N.1.1'~EM|V|ZUR:O3|14^5R&Y#<I15 ULOSPN- 9CS^< MG90^X9==F)| L |T|.QI?_9^NRO.2MEFM|I)^|3-0-S%;
|BX:R32R|U2B\$>Z7M^I^RQ-70P<+T+T^90PS2I M.&^ZPT?0ICIFA#Z L3.#ZK^I=^1.#B0B2R^N7?4M3K^"(IX^I03B7>WZ MC6Y?>AZ458
MS24I-9^G^0U5I.UF) C968D7:3F+=~J2^6+T16^GIV\$VGY0S^("Y*\$>S> R MB^)\|MS6^L|LKZ=6W%|LIV.7MK9:~?6W+~9C;
(K5+D^0IPD^%K>:0C0^ M|OXRC^:5:0|CB=0^GEX_HD(S.-9Q.=.DM1 U_08=.S\$E.NB^H%K&F:P.O MV=P^JR/XP=9QGM^VYK>I?/KR9OY|GK/-
2X YM&|Z.#. |P.C@X.GY.=+S MX2^#HW7K5=#JL^12:WIX7K5^#Z^EZO_U^O.WJ3|I NV|&KNOE7.#QBOW:2?I
M^/Z6YM.R1.K6LZ|N(C|PR5LK\$@:~"J1V|I165KWSTIO!>4ZZ4HH^TIA. MEMNW:RLG=2./I 2^100K:I^MVW9 CT/KRK6NW^|IEIZI|= "U%?
RV@GIW?>A?|52P |PQ2I/4 MO S:GS>G07SVE ^4\$L^H|O (V|F^B^?7&XID| ^7/DN?7G _LIL.V-F>Y8|>MHM^VVOL|N|JHU|UJ
M|T6%U62^#B|D\$S.0TDR233\$G|3|XN @>X\$Y 6=:\$A%LE O|X B|I ^?I7^1M:GWTC8^"X_2^A^?|(PL0I<+U+G^YO'A=9P?GWIS? ZI_V_||I1=
M7%W?HEO|@F+Q^O&^%UZ|I.-X^V^T|4@PYO^&?/ 3#V3EG^2)O^*=|@| ".N! M5|I>3 |S3|X^|I0096^7^*X/H95R310 DOV(XC N SW01(=Y^"O3Y^?>
8R7 MWZ ^YW2|CW18T<=H-|HM/DL.Q| ^?3^3N?T^H=^?2|I^#T^7CZ^H2^S3(GGCI MGL:I| ^A^|S0X^+U|IED)2U5#.4R7IGIOWR YWTO_?
O|S|I^Y|OVD^2CT2C7O M+<6<2=+^AW?PYRD^?LV S>S?Z)?>7A^#V0=RS2\$K^M^N|A7Z=B^4|A5^0+@)?
N>T+L&Q04/J6^I7O7:Q+B+^2.A#Q(72=+UAW=+QU_N?>KLL|WYI=+G+ON^IV4^3A|\$:T#_ K142Z^AAK^070#-O
M4M^16:M6 =|L:0Q7XJ\$^|ISQP?GJZ^<9S-8Y^2N|I2X U_5@O+I0I< M(B@%WXBBDK/GDK^YBI-%C.KAF@W%)510(YTISZ>KZIV^"?
GW9S^I|YI|@DK M^QOYNM^X^2QX3R7R^HW8L)X%+E<@O C5M+U @Q^I^1^:VK&|(UOR2C 2C3^6O M4R21^&^\$L0D@+@-22-E#F@51DC.
CFB^0D6.L82V=+JMDVLK^U9=5 G7>+|B7PWX|ZV@| M|A^V|J_E 3UIU|RW\$81 NDX|&G(Z%OY5A07W&CHY^9J-P69 |6LW4_#KAU
M:QO7:~(I^T:8WX MY1G2A^). A6:U&SCISIM8V88L.1:62K|7S D8?C>^QB MHHX|^42\$HC>D8^=|I^*QQ<.&RU^)^\$6P(8_>|O1=,672?|I
|R:&X|S|W MUIR4W8R^C9>3MX%_SU=D^I@|LOI& M+2LVI:>?OSMCS_F-2N5^OTS^:JPH4381H+ZVS:JO|I|=NM\$|W(3^>O 6Q^U
M|SAF2VIU|FKG^2E:ENORY|ICL|8U6 FIPE9RN03N32FCE+02M-|V4J SK_-M|QPG+V#R^OG:R^4^B4H=ASN2A|XSE/GD^F^O>V_>~:I?
YI8:0%4\$@=BW^| MZ6@H.Y.QQ2OGL| @.U:G=12)26Y\$IV\$S&21^3QSI=-8~.:I?Q#83L%&J#DM\$; M-
FTWZ9IP&JO|E)S\$A4B6YRPK2G|O|UV %38C10(8E1.\$*SMAT5GA=I@540 MO/39|V|O03T_OB|ILCVKOS5OY^I:M9PA.(YFKO)>VA^?>
T5^3_Y3= ^/CA M|W BEN3X:X.A0(C^==S/5O?|.\$IE M+7V3FFTJFE14|+ZY3.<1^<M(1^@Y^*C.8 M^I^*(T7C:F9X&KBZ&KH8^KO^+!#F|B_TK?
CIS1:=X|7("WVF">HV9 BR:1 M-OO+QGC:W1\$LF^&J|R52IE%U:VJ:U:S9T4|Z26|I&WK.I0#O|99.: M+2O:7W2FL:?
=ZJGGYU^QNH8U.YU|B|PNL|D2|U|_Q|FK 8Z|+%;#C2-8-G M3WL+M+V\$S@<Q2 YCS2Y>U4C7^|2\$IG08|PVF&7^%EW3^|V@0Y6#?6:L|7+
M^18|6|F|T|^>3>7M>|(UZO@|HOB3K%(G|I^)?SI:~91KCE4O|UQV6&4F04I5 MF<~2|D1K2^F8:Y3|X1QYIP
(H=L.CX&S6GF^! |ZW|=N.714.IDGZ^K#F71 M^MCG4^9|ZV^2.X3|V0.E.D|I V<.<5X^ \$EX6SUIRD<<<< O5I\$7I^X3IR M=AO(Q0P^H|)>V-
U|I8 |YH|TN^LDZP^Y.G&44\$B=.D\$2SOG(U_OYV78 M4 L^F^V^7^B+S_Q 3W:K#B>02T>VDX:N9=H=I.D WGD^-N2Z)W>M^7N2Z=JN-
^|ZLPEY|>YW12HHU9ZXD MP+&N^H^1LK8:>^FU:G|I568\$4Y.V.F|U|OYIE9U.V.F|U|U)S.HHV.IT.I
MAX5^JHSHC/GK7TW@|N:~N39IK3=O/V(\$I^W%DBS|OXO|K|&I==^>BIUG4Y M06+^R\$G4L |V|H^V^4ARNR+0^D&\$L
M.V.2SLIR078PR 8G\$P|Y3G\$1|F|J|P^9|QUE^JZVL2M6B&C6GMN@LTH1\$96I) M.M 3<^5^9ER&2L^1H^")^<I^D|D\$7L^VS^O?
I.9|I|MA&BOYVX9IPL.Z M+EIAY@HWW-S: C5:7N=J-IR@7RI^HCXB&IGH5N|;G|UW^1A|=I^H6CBK F\$ MW^>D HJMI<1LW9O:IFO-
AISC<<<I.4=+32 TMKMH6MU 8:H.65%XI^V^I-HD9VNL:23-CK@3|DD-3#- MFO-A-.H.(PCT)-I-U3|^M9W3| =+>2 OF6W2L&KJ|HZ=XRND@0?
KL36EE\$ MB^#ZW|5C|I|CN/W.3|8<84K^Q=K+^.=Z=0<@)I8=^4M449%."Ri&^+@G&I< M2UO^%Z:9|IAXYI=+.%Z:M> MWU|F 5#BRG>S<>Q|I?
RI:C4H|B|>@PR+E.I|I>LD(I^Z#I \$WO:G<+^K+P_ (S%\$X+@U.R=L|>3SK.4TMG|F^6|<+^D|Z M0V:<=.A3K=X^P0%I:M-N(S\$*+=^\$*+1!
<:QUOL2I M^S?^C(I|B-LY)BTG\$8Z^"^^S42 ^VR\$^CANN ^=+464QWRVYQ6ZGNMSKQ|I|MLN5|7R/AX6:~9W+61E5AX:<D_#522|OQ&_ \$P:93|4?
|4M M2-A@I#Z&OR-|30E^%7R&CGYM+0.-X^CDOZM^|N^F|I.VW7#;ZHIE?^8.O^? MVID8:~9-H:T|SOR)@?|B

/=XB3UJ=[JWS14WG\]M M1F,41#*92TMMQO6A*#B94> 00D8'I*0S=M%|_W&V5A=\$TZ/-7 M(0\LO*7V:USMRN]+5B%VWD?2136B(R-
TNDM&H4 M&L^K<=: LJ+EXXO NZ7^ S7 M6-UVFJ'78%;<:|@Q8'CTL\$3.0)*H-R8+I\H(B07>0MY0=\$A1.0*Z ^5CB^Z18.ZK\J.L(9(
S^B)1X6(@O"15U: ZST/6U+XQC"UBLC\MM1F0C2WP54 M5!;JJA BHG8K;K:AM6Y#JBWOXG5K*J'08MH_Q3CO^ AH7CF&D\EH"^_22|
M1E&G=/HA^+Y7M,P11,HP,UZ6?ON4^5+QKEIJ945&>YU7>@<"/> E.R.C\ MNDJX496\DI9:<B"##.L ^2)97^E. L,UZU/-5&*G&104FWWDR\ WP!;
|WFQCG MELX6=8&=C.#.+ @JSW6?D47F5%2"A E0^4D(GHY<=&5S2*K<9S?2.3;Y2^WAM MJ_5W5028_Y7?=&L;K2&C6)S. D'1!^MMXRK M(E)U#
<=&*IBO-<N2+U25<5@<T P1 FH/UF= :J'Q6"& B40+RE&I')RZ.W@ M^#K15I\N1LAP^E)93J3'2:9M0+;BX%#T\;U137 \$I9BY;10. +*T@%R/V&B
MS3N\#81_U166SEK\&MJG>ZSG1024D166\$ T+>WF.9."Q95W\$Q.Q:5E9. M8RIJ\J\JU4H^4^E'P:#W6:3"~U7Z\$=^%M*\$S".
T^W\J57E>E"/0+74"MY.@>- M<=>XH"Pl;# U/J:5.U.YL\$;HW9; +>OGI4.7B_083V73%G)PZ+LZ&\$^J5<M7V)3#JZE?I.D2NLGY3+<+<
&DCU^JZ601FFD7X:4G#1 V\!+M/YR**N\J(L (M?PKL91")P&:I9:EG837^N13%Y M6M1N;K\J\$9(1T42^YD8LSTY"Q. #?6I:X%>2SM,"R^YZIFLZ&!
(J^&H8?#IBG.8^H7_VY7 M.,GHQ%6"1I:AL-F1^CYXKF.'DLDV\#>1Z64\BO\3/3\&J3\N\AKVMAG3N"-O.MX0\$ZPEP5?>S=0:G\,5M"
MA>DYUX&20JRG=[J0L+AGY07V:M3WVFZ6A0M(M@="I-PG=0MN32.\$)'SS(F\ M95591^JTAE5T\JY\B)=Z%.W-
^=Z7;>LV<=78007EIP(YQO(L;+5.QB+UAZ MNT?J70^ULUT@Q=5J3K\$3 >=/(V*LI+>MLT2%.*ZSQ.E+4<I(TELE%BO_MRI\$89A'R'8D-
>Z\$ (8^3B)=12)15&\$W\!+?IV(\$Z* M3!*\$"QW6*@FBI?%+Y/E@_@71A\VB\$@7*M\I)M36=Y;>4KA&HTG0*:79\J4 MC4^F:3\HW99#.(3/;
/I2UQ^L^X4E&E>264B.LM+>+0:3B+E38N\3L'2'0^-M^JNS\J"/MX.L%;.6+74U\>=OFTS-ML<8^MDX\;D1.MNCEPC@U;T^+S-
D"*&WGQOKZD31N24M5A6E;=:(3Q0ZA\ZL@UL&W(HRK. M34VU=7G:\$J\J\U+0.9=IT E^29.L&\$E:60'5+1VH\T4 ^4^!>1 MQ_.LZ#"P&?
3RIG.;9:/1.1&SW%280RN:CX0VK8D^XYJ/.TODJ^K< E^Y.U#16 MV^7KDEIWP3J?XF\$N;38\I\$N_+%B>OA&1WFW:L/=/\$/"EQ2^'^S JJ5C/=5%\$
M4M/>5\$"/U/>S7_YI@JFH\$<^6&"5I:C89GKA K4HODU23BUEFUIZ\>=08X?7 MM6D7J\JNA81_N4=66M*M&M>UM1A** JJ)%A\YV<)T04M.T\<-
SGNB'VL\J\$E.1M=#8)MZ=S2'H M*1.ESBE\ PC99510^UHKJ3B+8;J3G.JHZUS\M7&OL54\$ JK<-+>VQJUI7H
M\I)I)O\^!:@M.V3SE4PCI\YP(FDH,1,0+5=:5*1YYRGDOY6F\JNMKINDZF* M0J/4)2Z&0.;7*HR-.EM,0Y=Y757EQPO-
!OTF6^Y+&EMPOD6\I70^DBFU77L M5MD\A ^ECH^Y#E?^>+&+GM;IR3?I\SYGG-9?Q>0.*@/I2T MMAB>P^SO^D
<12^!>=IX:IRB\$@U5\1U:UMH@?Y^2^J^2P MBNMLEM7P @.E.S.=\ABZ5;= MJ86\I9&.#U\XKP+811?WIFDIZ?X\ZV\DI _>OQ6=?
_H_WQAIQ@I';K0MD&'MF)3EI?>5B0<?%PT._M0@6U0:QM\JC5CZ:AO^JL\5V\^B\J^7I=X^XK# MFOXK/^48 A^G=3#0X=PS;.0HS^C\9@C&?
(L.921Y=& HW.GP>LPRMO;=VF MYZ^N.4#4J\= JM-2I=ISS(DC^7UG1TNG>4FV\8Z7+8^79M">1HL.WMV\I)&
M9H6*+9B\JTV2;2G8\I4&*V=+@N<0H MK^X.*\$RU0&71 Z\^L3B8X@O6 G=JF MTWL.FJ42-^X^*7E4ZMV/@O4R<5)8^35I-
NTL1VTE38YMIQOP.3JTOQC MH^% /O4D'JP@ZK>DSL\$C^J^ U&OLCA\Z\@I^'W^C#22CS>I M'+2\>Y+&N9\=FA=9.6*(M:\$WM(Z#(L.E?
VG\3900&O@ECA< 4B6I^52F M:3HP(K\$*B\J@-Z^J^+>OE^D%=5V&35+DA7TTN06E3:PG=[J251\IGH0_9S.MR^PT-
**0@9M>=XS400PH231Y9<-.C.IS;G. M-\$3Z\$O?Z->ZN<71F^NH_EV<=\$G4O^"MO/7IZ\IBA#*>V8YMZW+JPH@=3S5\!S%-
O1L8\JOH\J\DLTF6.\$5J2FL2-9\;RGI^%Q? MB016DN5\^#NM2&B&-VA56\3LT^ITZAT^I\H\I\FA16?2)@ (/*EIZ<<S7\I\&HJ G
PG8.1*KK.C\JZMZ3.^1^ACCU=Z' MLEUM?A*\$SX%M@XK8^*N)^0.5P(U)\<(R:(M\9MILA1ACMV5.ODZV\CF\$5IB
M\%D&J@1^1^KM)QV_OJZ3<=&2:FBE5\0;1^FYQHBX_45K9J0\$^?UODGO**G.^7P=SMJ-U:9G%9T&>4^ZMFZW7^C5B;5X3@2?
KJ M^J\Q14>0MS.;F9\K!>7;1V7IEJOL0H&E6B\=(%BK^Z87;+L2.MUGO_-@/>88Z(N CA5XJFU.U+U^9\47>S)M\$=W)H^*W19-
44'O.O' S@:BA#A65Z-AB&JHX/+KN/OPL%/68RM?S<I\&Z M9%.E"E2SOO:D5J4,Z\$T8K^EWFMV/V.^@")2=.)J8WZ#ILZ'H6.^Q*&I\$1%
M\$M(W=WA_6U@FR(MPE30X&1^2D109^P@58=S2T)KH CP&+HY>(B_!%2I)M8VFAR=-0Y/D7- M\SR^*N-
I3>A<C\J^AW9M4O>75\>I8.HEZ2+8^P#E\=GSV>8E"1%5 KRP\MTXOD_OZ=;\$M7&_7.G9J1&OE.FRC;.>^<0#VIAU->7\^ BG01NOACR@L-
MIP*77EXRII(\$)JF&C&4)B:3M.XN\I(%@YO?4J7J\Z\!A7;=RRTL3JDUGW MN&5_H3YS5\TK^GGY
R%J94%N.O5^FL%2..3&#@B2H^Q.1VYW0U1JZB^Z3CYP+SDG\^BP"B^MS:B/-..WMQ^IGT^U07I^RWM^I5CEM9C&I\X:I!=I^F&RG2IYOHEI
D9L%*9 MKB.&WD*P>6WX9U36;JHO.V@ M1J7BAPV.J\$ODPCJ\H.GVCF1^M65^C^T>C^N7?
(2^ZK13G3M+39812%I\+JVAI&#PB\P\O\$.8MJ^8A.^/+^AY7- MCP\JM\I;M2V5HPV.XX&HP^W#<+1\$^+.#.QE6E=J\$8>JRII\$^I2)H;3.R\$W
M1Z9M16(I)M\JZQT#;.W")\$&E.Y. TSRY:\$AF6V9JIC0I^#B1 M%IY%~D+I\$&44X*^;O: HZU7=)E997UM^JX3X?2BTM^VG5HW)% M\I
(.WYWFH\$>)/+031L5^#BM.D.SDU.H+""\C\I\$>O1AW@U31L\I=>HS1PLV< M2E+S2I8O=-\;Q5@>=>E3
MSJT.RG(OVH:\$DIM^PL_A(\$^Y+Y09^9;B42^QV4ZE@5JLGO+62X2Y\$4+ M+TMHLK570:B\I@ZNU\FTGO&?G-RU?0#I^+?^G:W5Y1F0U)L:1-
7IR-M-M^L,5^Z>I#;TLK;CL\$1.2:99VB@OY*)Q^N\$TK=0I\J\TZ&T9(9AHEPVSJG7- MK0:/>8E(C)>7W)\I^YA#N>8%;\$?
#GMS/+SPN\J^H^KVNHF\I\Z?RF0A+9&U@ MZ:X#\$3SSZ^C^I-O2P0&K.E^F^Q6+NT#="X^Z0(5>1.^>3)>+> MM&I?
FOY:W^V8=S2^OMB_4=IKTVL\$2.1%UMXM^9IGYBT7T5YQ&^Y8RZE&-&5OIL3P>1GEI\Z.OP) FFIW M6V\$>1%13;K3P>G\I\T\ M7H;K_!3F
F46G?J+.=CV(XW%16B:=Q I\OL@\$P^K"@PM=; "W&@!15\$A:4 MF\SO)6#7E@FY#1F3^>H\I+3 !1'C=::524UMT.>%B.R+3;B/G=WS^K\FBQ?
L.V.:22-15\J3\$S:-.%.#FR727S0L9VUK.M=6R@3JVMJJY6U^ M25+>I^J^B^GE9JTG&(6)W:8W*DEDUZ#0LVC1YD\CR@N_OXC\$54H;^I12#PAHI
M4=01.(LSD*%J8N;=C)D.\$1^H1\$=<+JF1&"OQ^CB\I(=/"G2AIG0&CZR\ MZ\JUT6;3P^00+5L1P0%6KRT.1 JIG\RR/ QE/QE-.0.X?
F@66-.Q\)&UAK)3 M3Z)6TNT?@QA GE8>=079ZMJV9C+C+LA^9;ZU\^L2M+H MGBR\!^P8U^1-(BK4WO\$!G&ZWN^NV^B\J.NU.M:5@SP+)(2?
4N57JPMZM M3^O.0W5<366723^BYC^"W76&5R&1\J-F-G\$>2--M& J%&="7S0(2PF_@5\$)UGOQ^U+>2IM;JTN&J0OZYVB>+A.E MH%:5@
898@ (99RRGW&>+39J3F>+>I3J#.#<@4?K(F)E3BZ\$?209B71M^M<5B9R5EZV_OQET^ACU1HN?0>@>I\I-
IKT&G2>1" \$2>7(C^\$NM2,J_29C9#M.44H3G9Y97. M5ZIJM\$&8ELJIB0T:QU0O(L@*1.0K)6JFG6VYP-GDXKO\1\|SR#J0:GP2OFY MLLND'+GW.
O#^+VA;I6J36&"Us\$TU2I\$#.MCB \$AD>K?^A*!"=P^L,+>+X ME)?=ER:N&Q\^4L>V+&@9R\51=KD"4@ (V\^L)9U6?8J-GPX\C)8?2Z2H-D
MTU&L\K(1^4.46IC9JOH9E/I@I9.W%BW\I(R+>9DO\$USJ=H\K;) RI=0\ M>=OQ WST.1:5S4Z4T@^*Y&^MN.WCF8JIT&94XJ/YR M9;1PK;
'ANQ\J01790&2D^XQ2:AUJBEO:K+2>+**R &A\!6L<:JVT;J MJ5JWFK.G^HNF+LC^1>1U8\LV3O^W=V7N+XDY3^A5=V2B-1\I)E9 M93FA9
E^R^A6^6K0=3K1@.7 FL% W:F/RSBC_*&8E\$3R&B'6\SE\I.M+& MYPEO"=@?2=LENKD"@=U&242\$S6I;-9 MW.FTG(I;.= (Q*SAIF-
M\LPK7=K.GP8L<"(JI MU\$!=^E2\$553TFXOO4U6NC?ZBN\$S=J;+>:C+V+)5=+K;AHFT_K^V?R12L=(>X M?J\T0^LS<=>I^V7^"J0K<
MLA_2E9J0^B^JN&I^8UA57Q\$B^X37F%2=F+IY3N^7BN\$S=J;+>:C+V+)5=+K;AHFT_K^V?R12L=(>X M?J\T0^LS<=>I^V7^"J0K<
M;V^T;X\PI2 TG_I5TZJVBSZ\AI_2E(R V\H\K_R\X^B^_JO:/3G&H1
MAMN144D_C15(4IKM.EGTF7AR^ZZ8P&^BNC.MWYNAP\$CX7J^YNWWJE@I: ML_038RG :S DIAM T\$.1)A43&7/E2"-OA7\$OT-
>@23\I:8!^P.0%MA3M". M\ 11%3070F=TOI<3A>I\9^9AW=EC3)M5.2H\I<^?EA@S'
M79/SOY.Y^# %4XG/#IFPB\@Z\B(&^+J.^R\&070@+E@/O=&7A26\^P.Y4^R/TZ6L^8+A7-@ (4K M^RRG5RX< V@7LJ^OX)S4#RB0_^\I-T/Z!%B*
(P0^V^I^@R2E^*6&I^+81^M^N-9VK\ SVC^T6.13+8Z9?>P.U^YXCO^R2^I^P1)R\YX\ZTG\I M8^JV_(Q8-D.^Z^O)J3(Q\KZY)26.8J'.GH^T\$7&5?TIG:
<#>1^>4^C5_0\$AR0 M6YQTE3B>\$.> (<1%W)@)SEV^BP\J^XOCM3ZFB\RL\CR4 +>C_31^AV M\SE&.\$(F_O_RGVA\$5?7)AAL!+0L86VL^A?
3&US\J0JWH;)7W"2PC^GE%BG M%1N#QE(\$ \$U1+M^J\;OHJW#I\COZN;!1C8\R@;J8/ JP+U6&CG\^AT#I
MP:3N\J^Y1YIV.B7&X2^3GXYT@CBHZM\$RG7N;Z5CP M#=#@70_~^EM=@>ND07SJ; 11)&+>=3;RC5(^:54FJ6)YZ^ANAPU(4KUT =
MT:C9YFP4.I293B41X8-VJ^79RQKAUHXK\I-L@F)^G_H\8OC\I&AB231\$S/> MN685WU5C6Q8
JJMP8>\$* =AOJOY5^86CH2^"=AD+IJBWB6"BBX? M7(UID+I^X8+>#%3+^X5NR&M2\ MTV_ZOA(JQ@1U:-6B
%\$3I48^C5A@91FUW6&FV>PU;U_4>223#7TXL "WE M.#3C#I:4^2R@:I:~?3Q> >2()RU-8E?>OPHZ(H#BLLB/#WUM4LMT#&I;
ML4\$EZ2C'S^?PPBO&OKP)_P=\$L3WCM_\$S:6080 <?24TU+*;>G6ON1 MXKE\$ZJ84UOLLJ+=7:IVQ#*LG7POL_U&\$ \$T4WK)-GR Y-
NBS:"0\$PXN MTSFO.KB>+*#HPHJD=?PZ8;AA9I-(U9.110#UJZ^G>+4F40:~4D:6!T)^V
M&GD>KJ67;B6T\ V_/\$G@GJ\RO\I\OT:GBAS9X=SWXD92%3GI\Y^AUS-O(>: MX:A=A=F+1C4WLFIXN<15^9E@M) D9L2\0@#N7?
3.^-0X(C9C+P%I!O% WMW=7^Z^O^W;M^#<^<7%X\WEVA^4IGM^>SAY_I MI>V7RX?%>TG-+N\0?7MJ\< JO\I7UE^OO\>7#V\$O ?
3UW\I0\ RJ3B \$OXGJ46Y7\^_I.*=O@-1^22D3H& M2_?E7\+I\O@+^B9A@:(S\B+0L=I^4-78.O<I9@)@#G\$Z;J\ROE\Y^UO
MMOBY\J(X6>#@G)R(P^6B7KM^B2%"#0ER11#;D+7W;IQ55SO# M31BL3WVJ.WE\I\N10W>D\$XBT)>>03^N.;K&B ?
FZR7V<=\$HA@F.9O\I^=> \$ M(E;-C\K@=9T^M6X5STOPY\$U/I\4X6=(A2)P^?ZV-"2.9 PL\);IW.S&. 460^+H\J2AY^C.V^~?<
M^<DJY(9)=AP\$^A1^>UOQJ\7YS&E:"DIG;ZRL_C(M>B\$U\TY)GB_J^ M^1<3\@ 0Y^H#I\$S\$WXJ^CY\J^I\<^\$92-8^4A_6C9@?
U1\$D_&X%L:NO@- M-J^+Y0IKK^K@^FT_C; <()J^EHZ,I#2&(87P4^1X6A;&SZ)3^Y):N\$4XZ)Y9DWH MT.C^*UR3O.MTB/-
B\(\$>^TTIH(V6X_-6G6^!= S=>0\$1N4\^FHH2E4#(8 SBZ M3^E@F^<5@SO^L^GAS2^I=AS+>J3\&DG1XN\)^2YO_+&#EUXB;XGN>(+2,1 5
M^V\$4T(Q^O^#AV\@;^;RH5J6Y>+>9\$&.*!-DCY^F^*FR^S^BP.3#^M^>D\I.C.IY\138U0(O U>TE_FI\2W KP^OA^YK^HM\2(T(EX
ME0W\$3EU@ /?2-1EV#0MT-Y8D&?KMG>JHW=CH^U7@R M^I_VHXJFL)O^S^>@M\TWHJC6I^A)I0X@4HAD MEB21\I\6/8?1#I"-
D_H^Q^SR^TO22 <Z\H3(2^Y%6B2\I\ M\LF@Y)Y%R6= M\$4JG=I@:Y(H+D\!&?&5^G^*DYV4FB:T.H?F55?3H^H6?C_RQ\I_#_HM?D\4+J\I_Q9W+R M-
STO@S^~ CCL7L.D.H^<+>(G-%)X/ &9II^5R.Z\H1D_R\$0\$S_P3C^X\$"
M,@P^QY>OY\I(W)0^0^PL\)\$ ^F\B>D\$A&I\H2\35V^T^_AX^>R+42XR\I:LA MAAI^P=I-R@W3;\$RF61B'.Z BHL\J_2A=^&.NC.@ULCHL
<@T.@(-6A M0S)<_QBBAS>Z^D^ND@EC\3^1HPV@W.6\$ #M^7YJEZ6WE;J<^#\$3_1 MF^JNL9&J^X\9Z62H\$&X^TF/M^9B3^X)QA9I9G(LQ
/@I67K D9/>AHR@: MK@^SXX\KH(E\8HC-#%V;"N=R^(6+833B523J4LDKIF^H^B&^CAO5^N\$K MD(O<=(N^+>31@T9S<
8A<@Y\I^P+ZGO(EQBI^~^V5.2?B&B\X(N ZR7@L MP^Z^EB^HLP^45X^9K^H@<4 MR^U4O^+VX1E3DB?Q2?SRIG8F@&^YUIH2CI@S:EDEI\$?W= JB
I<3UOS)0A MX94+2\I9\I=\$25\BU#N04A\$QFC\I6#<9(3\I<91@R6NW\J^B^7 ME:=S2_9JG\I7&7^H\@H_-J^5_E\+X8FF.\L_7+ASFR16-
SIV4#1\CV=W M02(3Q.IWO0U\$S\$178+GKX@N_#O#>I\$M@>7-8?7HK3VIRZQKUPHC#(RLC^D"2 ME?1IEC0U<IX?
CIDKHP6OHU@^Y&C2;B&4OY2I.NR82W610X7@I\WH4Y M.S.R^#=#GZ\IPGI\SB9_=:J^PG#^ MR&4&F;\$4NR(PD TGZNL M#-
J5\!# PVCPP74LP\WV^W@.I^U) O%/\$G:2I) M0#TM;VDD\&D_O\I3_993;&%X<J&KK#^*!5?+VB,OM=3FRV?2RD=\$2\^*@G; M8>F.= 3DT3Y8I
(0\$Q\$ W)WO<5V\&2D)B5O^~I@+>+@QJ_M)>J\K+PAX^8K= MJ^I\B2U26N:Q9HDPY\$S\ITRR.^OV5K&RG<
M^Z#") FCJ\I^64HSJ\ALRA.)X8P^2PE^BF JY\N0-P^6Q\O1K4.W.%@ M^9YV+WI/8 J9Q6L9J2J6U\U/8416^20YPO^SZ\$^*RIY(O)
MCNEUO\X9>GIC6;J@B/^74W%I2-(%\$8>E.6HH#1>_SHW9_!\$Y^VE+S.GDT^A ML11.T4\F^+@FQ.70^TFDM^R4J0)J1)#=QJ.2X0W8#E\QFGP9\^
5E558D@; M2W4<IIT^2^AI^SE^I^>#SG%-S2G <+>\$^S^D_>#%&I\J9\+>F\O\H^S-FC;G\I M^> A:~PT^W\$7V89)2\15EH<+>^~(02D)Y\I<S-
WZP4=<O\$9=S169PWUG^B\ M7P^.;JW\Z^AFR10^*^5Y4&=1 H^*8+4O\ "DGH:KTS\^IDYQ54PS^T(TZ3_D&5\$RC\N\Q\A_25XIR1^SB5^F
M+&E.F:L=GJKG.V5>APIU5S?S7OJ0U?W\YK?7=I/MGR=^CFW\AE^FZVR@Y MA9\$ME-03)= J2-(X^>WHLT? M.6^JN28;-3_-F&9BWO/I+HB+
0A6+^># MZE9P.UG/FAB1(&=@^F ZBHD.JYT^2G&YJ&@IPI#5PGFW9(15B&01YR4 +G M6:\$SU42;AN3TOCEBYD\!%250B<8Z3Q6)R1X;5B
VE87ET^U(N\)+6>H?IAP+ M9C&_IIP>AIEEL.%:7BN5J=\$A9^FAH\+R8F6^I^*6;BB2_J M5K<6-D=X:94ORJ6>Z(51)HUF@IDP3^+E/M^H
I\NEI_7^_SE2C7T+MBNH1B M^+>I_&0&CVHPG5^R=J0\B^7+>^&J\@30I6=VB3T:VCKUJ8LX^*00G2ZE M@22\2?:2?

ST(73%|U1&|JHTNM,JE4FPXJUDY0YT014KVD"94L2NF>|-<|K0T)M M5A7IG<R5=:2>:AUF4KN&9JA<633+2<:UN V3"H#R #1W7H_#(0FSW1 0-
,"GE/K:P>TS@?|U@E MAP6X;.&|.N>3) Z6&+XG00824,405+1HONFX0E+0T>];LD?&BNYY@|&QY(QY=<S^V|2DTHX!
ML_O)"^C'8#42UF09!1PQ_6L/)'WA?22T/CP(,+4|X7028@40FYG_OT_7 MA3SPKW'L -PJG:NKE Z.SK.KI!0)*B91@|_@_9@|V|3|WCZM2 L@7|S\$,
(M6|BND?BPP?@1;Z5">XGB49SDZ,"ZG>4(M<[D2|MS,|JZ1AB4BB0:=Y5P*M2D M3E=>%ME91HSFEDU:V&L|N|=@K|J!^I0ZU|U@<#ZB0-
Y^M5PSQ?&?JE*GRP<|E:P.A0;S.M.)|O^9'.>QKP(S.PX677E.5|Q120,|D3M1>>,>R|U|F2K&3L|9.R.3FD MT-B%|N*QC905S8IU#0^7SVFI>,
C4F4XUZ|H|5Y TK8*^C/Q^P AQEN,RAU MN"W6>Z,1.\$L|C|I{5Y^|X|I=^_X N^!6P2>>RELZH.|P@R7S3V%WO|I^V/? MY?AUZ^5X6!-JK^F^O^UKE?
A:7=>\$!1/(ALR5XF|9ZWX=C-3^|J0J3+&E:P M W^5!1#:+^?#7@+6/00/GD|.)|GPBPV1P7L|9(4^L^|W3S\$U^/7E&D6|HA\$ MM74&@?9B|,SB>
TQ_7STO74V9E2!&Z?+!|MD^,22LO?V N1P+K80S)A!4:K0Z.P^+&4Z>M5AXL5%6|(-O-!|T. MA2%
KS010_3..93-6R*G:VT1>=>AGKZU|.GAW|9U8-#D (|/R/HV? IPK JR,Z,7 MFA|A:LN2B(8 |L^DMBFTC6|' |6|S| U3BE%GB :NRR&+B!X%DI(
\$BB/0U, MNPINHG -7FE)?!\$#9/X 1LD"(N0!\$2H#-89CHO6IZ13^U\$| PBPZ1CGN| M<T.CZ17^%YL|)MW3|3#"/B5M%|J5BSFKF>"E%UA?
&=XIGS8|YY:R|P?*>X% U M+K2I5^!J9Y2#2T I#T2C/96^Z%BT).:*<9I>S^R%I#^"S/ZUSHPL|J|T-9C
M|9T M&B1V9#S21Z,^XN90^>K|L|>S^YU1WFO:S6%F8AP3|J X^KE_-65#|+8 MF|C N>FPZ1|OE4K|
_%>*B7G<<V|>)*1T|'WKO&K_99&8P.TPIY<4&," MF<(#.XN"?DEO0,"(A:W|3,ONY\$94UD4/WLQ\$9^YX=<13 MYO|7GH^P|IM3HV5@@@-
!>+!>B"BU&407E6" M2|!/"Y6Q|+5PQE M,WVY3Z_@7|O G^L|: @>P(19C=6QE+>_O|L|O%- -D S|I|E|@|9WSA=33 M3#E#A=2A/
BY_3@|HET8|0%&N<N<1^7GE#XIC>2IH4^7Z2UWPI3L|@E7>_@ M/P2&54K COP2,7U#^WT^H@B|B|391|7#5:AJ|?AN^X4A02.@GA4 M0/&X.*G#I
+*HW^25U|@)=CWGN%;S.*LTS3 "+M=@9U\$?|@Y%RCK9C*E|B(M'DQNJ9>5*=1BM-V-/|0W6E&-P@R+M6|7"-W*-40A?"1JXK(P^0PU47&*H@H
MRQZ^P^|O,"K=<2&%M.LQY|?E|)R^CQDV N^X/Y&|S.4U^P^E\$|WHM830TQ15|IX ^1Y%Q852)-6@D>0HR MZARR-U^|8QB2C<=B-
%|J|A7#H|_|T0V|3^JJO ME+NA|P^:*\$(L00 "ITV%BQ<34JB=B9J3T\$S&K%3.D3^|J.0M5A#L\$5VNXZ AWPJIG9;#&,
<^>3^1EFYK|I<5^!%4ASD^>BY+W2O*01 <1 M0=+3.2A2?2CV?#N|HXE-/COTA(K6H>:"><\$@:G0VOHV|/|.(5AMPJ4NN+^Z"
M6G34^AS3&10|.SAG|6^P4RZ P^RW6B7XU5^*YMS(70S?+>N0|@SRW33SC M/+CJR^&08Z=A@XJD4S/R3^Y\$EIA=Q5&8&Z|L>8>6X^X^CQV
M2.U1Q LR^K2\$=12&0+YZ1P^C=N?>6.PJJ?62|&R+<C^ID9V,FCO:|E NAI?<|O%|(C FH.TN:|).2K/^0^?>N
M%&@K@U<(W&S9X9X%1^5<4N2!;-EA0T5>=>86P2^9+Z^I|XD7+D &77+)|YTZB MJ| &YSV:Z1^60:*(+TCPI=.XO1S+C.22\$)T54..C>3NC 57|7>
<1\$F00",|>:4^:"\$QB %Z7|I6E"&|2LM:9S9ZP8 M-% #2X+(-8^F/P03OCK E!-XAM=AYO(N0.5G0#@VO39A>L.)^*Q|2IX%WX9 M^S>F6+B+0G>_3#
(%J*!&1^<248T518^R|(^L.%,?>?@O<.Q\$Y)?|A^N " MJ|3SDJA20XQ>M8>=>SK7^A(BP|H@GT&^|2NB BA92|828+Q?>FE|?QZV>DK
M%>9>|S^CG^R6S|K4|I|AP4|4ZGE10Z\$V\$AH-JH^|D8|G-G|P.M.F^*^>M|JR>.W)4B=8L|H|Q|IOWX|+7.Z#;HHQQD|T|@Q^6K8DUA6A:A6!#"|O|
M>WR0|PFL#K=A\$^FW-|7L&GN7|>@9|4+T@TFA|S+&8CBYPXCFK|_H,2|EW/M3.RGWH@9|Q|IMMUX<_U24CA&
(#9#Z#|079.&05XFC&8F1C|F^H1-PI|C2J3C(W MX|XR,02Z,O)-A:2>60UA= RS304/3N+L\$44>L_0=JA6|3Q->STDP^L^|I|J\$2_8GA^LZ3+ GG"
MP^N#M3P/HOW\$|>|P02EX|TITL8 O|L|L^Y|< (<N<57|C.Z|I5FQ N M^630^? 1\$N:DP4=>=OBT_-YA7(XH|_A^N^M^7|X|L-9.Z MY6/2")PWK17-
@%R^0L|K2A|9^H=Z&3T>8:OSPP/&O/A:~8* M8M>4YYC^W.K?P2|X&R9 P|37.JNGO2&F=IF:J WNX^I
MNV>5:12H02^W+CRGL=<4^&O|L|S)??:T%4YLLD5#|4P|>|>:3L|H@|>)>A MMV7U-XRD2!|"+>X^C^L3 M+>79(LS^OR^&^A|/ORG8ZE^XA
M\$ T50D|TD/52+IE72|6RL5|;M|LX^|R|7#&-&%S358H4|&OK3#ZEHCBIW^5Q|->KY^4#3;K%Z|36B|U|B24GY2 M^M5C)KIL=H\$^L^<
9E+M:10Z^L6/G MN:0(7SK7360I+IS<0^H%8#R=\$%DR7Y1/8T.(K>N^7@+VJ M|J|L|^+|ZOB\$W^~^U^B/^6S_/U?W^WQTI(YZE9:E\$K^Z
M3E^P|@3|&@_BHR^FKEX<\$@>XUXLM^%\$NA^H/_4| "EQEEX%*&G\$2/M^C.%53XKLV#?
@|1V/P|NZEOL|6ASD^IME<2|2S@DY|LH#<S7.X|H^RYD\$|?|OI<9YP11 M2A\$;48. "Y|Z^19Z(Q\$ 4KB|T(FE2+X\$>
|RY|2L|K|J^DU=%QE^VLL89 M^P\$="=PS_S%|O+QC(7|P%2_8+BC&|Y|LH=#|&+Y^N-%Q@OE)?0Y|K2DU< M|9M(W#O|BF=|%LT+EIPO
MB|921#D:8KJ+28^1E^|>8^4^D^&=<# @U^2-|RK|&=<GW|X73 U_7Q|<2 MHP52#S5|N^0+^%US/WZ3^Y22.Y\$?
@AA:W3=^WBY^R_|O9ABAA1^DC21D| MVD8.X_#_Y0Z8^2:K^S^DUE)<OSTC|IKYAJ|C_79|YB+Z|^31VS469<#>(> >
MY865|1.\$0^&F|P|P^<1.5QX>0^%6X4U^%7V4RU|^L1%|/I 7>=>K E8\$C:K^~^&38L4#*=.C21-<8R\$=IL|-J-GX\$>FTBC)< M^|9X6|YX IS|NWA90^R4
86:G|>R|L7|O.U@S(PZ-EK|I%+ 00O2H^P1<+ MRY|W\$^P.41^%>H6PTVEH1 M7?G&|11:SQ_O|RIO^<CF>G9V?
7.|N+X+<+3N^VA^5|&QXS:AI&|HETFOM\$5ZR M6;+88^C|L+&N^I^R^7=Z0+>^1.8R?M4RG/V MRMZE%1 UV9Y&*COD@C|Z9.T*=2L-
N^"AM|T|4QXCVU,M|B=1>@>|V>E0W^; M. N^7> ">1 G=0^U63CXQ^>T T@K8D.K2|XJ&K.E.M.4B\$T2^3^H\$S_3|G.#F4TC-
F&U.\$^IK4BIU^156X|R=12AR40|/M#>|N M-Q##115W|L|I|Z:AF4 \$6SBL8_#RW>|>6|JIM1TA0/CR&|I 71-E/1:D8=| M^D|C|?|V|L^+|4L<#^%H?
OB^?|@|K>2BM^DH>44D3N)9%-GKQ UE>3&?^M 39|9DBCRE00|33F4|J#H7:A23UF>I&? |L|Q|C.5E.OR:=941_9L.P83.D MSA?
G%>@|_|H>+W|X\$|;|+!M^C|Q|A|A^M^|2E/>6|L TSW^5YQ<@?7|2R 4XYEH>2>3KGI|SRF>2N|C-92^4H\$S,HU#|)R8|IKTG\$O 6 M1WVS%00=1
B9B=N_ %|V+9|)E)EAX< |Q|EJ^Y^|N|I^M SZ%,|J7|QE+4 M51&4^1%>N1RW_72EO(H=X@+ ^#T@:17^>)"*1O#|NPKZF2F_V\$Y4X(6ZW#=
N^"1#>|F7|I|U|XZ.F@N\$0E^"T|TGH8_2A^%|^O|E|>\$L4^2S+>6|)BC0U|HM MLR74Q|+ER(N|DFDA?YP@&|E|I^V- M^W^L^%
(KY4T3F7|I|N|P0|XD3FU=|"|^I^&A|AN77+ W2S0@>E>1R^41HO?<L3 MD^M^M^B!|GOV\$ORA<
Y#0("K.D^*OHR<,%6&0Y>3L^X^%S7|KRN/4(7^F M:@T.N^H:(W|V|)8T ?LTXC|G|1J5?>^>BP-7^2?N7H9-\$(M^A4|I(59>^#FAR MXA
I^"TM\$>2.3|P_X|A|&R^%O/W!:=^&4Q|8|1 MIVKT2?>X#5>G-/VE&|&|O2+T8CTB|E0M^H|^1C5.Y M2=P86RG7|O9E^@FB
M0N7VSW^4H+D|)6X;G@.SY.O142|FVN\$=R.Y)7|CD_5/OE^>^&L^Y-OD|GZ MS BI@X.#_||+J-
V2SF9|14:|/"#-.7%5O2E9^YP\$LMZ^* @|UL+=5OZ^EOR MY6=N5T^XJ^F^\$P8C%|I|1KDF|I|L^Z\$LD68C|B0P8?ZG^/E |XH Y^YE^5\$CG
M^%7X#D|9Y|I|C M>X.R05HU_?26|Q\$>EO@IFL|Z F<3#L^MMXS| M(FI18DA0.P^H|>_>_@.PD4>&.(6-
W7E|OK66R@4%>A|IHJU\$ZPP=YZ&+F=- M@8L-206N\$X_#_XN4>IK6^"IN.8=>5^2+7R934GH\$S1Y1MF?>|>^4@V5ZW|UN|1|&6F\$E9J
M2+G^SYAH+&2+O7PE^V#>@>^"1|L|L^>L(H+EX\$=5 MNTP4|TROT|= IP NP-CR0A- S|7^V#>ZNIG_!H^N M|N>2T27ME|N^Q27M\$0|7UO_H3E.?
Q\$5W|2F|L|UY7G|_7F6D L.(T86^>IF M|&=#|>- ./SD38.E+(W^|/K^N^Y4D>OVBY=LQ+T| V?>3B7_|RZQEI\$Q5|Z45Q|IY&:&C%\$S79|J|_BIL;\$ (*CR
M8&HLCV8@Z^Z&AZPL|PY9EZ|SIZZP^?Z^*>@_1|L28\$Y80(=+H^Z^?>Q^ MZ 4^>D).%2#07^4Q|L: J:J=&5&CD7T|A|Y%>0L4YTH?S-
A+5^UO_+S|I M|OVZ^34#LL\$WZ\$KR@>D49|YTKK15<5Q|)SW(9_ R^TP2|J5|S-/H2GB MPH^<(K>S#F^>#>#-JLG+@#|YXPH>@H-
GM|7KX>79_#?>|Y^N+R_N%?>?O^CQ|>^M_R=T^9^>UXO|J|H|H56<1|^>4YK|&#|=|5@:K|I|QFZ-|H|JCE20\$G^#33WY% M^?>P^%FMR|I0?
|O|F4A>8>_#9>|>=>=|O|1-N ON\$A(<#G^KIA";7^L-1 MW@20VG=|^BK|I^%M^S|WCY51136C^W9W^Z;09W^R^8^K| MG^K2^" BL^AC3_ERN_/#
|9GY-M>>3150SP\$OU=4 5JXA|_R J- V-@OE= M^U-D9|7H|>C6->C-P6F5|J^I|OG|FW5 BT7|V?>SSNZ |SIW>OT V48^M^Q516.9
M(@XLU2F<2,B/PPG:BFD@ @|TE2U3I0|FPPV3(P_+&8@RHE_9^NGO&@8X2Z; MW32|^D.UNB>3B3P(6F5F>@>@8|9.7|!^?J)
(4A_7&Z;Q3GTR\$TKS&OE=4FVYKND;^%S.0+>^KP M^K^A^9+>H PY\$QZ62/EEO1KN=3|W^>O.K.U-AE9NSM M:L V>KZZ="*(=HS)E4&_*;
|SN_>Z-7D_DS(M\$MPV44|+D<#E6^BE(F^C^N\$;Z#&^Y2(TXW4DD7C
M.N_G=K|I^*KH=2\$|ODGFI|E@0\$45^4E(\$K^QMOU3@+EF^E>0+28\$OK9K2T1&|NRW)YP X)?:%0?*>J^PI80B MDB1|\$! U%|%6BO+01U.6|\$4#
2PNM&|K|J>2C>|JX|I^&X^M4^AW%>YY M^|DC8L2FD^E|Y2SR7SMG^*PGC^HH>ESP^>0#XND3<+>#_V2^Y^Q>=>
2.5|U^E7|I<004#%3\$G>7E|US|P-G7YK\$D\$KR|<M-L|2\$B|L|.)ZDC^XP-X#V.QXJ^7M|&65&4KHGYI^?R/8Z3^O^Q^T\$Y>22 M Z0Z):H|C|@P#
MXBK-"4|P:6ARFADA\$S11Z2H^88< MU6-R= XS\$=|I-W5S<|I|VW-WC@0M1(B9|?@_|/|T|<^&^?+>Z\$8GAG-; MN0YX<2"
(XB|8.GM.B|N|I01+|CC|)|UBF%|BC^4E4RS|MZVY|G+|02U4PR|8 OKN^3|&57U9IH ">_>WV/R@L|J|@ M^H ESJ_B_1K#K3Y?G3|J|CTC4?
>Z|OR^|I0^C=N>#>X|A6|I^&1PP:F><4T M_YB-?2P|SNO8(731->6P20R/|C|L_6E:X|G#ZK|1E|L.G^="39=>X|F^42@>
MV AQ:1%6VY|L|HB5U^%5PCL^1+L(8/4U/NN^Z3|B2C&AYC&321.O^WYU+M^M MUOXO^K^D_|J|G4\$V42^N^L^O^F4BOYB/G1N6_|
5#9/R2|:%**3+>N|^>^: MAMU|Y100.8N)QQ<#>|V|X1K(O2)|2|OIG<(S.93|A2Z^*%\$&T= T.2\$^PO@A
M|(>?>T3^>48/H1EDV7YSSF>^F)M|+H|J^VDN>I:2HK04^>,>|M^%5^GKTBS M@8L^A|&K|K("V-V2("0^H^>@I(| B
M^=Z|);F8Y^K@>DQ6<Y5148V<^>V9|J#Z= +8|2YA M^<=>X^9_U>1Y3|1.58C01(VKD6 |I3NYD6E.K8S1X|^~^|0|Z_|O^" G(OA
M8T^G4|Y0UXJZ+I7R5Z(@F%H.S<|+>K^S.\$^4> M1B_7S.|L+B|_JU7/=KLH=);GO%"A^22-)\$@.BAN:#A^"O%#>OE^WS0-E LW MS:NS1^YH8P#
(:|NQ.C(290^=E_7@N1^&V5A=>@VPJ5 UV4%Z_)@>S<8|I@ M^FA<7 M(Q^NM.M^7S^C0^%68%|7."%DTQ^>2^4Y0T|LM@2|F|C^%75^FEG)R"
M\$S0:IK.19Z^GN5|GY^Y 0|T|L9L_#M#-8B;JM_ FHH2D(PQM&^>KY9\$^J4G+I^M| MWIHW\$W00820H9CIGA.O1 T.9^V|PTB|GI|V14Y;
(8^ZBIP= _KJS#B(7N| MRGG1^Y|GI9TPV>FH>2.5MF2R^6^E@M2X|O.H<|B+5HP?SBML\$*HUNH<=(F^<(M^F^F^V7+^6 |J)^7TY^|G\$)0KKVH^R-
N^5F 2^K<I>X^KVXY^B@X|I|C^M|)4CRD^|>><+>D\$C31YM=PC ON>S^R>9^X^JY|O^HA2B|QO^>I^E+=OOL^O^K.M_>:G%|TY^T^W:~%*
(7:7SE:S507.PB^DU\$LSR(FE|T^I^YK\$25^U2@G M.4TV^3^<3^>?>72LH|^D(K|8J2O|UB6UO|L^E+>*>O|>+>FEM8=&+4P)P>#># YC|I%74D|J
M1M|LGG|_W6KFYEYPT%"-E8&BK1YC|B5T09D^?J^AZG0?B^-.ZXR+V70=CY5 M4|T?^J%=^>+>=; 2-50|VG8>N_N;BX_7|
|3^7QO_7|>_W|XO+>|S|RLD2ZVC MZ|NK?>WGV>?ZFL\$|V>|>S_Q_EA@>|R^+>2>N|9D87P&9#96KG3|50|Z0|F
MF:M02C_G|S6|ZC6|J|RP&4^|R|8^>|J|E-ML7.%\$V1:AD9UK,J8(?-2UPW|G MS+CC%E|J4.ESPO,N2|&CWF5AD&S|PWU?@PZG@^Y-%0KH?^|V6R2
<5A|R= M3U>8H^B\$^2ON2UHD>|3\$|L|W518OQ5=B^C^E|>?>2&71Z0ALB29^J M5>S+Z^-|RBEX|X#5^3QB(<^-70?
+7M^H8@|(2:321(2HD>|F0^R51|M ML26_|B|JE=ZSD4@PTXX5D#>FZO280K@."NIG_J8T|94PV:27^>#UKU>0DGH^L^ MS6L^3+P|0^L^CDNU1+?
W^Y^X6N3|>L(7OG^)|LDRQ^>+4 JT|5|?0|I^ MHC|?H:NO=86&|RBI_W669@.G^Y2X^J^I-O-^I@P4^NR.CM5&M3 JI3ZE^@K
M|T2UB8=>U^|MZN7\$|_9E\$3D^81.G|>?>MPT^&A^R^HNP&OF?|U0TL>D^UO#07OSNJA) 1ML|Q>OP=IA|I^%#>2^TASHG.Q M|3O^AZYV6QJ-
Z_(OFH^2F^X#9@Y&>Q1S_F_4^6D&W|L-T|0&*O IUIB|MSU9:N(+X06FSW^L3 3|T|<^CY|OD+9Z|E=16_|>*>^4Q_>P^"SO!
M3^>?>JN#HT81-O.A(+.5)Q3RDCSN)^~^L2CRHN^O#UX<0DA> Y|E| (7.5 MCLY^K)=<=89-N-G07/3>DPR|(329XR8(47^)% QUG^2N?
DG3LOA^A+6NYA MS^"2|J9.5%GPO|TBX+6R^N^>#>5%M^X^S|B|TVY|I^>^*J^5AS=EKE-HQA- M3G=HG>0^E|4H >>O?A 2#
(XDFBT8LC>U/\$>D|GO1V>|8%N^|P&1MFR=J| M6+>@90|J29_|17N5|O %^<HAZ^@|Y.A.2|176=XZR3>SFH|3^% M_|8@@Y\$S-|@X^&D-
V^2^VONH>P>|>A|A|O^>^&^X^M^;T|S|>+^|>+>X M^9>?^TNASYN&|T|S(7^&S|Z|S2^"RM+|I2^>^BY-/E^U.NC.3930A-^V^1< MFEGZ+5J|RZCAH>?
5^/2>+>?RMG 1%@G9 BP&9T?2>^? XQ MOH_OAQB3 T M|D^>20S^3^OVF1S1Z|F|I^|/LDV|I^YZV)=R_ |9|5#R(O|F81|MP|U^F0
M&2^>7K+1C|Z>J4^K+O2|WC^A|X|_BD|ON7|J|HX(C9@|5Q.Q8(ZVNSCQDP= MXJ^2S|(B|I^3^H_O|9KLPD?W\$|G^>#N^!-BYR<3@=!
(W0^L^%1BY3|Q\$A_Q M^T|S?^>4^BL8N@>^&65=>=>^Y7Y>#>I|BCE^HDWF=2|Q MUNRN8%|D2-W5-AC27G<2D|3P4|J|^#>+>(\$6^PO_3_Q_>|>-
&+BGSP^|QDR/ MH/AY|I\$K4Z^K;T=|^F^P^QEF&N8Y^*%\$&K;|I+B=P9_U@+>+>Y|ZTT&|^*S M8-\$&X\$Y_>^O|LM\$&
(J.FFQBB9XR^ANOB\$9^R9:Z70T^H OV64|@+PL^< NBY^F|J0O2X^#V3T^&(& (D)^JLX4W@VQ:>+6%1S2)P3|SIS7 W)+U_#07ZJ5
M|A_>M\$V62|T|^+>#M^?>O^TVK| MYSP^= X2C^3| |\$KT5?>N23|(^>^J9T4(^ZM^8@TG@>(86E9:M|^E;@>L_#22.0 MS-I^2)P2Z>P(S=Z:5J7ZH
KHFMOE4:YP2^N|JN(3?>^|L|YB^2^R6:6^V M^?M0S^X/Z=>S^Q3;H8.#JF^EY^=591|,QOD0^IM_SEKO.^@>W.F48P^4^Z MOEP9_6|KJ|QYO@&)_O?
|8.3Y>3VP9^SXY+X|JOKRL5>KES+|^>T^G^&F^N MZC|S|T^*7;HN80^3%380E^|>#>^25>D9:F|O9N^K^W^>@>W^F8S2P-4^Z MOEP9_6|KJ|QYO@&)_O?

[illegible]

15M!X5^0Q<8JG1B=2L>.@P>+9#B7IT0?>=7RMAJ\$?<=K0(Z& MX&4&W9P@KU@2A]=JV[M!#^C5P14YB).I&GK5UX+;L.;WC4#;?N01D
B! M!W1BY^4+CU4;ECBO#1=U!;VO!2>.[S2HA03A2YD](%&U;B;^>.)>1E8+V! M! S48YTW7&^L+ +((^F:6KK!^&E\$ _09W)5F^%#SB+>O%&W-
A_**380*.C9 MB@78SA)2>8QZEV:K8A=>^F\$(^F2.D;RC%A^PUT/2^4)H:6SVGU-V=N2!K3
M/2+Y1JHHID3VR! @0I/31P1X^N#M+4#;P9&MPW**V7_ N@C!J!^PDH9NK\$J. MW_?E! 18BHJ^9JHUFHC)Z9^ M:Ct\$JIV795+>X!AG6%/QOS%W
Y/20:5YERLL.D=XR!@D.RJ.9:~!163!#B MX I_Q_SGHBV3ZT^F->JFU=N^R\$XL^W_KWOYJWB62P)H& JE+ C.C:8IUK.M_ M\$JD?^!_D^!S@-U"
6JG:6^2@*B0N.*P!^T=1>5S=WX126T2+0B:AX3E8!\$J M6/CP-C&JD!E;T^VFB4_HW#)LFR4A1R^f[<Z>#84=MCG=N^J1XJLHPJ^MXQ6
M16^L66\$SPWG(N%>4:9T@I%3^6A^J531P8LHTC^*. M7KMY%J2I^=I.OT<1L^CP-L2B>K-^1B1?KF\$UV_HV01!& DXR4MU3!B! MJ
M=>05PM509>J!#^!N^0Q^XT9X^=>K^6J#LJ^UZPP.<5CY)PX5 M@-2.U!^L.DH^!>I@>KOC/=2OIN^_ D4GMGW^OZ@.W9 VM+ZU
MG^~*KI_RL_6MZI(EZ^~#.24@QNS^OU@.8MF2:_.CJ\$N1_92@JOU7.H)S9-MAG!8C6Z.I&T^*O09T@B7\$2-O+^!OX0111^QY:9857VHV!==(D+
>UJO M^!^#6J_PSI-(\$I3 &+ ^!4^004HT@_ N8KDDW^_ ^8TIS!7Z/ M3)=I^K/_9E!2X(L0Y&^PI.ZI1/GL1R_V53@2=W: ^HIT5D^+D/<!)^0E6M> M-
W^W^@FJ)07.C?J^>4PL#&=^!D4/9+ZE^FVDJ!-JXIO/H&Q^UXFR5LZO<0C M)CC^LJ0@K^K^ M%=-.3AP:63(T13!I90-G5C5&ZSF9BC\$2NZRFN!(
M(C^P^J/3?>^CE!(*N^)*ZV&I&E-NCFI^F-MVK:OGIS!4>1T0\$4LZN34M^ MGH/IJ!5Z:Z^SU7HF^GC!N7PJGL_1#P5:2Z:0SL;[TV4L8K^&I 9+)^#SDV
M=K0D):G4B?FF_9PXSE^1^V!Q5JU9:IA3M76^\$ A&GZV\$#.D^8I!^R-%E>JHEU!>O\$^DBP
MSG10:9KFKI3+FBN^9KTMX@|A|>R>3ZG;G/HZ!|>=>IY1!6S!J!<^W!>:E MN=:B>_3-G@^UJ1:24W^XHM^&UZNS\$6BB^)*-
E&#^AVC4@<C^K\$3_3TB(IJ5?RS_M:CUQCX)6\$!D\$TM^T96?>1!I9%>:S8;#F1!JDEF7Q! OXIQ@^RD.42^#DZ0 M1)R61.0+>!)JD2K2LG1.\$W&YW?
!I00#(R20B%ELK!LH9.D.T\$18%/H2S_H> MU@_!5:P@<7_O?<3?)C#PO:O4GMO"N:..\$FXZ56?R=VU0KIO^T^*RTGY12 M^6^"U_8+>723*
U6C1W0ERQ2IC>?#MMVC^*HRA)5:/^X.TJ3#F^J @/ MDX1C6M42SXL2H^Z!9T<?>C046_ ^8+6CEQ.3%SKOU0IR^P M8B!A5!V?
KQ.TYF!U&JH=HRUZN@S>B>HRMW^J!UJ\$2(CRIV-C^ACI!9&>1NT4_ ^>C^LXJ!/_:ZX+A)84W(85-23.1% MVF6<0/D%/_L^<0.LW!\$B?_A_
=6C6Q>J&-J!^CWHMLML3X=TTU;3LZ)L^K> MJL+X@!##19\$S)P=;HP4FYW\$&6!X^>33ASC!&J>T^>1!&OF.\$^7CKLG^" M=E+^W;0S<(+I9D=?
855?G)ADY7!6W&5HNG^DP MK! INSPD^KONEN!F!L^I^03NP_#C4B8/MJKU9=>R<(>D!O^>!)I&W\$?XCE859 M+
!7ZUUKNT8UKW8UV!E4IOIQUDRCL4Y7UJS9Q8-X^XV)VBSS\$Z3ZU.7 MYU5NX<2D.5H RZOA^B=)5)JYKV3A TWNO^AZZE=2+PBI6^DRW<
M!^3E8!ND@K7-:8?X7W\$;.TR2%W:PV<..15%X(NM%?6T@DBBO!!^A77 PL M(E(H37Q^FT^V>@SI/V35:J+
!3XT>:!I9"N:UUOD@5GWBU3_/78F!A29> MIO\$!+4<ZC60\$ULKFUE>4Y08J3&WE7YVW@?3DHLR(A7+%0 M7I^64B=;\$:CF%JE>[Q24^7?
A+&15J=BO(X3V<6\$V9?HG/B!^AFZPUYKV= M09>=4(IKH2^+;_9:4V^W 4UT MP13)Q+?_ W15>@DTACH!A!-.
D7<65W!@TKL2<2KJH#>~*N8&^9T@ MD=>QR9>0%AZZ@^T9R4L\$S_KKW(60+BP95^9%1W!)S)UQ9TBF^!JZMK(>E.!SY@^JIAD)(/F!
<+S;Z&G1PMOI:QIBT(P^! MK@!#6!^!+^K5AF^V>?SA_?3E91YD8>T5GIWXP^2I7>?/2_>^8G\$JYMSBKJ\$
MGTQ6E8H11^L:C!<95+^P:PV<6)4)Q%IK!ZGLU!348=K9!4_C+!=I.G^WGF MT&?^JIZP6D.G5DF:P2!^6T!TBB^ANIG066X%<_B^ (+04E!^<-
#X:;HRTD M2^". DO!^+W14)Y@O=RD51MWN\$SUB_AZ5N^RO PPLB+01.EP#;N#&CFF1 M!)^!VHUA!_DEQV@5P^4NHF6@!^M IOI!M!C!+
M=N(A.8TVCDUS9T@YWG_MDD)_!>S^M>F4^HOIO1MG8^5\$3R&)/9BMOK^8@R:8J6Y\$^0(C%G*=7FC0W ER MI-V4!+^N6^*7_&7DX05!@EY.IS+7:
(0B^YKUI(G&MC^1CB!^@O/O!XH: MMOP^!)5!JOG03VN7^)"5\$.2BJ^*C M:N!\$066719@IAC:4:..!S(J^BWS&MG!@R H32^*HYLZ^?F?
J207:46!BQ+19 MO20!OSU+B+1^N^6_YBR7^7EBSH^9WC/F \$EBE>ILL4F^O+R5!EDG!A^P2!(-JR^<4E.U.P^X^<C!DP.0!\$KBM>)OJM
K@H@ M0+>21X^FAO,O)INL SY^!4*U?9:92-G2#E 66&=8=U6! J^*-O-R\$0B=>9 M5^@.C.+T&VX4@;SUO\$+;\$GR^7)(C2#PM179^>9&\$;K^?
Y+5Y.NCD!&E:BL^2^Y!R>(ND^!)"V^?&IMBRQ<M^! JKXN(US9T@1XS!BY:M@AL^S!L:\$TFYAXZ+@U2!>HYD+V UC2!M:VYW7I4
M9X^ZL5R^2VO M^7RD9.K^M^JLT3C_K9MX7D+GM^K^Q@.8.-!J9@B^OBI13 MYN&##B5W!;28_H90<=G21N!<S!>#M:5-(E
=2DOZYN#S!T^=(8ZXP@Q MJZ68..^V_W^?>IJDJO^MHJ4B9 MKS:P/F5(1T2!2@UD+L&SJK2HUTQ7K7H!L87EE5!G:G\$693?3A!F9MS9^5)9
M^F!U!IZ E6-K6_1XCYXW^>+^1^L M3^"RFBIN#\$ZN0Y7>=>[O!T@/>!/W!J M36V=H(8:9^14A00M!N^S^+X/^A^Q^*7JOG42G2!@W63A^+^K6R?
JCOR?2_M!TM?>5!5^M4)3HM5F^4IV2\$8!1GUZRKS^V0^>O\$./!X^B!/(Q_<Y<8!K6!7U_M9-#^?D.2RS?9:B58C;1SWO!IO@K^*^\$04-IKZT?
F:MF2!NH3.) G>P!(M!<1(WD8^OH^TFO!WPF^"5=62<=<5ICY;\$\$.%BY DU.IJL_!WEF^P^#WA MI&^+!5:SNHP4AW!_IQF^T^"(B>G=WJ=
0)6VL3_R2PN_C1^JR ZE@MY^8 M0^&(%L\$N&K&^&W5R8GN.5!E.9^P= &-L+(1 D5=KM&HIQM\$TC^XK^8G^).38
M8C\$+ES8!AP6P^!KIMM(UN^~W^W^H!PXL5UUBMA1LKESLSC8XA)\$HLAK.Y7J3 M!!^8T.Z!><8&4U-4K\$-#5^J^KWB+!C9T<8^LZJ:1^*JMM:OS
H\$JSHV4!15K7UCKP?1Y-6 JDBKR^MJ3^M!JHL PF05!Q@:BS\$Z!E_1L!>=>^4H&T^<6)R1I4X^6QZNZW\$-!Y_NV>+ M:Z9R^8R^"IL"S(>:!P
H>CA!% I2/I9>.7D:6V!M9?C?2.D MBM(G6^H5?I5#>Y38RG1NYTR!32AM;Y72E4^N!3HX+^F>3LGUI0^"J!J3S3 MBX/P-Q^J!5>S:POG)@D
^6>+Y@R(C-MRRBCIMZJ;N2?/^!R!>:22E9B M(S>V7<=>5T!J9Q&_1!U7Q_ZH\$Z509FI4:/5K:V?U/O^Z^O! B1DMTMB?[%I
ME5T2YZ_#J#;D20!N!J!L:68^4^F+!T M\$=(9A^UJ8!1=4C9T@Y7RHOJYWS^PA-!_422\$WEH3:~@<=V!J!A!M:-O!Z M!<^C^Q8INN(#
(S!^2FZNIPOJ^">@V!>L^Y@IE^GZMS.Y!%3YV8U=4@:QU6!Y MR!M!M^OQB#U:=>M+XYV/Z>K?)<Q)&@D4O_7\$(@F3K9=;>SJOI9I0&J17
M:5:2)PBK&A@B(BDP.E<0+^M^LG53A.D.6272>4JFTL7ZV:)?G^@!#16? MG>I\$69PP0^C7=G^"1?^#BL>L^Q!\$S_N:L+X38^ZUYK>MJ2^E@91R-QZ
M^R2!JH!B2079W8!O:E3!C@:B!%I\$JTBFI^D!PXMG?U4:8)T^*%Y_M R3A^+Y4KR!)6Y_Y!S614^9I:
M!_Y6!5P6/"3TYPN!D)D_S/=WJ5TLTD#8!<9%O!V6):EVSH;UA_M^WC F3KUHI^B=5^B^*8BR1TL!(H/VU9E:9.UA!<9LZ@9=@AWD\$!WZUJY13:
M^*%1 X@/(TY.\$5H:7D6+5FV!UO!R!@IE:!)JMI^=(8(^(2^4)^\$HNKST_MBI@+0+76/M!S^#<+G6%)-\$SYT-D ^LDL(7<IE7JY.E_*L3^"2!F#=
(X=7B/SHQ504^FRJ06-!<^7+ZAM.)!(EX7V\$U M.T6H1Y^3 FIBL+^**MYLDR55PF^SJK:62>@~"G.L;AZ^TU8!54HH;VU@GB=15EV5&RWYTX
M+QT@!KOHXHP(# M6^IF^K\$8M05Y8B.I4ZG MUZ?_) R!\$^PVU!G\$YSU5)LHM7!BTG@O+1!\$!@U
M4%9!\$F@L!\$!%M1W!HGP0\$OT@3K^F+^#U705TRNO4!C^"9^"Q^P+^*L1("M9720M7>"8(ZO^+UA-O?.\$F!3V_LA^2_#^!L=)^&\$^Q7(+ (S67:O)
!2_!_E3O%YH6IWJ_ N MZ3>B!77!P^BU!V!8\$5^*W!>5+<2PKN^N(O8.T^UYV>7<9Q@%A.1(7!^W! M:GX60RS@B^&H.KUKU?|S!K5
%)^%B3V\$@9K^A14X^X^N!<S!6!J5V<15QQ M!V2\$;6(KZ<BA>U>!)2Y4EX?>".NFEM9W=H!)8!^FH@!GOL^Q!605U:
M:~A1G6^".MOHJU6^"6\$>=3).!W^H1W&^"~!4L!E5-G:~F5\$&!)GBIA^"UD: MU8!LG^C+^X\$3_!/:X#D!/_9 TP.HJC=?
Z/M979+9:075ZO!L6!IM8R?6 M^"1\$S(X^VS!5^D)QO0_P!>/_GOZDZ?<9S@B&MHHWTT?D=AW^*#7E.EEJF
M+5P8M+JVE&=P^!<M^SF_?7T^"OXC=%1DBUE!L3K!J4!&J23!G!^A^3!N\$ M.E!\$%4Z6(B>4(I2J!HM2J6W6R9\$
0!7H!@A6RWYU8^W@1FU!-!C^^(MIR2L^N.2:~B!^B4^*W>K5^>W.U) N?^<R6^"X+L\$N^MPRI^/BO M(GY3V=@)40^"&_UF)=N^G-
+V>=>4KK\$IN65^*XQ9I0Y-M^4FZ^IQB(7=W*3>7&7I01+A_WJPU^!|BBV^3)I2#_YH#?>+OE:(6M^76B74QA!969KFW^O!OM8++&8;#4.
J379CQ MVFE8? PO-D2J!YV4-!<7+ZAM.)!(EX7V\$U M.T6H1Y^3 FIBL+^**MYLDR55PF^SJK:62>@~"G.L;AZ^TU8!54HH;VU@GB=15EV5&RWYTX
M!@E^":S@I7Q\$6^/S=!@MG8=VRI&UH77RXBA2+XUC3# MEEV=6-T:~?JE^O?)|WNR^F&P MBLH!&_P@5IL@A1!UNPEF!^H\$&7!
MKK^>DZ:Y=87\$J!B+>^!2QLM263^A-R^XCH65^\$124!H40!L_U_~8TK10R FMUPI:3>^X\$0+>~"X:(AZ^*NO(V4!>J!^J1C5IU#>THD5R-
O^Y^4!+>03D08 M!L!SC2^@#3ITR^QJ?27.OXM!@.I^P!L9G0J!E=44R=6JRAK1V0B!%M#7^B>X&7&I^M^O^H:ET&0HOY^~M;L\$@J+^P_7
>CV74@M^Z\$!9LZ0:/ M.\$ZL!JQ^5PM#^/0 UL7L>|BA1!^N):(\$:9>=V)-2TV!\$003R!PMNY5C^ MALEXO8=W@EVRI!
ANKC93E!KX@19YYCU2ZCJ:RBHNKY13NHT6A)7G:W9Z2 MPFK\$^T^_ WRHL9U@E^*4^EM5>J)VEIZ^OE^T^CL@7-#>>U8DK!_RZ!+E>MIV-
D!4A55W356^T7Z!L6N\$ME!MTNB?W% MYF!^N\$!YYRO:M+&DZL\$XF:76^Y!FK&@26 NNT!L^XYT<@J51R!O: (& MR%)@JVB
L6:~B(A+U)DY0L(H)EN4ZG-2^*WL&RQ=LML(HG0+C_(EYCX MA#(2Z2)+!IZJ-X:!!-<."?>8A+@!63!A GR!^NIHL!J
(GI+M^!A0Q^G56SAQ_N_P0B^D M\$&8F1@R!Z_Q5^O4+LAG^!EQ^F+&@)@G_M-6@JK:6-QW48D#4>\$%+>RJC
M6J^>...3J068^FV^ZT\$Z+THO:4TBTGP0: M54LY.^5R!)MDGVNHYE_W&NL BX^AW2@QF0-G3@1FI!+ MLY^!5@-8!P.P9)EJ!75%O)99R?
64?>2(KCROG4XBBY OL96BK15H^M80T4ADH2G!N^K(T3:U^2^E0-H0WML(H)-L% TMF!4KOF8!L9=3 M^2+>63M-).Y^ (S!@%&@M^B%/
+5P%:~C!+5 VM7TY^YT5/G<EN#1/O!W M6Y2G_=(DX)9@U:G:C65_3>9^"!>H6YM8M!W!G: \$1R7\$>8#>Z7.K7^F6
MW9TXUQ2C2)RF)E9\$TIP)3M:\$^<IB!M!/_ DGRDAY+!)IFEX1TWI6^21!P&0>2C MMV\$7ZV1A4!J!8D&SPCYXZMTR-HX^LGK%
<V:~M33^2^<-(GM\$!^*TC^#TBC=>C:~M!&+>3\$A^T4HCG+@F8U M^"VLT!&_&ZCWO.<I&\$ZOL>=>A95!\$%ED(3^C+>8_@GX:JH@Y)_6TG
M&T^F=;GJL<0NNU^#EVE!)TNZ:~!/:!%L_!#O.WV)^*WE=^L3+AXT+^#R MDI3&9E9^UR^FE&1&\$5^H^WYPH^X%!OI!-IG6^*~.P
!B)G^+^7^>F- J M=I^T@QPH=EE8!GG2V^N^):8(=IN!40A<-_2Q^P!^WE=^G7+IQO-B7U32^X MZE N^WBA5\$^MHCSL5GL5WR!C15?
2DQ0I7B-N_P!H^T^2!IO)2:~T87 M^WYRH(9D!<=4O!G^M3!0BP9^H^B^9_5>P:PH!04!95J!J TM^5-82.CN& M\$X!72!S7J!QM8?
%B:VT!IG_(!>?<#A\$>S_ \$H@2^+>L^6L3-6=J!Y.MK!MW&V+)^FY!P=CN:4:1(1A_~W:=9^K^+J2!~AW5_J(ZV@-8WZ18C0?# M-KX-
6\$FN^W!^FEL_Y: MJT3^! WH!+S+S^Q!<3 LA.(7^OI<@E@)^Q^>+>T>ZQ^8(^*_G^O_!QOSID M_GL!K!>TCY.9A@U8A^V+^*DY5^
MEVY3\$25^CXB\$25\$OT!T93.10>7!U^Z^E^K4^P=+!\$V48RSW^!B2=)X?^H\$HUYB43K>U.ME;
M.7GE5(N6\$TV4B33\$U!6KKVPZT52I^_ 4&X(Q^D47^%&M-JIW:\$UH^!&A\$&4"> M^*=7:3:I%)J)S(7M!W_XT.RCE6VTTZR;G_?
KMD:"9\$8FA8;U7!22<-AM5D M^%U_3^D&=N@1Y+^F(15!K4!^WFI2^!4R@7)9!#182\$^*H:~I^2QL3)4L!2XA!+EJ!HX.BN8T!9IYH!
!VS@F@TL:355V4R!2R^ M5^+>(STU59)^F%:MR4138Z6AY^!>O!@ IG4^DFFA!J^EG@^% B4^*O!N3 M!<OZJ!<5!^#B39\$4B_8IB3
MO!>2YI!+G+U^R!K!J4G!EFU8^*~R MHQ+6TW!T@!^P:9ZE1M>=>P4N?KIUW623%!TW_UB&-WY<?9_6&R^<%FVBR! M^!7B.
<1\$B=>+E/SG; J!U!_!^!MO!IG0F+S_~V7WWC!\$!D)M\$Y2@B_0/P M^66&FVPC/6_4C2K&@Q@3.H(HV6!99PM^U&T57I%._^
MHG^K!^!PSQG^<5GZ.^!<9 B^LFCO^GQ\$<7.NB+<^<C.BK5UWOGGOD<4:2ON M.LZ^CRC^RIVC^/_IG\$E6\$5/DG/FXXJ^MW5O>6
MO+&R!J^PDWB=U/(%NXUA:16X@03K?^ X9!L M4GD1GAPU62ER#^F5U\$48RPIJ94FUE..=/SPHY<62\$IM^G6^*EQ!T6FN+ M?
#:3:SQWZ^K^M^KLY1J=2OPP!RS:(.2-4E:(P1?^*~DA& K!KE^VJ;ZM6_MHU@6!J!1BB+W)73&E^F:~I8?2VH6EN7GIB_C_(9^ITD\$7:~6-X^G&NQD
MC4^>WLKG5\$JFA-IOD@5:UL+@.F8^~HNB6UP^!8^K<1E<^<E6!G!HT=>2JR_S!8 MLKJ3^2D03H5A^5NMZ> V>>90HA>JAE^4G!T-62U!
J!OIN2FR<^!2!6 ES!<^Z6!UEDG^Q=!:2+&IM MG!<=H+K!^ZN+HZ!DYT^K2FEF!<C^JAKO6!VD)PP4D=X6N!L!AGY!CMR9D72!U+G5:E!J
MG=>GSR)SUW?IAJ!XED^=3W!>ITC^~Y&A:DI.Y!QI:23!5-K>4GE=7^U!EE M(D)UC&8X=8-)%3>)/^!6&+CEU?K:~?7XE-
/G3S>QR_R(GSH^306R MCWB&N:>S^Y^LRBR4^280+>7 M2..5^~M&^+!|5>7^9QO.OOX@_ \$ MN:~WG!&= F3YUO^D5O?
37T!Z&ENGD/<+1^~#IR!MM86.L! I!<=66-GV!X MKC+W:73!1W^L6^2HXX(JK)UOWM M52%8?Q&^/LXN8KW+JE!^I8!JH2KEJ-
82_-.O13_Z2&_TJWO!M2:XIN&@ MN7K^*(^Y0DM\$=H2UL31^THR<)R68X_OD:1&=^~K!_67\$+
MG+!^C2>YUMX^~8Y!F\$E/0L7N!P#6^1DDP:ZM^!G=>\$SA!<Q2>VB!<^+JQ@_MMVEO5!BCO.FW:8!5^C.22CW<@D-
!>MFXERL\$W07X!TLB=>K^Y^R129\$R:LZ M@AJIO T.E\$M^_TRY ML@!7U7X6J!34!H3!^F@U_!>J!XEN_@U!@JY M6Q>E:G@P=#W<(4-
D)%2MW9E^!V^0=G^#N!J)604N^Y7:Z!A@>|I9!>I^?_ MM=635W34!2EOT2CWRPS^G94!+E:D^AD_2^ZM!3!UO!46)TQ@WX?ABO:5
M.S9^K!H?^*QK010^GD^!8-.KT!6KQ!5^GM!/_T!XMD<5_%.ZM Y4!JM3 M^X4QXY7^&G;JXIM=^%W^8P15W_!7^K0!^N^B=)TROES^J!C_!GJ&?
O!6T)X!IRAF#<=:!3/7C:M2M/< MDH8^4:7EPC!T!YE=>+>Q.D_DER#>7^S3\$^TUR<@R!_ MU27G^<DRDKV M
G2W16N6^MA4\$=WE&ASX30(\$ EOL^L#V:"?<F!UCP71!K!\$S@X\$SF)X0 MAG&I7Y7F?C9+>F%!LU^T!^5.5.TMT8 SR?F%L&I5 VM!>I4%9

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d=71\$G=VESBZ^%V18JTGDU6QWU@/BE1" M7Q7E6S^*8=Y:X@*4+> "87QIVG@U5E+%"F"?I+Q:0I0_SQ9->I+N:% <^IW"! M&^*I,K;HW&\$<C<95(,93M Y&\$V+? JBL:Q9ZOGWI|<21&P:Q\$K&R;QHB3 MV=\$+> _3S*58&7,O,H> _TKAS3QU6TL@57(JNECM<3YU/6C^SNE#^IJE&I

CE+G M<'P,C;& MT90N(XD@RAGT^I- S)3W5J&^C#@J1WL?C9PV,VC2YS%?;*HXG%%.35U#?VDA M-PB;J=0125M8;-O\$0)TZ5*F>?=UBK<8 !SL>GK4(VSIU^"+J>C"H%@XTI|W4R MG*!F(T!O^7N:JA!;J59-BP^U7&QK&?8W,G#+?4 HF9O9J, #9T,(JM\$!)T MXE#_+2D)? IL&>A8N:;.&>1L^Z:'.0MHO)ZN3R7I+!)Z1!^N#Z@/IC/E)RWGYO MI:)N\$:-GU,DBW#9S2A<4RMESLL"l+=BC='J^=00)(6M,7=&B ZXCIP)=Q M2@(":'7,N#2K2JED\$P_33S+6^"R,2JBLA#C"C^P^Z)6^XV>DSB-69S@N,C:1RAY(IG 4=UIVOSN\$16&S1% MK->@U+9E;V7ZZL 2@*U7+!\$@N447J@PJ#6D3/11: 'R>)X)PA.^002_MU%> MHN72WP69'S9#D)H.X!"1?%>T (%KQI&J.N-J\$|X/I!6Q(L@)D2Z7,AGUJV-OB!4_K-CWZ =B< ME?=[N94]:*IK"@%T!<"RU=IB\$KWW#P>YK(TY5/6&>%L*B)"P6J76^A9)> MOY*^NC7I7#MALV9ZKXWK&@)IYV8L(CB&2)28H#^FAO0P5.KJ#8^A^FID29QO(M^"5W&J9(4;9=I|ZO|KB=C MW12)D/L,HFC9.M%L D.WGD.W&KY0= @87+%;EPJ|C9:E4M&G&UYW18*)\$Q(I MKK=J8-C-RXX)WF7P^>U^5-3BF%5JEKSOL!RO:;LDB^F M_6_1\$HD^7DB,D^Y I|&L8AP6^%CNJ^BY4^*Y9"U=A^ZV#@[CF8:QH7+I(A M Ts:>I7C%AD>:09 (#G6_X'H26-2*B3S^T^7I|OB^?2IR<_016J^E+K6Q)-P M|3I6.16.UZF VJO=J^C^5^=>G04B.P.L#WIU!)^0_MU^V>=,W&V:13U^_B M26>KK-J#M\$M^FZM\$!F^N@CCXJ1I:4FCI?L M00S62K72N)NASV_#6#/\$S=A|Q6I?>L+=KPK\$X+=>8V1IRR>@-I|Q MKUM^&_XBWASE0>NXVCG6R*.J:;#Y+H+53=00R@3A,*=,D19 M^>@.J.236+*QM4I|^E?P0FL_+7(6KE[*QGX6E3,+4*EUKS^M2/!%AQ+X5Z#_N_4)<9Q+M|3W|I#29Q:Z>K4>3B0Q-DB7O*#7 R19,IZ M8_:I|I,Q^F^-%3Y_- \$J@V6BPUBI<=E^L:|JA M+)S<<C%-IXM\$+2+6.2F)5 MW_CYD|I9NDA:VKC|4P?^*!LG:,1U/FNMGWEITXO&*4RAFNBUC 6JS:)"^" MK6=>^CT24^I|6AE >B1UC\$H-IT52(=^ 95D)!^E;P4CUIKV@/NO.IHFE=4FH^**=OH3^N=OJF YB> <I|U24T6=K/J=V^DS?IC9I\$U>VA@<=>"N16544:\$Z'&=M+G60 MZ<.#\$;:I/D%SO,87H1J<9#/N'\$E#;JQO#MH^&69))-IZM(^W63PZSU7.P MCH)5L(^@:(\$&V:0@/Z.CZP)I @IY=0=[J]Z16BZ^PP|NWS#-"I7R8IA MR)=3/P22R1S5.M,BT=W?B5D0I0/R.HDIX=*PUGNN4@+H%'F29I*^: MQIC3I MTR^P@I:IE:LNX4CSPJZ\$S(B<,<(BE3I+KQW4KT#DW^M^XO(5:;L5IA_B#)D? M:./^:IOF^>*4C&7F#G)DPKD "B^DUT'\$>P6^V2AYE3I8I"<^"3J IRS1 Z M>0!OPY'M,:A- V&S>5^>(VXZ^U^>=,Z&G:C5*7^G^I%'|510RCXG90^6>VP MX|A55^0TW|N-W:S=#*I9F3 :49PX|2+>JXIEOQZ3I/IV4^JE MI- |K(B)|V\$2*.\$&I562DEMDOE:OJBAW7C>=>XG91OYQZ8(I/24^H^XE MI1? :XT&O 1BZ^*%S'=-=%?H- JX^RN3W37&5&C:8X97LWCFS3@I3S|I2TCW^H M,I38?ZK-PDH_PTL'E<.%|RI!M AV(6Q02=LF_2R%QWGP8P&^H63ZJ@>"D,Z58A:2Z:F@S4B)OT^F4:0#6\$;AM MXW+I^UB,3J%:@R? 1&5\$JQZINH1I1HU97 ="@LVH_YNXXJL.FS0C,06 S@3 M_TFL^X N4-|833W M(REO-W^RBP^>A-IRJB:1:(L2LR5H.8C% ML- (TFZT|M^D989H.L+GW5D&H^%3GQ<+M^K:DET^LB^L^X=XE5+G7^#M;EIE9 MV33Q<4K4S1W2&|^<IYB,@_Y_/S,ZFGI9(^@ZOE M,U6Y-1^RV-W%|BWW(9JM9-\$,A-7:~TVW6VF-OGK=8+6K,X4TJ2UU+7K;R|| MF2U 2@I+U^4)7RB0?K/BP|IPW>-7'2&)O<823K9.? K<7&XJ_1D)S8DN+Y MHEV

180)%8Y8&Y9P\$R3I?ZI3G(OW(%O!% Y735FEOL< ML11GCP&\$I<>1,?/=1HCP2RM9K% LTDV594;-/'O'KRSZTP-*YJ0>DG+% R M%*O'S.M^V8?4@I;0 48^ML)/27.FKO*BW:7B?O(L|P|G>R|JF0(=E#JE MEA: +P=5HYG *6AN83J@^T^R/O3JLN.8IZ|SN? PJ<"KK9J|A8:'.I/L|>I MV8I#6?7UC.(V-%CH!P?QOXD|@IIF2T^429U)QKFZ;|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|U|V&P\$R<@F.N.S:6T1D@/I|+9\$QY^I.8,*Z8%6%XL;%B+^ MCFJG=0SC^>_>: H/,I6JW08:"E6"4>0(IW5:;%RXP2+B:;S8(2 @R.YIHY MT|A%J|P!^YON " ALV8V+>G M4S:79+2,,OVM"JJ;\$ 4JW6PNCVD;+4YJGG^*DRZ:5'4- =F:J2V\$2M)2B^M^V2HF:4!>+QNIQ Q?5<<+S>K&KN<@2W@UVDFOT0^218LX&5(9ZB^"/4 M%7I|UWC:G>2F7C|7X&C9>7UVO:"N3N^42I!:"? "EVT2JN.8QM\$J ME)A: ""ZPXW#^XCI|LWVYI:Y:4C5ZDDI!& F!!@K1F+LSD M9MU&YE^D5I21/8.50^2YH(4A.L^B:G4.#EFETE#JW^!J!&2IAXOX6IZ5&# MO8=M) ^BJ00(" D0=T)JU^N4%EI|> 90O?BI(%\$W)NR!UY@8MS- M2+2.\$ (D2Y(%<)Q^RPV:??T\$|VY@GLF|&F|E^MTX %>+ KA^<M&O=X@10N^!Q1I MY=MK=^F.E^Q04E>P6FO90A+7X-/JMU5? B1:OP^1-P^M^P>MBV^F>Z8W<?>? MI9S|D.V1X^8N M> 'R5H!<%8:3.E\$|I_10N;M#|B|I.E^HXN+3.S? M;".TOG^@4(L>P-JM1D8H&8(J^<4P^WS(4?P8^5"4 F(&Z9!'<8W(?!LOD^ ^ MBBKY^C|J|D2+T%\$KW"@:3!&I@|W5')=JG@/ 8J(Y1JKMIOI\$II6&QRN^3=8J(MM :J4^R>EA02^OX;^ZH+1^DWK U-8POIH4#S1B,U,3!I|SC:GF.K\$16_K MWI3-5TSN!|0:0.X.5R19:1\$C8M56XG:S:\$-O-CUYGC=?%N0A:0W3^7(6U.K MAIDD|AP^&^*E&KAO@>:FR!7&KL1C+3%GU0IBGR!\$T)GH2C@C|99P4 TP_XS|OI 9 MB1\$)M^C&% MX% AKJDI^1^,C1Z15GVQD8DVBL&K^":&+7@G^SGWD0|N0?OYI?2^K#9^K5%Q@-I|= @J|H M-+8WALCNR-ISA1GK- WYAQT498S!|MQ7C10^8^X+ONRWX/G1U|6KC120L39\$T^X%:G0A,D",M# 0ZUC: M\$Z+=^@<I Y^C.H 102Z^W7C\$GA8OLC/((9VY R:* M^"1I/T6+RT4B!>0%6;=I|J9?I=H22&>900.7L^J@&6|OIT^0BKTK:M%34% M8YNU2%2PGLU3V? Y^C^*6[P:] ZH|N26I^M M^X-VENV! 5=<^@%:!"Z^="I(LAC)F75#X%521YI(36%RZ?D)MQ|E=I= M M^MZIVK^CGWDHDI|B\$A\$K0K5CRXT=H2)A,(W1U#;W20X@T48HF.C|H\$ZGUD. MHU53+!OK^MGSRS M">.%37(8.OP(X P2.@OK|TV2G^&0%N|I|J<:VO1^I:VS1&EEV%6631BD)XJD9W M&)Y:|I(&4#.^_8B(=^|BR(VZ=UY% (I4C6X^1|GJ^"(C1I?&D(CDID9?# M)I&M^*KX6I75UGV4(L1LDUB<:I+!\$?:@|B O0\$|J|XJZWI^V^+VKZDIT- ROR^%O9DRXPB@+E3BUON.8D|I M-FB&2P0+08;I@A|J0Z1^8; M^7Y0R8,5E)F|: <&+8MM=M^Z^P6SE\$DL=O6)S >).Y9:4DOXYM NB.80=RV|MT MSH(I|XUBR9+>D@%C1PF0 M&DE&F9^ HRD/W<#X:50-*WB%)"@K|U=P->C\$4H>[3@:!(5U#6RC^X2'. M>I#ZU6VDM/J^-.H\$3\$P27N6: ^3T\$X6 M,#U1LZ0I>K2 Z8DV->I?22 NLGIG67\$|O(X0I\$D4W,S@66VC#\$. Q@U@R/R^YOU.7@JG MUZ1^G5|^0^7&8TFG22WYEUKK02VSE? @4(4ZD6^OR=19#M^NGW/O:(A3ZL_MZ|2DCW2I7&C3JS|^ 240ICV3<I-L|U|WVYZJGM^P52C_9IB|H>721S! MPK=\$>EJF2C\$&D8^R08O6A|T3VQ(MT#F!^>8FPN24)-GL<5<>M^?232TYE M<24UD9Y^+DL3,6&|G5#|RY|GO^5G\$ 1X+ I@OHTI1ZK^9NS:E. QM(D%>SVZ,## MP_UNT00XTFX|1^0,M^7Y4EY&5YIY%5_4M@3TH)7:IT-D^3>A;IM9% 1^M M@: -(CV-+>L!9!D M:=5LGD 009>=SA0B!8|LH8E5A#\$X^XGC|^I- VM%="F 2XBU^MT YG2EN26>I=DEF>RS2<3N52<64W^87(MKJT08@IYM! <@LJ^+>7@LK2>6KR%|SP/RU^=1S_YSO29XZA7:3=4OH)LT^I M15?QUEI^VN^HHM1J#2R4E(QO+O4|IH\$X\$X15(T|IR+^N4JW+T5E2YC0ZWNWV< MJA|B^A |VICMY^!+DIIV).@+G_16&3C@E^!9455%V&G&+Q+=P^MTD6I|& M+G^5SM#D:5IKNXQVS.20K|YV+>_AVD63? W.VY+Y1|OJQO@/TSOB8RDV^R^P^L^0V%YS+K9ZD=P/H?I^E;9 <"1-9+RGHLNTIM\$ MY+^BOHA^M=60",DV?_K8:(FG:@|JL^@#JX^#DW @1B83#>QL>|<C|I|A MS8T^>P@<(B&^I>B8;A6XV T4CZH:2^A^F|XJ75D(Q5K5E^AJETNH&UZ^I MC077+N4(B;JA(O1W+I6_WBAI%@0- HNZ82N5=R_J0#NM.J\$6".*G#R9@C M)&NT^VCM66D|G^""P0<.0R%MF&H%-SB|)9AJALBX>@B1IHQF(57ID.Q1:> M1(Y6I8.>>Z%G_7.T&-0X=M>.FW^TX2-Y@DAQ4:9C(I>+&0%.\$X>3))BAZ^+9DLG|I:R.F%1 \$E*\$8GALQD1 M?3@TM|N MU^OQC0(3.BWZ17W)&B) W09%>)##+2P>.NEI:3Q(1<=>Y2+3M)A^AZZ77 MGLUQ:Q3&R^VW24^<|HKA|SL9N^NX0<7P(X@)4 M)GI&MX/I4H^ :A>K/PJDPI^WN>)%@MG@F^A/DA2:CU^I^:@8+^F,SEI|I(L MD:SEG^ZV+8E,C(#?S|EG9W/G)R4EL.NFA?^(HA+|M>:;@AC.T-X80SS@VM MM573QW^\$@S\$U: Y^2>H>?>%FFW|I^F8>K3^DF\$.S^5.^IW0URA^BG^&:- M,\$(CXQO=DDAXAXRSJ3(CZ<=>E36?T\$C3))AITHG- ES|D.3T\$<7Y@T>@&(B8X) ML#9CT,39?X\$XBHBYX9H1&ES%)*PS^684-E|.#/).(X@PXHWU_>Y&J|I=K MG)ILS@C/ _D5- 0V05%E5IL1&D<^9&&VH2&Z6&DU\$D) B% M^8IIT UED.1IFZ.X%#>7LS0&FS&E.<*W/0V8Z7U3&D.^)I|P<,>.#^1^4IH MJB.- PE!GM3E(12,"TB?|KSU|@+>_+JXL|3LIG^G3E^|WQNA4L55I%:TV^2T\$PYFU MWLX:TS@4|SO5!"2LMD?>5;RM JBUI%FE!""5?QID>4? T9S>W:|Q7^3|RJO MA|I+>WYVU12^MPL(5I\$GQ^!7_&I&S^":WF=RB/WZ/D+I_1+2<01-5ZT|L.RT_|>T6W9PU^2P/M? M9A1+V^TAT(<98|UN.%HI&QS<>CIU^AV)5U?CF:52=5M.*FU^"M^C8JOYL_E@U#U@M^MLBC M=IS-DB ^9%V I(5C/8\$V>JQU6S(C- N%40:L@Q5)CID.@X*W #7^C-COE7I9E#^HDS(I M8N>I/H^Q^K(S^6^IJBHFE.KGU13.F9!<-1= 97^FS^>A5D43:T\$V6# M3:~>GZK^K&K8B64TOD8T#>@#V:8E0E^DS^Q2Z>?>20^A2_2 I|K@KLN M^:C^GD58E^HS+N=WMTO04^ENL!^ \$^P3>_0L@YR6X.K^T^OYCH:BS.5P\$^4K7PHK@%&*M^?OH%HTNU<+WRJ><2Z^S&7SZZ:E2\$J|@#; @EF|MG/0,9->2>CZGV2!|DF M0G= @126B#M|IS>^3>ND(Z<0IF=X=?@: &I^K^,@XQK%1@UE03ITSK\$SDJ+ M#6+JB>V+>QZ!(CV+C.TQ0?@QW; "0IRF4M5VT^/HMS7R/L.#. NN^|2.8Q8 M=A1E9O|H<=>)G+GIHY&|H.VY?GF^Z EGV#*#_.0FG^#/:32/4DAUQ? M^?I|>I^M;W^ ^P&I+^QS^&Y80&&R8UK- 8&N|HFLZ4O,VRV|57(I=)X V2IN%="I!&M^34&S;Q1 UNPH4W|B>QIL/7N8 M^A)Z<3T:??- W".4|LZKGZPOX0ABS(K3DT+F^"H^7C3+0(5U=)UG&CS;),4 ME1V^1Q6K%M;#K<9+B\$>|U.G):%T6KS8#G2,|^X^R YW-ET19MZ &;S-8(P(Q

M9%ZG/[6]/@ZZDTA*-1#F+EKUC2IFJ+9\$K E.UF0J3A-ZS[J@3&+4,8C;% M-2%SEM)S'7*+SR=9..F(^\Y4="3:GD^W
MMU^/G/'SV>Y@&JRVB]?'KN2D :O(K43;1) T] 20:A.FG2YCU8:R3JF57F2*QO MDNQ 6D+B.-+@+(5G\$Y*4?^6I&I@9. XGJTROR 7S^DAB/##@.B.
[KH71Z M/P.P.UHX\$[7< @PVX3C-TEUX'^R@/^@ DW.9)*S;@;/^0(P\$S>.Q(LR.W)P9 M=WNZ*-IYE> ?)
C8;3P4D)K%#"NOCJ+U/P7+KKLAZ4Q.UP1+UU4DNM914\$ M^\$TS29J92SJ@ M.F4X\$SCU'I@_ FS#\$E1G>?UBXY.G CEN->?3 E7%LCC
MIQ(\$V%J:N#0#;.CUS.^I@'EY'M?@2VA-(JX'J28XJOCY8B=PH2JU-R 4Z6H\$SRA1IGGMM8+DX+(8H*5GILJ.%1_1/FVJ;3IFC)>S;X/R+B9LOZJ@
MT_)1G2FJ-U!\$(J8Z*W=6 *7BD4#1:Q'0IL1JK4'\$2BF0/B4A9=;^Y*W:702S !4DUT&U/<4N=< \$ M:6CLU+8+<-@N2J+X'2>;B^C+ ?)'M8LC1Q(LFQ-
\$M0#J|<-&HIE4)2C4M MXD0:'FNLR>0L[*R65I' Z'W7N=E=Y%X 4D&3RVMPAA=JN CB^O">.(MWOI M1J>U^%7A=EMC"-
>.7%=>G>A&QJME48\$J|*"?@U0FZI5?2S0J?9?IW> VJ;3 T MTD1QI(=) #B#(0 .M)%\$(H/HFJ>F:N7\$X! 7F 5XFBAB+;7%-
%)|PTDEKT&GRKE[8;BDVB76TXZV4\$.BS.YCND%>5 M)DBCM/ \$D>?!: ZJQT-SI;T:|*\$24?7T<@? 4Q A.6)HTV4!'UI'-L MK\$78H'-
&TW)\$GZMRKS3Z)S8SIWJ#|UIC6R/8IUE\$NRCZKW')J#\$48 MY=<%A/3+C=C4H#T \$66\$2JN@VO+U?D|COS*9QT=|@:Q/UHB.F)36P3+TU+
MRC>|NWZ2Q%Q-L X(<8CJ|< "/(=<I3^RXI=,RKKXZ2RP>8#J|W ^TZ MV4(B)?UBJ0%QBC1J|J:~RD X'8TMJCLK?M1MDH3M|
J|J8 3?)*=U3^@6XCM M^Z6C2N(GFQGRLIH89+<#U M1;+^6DX@FT^QFNDI)Q% 9^& BNK^%U0L6BBIBNF-6:8DG\$&SY?I3M|
MG.)02%K85B^:RS29\$AL-?VX'3BR>AII/& YCC#"RXFS\$V.I\FX>;Y(XA.V M8Z(PT(IR=|B|>@:C% *H.O+^H8>-PL>Z:K;@;\$'UI:\$YX%)D
W3KNBCW2G.>|!\$Z=Z8F.'9GLHG|+^J.%\$H0.E(GC9# MHHIM4(T+R)F7^1KT68%QV:~!ES207Q |M=U^OTQ4(>Y3:CQ+*7TFV/ES MR+
JMI^MUE@J|JHZ^CJ\$YCT|NNO=ZGYIUHG84D/(H>4;K6/U2I>)'\$2IL'4 M0:~!@W0^:~!K'Z|H&2-R|J9SN9:X+*~DUV6M>R;NN.;0/2
=RW+ MMLJ60(2AU)VZ 3\$OAN^EE5;IR20 ?FUK-T:8?G|D M^%@C/5(C|KOLVRI9 ML16AH&6OUDF#
(C5)6MX(K)\$68\$26ENC9J?'B|<0FH71+Q>V(9S>4M/U11? MBOV~"O@XJL@QJMVZ0*0WR?K%.'*FIU^~GM-CW2.-. |I-HD|X:FFVIRGOI^<
M5LRHG\$OKNAW('CZBMJ|<+<Q92V*L'7BL'F9#J0I>4J>A>31C9J:C+OFI>|Y MFF?K:UF5M9NR[G8?J'."F3.0T<&'19R=9HZ<\$X+.
(NDYM+AJ+*~ ARAXBV)T MS|F%CY#F=;%O.(JHZQZRGU<^V)>|>B/' (LM;4L+6+6 J#16 M|~7HY4H.8N?N-J62L(-
% .HX9G%)PIBXN^++E1S\$?>08@A.H0668B6P.2I+ MV#=-1P XR>|(BVAMLI1D+^CF#."BF^ZL|8J2YI7F7(3A0FPL)T<+12.1(N+
MGI:>E>CHX 4WUS@:~Z1 M?B:Y&(/O:E7Q@GNNJ6CHZ R+CKF(O \$8@>P8A0(2A+<~:~%4CBO6T7P M|NB:"5 R=4I4I02M@\$\$VS1&VY7A.!
<<~^V|>|>OK.BRY:JX9F'E3D9-."I5HZC7P-CF>U!S |EL<*(DQ.YN@A62 J#S =B53L M.1TTF>~YJOADM<=E6&)PY-&80RS7+1IF.C.*#17+PI&
JUC.B8.504XDII&Q MR7|O|' M^O178+T|~DTDBWC3M355OU^2Q|L^K^K|/=DW^T= 6B^V.;4 MWFR8NT|N;
I)^2P:~*~D| AZIYIBX4I|=(TV2R=VMX@)V K=OP^3F@ZJ=CP MC.5 XAS|OTXZK3J#"G5BW=^~
36SUD|OKIEM4V|K|XR3QBAH=H"C:6E9^%M M^?75I4=80HC1E<3K 9PG&9 (KJRV M%\$?:~*DA ID^QP:KD|RI-"
<1>\$#9PVG#&~1TA|=RNWTM %|M6I|X9X> M|=#L|A**E.0H30EJ8^K+2F2>.\$XO4Q=J6GNUV:*718;M19;XH8RZL4I?T*.SIW(C32PIL;\$9P
MTQ|@+9D KR\$US\$|I~^WQ7X@?~1^9V GPJEH>3>R5>|LD|J~|NJUI^OQ U3 MC%:2Q|?7?>W=GF|Y.L7Q&~&D81.+F-
6\$J|J 2|S|VJX<JRV2#2%VU|=(G4Q2SBV4&AM91(3E=3NT>J6Y59PZH=U3 M+=|~KBH2U Y#99!L (O:~%4M\$HCL;JR4:~T1J|36+MJJLU6_#."
077Y1 M1K#B"G4Q9VBH|=T28+@L'?(S7A+;VWEXT USWAK5>..UM|\$W-|K;& \$V6FY#;V3&5|J| MXEEY:& G?
J)EG#F8;8LOI2I%:~>.99>Y0L"4R.NF1R <1Y^M%1&3+4L8G&O MLLT(C;&..FP00WHWN|B#;HCK&Z/4F/<~HSJ;R9Z9=*E31Y&5XLCF'-3"^>L%
MDEAU *\$G2J(9#D9F-?%>2DU|GYRT<T7WFSR1I(1#1J|S6H-X 1-3X0A M&M)49R&L|&K0'J<:K.60X=J|S0J0-2.
J37G@OTXPCZV55"F)9RO&@<^~V0E>JRE(PG^KIR2U:2J#7F9 MJOHU"DA MO 1B#.;O! 3^"R
S.TX^O|V6I(Y@)IVZ0BF('CSDI\$5:8NDV+^1E:C4\$ M2|@9MCLD0J|B^KP>#>~"JR&367"<1:9352;+ER9(JEDV6NE K YM)XNDRT
M^"G59BB4FY=)~X>7;PB\$ZU MBW' 1+6Q F9NAO=;D|J^Z9N|18;A4D2V=VU>#>~%Q8*6^L 1X:5%Z;G4?M;IDD_C+|JCM%X?0
HAU4K|X0DMB-@D\$)-K6FA9MHU2<*~I MAI9UVR3E"B4C8Y238V/37(MTUZM 27LK|J)LW^%(H6;9.0
MVHN.950:T0%34+HR>~N88T2.3^Y^<>4&A2O|=(^OJ:S:P1%)Y@#G>VB6T \$J MK7.'1*~S|W|6I^SH/-~\$EWAYI+S%ZFW2Z
AQJ293G%Q0KICAZ'N|ZL|~ M9*R"\$CFCXBD5R-7AU.OI)3IX3%?"NOLOY\$2^0;~RMU"BOBK2C+;3A-3' M1MGXYLKZ04\$RS)73+X 7::2TM-
3K1 JZ38L<~V.J+~|JH|V130R&B=95^Q&43 MXQ.5.& 'AH^%5.0/4Z|~X"WR37F 5^8G?=(D
MA|J+X(8^Z= 84\$J|4Q|H.IIM*8HR:)|52^NEXY|WV(PBK0Y#D)T2A02ZKG|I+ O.2|H H%:V%M4+O40A&D1Y@>..8-
J)\$XTOVPL:CCX35FLM.P% #1|I66P#"|L| M7Y@QI=C'KJ4FY|JF="ZE11D7B?P|OV:~XG^~RAOJ 'F/ 39@VCM\$4LY: "CK MKE>'7Y0\$S6^~:~#
(\$*IR@LR>FM5BMO&?X'4|&=.;~Q&R#F/##SC(=|TZI4|D 2 M=K>|TP. 5;DZ*~YHFVKALC3^JH MW2|4|:YCAFY@M|L9J3/- @ P9K)-
@C.LG\$;J.O6E? ZQ3C|?I7?0L ^2 MM/MHVDDH+>~&U\$~P^D?T'?9W|E/O/ YIPOLJ@ (22 "((DOH/TW-~Z/LG| M +D<+97+=B-IG^*5^%0YCI
F)63OFF4USD+ESDG.5YWHJQZQ.C+BVNM*P9^/ M'E0E6+WU.MGXU:K4DY)RN7>T.SV^KY(CZ609L :F|J|IPOO&L>@|~E+~TLPR
MO.6J 1PO^N8L @+~EXY7Z;L|U.C.@(X7N#M\$MK OME0'R|W#1*~5V0V^689R8 O8^2I2+M M=D+~U'D6NXF
DNK'J6V'EZ'S59WL#<\$^TC7*T>|~I7I*~TO7*U79R83L MX3.;&|@E7#=-K|E|T'.XZ?K1;FFO-S<+~INEJW .<~&UUO6^8)I%A8H=8|J T M GD
4LT432~1%#L|B|C|L:RUJ<~K4QG^RIM(P9X |M|4+3&CFJ69J86D>5 MWS|&W3TZ~*OPD@=YR1D>ZLDR4N60>MBV#&8B/78?
8TNI^90I%MVQ(Y@9Z7Q M%YB.7& @Z0 &37K|K&9R2D@H@'I|I=(B;M^4XG2|:~#&A|&C&F9JF."&(T7;L M+>O ?P=V>?ZIB5< EL>0?DCD^CL;
:1)OB&' RF5^3SST=<@+~I4W@2E= MV RE6R+@/ D@ (83D2|V7:"RTJ&CF.D) P>RKT19^*~^~\$49 2IOS(&)% M&A2^..AXY(@T(H+2L.'E+~|OU)B=
<7.1S;OU7;J1HQD|N |7)&+~%9CQ% MH-S11:~%5E:M8|P1AKKI|J69939JZHPK)1MDX^NDP?~\$? 560(+5-HG^*A6)<~%QEF#|55N7HJW#~"
D'S^ MCC<?~J8UQ9UIKFZ;Y;TJFJZD&~7WTM|4T5J^>18BTC8 5IGG=97) +N MBAU8MWV?|TCJ|J#35|DU^H="M;RZ=LR3;W#OGIV?|+~
|X+~"Z/L:5@9)?K MUD8PN|Y|?0^GC#%|F^VL%V|Q2OK3GIYWC.Z 30;3/SK7&?KNZ'4^~(28J M\$U^C6|V-|38"?I=6ZM5UL(R'C^X|QR7+ 7P^X5T*
|PH)-^3:~HVJ A; K7LD' MTM^*O:LZ^A/P/^@~739K^|I&@~8^8M342;ERW|>H/D|Q DX=2@=KYK /YF M^1B<6V>23|I^O^@QQSFOYB0W1
|Y1YXA9 M04:43S|F9P3^<@~\$H^1(1X^:G86|8M0#~(#+7&3^C7E;FS8NT@~OY\$?~LO4X6H1Z0HOLLW1OG3IMAMOL MP2>YI.XYGU6"?7(YGL^~
K5WLF9W^WMAET.^|8GIKE>((7RVZ.)|N4^*QKU0.1BKD-LE-BM^*~ ER6#6IK0^M:E.OG|8S|J|:'S&J|J M&M H|V^&~&IPOD+X.YKO^|@SB2T?
H9Q+CRP5. |T:5|'~E:-4^OIV>|~L MCL/ @G34-.RO#IU^A%)/RXPUY <|Y0=K ITK'.0/15PM44.9(C%NO +3U^Q. M_#
|FB|\$|F'7(19HSDFFXJ:54^C^C^H (F:-TBLZ|)W\$ZC'^~^R3\$AH(B MB^FI^LGM\$S|UIY1ORI.*B7<:
J5 3VR1^5P@Q/^8\$H^J|E"C.08477ZG^|J|B|J>~:T5@)TAE8.1)DW|.052|CVP MPA;IY3<~&?QO^5HK34R#|~"
PIHI>@)B^*UJ4&F5Y4I2L.Y| U4.6S/ MSR@\$LAIH&C (SY9T25#1FM;+D>7^"@C@ MZ41A%|~#2VWB~";DIN9%|S;C%Q^+!~TGTL>P";
~\$SV+~\$J2^RNX|N)~I|E M|~M&@/OK|K0>A:4LIX^|I|I 45CN#7X|I^002QNG\$S09MES|A>T "QMHZ?~?PG.E+<~?LKV-E<5#D;OB^Z>XF|
MMWUS&JUM5^L8?C ("H,*?I|MX>+BFYJLYC846G\$).FRG7/37E|Z9D> S76 M6 #1=2T(C28 P4AT J|/L<~U9Z;3 %<~Q>:
F#513\$+U%>9< *L*6\$=1)\$>BF= MYO|+=H^~L^U?C9W#4F2|J2^K|O>HSJ^+9.\$V(6-4^6UJ2RR=@48^)?;Z M:KDQN^>\$5OKU:8V=B|A.;
N T.S.E|ITW&Y|?O7^D7 MR \$W^YXJ.P&R^77>~RWYBN11DCN\$761UG..19>:WP AU:~%63(C&J)=RK
MVKC2Y7%~%3T5T3;~%|@~Q5B5F=6%W5|9DVYBK E(G\$+<3^8M5YU^~LB-C6H M3J4K.+L#J|D|I/BG V6E3F^O@ DHV|?2KC^CA
M=^L^S0#VW J1PM JI:F| PB7@KYOF2-4S|P2%2446B:AMSI^DYV&:OZ6+U M10%!)~6D>X X<|GD2-.CZ84&GF^#V|0|25;0/XF8^"MAJU^*~
NZQ&S.ZFM7YPI|3BUU:~\$S|4IN:~UY^K? \$ M.@0=J|+B^D4SVEL6H-I0QF@7VEE6(5A6)U.58?0V6&V|;6(HX1QS99@
MJ56&COV0H=2VIN@2PEM@-9<=OU=G/PMV("N6H9Z>2L=|~GPB5^M@B^:~0% MN<2&5#~"S?EAJ|I<9B1|IX48\$~IK^* #O7
MDYF<:3#)/XYI52D^J8ZNW7R.|+D&C|7\$3P|@Z|Q^EL>^XP@N4\$V;~*M5& U MNN?J/VQ J.PR^*T=WSU<^~T48\$@H^"10^D/^"
SJ^4P@WA+L0.\$(-** MNJ.I2Y4(5^C6 V3>AX|@P.K|I1(0-TIUG44HC.@)&DQ.\$ M.;Q195.18?W<8 MT&~%S|27JMG|&>
(GCP.C8Z^6C6A\$1LX@S0N^<10.GD&^7)C|Z^G-|4R1%>;M@5)AAFO\$-SF^=&D33^NHRM&U^Y Q21%>~A>~.W27^OEC+~NSV\$HM5L7OMT
MEPAI^<~&M6|LO.R:~5.DVN.;UXI\$=7+^S<.; QJM^G6TPN2.L8.FXOD3>M\$ MUH|I=10948U.YI\$Q6^5OY^AN-TY7@MQS
D9&4W1^%*~\$J.*1K9YA08.%O3G M1|2+6HZZ5J2^PFT&R^*IB^S.ZAY3F4L6";R.O^W|Z3-K>~& I54OJ=FL >F
MDJWR<~9;J|+UGM3^4A3D(0.13H|I.YY|=L >(D+AX2&QY5:6WFB0).C0:M?3=FQJWV79?@3SO-SI|RD19LP
S6M^H3|>MK|V4IU#08.+1&#&T3|2LE MK|@R^P86G)7W "I|>L83+6B6 |E>IOM<1JX:XWA5U(SK5Q^OQ3^I)JLV MH#D|WU1ZD:QL(FOK?
F'(12X44WYMG#F7)^HHL1|S\$=^*~2D(M|(O3-R)'G:-I|5Q:XGM^HNNJENWV MABU7T|ZKCLPSU^E4WU%+MP7CI|U&EJ|LU>LJW9(U"?
=Q\$B4DM^4UA@J:~!A SGI.8^1A+~IRN2BFSE+~8VJ3Z562;SW2@W R^4|=F7.L M@9 4EF#|Q|XKVE
M441S^~8Y^W:AC&'Y>S|J(4A)3G|MROD.PX3%~@+B+8L@6G><@>J^"~%SCZ5SN
M8DA8@E+5/6D&T^ESK(VO@9L(BAD%QRI445XG@+F)@Y81?V4&SX< DIV/ M19@- 7J|PI/C\$ M!5%
<~#94(07M^DDB@~X (L O^99\$U)D^~5%~"+F:E.Q5T|8|I^>CG>Z2^RH M|OX:2% 1 1.CUV L-?27ZV.62KK&J|L2|IV-5^W^ OWZJ^M7\$>\$4&W
M-R:(H|N|E&Q%\$S E|P@F2GK^03JN-APCZVP?"(P<~>+TFERR9Z3J|TTFE^664EN M.FK1(C%&4Y?|=~<~%7A-PXQP+5=18Q9W28L_";V:1-
LJ3^E+D M3&J8)U^9^AWGH#~\$SEJ|28^Q\$|&8= ~"~W AVB^3X-)(ER5=;5YQ:EO#6 M|[N [-MVSJ|130^SC|3-579:~|EE|ZK 7F^"=|=
<>~?PID=QAJ;XPV^L M^E;M3GQGP16TRCJ0IF^>@~O-P.M=H-Q^GEA>Z^Y|Q<~;|=H^Y^~Y<~<~.7C.M5 2>@~?P.7(FH.7M6K(-
L I^D(4JS6~ZM7>|>+1G@L4#|~\$Z94 6|.DHJK:LA8JP W-2MCN:Y|F M^*|~HSR^K9S#5LYA^VB1|H+~S.~"OI|P\$W^IK.4VD1(W#<_)IV;5D9^P
MYTB2|;J00 |=IS>|I#>Y.A+|^+~# M1745%Z|E=K<>JZ 50=MRHRY9R9C|SXY =>6WE^F>8^IAZ.8.&|~>AKLDO@Y MI(C2)AW?
WUJ|24\$ %@4>J0T5#70Q8(&3Q F.^G(G)ONQGV6K0|UG^+G:YZ MKZOWF^39GKXV3TTA^L^2S\$0+XL.Q+6.=~%|H7\$9#@~*VZ:41SE;DF:DLV?
M-5 .6@+963X1T07L"S V%EJXB059="1&L;X4WJVZ/F^IK ZH=1?DUJIE MY|MV^|OKJ^*~UCC^6V?JN1|JN".CDC:F^3+<|~;IR:4^>495|C:|SK?
8I MQ^7^I4+~U@QIV|I|H8K062USWD8<9)WY6-C|1.DAEY1|'RO.4RELQ00|3PCW+~\$|UW0| MB>?YVJZ=24\$&XJ|J|B^X;EXR<@ " :
O!%4:8L|&L-DGVB'+^~N (Z07 M#3U|6.>|TY|6^0|;~>PVI|LOPI=WCFA4BWVDKX|JHM^28N|M1C2M^>SY& M06C0QJIP9C.5R|UX.P6 1Q
)%~%&P7) ^~V7^SO8LE2G\$@+~NL2R|="FO M+GABRDLWSUG=|>4;#~?/58+&~8L^~>O.KI1J 5CE|NWS4Y^8WU9+ MW ONN^
@T62")620I TT^G|M M)M1\$A^R\$;6I8&LVGRU|8I(6FQ:~)BP^WR4G+~FZLF|F54|~SIR-PRQ M(M;|O5EA>J|M0\$|6^XVI-
J|DZ:TWET^KS3OY|TH;<+8.;^I+1PPOB|Y2AA MB\$HF40WF^*9KX.KC0DS2N;GDV;JW/<OJ0^DT:288;~*~E1M;P|K.@0*
M:~3U/4YLG#UCE.#A%~D6!E%81.%Q0L7D2C>J9@O2^U>~>CP+ F7P |&? K<9^~M5AP.^*D 4<~HQOC(T0HU4+^~IOY^~"3R=2)T^W^YP+
(U9R.SD|G#CV202;S<2. MHWZKB8A^H=3^*~B|&|S2| AM@D&XUV;I^~A5DK(\$9^QIV MIF J|C(E%|%)2H|O-|@C7 K N#|J@1(1^|I3C^&?>CY?
U M.M30N7\$9R8S:IE#LX(UAJ008FE=&TRL>UK|C<2BS6(@|@|JL#;5^@UA+LLZ| MQ ZBE==6?>.)A OX+>5AW0.RB=66Q:D(WAY<0.9Y +.E|I".
(J W|U|UQ M=F^YR|~^QO|ODRUC+TXG|JN|B4.%Y^G M:X|*6|E:E8+22C8.78D6-DYRT&|R3|<~\$K|@6H0^WY^H^Q:RQ0ZD7D> B M(AW%&ZE&-
G5|~^90VTWRD+^FNLG^I=-.33RPS.^~FR". Y\$78 1^GKH0M+GN2|<~. S4;R>J MGBM#B=VB^~.CPILS^|9MCUFV^812^E>U?
F@/7#|K3^&E5>Y:-7^Q:~QJ0QT8 MK-.P&3?XIMFN^D8N^BC9=7+U^~.SF+L<>AQ0 QU:5V^BU54@&FH&A3H&1 MDKK#%MVPUIJVJW;MNOKR-
9FPNT=V7&8L2C753D.CI551(0G;E|)X5F *RD M.L(CV2.>X6LL>0K#~)"ZLOFTRG^55(|&S)4 ^U|'64<79^~B\$OOI:RZ&BK:~
M40E9:IC20+^O+51QOM|H?~LXA34X-IAZH(-8^RN/R58A.7:PRDIA2QJ|^*XJG;^C.G-6:~#5S|03 1TG+EMY
M|N|74F)=79AVZV|SIA@W^5>9YMUW.WWHJ9-G^>R|B:SVS^@A@LF^~

MT4. WZ@.3T4/TI:DKS\$(KFP)J\$AKJEL2.*QDN G6A3+E5SOD6;IB!@H0^ON2/\$Z/TI#6JR;YART34A ;
M((P8YWF/F=EHO)M<@FTH)DUQO:3NRLI@IKJ\$LIUN #2WT1WZ+1K+!>#R36 MIE/M.ATG@ //=-Q:N,AX"+DNJ,#I^!;A=.,QB4(UB5G0)C2, V7
NTN2B&Z8 MH:S^C)O+=%FW^C(Y%WXC\$+>J^QJ57F+RR"CH>H9:YPBS#(@U)@9C: P1) M=EDFPQ-AIHN
:QH5>4,2@U0\$SO<+^5D)W@1W0;:B' %2;[Z.CI@I]6(CH, MJ1=GB.HN NG0IK6UTY%6+NT)RD:R&Z5QH:/JCD/=J5B->QD()@/["CX\$@I
M2(VK05SHR#.G0N-0%N;#Z4:HW.IJN&23EV00_U0%+XZP+M@I:~D^I<~<5@;
[4S]#H@XC%)^Y:P=DLG@DFZ=^#Q7=W<4Y2DBES=6L+>O.G0:\$2 91) M> ME!W:."*0T!HH%T%#!#ZU!"<9GL<1C2?XJ2FYVWBR4S"%P*(L2?
&:O)SH MX3DL=EX NJ7% JY4VVS7FGGP R8.T5%;>:&?I59#D02%G^H^GK->0?B MC5R!#SOH2G151T\$+0YZ=CJF:V^O:0PSLH(3#+^MY
I<3>GPF?>#NXLX=X[/:>M'+%#EM2TYO JH/Z&\$ MRI%M*PI9P@<22>?>F#GPMCK9SK=R;)Q#-S)B\VTI@UDK+5ME0&H+/,DZB=#M@I?>
T.NZWU9 JY%XM8N=76 MEO+P9V .3HAJ>[P&M*486*UJ(3^WK>0^2^].J*E!&7^G-CI:6HM8I%WR0I M TM5!M!13FIQU4V1S0?
[T:IL>5C.ON/0RZ>4QJYCG\$G5I]WS:3;4MFK&N, M7AK"TPS8=IV.4I@CH(N!J31>#UNR91KDS5,N7WSG,5 44AGG8W+(Q:\$^C3
MG.8KJ[!%A!M@D%:/RYD/+^T*(H0=J4+;="^-[I]O@F:IC>? M)BE 6M8^3 6P%R@I!>JA>>% ZL\$:/DJW+DI:3?&GJTMK0U&+JUVOEG#
M=Y3^CDIE>CEN C^&F-D&VXZ2MYL1,GE621CVIY@4:R;X OF5,XN) :^ %S8^0R 1/P 5N MMEL2J[.5]MQ63Y ZC<U<#G@A40AJ4#%16,[T]
(YB9C2).+YJCLRF:<3JEB.IB=X9 MQV^83: HS09+=DWD^3BWRD)I+\$\$+RV42:I&PTEQ&/H9M^M):/7(4^DQ^FB)H0IP^6YV M6P/KEOA-
Z8)4&#6#EP&+>HIAU=77+U\$=-=YRWWW@R/G#J[R7?Q/VWVG M^IKR/+^IKV?8:J6W YKD2IFY<9M6PVOL ?GOGI=R&D9I.&I:DO .YL=#7
M(1-#QJLQI+ [WU]1=35K66/0&IGFOD+9/CJ8^7I(M2@I][WZ2?P:TW3 ZC> M:M#CJ2HY&CO6O@.#M:3:10T,Q\$ (HL)U@7-
DO.CS,*@;N>A6F#! FY6#I<2 M-OL;.=F,RZG9MJ 136903(6T /-NY.+!%S-7=T++3;F+IJ(&U!L2,Z89 MRUT)H J:DIPT@X^!<2=GEPIC+I-GW?
1(GU10 /<669SQCQ\$W+1GQ MB 51I:4.[2@ID3^#P.O.VIG5R^05HVG:0?NG /71P Z^+C1 ANUECIR-00I
M@&K C)~RZ0E,@=W"QI.G69B@BPELO\$2Y#B)OW/P>CC Z+88(>#>OOD^2 M-ZZ&/AA34+=Y^~C1/QZS/4/IOVC1374RW-&2F"%FO
981\$XH;.+O&L; M9@I%D9=6@+)3P5>2,RY<I4%JC2^IS&/(P3LW'3TW'3TW'474[N <=%1UVL7/3 MT7/3T7/3T7/3T:;=:M(SG(K+'A/C\$)=D6W
G1IIX+XOR#I6P5@:*Y&G) MEH2^R/9I23+&)EVM4YV4F^~.B&5(6^U :9%I'H+4PV%.\$[I:Z>395;.\$8? M-P3
M#BQM;&I02BA,Y+VY^~8REAGFYU7)R(PWX Z G2&2816JIT-SOR3)YU& MD\$H=ZIC1*8Z8D8-Q8 HC3G@50=I>0"-M6VQ31PST\$S^V^: J:
#3\$;P3 M;)K)BP\$WA@R5@Y8R!>^>UOD14KDK9?AD8BXLO^J&GW"=;&I]4) (G: LIXRE M,F0 WM))D^K#I(^G:J >MW\$KVI!Y^&JZ.5T,700%
DLD\$""(PI&O_ E^XK M>X^6/OW.@)^>HKCXO11>7/^Y^ (5E >F% 3191^QI_ G/6&6^&V2^BIS1A# MMDZ:6BE=M1Z3I5GLC/IJ298=(F8:MJ<;2DD
IIOFFV) "2RAI|ZVF2IJAHN, M/W9F4B-!H^H^@SM-JZ6P5OD-19C 7.6.WJD^CIND G^QUMUY^_G6SL I
MAN6U@OIC>:GE>Z8I)7YI&VAV/[I9@RIHJ]@AAAMZ\$>BYOKYE,P3DSIB M M0D5^ (SY+=HR\$62YI\$X1W> :+/PZX "40@ :O*A.' X6%
6S:O^+OII/C4Y M5/5IKINN|59QIJKCM _PG@#;OK:9D&+TUR T3.IM<="RIGX162\$;.2B% M797U>^~)Z3\$A(O.#D:78 TTR398JIL?C+^F(^5!
<5^I0I7Q:IO4ZES^1&9H(9DSJH\$X8EJ MT:J3@G*=) &JXL^?@F G1 VO(+[:LBC5C-5P]!W/19)+.ME\$.UD<=+UMWC M&L/H2J956^U6-/&R1X
C4=8;10G3K/F\$M^T+B>@ (I:VLGCGF&8Y^ V-E.%T M KOIGHJ\$JORI>\$/Z?8H(HNA#JO)^GLE=PV@68<#M?R:1YC9I)&W5.2;:
MO/DI3^E+D804>>9D@C\$ (6QF=Q?G)"59&30@=L.W.K+K+IIR%=IDA0%+X*@ MIOBV^\$S=L9 /0=?I:G0IU:<-6-UAO>V!> I:RX%HN^MG)=?SD?
2-CZ%\$ZE M-L20,+&\$;UI#@&GMTIZWE5 :7D^% \$J2D@>T>+==8#H?I"X X?FYN^MIT%4+GWJ35-&G#?I!4I/B-4E]"VX%+1(%I
P/I02UZO4#4E+8;9+Q.U2 M0L0#0>:/V+P KA J^L8VB#(3-OA>7IHJ:1V09;B:VXLZJN MBCS+@YBOQE^X^I\$V%V =G9E.A?
OH1;SS0!/6Y/T4"%RB;|LSD!@LL+>P@=0 M18+;I\$C57\$+^@O%"B0:+O\$SE:KN%M>/=8TI#416K72=WXGYD]=\$/F^&X-GS, M!)AIS
@GGWQM>JL^1I]2>+S P\$^HBI1X M J K^">W4J9.R6M2W+40R? MB0.]!#GK 7>^YU>?2A\$!@C^30-#<@I^#W&?IWC@Q^B-FAIKJ6.'^|KH+.
ME E G2I+ISO#>^~!_H0 &AOA?XZXF&R6M87JF4L8Z4I^X:GC^QO@ M=#99@IY@H^N4IG:2.S+&6CCQI AK^?>H,T,NK|BO.ZVKHN2I-
JZ\$8:/P(I0 M: R>WISWE.8YB2NQH^VNIA\$8SWA^3^N2DB>LX,W+70>>?V+OR/05L^,@S M^I[6Y@D>PM#1F)7?
4)*O!P@KO+L@+4K^C*5I]UJ3.QOAF>^ JF*OHX+H M^GBE>1#1WVA>61%(&?KO:&Z95=I(B(O#-CU MJI]8><I@BN2-'C|HXB^~\$4
ARP&K^JRU(Z&^@S3J@O.0)T#?35CBU(OWGV4F>I|H^4IS M 3WA=DC4)IW\$2)3M^LNK:P=I;DQ_Y90I4US1FM^6ZF,FK3PN?>74:J\$K^2G
MR^RBJ=718,YV,IXVNOW9+U/B@R\$XC41+9Z\$Q9955FY^YC04(XPN5OXW1@H- M4?MCI^XU7I&>O/^#I;=&IMGSJ27I0K)I)S2 H21--
MO^N8@ZD^V^X^YZ IJ648U^L^!I0R-YZ,^R%\$8< M^I.G.I0-3NL0.U3.)BY3I(\$\$)#>L(4LE=9!%6Z>ZLG?IFS>4AF7 M^L\$2ILVX|^;IIOIS:9
BNYSV)XW>E6\$?#-R;O(="@RBJXBWTS6^YI M2P<?UG&X61F3PE^T&4?ZRZ:6S|WS^N F+SCP(P+JP4S^..IDP1M8ZI&\$\$
M/1WD<0)JMRU971 Q7A^P-V35%@G0 &@+M^Q YPY&HK5\$SFF53Z^ BW/B^F MRBOLM+Q!S(I+&DL(IJ5H8367-0S >
\$NOCITIM @& UPI>L\$-PM^J\$+W1 MOKCWVO?>#20L (QOIVT:997026I285H#4,+3B"(C%N<9^FUA
M^1CMIEG\$5<+62\$2.KL2ELXMR=DIH^REQ:MSQO6>?>?@R@BSZ^LWOT#^I: ME!)@1IE>I]3/4)1D+<~
I^@%85QLEIVM>@*87J#1Z/ELUA5&K2^Z+E+ON.(?X#EK4F2JLIE<7@I)VP MX(\$URS:50&M:P W\$.=TZ%, JFX1B^6;&^RX
D9E++@+.R7;\$25L(9+N74 M2 'O1 J+:/N>I0^<\$1<AS2UT@:~N@T%.T%GJ|=F8W;S:@T5CS>O4I1.=DP M%UK7P^ ^-O-5.%I25G..&G @
QP4^ FQ^KK=@(80QW^? K3+>+>B@>F M-;|BIBDI1)=UQ2A (11).Z@G8Y%&I36EIJUAX&^W^L0M;9)F^#N26W/QV M\$SGF01C/LL^#C)Q6.
(G&R7^37IHJAH@H^T60GJXJ#11YG|^V#B@L.R*L% M_089L^Y73. GYMDVU1W5\$^ET^L>K0^ZULN)BS@S^HND10 Q2F^1 X9J
MEBZ@T3\$F+N+179.ML)45AP5%M?UOIG\$RRR\$A^JIX>KWZ&.PVGf/4,M.I0&-! M5GD1+BU+!<IIR BOZ^W1?<<(39EUTLDOZOZ^<>?(-
IWM(OQ3Y-B5%0.EPA X^C =9%Q408G0%0.E..KP6+HSC(HBJ M^C^<@SPU+Q^X:W?I?XSP%&4@^XM# 1+;>X&PL ^DF90|SB|B|)@ *DI/TIS
MAI@ET:ZKTDFRR96B>^GDI"PRH^T+33V2YH<8&3^2^14Z03\$1CON@CBD.A M0^J]3.(BX^% 65E6J8B8...^FJ@3.<-9
JH;V5R|1W:\$8 W7R&Q4MDN6IQS| M(%D J)|/I\$F5WK!|VCF^XK1DAZ 1:~3DD\$ MVF&O^+C#0&JXK#(W L(A? X^"U\$^~^V%0Y9X5X49.@|C|
L:CEIV76&^~) MF0W0ZQ3 QWC(OH A>9YT^S\$^\$2.%+6.N/JM39 M@I?2^*W#T^ WJ^ XO^V ..I]ZD)HL&9I^6Z"-&Z*7(IICIE3AHCF F77P4;A
M=QR44|TMGYK5UNJ&ZT1D.IU <^36BZ^H=<,%+6T4|8A| T#<?>P 36AZI, MPY9S\$(3ANB|7WPIK)D:|LH>OM3|9SY#
M7E4IF#%1:1VP7= G56PGF7^2@7ADAU1? Q GD0<0KHLH4B3P.8 ^5J8 MNQIR%:114ILE>4R^L^BVR^823&\$V79E.
&5MMO.>5%\$8^UYSO- 0C3-/: MK@I6G|5KH|&@K^&A^NOSE8.%&G5 D^C&5KW|&C.^9I!&N.HH:V7H->)I)P?> MA/V-7.V9X:S.,9(S:6IXW
^CN6)6:64GYMX2^4B+>PX^*)&^2=I]J^I]Z M!O!^|X\$S|^I&P?>>(9^B>IQR C^5A|30TC(XK7.Y5V@PGM6|X?E2?L.(
M1:V6A:~7UJ2:SY@4|DN4A^LMO?^I2^?I|HXAI^VRR|V|K.^|X^F^H+1EIA MT^2E=-G=P+8.&I)V@Q36(I@TZ->)=U&D&:I^Z#4) ^A#6^TTT@
M^IV+NBEX)K^8#RM^P2>.. 0FW69^J8NJI^I/..#<K34>70G>97+WO^K.=T MKM-ES&\$HXGU-1.H-I?
TC6Y(#G4I+OJ:5B^4I/4C4.PPM06:7I&#.WG16^YZTJ,E"SG?WB|OW?0:IOV^\$YIM^MR:ABVEO1 +2=<340>2 1%9(97AN.@6I
M8Y\$0C98C#JIR.#>0 P2\$|^@LVVIOJ.ZL>XLV=D^Y?I;T7>=>J)I(91Z4+J MF<@G8P-4B@MC|YI^#E1EQ#IR="GA92B5I|/AB4ARU(I^M.YN +W%
7^.. M.IVW9\$>M8Y U>2;2^KP4&6CV&PS9N55,+>B|3T|I|HB9R+O2Y5OLFJ&3I\$-8FOE)A&:Q3(I,OS08,C5 M%3|H5:RG>0%1K/ O^GSYK|EG#-
>@ YDYPD?I04I=(E>B1F)M^N09FV2^I^ M7QKLS#&#&OQ@I|>B|_#B#BIO:&BH:D4&8)VQ&I+>&^I10@I^Y.SY\$V8BOV M DP4Q7X5I^*
.:9@(+11EIX^CNO^I11^7-PIA40^I@TV@-5& MM1SEFQ@:DW.ZM^QI2=3%N.R8I+>4I45&D|G.FOK X5.CEA|S6G6IT+Y\$Y*+W2&%;D:(IDK?
HKK>ZJ& MD^3BSJ|IUY|^\$I.YYS^IE/>I7^*%:SX4|VEMO.8J^00YBW \$>)0W&V3K+ZS-7 MIEJIM^I6Z9IF^A^%+FEE4<Z2PZ-
806RVT5L=PT.1A^51.PX>KTT=79+2N|X MH (C^&S^D%L:~\$96^G-RS#%2\$T\$M)=6/P5#\$S -9I>:/E(IJMRD)^FLRY2 M G&%DG\$9&?
OIT.^I/6^B=2I|K:IGYK^G^VL^P9.Y:(&6I^C+@G(I^X3@I.P! M?+>+>IG>V1#40^G.11^ME\$7C0Q3J|@HRW^PK9D-A1IR@I0%&I1;\$+6(LDX
MBA0F5F^L^I|,ULTF|H&|9HB%<4B7@A#TY/Q X^%I@I9V#>G>W2V&@LAKZ-#I-0@-UTPI\$EZQYH|@QX3BK\$
M=.:1\$C^43)=1XN:V|XOHB;^I|IG+ 4-L>J|H6:M^F428U2K05/NT@UU^A MCO>IU6Y+&4UP^V:~^UJ^A^V|=KOINA,+NVIL) "Z^9\$QM^9
&VAXCKL<0W6M=Z4DI/PE).QM=5J3.O1^..P|@OVW@7 0/GKWNC.4 M^O9Z^OA5> 50X*+2J2O&I/65B0/2^LAENMZ9I,4=X<#W7R1,NQHK;WF
M4EYI-LX^.-&5\$9D1.^HE.M^5:5GVT^2SK\$|S?K7^I.OC.^I|OSGX.E:9Q< M^U6I^L!^%9BXM.QRE7
@P(K84I)ETG3I^T%6EA)U2I^K3<4 &R9N^*#EKP\$6)R%4A>47V9DDP3FYI9(66L-D0R":\$S5 X)\$IVC
MN2+L K^C^IL.U(E3^>\$7@C:JQRJ3GI6FI/SW:=Q4>X;.. SMORBF.HE 0#|7 M<H^R 23.4)IE6<A>F83^ZX,4\$ %|91=S. WF.BS|9-4
M&\$(X1HXXJ^FBXO(4Q 65S.PPC5.O#A@6+=U#^2EL8E.M.^P|Z/TI979908.J^VT<9.Q.O=0413 ^/SRL3 M7T 9EL\$-8M66G10#^#
I>:~Y@L3/#T3>0FNV.2-BI./#2A>N116L3M-&= MT^UQ:S&NW6|SO/6P8C):IZ="2TU0RN" S\$UB8B4#8C|LB2&PU5@+U<76N(M|O!D^D@ =
(Z>J8 -Y44N*5I|A#Z@5S|+F.8C-F^D1B9NSU|H=I|>4>I|U^WFH% <^APX1-6I=9Q0F=1^TD0I?)IO2^~FB=^?F I0B MUVSUVF8;I
I^Z^KD39I7?F-O3#^.;I^N^KFYG#U?G I^N^TC.=690.O^M^G20^I^ZRX2B7^0I47^L<%>U04 K/4^3L7X<%>B#W\$X<^~).VP2X^N9
M^ ^A^K^N, 5L9ELS4UAU^N0?JE^233L@WU|I\$14!T/8J4X-I^*7B(JW9QID5 M/I31I/O)Z:>~\$J^I!^=MA4\$S7=-NFWH5,4V4^A:ZOJPG/?
Z^F=WPB;BW> MDJ|WME.N.R.S.^P:@3=I-6-29G;7%RQ^=-=>?SP^27Y^N=P7IYR/HU5^I+>.
M^E_YJ.7S18(UML^7D3RLMNDWXQ^T.W:7JMG102P.#M @ #8%L6L72\$ M2^I^2^ HCX^I^O8W@M97@S.5I)Q+FAI>U:6W;MA) ^I^Z <:8=9U5^R
M)=FN4|K-3\$|ISO@I)&TF#WT^R:6\$8Y!@ 5^7 OKS+&:LBS^=NKXTN.|6I&Y M6^P6W|<7D#J9^E^ 4Z<3\$GF^!0G7GE-
^T_ZI^JX8G^> \$KJ:9:B9/4Y\$OA M^+&3SNEM!-5J4(VWOQ+&E:6Q7E9^7.L|5I4D\$6 JQ5BKBOI34I.I3|IPO!^F
MR=6LT^77U4Y+9+&P:A452>3Y6GO|MEIDEMJ3^4WLH|3S>.:4I/S89M M7S0^MLQ5I|=H7P @R15;I8I2Y47<\$=8)J2W=
<%P=..TUWLA@P%DGX@: MWI|^GSVZIGI=Y /GYX6# |MW%>X%>T<QI^HC:=&YOW4DCQ|SHEJ
MV^*^GOM4%~)4I.075K|S=KC7>7PM@L5IAH^|IOL^PDO8BIG)^S-%.T|U^4 M\$WV6 I9Q<1U#M^5.)78TLQ^/1 %Z80^ZO.9\$M/XKVQ\$)
<=I<7^_0NPJ M+S#IOC /0.8 1M|DC.RJ4XK|O<4S47D1B|^<O%-EO.1I4E5^5D10-1XV
M|N#E#X|A|SE1XIM54HM^9KADA2F1R)X^YV9.N<B5@NTN6Z&UY8I|L.G.C^+^I) HX9^PS^=I|PZ9I/6^UJUB^8:4V2)3@ M/99H- 3)0-
HANE3\$*^*;>N^YJE"=ILT0P(R1>CW^RM87UQESQ=H7 MRCP290Z? 64^7I+7#Z|6H^P|I%K6=&6QOR135\$H^W.O.O/24@ Y0^M230Q&
M05AW^A1-69S^2F0ISE3I^60-M^S-QO^DUNB(MJ^C)^=F(7X.X).D(IEUD M4UE+2+Q#&C4&A>P/CW:I=1@V0/KCM A5<7-
519^Q>I^18XUIDOMLIRDWS MN&ZBXM)\$I2:B96XRS^A<(B;WP.^6&H^J^ST@PH\$%.;XY@DS?Y\$S^UJE1EC9.QSGHR+&K^I7^KYM:DOC&I^P
MWFDT^/Z I7X0^C^I^C^P^Y:Y5T<@I>+O-^#Y>B:\$N^#C|I|JVD2I|7G^2V^X ME.GT^Y\$WT^~^RO^?P.OI^N^NO(IPT+=E42 68J|&3TC+L@I.6F?
Z^=LVPU@9 M^L^DW/U/34QK|A^P:G|^3^WKD^I|MW^P|AI^WK0E^IYQ=CP 9?>0^I|I|^I|YVYA2AAVR8FEIB
MA:5|MX|X81H\$&+6@?^I^PU^PWV\$S1:~6R6EK6CQ.4CXJOFD^YI33S<6L.DDG MW0I^*M2GU^S6GR>+T^X+I%> G5YU^IOK>:T|2OL(;MV>K&M>
.:O:YPA9+ M9EPVHR=LMPE|W^VVV|6|H0H|QH^KV^B^OLBM^<^BB?+0E^T+C^VWO .>XOI M^LW73I.CU GOP7RWY2W1OW?FUT?
PZ.SYFTEG@I/O|S|5\$A3A>4-7P4^C|M-O8%IG=UZ^YOJ3D2IHKWGSJ?7BD /4ZUUCQI^I^V:YU+^C5^S7YF.1I/ID G04E-5&S|Y
XNMQY3M5^1=>.;&J^%>VHVEJ&X-0 B^I M^FY#QY1M0^>^146^UE>#>Q7S(N^I|5M:<I^NV\$G|O MKT^=">9\$6U)MNJ4+P^OZ+ M?
BMQGI^FQ8.XO%+S=J=B=2)TRWGC\$O:QJ8SW7?EQS(2>I.O-/1^KJ2\$IO4Y^ MG|+I>^?.(N2TT^H^G(K6
>9HU&E.^X50I)|D7Z1%3CV\$6:LLZFXI@0SX|VI M4:~#W^=8^=F&I L JP^%C M.5BRAOF2^W3-342L7^GWNZ@-56BI/)^*B -
@0M|L^N=8+Z6K6%VFA8I^ M5>V.T.D.(I^MWX7PEAL5I!OW^VL^PDQK.138I:5^F\$8@ M^C2L3I^!8M<#K%>B9T>R^L14I);-?
F2G8)YV:2^I03.6I3@I^W0\$EO^CH M+D/O^R^."QI M6 7VLP4B GTM:IC F#FK3QC\$9QJIG7^I9H M.O.MO 6ID@P^<P<5;A-RNY8@7A9)EIL^GP

MFD!C<\$!%68CF((%Q+LT I@<2>?C7?\$.F*C4DM:M8AV:U.C MI2(4X3V2:~0*)<0C-.YX(I.7& ("DG.0!5%*4!>@|KC57QC4XB:W1D6TU|D@("R8|L@(' MEHC|DLE>#(<|+K.('P\$O%,"JIO=*19*2>4?I8X5|D M IERTSRNFZBX,E&|!\$!\$RUQF)\$E0BIO?|LI88"@I/2|R^68+DWT^|H|P ?OHT? 1.28Z *#73S63I4567|;|= ?@B55QD@|MN9 M81%&FHL*\$(-324)B0B0G00 UQ.N4MIH6XQ\$24|FMV|9T2+4IDVY*3&|HBS-* M^N^#H9F30G(K:0\$RUI44A602U@BJ|4+@<:.\$P#&G\$. \$"#/*9- &E3CGLJ|49RR M+RXX&+&L7%\$K\$!#^HL7\$=Y5T^|I OJLX>*0-Q+9GSA!#?@:/L. 'OK.'- MNK?7/+>F+)^*@41DSNC.65H1'- CJ54CMG(K.N8@ER7|D)"0?7FIDIC@22 MI=K\$%!"%=*75^X7 0%U0W=@:'>M^?29SGB(Q@0&CZ|)"Q|?5(8|P#-<4\$!&L& M- C(4XXBL1F 9QF|WX3:YGE|* S6M0KNC^~?^0|2X.M94; WD.9|!*=-3L+> .J-5ETBE>A CXX&UH13U,W9|N<*#R^2SG7UM|X=CD\$6X= |U8/#JL^U3(?C01V\$U M:;+>^+SCI3|RFI2\FWP-U@BSE'W\$:XRW/+|L.>& >'A RZ?@MZC|JT|YWMV MS|F'K|A:GJ-="VENPG&=- @)|%\$\$.H>=3?PR#2RN-F*5X|2%T|H|XLB|J MMYUF.FZ.62?M\$!LAE|(:XE-FYK1<J-= ?IO'EY#|2|JW =V29KV)=P/|O= MN|)+ |790.U3CCM^C^+|H3R^WZ0>^|H|LJW M F/|5|YTWS\$(H F|:2IT^V9|&|M^%=Z<=WY|^XEM?BXE%.S#91+^%)O7 M%VC>U9& |XU|1|)"|USY^FONQ\$*^ @^4 ID4^W0.4?|JOOGH%)|^ 7RW?@/^H(W M7HUA| P04 ^-@6Q9GNPITE|"(P #@ &|C>|"UE>#R7\$S\$N:'1M M|5IM4|JLX\$Y^OT(TP|Q.%,2J>U4V9R:9BCLJ2ZZDD*2 M E'R:4|@/5H2E8AF|KM2^|GEVM%7DW^YF("JF985\$^C@U|)P M>N@>)SLE1:TBE<|XFGV|/+ \$Y5>>486H1^YL93FC" "\$\$4^-(?7L^|STI M3(+VH= X^K"@FR^/JGND?3?LY& ^>K^/VJ:-24>.V)(-C.OJ\$3X=|S^Z MI VA- CX5 JOITNV|S^C+|JULF| 3+5AZ>)|@:H+|B>^X|6|698.F.F(R8# M|G%*2X>7Y|SL 6>X."Q\$D|2|.JD2D9B^G^C^P.D)Q4+4#*=|STY|OCM0^4\$< M|61>4+&S^H+Y-HGZ12.=V2|T\$|L (G9 B%>7R.UVV @>BW7A"J229V1 M- KC6D>.Y9 7K<\$PUV&|@6D9<K3=;+?; MSWY@BE0.S*1*O#\$N|:2P\$T"!OO"HAH)U|X)+X2^3KEF/0ODI3;.%MFH(+/4Z8<+;1EU4| ^@^P2 24+ M+ -UF:L5^8/7|11D C>/0-QD|A M?Q*Z|A6.Y F|K|S(W^6X0Q)*2RHMRL@U:Y63|@/DAO?8P=E 1/M|- M70K16G^&CCG4EL>87Z"?<? N4BY|:40^S14XOR|@<2|LDRY|82|47^"U."PVA MAH(BO:|L&#:MJE9JP30^ZG^F%F\$M70FA5^|U30 ^=YKD-UI|118^XS=U3LDGN M- 4>O>5< F#MH:X5^I3.ZO9V <\$%. "%8|BRJOE16|4&-6KWSPL<*4E9W;Z M@W/KUGEEQ4-F4%|D5 ^F"EVUPAUHUK|]"W0D-W4 ? CM1PK2)DC(32@|~V M^|I(6B|J0GT4|+C|+|^ 2S^~7X3C+=ZJEV%>HLHLG>F&+9P!2PUP+^TJQ MI)Y^A^ @B?NKC LXM;/>U|ZN.>^>V" |(|ENC| BLO+|JBR M5M^4@ HIG|&%=6K"TR.#(T.#DS."YX XML 76 oxc-20240930 .htm.xml IDEA: XBRL DOCUMENT 0001642380 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember 2023-09-30 0001642380 oxc:PharmaServicesCompanyCMember us- gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001642380 us- gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-09-30 0001642380 oxc:MilestoneOneMember 2024-09-30 0001642380 oxc:PreFundedWarrantMember oxc:SecuritiesPurchaseAgreementMember 2024-04-15 0001642380 oxc:PharmaServicesCompanyBMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0001642380 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001642380 oxc:OperatingAndFinancingLeasesMember 2023-12-31 0001642380 oxc:TwoThousandEighteenIncentivePlanMember us-gaap:SubsequentEventMember 2024-10-11 2024-10-11 0001642380 2024-04-05 2024-04-05 0001642380 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-01 2024-09-30 0001642380 oxc:PharmaServicesCompanyBMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0001642380 oxc:RazorGenomicsIncMember oxc:RazorStockPurchaseAgreementMember 2023-02-16 0001642380 oxc:InterestMember oxc:SeriesARedeemableConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-04-13 0001642380 us- gaap:RetainedEarningsMember 2024-01-01 2024-09-30 0001642380 oxc:PharmaServicesMember 2023-01-01 2023-09-30 0001642380 oxc:ExecutiveOfficersMember 2023-01-01 2023-12-31 0001642380 us-gaap:CommonStockMember oxc:SecuritiesPurchaseAgreementMember oxc:BroadwoodPartnersLPMember 2023-04-03 2023-04-03 0001642380 oxc:ChronixMergerMember us- gaap:ValuationTechniqueDiscountedCashFlowMember 2024-01-01 2024-09-30 0001642380 oxc:BioRadLaboratoriesIncMember 2024-09-30 0001642380 us-gaap:CommonStockMember oxc:SecuritiesPurchaseAgreementMember 2024-04-15 2024-04-15 0001642380 oxc:ChronixMergerMember us-gaap:FairValueInputsLevel3Member 2022-12-31 0001642380 oxc:OfficeSubleaseAgreementMember 2023-08-08 2023-08-08 0001642380 oxc:SeriesARedeemableConvertiblePreferredStockMember 2022-04-13 0001642380 oxc:SalesAgreementMember 2024-08-09 2024-08-09 0001642380 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001642380 us-gaap:RetainedEarningsMember 2023-01-01 2023-09-30 0001642380 us-gaap:CommonStockMember 2022-12-31 0001642380 us-gaap:CustomerRelationshipsMember 2023-01-01 2023-12-31 0001642380 oxc:SeriesARedeemableConvertiblePreferredStockMember oxc:SecuritiesPurchaseAgreementMember 2024-01-01 2024-09-30 0001642380 srt:MinimumMember us-gaap:EquipmentMember 2024-09-30 0001642380 srt:MaximumMember oxc:ChronixMergerMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputExpectedTermMember 2024-01-01 2024-09-30 0001642380 oxc:LeaseAgreementMember 2023-12-31 0001642380 us-gaap:CommonStockMember 2023-12-31 0001642380 oxc:SubleasePeriodFiveMember oxc:OfficeSubleaseAgreementMember 2024-01-01 2024-09-30 0001642380 us-gaap:CommonStockMember oxc:SecuritiesPurchaseAgreementMember 2024-04-15 0001642380 us-gaap:RestrictedStockUnitsRSUMember 2024-07-01 2024-09-30 0001642380 us-gaap:CustomerRelationshipsMember 2023-12-31 0001642380 oxc:SeriesARedeemableConvertiblePreferredStockMember oxc:SecuritiesPurchaseAgreementMember 2022-04-13 0001642380 srt:MaximumMember oxc:InsightGeneticsIncMember us- gaap:FairValueInputsLevel3Member oxc:MeasurementInputManagementProbabilityEstimateMember 2023-09-30 0001642380 oxc:InsightGeneticsIncMember us-gaap:FairValueInputsLevel3Member 2023-12-31 0001642380 oxc:BioRadLaboratoriesIncMember us- gaap:CommonStockMember us-gaap:SubsequentEventMember oxc:SecuritiesPurchaseAgreementMember 2024-10-04 2024-10-04 0001642380 oxc:RazorGenomicsIncMember oxc:RazorStockPurchaseAgreementMember 2022-01-01 2022-12-31 0001642380 us-gaap:WarrantMember 2023-01-01 2023-09-30 0001642380 us-gaap:SellingAndMarketingExpenseMember 2024-01-01 2024-09-30 0001642380 oxc:SeriesARedeemableConvertiblePreferredStockMember 2023-07-01 2023-09-30 0001642380 oxc:SalesAgreementMember 2024-09-30 0001642380 oxc:InsightGeneticsIncMember us-gaap:FairValueInputsLevel3Member 2024-01-01 2024-09-30 0001642380 oxc:PharmaServicesMember oxc:OutsideOfUnitedStatesMember us-gaap:ProductConcentrationRiskMember 2023-07-01 2023-09-30 0001642380 us-gaap:PrivatePlacementMember 2024-04-15 2024-04-15 0001642380 us-gaap:StockOptionMember 2023-07-01 2023-09-30 0001642380 oxc:PharmaServicesMember 2023-12-31 0001642380 oxc:LaboratoryDevelopedTestServicesMember country:US us-gaap:SalesRevenueNetMember us- gaap:ProductConcentrationRiskMember 2023-01-01 2023-09-30 0001642380 2024-08-01 2024-08-01 0001642380 us- gaap:SubsequentEventMember us-gaap:PrivatePlacementMember oxc:SecuritiesPurchaseAgreementMember 2024-10-04 2024-10-04 0001642380 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001642380 oxc:ChronixMergerMember us- gaap:FairValueInputsLevel3Member 2024-09-30 0001642380 oxc:MPCHoldingsLLCMember oxc:LeaseAgreementMember 2024-01-01 2024-01-01 0001642380 oxc:UnderwrittenOfferingMember oxc:PuraVidaInvestmentsLLCMember 2022-04-13 0001642380 us- gaap:CommonStockMember us-gaap:SubsequentEventMember oxc:SecuritiesPurchaseAgreementMember 2024-10-04 2024-10-04 0001642380 oxc:TwoThousandTenPlanAndTwoThousandEighteenIncentivePlanActivityMember 2023-12-31 0001642380 oxc:InsightGeneticsIncMember 2024-01-01 2024-09-30 0001642380 oxc:CustomerOneMember oxc:PharmaServicesMember us-gaap:AccountsReceivableMember us- gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001642380 2023-09-30 0001642380 oxc:ChronixAcquisitionMember 2024-01-01 2024-09-30 0001642380 oxc:PharmaServicesMember country:US us-gaap:SalesRevenueNetMember us- gaap:ProductConcentrationRiskMember 2023-01-01 2023-09-30 0001642380 oxc:PharmaServicesMember oxc:OutsideOfUnitedStatesMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2023-01-01 2023-09-30 0001642380 us- gaap:MeasurementInputDiscountRateMember 2023-09-30 0001642380 2023-10-01 2023-12-31 0001642380 srt:MinimumMember oxc:InsightGeneticsIncMember us-gaap:FairValueInputsLevel3Member oxc:MeasurementInputManagementProbabilityEstimateMember 2023-09-30 0001642380 oxc:ArnosSonMember 2022-01-01 2023-07-27 0001642380 oxc:CostOfRevenuesMember 2024-07-01 2024-09-30 0001642380 srt:MinimumMember oxc:InsightGeneticsIncMember us-gaap:FairValueInputsLevel3Member us- gaap:MeasurementInputDiscountRateMember 2024-09-30 0001642380 oxc:FirstTenCalendarMember oxc:OfficeLeaseAgreementMember 2019-12-23 2019-12-23 0001642380 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-09-30 0001642380 oxc:SeriesARedeemableConvertiblePreferredStockMember oxc:SecuritiesPurchaseAgreementMember 2024-04-15 0001642380 oxc:PharmaServicesCompanyAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001642380 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001642380 oxc:SeriesARedeemableConvertiblePreferredStockMember oxc:SecuritiesPurchaseAgreementMember 2024-04-15 2024-04-15 0001642380 oxc:ChronixMergerMember 2024-01-01 2024-09-30 0001642380 2023-07-01 2023-09-30 0001642380 oxc:TwoThousandTenStockOptionPlanMember 2023-12-31 0001642380 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001642380 2024-04-05 0001642380 oxc:LifeTechnologiesCorporationMember 2024-01-01 2024-09-30 0001642380 us- gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001642380 us-gaap:CommonStockMember oxc:SecuritiesPurchaseAgreementMember 2023-04-03 0001642380 oxc:RazorGenomicsIncMember oxc:RazorStockPurchaseAgreementMember 2023-02-16 2023-02-16 0001642380 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2023-07-01 2023-09-30 0001642380 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2024-07-01 2024-09-30 0001642380 oxc:PharmaServicesMember country:US us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2023-07-01 2023-09-30 0001642380 oxc:OfficeSubleaseAgreementMember 2024-01-01 2024-09-30 0001642380 oxc:PharmaServicesCompanyBMember us- gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001642380 oxc:LeaseAgreementMember 2021-08-27 2021-08-27 0001642380 us-gaap:SellingAndMarketingExpenseMember 2023-01-01 2023-09-30 0001642380 oxc:RazorGenomicsIncMember 2021-02-23 0001642380 oxc:InsightGeneticsIncMember oxc:MilestoneThreeMember 2024-09-30 0001642380 us- gaap:CommonStockMember us-gaap:SubsequentEventMember oxc:SecuritiesPurchaseAgreementMember 2024-10-04 0001642380 oxc:PharmaServicesCompanyAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0001642380 oxc:SeriesARedeemableConvertiblePreferredStockMember us-gaap:PreferredStockMember 2024-09-30 0001642380 us- gaap:RetainedEarningsMember 2024-09-30 0001642380 2024-06-30 0001642380 oxc:UnderwritersMember oxc:UnderwrittenOfferingMember oxc:BroadwoodCapitalLPMember 2022-04-13 0001642380 oxc:CustomerThreeMember oxc:PharmaServicesMember us-

gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001642380
ocx:PharmaServicesCompanyDMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30
0001642380 ocx:LaboratoryDevelopedTestServicesMember 2023-01-01 2023-09-30 0001642380 srt:MaximumMember
ocx:UnderwrittenOfferingMember ocx:HalleSpecialSituationsFundLLCMember 2022-04-13 0001642380 us-
gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0001642380 us-gaap:CommonStockMember us-
gaap:SubsequentEventMember us-gaap:PrivatePlacementMember 2024-10-04 2024-10-04 0001642380 ocx:BioRadLaboratoriesIncMember
ocx:LaboratoryEquipmentMember 2023-01-01 2023-09-30 0001642380 ocx:UnderwrittenOfferingMember ocx:BroadwoodCapitalLPMember
2022-04-13 0001642380 ocx:DetermaIOMember 2024-01-01 2024-09-30 0001642380
ocx:SeriesARedeemableConvertiblePreferredStockMember 2024-07-01 2024-09-30 0001642380 ocx:PharmaServicesCompanyBMember us-
gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001642380 us-
gaap:CommonStockMember 2024-09-30 0001642380 ocx:SeriesARedeemableConvertiblePreferredStockMember 2023-01-01 2023-09-30
0001642380 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember 2023-01-01 2023-09-30 0001642380 ocx:ChronixMergerMember us-
gaap:FairValueInputsLevel3Member 2023-09-30 0001642380 ocx:RazorGenomicsIncMember ocx:RazorStockPurchaseAgreementMember 2023-
02-15 2023-02-16 0001642380 ocx:PharmaServicesMember ocx:OutsideOfUnitedStatesMember us-gaap:SalesRevenueNetMember us-
gaap:ProductConcentrationRiskMember 2024-01-01 2024-09-30 0001642380 ocx:SeriesARedeemableConvertiblePreferredStockMember
ocx:SecuritiesPurchaseAgreementMember 2022-04-12 2022-04-13 0001642380 us-gaap:DiscontinuedOperationsHeldforsaleMember
ocx:RazorGenomicsIncMember 2023-01-01 2023-09-30 0001642380 ocx:InsightGeneticsIncMember us-gaap:FairValueInputsLevel3Member
2023-01-01 2023-09-30 0001642380 ocx:InsightGeneticsIncMember ocx:RoyaltyOneMember 2024-09-30 0001642380 ocx:MrGutfreundMember
us-gaap:CommonStockMember ocx:SecuritiesPurchaseAgreementMember 2023-04-03 2023-04-03 0001642380 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001642380 2023-01-01 2023-09-30 0001642380 us-
gaap:CommonStockMember us-gaap:SubsequentEventMember us-gaap:PrivatePlacementMember 2024-10-04 0001642380
ocx:LaboratoryDevelopedTestServicesMember 2024-01-01 2024-09-30 0001642380 ocx:LaboratoryDevelopedTestServicesMember 2024-07-01
2024-09-30 0001642380 ocx:RazorGenomicsIncMember ocx:DragonScientificLLCMember ocx:RazorStockPurchaseAgreementMember 2022-12-
15 2022-12-15 0001642380 us-gaap:SubsequentEventMember ocx:SecuritiesPurchaseAgreementMember 2024-10-04 2024-10-04 0001642380
ocx:InvestorsMember ocx:SeriesARedeemableConvertiblePreferredStockMember ocx:SecuritiesPurchaseAgreementMember 2022-04-12 2022-
04-13 0001642380 us-gaap:GeneralAndAdministrativeExpenseMember 2024-07-01 2024-09-30 0001642380 ocx:CustomerOneMember
ocx:PharmaServicesMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31
0001642380 country:DE 2024-09-30 0001642380 ocx:LaboratoryDevelopedTestServicesMember country:US us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember 2023-07-01 2023-09-30 0001642380 ocx:OfficeLeaseAgreementMember 2024-01-01 2024-09-30
0001642380 2024-01-01 2024-03-31 0001642380 ocx:InsightGeneticsIncMember us-gaap:ValuationTechniqueDiscountedCashFlowMember
2024-01-01 2024-09-30 0001642380 srt:MaximumMember ocx:UnderwrittenOfferingMember ocx:BroadwoodCapitalLPMember 2022-04-12
2022-04-13 0001642380 2024-11-05 0001642380 ocx:SeriesARedeemableConvertiblePreferredStockMember
ocx:SecuritiesPurchaseAgreementMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2022-04-12 2022-04-13 0001642380
srt:MaximumMember ocx:UnderwrittenOfferingMember ocx:PuraVidaInvestmentsLLCMember 2022-04-13 0001642380 us-
gaap:CommonStockMember 2023-06-30 0001642380 ocx:OfficeLeaseAgreementMember 2021-06-21 2021-06-21 0001642380
ocx:InsightGeneticsIncMember ocx:RoyaltyTwoMember 2024-09-30 0001642380 srt:MinimumMember ocx:InsightGeneticsIncMember us-
gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember 2023-09-30 0001642380 ocx:InsightGeneticsIncMember
us-gaap:FairValueInputsLevel3Member 2022-12-31 0001642380 ocx:ChronixAcquisitionMember 2023-01-01 2023-12-31 0001642380 us-
gaap:InProcessResearchAndDevelopmentMember ocx:DetermaIOMember 2023-01-01 2023-12-31 0001642380 srt:MaximumMember us-
gaap:MachineryAndEquipmentMember 2024-09-30 0001642380 ocx:PharmaServicesMember us-gaap:SalesRevenueNetMember us-
gaap:ProductConcentrationRiskMember 2023-01-01 2023-09-30 0001642380 us-gaap:CommonStockMember ocx:UnderwrittenOfferingMember
ocx:HalleSpecialSituationsFundLLCMember 2022-04-12 2022-04-13 0001642380 ocx:ArnoMember us-gaap:CommonStockMember
ocx:SecuritiesPurchaseAgreementMember 2023-04-03 2023-04-03 0001642380 ocx:ChronixMergerMember us-
gaap:FairValueInputsLevel3Member 2023-12-31 0001642380 ocx:LaboratoryDevelopedTestServicesMember us-gaap:SalesRevenueNetMember
us-gaap:ProductConcentrationRiskMember 2023-01-01 2023-09-30 0001642380 us-gaap:AccumulatedOtherComprehensiveIncomeMember
2023-07-01 2023-09-30 0001642380 ocx:SeriesARedeemableConvertiblePreferredStockMember 2022-04-13 2022-04-13 0001642380 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-09-30 0001642380 ocx:PharmaServicesMember country:US us-
gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2024-07-01 2024-09-30 0001642380
ocx:UnderwrittenOfferingMember ocx:HalleSpecialSituationsFundLLCMember 2022-04-13 0001642380
ocx:SeriesARedeemableConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-09-30 0001642380 srt:MaximumMember
ocx:InsightGeneticsIncMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember 2023-09-30
0001642380 us-gaap:CommonStockMember us-gaap:SubsequentEventMember ocx:SecuritiesPurchaseAgreementMember
ocx:BroadwoodPartnersLPMember 2024-10-04 2024-10-04 0001642380 srt:MaximumMember ocx:ChronixMergerMember us-
gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputExpectedTermMember 2023-01-01 2023-09-30 0001642380
ocx:LaboratoryDevelopedTestServicesMember 2023-12-31 0001642380 us-gaap:CommonStockMember 2024-01-01 2024-09-30 0001642380
ocx:SeriesARedeemableConvertiblePreferredStockMember 2024-01-01 2024-09-30 0001642380 ocx:OfficeLeaseAgreementMember 2019-12-23
2019-12-23 0001642380 us-gaap:CustomerRelationshipsMember 2024-09-30 0001642380
ocx:SeriesARedeemableConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-07-01 2023-09-30 0001642380 2023-07-24
0001642380 2023-12-31 0001642380 ocx:TwoThousandTenStockOptionPlanMember 2024-09-30 0001642380 ocx:MonthlyRentMember
ocx:OfficeLeaseAgreementMember 2019-12-23 2019-12-23 0001642380 ocx:MergerAgreementMember ocx:ChronixEquityMember 2023-02-07
2023-02-08 0001642380 us-gaap:RetainedEarningsMember 2022-12-31 0001642380 ocx:RegisteredDirectOfferingMember 2023-04-03 2023-
04-03 0001642380 ocx:JamesMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember
ocx:SecuritiesPurchaseAgreementMember 2024-10-04 2024-10-04 0001642380 us-gaap:AccumulatedOtherComprehensiveIncomeMember
2024-06-30 0001642380 ocx:LaboratoryDevelopedTestServicesMember us-gaap:SalesRevenueNetMember us-
gaap:ProductConcentrationRiskMember 2024-01-01 2024-09-30 0001642380 ocx:PreFundedWarrantMember
ocx:SecuritiesPurchaseAgreementMember 2024-09-30 0001642380 ocx:PharmaServicesCompanyAMember us-gaap:SalesRevenueNetMember
us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0001642380 srt:MinimumMember ocx:ChronixMergerMember us-
gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember 2023-09-30 0001642380 ocx:MrGutfreundMember us-
gaap:CommonStockMember ocx:SecuritiesPurchaseAgreementMember 2023-04-05 2023-04-05 0001642380 us-gaap:SubsequentEventMember
2024-10-04 2024-10-04 0001642380 ocx:InsightGeneticsIncMember us-gaap:FairValueInputsLevel3Member 2024-09-30 0001642380 us-
gaap:SeriesBPreferredStockMember ocx:RegisteredDirectOfferingMember 2023-04-03 2023-04-03 0001642380 srt:MinimumMember us-
gaap:MachineryAndEquipmentMember 2024-09-30 0001642380 us-gaap:WarrantMember 2024-07-01 2024-09-30 0001642380
srt:ScenarioPreviouslyReportedMember 2023-01-01 2023-09-30 0001642380 ocx:MrGutfreundMember ocx:ArnoMember us-
gaap:CommonStockMember ocx:SecuritiesPurchaseAgreementMember 2023-04-03 2023-04-03 0001642380 ocx:CustomerFourMember
ocx:PharmaServicesMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30
0001642380 us-gaap:RetainedEarningsMember 2023-06-30 0001642380 us-gaap:WarrantMember 2019-10-31 0001642380
srt:MaximumMember ocx:InsightGeneticsIncMember us-gaap:FairValueInputsLevel3Member
ocx:MeasurementInputManagementProbabilityEstimateMember 2024-09-30 0001642380 us-gaap:SeriesAPreferredStockMember
ocx:RegisteredDirectOfferingMember 2023-04-04 2023-04-05 0001642380 ocx:ExecutiveOfficersMember 2024-01-01 2024-09-30 0001642380
us-gaap:CommonStockMember 2023-09-30 0001642380 ocx:PharmaServicesMember us-gaap:SalesRevenueNetMember us-
gaap:ProductConcentrationRiskMember 2023-07-01 2023-09-30 0001642380 ocx:SeriesARedeemableConvertiblePreferredStockMember us-
gaap:PreferredStockMember 2022-12-31 0001642380 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2024-01-
01 2024-09-30 0001642380 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2024-04-15 2024-04-15 0001642380
ocx:SalesAgreementMember 2024-01-01 2024-09-30 0001642380 ocx:ExpenseIncludedInDiscontinuedOperationsMember 2023-01-01 2023-09-
30 0001642380 ocx:PharmaServicesMember 2024-07-01 2024-09-30 0001642380 us-gaap:CommonStockMember
ocx:SecuritiesPurchaseAgreementMember ocx:BroadwoodPartnersLPMember 2024-04-15 2024-04-15 0001642380
ocx:MPPEMValuationApproachMember 2024-01-01 2024-09-30 0001642380 ocx:InsightGeneticsIncMember us-
gaap:FairValueInputsLevel3Member 2023-09-30 0001642380 srt:MinimumMember ocx:InsightGeneticsIncMember us-
gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputExpectedTermMember 2024-01-01 2024-09-30 0001642380
ocx:SeriesARedeemableConvertiblePreferredStockMember us-gaap:PreferredStockMember 2024-01-01 2024-09-30 0001642380
srt:MaximumMember ocx:InsightGeneticsIncMember us-gaap:FairValueInputsLevel3Member us-
gaap:MeasurementInputExpectedTermMember 2023-01-01 2023-09-30 0001642380 srt:MinimumMember
ocx:MonteCarloValuationTechniqueMember 2023-08-01 2023-08-31 0001642380 ocx:PharmaServicesMember 2024-09-30 0001642380 us-
gaap:CommonStockMember ocx:UnderwrittenOfferingMember ocx:PuraVidaInvestmentsLLCMember 2022-04-12 2022-04-13 0001642380
2024-01-01 2024-09-30 0001642380 ocx:MrGutfreundMember us-gaap:SeriesAPreferredStockMember
ocx:SecuritiesPurchaseAgreementMember 2022-04-12 2022-04-13 0001642380 ocx:TwoThousandEighteenIncentivePlanMember 2024-09-30
0001642380 ocx:OtherInvestorsMember ocx:RegisteredDirectOfferingMember 2023-04-03 0001642380 us-
gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-09-30 0001642380
ocx:SeriesARedeemableConvertiblePreferredStockMember ocx:SecuritiesPurchaseAgreementMember 2024-04-15 2024-04-15 0001642380

2023-08-01 2023-08-31 0001642380 ocx:SeriesARedeemableConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-12-31 0001642380 ocx:CustomerTwoMember ocx:PharmaServicesMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001642380 ocx:SecuritiesPurchaseAgreementMember 2024-04-15 2024-04-15 0001642380 us-gaap:WarrantMember 2017-02-28 0001642380 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-09-30 0001642380 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001642380 ocx:SalesAgreementMember 2024-08-09 0001642380 ocx:PharmaServicesMember 2023-07-01 2023-09-30 0001642380 ocx:CostOfRevenuesMember 2023-01-01 2023-09-30 0001642380 ocx:PharmaServicesCompanyAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001642380 ocx:BioRadLaboratoriesIncMember 2023-12-31 0001642380 us-gaap:StockOptionMember 2024-01-01 2024-09-30 0001642380 ocx:ChronixMergerMember us-gaap:FairValueInputsLevel3Member 2024-01-01 2024-09-30 0001642380 ocx:TwoThousandTenPlanAndTwoThousandEighteenIncentivePlanActivityMember 2024-01-01 2024-09-30 0001642380 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001642380 ocx:MonthlyRentMember ocx:OfficeSubleaseAgreementMember 2024-01-01 2024-09-30 0001642380 srt:MaximumMember ocx:ChronixMergerMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember 2023-09-30 0001642380 srt:MaximumMember 2024-09-30 0001642380 us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-01 2023-09-30 0001642380 ocx:PreFundedWarrantMember 2024-09-30 0001642380 ocx:LaboratoryDevelopedTestServicesMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2023-07-01 2023-09-30 0001642380 ocx:TwoThousandTenPlanAndTwoThousandEighteenIncentivePlanActivityMember 2024-09-30 0001642380 srt:MaximumMember ocx:ChronixMergerMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember 2024-09-30 0001642380 ocx:SeriesARedeemableConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-01-01 2023-09-30 0001642380 2022-12-31 0001642380 srt:MinimumMember ocx:ChronixMergerMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputExpectedTermMember 2024-01-01 2024-09-30 0001642380 ocx:MPEEMValuationApproachMember 2023-03-31 2023-03-31 0001642380 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001642380 us-gaap:CustomerRelationshipsMember 2024-01-01 2024-09-30 0001642380 srt:MaximumMember us-gaap:EquipmentMember 2024-09-30 0001642380 ocx:MPCHoldingsLLCMember ocx:LeaseAgreementMember 2024-01-01 2024-09-30 0001642380 ocx:SubleasePeriodOneMember ocx:OfficeSubleaseAgreementMember 2024-01-01 2024-09-30 0001642380 us-gaap:InProcessResearchAndDevelopmentMember ocx:DetermaCNIAndVitaGraftMember 2024-01-01 2024-09-30 0001642380 ocx:BoardMembersMember ocx:RegisteredDirectOfferingMember 2023-04-03 0001642380 ocx:LaboratoryDevelopedTestServicesMember 2022-12-31 0001642380 ocx:PharmaServicesMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2024-01-01 2024-09-30 0001642380 srt:MaximumMember ocx:InsightGeneticsIncMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputExpectedTermMember 2024-01-01 2024-09-30 0001642380 ocx:LaboratoryDevelopedTestServicesMember 2023-03-31 0001642380 ocx:TwoThousandTenPlanAndTwoThousandEighteenIncentivePlanActivityMember 2023-01-01 2023-09-30 0001642380 ocx:SubleasePeriodThreeMember ocx:OfficeSubleaseAgreementMember 2024-01-01 2024-09-30 0001642380 ocx:PerformanceBasedOptionsMember 2023-08-01 2023-08-31 0001642380 ocx:OfficeSubleaseAgreementMember 2024-09-30 0001642380 us-gaap:CommonStockMember 2024-06-30 0001642380 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-09-30 0001642380 us-gaap:StockOptionMember 2024-07-01 2024-09-30 0001642380 ocx:BioRadLaboratoriesIncMember us-gaap:CommonStockMember ocx:SecuritiesPurchaseAgreementMember 2024-04-15 2024-04-15 0001642380 us-gaap:CommonStockMember ocx:SecuritiesPurchaseAgreementMember ocx:AVMMember 2023-04-03 2023-04-03 0001642380 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2024-04-15 0001642380 us-gaap:RestrictedStockUnitsRSUMember 2023-07-01 2023-09-30 0001642380 ocx:InsightGeneticsIncMember 2024-09-30 0001642380 us-gaap:StockOptionMember 2023-01-01 2023-09-30 0001642380 us-gaap:SeriesAPreferredStockMember ocx:RegisteredDirectOfferingMember 2024-04-15 2024-04-15 0001642380 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2023-01-01 2023-09-30 0001642380 ocx:OperatingAndFinancingLeasesMember 2024-09-30 0001642380 2023-06-30 0001642380 us-gaap:RetainedEarningsMember 2024-06-30 0001642380 us-gaap:CommonStockMember ocx:UnderwrittenOfferingMember ocx:BroadwoodCapitalLPMember 2022-04-12 2022-04-13 0001642380 ocx:UnderwritersMember ocx:UnderwrittenOfferingMember ocx:HalleSpecialSituationsFundLLCMember 2022-02-12 2022-04-13 0001642380 srt:ScenarioPreviouslyReportedMember 2023-09-30 0001642380 ocx:PharmaServicesMember ocx:OutsideOfUnitedStatesMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2024-07-01 2024-09-30 0001642380 ocx:UnderwritersMember ocx:UnderwrittenOfferingMember ocx:PuraVidaInvestmentsLLCMember 2022-04-12 2022-04-13 0001642380 srt:MaximumMember ocx:RegisteredDirectOfferingMember 2023-04-03 2023-04-03 0001642380 ocx:SubleasePeriodTwoMember ocx:OfficeSubleaseAgreementMember 2024-01-01 2024-09-30 0001642380 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001642380 us-gaap:SeriesAPreferredStockMember ocx:SecuritiesPurchaseAgreementMember ocx:BroadwoodCapitalLPMember 2022-04-12 2022-04-13 0001642380 ocx:CustomerTwoMember ocx:PharmaServicesMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001642380 country:DE 2023-12-31 0001642380 ocx:LaboratoryDevelopedTestServicesMember country:US us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2024-07-01 2024-09-30 0001642380 ocx:PharmaServicesMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2024-07-01 2024-09-30 0001642380 srt:MaximumMember ocx:InsightGeneticsIncMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember 2024-09-30 0001642380 ocx:RazorGenomicsIncMember ocx:DragonScientificLLCMember ocx:RazorStockPurchaseAgreementMember 2022-02-16 0001642380 ocx:PreFundedWarrantMember ocx:SecuritiesPurchaseAgreementMember 2024-04-15 2024-04-15 0001642380 ocx:LeaseAgreementMember 2021-08-27 0001642380 ocx:SeriesARedeemableConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-06-30 0001642380 2023-07-24 2023-07-24 0001642380 ocx:SeriesARedeemableConvertiblePreferredStockMember 2023-12-31 0001642380 us-gaap:SubsequentEventMember ocx:SecuritiesPurchaseAgreementMember 2024-10-04 2024-10-04 0001642380 ocx:ChronixMember 2024-01-01 2024-09-30 0001642380 ocx:ChronixMergerMember us-gaap:FairValueInputsLevel3Member 2023-01-01 2023-09-30 0001642380 ocx:RazorGenomicsIncMember ocx:DragonScientificLLCMember ocx:RazorStockPurchaseAgreementMember 2022-12-15 0001642380 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001642380 us-gaap:SellingAndMarketingExpenseMember 2023-07-01 2023-09-30 0001642380 us-gaap:WarrantMember 2024-01-01 2024-09-30 0001642380 us-gaap:SellingAndMarketingExpenseMember 2024-07-01 2024-09-30 0001642380 ocx:BioRadLaboratoriesIncMember ocx:LaboratoryEquipmentMember 2024-01-01 2024-09-30 0001642380 us-gaap:RetainedEarningsMember 2023-12-31 0001642380 us-gaap:InProcessResearchAndDevelopmentMember ocx:DetermaIOMember 2024-01-01 2024-09-30 0001642380 2024-07-01 2024-09-30 0001642380 us-gaap:CommonStockMember ocx:SecuritiesPurchaseAgreementMember 2023-04-03 2023-04-03 0001642380 ocx:LaboratoryDevelopedTestServicesMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2024-07-01 2024-09-30 0001642380 ocx:RazorGenomicsIncMember ocx:RazorStockPurchaseAgreementMember 2023-01-01 2023-03-31 0001642380 us-gaap:CommonStockMember ocx:SecuritiesPurchaseAgreementMember ocx:AVMMember 2024-04-15 2024-04-15 0001642380 us-gaap:RetainedEarningsMember 2023-09-30 0001642380 ocx:LaboratoryDevelopedTestServicesMember country:US us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2024-01-01 2024-09-30 0001642380 ocx:LeaseAgreementMember 2023-01-01 2023-12-31 0001642380 srt:MinimumMember ocx:InsightGeneticsIncMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputExpectedTermMember 2023-01-01 2023-09-30 0001642380 srt:MaximumMember us-gaap:CaliforniaFranchiseTaxBoardMember us-gaap:ResearchMember 2024-06-27 0001642380 ocx:MPCHoldingsLLCMember ocx:LeaseAgreementMember 2024-01-01 0001642380 ocx:PharmaServicesMember country:US us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2024-01-01 2024-09-30 0001642380 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001642380 us-gaap:CommonStockMember 2024-04-15 0001642380 ocx:MonteCarloValuationTechniqueMember 2023-08-01 2023-08-31 0001642380 srt:MaximumMember ocx:MonteCarloValuationTechniqueMember 2023-08-01 2023-08-31 0001642380 2024-09-30 0001642380 srt:MinimumMember 2024-09-30 0001642380 ocx:OfficeLeaseAgreementMember 2019-12-23 0001642380 srt:MinimumMember ocx:ChronixMergerMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputExpectedTermMember 2023-01-01 2023-09-30 0001642380 ocx:ArnoMember us-gaap:CommonStockMember ocx:SecuritiesPurchaseAgreementMember 2024-04-15 2024-04-15 0001642380 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001642380 ocx:MPEEMValuationApproachMember 2023-03-31 0001642380 ocx:InsightGeneticsIncMember ocx:MilestoneTwoMember 2024-09-30 0001642380 ocx:TwoThousandTenPlanAndTwoThousandEighteenIncentivePlanActivityMember 2023-01-01 2023-12-31 0001642380 ocx:MPCHoldingsLLCMember ocx:LeaseAgreementMember 2024-09-30 0001642380 us-gaap:InProcessResearchAndDevelopmentMember ocx:DetermaCNIAndVitaGraftMember 2023-01-01 2023-12-31 0001642380 srt:MinimumMember ocx:ChronixMergerMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember 2024-09-30 0001642380 ocx:LeaseAgreementMember 2024-01-01 2024-09-30 0001642380 ocx:LaboratoryDevelopedTestServicesMember 2023-07-01 2023-09-30 0001642380 ocx:SubleasePeriodFourMember ocx:OfficeSubleaseAgreementMember 2024-01-01 2024-09-30 0001642380 us-gaap:WarrantMember 2017-03-31 0001642380 ocx:OfficeSubleaseAgreementMember 2023-08-08 0001642380 us-gaap:CommonStockMember ocx:SecuritiesPurchaseAgreementMember ocx:PuraVidaMember 2023-04-03 2023-04-03 0001642380 2023-01-01 2023-12-31 0001642380 srt:MinimumMember ocx:InsightGeneticsIncMember us-gaap:FairValueInputsLevel3Member ocx:MeasurementInputManagementProbabilityEstimateMember 2024-09-30 0001642380 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-09-30 0001642380 ocx:CostOfRevenuesMember 2023-07-01 2023-09-30 0001642380 ocx:PharmaServicesMember 2024-01-01 2024-09-30 pure utr:sqft iso4217:USD shares shares iso4217:USD false 0001642380 Q3 --12-31 10-Otrue2024-09-302024false1-37648Oncocyte CorporationCA27-104156315 CushingIrvineCA92618(949)409-7600Common Stock, no par valueOCXNASDAQYesYesNon-accelerated

Filetruefalsefalse168352473363000943200020005000209000484000232000330000627000643000320001390004793000106980003001000163317028000-
289876000971100020468000702160007489200011500042900039500011890004300015900018400059300022000220006600066000500002480
4350009421000-1694700018110006761000-169000-1283000135650006761000275590009487000-13515000-6513000-27414000-8957000-
31000-14000-54000-39000-89000800053000127000316000125000220002400026200094000-13493000-6489000-27152000-8863000-2926000-
13493000-6489000-27152000-11789000-13493000-13493000-6687000-6687000-27415000-27415000-9602000-9602000-2926000-2926000-
13493000-13493000-6687000-6687000-27415000-27415000-12528000-12528000-0.98-0.98-0.81-0.81-2.36-2.36-1.29-1.29-0.39-0.39-0.98-0.98-
0.81-0.81-2.36-2.36-1.68-1.68137140001371400082560008256000116240001162400074460007446000-13493000-6489000-27152000-
1178900020000-90008000-7000-13473000-6498000-27144000-117960001336800032620100037000-30353500022703000-13493000-
1349300020000200004500004500001400014000600017000170001337400032668200057000-
31702800097110005000472500082500030953500041000-26597600043600000-1419000-14190005000472500082500030953500041000-
26739500042181000-6489000-6489000-9000-9006080006080001400014000200090003600036000198000-198000-
19800050004923000826100030999500032000-2738840003614300050005126000826100031029500049000-28987600020468000-27152000-
271520008000800012540001254000380003800050770001526900015269000600017000170004000260007200072000-5000-3389000263000-
263000-2630001337400032668200057000-317028000971100060005302000593200029492900039000-26067600034292000-1419000-
141900060005302000593200029492900039000-26209500032873000-11789000-11789000-7000-
700022760002276000720007200022750001342100013421000118000-118000-1180004500090003600036000-1000-1118000621000-621000-
62100050004923000826100030999500032000-27388400036143000-27152000-
11789000935000128900066000660001254000227600011000010800080009421000-169470006761000-1521000-169000-1283000-275000-
130000232000345000-645000263000-4193000-123000-43000-15359000-18901000354000302000170001372000-302000-
1035000158070001384800053800042700018000187000538900011800011900087000959200012216000-6069000-
77200001113200023203000506300015483000170003010002150002630006210001000001202000

1. Organization and Description of the Business</p><p style="font-size: 10pt; margin-top: 6pt; font-family: Times New Roman; margin-bottom: 0; text-align: justify;">Oncocyte Corporation ("Oncocyte," the "Company," "we" or "us"), incorporated in 2009 in California, is a diagnostics technology company. The Company's tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft™ is a clinical blood-based solid organ transplantation monitoring test, GraftAssure™ is a research use only ("RUO") blood-based donor-derived cell-free DNA test, DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies, and the pipeline test DetermaCNI™ is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients.</p><p style="font-size: 10pt; margin-top: 18pt; font-family: Times New Roman; margin-bottom: 0; text-align: justify;">Razor Transactions</p><p style="font-size: 10pt; margin-top: 6pt; font-family: Times New Roman; margin-bottom: 0; text-align: justify;">Oncocyte's first product for commercial release was a proprietary treatment stratification test called DetermaRx that identifies which patients with early-stage non-small cell lung cancer may benefit from chemotherapy, resulting in a significantly higher, five-year survival rate. Beginning in September 2019 through February 23, 2021, Oncocyte held a 25% equity interest in Razor Genomics, Inc. ("Razor"), a privately held company, that had developed and licensed to Oncocyte the lung cancer treatment stratification laboratory test that Oncocyte was commercializing as DetermaRx. On February 24, 2021, Oncocyte completed the purchase of all the remaining issued and outstanding shares of common stock of Razor. As a result of the purchase of the Razor common stock, Oncocyte became the sole shareholder of Razor.</p><p style="font-size: 10pt; margin-top: 12pt; font-family: Times New Roman; margin-bottom: 0; text-align: justify;">On December 15, 2022, the Company entered into a Stock Purchase Agreement (the "Razor Stock Purchase Agreement") with Dragon Scientific, LLC, a Delaware limited liability company ("Dragon"), and Razor. Pursuant to the Razor Stock Purchase Agreement, Oncocyte agreed to sell to Dragon, 3,188,181 shares of common stock of Razor, which constituted approximately 70% of the issued and outstanding equity interests of Razor on a fully-diluted basis, and transfer to Razor all of the assets and liabilities related to DetermaRx (the "Razor Sale Transaction").</p><p style="font-size: 10pt; margin-top: 12pt; font-family: Times New Roman; margin-bottom: 0; text-align: justify;">On February 16, 2023, Oncocyte completed the Razor Sale Transaction (the "Razor Closing"). In connection with the Razor Closing, Oncocyte transferred to Razor all of the assets and liabilities related to DetermaRx. While no monetary consideration was received for the sale of 70% of the equity interests of Razor, the transaction allowed the Company to eliminate all development and commercialization costs with respect to DetermaRx. Following the Razor Closing, Oncocyte continues to own 1,366,364 shares of common stock of Razor, which constitutes approximately 30% of the issued and outstanding equity interests of Razor on a fully-diluted basis.</p><p style="font-size: 10pt; margin-top: 12pt; font-family: Times New Roman; margin-bottom: 0; text-align: justify;">As a result of the divestiture of Razor, the Company has reflected the 2023 operations of Razor as a discontinued operation. See Note 11, "Discontinued Operations of Razor" for additional information.</p><p style="font-size: 10pt; margin-top: 18pt; font-family: Times New Roman; margin-bottom: 0; text-align: justify;">Going Concern</p><p style="font-size: 10pt; margin-top: 6pt; font-family: Times New Roman; margin-bottom: 0; text-align: justify;">Oncocyte has incurred operating losses and negative cash flows since inception and had an accumulated deficit of \$317.0 million as of September 30, 2024. Oncocyte expects to continue to incur operating losses and negative cash flows for the foreseeable future. Since its formation, Oncocyte has financed its operations primarily through the sale of shares of its common stock, convertible preferred stock and warrants to acquire common stock. As of September 30, 2024, Oncocyte had 3.4 million of cash and cash equivalents. On October 4, 2024, we raised additional capital as discussed below.</p><p style="font-size: 10pt; margin-top: 12pt; font-family: Times New Roman; margin-bottom: 0; text-align: justify;">As of September 30, 2024, Oncocyte is completing clinical development and planning commercialization of DetermaIO, although DetermaIO is currently available for biopharma diagnostic development and RUO as a companion test in immunotherapy drug development to select patients for clinical trials. Oncocyte received a positive coverage decision from MoLDx for VitaGraft Kidney in August of 2023, and it became commercially available for ordering in January 2024 through Oncocyte's Clinical Laboratory Improvements Amendment ("CLIA") Laboratory in Nashville, Tennessee. VitaGraft Kidney is now broadly available to transplant professionals upon request. In July 2024, Oncocyte began to commercialize the technology underlying VitaGraft Kidney by distributing its sister product, GraftAssure, which is intended to be sold and used for research purposes and is labeled as RUO. Oncocyte expects to distribute its RUO production through a mix of direct sales, partnering and distribution agreements, and licensing.</p><p style="font-size: 10pt; margin-top: 12pt; font-family: Times New Roman; margin-bottom: 0; text-align: justify;">On April 5, 2024, the Company entered into an agreement with Bio-Rad Laboratories, Inc. ("Bio-Rad"), our global strategic partner, to collaborate in the development and the commercialization of RUO and in vitro diagnostic ("IVD") kitted transplant products. See Note 10, "Collaborative Arrangements" for additional information. On November 8, 2024, the Company and Bio-Rad entered into a memorandum of understanding with respect to such agreement to establish additional activities to be performed by each party pursuant to such agreement (see Note 10 for additional information).</p><p style="font-size: 10pt; margin-top: 12pt; font-family: Times New Roman; margin-bottom: 0; text-align: justify;">On April 15, 2024, the Company consummated a private placement of its securities to certain accredited investors (the "April 2024 Offering"). The

resulting net proceeds were approximately \$5.9 million, after deducting offering expenses of \$538,000 and deducting \$5.4 million for the redemption of all remaining shares of the Company's Series A Redeemable Convertible Preferred Stock. These net proceeds are inclusive of an investment from Bio-Rad (see Note 9), our aforementioned global strategic partner. See Note 7, "Common Stock - April 2024 Offering" for additional information.

On August 1, 2024, the Company filed a shelf registration statement on Form S-3, pursuant to which it registered for sale up to \$100.0 million of any combination of its common stock, preferred stock, warrants and/or units from time to time and at prices and on terms that it may determine (the "Primary Shelf Registration Statement"). On August 9, 2024, the Company entered into a sales agreement with a sales agent, pursuant to which the Company may offer and sell from time to time up to an aggregate of \$7.5 million of shares of the Company's common stock, registered on the Primary Shelf Registration Statement, through the sales agent through an at-the-market facility (the "August 2024 Offering"). As of September 30, 2024, net proceeds to the Company from the sale of such shares were approximately \$17,000.

See Note 7, "Common Stock - August 2024 Offering" for additional information.

On October 4, 2024, the Company consummated a private placement of its securities to certain accredited investors (the "October 2024 Offering"). The gross proceeds from the October 2024 Offering were approximately \$10.2 million. After deducting placement agent fees and expenses and offering expenses payable by the Company of \$795,000, the resulting net proceeds were approximately \$9.4 million. These net proceeds are inclusive of an investment from Bio-Rad (see Note 9), our aforementioned global strategic partner. See Note 12, "Subsequent Events" for additional information.

In addition to general economic and capital market trends and conditions, Oncocyte's ability to raise sufficient additional capital to finance its operations from time to time will depend on a number of factors specific to Oncocyte's operations such as operating revenues and expenses, progress in our collaborative arrangement for the development and the commercialization of RUO and IVD kitted transplant products, progress in obtaining regulatory approval to distribute our products for clinical use, and progress in the development of, or in obtaining reimbursement coverage from Medicare for DetermaIO and other future laboratory tests that Oncocyte may develop or acquire.

The unavailability or inadequacy of financing or revenues to meet future capital needs could force Oncocyte to modify, curtail, delay, or suspend some or all aspects of planned operations. Sales of additional equity securities could result in the dilution of the interests of Oncocyte's current stockholders. Oncocyte cannot assure that adequate long-term financing will be available on favorable terms, if at all.

In accordance with Accounting Standards Codification ("ASC") 205-40, "Going Concern," we evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern within one year after the date that the consolidated financial statements included in this Report are issued. This evaluation initially does not take into consideration the potential mitigating effect of our plans that have not been fully implemented as of the date the consolidated financial statements included in this Report are issued. When substantial doubt exists under this methodology, we evaluate whether the mitigating effect of our plans sufficiently alleviates substantial doubt about our ability to continue as a going concern. The mitigating effect of our plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that such financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about our ability to continue as a going concern within one year after the date that such financial statements are issued. In performing this analysis, we excluded certain elements of our operating plan that cannot be considered probable.

Our expectation to generate operating losses and negative operating cash flows in the future and the need for additional funding to support our planned operations raise substantial doubt regarding our ability to continue as a going concern for a period of one year after the date that the consolidated financial statements are issued. Management intends to complete additional equity financings while maintaining reduced spending levels. However, due to several factors, including those outside management's control, there can be no assurance that we will be able to complete additional equity financings. If we are unable to complete additional financings, management's plans include further reducing or delaying operating expenses. We have concluded the likelihood that our plan to successfully obtain sufficient funding from one or more of these sources or adequately reduce expenditures, while reasonably possible, is less than probable. Accordingly, we have concluded that substantial doubt exists about our ability to continue as a going concern for a period of at least one year from the date of issuance of these consolidated financial statements.

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.

0.2531881810.700.7013663640.30-317000000340000099000005380005400000100000000750000017000102000007950009400000

2. Summary of Significant Accounting Policies

The consolidated financial statements and accompanying notes are prepared on the accrual basis of accounting in accordance with U.S. generally accepted accounting principles ("GAAP").

Principles of Consolidation and Basis of Presentation

The unaudited condensed consolidated interim financial statements presented herein have been prepared in accordance with GAAP for financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. In accordance with those rules and regulations, certain information and footnote disclosures normally included in comprehensive consolidated financial statements may have been condensed or omitted. The consolidated balance sheet as of December 31, 2023 was derived from the audited consolidated financial statements at that date. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in Oncocyte's Annual Report on Form 10-K for the year ended December 31, 2023. The accompanying unaudited condensed consolidated financial statements, in the opinion of management, include all adjustments of a normal recurring nature necessary for a fair presentation of Oncocyte's financial condition and results of operations. The consolidated results of operations are not necessarily indicative of the results to be expected for any other interim period or for the entire year.

Item 0:text-align:justify;">On January 31, 2020, with the acquisition of Insight Genetics, Inc. ("Insight") through a merger with a newly incorporated wholly-owned subsidiary of Oncocyte (the "Insight Merger") under the terms of an Agreement and Plan of Merger (the "Insight Merger Agreement"), Insight became a wholly-owned subsidiary of Oncocyte, and on that date Oncocyte began consolidating Insight's operations and results with Oncocyte's operations and results (see Note 3).</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">On April 15, 2021, with the acquisition of Chronix Biomedical, Inc. ("Chronix") pursuant to an Agreement and Plan of Merger dated February 2, 2021, amended February 23, 2021, and amended and restated as of April 15, 2021 (as amended and restated, the "Chronix Merger Agreement"), by and among Oncocyte, CNI Monitor Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Oncocyte ("Merger Sub"), Chronix became a wholly-owned subsidiary of Oncocyte (the "Chronix Merger"), and on that date Oncocyte began consolidating Chronix's operations and results with Oncocyte's operations and results (see Note 3).</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">All material intercompany accounts and transactions have been eliminated in consolidation.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">We have reflected the 2023 operations of Razor as discontinued operations. See Note 11 for further information. Amounts and disclosures throughout these notes to consolidated financial statements relate solely to continuing operations and exclude all discontinued operations, unless otherwise noted. Discontinued operations comprise activities that were disposed of or discontinued at the end of the period, represent a separate major line of business that can be clearly distinguished for operational and financial reporting purposes and represent a strategic business shift having a major effect on the Company's operations and financial results.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">On July 24, 2023, the Company implemented areverse stock split of the outstanding shares of its common stock. The par value per share and the authorized number of shares of common stock and preferred stock were not adjusted as a result of the reverse stock split. All common stock share and per-share amounts for all periods presented in these consolidated financial statements have been adjusted to reflect the reverse stock split. The number of authorized shares of common stock remains at230,000,000 shares.</p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Reclassifications</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Certain prior period amounts in the consolidated financial statements and notes to consolidated financial statements have been reclassified to conform to the current period presentation. Included in such prior period amounts is contingent consideration liabilities, current, which was previously presented in the noncurrent balance. These changes had no impact on the previously reported consolidated financial condition, results of operations or cash flows.</p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Prior Period Revisions</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;min-width:fit-content;">In connection with the preparation of the Company's consolidated financial statements for the year ended December 31, 2023, the Company recorded certain adjustments that impacted previously reported financial statement amounts from the period ended September 30, 2023. As further discussed below in "Revenue Recognition - Laboratory Developed Test Services - Allowance for Credit Losses," as a result of the January 1, 2023 adoption of the new current expected credit loss accounting policy, the Company adjusted its accounts receivable. In addition, the Company reclassified cash sold in discontinued operations from an operating cash outflow to an investing cash outflow. See Note 11, "Discontinued Operations of Razor" for additional information. The following are the relevant line items from the Company's prior period consolidated financial statements illustrating the effect of the revisions to the period presented:</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"></p><div style="font-size:10pt;font-family:Times New Roman;"><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:57.477%;box-sizing:content-box;"></td><td style="width:1.399%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.776%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.399%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.776%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.776%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="height:8pt;background-color:#fffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">For the Period Ended September 30, 2023</p><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">As Previously Reported</p><td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff0;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Adjusted</p><td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff0;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Balance Sheet and Shareholders' Equity</p><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Adjustment</p><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(In thousands)</p><td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Balance Sheet and Shareholders' Equity</p><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Adjustment</p><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(In thousands)</p></div></div>

[illegible]

[illegible]

content;"></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">138</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(1,035</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td></tr></table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Use of Estimates<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and contingent assets and liabilities, at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates estimates which are subject to significant judgment, including, but not limited to, valuation methods used, assumptions requiring the use of judgment to prepare financial projections and forecasted financial information, timing of potential commercialization of acquired in-process intangible assets, applicable discount rates, probabilities of the likelihood of multiple outcomes of certain events related to contingent consideration, comparable companies or transactions, determination of fair value of the assets acquired and liabilities assumed (including those relating to contingent consideration), the carrying value of goodwill and other intangibles, impairments, assumptions related to going concern assessments, revenue recognition, allocation of direct and indirect expenses, useful lives associated with long-lived intangible and other assets, key assumptions in operating and financing leases including incremental borrowing rates, loss contingencies, valuation allowances related to deferred income taxes, allowances for credit losses, and assumptions used to value stock-based awards and other equity instruments. These assessments are made in the context of information reasonably available to Oncocyte. Actual results may differ materially from those estimates.</p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Segments<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Oncocyte's executive management team, as a group, represents the entity's chief operating decision makers. To date, Oncocyte's executive management team has viewed Oncocyte's operations as one segment that includes the research, development and commercialization of diagnostic tests, including molecular diagnostic services to pharmaceutical customers. As a result, the financial information disclosed materially represents all of the financial information related to Oncocyte's sole operating segment.</p></div><div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Fair Value Measurements, Business Combinations and Contingent Consideration Liabilities<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Oncocyte accounts for business combinations in accordance with ASC 805, which requires the purchase consideration transferred to be measured at fair value on the acquisition date in accordance with ASC 820.Fair Value Measurement. ASC 820 establishes a single authoritative definition of fair value, sets out a framework for measuring fair value and expands on required disclosures about fair value measurement. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. ASC 820 describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value, which are the following:</p></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;">•<div style="width:100%;display:inline;">Level 1- Quoted prices in active markets for identical assets and liabilities.</div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;">•<div style="width:100%;display:inline;">Level 2- Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted market prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;">•<div style="width:100%;display:inline;">Level 3- Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Such inputs reflect management's best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. Management estimates include certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs, including the entity's own assumptions in determining fair value.</div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">When a part of the purchase consideration consists of shares of Oncocyte common stock, Oncocyte calculates the purchase price attributable to those shares, a Level 1 security, by determining the fair value of those shares as of the acquisition date based on prices quoted on the principal national securities exchange on which the shares traded. Oncocyte recognizes estimated fair values of the tangible assets and identifiable intangible assets acquired, including in-process research and development ("IPR&D"), and liabilities assumed, including any contingent consideration, as of the acquisition date. Goodwill is recognized as any amount of excess consideration transferred over the fair value of the tangible and identifiable intangible assets acquired net of the liabilities assumed. ASC 805 precludes the recognition of an assembled workforce as an asset, effectively subsuming any assembled workforce value into goodwill.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">In determining fair value, Oncocyte utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, and also considers counterparty credit risk in its assessment of fair value. For the periods presented, Oncocyte has no financial assets recorded at fair value on a recurring basis, except for money market funds. These assets are measured at fair value using the period-end quoted market prices as a Level 1 input.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Certain of Oncocyte's asset and business acquisitions involve the potential for future payment of consideration to third-parties and former selling shareholders in amounts determined as a percentage of future net revenues generated, or upon attainment of revenue milestones, from Pharma Services or laboratory tests, as applicable, or annual minimum royalties to certain licensors, as provided in the applicable agreements. The fair value of such liabilities is determined using unobservable inputs. These inputs include the estimated amount and timing of projected cash flows and the risk-adjusted discount rate used to present value the cash flows. These obligations are referred to as contingent consideration, which are carried at fair value based on Level 3 inputs on a recurring basis.</p><p style="font-

Oncocyte margin-top: 12pt; font-family: Times New Roman; margin-bottom: 0; text-align: justify;">>ASC 805 requires that contingent consideration be estimated and recorded at fair value as of the acquisition date as part of the total consideration transferred. Contingent consideration is an obligation of the acquirer to transfer additional assets or equity interests to the selling shareholders in the future if certain future events occur or conditions are met, such as the attainment of product development milestones. Contingent consideration also includes additional future payments to selling shareholders based on achievement of components of earnings, such as "earn-out" provisions or percentage of future revenues, including royalties paid to the selling shareholders based on a percentage of certain revenues generated.

Oncocyte margin-top: 12pt; font-family: Times New Roman; margin-bottom: 0; text-align: justify;">>The fair value of contingent consideration after the acquisition date is reassessed by Oncocyte as changes in circumstances and conditions occur, with the subsequent change in fair value recorded in the consolidated statements of operations. Changes in key assumptions can materially affect the estimated fair value of contingent consideration liabilities and, accordingly, the resulting gain or loss that Oncocyte records in its consolidated financial statements. See Note 3 for a full discussion of these liabilities and additional Level 3 fair value disclosures.

Oncocyte margin-top: 12pt; font-family: Times New Roman; margin-bottom: 0; text-align: justify;">>The carrying amounts of cash and cash equivalents, restricted cash, net accounts receivable, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities approximate fair values because of the short-term nature of these items.

Oncocyte margin-top: 12pt; font-family: Times New Roman; margin-bottom: 0; text-align: justify;">>In accordance with GAAP, from time to time, the Company measures certain assets at fair value on a nonrecurring basis. The Company reviews the carrying value of intangibles, including IPR&D (see Note 5), and other long-lived assets for indications of impairment at least annually. Refer to related discussions of impairments below.

Oncocyte margin-top: 12pt; font-family: Times New Roman; margin-bottom: 0; text-align: justify;">>Cash, Cash Equivalents and Restricted Cash

Oncocyte margin-top: 6pt; font-family: Times New Roman; margin-bottom: 0; text-align: justify;">>Oncocyte considers all highly liquid securities with original maturities of three months or less when purchased to be cash equivalents. For the periods presented, Oncocyte's cash equivalents are comprised of investments in AAA rated money market funds that invest in first-tier only securities, which primarily include domestic commercial paper and securities issued or guaranteed by the U.S. government or its agencies. Restricted cash relates to a bank letter of credit required under our office lease arrangement, refer to Note 6 for additional information.

Oncocyte margin-top: 18pt; font-family: Times New Roman; margin-bottom: 0; text-align: justify;">>Marketable Equity Securities

Oncocyte margin-top: 6pt; font-family: Times New Roman; margin-bottom: 0; text-align: justify;">>Oncocyte accounts for shares of public common stock it may hold as marketable equity securities in accordance with ASC 321-10.

Oncocyte margin-top: 10pt; font-family: Times New Roman; font-style: italic; min-width: fit-content;">Investments - Equity Securities</font-family>

Oncocyte margin-top: 10pt; font-family: Times New Roman; min-width: fit-content;">, as the shares have a readily determinable fair value quoted on national stock exchange. The securities are measured at fair value, with related gains and losses in the value of such securities recorded in the consolidated statements of operations in other income or expense, and are reported as current assets in the consolidated balance sheet based on the closing trading price of the security as of the date being presented. During the fourth quarter of 2023, Oncocyte sold its remaining marketable equity securities for an aggregate realized loss of approximately \$1.4 million.

Oncocyte margin-top: 10pt; font-family: Times New Roman; min-width: fit-content;">During the nine months ended September 30, 2023,

Oncocyte margin-top: 10pt; font-family: Times New Roman; min-width: fit-content;">Oncocyte recorded an unrealized gain on marketable equity securities of \$8,000.

Oncocyte margin-top: 18pt; font-family: Times New Roman; margin-bottom: 0; text-align: justify;">>Investments in Privately Held Companies

Oncocyte margin-top: 6pt; font-family: Times New Roman; margin-bottom: 0; text-align: justify;">>Oncocyte evaluates whether investments held in common stock of other companies require consolidation of the company under, first, the variable interest entity ("VIE") model, and then under the voting interest model in accordance with accounting guidance for consolidations under ASC 810-10. If consolidation of the entity is not required under either the VIE model or the voting interest model, Oncocyte determines whether the equity method of accounting should be applied in accordance with ASC 323.

Oncocyte margin-top: 10pt; font-family: Times New Roman; font-style: italic; min-width: fit-content;">Investments - Equity Method and Joint Ventures</font-family>

Oncocyte margin-top: 10pt; font-family: Times New Roman; min-width: fit-content;">. The equity method applies to investments in common stock or in-substance common stock if Oncocyte exercises significant influence over, but does not control, the entity, where significant influence is typically represented by ownership of 20% or more, but less than majority ownership, of the voting interests of a company.

Oncocyte margin-top: 12pt; font-family: Times New Roman; margin-bottom: 0; text-align: justify;">>Oncocyte initially records equity method investments at fair value on the date of the acquisition with subsequent adjustments to the investment balance based on Oncocyte's pro rata share of earnings or losses from the investment.

Oncocyte margin-top: 12pt; font-family: Times New Roman; margin-bottom: 0; text-align: justify;">>Since February 16, 2023, Oncocyte continues to own an equity interest Razor, however, based on the Razor transactions as discussed in Note 1, the remaining common stock held is accounted for at historical cost less impairment, which is currently zero.

Oncocyte margin-top: 18pt; font-family: Times New Roman; margin-bottom: 0; text-align: justify;">>Inventories

Oncocyte margin-top: 6pt; font-family: Times New Roman; margin-bottom: 0; text-align: justify;">>Inventories include raw materials, work-in-process and finished goods and are valued at the lower of cost or net realizable value. In September 2024, the Company capitalized certain initial RUO inventory costs in connection with its collaboration arrangement with Bio-Rad to develop and commercialize its GraftAssure RUO kitted tests and eventual IVD kitted transplant testing products. See Note 10, "Collaborative Arrangements" for additional information. As of September 30, 2024, inventories, comprised primarily of raw materials, totaled \$232,000.

Oncocyte margin-top: 18pt; font-family: Times New Roman; margin-bottom: 0; text-align: justify;">>Assets Held for Sale and Discontinued Operations

Oncocyte margin-top: 6pt; font-family: Times New Roman; margin-bottom: 0; text-align: justify;">>Assets and liabilities are classified as held for sale when all of the following criteria for a plan of sale have been met: (1) management, having the authority to approve the action, commits to a plan to sell the assets; (2) the assets are available for immediate sale, in their present condition, subject only to terms that are usual and customary for sales of such assets; (3) an active program to locate a buyer and other actions required to complete the plan to sell the assets have been initiated; (4) the sale of the assets is probable and is expected to be completed within one year; (5) the assets are being actively marketed for a price that is reasonable in relation to their current fair value; and (6) actions required to complete the plan indicate that it is unlikely that significant changes to the plan will be made or the plan will be withdrawn. When all of these criteria have been met, the assets and liabilities are classified as held for sale in the consolidated balance sheet. Assets classified as held for sale are reported at the lower of their carrying value or fair value less costs to sell. Depreciation and amortization of assets ceases upon designation as held for sale.

Oncocyte margin-top: 12pt; font-family: Times New Roman; margin-bottom: 0; text-align: justify;">>The Company has entered into various agreements to sell laboratory equipment. As a result, the Company classified the equipment as held for sale current assets in the consolidated balance sheets, as all the criteria of ASC Subtopic 360-10.

Oncocyte margin-top: 10pt; font-family: Times New Roman; font-style: italic; min-width: fit-content;">Property, Plant, and Equipment</font-family>

Oncocyte margin-top: 10pt; font-family: Times New Roman; min-width: fit-content;">had been met. The equipment was written down to its fair value, less cost to sell, the remainder of which was

10pt;font-family:Times New Roman;color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">32,000

as of September 30, 2024 and December 31, 2023, respectively. During the nine months ended September 30, 2024 and 2023, the Company recorded an impairment loss on held for sale assets of \$169,000.

Discontinued operations comprise activities that were disposed of, discontinued or held for sale at the end of the period, represent a separate major line of business that can be clearly distinguished for operational and financial reporting purposes and represent a strategic business shift having a major effect on the Company's operations and financial results according to ASC Topic 205.

Presentation of Financial Statements

Razor has been reflected as a discontinued operation in the 2023 consolidated financial statements. See Note 11, "Discontinued Operations of Razor" for additional information.

Machinery and Equipment, Net, Financing Leases, Net, and Construction in Progress

Machinery and equipment are stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally over a period of 3 to 10 years. For equipment purchased under financing leases, Oncocyte depreciates the equipment based on the shorter of the useful life of the equipment or the term of the lease, ranging from 3 to 5 years, depending on the nature and classification of the financing lease. Maintenance and repairs are expensed as incurred whereas significant renewals and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and the related accumulated depreciation are removed from the respective accounts and any resulting gain or loss is reflected in Oncocyte's results of operations.

Construction in progress, comprised primarily of leasehold improvements under construction, is not depreciated until the underlying asset is placed into service.

Intangible Assets

Intangible Assets - Goodwill and Other

IPR&D projects acquired in a business combination that are not complete as of the acquisition date are capitalized and accounted for as indefinite-lived intangible assets until completion or abandonment of the related research and development efforts. Upon successful completion of the project, the capitalized amount is amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts are written off immediately. Oncocyte considers various factors and risks for potential impairment of IPR&D assets, including the current legal and regulatory environment and the competitive landscape. Adverse clinical trial results, significant delays or inability to obtain local coverage determination ("LCD") from the Centers for Medicare and Medicaid Services ("CMS") for Medicare reimbursement for a diagnostic test, the inability to bring a diagnostic test to market and the introduction or advancement of competitors' diagnostic tests could result in partial or full impairment of the related intangible assets. Consequently, the eventual realized value of the IPR&D project may vary from its fair value at the date of acquisition, and IPR&D impairment charges may occur in future periods. During the period between completion or abandonment, the IPR&D assets will not be amortized but will be tested for impairment on an annual basis and between annual tests if Oncocyte becomes aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&D projects below their respective carrying amounts.

Oncocyte does not have intangible assets with indefinite useful lives other than the acquired IPR&D discussed in Note 5, which as of September 30, 2024, has been partially impaired.

Goodwill represents the excess of the purchase price over the fair value of net identifiable assets and liabilities. Goodwill, similar to IPR&D, is not amortized but is tested for impairment at least annually, or if circumstances indicate that it is more-likely-than-not that the carrying value of the associated reporting unit exceeds its fair value. Qualitative factors considered in this assessment include industry and market conditions, overall financial performance, and other relevant events and factors affecting Oncocyte's business. Based on the qualitative assessment, if it is determined that the fair value of goodwill is more-likely-than-not to be less than its carrying amount, the fair value of a reporting unit will be calculated and compared with its carrying amount and an impairment charge will be recognized for the amount that the carrying value exceeds the fair value. Oncocyte continues to operate in one segment and considered to be the sole reporting unit and, therefore, goodwill is tested for impairment at the enterprise level, when applicable.

In accordance with ASC 350, we review and evaluate our long-lived assets, including intangible assets with finite lives, for impairment whenever events or changes in circumstances indicate that we may not recover their net book value. When applicable, we test goodwill for impairment on an annual basis in the fourth quarter of each year, and between annual tests, if indicators of potential impairment exist, using a fair-value approach. We typically use an income method to estimate the fair value of these assets, which is based on forecasts of the expected future cash flows attributable to the respective assets. Significant estimates and assumptions inherent in the valuations reflect a consideration of other marketplace participants and include the amount and timing of future cash flows (including expected growth rates). Estimates utilized in the projected cash flows include consideration of macroeconomic conditions, overall category growth rates, competitive activities, cost containment and margin expansion, Company business plans, the underlying product or technology life cycles, economic barriers to entry, and the discount rate applied to the cash flows. Unanticipated market or macroeconomic events and circumstances may occur, which could affect the accuracy or validity of the estimates and assumptions.

Long-Lived Intangible Assets

Long-lived intangible assets subject to amortization are stated at acquired cost, less accumulated amortization. We amortize intangible assets not considered to have an indefinite useful life using the straight-line method over their estimated period of benefit, which generally ranges from 1 to 9 years. Each reporting period, we evaluate the estimated remaining useful life of intangible assets and assess whether events or changes in circumstances warrant a revision to the remaining period of amortization or indicate that impairment exists. Long-lived intangible assets currently consist of

acquired customer relationships with an estimated useful life of 5 years (see Note 5).</p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Impairment of Long-Lived Assets</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Oncocyte assesses the impairment of long-lived assets whenever events or changes in circumstances indicate that such assets might be impaired and the carrying value may not be recoverable. Oncocyte's long-lived assets consist primarily of intangible assets, right-of-use assets for operating and financing leases, customer relationships, and machinery and equipment. If events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable and the expected undiscounted future cash flows attributable to the asset are less than the carrying amount of the asset, an impairment loss, equal to the excess of the carrying value of the asset over its fair value, is recorded.</p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Leases</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Oncocyte accounts for leases in accordance with ASC 842, Leases. Oncocyte determines if an arrangement is a lease at inception. Leases are classified as either financing or operating, with classification affecting the pattern of expense recognition in the consolidated statements of operations. Under the available practical expedients for the adoption of ASC 842, Oncocyte accounts for the lease and non-lease components as a single lease component. Oncocyte recognizes right-of-use ("ROU") assets and lease liabilities for leases with terms greater than twelve months in the consolidated balance sheet. ROU assets represent the right to use an underlying asset during the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most leases do not provide an implicit rate, Oncocyte uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. Oncocyte uses the implicit rate when it is readily determinable. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. Lease terms may include options to extend or terminate the lease when it is reasonably certain that Oncocyte will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Operating leases include office leases and related ROU lease liabilities, current and long-term, in the consolidated balance sheets. Financing leases include machinery and equipment and related financing lease liabilities, current and long-term, in the consolidated balance sheets. Oncocyte discloses the amortization of our operating lease ROU assets and payments as a net amount in the consolidated statements of cash flows. Oncocyte has entered into various operating and financing leases in accordance with ASC 842 as further discussed in Note 6.</div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Accounting for Warrants</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Oncocyte determines the accounting classification of warrants it issues, as either liability or equity classified, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity, then in accordance with ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company's Own Stock. Under ASC 480, warrants are considered liability classified if the warrants are mandatorily redeemable, obligate Oncocyte to settle the warrants or the underlying shares by paying cash or other assets or warrants that must or may require settlement by issuing variable number of shares. If warrants do not meet liability classification under ASC 480, Oncocyte assesses the requirements under ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. This liability classification guidance also applies to financial instruments that may require cash or other form of settlement for transactions outside of the company's control and, in which the form of consideration to the warrant holder may not be the same as to all other shareholders in connection with the transaction. However, if a transaction is not within the company's control but the holder of the financial instrument can solely receive the same type or form of consideration as is being offered to all the shareholders in the transaction, then equity classification of the financial instrument is not precluded, if all other applicable equity classification criteria are met.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">After all relevant assessments, Oncocyte concludes whether the warrants are classified as liability or equity. Liability classified warrants require fair value accounting at issuance and subsequent to initial issuance with all changes in fair value after the issuance date recorded in the statements of operations. Equity classified warrants only require fair value accounting at issuance with no changes recognized subsequent to the issuance date. Based on the above guidance and, among other factors, the fact that our warrants cannot be cash settled under any circumstance but require share settlement, all of our outstanding warrants meet the equity classification criteria and have been classified as equity. Refer to Note 7 for details about our outstanding warrants.</p></div><div style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Revenue Recognition</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Revenue from Contracts with Customers, revenues are recognized when control of services performed is transferred to customers, in an amount that reflects the consideration Oncocyte expects to be entitled to in exchange for those services. ASC 606 provides for a five-step model that includes:</p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;">(i)<div style="width:100%;display:inline;">identifying the contract with a customer,</div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;">(ii)<div style="width:100%;display:inline;">identifying the performance obligations in the contract,</div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;">(iii)<div style="width:100%;display:inline;">determining the transaction price,</div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;">(iv)<div style="width:100%;display:inline;">allocating the transaction price to the performance obligations, and</div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;">(v)<div style="width:100%;display:inline;">recognizing revenue when, or as, an entity satisfies a performance obligation.</div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Oncocyte determines transaction prices based on the amount of consideration we expect to receive for transferring the promised goods or services in the contract. Consideration may be fixed, variable, or a combination of both. The Company considers any constraints on the variable consideration and includes in the transaction price variable consideration to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur

The following table presents consolidated revenues by service:

	Pharma Services	Laboratory Developed Test Services
2024	1,160	423
2023	1,155	373

(In thousands)

[illegible]

Oncocyte establishes an allowance for credit losses based on the evaluation of the collectability of its Pharma Services accounts receivables after considering a variety of factors, including the length of time receivables are past due, significant events that may impair the customer's ability to pay, such as a bankruptcy filing or deterioration in the customer's operating results or financial position, reasonable and supportable forecast that affect the collectability of the reported amount, and historical experience. If circumstances related to customers change, estimates of the recoverability of receivables would be further adjusted. Oncocyte continuously monitors collections and payments from customers and maintains a provision for estimated credit losses and uncollectible accounts, if any, based upon its historical experience and any specific customer collection issues that have been identified. Amounts determined to be uncollectible are written off against the credit loss reserve accounts. As of September 30, 2024 and December 31, 2023, Oncocyte had an allowance for credit losses of \$2,000 and \$5,000, respectively, related to Pharma Services.

Prior to the Razor Sale Transaction, Oncocyte generated revenue from performing DetermaRx tests on clinical samples through orders received from physicians, hospitals, and other healthcare providers. In determining whether all the revenue recognition criteria in (i) through (v) above are met with respect to DetermaRx tests, each test result is considered a single performance obligation and is generally considered complete when the test result is delivered or made available to the prescribing physician electronically, and, as such, there are no shipping or handling fees incurred by Oncocyte or billed to customers. Although Oncocyte has billed a list price for all tests ordered and completed for all payer types, Oncocyte considers constraints on the variable consideration when recognizing revenue for DetermaRx. Because DetermaRx is a novel test and there are no current reimbursement arrangements with third-party payers other than Medicare, the transaction price represents variable consideration. Application of the constraint for variable consideration is an area that requires significant judgment. For all payers other than Medicare, Oncocyte must consider the novelty of the test, the uncertainty of receiving payment, or being subject to claims for a refund, from payers with whom it does not have a sufficient payment collection history or contractual reimbursement agreements. Accordingly, for those payers, Oncocyte has recognized revenue upon payment because it has had insufficient history to reliably estimate payment patterns.

As of September 30, 2024 and December 31, 2023, Oncocyte had no accounts receivable from Medicare and Medicare Advantage covered DetermaRx tests. Laboratory Developed Test Services revenue recorded during the nine months ended September 30, 2024 was the result of payments received.

Allowance for Credit Losses

We maintained an allowance for credit losses related to Laboratory Developed Test Services at an amount we estimated to be sufficient to provide adequate protection against losses resulting from extending credit to our customers. We based this allowance, in the aggregate, on historical collection experience, age of receivables and general economic conditions, as well as specific identification of uncollectible accounts. We initially established an allowance in 2022 in connection with remaining Medicare and Medicare Advantage account balances and continued to add to the allowance as appropriate. In the first quarter of 2023, in connection with the adoption of the new current expected credit loss model, the Company determined that the Medicare and Medicare Advantage accounts receivable net balance of approximately \$1.4 million was uncollectible and should therefore be written-off as of the adoption date, January 1, 2023. Refer to additional information above in "Principles of Consolidation and Basis of Presentation - Prior Period Revisions."

As of December 31, 2023, we had no allowance for credit losses related to Laboratory Developed Test Services. The 2023 allowance for credit losses activity included a beginning balance of \$154,000, no credit loss provisions, and the full write-off to an ending balance of zero as of December 31, 2023.

Revenues that may be recognized include licensing revenue derived from agreements with customers for exclusive rights to market Oncocyte's proprietary testing technology. Under the agreements, Oncocyte grants exclusive rights to certain trademarks and technology of Oncocyte for the purpose of marketing Oncocyte's tests within a defined geographic territory. A license agreement may specify milestone deliverables or performance obligations, for which Oncocyte recognizes revenue when its licensee confirms the completion of Oncocyte's performance obligation. A licensing agreement may also include ongoing sales support from Oncocyte and typically includes non-refundable licensing fees and per-test Pharma Services revenues discussed above, for which Oncocyte treats the licensing of the technology, trademarks, and ongoing support as a single performance obligation satisfied by the passage of time over the term of the agreement.

	Three Months Ended September 30, 2024	Three Months Ended September 30, 2023	Nine Months Ended September 30, 2024	Nine Months Ended September 30, 2023
Disaggregation of Revenues and Concentrations of Credit Risk				
Revenues	\$1,000	\$1,000	\$1,000	\$1,000
Licensing Revenue	\$1,000	\$1,000	\$1,000	\$1,000

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">"> \$66,000, respectively.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Financial instruments that potentially subject the Company to concentrations of credit risk are cash equivalents and accounts receivable. The Company places its cash equivalents primarily in highly rated money market funds. Cash and cash equivalents are also invested in deposits with certain financial institutions and may, at times, exceed federally insured limits. The Company has not experienced any significant losses on its deposits of cash and cash equivalents.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Four Pharma Services customers individually represented approximately51%,17%,12% of accounts receivable as of September 30, 2024. Two Pharma Services customers individually represented approximately79% of accounts receivable as of December 31, 202313% of accounts receivable as of December 31, 2023.</p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Cost of Revenues</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Cost of revenues generally consists of cost of materials, direct labor including benefits, bonus and stock-based compensation, equipment and infrastructure expenses, clinical sample related costs associated with performing Pharma Services and Laboratory Developed Test Services, providing deliverables according to our licensing agreements, license fees due to third-parties, and amortization of acquired intangible assets such as the customer relationship intangible assets (see Note 5). Infrastructure expenses include depreciation of laboratory equipment, allocated rent costs, leasehold improvements, and allocated information technology costs for operations at Oncocyte's CLIA laboratory in Tennessee. Costs associated with generating the revenues are recorded as the tests or services are performed regardless of whether revenue was recognized. Royalties or revenue share payments for licensed technology calculated as a percentage of revenues generated using the associated technology are recorded as expenses at the time the related revenues are recognized.</p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Research and Development Expenses</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Research and development expenses are comprised of costs incurred to develop technology, which include salaries and benefits (including stock-based compensation), laboratory expenses (including reagents and supplies used in research and development laboratory work), infrastructure expenses (including allocated facility occupancy costs), and contract services and other outside costs. Indirect research and development expenses are allocated primarily based on headcount, as applicable, and include rent and utilities, common area maintenance, telecommunications, property taxes and insurance. Research and development costs are expensed as incurred. Certain research and development expenses are attributed to our collaboration arrangement with Bio-Rad, our global strategic partner, for commercializing our RUO kitted tests and IVD kitted transplant testing products. See Note 10, "Collaborative Arrangements" for additional information.</p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Sales and Marketing Expenses</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Sales and marketing expenses consist primarily of personnel costs and related benefits, including stock-based compensation, trade show expenses, branding and positioning expenses, and consulting fees. Sales and marketing expenses also include indirect expenses for applicable overhead allocated based on headcount, and include allocated costs for rent and utilities, common area maintenance, telecommunications, property taxes and insurance. During the three months ended September 30, 2024 and 2023, Oncocyte's total advertising expenses were40,000 and46,000, respectively. During the nine months ended September 30, 2024 and 2023, Oncocyte's total advertising expenses were123,000 and125,000, respectively. Certain sales and marketing expenses are attributed to our collaboration arrangement with Bio-Rad, our global strategic partner, for commercializing our RUO kitted tests and IVD kitted transplant testing products. See Note 10, "Collaborative Arrangements" for additional information.</p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">General and Administrative Expenses</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">General and administrative expenses consist primarily of compensation and related benefits (including stock-based compensation) for executive and corporate personnel, professional and consulting fees, rent and utilities, common area maintenance, telecommunications, property taxes and insurance.</p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Stock-Based Compensation</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Oncocyte recognizes compensation expense related to employee, Board of Director and other non-employee option grants and restricted stock grants in accordance with ASC 718, Compensation - Stock Compensation.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Oncocyte estimates the fair value of stock-based payment awards on the grant date and recognizes the resulting fair value over the requisite service period, which is generally a four-year vesting period. For stock-based awards that vest only upon the attainment of one or more performance goals set by Oncocyte at the time of the grant (sometimes referred to as milestone vesting), compensation cost is recognized if and when Oncocyte determines that it is probable that the performance condition or conditions will be, or have been, achieved. Oncocyte uses the Black-Scholes option pricing model for estimating the fair value of time-based options granted under Oncocyte's equity plan. The fair value of each restricted

stock unit ("RSU") or award is determined by the product of the number of units or shares granted and the grant date market price of the underlying common stock. Oncocyte has elected to treat stock-based payment awards with graded vesting schedules and time-based service conditions as a single award and recognizes stock-based compensation ratably on a straight-line basis over the requisite service period. Options have a maximum contractual term of ten years . Forfeitures are accounted for as they occur. Refer to Note 8 for additional information. </p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The Black-Scholes option pricing model requires Oncocyte to make certain assumptions including the expected option term, the expected volatility, the risk-free interest rate and the dividend yield. The expected term of employee stock options represents the weighted average period that the stock options are expected to remain outstanding. Oncocyte estimates the expected term of options granted based on its own experience. Oncocyte estimates the expected volatility using its own stock price volatility for a period equal to the expected term of the options. The risk-free interest rate assumption is based upon observed interest rates on the United States government securities appropriate for the expected term of Oncocyte's stock options. The dividend yield assumption is based on Oncocyte's history and expectation of dividend payouts. Oncocyte has never declared or paid any cash dividends on its common stock, and Oncocyte does not anticipate paying any cash dividends in the foreseeable future.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">All excess tax benefits and tax deficiencies from stock-based compensation awards accounted for under ASC 718 are recognized as income tax benefit or expense, respectively, in the statements of operations. An excess income tax benefit arises when the tax deduction of a share-based award for income tax purposes exceeds the compensation cost recognized for financial reporting purposes and, a tax deficiency arises when the compensation cost exceeds the tax deduction. Because Oncocyte has a full valuation allowance for all periods presented (see "Income Taxes" below), there was no impact to Oncocyte statements of operations for any excess tax benefits or deficiencies, as any excess benefit or deficiency would be offset by the change in the valuation allowance.</p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Retirement Plan</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Oncocyte has an employee savings and retirement plan under Section 401(k) of the Internal Revenue Code. The plan is a defined contribution plan in which eligible employees may elect to have a percentage of their compensation contributed to the plan, subject to certain guidelines issued by the Internal Revenue Service. During the three months ended September 30, 2024 and 2023, Oncocyte's total contributions to the plan were \$81,000 and \$67,000, respectively. During the nine months ended September 30, 2024 and 2023, Oncocyte's total contributions to the plan were \$248,000 and \$245,000, respectively.</p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Collaborative Arrangements</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808, Collaborative Arrangements, which includes determining whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. To the extent that the arrangement falls within the scope of ASC 808, the Company assesses whether the payments between the Company and its collaboration partner fall within the scope of other accounting literature. If the Company concludes that payments from the collaboration partner to the Company would represent consideration from a customer, the Company accounts for those payments within the scope of ASC 606. However, if the Company concludes that its collaboration partner is not a customer for certain activities and associated payments, the Company presents such payments as a reduction of research and development expense or general and administrative expense, based on where the Company presents the underlying expense. See Note 10, "Collaborative Arrangements" for additional information.</p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Income Taxes</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The provision for income taxes for interim periods is determined using an estimated annual effective tax rate in accordance with ASC 740-270, Income Taxes, Interim Reporting. The effective tax rate may be subject to fluctuations during the year as new information is obtained, which may affect the assumptions used to estimate the annual effective tax rate, including factors such as valuation allowances against deferred tax assets, the recognition or de-recognition of tax benefits related to uncertain tax positions, if any, and changes in or the interpretation of tax laws in jurisdictions where Oncocyte conducts business.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Oncocyte did not record any provision or benefit for income taxes for the three and nine months ended September 30, 2024 and 2023, as Oncocyte had a full valuation allowance for the periods presented.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">A valuation allowance is provided when it is more likely than not that some portion of the deferred tax assets will not be realized. Oncocyte established a full valuation allowance for all periods presented due to the uncertainty of realizing future tax benefits from its net operating loss carry-forwards and other deferred tax assets.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The guidance also prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not sustainable upon examination by taxing authorities. Oncocyte will recognize accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties as of September 30, 2024 and December 31, 2023. Oncocyte is not aware of any uncertain tax positions that could result in significant additional payments, accruals, or other material deviation as of September 30, 2024. Oncocyte is currently unaware of any tax issues under review. As of September 30, 2024 and December 31, 2023, the Company had unrecognized tax benefits totaling 2.3 million.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">On June 27, 2024, California enacted SB-167, which suspends the use of California net operating loss and limits the use of California research tax credits to 5.0 million each year for our fiscal years 2025-2027. On June 29, 2024, California enacted SB-175, which provides a refund mechanism for the incremental tax that was paid as a result of SB-167. The Company is evaluating the impact of the law changes but does not expect these law changes to have a material impact on the Company's consolidated financial

statements.

><Net Loss Per Common Share>

Basic loss per share is computed by dividing the net loss applicable to common stockholders after deducting cumulative unpaid dividends and accretion of the preferred stock, by the weighted average number of shares of common stock outstanding during the year. The 2024 weighted average shares outstanding - basic in the following table includes the effects of pre-funded warrants that were issued in April 2024 (refer to Note 7, "Common Stock Purchase Warrants" for additional information). Diluted loss per share is computed by dividing the net loss applicable to common stockholders after deducting cumulative unpaid dividends and accretion of the preferred stock, by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued, using the treasury stock method or the if-converted method, or the two-class method for participating securities, whichever is more dilutive. Potential common shares are excluded from the computation if their effect is antidilutive.

	For the three months ended September 30, 2024	For the nine months ended September 30, 2024	For the nine months ended September 30, 2023
Diluted loss per share:	\$.049%	\$.798%	\$.798%

The following table presents the calculation of basic and diluted loss per share of common stock:

	Three Months Ended September 30, 2024	Nine Months Ended September 30, 2024	Nine Months Ended September 30, 2023
(In thousands, except per share data)			
Numerator—loss available to common shareholders (\$ millions)	\$ 0.5	\$ 3.8	\$ 3.8
Denominator—weighted average common shares outstanding (in millions)	1.0	4.8	4.8
Diluted loss per share	\$.049%	\$.798%	\$.798%

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

Total

In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires public entities to improve financial reporting by requiring disclosure of incremental segment information on an annual and interim basis for all public entities to enable investors to develop more decision-useful financial analyses. The amendments in this Update:

- (i) require enhanced disclosures about significant segment expenses,
- (ii) clarify that if the chief operating decision maker ("CODM") uses more than one measure of a segment's profit or loss, a public entity may report one or more of those additional measures of segment profit or loss,
- (iii) require disclose of the title and position of the CODM and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources, and
- (iv) require that a public entity that has a single reportable segment provide all the disclosures required by the amendments in this Update and all existing segment disclosures in Topic 280.

The amendments in this Update should be applied retrospectively, and are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. Management is currently evaluating the impact that the amendments in this Update will have on the Company's financial statement disclosures. The adoption of this new standard will not have an impact on the Company's consolidated balance sheets and consolidated statements of operations, comprehensive loss, shareholders' equity and cash flows.

In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires public entities to address investor requests for more transparency about income tax information by requiring improvements to income tax disclosures, including:

- (i) consistent categories and greater disaggregation of information in the rate reconciliation, and
- (ii) income taxes paid disaggregated by jurisdiction.

Additional amendments in this Update improve the effectiveness and comparability of disclosures by:

- (i) adding disclosures of pretax income (or loss) and income tax expense (or benefit), and
- (ii) removing disclosures that no longer are considered cost beneficial or relevant.

The amendments in this Update should be applied prospectively (retrospective application is permitted) and are effective for annual periods beginning after December 15, 2024, with early adoption permitted. Management is currently evaluating the impact that the amendments in this Update will have on the Company's financial statement disclosures. The adoption of this new standard will not have an

on the Company's consolidated balance sheets and consolidated statements of operations, comprehensive loss, shareholders' equity and cash flows.

In November 2024, the FASB issued ASU No. 2024-03, "Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses", to address investor requests for more detailed information about certain types of reported costs and expenses. The amendments in this Update require disclosure, in the notes to financial statements, at each interim and annual reporting period an entity: 1) disclose the amounts of (a) purchases of inventory, (b) employee compensation, (c) depreciation, and (d) intangible asset amortization included in each expense caption presented on the face of the income statement within continuing operations; 2) include certain amounts that are already required to be disclosed under current GAAP in the same disclosure as the other disaggregation requirements; 3) disclose a qualitative description of the amounts remaining that are not separately disaggregated quantitatively; and 4) disclose the total amount of selling expenses and, in annual reporting periods, an entity's definition of selling expenses. The amendments in this Update should be applied either prospectively or retrospectively, and are effective for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027, with early adoption permitted. Management is currently evaluating the impact that the amendments in this Update will have on the Company's financial statement disclosures. The adoption of this new standard will not have an impact on the Company's consolidated balance sheets and consolidated statements of operations, comprehensive loss, shareholders' equity and cash flows.

Accounting Principles of Consolidation and Basis of Presentation

The consolidated financial statements and accompanying notes are prepared on the accrual basis of accounting in accordance with U.S. generally accepted accounting principles ("GAAP").

Principles of Consolidation and Basis of Presentation

The unaudited condensed consolidated interim financial statements presented herein have been prepared in accordance with GAAP for financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. In accordance with those rules and regulations, certain information and footnote disclosures normally included in comprehensive consolidated financial statements may have been condensed or omitted. The consolidated balance sheet as of December 31, 2023 was derived from the audited consolidated financial statements at that date. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in Oncocyte's Annual Report on Form 10-K for the year ended December 31, 2023. The accompanying unaudited condensed consolidated financial statements, in the opinion of management, include all adjustments of a normal recurring nature necessary for a fair presentation of Oncocyte's financial condition and results of operations. The consolidated results of operations are not necessarily indicative of the results to be expected for any other interim period or for the entire year.

On January 31, 2020, with the acquisition of Insight Genetics, Inc. ("Insight") through a merger with a newly incorporated wholly-owned subsidiary of Oncocyte (the "Insight Merger") under the terms of an Agreement and Plan of Merger (the "Insight Merger Agreement"), Insight became a wholly-owned subsidiary of Oncocyte, and on that date Oncocyte began consolidating Insight's operations and results with Oncocyte's operations and results (see Note 3).

On April 15, 2021, with the acquisition of Chronix Biomedical, Inc. ("Chronix") pursuant to an Agreement and Plan of Merger dated February 2, 2021, amended February 23, 2021, and amended and restated as of April 15, 2021 (as amended and restated, the "Chronix Merger Agreement"), by and among Oncocyte, CNI Monitor Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Oncocyte ("Merger Sub"), Chronix became a wholly-owned subsidiary of Oncocyte (the "Chronix Merger"), and on that date Oncocyte began consolidating Chronix's operations and results with Oncocyte's operations and results (see Note 3).

All material intercompany accounts and transactions have been eliminated in consolidation.

We have reflected the 2023 operations of Razor as discontinued operations. See Note 11 for further information. Amounts and disclosures throughout these notes to consolidated financial statements relate solely to continuing operations and exclude all discontinued operations, unless otherwise noted. Discontinued operations comprise activities that were disposed of or discontinued at the end of the period, represent a separate major line of business that can be clearly distinguished for operational and financial reporting purposes and represent a strategic business shift having a major effect on the Company's operations and financial results.

On July 24, 2023, the Company implemented a 1-for-20 reverse stock split of the outstanding shares of its common stock. The par value per share and the authorized number of shares of common stock and preferred stock were not adjusted as a result of the reverse stock split. All common stock share and per-share amounts for all periods presented in these consolidated financial statements have been adjusted to reflect the reverse stock split. The number of authorized shares of common stock remains at 230,000,000 shares.

1-for-202300000000 reverse stock split of the outstanding shares of its common stock. The par value per share and the authorized number of shares of common stock and preferred stock were not adjusted as a result of the reverse stock split. All common stock share and per-share amounts for all periods presented in these consolidated financial statements have been adjusted to reflect the reverse stock split. The number of authorized shares of common stock remains at 230,000,000 shares.

1-for-202300000000 reverse stock split of the outstanding shares of its common stock. The par value per share and the authorized number of shares of common stock and preferred stock were not adjusted as a result of the reverse stock split. All common stock share and per-share amounts for all periods presented in these consolidated financial statements have been adjusted to reflect the reverse stock split. The number of authorized shares of common stock remains at 230,000,000 shares.

1-for-202300000000 reverse stock split of the outstanding shares of its common stock. The par value per share and the authorized number of shares of common stock and preferred stock were not adjusted as a result of the reverse stock split. All common stock share and per-share amounts for all periods presented in these consolidated financial statements have been adjusted to reflect the reverse stock split. The number of authorized shares of common stock remains at 230,000,000 shares.

1-for-202300000000 reverse stock split of the outstanding shares of its common stock. The par value per share and the authorized number of shares of common stock and preferred stock were not adjusted as a result of the reverse stock split. All common stock share and per-share amounts for all periods presented in these consolidated financial statements have been adjusted to reflect the reverse stock split. The number of authorized shares of common stock remains at 230,000,000 shares.

1-for-202300000000 reverse stock split of the outstanding shares of its common stock. The par value per share and the authorized number of shares of common stock and preferred stock were not adjusted as a result of the reverse stock split. All common stock share and per-share amounts for all periods presented in these consolidated financial statements have been adjusted to reflect the reverse stock split. The number of authorized shares of common stock remains at 230,000,000 shares.

1-for-202300000000 reverse stock split of the outstanding shares of its common stock. The par value per share and the authorized number of shares of common stock and preferred stock were not adjusted as a result of the reverse stock split. All common stock share and per-share amounts for all periods presented in these consolidated financial statements have been adjusted to reflect the reverse stock split. The number of authorized shares of common stock remains at 230,000,000 shares.

1-for-202300000000 reverse stock split of the outstanding shares of its common stock. The par value per share and the authorized number of shares of common stock and preferred stock were not adjusted as a result of the reverse stock split. All common stock share and per-share amounts for all periods presented in these consolidated financial statements have been adjusted to reflect the reverse stock split. The number of authorized shares of common stock remains at 230,000,000 shares.

1-for-202300000000 reverse stock split of the outstanding shares of its common stock. The par value per share and the authorized number of shares of common stock and preferred stock were not adjusted as a result of the reverse stock split. All common stock share and per-share amounts for all periods presented in these consolidated financial statements have been adjusted to reflect the reverse stock split. The number of authorized shares of common stock remains at 230,000,000 shares.

1-for-202300000000 reverse stock split of the outstanding shares of its common stock. The par value per share and the authorized number of shares of common stock and preferred stock were not adjusted as a result of the reverse stock split. All common stock share and per-share amounts for all periods presented in these consolidated financial statements have been adjusted to reflect the reverse stock split. The number of authorized shares of common stock remains at 230,000,000 shares.

1-for-202300000000 reverse stock split of the outstanding shares of its common stock. The par value per share and the authorized number of shares of common stock and preferred stock were not adjusted as a result of the reverse stock split. All common stock share and per-share amounts for all periods presented in these consolidated financial statements have been adjusted to reflect the reverse stock split. The number of authorized shares of common stock remains at 230,000,000 shares.

1-for-202300000000 reverse stock split of the outstanding shares of its common stock. The par value per share and the authorized number of shares of common stock and preferred stock were not adjusted as a result of the reverse stock split. All common stock share and per-share amounts for all periods presented in these consolidated financial statements have been adjusted to reflect the reverse stock split. The number of authorized shares of common stock remains at 230,000,000 shares.

1-for-202300000000 reverse stock split of the outstanding shares of its common stock. The par value per share and the authorized number of shares of common stock and preferred stock were not adjusted as a result of the reverse stock split. All common stock share and per-share amounts for all periods presented in these consolidated financial statements have been adjusted to reflect the reverse stock split. The number of authorized shares of common stock remains at 230,000,000 shares.

1-for-202300000000 reverse stock split of the outstanding shares of its common stock. The par value per share and the authorized number of shares of common stock and preferred stock were not adjusted as a result of the reverse stock split. All common stock share and per-share amounts for all periods presented in these consolidated financial statements have been adjusted to reflect the reverse stock split. The number of authorized shares of common stock remains at 230,000,000 shares.

1-for-202300000000 reverse stock split of the outstanding shares of its common stock. The par value per share and the authorized number of shares of common stock and preferred stock were not adjusted as a result of the reverse stock split. All common stock share and per-share amounts for all periods presented in these consolidated financial statements have been adjusted to reflect the reverse stock split. The number of authorized shares of common stock remains at 230,000,000 shares.

1-for-202300000000 reverse stock split of the outstanding shares of its common stock. The par value per share and the authorized number of shares of common stock and preferred stock were not adjusted as a result of the reverse stock split. All common stock share and per-share amounts for all periods presented in these consolidated financial statements have been adjusted to reflect the reverse stock split. The number of authorized shares of common stock remains at 230,000,000 shares.

1-for-202300000000 reverse stock split of the outstanding shares of its common stock. The par value per share and the authorized number of shares of common stock and preferred stock were not adjusted as a result of the reverse stock split. All common stock share and per-share amounts for all periods presented in these consolidated financial statements have been adjusted to reflect the reverse stock split. The number of authorized shares of common stock remains at 230,000,000 shares.

1-for-202300000000 reverse stock split of the outstanding shares of its common stock. The par value per share and the authorized number of shares of common stock and preferred stock were not adjusted as a result of the reverse stock split. All common stock share and per-share amounts for all periods presented in these consolidated financial statements have been adjusted to reflect the reverse stock split. The number of authorized shares of common stock remains at 230,000,000 shares.

1-for-202300000000 reverse stock split of the outstanding shares of its common stock. The par value per share and the authorized number of shares of common stock and preferred stock were not adjusted as a result of the reverse stock split. All common stock share and per-share amounts for all periods presented in these consolidated financial statements have been adjusted to reflect the reverse stock split. The number of authorized shares of common stock remains at 230,000,000 shares.

1-for-202300000000 reverse stock split of the outstanding shares of its common stock. The par value per share and the authorized number of shares of common stock and preferred stock were not adjusted as a result of the reverse stock split. All common stock share and per-share amounts for all periods presented in these consolidated financial statements have been adjusted to reflect the reverse stock split. The number of authorized shares of common stock remains at 230,000,000 shares.

1-for-202300000000 reverse stock split of the outstanding shares of its common stock. The par value per share and the authorized number of shares of common stock and preferred stock were not adjusted as a result of the reverse stock split. All common stock share and per-share amounts for all periods presented in these consolidated financial statements have been adjusted to reflect the reverse stock split. The number of authorized shares of common stock remains at 230,000,000 shares.

1-for-202300000000 reverse stock split of the outstanding shares of its common stock. The par value per share and the authorized number of shares of common stock and preferred stock were not adjusted as a result of the reverse stock split. All common stock share and per-share amounts for all periods presented in these consolidated financial statements have been adjusted to reflect the reverse stock split. The number of authorized shares of common stock remains at 230,000,000 shares.

1-for-202300000000 reverse stock split of the outstanding shares of its common stock. The par value per share and the authorized number of shares of common stock and preferred stock were not adjusted as a result of the reverse stock split. All common stock share and per-share amounts for all periods presented in these consolidated financial statements have been adjusted to reflect the reverse stock split. The number of authorized shares of common stock remains at 230,000,000 shares.

1-for-202300000000 reverse stock split of the outstanding shares of its common stock. The par value per share and the authorized number of shares of common stock and preferred stock were not adjusted as a result of the reverse stock split. All common stock share and per-share amounts for all periods presented in these consolidated financial statements have been adjusted to reflect the reverse stock split. The number of authorized shares of common stock remains at 230,000,000 shares.

1-for-202300000000 reverse stock split of the outstanding shares of its common stock. The par value per share and the authorized number of shares of common stock and preferred stock were not adjusted as a result of the reverse stock split. All common stock share and per-share amounts for all periods presented in these consolidated financial statements have been adjusted to reflect the reverse stock split. The number of authorized shares of common stock remains at 230,000,000 shares.

1-for-202300000000 reverse stock split of the outstanding shares of its common stock. The par value per share and the authorized number of shares of common stock and preferred stock were not adjusted as a result of the reverse stock split. All common stock share and per-share amounts for all periods presented in these consolidated financial statements have been adjusted to reflect the reverse stock split. The number of authorized shares of common stock remains at 230,000,000 shares.

1-for-202300000000 reverse stock split of the outstanding shares of its common stock. The par value per share and the authorized number of shares of common stock and preferred stock were not adjusted as a result of the reverse stock split. All common stock share and per-share amounts for all periods presented in these consolidated financial statements have been adjusted to reflect

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

content;"></p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">138</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,035</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">></p></td><tr><td style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Use of Estimates</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and contingent assets and liabilities, at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates estimates which are subject to significant judgment, including, but not limited to, valuation methods used, assumptions requiring the use of judgment to prepare financial projections and forecasted financial information, timing of potential commercialization of acquired in-process intangible assets, applicable discount rates, probabilities of the likelihood of multiple outcomes of certain events related to contingent consideration, comparable companies or transactions, determination of fair value of the assets acquired and liabilities assumed (including those relating to contingent consideration), the carrying value of goodwill and other intangibles, impairments, assumptions related to going concern assessments, revenue recognition, allocation of direct and indirect expenses, useful lives associated with long-lived intangible and other assets, key assumptions in operating and financing leases including incremental borrowing rates, loss contingencies, valuation allowances related to deferred income taxes, allowances for credit losses, and assumptions used to value stock-based awards and other equity instruments. These assessments are made in the context of information reasonably available to Oncocyte. Actual results may differ materially from those estimates.</p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Segments</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Oncocyte's executive management team, as a group, represents the entity's chief operating decision makers. To date, Oncocyte's executive management team has viewed Oncocyte's operations as one segment that includes the research, development and commercialization of diagnostic tests, including molecular diagnostic services to pharmaceutical customers. As a result, the financial information disclosed materially represents all of the financial information related to Oncocyte's sole operating segment.</p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Fair Value Measurements, Business Combinations and Contingent Consideration Liabilities</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Oncocyte accounts for business combinations in accordance with ASC 805, which requires the purchase consideration transferred to be measured at fair value on the acquisition date in accordance with ASC 820,Fair Value Measurement</p>ASC 820 establishes a single authoritative definition of fair value, sets out a framework for measuring fair value and expands on required disclosures about fair value measurement. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. ASC 820 describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value, which are the following:</p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;">•<div style="width:100%;display:inline;">Level 1- Quoted prices in active markets for identical assets and liabilities.</div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;">•<div style="width:100%;display:inline;">Level 2- Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted market prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;">•<div style="width:100%;display:inline;">Level 3- Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Such inputs reflect management's best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. Management estimates include certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs, including the entity's own assumptions in determining fair value.</div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">When a part of the purchase consideration consists of shares of Oncocyte common stock, Oncocyte calculates the purchase price attributable to those shares, a Level 1 security, by determining the fair value of those shares as of the acquisition date based on prices quoted on the principal national securities exchange on which the shares traded. Oncocyte recognizes estimated fair values of the tangible assets and identifiable intangible assets acquired, including in-process research and development ("IPR&D"), and liabilities assumed, including any contingent consideration, as of the acquisition date. Goodwill is recognized as any amount of excess consideration transferred over the fair value of the tangible and identifiable intangible assets acquired net of the liabilities assumed. ASC 805 precludes the recognition of an assembled workforce as an asset, effectively subsuming any assembled workforce value into goodwill.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">In determining fair value, Oncocyte utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, and also considers counterparty credit risk in its assessment of fair value. For the periods presented, Oncocyte has no financial assets recorded at fair value on a recurring basis, except for money market funds. These assets are measured at fair value using the period-end quoted market prices as a Level 1 input.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Certain of Oncocyte's asset and business acquisitions involve the potential for future payment of consideration to third-parties and former selling shareholders in amounts determined as a percentage of future net revenues generated, or upon attainment of revenue milestones, from Pharma Services or laboratory tests, as applicable, or annual minimum royalties to certain licensors, as provided in the applicable agreements. The fair value of such liabilities is determined using unobservable inputs. These inputs include the estimated amount and timing of projected cash flows and the risk-adjusted discount rate used to present value the cash flows. These obligations are referred to as contingent consideration, which are carried at fair value based on Level 3 inputs on a recurring basis.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">ASC 805 requires that contingent consideration be estimated and

recorded at fair value as of the acquisition date as part of the total consideration transferred. Contingent consideration is an obligation of the acquirer to transfer additional assets or equity interests to the selling shareholders in the future if certain future events occur or conditions are met, such as the attainment of product development milestones. Contingent consideration also includes additional future payments to selling shareholders based on achievement of components of earnings, such as "earn-out" provisions or percentage of future revenues, including royalties paid to the selling shareholders based on a percentage of certain revenues generated.

The fair value of contingent consideration after the acquisition date is reassessed by Oncocyte as changes in circumstances and conditions occur, with the subsequent change in fair value recorded in the consolidated statements of operations. Changes in key assumptions can materially affect the estimated fair value of contingent consideration liabilities and, accordingly, the resulting gain or loss that Oncocyte records in its consolidated financial statements. See Note 3 for a full discussion of these liabilities and additional Level 3 fair value disclosures.

The carrying amounts of cash and cash equivalents, restricted cash, net accounts receivable, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities approximate fair values because of the short-term nature of these items.

In accordance with GAAP, from time to time, the Company measures certain assets at fair value on a nonrecurring basis. The Company reviews the carrying value of intangibles, including IPR&D (see Note 5), and other long-lived assets for indications of impairment at least annually. Refer to related discussions of impairments below.

Cash, Cash Equivalents and Restricted Cash

Oncocyte considers all highly liquid securities with original maturities of three months or less when purchased to be cash equivalents. For the periods presented, Oncocyte's cash equivalents are comprised of investments in AAA rated money market funds that invest in first-tier only securities, which primarily include domestic commercial paper and securities issued or guaranteed by the U.S. government or its agencies. Restricted cash relates to a bank letter of credit required under our office lease arrangement, refer to Note 6 for additional information.

Marketable Equity Securities

Oncocyte accounts for shares of public common stock it may hold as marketable equity securities in accordance with ASC 321-10, *Investments - Equity Securities*, as the shares have a readily determinable fair value quoted on national stock exchange. The securities are measured at fair value, with related gains and losses in the value of such securities recorded in the consolidated statements of operations in other income or expense, and are reported as current assets in the consolidated balance sheet based on the closing trading price of the security as of the date being presented. During the fourth quarter of 2023, Oncocyte sold its remaining marketable equity securities for an aggregate realized loss of approximately \$1.4 million. During the nine months ended September 30, 2023, Oncocyte recorded an unrealized gain on marketable equity securities of \$8,000.

Investments in Privately Held Companies

Oncocyte evaluates whether investments held in common stock of other companies require consolidation of the company under, first, the variable interest entity ("VIE") model, and then under the voting interest model in accordance with accounting guidance for consolidations under ASC 810-10. If consolidation of the entity is not required under either the VIE model or the voting interest model, Oncocyte determines whether the equity method of accounting should be applied in accordance with ASC 323, *Investments - Equity Method and Joint Ventures*. The equity method applies to investments in common stock or in-substance common stock if Oncocyte exercises significant influence over, but does not control, the entity, where significant influence is typically represented by ownership of 20% or more, but less than majority ownership, of the voting interests of a company.

Oncocyte initially records equity method investments at fair value on the date of the acquisition with subsequent adjustments to the investment balance based on Oncocyte's pro rata share of earnings or losses from the investment.

Since February 16, 2023, Oncocyte continues to own an equity interest in Razor, however, based on the Razor transactions as discussed in Note 1, the remaining common stock held is accounted for at historical cost less impairment, which is currently zero.

Inventories

Inventories include raw materials, work-in-process and finished goods and are valued at the lower of cost or net realizable value. In September 2024, the Company capitalized certain initial RUO inventory costs in connection with its collaboration arrangement with Bio-Rad to develop and commercialize its GraftAssure RUO kitted tests and eventual IVD kitted transplant testing products. See Note 10, "Collaborative Arrangements" for additional information. As of September 30, 2024, inventories, comprised primarily of raw materials, totaled 232,000.

Assets Held for Sale and Discontinued Operations

Assets and liabilities are classified as held for sale when all of the following criteria for a plan of sale have been met: (1) management, having the authority to approve the action, commits to a plan to sell the assets; (2) the assets are available for immediate sale, in their present condition, subject only to terms that are usual and customary for sales of such assets; (3) an active program to locate a buyer and other actions required to complete the plan to sell the assets have been initiated; (4) the sale of the assets is probable and is expected to be completed within one year; (5) the assets are being actively marketed for a price that is reasonable in relation to their current fair value; and (6) actions required to complete the plan indicate that it is unlikely that significant changes to the plan will be made or the plan will be withdrawn. When all of these criteria have been met, the assets and liabilities are classified as held for sale in the consolidated balance sheet. Assets classified as held for sale are reported at the lower of their carrying value or fair value less costs to sell. Depreciation and amortization of assets ceases upon designation as held for sale.

Property, Plant, and Equipment

had been met. The equipment was written down to its fair value, less cost to sell, the remainder of which was 32,000.

The Company has entered into various agreements to sell laboratory equipment. As a result, the Company classified the equipment as held for sale current assets in the consolidated balance sheets, as all the criteria of ASC subtopic 360-10, *Property, Plant, and Equipment*, had been met. The equipment was written down to its fair value, less cost to sell, the remainder of which was 139,000.

as of September 30, 2024 and December 31, 2023, respectively. During the nine months ended September 30, 2024 and 2023, the Company recorded an impairment loss on held for sale assets of \$169,000 and \$1.3 million, respectively, in the consolidated statements of operations. Presentation of Financial Statements. Razor has been reflected as a discontinued operation in the 2023 consolidated financial statements. See Note 11, "Discontinued Operations of Razor" for additional information. Machinery and Equipment, Net, and Construction in Progress. Machinery and equipment are stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally over a period of 3 to 10 years. For equipment purchased under financing leases, Oncocyte depreciates the equipment based on the shorter of the useful life of the equipment or the term of the lease, ranging from 3 to 5 years, depending on the nature and classification of the financing lease. Maintenance and repairs are expensed as incurred whereas significant renewals and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and the related accumulated depreciation are removed from the respective accounts and any resulting gain or loss is reflected in Oncocyte's results of operations. Construction in progress, comprised primarily of leasehold improvements under construction, is not depreciated until the underlying asset is placed into service. Intangible Assets. In accordance with ASC 350, Intangibles - Goodwill and Other, IPR&D projects acquired in a business combination that are not complete as of the acquisition date are capitalized and accounted for as indefinite-lived intangible assets until completion or abandonment of the related research and development efforts. Upon successful completion of the project, the capitalized amount is amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts are written off immediately. Oncocyte considers various factors and risks for potential impairment of IPR&D assets, including the current legal and regulatory environment and the competitive landscape. Adverse clinical trial results, significant delays or inability to obtain local coverage determination ("LCD") from the Centers for Medicare and Medicaid Services ("CMS") for Medicare reimbursement for a diagnostic test, the inability to bring a diagnostic test to market and the introduction or advancement of competitors' diagnostic tests could result in partial or full impairment of the related intangible assets. Consequently, the eventual realized value of the IPR&D project may vary from its fair value at the date of acquisition, and IPR&D impairment charges may occur in future periods. During the period between completion or abandonment, the IPR&D assets will not be amortized but will be tested for impairment on an annual basis and between annual tests if Oncocyte becomes aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&D projects below their respective carrying amounts. Oncocyte does not have intangible assets with indefinite useful lives other than the acquired IPR&D discussed in Note 5, which as of September 30, 2024, has been partially impaired. Goodwill represents the excess of the purchase price over the fair value of net identifiable assets and liabilities. Goodwill, similar to IPR&D, is not amortized but is tested for impairment at least annually, or if circumstances indicate that it is more-likely-than-not that the carrying value of the associated reporting unit exceeds its fair value. Qualitative factors considered in this assessment include industry and market conditions, overall financial performance, and other relevant events and factors affecting Oncocyte's business. Based on the qualitative assessment, if it is determined that the fair value of goodwill is more-likely-than-not to be less than its carrying amount, the fair value of a reporting unit will be calculated and compared with its carrying amount and an impairment charge will be recognized for the amount that the carrying value exceeds the fair value. Oncocyte continues to operate in one segment and considered to be the sole reporting unit and, therefore, goodwill is tested for impairment at the enterprise level, when applicable. In accordance with ASC 350, we review and evaluate our long-lived assets, including intangible assets with finite lives, for impairment whenever events or changes in circumstances indicate that we may not recover their net book value. When applicable, we test goodwill for impairment on an annual basis in the fourth quarter of each year, and between annual tests, if indicators of potential impairment exist, using a fair-value approach. We typically use an income method to estimate the fair value of these assets, which is based on forecasts of the expected future cash flows attributable to the respective assets. Significant estimates and assumptions inherent in the valuations reflect a consideration of other marketplace participants and include the amount and timing of future cash flows (including expected growth rates). Estimates utilized in the projected cash flows include consideration of macroeconomic conditions, overall category growth rates, competitive activities, cost containment and margin expansion, Company business plans, the underlying product or technology life cycles, economic barriers to entry, and the discount rate applied to the cash flows. Unanticipated market or macroeconomic events and circumstances may occur, which could affect the accuracy or validity of the estimates and assumptions. Long-Lived Intangible Assets. Long-lived intangible assets subject to amortization are stated at acquired cost, less accumulated amortization. We amortize intangible assets not considered to have an indefinite useful life using the straight-line method over their estimated period of benefit, which generally ranges from 1 to 9 years. Each reporting period, we evaluate the estimated remaining useful life of intangible assets and assess whether events or changes in circumstances warrant a revision to the remaining period of amortization or indicate that impairment exists. Long-lived intangible assets currently consist of acquired customer relationships with an estimated useful life of 5 to 9 years. Impairment of Long-Lived Assets. Impairment of long-lived assets is tested for impairment at least annually, or if circumstances indicate that it is more-likely-than-not that the carrying value of the associated reporting unit exceeds its fair value. Qualitative factors considered in this assessment include industry and market conditions, overall financial performance, and other relevant events and factors affecting Oncocyte's business. Based on the qualitative assessment, if it is determined that the fair value of the reporting unit is more-likely-than-not to be less than its carrying amount, the fair value of the reporting unit will be calculated and compared with its carrying amount and an impairment charge will be recognized for the amount that the carrying value exceeds the fair value. Oncocyte continues to operate in one segment and considered to be the sole reporting unit and, therefore, long-lived assets are tested for impairment at the enterprise level, when applicable.

Oncocyte assesses the impairment of long-lived assets whenever events or changes in circumstances indicate that such assets might be impaired and the carrying value may not be recoverable. Oncocyte's long-lived assets consist primarily of intangible assets, right-of-use assets for operating and financing leases, customer relationships, and machinery and equipment. If events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable and the expected undiscounted future cash flows attributable to the asset are less than the carrying amount of the asset, an impairment loss, equal to the excess of the carrying value of the asset over its fair value, is recorded.

Leases

Oncocyte accounts for leases in accordance with ASC 842, and determines if an arrangement is a lease at inception. Leases are classified as either financing or operating, with classification affecting the pattern of expense recognition in the consolidated statements of operations. Under the available practical expedients for the adoption of ASC 842, Oncocyte accounts for the lease and non-lease components as a single lease component. Oncocyte recognizes right-of-use ("ROU") assets and lease liabilities for leases with terms greater than twelve months in the consolidated balance sheet. ROU assets represent the right to use an underlying asset during the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most leases do not provide an implicit rate, Oncocyte uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. Oncocyte uses the implicit rate when it is readily determinable. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. Lease terms may include options to extend or terminate the lease when it is reasonably certain that Oncocyte will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Operating leases include office leases and related ROU lease liabilities, current and long-term, in the consolidated balance sheets. Financing leases include machinery and equipment and related financing lease liabilities, current and long-term, in the consolidated balance sheets. Oncocyte discloses the amortization of our operating lease ROU assets and payments as a net amount in the consolidated statements of cash flows. Oncocyte has entered into various operating and financing leases in accordance with ASC 842 as further discussed in Note 6.

Accounting for Warrants

Oncocyte determines the accounting classification of warrants it issues, as either liability or equity classified, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, and then in accordance with ASC 815-40, and then in accordance with ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. This liability classification guidance also applies to financial instruments that may require cash or other form of settlement for transactions outside of the company's control and, in which the form of consideration to the warrant holder may not be the same as to all other shareholders in connection with the transaction. However, if a transaction is not within the company's control but the holder of the financial instrument can solely receive the same type or form of consideration as is being offered to all the shareholders in the transaction, then equity classification of the financial instrument is not precluded, if all other applicable equity classification criteria are met.

After all relevant assessments, Oncocyte concludes whether the warrants are classified as liability or equity. Liability classified warrants require fair value accounting at issuance and subsequent to initial issuance with all changes in fair value after the issuance date recorded in the statements of operations. Equity classified warrants only require fair value accounting at issuance with no changes recognized subsequent to the issuance date. Based on the above guidance and, among other factors, the fact that our warrants cannot be cash settled under any circumstance but require share settlement, all of our outstanding warrants meet the equity classification criteria and have been classified as equity. Refer to Note 7 for details about our outstanding warrants.

Revenue Recognition

Pursuant to ASC 606, and Revenue from Contracts with Customers, revenues are recognized when control of services performed is transferred to customers, in an amount that reflects the consideration Oncocyte expects to be entitled to in exchange for those services. ASC 606 provides for a five-step model that includes:

- (i) identifying the contract with a customer,*
- (ii) identifying the performance obligations in the contract,*
- (iii) determining the transaction price,*
- (iv) allocating the transaction price to the performance obligations, and*
- (v) recognizing revenue when, or as, an entity satisfies a performance obligation.*

Oncocyte determines transaction prices based on the amount of consideration we expect to receive for transferring the promised goods or services in the contract. Consideration may be fixed, variable, or a combination of both. The Company considers any constraints on the variable consideration and includes in the transaction price variable consideration to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved.

The following table presents consolidated revenues by service:

[illegible]

Pharma Services Revenue

Revenues recognized include Pharma Services performed by Oncocyte's Insight and Chronix subsidiaries for its pharmaceutical customers, including testing for biomarker discovery, assay design and development, clinical trial support, and a broad spectrum of biomarker tests. These Pharma Services are generally performed under individual scope of work ("SOW") arrangements or license agreements (together with SOW the "Pharma Services Agreements") with specific deliverables defined by the customer. Pharma Services are performed on a (i) time and materials basis or (ii) per test completed basis. Upon completion of the service to the customer in accordance with a Pharma Services Agreement, Oncocyte has the right to bill the customer for the agreed upon price (either on a per test or per deliverable basis) and recognizes Pharma Service revenue at that time. Insight identifies each service of its Pharma Service offering as a single performance obligation. Offerings include services such as recurring fees for project management, fees for storage and handling, pass through expenses for shipping or calibration, training, proficiency, reproducibility tests, etc. Chronix identifies the processing of test samples as a separate performance obligation (considered a series) within license agreements with customers.

Completion of the service and satisfaction of the performance obligation is typically evidenced by acknowledgment of completed services, and access to the report or test made available to the customer or any other form or applicable manner of delivery defined in the Pharma Services Agreements. However, for certain SOWs under which work is performed pursuant to the customer's highly customized specifications, Oncocyte has the enforceable right to bill the customer for work completed, rather than upon completion of the SOW. For those SOWs, Oncocyte recognizes revenue over a period during which the work is performed using a formula that accounts for expended efforts, generally measured in labor hours, as a percentage of total estimated efforts for the completion of the SOW. As performance obligations are satisfied under the Pharma Services Agreements, any amounts earned as revenue and billed to the customer are included in accounts receivable. Any revenues earned but not yet billed to the customer as of the date of Oncocyte's consolidated financial statements are recorded as contract assets and are included in prepaids and other current assets as of the financial statement date. Amounts recorded in contract assets are reclassified to accounts receivable in Oncocyte's consolidated balance sheets when the customer is invoiced according to the billing schedule in the contract.

As of September 30, 2024 and December 31, 2023, Oncocyte had gross accounts receivable from Pharma Services customers of \$211,000 and \$489,000, respectively. Completion of the service and satisfaction of the performance obligation is typically evidenced by acknowledgment of completed services, and access to the report or test made available to the customer or any other form or applicable manner of delivery defined in the Pharma Services Agreements. However, for certain SOWs under which work is performed pursuant to the customer's highly customized specifications, Oncocyte has the enforceable right to bill the customer for work completed, rather than upon completion of the SOW. For those SOWs, Oncocyte recognizes revenue over a period during which the work is performed using a formula that accounts for expended efforts, generally measured in labor hours, as a percentage of total estimated efforts for the completion of the SOW. As performance obligations are satisfied under the Pharma Services Agreements, any amounts earned as revenue and billed to the customer are included in accounts receivable. Any revenues earned but not yet billed to the customer as of the date of Oncocyte's consolidated financial statements are recorded as contract assets and are included in prepaids and other current assets as of the financial statement date. Amounts recorded in contract assets are reclassified to accounts receivable in Oncocyte's consolidated balance sheets when the customer is invoiced according to the billing schedule in the contract.

supportable forecast that affect the collectability of the reported amount, and historical experience. If circumstances related to customers change, estimates of the recoverability of receivables would be further adjusted. Oncocyte continuously monitors collections and payments from customers and maintains a provision for estimated credit losses and uncollectible accounts, if any, based upon its historical experience and any specific customer collection issues that have been identified. Amounts determined to be uncollectible are written off against the credit loss reserve accounts. As of September 30, 2024 and December 31, 2023, Oncocyte had an allowance for credit losses of

	2024	2023
As of September 30,	\$2,000	\$5,000
As of December 31,	\$1.4 million	\$154,000

no credit loss provisions, and the full write-off to an ending balance of zero as of December 31, 2023.

Revenues that may be recognized include licensing revenue derived from agreements with customers for exclusive rights to market Oncocyte's proprietary testing technology. Under the agreements, Oncocyte grants exclusive rights to certain trademarks and technology of Oncocyte for the purpose of marketing Oncocyte's tests within a defined geographic territory. A license agreement may specify milestone deliverables or performance obligations, for which Oncocyte recognizes revenue when its licensee confirms the completion of Oncocyte's performance obligation. A licensing agreement may also include ongoing sales support from Oncocyte and typically includes non-refundable licensing fees and per-test Pharma Services revenues discussed above, for which Oncocyte treats the licensing of the technology, trademarks, and ongoing support as a single performance obligation satisfied by the passage of time over the term of the agreement.

	2024	2023
Three Months Ended September 30,	9.32%	9.32%
Nine Months Ended September 30,	9.66%	9.66%

2024

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

exceed federally insured limits. The Company has not experienced any significant losses on its deposits of cash and cash equivalents.

Four Pharma Services customers individually represented approximately 51% of accounts receivable as of September 30, 2024. Two Pharma Services customers individually represented approximately 79% of accounts receivable as of September 30, 2023.

The following table presents consolidated revenues by service:

	Three Months Ended September 30, 2024	Three Months Ended September 30, 2023
Pharma Services	\$115	\$115

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

#000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">100</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">%</p></td> </tr></table>10.420.460.5400.570.480.4200.010.060.041111392000660000.510.200.170.120.790.13<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Cost of Revenues</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Cost of revenues generally consists of cost of materials, direct labor including benefits, bonus and stock-based compensation, equipment and infrastructure expenses, clinical sample related costs associated with performing Pharma Services and Laboratory Developed Test Services, providing deliverables according to our licensing agreements, license fees due to third-parties, and amortization of acquired intangible assets such as the customer relationship intangible assets (see Note 5). Infrastructure expenses include depreciation of laboratory equipment, allocated rent costs, leasehold improvements, and allocated information technology costs for operations at Oncocyte's CLIA laboratory in Tennessee. Costs associated with generating the revenues are recorded as the tests or services are performed regardless of whether revenue was recognized. Royalties or revenue share payments for licensed technology calculated as a percentage of revenues generated using the associated technology are recorded as expenses at the time the related revenues are recognized.</p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Research and Development Expenses</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Research and development expenses are comprised of costs incurred to develop technology, which include salaries and benefits (including stock-based compensation), laboratory expenses (including reagents and supplies used in research and development laboratory work), infrastructure expenses (including allocated facility occupancy costs), and contract services and other outside costs. Indirect research and development expenses are allocated primarily based on headcount, as applicable, and include rent and utilities, common area maintenance, telecommunications, property taxes and insurance. Research and development costs are expensed as incurred. Certain research and development expenses are attributed to our collaboration arrangement with Bio-Rad, our global strategic partner, for commercializing our RUO kitted tests and IVD kitted transplant testing products. See Note 10, "Collaborative Arrangements" for additional information.</p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Sales and Marketing Expenses</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Sales and marketing expenses consist primarily of personnel costs and related benefits, including stock-based compensation, trade show expenses, branding and positioning expenses, and consulting fees. Sales and marketing expenses also include indirect expenses for applicable overhead allocated based on headcount, and include allocated costs for rent and utilities, common area maintenance, telecommunications, property taxes and insurance. During the three months ended September 30, 2024 and 2023, Oncocyte's total advertising expenses were \$40,000 and \$46,000, respectively. During the nine months ended September 30, 2024 and 2023, Oncocyte's total advertising expenses were \$123,000 and \$125,000, respectively. Certain sales and marketing expenses are attributed to our collaboration arrangement with Bio-Rad, our global strategic partner, for commercializing our RUO kitted tests and IVD kitted transplant testing products. See Note 10, "Collaborative Arrangements" for additional information.</p>4000046000123000125000<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">General and Administrative Expenses</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">General and administrative expenses consist primarily of compensation and related benefits (including stock-based compensation) for executive and corporate personnel, professional and consulting fees, rent and utilities, common area maintenance, telecommunications, property taxes and insurance.</p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Stock-Based Compensation</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Oncocyte recognizes compensation expense related to employee, Board of Director and other non-employee option grants and restricted stock grants in accordance with ASC 718, Compensation - Stock Compensation.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Oncocyte estimates the fair value of stock-based payment awards on the grant date and recognizes the resulting fair value over the requisite service period, which is generally a four-yearvesting period. For stock-based awards that vest only upon the attainment of one or more performance goals set by Oncocyte at the time of the grant (sometimes referred to as milestone vesting), compensation cost is recognized if and when Oncocyte determines that it is probable that the performance condition or conditions will be, or have been, achieved. Oncocyte uses the Black-Scholes option pricing model for estimating the fair value of time-based options granted under Oncocyte's equity plan. The fair value of each restricted stock unit ("RSU") or award is determined by the product of the number of units or shares granted and the grant date market price of the underlying common stock. Oncocyte has elected to treat stock-based payment awards with graded vesting schedules and time-based service conditions as a single award and recognizes stock-based compensation ratably on a straight-line basis over the requisite service period. Options have a maximum contractual term of ten yearsForfeitures are accounted for as they occur. Refer to Note 8 for additional information.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The Black-Scholes option pricing model requires Oncocyte to make certain assumptions including the expected option term, the expected volatility, the risk-free interest rate and the dividend yield. The expected term of employee stock options represents the weighted average period that the stock options are expected to remain outstanding. Oncocyte estimates the expected term of options granted based on its own experience. Oncocyte estimates the expected volatility using its own stock price volatility for a period equal to the expected term of the options. The risk-free interest rate assumption is based upon observed interest rates on the United States government securities appropriate for the expected term of Oncocyte's stock options. The dividend yield assumption is based on Oncocyte's history and expectation of dividend payouts. Oncocyte has never declared or paid any cash dividends on its common stock, and Oncocyte does not anticipate paying any cash dividends in the foreseeable future.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">All excess tax benefits and tax deficiencies from stock-based compensation awards accounted for under ASC 718 are recognized as income tax benefit or expense, respectively, in the statements of operations. An excess income tax benefit arises when the tax deduction of a share-based award for income tax purposes exceeds the compensation cost recognized for financial reporting purposes and, a tax deficiency arises when the compensation cost exceeds the tax deduction. Because Oncocyte has a full valuation allowance for all periods presented (see "Income Taxes" below), there was no impact to Oncocyte statements of operations for any excess tax benefits or deficiencies, as any excess benefit or deficiency would be offset by the change in the valuation allowance.</p>P4YP10Y<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Retirement Plan</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-

0;text-align:justify;">Oncocyte has an employee savings and retirement plan under Section 401(k) of the Internal Revenue Code. The plan is a defined contribution plan in which eligible employees may elect to have a percentage of their compensation contributed to the plan, subject to certain guidelines issued by the Internal Revenue Service. During the three months ended September 30, 2024 and 2023, Oncocyte's total contributions to the plan were \$81,000 and \$67,000, respectively. During the nine months ended September 30, 2024 and 2023, Oncocyte's total contributions to the plan were \$248,000 and \$245,000, respectively.</p><p>8100067000248000245000<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Collaborative Arrangements<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808,Collaborative Arrangements, which includes determining whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. To the extent that the arrangement falls within the scope of ASC 808, the Company assesses whether the payments between the Company and its collaboration partner fall within the scope of other accounting literature. If the Company concludes that payments from the collaboration partner to the Company would represent consideration from a customer, the Company accounts for those payments within the scope of ASC 606. However, if the Company concludes that its collaboration partner is not a customer for certain activities and associated payments, the Company presents such payments as a reduction of research and development expense or general and administrative expense, based on where the Company presents the underlying expense. See Note 10, "Collaborative Arrangements" for additional information.</p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Income Taxes<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The provision for income taxes for interim periods is determined using an estimated annual effective tax rate in accordance with ASC 740-270.Income Taxes, Interim Reporting. The effective tax rate may be subject to fluctuations during the year as new information is obtained, which may affect the assumptions used to estimate the annual effective tax rate, including factors such as valuation allowances against deferred tax assets, the recognition or de-recognition of tax benefits related to uncertain tax positions, if any, and changes in or the interpretation of tax laws in jurisdictions where Oncocyte conducts business.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Oncocyte did not record any provision or benefit for income taxes for the three and nine months ended September 30, 2024 and 2023, as Oncocyte had a full valuation allowance for the periods presented.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">A valuation allowance is provided when it is more likely than not that some portion of the deferred tax assets will not be realized. Oncocyte established a full valuation allowance for all periods presented due to the uncertainty of realizing future tax benefits from its net operating loss carry-forwards and other deferred tax assets.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The guidance also prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not sustainable upon examination by taxing authorities. Oncocyte will recognize accrued interest and penalties related to unrecognized tax benefits as income tax expense.No amounts were accrued for the payment of interest and penalties as ofSeptember 30, 2024 and December 31, 2023.Oncocyte is not aware of any uncertain tax positions that could result in significant additional payments, accruals, or other material deviation as of September 30, 2024. Oncocyte is currently unaware of any tax issues under review. As of September 30, 2024 and December 31, 2023, the Company had unrecognized tax benefits totaling2.3 million.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">On June 27, 2024, California enacted SB-167, which suspends the use of California net operating loss and limits the use of California research tax credits to5.0 million each year for our fiscal years 2025-2027.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">On June 29, 2024, California enacted SB-175, which provides a refund mechanism for the incremental tax that was paid as a result of SB-167. The Company is evaluating the impact of the law changes but does not expect these law changes to have a material impact on the Company's consolidated financial statements.</p><p>0023000002300000<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Net Loss Per Common Share<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Basic loss per share is computed by dividing the net loss applicable to common stockholders after deducting cumulative unpaid dividends and accretion of the preferred stock, by the weighted average number of shares of common stock outstanding during the year. The 2024 weighted average shares outstanding - basic in the following table includes the effects of pre-funded warrants that were issued in April 2024 (refer to Note 7, "Common Stock Purchase Warrants" for additional information). Diluted loss per share is computed by dividing the net loss applicable to common stockholders after deducting cumulative unpaid dividends and accretion of the preferred stock, by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued, using the treasury stock method or the if-converted method, or the two-class method for participating securities, whichever is more dilutive. Potential common shares are excluded from the computation if their effect is antidilutive.</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">For the three andnine months ended September 30, 2024 and 2023, all common stock equivalents are antidilutive because Oncocyte reported a net loss. The following table presents the calculation of basic and diluted loss per share of common stock:</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:55.049%;box-sizing:content-box;"></td><td style="width:1.34%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:7.898%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.34%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:7.898%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.34%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:7.898%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.34%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:7.898%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"&

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

<table border=

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

**space-pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, to improve financial reporting by requiring disclosure of incremental segment information on an annual and interim basis for all public entities to enable investors to develop more decision-useful financial analyses. The amendments in this Update: (i) require enhanced disclosures about significant segment expenses, (ii) clarify that if the chief operating decision maker ("CODM") uses more than one measure of a segment's profit or loss, a public entity may report one or more of those additional measures of segment profit or loss, (iii) require disclose of the title and position of the CODM and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources, and (iv) require that a public entity that has a single reportable segment provide all the disclosures required by the amendments in this Update and all existing segment disclosures in Topic 280. The amendments in this Update should be applied retrospectively, and are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. Management is currently evaluating the impact that the amendments in this Update will have on the Company's financial statement disclosures. The adoption of this new standard will not have an impact on the Company's consolidated balance sheets and consolidated statements of operations, comprehensive loss, shareholders' equity and cash flows.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, to address investor requests for more transparency about income tax information by requiring improvements to income tax disclosures, including, (i) consistent categories and greater disaggregation of information in the rate reconciliation, and (ii) income taxes paid disaggregated by jurisdiction. Additional amendments in this Update improve the effectiveness and comparability of disclosures by, (i) adding disclosures of pretax income (or loss) and income tax expense (or benefit), and (ii) removing disclosures that no longer are considered cost beneficial or relevant. The amendments in this Update should be applied prospectively (retrospective application is permitted) and are effective for annual periods beginning after December 15, 2024, with early adoption permitted. Management is currently evaluating the impact that the amendments in this Update will have on the Company's financial statement disclosures. The adoption of this new standard will not have an impact on the Company's consolidated balance sheets and consolidated statements of operations, comprehensive loss, shareholders' equity and cash flows.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">In November 2024, the FASB issued ASU No. 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, to address investor requests for more detailed information about certain types of reported costs and expenses. The amendments in this Update require disclosure, in the notes to financial statements, at each interim and annual reporting period an entity: 1) disclose the amounts of (a) purchases of inventory, (b) employee compensation, (c) depreciation, and (d) intangible asset amortization included in each expense caption presented on the face of the income statement within continuing operations; 2) include certain amounts that are already required to be disclosed under current GAAP in the same disclosure as the other disaggregation requirements; 3) disclose a qualitative description of the amounts remaining that are not separately disaggregated quantitatively; and 4) disclose the total amount of selling expenses and, in annual reporting periods, an entity's definition of selling expenses. The amendments in this Update should be applied either prospectively or retrospectively, and are effective for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027, with early adoption permitted. Management is currently evaluating the impact that the amendments in this Update will have on the Company's financial statement disclosures. The adoption of this new standard will not have an impact on the Company's consolidated balance sheets and consolidated statements of operations, comprehensive loss, shareholders' equity and cash flows.</p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">3. Business Combinations and Contingent Consideration Liabilities</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Acquisition of Insight Genetics, Inc.</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">On January 31, 2020 (the "Insight Merger Date"), Oncocyte completed its acquisition of Insight pursuant to the Insight Merger Agreement. Oncocyte determined there are two types of contingent consideration in connection with the Insight Merger, the Milestone Contingent Consideration and the Royalty Contingent Consideration discussed below.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">There were three milestones comprising the Milestone Contingent Consideration, in connection with the Insight Merger which Oncocyte valued and recorded as part of the contingent consideration as of the Insight Merger Date (see table below), which consisted of (i) a payment for clinical trial completion and related data publication ("Milestone 1"), (ii) a payment for an affirmative final LCD from CMS for a specified lung cancer test ("Milestone 2"), and (iii) a payment for achieving specified CMS reimbursement milestones ("Milestone 3"). If achieved, any respective Milestone will be paid at the contractual value shown below, with the payment made either in cash or in shares of Oncocyte's common stock as determined by Oncocyte. There can be no assurance that any of the Milestones will be achieved.</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The following table shows the Insight Merger Date contractual payment amounts, as applicable, and the corresponding fair value of each respective contingent consideration liability:</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:66.993%;box-sizing:content-box;"></td><td style="width:1.62%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.883000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.883000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"></td><td style="vertical-align:bottom;text-align:left;"></td></tr><tr style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><td style="color:#000000:white-space:pre-wrap;font-weight:bold;min-width:fit-content;"></td><td style="vertical-align:bottom;"></td><td style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"></td><td style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></td><td style="color:#000000:white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Contractual
Value</td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff;text-align:left;"></td><td style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></td><td style="color:#000000:white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value on the
Merger Date</td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff;text-align:left;"></td><td style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></td><td style="color:#000000:white-space:pre-wrap;font-weight:bold;min-width:fit-content;"></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff;text-align:left;"></td><td style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></td><td style="color:#000000:white-space:pre-wrap;font-weight:bold;min-width:fit-content;"></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff;text-align:left;"></td><td style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></td><td style="color:#000000:white-space:pre-wrap;font-weight:bold;min-width:fit-content;"></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff;text-align:left;"></td><td style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></td><td style="color:#000000:white-space:pre-wrap;font-weight:bold;min-width:fit-content;"></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff;text-align:left;"></td><td style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></td><td style="color:#000000:white-space:pre-wrap;font-weight:bold;min-width:fit-content;"></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff;text-align:left;"></td><td style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></td><td style="color:#000000:white-space:pre-wrap;font-weight:bold;min-width:fit-content;"></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff;text-align:left;"></td><td style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></td><td style="color:#000000:white-space:pre-wrap;font-weight:bold;min-width:fit-content;"></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff;text-align:left;"></td><td style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></td><td style="color:#000000:white-space:pre-wrap;font-weight:bold;min-width:fit-content;"></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff;text-align:left;"></td><td style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></td><td style="color:#000000:white-space:pre-wrap;font-weight:bold;min-width:fit-content;"></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff;text-align:left;"></td><td style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></td><td style="color:#000000:white-space:pre-wrap;font-weight:bold;min-width:fit-content;"></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff;text-align:left;"></td><td style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></td><td style="color:#000000:white-space:pre-wrap;font-weight:bold;min-width:fit-content;"></td><td style="**

[illegible]

font-size: 10pt; font-family: Times New Roman; margin-bottom: 0; text-align: right;

<p style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.25pt double #ffffff03;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;"></p></td></tr></table><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;"></p><div class="item-list-element-wrapper" style="display: flex; margin-top: 0; justify-content: flex-start; align-items: baseline; margin-bottom: 0; min-width: 4.537%; text-align: left;">(a)<div style="width: 100%; display: inline;">Indicates the maximum amount payable if the Milestone is achieved.</div><div class="item-list-element-wrapper" style="display: flex; margin-top: 0; justify-content: flex-start; align-items: baseline; margin-bottom: 0; min-width: 4.537%; text-align: justify;">(b)<div style="width: 100%; display: inline;">As defined, Royalty Payments are based on a percentage of future revenues of DetermaIO and Pharma Services over their respective useful life, accordingly there is no fixed contractual value for the Royalty Contingent Consideration.</div></div><p style="font-size: 10pt; margin-top: 12pt; font-family: Times New Roman; margin-bottom: 0; text-align: justify;">The fair value of the contingent consideration after the Insight Merger Date is reassessed by Oncocyte as changes in circumstances and conditions occur, with the subsequent change in fair value recorded in Oncocyte's consolidated statements of operations. Since December 2023, Milestone 1 and Royalty 2 (Pharma Services) are not expected to be paid and are excluded from the current fair value. During 2024, based on Oncocyte's reassessment of significant assumptions, there was an increase of approximately\$30,000to the fair value of the contingent consideration primarily attributable to revised estimates of the possible future payouts and, accordingly, this increase was recorded as change in fair value of contingent consideration in the consolidated statement of operations for the nine months ended September 30, 2024.</p><p style="font-size: 10pt; margin-top: 12pt; font-family: Times New Roman; margin-bottom: 0; text-align: justify;">Oncocyte uses a discounted cash flow valuation technique to determine the fair value of its Level 3 contingent consideration liabilities.The significant unobservable inputs used in Insight's contingent consideration valuation onSeptember 30, 2024, included: (i) a discount period, based on the expected Milestone payment dates, ranging from1.7years to8.0yearsand (ii) a discount rate of13.3% to13.5%and (iii) a management probability estimate of25% to50%and (iii) a management probability estimate of15.2% to15.4%and (iii) a management probability estimate of15% to50%Changes to significant unobservable inputs to different amounts could result in a significantly higher or lower fair value measurement at the reporting date.</p><div style="font-size: 10pt; font-family: Times New Roman;"><p style="font-size: 10pt; margin-top: 12pt; font-family: Times New Roman; margin-bottom: 0; text-align: justify;">The following tables reflect the activity for the Insight contingent consideration measured at fair value using Level 3 inputs:</p><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;"></p><table style="margin-left: auto; border-spacing: 0; table-layout: fixed; width: 100.0%; border-collapse: separate; margin-right: auto;"><tr style="height: 8pt; background-color: #ffffff; white-space: pre-wrap; word-break: break-word;"><td style="vertical-align: bottom; text-align: left;"><p style="font-size: 8pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;"></p></td><td style="vertical-align: bottom;"><p style="font-size: 8pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;">Fair Value</p></td><td style="vertical-align: bottom; border-bottom: 0.5pt solid #ffffff03; text-align: left;"><p style="font-size: 8pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;"></p></td><tr style="height: 8pt; background-color: #ffffff; white-space: pre-wrap; word-break: break-word;"><td style="vertical-align: bottom; text-align: left;"><p style="font-size: 8pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;">Balance at December 31, 2022</p></td><td style="vertical-align: bottom;"><p style="font-size: 8pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;"></p></td><td style="vertical-align: bottom; border-bottom: 0.5pt solid #ffffff03; text-align: left;"><p style="font-size: 8pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;"></p></td><tr style="height: 10pt; background-color: #cfcf0c; word-break: break-word;"><td style="vertical-align: bottom; text-align: left;"><p style="font-size: 8pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;"></p></td><td style="vertical-align: bottom; text-align: left;"><p style="font-size: 8pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;"></span

[illegible]

[illegible]

[illegible]

vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,830</p></td><td style="white-space:nospace;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#cfff0f;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Milestone 3 (a)</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">>1,500</p></td><td style="white-space:nospace;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">>770</p></td><td style="white-space:nospace;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Royalty 1 (b)</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">>See(b)</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nospace;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">>1,210</p></td><td style="white-space:nospace;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">>6,000</p></td><td style="white-space:nospace;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nospace;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">>11,130</p></td><td style="white-space:nospace;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><tr><table style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;">(a)<div style="width:100%;display:inline;">Indicates the maximum amount payable if the Milestone is achieved.</div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;">(b)<div style="width:100%;display:inline;">As defined, Royalty Payments are based on a percentage of future revenues of DetermaIO and Pharma Services over their respective useful life, accordingly there is no fixed contractual value for the Royalty Contingent Consideration.</div></div>1500000134000030000001830000150000077000059800001210000600000011130000300000The significant unobservable inputs used in Insight's contingent consideration valuation on September 30, 2024, included: (i) a discount period, based on the expected Milestone payment dates, ranging from 1.7 years to 8.0 years, (ii) a discount rate of 13.3% to 13.5%, and (iii) a management probability estimate of 25% to 50%. The significant unobservable inputs used in Insight's contingent consideration valuation on September 30, 2023, included: (i) a discount period, based on the expected Milestone payment dates, ranging from 0.50 years to 1.5 years, (ii) a discount rate of 15.2% to 15.4%, and (iii) a management probability estimate of 15% to 50%.PIY8MJ12DP8Y0.1330.1350.250.50POY6MPIY6M0.1520.1540.150.50<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The following tables reflect the activity for the Insight contingent consideration measured at fair value using Level 3 inputs:</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:80.236%;box-sizing:content-box;"></td><td style="width:1.94%;box-

Fair Value

Balance at December 31, 2022

Balance at September 30, 2023

Balance at December 31, 2023

The significant unobservable inputs used in Chronix's contingent consideration valuation on September 30, 2024, included:

(i) a discount period, based on the related patent expiration dates, ranging from 9.1 years to 11.0 years,	(ii) a discount rate of 13.3% to 14.3%, and	(iii) a payout percentage of 10% based on the earnout provision.
The significant unobservable inputs used in Chronix's contingent consideration valuation on September 30, 2023, included:	(i) a discount period, based on the related patent expiration dates, ranging from 10.4 years to 12.2 years,	(ii) a discount rate of 15.5% to 16.4%, and
(iii) a payout percentage of 10% based on the earnout provision.	P9Y1M6DP11Y0.1330.1430.10P10Y4M24DP12Y2M12D0.1550.1640.10	p style="font-size: 10pt; margin-top: 12pt; font-family: Times New Roman; margin-bottom: 0; text-align: justify;">The following tables reflect the activity for the Chronix contingent consideration measured at fair value using Level 3 inputs:

[illegible]

[illegible]

[illegible]

[illegible]

min-width:fit-content;"/></p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,436</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr>

</table>53230004036000792300069090007053000623500061930004710000302000726000649500054360003180004040009350001300000180

**style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">5. Intangible Assets, Net</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">As part of the Insight and Chronix acquisitions completed on January 31, 2020 and April 15, 2021, respectively, the Company has acquired IPR&D and customer relationships (see Note 3).</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">During the first quarter of 2023, due to changes in management and the economic condition of the Company, management shifted the Company's business strategy to direct efforts on fewer studies and to transition from tests that are laboratory developed tests to RUO. Due to the change in strategy, the Company's long range plan forecasts were updated, resulting in a change to anticipated future benefits derived from the Company's assets. The change in strategy represented a significant indicator for change in value of the Company's long-lived assets. The original IPR&D balances were reassessed based on the updated long range plan, using the multi-period excess earnings method ("MPEEM") approach. The results of the valuation noted that the carrying value of the DetermaIO related IPR&D intangible assets was greater than the fair market value, whereas the carrying values of the CNI and VitaGraft related IPR&D intangible assets were lower than the fair market value. Accordingly, the Company recorded an impairment of approximately \$5.0</p> million related to DetermaIO as of March 31, 2023. During the fourth quarter of 2023, the IPR&D balances were reassessed using the MPEEM approach and the results of the valuation noted that the carrying values of the DetermaIO, CNI and VitaGraft related IPR&D intangible assets were lower than the fair market value. Accordingly, the Company did not record any additional adjustment as of December 31, 2023, and no such adjustments have been recorded in 2024.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The MPEEM valuation approach is a discounted cash flow valuation technique and was used to determine the Level 3 fair value of Insight's IPR&D discussed above.The significant unobservable inputs used as of March 31, 2023, included: (i) a discount period of 20.0 years, based on the expected life of patent, (ii) a royalty rate of 0.3, and (iii) a weighted average cost of capital rate of 30.0%. This valuation approach yielded a fair value of \$9.7 million as of March 31, 2023. As market conditions change, the Company will re-evaluate assumptions used in the determination of fair value for IPR&D and is uncertain to the extent of the volatility in the unobservable inputs in the foreseeable future.</p>Refer to Note 2, "Intangible Assets" for additional IPR&D information.</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Intangible assets, net, consisted of the following:</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"></p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:66.993%;box-sizing:content-box;"></td><td style="width:1.62%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.883000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.62%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.883000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">September 30,
2024</p><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">December 31,
2023</p><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p><td style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p><td style="height:10pt;background-color:#cfff0c;white-space:pre-wrap;word-break:break-word;"></td><td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p><td style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"></p><td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"></p><td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"></p><td style="height:10pt;background-color:#ffffff;word-break:break-word;"></td><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Acquired IPR&D - DetermaIOTM</p>(1)</p><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Acquired IPR&D - DetermaIOTM</p>(1)</p><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Acquired IPR&D - DetermaIOTM</p><span style**

[illegible]

[illegible]

space:nowrap;vertical-align:bottom;"/>
<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><p></td></tr><tr style="height:10pt;background-color:#c0c0c0;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2025<p></td><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7<p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total<p></td><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$(<p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">29<p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><p></td></tr></table></div>5000000 The significant unobservable inputs used as of March 31, 2023, included: (i) a discount period of 20.0 years, based on the expected life of patent, (ii) a royalty rate of 0.3%, and (iii) a weighted average cost of capital rate of 30.0%. This valuation approach yielded a fair value of \$9.7 million as of March 31, 2023. As market conditions change, the Company will re-evaluate assumptions used in the determination of fair value for IPR&D and is uncertain to the extent of the volatility in the unobservable inputs in the foreseeable future.P20Y0.0030.309700000<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Intangible assets, net, consisted of the following:<p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:66.993%;box-sizing:content-box;"></td><td style="width:1.62%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.883000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.62%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.883000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">September 30,
2024<p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">December 31,
2023<p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><p></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">(In thousands)<p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><p></td><td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><p></td></tr><tr style="height:10pt;background-color:#c0c0c0;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Intangible assets:<p></td><td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><p></td><td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><p></td><td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><p></td><td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Acquired IPR&D - DetermaIOTM(1)<p></td><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">9,700<p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9,700<p></td><td style="white-space:nowrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9,700<p></td><td style="white-space:nowrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="min

[illegible]

[illegible]

space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Irvine Office Lease

On December 23, 2019, Oncocyte and Cushing Ventures, LLC ("Landlord") entered into an Office Lease Agreement (the "Irvine Lease") of a building containing approximately 26,800 square feet of rentable space located at 15 Cushing in Irvine, California (the "Premises") that serves as Oncocyte's principal executive and administrative offices.

The Irvine Lease has an initial term of 89 calendar months (the "Term"), which commenced on June 1, 2020 (the "Commencement Date") and will end in September of 2027.

Oncocyte has an option to extend the Term for a period of five years (the "Extended Term").

Oncocyte agreed to pay base monthly rent in the amount of \$61,640 during the first 12 months of the Term. Base monthly rent increases annually, over the base monthly rent then in effect, by 3.5%. Oncocyte was entitled to an abatement of 50% of the base monthly rent during the first ten calendar months of the Term. If the Irvine Lease is terminated based on the occurrence of an "event of default," Oncocyte will be obligated to pay the abated rent to the lessor.

If Oncocyte exercises its option to extend the Term, the initial base monthly rent during the Extended Term will be the greater of the base monthly rent in effect during the last year of the Term or the prevailing market rate. The prevailing market rate will be determined based on annual rental rates per square foot for comparable space in the area where the Premises are located. If Oncocyte does not agree with the prevailing market rate proposed by the lessor, the rate may be determined through an appraisal process. The base monthly rent during the Extended Term shall be subject to the same annual rent adjustment as applicable for base monthly rent during the Term.

In addition to base monthly rent, Oncocyte agreed to pay in monthly installments (a) all costs and expenses, other than certain excluded expenses, incurred by the lessor in each calendar year in connection with operating, maintaining, repairing (including replacements if repairs are not feasible or would not be effective) and managing the Premises and the building in which the Premises are located ("Expenses"), and (b) all real estate taxes and assessments on the Premises and the building in which the Premises are located, all personal property taxes for property that is owned by lessor and used in connection with the operation, maintenance and repair of the Premises, and costs and fees incurred in connection with seeking reductions in such tax liabilities ("Taxes"). Subject to certain exceptions, Expenses shall not be increased by more than 4% annually on a cumulative, compounded basis.

Oncocyte was entitled to an abatement of its obligations to pay Expenses and Taxes while constructing improvements to the Premises constituting "Tenant's Work" under the Irvine Lease prior to the Commencement Date, except that Oncocyte was obligated to pay 43.7% of Expenses and Taxes during the period prior to the Commencement Date for its use of the second floor of the Premises, which was already built out as office space.

The lessor provided Oncocyte with a "Tenant Improvement Allowance" in the amount of \$1.3 million to pay for the plan, design, permitting, and construction of the improvements constituting Tenant's Work. The lessor retained 1.5% of the Tenant Improvement Allowance as an administrative fee as provided in the Irvine Lease. As of June 2021, the lessor had provided \$1.3 million of the total Tenant Improvement Allowance, which is being amortized over the Term.

Oncocyte has provided the lessor with a security deposit in the amount of \$150,000 and a letter of credit in the amount of \$1.7 million. The lessor may apply the security deposit, in whole or in part, for the payment of rent and any other amount that Oncocyte is or becomes obligated to pay under the Irvine Lease but fails to pay when due and beyond any cure period. The lessor may draw on the letter of credit from time to time to pay any amount that is unpaid and due, or if the original issuing bank notifies the lessor that the letter of credit will not be renewed or extended for the period required under the Irvine Lease and Oncocyte fails to timely provide a replacement letter of credit, or an event of default under the Irvine Lease occurs and continues beyond the applicable cure period, or if certain instances of insolvency or bankruptcy with respect to Oncocyte occur. Oncocyte is required to restore any portion of the security deposit that is applied by the lessor to payments due under the Irvine Lease, and Oncocyte is required to restore the amount available under the letter of credit to the required amount if any portion of the letter of credit is drawn by the lessor. The Irvine Lease provides that commencing on the 34th month of the Term, (a) the amount of the letter of credit that Oncocyte is required to maintain shall be reduced on a monthly basis, in equal installments, to amortize the required amount to zero at the end of the Term, and (b) Oncocyte has the right to cancel the letter of credit at any time if it meets certain market capitalization and balance sheets thresholds; provided, in each case, that Oncocyte is not then in default under the Irvine Lease beyond any applicable notice and cure period and the lessor has not determined that an event exists that would lead to an event of default. As of September 30, 2024, Oncocyte was not in default based on any provision of the Irvine Lease, however, neither of the provisions discussed in the preceding sentence were available to Oncocyte based on the lessor's related rights.

To obtain the letter of credit, Oncocyte has provided the issuing bank with a restricted cash deposit that the bank will hold to cover its obligation to pay any draws on the letter of credit by the lessor. The restricted cash may not be used for any other purpose. Accordingly, Oncocyte has reflected \$1.7 million as restricted cash in the accompanying consolidated balance sheets as of September 30, 2024 and December 31, 2023.

Irvine Office Sublease

align:justify; ">On August 8, 2023, Oncocyte and Induce Biologics USA, Inc. ("Subtenant") entered into a Sublease Agreement (the "Sublease Agreement"), which subsequently became effective as of September 14, 2023, upon the execution and delivery by the Company, Subtenant, and Landlord, of that certain Landlord's Consent to Sublease dated September 12, 2023 (the "Consent Agreement"), under which Landlord consented to the Sublease Agreement, on the terms and subject to the conditions set forth therein. The Sublease Agreement is subject and subordinate to the Irvine Lease.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Under the Sublease Agreement, the Company agreed to initially sublet to Subtenant a portion of the Premises consisting of approximately 13,400 square feet of rentable space for a term (the "Initial Period") commencing on the date that is 120 days after the effective date of the Consent Agreement (the "Sublease Commencement Date") and ending on the date that is 18 months following the Sublease Commencement Date or such earlier date as Subtenant may elect upon the exercise of its one-time option to accelerate such date upon 90 days prior written notice to the Company (the date on which the Initial Period ends, the "Expansion Date"). On the Expansion Date, the portion of the Premises that is subleased to Subtenant under the Sublease Agreement will automatically increase to include the remaining portion of the Premises, which consists of approximately 13,400 square feet of additional rentable space for a term (the "Expansion Period") beginning on the Expansion Date through the expiration of the Irvine Lease on October 31, 2027, unless earlier terminated.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The Sublease Agreement provides that, from and after the Sublease Commencement Date, Subtenant will pay to the Company monthly base rent in the following amounts: (i) 36,850 for rental periods beginning on the Sublease Commencement Date and ending on or before December 31, 2024 (subject to adjustment in the event that Subtenant exercises its option to accelerate the Expansion Date, such that the Expansion Period begins prior to December 31, 2024); (ii) 37,955 for rental periods beginning on or after January 1, 2025 and ending on or before June 20, 2025 (subject to adjustment in the event that Subtenant exercises its option to accelerate the Expansion Date, such that the Expansion Period begins prior to June 20, 2025); (iii) 75,844 for rental periods beginning on or after July 1, 2025 and ending on or before December 31, 2025; (iv) 78,188 for rental periods beginning on or after January 1, 2026 and ending on or before December 31, 2026; and (v) 80,534 for rental periods beginning on or after January 1, 2027 and ending on or before October 31, 2027.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Following the Sublease Commencement Date, Subtenant is responsible for the payment of Additional Rent, including Expenses and Taxes (as each such term is defined in the Irvine Lease), provided that, with respect to the Initial Period, Subtenant will be responsible for only 50 % of the Expenses and Taxes due. In addition, Subtenant will pay the Company a security deposit in the amount of 101,987 in connection with the transactions contemplated by the Sublease Agreement.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The Sublease Agreement contains customary provisions with respect to, among other things, Subtenant's obligation to comply with the Irvine Lease and applicable laws, the payment of utilities and similar services utilized by Subtenant with respect its use of the Premises, the indemnification of the Company by Subtenant, and the right of the Company to terminate the Sublease Agreement in its entirety and retake the Premises if Subtenant fails to remedy certain defaults of its obligations under the Sublease Agreement within specified time periods.</p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Nashville Leases</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Insight operates a CLIA-certified laboratory and has additional office space located at 2 International Plaza, Nashville, Tennessee, under lease arrangements with MPC Holdings, LLC. As of December 31, 2023, the Company had Nashville office leases that comprised 8,362 square feet of rentable office space with a term ending April 2024, On January 1, 2024, the Company renewed its exiting leases with MPC Holdings, LLC and added a new lease agreement to further expand its Nashville office space. The new lease contains 2,319 square feet for an aggregate of 10,681 square feet of rentable space as of September 30, 2024, Lab space is approximately 4,826 square feet of the total. The new lease agreements each have an initial term of 36 months, which commenced on January 1, 2024 and will end in January 2027, The Company has the option to renew the term of each lease for four additional one year periods.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Financing Leases</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">As of September 30, 2024, Oncocyte had various financing leases for certain laboratory equipment, as shown in the tables below. As of December 31, 2023, Oncocyte had

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

"color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman,min-width:fit-content;">and ">183,000">, which was net of sublease income of ">">111,000"> and ">">28,000">, for the three months ended September 30, 2024 and 2023, respectively. The Company incurred total lease cost, including short-term lease expense, of ">">532,000"> and ">">636,000">, which was net of sublease income of ">">332,000"> and ">">64,000">, for the nine months ended September 30, 2024 and 2023, respectively.</p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">">Litigation - General</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">">Oncocyte may be subject to various claims and contingencies in the ordinary course of its business, including those related to litigation, business transactions, employee-related matters, and other matters. When Oncocyte is aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, Oncocyte will record a liability for the loss. If the loss is not probable or the amount of the loss cannot be reasonably estimated, Oncocyte discloses the claim if the likelihood of a potential loss is reasonably possible and the amount involved could be material.</p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">">Tax Filings</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">">Oncocyte tax filings are subject to audit by taxing authorities in jurisdictions where it conducts business. These audits may result in assessments of additional taxes that are subsequently resolved with the authorities or potentially through the courts. Management believes Oncocyte has adequately provided for any ultimate amounts that are likely to result from these audits; however, final assessments, if any, could be significantly different than the amounts recorded in the consolidated financial statements.</p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">">Employment Contracts</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">">Oncocyte has entered into employment and severance benefit contracts with certain executive officers. Under the provisions of the contracts, Oncocyte may be required to incur severance obligations for matters relating to changes in control, as defined in the respective contracts, and certain terminations of executives. As of September 30, 2024 and December 31, 2023, Oncocyte has accrued approximately ">2.3"> million, and ">2.7"> million, respectively, in severance obligations for certain executive officers, in accordance with the severance benefit provisions of their respective employment and severance benefit agreements, primarily related to Oncocyte's acquisition of Chronix in 2021. For the periods presented, management has classified ">2.3"> million of the accrued severance obligations related to the Chronix acquisition as current based on our expectations of the timing of product commercialization and subsequent revenues that trigger the payouts.</p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">">Indemnification</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">">In the normal course of business, Oncocyte may provide indemnification of varying scope under Oncocyte's agreements with other companies or consultants, typically Oncocyte's clinical research organizations, investigators, clinical sites, suppliers and others. Pursuant to these agreements, Oncocyte will generally agree to indemnify, hold harmless, and reimburse the indemnified parties for losses and expenses suffered or incurred by the indemnified parties arising from claims of third parties in connection with the use or testing of Oncocyte's diagnostic tests. Indemnification provisions could also cover third party infringement claims with respect to patent rights, copyrights, or other intellectual property pertaining to Oncocyte's diagnostic tests. Oncocyte's office and laboratory facility leases also will generally contain indemnification obligations, including obligations for indemnification of the lessor for environmental law matters and injuries to persons or property of others, arising from Oncocyte's use or occupancy of the leased property. The term of these indemnification agreements will generally continue in effect after the termination or expiration of the particular research, development, services, lease, or license agreement to which they relate. The Razor Stock Purchase Agreement also contains provisions under which Oncocyte has agreed to indemnify Razor and Encore Clinical, Inc., a former stockholder of Razor, from losses and expenses resulting from breaches or inaccuracy of Oncocyte's representations and warranties and breaches or nonfulfillment of Oncocyte's covenants, agreements, and obligations under the Razor Stock Purchase Agreement. Oncocyte periodically enters into underwriting and securities sales agreements with broker-dealers in connection with the offer and sale of Oncocyte securities. The terms of those underwriting and securities sales agreements include indemnification provisions pursuant to which Oncocyte agrees to indemnify the broker-dealers from certain liabilities, including liabilities arising under the Securities Act of 1933, as amended (the "Securities Act"), in connection with the offer and sale of Oncocyte securities. The potential future payments Oncocyte could be required to make under these indemnification agreements will generally not be subject to any specified maximum amounts. Historically, Oncocyte has not been subject to any claims or demands for indemnification. Oncocyte also maintains various liability insurance policies that limit Oncocyte's financial exposure. As a result, Oncocyte management believes that the fair value of these indemnification agreements is minimal. Accordingly, Oncocyte has not recorded any liabilities for these agreements as of September 30, 2024 and December 31, 2023</p><p>26800P89M2027-09Oncocyte has an option to extend the Term for a period of five years (the "Extended Term").truePY616400.0350.500.040.43713000000.015130000001500001700000170000013400134002027-10-31The Sublease Agreement provides that, from and after the Sublease Commencement Date, Subtenant will pay to the Company monthly base rent in the following amounts: (i) \$36,850 for rental periods beginning on the Sublease Commencement Date and ending on or before December 31, 2024 (subject to adjustment in the event that Subtenant exercises its option to accelerate the Expansion Date, such that the Expansion Period begins prior to December 31, 2024); (ii) \$37,955 for rental periods beginning on or after January 1, 2025 and ending on or before June 20, 2025 (subject to adjustment in the event that Subtenant exercises its option to accelerate the Expansion Date, such that the Expansion Period begins prior to June 20, 2025); (iii) \$75,844 for rental periods beginning on or after July 1, 2025 and ending on or before December 31, 2025; (iv) \$78,188 for rental periods beginning on or after January 1, 2026 and ending on or before December 31, 2026; and (v) \$80,534 for rental periods beginning on or after January 1, 2027 and ending on or before October 31, 2027.36850379557584478188805340.5010198783622024-042319106814826P36M2027-01The Company has the option to renew the term of each lease for four additional one year periods.truePY1YPIY<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">">The following table presents supplemental balance sheet information related to operating and financing leases:</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;">"></p><table

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

2

2024

(In thousands)

Cash paid for amounts included in the measurement of lease liabilities:

Operating cash flows from operating leases	
827	
Financing cash flows from financing leases	
7	
Financing cash flows from financing leases	
86	

8270007930001700070001190008600023400018300011100028000532000636000332000640002300000270000023000002300000

Series A Redeemable Convertible Preferred Stock and Shareholders' Equity

Series A Redeemable Convertible Preferred Stock

On April 13, 2022, the Company entered into a Securities Purchase Agreement with institutional accredited investors (the "Investors") in a registered direct offering of

11,765 shares of the Company's Series A Preferred Stock, which shares of Series A Preferred Stock are convertible into a total of

384,477 shares of the Company's common stock, at a conversion price of

30.60

per share. The purchase

price of each share of Series A Preferred Stock was \$850, which included an original issue discount to the stated value of \$1,000 per share. The rights, preferences and privileges of the Series A Preferred Stock are set forth in the Company's Certificate of Determination, which the Company filed with the Secretary of State of the State of California. The Securities Purchase Agreement provided that the closing of the Series A Preferred Stock offering will occur, subject to the satisfaction of certain closing conditions, in two equal tranches of \$5,000,000 each for aggregate gross proceeds from both closings of \$10,000,000. The first closing occurred on June 1, 2022, and Oncocyte received net proceeds of approximately \$4.9 million from the Series A Preferred Stock issued from the first tranche. The second closing did not occur due to certain closing conditions.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The Series A Preferred Stock was convertible into shares of the Company's common stock at any time at the holder's option. The conversion price would be subject to customary anti-dilution adjustments for matters such as stock splits, stock dividends and other distributions on our common stock, and recapitalizations. A holder was prohibited from converting shares of Series A Preferred Stock into shares of common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 4.99% of the shares of our common stock then issued and outstanding (provided a holder may elect, at the first closing, to increase such beneficial ownership limitation solely as to itself up to 19.99% of the number of shares of our common stock outstanding immediately after giving effect to the conversion, provided further that following the receipt of shareholder approval required by applicable Nasdaq Stock Market LLC ("Nasdaq") rules with respect to the issuance of common stock that would exceed the beneficial ownership limitation, such beneficial ownership limitation will no longer apply to the holder if the holder notified the Company that the holder wishes the Company to seek such shareholder approval). On July 15, 2022, the Company received such shareholder approval to remove the beneficial ownership limitation with respect to the Series A Preferred Stock held by Broadwood Partners, L.P. ("Broadwood"). In the event of the Company's liquidation, dissolution, or winding up, holders of Series A Preferred Stock would have received a payment equal to the stated value of the Series A Preferred Stock plus accrued but unpaid dividends and any other amounts that may have become payable on the Series A Preferred Stock due to any failure or delay that may have occurred in issuing shares of common stock upon conversion of a portion of the Series A Preferred Stock, before any distribution or payment to the holders of common stock or any of our other junior equity. </p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Shares of Series A Preferred Stock generally had no voting rights, except as required by law and except that the consent of holders of a majority of the outstanding Series A Preferred Stock would be required to amend any provision of our certificate of incorporation that would have had a materially adverse effect on the rights of the holders of the Series A Preferred Stock. Additionally, as long as any shares of Series A Preferred Stock remained outstanding, unless the holders of at least 51% of the then outstanding shares of Series A Preferred Stock shall have otherwise given prior written consent, we, on a consolidated basis with our subsidiaries, were not permitted to (1) have less than 8 million of unrestricted, unencumbered cash on hand ("Cash Minimum Requirement"); (2) other than certain permitted indebtedness, incur indebtedness to the extent that our aggregate indebtedness exceeds \$15 million; (3) enter into any agreement (including any indenture, credit agreement or other debt instrument) that by its terms prohibited, prevented, or otherwise limited our ability to pay dividends on, or redeem, the Series A Preferred Stock in accordance with the terms of the Certificate of Determination; or (4) authorize or issue any class or series of preferred stock or other capital stock of the Company that ranks senior or pari passu with the Series A Preferred Stock.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Shares of Series A Preferred Stock were entitled to receive cumulative dividends at a rate per share (as a percentage of stated value) of 6% per annum, payable quarterly in cash or, at our option, by accreting such dividends to the stated value.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The Company was required to redeem, for cash, the shares of Series A Preferred Stock on the earlier to occur of (1) April 8, 2024, (2) the commencement of certain a voluntary or involuntary bankruptcy, receivership, or similar proceedings against the Company or its assets, (3) a Change of Control Transaction (as defined) and (4) at the election and upon notice of 51% in interest of the holders, if the Company failed to meet the Cash Minimum Requirement. Additionally, the Company had the right to redeem the Series A Preferred Stock for cash upon 30 days prior notice to the holders; provided if the Company undertakes a capital raise in connection with such redemption, the Investors will have the right to participate in such financing.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">On April 5, 2023, the Company redeemed 1,064 shares of the Series A Preferred Stock for approximately \$1.1 million (see "Common Stock - April 2023 Offering" below). In connection with the April 2023 redemption, the Company recorded a deemed dividend of \$118,000 based on the difference between the Series A Preferred Stock redemption value and carrying value. On April 15, 2024, Company redeemed the remaining 4,818 shares of the Series A Preferred Stock for approximately \$5.4 million (see "Common Stock - April 2024 Offering" below). As of April 15, 2024, the Company accreted dividends of \$570,000, net of the April 2023 redemption.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The issuance and sale of the Series A Preferred Stock was completed pursuant to the Company's effective "shelf" registration statement on Form S-3 (Registration No. 333-256650), filed with the SEC on May 28, 2021 and declared effective by the SEC on June 8, 2021, and an accompanying prospectus dated June 8, 2021 as supplemented by a prospectus supplement dated April 13, 2022.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">As of September 30, 2024 and December 31, 2023, Oncocyte had </p></div>

space:pre-wrap;min-width:fit-content;">zero and 4,818 shares of the Series A Preferred Stock issued and outstanding, respectively.</p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Preferred Stock</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">As of September 30, 2024 and December 31, 2023, Oncocyte had 5,000,000 shares of preferred stock</p><p style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no par value, authorized. As of September 30, 2024 and December 31, 2023, Oncocyte had no shares of preferred stock issued and outstanding.</p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Common Stock</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">As of September 30, 2024 and December 31, 2023, Oncocyte had 230,000,000 shares of common stock.</p><p style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no par value, authorized. As of September 30, 2024 and December 31, 2023, Oncocyte had 13,374,109 and 8,261,073 shares of common stock issued and outstanding, respectively.</p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">April 2023 Offering</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">On April 3, 2023, the Company entered into an agreement (the "April 2023 Offering") with several institutional and accredited investors, including Broadwood, the Company's largest shareholder, and certain members of the Company's board of directors (and certain of their affiliated parties), relating to their purchase of an aggregate of up to 2,278,121 shares of the Company's common stock at an offering price of 7.08 per share to board members and 6.03 per share to the other investors participating in the April 2023 Offering. The April 2023 Offering was intended to be priced at the market for purposes of complying with applicable Nasdaq Listing Rules. The Company issued an aggregate of 2,274,709 shares of common stock from this offering, as further discussed in Note 9, "Related Party Transactions". The aggregate gross proceeds from the offering were approximately 13.9 million. The Company used approximately 1.1 million of the net proceeds to immediately redeem an aggregate of 1,064 shares of its Series A Preferred Stock.</p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">April 2024 Offering</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">On April 15, 2024, the Company consummated a private placement of its securities to certain accredited investors for the issuance and sale of 5,076,900 shares of the Company's common stock and Pre-Funded Warrants to purchase 342,888 shares of the Company's common stock, with an exercise price of 0.0001 per share. The purchase price for one common share was 2.9164, and the purchase price for one Pre-Funded Warrant was 2.9163. Certain insiders of the Company subscribed for 42,373 of the shares of common stock sold in the private placement, at a purchase price of 2.95 per share (see Note 9). The related securities purchase agreement contains customary representations, warranties and agreements by the Company, indemnification obligations of the Company and the accredited investors, including for liabilities under the Securities Act, other obligations of the parties and termination provisions.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">A holder of the Pre-Funded Warrants may not exercise any portion of such holder's Pre-Funded Warrants to the extent that the holder, together with its affiliates, would beneficially own more than 4.99% (or, at the election of the holder, 9.99%) of the Company's outstanding shares of common stock immediately after exercise, except that upon at least 61 days' prior notice from the holder to the Company, the holder may increase the beneficial ownership limitation to up to 9.99% of the number of shares of common stock outstanding immediately after giving effect to the exercise. The Pre-Funded Warrants are exercisable immediately and will expire when exercised in full. As of September 30, 2024, no Pre-Funded Warrants have been exercised. See Note 9 "Related Party Transactions" for additional information.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The gross proceeds to the Company from the April 2024 Offering were approximately 15.8

 million, before deducting approximately \$ 538,000 in placement agent fees and expenses and offering expenses payable by the Company. The Company is using the net proceeds received for general corporate purposes and working capital. In addition, approximately \$ 5.4 million of the net proceeds was used to redeem the outstanding shares of the Company's Series A Redeemable Convertible Preferred Stock.</p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"> August 2024 Offering</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"> On August 9, 2024, the Company entered into a sales agreement with a sales agent, pursuant to which the Company may offer and sell from time to time up to an aggregate of \$ 7.5 million of shares of the Company's common stock (the "Placement Shares"), through the sales agent.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"> Sales of the Placement Shares may be made in sales deemed to be "at-the-market offerings" as defined in Rule 415 promulgated under the Securities Act. The sales agent will use commercially reasonable efforts to sell, on the Company's behalf, all of the Placement Shares requested to be sold by the Company, consistent with its normal trading and sales practices, the terms of the sales agreement, and applicable law and regulations. The Company may also sell Placement Shares to the sales agent as principal in negotiated transactions. The Company has no obligation to sell any Placement Shares, and may at any time suspend offers under the sales agreement or terminate the sales agreement. The Company intends to use the net proceeds from this offering for working capital and other general corporate purposes. The sales agreement will terminate, and offer and sale of the Placement Shares pursuant to the sales agreement will cease, upon the earlier of (a) the issuance and sale of all of the Placement Shares subject to the sales agreement or (b) the termination of the sales agreement by the sales agent or the Company pursuant to the terms thereof. The sales agreement contains customary representations, warranties and agreements by the Company, as well as indemnification obligations of the Company for certain liabilities under the Securities Act.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"> Under the terms of the sales agreement, the Company will pay the sales agent a commission equal to 3.0 % of the aggregate gross proceeds from each sale of Placement Shares. As of September 30, 2024, the Company has sold 5,722 Placement Shares for net proceeds of approximately 17,000 , at an average purchase price of 3.25 per share. In addition, the Company agreed to pay certain expenses incurred by the sales agent in connection with the offering. Total offering expenses incurred in the amount of 286,000 are being deferred and expensed over a one year period. As of September 30, 2024, the remaining deferred financing costs of 285,000 are included in deferred financing costs in the consolidated balance sheet.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"> The Placement Shares were registered under the Securities Act pursuant to the Registration Statement on Form S-3 (File No. 333-281159) filed with the SEC on August 1, 2024 and declared effective by the SEC on August 7, 2024, the base prospectus contained within the Registration Statement, and a prospectus supplement dated August 9, 2024. October 2024 Offering</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"> On October 4, 2024, the Company consummated the October 2024 Offering. The gross proceeds from the October 2024 Offering were approximately \$ 10.2 million. After deducting placement agent fees and expenses and offering expenses payable by the Company of \$ 795,000 , the resulting net proceeds were approximately \$ 9.4 million. See Note 12, "Subsequent Events" for additional information.</p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"> Unregistered Restricted Stock Issuance</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"> During the nine months ended September 30, 2024, the Company issued 26,664 shares of restricted common stock in connection with an ongoing consulting service arrangement for a total fair value of 72,000 . During the nine months ended September 30, 2023, the Company issued 9,091 shares of restricted common stock to this consulting firm for a total fair value of 36,000 .</p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"> Common Stock Purchase Warrants</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"> As of September 30, 2024 and December 31, 2023, Oncocyte had common stock purchase warrants issued and outstanding of 760,866 and 819,767 , respectively. During the nine months ended September 30, 2024, 58,901 warrants expired. As of September 30, 2024, the outstanding warrants had exercise prices ranging from 30.60 to 30.60 .</p></div>

“color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;”>\$<span style=

font-size:10pt;font-family:Times New Roman;color:#000000:white-space:pre-wrap;min-width:fit-content;”>109.20<span style=

style=”color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;”> per share, are set to expire on various dates ranging from February 2027 to October 2029 and have a weighted average remaining life of <span style=’font-

**size:10pt;font-family:Times New Roman;”><span style=”color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-
width:fit-content;”>2.57<span style=”color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-
width:fit-content;”>** years. Certain warrants have “cashless exercise” provisions meaning that the value of a portion of warrant shares may be used to pay the exercise price rather than payment in cash, which may be exercised under any circumstances in the case of the Bank Warrants discussed below or, in the case of certain other warrants, only if a registration statement for the warrants and underlying shares of common stock is not effective under the Securities Act or a prospectus in the registration statement is not available for the issuance of shares upon the exercise of the warrants. All of the outstanding warrants meet the equity classification criteria and have been classified as equity, refer to Note 2, “Accounting for Warrants” for additional information.</p><p style=’font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;”>

In connection with the April 2024 Offering, discussed above, the Company issued Pre-Funded Warrants to purchase <span style=’font-size:10pt;font-family:Times New Roman;color:#000000:white-space:pre-wrap;min-width:fit-

content;”>342,888<span style=”color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-

content;”> shares of common stock. For accounting purposes, the Pre-Funded Warrants are equity-classified, contain no contingencies to exercise and are therefore considered outstanding for purposes of calculating basic earnings per share. As of September 30, 2024,

no

Pre-Funded Warrants have been exercised.</p><p style=’font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;”><span style=”color:#000000:white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-

content;”>Bank Warrants</p><p style=’font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-

align:justify;”>

In connection with a loan that matured in September 2022 from Silicon Valley Bank (the “Bank”), in February 2017, Oncocyte issued common stock purchase warrants to the Bank (the “2017 Bank Warrants”). The Bank was issued warrants to purchase <span style=’font-

size:10pt;font-family:Times New Roman;color:#000000:white-space:pre-wrap;min-width:fit-content;”>412

shares of Oncocyte common stock at an exercise price of \$<span style=’font-size:10pt;font-family:Times New Roman;color:#000000:white-space:pre-wrap;min-

width:fit-content;”>.97.00<span style=’color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-

content;”>

per share, through February 21, 2027. In March 2017, the Bank was issued warrants to purchase an additional

366

shares at an exercise price of \$<span style=’font-size:10pt;font-family:Times New Roman;color:#000000:white-space:pre-wrap;min-width:fit-

content;”>109.20<span style=’color:#000000:white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-

content;”>

per share, through March 23, 2027. In October 2019, Oncocyte issued a common stock purchase warrant to the Bank (the “2019 Bank Warrant”) entitling the Bank to purchase <span style=’font-size:10pt;font-family:Times New Roman;color:#000000:white-

-space:pre-wrap;min-width:fit-content;”>4,928

shares of Oncocyte common stock at an exercise price of \$<span style=’font-size:10pt;font-

family:Times New Roman;color:#000000:white-space:pre-wrap;min-width:fit-content;”>33.80<span style=’color:#000000:white-

-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;”>

per share, through October 17, 2029. The Bank may elect to exercise the 2017 Bank Warrants and the 2019 Bank Warrant on a “cashless exercise” basis and receive a number of shares determined by multiplying the number of shares for which the Bank Warrant is being exercised by (A) the excess of the fair market value of the common stock over the applicable Warrant Price, divided by (B) the fair market value of the common stock. The fair market value of the common stock will be last closing or sale price on a national securities exchange, interdealer quotation system, or over-the-counter market. These warrants meet the equity classification criteria and have been classified as equity. As of <span style=’color:#000000:white-space:pre-wrap;font-

size:10pt;font-family:Times New Roman;min-width:fit-content;”>September 30, 2024, no<span style=’color:#000000:white-space:pre-

-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;”>

Bank Warrants have been exercised.</p><p>1176538447730.6850100050000001000000004900000A holder was prohibited from converting shares of Series A Preferred Stock into shares of common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 4.99% of the shares of our common stock then issued and outstanding (provided a holder may elect, at the first closing, to increase such beneficial ownership limitation solely as to itself up to 19.99% of the number of shares of our common stock outstanding immediately after giving effect to the conversion, provided further that following the receipt of shareholder approval required by applicable Nasdaq Stock Market LLC (“Nasdaq”) rules with respect to the issuance of common stock that would exceed the beneficial ownership limitation, such beneficial ownership limitation will no longer apply to the holder if the holder notified the Company that the holder wishes the Company to seek such shareholder approval).0.04990.1999the Company received such shareholder approval to remove the beneficial ownership limitation with respect to the Series A Preferred Stock held by Broadwood Partners, L.P. (“Broadwood”),

0.518000000150000000.060.5110641100000118000481854000005700000004818481850000005000000000000230000000230000000001337410:

style=’font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;”><span style=”color:#000000:white-

-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;”>

8. Stock-Based Compensation</p><p style=’font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;”>

Equity Incentive Plan</p><p style=’font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;”>

On August 27, 2018, Oncocyte shareholders approved a new Equity Incentive Plan (the “2018 Incentive Plan”) to replace the 2010 Stock Option Plan (the “2010 Plan”). In adopting the 2018 Incentive Plan, Oncocyte terminated the 2010 Plan and ceased to grant any additional stock options or sell any stock under restricted stock purchase agreements under the 2010 Plan; however, stock options issued under the 2010 Plan continue in effect in accordance with their terms and the terms of the 2010 Plan until the exercise or expiration of the individual options. Total remaining stock options outstanding under the 2010 Plan as of September 30, 2024 and December 31, 2023 were <span style=’font-size:10pt;font-

family:Times New Roman;color:#000000:white-space:pre-wrap;min-width:fit-content;”>

16,217<span style=’color:#000000:white-

-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;”>

</p><p style=’font-size:10pt;margin-

-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;”><span style=’color:#000000:white-space:pre-wrap;font-

-size:10pt;font-family:Times New Roman;min-width:fit-content;”>

As of September 30, 2024, <span style=’font-size:10pt;font-

family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;”>

1,310,000<span style=’color:#000000:white-

-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;”>

aggregate shares of common stock have been reserved for issuance under the equity incentive plans for the grant of stock options or the sale of restricted stock or for the settlement of RSUs. Oncocyte may also grant stock appreciation rights under the 2018 Incentive Plan. Upon the exercise of stock options, the sale of restricted stock, or the delivery of shares pursuant to vested RSUs, it is Oncocyte’s policy to issue new shares of common stock. The Board may amend or modify the 2018 Incentive Plan at any time, subject to any required stockholder approval. As of <span style=’color:#000000:white-

-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;”>September 30, 2024, <span style=’font-

-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;”>

124,768<span style=’color:#000000:white-

-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;”>

shares were available for grant under the 2018 Incentive Plan. On October 11, 2024, Oncocyte shareholders approved an amendment and restatement of the 2018 Incentive Plan to provide for, among other things, an additional

1,250,000<span style=’color:#000000:white-space:pre-wrap;font-

-size:10pt;font-family:Times New Roman;min-width:fit-content;”>

shares of common stock to be available for the issuance of equity awards thereunder.</p><p style=’font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;”>

Plan Activity</span

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

colspan="2"

2024

(In thousands)

Cost of revenues

Research and development

Sales and marketing

607

926

64

[illegible]

[illegible]

[illegible]

[illegible]

Options forfeited/expired

Balance at September 30, 2024

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

space:pre-wrap;min-width:fit-content;">5,882

Roman;min-width:fit-content;">> and

shares, respectively, in the Series A Preferred Stock offering and on the same terms as other investors. Additionally, Halle Capital Management, L.P. received

Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">85,000

from the Company as reimbursement for its legal fees and expenses. Mr. Gutfreund is the Managing Partner of Halle Capital Management, L.P. On April 5, 2023, Oncocyte redeemed all of the

shares of Series A Preferred Stock held by Mr. Gutfreund for

shares of Series A Preferred Stock offering.

Further, on April 13, 2022, Oncocyte entered into an underwriting agreement pursuant to which the Company agreed to issue and sell certain shares of common stock and warrants to purchase common stock ("April 2022 Warrants"). The April 2022 Warrants have an exercise price of

30.60

per share and will expire on April 19, 2027. Pursuant to the underwritten offering, Broadwood acquired from us (i)

shares of common stock, and (ii)

300,187

April 2022 Warrants to purchase up to

150,093

shares of common stock. However, the total number of shares of common stock that Broadwood purchased in the underwritten offering was

300,187

of which

39,154

existing shares were acquired by the underwriters in the open market and re-sold to Broadwood. Pura Vida acquired from us (i)

249,204

shares of common stock, and (ii)

286,585

April 2022 Warrants to purchase up to

143,292

shares of common stock. However, the total number of shares of common stock that Pura Vida purchased in the underwritten offering was

286,585

of which

37,380

existing shares were acquired by the underwriters in the open market and re-sold to Pura Vida. Halle Special Situations Fund LLC purchased from us (i)

309,976

shares of common stock, and (ii)

356,472

April 2022 Warrants to purchase up to

178,236

shares of common stock. Mr. Gutfreund is the investment manager and a control person of Halle Capital Partners GP LLC, the managing member of Halle Special Situations Fund LLC. However, the total number of shares of common stock that Halle Special Situations Fund LLC purchased in the underwritten offering was

356,472

of which

46,496

existing shares were acquired by the underwriters in the open market and re-sold to Halle Special Situations Fund LLC. Mr. Gutfreund is no longer a related party as of June 23, 2023.

On April 3, 2023, Oncocyte entered into a securities purchase agreement with certain investors, including Broadwood, Pura Vida and entities affiliated with AWM, and certain individuals, including Oncocyte's Chairman, Andrew Arno, and former director, John Peter Gutfreund, and certain of their affiliated parties, which provided for the sale and issuance by the Company of an aggregate

2,274,709

shares of common stock at an offering price of:

6.03

to investors who are not considered to be "insiders" of the Company pursuant to Nasdaq Listing Rules ("Insiders"), which amount reflected the average closing price of our common stock on Nasdaq during the five trading day period immediately prior to pricing, and (ii)

7.08

to Insiders, which amount reflected the final closing price of our common stock on Nasdaq on the last trading day immediately prior to pricing.

Broadwood purchased

1,341,381

shares of common stock for

8,093,362

Pura Vida purchased

33,150

shares of common stock for

200,014

and entities affiliated with AWM purchased

472,354

shares of common stock for

2,850,000

Mr. Arno and his affiliated parties purchased

21,162

shares of common stock for

150,001

and Mr. Gutfreund and his affiliated parties purchased

85,250

for

604,252

See Note 7, "Common Stock - April 2023 Offering" for additional information.

font-size:10pt;margin-top:12pt;font-family:Times New Roman;min-width:fit-content;">>

size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 15, 2024, OncocYTE consummated a private placement of its securities to certain investors, including Broadwood, entities affiliated with AWM, Bio-Rad, and certain individuals, including OncocYTE's Chairman, Andrew Arno, for the issuance and sale of

5,076,900 shares of its common stock and Pre-Funded Warrants

342,888 shares of its common stock. The purchase price for one share of common stock was \$

2.9164 and the purchase price for one Pre-Funded Warrant was \$

2.9163. Insiders subscribed for 42,373 of the shares of common stock sold in the private placement, at a purchase price of \$

2.95 per share of common stock, which amount reflected the final closing price of the common stock on Nasdaq on the last trading day immediately prior to pricing. Broadwood purchased

2,420,000 shares of common stock for \$

7,057,688, entities affiliated with AWM purchased

342,889 shares of common stock and

342,889 Pre-Funded Warrants for \$

2,000,000 and Bio-Rad purchased

1,200,109 shares of common stock for \$

3,499,998. Mr. Arno purchased

33,898 shares of common stock for \$

100,000

One of OncocYTE's directors, Andrew Last, served as the Executive Vice President and Chief Operating Officer of Bio-Rad before retiring on September 6, 2024. See Note 7, "Common Stock - April 2024 Offering" for additional information.

On October 4, 2024, OncocYTE consummated the October 2024 Offering involving certain investors, including Broadwood, Bio-Rad, and certain individuals, including OncocYTE's Chief Financial Officer, Andrea James. The gross proceeds from the October 2024 Offering were approximately

10.2 million. After deducting placement agent fees and expenses and offering expenses payable by the Company of

795,000, the resulting net proceeds were approximately

9.4 million. Insiders subscribed for 37,037 of the shares of common stock sold in the October 2024 Offering, at a purchase price of \$

2.97 per share of common stock. Broadwood purchased

1,315,339 shares of common stock for approximately \$

3,878,000 and Bio-Rad purchased

310,835 shares of common stock for approximately \$

916,000. Ms. James purchased

33,670 shares of common stock for \$

100,000

See Note 12, "Subsequent Events" for additional information.

Other Transactions

The Company previously employed the son of Andrew Arno, Chairman of the Board as its Senior Manager, Investor Relations, Corporate Planning & Development. The total compensation paid by the Company to Mr. Arno's son since January 1, 2022 is approximately \$

200,000

Mr. Arno's son is no longer an employee of the Company as of July 28, 2023.

During 2024, the Company purchased

294,000 in laboratory equipment and incurred

230,000 in laboratory equipment and incurred

126,000 under four laboratory equipment leases from Bio-Rad with an initial capitalized total value of

976,000

During 2023, the Company purchased

581,000 in laboratory equipment and incurred

375,000 in laboratory related costs from Bio-Rad. As of September 30, 2024 and December 31, 2023, the Company had accounts payable due to Bio-Rad of

content;">7,000 and 206,000, respectively. One of Oncocyte's directors, Andrew Last, served as the Executive Vice President and Chief Operating Officer of Bio-Rad before retiring on September 6, 2024.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">On April 5, 2024, the Company entered into an agreement with Bio-Rad to collaborate in the development and the commercialization of RUO and IVD kitted transplant products (the "Collaboration Agreement"). Under the Collaboration Agreement, Bio-Rad agreed to purchase shares of our common stock equal to 9.99% of the total number of shares of common stock issued and outstanding immediately after the closing of such investment, provided that the total purchase price would not exceed 3,500,000 unless Bio-Rad chooses to exceed such limit (the "Bio-Rad Investment") (see "Financing Transactions" above). The Bio-Rad Investment was completed in connection with a private placement (See Note 7, "Common Stock - April 2024 Offering"). In addition, we will pay Bio-Rad a single digit royalty payment based on certain net sales under the Collaboration Agreement, and Bio-Rad has an option for the exclusive right to promote, market and sell certain kits worldwide subject to certain conditions. If and when such option is exercised, Bio-Rad will purchase additional shares of our common stock, at the then-current market price per share, up to a specified maximum aggregate purchase price. One of Oncocyte's directors, Dr. Last, recused himself from all Board discussions related to transactions with Bio-Rad. See Note 10, "Collaborative Arrangements" for additional information. On November 8, 2024, the Company and Bio-Rad entered into a memorandum of understanding with respect to the Collaboration Agreement to establish additional activities to be performed by each party pursuant to the Collaboration Agreement (see Note 10 for additional information).</p><p>588211768500058861867230.6261032300187150093300187391542492042865851432922865853738030997635647217823635647246496.56.03 to investors who are not considered to be "insiders" of the Company pursuant to Nasdaq Listing Rules ("Insiders"), which amount reflected the average closing price of our common stock on Nasdaq during the five trading day period immediately prior to pricing, and (ii) \$7.08 to Insiders, which amount reflected the final closing price of our common stock on Nasdaq on the last trading day immediately prior to pricing.6.037.081341381809336233150200014472354285000021162150001852506042525076900to purchase 342,888 shares of its common stock. The purchase price for one share of common stock was \$2.9164, and the purchase price for one Pre-Funded Warrant was \$2.9163. Insiders subscribed for 42,373 of the shares of common stock sold in the private placement, at a purchase price of \$2.95 per share of common stock, which amount reflected the final closing price of the common stock on Nasdaq on the last trading day immediately prior to pricing. Broadwood purchased 2,420,000 shares of common stock for \$7,057,688, entities affiliated with AWM purchased 342,889 shares of common stock and 342,889 Pre-Funded Warrants for \$2,000,000, and Bio-Rad purchased 1,200,109 shares of common stock for \$3,499,998. Mr. Arno purchased 33,898 shares of common stock for \$100,000.3428882.91642.91632.952420000705768834288934288920000012001093499998338981000001020000079500094000002.97131533 style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">10. Collaborative Arrangements</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Bio-Rad<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">On April 5, 2024, the Company entered into the Collaboration Agreement with Bio-Rad to collaborate in the development and the commercialization of RUO and IVD kitted transplant products using Bio-Rad's ddPCR instruments and reagents. The Collaboration Agreement has a term of 10 years unless earlier terminated pursuant to customary termination provisions.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The Collaboration Agreement provides that through the oversight of a joint steering committee comprised of representatives from both parties, the parties will collaborate on the development of (i) the Company's series of GraftAssure™ Transplant Monitoring Assays to measure and test the concentration of donor-derived cell free DNA for RUO (the "RUO Assays"); and (ii) the Company's VitaGraft™ Transplant Monitoring Assays that have received regulatory approval as an in vitro diagnostic device (the "IVD Kits") for exclusive use on one or more Bio-Rad ddPCR instruments. Pursuant to the Collaboration Agreement, and toward the development of the RUO Assays and the IVD Kits, the Company will collect and screen samples, conduct feasibility testing and stability studies, and perform analytical validation, among other things; and Bio-Rad will supply its ddPCR instruments and platforms as well as manufacture and supply all consumables.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Prior to the commercial launch of the RUO Assays, under the Collaboration Agreement, the parties will develop a plan to market and sell the RUO Assays. The Company will be responsible for the manufacture and supply of all RUO Assays, and Bio-Rad will supply to the Company Bio-Rad's ddPCR instruments and reagents for use in commercializing the RUO Assays, which products will be purchased by the Company exclusively from Bio-Rad. The Company and Bio-Rad will be jointly responsible for co-promoting and co-marketing the RUO Assays within the United States and Germany (the "Territory"). The Company has the exclusive right to sell the RUO Assays in the Territory exclusively with the use of Bio-Rad ddPCR instruments and reagents. Bio-Rad will be responsible for promoting and marketing, and has the exclusive right to sell, the RUO Assays outside the Territory. For the sales of the RUO Assays in the Territory, the Company will pay to Bio-Rad a single digit royalty payment based on net sales. The Company will manufacture and supply the RUO Assays to Bio-Rad for resale outside the Territory.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Additionally, the Collaboration Agreement provides Bio-Rad an option for the exclusive right to promote, market and sell IVD Kits worldwide subject to certain conditions. If and when such option is exercised, Bio-Rad will purchase additional shares of the Company's common stock, no par value per share, at the then-current market price per share, up to a specified maximum aggregate purchase price, and the Company will manufacture and supply IVD Kits exclusively for Bio-Rad. See Note 9 "Related Party Transactions" for additional information.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">For the three and nine months ended September 30, 2024, the income statement amounts attributable to transactions arising from the Collaboration Agreement have not been significant. Beginning in September 2024, the Company has capitalized certain inventory costs (see Note 2 "Inventories" for additional information).</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">On November 8, 2024, Oncocyte and Bio-Rad entered into a binding Memorandum of Understanding (the "Memorandum") in connection with the Collaboration Agreement. The Memorandum establishes additional activities (described below) to be performed by Oncocyte and Bio-Rad prior to the commercial launch of the RUO Assays specifically related to pilot study sites outside the Territory (the "Pilot Sites").</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Pursuant to the Memorandum, Oncocyte (i) will setup commercialization of Pilot Sites to use the RUO Assays, (ii) may sell RUO Assays to Pilot Sites, (iii) will train and support the Pilot Sites on the use of the RUO Assays, and (iv) if Oncocyte receives any net sales from the sale of the RUO Assays to the Pilot Sites, then Oncocyte shall pay to Bio-Rad a royalty payment based on a percentage of such net sales under the terms and conditions of the Collaboration Agreement. In addition, pursuant to the Memorandum, Bio-Rad will evaluate commercialization efforts for the RUO Assays, which will include (i) supporting installation and training for Pilot Sites, and (ii) evaluating distribution of the RUO Assays to Pilot Sites.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The foregoing description of the material terms and conditions of the Memorandum does not purport to be complete and is qualified in its entirety by the full text of the Memorandum, which is attached hereto as Exhibit 10.6.</p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Life Technologies Corporation</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">In January 2022, Oncocyte entered into a collaboration agreement (the "LTC Agreement") with Life Technologies Corporation, a Delaware corporation and subsidiary of Thermo Fisher Scientific ("LTC"), in order to partner in the development and collaborate in the commercialization of Thermo Fisher Scientific's existing Oncine Comprehensive Assay Plus and Oncocyte's DetermaIO assay for use with LTC's Ion Torrent</p>TM

GenexusTMIntegrated Sequencer and LTC's Ion TorrentTMGenexusTMPurification System in order to obtain IVD regulatory approval. In February 2023, Oncocyte entered into a Termination Agreement with LTC, pursuant to which the parties terminated the LTC Agreement. As of the termination date, Oncocyte was responsible for reimbursing LTC for \$749,000 of certain development costs under the terms of the LTC Agreement, which were fully paid in 2023.</p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">11. Discontinued Operations of Razor</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">On December 15, 2022, the Company entered into the Razor Stock Purchase Agreement with Dragon and Razor. Pursuant to the Razor Stock Purchase Agreement, Oncocyte agreed to sell, and Dragon agreed to purchase,3,188,181 shares of common stock of Razor, which constitutes approximately70% of the issued and outstanding equity interests of Razor on a fully-diluted basis. On February 16, 2023, Oncocyte completed the Razor Sale Transaction. In connection with the Razor Closing, Oncocyte transferred to Razor all of the assets and liabilities related to DetermaRx. Refer to additional Razor information in Note 1.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">In addition to the transfer of70% of the equity interests of Razor, the Razor Stock Purchase Agreement provided that Dragon would purchase furniture, fixtures, and equipment from the Company for a cash consideration of approximately \$116,000. Upon the Razor Closing, the Company deconsolidated the assets and liabilities of Razor as control of Razor had transferred to Dragon.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The Company recorded the final adjustment related to the disposal, including final working capital adjustments, and recognized an impairment loss of \$1.3 million during the first quarter of 2023. Including the impairment losses we recognized as of December 31, 2022 related to this transaction, we recorded an overall impairment loss of \$27.2 million.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The operating results for Razor have been recorded in discontinued operations of the accompanying 2023 consolidated statement of operations and we have reclassified the remaining liabilities as discontinued operations in the accompanying balance sheet. The 2023 discontinued operations reflect operating results of Razor up to the closing of the sale.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The Company's 2023 consolidated balance sheet and consolidated statement of operations report discontinued operations separate from continuing operations. Our 2023 consolidated statement of comprehensive loss, statement of shareholders' equity and statement of cash flows combined continuing and discontinued operations. A summary of financial information related to the Company's discontinued operations is as follows.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">As of December 31, 2023, the Company's consolidated balance sheet included \$45,000 in accounts payable related to discontinued operations, which was paid during the first quarter of 2024.</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The following table represents the results of the discontinued operations of Razor:</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"></p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:80.236%;box-sizing:content-box;"></td><td style="width:1.94%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"></td><td style="vertical-align:bottom;"></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;">Nine Months Ended
September 30, 2023</td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"></td><td style="vertical-align:bottom;"></td><td colspan="2" style="vertical-align:bottom;text-align:left;">(In thousands)</td><td style="vertical-align:bottom;text-align:left;"></td></tr><tr style="height:10pt;background-color:#cfff0c;word-break:break-word;"><td style="vertical-align:bottom;">Net revenue</td><td style="vertical-align:bottom;"></td><td colspan="2" style="vertical-align:bottom;text-align:left;"></td></tr><tr style="height:10pt;background-color:#cfff0c;word-break:break-word;"><td style="vertical-align:bottom;">421</td><td colspan="3" style="vertical-align:bottom;text-align:left;"></td></tr></div></p></div>

[illegible]

[illegible]

[illegible]

family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"></td></tr></table>4210005070007020004980003290001311000-2926000-2985000-1372000<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">12. Subsequent Events</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Securities Purchase Agreement</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">On October 4, 2024, the Company consummated a private placement of its securities to certain accredited investors (collectively, the "Purchasers") for the issuance and sale of3,461,138 shares of the Company's common stock. The purchase price for one common share was \$2.948. Certain insiders of the Company subscribed for37,037 of the shares of common stock sold in the private placement, at a purchase price of \$2.97 per share. The related securities purchase agreement contains customary representations, warranties and agreements by the Company, indemnification obligations of the Company and the Purchasers, including for liabilities under the Securities Act, other obligations of the parties and termination provisions.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The gross proceeds to the Company from the October 2024 Offering were approximately \$10.2 million, before deducting approximately \$795,000 in placement agent fees and expenses and offering expenses payable by the Company. The Company intends to use the net proceeds received of approximately \$9.4 million for general corporate purposes and working capital.</p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">Collaboration Agreement Amendment</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">On November 8, 2024, Oncocyte and Bio-Rad entered into the Memorandum in connection with the Collaboration Agreement. The Memorandum establishes additional activities to be performed by Oncocyte and Bio-Rad prior to the commercial launch of the RUO Assays specifically related to Pilot Sites. See Note 10, "Collaborative Arrangements" for additional information.</p></p>34611382.948370372.97102000007950009400000falsefalsefalsefalse Indicates the maximum amount payable if the Milestone is achieved. As defined, Royalty Payments are based on a percentage of future revenues of DetermaIO and Pharma Services over their respective useful life, accordingly there is no fixed contractual value for the Royalty Contingent Consideration. See Note 3 for information on the Insight Merger. See Note 3 for information on the Chronix Merger. Amortization of intangible assets is included in "Cost of revenues - amortization of acquired intangibles" on the consolidated statements of operations because the intangible assets pertain directly to the revenues generated from the acquired intangibles.

V-FG9 M/F-62U:I+F>9JBIC(5JWL/_R/8M1P=I?^#C9.6<:O5"3Q)'>RQU(J1A^;\$ M"C4*2S1:8:V*FP@:1<'1\$S) _/I/(Q-L9+F@F?_+IA4D/-TJX^V6#%R=OLO M/WW^N^J^>M#C(I+53TX<_)@A=Q5L 4&^?<:U+QWBX T>L I S+&%H' M>X^V+RBIS\$|= "1IH^+B84DH^J):T&1E^+CAU^E(MRCP)^P=97G522FX1+UBHT)PP M,1WL& U%RMRV/HMIF\$^DG6RXY60YUE+ =UGL\$9; <#K^208JTHQ81/ M/N^&7=CI7.CM1^UVVZDK)8-Q=9Y2<Q(JR/A)2 PKM(3HCCS5V5T..?04:HR1 M+X.%R:- VA2\$/G1@J9^7 _@_/_EY@Y@ 869KIS# <2(31TW:/C^-VOR5\$S/AI M\$R2UF>(_ TRSP^Q0.IY6)UQ=OG&["^&V M54.Y<:5WNF@U@U078D)^: %v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~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|=I9TIFG^<^#7N+##AK5+T^VN<I/ M=:R^QT^56:..H31^0^0^7^~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|A|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

MV3R (.O.YP49:\$)=8*=#2VJ+L(5Q9J[B-Y!>). D0;+!(04+#+_9@EUM4@D M>P3Y=0&Q XBP6-;J8FXA<9Q^>|B\$INTOA35J|Y0C:X4QI2Q+K;-[F]N#I
(RR^#AfK.GV\$52-??2PY*MB3 M(^X35B5ADU8;|QH6\$51=A1CR|72|"K=)|%>@QKYDU<|OY&E;L|=^P|G^P> M=BWC=I^E2|FMDR^4>|L;X&S|
|XF,I/#P"U#1/51\$)<.7L5^Z/#0#U MG&|F% 0#Z9/@)OV@^YX&|J;-&>L%P |\$BSPKI(J8#D_P|QB&1>.H&)|55K
MD&T^|J|6EQ|TPE|IA|B=>R|R8SWS*3|VR|@|H|S|O62|6==='1#EVP'/#AO + MGO-QKP@SR> 6=Q(2|E=EE5T/ON|5>^&I#-Y.(8#Q_55_Q8GNZ-
L>X6;J.S|< M_ |EAP09Y|5G;+B.OPTT'|/OVAZCG5>L|'B1T^HT%5P1;KU|H9^!| M30FE|TZWOE'F%==(Q^#2-Q>L^)|R|VZ |>=KZBIV02V|K1A>L;
|B;|=(NTU; M3\$=|17Y&3LI<@NJC|6AUFE &EY2/O.RX| TK7 M^=17%\$%#Y@|1!> U|AUA;B>(N3U+W6L^3YBLTX;MR.#O&|7I(D)U|9C9N(I MM-
^DOOQ|BM.H|YF.QK(IQ|O|HXF^?Y(I|VP6UHX8|>Q^3)FHA|3B|NA1KY7 M^5-%@;+@K>(25^*92)B>|U70I^4)DNN|(R|)T|58I^30A=VD^*8OQR.H|5I(\$
MQHY8U5&H\$KKB^X57^(-^S2/P|K^4)AA^K^*.2GTVPD2(SED>2X^IX^1Z^A^: MA+&8OT(ZM+XCU)OVTPO|YU|U-ST;8K408H\$H+
|IM=1)=|BLU.82|+BXAATU20@ M|X+^H^B2T\$HDC+O^|G^ F==\$(|L^32@|I3;|^@24%|2;^8R1RTU^|T7681\$INA MI|?<
X|CQ\$U/HJ>|G^VRM|I|=ZNPY^Y18RHT&|6|EVW|V%CI|G|HT^%#^J| 1L|8 M2<>K NF?|N0 Q|6RUJ8|U5UH3?H6^A|6136%7.Z^HN MBDN7A)-
%Y0Y1W?<@ M+D+UC^P;H=G^R^B|E42*^ SG|3^9|Q^5^V-6|>#W| 8DAI^7P\$^**(|I|XW|FJ8 M7=0F0>:A.0@m2@|< 340-; M^?Q,K22\$XC^';>|G0?
26ELU?2^>-B@C@ L.APT3^1%B;6ABAU(D+;GV7O9XL^P>9.RLN^7|PUU+U+L4 M13.D07N 5\$ARW=;OXJ=;52IDISOX G+@;Y9IDMCEP@5Y9X00-
5WM(3-^@UA MD:1JW|T204S\$N|J|815R2|I\$^?81Q_8^|@U8-F6;-UZ^T-C55_9I<4PRX- MT| 4X^M8YUB(AN^Q^K|>9R^4^9E+9208_\$"
|RXH.GD|<Q9|E?8Y_#>=\$@E7 M^V|S07\$^L;+>=C97_|&95+U;98?^X4R9IGY;8P;N2^T_>|JPU#|B|L^L^W^G> ME#9I;3^>=OUT.KV|KH |I-ID6?
EE212\$SKEK|Y6D8J\$K^Q|MI^*-LFNM.B/ M|JTG@P-P|E^|G^Y5=9.2ZDHZ_ =R.F150ZVD3^Z.M\$&E;|3|CMI|O&W^A7REJ|J^C%
<|J=)CZ^"^(?|11A&U>); :^SZ|W|>F=LJ6U|Y\$P8HC|Z5|> MT9|R|U^5C^F;:KF5^41L14MZ^BPVZ/=OU.08V2W|(8|BWZ^*)4=|A|KXP.UBP"
MT|@L^*C|3D|L|P^CDD5E8|73|GW_.011M|I|TAR|L^<|NT5..R>2>|/B.SM M5U+Z R%>M.W|Q+J_ &|MR\$^?>Z|9=Q2|7YQQE_<
M3|O|S^DK^Q@(<@<^*#^N|R1XZ-^>DEFT8S.G/G^CX.FXG|CL>3Y|L.G+C^7| M+L+K-(O>Q>D^TOET8ZFNXT=187^6A M^ MY0>=NM1I-
:U^("5LD:CSN_E#V:9208 \$|D^W|-TB^>)|%#F4W(%O|:|\$0G.X9 MZ=(=U_J^'=??^6XP^4D4XY\$1RW8-N%>7^A|^95.9L0|SW\$^=?PPLQ5C#J1
MQ>H|(^X|DL|L|A^Q2^ST^C7\$K-CZ90^CFRA|O|O|E|^<^%#^?EPOV< MM|6AZQYV4>?|BY60^%SL=B^F3 MF9OYVM?
SM2^L|E.2NP70389T9_?2.6|OQYV^H_>O/S%06AM|^1=3%9GNXK M^T:7\$2K.#^8|=(^)|B|W^L.B=97 F3X&\$4AN>U>(>G|I|O4=YT(6FL-
;DOB^6^H^|8E%| M^ 5.HV>G|1DZP.E(5N|E74JFC=.;=|?E7FMU@#^M>90CD420^E%T%>NKB>8|@^\$MNX0OYOL M.4< 8?J.G|3-5HK^OT.7:
D^EYK#TB^Z 7.3/8U^N3-CL PCR^IU7EL.B M|2|U^U@R;2.9EMJP|^*0Z20+U23L(?
C^U^WQ;BW7WZB|10@4G|63W4.X^C=C.Y=|4S^%>CT>_>UOD|E^%& MLD-@\$.EQD|I^?^|JN|. %&8B|OW^|Y1@^F|^I2^O^Q:P9L@92P^5N7A^84R
M^|I|18D|AR|V^C2F|>L.7+H|U^Y78|Y>TOUNC|@ MGLMR67J|V.O|DVQ2606YKD^#Z+Y4 ^K^U2|_<"K93C<B?>W8(FR.8->MHA
M.4|E\$+55%*,H.-&8V^A|J2D\$#BE^F^~8FIDC;@01.28<8UF&K^WGW2^3=O:
M^%GM(B+V|KZM|^O|J|R;9N0Z897@|(F)TS.X^W|U|@O^#B4W7^X^H>S1:LHD0 M^ZG
1U3G|S03791\$.=K+>Q#VEW|U^|K|;P|QXR#&+6%>4O489P^E3 (TQ<=+@ MQS;^R8|B>^>DU1/\$ |H+|J36)=;^%.:^<(LQ3^8|E|I^1^8-
M&>W8Q1E8|I|V8T:B@+^AZ39EN^UU-MFX^*|+5C>.:Q8=A1;ERO|DL>_9^#92)=? M@2Q|1C(|#N5^\$MD-#N9^|J22JW|I|C2WM2YJ&^U\$(<
T|JR.H^O^C3^>XRFQNGZ)CL |>F&G^P|ZET|I\$>7< M|XMM5Z^U|^F^BQ|ID|WAL|(OH;E|I66^H|?< >5RNU&; M^V8?KZ8|>4 W|S^V MF
+O^SOZ^+^/+HRFSB+5S|J|8Q6|;|AX-O|E;6L 79<V;R|D|2>F^7^&=+INR^*E|K\$|L|DD&G^2ANJ^G M3Q8S^N|E|^R Z+NY2H.+2^*
(^PT^VO.VB|S=@>414>SK|XC?P=3^??"V88K)|^<^V|;X;M^B^|WE|+8HLD5_5FI MS)V;SV7%W LUD3)U^ MLKHR8B2UW+M.& \$D(05+I.F&MY#M
;+=549B.321|J9RY^U2D.F^A9D9VM M=(L^N-3Z2XG^|WTW;^H25V|B3NLR^Y2- %SDRO+=M4J.4_T|U|>#8S92KK
MX6KUE|V&UEH|L3V|QPS&853N2|F#IT5^*T(CO62^Z^3JG>|^"JEPZH^8%6=>Q6| M^:XPXG7S2^PB^Y^HA2&AOHJT|B=YK^"2<58GJ@M_ O^*
(.94%5T|29)45V^%5F MSN5Z:U 51^L P&@YG3A-^|I|QG.6 BCOYVPIW_Y|I6?N|^*#&.E081^\$A)CNS4_T|Y=MYV|1KRGA.^S^|TX UUN8)M^%GJ^<
ME5Z|38UQ^|P#FE^"V;@7 MR&V-3;TD.1 ^|9^R|8R&B|^PK ^<Q^M@A7^MXN&8|7L:37KVC^2|RP|H@GAZE M^%9%Q^C2M5.LQ?
TNR|5A^ZPB\$5(9\$VL%=:9OS^M^<^Q?&69.8X/^<6L95E^*+ MTZ(N&G)CJ.4QV^|V|I|O|D|G&:9L.X^283K JL;512^R0+D:R62J=32GVWG_NH
M^O97^A|IM^B\$|@M@> SC4B|BEQ|A:>V53NTN|EG^~+|K(\$8^8 "I9H|M^I)A5WD3C|208Q|+W^&-URX^"(7P<20<@|J437=12
ME(;:L|K|JWR7+=_ O|@4VWR=) M\$<3W20X@R^**WZ+D #K11+^*8^)|G|F|H^V. SVA4|I|D\$5-DUOL^6AQ^*1S^< M6?
BD>BH5HA|BZ.R4|K^BFB^<^O.2^K^U^#3Y^=ID^2YT|VG>6RU|J|I.(SN8+I# MAXNC17^Z4> 1^<^"V|U5KH;G:T|HUV41^C%P@K&^O|083D@^6.-
E\$2Q-6# MVK&Z^V%#&SAE-RO^K|O|1 |I|FYGI^7@|&@U^1|T|BVD71.V5.3|J M6?EP4;XU^?RD^B^@<
/R(EM^#&0@\$>28KV#3^Z_I^RKWTH|&YS>3=(O_T MERTD4M(O5A|O|T@3EK^0H^*Q175GA6|YRB(|(#73X^MT7+<(^#XHAP|?>\$.%
M==|J^Q^08|A)H^Z031^#K^LVXWT7VD>0 M1^&^(|L^*P.-^&|>5T<8GQ@T|(N3T>6/20^|1E7D1ZK^54MQ52.1/LV^Z
MT^Q\$^Q8EBAW5V>^"VY7ERG|J^V_ W2|<^#RF^M\$=Q|NQNU|X7.(A^C5@_ #M M^<V6 |A|S55:OUXF6>^:S2V; M<33R^A#3 7|VC\$/(N#
O0&^_LD9)6 M^*T2P.=U8D.7#Z\$34+&\$K56^=R=I)^>#J+EEC.3|6J\$^L.P5&#L|I^K%&# MBU)1W|U<>L^|/#1H7^F+>+Q^LU4%VHD.V^XFJ>^B|4?
J^SC6P7^A|S2 JK<=% MK^<|L+<(7RRVH+P@^* K+X4^WU<A3\$5T^>7C9 I^#2^>L4|L|U|EUX.K^GQ7^"V2 M^ Y|JZ_<^# JF^#^\$AN| M DBD
805JM@51433^J^#6= HX6P8O-G275JT_KL6(8P9Y1V|L6LA7^|I(ZV77 M^98M;DY@|6:2^L6^O1B|7|>HB=A>|JWYS|2QK&
MQMT57Z|D^88L@2,%8-W^Z)1P^?P7D^K MU@|! @_\$;:4#BT=6E|+/@6T.. M3F1^X3O8)V=H+>|)^O^3YK;|Z^39S|JH;HU0R8^65NQ|S4 5CUJFN+T
M4AQ|X^9@YVUXOD:NZ0&3ZD;|I|J9^*Q@34^K5^T|N;F@|J|^O/U^O66V|48:8GL2^_REO% 8^N5.HI|!<%8ISC ^>Q_5H|82F|C|P^7ZQP.Q
MKLC|I^>BHI|@K=K4^|YB9NDZNA:TZ^I^LP ED3IGE3|VRO^_PXAGH<-DW.PPX M^B|P^M^O|OM/F(|(*84|KYC(\$L>=>P;M:=20UA56N:L73YCP-
DET/|I|A3YB)CJZP>(^ MWT^9B9?F\$^P|C-T\$+K|PT<-9N^XZ+U^I^).WNNEM^?ZRERD|BMV|B1-HG;? M97W=I2Q5/EQK-
W5D9M|QZ>N766|B=)W^\$^SUO^#>?|I|O|A8|_#>9|..8>=> M2BYYW^AVI^+^S|@^8PL V&CD|6RNM9|JC|VNCNP>^\$P+|<8-9<7^*#|K-8W2VZ/ M^?>
6TL@^B\$J@^#L|D^ZET\$D9PR0^?S09D^_I-W=5J|3.IH^=#A^XV^D69D|=#@<U7C|ZD^V|G LA^>Z M|L15|T|TIE7|6RT3F+87|V8K^|<\$4^165J|>8|U
M7^PW|2D|QD DG|I\$32P=O "(X^D&O |^+6.4\$."7QZA^SVU^WG|T|7O^>^<7 M+=|J^1;1HC%#>|<@07L^BE@%#>4L^M.BC-
6|J|P46|J2TEX^8Y|L_J|QZCR|D1U^M^J3|81|E&|R|C^CERS5B.XAS4|G M=)B4BBF^CP^2^2VYG=JH_HGQ|JG|X9|2|_C6|
|125YR^>X^YEA<^>33F\$.MU MBX:9>9\$%.AI^%|)(WG^H6|RLRG|>^&4QLF^ QWOQ^F^H^|+|I^F|EDD6X; M|>^=2|BX7>?)B4#%
|CZB7V^+>4W&E;ZY+^F=1%K^| 2|8T;^=5Z%.L "EM M:9H^F32VQM^DDBVTUA<^4^4TG08.2L5|^%G&| UTFG5>=>I4ZL^|NQK<DMERW
MA^7&42.W-1.T^%IM^T|_L|C9|J^?T|L^2|T|HTCA|I.WW6<1X9> M(UNN|R9S);P0?Y4|T^56HL|G^X8E|86B#H_#;LX93-
^#H7>07G;HWTM^:3.^%I=PCV|I-P MD>^#KORPIC^TD^KC(O);^""@VQ+>^AC-O^ F^?E V&Y;V^:I^4.7K3N_FV-J ME5 GH4VQ>EBB#;8\$T^KVP%
<XWU^M+228WF5(K^X4;G3H1&.GC#><(^EH^ MCB2N3C(7D9|H|G0C; |L^OTG^<^_L^Z%.A-#1|>J^D3R^YAWVGM ICAH2D|QBM
MI(|O|O|O:NSW? LB7+XC-C^"-G|R&|/B=E;I ^7V|76@_#>6<^\$UL^PE=|P5P M^4M3?|@|B O>>@0|VZ;KE;:J>KU^AK8ZA| MKLE_X6ZCZ&.RA?<
TRS_4>9>S^U6^164^#39|U2^8VMS-|M|J5ACG|2; (P1MBFPG(LMM;M^49L^3|T|MNCAOL=P&2L|B=KCY4ET-V|J^E1X(TC:Y=7WN)C5U=U-
K;XYKC=O^N|G|74+&#;IS^A^HH MM.5>VILHHX=^RVC=4S(K;7>SA&57\$UL4B\$ |Z# 4K>#4LL^<^|@BW8-U|EM
M+=D^|N|RIS2U9@.#Y9G2P:A^|TWK9<-Y\$#S9K|V+(-)5|36|DR^23U^+I89 M&%ISE;(EM/M9X7M=8.LA^DN+^;Z3EDNU@|WTTK
MT^2L;L:U^Y+;322+165\$2^2^>L>L C6CUT^2Y8-9^|DI^8U M5 NT|^P^CE91\$|5X^<L^TR9#F G^X^Y\$%="^X1R^QZ M-
^81;B&6E^*(N51)E.^%V|XNVE7G\$6V (W4#OKYE)6Q?5&N#08^#R^#P^#(2R_O M^S^
HSQ_I^W|9UL@J^+C.|@^OZ44\$OKK^J4X7ASU.R1W(OCU)^DB^7^ MF^! 8F6CAYIXO>>NPN#4VYRXXY:Q^J/-
AN@|H638-19Z\$T3QH<W>QH7.W^< M855C^46^#FF9%MOG\$|+XKW.BA|61;|Y|:8927\$)|%>K;50^NC->+P=-S&6@
MPOY.E)F2V|@FQ^2RZS/(N\$^@FREL|@VJ40BW5^-%7^487L9TKO911YT0US^?&7^O#<8U8Y< M6P^Y|D|J9M1^YBGO-
|R>XP@#14HZY^LR^5&S^W4P.7^&^OK?<RT0QB@40E M2\$6.|\$3@O4YEVTO^N^HT5(V=>E|92HJT|J3|>=O^| M2D G|9VRF(E.NF8DL:1^O@-
&3%|:4HF19&O^F\$^;-123)M M|JM(C^<(K52|LX1=3WM6^*O&V7E|X^ M/U^1424C\$3./Z@#-.BL55S9B)43TG:QDQ^)*UL5+@FB<6#|(ZN@I9-Q^?1V5
MA\$^"4_>6D|J>M5W MC.8Z.)=PV|T MM7M\$8^_1.N+X^M|J^SGO>\$50/Y5U^|/?MN)^F6 =>2,|I
M2^W2_B3HK^4<5|(SMX|LGIK&|H7^4|6|O^U^S|C|W5>DASF-G8;:=YA&\$|31
M^|S&Z1^<^XB|I3F+)^T^T^39^X^C7^WJ^T|S04%&M^4VK|L|U|GD5&61P@4-J|G|GP=1)X|<^Y;T^E^U^*
M&^*P;Y|2^T|IR(S^|H|3^:9V6E0K0^>4)BP254AG>.G>J|T^Y|CZ^? 9L:22B1 M6|T^O^V^L.A|J|S|+|X^<|Z^J7_HYB=2=EF5|J=9+A>HVM^
I50Z=UD^D^L+ MT| W^"P^|P|L|T8_K&Y|Y|U:1|2^M|N|U|L^<42^|MI6<5P^W&G&NUS^7L6|GP;P^ MRU4^*)6\$&F^4|@^N^Z>#^18X;O|3|I&
|BQ:<^VU("E5^%P#ZSC4P:MHE.#DU^*= MP%V<)|\$M^>@I50G<0T^N:E4^FE+1WTW0-:..H(5+OXQX^OR7 V.%_Y0.^(\$ M6(1@|I&.
<(&J|U|^QCYQ^RL<|A|^>?2^I^B^>E|Q5|J|P^Q|JWK^ M^5C3.IOP3ZMT|V-322.Q^"|^D M^S|OXJ| JG_Y3|U=A|EY|Y^IG4ON3L2K-<9.^\$P?
&5YX0^BFEM9(KZD:YNT^R^# M|_5|A^Z^2V_O56DQ_R7V|^|H^9|L-|B|^>2OJ6|L^U5SQ77>^E_*PZO# M|_NH8&^W0D^:9055UO_-4;4|YBKP^X?
VW8R.- X^WR37F^5 @^_DJ5) M24-%\$&^!^<R|L|^>>B0|428_6%"59M^JC:733<>|I|D^8|OG>)>XBS^263^PV| MK|L@J1?
|F^9|U\$|^|PH|T|WV^N^=40V^%|@9=2^=!!+40M;J|N;< M9>?GWA;5^|U+X1|S>8^CHS21.^+|L+&XX^<U^9A@T|+3L^?PT4>UAL @NQL
MP^#^8;79OZZE)N?>Y|YV- VRW|I|@9|JAKG^?2OFK^PB-1+|I|O2^\$31-301 M^|_W6N4|U^O^Q^?VVR_<|O.DK7^@FOLR1V7^M-|3|=>T)?|YV@<
WEM5BMO&2X^4.46=.;QR^F^#^SC| M>TZ|A|Z2>E>K>|TP.52Z.TOF63&D4L3|U^MBNSWV_CA^AK(22V^#V^4|S1-7 MG1&
/+YC2%Z>H>PUS7\$&|^EWL^?TE; |JODS6^6;|^|=)|U4>=J+^1QBG7X^ MZN^<2PUN:~21M).PPT>?D|/=A^ M^L^#TZA|KV<2E)U^9|Y^J<8|NG|4U6V.
|I^>|SV09>G|3 MW.^+I6C|^#^3LO84|J_>?)J|O;? QN_9E_E^81R^I M>A^F^UK6419^M^WL9S8Q^+Z=N9BM4QD^X^7Z\$|^46W+I
5|Z&VH|=|B|U|O^>D8\$^<+C^M^V^L^S^C|J^M^#Z2^?<^>+^#^"I^W|^J^D^Y^Y^K: M|Y|H^E^S:6<-3S0^=8^>^Y^E^=2E9Y72F0E^*Y^YOA^AK|TSH@^3|U+Z4-
M^<S^E9;|=HLFN^N5D|I|O15YAXI03X&7^+<5#WPW9DM^J|B|3|O^>+W^56J|O MCD1PQFWU91-J;9M_#<6^16X92^W MP;.
(*AC8/51.%QXU^:#=NI0%"E|4C8|JG^WE%?|J09DLU/HT=1>GL_HJN^"= MP^#C%;|SE5KR^U3;)_BC(E|C|3L^VA)3LGI(MS;Z|O11O&4^ (OGZ^6|T^A1C
MSK36-DV>?471VZM=O@;SUO31WTY31W_Y|I2P+>^)|A|W^>T^?D92?M^4B4B75_M-|I>=>6ZQ;#8E LN>WTFTV880ZBYPI_NR0H.A M@:
<8\$5L_B>@&K(|&=^X|N|TLKG>4ZV\$Y\$)>09MC^<|^|=)^?NP(GE^O|LB|)
M\$5\$OY<>9|JL|MEW3N=WC3KER^)*B^|USW^CNJ5^5^E0\$RFSQ^DQ09GR(N.I\$ M1|JU_-|GS^EC)<|G2|^=-O:N-25..RT@^84L0UH^I907/^X3N\$.|
|JR^K6: M3\$WE|9V5\$1^&44V5^E3N=\$^I6E7NVW|J|SY^=O^XW:7.;|T^G\$=24^*XR&%4^&Y|QJ(|@Y.I6B8>4Y5.^<D^?TNFNHIT-8OB(|@
M|I+X^M30Z_U6J\$ MOZ^O0^DN^I3IZ^H3^*Y4.1^WS&5.2^=-.WU2+>@.3UTG1|_T@^<^Y+030^*
M8|>|I2=OA2(M_>+G9|L.G^Q^RW&^Z|CU^AEL.I73MXY=L4^QUQCCP^ACUWF>PHG;=W-<|Q.33^S^80\$<^GW<- WU++V(A.Z^|>DV2|^D;M<:|5)O

MA=+BK09=EEJ17.%FZJ|@%?P^\$L2B>>IOFTKW3;-)T(2FE18!MO*WUJ8^F(*-Z M8^9:0^9.#?*E|+ZOI=U900&/S40'?YJUE9(R7*Q5LVF>/O^9-
EQD8L::C:(M6X.U:OM\$43A F8U<5FZ0N!;TB >V.;NDI7.CRYIMFXT.4ONE.1RMV9'9GF#-' MCE"BVYIM4FI=.)W.O.9:20I@?
FC[IT+N=S]^#G.\$08%4@\$HM IE3 U1;1J0*Q MJ?+3U*OM_#X&DY(1Z6OPP =YR3C=S\$6'XV=PI.F*|'4\$>K*IN\$;EC? (/LJ? MJ-G&Q#1/FJGT%9_LY?
H^";YH0AB2DYG%<%Y6J'/7G5PRI@RRK11HF MZ1\$;&BQ<#Y\$ZMGAJC +EI#@UZ^DI:%/?F-O_IJ.4"RQ@DE)/2NO'N3.>4N%
MIU&+1/RESP&VEJ40IT#?\$Y^LZ\$(QH4MEZ-318;0=*(P"N"AI3%R!-R>RLH MN2VYL.Z99EJZ6I46Z=-Y.VPV3SI;!@2<2/E:WT2OK6DL+^?LKW-
U:6\$T3NB MJZKNE*#JNY>:M16S 7L1@-VMM0K8Q) M\$|-VRN7<|'6E5WWK=-!CX0607CB(T&AR)H3DS\$".!J6=E4I/Z7T\$<@Y<16\$5!
M_!+E59+.\$#)LC6(=9I-= \$UO(L GBRB9..+>D%DKQ^W_!#M!)KOVK.091KQ!. M4%_!3K_K>4W DE""""%?D.6'0UK9'U-
)?>0:J^OEMN8> ^:OK6^.&M3YO(^ M8V>^VTI 5U\$&2I9W_#&K?|UH^90'C:7VVOO^E7|C'7^SXHVVDY2@HL|J|'6I
M"+S6PBZR.|STZGUSCBRN|.Q2I0H:.)\$;UC7M5&U=Z98YQ_Z@ZVJ:TWX!L M!:/2R:WC2B!|^Z6-8FRY2 Y\$' QE:9I RJ|30VJ|JND*#@#"
I@^FN2;BW7=U M4JKJ*M19*1- !+G89|IE92I|+P#)*.A9\$^ZQ=0.@NW6?9@!|XOU(X>_HU-1N
M\$81+0=^WS!\$J9@LX0BS!)")1MXTYTJOSGKZFB|4?1021E)#N >(&..U.CC |MFJEHY"D^@&\$+0%9ZA39PMSD>U3C Z&!)L(7=1@L_& PA*^2Y91?
L@G: LAI)VM'Z5LXQ|!7Z.C69T_!JZ|V*4%L!:@OM:FY.E?1BLCQ>K@BC-X&|VVVWK1IOE#"NV8I5MQMT*:\$5 MT)JKK|Z.Z@&&|!5RQ O:16+
(1T>L8YVLF<60=&(&#!|^SDHD\$.G3A P3@=" M7|'CAAXTR4BEG?YJ18QD.V*!'C1'E.6C|RM:-&?_!A.Z|ZOB R>65G_.)V M2|++O/-N+YI*WE_!YF)@
B@QXU&.>:@IWNZ^@C.JSH9W*#XQ_8S972 M>LC10P_@T2:QO:^PK.7&6'/REP%*)9+OR^PS.7(90 BAEJ MT_%*0+OUG:)\$ QO(Q02EM)4+A9)&?
9S:|\$+18DINT.#S'\$S\$T!\$<"Z@/HTU M14014P.C.:WNH R3PS203LZP+-/'!\$RF_ B@WRE-YI9G!V8Y"J|RDW"C- H MWS&CP9L5>^8R-MC&D'A?
D*C@)1BQ3"YBM<.B6&)L).1U50:P0&WA4H%-7G M>|W4LV1"8GBA|ZA|)?=.1*/OR'!CQ3N2 >%9Q|JRSXQ W.8@1V@/(3B'(>|
M5J2NKNW56A7V>AE#OD*B7'.3.9'Z#JI'QI=^Z+2G17=%S2RIX^EQQ=QSCR2# MG=AWL:9I9/^^.|AJ.N1ZF<\$CH\$EMT'069 MW8SF&|S333WE?
*%WV M>5UC&BPM-<|ME'E&L:NT%|V'4|V3C.MA:>M98YIS=. M"C(M|:&=|HZ=&\$U+H6JG|>+E8VL0|U:(\$MCW'10#7"52C:>5\$K*3->XIO@=
M\$#K*JD?<=> YG?RIFO213_.'3A'@I52/(Z/W/SP/PT/1_.\$4@ M_EXOK(-DFJS2U2\$/ZW2W<|LL.2^ S3=+=H9K\$=1K'591=|J:X7HW(^ B M.'O\$#
O_<H0..UW|T_|J_!IL|W@.P%4RF*V6FBPCXD+Y=ZHH.2U=:W MBL:@:RV21JG&RP.U?;MB%5MT_3NMIK_1MEU=A^# MIK_'!?'
HS>QV.#L86<9|@11D^3V2(7>@GLXCH"53IS.W0R^@ MBX-MI6DH?WY.:CY.42%(JIS7O\$=(#B:Z6JHTZO/7"J0\$G>^!FOPC>;D XO%PA1OE:0
X7('DVB M>:IQZX6FVL'CKE!%.78->MD^@#W0%F\$857MVDH2SJP|ZRSI-@O@+3(L|SCT= M% B|C@P+PS0|T|M91FCI_JZ'=15.L%\$ZV@5 MG.*
(^%1\$Z&5R:.0#C&3:SIY0'E+&CF+C|HES 6(C_|J0'B9_P.6_"?T)XO M>|K2|U|G5FSQA(ZN> MMIKA<"Z0HDU2BA7X
M":)&%VN&*UKO8286=VE\$&_XJ2=: ?:-UM+MH^B|H)N1.%E#.\$0:J:0T6':^\$L=|I^|<\$^OY MU#TAZ<"^8S12:~X:1#;XQ"YR#)0A@LJ1L.%:%)?
Y=F8GR%!)|IGV":9(L_+|VW"6WONDJH*.XS162.HM:QO.BD<.9"Z_C=A\$SR9M(6?IJ M8JIX>FVE9MR6S MEI:L167_7HS7*3KYELX3TGT">7:%LY-
%_|W:(V7F" _&&.TNCX\$\$.?"G|0N"> MG0IGYT./&?|L.C|HYZY2YE2YKPE#|JAXF=#2=^ZRKDN|I>Y2(6|23-J M+BF'E-
Z6RMPD)VQ*LB0)IEEVGN!:"ME=K'3B*8JEl0_355BNN-%|Z6|_9Y84\$ M%3#?59RKYOCT?+FT*CIT5>X8S4O7L2X)#'JK%LI90BMIXB=6US'.V!4:
<.8 M0A\$AQ%<G4^?OC|DBU&G! M!89WC(#:CCH>.#_|@%4|2|< <6<&?AIS3^0!%E%+VR'6|?K%GL5VB|CL86 M|02C=|0EGN)@1=|83F-S.J
(|I0/V-|'6G.K2*K 6**_E\$!_U5'?=*B%_ 'B MX@YAWKVD\$A^/(<)8N8#820P_Q9X2G:./KFM+>><%F)8^%:-VS1|-M^EMC>7 MKB#=[=*D*/U.3CML-
OPG4TP3.3);8U_0JC_1Y:#|YS6.GM:4&?Z5AGFK+ MQ'D^GM3FYA:0\$@^0S+8"3P"6_T9:;6|0:DT70\$05KE&T<1P!_MRW1=|7*J
M4&=CBUOF6P#K|+6T_IUMHU00>P2Y&\$XC.NN|"+!|7B04|A|(?Z|@#BW*U8H M?Z3P|RC97 ?
|*!|XG>GJE@U"N|AHC6WPZYTIK^,@(JO_9.@L%V@:FC*=XZ MT++O/9"CN">LYE(Z\F7)Z)-Q|MI|CJ|K|R>3K>|VJ|(RN6_J.\$M.@T M?
<=F|H54>;HE\$51U"^@F2.T?>IE2).U+HVRL_M-Y_80"Q_8Y)8%X80ESY MDVY_|=[U3|/"DL7U|+P4>F7V_/ NA24F&=-U.KG02N>Z17'5@00#"8F:2
5L MKM|I|W4D(213|(|@(|F%9G.Y#|=%*Q6<\$<8^LJREFU">1#)6@_Y.(UE\$2I=P7 M>VZ#|J\$.S6V4|9E3R7"6Y1*|J\$XQX|_ VS.G&80UEM%G&
MIG41-JL.SV_%\$@/AIC>0&|<&PS.T5J2*@D M|<4<>0O05STF0V|K3GGKKNZ4T(26L-SVL)P8YVE:M+T-SC06YKPI0%#P:KASW+
M8!X)6FM|JL_#PNA(6<5'NBB>1DL<>+^/"_BP.00?C|/6P).7Z'I.D|Y_Y M:5R*T/_!4P8V:9?5OH7E:)Z(DOSG.-
H=#2Q!/?2K')FEAJ6@_N==114:LVA)5=IQ3.A*T|NIFT"0!;VA"B;DVJ.J+|Q")_W8*O ?P=Y.LU.F6(?5 = M>AMS5/RG-
:*8%*ELZ=^MFNOXD=>3A(^FWS*9D|^WS^@Q0^JXH|?9 TI+ MT:=U.UU+7\$FNJPCRIEH|3ILF6ZWC3GW1-6IV|5E2NDRE@K?H4@-P@|N|Z":
M(#L5L7L_LWFX"/"P-^E\$&2:|/(96+6+!2"-L/Q:7_75A/l:5#GQ'!&<^A|_M40#0!#&#Y0ESQ'M!>!Q
!+!\$=EYJ2F.S6MZPOF!IU2LYW%60@1#0%MJJ\$OHO MD'YBQXFZ5B!B3.(IR^T+|OU59H4V>(C@&%_+.&L'+_RH.V8J>J?K8MJ:YO MY=?
4|FC:HD|J6V4I?2J|U->V1QU*E.KOV?F+(Q<.BBWD-HKR HZA4.%C: *EH4#TB\$N/: M|DFYF=4_HVDB6G^/5J.(8CB&:4MM/VZ-
7BMM\$+._K:@3TD:@=1#^A-UA+9+? MV=[%5=LQ=G5U|ED5:0W0H!EY.:1CGJ7O*9XWKORJ9\$6@ZGK2TKAN*X49:02
M7FJQ2J7|INH5GB^:"K:#|I-Q/N|?< I=-:;%M8S&:>QGDEQ:%CLMG-@B#4N MWLK|DADZOK'I=)|/U|%TC =TQI=I3|S_FY?N:@^I M=6IQ/7|&QJ.
(GBN9-/Y<1V'R^3|IE M1#|K'UM^864UDAW%AP10J?5\$4?Q4/XT5T2.\$83(2L_!*:..VM MFCI^ (P2I:MT""^GV4^K0>XIV?/:
<66|)%IE|F*FL2|VM0_C/54-#H=2J| M^P|"#.GPX2*_ "Z(J15W)JVCG7=&@:CWLMS!-HL^O &X I-(2J96S7N\$B5W%' M_Y.^16QV:A*0(S4"Q+|A:
<9.W""U@D)#41I5ZH=J.T#CJ(M)"C=)"Q_.L1D+(MCY(C-?HH8>:(WBP?&Y5_I+7X7:"QM1AJQ*OS^+C:'0I!CAAS:JL56YT M
<+EQMIC: +E^#OZ30L-&C|K3ZVB6:A=S7B3A@RC"E"!D04^#WLZH#^LD^S M(X"TV*|N7U<8
L5>9TI&|J4.S"F5^E?),N2,|77C<^F6OISARMHU7_L7#P M>MFX*86SN_GWY(L2*!XO,ZECLR(OREN19QN)B8IBK"6?X\$X7*<0+9V=X4^T MMLF%
,7>UORG^S"LUFAS\$C9&3"P>M#>*>W7:#+^8|B|H'0BBXI\$FKP,81T)H M^2JJ809J1*IP2,N\$A